Disease code,Weight,Group,Group_Description,Study,Study_Name,D_Name
D009026,4.17,NCT00090545-2,Second Stage - Increased Accrual,NCT00090545,A Phase II Study of BAY 43-9006 (Sorafenib) in Metastatic  Androgen-Independent Prostate Cancer,mortality
D064420,9.09,NCT00090545-1,First Stage - Disease Progression,NCT00090545,A Phase II Study of BAY 43-9006 (Sorafenib) in Metastatic  Androgen-Independent Prostate Cancer,adverse drug events
D064420,25.0,NCT00090545-2,Second Stage - Increased Accrual,NCT00090545,A Phase II Study of BAY 43-9006 (Sorafenib) in Metastatic  Androgen-Independent Prostate Cancer,adverse drug events
D003248,4.17,NCT00090545-2,Second Stage - Increased Accrual,NCT00090545,A Phase II Study of BAY 43-9006 (Sorafenib) in Metastatic  Androgen-Independent Prostate Cancer,constipation
D003681,4.17,NCT00090545-2,Second Stage - Increased Accrual,NCT00090545,A Phase II Study of BAY 43-9006 (Sorafenib) in Metastatic  Androgen-Independent Prostate Cancer,dehydration
D003643,4.17,NCT00090545-2,Second Stage - Increased Accrual,NCT00090545,A Phase II Study of BAY 43-9006 (Sorafenib) in Metastatic  Androgen-Independent Prostate Cancer,death
10005047,4.17,NCT00090545-2,Second Stage - Increased Accrual,NCT00090545,A Phase II Study of BAY 43-9006 (Sorafenib) in Metastatic  Androgen-Independent Prostate Cancer,bladder infection
10061229,4.17,NCT00090545-2,Second Stage - Increased Accrual,NCT00090545,A Phase II Study of BAY 43-9006 (Sorafenib) in Metastatic  Androgen-Independent Prostate Cancer,lung infection
D006454,8.33,NCT00090545-2,Second Stage - Increased Accrual,NCT00090545,A Phase II Study of BAY 43-9006 (Sorafenib) in Metastatic  Androgen-Independent Prostate Cancer,hemoglobin
D001416,4.17,NCT00090545-2,Second Stage - Increased Accrual,NCT00090545,A Phase II Study of BAY 43-9006 (Sorafenib) in Metastatic  Androgen-Independent Prostate Cancer,back pain
10006002,4.17,NCT00090545-2,Second Stage - Increased Accrual,NCT00090545,A Phase II Study of BAY 43-9006 (Sorafenib) in Metastatic  Androgen-Independent Prostate Cancer,bone pain
D018771,4.17,NCT00090545-2,Second Stage - Increased Accrual,NCT00090545,A Phase II Study of BAY 43-9006 (Sorafenib) in Metastatic  Androgen-Independent Prostate Cancer,joint pain
D063806,4.17,NCT00090545-2,Second Stage - Increased Accrual,NCT00090545,A Phase II Study of BAY 43-9006 (Sorafenib) in Metastatic  Androgen-Independent Prostate Cancer,muscle pain
10023030,4.17,NCT00090545-2,Second Stage - Increased Accrual,NCT00090545,A Phase II Study of BAY 43-9006 (Sorafenib) in Metastatic  Androgen-Independent Prostate Cancer,ischemia cerebrovascular
D006261,4.17,NCT00090545-2,Second Stage - Increased Accrual,NCT00090545,A Phase II Study of BAY 43-9006 (Sorafenib) in Metastatic  Androgen-Independent Prostate Cancer,headache
D006973,4.55,NCT00090545-1,First Stage - Disease Progression,NCT00090545,A Phase II Study of BAY 43-9006 (Sorafenib) in Metastatic  Androgen-Independent Prostate Cancer,hypertension
D007022,4.55,NCT00090545-1,First Stage - Disease Progression,NCT00090545,A Phase II Study of BAY 43-9006 (Sorafenib) in Metastatic  Androgen-Independent Prostate Cancer,hypotension
D064420,29.73,NCT00098254-1,BAY 43-9006 (Sorafenib),NCT00098254,BAY 43-9006 (Sorafenib) to Treat Relapsed Non-Small Cell Lung Cancer,adverse drug events
D000740,2.7,NCT00098254-1,BAY 43-9006 (Sorafenib),NCT00098254,BAY 43-9006 (Sorafenib) to Treat Relapsed Non-Small Cell Lung Cancer,anemia
10011914,2.7,NCT00098254-1,BAY 43-9006 (Sorafenib),NCT00098254,BAY 43-9006 (Sorafenib) to Treat Relapsed Non-Small Cell Lung Cancer,death nos
D005221,2.7,NCT00098254-1,BAY 43-9006 (Sorafenib),NCT00098254,BAY 43-9006 (Sorafenib) to Treat Relapsed Non-Small Cell Lung Cancer,fatigue
10061229,5.41,NCT00098254-1,BAY 43-9006 (Sorafenib),NCT00098254,BAY 43-9006 (Sorafenib) to Treat Relapsed Non-Small Cell Lung Cancer,lung infection
10001551,2.7,NCT00098254-1,BAY 43-9006 (Sorafenib),NCT00098254,BAY 43-9006 (Sorafenib) to Treat Relapsed Non-Small Cell Lung Cancer,alanine aminotransferase increased
10001675,2.7,NCT00098254-1,BAY 43-9006 (Sorafenib),NCT00098254,BAY 43-9006 (Sorafenib) to Treat Relapsed Non-Small Cell Lung Cancer,alkaline phosphatase increased
10003481,2.7,NCT00098254-1,BAY 43-9006 (Sorafenib),NCT00098254,BAY 43-9006 (Sorafenib) to Treat Relapsed Non-Small Cell Lung Cancer,aspartate aminotransferase increased
10035528,2.7,NCT00098254-1,BAY 43-9006 (Sorafenib),NCT00098254,BAY 43-9006 (Sorafenib) to Treat Relapsed Non-Small Cell Lung Cancer,platelet count decreased
10020670,2.7,NCT00098254-1,BAY 43-9006 (Sorafenib),NCT00098254,BAY 43-9006 (Sorafenib) to Treat Relapsed Non-Small Cell Lung Cancer,hypermagnesemia
D034141,2.7,NCT00098254-1,BAY 43-9006 (Sorafenib),NCT00098254,BAY 43-9006 (Sorafenib) to Treat Relapsed Non-Small Cell Lung Cancer,hypoalbuminemia
10021028,2.7,NCT00098254-1,BAY 43-9006 (Sorafenib),NCT00098254,BAY 43-9006 (Sorafenib) to Treat Relapsed Non-Small Cell Lung Cancer,hypomagnesemia
D007010,2.7,NCT00098254-1,BAY 43-9006 (Sorafenib),NCT00098254,BAY 43-9006 (Sorafenib) to Treat Relapsed Non-Small Cell Lung Cancer,hyponatremia
D003221,2.7,NCT00098254-1,BAY 43-9006 (Sorafenib),NCT00098254,BAY 43-9006 (Sorafenib) to Treat Relapsed Non-Small Cell Lung Cancer,confusion
10065746,2.7,NCT00098254-1,BAY 43-9006 (Sorafenib),NCT00098254,BAY 43-9006 (Sorafenib) to Treat Relapsed Non-Small Cell Lung Cancer,bronchopulmonary hemorrhage
D001986,2.7,NCT00098254-1,BAY 43-9006 (Sorafenib),NCT00098254,BAY 43-9006 (Sorafenib) to Treat Relapsed Non-Small Cell Lung Cancer,bronchospasm
D003371,2.7,NCT00098254-1,BAY 43-9006 (Sorafenib),NCT00098254,BAY 43-9006 (Sorafenib) to Treat Relapsed Non-Small Cell Lung Cancer,cough
D004417,10.81,NCT00098254-1,BAY 43-9006 (Sorafenib),NCT00098254,BAY 43-9006 (Sorafenib) to Treat Relapsed Non-Small Cell Lung Cancer,dyspnea
D000860,5.41,NCT00098254-1,BAY 43-9006 (Sorafenib),NCT00098254,BAY 43-9006 (Sorafenib) to Treat Relapsed Non-Small Cell Lung Cancer,hypoxia
10054524,2.7,NCT00098254-1,BAY 43-9006 (Sorafenib),NCT00098254,BAY 43-9006 (Sorafenib) to Treat Relapsed Non-Small Cell Lung Cancer,palmar-plantar erythrodysesthesia syndrome
D006973,2.7,NCT00098254-1,BAY 43-9006 (Sorafenib),NCT00098254,BAY 43-9006 (Sorafenib) to Treat Relapsed Non-Small Cell Lung Cancer,hypertension
D014657,2.7,NCT00098254-1,BAY 43-9006 (Sorafenib),NCT00098254,BAY 43-9006 (Sorafenib) to Treat Relapsed Non-Small Cell Lung Cancer,vasculitis
D064420,11.76,NCT00112671-1,Treatment (Sorafenib Tosylate),NCT00112671,Sorafenib in Treating Patients With Advanced or Metastatic Cancer of the Urinary Tract,adverse drug events
D009102,5.88,NCT00112671-1,Treatment (Sorafenib Tosylate),NCT00112671,Sorafenib in Treating Patients With Advanced or Metastatic Cancer of the Urinary Tract,multiple organ failure
10011914,5.88,NCT00112671-1,Treatment (Sorafenib Tosylate),NCT00112671,Sorafenib in Treating Patients With Advanced or Metastatic Cancer of the Urinary Tract,death nos
D064420,40.0,NCT00126568-1,BAY 43-9006,NCT00126568,Sorafenib in Treating Patients With Advanced Anaplastic Thyroid Cancer,adverse drug events
10050068,5.0,NCT00126568-1,BAY 43-9006,NCT00126568,Sorafenib in Treating Patients With Advanced Anaplastic Thyroid Cancer,edema limbs
D008231,5.0,NCT00126568-1,BAY 43-9006,NCT00126568,Sorafenib in Treating Patients With Advanced Anaplastic Thyroid Cancer,lymphopenia
D058447,5.0,NCT00126568-1,BAY 43-9006,NCT00126568,Sorafenib in Treating Patients With Advanced Anaplastic Thyroid Cancer,eye pain
D005767,5.0,NCT00126568-1,BAY 43-9006,NCT00126568,Sorafenib in Treating Patients With Advanced Anaplastic Thyroid Cancer,functional gastrointestinal disorders
D000005,5.0,NCT00126568-1,BAY 43-9006,NCT00126568,Sorafenib in Treating Patients With Advanced Anaplastic Thyroid Cancer,abdomen
D001065,5.0,NCT00126568-1,BAY 43-9006,NCT00126568,Sorafenib in Treating Patients With Advanced Anaplastic Thyroid Cancer,appendix
D003643,5.0,NCT00126568-1,BAY 43-9006,NCT00126568,Sorafenib in Treating Patients With Advanced Anaplastic Thyroid Cancer,death
D018450,15.0,NCT00126568-1,BAY 43-9006,NCT00126568,Sorafenib in Treating Patients With Advanced Anaplastic Thyroid Cancer,disease progression
D003645,5.0,NCT00126568-1,BAY 43-9006,NCT00126568,Sorafenib in Treating Patients With Advanced Anaplastic Thyroid Cancer,death sudden
10061229,5.0,NCT00126568-1,BAY 43-9006,NCT00126568,Sorafenib in Treating Patients With Advanced Anaplastic Thyroid Cancer,lung infection
D001037,5.0,NCT00126568-1,BAY 43-9006,NCT00126568,Sorafenib in Treating Patients With Advanced Anaplastic Thyroid Cancer,aphasia
D004417,10.0,NCT00126568-1,BAY 43-9006,NCT00126568,Sorafenib in Treating Patients With Advanced Anaplastic Thyroid Cancer,breath shortness
D011030,5.0,NCT00126568-1,BAY 43-9006,NCT00126568,Sorafenib in Treating Patients With Advanced Anaplastic Thyroid Cancer,pneumothorax
D012141,5.0,NCT00126568-1,BAY 43-9006,NCT00126568,Sorafenib in Treating Patients With Advanced Anaplastic Thyroid Cancer,infections upper respiratory
D016769,5.0,NCT00126568-1,BAY 43-9006,NCT00126568,Sorafenib in Treating Patients With Advanced Anaplastic Thyroid Cancer,embolism and thrombosis
D064420,72.5,NCT00126594-1,Sorafenib Tosylate,NCT00126594,Sorafenib Tosylate With or Without Recombinant Interferon Alfa-2b in Treating Patients With Metastatic Kidney Cancer,adverse drug events
D064420,75.0,NCT00126594-2,Sorafenib Tosylate Recombinant Interferon Alfa-2b,NCT00126594,Sorafenib Tosylate With or Without Recombinant Interferon Alfa-2b in Treating Patients With Metastatic Kidney Cancer,adverse drug events
D003643,67.5,NCT00126594-1,Sorafenib Tosylate,NCT00126594,Sorafenib Tosylate With or Without Recombinant Interferon Alfa-2b in Treating Patients With Metastatic Kidney Cancer,death
D003643,72.5,NCT00126594-2,Sorafenib Tosylate Recombinant Interferon Alfa-2b,NCT00126594,Sorafenib Tosylate With or Without Recombinant Interferon Alfa-2b in Treating Patients With Metastatic Kidney Cancer,death
D010195,2.5,NCT00126594-1,Sorafenib Tosylate,NCT00126594,Sorafenib Tosylate With or Without Recombinant Interferon Alfa-2b in Treating Patients With Metastatic Kidney Cancer,pancreatitis
D001064,2.5,NCT00126594-1,Sorafenib Tosylate,NCT00126594,Sorafenib Tosylate With or Without Recombinant Interferon Alfa-2b in Treating Patients With Metastatic Kidney Cancer,appendicitis
D033461,15.0,NCT00126594-1,Sorafenib Tosylate,NCT00126594,Sorafenib Tosylate With or Without Recombinant Interferon Alfa-2b in Treating Patients With Metastatic Kidney Cancer,hyperuricemia
D033461,5.0,NCT00126594-2,Sorafenib Tosylate Recombinant Interferon Alfa-2b,NCT00126594,Sorafenib Tosylate With or Without Recombinant Interferon Alfa-2b in Treating Patients With Metastatic Kidney Cancer,hyperuricemia
10040139,2.5,NCT00126594-1,Sorafenib Tosylate,NCT00126594,Sorafenib Tosylate With or Without Recombinant Interferon Alfa-2b in Treating Patients With Metastatic Kidney Cancer,serum amylase increased
10024574,2.5,NCT00126594-2,Sorafenib Tosylate Recombinant Interferon Alfa-2b,NCT00126594,Sorafenib Tosylate With or Without Recombinant Interferon Alfa-2b in Treating Patients With Metastatic Kidney Cancer,lipase increased
D064420,55.91,NCT00131911-1,All Patients,NCT00131911,Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors,adverse drug events
D002263,3.23,NCT00131911-1,All Patients,NCT00131911,Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors,carboxyhemoglobin
D007037,1.08,NCT00131911-1,All Patients,NCT00131911,Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors,hypothyroidism
10000060,1.08,NCT00131911-1,All Patients,NCT00131911,Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors,abdominal distension
D015746,19.35,NCT00131911-1,All Patients,NCT00131911,Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors,abdominal pain
D001201,3.23,NCT00131911-1,All Patients,NCT00131911,Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors,ascites
D003248,3.23,NCT00131911-1,All Patients,NCT00131911,Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors,constipation
D003967,5.38,NCT00131911-1,All Patients,NCT00131911,Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors,diarrhea
10013781,1.08,NCT00131911-1,All Patients,NCT00131911,Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors,dry mouth
10055242,1.08,NCT00131911-1,All Patients,NCT00131911,Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors,duodenal hemorrhage
10013832,1.08,NCT00131911-1,All Patients,NCT00131911,Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors,duodenal perforation
D004381,1.08,NCT00131911-1,All Patients,NCT00131911,Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors,duodenal ulcer
D006330,4.3,NCT00131911-1,All Patients,NCT00131911,Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors,heart abnormalities
D005767,2.15,NCT00131911-1,All Patients,NCT00131911,Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors,gastrointestinal disorder
10055291,1.08,NCT00131911-1,All Patients,NCT00131911,Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors,intra-abdominal hemorrhage
10051746,1.08,NCT00131911-1,All Patients,NCT00131911,Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors,lower gastrointestinal hemorrhage
10028130,1.08,NCT00131911-1,All Patients,NCT00131911,Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors,mucositis oral
D009325,13.98,NCT00131911-1,All Patients,NCT00131911,Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors,nausea
D012003,1.08,NCT00131911-1,All Patients,NCT00131911,Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors,rectal fistula
10041101,3.23,NCT00131911-1,All Patients,NCT00131911,Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors,small intestinal obstruction
10041103,1.08,NCT00131911-1,All Patients,NCT00131911,Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors,small intestinal perforation
D014839,8.6,NCT00131911-1,All Patients,NCT00131911,Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors,vomiting
D023341,1.08,NCT00131911-1,All Patients,NCT00131911,Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors,chills
D018450,1.08,NCT00131911-1,All Patients,NCT00131911,Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors,disease progression
10050068,3.23,NCT00131911-1,All Patients,NCT00131911,Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors,edema limbs
D005221,16.13,NCT00131911-1,All Patients,NCT00131911,Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors,fatigue
D005334,4.3,NCT00131911-1,All Patients,NCT00131911,Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors,fever
10062466,1.08,NCT00131911-1,All Patients,NCT00131911,Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors,localized edema
D002764,1.08,NCT00131911-1,All Patients,NCT00131911,Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors,cholecystitis
10017638,1.08,NCT00131911-1,All Patients,NCT00131911,Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors,gallbladder pain
D004066,1.08,NCT00131911-1,All Patients,NCT00131911,Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors,hepatobiliary disease
D006967,1.08,NCT00131911-1,All Patients,NCT00131911,Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors,hypersensitivity
10005047,1.08,NCT00131911-1,All Patients,NCT00131911,Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors,bladder infection
10061351,1.08,NCT00131911-1,All Patients,NCT00131911,Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors,pleural infection
D011014,1.08,NCT00131911-1,All Patients,NCT00131911,Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors,pneumonia
D018805,1.08,NCT00131911-1,All Patients,NCT00131911,Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors,sepsis
10040872,1.08,NCT00131911-1,All Patients,NCT00131911,Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors,skin infection
10001551,1.08,NCT00131911-1,All Patients,NCT00131911,Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors,alanine aminotransferase increased
10001675,3.23,NCT00131911-1,All Patients,NCT00131911,Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors,alkaline phosphatase increased
10003481,4.3,NCT00131911-1,All Patients,NCT00131911,Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors,aspartate aminotransferase increased
10005364,2.15,NCT00131911-1,All Patients,NCT00131911,Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors,blood bilirubin increased
10011368,1.08,NCT00131911-1,All Patients,NCT00131911,Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors,creatinine increased
D007958,1.08,NCT00131911-1,All Patients,NCT00131911,Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors,leukocyte count
10025256,1.08,NCT00131911-1,All Patients,NCT00131911,Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors,lymphocyte count decreased
10029366,1.08,NCT00131911-1,All Patients,NCT00131911,Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors,neutrophil count decreased
D015430,1.08,NCT00131911-1,All Patients,NCT00131911,Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors,weight gain
D015431,1.08,NCT00131911-1,All Patients,NCT00131911,Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors,weight loss
D000471,1.08,NCT00131911-1,All Patients,NCT00131911,Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors,alkalosis
D000855,10.75,NCT00131911-1,All Patients,NCT00131911,Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors,anorexia
D001786,2.15,NCT00131911-1,All Patients,NCT00131911,Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors,blood glucose
D003681,6.45,NCT00131911-1,All Patients,NCT00131911,Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors,dehydration
D012709,3.23,NCT00131911-1,All Patients,NCT00131911,Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors,serum albumin
D002118,2.15,NCT00131911-1,All Patients,NCT00131911,Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors,calcium
D000255,1.08,NCT00131911-1,All Patients,NCT00131911,Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors,adenylpyrophosphate
D011188,3.23,NCT00131911-1,All Patients,NCT00131911,Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors,potassium
10040139,3.23,NCT00131911-1,All Patients,NCT00131911,Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors,serum amylase increased
D012964,3.23,NCT00131911-1,All Patients,NCT00131911,Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors,sodium
10040139,1.08,NCT00131911-1,All Patients,NCT00131911,Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors,serum amylase increased
10040139,1.08,NCT00131911-1,All Patients,NCT00131911,Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors,serum amylase increased
D018771,2.15,NCT00131911-1,All Patients,NCT00131911,Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors,arthralgia
D001416,3.23,NCT00131911-1,All Patients,NCT00131911,Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors,back pain
10006002,1.08,NCT00131911-1,All Patients,NCT00131911,Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors,bone pain
D063806,6.45,NCT00131911-1,All Patients,NCT00131911,Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors,myalgia
D019547,1.08,NCT00131911-1,All Patients,NCT00131911,Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors,neck pain
10033425,1.08,NCT00131911-1,All Patients,NCT00131911,Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors,pain in extremity
D004244,2.15,NCT00131911-1,All Patients,NCT00131911,Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors,dizziness
D006261,2.15,NCT00131911-1,All Patients,NCT00131911,Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors,headache
D003221,1.08,NCT00131911-1,All Patients,NCT00131911,Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors,confusion
D007319,1.08,NCT00131911-1,All Patients,NCT00131911,Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors,insomnia
D004417,6.45,NCT00131911-1,All Patients,NCT00131911,Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors,dyspnea
D011014,1.08,NCT00131911-1,All Patients,NCT00131911,Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors,pneumonitis
D012137,1.08,NCT00131911-1,All Patients,NCT00131911,Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors,respiratory tract
10047681,2.15,NCT00131911-1,All Patients,NCT00131911,Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors,voice alteration
D000505,2.15,NCT00131911-1,All Patients,NCT00131911,Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors,alopecia
D060831,4.3,NCT00131911-1,All Patients,NCT00131911,Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors,hand-foot syndrome
10037847,4.3,NCT00131911-1,All Patients,NCT00131911,Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors,rash acneiform
D005076,2.15,NCT00131911-1,All Patients,NCT00131911,Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors,rash
D012871,1.08,NCT00131911-1,All Patients,NCT00131911,Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors,skin and subcutaneous tissue disorders
10040947,1.08,NCT00131911-1,All Patients,NCT00131911,Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors,skin ulceration
D013546,3.23,NCT00131911-1,All Patients,NCT00131911,Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors,sweating
D005483,1.08,NCT00131911-1,All Patients,NCT00131911,Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors,flushing
D006470,1.08,NCT00131911-1,All Patients,NCT00131911,Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors,hemorrhage
D019584,1.08,NCT00131911-1,All Patients,NCT00131911,Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors,hot flashes
D007022,2.15,NCT00131911-1,All Patients,NCT00131911,Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors,hypotension
D013927,2.15,NCT00131911-1,All Patients,NCT00131911,Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors,thrombosis
D064420,15.79,NCT00182689-1,Platinum Sensitive,NCT00182689,Sorafenib in Treating Patients With Extensive Stage Small Cell Lung Cancer,adverse drug events
D064420,15.91,NCT00182689-2,Platinum Refractory,NCT00182689,Sorafenib in Treating Patients With Extensive Stage Small Cell Lung Cancer,adverse drug events
D003967,2.27,NCT00182689-2,Platinum Refractory,NCT00182689,Sorafenib in Treating Patients With Extensive Stage Small Cell Lung Cancer,diarrhea
D004415,2.63,NCT00182689-1,Platinum Sensitive,NCT00182689,Sorafenib in Treating Patients With Extensive Stage Small Cell Lung Cancer,dyspepsia
D009325,2.63,NCT00182689-1,Platinum Sensitive,NCT00182689,Sorafenib in Treating Patients With Extensive Stage Small Cell Lung Cancer,nausea
D000005,2.27,NCT00182689-2,Platinum Refractory,NCT00182689,Sorafenib in Treating Patients With Extensive Stage Small Cell Lung Cancer,abdomen
D010195,2.27,NCT00182689-2,Platinum Refractory,NCT00182689,Sorafenib in Treating Patients With Extensive Stage Small Cell Lung Cancer,pancreatitis
D001037,2.63,NCT00182689-1,Platinum Sensitive,NCT00182689,Sorafenib in Treating Patients With Extensive Stage Small Cell Lung Cancer,logasthenia
D014552,2.27,NCT00182689-2,Platinum Refractory,NCT00182689,Sorafenib in Treating Patients With Extensive Stage Small Cell Lung Cancer,urinary tract infections
D001219,2.63,NCT00182689-1,Platinum Sensitive,NCT00182689,Sorafenib in Treating Patients With Extensive Stage Small Cell Lung Cancer,serum glutamic-oxaloacetic transaminase
D008049,2.27,NCT00182689-2,Platinum Refractory,NCT00182689,Sorafenib in Treating Patients With Extensive Stage Small Cell Lung Cancer,lipase
D003681,2.27,NCT00182689-2,Platinum Refractory,NCT00182689,Sorafenib in Treating Patients With Extensive Stage Small Cell Lung Cancer,dehydration
D004039,2.63,NCT00182689-1,Platinum Sensitive,NCT00182689,Sorafenib in Treating Patients With Extensive Stage Small Cell Lung Cancer,diet low-sodium
D004039,4.55,NCT00182689-2,Platinum Refractory,NCT00182689,Sorafenib in Treating Patients With Extensive Stage Small Cell Lung Cancer,diet low-sodium
10062572,2.27,NCT00182689-2,Platinum Refractory,NCT00182689,Sorafenib in Treating Patients With Extensive Stage Small Cell Lung Cancer,generalized muscle weakness
D018771,2.63,NCT00182689-1,Platinum Sensitive,NCT00182689,Sorafenib in Treating Patients With Extensive Stage Small Cell Lung Cancer,joint pain
D001259,2.27,NCT00182689-2,Platinum Refractory,NCT00182689,Sorafenib in Treating Patients With Extensive Stage Small Cell Lung Cancer,ataxia
D004244,2.63,NCT00182689-1,Platinum Sensitive,NCT00182689,Sorafenib in Treating Patients With Extensive Stage Small Cell Lung Cancer,dizziness
D002607,2.63,NCT00182689-1,Platinum Sensitive,NCT00182689,Sorafenib in Treating Patients With Extensive Stage Small Cell Lung Cancer,hereditary type i motor and sensory neuropathy
D002607,2.63,NCT00182689-1,Platinum Sensitive,NCT00182689,Sorafenib in Treating Patients With Extensive Stage Small Cell Lung Cancer,hereditary type i motor and sensory neuropathy
D006261,2.63,NCT00182689-1,Platinum Sensitive,NCT00182689,Sorafenib in Treating Patients With Extensive Stage Small Cell Lung Cancer,headache
D001037,2.27,NCT00182689-2,Platinum Refractory,NCT00182689,Sorafenib in Treating Patients With Extensive Stage Small Cell Lung Cancer,aphasia
D013575,2.63,NCT00182689-1,Platinum Sensitive,NCT00182689,Sorafenib in Treating Patients With Extensive Stage Small Cell Lung Cancer,syncope
D014202,2.63,NCT00182689-1,Platinum Sensitive,NCT00182689,Sorafenib in Treating Patients With Extensive Stage Small Cell Lung Cancer,tremor
D003221,2.63,NCT00182689-1,Platinum Sensitive,NCT00182689,Sorafenib in Treating Patients With Extensive Stage Small Cell Lung Cancer,confusion
D003221,4.55,NCT00182689-2,Platinum Refractory,NCT00182689,Sorafenib in Treating Patients With Extensive Stage Small Cell Lung Cancer,confusion
D004417,2.63,NCT00182689-1,Platinum Sensitive,NCT00182689,Sorafenib in Treating Patients With Extensive Stage Small Cell Lung Cancer,breath shortness
D016066,2.27,NCT00182689-2,Platinum Refractory,NCT00182689,Sorafenib in Treating Patients With Extensive Stage Small Cell Lung Cancer,pleural effusion malignant
D006973,2.63,NCT00182689-1,Platinum Sensitive,NCT00182689,Sorafenib in Treating Patients With Extensive Stage Small Cell Lung Cancer,hypertension
D064420,34.29,NCT00217399-1,Sorafenib and Anastrozole,NCT00217399,Sorafenib and Anastrozole in Treating Postmenopausal Women With Metastatic Breast Cancer,adverse drug events
D060831,34.29,NCT00217399-1,Sorafenib and Anastrozole,NCT00217399,Sorafenib and Anastrozole in Treating Postmenopausal Women With Metastatic Breast Cancer,hand-foot syndrome
D064420,27.03,NCT00217620-1,Sorafenib (BAY 43-9006),NCT00217620,S0505 Sorafenib in Treating Patients With Advanced Soft Tissue Sarcomas,adverse drug events
D006454,2.7,NCT00217620-1,Sorafenib (BAY 43-9006),NCT00217620,S0505 Sorafenib in Treating Patients With Advanced Soft Tissue Sarcomas,hemoglobin
D003248,2.7,NCT00217620-1,Sorafenib (BAY 43-9006),NCT00217620,S0505 Sorafenib in Treating Patients With Advanced Soft Tissue Sarcomas,constipation
D006471,2.7,NCT00217620-1,Sorafenib (BAY 43-9006),NCT00217620,S0505 Sorafenib in Treating Patients With Advanced Soft Tissue Sarcomas,gastrointestinal hemorrhage
D009325,2.7,NCT00217620-1,Sorafenib (BAY 43-9006),NCT00217620,S0505 Sorafenib in Treating Patients With Advanced Soft Tissue Sarcomas,nausea
D000005,8.11,NCT00217620-1,Sorafenib (BAY 43-9006),NCT00217620,S0505 Sorafenib in Treating Patients With Advanced Soft Tissue Sarcomas,abdomen
D010195,2.7,NCT00217620-1,Sorafenib (BAY 43-9006),NCT00217620,S0505 Sorafenib in Treating Patients With Advanced Soft Tissue Sarcomas,pancreatitis
D002637,2.7,NCT00217620-1,Sorafenib (BAY 43-9006),NCT00217620,S0505 Sorafenib in Treating Patients With Advanced Soft Tissue Sarcomas,chest pain
D000068258,2.7,NCT00217620-1,Sorafenib (BAY 43-9006),NCT00217620,S0505 Sorafenib in Treating Patients With Advanced Soft Tissue Sarcomas,avastin
D000681,2.7,NCT00217620-1,Sorafenib (BAY 43-9006),NCT00217620,S0505 Sorafenib in Treating Patients With Advanced Soft Tissue Sarcomas,amylase
D008049,5.41,NCT00217620-1,Sorafenib (BAY 43-9006),NCT00217620,S0505 Sorafenib in Treating Patients With Advanced Soft Tissue Sarcomas,lipase
D001792,2.7,NCT00217620-1,Sorafenib (BAY 43-9006),NCT00217620,S0505 Sorafenib in Treating Patients With Advanced Soft Tissue Sarcomas,platelets
D000855,2.7,NCT00217620-1,Sorafenib (BAY 43-9006),NCT00217620,S0505 Sorafenib in Treating Patients With Advanced Soft Tissue Sarcomas,anorexia
D016895,2.7,NCT00217620-1,Sorafenib (BAY 43-9006),NCT00217620,S0505 Sorafenib in Treating Patients With Advanced Soft Tissue Sarcomas,low-serum media
D016895,2.7,NCT00217620-1,Sorafenib (BAY 43-9006),NCT00217620,S0505 Sorafenib in Treating Patients With Advanced Soft Tissue Sarcomas,low-serum media
D004039,2.7,NCT00217620-1,Sorafenib (BAY 43-9006),NCT00217620,S0505 Sorafenib in Treating Patients With Advanced Soft Tissue Sarcomas,diet low-sodium
D018450,5.41,NCT00217620-1,Sorafenib (BAY 43-9006),NCT00217620,S0505 Sorafenib in Treating Patients With Advanced Soft Tissue Sarcomas,disease progression
D000073216,2.7,NCT00217620-1,Sorafenib (BAY 43-9006),NCT00217620,S0505 Sorafenib in Treating Patients With Advanced Soft Tissue Sarcomas,mental status and dementia tests
D002607,2.7,NCT00217620-1,Sorafenib (BAY 43-9006),NCT00217620,S0505 Sorafenib in Treating Patients With Advanced Soft Tissue Sarcomas,hereditary type i motor and sensory neuropathy
D013575,2.7,NCT00217620-1,Sorafenib (BAY 43-9006),NCT00217620,S0505 Sorafenib in Treating Patients With Advanced Soft Tissue Sarcomas,syncope
D014517,2.7,NCT00217620-1,Sorafenib (BAY 43-9006),NCT00217620,S0505 Sorafenib in Treating Patients With Advanced Soft Tissue Sarcomas,ureteral obstruction
D004417,2.7,NCT00217620-1,Sorafenib (BAY 43-9006),NCT00217620,S0505 Sorafenib in Treating Patients With Advanced Soft Tissue Sarcomas,breath shortness
D007022,2.7,NCT00217620-1,Sorafenib (BAY 43-9006),NCT00217620,S0505 Sorafenib in Treating Patients With Advanced Soft Tissue Sarcomas,hypotension
D064420,20.63,NCT00281957-1,Arm I,NCT00281957,Sorafenib With Either Temsirolimus or Tipifarnib in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed By Surgery,adverse drug events
D064420,15.38,NCT00281957-2,Arm II,NCT00281957,Sorafenib With Either Temsirolimus or Tipifarnib in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed By Surgery,adverse drug events
D006454,1.59,NCT00281957-1,Arm I,NCT00281957,Sorafenib With Either Temsirolimus or Tipifarnib in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed By Surgery,hemoglobin
10069501,1.59,NCT00281957-1,Arm I,NCT00281957,Sorafenib With Either Temsirolimus or Tipifarnib in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed By Surgery,left ventricular systolic dysfunction
D005767,1.59,NCT00281957-1,Arm I,NCT00281957,Sorafenib With Either Temsirolimus or Tipifarnib in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed By Surgery,functional gastrointestinal disorders
D009325,1.59,NCT00281957-1,Arm I,NCT00281957,Sorafenib With Either Temsirolimus or Tipifarnib in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed By Surgery,nausea
D000005,1.59,NCT00281957-1,Arm I,NCT00281957,Sorafenib With Either Temsirolimus or Tipifarnib in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed By Surgery,abdomen
D010195,1.59,NCT00281957-1,Arm I,NCT00281957,Sorafenib With Either Temsirolimus or Tipifarnib in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed By Surgery,pancreatitis
D010195,2.56,NCT00281957-2,Arm II,NCT00281957,Sorafenib With Either Temsirolimus or Tipifarnib in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed By Surgery,pancreatitis
D014839,3.17,NCT00281957-1,Arm I,NCT00281957,Sorafenib With Either Temsirolimus or Tipifarnib in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed By Surgery,vomiting
D001037,1.59,NCT00281957-1,Arm I,NCT00281957,Sorafenib With Either Temsirolimus or Tipifarnib in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed By Surgery,logasthenia
D000069544,1.59,NCT00281957-1,Arm I,NCT00281957,Sorafenib With Either Temsirolimus or Tipifarnib in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed By Surgery,encephalitis infection
10040872,1.59,NCT00281957-1,Arm I,NCT00281957,Sorafenib With Either Temsirolimus or Tipifarnib in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed By Surgery,skin infection
D000681,2.56,NCT00281957-2,Arm II,NCT00281957,Sorafenib With Either Temsirolimus or Tipifarnib in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed By Surgery,amylase
D008049,2.56,NCT00281957-2,Arm II,NCT00281957,Sorafenib With Either Temsirolimus or Tipifarnib in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed By Surgery,lipase
D034141,1.59,NCT00281957-1,Arm I,NCT00281957,Sorafenib With Either Temsirolimus or Tipifarnib in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed By Surgery,hypoalbuminemia
D016895,1.59,NCT00281957-1,Arm I,NCT00281957,Sorafenib With Either Temsirolimus or Tipifarnib in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed By Surgery,low-serum media
D003681,3.17,NCT00281957-1,Arm I,NCT00281957,Sorafenib With Either Temsirolimus or Tipifarnib in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed By Surgery,dehydration
D003847,1.59,NCT00281957-1,Arm I,NCT00281957,Sorafenib With Either Temsirolimus or Tipifarnib in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed By Surgery,deoxyglucose
D017674,3.17,NCT00281957-1,Arm I,NCT00281957,Sorafenib With Either Temsirolimus or Tipifarnib in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed By Surgery,hypophosphatemia
D016895,3.17,NCT00281957-1,Arm I,NCT00281957,Sorafenib With Either Temsirolimus or Tipifarnib in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed By Surgery,low-serum media
10062572,3.17,NCT00281957-1,Arm I,NCT00281957,Sorafenib With Either Temsirolimus or Tipifarnib in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed By Surgery,generalized muscle weakness
10062572,2.56,NCT00281957-2,Arm II,NCT00281957,Sorafenib With Either Temsirolimus or Tipifarnib in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed By Surgery,generalized muscle weakness
D001416,2.56,NCT00281957-2,Arm II,NCT00281957,Sorafenib With Either Temsirolimus or Tipifarnib in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed By Surgery,back pain
D018771,1.59,NCT00281957-1,Arm I,NCT00281957,Sorafenib With Either Temsirolimus or Tipifarnib in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed By Surgery,joint pain
D009462,1.59,NCT00281957-1,Arm I,NCT00281957,Sorafenib With Either Temsirolimus or Tipifarnib in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed By Surgery,neurology
D002607,2.56,NCT00281957-2,Arm II,NCT00281957,Sorafenib With Either Temsirolimus or Tipifarnib in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed By Surgery,hereditary type i motor and sensory neuropathy
D006261,1.59,NCT00281957-1,Arm I,NCT00281957,Sorafenib With Either Temsirolimus or Tipifarnib in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed By Surgery,headache
D003221,1.59,NCT00281957-1,Arm I,NCT00281957,Sorafenib With Either Temsirolimus or Tipifarnib in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed By Surgery,confusion
D051437,1.59,NCT00281957-1,Arm I,NCT00281957,Sorafenib With Either Temsirolimus or Tipifarnib in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed By Surgery,renal failure
D011014,3.17,NCT00281957-1,Arm I,NCT00281957,Sorafenib With Either Temsirolimus or Tipifarnib in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed By Surgery,pneumonitis
D012141,1.59,NCT00281957-1,Arm I,NCT00281957,Sorafenib With Either Temsirolimus or Tipifarnib in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed By Surgery,infections upper respiratory
D011537,1.59,NCT00281957-1,Arm I,NCT00281957,Sorafenib With Either Temsirolimus or Tipifarnib in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed By Surgery,pruritus
D005076,1.59,NCT00281957-1,Arm I,NCT00281957,Sorafenib With Either Temsirolimus or Tipifarnib in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed By Surgery,rash
D005483,1.59,NCT00281957-1,Arm I,NCT00281957,Sorafenib With Either Temsirolimus or Tipifarnib in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed By Surgery,flushing
D006973,1.59,NCT00281957-1,Arm I,NCT00281957,Sorafenib With Either Temsirolimus or Tipifarnib in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed By Surgery,hypertension
D006973,2.56,NCT00281957-2,Arm II,NCT00281957,Sorafenib With Either Temsirolimus or Tipifarnib in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed By Surgery,hypertension
D016769,2.56,NCT00281957-2,Arm II,NCT00281957,Sorafenib With Either Temsirolimus or Tipifarnib in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed By Surgery,embolism and thrombosis
D009026,4.0,NCT00326495-1,BAY 43-9006 & Cetuximab,NCT00326495,BAY 43-9006 Plus Cetuximab to Treat Colorectal Cancer,mortality
D064420,44.0,NCT00326495-1,BAY 43-9006 & Cetuximab,NCT00326495,BAY 43-9006 Plus Cetuximab to Treat Colorectal Cancer,adverse drug events
D000740,4.0,NCT00326495-1,BAY 43-9006 & Cetuximab,NCT00326495,BAY 43-9006 Plus Cetuximab to Treat Colorectal Cancer,anemia
10000060,4.0,NCT00326495-1,BAY 43-9006 & Cetuximab,NCT00326495,BAY 43-9006 Plus Cetuximab to Treat Colorectal Cancer,abdominal distension
D003681,2.0,NCT00326495-1,BAY 43-9006 & Cetuximab,NCT00326495,BAY 43-9006 Plus Cetuximab to Treat Colorectal Cancer,dehydration
D003967,2.0,NCT00326495-1,BAY 43-9006 & Cetuximab,NCT00326495,BAY 43-9006 Plus Cetuximab to Treat Colorectal Cancer,diarrhea
D004380,2.0,NCT00326495-1,BAY 43-9006 & Cetuximab,NCT00326495,BAY 43-9006 Plus Cetuximab to Treat Colorectal Cancer,duodenal obstruction
D045823,2.0,NCT00326495-1,BAY 43-9006 & Cetuximab,NCT00326495,BAY 43-9006 Plus Cetuximab to Treat Colorectal Cancer,ileus
D009325,2.0,NCT00326495-1,BAY 43-9006 & Cetuximab,NCT00326495,BAY 43-9006 Plus Cetuximab to Treat Colorectal Cancer,nausea
10038064,2.0,NCT00326495-1,BAY 43-9006 & Cetuximab,NCT00326495,BAY 43-9006 Plus Cetuximab to Treat Colorectal Cancer,rectal hemorrhage
10041101,12.0,NCT00326495-1,BAY 43-9006 & Cetuximab,NCT00326495,BAY 43-9006 Plus Cetuximab to Treat Colorectal Cancer,small intestinal obstruction
D014839,4.0,NCT00326495-1,BAY 43-9006 & Cetuximab,NCT00326495,BAY 43-9006 Plus Cetuximab to Treat Colorectal Cancer,vomiting
D023341,2.0,NCT00326495-1,BAY 43-9006 & Cetuximab,NCT00326495,BAY 43-9006 Plus Cetuximab to Treat Colorectal Cancer,chills
10011914,4.0,NCT00326495-1,BAY 43-9006 & Cetuximab,NCT00326495,BAY 43-9006 Plus Cetuximab to Treat Colorectal Cancer,death nos
D005334,10.0,NCT00326495-1,BAY 43-9006 & Cetuximab,NCT00326495,BAY 43-9006 Plus Cetuximab to Treat Colorectal Cancer,fever
D010146,2.0,NCT00326495-1,BAY 43-9006 & Cetuximab,NCT00326495,BAY 43-9006 Plus Cetuximab to Treat Colorectal Cancer,pain
D000707,2.0,NCT00326495-1,BAY 43-9006 & Cetuximab,NCT00326495,BAY 43-9006 Plus Cetuximab to Treat Colorectal Cancer,anaphylaxis
10005047,4.0,NCT00326495-1,BAY 43-9006 & Cetuximab,NCT00326495,BAY 43-9006 Plus Cetuximab to Treat Colorectal Cancer,bladder infection
10007810,2.0,NCT00326495-1,BAY 43-9006 & Cetuximab,NCT00326495,BAY 43-9006 Plus Cetuximab to Treat Colorectal Cancer,catheter related infection
10048762,2.0,NCT00326495-1,BAY 43-9006 & Cetuximab,NCT00326495,BAY 43-9006 Plus Cetuximab to Treat Colorectal Cancer,tooth infection
D014552,2.0,NCT00326495-1,BAY 43-9006 & Cetuximab,NCT00326495,BAY 43-9006 Plus Cetuximab to Treat Colorectal Cancer,urinary tract infection
D014946,2.0,NCT00326495-1,BAY 43-9006 & Cetuximab,NCT00326495,BAY 43-9006 Plus Cetuximab to Treat Colorectal Cancer,wound infection
10005364,2.0,NCT00326495-1,BAY 43-9006 & Cetuximab,NCT00326495,BAY 43-9006 Plus Cetuximab to Treat Colorectal Cancer,blood bilirubin increased
10024574,2.0,NCT00326495-1,BAY 43-9006 & Cetuximab,NCT00326495,BAY 43-9006 Plus Cetuximab to Treat Colorectal Cancer,lipase increased
D007008,2.0,NCT00326495-1,BAY 43-9006 & Cetuximab,NCT00326495,BAY 43-9006 Plus Cetuximab to Treat Colorectal Cancer,hypokalemia
D007010,2.0,NCT00326495-1,BAY 43-9006 & Cetuximab,NCT00326495,BAY 43-9006 Plus Cetuximab to Treat Colorectal Cancer,hyponatremia
D001416,2.0,NCT00326495-1,BAY 43-9006 & Cetuximab,NCT00326495,BAY 43-9006 Plus Cetuximab to Treat Colorectal Cancer,back pain
D006261,4.0,NCT00326495-1,BAY 43-9006 & Cetuximab,NCT00326495,BAY 43-9006 Plus Cetuximab to Treat Colorectal Cancer,headache
10023030,2.0,NCT00326495-1,BAY 43-9006 & Cetuximab,NCT00326495,BAY 43-9006 Plus Cetuximab to Treat Colorectal Cancer,ischemia cerebrovascular
10028041,2.0,NCT00326495-1,BAY 43-9006 & Cetuximab,NCT00326495,BAY 43-9006 Plus Cetuximab to Treat Colorectal Cancer,movements involuntary
D006417,2.0,NCT00326495-1,BAY 43-9006 & Cetuximab,NCT00326495,BAY 43-9006 Plus Cetuximab to Treat Colorectal Cancer,hematuria
10061574,2.0,NCT00326495-1,BAY 43-9006 & Cetuximab,NCT00326495,BAY 43-9006 Plus Cetuximab to Treat Colorectal Cancer,urinary tract obstruction
10046912,2.0,NCT00326495-1,BAY 43-9006 & Cetuximab,NCT00326495,BAY 43-9006 Plus Cetuximab to Treat Colorectal Cancer,vaginal hemorrhage
D064420,58.88,NCT00326898-1,Arm A (Sunitinib + Sorafenib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,adverse drug events
D064420,67.52,NCT00326898-2,Arm B (Sorafenib + Sunitinib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,adverse drug events
D064420,12.94,NCT00326898-3,Arm C (Sunitinib Placebo + Sorafenib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,adverse drug events
D000740,0.32,NCT00326898-1,Arm A (Sunitinib + Sorafenib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,anemia
D000740,0.16,NCT00326898-2,Arm B (Sorafenib + Sunitinib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,anemia
D057049,0.16,NCT00326898-1,Arm A (Sunitinib + Sorafenib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,thrombotic microangiopathy
D064147,0.32,NCT00326898-1,Arm A (Sunitinib + Sorafenib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,febrile neutropenia
D006327,0.16,NCT00326898-3,Arm C (Sunitinib Placebo + Sorafenib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,heart block
D001281,0.16,NCT00326898-1,Arm A (Sunitinib + Sorafenib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,atrial fibrillation
D001281,0.32,NCT00326898-3,Arm C (Sunitinib Placebo + Sorafenib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,atrial fibrillation
D001282,0.32,NCT00326898-3,Arm C (Sunitinib Placebo + Sorafenib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,atrial flutter
10040741,0.16,NCT00326898-1,Arm A (Sunitinib + Sorafenib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,sinus bradycardia
D013617,0.16,NCT00326898-1,Arm A (Sunitinib + Sorafenib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,supraventricular tachycardia
UNKNOWN-check-for-typo,0.16,NCT00326898-1,Arm A (Sunitinib + Sorafenib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,D00
D007511,0.16,NCT00326898-1,Arm A (Sunitinib + Sorafenib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,ischemia
D007511,0.48,NCT00326898-2,Arm B (Sorafenib + Sunitinib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,ischemia
D007511,0.64,NCT00326898-3,Arm C (Sunitinib Placebo + Sorafenib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,ischemia
10069501,0.64,NCT00326898-1,Arm A (Sunitinib + Sorafenib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,left ventricular systolic dysfunction
10069501,0.64,NCT00326898-2,Arm B (Sorafenib + Sunitinib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,left ventricular systolic dysfunction
10069501,0.32,NCT00326898-3,Arm C (Sunitinib Placebo + Sorafenib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,left ventricular systolic dysfunction
D011660,0.16,NCT00326898-2,Arm B (Sorafenib + Sunitinib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,cor pulmonale
10007541,0.16,NCT00326898-2,Arm B (Sorafenib + Sunitinib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,cardiac disorders - other specify
10008481,0.32,NCT00326898-1,Arm A (Sunitinib + Sorafenib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,chest pain - cardiac
10008481,0.48,NCT00326898-2,Arm B (Sorafenib + Sunitinib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,chest pain - cardiac
D000079687,0.16,NCT00326898-1,Arm A (Sunitinib + Sorafenib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,biomonitoring
D000309,0.16,NCT00326898-2,Arm B (Sorafenib + Sunitinib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,adrenal insufficiency
UNKNOWN-check-for-typo,0.32,NCT00326898-1,Arm A (Sunitinib + Sorafenib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,D00
D002386,0.16,NCT00326898-3,Arm C (Sunitinib Placebo + Sorafenib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,cataract
D004172,0.16,NCT00326898-3,Arm C (Sunitinib Placebo + Sorafenib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,double vision
D012163,0.16,NCT00326898-1,Arm A (Sunitinib + Sorafenib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,retinal detachment
D061351,0.16,NCT00326898-2,Arm B (Sorafenib + Sunitinib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,binoculars
D003092,0.48,NCT00326898-2,Arm B (Sorafenib + Sunitinib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,colitis
D003248,0.16,NCT00326898-1,Arm A (Sunitinib + Sorafenib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,constipation
D000930,9.12,NCT00326898-1,Arm A (Sunitinib + Sorafenib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,antidiarrheals
D000930,8.76,NCT00326898-2,Arm B (Sorafenib + Sunitinib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,antidiarrheals
D000930,0.32,NCT00326898-3,Arm C (Sunitinib Placebo + Sorafenib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,antidiarrheals
10005265,0.16,NCT00326898-2,Arm B (Sorafenib + Sunitinib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,bloating
D004941,0.16,NCT00326898-2,Arm B (Sorafenib + Sunitinib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,esophagitis
D005756,0.16,NCT00326898-1,Arm A (Sunitinib + Sorafenib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,gastritis
D005756,0.16,NCT00326898-2,Arm B (Sorafenib + Sunitinib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,gastritis
D004415,2.24,NCT00326898-1,Arm A (Sunitinib + Sorafenib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,dyspepsia
D004415,0.64,NCT00326898-2,Arm B (Sorafenib + Sunitinib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,dyspepsia
D004415,0.16,NCT00326898-3,Arm C (Sunitinib Placebo + Sorafenib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,dyspepsia
D045823,0.16,NCT00326898-3,Arm C (Sunitinib Placebo + Sorafenib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,ileus
D009090,0.32,NCT00326898-1,Arm A (Sunitinib + Sorafenib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,mucorales
D009090,0.48,NCT00326898-1,Arm A (Sunitinib + Sorafenib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,mucorales
D009090,0.16,NCT00326898-2,Arm B (Sorafenib + Sunitinib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,mucorales
D009325,3.52,NCT00326898-1,Arm A (Sunitinib + Sorafenib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,nausea
D009325,0.8,NCT00326898-2,Arm B (Sorafenib + Sunitinib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,nausea
10010001,0.16,NCT00326898-2,Arm B (Sorafenib + Sunitinib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,colonic perforation
D014839,1.76,NCT00326898-1,Arm A (Sunitinib + Sorafenib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,vomiting
D014839,0.48,NCT00326898-2,Arm B (Sorafenib + Sunitinib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,vomiting
D014839,0.16,NCT00326898-3,Arm C (Sunitinib Placebo + Sorafenib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,vomiting
10009998,0.32,NCT00326898-1,Arm A (Sunitinib + Sorafenib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,colonic hemorrhage
10051746,0.16,NCT00326898-2,Arm B (Sorafenib + Sunitinib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,lower gastrointestinal hemorrhage
D006470,0.16,NCT00326898-1,Arm A (Sunitinib + Sorafenib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,hemorrhage
D010195,0.48,NCT00326898-1,Arm A (Sunitinib + Sorafenib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,pancreatitis
D010195,0.16,NCT00326898-2,Arm B (Sorafenib + Sunitinib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,pancreatitis
D000005,0.64,NCT00326898-1,Arm A (Sunitinib + Sorafenib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,abdomen
D000005,1.27,NCT00326898-2,Arm B (Sorafenib + Sunitinib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,abdomen
D000005,0.32,NCT00326898-3,Arm C (Sunitinib Placebo + Sorafenib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,abdomen
D000080867,0.16,NCT00326898-1,Arm A (Sunitinib + Sorafenib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,gingipains
D009055,0.16,NCT00326898-1,Arm A (Sunitinib + Sorafenib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,oral cavity
D009055,0.16,NCT00326898-2,Arm B (Sorafenib + Sunitinib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,oral cavity
10042112,0.16,NCT00326898-2,Arm B (Sorafenib + Sunitinib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,stomach pain
D005221,17.28,NCT00326898-1,Arm A (Sunitinib + Sorafenib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,fatigue
D005221,6.53,NCT00326898-2,Arm B (Sorafenib + Sunitinib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,fatigue
D005221,2.4,NCT00326898-3,Arm C (Sunitinib Placebo + Sorafenib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,fatigue
D005334,0.16,NCT00326898-1,Arm A (Sunitinib + Sorafenib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,fever
D005334,0.32,NCT00326898-2,Arm B (Sorafenib + Sunitinib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,fever
10054482,0.48,NCT00326898-1,Arm A (Sunitinib + Sorafenib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,neck edema
10054482,0.16,NCT00326898-2,Arm B (Sorafenib + Sunitinib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,neck edema
10050068,0.32,NCT00326898-1,Arm A (Sunitinib + Sorafenib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,edema limbs
D002637,0.64,NCT00326898-1,Arm A (Sunitinib + Sorafenib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,chest pain
D002637,0.64,NCT00326898-2,Arm B (Sorafenib + Sunitinib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,chest pain
D000080867,0.16,NCT00326898-2,Arm B (Sorafenib + Sunitinib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,gingipains
D003057,0.48,NCT00326898-1,Arm A (Sunitinib + Sorafenib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,progeria-like syndrome
D002764,0.16,NCT00326898-1,Arm A (Sunitinib + Sorafenib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,cholecystitis
D008107,0.16,NCT00326898-1,Arm A (Sunitinib + Sorafenib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,liver dysfunction
D029626,0.16,NCT00326898-1,Arm A (Sunitinib + Sorafenib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,hepatica
D006967,0.16,NCT00326898-1,Arm A (Sunitinib + Sorafenib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,allergic reaction
D000069544,0.16,NCT00326898-1,Arm A (Sunitinib + Sorafenib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,encephalitis infection
D000069544,0.16,NCT00326898-3,Arm C (Sunitinib Placebo + Sorafenib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,encephalitis infection
D000069544,0.32,NCT00326898-2,Arm B (Sorafenib + Sunitinib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,encephalitis infection
10023424,0.16,NCT00326898-1,Arm A (Sunitinib + Sorafenib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,kidney infection
10023424,0.16,NCT00326898-2,Arm B (Sorafenib + Sunitinib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,kidney infection
10061229,0.32,NCT00326898-1,Arm A (Sunitinib + Sorafenib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,lung infection
10061229,0.48,NCT00326898-2,Arm B (Sorafenib + Sunitinib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,lung infection
10061229,0.32,NCT00326898-3,Arm C (Sunitinib Placebo + Sorafenib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,lung infection
D000069544,0.16,NCT00326898-3,Arm C (Sunitinib Placebo + Sorafenib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,encephalitis infection
10065764,0.16,NCT00326898-2,Arm B (Sorafenib + Sunitinib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,mucosal infection
D000069544,0.16,NCT00326898-2,Arm B (Sorafenib + Sunitinib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,encephalitis infection
10065765,0.16,NCT00326898-1,Arm A (Sunitinib + Sorafenib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,cranial nerve infection
10040872,0.16,NCT00326898-2,Arm B (Sorafenib + Sunitinib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,skin infection
D014552,0.16,NCT00326898-1,Arm A (Sunitinib + Sorafenib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,urinary tract infections
D014552,0.16,NCT00326898-3,Arm C (Sunitinib Placebo + Sorafenib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,urinary tract infections
10046914,0.16,NCT00326898-1,Arm A (Sunitinib + Sorafenib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,vaginal infection
D014946,0.16,NCT00326898-2,Arm B (Sorafenib + Sunitinib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,wound infection
10040872,0.32,NCT00326898-2,Arm B (Sorafenib + Sunitinib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,skin infection
D014552,0.16,NCT00326898-2,Arm B (Sorafenib + Sunitinib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,urinary tract infections
D000069544,0.16,NCT00326898-1,Arm A (Sunitinib + Sorafenib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,encephalitis infection
10021881,0.16,NCT00326898-1,Arm A (Sunitinib + Sorafenib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,infections and infestations - other specify
10021881,0.16,NCT00326898-2,Arm B (Sorafenib + Sunitinib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,infections and infestations - other specify
D000073296,0.16,NCT00326898-2,Arm B (Sorafenib + Sunitinib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,noninfectious diseases
D004617,0.16,NCT00326898-2,Arm B (Sorafenib + Sunitinib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,embolism
D007962,0.48,NCT00326898-1,Arm A (Sunitinib + Sorafenib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,leukocytes
D009504,1.12,NCT00326898-1,Arm A (Sunitinib + Sorafenib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,neutrophils
D009504,0.32,NCT00326898-2,Arm B (Sorafenib + Sunitinib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,neutrophils
D001792,2.08,NCT00326898-1,Arm A (Sunitinib + Sorafenib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,platelets
D001792,0.32,NCT00326898-2,Arm B (Sorafenib + Sunitinib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,platelets
D001792,0.16,NCT00326898-3,Arm C (Sunitinib Placebo + Sorafenib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,platelets
D015430,0.32,NCT00326898-3,Arm C (Sunitinib Placebo + Sorafenib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,weight gain
10001551,0.64,NCT00326898-1,Arm A (Sunitinib + Sorafenib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,alanine aminotransferase increased
10001551,0.64,NCT00326898-2,Arm B (Sorafenib + Sunitinib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,alanine aminotransferase increased
10040139,0.16,NCT00326898-2,Arm B (Sorafenib + Sunitinib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,serum amylase increased
10003481,0.96,NCT00326898-1,Arm A (Sunitinib + Sorafenib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,aspartate aminotransferase increased
10003481,0.64,NCT00326898-2,Arm B (Sorafenib + Sunitinib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,aspartate aminotransferase increased
10005364,0.16,NCT00326898-1,Arm A (Sunitinib + Sorafenib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,blood bilirubin increased
10005364,0.16,NCT00326898-2,Arm B (Sorafenib + Sunitinib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,blood bilirubin increased
10005364,0.16,NCT00326898-3,Arm C (Sunitinib Placebo + Sorafenib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,blood bilirubin increased
D006937,0.16,NCT00326898-1,Arm A (Sunitinib + Sorafenib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,hypercholesterolemia
10011268,0.16,NCT00326898-1,Arm A (Sunitinib + Sorafenib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,cpk increased
10011268,0.16,NCT00326898-2,Arm B (Sorafenib + Sunitinib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,cpk increased
10011368,0.16,NCT00326898-1,Arm A (Sunitinib + Sorafenib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,creatinine increased
10011368,0.48,NCT00326898-2,Arm B (Sorafenib + Sunitinib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,creatinine increased
10024574,0.64,NCT00326898-1,Arm A (Sunitinib + Sorafenib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,lipase increased
10024574,0.48,NCT00326898-2,Arm B (Sorafenib + Sunitinib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,lipase increased
10024574,0.16,NCT00326898-3,Arm C (Sunitinib Placebo + Sorafenib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,lipase increased
D000855,1.76,NCT00326898-1,Arm A (Sunitinib + Sorafenib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,anorexia
D000855,0.8,NCT00326898-2,Arm B (Sorafenib + Sunitinib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,anorexia
D003681,1.6,NCT00326898-1,Arm A (Sunitinib + Sorafenib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,dehydration
D003681,0.48,NCT00326898-2,Arm B (Sorafenib + Sunitinib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,dehydration
D034141,0.16,NCT00326898-1,Arm A (Sunitinib + Sorafenib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,hypoalbuminemia
D006996,0.16,NCT00326898-1,Arm A (Sunitinib + Sorafenib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,hypocalcemia
D006996,0.16,NCT00326898-2,Arm B (Sorafenib + Sunitinib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,hypocalcemia
D006943,0.16,NCT00326898-2,Arm B (Sorafenib + Sunitinib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,hyperglycemia
D006943,0.16,NCT00326898-3,Arm C (Sunitinib Placebo + Sorafenib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,hyperglycemia
D017674,0.16,NCT00326898-1,Arm A (Sunitinib + Sorafenib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,hypophosphatemia
D017674,0.16,NCT00326898-2,Arm B (Sorafenib + Sunitinib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,hypophosphatemia
D006947,0.48,NCT00326898-1,Arm A (Sunitinib + Sorafenib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,hyperkalemia
D006947,0.16,NCT00326898-2,Arm B (Sorafenib + Sunitinib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,hyperkalemia
D007008,0.32,NCT00326898-1,Arm A (Sunitinib + Sorafenib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,hypokalemia
D007008,0.16,NCT00326898-2,Arm B (Sorafenib + Sunitinib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,hypokalemia
D006955,0.16,NCT00326898-1,Arm A (Sunitinib + Sorafenib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,hypernatremia
D007010,0.16,NCT00326898-1,Arm A (Sunitinib + Sorafenib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,hyponatremia
D007010,0.8,NCT00326898-2,Arm B (Sorafenib + Sunitinib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,hyponatremia
D007010,0.64,NCT00326898-3,Arm C (Sunitinib Placebo + Sorafenib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,hyponatremia
D015228,0.32,NCT00326898-1,Arm A (Sunitinib + Sorafenib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,hypertriglyceridemia
D033461,0.16,NCT00326898-2,Arm B (Sorafenib + Sunitinib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,hyperuricemia
D033461,0.48,NCT00326898-3,Arm C (Sunitinib Placebo + Sorafenib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,hyperuricemia
10065895,0.16,NCT00326898-1,Arm A (Sunitinib + Sorafenib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,muscle weakness upper limb
10065780,0.16,NCT00326898-2,Arm B (Sorafenib + Sunitinib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,muscle weakness left-sided
10065794,0.16,NCT00326898-3,Arm C (Sunitinib Placebo + Sorafenib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,muscle weakness right-sided
10062572,0.16,NCT00326898-1,Arm A (Sunitinib + Sorafenib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,generalized muscle weakness
10062572,0.16,NCT00326898-2,Arm B (Sorafenib + Sunitinib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,generalized muscle weakness
10062572,0.16,NCT00326898-3,Arm C (Sunitinib Placebo + Sorafenib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,generalized muscle weakness
D009220,0.16,NCT00326898-1,Arm A (Sunitinib + Sorafenib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,myositis
D012509,0.32,NCT00326898-2,Arm B (Sorafenib + Sunitinib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,sarcoma soft tissue
D001416,0.16,NCT00326898-1,Arm A (Sunitinib + Sorafenib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,back pain
D001416,0.48,NCT00326898-2,Arm B (Sorafenib + Sunitinib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,back pain
10006002,0.32,NCT00326898-1,Arm A (Sunitinib + Sorafenib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,bone pain
10006002,0.16,NCT00326898-2,Arm B (Sorafenib + Sunitinib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,bone pain
D010591,0.64,NCT00326898-1,Arm A (Sunitinib + Sorafenib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,phantom limb pain
D010591,0.48,NCT00326898-2,Arm B (Sorafenib + Sunitinib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,phantom limb pain
D018771,1.28,NCT00326898-1,Arm A (Sunitinib + Sorafenib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,joint pain
D018771,1.27,NCT00326898-2,Arm B (Sorafenib + Sunitinib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,joint pain
D018771,0.48,NCT00326898-3,Arm C (Sunitinib Placebo + Sorafenib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,joint pain
D063806,0.32,NCT00326898-1,Arm A (Sunitinib + Sorafenib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,muscle pain
D063806,1.27,NCT00326898-2,Arm B (Sorafenib + Sunitinib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,muscle pain
D063806,0.16,NCT00326898-3,Arm C (Sunitinib Placebo + Sorafenib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,muscle pain
10049737,0.16,NCT00326898-2,Arm B (Sorafenib + Sunitinib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,treatment related secondary malignancy
10049737,0.16,NCT00326898-3,Arm C (Sunitinib Placebo + Sorafenib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,treatment related secondary malignancy
D013575,0.16,NCT00326898-1,Arm A (Sunitinib + Sorafenib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,syncopal episode
D001259,0.16,NCT00326898-3,Arm C (Sunitinib Placebo + Sorafenib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,ataxia
10023030,0.64,NCT00326898-1,Arm A (Sunitinib + Sorafenib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,ischemia cerebrovascular
10023030,0.16,NCT00326898-3,Arm C (Sunitinib Placebo + Sorafenib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,ischemia cerebrovascular
10009845,0.16,NCT00326898-2,Arm B (Sorafenib + Sunitinib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,cognitive disturbance
D004244,0.64,NCT00326898-1,Arm A (Sunitinib + Sorafenib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,dizziness
D004244,0.32,NCT00326898-2,Arm B (Sorafenib + Sunitinib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,dizziness
D004244,0.32,NCT00326898-3,Arm C (Sunitinib Placebo + Sorafenib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,dizziness
10027175,0.16,NCT00326898-1,Arm A (Sunitinib + Sorafenib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,memory impairment
10027175,0.16,NCT00326898-3,Arm C (Sunitinib Placebo + Sorafenib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,memory impairment
D002607,0.48,NCT00326898-1,Arm A (Sunitinib + Sorafenib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,hereditary type i motor and sensory neuropathy
D002607,0.16,NCT00326898-2,Arm B (Sorafenib + Sunitinib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,hereditary type i motor and sensory neuropathy
D002607,0.48,NCT00326898-1,Arm A (Sunitinib + Sorafenib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,hereditary type i motor and sensory neuropathy
D002607,1.91,NCT00326898-2,Arm B (Sorafenib + Sunitinib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,hereditary type i motor and sensory neuropathy
D002607,0.48,NCT00326898-3,Arm C (Sunitinib Placebo + Sorafenib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,hereditary type i motor and sensory neuropathy
D013575,0.64,NCT00326898-1,Arm A (Sunitinib + Sorafenib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,syncope
D013575,0.32,NCT00326898-2,Arm B (Sorafenib + Sunitinib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,syncope
D003027,0.96,NCT00326898-1,Arm A (Sunitinib + Sorafenib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,cluster headache
D003027,0.64,NCT00326898-2,Arm B (Sorafenib + Sunitinib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,cluster headache
D007319,0.64,NCT00326898-2,Arm B (Sorafenib + Sunitinib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,insomnia
D003221,0.32,NCT00326898-1,Arm A (Sunitinib + Sorafenib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,confusion
D003221,0.16,NCT00326898-3,Arm C (Sunitinib Placebo + Sorafenib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,confusion
D001007,0.16,NCT00326898-2,Arm B (Sorafenib + Sunitinib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,anxiety
D003863,0.16,NCT00326898-1,Arm A (Sunitinib + Sorafenib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,depression
D003863,0.32,NCT00326898-2,Arm B (Sorafenib + Sunitinib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,depression
D003863,0.32,NCT00326898-3,Arm C (Sunitinib Placebo + Sorafenib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,depression
D006470,0.16,NCT00326898-1,Arm A (Sunitinib + Sorafenib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,hemorrhage
D011507,0.32,NCT00326898-1,Arm A (Sunitinib + Sorafenib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,proteinuria
D011507,0.32,NCT00326898-2,Arm B (Sorafenib + Sunitinib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,proteinuria
D051437,0.96,NCT00326898-1,Arm A (Sunitinib + Sorafenib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,renal failure
D051437,0.64,NCT00326898-2,Arm B (Sorafenib + Sunitinib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,renal failure
D000071477,0.16,NCT00326898-2,Arm B (Sorafenib + Sunitinib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,gubernaculum
D020018,0.16,NCT00326898-2,Arm B (Sorafenib + Sunitinib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,psychosexual dysfunctions
D006976,0.16,NCT00326898-3,Arm C (Sunitinib Placebo + Sorafenib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,pulmonary hypertension
D000111,3.84,NCT00326898-1,Arm A (Sunitinib + Sorafenib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,solmucol
D000111,2.23,NCT00326898-2,Arm B (Sorafenib + Sunitinib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,solmucol
D000068884,0.48,NCT00326898-1,Arm A (Sunitinib + Sorafenib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,immunosenescence
D004417,0.64,NCT00326898-1,Arm A (Sunitinib + Sorafenib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,dyspnea
D004417,0.64,NCT00326898-2,Arm B (Sorafenib + Sunitinib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,dyspnea
D004417,0.32,NCT00326898-3,Arm C (Sunitinib Placebo + Sorafenib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,dyspnea
D016066,0.16,NCT00326898-1,Arm A (Sunitinib + Sorafenib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,pleural effusion malignant
D016066,0.16,NCT00326898-2,Arm B (Sorafenib + Sunitinib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,pleural effusion malignant
D004401,0.16,NCT00326898-2,Arm B (Sorafenib + Sunitinib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,dysarthria
10013786,0.16,NCT00326898-2,Arm B (Sorafenib + Sunitinib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,dry skin
10028689,0.16,NCT00326898-1,Arm A (Sunitinib + Sorafenib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,nail changes
D011537,0.16,NCT00326898-1,Arm A (Sunitinib + Sorafenib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,pruritus
D011537,1.75,NCT00326898-2,Arm B (Sorafenib + Sunitinib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,pruritus
D011537,0.16,NCT00326898-3,Arm C (Sunitinib Placebo + Sorafenib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,pruritus
D005076,2.4,NCT00326898-1,Arm A (Sunitinib + Sorafenib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,rash
D005076,14.81,NCT00326898-2,Arm B (Sorafenib + Sunitinib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,rash
D005076,0.48,NCT00326898-3,Arm C (Sunitinib Placebo + Sorafenib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,rash
10037847,0.32,NCT00326898-2,Arm B (Sorafenib + Sunitinib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,rash acneiform
D004892,0.16,NCT00326898-2,Arm B (Sorafenib + Sunitinib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,erythema multiforme
D060831,15.04,NCT00326898-1,Arm A (Sunitinib + Sorafenib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,hand-foot syndrome
D060831,33.12,NCT00326898-2,Arm B (Sorafenib + Sunitinib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,hand-foot syndrome
D060831,1.12,NCT00326898-3,Arm C (Sunitinib Placebo + Sorafenib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,hand-foot syndrome
D014581,0.16,NCT00326898-2,Arm B (Sorafenib + Sunitinib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,urticaria
10049120,0.32,NCT00326898-2,Arm B (Sorafenib + Sunitinib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,scalp pain
10033474,0.16,NCT00326898-2,Arm B (Sorafenib + Sunitinib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,pain of skin
D006973,16.64,NCT00326898-1,Arm A (Sunitinib + Sorafenib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,hypertension
D006973,15.29,NCT00326898-2,Arm B (Sorafenib + Sunitinib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,hypertension
D006973,2.4,NCT00326898-3,Arm C (Sunitinib Placebo + Sorafenib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,hypertension
D007022,0.16,NCT00326898-1,Arm A (Sunitinib + Sorafenib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,hypotension
D016769,0.48,NCT00326898-1,Arm A (Sunitinib + Sorafenib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,embolism and thrombosis
D016769,0.8,NCT00326898-2,Arm B (Sorafenib + Sunitinib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,embolism and thrombosis
D016769,0.16,NCT00326898-3,Arm C (Sunitinib Placebo + Sorafenib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,embolism and thrombosis
10047065,0.16,NCT00326898-2,Arm B (Sorafenib + Sunitinib Placebo),NCT00326898,Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery,vascular disorders - other specify
D064420,8.33,NCT00329641-1,Intervention,NCT00329641,Sorafenib  Carboplatin  and Paclitaxel in Treating Patients With Stage IV Melanoma of the Eye,adverse drug events
D006098,4.17,NCT00329641-1,Intervention,NCT00329641,Sorafenib  Carboplatin  and Paclitaxel in Treating Patients With Stage IV Melanoma of the Eye,granulocytes
D005076,4.17,NCT00329641-1,Intervention,NCT00329641,Sorafenib  Carboplatin  and Paclitaxel in Treating Patients With Stage IV Melanoma of the Eye,rash
D064420,73.33,NCT00330421-1,Group II (Metastatic or Inoperable Sarcomas),NCT00330421,Sorafenib in Treating Patients With Soft Tissue Sarcomas (Extremity Sarcoma Closed to Entry as of 5/30/07),adverse drug events
D006454,53.33,NCT00330421-1,Group II (Metastatic or Inoperable Sarcomas),NCT00330421,Sorafenib in Treating Patients With Soft Tissue Sarcomas (Extremity Sarcoma Closed to Entry as of 5/30/07),hemoglobin
D006401,40.0,NCT00330421-1,Group II (Metastatic or Inoperable Sarcomas),NCT00330421,Sorafenib in Treating Patients With Soft Tissue Sarcomas (Extremity Sarcoma Closed to Entry as of 5/30/07),hematologic agents
D003967,40.0,NCT00330421-1,Group II (Metastatic or Inoperable Sarcomas),NCT00330421,Sorafenib in Treating Patients With Soft Tissue Sarcomas (Extremity Sarcoma Closed to Entry as of 5/30/07),diarrhea
D015746,33.33,NCT00330421-1,Group II (Metastatic or Inoperable Sarcomas),NCT00330421,Sorafenib in Treating Patients With Soft Tissue Sarcomas (Extremity Sarcoma Closed to Entry as of 5/30/07),abdominal pain
D005221,73.33,NCT00330421-1,Group II (Metastatic or Inoperable Sarcomas),NCT00330421,Sorafenib in Treating Patients With Soft Tissue Sarcomas (Extremity Sarcoma Closed to Entry as of 5/30/07),fatigue
D000855,33.33,NCT00330421-1,Group II (Metastatic or Inoperable Sarcomas),NCT00330421,Sorafenib in Treating Patients With Soft Tissue Sarcomas (Extremity Sarcoma Closed to Entry as of 5/30/07),anorexia
D000469,46.67,NCT00330421-1,Group II (Metastatic or Inoperable Sarcomas),NCT00330421,Sorafenib in Treating Patients With Soft Tissue Sarcomas (Extremity Sarcoma Closed to Entry as of 5/30/07),alkaline phosphatase
D000009,46.67,NCT00330421-1,Group II (Metastatic or Inoperable Sarcomas),NCT00330421,Sorafenib in Treating Patients With Soft Tissue Sarcomas (Extremity Sarcoma Closed to Entry as of 5/30/07),cremaster muscle
D009026,93.75,NCT00335764-1,Group 1 Phase I Sorafenib and Erlotinib,NCT00335764,Sorafenib Combined With Erlotinib  Tipifarnib  or Temsirolimus in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma,mortality
D009026,100.0,NCT00335764-2,Group 2 Phase I Sorafenib and Temsirolimus,NCT00335764,Sorafenib Combined With Erlotinib  Tipifarnib  or Temsirolimus in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma,mortality
D009026,100.0,NCT00335764-3,Group 3 Phase I Sorafenib and Tipifarnib,NCT00335764,Sorafenib Combined With Erlotinib  Tipifarnib  or Temsirolimus in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma,mortality
D009026,100.0,NCT00335764-4,Group 1 Phase II Sorafenib and Erlotinib,NCT00335764,Sorafenib Combined With Erlotinib  Tipifarnib  or Temsirolimus in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma,mortality
D009026,100.0,NCT00335764-5,Group 2 Phase II Sorafenib and Temsirolimus,NCT00335764,Sorafenib Combined With Erlotinib  Tipifarnib  or Temsirolimus in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma,mortality
D064420,16.67,NCT00335764-3,Group 3 Phase I Sorafenib and Tipifarnib,NCT00335764,Sorafenib Combined With Erlotinib  Tipifarnib  or Temsirolimus in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma,adverse drug events
D064420,5.26,NCT00335764-4,Group 1 Phase II Sorafenib and Erlotinib,NCT00335764,Sorafenib Combined With Erlotinib  Tipifarnib  or Temsirolimus in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma,adverse drug events
D064420,11.11,NCT00335764-5,Group 2 Phase II Sorafenib and Temsirolimus,NCT00335764,Sorafenib Combined With Erlotinib  Tipifarnib  or Temsirolimus in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma,adverse drug events
D015746,4.17,NCT00335764-3,Group 3 Phase I Sorafenib and Tipifarnib,NCT00335764,Sorafenib Combined With Erlotinib  Tipifarnib  or Temsirolimus in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma,abdominal pain
D003967,5.26,NCT00335764-4,Group 1 Phase II Sorafenib and Erlotinib,NCT00335764,Sorafenib Combined With Erlotinib  Tipifarnib  or Temsirolimus in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma,diarrhea
D003967,5.56,NCT00335764-5,Group 2 Phase II Sorafenib and Temsirolimus,NCT00335764,Sorafenib Combined With Erlotinib  Tipifarnib  or Temsirolimus in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma,diarrhea
D000069544,4.17,NCT00335764-3,Group 3 Phase I Sorafenib and Tipifarnib,NCT00335764,Sorafenib Combined With Erlotinib  Tipifarnib  or Temsirolimus in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma,encephalitis infection
10024574,4.17,NCT00335764-3,Group 3 Phase I Sorafenib and Tipifarnib,NCT00335764,Sorafenib Combined With Erlotinib  Tipifarnib  or Temsirolimus in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma,lipase increased
10040139,4.17,NCT00335764-3,Group 3 Phase I Sorafenib and Tipifarnib,NCT00335764,Sorafenib Combined With Erlotinib  Tipifarnib  or Temsirolimus in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma,serum amylase increased
D015228,5.56,NCT00335764-5,Group 2 Phase II Sorafenib and Temsirolimus,NCT00335764,Sorafenib Combined With Erlotinib  Tipifarnib  or Temsirolimus in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma,hypertriglyceridemia
D001927,4.17,NCT00335764-3,Group 3 Phase I Sorafenib and Tipifarnib,NCT00335764,Sorafenib Combined With Erlotinib  Tipifarnib  or Temsirolimus in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma,encephalopathy
D006261,4.17,NCT00335764-3,Group 3 Phase I Sorafenib and Tipifarnib,NCT00335764,Sorafenib Combined With Erlotinib  Tipifarnib  or Temsirolimus in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma,headache
D012640,5.56,NCT00335764-5,Group 2 Phase II Sorafenib and Temsirolimus,NCT00335764,Sorafenib Combined With Erlotinib  Tipifarnib  or Temsirolimus in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma,seizure
D003221,4.17,NCT00335764-3,Group 3 Phase I Sorafenib and Tipifarnib,NCT00335764,Sorafenib Combined With Erlotinib  Tipifarnib  or Temsirolimus in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma,confusion
D003221,5.26,NCT00335764-4,Group 1 Phase II Sorafenib and Erlotinib,NCT00335764,Sorafenib Combined With Erlotinib  Tipifarnib  or Temsirolimus in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma,confusion
10037847,4.17,NCT00335764-3,Group 3 Phase I Sorafenib and Tipifarnib,NCT00335764,Sorafenib Combined With Erlotinib  Tipifarnib  or Temsirolimus in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma,rash acneiform
D006973,4.17,NCT00335764-3,Group 3 Phase I Sorafenib and Tipifarnib,NCT00335764,Sorafenib Combined With Erlotinib  Tipifarnib  or Temsirolimus in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma,hypertension
10043565,4.17,NCT00335764-3,Group 3 Phase I Sorafenib and Tipifarnib,NCT00335764,Sorafenib Combined With Erlotinib  Tipifarnib  or Temsirolimus in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma,thromboembolic event
D009026,4.76,NCT00390325-1,Arm A (Hereditary MTC) and Arm B (Sporadic MTC),NCT00390325,Sorafenib Tosylate in Treating Patients With Metastatic  Locally Advanced  or Recurrent Medullary Thyroid Cancer,mortality
D064420,23.81,NCT00390325-1,Arm A (Hereditary MTC) and Arm B (Sporadic MTC),NCT00390325,Sorafenib Tosylate in Treating Patients With Metastatic  Locally Advanced  or Recurrent Medullary Thyroid Cancer,adverse drug events
D006342,4.76,NCT00390325-1,Arm A (Hereditary MTC) and Arm B (Sporadic MTC),NCT00390325,Sorafenib Tosylate in Treating Patients With Metastatic  Locally Advanced  or Recurrent Medullary Thyroid Cancer,cardiac rupture post-infarction
10041103,4.76,NCT00390325-1,Arm A (Hereditary MTC) and Arm B (Sporadic MTC),NCT00390325,Sorafenib Tosylate in Treating Patients With Metastatic  Locally Advanced  or Recurrent Medullary Thyroid Cancer,small intestinal perforation
D007239,4.76,NCT00390325-1,Arm A (Hereditary MTC) and Arm B (Sporadic MTC),NCT00390325,Sorafenib Tosylate in Treating Patients With Metastatic  Locally Advanced  or Recurrent Medullary Thyroid Cancer,infection
D007008,4.76,NCT00390325-1,Arm A (Hereditary MTC) and Arm B (Sporadic MTC),NCT00390325,Sorafenib Tosylate in Treating Patients With Metastatic  Locally Advanced  or Recurrent Medullary Thyroid Cancer,hypokalemia
D051437,4.76,NCT00390325-1,Arm A (Hereditary MTC) and Arm B (Sporadic MTC),NCT00390325,Sorafenib Tosylate in Treating Patients With Metastatic  Locally Advanced  or Recurrent Medullary Thyroid Cancer,renal failure
D013927,4.76,NCT00390325-1,Arm A (Hereditary MTC) and Arm B (Sporadic MTC),NCT00390325,Sorafenib Tosylate in Treating Patients With Metastatic  Locally Advanced  or Recurrent Medullary Thyroid Cancer,thrombosis
D064420,27.91,NCT00390611-1,Paclitaxel/Carboplatin/Sorafenib,NCT00390611,Paclitaxel and Carboplatin With Or Without Sorafenib In The First-Line Treatment Of Patients With Ovarian Cancer,adverse drug events
D064420,23.81,NCT00390611-2,Paclitaxel/Carboplatin,NCT00390611,Paclitaxel and Carboplatin With Or Without Sorafenib In The First-Line Treatment Of Patients With Ovarian Cancer,adverse drug events
D000740,2.38,NCT00390611-2,Paclitaxel/Carboplatin,NCT00390611,Paclitaxel and Carboplatin With Or Without Sorafenib In The First-Line Treatment Of Patients With Ovarian Cancer,anemia
D064147,2.33,NCT00390611-1,Paclitaxel/Carboplatin/Sorafenib,NCT00390611,Paclitaxel and Carboplatin With Or Without Sorafenib In The First-Line Treatment Of Patients With Ovarian Cancer,febrile neutropenia
D001281,2.33,NCT00390611-1,Paclitaxel/Carboplatin/Sorafenib,NCT00390611,Paclitaxel and Carboplatin With Or Without Sorafenib In The First-Line Treatment Of Patients With Ovarian Cancer,atrial fibrillation
D015746,6.98,NCT00390611-1,Paclitaxel/Carboplatin/Sorafenib,NCT00390611,Paclitaxel and Carboplatin With Or Without Sorafenib In The First-Line Treatment Of Patients With Ovarian Cancer,abdominal pain
D015746,4.76,NCT00390611-2,Paclitaxel/Carboplatin,NCT00390611,Paclitaxel and Carboplatin With Or Without Sorafenib In The First-Line Treatment Of Patients With Ovarian Cancer,abdominal pain
D009325,2.33,NCT00390611-1,Paclitaxel/Carboplatin/Sorafenib,NCT00390611,Paclitaxel and Carboplatin With Or Without Sorafenib In The First-Line Treatment Of Patients With Ovarian Cancer,nausea
D009325,7.14,NCT00390611-2,Paclitaxel/Carboplatin,NCT00390611,Paclitaxel and Carboplatin With Or Without Sorafenib In The First-Line Treatment Of Patients With Ovarian Cancer,nausea
D014839,2.33,NCT00390611-1,Paclitaxel/Carboplatin/Sorafenib,NCT00390611,Paclitaxel and Carboplatin With Or Without Sorafenib In The First-Line Treatment Of Patients With Ovarian Cancer,vomiting
D014839,7.14,NCT00390611-2,Paclitaxel/Carboplatin,NCT00390611,Paclitaxel and Carboplatin With Or Without Sorafenib In The First-Line Treatment Of Patients With Ovarian Cancer,vomiting
D005767,2.33,NCT00390611-1,Paclitaxel/Carboplatin/Sorafenib,NCT00390611,Paclitaxel and Carboplatin With Or Without Sorafenib In The First-Line Treatment Of Patients With Ovarian Cancer,gastrointestinal disorders
D005767,2.38,NCT00390611-2,Paclitaxel/Carboplatin,NCT00390611,Paclitaxel and Carboplatin With Or Without Sorafenib In The First-Line Treatment Of Patients With Ovarian Cancer,gastrointestinal disorders
D003092,2.38,NCT00390611-2,Paclitaxel/Carboplatin,NCT00390611,Paclitaxel and Carboplatin With Or Without Sorafenib In The First-Line Treatment Of Patients With Ovarian Cancer,colitis
D003248,2.38,NCT00390611-2,Paclitaxel/Carboplatin,NCT00390611,Paclitaxel and Carboplatin With Or Without Sorafenib In The First-Line Treatment Of Patients With Ovarian Cancer,constipation
D003967,2.38,NCT00390611-2,Paclitaxel/Carboplatin,NCT00390611,Paclitaxel and Carboplatin With Or Without Sorafenib In The First-Line Treatment Of Patients With Ovarian Cancer,diarrhea
D005767,2.38,NCT00390611-2,Paclitaxel/Carboplatin,NCT00390611,Paclitaxel and Carboplatin With Or Without Sorafenib In The First-Line Treatment Of Patients With Ovarian Cancer,gastrointestinal disorders
10051746,2.33,NCT00390611-1,Paclitaxel/Carboplatin/Sorafenib,NCT00390611,Paclitaxel and Carboplatin With Or Without Sorafenib In The First-Line Treatment Of Patients With Ovarian Cancer,lower gastrointestinal hemorrhage
10055356,2.33,NCT00390611-1,Paclitaxel/Carboplatin/Sorafenib,NCT00390611,Paclitaxel and Carboplatin With Or Without Sorafenib In The First-Line Treatment Of Patients With Ovarian Cancer,upper gastrointestinal hemorrhage
10018065,2.33,NCT00390611-1,Paclitaxel/Carboplatin/Sorafenib,NCT00390611,Paclitaxel and Carboplatin With Or Without Sorafenib In The First-Line Treatment Of Patients With Ovarian Cancer,general disorders and administration site conditions - other specify
10018065,2.38,NCT00390611-2,Paclitaxel/Carboplatin,NCT00390611,Paclitaxel and Carboplatin With Or Without Sorafenib In The First-Line Treatment Of Patients With Ovarian Cancer,general disorders and administration site conditions - other specify
10051792,2.33,NCT00390611-1,Paclitaxel/Carboplatin/Sorafenib,NCT00390611,Paclitaxel and Carboplatin With Or Without Sorafenib In The First-Line Treatment Of Patients With Ovarian Cancer,infusion related reaction
D002764,2.33,NCT00390611-1,Paclitaxel/Carboplatin/Sorafenib,NCT00390611,Paclitaxel and Carboplatin With Or Without Sorafenib In The First-Line Treatment Of Patients With Ovarian Cancer,cholecystitis
D006967,9.3,NCT00390611-1,Paclitaxel/Carboplatin/Sorafenib,NCT00390611,Paclitaxel and Carboplatin With Or Without Sorafenib In The First-Line Treatment Of Patients With Ovarian Cancer,allergic reaction
D006967,2.38,NCT00390611-2,Paclitaxel/Carboplatin,NCT00390611,Paclitaxel and Carboplatin With Or Without Sorafenib In The First-Line Treatment Of Patients With Ovarian Cancer,allergic reaction
D010198,2.38,NCT00390611-2,Paclitaxel/Carboplatin,NCT00390611,Paclitaxel and Carboplatin With Or Without Sorafenib In The First-Line Treatment Of Patients With Ovarian Cancer,pancytopenia
D003681,7.14,NCT00390611-2,Paclitaxel/Carboplatin,NCT00390611,Paclitaxel and Carboplatin With Or Without Sorafenib In The First-Line Treatment Of Patients With Ovarian Cancer,dehydration
D007008,2.38,NCT00390611-2,Paclitaxel/Carboplatin,NCT00390611,Paclitaxel and Carboplatin With Or Without Sorafenib In The First-Line Treatment Of Patients With Ovarian Cancer,hypokalemia
D009748,2.38,NCT00390611-2,Paclitaxel/Carboplatin,NCT00390611,Paclitaxel and Carboplatin With Or Without Sorafenib In The First-Line Treatment Of Patients With Ovarian Cancer,nutrition disorders
D004417,2.33,NCT00390611-1,Paclitaxel/Carboplatin/Sorafenib,NCT00390611,Paclitaxel and Carboplatin With Or Without Sorafenib In The First-Line Treatment Of Patients With Ovarian Cancer,dyspnea
D010996,2.33,NCT00390611-1,Paclitaxel/Carboplatin/Sorafenib,NCT00390611,Paclitaxel and Carboplatin With Or Without Sorafenib In The First-Line Treatment Of Patients With Ovarian Cancer,pleural effusion
D005076,2.33,NCT00390611-1,Paclitaxel/Carboplatin/Sorafenib,NCT00390611,Paclitaxel and Carboplatin With Or Without Sorafenib In The First-Line Treatment Of Patients With Ovarian Cancer,rash
10043565,2.33,NCT00390611-1,Paclitaxel/Carboplatin/Sorafenib,NCT00390611,Paclitaxel and Carboplatin With Or Without Sorafenib In The First-Line Treatment Of Patients With Ovarian Cancer,thromboembolic event
10043565,2.38,NCT00390611-2,Paclitaxel/Carboplatin,NCT00390611,Paclitaxel and Carboplatin With Or Without Sorafenib In The First-Line Treatment Of Patients With Ovarian Cancer,thromboembolic event
D007022,2.38,NCT00390611-2,Paclitaxel/Carboplatin,NCT00390611,Paclitaxel and Carboplatin With Or Without Sorafenib In The First-Line Treatment Of Patients With Ovarian Cancer,hypotension
D009026,1.82,NCT00436215-1,BAY 43-9006 + Bevacizumab,NCT00436215,Sorafenib and Bevacizumab to Treat Ovarian  Fallopian and Peritoneal Cancer,mortality
D064420,45.45,NCT00436215-1,BAY 43-9006 + Bevacizumab,NCT00436215,Sorafenib and Bevacizumab to Treat Ovarian  Fallopian and Peritoneal Cancer,adverse drug events
D010490,1.82,NCT00436215-1,BAY 43-9006 + Bevacizumab,NCT00436215,Sorafenib and Bevacizumab to Treat Ovarian  Fallopian and Peritoneal Cancer,pericardial effusion
D015746,9.09,NCT00436215-1,BAY 43-9006 + Bevacizumab,NCT00436215,Sorafenib and Bevacizumab to Treat Ovarian  Fallopian and Peritoneal Cancer,abdominal pain
D003967,1.82,NCT00436215-1,BAY 43-9006 + Bevacizumab,NCT00436215,Sorafenib and Bevacizumab to Treat Ovarian  Fallopian and Peritoneal Cancer,diarrhea
10017947,1.82,NCT00436215-1,BAY 43-9006 + Bevacizumab,NCT00436215,Sorafenib and Bevacizumab to Treat Ovarian  Fallopian and Peritoneal Cancer,gastrointestinal disorders - other specify
D009325,3.64,NCT00436215-1,BAY 43-9006 + Bevacizumab,NCT00436215,Sorafenib and Bevacizumab to Treat Ovarian  Fallopian and Peritoneal Cancer,nausea
10029957,1.82,NCT00436215-1,BAY 43-9006 + Bevacizumab,NCT00436215,Sorafenib and Bevacizumab to Treat Ovarian  Fallopian and Peritoneal Cancer,obstruction gastric
10041101,12.73,NCT00436215-1,BAY 43-9006 + Bevacizumab,NCT00436215,Sorafenib and Bevacizumab to Treat Ovarian  Fallopian and Peritoneal Cancer,small intestinal obstruction
D014839,1.82,NCT00436215-1,BAY 43-9006 + Bevacizumab,NCT00436215,Sorafenib and Bevacizumab to Treat Ovarian  Fallopian and Peritoneal Cancer,vomiting
D005334,3.64,NCT00436215-1,BAY 43-9006 + Bevacizumab,NCT00436215,Sorafenib and Bevacizumab to Treat Ovarian  Fallopian and Peritoneal Cancer,fever
D002779,1.82,NCT00436215-1,BAY 43-9006 + Bevacizumab,NCT00436215,Sorafenib and Bevacizumab to Treat Ovarian  Fallopian and Peritoneal Cancer,bile duct obstruction
D006967,1.82,NCT00436215-1,BAY 43-9006 + Bevacizumab,NCT00436215,Sorafenib and Bevacizumab to Treat Ovarian  Fallopian and Peritoneal Cancer,allergic reaction
10007810,1.82,NCT00436215-1,BAY 43-9006 + Bevacizumab,NCT00436215,Sorafenib and Bevacizumab to Treat Ovarian  Fallopian and Peritoneal Cancer,catheter related infection
10065761,1.82,NCT00436215-1,BAY 43-9006 + Bevacizumab,NCT00436215,Sorafenib and Bevacizumab to Treat Ovarian  Fallopian and Peritoneal Cancer,cecal infection
D014946,1.82,NCT00436215-1,BAY 43-9006 + Bevacizumab,NCT00436215,Sorafenib and Bevacizumab to Treat Ovarian  Fallopian and Peritoneal Cancer,wound infection
10062169,1.82,NCT00436215-1,BAY 43-9006 + Bevacizumab,NCT00436215,Sorafenib and Bevacizumab to Treat Ovarian  Fallopian and Peritoneal Cancer,vascular access complication
D003681,1.82,NCT00436215-1,BAY 43-9006 + Bevacizumab,NCT00436215,Sorafenib and Bevacizumab to Treat Ovarian  Fallopian and Peritoneal Cancer,dehydration
D007010,1.82,NCT00436215-1,BAY 43-9006 + Bevacizumab,NCT00436215,Sorafenib and Bevacizumab to Treat Ovarian  Fallopian and Peritoneal Cancer,hyponatremia
D006261,1.82,NCT00436215-1,BAY 43-9006 + Bevacizumab,NCT00436215,Sorafenib and Bevacizumab to Treat Ovarian  Fallopian and Peritoneal Cancer,headache
10061574,1.82,NCT00436215-1,BAY 43-9006 + Bevacizumab,NCT00436215,Sorafenib and Bevacizumab to Treat Ovarian  Fallopian and Peritoneal Cancer,urinary tract obstruction
D010996,3.64,NCT00436215-1,BAY 43-9006 + Bevacizumab,NCT00436215,Sorafenib and Bevacizumab to Treat Ovarian  Fallopian and Peritoneal Cancer,pleural effusion
D011014,1.82,NCT00436215-1,BAY 43-9006 + Bevacizumab,NCT00436215,Sorafenib and Bevacizumab to Treat Ovarian  Fallopian and Peritoneal Cancer,pneumonitis
D006973,1.82,NCT00436215-1,BAY 43-9006 + Bevacizumab,NCT00436215,Sorafenib and Bevacizumab to Treat Ovarian  Fallopian and Peritoneal Cancer,hypertension
10043565,7.27,NCT00436215-1,BAY 43-9006 + Bevacizumab,NCT00436215,Sorafenib and Bevacizumab to Treat Ovarian  Fallopian and Peritoneal Cancer,thromboembolic event
10047065,1.82,NCT00436215-1,BAY 43-9006 + Bevacizumab,NCT00436215,Sorafenib and Bevacizumab to Treat Ovarian  Fallopian and Peritoneal Cancer,vascular disorders - other specify
D064420,27.66,NCT00454194-1,Arm I (Pemetrexed + Sorafenib),NCT00454194,Pemetrexed Disodium With or Without Sorafenib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer,adverse drug events
D064420,13.73,NCT00454194-2,Arm II (Pemetrexed),NCT00454194,Pemetrexed Disodium With or Without Sorafenib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer,adverse drug events
D064147,2.13,NCT00454194-1,Arm I (Pemetrexed + Sorafenib),NCT00454194,Pemetrexed Disodium With or Without Sorafenib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer,febrile neutropenia
D002263,2.13,NCT00454194-1,Arm I (Pemetrexed + Sorafenib),NCT00454194,Pemetrexed Disodium With or Without Sorafenib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer,carboxyhemoglobin
D002263,3.92,NCT00454194-2,Arm II (Pemetrexed),NCT00454194,Pemetrexed Disodium With or Without Sorafenib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer,carboxyhemoglobin
D015746,4.26,NCT00454194-1,Arm I (Pemetrexed + Sorafenib),NCT00454194,Pemetrexed Disodium With or Without Sorafenib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer,abdominal pain
10013781,2.13,NCT00454194-1,Arm I (Pemetrexed + Sorafenib),NCT00454194,Pemetrexed Disodium With or Without Sorafenib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer,dry mouth
10041103,2.13,NCT00454194-1,Arm I (Pemetrexed + Sorafenib),NCT00454194,Pemetrexed Disodium With or Without Sorafenib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer,small intestinal perforation
D014839,1.96,NCT00454194-2,Arm II (Pemetrexed),NCT00454194,Pemetrexed Disodium With or Without Sorafenib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer,vomiting
D005221,2.13,NCT00454194-1,Arm I (Pemetrexed + Sorafenib),NCT00454194,Pemetrexed Disodium With or Without Sorafenib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer,fatigue
D003645,2.13,NCT00454194-1,Arm I (Pemetrexed + Sorafenib),NCT00454194,Pemetrexed Disodium With or Without Sorafenib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer,sudden death
10003481,2.13,NCT00454194-1,Arm I (Pemetrexed + Sorafenib),NCT00454194,Pemetrexed Disodium With or Without Sorafenib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer,aspartate aminotransferase increased
10005364,1.96,NCT00454194-2,Arm II (Pemetrexed),NCT00454194,Pemetrexed Disodium With or Without Sorafenib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer,blood bilirubin increased
D007958,2.13,NCT00454194-1,Arm I (Pemetrexed + Sorafenib),NCT00454194,Pemetrexed Disodium With or Without Sorafenib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer,leukocyte count
D007958,1.96,NCT00454194-2,Arm II (Pemetrexed),NCT00454194,Pemetrexed Disodium With or Without Sorafenib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer,leukocyte count
10024574,1.96,NCT00454194-2,Arm II (Pemetrexed),NCT00454194,Pemetrexed Disodium With or Without Sorafenib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer,lipase increased
10029366,8.51,NCT00454194-1,Arm I (Pemetrexed + Sorafenib),NCT00454194,Pemetrexed Disodium With or Without Sorafenib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer,neutrophil count decreased
10029366,1.96,NCT00454194-2,Arm II (Pemetrexed),NCT00454194,Pemetrexed Disodium With or Without Sorafenib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer,neutrophil count decreased
10035528,6.38,NCT00454194-1,Arm I (Pemetrexed + Sorafenib),NCT00454194,Pemetrexed Disodium With or Without Sorafenib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer,platelet count decreased
10035528,3.92,NCT00454194-2,Arm II (Pemetrexed),NCT00454194,Pemetrexed Disodium With or Without Sorafenib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer,platelet count decreased
D015431,2.13,NCT00454194-1,Arm I (Pemetrexed + Sorafenib),NCT00454194,Pemetrexed Disodium With or Without Sorafenib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer,weight loss
D000855,2.13,NCT00454194-1,Arm I (Pemetrexed + Sorafenib),NCT00454194,Pemetrexed Disodium With or Without Sorafenib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer,anorexia
10008496,1.96,NCT00454194-2,Arm II (Pemetrexed),NCT00454194,Pemetrexed Disodium With or Without Sorafenib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer,chest wall pain
D006261,1.96,NCT00454194-2,Arm II (Pemetrexed),NCT00454194,Pemetrexed Disodium With or Without Sorafenib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer,headache
10023030,2.13,NCT00454194-1,Arm I (Pemetrexed + Sorafenib),NCT00454194,Pemetrexed Disodium With or Without Sorafenib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer,ischemia cerebrovascular
D006470,2.13,NCT00454194-1,Arm I (Pemetrexed + Sorafenib),NCT00454194,Pemetrexed Disodium With or Without Sorafenib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer,hemorrhage
D006470,1.96,NCT00454194-2,Arm II (Pemetrexed),NCT00454194,Pemetrexed Disodium With or Without Sorafenib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer,hemorrhage
D004417,3.92,NCT00454194-2,Arm II (Pemetrexed),NCT00454194,Pemetrexed Disodium With or Without Sorafenib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer,dyspnea
D013927,1.96,NCT00454194-2,Arm II (Pemetrexed),NCT00454194,Pemetrexed Disodium With or Without Sorafenib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer,thrombosis
D064420,41.77,NCT00474786-1,Temsirolimus,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,adverse drug events
D064420,34.52,NCT00474786-2,Sorafenib,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,adverse drug events
D000741,2.01,NCT00474786-1,Temsirolimus,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,aplastic anaemia
D000741,1.59,NCT00474786-2,Sorafenib,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,aplastic anaemia
D064147,0.4,NCT00474786-1,Temsirolimus,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,febrile neutropenia
D008231,0.4,NCT00474786-1,Temsirolimus,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,lymphopenia
D013921,0.4,NCT00474786-1,Temsirolimus,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,thrombocytopenia
D056988,0.4,NCT00474786-1,Temsirolimus,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,acute anterior wall myocardial infarction
D001281,1.19,NCT00474786-2,Sorafenib,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,atrial fibrillation
D001282,0.4,NCT00474786-2,Sorafenib,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,atrial flutter
D006323,0.4,NCT00474786-1,Temsirolimus,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,cardiac arrest
D002305,0.4,NCT00474786-1,Temsirolimus,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,cardiac tamponade
D000072599,0.4,NCT00474786-1,Temsirolimus,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,cardiorespiratory fitness
D000072599,0.4,NCT00474786-2,Sorafenib,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,cardiorespiratory fitness
D000028,0.8,NCT00474786-1,Temsirolimus,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,abortion failure
D009203,0.4,NCT00474786-1,Temsirolimus,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,myocardial infarction
D009203,1.59,NCT00474786-2,Sorafenib,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,myocardial infarction
D000071956,0.4,NCT00474786-2,Sorafenib,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,myocardial contusions
10033557,0.4,NCT00474786-2,Sorafenib,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,palpitations
D010490,0.4,NCT00474786-1,Temsirolimus,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,pericardial effusion
D000788,0.4,NCT00474786-1,Temsirolimus,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,prinzmetal angina
D006980,0.4,NCT00474786-2,Sorafenib,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,hyperthyroidism
D000081015,0.4,NCT00474786-2,Sorafenib,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,ototoxicity
D015356,0.4,NCT00474786-2,Sorafenib,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,retinal artery occlusion
10000060,0.4,NCT00474786-1,Temsirolimus,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,abdominal distension
10000060,0.4,NCT00474786-2,Sorafenib,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,abdominal distension
D015746,2.81,NCT00474786-1,Temsirolimus,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,abdominal pain
D015746,0.4,NCT00474786-2,Sorafenib,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,abdominal pain
D001201,1.2,NCT00474786-1,Temsirolimus,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,ascites
D001201,0.4,NCT00474786-2,Sorafenib,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,ascites
D003248,0.4,NCT00474786-1,Temsirolimus,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,constipation
D003248,0.4,NCT00474786-2,Sorafenib,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,constipation
UNKNOWN-check-for-typo,1.2,NCT00474786-1,Temsirolimus,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,D00
UNKNOWN-check-for-typo,0.4,NCT00474786-2,Sorafenib,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,D00
10013832,0.4,NCT00474786-1,Temsirolimus,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,duodenal perforation
D003680,0.4,NCT00474786-2,Sorafenib,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,dysphagia
D000069196,0.4,NCT00474786-2,Sorafenib,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,gastrointestinal microbiome
D000069196,0.8,NCT00474786-1,Temsirolimus,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,gastrointestinal microbiome
D003965,0.4,NCT00474786-1,Temsirolimus,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,diaphragmatic eventration
D006551,0.4,NCT00474786-2,Sorafenib,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,hiatus hernia
D007415,0.4,NCT00474786-1,Temsirolimus,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,intestinal obstruction
D007416,0.4,NCT00474786-1,Temsirolimus,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,intestinal perforation
D007420,0.4,NCT00474786-2,Sorafenib,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,intestine large
D009325,0.4,NCT00474786-1,Temsirolimus,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,nausea
10029957,0.4,NCT00474786-2,Sorafenib,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,obstruction gastric
D000071041,0.4,NCT00474786-1,Temsirolimus,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,oesophageal mucosa
D000071056,0.4,NCT00474786-1,Temsirolimus,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,anorectal malformations
D012469,0.4,NCT00474786-1,Temsirolimus,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,salivary glands
D013280,0.4,NCT00474786-1,Temsirolimus,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,stomatitis
D014839,2.41,NCT00474786-1,Temsirolimus,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,vomiting
D014839,1.59,NCT00474786-2,Sorafenib,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,vomiting
D001247,1.2,NCT00474786-1,Temsirolimus,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,asthenia
D001247,0.4,NCT00474786-2,Sorafenib,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,asthenia
D002637,0.4,NCT00474786-1,Temsirolimus,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,chest pain
D002637,1.19,NCT00474786-2,Sorafenib,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,chest pain
D005221,0.8,NCT00474786-1,Temsirolimus,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,fatigue
D005221,1.59,NCT00474786-2,Sorafenib,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,fatigue
D003695,3.21,NCT00474786-1,Temsirolimus,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,healthcare
D003695,3.57,NCT00474786-2,Sorafenib,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,healthcare
D009102,0.4,NCT00474786-2,Sorafenib,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,multiple organ failure
D000799,0.8,NCT00474786-1,Temsirolimus,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,angioedema
D010146,0.4,NCT00474786-1,Temsirolimus,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,pain
D010146,0.79,NCT00474786-2,Sorafenib,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,pain
D017567,0.4,NCT00474786-1,Temsirolimus,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,karnofsky performance status
D005334,2.81,NCT00474786-1,Temsirolimus,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,pyrexia
D005334,1.59,NCT00474786-2,Sorafenib,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,pyrexia
D003645,0.4,NCT00474786-1,Temsirolimus,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,sudden death
D003645,0.4,NCT00474786-2,Sorafenib,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,sudden death
D018746,0.4,NCT00474786-2,Sorafenib,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,systemic inflammatory response syndrome
D041881,0.4,NCT00474786-1,Temsirolimus,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,acute cholecystitis
D042882,0.4,NCT00474786-1,Temsirolimus,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,gallstones common bile duct
D002764,0.4,NCT00474786-1,Temsirolimus,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,cholecystitis
D002779,0.4,NCT00474786-1,Temsirolimus,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,cholestasis
10017636,0.4,NCT00474786-2,Sorafenib,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,gallbladder obstruction
D004066,0.4,NCT00474786-2,Sorafenib,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,hepatobiliary disease
D000707,0.4,NCT00474786-1,Temsirolimus,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,anaphylactic reaction
D004342,0.4,NCT00474786-2,Sorafenib,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,drug hypersensitivity
10056519,0.4,NCT00474786-1,Temsirolimus,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,abdominal infection
D000038,0.4,NCT00474786-2,Sorafenib,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,abscess
D000038,0.4,NCT00474786-2,Sorafenib,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,abscess
D001991,0.4,NCT00474786-1,Temsirolimus,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,bronchitis
D035441,0.4,NCT00474786-2,Sorafenib,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,chest wall
D008105,0.4,NCT00474786-2,Sorafenib,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,cholangitis chronic nonsuppurative destructive
10064687,0.8,NCT00474786-1,Temsirolimus,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,device related infection
UNKNOWN-check-for-typo,0.4,NCT00474786-2,Sorafenib,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,D00
D006509,0.4,NCT00474786-1,Temsirolimus,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,hepatitis b
D006562,0.4,NCT00474786-1,Temsirolimus,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,herpes zoster
D007239,0.4,NCT00474786-2,Sorafenib,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,infection
D010996,0.4,NCT00474786-2,Sorafenib,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,pleural effusion
D011014,0.4,NCT00474786-1,Temsirolimus,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,lobar pneumonia
D012141,0.8,NCT00474786-1,Temsirolimus,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,respiratory tract infections
10061229,0.4,NCT00474786-1,Temsirolimus,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,lung infection
D000038,0.4,NCT00474786-1,Temsirolimus,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,abscess
D010612,0.4,NCT00474786-1,Temsirolimus,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,pharyngitis
D011020,0.4,NCT00474786-1,Temsirolimus,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,pneumocystis jirovecii pneumonia
D011014,2.81,NCT00474786-1,Temsirolimus,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,pneumonia
D011014,2.78,NCT00474786-2,Sorafenib,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,pneumonia
D001996,0.4,NCT00474786-1,Temsirolimus,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,bronchopneumonia
D001996,0.4,NCT00474786-1,Temsirolimus,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,bronchopneumonia
D014397,0.4,NCT00474786-2,Sorafenib,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,pulmonary tuberculosis
D012141,0.4,NCT00474786-1,Temsirolimus,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,respiratory tract infection
D018805,0.8,NCT00474786-1,Temsirolimus,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,sepsis
D018805,0.79,NCT00474786-2,Sorafenib,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,sepsis
D012772,0.4,NCT00474786-1,Temsirolimus,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,septic shock
D000038,0.4,NCT00474786-1,Temsirolimus,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,abscess
D000038,0.4,NCT00474786-2,Sorafenib,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,abscess
10040047,0.4,NCT00474786-2,Sorafenib,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,sepsis
D014946,0.4,NCT00474786-2,Sorafenib,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,wound infection
D050815,0.4,NCT00474786-1,Temsirolimus,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,compression fracture
10020100,0.4,NCT00474786-2,Sorafenib,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,hip fracture
D006811,0.4,NCT00474786-2,Sorafenib,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,humerus
10051792,0.4,NCT00474786-1,Temsirolimus,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,infusion related reaction
D008022,0.4,NCT00474786-2,Sorafenib,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,ligaments
D015775,0.4,NCT00474786-1,Temsirolimus,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,microfractures
D062787,0.4,NCT00474786-2,Sorafenib,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,drug overdose
D015775,0.4,NCT00474786-1,Temsirolimus,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,microfractures
D000069475,0.4,NCT00474786-2,Sorafenib,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,reirradiation
10001551,0.79,NCT00474786-2,Sorafenib,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,alanine aminotransferase increased
10003481,1.19,NCT00474786-2,Sorafenib,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,aspartate aminotransferase increased
10005364,0.4,NCT00474786-2,Sorafenib,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,blood bilirubin increased
D000939,0.4,NCT00474786-2,Sorafenib,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,antigenic specificity
D013851,0.4,NCT00474786-2,Sorafenib,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,underweight
D002100,0.4,NCT00474786-1,Temsirolimus,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,cachexia
D001066,0.79,NCT00474786-2,Sorafenib,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,appetite
D003681,2.81,NCT00474786-1,Temsirolimus,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,dehydration
D003681,2.38,NCT00474786-2,Sorafenib,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,dehydration
D003920,0.4,NCT00474786-1,Temsirolimus,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,diabetes mellitus
UNKNOWN-check-for-typo,0.4,NCT00474786-1,Temsirolimus,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,D00
UNKNOWN-check-for-typo,1.19,NCT00474786-2,Sorafenib,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,D00
UNKNOWN-check-for-typo,0.4,NCT00474786-1,Temsirolimus,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,D00
UNKNOWN-check-for-typo,0.8,NCT00474786-1,Temsirolimus,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,D00
UNKNOWN-check-for-typo,0.4,NCT00474786-2,Sorafenib,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,D00
UNKNOWN-check-for-typo,0.4,NCT00474786-2,Sorafenib,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,D00
UNKNOWN-check-for-typo,0.4,NCT00474786-1,Temsirolimus,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,D00
UNKNOWN-check-for-typo,1.19,NCT00474786-2,Sorafenib,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,D00
D044342,0.4,NCT00474786-2,Sorafenib,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,malnutrition
D018771,0.8,NCT00474786-1,Temsirolimus,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,arthralgia
D001416,1.19,NCT00474786-2,Sorafenib,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,back pain
D000077553,0.4,NCT00474786-1,Temsirolimus,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,edarabone
10006002,0.4,NCT00474786-1,Temsirolimus,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,bone pain
UNKNOWN-check-for-typo,0.4,NCT00474786-2,Sorafenib,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,D00
D021501,0.4,NCT00474786-1,Temsirolimus,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,flank pain
D007403,0.4,NCT00474786-2,Sorafenib,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,intervertebral disc
D002637,0.4,NCT00474786-2,Sorafenib,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,chest pain
D059352,0.4,NCT00474786-1,Temsirolimus,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,musculoskeletal pain
D019547,0.4,NCT00474786-2,Sorafenib,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,neck pain
D010014,0.4,NCT00474786-1,Temsirolimus,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,osteolysis
D010014,0.4,NCT00474786-2,Sorafenib,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,osteolysis
10033425,0.8,NCT00474786-1,Temsirolimus,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,pain in extremity
10033425,1.19,NCT00474786-2,Sorafenib,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,pain in extremity
D005598,0.4,NCT00474786-1,Temsirolimus,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,pathological fracture
D013118,0.4,NCT00474786-2,Sorafenib,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,spinal cord disorders
D016066,0.4,NCT00474786-1,Temsirolimus,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,malignant pleural effusion
D002294,0.79,NCT00474786-2,Sorafenib,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,squamous cell carcinoma
D002544,0.4,NCT00474786-2,Sorafenib,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,cerebral infarction
D000070624,0.4,NCT00474786-2,Sorafenib,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,cerebral contusion
D020521,0.8,NCT00474786-1,Temsirolimus,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,cerebrovascular accident
D008569,0.4,NCT00474786-2,Sorafenib,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,retention disorders cognitive
D012640,0.4,NCT00474786-2,Sorafenib,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,convulsion
D006261,0.4,NCT00474786-1,Temsirolimus,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,headache
D006261,0.4,NCT00474786-2,Sorafenib,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,headache
UNKNOWN-check-for-typo,0.4,NCT00474786-2,Sorafenib,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,D00
UNKNOWN-check-for-typo,0.4,NCT00474786-1,Temsirolimus,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,D00
10034580,0.4,NCT00474786-2,Sorafenib,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,peripheral motor neuropathy
D013117,0.4,NCT00474786-1,Temsirolimus,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,spinal cord compression
D013117,0.79,NCT00474786-2,Sorafenib,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,spinal cord compression
D013575,0.4,NCT00474786-2,Sorafenib,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,syncope
D000080762,0.4,NCT00474786-2,Sorafenib,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,stimuli responsive polymers
D000081013,0.4,NCT00474786-1,Temsirolimus,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,completed suicide
D000081013,0.4,NCT00474786-2,Sorafenib,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,completed suicide
D003221,1.19,NCT00474786-2,Sorafenib,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,confusional state
UNKNOWN-check-for-typo,0.4,NCT00474786-1,Temsirolimus,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,D00
D009404,0.4,NCT00474786-2,Sorafenib,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,nephrotic syndrome
D051437,1.61,NCT00474786-1,Temsirolimus,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,renal failure
D051437,0.4,NCT00474786-2,Sorafenib,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,renal failure
D058186,0.4,NCT00474786-1,Temsirolimus,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,acute renal failure
D058186,0.4,NCT00474786-2,Sorafenib,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,acute renal failure
D000141,0.4,NCT00474786-1,Temsirolimus,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,acidosis renal tubular
D016055,0.8,NCT00474786-1,Temsirolimus,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,urinary retention
D007917,0.4,NCT00474786-2,Sorafenib,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,leprostatics
D013224,0.4,NCT00474786-2,Sorafenib,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,asthmatic crisis
UNKNOWN-check-for-typo,2.81,NCT00474786-1,Temsirolimus,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,D00
UNKNOWN-check-for-typo,3.17,NCT00474786-2,Sorafenib,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,D00
D004844,0.4,NCT00474786-1,Temsirolimus,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,epistaxis
UNKNOWN-check-for-typo,0.4,NCT00474786-2,Sorafenib,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,D00
D017563,0.8,NCT00474786-1,Temsirolimus,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,interstitial lung disease
D008168,0.8,NCT00474786-1,Temsirolimus,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,lung
D010996,2.81,NCT00474786-1,Temsirolimus,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,pleural effusion
D010996,1.98,NCT00474786-2,Sorafenib,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,pleural effusion
10035623,0.4,NCT00474786-1,Temsirolimus,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,pleuritic pain
D011014,2.81,NCT00474786-1,Temsirolimus,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,pneumonitis
D011030,1.2,NCT00474786-1,Temsirolimus,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,pneumothorax
D011655,0.4,NCT00474786-1,Temsirolimus,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,pulmonary embolism
D019390,0.4,NCT00474786-2,Sorafenib,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,arrestins
D012127,0.4,NCT00474786-1,Temsirolimus,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,respiratory distress syndrome newborn
D012131,0.8,NCT00474786-1,Temsirolimus,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,respiratory failure
D012131,0.79,NCT00474786-2,Sorafenib,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,respiratory failure
10054524,0.4,NCT00474786-2,Sorafenib,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,palmar-plantar erythrodysesthesia syndrome
D005076,0.4,NCT00474786-1,Temsirolimus,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,rash
D005076,0.79,NCT00474786-2,Sorafenib,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,rash
10037868,0.4,NCT00474786-2,Sorafenib,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,rash maculo-papular
D008168,0.4,NCT00474786-1,Temsirolimus,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,lung
D004864,0.4,NCT00474786-1,Temsirolimus,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,medical devices
UNKNOWN-check-for-typo,0.4,NCT00474786-2,Sorafenib,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,D00
D000074042,0.4,NCT00474786-1,Temsirolimus,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,cerebral intraventricular haemorrhage
D006973,0.4,NCT00474786-1,Temsirolimus,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,hypertension
D007022,0.4,NCT00474786-1,Temsirolimus,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,hypotension
D013927,0.4,NCT00474786-1,Temsirolimus,NCT00474786,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,thrombosis
D064420,33.33,NCT00474929-1,Phase I Dose Level 0,NCT00474929,Sorafenib and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma,adverse drug events
D064420,20.0,NCT00474929-2,Phase I Dose Level 1,NCT00474929,Sorafenib and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma,adverse drug events
D064420,40.0,NCT00474929-3,Phase I Dose Level 2,NCT00474929,Sorafenib and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma,adverse drug events
D064420,20.0,NCT00474929-4,Phase I Dose Level 3,NCT00474929,Sorafenib and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma,adverse drug events
D064420,28.57,NCT00474929-5,Phase II,NCT00474929,Sorafenib and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma,adverse drug events
D002263,3.9,NCT00474929-5,Phase II,NCT00474929,Sorafenib and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma,carboxyhemoglobin
D006331,1.3,NCT00474929-5,Phase II,NCT00474929,Sorafenib and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma,cardiac diseases
10040741,1.3,NCT00474929-5,Phase II,NCT00474929,Sorafenib and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma,sinus bradycardia
D003967,1.3,NCT00474929-5,Phase II,NCT00474929,Sorafenib and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma,diarrhea
D006330,2.6,NCT00474929-5,Phase II,NCT00474929,Sorafenib and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma,heart abnormalities
D009325,1.3,NCT00474929-5,Phase II,NCT00474929,Sorafenib and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma,nausea
D003643,1.3,NCT00474929-5,Phase II,NCT00474929,Sorafenib and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma,death
D018450,1.3,NCT00474929-5,Phase II,NCT00474929,Sorafenib and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma,disease progression
D005221,2.6,NCT00474929-5,Phase II,NCT00474929,Sorafenib and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma,fatigue
D005334,1.3,NCT00474929-5,Phase II,NCT00474929,Sorafenib and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma,fever
D003645,1.3,NCT00474929-5,Phase II,NCT00474929,Sorafenib and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma,sudden death
D006967,1.3,NCT00474929-5,Phase II,NCT00474929,Sorafenib and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma,hypersensitivity
10058838,1.3,NCT00474929-5,Phase II,NCT00474929,Sorafenib and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma,enterocolitis infectious
D018805,1.3,NCT00474929-5,Phase II,NCT00474929,Sorafenib and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma,sepsis
10005364,1.3,NCT00474929-5,Phase II,NCT00474929,Sorafenib and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma,blood bilirubin increased
D007958,2.6,NCT00474929-5,Phase II,NCT00474929,Sorafenib and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma,leukocyte count
10025256,1.3,NCT00474929-5,Phase II,NCT00474929,Sorafenib and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma,lymphocyte count decreased
10029366,16.67,NCT00474929-1,Phase I Dose Level 0,NCT00474929,Sorafenib and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma,neutrophil count decreased
10029366,20.0,NCT00474929-3,Phase I Dose Level 2,NCT00474929,Sorafenib and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma,neutrophil count decreased
10029366,2.6,NCT00474929-5,Phase II,NCT00474929,Sorafenib and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma,neutrophil count decreased
10035528,16.67,NCT00474929-1,Phase I Dose Level 0,NCT00474929,Sorafenib and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma,platelet count decreased
10035528,20.0,NCT00474929-2,Phase I Dose Level 1,NCT00474929,Sorafenib and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma,platelet count decreased
10035528,20.0,NCT00474929-3,Phase I Dose Level 2,NCT00474929,Sorafenib and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma,platelet count decreased
10035528,20.0,NCT00474929-4,Phase I Dose Level 3,NCT00474929,Sorafenib and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma,platelet count decreased
10035528,2.6,NCT00474929-5,Phase II,NCT00474929,Sorafenib and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma,platelet count decreased
D000855,1.3,NCT00474929-5,Phase II,NCT00474929,Sorafenib and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma,anorexia
D063806,1.3,NCT00474929-5,Phase II,NCT00474929,Sorafenib and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma,myalgia
10045158,20.0,NCT00474929-3,Phase I Dose Level 2,NCT00474929,Sorafenib and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma,tumor pain
D001259,1.3,NCT00474929-5,Phase II,NCT00474929,Sorafenib and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma,ataxia
D060831,1.3,NCT00474929-5,Phase II,NCT00474929,Sorafenib and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma,hand-foot syndrome
D005076,20.0,NCT00474929-3,Phase I Dose Level 2,NCT00474929,Sorafenib and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma,rash
D005076,2.6,NCT00474929-5,Phase II,NCT00474929,Sorafenib and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma,rash
D014581,1.3,NCT00474929-5,Phase II,NCT00474929,Sorafenib and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma,urticaria
D007022,1.3,NCT00474929-5,Phase II,NCT00474929,Sorafenib and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma,hypotension
D013927,20.0,NCT00474929-3,Phase I Dose Level 2,NCT00474929,Sorafenib and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma,thrombosis
D064420,19.05,NCT00565370-1,XP Plus Sorafenib,NCT00565370,Capecitabine and Cisplatin (XP)+Sorafenib in Advanced Gastric Cancer (AGC): Sorafenib+XP,adverse drug events
D064147,4.76,NCT00565370-1,XP Plus Sorafenib,NCT00565370,Capecitabine and Cisplatin (XP)+Sorafenib in Advanced Gastric Cancer (AGC): Sorafenib+XP,febrile neutropenia
D020246,9.52,NCT00565370-1,XP Plus Sorafenib,NCT00565370,Capecitabine and Cisplatin (XP)+Sorafenib in Advanced Gastric Cancer (AGC): Sorafenib+XP,deep vein thrombosis
D003967,4.76,NCT00565370-1,XP Plus Sorafenib,NCT00565370,Capecitabine and Cisplatin (XP)+Sorafenib in Advanced Gastric Cancer (AGC): Sorafenib+XP,diarrhea
10017815,4.76,NCT00565370-1,XP Plus Sorafenib,NCT00565370,Capecitabine and Cisplatin (XP)+Sorafenib in Advanced Gastric Cancer (AGC): Sorafenib+XP,gastric perforation
D064420,50.0,NCT00573755-1,Sorafenib Plus Aromatase Inhibitor,NCT00573755,Sorafenib and Letrozole  Anastrozole  or Exemestane in Treating Postmenopausal Women With Estrogen Receptor-Positive and/or Progesterone Receptor-Positive Metastatic Breast Cancer,adverse drug events
D002263,50.0,NCT00573755-1,Sorafenib Plus Aromatase Inhibitor,NCT00573755,Sorafenib and Letrozole  Anastrozole  or Exemestane in Treating Postmenopausal Women With Estrogen Receptor-Positive and/or Progesterone Receptor-Positive Metastatic Breast Cancer,carboxyhemoglobin
D057049,50.0,NCT00573755-1,Sorafenib Plus Aromatase Inhibitor,NCT00573755,Sorafenib and Letrozole  Anastrozole  or Exemestane in Treating Postmenopausal Women With Estrogen Receptor-Positive and/or Progesterone Receptor-Positive Metastatic Breast Cancer,thrombotic microangiopathy
D006330,50.0,NCT00573755-1,Sorafenib Plus Aromatase Inhibitor,NCT00573755,Sorafenib and Letrozole  Anastrozole  or Exemestane in Treating Postmenopausal Women With Estrogen Receptor-Positive and/or Progesterone Receptor-Positive Metastatic Breast Cancer,heart abnormalities
10028130,50.0,NCT00573755-1,Sorafenib Plus Aromatase Inhibitor,NCT00573755,Sorafenib and Letrozole  Anastrozole  or Exemestane in Treating Postmenopausal Women With Estrogen Receptor-Positive and/or Progesterone Receptor-Positive Metastatic Breast Cancer,mucositis oral
D005221,50.0,NCT00573755-1,Sorafenib Plus Aromatase Inhibitor,NCT00573755,Sorafenib and Letrozole  Anastrozole  or Exemestane in Treating Postmenopausal Women With Estrogen Receptor-Positive and/or Progesterone Receptor-Positive Metastatic Breast Cancer,fatigue
10035528,50.0,NCT00573755-1,Sorafenib Plus Aromatase Inhibitor,NCT00573755,Sorafenib and Letrozole  Anastrozole  or Exemestane in Treating Postmenopausal Women With Estrogen Receptor-Positive and/or Progesterone Receptor-Positive Metastatic Breast Cancer,platelet count decreased
10040139,50.0,NCT00573755-1,Sorafenib Plus Aromatase Inhibitor,NCT00573755,Sorafenib and Letrozole  Anastrozole  or Exemestane in Treating Postmenopausal Women With Estrogen Receptor-Positive and/or Progesterone Receptor-Positive Metastatic Breast Cancer,serum amylase increased
D012964,50.0,NCT00573755-1,Sorafenib Plus Aromatase Inhibitor,NCT00573755,Sorafenib and Letrozole  Anastrozole  or Exemestane in Treating Postmenopausal Women With Estrogen Receptor-Positive and/or Progesterone Receptor-Positive Metastatic Breast Cancer,sodium
D018908,50.0,NCT00573755-1,Sorafenib Plus Aromatase Inhibitor,NCT00573755,Sorafenib and Letrozole  Anastrozole  or Exemestane in Treating Postmenopausal Women With Estrogen Receptor-Positive and/or Progesterone Receptor-Positive Metastatic Breast Cancer,muscle weakness
D064420,44.0,NCT00609804-1,Sorafenib+Erlotinib,NCT00609804,Sorafenib and Erlotinib or Sorafenib Alone in Advanced Non-Small Cell Lung Cancer Progressing on Erlotinib,adverse drug events
D064420,17.86,NCT00609804-2,Sorafenib,NCT00609804,Sorafenib and Erlotinib or Sorafenib Alone in Advanced Non-Small Cell Lung Cancer Progressing on Erlotinib,adverse drug events
D006331,4.0,NCT00609804-1,Sorafenib+Erlotinib,NCT00609804,Sorafenib and Erlotinib or Sorafenib Alone in Advanced Non-Small Cell Lung Cancer Progressing on Erlotinib,cardiac disorders
D006333,4.0,NCT00609804-1,Sorafenib+Erlotinib,NCT00609804,Sorafenib and Erlotinib or Sorafenib Alone in Advanced Non-Small Cell Lung Cancer Progressing on Erlotinib,heart failure
D003248,4.0,NCT00609804-1,Sorafenib+Erlotinib,NCT00609804,Sorafenib and Erlotinib or Sorafenib Alone in Advanced Non-Small Cell Lung Cancer Progressing on Erlotinib,constipation
D003248,3.57,NCT00609804-2,Sorafenib,NCT00609804,Sorafenib and Erlotinib or Sorafenib Alone in Advanced Non-Small Cell Lung Cancer Progressing on Erlotinib,constipation
D003967,12.0,NCT00609804-1,Sorafenib+Erlotinib,NCT00609804,Sorafenib and Erlotinib or Sorafenib Alone in Advanced Non-Small Cell Lung Cancer Progressing on Erlotinib,diarrhea
D003680,4.0,NCT00609804-1,Sorafenib+Erlotinib,NCT00609804,Sorafenib and Erlotinib or Sorafenib Alone in Advanced Non-Small Cell Lung Cancer Progressing on Erlotinib,dysphagia
10017815,4.0,NCT00609804-1,Sorafenib+Erlotinib,NCT00609804,Sorafenib and Erlotinib or Sorafenib Alone in Advanced Non-Small Cell Lung Cancer Progressing on Erlotinib,gastric perforation
D045823,4.0,NCT00609804-1,Sorafenib+Erlotinib,NCT00609804,Sorafenib and Erlotinib or Sorafenib Alone in Advanced Non-Small Cell Lung Cancer Progressing on Erlotinib,ileus
D009325,4.0,NCT00609804-1,Sorafenib+Erlotinib,NCT00609804,Sorafenib and Erlotinib or Sorafenib Alone in Advanced Non-Small Cell Lung Cancer Progressing on Erlotinib,nausea
10029957,4.0,NCT00609804-1,Sorafenib+Erlotinib,NCT00609804,Sorafenib and Erlotinib or Sorafenib Alone in Advanced Non-Small Cell Lung Cancer Progressing on Erlotinib,obstruction gastric
D015746,4.0,NCT00609804-1,Sorafenib+Erlotinib,NCT00609804,Sorafenib and Erlotinib or Sorafenib Alone in Advanced Non-Small Cell Lung Cancer Progressing on Erlotinib,abdominal pain
D014839,4.0,NCT00609804-1,Sorafenib+Erlotinib,NCT00609804,Sorafenib and Erlotinib or Sorafenib Alone in Advanced Non-Small Cell Lung Cancer Progressing on Erlotinib,vomiting
D005221,8.0,NCT00609804-1,Sorafenib+Erlotinib,NCT00609804,Sorafenib and Erlotinib or Sorafenib Alone in Advanced Non-Small Cell Lung Cancer Progressing on Erlotinib,fatigue
10062501,3.57,NCT00609804-2,Sorafenib,NCT00609804,Sorafenib and Erlotinib or Sorafenib Alone in Advanced Non-Small Cell Lung Cancer Progressing on Erlotinib,non-cardiac chest pain
D000855,4.0,NCT00609804-1,Sorafenib+Erlotinib,NCT00609804,Sorafenib and Erlotinib or Sorafenib Alone in Advanced Non-Small Cell Lung Cancer Progressing on Erlotinib,anorexia
D003681,12.0,NCT00609804-1,Sorafenib+Erlotinib,NCT00609804,Sorafenib and Erlotinib or Sorafenib Alone in Advanced Non-Small Cell Lung Cancer Progressing on Erlotinib,dehydration
D006943,4.0,NCT00609804-1,Sorafenib+Erlotinib,NCT00609804,Sorafenib and Erlotinib or Sorafenib Alone in Advanced Non-Small Cell Lung Cancer Progressing on Erlotinib,hyperglycemia
D007008,3.57,NCT00609804-2,Sorafenib,NCT00609804,Sorafenib and Erlotinib or Sorafenib Alone in Advanced Non-Small Cell Lung Cancer Progressing on Erlotinib,hypokalemia
D007010,4.0,NCT00609804-1,Sorafenib+Erlotinib,NCT00609804,Sorafenib and Erlotinib or Sorafenib Alone in Advanced Non-Small Cell Lung Cancer Progressing on Erlotinib,hyponatremia
D004244,3.57,NCT00609804-2,Sorafenib,NCT00609804,Sorafenib and Erlotinib or Sorafenib Alone in Advanced Non-Small Cell Lung Cancer Progressing on Erlotinib,dizziness
D020300,4.0,NCT00609804-1,Sorafenib+Erlotinib,NCT00609804,Sorafenib and Erlotinib or Sorafenib Alone in Advanced Non-Small Cell Lung Cancer Progressing on Erlotinib,intracranial hemorrhage
10034580,4.0,NCT00609804-1,Sorafenib+Erlotinib,NCT00609804,Sorafenib and Erlotinib or Sorafenib Alone in Advanced Non-Small Cell Lung Cancer Progressing on Erlotinib,peripheral motor neuropathy
10009845,4.0,NCT00609804-1,Sorafenib+Erlotinib,NCT00609804,Sorafenib and Erlotinib or Sorafenib Alone in Advanced Non-Small Cell Lung Cancer Progressing on Erlotinib,cognitive disturbance
D003221,3.57,NCT00609804-2,Sorafenib,NCT00609804,Sorafenib and Erlotinib or Sorafenib Alone in Advanced Non-Small Cell Lung Cancer Progressing on Erlotinib,confusion
10034719,4.0,NCT00609804-1,Sorafenib+Erlotinib,NCT00609804,Sorafenib and Erlotinib or Sorafenib Alone in Advanced Non-Small Cell Lung Cancer Progressing on Erlotinib,personality change
10038738,3.57,NCT00609804-2,Sorafenib,NCT00609804,Sorafenib and Erlotinib or Sorafenib Alone in Advanced Non-Small Cell Lung Cancer Progressing on Erlotinib,respiratory thoracic and mediastinal disorders - other specify
D003371,4.0,NCT00609804-1,Sorafenib+Erlotinib,NCT00609804,Sorafenib and Erlotinib or Sorafenib Alone in Advanced Non-Small Cell Lung Cancer Progressing on Erlotinib,cough
D012131,4.0,NCT00609804-1,Sorafenib+Erlotinib,NCT00609804,Sorafenib and Erlotinib or Sorafenib Alone in Advanced Non-Small Cell Lung Cancer Progressing on Erlotinib,respiratory failure
D005076,3.57,NCT00609804-2,Sorafenib,NCT00609804,Sorafenib and Erlotinib or Sorafenib Alone in Advanced Non-Small Cell Lung Cancer Progressing on Erlotinib,rash
D006973,4.0,NCT00609804-1,Sorafenib+Erlotinib,NCT00609804,Sorafenib and Erlotinib or Sorafenib Alone in Advanced Non-Small Cell Lung Cancer Progressing on Erlotinib,hypertension
D006973,3.57,NCT00609804-2,Sorafenib,NCT00609804,Sorafenib and Erlotinib or Sorafenib Alone in Advanced Non-Small Cell Lung Cancer Progressing on Erlotinib,hypertension
10043565,3.57,NCT00609804-2,Sorafenib,NCT00609804,Sorafenib and Erlotinib or Sorafenib Alone in Advanced Non-Small Cell Lung Cancer Progressing on Erlotinib,thromboembolic event
D064420,22.22,NCT00632541-1,Single Arm A,NCT00632541,A Phase II Study of Bevacizumab + Sorafenib in Metastatic Breast Cancer,adverse drug events
D000068757,5.56,NCT00632541-1,Single Arm A,NCT00632541,A Phase II Study of Bevacizumab + Sorafenib in Metastatic Breast Cancer,ononis
D018450,5.56,NCT00632541-1,Single Arm A,NCT00632541,A Phase II Study of Bevacizumab + Sorafenib in Metastatic Breast Cancer,disease progression
D002607,5.56,NCT00632541-1,Single Arm A,NCT00632541,A Phase II Study of Bevacizumab + Sorafenib in Metastatic Breast Cancer,hereditary type i motor and sensory neuropathy
10008496,5.56,NCT00632541-1,Single Arm A,NCT00632541,A Phase II Study of Bevacizumab + Sorafenib in Metastatic Breast Cancer,chest wall pain
D064420,40.67,NCT00678392-1,Axitinib 5 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,adverse drug events
D064420,35.77,NCT00678392-2,Sorafenib 400 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,adverse drug events
D000741,2.25,NCT00678392-2,Sorafenib 400 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,aplastic anaemia
D013159,0.28,NCT00678392-2,Sorafenib 400 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,splenic infarction
D054058,0.56,NCT00678392-2,Sorafenib 400 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,acute coronary syndrome
D056988,0.56,NCT00678392-1,Axitinib 5 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,acute anterior wall myocardial infarction
D000787,0.56,NCT00678392-2,Sorafenib 400 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,angina pectoris
D001145,0.28,NCT00678392-1,Axitinib 5 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,arrhythmia
D003324,0.28,NCT00678392-1,Axitinib 5 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,coronary arteriosclerosis
D001281,0.56,NCT00678392-1,Axitinib 5 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,atrial fibrillation
D001282,0.28,NCT00678392-1,Axitinib 5 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,atrial flutter
D054537,0.28,NCT00678392-2,Sorafenib 400 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,atrioventricular block
D001919,0.28,NCT00678392-1,Axitinib 5 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,bradycardia
D006323,0.28,NCT00678392-1,Axitinib 5 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,cardiac arrest
D006333,0.56,NCT00678392-1,Axitinib 5 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,cardiac failure
D006333,0.28,NCT00678392-2,Sorafenib 400 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,cardiac failure
D000028,0.56,NCT00678392-1,Axitinib 5 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,abortion failure
D000028,0.28,NCT00678392-2,Sorafenib 400 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,abortion failure
D002311,0.28,NCT00678392-2,Sorafenib 400 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,congestive cardiomyopathy
D003331,0.28,NCT00678392-1,Axitinib 5 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,artery coronary
D003331,0.28,NCT00678392-1,Axitinib 5 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,artery coronary
D008944,0.28,NCT00678392-1,Axitinib 5 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,mitral valve incompetence
D009203,1.67,NCT00678392-1,Axitinib 5 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,myocardial infarction
D009203,1.13,NCT00678392-2,Sorafenib 400 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,myocardial infarction
D000071956,0.28,NCT00678392-1,Axitinib 5 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,myocardial contusions
D000788,0.28,NCT00678392-1,Axitinib 5 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,prinzmetal angina
D013617,0.28,NCT00678392-1,Axitinib 5 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,supraventricular tachycardia
D013610,0.28,NCT00678392-2,Sorafenib 400 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,tachycardia
D000309,0.28,NCT00678392-2,Sorafenib 400 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,adrenal insufficiency
D007037,0.28,NCT00678392-1,Axitinib 5 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,hypothyroidism
D007037,0.28,NCT00678392-1,Axitinib 5 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,secondary hypothyroidism
D013966,0.28,NCT00678392-2,Sorafenib 400 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,thyroiditis
D004172,0.28,NCT00678392-1,Axitinib 5 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,diplopia
D012161,0.28,NCT00678392-2,Sorafenib 400 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,retinal artery
D015356,0.28,NCT00678392-1,Axitinib 5 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,retinal artery occlusion
D012170,0.28,NCT00678392-1,Axitinib 5 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,retinal vein occlusion
D012170,0.28,NCT00678392-1,Axitinib 5 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,retinal vein thrombosis
D015746,0.28,NCT00678392-1,Axitinib 5 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,abdominal pain
D015746,0.56,NCT00678392-2,Sorafenib 400 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,abdominal pain
D012003,0.28,NCT00678392-1,Axitinib 5 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,anal fistula
D001201,0.28,NCT00678392-2,Sorafenib 400 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,ascites
D003093,0.28,NCT00678392-2,Sorafenib 400 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,ulcerative colitis
D003248,0.56,NCT00678392-1,Axitinib 5 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,constipation
D003248,0.28,NCT00678392-2,Sorafenib 400 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,constipation
UNKNOWN-check-for-typo,2.23,NCT00678392-1,Axitinib 5 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,D00
UNKNOWN-check-for-typo,1.41,NCT00678392-2,Sorafenib 400 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,D00
D004381,0.28,NCT00678392-2,Sorafenib 400 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,duodenal ulcer
D004760,0.28,NCT00678392-2,Sorafenib 400 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,enterocolitis
D020115,0.56,NCT00678392-1,Axitinib 5 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,progastricsin
D013276,0.28,NCT00678392-1,Axitinib 5 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,gastric ulcer
D005756,0.28,NCT00678392-2,Sorafenib 400 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,gastritis
D000069196,1.41,NCT00678392-2,Sorafenib 400 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,gastrointestinal microbiome
D000069196,0.28,NCT00678392-1,Axitinib 5 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,gastrointestinal microbiome
UNKNOWN-check-for-typo,0.28,NCT00678392-2,Sorafenib 400 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,D00
D006552,0.84,NCT00678392-1,Axitinib 5 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,inguinal hernia
D007415,1.11,NCT00678392-1,Axitinib 5 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,intestinal obstruction
D007415,0.28,NCT00678392-2,Sorafenib 400 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,intestinal obstruction
D041741,0.28,NCT00678392-1,Axitinib 5 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,lower gastrointestinal tract
D041741,0.28,NCT00678392-2,Sorafenib 400 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,lower gastrointestinal tract
D050686,0.28,NCT00678392-1,Axitinib 5 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,globicephala melaena
D009325,0.28,NCT00678392-1,Axitinib 5 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,nausea
D009325,0.28,NCT00678392-2,Sorafenib 400 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,nausea
D010195,0.28,NCT00678392-2,Sorafenib 400 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,pancreatitis
D000071056,0.28,NCT00678392-2,Sorafenib 400 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,anorectal malformations
D012185,0.28,NCT00678392-2,Sorafenib 400 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,retroperitoneal fibrosis
10041101,0.28,NCT00678392-1,Axitinib 5 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,small intestinal obstruction
10021328,0.28,NCT00678392-2,Sorafenib 400 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,ileus
D041742,0.28,NCT00678392-2,Sorafenib 400 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,upper gastrointestinal tract
D014839,1.39,NCT00678392-1,Axitinib 5 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,vomiting
D014839,0.56,NCT00678392-2,Sorafenib 400 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,vomiting
D001247,0.56,NCT00678392-1,Axitinib 5 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,asthenia
D001247,0.28,NCT00678392-2,Sorafenib 400 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,asthenia
D002637,0.56,NCT00678392-1,Axitinib 5 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,chest pain
D002637,0.56,NCT00678392-2,Sorafenib 400 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,chest pain
D023341,0.28,NCT00678392-1,Axitinib 5 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,chills
D003643,0.84,NCT00678392-1,Axitinib 5 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,death
D003643,1.69,NCT00678392-2,Sorafenib 400 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,death
D004864,0.28,NCT00678392-2,Sorafenib 400 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,devices
D018450,8.91,NCT00678392-1,Axitinib 5 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,disease progression
D018450,5.07,NCT00678392-2,Sorafenib 400 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,disease progression
D005221,1.11,NCT00678392-1,Axitinib 5 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,fatigue
D003695,0.84,NCT00678392-1,Axitinib 5 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,healthcare
D003695,1.41,NCT00678392-2,Sorafenib 400 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,healthcare
D006547,0.28,NCT00678392-1,Axitinib 5 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,hernia
D006987,0.28,NCT00678392-2,Sorafenib 400 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,impaired sensation
D007249,0.28,NCT00678392-2,Sorafenib 400 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,inflammation
10025482,0.28,NCT00678392-1,Axitinib 5 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,malaise
D007249,0.28,NCT00678392-1,Axitinib 5 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,inflammation
D000799,0.28,NCT00678392-1,Axitinib 5 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,angioedema
D010146,0.56,NCT00678392-1,Axitinib 5 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,pain
D010146,0.85,NCT00678392-2,Sorafenib 400 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,pain
D005334,1.95,NCT00678392-1,Axitinib 5 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,pyrexia
D005334,1.41,NCT00678392-2,Sorafenib 400 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,pyrexia
D015529,0.28,NCT00678392-2,Sorafenib 400 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,congenital biliary dilatation
D006502,0.28,NCT00678392-1,Axitinib 5 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,budd chiari syndrome
D002761,0.28,NCT00678392-1,Axitinib 5 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,cholangitis
D002761,0.28,NCT00678392-2,Sorafenib 400 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,cholangitis
D002764,0.28,NCT00678392-1,Axitinib 5 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,cholecystitis
D002764,0.28,NCT00678392-2,Sorafenib 400 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,cholecystitis
D002769,0.28,NCT00678392-2,Sorafenib 400 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,cholelithiasis
D011681,0.28,NCT00678392-2,Sorafenib 400 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,pupillary functions abnormal
D006967,0.28,NCT00678392-1,Axitinib 5 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,hypersensitivity
D018784,0.28,NCT00678392-1,Axitinib 5 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,abdominal abscess
D001064,0.28,NCT00678392-1,Axitinib 5 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,appendicitis
D001064,0.56,NCT00678392-2,Sorafenib 400 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,appendicitis
D001228,0.28,NCT00678392-2,Sorafenib 400 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,aspergillus infection
D016931,0.28,NCT00678392-1,Axitinib 5 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,halobacteriales
D002481,0.28,NCT00678392-2,Sorafenib 400 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,cellulitis
D004238,0.28,NCT00678392-2,Sorafenib 400 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,diverticulitis
D004886,0.28,NCT00678392-1,Axitinib 5 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,erysipelas
D005759,0.28,NCT00678392-1,Axitinib 5 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,gastroenteritis
D000072139,0.28,NCT00678392-1,Axitinib 5 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,megavirales
D006562,0.28,NCT00678392-2,Sorafenib 400 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,herpes zoster
D007239,0.84,NCT00678392-1,Axitinib 5 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,infection
D015299,0.28,NCT00678392-2,Sorafenib 400 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,discitis
D012141,1.13,NCT00678392-2,Sorafenib 400 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,respiratory tract infections
D012141,0.28,NCT00678392-1,Axitinib 5 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,respiratory tract infections
10061229,0.28,NCT00678392-2,Sorafenib 400 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,lung infection
D000038,0.28,NCT00678392-2,Sorafenib 400 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,abscess
D011014,1.39,NCT00678392-1,Axitinib 5 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,pneumonia
D011014,1.13,NCT00678392-2,Sorafenib 400 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,pneumonia
D001996,0.28,NCT00678392-1,Axitinib 5 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,bronchopneumonia
D011024,0.28,NCT00678392-1,Axitinib 5 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,viral pneumonia
D014397,0.28,NCT00678392-2,Sorafenib 400 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,pulmonary tuberculosis
D011704,0.28,NCT00678392-2,Sorafenib 400 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,pyelonephritis
D012141,0.28,NCT00678392-1,Axitinib 5 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,respiratory tract infection
D012141,0.28,NCT00678392-2,Sorafenib 400 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,respiratory tract infection
D018805,0.28,NCT00678392-1,Axitinib 5 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,sepsis
D018805,0.56,NCT00678392-2,Sorafenib 400 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,sepsis
D012772,0.28,NCT00678392-2,Sorafenib 400 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,septic shock
D014552,0.56,NCT00678392-1,Axitinib 5 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,urinary tract infection
D014552,0.56,NCT00678392-2,Sorafenib 400 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,urinary tract infection
10016173,0.28,NCT00678392-1,Axitinib 5 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,fall
10016173,0.56,NCT00678392-2,Sorafenib 400 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,fall
D005265,0.28,NCT00678392-1,Axitinib 5 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,femoral neck fracture
10065879,0.28,NCT00678392-1,Axitinib 5 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,gastrointestinal anastomotic leak
D006811,0.28,NCT00678392-1,Axitinib 5 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,humerus
D022125,0.28,NCT00678392-1,Axitinib 5 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,laceration
D015775,0.56,NCT00678392-1,Axitinib 5 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,microfractures
D000073818,0.28,NCT00678392-1,Axitinib 5 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,procedural pain
D017564,0.28,NCT00678392-1,Axitinib 5 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,radiation pneumonitis
D012253,0.28,NCT00678392-2,Sorafenib 400 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,rib fracture
D017695,0.28,NCT00678392-2,Sorafenib 400 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,soft tissue injury
D016103,0.28,NCT00678392-1,Axitinib 5 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,spinal fractures
10029366,0.28,NCT00678392-1,Axitinib 5 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,neutrophil count decreased
10001551,0.28,NCT00678392-2,Sorafenib 400 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,alanine aminotransferase increased
10003481,0.28,NCT00678392-2,Sorafenib 400 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,aspartate aminotransferase increased
10001675,0.28,NCT00678392-2,Sorafenib 400 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,alkaline phosphatase increased
10011368,0.56,NCT00678392-1,Axitinib 5 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,creatinine increased
10011368,0.28,NCT00678392-2,Sorafenib 400 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,creatinine increased
10005630,0.28,NCT00678392-2,Sorafenib 400 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,blood lactate dehydrogenase increased
D002097,0.28,NCT00678392-2,Sorafenib 400 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,c-reactive protein
D005723,0.28,NCT00678392-2,Sorafenib 400 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,gammaglutamyltransferase
D001051,0.28,NCT00678392-2,Sorafenib 400 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,apoenzymes
D001066,0.84,NCT00678392-1,Axitinib 5 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,appetite
D003681,2.79,NCT00678392-1,Axitinib 5 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,dehydration
D003681,0.28,NCT00678392-2,Sorafenib 400 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,dehydration
UNKNOWN-check-for-typo,0.28,NCT00678392-1,Axitinib 5 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,D00
UNKNOWN-check-for-typo,0.56,NCT00678392-2,Sorafenib 400 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,D00
UNKNOWN-check-for-typo,0.56,NCT00678392-1,Axitinib 5 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,D00
UNKNOWN-check-for-typo,0.28,NCT00678392-2,Sorafenib 400 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,D00
UNKNOWN-check-for-typo,0.28,NCT00678392-2,Sorafenib 400 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,D00
UNKNOWN-check-for-typo,0.28,NCT00678392-1,Axitinib 5 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,D00
UNKNOWN-check-for-typo,0.56,NCT00678392-1,Axitinib 5 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,D00
UNKNOWN-check-for-typo,0.28,NCT00678392-1,Axitinib 5 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,D00
UNKNOWN-check-for-typo,0.85,NCT00678392-2,Sorafenib 400 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,D00
UNKNOWN-check-for-typo,0.28,NCT00678392-1,Axitinib 5 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,D00
D018771,0.28,NCT00678392-1,Axitinib 5 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,arthralgia
D018771,0.28,NCT00678392-2,Sorafenib 400 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,arthralgia
D001416,0.84,NCT00678392-1,Axitinib 5 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,back pain
D001416,0.56,NCT00678392-2,Sorafenib 400 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,back pain
D021501,0.28,NCT00678392-2,Sorafenib 400 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,flank pain
D002637,0.28,NCT00678392-2,Sorafenib 400 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,chest pain
10033425,0.56,NCT00678392-1,Axitinib 5 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,pain in extremity
D001168,0.28,NCT00678392-2,Sorafenib 400 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,polyarthritis
D013130,0.28,NCT00678392-2,Sorafenib 400 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,spinal stenosis
D013168,0.28,NCT00678392-2,Sorafenib 400 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,spondylolisthesis
D009362,0.28,NCT00678392-1,Axitinib 5 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,metastasis
D000080867,0.28,NCT00678392-2,Sorafenib 400 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,gingipains
D009369,0.28,NCT00678392-1,Axitinib 5 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,neoplasms
D002292,0.28,NCT00678392-1,Axitinib 5 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,renal cell carcinoma
D002292,0.28,NCT00678392-2,Sorafenib 400 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,renal cell carcinoma
D002294,0.28,NCT00678392-2,Sorafenib 400 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,squamous cell carcinoma
D005334,0.28,NCT00678392-1,Axitinib 5 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,fever
D001037,0.28,NCT00678392-1,Axitinib 5 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,aphasia
D000067571,0.28,NCT00678392-2,Sorafenib 400 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,balance sheet
D002490,0.28,NCT00678392-1,Axitinib 5 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,central nervous system
D002544,0.28,NCT00678392-2,Sorafenib 400 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,cerebral infarction
D000070624,0.28,NCT00678392-2,Sorafenib 400 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,cerebral contusion
D020521,0.56,NCT00678392-1,Axitinib 5 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,cerebrovascular accident
D020521,0.28,NCT00678392-2,Sorafenib 400 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,cerebrovascular accident
D004244,0.84,NCT00678392-1,Axitinib 5 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,dizziness
D006261,0.28,NCT00678392-1,Axitinib 5 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,headache
D010291,0.28,NCT00678392-2,Sorafenib 400 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,hemiparesis
D013474,0.28,NCT00678392-2,Sorafenib 400 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,sunstroke
D056784,0.28,NCT00678392-1,Axitinib 5 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,leukoencephalopathy
D014474,0.56,NCT00678392-1,Axitinib 5 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,loss of consciousness
D000067836,0.28,NCT00678392-1,Axitinib 5 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,hoarding disorder
D006429,0.28,NCT00678392-2,Sorafenib 400 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,monoplegia
D013575,0.28,NCT00678392-1,Axitinib 5 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,presyncope
D012640,0.28,NCT00678392-1,Axitinib 5 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,seizure
D013117,0.56,NCT00678392-1,Axitinib 5 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,spinal cord compression
D013575,0.56,NCT00678392-1,Axitinib 5 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,syncope
D002546,0.84,NCT00678392-1,Axitinib 5 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,ischemic attack transient
D001007,0.28,NCT00678392-2,Sorafenib 400 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,anxiety
D003221,0.28,NCT00678392-1,Axitinib 5 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,confusional state
D003221,0.28,NCT00678392-1,Axitinib 5 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,disorientation
D000073216,0.28,NCT00678392-1,Axitinib 5 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,mental status tests
D000073216,0.28,NCT00678392-2,Sorafenib 400 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,mental status tests
D058186,1.11,NCT00678392-1,Axitinib 5 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,acute kidney injury
D058186,0.56,NCT00678392-2,Sorafenib 400 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,acute kidney injury
D017114,0.28,NCT00678392-1,Axitinib 5 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,liver failure acute
UNKNOWN-check-for-typo,0.28,NCT00678392-1,Axitinib 5 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,D00
D001449,0.28,NCT00678392-2,Sorafenib 400 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,balkan nephropathy
D009846,0.28,NCT00678392-2,Sorafenib 400 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,oliguria
D051437,0.28,NCT00678392-1,Axitinib 5 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,renal failure
D016055,0.28,NCT00678392-1,Axitinib 5 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,urinary retention
D011470,0.38,NCT00678392-1,Axitinib 5 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,benign prostatic hyperplasia
UNKNOWN-check-for-typo,0.96,NCT00678392-2,Sorafenib 400 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,D00
D000081026,1.04,NCT00678392-1,Axitinib 5 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,polyprenols
D029424,0.28,NCT00678392-2,Sorafenib 400 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,chronic obstructive pulmonary disease
D003371,0.28,NCT00678392-2,Sorafenib 400 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,cough
UNKNOWN-check-for-typo,1.95,NCT00678392-1,Axitinib 5 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,D00
UNKNOWN-check-for-typo,0.85,NCT00678392-2,Sorafenib 400 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,D00
D051270,0.28,NCT00678392-1,Axitinib 5 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,primary exertional headache
D004844,0.28,NCT00678392-1,Axitinib 5 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,epistaxis
D004844,0.28,NCT00678392-2,Sorafenib 400 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,epistaxis
UNKNOWN-check-for-typo,0.28,NCT00678392-1,Axitinib 5 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,D00
UNKNOWN-check-for-typo,0.56,NCT00678392-2,Sorafenib 400 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,D00
UNKNOWN-check-for-typo,0.28,NCT00678392-2,Sorafenib 400 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,D00
D017563,0.28,NCT00678392-1,Axitinib 5 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,interstitial lung disease
D008168,0.28,NCT00678392-1,Axitinib 5 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,lung
D010996,0.84,NCT00678392-1,Axitinib 5 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,pleural effusion
D010996,1.41,NCT00678392-2,Sorafenib 400 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,pleural effusion
D010998,0.28,NCT00678392-2,Sorafenib 400 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,pleurisy
D011030,1.11,NCT00678392-1,Axitinib 5 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,pneumothorax
D011030,0.28,NCT00678392-2,Sorafenib 400 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,pneumothorax
D011030,0.28,NCT00678392-1,Axitinib 5 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,spontaneous pneumothorax
D011655,1.95,NCT00678392-1,Axitinib 5 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,pulmonary embolism
D011655,0.28,NCT00678392-2,Sorafenib 400 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,pulmonary embolism
D001261,0.56,NCT00678392-2,Sorafenib 400 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,pulmonary atelectasis
D012127,0.28,NCT00678392-1,Axitinib 5 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,respiratory distress syndrome newborn
D004892,0.85,NCT00678392-2,Sorafenib 400 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,erythema multiforme
D006945,0.28,NCT00678392-1,Axitinib 5 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,hyperhidrosis
10054524,0.28,NCT00678392-2,Sorafenib 400 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,palmar-plantar erythrodysesthesia syndrome
D011565,0.28,NCT00678392-2,Sorafenib 400 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,pustular psoriasis of palms and soles
D005076,0.56,NCT00678392-2,Sorafenib 400 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,rash
D014581,0.28,NCT00678392-1,Axitinib 5 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,urticaria
D059408,0.28,NCT00678392-2,Sorafenib 400 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,pain management
D054854,0.28,NCT00678392-2,Sorafenib 400 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,vertebroplasty
D006973,0.28,NCT00678392-1,Axitinib 5 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,hypertension
D020246,0.28,NCT00678392-1,Axitinib 5 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,deep vein thrombosis
D020246,0.28,NCT00678392-2,Sorafenib 400 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,deep vein thrombosis
D006973,0.28,NCT00678392-1,Axitinib 5 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,hypertension
D006973,0.56,NCT00678392-2,Sorafenib 400 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,hypertension
D000959,0.28,NCT00678392-1,Axitinib 5 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,antihypertensives
D007022,0.28,NCT00678392-1,Axitinib 5 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,hypotension
D007022,1.13,NCT00678392-2,Sorafenib 400 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,hypotension
D007238,0.28,NCT00678392-2,Sorafenib 400 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,infarction
D007601,0.28,NCT00678392-1,Axitinib 5 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,jugular veins
D013350,0.28,NCT00678392-1,Axitinib 5 mg,NCT00678392,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,subclavian vein
D064420,23.08,NCT00687674-1,Sorafenib + Lenalidomide + Dexamethasone,NCT00687674,Sorafenib  Lenalidomide  and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma,adverse drug events
D011014,7.69,NCT00687674-1,Sorafenib + Lenalidomide + Dexamethasone,NCT00687674,Sorafenib  Lenalidomide  and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma,pneumonia
D007970,7.69,NCT00687674-1,Sorafenib + Lenalidomide + Dexamethasone,NCT00687674,Sorafenib  Lenalidomide  and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma,leukopenia
D005076,7.69,NCT00687674-1,Sorafenib + Lenalidomide + Dexamethasone,NCT00687674,Sorafenib  Lenalidomide  and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma,rash
D064420,9.09,NCT00754923-1,Treatment: Sorafenib,NCT00754923,Sorafenib in Treating Non-Smokers or Former Light Smokers With Relapsed or Refractory Stage IIIB or Stage IV Non-Small Cell Lung Cancer,adverse drug events
D005221,9.09,NCT00754923-1,Treatment: Sorafenib,NCT00754923,Sorafenib in Treating Non-Smokers or Former Light Smokers With Relapsed or Refractory Stage IIIB or Stage IV Non-Small Cell Lung Cancer,fatigue
D064420,11.11,NCT00813293-1,Sorafenib,NCT00813293,Sorafenib Therapy Prior to Radiofrequency Ablation for Intermediate Sized Hepatocellular Cancer,adverse drug events
D064420,10.0,NCT00813293-2,Placebo,NCT00813293,Sorafenib Therapy Prior to Radiofrequency Ablation for Intermediate Sized Hepatocellular Cancer,adverse drug events
D001664,10.0,NCT00813293-2,Placebo,NCT00813293,Sorafenib Therapy Prior to Radiofrequency Ablation for Intermediate Sized Hepatocellular Cancer,biliverdine
D007962,11.11,NCT00813293-1,Sorafenib,NCT00813293,Sorafenib Therapy Prior to Radiofrequency Ablation for Intermediate Sized Hepatocellular Cancer,leukocytes
D008231,11.11,NCT00813293-1,Sorafenib,NCT00813293,Sorafenib Therapy Prior to Radiofrequency Ablation for Intermediate Sized Hepatocellular Cancer,lymphopenia
D000068258,11.11,NCT00813293-1,Sorafenib,NCT00813293,Sorafenib Therapy Prior to Radiofrequency Ablation for Intermediate Sized Hepatocellular Cancer,avastin
D001663,11.11,NCT00813293-1,Sorafenib,NCT00813293,Sorafenib Therapy Prior to Radiofrequency Ablation for Intermediate Sized Hepatocellular Cancer,bilirubin
D064420,12.5,NCT00815295-1,Phase 1 - Dose Level 1,NCT00815295,Study of Sorafenib/Cetuximab in Head and Neck Cancer,adverse drug events
D064420,12.5,NCT00815295-2,Phase 1 - Dose Level 2,NCT00815295,Study of Sorafenib/Cetuximab in Head and Neck Cancer,adverse drug events
D064420,41.67,NCT00815295-3,Phase 2,NCT00815295,Study of Sorafenib/Cetuximab in Head and Neck Cancer,adverse drug events
D009203,12.5,NCT00815295-1,Phase 1 - Dose Level 1,NCT00815295,Study of Sorafenib/Cetuximab in Head and Neck Cancer,myocardial infarction
D009325,12.5,NCT00815295-2,Phase 1 - Dose Level 2,NCT00815295,Study of Sorafenib/Cetuximab in Head and Neck Cancer,nausea
D014839,12.5,NCT00815295-2,Phase 1 - Dose Level 2,NCT00815295,Study of Sorafenib/Cetuximab in Head and Neck Cancer,vomiting
10011914,16.67,NCT00815295-3,Phase 2,NCT00815295,Study of Sorafenib/Cetuximab in Head and Neck Cancer,death nos
10018065,8.33,NCT00815295-3,Phase 2,NCT00815295,Study of Sorafenib/Cetuximab in Head and Neck Cancer,general disorders and administration site conditions - other specify
D000080424,8.33,NCT00815295-3,Phase 2,NCT00815295,Study of Sorafenib/Cetuximab in Head and Neck Cancer,cytokine release syndrome
D003681,12.5,NCT00815295-2,Phase 1 - Dose Level 2,NCT00815295,Study of Sorafenib/Cetuximab in Head and Neck Cancer,dehydration
10038738,8.33,NCT00815295-3,Phase 2,NCT00815295,Study of Sorafenib/Cetuximab in Head and Neck Cancer,respiratory thoracic and mediastinal disorders - other specify
D064420,7.89,NCT00825734-1,Dose Level 1a,NCT00825734,Phase I/II Trial of Sorafenib Plus Ixabepilone in HER2-Negative Metastatic Breast Cancer,adverse drug events
D000740,1.32,NCT00825734-1,Dose Level 1a,NCT00825734,Phase I/II Trial of Sorafenib Plus Ixabepilone in HER2-Negative Metastatic Breast Cancer,anemia
D003643,1.32,NCT00825734-1,Dose Level 1a,NCT00825734,Phase I/II Trial of Sorafenib Plus Ixabepilone in HER2-Negative Metastatic Breast Cancer,death
D007239,1.32,NCT00825734-1,Dose Level 1a,NCT00825734,Phase I/II Trial of Sorafenib Plus Ixabepilone in HER2-Negative Metastatic Breast Cancer,infection
D015431,1.32,NCT00825734-1,Dose Level 1a,NCT00825734,Phase I/II Trial of Sorafenib Plus Ixabepilone in HER2-Negative Metastatic Breast Cancer,weight loss
D001416,1.32,NCT00825734-1,Dose Level 1a,NCT00825734,Phase I/II Trial of Sorafenib Plus Ixabepilone in HER2-Negative Metastatic Breast Cancer,back pain
D058186,1.32,NCT00825734-1,Dose Level 1a,NCT00825734,Phase I/II Trial of Sorafenib Plus Ixabepilone in HER2-Negative Metastatic Breast Cancer,acute renal failure
D004417,2.63,NCT00825734-1,Dose Level 1a,NCT00825734,Phase I/II Trial of Sorafenib Plus Ixabepilone in HER2-Negative Metastatic Breast Cancer,dyspnea
D011014,1.32,NCT00825734-1,Dose Level 1a,NCT00825734,Phase I/II Trial of Sorafenib Plus Ixabepilone in HER2-Negative Metastatic Breast Cancer,pneumonia
10054524,1.32,NCT00825734-1,Dose Level 1a,NCT00825734,Phase I/II Trial of Sorafenib Plus Ixabepilone in HER2-Negative Metastatic Breast Cancer,palmar-plantar erythrodysesthesia syndrome
D005076,1.32,NCT00825734-1,Dose Level 1a,NCT00825734,Phase I/II Trial of Sorafenib Plus Ixabepilone in HER2-Negative Metastatic Breast Cancer,rash
D009026,6.0,NCT00844883-1,Sorafenib and Drug Eluting Beads,NCT00844883,Study of Sorafenib and Transarterial Chemoembolization (TACE) to Treat Hepatocellular Carcinoma,mortality
D064420,16.0,NCT00844883-1,Sorafenib and Drug Eluting Beads,NCT00844883,Study of Sorafenib and Transarterial Chemoembolization (TACE) to Treat Hepatocellular Carcinoma,adverse drug events
D015746,2.0,NCT00844883-1,Sorafenib and Drug Eluting Beads,NCT00844883,Study of Sorafenib and Transarterial Chemoembolization (TACE) to Treat Hepatocellular Carcinoma,abdominal pain
10062501,4.0,NCT00844883-1,Sorafenib and Drug Eluting Beads,NCT00844883,Study of Sorafenib and Transarterial Chemoembolization (TACE) to Treat Hepatocellular Carcinoma,non-cardiac chest pain
D000069342,2.0,NCT00844883-1,Sorafenib and Drug Eluting Beads,NCT00844883,Study of Sorafenib and Transarterial Chemoembolization (TACE) to Treat Hepatocellular Carcinoma,overmedication
D002761,2.0,NCT00844883-1,Sorafenib and Drug Eluting Beads,NCT00844883,Study of Sorafenib and Transarterial Chemoembolization (TACE) to Treat Hepatocellular Carcinoma,cholangitis
D003404,2.0,NCT00844883-1,Sorafenib and Drug Eluting Beads,NCT00844883,Study of Sorafenib and Transarterial Chemoembolization (TACE) to Treat Hepatocellular Carcinoma,creatinine
D009369,2.0,NCT00844883-1,Sorafenib and Drug Eluting Beads,NCT00844883,Study of Sorafenib and Transarterial Chemoembolization (TACE) to Treat Hepatocellular Carcinoma,tumors
D001927,2.0,NCT00844883-1,Sorafenib and Drug Eluting Beads,NCT00844883,Study of Sorafenib and Transarterial Chemoembolization (TACE) to Treat Hepatocellular Carcinoma,encephalopathy
D064420,62.5,NCT00862082-1,PR104 550 mg/m^2 + Sorafenib,NCT00862082,Randomized Phase 1/2 Open-Label Trial of PR104 and Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC),adverse drug events
D064420,33.33,NCT00862082-2,PR104 770 mg/m^2 + Sorafenib,NCT00862082,Randomized Phase 1/2 Open-Label Trial of PR104 and Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC),adverse drug events
D064147,12.5,NCT00862082-1,PR104 550 mg/m^2 + Sorafenib,NCT00862082,Randomized Phase 1/2 Open-Label Trial of PR104 and Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC),febrile neutropenia
D015746,25.0,NCT00862082-1,PR104 550 mg/m^2 + Sorafenib,NCT00862082,Randomized Phase 1/2 Open-Label Trial of PR104 and Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC),abdominal pain
D000389,12.5,NCT00862082-1,PR104 550 mg/m^2 + Sorafenib,NCT00862082,Randomized Phase 1/2 Open-Label Trial of PR104 and Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC),air conditioning
D005221,16.67,NCT00862082-2,PR104 770 mg/m^2 + Sorafenib,NCT00862082,Randomized Phase 1/2 Open-Label Trial of PR104 and Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC),fatigue
D005334,25.0,NCT00862082-1,PR104 550 mg/m^2 + Sorafenib,NCT00862082,Randomized Phase 1/2 Open-Label Trial of PR104 and Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC),fever
D002481,12.5,NCT00862082-1,PR104 550 mg/m^2 + Sorafenib,NCT00862082,Randomized Phase 1/2 Open-Label Trial of PR104 and Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC),cellulitis
D018805,16.67,NCT00862082-2,PR104 770 mg/m^2 + Sorafenib,NCT00862082,Randomized Phase 1/2 Open-Label Trial of PR104 and Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC),sepsis
D013921,12.5,NCT00862082-1,PR104 550 mg/m^2 + Sorafenib,NCT00862082,Randomized Phase 1/2 Open-Label Trial of PR104 and Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC),thrombocytopenia
D064420,40.0,NCT00864032-2,Sorafenib 200/400,NCT00864032,Trial of Neoadjuvant Conformal Radiotherapy Plus Sorafenib for Patients With Soft Tissue Sarcoma of the Extremity and Body Wall,adverse drug events
D005076,40.0,NCT00864032-2,Sorafenib 200/400,NCT00864032,Trial of Neoadjuvant Conformal Radiotherapy Plus Sorafenib for Patients With Soft Tissue Sarcoma of the Extremity and Body Wall,rash
D064420,66.67,NCT00906373-1,Cohort 1 - 10 mg/kg Cixutumumab,NCT00906373,A Study of IMC-A12 in Combination With Sorafenib in Participants With Advanced Cancer of the Liver,adverse drug events
D064420,36.59,NCT00906373-2,Cohort 2 - 20 mg/kg Cixutumumab,NCT00906373,A Study of IMC-A12 in Combination With Sorafenib in Participants With Advanced Cancer of the Liver,adverse drug events
D012167,2.44,NCT00906373-2,Cohort 2 - 20 mg/kg Cixutumumab,NCT00906373,A Study of IMC-A12 in Combination With Sorafenib in Participants With Advanced Cancer of the Liver,retinal tear
D015746,2.44,NCT00906373-2,Cohort 2 - 20 mg/kg Cixutumumab,NCT00906373,A Study of IMC-A12 in Combination With Sorafenib in Participants With Advanced Cancer of the Liver,abdominal pain
D003092,2.44,NCT00906373-2,Cohort 2 - 20 mg/kg Cixutumumab,NCT00906373,A Study of IMC-A12 in Combination With Sorafenib in Participants With Advanced Cancer of the Liver,colitis
UNKNOWN-check-for-typo,16.67,NCT00906373-1,Cohort 1 - 10 mg/kg Cixutumumab,NCT00906373,A Study of IMC-A12 in Combination With Sorafenib in Participants With Advanced Cancer of the Liver,D00
D000069196,33.33,NCT00906373-1,Cohort 1 - 10 mg/kg Cixutumumab,NCT00906373,A Study of IMC-A12 in Combination With Sorafenib in Participants With Advanced Cancer of the Liver,gastrointestinal microbiome
D000069196,4.88,NCT00906373-2,Cohort 2 - 20 mg/kg Cixutumumab,NCT00906373,A Study of IMC-A12 in Combination With Sorafenib in Participants With Advanced Cancer of the Liver,gastrointestinal microbiome
D010195,16.67,NCT00906373-1,Cohort 1 - 10 mg/kg Cixutumumab,NCT00906373,A Study of IMC-A12 in Combination With Sorafenib in Participants With Advanced Cancer of the Liver,pancreatitis
10041103,2.44,NCT00906373-2,Cohort 2 - 20 mg/kg Cixutumumab,NCT00906373,A Study of IMC-A12 in Combination With Sorafenib in Participants With Advanced Cancer of the Liver,small intestinal perforation
D001247,2.44,NCT00906373-2,Cohort 2 - 20 mg/kg Cixutumumab,NCT00906373,A Study of IMC-A12 in Combination With Sorafenib in Participants With Advanced Cancer of the Liver,asthenia
D002637,2.44,NCT00906373-2,Cohort 2 - 20 mg/kg Cixutumumab,NCT00906373,A Study of IMC-A12 in Combination With Sorafenib in Participants With Advanced Cancer of the Liver,chest pain
D005334,4.88,NCT00906373-2,Cohort 2 - 20 mg/kg Cixutumumab,NCT00906373,A Study of IMC-A12 in Combination With Sorafenib in Participants With Advanced Cancer of the Liver,pyrexia
10051341,2.44,NCT00906373-2,Cohort 2 - 20 mg/kg Cixutumumab,NCT00906373,A Study of IMC-A12 in Combination With Sorafenib in Participants With Advanced Cancer of the Liver,bile duct stenosis
D002761,16.67,NCT00906373-1,Cohort 1 - 10 mg/kg Cixutumumab,NCT00906373,A Study of IMC-A12 in Combination With Sorafenib in Participants With Advanced Cancer of the Liver,cholangitis
D029626,2.44,NCT00906373-2,Cohort 2 - 20 mg/kg Cixutumumab,NCT00906373,A Study of IMC-A12 in Combination With Sorafenib in Participants With Advanced Cancer of the Liver,hepatica
D010538,2.44,NCT00906373-2,Cohort 2 - 20 mg/kg Cixutumumab,NCT00906373,A Study of IMC-A12 in Combination With Sorafenib in Participants With Advanced Cancer of the Liver,peritonitis
D010538,2.44,NCT00906373-2,Cohort 2 - 20 mg/kg Cixutumumab,NCT00906373,A Study of IMC-A12 in Combination With Sorafenib in Participants With Advanced Cancer of the Liver,peritonitis
D012772,16.67,NCT00906373-1,Cohort 1 - 10 mg/kg Cixutumumab,NCT00906373,A Study of IMC-A12 in Combination With Sorafenib in Participants With Advanced Cancer of the Liver,septic shock
D012772,2.44,NCT00906373-2,Cohort 2 - 20 mg/kg Cixutumumab,NCT00906373,A Study of IMC-A12 in Combination With Sorafenib in Participants With Advanced Cancer of the Liver,septic shock
10051792,16.67,NCT00906373-1,Cohort 1 - 10 mg/kg Cixutumumab,NCT00906373,A Study of IMC-A12 in Combination With Sorafenib in Participants With Advanced Cancer of the Liver,infusion related reaction
D016103,2.44,NCT00906373-2,Cohort 2 - 20 mg/kg Cixutumumab,NCT00906373,A Study of IMC-A12 in Combination With Sorafenib in Participants With Advanced Cancer of the Liver,spinal fractures
10005364,2.44,NCT00906373-2,Cohort 2 - 20 mg/kg Cixutumumab,NCT00906373,A Study of IMC-A12 in Combination With Sorafenib in Participants With Advanced Cancer of the Liver,blood bilirubin increased
10024574,2.44,NCT00906373-2,Cohort 2 - 20 mg/kg Cixutumumab,NCT00906373,A Study of IMC-A12 in Combination With Sorafenib in Participants With Advanced Cancer of the Liver,lipase increased
D008111,2.44,NCT00906373-2,Cohort 2 - 20 mg/kg Cixutumumab,NCT00906373,A Study of IMC-A12 in Combination With Sorafenib in Participants With Advanced Cancer of the Liver,liver function tests
D003681,16.67,NCT00906373-1,Cohort 1 - 10 mg/kg Cixutumumab,NCT00906373,A Study of IMC-A12 in Combination With Sorafenib in Participants With Advanced Cancer of the Liver,dehydration
UNKNOWN-check-for-typo,4.88,NCT00906373-2,Cohort 2 - 20 mg/kg Cixutumumab,NCT00906373,A Study of IMC-A12 in Combination With Sorafenib in Participants With Advanced Cancer of the Liver,D00
D009369,16.67,NCT00906373-1,Cohort 1 - 10 mg/kg Cixutumumab,NCT00906373,A Study of IMC-A12 in Combination With Sorafenib in Participants With Advanced Cancer of the Liver,malignant neoplasm
D009369,4.88,NCT00906373-2,Cohort 2 - 20 mg/kg Cixutumumab,NCT00906373,A Study of IMC-A12 in Combination With Sorafenib in Participants With Advanced Cancer of the Liver,malignant neoplasm
D009369,2.44,NCT00906373-2,Cohort 2 - 20 mg/kg Cixutumumab,NCT00906373,A Study of IMC-A12 in Combination With Sorafenib in Participants With Advanced Cancer of the Liver,neoplasms
D006261,2.44,NCT00906373-2,Cohort 2 - 20 mg/kg Cixutumumab,NCT00906373,A Study of IMC-A12 in Combination With Sorafenib in Participants With Advanced Cancer of the Liver,headache
D058186,16.67,NCT00906373-1,Cohort 1 - 10 mg/kg Cixutumumab,NCT00906373,A Study of IMC-A12 in Combination With Sorafenib in Participants With Advanced Cancer of the Liver,acute renal failure
D058186,2.44,NCT00906373-2,Cohort 2 - 20 mg/kg Cixutumumab,NCT00906373,A Study of IMC-A12 in Combination With Sorafenib in Participants With Advanced Cancer of the Liver,acute renal failure
D010996,2.44,NCT00906373-2,Cohort 2 - 20 mg/kg Cixutumumab,NCT00906373,A Study of IMC-A12 in Combination With Sorafenib in Participants With Advanced Cancer of the Liver,pleural effusion
D012131,2.44,NCT00906373-2,Cohort 2 - 20 mg/kg Cixutumumab,NCT00906373,A Study of IMC-A12 in Combination With Sorafenib in Participants With Advanced Cancer of the Liver,respiratory failure
D009026,100.0,NCT00917462-1,Sorafenib,NCT00917462,Sorafenib for Patients With Metastatic or Recurrent Esophageal and Gastroesophageal Junction Cancer,mortality
D064420,42.86,NCT00917462-1,Sorafenib,NCT00917462,Sorafenib for Patients With Metastatic or Recurrent Esophageal and Gastroesophageal Junction Cancer,adverse drug events
D013616,2.86,NCT00917462-1,Sorafenib,NCT00917462,Sorafenib for Patients With Metastatic or Recurrent Esophageal and Gastroesophageal Junction Cancer,sinus tachycardia
D003248,2.86,NCT00917462-1,Sorafenib,NCT00917462,Sorafenib for Patients With Metastatic or Recurrent Esophageal and Gastroesophageal Junction Cancer,constipation
10013781,2.86,NCT00917462-1,Sorafenib,NCT00917462,Sorafenib for Patients With Metastatic or Recurrent Esophageal and Gastroesophageal Junction Cancer,dry mouth
D003680,2.86,NCT00917462-1,Sorafenib,NCT00917462,Sorafenib for Patients With Metastatic or Recurrent Esophageal and Gastroesophageal Junction Cancer,dysphagia
10017877,5.71,NCT00917462-1,Sorafenib,NCT00917462,Sorafenib for Patients With Metastatic or Recurrent Esophageal and Gastroesophageal Junction Cancer,gastrointestinal fistula
D014839,2.86,NCT00917462-1,Sorafenib,NCT00917462,Sorafenib for Patients With Metastatic or Recurrent Esophageal and Gastroesophageal Junction Cancer,vomiting
D000071896,2.86,NCT00917462-1,Sorafenib,NCT00917462,Sorafenib for Patients With Metastatic or Recurrent Esophageal and Gastroesophageal Junction Cancer,somatic symptoms
D000799,2.86,NCT00917462-1,Sorafenib,NCT00917462,Sorafenib for Patients With Metastatic or Recurrent Esophageal and Gastroesophageal Junction Cancer,angioedema
D005221,5.71,NCT00917462-1,Sorafenib,NCT00917462,Sorafenib for Patients With Metastatic or Recurrent Esophageal and Gastroesophageal Junction Cancer,fatigue
D005334,2.86,NCT00917462-1,Sorafenib,NCT00917462,Sorafenib for Patients With Metastatic or Recurrent Esophageal and Gastroesophageal Junction Cancer,fever
D000080867,2.86,NCT00917462-1,Sorafenib,NCT00917462,Sorafenib for Patients With Metastatic or Recurrent Esophageal and Gastroesophageal Junction Cancer,gingipains
D023341,2.86,NCT00917462-1,Sorafenib,NCT00917462,Sorafenib for Patients With Metastatic or Recurrent Esophageal and Gastroesophageal Junction Cancer,chills
10061351,2.86,NCT00917462-1,Sorafenib,NCT00917462,Sorafenib for Patients With Metastatic or Recurrent Esophageal and Gastroesophageal Junction Cancer,pleural infection
D006932,2.86,NCT00917462-1,Sorafenib,NCT00917462,Sorafenib for Patients With Metastatic or Recurrent Esophageal and Gastroesophageal Junction Cancer,hyperbilirubinemia
D006934,2.86,NCT00917462-1,Sorafenib,NCT00917462,Sorafenib for Patients With Metastatic or Recurrent Esophageal and Gastroesophageal Junction Cancer,hypercalcemia
D003681,11.43,NCT00917462-1,Sorafenib,NCT00917462,Sorafenib for Patients With Metastatic or Recurrent Esophageal and Gastroesophageal Junction Cancer,dehydration
10008496,2.86,NCT00917462-1,Sorafenib,NCT00917462,Sorafenib for Patients With Metastatic or Recurrent Esophageal and Gastroesophageal Junction Cancer,chest wall pain
10033425,2.86,NCT00917462-1,Sorafenib,NCT00917462,Sorafenib for Patients With Metastatic or Recurrent Esophageal and Gastroesophageal Junction Cancer,pain in extremity
10049737,2.86,NCT00917462-1,Sorafenib,NCT00917462,Sorafenib for Patients With Metastatic or Recurrent Esophageal and Gastroesophageal Junction Cancer,treatment related secondary malignancy
D002607,5.71,NCT00917462-1,Sorafenib,NCT00917462,Sorafenib for Patients With Metastatic or Recurrent Esophageal and Gastroesophageal Junction Cancer,hereditary type i motor and sensory neuropathy
D003221,5.71,NCT00917462-1,Sorafenib,NCT00917462,Sorafenib for Patients With Metastatic or Recurrent Esophageal and Gastroesophageal Junction Cancer,confusion
D000308,2.86,NCT00917462-1,Sorafenib,NCT00917462,Sorafenib for Patients With Metastatic or Recurrent Esophageal and Gastroesophageal Junction Cancer,hyperadrenalism
D003371,2.86,NCT00917462-1,Sorafenib,NCT00917462,Sorafenib for Patients With Metastatic or Recurrent Esophageal and Gastroesophageal Junction Cancer,cough
D004417,2.86,NCT00917462-1,Sorafenib,NCT00917462,Sorafenib for Patients With Metastatic or Recurrent Esophageal and Gastroesophageal Junction Cancer,dyspnea
D010996,2.86,NCT00917462-1,Sorafenib,NCT00917462,Sorafenib for Patients With Metastatic or Recurrent Esophageal and Gastroesophageal Junction Cancer,pleural effusion
D011014,2.86,NCT00917462-1,Sorafenib,NCT00917462,Sorafenib for Patients With Metastatic or Recurrent Esophageal and Gastroesophageal Junction Cancer,pneumonitis
D006973,2.86,NCT00917462-1,Sorafenib,NCT00917462,Sorafenib for Patients With Metastatic or Recurrent Esophageal and Gastroesophageal Junction Cancer,hypertension
D016769,2.86,NCT00917462-1,Sorafenib,NCT00917462,Sorafenib for Patients With Metastatic or Recurrent Esophageal and Gastroesophageal Junction Cancer,embolism and thrombosis
D064420,33.86,NCT00920816-1,Axitinib (First-line Participants),NCT00920816,Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer,adverse drug events
D064420,25.0,NCT00920816-2,Sorafenib (First-line Participants),NCT00920816,Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer,adverse drug events
D064420,29.63,NCT00920816-3,Axitinib (Second-line Participants),NCT00920816,Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer,adverse drug events
D064420,20.29,NCT00920816-4,Sorafenib (Second-line Participants),NCT00920816,Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer,adverse drug events
D000741,0.74,NCT00920816-3,Axitinib (Second-line Participants),NCT00920816,Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer,aplastic anaemia
D013921,0.53,NCT00920816-1,Axitinib (First-line Participants),NCT00920816,Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer,thrombocytopenia
D006333,0.74,NCT00920816-3,Axitinib (Second-line Participants),NCT00920816,Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer,cardiac failure
D006333,1.45,NCT00920816-4,Sorafenib (Second-line Participants),NCT00920816,Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer,cardiac failure
D009203,0.53,NCT00920816-1,Axitinib (First-line Participants),NCT00920816,Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer,myocardial infarction
D009203,1.48,NCT00920816-3,Axitinib (Second-line Participants),NCT00920816,Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer,myocardial infarction
D000071956,0.53,NCT00920816-1,Axitinib (First-line Participants),NCT00920816,Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer,myocardial contusions
D000071956,0.74,NCT00920816-3,Axitinib (Second-line Participants),NCT00920816,Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer,myocardial contusions
D056988,2.08,NCT00920816-2,Sorafenib (First-line Participants),NCT00920816,Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer,acute anterior wall myocardial infarction
D001282,0.53,NCT00920816-1,Axitinib (First-line Participants),NCT00920816,Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer,atrial flutter
D006323,1.59,NCT00920816-1,Axitinib (First-line Participants),NCT00920816,Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer,cardiac arrest
D000072599,1.06,NCT00920816-1,Axitinib (First-line Participants),NCT00920816,Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer,cardiorespiratory fitness
D015746,0.53,NCT00920816-1,Axitinib (First-line Participants),NCT00920816,Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer,abdominal pain
D015746,3.12,NCT00920816-2,Sorafenib (First-line Participants),NCT00920816,Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer,abdominal pain
D015746,0.74,NCT00920816-3,Axitinib (Second-line Participants),NCT00920816,Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer,abdominal pain
D012003,0.53,NCT00920816-1,Axitinib (First-line Participants),NCT00920816,Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer,anal fistula
D012003,1.45,NCT00920816-4,Sorafenib (Second-line Participants),NCT00920816,Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer,anal fistula
UNKNOWN-check-for-typo,2.65,NCT00920816-1,Axitinib (First-line Participants),NCT00920816,Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer,D00
UNKNOWN-check-for-typo,2.08,NCT00920816-2,Sorafenib (First-line Participants),NCT00920816,Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer,D00
UNKNOWN-check-for-typo,1.48,NCT00920816-3,Axitinib (Second-line Participants),NCT00920816,Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer,D00
D005756,0.74,NCT00920816-3,Axitinib (Second-line Participants),NCT00920816,Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer,gastritis
D007415,1.45,NCT00920816-4,Sorafenib (Second-line Participants),NCT00920816,Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer,intestinal obstruction
10015461,0.74,NCT00920816-3,Axitinib (Second-line Participants),NCT00920816,Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer,esophagitis
D041742,0.74,NCT00920816-3,Axitinib (Second-line Participants),NCT00920816,Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer,upper gastrointestinal tract
10000060,0.53,NCT00920816-1,Axitinib (First-line Participants),NCT00920816,Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer,abdominal distension
D020115,1.04,NCT00920816-2,Sorafenib (First-line Participants),NCT00920816,Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer,progastricsin
D013276,0.53,NCT00920816-1,Axitinib (First-line Participants),NCT00920816,Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer,gastric ulcer
D000069196,0.53,NCT00920816-1,Axitinib (First-line Participants),NCT00920816,Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer,gastrointestinal microbiome
D005746,0.53,NCT00920816-1,Axitinib (First-line Participants),NCT00920816,Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer,gastric emptying
D050686,0.53,NCT00920816-1,Axitinib (First-line Participants),NCT00920816,Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer,globicephala melaena
D009325,0.53,NCT00920816-1,Axitinib (First-line Participants),NCT00920816,Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer,nausea
D009325,1.04,NCT00920816-2,Sorafenib (First-line Participants),NCT00920816,Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer,nausea
D014648,0.53,NCT00920816-1,Axitinib (First-line Participants),NCT00920816,Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer,varices
D010437,0.53,NCT00920816-1,Axitinib (First-line Participants),NCT00920816,Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer,peptic ulcer
10036774,1.04,NCT00920816-2,Sorafenib (First-line Participants),NCT00920816,Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer,proctitis
D000071056,1.06,NCT00920816-1,Axitinib (First-line Participants),NCT00920816,Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer,anorectal malformations
D012185,0.53,NCT00920816-1,Axitinib (First-line Participants),NCT00920816,Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer,retroperitoneal fibrosis
D014839,0.53,NCT00920816-1,Axitinib (First-line Participants),NCT00920816,Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer,vomiting
D003643,0.53,NCT00920816-1,Axitinib (First-line Participants),NCT00920816,Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer,death
D003643,1.48,NCT00920816-3,Axitinib (Second-line Participants),NCT00920816,Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer,death
D009102,1.45,NCT00920816-4,Sorafenib (Second-line Participants),NCT00920816,Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer,multiple organ failure
D000799,0.74,NCT00920816-3,Axitinib (Second-line Participants),NCT00920816,Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer,angioedema
D018450,10.58,NCT00920816-1,Axitinib (First-line Participants),NCT00920816,Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer,disease progression
D018450,7.29,NCT00920816-2,Sorafenib (First-line Participants),NCT00920816,Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer,disease progression
D018450,8.89,NCT00920816-3,Axitinib (Second-line Participants),NCT00920816,Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer,disease progression
D018450,7.25,NCT00920816-4,Sorafenib (Second-line Participants),NCT00920816,Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer,disease progression
D001247,1.06,NCT00920816-1,Axitinib (First-line Participants),NCT00920816,Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer,asthenia
D002637,1.06,NCT00920816-1,Axitinib (First-line Participants),NCT00920816,Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer,chest pain
D002637,1.04,NCT00920816-2,Sorafenib (First-line Participants),NCT00920816,Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer,chest pain
D003695,0.53,NCT00920816-1,Axitinib (First-line Participants),NCT00920816,Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer,healthcare
D006987,1.04,NCT00920816-2,Sorafenib (First-line Participants),NCT00920816,Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer,impaired sensation
D007249,0.53,NCT00920816-1,Axitinib (First-line Participants),NCT00920816,Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer,inflammation
D005334,0.53,NCT00920816-1,Axitinib (First-line Participants),NCT00920816,Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer,pyrexia
D003645,0.53,NCT00920816-1,Axitinib (First-line Participants),NCT00920816,Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer,sudden death
D042882,0.74,NCT00920816-3,Axitinib (Second-line Participants),NCT00920816,Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer,gallstones common bile duct
D002761,0.74,NCT00920816-3,Axitinib (Second-line Participants),NCT00920816,Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer,cholangitis
D041881,0.53,NCT00920816-1,Axitinib (First-line Participants),NCT00920816,Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer,acute cholecystitis
D041881,1.48,NCT00920816-3,Axitinib (Second-line Participants),NCT00920816,Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer,acute cholecystitis
D017093,1.45,NCT00920816-4,Sorafenib (Second-line Participants),NCT00920816,Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer,hepatic failure
10051341,0.74,NCT00920816-3,Axitinib (Second-line Participants),NCT00920816,Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer,bile duct stenosis
D055732,0.74,NCT00920816-3,Axitinib (Second-line Participants),NCT00920816,Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer,bronchopulmonary aspergillosis
D005759,0.53,NCT00920816-1,Axitinib (First-line Participants),NCT00920816,Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer,gastroenteritis
D005759,0.74,NCT00920816-3,Axitinib (Second-line Participants),NCT00920816,Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer,gastroenteritis
D012141,0.74,NCT00920816-3,Axitinib (Second-line Participants),NCT00920816,Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer,upper respiratory tract infections
D000038,1.45,NCT00920816-4,Sorafenib (Second-line Participants),NCT00920816,Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer,abscess
10035759,0.74,NCT00920816-3,Axitinib (Second-line Participants),NCT00920816,Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer,pneumothorax
10061229,0.53,NCT00920816-1,Axitinib (First-line Participants),NCT00920816,Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer,lung infection
10061229,1.48,NCT00920816-3,Axitinib (Second-line Participants),NCT00920816,Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer,lung infection
D000038,0.53,NCT00920816-1,Axitinib (First-line Participants),NCT00920816,Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer,abscess
D002764,0.53,NCT00920816-1,Axitinib (First-line Participants),NCT00920816,Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer,cholecystitis
D007239,0.53,NCT00920816-1,Axitinib (First-line Participants),NCT00920816,Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer,infection
D010019,0.53,NCT00920816-1,Axitinib (First-line Participants),NCT00920816,Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer,osteomyelitis
D010497,0.53,NCT00920816-1,Axitinib (First-line Participants),NCT00920816,Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer,pericoronitis
D011014,1.06,NCT00920816-1,Axitinib (First-line Participants),NCT00920816,Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer,pneumonia
D011014,1.04,NCT00920816-2,Sorafenib (First-line Participants),NCT00920816,Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer,pneumonia
D011704,0.53,NCT00920816-1,Axitinib (First-line Participants),NCT00920816,Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer,pyelonephritis
D018805,0.53,NCT00920816-1,Axitinib (First-line Participants),NCT00920816,Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer,sepsis
D001424,1.04,NCT00920816-2,Sorafenib (First-line Participants),NCT00920816,Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer,bacterial infections
D014069,0.53,NCT00920816-1,Axitinib (First-line Participants),NCT00920816,Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer,tonsillitis
D014552,1.06,NCT00920816-1,Axitinib (First-line Participants),NCT00920816,Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer,urinary tract infection
D014946,0.53,NCT00920816-1,Axitinib (First-line Participants),NCT00920816,Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer,wound infection
D064386,1.04,NCT00920816-2,Sorafenib (First-line Participants),NCT00920816,Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer,ankle fracture
D005147,1.04,NCT00920816-2,Sorafenib (First-line Participants),NCT00920816,Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer,facial bones
D006811,0.53,NCT00920816-1,Axitinib (First-line Participants),NCT00920816,Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer,humerus
D009104,1.04,NCT00920816-2,Sorafenib (First-line Participants),NCT00920816,Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer,multiple injuries
D010329,1.04,NCT00920816-2,Sorafenib (First-line Participants),NCT00920816,Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer,patella
D034941,1.04,NCT00920816-2,Sorafenib (First-line Participants),NCT00920816,Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer,upper limb
10048031,0.53,NCT00920816-1,Axitinib (First-line Participants),NCT00920816,Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer,wound dehiscence
D007989,0.74,NCT00920816-3,Axitinib (Second-line Participants),NCT00920816,Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer,decreased libido
D001066,0.53,NCT00920816-1,Axitinib (First-line Participants),NCT00920816,Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer,appetite
D001066,1.45,NCT00920816-4,Sorafenib (Second-line Participants),NCT00920816,Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer,appetite
D003681,0.53,NCT00920816-1,Axitinib (First-line Participants),NCT00920816,Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer,dehydration
D003681,1.04,NCT00920816-2,Sorafenib (First-line Participants),NCT00920816,Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer,dehydration
UNKNOWN-check-for-typo,1.04,NCT00920816-2,Sorafenib (First-line Participants),NCT00920816,Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer,D00
D001416,0.53,NCT00920816-1,Axitinib (First-line Participants),NCT00920816,Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer,back pain
D001416,0.74,NCT00920816-3,Axitinib (Second-line Participants),NCT00920816,Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer,back pain
D018908,0.53,NCT00920816-1,Axitinib (First-line Participants),NCT00920816,Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer,muscular weakness
D005598,0.53,NCT00920816-1,Axitinib (First-line Participants),NCT00920816,Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer,pathological fracture
D005598,1.04,NCT00920816-2,Sorafenib (First-line Participants),NCT00920816,Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer,pathological fracture
D006338,0.53,NCT00920816-1,Axitinib (First-line Participants),NCT00920816,Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer,neoplasms cardiac
D007680,0.53,NCT00920816-1,Axitinib (First-line Participants),NCT00920816,Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer,renal cancer
D000310,1.06,NCT00920816-1,Axitinib (First-line Participants),NCT00920816,Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer,adrenal cancer
D002292,1.04,NCT00920816-2,Sorafenib (First-line Participants),NCT00920816,Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer,renal cell carcinoma
D018365,0.53,NCT00920816-1,Axitinib (First-line Participants),NCT00920816,Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer,residual tumour
D001933,1.45,NCT00920816-4,Sorafenib (Second-line Participants),NCT00920816,Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer,brainstem
D002544,1.48,NCT00920816-3,Axitinib (Second-line Participants),NCT00920816,Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer,cerebral infarction
D002544,1.45,NCT00920816-4,Sorafenib (Second-line Participants),NCT00920816,Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer,cerebral infarction
D020521,0.74,NCT00920816-3,Axitinib (Second-line Participants),NCT00920816,Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer,cerebrovascular accident
D006429,1.45,NCT00920816-4,Sorafenib (Second-line Participants),NCT00920816,Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer,hemiplegia
D014474,0.74,NCT00920816-3,Axitinib (Second-line Participants),NCT00920816,Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer,loss of consciousness
D010243,1.45,NCT00920816-4,Sorafenib (Second-line Participants),NCT00920816,Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer,paralysis
D002546,0.74,NCT00920816-3,Axitinib (Second-line Participants),NCT00920816,Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer,ischemic attack transient
D000074042,0.53,NCT00920816-1,Axitinib (First-line Participants),NCT00920816,Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer,cerebral intraventricular haemorrhage
D000070624,1.06,NCT00920816-1,Axitinib (First-line Participants),NCT00920816,Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer,cerebral contusion
D020275,1.04,NCT00920816-2,Sorafenib (First-line Participants),NCT00920816,Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer,acute inflammatory demyelinating polyneuropathy
D020335,1.04,NCT00920816-2,Sorafenib (First-line Participants),NCT00920816,Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer,paraparesis
D010264,1.04,NCT00920816-2,Sorafenib (First-line Participants),NCT00920816,Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer,paraplegia
D013117,1.04,NCT00920816-2,Sorafenib (First-line Participants),NCT00920816,Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer,spinal cord compression
D013575,1.04,NCT00920816-2,Sorafenib (First-line Participants),NCT00920816,Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer,syncope
D051437,1.45,NCT00920816-4,Sorafenib (Second-line Participants),NCT00920816,Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer,renal failure
D058186,1.48,NCT00920816-3,Axitinib (Second-line Participants),NCT00920816,Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer,acute renal failure
D000402,0.74,NCT00920816-3,Axitinib (Second-line Participants),NCT00920816,Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer,airway obstruction
D053159,0.53,NCT00920816-1,Axitinib (First-line Participants),NCT00920816,Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer,dysuria
UNKNOWN-check-for-typo,0.53,NCT00920816-1,Axitinib (First-line Participants),NCT00920816,Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer,D00
D016055,1.04,NCT00920816-2,Sorafenib (First-line Participants),NCT00920816,Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer,urinary retention
D012131,0.74,NCT00920816-3,Axitinib (Second-line Participants),NCT00920816,Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer,respiratory failure
D029424,0.74,NCT00920816-3,Axitinib (Second-line Participants),NCT00920816,Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer,chronic obstructive pulmonary disease
D004844,0.74,NCT00920816-3,Axitinib (Second-line Participants),NCT00920816,Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer,epistaxis
D010996,1.59,NCT00920816-1,Axitinib (First-line Participants),NCT00920816,Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer,pleural effusion
D010996,3.12,NCT00920816-2,Sorafenib (First-line Participants),NCT00920816,Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer,pleural effusion
D010996,0.74,NCT00920816-3,Axitinib (Second-line Participants),NCT00920816,Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer,pleural effusion
D011030,0.74,NCT00920816-3,Axitinib (Second-line Participants),NCT00920816,Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer,pneumothorax
D001261,0.53,NCT00920816-1,Axitinib (First-line Participants),NCT00920816,Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer,atelectasis
UNKNOWN-check-for-typo,0.53,NCT00920816-1,Axitinib (First-line Participants),NCT00920816,Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer,D00
UNKNOWN-check-for-typo,0.53,NCT00920816-1,Axitinib (First-line Participants),NCT00920816,Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer,D00
UNKNOWN-check-for-typo,1.04,NCT00920816-2,Sorafenib (First-line Participants),NCT00920816,Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer,D00
D010998,1.04,NCT00920816-2,Sorafenib (First-line Participants),NCT00920816,Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer,pleurisy
D000799,0.53,NCT00920816-1,Axitinib (First-line Participants),NCT00920816,Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer,angioedema
D012127,0.53,NCT00920816-1,Axitinib (First-line Participants),NCT00920816,Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer,respiratory distress syndrome newborn
D012131,1.04,NCT00920816-2,Sorafenib (First-line Participants),NCT00920816,Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer,respiratory failure
D005076,1.45,NCT00920816-4,Sorafenib (Second-line Participants),NCT00920816,Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer,rash
D004892,1.04,NCT00920816-2,Sorafenib (First-line Participants),NCT00920816,Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer,erythema multiforme
10054524,1.04,NCT00920816-2,Sorafenib (First-line Participants),NCT00920816,Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer,palmar-plantar erythrodysesthesia syndrome
D007022,0.74,NCT00920816-3,Axitinib (Second-line Participants),NCT00920816,Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer,hypotension
D007024,0.74,NCT00920816-3,Axitinib (Second-line Participants),NCT00920816,Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer,orthostatic hypotension
D020246,0.74,NCT00920816-3,Axitinib (Second-line Participants),NCT00920816,Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer,deep vein thrombosis
D001167,0.74,NCT00920816-3,Axitinib (Second-line Participants),NCT00920816,Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer,arterial inflammation
D007412,0.53,NCT00920816-1,Axitinib (First-line Participants),NCT00920816,Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer,cholecystoduodenal fistula
D012769,1.04,NCT00920816-2,Sorafenib (First-line Participants),NCT00920816,Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer,circulatory collapse
D000959,0.53,NCT00920816-1,Axitinib (First-line Participants),NCT00920816,Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer,antihypertensives
D064420,71.43,NCT00941863-1,Sorafenib 100 mg (50-mg Tablet),NCT00941863,Study to Determine the Safety  Maximum Tolerated Dose  Pharmacokinetics of Sorafenib (BAY43-9006),adverse drug events
D064420,33.33,NCT00941863-2,Sorafenib 200 mg (50-mg Tablet),NCT00941863,Study to Determine the Safety  Maximum Tolerated Dose  Pharmacokinetics of Sorafenib (BAY43-9006),adverse drug events
D064420,66.67,NCT00941863-3,Sorafenib 400 mg (50-mg Tablet),NCT00941863,Study to Determine the Safety  Maximum Tolerated Dose  Pharmacokinetics of Sorafenib (BAY43-9006),adverse drug events
D064420,52.94,NCT00941863-4,Sorafenib 400 mg (200-mg Tablet),NCT00941863,Study to Determine the Safety  Maximum Tolerated Dose  Pharmacokinetics of Sorafenib (BAY43-9006),adverse drug events
D064420,63.87,NCT00941863-5,Sorafenib 400 mg (Expansion),NCT00941863,Study to Determine the Safety  Maximum Tolerated Dose  Pharmacokinetics of Sorafenib (BAY43-9006),adverse drug events
D006098,16.67,NCT00941863-3,Sorafenib 400 mg (50-mg Tablet),NCT00941863,Study to Determine the Safety  Maximum Tolerated Dose  Pharmacokinetics of Sorafenib (BAY43-9006),granulocytes
D006098,3.36,NCT00941863-5,Sorafenib 400 mg (Expansion),NCT00941863,Study to Determine the Safety  Maximum Tolerated Dose  Pharmacokinetics of Sorafenib (BAY43-9006),granulocytes
D001792,5.04,NCT00941863-5,Sorafenib 400 mg (Expansion),NCT00941863,Study to Determine the Safety  Maximum Tolerated Dose  Pharmacokinetics of Sorafenib (BAY43-9006),platelets
D002263,2.52,NCT00941863-5,Sorafenib 400 mg (Expansion),NCT00941863,Study to Determine the Safety  Maximum Tolerated Dose  Pharmacokinetics of Sorafenib (BAY43-9006),carboxyhemoglobin
D007962,0.84,NCT00941863-5,Sorafenib 400 mg (Expansion),NCT00941863,Study to Determine the Safety  Maximum Tolerated Dose  Pharmacokinetics of Sorafenib (BAY43-9006),leukocytes
D004564,0.84,NCT00941863-5,Sorafenib 400 mg (Expansion),NCT00941863,Study to Determine the Safety  Maximum Tolerated Dose  Pharmacokinetics of Sorafenib (BAY43-9006),electrocoagulation
D000071235,5.88,NCT00941863-4,Sorafenib 400 mg (200-mg Tablet),NCT00941863,Study to Determine the Safety  Maximum Tolerated Dose  Pharmacokinetics of Sorafenib (BAY43-9006),fibromodulin
D000071235,3.36,NCT00941863-5,Sorafenib 400 mg (Expansion),NCT00941863,Study to Determine the Safety  Maximum Tolerated Dose  Pharmacokinetics of Sorafenib (BAY43-9006),fibromodulin
D001919,0.84,NCT00941863-5,Sorafenib 400 mg (Expansion),NCT00941863,Study to Determine the Safety  Maximum Tolerated Dose  Pharmacokinetics of Sorafenib (BAY43-9006),bradyarrhythmias
D002542,8.33,NCT00941863-3,Sorafenib 400 mg (50-mg Tablet),NCT00941863,Study to Determine the Safety  Maximum Tolerated Dose  Pharmacokinetics of Sorafenib (BAY43-9006),intracranial embolism and thrombosis
D002542,17.65,NCT00941863-4,Sorafenib 400 mg (200-mg Tablet),NCT00941863,Study to Determine the Safety  Maximum Tolerated Dose  Pharmacokinetics of Sorafenib (BAY43-9006),intracranial embolism and thrombosis
D002542,6.72,NCT00941863-5,Sorafenib 400 mg (Expansion),NCT00941863,Study to Determine the Safety  Maximum Tolerated Dose  Pharmacokinetics of Sorafenib (BAY43-9006),intracranial embolism and thrombosis
D006342,2.52,NCT00941863-5,Sorafenib 400 mg (Expansion),NCT00941863,Study to Determine the Safety  Maximum Tolerated Dose  Pharmacokinetics of Sorafenib (BAY43-9006),cardiac rupture post-infarction
D007022,5.88,NCT00941863-4,Sorafenib 400 mg (200-mg Tablet),NCT00941863,Study to Determine the Safety  Maximum Tolerated Dose  Pharmacokinetics of Sorafenib (BAY43-9006),hypotension
D007022,1.68,NCT00941863-5,Sorafenib 400 mg (Expansion),NCT00941863,Study to Determine the Safety  Maximum Tolerated Dose  Pharmacokinetics of Sorafenib (BAY43-9006),hypotension
D010490,2.52,NCT00941863-5,Sorafenib 400 mg (Expansion),NCT00941863,Study to Determine the Safety  Maximum Tolerated Dose  Pharmacokinetics of Sorafenib (BAY43-9006),pericardial effusion
10042554,5.88,NCT00941863-4,Sorafenib 400 mg (200-mg Tablet),NCT00941863,Study to Determine the Safety  Maximum Tolerated Dose  Pharmacokinetics of Sorafenib (BAY43-9006),superficial thrombophlebitis
10042554,0.84,NCT00941863-5,Sorafenib 400 mg (Expansion),NCT00941863,Study to Determine the Safety  Maximum Tolerated Dose  Pharmacokinetics of Sorafenib (BAY43-9006),superficial thrombophlebitis
D004487,0.84,NCT00941863-5,Sorafenib 400 mg (Expansion),NCT00941863,Study to Determine the Safety  Maximum Tolerated Dose  Pharmacokinetics of Sorafenib (BAY43-9006),edema
D000072038,5.88,NCT00941863-4,Sorafenib 400 mg (200-mg Tablet),NCT00941863,Study to Determine the Safety  Maximum Tolerated Dose  Pharmacokinetics of Sorafenib (BAY43-9006),cardiovascular rehabilitation
D014839,8.33,NCT00941863-3,Sorafenib 400 mg (50-mg Tablet),NCT00941863,Study to Determine the Safety  Maximum Tolerated Dose  Pharmacokinetics of Sorafenib (BAY43-9006),vomiting
D014839,11.76,NCT00941863-4,Sorafenib 400 mg (200-mg Tablet),NCT00941863,Study to Determine the Safety  Maximum Tolerated Dose  Pharmacokinetics of Sorafenib (BAY43-9006),vomiting
D014839,6.72,NCT00941863-5,Sorafenib 400 mg (Expansion),NCT00941863,Study to Determine the Safety  Maximum Tolerated Dose  Pharmacokinetics of Sorafenib (BAY43-9006),vomiting
D003681,8.33,NCT00941863-3,Sorafenib 400 mg (50-mg Tablet),NCT00941863,Study to Determine the Safety  Maximum Tolerated Dose  Pharmacokinetics of Sorafenib (BAY43-9006),dehydration
D003681,6.72,NCT00941863-5,Sorafenib 400 mg (Expansion),NCT00941863,Study to Determine the Safety  Maximum Tolerated Dose  Pharmacokinetics of Sorafenib (BAY43-9006),dehydration
D009325,8.33,NCT00941863-3,Sorafenib 400 mg (50-mg Tablet),NCT00941863,Study to Determine the Safety  Maximum Tolerated Dose  Pharmacokinetics of Sorafenib (BAY43-9006),nausea
D009325,5.88,NCT00941863-4,Sorafenib 400 mg (200-mg Tablet),NCT00941863,Study to Determine the Safety  Maximum Tolerated Dose  Pharmacokinetics of Sorafenib (BAY43-9006),nausea
D009325,5.04,NCT00941863-5,Sorafenib 400 mg (Expansion),NCT00941863,Study to Determine the Safety  Maximum Tolerated Dose  Pharmacokinetics of Sorafenib (BAY43-9006),nausea
D000930,5.88,NCT00941863-4,Sorafenib 400 mg (200-mg Tablet),NCT00941863,Study to Determine the Safety  Maximum Tolerated Dose  Pharmacokinetics of Sorafenib (BAY43-9006),antidiarrheals
D000930,1.68,NCT00941863-5,Sorafenib 400 mg (Expansion),NCT00941863,Study to Determine the Safety  Maximum Tolerated Dose  Pharmacokinetics of Sorafenib (BAY43-9006),antidiarrheals
10017947,2.52,NCT00941863-5,Sorafenib 400 mg (Expansion),NCT00941863,Study to Determine the Safety  Maximum Tolerated Dose  Pharmacokinetics of Sorafenib (BAY43-9006),gastrointestinal disorders - other specify
D000855,1.68,NCT00941863-5,Sorafenib 400 mg (Expansion),NCT00941863,Study to Determine the Safety  Maximum Tolerated Dose  Pharmacokinetics of Sorafenib (BAY43-9006),anorexia
D003092,0.84,NCT00941863-5,Sorafenib 400 mg (Expansion),NCT00941863,Study to Determine the Safety  Maximum Tolerated Dose  Pharmacokinetics of Sorafenib (BAY43-9006),colitis
D003248,5.88,NCT00941863-4,Sorafenib 400 mg (200-mg Tablet),NCT00941863,Study to Determine the Safety  Maximum Tolerated Dose  Pharmacokinetics of Sorafenib (BAY43-9006),constipation
D003679,0.84,NCT00941863-5,Sorafenib 400 mg (Expansion),NCT00941863,Study to Determine the Safety  Maximum Tolerated Dose  Pharmacokinetics of Sorafenib (BAY43-9006),swallowing
D045823,0.84,NCT00941863-5,Sorafenib 400 mg (Expansion),NCT00941863,Study to Determine the Safety  Maximum Tolerated Dose  Pharmacokinetics of Sorafenib (BAY43-9006),ileus
D010195,0.84,NCT00941863-5,Sorafenib 400 mg (Expansion),NCT00941863,Study to Determine the Safety  Maximum Tolerated Dose  Pharmacokinetics of Sorafenib (BAY43-9006),pancreatitis
D004381,0.84,NCT00941863-5,Sorafenib 400 mg (Expansion),NCT00941863,Study to Determine the Safety  Maximum Tolerated Dose  Pharmacokinetics of Sorafenib (BAY43-9006),duodenal ulcer
D005334,5.88,NCT00941863-4,Sorafenib 400 mg (200-mg Tablet),NCT00941863,Study to Determine the Safety  Maximum Tolerated Dose  Pharmacokinetics of Sorafenib (BAY43-9006),fever
D005334,5.88,NCT00941863-5,Sorafenib 400 mg (Expansion),NCT00941863,Study to Determine the Safety  Maximum Tolerated Dose  Pharmacokinetics of Sorafenib (BAY43-9006),fever
D001037,4.2,NCT00941863-5,Sorafenib 400 mg (Expansion),NCT00941863,Study to Determine the Safety  Maximum Tolerated Dose  Pharmacokinetics of Sorafenib (BAY43-9006),logasthenia
D000071896,2.52,NCT00941863-5,Sorafenib 400 mg (Expansion),NCT00941863,Study to Determine the Safety  Maximum Tolerated Dose  Pharmacokinetics of Sorafenib (BAY43-9006),somatic symptoms
D000080867,5.88,NCT00941863-4,Sorafenib 400 mg (200-mg Tablet),NCT00941863,Study to Determine the Safety  Maximum Tolerated Dose  Pharmacokinetics of Sorafenib (BAY43-9006),gingipains
D000080867,8.4,NCT00941863-5,Sorafenib 400 mg (Expansion),NCT00941863,Study to Determine the Safety  Maximum Tolerated Dose  Pharmacokinetics of Sorafenib (BAY43-9006),gingipains
D015746,14.29,NCT00941863-1,Sorafenib 100 mg (50-mg Tablet),NCT00941863,Study to Determine the Safety  Maximum Tolerated Dose  Pharmacokinetics of Sorafenib (BAY43-9006),abdominal pain
D015746,8.33,NCT00941863-3,Sorafenib 400 mg (50-mg Tablet),NCT00941863,Study to Determine the Safety  Maximum Tolerated Dose  Pharmacokinetics of Sorafenib (BAY43-9006),abdominal pain
D015746,5.88,NCT00941863-4,Sorafenib 400 mg (200-mg Tablet),NCT00941863,Study to Determine the Safety  Maximum Tolerated Dose  Pharmacokinetics of Sorafenib (BAY43-9006),abdominal pain
D015746,3.36,NCT00941863-5,Sorafenib 400 mg (Expansion),NCT00941863,Study to Determine the Safety  Maximum Tolerated Dose  Pharmacokinetics of Sorafenib (BAY43-9006),abdominal pain
10062501,14.29,NCT00941863-1,Sorafenib 100 mg (50-mg Tablet),NCT00941863,Study to Determine the Safety  Maximum Tolerated Dose  Pharmacokinetics of Sorafenib (BAY43-9006),non-cardiac chest pain
10062501,2.52,NCT00941863-5,Sorafenib 400 mg (Expansion),NCT00941863,Study to Determine the Safety  Maximum Tolerated Dose  Pharmacokinetics of Sorafenib (BAY43-9006),non-cardiac chest pain
D006261,14.29,NCT00941863-1,Sorafenib 100 mg (50-mg Tablet),NCT00941863,Study to Determine the Safety  Maximum Tolerated Dose  Pharmacokinetics of Sorafenib (BAY43-9006),headache
D006261,8.33,NCT00941863-3,Sorafenib 400 mg (50-mg Tablet),NCT00941863,Study to Determine the Safety  Maximum Tolerated Dose  Pharmacokinetics of Sorafenib (BAY43-9006),headache
D006261,1.68,NCT00941863-5,Sorafenib 400 mg (Expansion),NCT00941863,Study to Determine the Safety  Maximum Tolerated Dose  Pharmacokinetics of Sorafenib (BAY43-9006),headache
10045158,0.84,NCT00941863-5,Sorafenib 400 mg (Expansion),NCT00941863,Study to Determine the Safety  Maximum Tolerated Dose  Pharmacokinetics of Sorafenib (BAY43-9006),tumor pain
D000068736,0.84,NCT00941863-5,Sorafenib 400 mg (Expansion),NCT00941863,Study to Determine the Safety  Maximum Tolerated Dose  Pharmacokinetics of Sorafenib (BAY43-9006),cymbalta
D000068258,0.84,NCT00941863-5,Sorafenib 400 mg (Expansion),NCT00941863,Study to Determine the Safety  Maximum Tolerated Dose  Pharmacokinetics of Sorafenib (BAY43-9006),avastin
D006967,5.88,NCT00941863-4,Sorafenib 400 mg (200-mg Tablet),NCT00941863,Study to Determine the Safety  Maximum Tolerated Dose  Pharmacokinetics of Sorafenib (BAY43-9006),allergic reaction
D005335,10.08,NCT00941863-5,Sorafenib 400 mg (Expansion),NCT00941863,Study to Determine the Safety  Maximum Tolerated Dose  Pharmacokinetics of Sorafenib (BAY43-9006),unknown origin fever
D000069544,5.88,NCT00941863-4,Sorafenib 400 mg (200-mg Tablet),NCT00941863,Study to Determine the Safety  Maximum Tolerated Dose  Pharmacokinetics of Sorafenib (BAY43-9006),encephalitis infection
D000069544,4.2,NCT00941863-5,Sorafenib 400 mg (Expansion),NCT00941863,Study to Determine the Safety  Maximum Tolerated Dose  Pharmacokinetics of Sorafenib (BAY43-9006),encephalitis infection
D011008,8.33,NCT00941863-3,Sorafenib 400 mg (50-mg Tablet),NCT00941863,Study to Determine the Safety  Maximum Tolerated Dose  Pharmacokinetics of Sorafenib (BAY43-9006),pneumococcal infections
D011008,2.52,NCT00941863-5,Sorafenib 400 mg (Expansion),NCT00941863,Study to Determine the Safety  Maximum Tolerated Dose  Pharmacokinetics of Sorafenib (BAY43-9006),pneumococcal infections
D000069544,5.88,NCT00941863-4,Sorafenib 400 mg (200-mg Tablet),NCT00941863,Study to Determine the Safety  Maximum Tolerated Dose  Pharmacokinetics of Sorafenib (BAY43-9006),encephalitis infection
D000069544,1.68,NCT00941863-5,Sorafenib 400 mg (Expansion),NCT00941863,Study to Determine the Safety  Maximum Tolerated Dose  Pharmacokinetics of Sorafenib (BAY43-9006),encephalitis infection
D000069544,1.68,NCT00941863-5,Sorafenib 400 mg (Expansion),NCT00941863,Study to Determine the Safety  Maximum Tolerated Dose  Pharmacokinetics of Sorafenib (BAY43-9006),encephalitis infection
D006943,1.68,NCT00941863-5,Sorafenib 400 mg (Expansion),NCT00941863,Study to Determine the Safety  Maximum Tolerated Dose  Pharmacokinetics of Sorafenib (BAY43-9006),hyperglycemia
D007008,1.68,NCT00941863-5,Sorafenib 400 mg (Expansion),NCT00941863,Study to Determine the Safety  Maximum Tolerated Dose  Pharmacokinetics of Sorafenib (BAY43-9006),hypokalemia
10021028,1.68,NCT00941863-5,Sorafenib 400 mg (Expansion),NCT00941863,Study to Determine the Safety  Maximum Tolerated Dose  Pharmacokinetics of Sorafenib (BAY43-9006),hypomagnesemia
D000681,0.84,NCT00941863-5,Sorafenib 400 mg (Expansion),NCT00941863,Study to Determine the Safety  Maximum Tolerated Dose  Pharmacokinetics of Sorafenib (BAY43-9006),amylase
D006934,0.84,NCT00941863-5,Sorafenib 400 mg (Expansion),NCT00941863,Study to Determine the Safety  Maximum Tolerated Dose  Pharmacokinetics of Sorafenib (BAY43-9006),hypercalcemia
D007003,0.84,NCT00941863-5,Sorafenib 400 mg (Expansion),NCT00941863,Study to Determine the Safety  Maximum Tolerated Dose  Pharmacokinetics of Sorafenib (BAY43-9006),hypoglycemia
D008049,0.84,NCT00941863-5,Sorafenib 400 mg (Expansion),NCT00941863,Study to Determine the Safety  Maximum Tolerated Dose  Pharmacokinetics of Sorafenib (BAY43-9006),lipase
10028395,2.52,NCT00941863-5,Sorafenib 400 mg (Expansion),NCT00941863,Study to Determine the Safety  Maximum Tolerated Dose  Pharmacokinetics of Sorafenib (BAY43-9006),musculoskeletal and connective tissue disorder - other specify
D009462,8.33,NCT00941863-3,Sorafenib 400 mg (50-mg Tablet),NCT00941863,Study to Determine the Safety  Maximum Tolerated Dose  Pharmacokinetics of Sorafenib (BAY43-9006),neurology
D009462,5.88,NCT00941863-4,Sorafenib 400 mg (200-mg Tablet),NCT00941863,Study to Determine the Safety  Maximum Tolerated Dose  Pharmacokinetics of Sorafenib (BAY43-9006),neurology
D009462,7.56,NCT00941863-5,Sorafenib 400 mg (Expansion),NCT00941863,Study to Determine the Safety  Maximum Tolerated Dose  Pharmacokinetics of Sorafenib (BAY43-9006),neurology
D013575,5.88,NCT00941863-4,Sorafenib 400 mg (200-mg Tablet),NCT00941863,Study to Determine the Safety  Maximum Tolerated Dose  Pharmacokinetics of Sorafenib (BAY43-9006),syncope
D013575,2.52,NCT00941863-5,Sorafenib 400 mg (Expansion),NCT00941863,Study to Determine the Safety  Maximum Tolerated Dose  Pharmacokinetics of Sorafenib (BAY43-9006),syncope
10023030,33.33,NCT00941863-2,Sorafenib 200 mg (50-mg Tablet),NCT00941863,Study to Determine the Safety  Maximum Tolerated Dose  Pharmacokinetics of Sorafenib (BAY43-9006),ischemia cerebrovascular
10023030,8.33,NCT00941863-3,Sorafenib 400 mg (50-mg Tablet),NCT00941863,Study to Determine the Safety  Maximum Tolerated Dose  Pharmacokinetics of Sorafenib (BAY43-9006),ischemia cerebrovascular
10023030,0.84,NCT00941863-5,Sorafenib 400 mg (Expansion),NCT00941863,Study to Determine the Safety  Maximum Tolerated Dose  Pharmacokinetics of Sorafenib (BAY43-9006),ischemia cerebrovascular
D003221,5.88,NCT00941863-4,Sorafenib 400 mg (200-mg Tablet),NCT00941863,Study to Determine the Safety  Maximum Tolerated Dose  Pharmacokinetics of Sorafenib (BAY43-9006),confusion
D003221,0.84,NCT00941863-5,Sorafenib 400 mg (Expansion),NCT00941863,Study to Determine the Safety  Maximum Tolerated Dose  Pharmacokinetics of Sorafenib (BAY43-9006),confusion
D003294,1.68,NCT00941863-5,Sorafenib 400 mg (Expansion),NCT00941863,Study to Determine the Safety  Maximum Tolerated Dose  Pharmacokinetics of Sorafenib (BAY43-9006),seizures febrile
D003244,1.68,NCT00941863-5,Sorafenib 400 mg (Expansion),NCT00941863,Study to Determine the Safety  Maximum Tolerated Dose  Pharmacokinetics of Sorafenib (BAY43-9006),depressed level of consciousness
D001259,0.84,NCT00941863-5,Sorafenib 400 mg (Expansion),NCT00941863,Study to Determine the Safety  Maximum Tolerated Dose  Pharmacokinetics of Sorafenib (BAY43-9006),ataxia
D001037,14.29,NCT00941863-1,Sorafenib 100 mg (50-mg Tablet),NCT00941863,Study to Determine the Safety  Maximum Tolerated Dose  Pharmacokinetics of Sorafenib (BAY43-9006),aphasia
D002607,14.29,NCT00941863-1,Sorafenib 100 mg (50-mg Tablet),NCT00941863,Study to Determine the Safety  Maximum Tolerated Dose  Pharmacokinetics of Sorafenib (BAY43-9006),hereditary type i motor and sensory neuropathy
D002607,8.33,NCT00941863-3,Sorafenib 400 mg (50-mg Tablet),NCT00941863,Study to Determine the Safety  Maximum Tolerated Dose  Pharmacokinetics of Sorafenib (BAY43-9006),hereditary type i motor and sensory neuropathy
D000308,3.36,NCT00941863-5,Sorafenib 400 mg (Expansion),NCT00941863,Study to Determine the Safety  Maximum Tolerated Dose  Pharmacokinetics of Sorafenib (BAY43-9006),hyperadrenalism
D003404,8.33,NCT00941863-3,Sorafenib 400 mg (50-mg Tablet),NCT00941863,Study to Determine the Safety  Maximum Tolerated Dose  Pharmacokinetics of Sorafenib (BAY43-9006),creatinine
D003404,5.88,NCT00941863-4,Sorafenib 400 mg (200-mg Tablet),NCT00941863,Study to Determine the Safety  Maximum Tolerated Dose  Pharmacokinetics of Sorafenib (BAY43-9006),creatinine
D014517,0.84,NCT00941863-5,Sorafenib 400 mg (Expansion),NCT00941863,Study to Determine the Safety  Maximum Tolerated Dose  Pharmacokinetics of Sorafenib (BAY43-9006),ureteral obstruction
D016066,5.88,NCT00941863-4,Sorafenib 400 mg (200-mg Tablet),NCT00941863,Study to Determine the Safety  Maximum Tolerated Dose  Pharmacokinetics of Sorafenib (BAY43-9006),pleural effusion malignant
D016066,5.88,NCT00941863-5,Sorafenib 400 mg (Expansion),NCT00941863,Study to Determine the Safety  Maximum Tolerated Dose  Pharmacokinetics of Sorafenib (BAY43-9006),pleural effusion malignant
D004417,16.67,NCT00941863-3,Sorafenib 400 mg (50-mg Tablet),NCT00941863,Study to Determine the Safety  Maximum Tolerated Dose  Pharmacokinetics of Sorafenib (BAY43-9006),breath shortness
D004417,2.52,NCT00941863-5,Sorafenib 400 mg (Expansion),NCT00941863,Study to Determine the Safety  Maximum Tolerated Dose  Pharmacokinetics of Sorafenib (BAY43-9006),breath shortness
D010547,14.29,NCT00941863-1,Sorafenib 100 mg (50-mg Tablet),NCT00941863,Study to Determine the Safety  Maximum Tolerated Dose  Pharmacokinetics of Sorafenib (BAY43-9006),alveolar capillary dysplasia with misalignment of pulmonary veins and other congenital anomalies
D010547,1.68,NCT00941863-5,Sorafenib 400 mg (Expansion),NCT00941863,Study to Determine the Safety  Maximum Tolerated Dose  Pharmacokinetics of Sorafenib (BAY43-9006),alveolar capillary dysplasia with misalignment of pulmonary veins and other congenital anomalies
D011014,0.84,NCT00941863-5,Sorafenib 400 mg (Expansion),NCT00941863,Study to Determine the Safety  Maximum Tolerated Dose  Pharmacokinetics of Sorafenib (BAY43-9006),pneumonitis
D003880,14.29,NCT00941863-1,Sorafenib 100 mg (50-mg Tablet),NCT00941863,Study to Determine the Safety  Maximum Tolerated Dose  Pharmacokinetics of Sorafenib (BAY43-9006),dermatology
D003880,8.33,NCT00941863-3,Sorafenib 400 mg (50-mg Tablet),NCT00941863,Study to Determine the Safety  Maximum Tolerated Dose  Pharmacokinetics of Sorafenib (BAY43-9006),dermatology
D003880,8.4,NCT00941863-5,Sorafenib 400 mg (Expansion),NCT00941863,Study to Determine the Safety  Maximum Tolerated Dose  Pharmacokinetics of Sorafenib (BAY43-9006),dermatology
D014947,0.84,NCT00941863-5,Sorafenib 400 mg (Expansion),NCT00941863,Study to Determine the Safety  Maximum Tolerated Dose  Pharmacokinetics of Sorafenib (BAY43-9006),wounds
D000073296,0.84,NCT00941863-5,Sorafenib 400 mg (Expansion),NCT00941863,Study to Determine the Safety  Maximum Tolerated Dose  Pharmacokinetics of Sorafenib (BAY43-9006),noninfectious diseases
D005076,14.29,NCT00941863-1,Sorafenib 100 mg (50-mg Tablet),NCT00941863,Study to Determine the Safety  Maximum Tolerated Dose  Pharmacokinetics of Sorafenib (BAY43-9006),rash
D006470,16.67,NCT00941863-3,Sorafenib 400 mg (50-mg Tablet),NCT00941863,Study to Determine the Safety  Maximum Tolerated Dose  Pharmacokinetics of Sorafenib (BAY43-9006),hemorrhage
D006470,0.84,NCT00941863-5,Sorafenib 400 mg (Expansion),NCT00941863,Study to Determine the Safety  Maximum Tolerated Dose  Pharmacokinetics of Sorafenib (BAY43-9006),hemorrhage
D006470,2.52,NCT00941863-5,Sorafenib 400 mg (Expansion),NCT00941863,Study to Determine the Safety  Maximum Tolerated Dose  Pharmacokinetics of Sorafenib (BAY43-9006),hemorrhage
D006470,5.88,NCT00941863-4,Sorafenib 400 mg (200-mg Tablet),NCT00941863,Study to Determine the Safety  Maximum Tolerated Dose  Pharmacokinetics of Sorafenib (BAY43-9006),bleeding
D006470,0.84,NCT00941863-5,Sorafenib 400 mg (Expansion),NCT00941863,Study to Determine the Safety  Maximum Tolerated Dose  Pharmacokinetics of Sorafenib (BAY43-9006),bleeding
D006469,0.84,NCT00941863-5,Sorafenib 400 mg (Expansion),NCT00941863,Study to Determine the Safety  Maximum Tolerated Dose  Pharmacokinetics of Sorafenib (BAY43-9006),hemoptysis
D006470,0.84,NCT00941863-5,Sorafenib 400 mg (Expansion),NCT00941863,Study to Determine the Safety  Maximum Tolerated Dose  Pharmacokinetics of Sorafenib (BAY43-9006),bleeding
D001791,0.84,NCT00941863-5,Sorafenib 400 mg (Expansion),NCT00941863,Study to Determine the Safety  Maximum Tolerated Dose  Pharmacokinetics of Sorafenib (BAY43-9006),thrombocytopathy
D014592,0.84,NCT00941863-5,Sorafenib 400 mg (Expansion),NCT00941863,Study to Determine the Safety  Maximum Tolerated Dose  Pharmacokinetics of Sorafenib (BAY43-9006),vaginal bleeding
D014592,0.84,NCT00941863-5,Sorafenib 400 mg (Expansion),NCT00941863,Study to Determine the Safety  Maximum Tolerated Dose  Pharmacokinetics of Sorafenib (BAY43-9006),vaginal bleeding
D064420,100.0,NCT00964743-1,Intrathecal DepoCyt and Oral Sorafenib,NCT00964743,Depocyt® With Sorafenib in Neoplastic Meningitis,adverse drug events
D003643,50.0,NCT00964743-1,Intrathecal DepoCyt and Oral Sorafenib,NCT00964743,Depocyt® With Sorafenib in Neoplastic Meningitis,death
D018450,50.0,NCT00964743-1,Intrathecal DepoCyt and Oral Sorafenib,NCT00964743,Depocyt® With Sorafenib in Neoplastic Meningitis,disease progression
D064420,50.0,NCT00987935-1,Phase I Group I Nintedanib 100 mg Bid,NCT00987935,A Phase I / II Trial of Nintedanib in Asian Hepatocellular Carcinoma Patients,adverse drug events
D064420,33.33,NCT00987935-2,Phase I Group I Nintedanib 150 mg Bid,NCT00987935,A Phase I / II Trial of Nintedanib in Asian Hepatocellular Carcinoma Patients,adverse drug events
D064420,100.0,NCT00987935-4,Phase I Group II Nintedanib 50 mg Bid,NCT00987935,A Phase I / II Trial of Nintedanib in Asian Hepatocellular Carcinoma Patients,adverse drug events
D064420,57.14,NCT00987935-5,Phase I Group II Nintedanib 100 mg Bid,NCT00987935,A Phase I / II Trial of Nintedanib in Asian Hepatocellular Carcinoma Patients,adverse drug events
D064420,33.33,NCT00987935-6,Phase I Group II Nintedanib 150 mg Bid,NCT00987935,A Phase I / II Trial of Nintedanib in Asian Hepatocellular Carcinoma Patients,adverse drug events
D064420,62.5,NCT00987935-7,Phase I Group II Nintedanib 200 mg Bid,NCT00987935,A Phase I / II Trial of Nintedanib in Asian Hepatocellular Carcinoma Patients,adverse drug events
D064420,46.03,NCT00987935-8,Phase II Nintedanib 200 mg Bid,NCT00987935,A Phase I / II Trial of Nintedanib in Asian Hepatocellular Carcinoma Patients,adverse drug events
D064420,56.25,NCT00987935-9,Phase II Sorafenib 400 mg Bid,NCT00987935,A Phase I / II Trial of Nintedanib in Asian Hepatocellular Carcinoma Patients,adverse drug events
D000081032,33.33,NCT00987935-4,Phase I Group II Nintedanib 50 mg Bid,NCT00987935,A Phase I / II Trial of Nintedanib in Asian Hepatocellular Carcinoma Patients,haemorrhagic pancreatitis
D013921,1.59,NCT00987935-8,Phase II Nintedanib 200 mg Bid,NCT00987935,A Phase I / II Trial of Nintedanib in Asian Hepatocellular Carcinoma Patients,thrombocytopenia
D054058,3.12,NCT00987935-9,Phase II Sorafenib 400 mg Bid,NCT00987935,A Phase I / II Trial of Nintedanib in Asian Hepatocellular Carcinoma Patients,acute coronary syndrome
D056988,1.59,NCT00987935-8,Phase II Nintedanib 200 mg Bid,NCT00987935,A Phase I / II Trial of Nintedanib in Asian Hepatocellular Carcinoma Patients,acute anterior wall myocardial infarction
10000060,33.33,NCT00987935-2,Phase I Group I Nintedanib 150 mg Bid,NCT00987935,A Phase I / II Trial of Nintedanib in Asian Hepatocellular Carcinoma Patients,abdominal distension
10000060,14.29,NCT00987935-5,Phase I Group II Nintedanib 100 mg Bid,NCT00987935,A Phase I / II Trial of Nintedanib in Asian Hepatocellular Carcinoma Patients,abdominal distension
10000060,3.12,NCT00987935-9,Phase II Sorafenib 400 mg Bid,NCT00987935,A Phase I / II Trial of Nintedanib in Asian Hepatocellular Carcinoma Patients,abdominal distension
D015746,33.33,NCT00987935-4,Phase I Group II Nintedanib 50 mg Bid,NCT00987935,A Phase I / II Trial of Nintedanib in Asian Hepatocellular Carcinoma Patients,abdominal pain
D015746,6.25,NCT00987935-7,Phase I Group II Nintedanib 200 mg Bid,NCT00987935,A Phase I / II Trial of Nintedanib in Asian Hepatocellular Carcinoma Patients,abdominal pain
D015746,1.59,NCT00987935-8,Phase II Nintedanib 200 mg Bid,NCT00987935,A Phase I / II Trial of Nintedanib in Asian Hepatocellular Carcinoma Patients,abdominal pain
D015746,3.12,NCT00987935-9,Phase II Sorafenib 400 mg Bid,NCT00987935,A Phase I / II Trial of Nintedanib in Asian Hepatocellular Carcinoma Patients,abdominal pain
D012003,3.12,NCT00987935-9,Phase II Sorafenib 400 mg Bid,NCT00987935,A Phase I / II Trial of Nintedanib in Asian Hepatocellular Carcinoma Patients,anal fistula
D001201,3.17,NCT00987935-8,Phase II Nintedanib 200 mg Bid,NCT00987935,A Phase I / II Trial of Nintedanib in Asian Hepatocellular Carcinoma Patients,ascites
UNKNOWN-check-for-typo,3.17,NCT00987935-8,Phase II Nintedanib 200 mg Bid,NCT00987935,A Phase I / II Trial of Nintedanib in Asian Hepatocellular Carcinoma Patients,D00
D005517,1.59,NCT00987935-8,Phase II Nintedanib 200 mg Bid,NCT00987935,A Phase I / II Trial of Nintedanib in Asian Hepatocellular Carcinoma Patients,food poisoning
D020115,6.25,NCT00987935-7,Phase I Group II Nintedanib 200 mg Bid,NCT00987935,A Phase I / II Trial of Nintedanib in Asian Hepatocellular Carcinoma Patients,progastricsin
10017815,6.25,NCT00987935-7,Phase I Group II Nintedanib 200 mg Bid,NCT00987935,A Phase I / II Trial of Nintedanib in Asian Hepatocellular Carcinoma Patients,gastric perforation
D013276,6.25,NCT00987935-7,Phase I Group II Nintedanib 200 mg Bid,NCT00987935,A Phase I / II Trial of Nintedanib in Asian Hepatocellular Carcinoma Patients,gastric ulcer
D013276,1.59,NCT00987935-8,Phase II Nintedanib 200 mg Bid,NCT00987935,A Phase I / II Trial of Nintedanib in Asian Hepatocellular Carcinoma Patients,gastric ulcer
UNKNOWN-check-for-typo,1.59,NCT00987935-8,Phase II Nintedanib 200 mg Bid,NCT00987935,A Phase I / II Trial of Nintedanib in Asian Hepatocellular Carcinoma Patients,D00
D000069196,33.33,NCT00987935-4,Phase I Group II Nintedanib 50 mg Bid,NCT00987935,A Phase I / II Trial of Nintedanib in Asian Hepatocellular Carcinoma Patients,gastrointestinal microbiome
D000069196,1.59,NCT00987935-8,Phase II Nintedanib 200 mg Bid,NCT00987935,A Phase I / II Trial of Nintedanib in Asian Hepatocellular Carcinoma Patients,gastrointestinal microbiome
UNKNOWN-check-for-typo,3.12,NCT00987935-9,Phase II Sorafenib 400 mg Bid,NCT00987935,A Phase I / II Trial of Nintedanib in Asian Hepatocellular Carcinoma Patients,D00
UNKNOWN-check-for-typo,1.59,NCT00987935-8,Phase II Nintedanib 200 mg Bid,NCT00987935,A Phase I / II Trial of Nintedanib in Asian Hepatocellular Carcinoma Patients,D00
D009325,3.12,NCT00987935-9,Phase II Sorafenib 400 mg Bid,NCT00987935,A Phase I / II Trial of Nintedanib in Asian Hepatocellular Carcinoma Patients,nausea
D014648,1.59,NCT00987935-8,Phase II Nintedanib 200 mg Bid,NCT00987935,A Phase I / II Trial of Nintedanib in Asian Hepatocellular Carcinoma Patients,varices
D010195,3.12,NCT00987935-9,Phase II Sorafenib 400 mg Bid,NCT00987935,A Phase I / II Trial of Nintedanib in Asian Hepatocellular Carcinoma Patients,acute pancreatitis
D041742,33.33,NCT00987935-4,Phase I Group II Nintedanib 50 mg Bid,NCT00987935,A Phase I / II Trial of Nintedanib in Asian Hepatocellular Carcinoma Patients,upper gastrointestinal tract
D041742,33.33,NCT00987935-6,Phase I Group II Nintedanib 150 mg Bid,NCT00987935,A Phase I / II Trial of Nintedanib in Asian Hepatocellular Carcinoma Patients,upper gastrointestinal tract
D041742,4.76,NCT00987935-8,Phase II Nintedanib 200 mg Bid,NCT00987935,A Phase I / II Trial of Nintedanib in Asian Hepatocellular Carcinoma Patients,upper gastrointestinal tract
D041742,3.12,NCT00987935-9,Phase II Sorafenib 400 mg Bid,NCT00987935,A Phase I / II Trial of Nintedanib in Asian Hepatocellular Carcinoma Patients,upper gastrointestinal tract
D014839,25.0,NCT00987935-1,Phase I Group I Nintedanib 100 mg Bid,NCT00987935,A Phase I / II Trial of Nintedanib in Asian Hepatocellular Carcinoma Patients,vomiting
D014839,14.29,NCT00987935-5,Phase I Group II Nintedanib 100 mg Bid,NCT00987935,A Phase I / II Trial of Nintedanib in Asian Hepatocellular Carcinoma Patients,vomiting
D014839,6.25,NCT00987935-7,Phase I Group II Nintedanib 200 mg Bid,NCT00987935,A Phase I / II Trial of Nintedanib in Asian Hepatocellular Carcinoma Patients,vomiting
D001247,14.29,NCT00987935-5,Phase I Group II Nintedanib 100 mg Bid,NCT00987935,A Phase I / II Trial of Nintedanib in Asian Hepatocellular Carcinoma Patients,asthenia
D001247,6.25,NCT00987935-9,Phase II Sorafenib 400 mg Bid,NCT00987935,A Phase I / II Trial of Nintedanib in Asian Hepatocellular Carcinoma Patients,asthenia
D002637,1.59,NCT00987935-8,Phase II Nintedanib 200 mg Bid,NCT00987935,A Phase I / II Trial of Nintedanib in Asian Hepatocellular Carcinoma Patients,chest pain
D018450,14.29,NCT00987935-5,Phase I Group II Nintedanib 100 mg Bid,NCT00987935,A Phase I / II Trial of Nintedanib in Asian Hepatocellular Carcinoma Patients,disease progression
D005221,1.59,NCT00987935-8,Phase II Nintedanib 200 mg Bid,NCT00987935,A Phase I / II Trial of Nintedanib in Asian Hepatocellular Carcinoma Patients,fatigue
10025482,6.25,NCT00987935-7,Phase I Group II Nintedanib 200 mg Bid,NCT00987935,A Phase I / II Trial of Nintedanib in Asian Hepatocellular Carcinoma Patients,malaise
D005334,14.29,NCT00987935-5,Phase I Group II Nintedanib 100 mg Bid,NCT00987935,A Phase I / II Trial of Nintedanib in Asian Hepatocellular Carcinoma Patients,pyrexia
D005334,6.35,NCT00987935-8,Phase II Nintedanib 200 mg Bid,NCT00987935,A Phase I / II Trial of Nintedanib in Asian Hepatocellular Carcinoma Patients,pyrexia
D005334,9.38,NCT00987935-9,Phase II Sorafenib 400 mg Bid,NCT00987935,A Phase I / II Trial of Nintedanib in Asian Hepatocellular Carcinoma Patients,pyrexia
D041881,1.59,NCT00987935-8,Phase II Nintedanib 200 mg Bid,NCT00987935,A Phase I / II Trial of Nintedanib in Asian Hepatocellular Carcinoma Patients,acute cholecystitis
D017093,1.59,NCT00987935-8,Phase II Nintedanib 200 mg Bid,NCT00987935,A Phase I / II Trial of Nintedanib in Asian Hepatocellular Carcinoma Patients,hepatic failure
D017093,6.25,NCT00987935-9,Phase II Sorafenib 400 mg Bid,NCT00987935,A Phase I / II Trial of Nintedanib in Asian Hepatocellular Carcinoma Patients,hepatic failure
D011681,12.5,NCT00987935-7,Phase I Group II Nintedanib 200 mg Bid,NCT00987935,A Phase I / II Trial of Nintedanib in Asian Hepatocellular Carcinoma Patients,pupillary functions abnormal
D011681,6.25,NCT00987935-9,Phase II Sorafenib 400 mg Bid,NCT00987935,A Phase I / II Trial of Nintedanib in Asian Hepatocellular Carcinoma Patients,pupillary functions abnormal
D006505,33.33,NCT00987935-4,Phase I Group II Nintedanib 50 mg Bid,NCT00987935,A Phase I / II Trial of Nintedanib in Asian Hepatocellular Carcinoma Patients,hepatitis
UNKNOWN-check-for-typo,1.59,NCT00987935-8,Phase II Nintedanib 200 mg Bid,NCT00987935,A Phase I / II Trial of Nintedanib in Asian Hepatocellular Carcinoma Patients,D00
10061695,1.59,NCT00987935-8,Phase II Nintedanib 200 mg Bid,NCT00987935,A Phase I / II Trial of Nintedanib in Asian Hepatocellular Carcinoma Patients,biliary tract infection
D002481,1.59,NCT00987935-8,Phase II Nintedanib 200 mg Bid,NCT00987935,A Phase I / II Trial of Nintedanib in Asian Hepatocellular Carcinoma Patients,cellulitis
D010538,1.59,NCT00987935-8,Phase II Nintedanib 200 mg Bid,NCT00987935,A Phase I / II Trial of Nintedanib in Asian Hepatocellular Carcinoma Patients,peritonitis
D011014,3.12,NCT00987935-9,Phase II Sorafenib 400 mg Bid,NCT00987935,A Phase I / II Trial of Nintedanib in Asian Hepatocellular Carcinoma Patients,pneumonia
D018805,3.17,NCT00987935-8,Phase II Nintedanib 200 mg Bid,NCT00987935,A Phase I / II Trial of Nintedanib in Asian Hepatocellular Carcinoma Patients,sepsis
D012772,6.25,NCT00987935-7,Phase I Group II Nintedanib 200 mg Bid,NCT00987935,A Phase I / II Trial of Nintedanib in Asian Hepatocellular Carcinoma Patients,septic shock
D012141,6.25,NCT00987935-7,Phase I Group II Nintedanib 200 mg Bid,NCT00987935,A Phase I / II Trial of Nintedanib in Asian Hepatocellular Carcinoma Patients,upper respiratory tract infections
D005131,1.59,NCT00987935-8,Phase II Nintedanib 200 mg Bid,NCT00987935,A Phase I / II Trial of Nintedanib in Asian Hepatocellular Carcinoma Patients,eye injury
10003481,1.59,NCT00987935-8,Phase II Nintedanib 200 mg Bid,NCT00987935,A Phase I / II Trial of Nintedanib in Asian Hepatocellular Carcinoma Patients,aspartate aminotransferase increased
10003481,3.12,NCT00987935-9,Phase II Sorafenib 400 mg Bid,NCT00987935,A Phase I / II Trial of Nintedanib in Asian Hepatocellular Carcinoma Patients,aspartate aminotransferase increased
10005364,12.5,NCT00987935-7,Phase I Group II Nintedanib 200 mg Bid,NCT00987935,A Phase I / II Trial of Nintedanib in Asian Hepatocellular Carcinoma Patients,blood bilirubin increased
10005364,1.59,NCT00987935-8,Phase II Nintedanib 200 mg Bid,NCT00987935,A Phase I / II Trial of Nintedanib in Asian Hepatocellular Carcinoma Patients,blood bilirubin increased
10005364,3.12,NCT00987935-9,Phase II Sorafenib 400 mg Bid,NCT00987935,A Phase I / II Trial of Nintedanib in Asian Hepatocellular Carcinoma Patients,blood bilirubin increased
10011368,3.12,NCT00987935-9,Phase II Sorafenib 400 mg Bid,NCT00987935,A Phase I / II Trial of Nintedanib in Asian Hepatocellular Carcinoma Patients,creatinine increased
D001806,1.59,NCT00987935-8,Phase II Nintedanib 200 mg Bid,NCT00987935,A Phase I / II Trial of Nintedanib in Asian Hepatocellular Carcinoma Patients,blood urea nitrogen
D001066,14.29,NCT00987935-5,Phase I Group II Nintedanib 100 mg Bid,NCT00987935,A Phase I / II Trial of Nintedanib in Asian Hepatocellular Carcinoma Patients,appetite
UNKNOWN-check-for-typo,1.59,NCT00987935-8,Phase II Nintedanib 200 mg Bid,NCT00987935,A Phase I / II Trial of Nintedanib in Asian Hepatocellular Carcinoma Patients,D00
UNKNOWN-check-for-typo,3.17,NCT00987935-8,Phase II Nintedanib 200 mg Bid,NCT00987935,A Phase I / II Trial of Nintedanib in Asian Hepatocellular Carcinoma Patients,D00
UNKNOWN-check-for-typo,1.59,NCT00987935-8,Phase II Nintedanib 200 mg Bid,NCT00987935,A Phase I / II Trial of Nintedanib in Asian Hepatocellular Carcinoma Patients,D00
D001416,6.25,NCT00987935-7,Phase I Group II Nintedanib 200 mg Bid,NCT00987935,A Phase I / II Trial of Nintedanib in Asian Hepatocellular Carcinoma Patients,back pain
D002637,33.33,NCT00987935-4,Phase I Group II Nintedanib 50 mg Bid,NCT00987935,A Phase I / II Trial of Nintedanib in Asian Hepatocellular Carcinoma Patients,chest pain
D005598,6.25,NCT00987935-7,Phase I Group II Nintedanib 200 mg Bid,NCT00987935,A Phase I / II Trial of Nintedanib in Asian Hepatocellular Carcinoma Patients,pathological fracture
D005598,1.59,NCT00987935-8,Phase II Nintedanib 200 mg Bid,NCT00987935,A Phase I / II Trial of Nintedanib in Asian Hepatocellular Carcinoma Patients,pathological fracture
D008113,6.25,NCT00987935-7,Phase I Group II Nintedanib 200 mg Bid,NCT00987935,A Phase I / II Trial of Nintedanib in Asian Hepatocellular Carcinoma Patients,hepatic cancer
D006528,25.0,NCT00987935-1,Phase I Group I Nintedanib 100 mg Bid,NCT00987935,A Phase I / II Trial of Nintedanib in Asian Hepatocellular Carcinoma Patients,hepatocellular carcinoma
D006528,33.33,NCT00987935-4,Phase I Group II Nintedanib 50 mg Bid,NCT00987935,A Phase I / II Trial of Nintedanib in Asian Hepatocellular Carcinoma Patients,hepatocellular carcinoma
D006528,28.57,NCT00987935-5,Phase I Group II Nintedanib 100 mg Bid,NCT00987935,A Phase I / II Trial of Nintedanib in Asian Hepatocellular Carcinoma Patients,hepatocellular carcinoma
D006528,6.25,NCT00987935-7,Phase I Group II Nintedanib 200 mg Bid,NCT00987935,A Phase I / II Trial of Nintedanib in Asian Hepatocellular Carcinoma Patients,hepatocellular carcinoma
D009369,6.25,NCT00987935-7,Phase I Group II Nintedanib 200 mg Bid,NCT00987935,A Phase I / II Trial of Nintedanib in Asian Hepatocellular Carcinoma Patients,malignant neoplasms
D009369,9.52,NCT00987935-8,Phase II Nintedanib 200 mg Bid,NCT00987935,A Phase I / II Trial of Nintedanib in Asian Hepatocellular Carcinoma Patients,malignant neoplasms
D009369,6.25,NCT00987935-9,Phase II Sorafenib 400 mg Bid,NCT00987935,A Phase I / II Trial of Nintedanib in Asian Hepatocellular Carcinoma Patients,malignant neoplasms
D002490,1.59,NCT00987935-8,Phase II Nintedanib 200 mg Bid,NCT00987935,A Phase I / II Trial of Nintedanib in Asian Hepatocellular Carcinoma Patients,central nervous system
D002490,3.12,NCT00987935-9,Phase II Sorafenib 400 mg Bid,NCT00987935,A Phase I / II Trial of Nintedanib in Asian Hepatocellular Carcinoma Patients,central nervous system
D000080867,14.29,NCT00987935-5,Phase I Group II Nintedanib 100 mg Bid,NCT00987935,A Phase I / II Trial of Nintedanib in Asian Hepatocellular Carcinoma Patients,gingipains
D010255,1.59,NCT00987935-8,Phase II Nintedanib 200 mg Bid,NCT00987935,A Phase I / II Trial of Nintedanib in Asian Hepatocellular Carcinoma Patients,paranasal sinus cancer
D005334,1.59,NCT00987935-8,Phase II Nintedanib 200 mg Bid,NCT00987935,A Phase I / II Trial of Nintedanib in Asian Hepatocellular Carcinoma Patients,fever
D018365,3.12,NCT00987935-9,Phase II Sorafenib 400 mg Bid,NCT00987935,A Phase I / II Trial of Nintedanib in Asian Hepatocellular Carcinoma Patients,residual tumour
D012421,14.29,NCT00987935-5,Phase I Group II Nintedanib 100 mg Bid,NCT00987935,A Phase I / II Trial of Nintedanib in Asian Hepatocellular Carcinoma Patients,rupture
D012421,1.59,NCT00987935-8,Phase II Nintedanib 200 mg Bid,NCT00987935,A Phase I / II Trial of Nintedanib in Asian Hepatocellular Carcinoma Patients,rupture
D008569,1.59,NCT00987935-8,Phase II Nintedanib 200 mg Bid,NCT00987935,A Phase I / II Trial of Nintedanib in Asian Hepatocellular Carcinoma Patients,retention disorders cognitive
D006261,25.0,NCT00987935-1,Phase I Group I Nintedanib 100 mg Bid,NCT00987935,A Phase I / II Trial of Nintedanib in Asian Hepatocellular Carcinoma Patients,headache
D010291,1.59,NCT00987935-8,Phase II Nintedanib 200 mg Bid,NCT00987935,A Phase I / II Trial of Nintedanib in Asian Hepatocellular Carcinoma Patients,hemiparesis
D006501,3.12,NCT00987935-9,Phase II Sorafenib 400 mg Bid,NCT00987935,A Phase I / II Trial of Nintedanib in Asian Hepatocellular Carcinoma Patients,hepatic encephalopathy
D012585,1.59,NCT00987935-8,Phase II Nintedanib 200 mg Bid,NCT00987935,A Phase I / II Trial of Nintedanib in Asian Hepatocellular Carcinoma Patients,sciatica
D001007,1.59,NCT00987935-8,Phase II Nintedanib 200 mg Bid,NCT00987935,A Phase I / II Trial of Nintedanib in Asian Hepatocellular Carcinoma Patients,anxiety
D051437,1.59,NCT00987935-8,Phase II Nintedanib 200 mg Bid,NCT00987935,A Phase I / II Trial of Nintedanib in Asian Hepatocellular Carcinoma Patients,renal failure
D007676,1.59,NCT00987935-8,Phase II Nintedanib 200 mg Bid,NCT00987935,A Phase I / II Trial of Nintedanib in Asian Hepatocellular Carcinoma Patients,renal failure chronic
UNKNOWN-check-for-typo,3.17,NCT00987935-8,Phase II Nintedanib 200 mg Bid,NCT00987935,A Phase I / II Trial of Nintedanib in Asian Hepatocellular Carcinoma Patients,D00
D010996,1.59,NCT00987935-8,Phase II Nintedanib 200 mg Bid,NCT00987935,A Phase I / II Trial of Nintedanib in Asian Hepatocellular Carcinoma Patients,pleural effusion
D011015,1.59,NCT00987935-8,Phase II Nintedanib 200 mg Bid,NCT00987935,A Phase I / II Trial of Nintedanib in Asian Hepatocellular Carcinoma Patients,aspiration pneumonia
D011014,6.25,NCT00987935-7,Phase I Group II Nintedanib 200 mg Bid,NCT00987935,A Phase I / II Trial of Nintedanib in Asian Hepatocellular Carcinoma Patients,pneumonitis
D011655,3.12,NCT00987935-9,Phase II Sorafenib 400 mg Bid,NCT00987935,A Phase I / II Trial of Nintedanib in Asian Hepatocellular Carcinoma Patients,pulmonary embolism
D012131,1.59,NCT00987935-8,Phase II Nintedanib 200 mg Bid,NCT00987935,A Phase I / II Trial of Nintedanib in Asian Hepatocellular Carcinoma Patients,respiratory failure
10054692,1.59,NCT00987935-8,Phase II Nintedanib 200 mg Bid,NCT00987935,A Phase I / II Trial of Nintedanib in Asian Hepatocellular Carcinoma Patients,visceral arterial ischemia
D009026,7.19,NCT01015833-1,Arm I (Doxorubicin Hydrochloride Sorafenib Tosylate),NCT01015833,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,mortality
D009026,9.36,NCT01015833-2,Arm II (Sorafenib Tosylate),NCT01015833,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,mortality
D064420,42.51,NCT01015833-1,Arm I (Doxorubicin Hydrochloride Sorafenib Tosylate),NCT01015833,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,adverse drug events
D064420,33.33,NCT01015833-2,Arm II (Sorafenib Tosylate),NCT01015833,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,adverse drug events
D000740,5.39,NCT01015833-1,Arm I (Doxorubicin Hydrochloride Sorafenib Tosylate),NCT01015833,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,anemia
D000740,2.34,NCT01015833-2,Arm II (Sorafenib Tosylate),NCT01015833,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,anemia
D064147,4.19,NCT01015833-1,Arm I (Doxorubicin Hydrochloride Sorafenib Tosylate),NCT01015833,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,febrile neutropenia
D007964,0.6,NCT01015833-1,Arm I (Doxorubicin Hydrochloride Sorafenib Tosylate),NCT01015833,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,leukocytosis
D013154,0.58,NCT01015833-2,Arm II (Sorafenib Tosylate),NCT01015833,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,spleen
D011697,0.58,NCT01015833-2,Arm II (Sorafenib Tosylate),NCT01015833,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,thrombotic thrombocytopenic purpura
D001281,1.8,NCT01015833-1,Arm I (Doxorubicin Hydrochloride Sorafenib Tosylate),NCT01015833,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,atrial fibrillation
D001281,0.58,NCT01015833-2,Arm II (Sorafenib Tosylate),NCT01015833,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,atrial fibrillation
D006331,0.6,NCT01015833-1,Arm I (Doxorubicin Hydrochloride Sorafenib Tosylate),NCT01015833,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,cardiac disorder
10008481,0.58,NCT01015833-2,Arm II (Sorafenib Tosylate),NCT01015833,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,chest pain - cardiac
10069501,1.8,NCT01015833-1,Arm I (Doxorubicin Hydrochloride Sorafenib Tosylate),NCT01015833,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,left ventricular systolic dysfunction
D009203,0.6,NCT01015833-1,Arm I (Doxorubicin Hydrochloride Sorafenib Tosylate),NCT01015833,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,myocardial infarction
10033557,0.6,NCT01015833-1,Arm I (Doxorubicin Hydrochloride Sorafenib Tosylate),NCT01015833,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,palpitations
10040741,0.58,NCT01015833-2,Arm II (Sorafenib Tosylate),NCT01015833,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,sinus bradycardia
D013616,0.6,NCT01015833-1,Arm I (Doxorubicin Hydrochloride Sorafenib Tosylate),NCT01015833,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,sinus tachycardia
D013616,0.58,NCT01015833-2,Arm II (Sorafenib Tosylate),NCT01015833,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,sinus tachycardia
D007037,0.6,NCT01015833-1,Arm I (Doxorubicin Hydrochloride Sorafenib Tosylate),NCT01015833,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,hypothyroidism
D007037,0.58,NCT01015833-2,Arm II (Sorafenib Tosylate),NCT01015833,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,hypothyroidism
D003231,0.6,NCT01015833-1,Arm I (Doxorubicin Hydrochloride Sorafenib Tosylate),NCT01015833,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,conjunctivitis
10000060,0.58,NCT01015833-2,Arm II (Sorafenib Tosylate),NCT01015833,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,abdominal distension
D015746,13.17,NCT01015833-1,Arm I (Doxorubicin Hydrochloride Sorafenib Tosylate),NCT01015833,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,abdominal pain
D015746,16.37,NCT01015833-2,Arm II (Sorafenib Tosylate),NCT01015833,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,abdominal pain
10065721,0.6,NCT01015833-1,Arm I (Doxorubicin Hydrochloride Sorafenib Tosylate),NCT01015833,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,anal mucositis
D001201,1.8,NCT01015833-1,Arm I (Doxorubicin Hydrochloride Sorafenib Tosylate),NCT01015833,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,ascites
D001201,1.17,NCT01015833-2,Arm II (Sorafenib Tosylate),NCT01015833,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,ascites
D003092,1.2,NCT01015833-1,Arm I (Doxorubicin Hydrochloride Sorafenib Tosylate),NCT01015833,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,colitis
D003248,0.6,NCT01015833-1,Arm I (Doxorubicin Hydrochloride Sorafenib Tosylate),NCT01015833,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,constipation
D003967,16.17,NCT01015833-1,Arm I (Doxorubicin Hydrochloride Sorafenib Tosylate),NCT01015833,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,diarrhea
D003967,7.6,NCT01015833-2,Arm II (Sorafenib Tosylate),NCT01015833,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,diarrhea
D004415,0.6,NCT01015833-1,Arm I (Doxorubicin Hydrochloride Sorafenib Tosylate),NCT01015833,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,dyspepsia
D003680,1.8,NCT01015833-1,Arm I (Doxorubicin Hydrochloride Sorafenib Tosylate),NCT01015833,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,dysphagia
10015451,0.6,NCT01015833-1,Arm I (Doxorubicin Hydrochloride Sorafenib Tosylate),NCT01015833,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,esophageal ulcer
10015453,0.6,NCT01015833-1,Arm I (Doxorubicin Hydrochloride Sorafenib Tosylate),NCT01015833,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,esophageal varices hemorrhage
10015453,2.34,NCT01015833-2,Arm II (Sorafenib Tosylate),NCT01015833,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,esophageal varices hemorrhage
D004941,1.2,NCT01015833-1,Arm I (Doxorubicin Hydrochloride Sorafenib Tosylate),NCT01015833,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,esophagitis
10017789,1.17,NCT01015833-2,Arm II (Sorafenib Tosylate),NCT01015833,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,gastric hemorrhage
10017947,0.58,NCT01015833-2,Arm II (Sorafenib Tosylate),NCT01015833,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,gastrointestinal disorders - other specify
10060640,0.58,NCT01015833-2,Arm II (Sorafenib Tosylate),NCT01015833,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,hemorrhoidal hemorrhage
10051746,0.6,NCT01015833-1,Arm I (Doxorubicin Hydrochloride Sorafenib Tosylate),NCT01015833,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,lower gastrointestinal hemorrhage
10028130,10.18,NCT01015833-1,Arm I (Doxorubicin Hydrochloride Sorafenib Tosylate),NCT01015833,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,mucositis oral
10028130,2.34,NCT01015833-2,Arm II (Sorafenib Tosylate),NCT01015833,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,mucositis oral
D009325,20.36,NCT01015833-1,Arm I (Doxorubicin Hydrochloride Sorafenib Tosylate),NCT01015833,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,nausea
D009325,14.04,NCT01015833-2,Arm II (Sorafenib Tosylate),NCT01015833,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,nausea
D010195,1.2,NCT01015833-1,Arm I (Doxorubicin Hydrochloride Sorafenib Tosylate),NCT01015833,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,pancreatitis
10038064,0.6,NCT01015833-1,Arm I (Doxorubicin Hydrochloride Sorafenib Tosylate),NCT01015833,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,rectal hemorrhage
10063190,0.6,NCT01015833-1,Arm I (Doxorubicin Hydrochloride Sorafenib Tosylate),NCT01015833,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,rectal mucositis
10055356,0.6,NCT01015833-1,Arm I (Doxorubicin Hydrochloride Sorafenib Tosylate),NCT01015833,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,upper gastrointestinal hemorrhage
10055356,1.75,NCT01015833-2,Arm II (Sorafenib Tosylate),NCT01015833,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,upper gastrointestinal hemorrhage
D014839,2.4,NCT01015833-1,Arm I (Doxorubicin Hydrochloride Sorafenib Tosylate),NCT01015833,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,vomiting
D014839,3.51,NCT01015833-2,Arm II (Sorafenib Tosylate),NCT01015833,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,vomiting
10011914,2.4,NCT01015833-1,Arm I (Doxorubicin Hydrochloride Sorafenib Tosylate),NCT01015833,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,death nos
10011914,4.09,NCT01015833-2,Arm II (Sorafenib Tosylate),NCT01015833,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,death nos
10050068,0.6,NCT01015833-1,Arm I (Doxorubicin Hydrochloride Sorafenib Tosylate),NCT01015833,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,edema limbs
10058720,0.58,NCT01015833-2,Arm II (Sorafenib Tosylate),NCT01015833,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,edema trunk
D005221,29.34,NCT01015833-1,Arm I (Doxorubicin Hydrochloride Sorafenib Tosylate),NCT01015833,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,fatigue
D005221,18.71,NCT01015833-2,Arm II (Sorafenib Tosylate),NCT01015833,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,fatigue
D005334,1.2,NCT01015833-1,Arm I (Doxorubicin Hydrochloride Sorafenib Tosylate),NCT01015833,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,fever
D005334,0.58,NCT01015833-2,Arm II (Sorafenib Tosylate),NCT01015833,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,fever
10062466,0.58,NCT01015833-2,Arm II (Sorafenib Tosylate),NCT01015833,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,localized edema
D009102,0.6,NCT01015833-1,Arm I (Doxorubicin Hydrochloride Sorafenib Tosylate),NCT01015833,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,multiple organ failure
10062501,1.17,NCT01015833-2,Arm II (Sorafenib Tosylate),NCT01015833,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,non-cardiac chest pain
D010146,0.6,NCT01015833-1,Arm I (Doxorubicin Hydrochloride Sorafenib Tosylate),NCT01015833,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,pain
10042435,0.6,NCT01015833-1,Arm I (Doxorubicin Hydrochloride Sorafenib Tosylate),NCT01015833,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,sudden death nos
10042435,1.17,NCT01015833-2,Arm II (Sorafenib Tosylate),NCT01015833,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,sudden death nos
D002764,0.58,NCT01015833-2,Arm II (Sorafenib Tosylate),NCT01015833,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,cholecystitis
10017636,0.6,NCT01015833-1,Arm I (Doxorubicin Hydrochloride Sorafenib Tosylate),NCT01015833,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,gallbladder obstruction
10017636,0.58,NCT01015833-2,Arm II (Sorafenib Tosylate),NCT01015833,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,gallbladder obstruction
D017093,1.8,NCT01015833-1,Arm I (Doxorubicin Hydrochloride Sorafenib Tosylate),NCT01015833,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,hepatic failure
D017093,0.58,NCT01015833-2,Arm II (Sorafenib Tosylate),NCT01015833,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,hepatic failure
10019678,1.17,NCT01015833-2,Arm II (Sorafenib Tosylate),NCT01015833,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,hepatic hemorrhage
10019805,0.58,NCT01015833-2,Arm II (Sorafenib Tosylate),NCT01015833,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,hepatobiliary disorders - other specify
D000707,0.6,NCT01015833-1,Arm I (Doxorubicin Hydrochloride Sorafenib Tosylate),NCT01015833,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,anaphylaxis
10056519,0.58,NCT01015833-2,Arm II (Sorafenib Tosylate),NCT01015833,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,abdominal infection
10061017,0.6,NCT01015833-1,Arm I (Doxorubicin Hydrochloride Sorafenib Tosylate),NCT01015833,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,bone infection
10061017,0.58,NCT01015833-2,Arm II (Sorafenib Tosylate),NCT01015833,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,bone infection
10021881,1.8,NCT01015833-1,Arm I (Doxorubicin Hydrochloride Sorafenib Tosylate),NCT01015833,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,infections and infestations - other specify
10021881,0.58,NCT01015833-2,Arm II (Sorafenib Tosylate),NCT01015833,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,infections and infestations - other specify
10061229,3.59,NCT01015833-1,Arm I (Doxorubicin Hydrochloride Sorafenib Tosylate),NCT01015833,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,lung infection
10057262,0.6,NCT01015833-1,Arm I (Doxorubicin Hydrochloride Sorafenib Tosylate),NCT01015833,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,peritoneal infection
10057262,0.58,NCT01015833-2,Arm II (Sorafenib Tosylate),NCT01015833,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,peritoneal infection
10037888,0.6,NCT01015833-1,Arm I (Doxorubicin Hydrochloride Sorafenib Tosylate),NCT01015833,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,rash pustular
D018805,2.99,NCT01015833-1,Arm I (Doxorubicin Hydrochloride Sorafenib Tosylate),NCT01015833,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,sepsis
D018805,1.17,NCT01015833-2,Arm II (Sorafenib Tosylate),NCT01015833,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,sepsis
10040872,1.2,NCT01015833-1,Arm I (Doxorubicin Hydrochloride Sorafenib Tosylate),NCT01015833,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,skin infection
10040872,1.17,NCT01015833-2,Arm II (Sorafenib Tosylate),NCT01015833,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,skin infection
D014552,0.6,NCT01015833-1,Arm I (Doxorubicin Hydrochloride Sorafenib Tosylate),NCT01015833,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,urinary tract infection
D014946,0.58,NCT01015833-2,Arm II (Sorafenib Tosylate),NCT01015833,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,wound infection
10016173,1.17,NCT01015833-2,Arm II (Sorafenib Tosylate),NCT01015833,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,fall
10017076,0.58,NCT01015833-2,Arm II (Sorafenib Tosylate),NCT01015833,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,fracture
10053692,0.6,NCT01015833-1,Arm I (Doxorubicin Hydrochloride Sorafenib Tosylate),NCT01015833,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,wound complication
10000636,0.58,NCT01015833-2,Arm II (Sorafenib Tosylate),NCT01015833,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,activated partial thromboplastin time prolonged
10001551,1.8,NCT01015833-1,Arm I (Doxorubicin Hydrochloride Sorafenib Tosylate),NCT01015833,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,alanine aminotransferase increased
10001551,1.75,NCT01015833-2,Arm II (Sorafenib Tosylate),NCT01015833,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,alanine aminotransferase increased
10001675,1.8,NCT01015833-1,Arm I (Doxorubicin Hydrochloride Sorafenib Tosylate),NCT01015833,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,alkaline phosphatase increased
10001675,2.34,NCT01015833-2,Arm II (Sorafenib Tosylate),NCT01015833,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,alkaline phosphatase increased
10003481,2.4,NCT01015833-1,Arm I (Doxorubicin Hydrochloride Sorafenib Tosylate),NCT01015833,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,aspartate aminotransferase increased
10003481,3.51,NCT01015833-2,Arm II (Sorafenib Tosylate),NCT01015833,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,aspartate aminotransferase increased
10005364,4.79,NCT01015833-1,Arm I (Doxorubicin Hydrochloride Sorafenib Tosylate),NCT01015833,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,blood bilirubin increased
10005364,4.09,NCT01015833-2,Arm II (Sorafenib Tosylate),NCT01015833,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,blood bilirubin increased
10011368,1.8,NCT01015833-1,Arm I (Doxorubicin Hydrochloride Sorafenib Tosylate),NCT01015833,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,creatinine increased
10050528,1.8,NCT01015833-1,Arm I (Doxorubicin Hydrochloride Sorafenib Tosylate),NCT01015833,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,ejection fraction decreased
10050528,0.58,NCT01015833-2,Arm II (Sorafenib Tosylate),NCT01015833,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,ejection fraction decreased
10019150,0.6,NCT01015833-1,Arm I (Doxorubicin Hydrochloride Sorafenib Tosylate),NCT01015833,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,haptoglobin decreased
10022402,1.2,NCT01015833-1,Arm I (Doxorubicin Hydrochloride Sorafenib Tosylate),NCT01015833,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,inr increased
10022402,0.58,NCT01015833-2,Arm II (Sorafenib Tosylate),NCT01015833,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,inr increased
D007958,0.6,NCT01015833-1,Arm I (Doxorubicin Hydrochloride Sorafenib Tosylate),NCT01015833,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,leukocyte count
10024574,0.6,NCT01015833-1,Arm I (Doxorubicin Hydrochloride Sorafenib Tosylate),NCT01015833,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,lipase increased
10025256,3.59,NCT01015833-1,Arm I (Doxorubicin Hydrochloride Sorafenib Tosylate),NCT01015833,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,lymphocyte count decreased
10025256,1.17,NCT01015833-2,Arm II (Sorafenib Tosylate),NCT01015833,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,lymphocyte count decreased
10029366,18.56,NCT01015833-1,Arm I (Doxorubicin Hydrochloride Sorafenib Tosylate),NCT01015833,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,neutrophil count decreased
10035528,20.96,NCT01015833-1,Arm I (Doxorubicin Hydrochloride Sorafenib Tosylate),NCT01015833,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,platelet count decreased
10035528,11.7,NCT01015833-2,Arm II (Sorafenib Tosylate),NCT01015833,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,platelet count decreased
D015431,1.2,NCT01015833-1,Arm I (Doxorubicin Hydrochloride Sorafenib Tosylate),NCT01015833,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,weight loss
D015431,0.58,NCT01015833-2,Arm II (Sorafenib Tosylate),NCT01015833,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,weight loss
10049182,5.99,NCT01015833-1,Arm I (Doxorubicin Hydrochloride Sorafenib Tosylate),NCT01015833,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,white blood cell decreased
D000855,2.99,NCT01015833-1,Arm I (Doxorubicin Hydrochloride Sorafenib Tosylate),NCT01015833,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,anorexia
D000855,2.34,NCT01015833-2,Arm II (Sorafenib Tosylate),NCT01015833,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,anorexia
D003681,8.38,NCT01015833-1,Arm I (Doxorubicin Hydrochloride Sorafenib Tosylate),NCT01015833,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,dehydration
D003681,2.92,NCT01015833-2,Arm II (Sorafenib Tosylate),NCT01015833,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,dehydration
D006943,1.2,NCT01015833-1,Arm I (Doxorubicin Hydrochloride Sorafenib Tosylate),NCT01015833,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,hyperglycemia
D006943,1.17,NCT01015833-2,Arm II (Sorafenib Tosylate),NCT01015833,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,hyperglycemia
D006947,2.4,NCT01015833-1,Arm I (Doxorubicin Hydrochloride Sorafenib Tosylate),NCT01015833,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,hyperkalemia
D006947,0.58,NCT01015833-2,Arm II (Sorafenib Tosylate),NCT01015833,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,hyperkalemia
D006955,0.58,NCT01015833-2,Arm II (Sorafenib Tosylate),NCT01015833,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,hypernatremia
D034141,2.4,NCT01015833-1,Arm I (Doxorubicin Hydrochloride Sorafenib Tosylate),NCT01015833,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,hypoalbuminemia
D034141,0.58,NCT01015833-2,Arm II (Sorafenib Tosylate),NCT01015833,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,hypoalbuminemia
D007008,1.2,NCT01015833-1,Arm I (Doxorubicin Hydrochloride Sorafenib Tosylate),NCT01015833,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,hypokalemia
10021028,0.58,NCT01015833-2,Arm II (Sorafenib Tosylate),NCT01015833,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,hypomagnesemia
D007010,5.99,NCT01015833-1,Arm I (Doxorubicin Hydrochloride Sorafenib Tosylate),NCT01015833,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,hyponatremia
D007010,2.34,NCT01015833-2,Arm II (Sorafenib Tosylate),NCT01015833,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,hyponatremia
D017674,2.4,NCT01015833-1,Arm I (Doxorubicin Hydrochloride Sorafenib Tosylate),NCT01015833,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,hypophosphatemia
D017674,0.58,NCT01015833-2,Arm II (Sorafenib Tosylate),NCT01015833,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,hypophosphatemia
10027433,0.58,NCT01015833-2,Arm II (Sorafenib Tosylate),NCT01015833,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,metabolism and nutrition disorders - other specify
D000255,0.6,NCT01015833-1,Arm I (Doxorubicin Hydrochloride Sorafenib Tosylate),NCT01015833,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,adenylpyrophosphate
D001416,0.6,NCT01015833-1,Arm I (Doxorubicin Hydrochloride Sorafenib Tosylate),NCT01015833,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,back pain
D001416,0.58,NCT01015833-2,Arm II (Sorafenib Tosylate),NCT01015833,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,back pain
10006002,0.58,NCT01015833-2,Arm II (Sorafenib Tosylate),NCT01015833,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,bone pain
10062572,0.6,NCT01015833-1,Arm I (Doxorubicin Hydrochloride Sorafenib Tosylate),NCT01015833,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,generalized muscle weakness
10062572,0.58,NCT01015833-2,Arm II (Sorafenib Tosylate),NCT01015833,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,generalized muscle weakness
D063806,0.6,NCT01015833-1,Arm I (Doxorubicin Hydrochloride Sorafenib Tosylate),NCT01015833,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,myalgia
10029104,0.6,NCT01015833-1,Arm I (Doxorubicin Hydrochloride Sorafenib Tosylate),NCT01015833,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,neoplasms benign malignant and unspecified (incl cysts and polyps) - other specify
10029104,1.75,NCT01015833-2,Arm II (Sorafenib Tosylate),NCT01015833,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,neoplasms benign malignant and unspecified (incl cysts and polyps) - other specify
10049737,1.2,NCT01015833-1,Arm I (Doxorubicin Hydrochloride Sorafenib Tosylate),NCT01015833,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,treatment related secondary malignancy
D000647,0.6,NCT01015833-1,Arm I (Doxorubicin Hydrochloride Sorafenib Tosylate),NCT01015833,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,amnesia
D006261,0.58,NCT01015833-2,Arm II (Sorafenib Tosylate),NCT01015833,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,headache
D020300,0.58,NCT01015833-2,Arm II (Sorafenib Tosylate),NCT01015833,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,intracranial hemorrhage
10029205,0.6,NCT01015833-1,Arm I (Doxorubicin Hydrochloride Sorafenib Tosylate),NCT01015833,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,nervous system disorders - other specify
D012640,0.58,NCT01015833-2,Arm II (Sorafenib Tosylate),NCT01015833,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,seizure
D019462,0.6,NCT01015833-1,Arm I (Doxorubicin Hydrochloride Sorafenib Tosylate),NCT01015833,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,vasovagal syncope
D001007,0.6,NCT01015833-1,Arm I (Doxorubicin Hydrochloride Sorafenib Tosylate),NCT01015833,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,anxiety
D001007,0.58,NCT01015833-2,Arm II (Sorafenib Tosylate),NCT01015833,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,anxiety
D003221,0.6,NCT01015833-1,Arm I (Doxorubicin Hydrochloride Sorafenib Tosylate),NCT01015833,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,confusion
D003221,1.17,NCT01015833-2,Arm II (Sorafenib Tosylate),NCT01015833,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,confusion
D058186,0.6,NCT01015833-1,Arm I (Doxorubicin Hydrochloride Sorafenib Tosylate),NCT01015833,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,acute kidney injury
D006417,1.2,NCT01015833-1,Arm I (Doxorubicin Hydrochloride Sorafenib Tosylate),NCT01015833,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,hematuria
D006417,0.58,NCT01015833-2,Arm II (Sorafenib Tosylate),NCT01015833,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,hematuria
D000067836,0.6,NCT01015833-1,Arm I (Doxorubicin Hydrochloride Sorafenib Tosylate),NCT01015833,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,hoarding disorder
D004417,2.4,NCT01015833-1,Arm I (Doxorubicin Hydrochloride Sorafenib Tosylate),NCT01015833,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,dyspnea
D004417,2.34,NCT01015833-2,Arm II (Sorafenib Tosylate),NCT01015833,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,dyspnea
D004844,0.6,NCT01015833-1,Arm I (Doxorubicin Hydrochloride Sorafenib Tosylate),NCT01015833,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,epistaxis
D004844,1.75,NCT01015833-2,Arm II (Sorafenib Tosylate),NCT01015833,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,epistaxis
D000860,0.6,NCT01015833-1,Arm I (Doxorubicin Hydrochloride Sorafenib Tosylate),NCT01015833,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,hypoxia
D000860,0.58,NCT01015833-2,Arm II (Sorafenib Tosylate),NCT01015833,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,hypoxia
D011654,0.58,NCT01015833-2,Arm II (Sorafenib Tosylate),NCT01015833,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,pulmonary edema
D010612,0.6,NCT01015833-1,Arm I (Doxorubicin Hydrochloride Sorafenib Tosylate),NCT01015833,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,sore throat
D000505,1.2,NCT01015833-1,Arm I (Doxorubicin Hydrochloride Sorafenib Tosylate),NCT01015833,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,alopecia
D004892,0.6,NCT01015833-1,Arm I (Doxorubicin Hydrochloride Sorafenib Tosylate),NCT01015833,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,erythema multiforme
10054524,7.78,NCT01015833-1,Arm I (Doxorubicin Hydrochloride Sorafenib Tosylate),NCT01015833,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,palmar-plantar erythrodysesthesia syndrome
10054524,5.85,NCT01015833-2,Arm II (Sorafenib Tosylate),NCT01015833,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,palmar-plantar erythrodysesthesia syndrome
D011537,0.6,NCT01015833-1,Arm I (Doxorubicin Hydrochloride Sorafenib Tosylate),NCT01015833,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,pruritus
10037868,0.6,NCT01015833-1,Arm I (Doxorubicin Hydrochloride Sorafenib Tosylate),NCT01015833,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,rash maculo-papular
10037868,1.17,NCT01015833-2,Arm II (Sorafenib Tosylate),NCT01015833,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,rash maculo-papular
10049120,0.58,NCT01015833-2,Arm II (Sorafenib Tosylate),NCT01015833,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,scalp pain
10040947,1.8,NCT01015833-1,Arm I (Doxorubicin Hydrochloride Sorafenib Tosylate),NCT01015833,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,skin ulceration
10040947,1.75,NCT01015833-2,Arm II (Sorafenib Tosylate),NCT01015833,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,skin ulceration
D013262,0.6,NCT01015833-1,Arm I (Doxorubicin Hydrochloride Sorafenib Tosylate),NCT01015833,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,stevens johnson syndrome
D006973,12.57,NCT01015833-1,Arm I (Doxorubicin Hydrochloride Sorafenib Tosylate),NCT01015833,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,hypertension
D006973,9.36,NCT01015833-2,Arm II (Sorafenib Tosylate),NCT01015833,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,hypertension
D007022,1.2,NCT01015833-1,Arm I (Doxorubicin Hydrochloride Sorafenib Tosylate),NCT01015833,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,hypotension
D007022,0.58,NCT01015833-2,Arm II (Sorafenib Tosylate),NCT01015833,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,hypotension
10043565,1.75,NCT01015833-2,Arm II (Sorafenib Tosylate),NCT01015833,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,thromboembolic event
D064420,15.38,NCT01032850-1,Arm 1: Sorafenib & Capecitabine,NCT01032850,Sorafenib With Capecitabine for Patients With Measurable Hepatocellular Carcinoma,adverse drug events
D009325,7.69,NCT01032850-1,Arm 1: Sorafenib & Capecitabine,NCT01032850,Sorafenib With Capecitabine for Patients With Measurable Hepatocellular Carcinoma,nausea
D014839,7.69,NCT01032850-1,Arm 1: Sorafenib & Capecitabine,NCT01032850,Sorafenib With Capecitabine for Patients With Measurable Hepatocellular Carcinoma,vomiting
D005221,7.69,NCT01032850-1,Arm 1: Sorafenib & Capecitabine,NCT01032850,Sorafenib With Capecitabine for Patients With Measurable Hepatocellular Carcinoma,fatigue
D005334,7.69,NCT01032850-1,Arm 1: Sorafenib & Capecitabine,NCT01032850,Sorafenib With Capecitabine for Patients With Measurable Hepatocellular Carcinoma,fever
D003643,7.69,NCT01032850-1,Arm 1: Sorafenib & Capecitabine,NCT01032850,Sorafenib With Capecitabine for Patients With Measurable Hepatocellular Carcinoma,death
D004039,7.69,NCT01032850-1,Arm 1: Sorafenib & Capecitabine,NCT01032850,Sorafenib With Capecitabine for Patients With Measurable Hepatocellular Carcinoma,diet low-sodium
D000855,7.69,NCT01032850-1,Arm 1: Sorafenib & Capecitabine,NCT01032850,Sorafenib With Capecitabine for Patients With Measurable Hepatocellular Carcinoma,anorexia
D003681,7.69,NCT01032850-1,Arm 1: Sorafenib & Capecitabine,NCT01032850,Sorafenib With Capecitabine for Patients With Measurable Hepatocellular Carcinoma,dehydration
D018908,7.69,NCT01032850-1,Arm 1: Sorafenib & Capecitabine,NCT01032850,Sorafenib With Capecitabine for Patients With Measurable Hepatocellular Carcinoma,muscle weakness
D064420,50.0,NCT01093222-1,Sorafenib and Erlotinib,NCT01093222,Sorafenib Tosylate and Erlotinib Hydrochloride in Treating Patients With Locally Advanced  Unresectable  or Metastatic Gallbladder Cancer or Cholangiocarcinoma,adverse drug events
D006323,2.94,NCT01093222-1,Sorafenib and Erlotinib,NCT01093222,Sorafenib Tosylate and Erlotinib Hydrochloride in Treating Patients With Locally Advanced  Unresectable  or Metastatic Gallbladder Cancer or Cholangiocarcinoma,cardiac arrest
D015746,11.76,NCT01093222-1,Sorafenib and Erlotinib,NCT01093222,Sorafenib Tosylate and Erlotinib Hydrochloride in Treating Patients With Locally Advanced  Unresectable  or Metastatic Gallbladder Cancer or Cholangiocarcinoma,abdominal pain
D001201,2.94,NCT01093222-1,Sorafenib and Erlotinib,NCT01093222,Sorafenib Tosylate and Erlotinib Hydrochloride in Treating Patients With Locally Advanced  Unresectable  or Metastatic Gallbladder Cancer or Cholangiocarcinoma,ascites
D003967,2.94,NCT01093222-1,Sorafenib and Erlotinib,NCT01093222,Sorafenib Tosylate and Erlotinib Hydrochloride in Treating Patients With Locally Advanced  Unresectable  or Metastatic Gallbladder Cancer or Cholangiocarcinoma,diarrhea
D004381,2.94,NCT01093222-1,Sorafenib and Erlotinib,NCT01093222,Sorafenib Tosylate and Erlotinib Hydrochloride in Treating Patients With Locally Advanced  Unresectable  or Metastatic Gallbladder Cancer or Cholangiocarcinoma,duodenal ulcer
10017815,2.94,NCT01093222-1,Sorafenib and Erlotinib,NCT01093222,Sorafenib Tosylate and Erlotinib Hydrochloride in Treating Patients With Locally Advanced  Unresectable  or Metastatic Gallbladder Cancer or Cholangiocarcinoma,gastric perforation
D005756,2.94,NCT01093222-1,Sorafenib and Erlotinib,NCT01093222,Sorafenib Tosylate and Erlotinib Hydrochloride in Treating Patients With Locally Advanced  Unresectable  or Metastatic Gallbladder Cancer or Cholangiocarcinoma,gastritis
10017947,2.94,NCT01093222-1,Sorafenib and Erlotinib,NCT01093222,Sorafenib Tosylate and Erlotinib Hydrochloride in Treating Patients With Locally Advanced  Unresectable  or Metastatic Gallbladder Cancer or Cholangiocarcinoma,gastrointestinal disorders - other specify
D009325,8.82,NCT01093222-1,Sorafenib and Erlotinib,NCT01093222,Sorafenib Tosylate and Erlotinib Hydrochloride in Treating Patients With Locally Advanced  Unresectable  or Metastatic Gallbladder Cancer or Cholangiocarcinoma,nausea
10041101,2.94,NCT01093222-1,Sorafenib and Erlotinib,NCT01093222,Sorafenib Tosylate and Erlotinib Hydrochloride in Treating Patients With Locally Advanced  Unresectable  or Metastatic Gallbladder Cancer or Cholangiocarcinoma,small intestinal obstruction
D014839,5.88,NCT01093222-1,Sorafenib and Erlotinib,NCT01093222,Sorafenib Tosylate and Erlotinib Hydrochloride in Treating Patients With Locally Advanced  Unresectable  or Metastatic Gallbladder Cancer or Cholangiocarcinoma,vomiting
10011914,17.65,NCT01093222-1,Sorafenib and Erlotinib,NCT01093222,Sorafenib Tosylate and Erlotinib Hydrochloride in Treating Patients With Locally Advanced  Unresectable  or Metastatic Gallbladder Cancer or Cholangiocarcinoma,death nos
D009102,2.94,NCT01093222-1,Sorafenib and Erlotinib,NCT01093222,Sorafenib Tosylate and Erlotinib Hydrochloride in Treating Patients With Locally Advanced  Unresectable  or Metastatic Gallbladder Cancer or Cholangiocarcinoma,multiple organ failure
10051341,2.94,NCT01093222-1,Sorafenib and Erlotinib,NCT01093222,Sorafenib Tosylate and Erlotinib Hydrochloride in Treating Patients With Locally Advanced  Unresectable  or Metastatic Gallbladder Cancer or Cholangiocarcinoma,bile duct stenosis
10017636,2.94,NCT01093222-1,Sorafenib and Erlotinib,NCT01093222,Sorafenib Tosylate and Erlotinib Hydrochloride in Treating Patients With Locally Advanced  Unresectable  or Metastatic Gallbladder Cancer or Cholangiocarcinoma,gallbladder obstruction
10019692,2.94,NCT01093222-1,Sorafenib and Erlotinib,NCT01093222,Sorafenib Tosylate and Erlotinib Hydrochloride in Treating Patients With Locally Advanced  Unresectable  or Metastatic Gallbladder Cancer or Cholangiocarcinoma,hepatic necrosis
10019805,2.94,NCT01093222-1,Sorafenib and Erlotinib,NCT01093222,Sorafenib Tosylate and Erlotinib Hydrochloride in Treating Patients With Locally Advanced  Unresectable  or Metastatic Gallbladder Cancer or Cholangiocarcinoma,hepatobiliary disorders - other specify
D006967,2.94,NCT01093222-1,Sorafenib and Erlotinib,NCT01093222,Sorafenib Tosylate and Erlotinib Hydrochloride in Treating Patients With Locally Advanced  Unresectable  or Metastatic Gallbladder Cancer or Cholangiocarcinoma,allergic reaction
10064687,2.94,NCT01093222-1,Sorafenib and Erlotinib,NCT01093222,Sorafenib Tosylate and Erlotinib Hydrochloride in Treating Patients With Locally Advanced  Unresectable  or Metastatic Gallbladder Cancer or Cholangiocarcinoma,device related infection
10056522,2.94,NCT01093222-1,Sorafenib and Erlotinib,NCT01093222,Sorafenib Tosylate and Erlotinib Hydrochloride in Treating Patients With Locally Advanced  Unresectable  or Metastatic Gallbladder Cancer or Cholangiocarcinoma,hepatic infection
10061229,2.94,NCT01093222-1,Sorafenib and Erlotinib,NCT01093222,Sorafenib Tosylate and Erlotinib Hydrochloride in Treating Patients With Locally Advanced  Unresectable  or Metastatic Gallbladder Cancer or Cholangiocarcinoma,lung infection
D018805,8.82,NCT01093222-1,Sorafenib and Erlotinib,NCT01093222,Sorafenib Tosylate and Erlotinib Hydrochloride in Treating Patients With Locally Advanced  Unresectable  or Metastatic Gallbladder Cancer or Cholangiocarcinoma,sepsis
10001551,2.94,NCT01093222-1,Sorafenib and Erlotinib,NCT01093222,Sorafenib Tosylate and Erlotinib Hydrochloride in Treating Patients With Locally Advanced  Unresectable  or Metastatic Gallbladder Cancer or Cholangiocarcinoma,alanine aminotransferase increased
10001675,5.88,NCT01093222-1,Sorafenib and Erlotinib,NCT01093222,Sorafenib Tosylate and Erlotinib Hydrochloride in Treating Patients With Locally Advanced  Unresectable  or Metastatic Gallbladder Cancer or Cholangiocarcinoma,alkaline phosphatase increased
10003481,5.88,NCT01093222-1,Sorafenib and Erlotinib,NCT01093222,Sorafenib Tosylate and Erlotinib Hydrochloride in Treating Patients With Locally Advanced  Unresectable  or Metastatic Gallbladder Cancer or Cholangiocarcinoma,aspartate aminotransferase increased
10005364,11.76,NCT01093222-1,Sorafenib and Erlotinib,NCT01093222,Sorafenib Tosylate and Erlotinib Hydrochloride in Treating Patients With Locally Advanced  Unresectable  or Metastatic Gallbladder Cancer or Cholangiocarcinoma,blood bilirubin increased
D003681,5.88,NCT01093222-1,Sorafenib and Erlotinib,NCT01093222,Sorafenib Tosylate and Erlotinib Hydrochloride in Treating Patients With Locally Advanced  Unresectable  or Metastatic Gallbladder Cancer or Cholangiocarcinoma,dehydration
D034141,5.88,NCT01093222-1,Sorafenib and Erlotinib,NCT01093222,Sorafenib Tosylate and Erlotinib Hydrochloride in Treating Patients With Locally Advanced  Unresectable  or Metastatic Gallbladder Cancer or Cholangiocarcinoma,hypoalbuminemia
10062572,2.94,NCT01093222-1,Sorafenib and Erlotinib,NCT01093222,Sorafenib Tosylate and Erlotinib Hydrochloride in Treating Patients With Locally Advanced  Unresectable  or Metastatic Gallbladder Cancer or Cholangiocarcinoma,generalized muscle weakness
10029104,2.94,NCT01093222-1,Sorafenib and Erlotinib,NCT01093222,Sorafenib Tosylate and Erlotinib Hydrochloride in Treating Patients With Locally Advanced  Unresectable  or Metastatic Gallbladder Cancer or Cholangiocarcinoma,neoplasms benign malignant and unspecified (incl cysts and polyps) - other specify
D004244,2.94,NCT01093222-1,Sorafenib and Erlotinib,NCT01093222,Sorafenib Tosylate and Erlotinib Hydrochloride in Treating Patients With Locally Advanced  Unresectable  or Metastatic Gallbladder Cancer or Cholangiocarcinoma,dizziness
D053609,2.94,NCT01093222-1,Sorafenib and Erlotinib,NCT01093222,Sorafenib Tosylate and Erlotinib Hydrochloride in Treating Patients With Locally Advanced  Unresectable  or Metastatic Gallbladder Cancer or Cholangiocarcinoma,lethargy
D004417,2.94,NCT01093222-1,Sorafenib and Erlotinib,NCT01093222,Sorafenib Tosylate and Erlotinib Hydrochloride in Treating Patients With Locally Advanced  Unresectable  or Metastatic Gallbladder Cancer or Cholangiocarcinoma,dyspnea
D004892,2.94,NCT01093222-1,Sorafenib and Erlotinib,NCT01093222,Sorafenib Tosylate and Erlotinib Hydrochloride in Treating Patients With Locally Advanced  Unresectable  or Metastatic Gallbladder Cancer or Cholangiocarcinoma,erythema multiforme
D006973,2.94,NCT01093222-1,Sorafenib and Erlotinib,NCT01093222,Sorafenib Tosylate and Erlotinib Hydrochloride in Treating Patients With Locally Advanced  Unresectable  or Metastatic Gallbladder Cancer or Cholangiocarcinoma,hypertension
D064420,35.29,NCT01100242-1,VELCADE and Sorafenib,NCT01100242,Velcade and Sorafenib in Unresected or Metastatic Renal Cell Carcinoma,adverse drug events
D002637,5.88,NCT01100242-1,VELCADE and Sorafenib,NCT01100242,Velcade and Sorafenib in Unresected or Metastatic Renal Cell Carcinoma,chest pain
D000080867,5.88,NCT01100242-1,VELCADE and Sorafenib,NCT01100242,Velcade and Sorafenib in Unresected or Metastatic Renal Cell Carcinoma,gingipains
D010195,5.88,NCT01100242-1,VELCADE and Sorafenib,NCT01100242,Velcade and Sorafenib in Unresected or Metastatic Renal Cell Carcinoma,pancreatitis
10021881,5.88,NCT01100242-1,VELCADE and Sorafenib,NCT01100242,Velcade and Sorafenib in Unresected or Metastatic Renal Cell Carcinoma,infections and infestations - other specify
D012640,5.88,NCT01100242-1,VELCADE and Sorafenib,NCT01100242,Velcade and Sorafenib in Unresected or Metastatic Renal Cell Carcinoma,seizure
D016055,5.88,NCT01100242-1,VELCADE and Sorafenib,NCT01100242,Velcade and Sorafenib in Unresected or Metastatic Renal Cell Carcinoma,urinary retention
D004417,5.88,NCT01100242-1,VELCADE and Sorafenib,NCT01100242,Velcade and Sorafenib in Unresected or Metastatic Renal Cell Carcinoma,breath shortness
D064420,44.77,NCT01140347-1,Ramucirumab (IMC-1121B) + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,adverse drug events
D064420,33.33,NCT01140347-2,Placebo + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,adverse drug events
D000741,0.72,NCT01140347-2,Placebo + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,aplastic anaemia
D004211,0.36,NCT01140347-1,Ramucirumab (IMC-1121B) + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,disseminated intravascular coagulation
D009503,0.36,NCT01140347-1,Ramucirumab (IMC-1121B) + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,neutropenia
D013921,0.36,NCT01140347-1,Ramucirumab (IMC-1121B) + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,thrombocytopenia
D006333,0.36,NCT01140347-2,Placebo + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,cardiac failure
D010490,0.36,NCT01140347-1,Ramucirumab (IMC-1121B) + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,pericardial effusion
D013617,0.36,NCT01140347-1,Ramucirumab (IMC-1121B) + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,supraventricular tachycardia
D012163,0.36,NCT01140347-1,Ramucirumab (IMC-1121B) + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,retinal detachment
10000060,0.36,NCT01140347-1,Ramucirumab (IMC-1121B) + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,abdominal distension
10000060,0.36,NCT01140347-2,Placebo + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,abdominal distension
D015746,2.17,NCT01140347-1,Ramucirumab (IMC-1121B) + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,abdominal pain
D015746,3.26,NCT01140347-2,Placebo + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,abdominal pain
D015746,0.36,NCT01140347-2,Placebo + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,abdominal pain
D001201,2.89,NCT01140347-1,Ramucirumab (IMC-1121B) + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,ascites
D001201,1.09,NCT01140347-2,Placebo + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,ascites
D003092,0.36,NCT01140347-2,Placebo + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,colitis
UNKNOWN-check-for-typo,0.36,NCT01140347-1,Ramucirumab (IMC-1121B) + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,D00
D004381,0.36,NCT01140347-1,Ramucirumab (IMC-1121B) + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,duodenal ulcer
D003680,0.36,NCT01140347-1,Ramucirumab (IMC-1121B) + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,dysphagia
D005517,0.36,NCT01140347-1,Ramucirumab (IMC-1121B) + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,food poisoning
D020252,0.36,NCT01140347-1,Ramucirumab (IMC-1121B) + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,gastric antral vascular ectasia
D020115,0.36,NCT01140347-1,Ramucirumab (IMC-1121B) + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,progastricsin
D020115,0.36,NCT01140347-2,Placebo + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,progastricsin
D004932,0.36,NCT01140347-1,Ramucirumab (IMC-1121B) + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,varices gastric
UNKNOWN-check-for-typo,0.36,NCT01140347-1,Ramucirumab (IMC-1121B) + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,D00
D000069196,2.53,NCT01140347-1,Ramucirumab (IMC-1121B) + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,gastrointestinal microbiome
UNKNOWN-check-for-typo,0.36,NCT01140347-2,Placebo + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,D00
D045823,0.36,NCT01140347-2,Placebo + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,ileus
D006552,0.36,NCT01140347-2,Placebo + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,inguinal hernia
D007415,0.36,NCT01140347-2,Placebo + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,intestinal obstruction
D043183,0.36,NCT01140347-1,Ramucirumab (IMC-1121B) + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,irritable bowel syndrome
D007420,0.36,NCT01140347-1,Ramucirumab (IMC-1121B) + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,intestine large
D050686,0.36,NCT01140347-2,Placebo + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,globicephala melaena
D009325,0.72,NCT01140347-1,Ramucirumab (IMC-1121B) + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,nausea
D009325,0.36,NCT01140347-2,Placebo + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,nausea
D000071041,0.36,NCT01140347-1,Ramucirumab (IMC-1121B) + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,oesophageal mucosa
D000071041,0.36,NCT01140347-2,Placebo + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,oesophageal mucosa
D014648,1.44,NCT01140347-1,Ramucirumab (IMC-1121B) + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,varices
D014648,3.62,NCT01140347-2,Placebo + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,varices
D010195,0.36,NCT01140347-2,Placebo + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,pancreatitis
D001202,0.36,NCT01140347-1,Ramucirumab (IMC-1121B) + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,peritoneal fluid
10041101,0.36,NCT01140347-2,Placebo + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,small intestinal obstruction
D006554,0.36,NCT01140347-1,Ramucirumab (IMC-1121B) + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,umbilical hernia
D041742,0.72,NCT01140347-1,Ramucirumab (IMC-1121B) + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,upper gastrointestinal tract
D041742,0.36,NCT01140347-2,Placebo + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,upper gastrointestinal tract
D014648,0.36,NCT01140347-1,Ramucirumab (IMC-1121B) + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,varices
D014839,0.36,NCT01140347-1,Ramucirumab (IMC-1121B) + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,vomiting
D014839,0.36,NCT01140347-2,Placebo + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,vomiting
D001247,1.44,NCT01140347-1,Ramucirumab (IMC-1121B) + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,asthenia
D001247,0.36,NCT01140347-2,Placebo + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,asthenia
D023341,0.36,NCT01140347-1,Ramucirumab (IMC-1121B) + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,chills
D003643,0.36,NCT01140347-1,Ramucirumab (IMC-1121B) + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,death
D005119,0.36,NCT01140347-2,Placebo + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,extravasation of diagnostic and therapeutic materials
D005221,0.36,NCT01140347-1,Ramucirumab (IMC-1121B) + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,fatigue
D005221,0.72,NCT01140347-2,Placebo + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,fatigue
D003695,3.25,NCT01140347-1,Ramucirumab (IMC-1121B) + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,healthcare
D003695,1.09,NCT01140347-2,Placebo + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,healthcare
D000799,0.36,NCT01140347-1,Ramucirumab (IMC-1121B) + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,angioedema
D006547,0.36,NCT01140347-1,Ramucirumab (IMC-1121B) + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,hernia
D005334,0.36,NCT01140347-1,Ramucirumab (IMC-1121B) + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,hyperthermia
10025482,0.36,NCT01140347-2,Placebo + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,malaise
D009102,0.72,NCT01140347-1,Ramucirumab (IMC-1121B) + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,multiple organ failure
D009102,0.36,NCT01140347-2,Placebo + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,multiple organ failure
10062501,0.36,NCT01140347-1,Ramucirumab (IMC-1121B) + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,non-cardiac chest pain
10062501,0.36,NCT01140347-2,Placebo + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,non-cardiac chest pain
D000799,0.72,NCT01140347-2,Placebo + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,angioedema
D000799,0.72,NCT01140347-1,Ramucirumab (IMC-1121B) + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,angioedema
D000799,0.36,NCT01140347-2,Placebo + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,angioedema
D005334,2.53,NCT01140347-1,Ramucirumab (IMC-1121B) + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,pyrexia
D005334,1.09,NCT01140347-2,Placebo + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,pyrexia
D003645,0.36,NCT01140347-1,Ramucirumab (IMC-1121B) + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,sudden death
D017114,0.36,NCT01140347-1,Ramucirumab (IMC-1121B) + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,acute hepatic failure
D042882,0.36,NCT01140347-1,Ramucirumab (IMC-1121B) + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,gallstones common bile duct
D042882,0.36,NCT01140347-2,Placebo + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,gallstones common bile duct
D002761,1.81,NCT01140347-1,Ramucirumab (IMC-1121B) + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,cholangitis
D002761,0.36,NCT01140347-2,Placebo + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,cholangitis
D002761,0.36,NCT01140347-1,Ramucirumab (IMC-1121B) + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,cholangitis
D002761,0.36,NCT01140347-2,Placebo + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,cholangitis
D008103,0.36,NCT01140347-1,Ramucirumab (IMC-1121B) + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,hepatic cirrhosis
D008103,0.36,NCT01140347-2,Placebo + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,hepatic cirrhosis
D017093,2.17,NCT01140347-1,Ramucirumab (IMC-1121B) + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,hepatic failure
D017093,1.81,NCT01140347-2,Placebo + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,hepatic failure
D011681,0.36,NCT01140347-2,Placebo + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,pupillary functions abnormal
D006530,1.44,NCT01140347-1,Ramucirumab (IMC-1121B) + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,hepatorenal syndrome
D006530,0.36,NCT01140347-2,Placebo + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,hepatorenal syndrome
UNKNOWN-check-for-typo,0.36,NCT01140347-1,Ramucirumab (IMC-1121B) + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,D00
UNKNOWN-check-for-typo,1.09,NCT01140347-2,Placebo + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,D00
UNKNOWN-check-for-typo,0.36,NCT01140347-1,Ramucirumab (IMC-1121B) + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,D00
D007565,0.36,NCT01140347-1,Ramucirumab (IMC-1121B) + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,jaundice
D007565,0.36,NCT01140347-2,Placebo + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,jaundice
D041781,0.72,NCT01140347-2,Placebo + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,cholestatic jaundice
D001664,0.36,NCT01140347-1,Ramucirumab (IMC-1121B) + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,biliverdine
10036206,0.36,NCT01140347-1,Ramucirumab (IMC-1121B) + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,portal vein thrombosis
10036206,0.36,NCT01140347-2,Placebo + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,portal vein thrombosis
D000707,0.72,NCT01140347-1,Ramucirumab (IMC-1121B) + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,anaphylactic reaction
D000038,0.72,NCT01140347-1,Ramucirumab (IMC-1121B) + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,abscess
UNKNOWN-check-for-typo,0.36,NCT01140347-1,Ramucirumab (IMC-1121B) + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,D00
D002169,0.36,NCT01140347-1,Ramucirumab (IMC-1121B) + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,campylobacter infection
D000985,0.36,NCT01140347-1,Ramucirumab (IMC-1121B) + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,antisepsis
10064687,0.36,NCT01140347-1,Ramucirumab (IMC-1121B) + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,device related infection
10064687,0.36,NCT01140347-1,Ramucirumab (IMC-1121B) + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,device related infection
D007239,0.36,NCT01140347-1,Ramucirumab (IMC-1121B) + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,infection
D007251,0.36,NCT01140347-2,Placebo + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,influenza
D008100,0.36,NCT01140347-1,Ramucirumab (IMC-1121B) + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,liver abscess
D011014,0.36,NCT01140347-1,Ramucirumab (IMC-1121B) + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,lobar pneumonia
10061229,0.72,NCT01140347-1,Ramucirumab (IMC-1121B) + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,lung infection
D010538,0.36,NCT01140347-1,Ramucirumab (IMC-1121B) + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,peritonitis
D010538,0.36,NCT01140347-2,Placebo + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,peritonitis
D010538,0.36,NCT01140347-1,Ramucirumab (IMC-1121B) + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,peritonitis
D011014,1.08,NCT01140347-1,Ramucirumab (IMC-1121B) + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,pneumonia
D011014,1.09,NCT01140347-2,Placebo + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,pneumonia
D018410,0.36,NCT01140347-1,Ramucirumab (IMC-1121B) + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,bacterial pneumonia
D007711,0.36,NCT01140347-2,Placebo + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,klebsiella pneumoniae
D000985,0.36,NCT01140347-1,Ramucirumab (IMC-1121B) + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,antisepsis
D018805,1.08,NCT01140347-1,Ramucirumab (IMC-1121B) + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,sepsis
D018805,0.72,NCT01140347-2,Placebo + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,sepsis
D012772,0.36,NCT01140347-2,Placebo + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,septic shock
D012141,0.36,NCT01140347-1,Ramucirumab (IMC-1121B) + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,upper respiratory tract infections
D012141,0.36,NCT01140347-2,Placebo + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,upper respiratory tract infections
D014552,1.08,NCT01140347-1,Ramucirumab (IMC-1121B) + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,urinary tract infection
10016173,0.36,NCT01140347-2,Placebo + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,fall
D005265,0.36,NCT01140347-2,Placebo + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,femur neck fractures
10051792,0.36,NCT01140347-1,Ramucirumab (IMC-1121B) + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,infusion related reaction
10003481,0.36,NCT01140347-2,Placebo + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,aspartate aminotransferase increased
10005364,0.72,NCT01140347-1,Ramucirumab (IMC-1121B) + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,blood bilirubin increased
10011368,0.36,NCT01140347-1,Ramucirumab (IMC-1121B) + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,creatinine increased
D010805,0.36,NCT01140347-1,Ramucirumab (IMC-1121B) + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,physical conditioning animal
D008111,0.36,NCT01140347-1,Ramucirumab (IMC-1121B) + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,liver function tests
D002100,0.36,NCT01140347-1,Ramucirumab (IMC-1121B) + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,cachexia
D002100,0.36,NCT01140347-2,Placebo + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,cachexia
D001066,1.08,NCT01140347-1,Ramucirumab (IMC-1121B) + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,appetite
D003681,0.72,NCT01140347-1,Ramucirumab (IMC-1121B) + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,dehydration
D003681,0.36,NCT01140347-2,Placebo + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,dehydration
D003920,0.36,NCT01140347-1,Ramucirumab (IMC-1121B) + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,diabetes mellitus
UNKNOWN-check-for-typo,0.36,NCT01140347-1,Ramucirumab (IMC-1121B) + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,D00
UNKNOWN-check-for-typo,0.36,NCT01140347-2,Placebo + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,D00
UNKNOWN-check-for-typo,0.72,NCT01140347-2,Placebo + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,D00
UNKNOWN-check-for-typo,0.36,NCT01140347-1,Ramucirumab (IMC-1121B) + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,D00
UNKNOWN-check-for-typo,0.36,NCT01140347-1,Ramucirumab (IMC-1121B) + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,D00
UNKNOWN-check-for-typo,0.36,NCT01140347-1,Ramucirumab (IMC-1121B) + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,D00
UNKNOWN-check-for-typo,0.36,NCT01140347-2,Placebo + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,D00
UNKNOWN-check-for-typo,0.36,NCT01140347-1,Ramucirumab (IMC-1121B) + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,D00
UNKNOWN-check-for-typo,0.36,NCT01140347-2,Placebo + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,D00
D001168,0.36,NCT01140347-1,Ramucirumab (IMC-1121B) + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,arthritis
D001416,1.45,NCT01140347-2,Placebo + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,back pain
D021501,0.36,NCT01140347-2,Placebo + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,flank pain
D002637,0.36,NCT01140347-2,Placebo + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,chest pain
D019547,0.36,NCT01140347-1,Ramucirumab (IMC-1121B) + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,neck pain
D005598,0.36,NCT01140347-1,Ramucirumab (IMC-1121B) + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,pathological fracture
D000080867,0.36,NCT01140347-2,Placebo + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,gingipains
D006528,0.72,NCT01140347-1,Ramucirumab (IMC-1121B) + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,liver cell carcinoma
D006528,0.72,NCT01140347-2,Placebo + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,liver cell carcinoma
D009369,8.3,NCT01140347-1,Ramucirumab (IMC-1121B) + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,malignant neoplasms
D009369,5.8,NCT01140347-2,Placebo + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,malignant neoplasms
D000077553,0.36,NCT01140347-1,Ramucirumab (IMC-1121B) + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,edarabone
D000077553,0.36,NCT01140347-2,Placebo + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,edarabone
D002490,0.36,NCT01140347-1,Ramucirumab (IMC-1121B) + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,central nervous system
D008168,0.36,NCT01140347-1,Ramucirumab (IMC-1121B) + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,lung
D007421,0.36,NCT01140347-2,Placebo + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,intestine small
D005334,0.36,NCT01140347-1,Ramucirumab (IMC-1121B) + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,fever
D000080867,1.45,NCT01140347-2,Placebo + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,gingipains
D002490,0.36,NCT01140347-1,Ramucirumab (IMC-1121B) + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,central nervous system
D002544,0.36,NCT01140347-2,Placebo + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,cerebral infarction
D006501,0.36,NCT01140347-1,Ramucirumab (IMC-1121B) + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,hepatic coma
D012640,0.72,NCT01140347-1,Ramucirumab (IMC-1121B) + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,convulsion
D002547,0.36,NCT01140347-1,Ramucirumab (IMC-1121B) + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,spastic diplegia
D004244,0.36,NCT01140347-1,Ramucirumab (IMC-1121B) + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,dizziness
D004244,0.36,NCT01140347-2,Placebo + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,dizziness
D001927,0.36,NCT01140347-1,Ramucirumab (IMC-1121B) + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,encephalopathy
D006501,4.33,NCT01140347-1,Ramucirumab (IMC-1121B) + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,hepatic encephalopathy
D006501,0.36,NCT01140347-2,Placebo + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,hepatic encephalopathy
D000076563,0.36,NCT01140347-1,Ramucirumab (IMC-1121B) + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,mentalization
10034580,0.36,NCT01140347-2,Placebo + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,peripheral motor neuropathy
D000077260,0.36,NCT01140347-1,Ramucirumab (IMC-1121B) + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,somnolence
D013117,0.36,NCT01140347-1,Ramucirumab (IMC-1121B) + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,spinal cord compression
D007427,0.36,NCT01140347-2,Placebo + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,subarachnoid pressure
D001819,0.36,NCT01140347-2,Placebo + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,bluetongue
D000073216,0.36,NCT01140347-2,Placebo + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,mental status tests
D051437,0.72,NCT01140347-1,Ramucirumab (IMC-1121B) + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,renal failure
D058186,1.08,NCT01140347-1,Ramucirumab (IMC-1121B) + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,acute renal failure
D058186,0.36,NCT01140347-2,Placebo + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,acute renal failure
D000308,0.36,NCT01140347-1,Ramucirumab (IMC-1121B) + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,hyperadrenalism
D012128,0.36,NCT01140347-2,Placebo + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,acute respiratory distress syndrome
UNKNOWN-check-for-typo,0.36,NCT01140347-1,Ramucirumab (IMC-1121B) + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,D00
UNKNOWN-check-for-typo,0.72,NCT01140347-2,Placebo + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,D00
UNKNOWN-check-for-typo,0.72,NCT01140347-1,Ramucirumab (IMC-1121B) + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,D00
UNKNOWN-check-for-typo,0.36,NCT01140347-2,Placebo + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,D00
D000860,0.36,NCT01140347-1,Ramucirumab (IMC-1121B) + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,hypoxia
D010996,0.72,NCT01140347-1,Ramucirumab (IMC-1121B) + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,pleural effusion
D010996,1.09,NCT01140347-2,Placebo + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,pleural effusion
D011014,0.36,NCT01140347-2,Placebo + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,pneumonitis
D011655,0.36,NCT01140347-1,Ramucirumab (IMC-1121B) + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,pulmonary embolism
D011655,0.72,NCT01140347-2,Placebo + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,pulmonary embolism
D001261,0.36,NCT01140347-2,Placebo + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,pulmonary atelectasis
D017449,0.36,NCT01140347-1,Ramucirumab (IMC-1121B) + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,dermatitis allergic contact
D012867,0.36,NCT01140347-1,Ramucirumab (IMC-1121B) + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,skin
D012883,0.36,NCT01140347-1,Ramucirumab (IMC-1121B) + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,skin ulcer
D020246,0.72,NCT01140347-1,Ramucirumab (IMC-1121B) + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,deep vein thrombosis
D000074042,0.36,NCT01140347-2,Placebo + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,cerebral intraventricular haemorrhage
D006973,0.36,NCT01140347-1,Ramucirumab (IMC-1121B) + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,hypertension
D004597,0.36,NCT01140347-1,Ramucirumab (IMC-1121B) + BSC,NCT01140347,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,electroshock
D064420,25.4,NCT01203787-1,Sorafenib Standard Dosing Regimen,NCT01203787,Sorafenib Dose Ramp-Up in Hepatocellular Carcinoma (HCC),adverse drug events
D064420,22.81,NCT01203787-2,Sorafenib Ramp-Up Regimen,NCT01203787,Sorafenib Dose Ramp-Up in Hepatocellular Carcinoma (HCC),adverse drug events
D000740,3.17,NCT01203787-1,Sorafenib Standard Dosing Regimen,NCT01203787,Sorafenib Dose Ramp-Up in Hepatocellular Carcinoma (HCC),anemia
D013921,1.59,NCT01203787-1,Sorafenib Standard Dosing Regimen,NCT01203787,Sorafenib Dose Ramp-Up in Hepatocellular Carcinoma (HCC),thrombocytopenia
D006333,1.59,NCT01203787-1,Sorafenib Standard Dosing Regimen,NCT01203787,Sorafenib Dose Ramp-Up in Hepatocellular Carcinoma (HCC),congestive heart failure
D002637,1.59,NCT01203787-1,Sorafenib Standard Dosing Regimen,NCT01203787,Sorafenib Dose Ramp-Up in Hepatocellular Carcinoma (HCC),chest pain
D006323,1.59,NCT01203787-1,Sorafenib Standard Dosing Regimen,NCT01203787,Sorafenib Dose Ramp-Up in Hepatocellular Carcinoma (HCC),cardiac arrest
D006973,1.75,NCT01203787-2,Sorafenib Ramp-Up Regimen,NCT01203787,Sorafenib Dose Ramp-Up in Hepatocellular Carcinoma (HCC),hypertension
D007022,4.76,NCT01203787-1,Sorafenib Standard Dosing Regimen,NCT01203787,Sorafenib Dose Ramp-Up in Hepatocellular Carcinoma (HCC),hypotension
10005886,1.75,NCT01203787-2,Sorafenib Ramp-Up Regimen,NCT01203787,Sorafenib Dose Ramp-Up in Hepatocellular Carcinoma (HCC),blurred vision
D015746,1.59,NCT01203787-1,Sorafenib Standard Dosing Regimen,NCT01203787,Sorafenib Dose Ramp-Up in Hepatocellular Carcinoma (HCC),abdominal pain
D009325,1.59,NCT01203787-1,Sorafenib Standard Dosing Regimen,NCT01203787,Sorafenib Dose Ramp-Up in Hepatocellular Carcinoma (HCC),nausea
D041742,1.59,NCT01203787-1,Sorafenib Standard Dosing Regimen,NCT01203787,Sorafenib Dose Ramp-Up in Hepatocellular Carcinoma (HCC),upper gastrointestinal tract
D041742,3.51,NCT01203787-2,Sorafenib Ramp-Up Regimen,NCT01203787,Sorafenib Dose Ramp-Up in Hepatocellular Carcinoma (HCC),upper gastrointestinal tract
D014839,1.59,NCT01203787-1,Sorafenib Standard Dosing Regimen,NCT01203787,Sorafenib Dose Ramp-Up in Hepatocellular Carcinoma (HCC),vomiting
D000075902,1.75,NCT01203787-2,Sorafenib Ramp-Up Regimen,NCT01203787,Sorafenib Dose Ramp-Up in Hepatocellular Carcinoma (HCC),clinical deterioration
D007035,1.59,NCT01203787-1,Sorafenib Standard Dosing Regimen,NCT01203787,Sorafenib Dose Ramp-Up in Hepatocellular Carcinoma (HCC),hypothermia
D013575,1.59,NCT01203787-1,Sorafenib Standard Dosing Regimen,NCT01203787,Sorafenib Dose Ramp-Up in Hepatocellular Carcinoma (HCC),syncopal episode
D001201,1.59,NCT01203787-1,Sorafenib Standard Dosing Regimen,NCT01203787,Sorafenib Dose Ramp-Up in Hepatocellular Carcinoma (HCC),ascites
D001201,1.75,NCT01203787-2,Sorafenib Ramp-Up Regimen,NCT01203787,Sorafenib Dose Ramp-Up in Hepatocellular Carcinoma (HCC),ascites
D000080222,1.59,NCT01203787-1,Sorafenib Standard Dosing Regimen,NCT01203787,Sorafenib Dose Ramp-Up in Hepatocellular Carcinoma (HCC),pancreaticobiliary maljunction
D017093,1.59,NCT01203787-1,Sorafenib Standard Dosing Regimen,NCT01203787,Sorafenib Dose Ramp-Up in Hepatocellular Carcinoma (HCC),liver failure
D001927,9.52,NCT01203787-1,Sorafenib Standard Dosing Regimen,NCT01203787,Sorafenib Dose Ramp-Up in Hepatocellular Carcinoma (HCC),encephalopathy
D001927,1.75,NCT01203787-2,Sorafenib Ramp-Up Regimen,NCT01203787,Sorafenib Dose Ramp-Up in Hepatocellular Carcinoma (HCC),encephalopathy
D017093,7.02,NCT01203787-2,Sorafenib Ramp-Up Regimen,NCT01203787,Sorafenib Dose Ramp-Up in Hepatocellular Carcinoma (HCC),liver failure
D002481,1.59,NCT01203787-1,Sorafenib Standard Dosing Regimen,NCT01203787,Sorafenib Dose Ramp-Up in Hepatocellular Carcinoma (HCC),cellulitis
D007251,1.59,NCT01203787-1,Sorafenib Standard Dosing Regimen,NCT01203787,Sorafenib Dose Ramp-Up in Hepatocellular Carcinoma (HCC),influenza
D008581,1.59,NCT01203787-1,Sorafenib Standard Dosing Regimen,NCT01203787,Sorafenib Dose Ramp-Up in Hepatocellular Carcinoma (HCC),meningitis
D011014,1.59,NCT01203787-1,Sorafenib Standard Dosing Regimen,NCT01203787,Sorafenib Dose Ramp-Up in Hepatocellular Carcinoma (HCC),pneumonia
D011014,1.75,NCT01203787-2,Sorafenib Ramp-Up Regimen,NCT01203787,Sorafenib Dose Ramp-Up in Hepatocellular Carcinoma (HCC),pneumonia
D018805,3.17,NCT01203787-1,Sorafenib Standard Dosing Regimen,NCT01203787,Sorafenib Dose Ramp-Up in Hepatocellular Carcinoma (HCC),sepsis
D018805,1.75,NCT01203787-2,Sorafenib Ramp-Up Regimen,NCT01203787,Sorafenib Dose Ramp-Up in Hepatocellular Carcinoma (HCC),sepsis
D016931,1.59,NCT01203787-1,Sorafenib Standard Dosing Regimen,NCT01203787,Sorafenib Dose Ramp-Up in Hepatocellular Carcinoma (HCC),halobacteriales
D014552,1.75,NCT01203787-2,Sorafenib Ramp-Up Regimen,NCT01203787,Sorafenib Dose Ramp-Up in Hepatocellular Carcinoma (HCC),urinary tract infection
D064420,1.59,NCT01203787-1,Sorafenib Standard Dosing Regimen,NCT01203787,Sorafenib Dose Ramp-Up in Hepatocellular Carcinoma (HCC),drug toxicity
D011178,4.76,NCT01203787-1,Sorafenib Standard Dosing Regimen,NCT01203787,Sorafenib Dose Ramp-Up in Hepatocellular Carcinoma (HCC),postgastrectomy syndromes
D003681,3.17,NCT01203787-1,Sorafenib Standard Dosing Regimen,NCT01203787,Sorafenib Dose Ramp-Up in Hepatocellular Carcinoma (HCC),dehydration
D003681,1.75,NCT01203787-2,Sorafenib Ramp-Up Regimen,NCT01203787,Sorafenib Dose Ramp-Up in Hepatocellular Carcinoma (HCC),dehydration
D005183,1.59,NCT01203787-1,Sorafenib Standard Dosing Regimen,NCT01203787,Sorafenib Dose Ramp-Up in Hepatocellular Carcinoma (HCC),failure to thrive
D012253,1.59,NCT01203787-1,Sorafenib Standard Dosing Regimen,NCT01203787,Sorafenib Dose Ramp-Up in Hepatocellular Carcinoma (HCC),rib fracture
D004244,1.59,NCT01203787-1,Sorafenib Standard Dosing Regimen,NCT01203787,Sorafenib Dose Ramp-Up in Hepatocellular Carcinoma (HCC),dizziness
D014717,1.75,NCT01203787-2,Sorafenib Ramp-Up Regimen,NCT01203787,Sorafenib Dose Ramp-Up in Hepatocellular Carcinoma (HCC),vertigo
D020233,1.75,NCT01203787-2,Sorafenib Ramp-Up Regimen,NCT01203787,Sorafenib Dose Ramp-Up in Hepatocellular Carcinoma (HCC),unsteady gait
D058186,4.76,NCT01203787-1,Sorafenib Standard Dosing Regimen,NCT01203787,Sorafenib Dose Ramp-Up in Hepatocellular Carcinoma (HCC),acute renal failure
D010996,1.59,NCT01203787-1,Sorafenib Standard Dosing Regimen,NCT01203787,Sorafenib Dose Ramp-Up in Hepatocellular Carcinoma (HCC),pleural effusion
D010996,1.75,NCT01203787-2,Sorafenib Ramp-Up Regimen,NCT01203787,Sorafenib Dose Ramp-Up in Hepatocellular Carcinoma (HCC),pleural effusion
D011655,1.59,NCT01203787-1,Sorafenib Standard Dosing Regimen,NCT01203787,Sorafenib Dose Ramp-Up in Hepatocellular Carcinoma (HCC),pulmonary embolism
D012131,3.17,NCT01203787-1,Sorafenib Standard Dosing Regimen,NCT01203787,Sorafenib Dose Ramp-Up in Hepatocellular Carcinoma (HCC),respiratory failure
D012131,1.75,NCT01203787-2,Sorafenib Ramp-Up Regimen,NCT01203787,Sorafenib Dose Ramp-Up in Hepatocellular Carcinoma (HCC),respiratory failure
D003869,1.59,NCT01203787-1,Sorafenib Standard Dosing Regimen,NCT01203787,Sorafenib Dose Ramp-Up in Hepatocellular Carcinoma (HCC),dermabrasion
D064420,37.5,NCT01205828-1,Temozolomide + ABT-888,NCT01205828,ABT-888 and Temozolomide for Liver Cancer,adverse drug events
D020250,18.75,NCT01205828-1,Temozolomide + ABT-888,NCT01205828,ABT-888 and Temozolomide for Liver Cancer,postoperative nausea and vomiting
D006470,6.25,NCT01205828-1,Temozolomide + ABT-888,NCT01205828,ABT-888 and Temozolomide for Liver Cancer,bleeding
D005221,6.25,NCT01205828-1,Temozolomide + ABT-888,NCT01205828,ABT-888 and Temozolomide for Liver Cancer,fatigue
D000028,6.25,NCT01205828-1,Temozolomide + ABT-888,NCT01205828,ABT-888 and Temozolomide for Liver Cancer,abortion failure
D064420,30.77,NCT01234337-1,Sorafenib (Nexavar BAY43-9006) + Capecitabine,NCT01234337,Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer,adverse drug events
D064420,26.59,NCT01234337-2,Placebo + Capecitabine,NCT01234337,Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer,adverse drug events
D000741,0.77,NCT01234337-1,Sorafenib (Nexavar BAY43-9006) + Capecitabine,NCT01234337,Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer,aplastic anaemia
D000741,0.75,NCT01234337-2,Placebo + Capecitabine,NCT01234337,Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer,aplastic anaemia
D064147,0.37,NCT01234337-2,Placebo + Capecitabine,NCT01234337,Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer,febrile neutropenia
D009503,0.77,NCT01234337-1,Sorafenib (Nexavar BAY43-9006) + Capecitabine,NCT01234337,Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer,neutropenia
D013921,0.37,NCT01234337-2,Placebo + Capecitabine,NCT01234337,Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer,thrombocytopenia
D002037,0.37,NCT01234337-2,Placebo + Capecitabine,NCT01234337,Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer,right bundle-branch block
D010490,1.87,NCT01234337-2,Placebo + Capecitabine,NCT01234337,Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer,pericardial effusion
D000028,0.37,NCT01234337-2,Placebo + Capecitabine,NCT01234337,Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer,abortion failure
D000708,0.37,NCT01234337-2,Placebo + Capecitabine,NCT01234337,Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer,anaplasia
D001248,0.38,NCT01234337-1,Sorafenib (Nexavar BAY43-9006) + Capecitabine,NCT01234337,Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer,eyestrain
D000007,0.37,NCT01234337-2,Placebo + Capecitabine,NCT01234337,Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer,abdominal injuries
D015746,0.77,NCT01234337-1,Sorafenib (Nexavar BAY43-9006) + Capecitabine,NCT01234337,Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer,abdominal pain
D015746,0.37,NCT01234337-2,Placebo + Capecitabine,NCT01234337,Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer,abdominal pain
D000006,0.38,NCT01234337-1,Sorafenib (Nexavar BAY43-9006) + Capecitabine,NCT01234337,Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer,acute abdomen
D001201,0.38,NCT01234337-1,Sorafenib (Nexavar BAY43-9006) + Capecitabine,NCT01234337,Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer,ascites
D001201,0.75,NCT01234337-2,Placebo + Capecitabine,NCT01234337,Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer,ascites
D003092,0.38,NCT01234337-1,Sorafenib (Nexavar BAY43-9006) + Capecitabine,NCT01234337,Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer,colitis
D003092,0.75,NCT01234337-2,Placebo + Capecitabine,NCT01234337,Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer,colitis
D003248,0.38,NCT01234337-1,Sorafenib (Nexavar BAY43-9006) + Capecitabine,NCT01234337,Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer,constipation
UNKNOWN-check-for-typo,1.15,NCT01234337-1,Sorafenib (Nexavar BAY43-9006) + Capecitabine,NCT01234337,Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer,D00
UNKNOWN-check-for-typo,3.0,NCT01234337-2,Placebo + Capecitabine,NCT01234337,Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer,D00
D004751,0.37,NCT01234337-2,Placebo + Capecitabine,NCT01234337,Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer,enteritis
D050686,0.38,NCT01234337-1,Sorafenib (Nexavar BAY43-9006) + Capecitabine,NCT01234337,Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer,globicephala melaena
D009325,1.15,NCT01234337-1,Sorafenib (Nexavar BAY43-9006) + Capecitabine,NCT01234337,Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer,nausea
D009325,0.75,NCT01234337-2,Placebo + Capecitabine,NCT01234337,Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer,nausea
D003251,0.38,NCT01234337-1,Sorafenib (Nexavar BAY43-9006) + Capecitabine,NCT01234337,Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer,stenosis
D010195,0.38,NCT01234337-1,Sorafenib (Nexavar BAY43-9006) + Capecitabine,NCT01234337,Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer,pancreatitis
D001819,0.38,NCT01234337-1,Sorafenib (Nexavar BAY43-9006) + Capecitabine,NCT01234337,Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer,bluetongue
D014839,2.69,NCT01234337-1,Sorafenib (Nexavar BAY43-9006) + Capecitabine,NCT01234337,Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer,vomiting
D014839,0.37,NCT01234337-2,Placebo + Capecitabine,NCT01234337,Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer,vomiting
10050094,0.38,NCT01234337-1,Sorafenib (Nexavar BAY43-9006) + Capecitabine,NCT01234337,Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer,duodenal stenosis
10021328,0.37,NCT01234337-2,Placebo + Capecitabine,NCT01234337,Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer,ileus
D044504,1.12,NCT01234337-2,Placebo + Capecitabine,NCT01234337,Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer,enterocolitis neutropenic
D003643,0.77,NCT01234337-1,Sorafenib (Nexavar BAY43-9006) + Capecitabine,NCT01234337,Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer,death
D003643,0.37,NCT01234337-2,Placebo + Capecitabine,NCT01234337,Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer,death
D005221,0.77,NCT01234337-1,Sorafenib (Nexavar BAY43-9006) + Capecitabine,NCT01234337,Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer,fatigue
D005221,0.75,NCT01234337-2,Placebo + Capecitabine,NCT01234337,Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer,fatigue
D007249,0.38,NCT01234337-1,Sorafenib (Nexavar BAY43-9006) + Capecitabine,NCT01234337,Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer,inflammation
D010146,0.77,NCT01234337-1,Sorafenib (Nexavar BAY43-9006) + Capecitabine,NCT01234337,Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer,pain
D005334,1.12,NCT01234337-2,Placebo + Capecitabine,NCT01234337,Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer,pyrexia
D003695,1.15,NCT01234337-1,Sorafenib (Nexavar BAY43-9006) + Capecitabine,NCT01234337,Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer,healthcare
D003695,1.12,NCT01234337-2,Placebo + Capecitabine,NCT01234337,Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer,healthcare
10017638,0.38,NCT01234337-1,Sorafenib (Nexavar BAY43-9006) + Capecitabine,NCT01234337,Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer,gallbladder pain
D017093,0.77,NCT01234337-1,Sorafenib (Nexavar BAY43-9006) + Capecitabine,NCT01234337,Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer,hepatic failure
D017093,0.37,NCT01234337-2,Placebo + Capecitabine,NCT01234337,Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer,hepatic failure
UNKNOWN-check-for-typo,0.38,NCT01234337-1,Sorafenib (Nexavar BAY43-9006) + Capecitabine,NCT01234337,Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer,D00
D041781,0.38,NCT01234337-1,Sorafenib (Nexavar BAY43-9006) + Capecitabine,NCT01234337,Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer,cholestatic jaundice
D001991,0.38,NCT01234337-1,Sorafenib (Nexavar BAY43-9006) + Capecitabine,NCT01234337,Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer,bronchitis
D000072139,0.38,NCT01234337-1,Sorafenib (Nexavar BAY43-9006) + Capecitabine,NCT01234337,Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer,megavirales
D011014,0.77,NCT01234337-1,Sorafenib (Nexavar BAY43-9006) + Capecitabine,NCT01234337,Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer,pneumonia
D018805,0.77,NCT01234337-1,Sorafenib (Nexavar BAY43-9006) + Capecitabine,NCT01234337,Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer,sepsis
D014552,0.77,NCT01234337-1,Sorafenib (Nexavar BAY43-9006) + Capecitabine,NCT01234337,Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer,urinary tract infection
D014552,0.37,NCT01234337-2,Placebo + Capecitabine,NCT01234337,Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer,urinary tract infection
D003587,0.38,NCT01234337-1,Sorafenib (Nexavar BAY43-9006) + Capecitabine,NCT01234337,Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer,cytomegalovirus
10061229,0.77,NCT01234337-1,Sorafenib (Nexavar BAY43-9006) + Capecitabine,NCT01234337,Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer,lung infection
D005265,0.38,NCT01234337-1,Sorafenib (Nexavar BAY43-9006) + Capecitabine,NCT01234337,Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer,femoral neck fracture
D005265,0.38,NCT01234337-1,Sorafenib (Nexavar BAY43-9006) + Capecitabine,NCT01234337,Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer,femur neck fractures
D005265,0.37,NCT01234337-2,Placebo + Capecitabine,NCT01234337,Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer,femur neck fractures
10020100,0.37,NCT01234337-2,Placebo + Capecitabine,NCT01234337,Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer,hip fracture
D006811,0.37,NCT01234337-2,Placebo + Capecitabine,NCT01234337,Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer,humerus
D012421,0.37,NCT01234337-2,Placebo + Capecitabine,NCT01234337,Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer,rupture
10048049,0.38,NCT01234337-1,Sorafenib (Nexavar BAY43-9006) + Capecitabine,NCT01234337,Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer,wrist fracture
D001706,0.38,NCT01234337-1,Sorafenib (Nexavar BAY43-9006) + Capecitabine,NCT01234337,Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer,biopsy
10005364,0.37,NCT01234337-2,Placebo + Capecitabine,NCT01234337,Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer,blood bilirubin increased
D007958,0.38,NCT01234337-1,Sorafenib (Nexavar BAY43-9006) + Capecitabine,NCT01234337,Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer,blood cell count white
D003681,0.77,NCT01234337-1,Sorafenib (Nexavar BAY43-9006) + Capecitabine,NCT01234337,Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer,dehydration
UNKNOWN-check-for-typo,0.75,NCT01234337-2,Placebo + Capecitabine,NCT01234337,Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer,D00
UNKNOWN-check-for-typo,0.37,NCT01234337-2,Placebo + Capecitabine,NCT01234337,Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer,D00
UNKNOWN-check-for-typo,0.37,NCT01234337-2,Placebo + Capecitabine,NCT01234337,Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer,D00
UNKNOWN-check-for-typo,0.38,NCT01234337-1,Sorafenib (Nexavar BAY43-9006) + Capecitabine,NCT01234337,Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer,D00
UNKNOWN-check-for-typo,1.5,NCT01234337-2,Placebo + Capecitabine,NCT01234337,Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer,D00
UNKNOWN-check-for-typo,0.38,NCT01234337-1,Sorafenib (Nexavar BAY43-9006) + Capecitabine,NCT01234337,Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer,D00
UNKNOWN-check-for-typo,0.37,NCT01234337-2,Placebo + Capecitabine,NCT01234337,Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer,D00
D018771,1.15,NCT01234337-1,Sorafenib (Nexavar BAY43-9006) + Capecitabine,NCT01234337,Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer,arthralgia
D018771,0.37,NCT01234337-2,Placebo + Capecitabine,NCT01234337,Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer,arthralgia
D001416,0.77,NCT01234337-1,Sorafenib (Nexavar BAY43-9006) + Capecitabine,NCT01234337,Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer,back pain
10006002,0.37,NCT01234337-2,Placebo + Capecitabine,NCT01234337,Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer,bone pain
D059352,0.37,NCT01234337-2,Placebo + Capecitabine,NCT01234337,Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer,musculoskeletal pain
D009135,0.38,NCT01234337-1,Sorafenib (Nexavar BAY43-9006) + Capecitabine,NCT01234337,Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer,myopathy
D002322,0.37,NCT01234337-2,Placebo + Capecitabine,NCT01234337,Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer,career mobility
D002637,0.38,NCT01234337-1,Sorafenib (Nexavar BAY43-9006) + Capecitabine,NCT01234337,Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer,chest pain
D001943,0.37,NCT01234337-2,Placebo + Capecitabine,NCT01234337,Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer,breast cancer
D016066,0.38,NCT01234337-1,Sorafenib (Nexavar BAY43-9006) + Capecitabine,NCT01234337,Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer,malignant pleural effusion
D001664,0.37,NCT01234337-2,Placebo + Capecitabine,NCT01234337,Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer,biliverdine
D009362,0.37,NCT01234337-2,Placebo + Capecitabine,NCT01234337,Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer,metastases
D008578,0.37,NCT01234337-2,Placebo + Capecitabine,NCT01234337,Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer,meninges
D005334,0.38,NCT01234337-1,Sorafenib (Nexavar BAY43-9006) + Capecitabine,NCT01234337,Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer,fever
D001943,0.38,NCT01234337-1,Sorafenib (Nexavar BAY43-9006) + Capecitabine,NCT01234337,Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer,breast cancer
D001943,0.75,NCT01234337-2,Placebo + Capecitabine,NCT01234337,Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer,breast cancer
D000072716,0.38,NCT01234337-1,Sorafenib (Nexavar BAY43-9006) + Capecitabine,NCT01234337,Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer,cancer pain
D002490,0.38,NCT01234337-1,Sorafenib (Nexavar BAY43-9006) + Capecitabine,NCT01234337,Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer,central nervous system
D001288,0.38,NCT01234337-1,Sorafenib (Nexavar BAY43-9006) + Capecitabine,NCT01234337,Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer,attention
D004244,0.37,NCT01234337-2,Placebo + Capecitabine,NCT01234337,Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer,dizziness
D004827,0.38,NCT01234337-1,Sorafenib (Nexavar BAY43-9006) + Capecitabine,NCT01234337,Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer,epilepsy
D005158,0.37,NCT01234337-2,Placebo + Capecitabine,NCT01234337,Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer,facial paralysis
D006261,0.77,NCT01234337-1,Sorafenib (Nexavar BAY43-9006) + Capecitabine,NCT01234337,Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer,headache
D006261,0.37,NCT01234337-2,Placebo + Capecitabine,NCT01234337,Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer,headache
D006501,0.38,NCT01234337-1,Sorafenib (Nexavar BAY43-9006) + Capecitabine,NCT01234337,Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer,hepatic encephalopathy
D006501,0.37,NCT01234337-2,Placebo + Capecitabine,NCT01234337,Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer,hepatic encephalopathy
D053609,0.37,NCT01234337-2,Placebo + Capecitabine,NCT01234337,Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer,lethargy
D009437,0.38,NCT01234337-1,Sorafenib (Nexavar BAY43-9006) + Capecitabine,NCT01234337,Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer,neuralgia
D013575,0.38,NCT01234337-1,Sorafenib (Nexavar BAY43-9006) + Capecitabine,NCT01234337,Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer,presyncope
D012585,0.38,NCT01234337-1,Sorafenib (Nexavar BAY43-9006) + Capecitabine,NCT01234337,Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer,sciatica
D013117,0.37,NCT01234337-2,Placebo + Capecitabine,NCT01234337,Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer,spinal cord compression
D000799,0.37,NCT01234337-2,Placebo + Capecitabine,NCT01234337,Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer,angioedema
D002490,0.37,NCT01234337-2,Placebo + Capecitabine,NCT01234337,Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer,central nervous system
D000799,0.38,NCT01234337-1,Sorafenib (Nexavar BAY43-9006) + Capecitabine,NCT01234337,Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer,angioedema
D003221,0.38,NCT01234337-1,Sorafenib (Nexavar BAY43-9006) + Capecitabine,NCT01234337,Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer,confusional state
D006869,0.38,NCT01234337-1,Sorafenib (Nexavar BAY43-9006) + Capecitabine,NCT01234337,Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer,hydronephrosis
D006869,0.37,NCT01234337-2,Placebo + Capecitabine,NCT01234337,Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer,hydronephrosis
D056844,0.38,NCT01234337-1,Sorafenib (Nexavar BAY43-9006) + Capecitabine,NCT01234337,Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer,renal colic
D058186,0.38,NCT01234337-1,Sorafenib (Nexavar BAY43-9006) + Capecitabine,NCT01234337,Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer,acute kidney injury
D008595,0.38,NCT01234337-1,Sorafenib (Nexavar BAY43-9006) + Capecitabine,NCT01234337,Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer,menorrhagia
D001237,0.38,NCT01234337-1,Sorafenib (Nexavar BAY43-9006) + Capecitabine,NCT01234337,Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer,asphyxia
D001986,0.38,NCT01234337-1,Sorafenib (Nexavar BAY43-9006) + Capecitabine,NCT01234337,Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer,bronchospasm
UNKNOWN-check-for-typo,3.08,NCT01234337-1,Sorafenib (Nexavar BAY43-9006) + Capecitabine,NCT01234337,Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer,D00
UNKNOWN-check-for-typo,1.12,NCT01234337-2,Placebo + Capecitabine,NCT01234337,Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer,D00
UNKNOWN-check-for-typo,0.37,NCT01234337-2,Placebo + Capecitabine,NCT01234337,Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer,D00
D010996,2.31,NCT01234337-1,Sorafenib (Nexavar BAY43-9006) + Capecitabine,NCT01234337,Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer,pleural effusion
D010996,4.12,NCT01234337-2,Placebo + Capecitabine,NCT01234337,Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer,pleural effusion
D011014,0.38,NCT01234337-1,Sorafenib (Nexavar BAY43-9006) + Capecitabine,NCT01234337,Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer,pneumonitis
D011030,0.38,NCT01234337-1,Sorafenib (Nexavar BAY43-9006) + Capecitabine,NCT01234337,Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer,pneumothorax
D011030,1.12,NCT01234337-2,Placebo + Capecitabine,NCT01234337,Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer,pneumothorax
D011655,1.15,NCT01234337-1,Sorafenib (Nexavar BAY43-9006) + Capecitabine,NCT01234337,Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer,pulmonary embolism
D011655,1.5,NCT01234337-2,Placebo + Capecitabine,NCT01234337,Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer,pulmonary embolism
D001261,0.38,NCT01234337-1,Sorafenib (Nexavar BAY43-9006) + Capecitabine,NCT01234337,Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer,pulmonary atelectasis
D012131,1.15,NCT01234337-1,Sorafenib (Nexavar BAY43-9006) + Capecitabine,NCT01234337,Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer,respiratory failure
10044291,0.38,NCT01234337-1,Sorafenib (Nexavar BAY43-9006) + Capecitabine,NCT01234337,Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer,tracheal obstruction
D004892,0.38,NCT01234337-1,Sorafenib (Nexavar BAY43-9006) + Capecitabine,NCT01234337,Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer,erythema multiforme
10054524,0.37,NCT01234337-2,Placebo + Capecitabine,NCT01234337,Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer,palmar-plantar erythrodysesthesia syndrome
D005076,0.38,NCT01234337-1,Sorafenib (Nexavar BAY43-9006) + Capecitabine,NCT01234337,Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer,rash
D002763,0.37,NCT01234337-2,Placebo + Capecitabine,NCT01234337,Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer,cholecystectomy
D007044,0.38,NCT01234337-1,Sorafenib (Nexavar BAY43-9006) + Capecitabine,NCT01234337,Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer,hysterectomy
D018700,0.77,NCT01234337-1,Sorafenib (Nexavar BAY43-9006) + Capecitabine,NCT01234337,Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer,pleurodesis
D002405,0.38,NCT01234337-1,Sorafenib (Nexavar BAY43-9006) + Capecitabine,NCT01234337,Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer,catheterization central venous
D006498,0.38,NCT01234337-1,Sorafenib (Nexavar BAY43-9006) + Capecitabine,NCT01234337,Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer,hepatectomy
D008197,0.38,NCT01234337-1,Sorafenib (Nexavar BAY43-9006) + Capecitabine,NCT01234337,Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer,lymphadenectomy
D003452,0.37,NCT01234337-2,Placebo + Capecitabine,NCT01234337,Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer,cryosurgery
UNKNOWN-check-for-typo,0.38,NCT01234337-1,Sorafenib (Nexavar BAY43-9006) + Capecitabine,NCT01234337,Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer,D00
D013479,0.38,NCT01234337-1,Sorafenib (Nexavar BAY43-9006) + Capecitabine,NCT01234337,Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer,superior vena cava syndrome
D020246,0.38,NCT01234337-1,Sorafenib (Nexavar BAY43-9006) + Capecitabine,NCT01234337,Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer,deep vein thrombosis
D020246,1.12,NCT01234337-2,Placebo + Capecitabine,NCT01234337,Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer,deep vein thrombosis
D015356,0.38,NCT01234337-1,Sorafenib (Nexavar BAY43-9006) + Capecitabine,NCT01234337,Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer,retinal artery occlusion
D020246,0.37,NCT01234337-2,Placebo + Capecitabine,NCT01234337,Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer,venous thrombosis
D009026,78.43,NCT01258608-1,Sorafenib+Placebo,NCT01258608,Study of Mapatumumab in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma,mortality
D009026,78.0,NCT01258608-2,Sorafenib+Mapatumumab 30 mg/kg,NCT01258608,Study of Mapatumumab in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma,mortality
D064420,52.94,NCT01258608-1,Sorafenib+Placebo,NCT01258608,Study of Mapatumumab in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma,adverse drug events
D064420,42.0,NCT01258608-2,Sorafenib+Mapatumumab 30 mg/kg,NCT01258608,Study of Mapatumumab in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma,adverse drug events
D004211,2.0,NCT01258608-2,Sorafenib+Mapatumumab 30 mg/kg,NCT01258608,Study of Mapatumumab in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma,disseminated intravascular coagulation
D056988,4.0,NCT01258608-2,Sorafenib+Mapatumumab 30 mg/kg,NCT01258608,Study of Mapatumumab in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma,acute anterior wall myocardial infarction
D000072599,2.0,NCT01258608-2,Sorafenib+Mapatumumab 30 mg/kg,NCT01258608,Study of Mapatumumab in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma,cardiorespiratory fitness
D000071956,2.0,NCT01258608-2,Sorafenib+Mapatumumab 30 mg/kg,NCT01258608,Study of Mapatumumab in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma,myocardial contusions
D001281,1.96,NCT01258608-1,Sorafenib+Placebo,NCT01258608,Study of Mapatumumab in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma,atrial fibrillation
D001282,1.96,NCT01258608-1,Sorafenib+Placebo,NCT01258608,Study of Mapatumumab in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma,atrial flutter
D054537,1.96,NCT01258608-1,Sorafenib+Placebo,NCT01258608,Study of Mapatumumab in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma,atrioventricular block
D014648,6.0,NCT01258608-2,Sorafenib+Mapatumumab 30 mg/kg,NCT01258608,Study of Mapatumumab in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma,varices
D020115,3.92,NCT01258608-1,Sorafenib+Placebo,NCT01258608,Study of Mapatumumab in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma,progastricsin
D020115,2.0,NCT01258608-2,Sorafenib+Mapatumumab 30 mg/kg,NCT01258608,Study of Mapatumumab in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma,progastricsin
D041742,3.92,NCT01258608-1,Sorafenib+Placebo,NCT01258608,Study of Mapatumumab in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma,upper gastrointestinal tract
D041742,2.0,NCT01258608-2,Sorafenib+Mapatumumab 30 mg/kg,NCT01258608,Study of Mapatumumab in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma,upper gastrointestinal tract
D005517,2.0,NCT01258608-2,Sorafenib+Mapatumumab 30 mg/kg,NCT01258608,Study of Mapatumumab in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma,food poisoning
D001201,1.96,NCT01258608-1,Sorafenib+Placebo,NCT01258608,Study of Mapatumumab in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma,ascites
D013276,1.96,NCT01258608-1,Sorafenib+Placebo,NCT01258608,Study of Mapatumumab in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma,gastric ulcer
D013276,1.96,NCT01258608-1,Sorafenib+Placebo,NCT01258608,Study of Mapatumumab in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma,gastric ulcer
D003695,3.92,NCT01258608-1,Sorafenib+Placebo,NCT01258608,Study of Mapatumumab in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma,healthcare
D003695,2.0,NCT01258608-2,Sorafenib+Mapatumumab 30 mg/kg,NCT01258608,Study of Mapatumumab in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma,healthcare
D018450,1.96,NCT01258608-1,Sorafenib+Placebo,NCT01258608,Study of Mapatumumab in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma,disease progression
D005221,1.96,NCT01258608-1,Sorafenib+Placebo,NCT01258608,Study of Mapatumumab in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma,fatigue
D017093,6.0,NCT01258608-2,Sorafenib+Mapatumumab 30 mg/kg,NCT01258608,Study of Mapatumumab in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma,hepatic failure
UNKNOWN-check-for-typo,1.96,NCT01258608-1,Sorafenib+Placebo,NCT01258608,Study of Mapatumumab in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma,D00
D001064,2.0,NCT01258608-2,Sorafenib+Mapatumumab 30 mg/kg,NCT01258608,Study of Mapatumumab in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma,appendicitis
D005734,2.0,NCT01258608-2,Sorafenib+Mapatumumab 30 mg/kg,NCT01258608,Study of Mapatumumab in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma,gangrene
D002177,2.0,NCT01258608-2,Sorafenib+Mapatumumab 30 mg/kg,NCT01258608,Study of Mapatumumab in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma,candidiasis
10064687,1.96,NCT01258608-1,Sorafenib+Placebo,NCT01258608,Study of Mapatumumab in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma,device related infection
D006259,1.96,NCT01258608-1,Sorafenib+Placebo,NCT01258608,Study of Mapatumumab in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma,craniocerebral injury
D006259,2.0,NCT01258608-2,Sorafenib+Mapatumumab 30 mg/kg,NCT01258608,Study of Mapatumumab in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma,craniocerebral injury
D000063,2.0,NCT01258608-2,Sorafenib+Mapatumumab 30 mg/kg,NCT01258608,Study of Mapatumumab in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma,accidents traffic
D005723,5.88,NCT01258608-1,Sorafenib+Placebo,NCT01258608,Study of Mapatumumab in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma,gammaglutamyltransferase
10005364,1.96,NCT01258608-1,Sorafenib+Placebo,NCT01258608,Study of Mapatumumab in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma,blood bilirubin increased
10005364,4.0,NCT01258608-2,Sorafenib+Mapatumumab 30 mg/kg,NCT01258608,Study of Mapatumumab in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma,blood bilirubin increased
10001551,2.0,NCT01258608-2,Sorafenib+Mapatumumab 30 mg/kg,NCT01258608,Study of Mapatumumab in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma,alanine aminotransferase increased
10024574,1.96,NCT01258608-1,Sorafenib+Placebo,NCT01258608,Study of Mapatumumab in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma,lipase increased
UNKNOWN-check-for-typo,1.96,NCT01258608-1,Sorafenib+Placebo,NCT01258608,Study of Mapatumumab in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma,D00
UNKNOWN-check-for-typo,4.0,NCT01258608-2,Sorafenib+Mapatumumab 30 mg/kg,NCT01258608,Study of Mapatumumab in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma,D00
D003681,2.0,NCT01258608-2,Sorafenib+Mapatumumab 30 mg/kg,NCT01258608,Study of Mapatumumab in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma,dehydration
D044342,2.0,NCT01258608-2,Sorafenib+Mapatumumab 30 mg/kg,NCT01258608,Study of Mapatumumab in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma,malnutrition
D002100,1.96,NCT01258608-1,Sorafenib+Placebo,NCT01258608,Study of Mapatumumab in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma,cachexia
UNKNOWN-check-for-typo,1.96,NCT01258608-1,Sorafenib+Placebo,NCT01258608,Study of Mapatumumab in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma,D00
D001168,1.96,NCT01258608-1,Sorafenib+Placebo,NCT01258608,Study of Mapatumumab in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma,arthritis
D006528,17.65,NCT01258608-1,Sorafenib+Placebo,NCT01258608,Study of Mapatumumab in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma,hepatocellular carcinoma
D006528,8.0,NCT01258608-2,Sorafenib+Mapatumumab 30 mg/kg,NCT01258608,Study of Mapatumumab in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma,hepatocellular carcinoma
D008113,1.96,NCT01258608-1,Sorafenib+Placebo,NCT01258608,Study of Mapatumumab in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma,hepatic cancer
D006501,2.0,NCT01258608-2,Sorafenib+Mapatumumab 30 mg/kg,NCT01258608,Study of Mapatumumab in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma,hepatic encephalopathy
D013474,1.96,NCT01258608-1,Sorafenib+Placebo,NCT01258608,Study of Mapatumumab in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma,sunstroke
D051437,2.0,NCT01258608-2,Sorafenib+Mapatumumab 30 mg/kg,NCT01258608,Study of Mapatumumab in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma,renal failure
D011655,3.92,NCT01258608-1,Sorafenib+Placebo,NCT01258608,Study of Mapatumumab in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma,pulmonary embolism
D029481,2.0,NCT01258608-2,Sorafenib+Mapatumumab 30 mg/kg,NCT01258608,Study of Mapatumumab in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma,chronic bronchitis
D012883,1.96,NCT01258608-1,Sorafenib+Placebo,NCT01258608,Study of Mapatumumab in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma,skin ulcer
D009026,59.26,NCT01306058-1,Sorafenib & TRC105 in Hepatocellular CA,NCT01306058,Sorafenib and TRC105 in Hepatocellular Cancer,mortality
D064420,40.74,NCT01306058-1,Sorafenib & TRC105 in Hepatocellular CA,NCT01306058,Sorafenib and TRC105 in Hepatocellular Cancer,adverse drug events
10069501,3.7,NCT01306058-1,Sorafenib & TRC105 in Hepatocellular CA,NCT01306058,Sorafenib and TRC105 in Hepatocellular Cancer,left ventricular systolic dysfunction
D009203,3.7,NCT01306058-1,Sorafenib & TRC105 in Hepatocellular CA,NCT01306058,Sorafenib and TRC105 in Hepatocellular Cancer,myocardial infarction
D003967,3.7,NCT01306058-1,Sorafenib & TRC105 in Hepatocellular CA,NCT01306058,Sorafenib and TRC105 in Hepatocellular Cancer,diarrhea
10017999,3.7,NCT01306058-1,Sorafenib & TRC105 in Hepatocellular CA,NCT01306058,Sorafenib and TRC105 in Hepatocellular Cancer,gastrointestinal pain
10028130,3.7,NCT01306058-1,Sorafenib & TRC105 in Hepatocellular CA,NCT01306058,Sorafenib and TRC105 in Hepatocellular Cancer,mucositis oral
D010195,3.7,NCT01306058-1,Sorafenib & TRC105 in Hepatocellular CA,NCT01306058,Sorafenib and TRC105 in Hepatocellular Cancer,pancreatitis
D005334,3.7,NCT01306058-1,Sorafenib & TRC105 in Hepatocellular CA,NCT01306058,Sorafenib and TRC105 in Hepatocellular Cancer,fever
10051792,3.7,NCT01306058-1,Sorafenib & TRC105 in Hepatocellular CA,NCT01306058,Sorafenib and TRC105 in Hepatocellular Cancer,infusion related reaction
D017093,3.7,NCT01306058-1,Sorafenib & TRC105 in Hepatocellular CA,NCT01306058,Sorafenib and TRC105 in Hepatocellular Cancer,hepatic failure
10061229,3.7,NCT01306058-1,Sorafenib & TRC105 in Hepatocellular CA,NCT01306058,Sorafenib and TRC105 in Hepatocellular Cancer,lung infection
D018805,3.7,NCT01306058-1,Sorafenib & TRC105 in Hepatocellular CA,NCT01306058,Sorafenib and TRC105 in Hepatocellular Cancer,sepsis
10003481,3.7,NCT01306058-1,Sorafenib & TRC105 in Hepatocellular CA,NCT01306058,Sorafenib and TRC105 in Hepatocellular Cancer,aspartate aminotransferase increased
10005364,3.7,NCT01306058-1,Sorafenib & TRC105 in Hepatocellular CA,NCT01306058,Sorafenib and TRC105 in Hepatocellular Cancer,blood bilirubin increased
10024574,3.7,NCT01306058-1,Sorafenib & TRC105 in Hepatocellular CA,NCT01306058,Sorafenib and TRC105 in Hepatocellular Cancer,lipase increased
10040139,3.7,NCT01306058-1,Sorafenib & TRC105 in Hepatocellular CA,NCT01306058,Sorafenib and TRC105 in Hepatocellular Cancer,serum amylase increased
D020300,3.7,NCT01306058-1,Sorafenib & TRC105 in Hepatocellular CA,NCT01306058,Sorafenib and TRC105 in Hepatocellular Cancer,intracranial hemorrhage
D020521,3.7,NCT01306058-1,Sorafenib & TRC105 in Hepatocellular CA,NCT01306058,Sorafenib and TRC105 in Hepatocellular Cancer,stroke
D004844,3.7,NCT01306058-1,Sorafenib & TRC105 in Hepatocellular CA,NCT01306058,Sorafenib and TRC105 in Hepatocellular Cancer,epistaxis
10037868,7.41,NCT01306058-1,Sorafenib & TRC105 in Hepatocellular CA,NCT01306058,Sorafenib and TRC105 in Hepatocellular Cancer,rash maculo-papular
D005483,3.7,NCT01306058-1,Sorafenib & TRC105 in Hepatocellular CA,NCT01306058,Sorafenib and TRC105 in Hepatocellular Cancer,flushing
D007022,3.7,NCT01306058-1,Sorafenib & TRC105 in Hepatocellular CA,NCT01306058,Sorafenib and TRC105 in Hepatocellular Cancer,hypotension
D009026,35.42,NCT01371981-1,Arm A,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,mortality
D009026,32.87,NCT01371981-2,Arm B,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,mortality
D009026,58.33,NCT01371981-3,Arm C (Cohort 1),NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,mortality
D009026,33.33,NCT01371981-4,Arm C (Cohort 2),NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,mortality
D009026,34.04,NCT01371981-5,Arm C (Cohort 3),NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,mortality
D009026,0.53,NCT01371981-6,Arm D,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,mortality
D064420,14.67,NCT01371981-1,Arm A,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,adverse drug events
D064420,53.04,NCT01371981-2,Arm B,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,adverse drug events
D064420,50.0,NCT01371981-3,Arm C (Cohort 1),NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,adverse drug events
D064420,48.48,NCT01371981-4,Arm C (Cohort 2),NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,adverse drug events
D064420,63.83,NCT01371981-5,Arm C (Cohort 3),NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,adverse drug events
D064420,0.53,NCT01371981-6,Arm D,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,adverse drug events
D000740,0.52,NCT01371981-2,Arm B,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,anemia
10005329,0.18,NCT01371981-1,Arm A,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,blood and lymphatic system disorders - other specify
10005329,0.7,NCT01371981-2,Arm B,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,blood and lymphatic system disorders - other specify
10048580,0.35,NCT01371981-2,Arm B,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,bone marrow hypocellular
D004211,0.54,NCT01371981-1,Arm A,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,disseminated intravascular coagulation
D004211,0.52,NCT01371981-2,Arm B,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,disseminated intravascular coagulation
D064147,3.65,NCT01371981-2,Arm B,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,febrile neutropenia
D064147,3.03,NCT01371981-4,Arm C (Cohort 2),NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,febrile neutropenia
D006461,0.17,NCT01371981-2,Arm B,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,hemolysis
D006463,0.17,NCT01371981-2,Arm B,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,hemolytic uremic syndrome
D007964,0.52,NCT01371981-2,Arm B,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,leukocytosis
D006323,0.17,NCT01371981-2,Arm B,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,asystole
D001281,0.17,NCT01371981-2,Arm B,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,atrial fibrillation
D001282,0.17,NCT01371981-2,Arm B,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,atrial flutter
D006323,0.54,NCT01371981-1,Arm A,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,cardiac arrest
D006323,0.7,NCT01371981-2,Arm B,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,cardiac arrest
10007541,1.22,NCT01371981-2,Arm B,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,cardiac disorders - other specify
10007541,3.03,NCT01371981-4,Arm C (Cohort 2),NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,cardiac disorders - other specify
10007541,4.26,NCT01371981-5,Arm C (Cohort 3),NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,cardiac disorders - other specify
10008481,0.17,NCT01371981-2,Arm B,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,chest pain - cardiac
D006333,0.72,NCT01371981-1,Arm A,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,heart failure
D006333,2.61,NCT01371981-2,Arm B,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,heart failure
D006333,3.03,NCT01371981-4,Arm C (Cohort 2),NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,heart failure
D006333,4.26,NCT01371981-5,Arm C (Cohort 3),NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,heart failure
10069501,0.54,NCT01371981-1,Arm A,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,left ventricular systolic dysfunction
10069501,4.0,NCT01371981-2,Arm B,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,left ventricular systolic dysfunction
10069501,6.06,NCT01371981-4,Arm C (Cohort 2),NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,left ventricular systolic dysfunction
10069501,8.51,NCT01371981-5,Arm C (Cohort 3),NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,left ventricular systolic dysfunction
D009203,0.17,NCT01371981-2,Arm B,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,myocardial infarction
D010490,0.35,NCT01371981-2,Arm B,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,pericardial effusion
D010493,0.17,NCT01371981-2,Arm B,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,pericarditis
D002313,0.7,NCT01371981-2,Arm B,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,restrictive cardiomyopathy
D018497,0.36,NCT01371981-1,Arm A,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,right ventricular dysfunction
D018497,0.35,NCT01371981-2,Arm B,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,right ventricular dysfunction
10040741,0.18,NCT01371981-1,Arm A,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,sinus bradycardia
D013616,1.74,NCT01371981-2,Arm B,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,sinus tachycardia
D013616,2.13,NCT01371981-5,Arm C (Cohort 3),NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,sinus tachycardia
D013617,0.35,NCT01371981-2,Arm B,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,supraventricular tachycardia
10047281,0.52,NCT01371981-2,Arm B,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,ventricular arrhythmia
D014693,0.18,NCT01371981-1,Arm A,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,ventricular fibrillation
D014693,0.17,NCT01371981-2,Arm B,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,ventricular fibrillation
D017180,0.35,NCT01371981-2,Arm B,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,ventricular tachycardia
D000309,0.52,NCT01371981-2,Arm B,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,adrenal insufficiency
10014698,0.17,NCT01371981-2,Arm B,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,endocrine disorders - other specify
D007037,0.17,NCT01371981-2,Arm B,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,hypothyroidism
10015919,0.18,NCT01371981-1,Arm A,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,eye disorders - other specify
10015919,0.35,NCT01371981-2,Arm B,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,eye disorders - other specify
10061322,2.13,NCT01371981-5,Arm C (Cohort 3),NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,optic nerve disorder
D010211,2.13,NCT01371981-5,Arm C (Cohort 3),NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,papilledema
10000060,0.35,NCT01371981-2,Arm B,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,abdominal distension
10000060,3.03,NCT01371981-4,Arm C (Cohort 2),NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,abdominal distension
D015746,0.35,NCT01371981-2,Arm B,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,abdominal pain
10002167,0.17,NCT01371981-2,Arm B,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,anal pain
D001201,0.18,NCT01371981-1,Arm A,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,ascites
D003092,1.57,NCT01371981-2,Arm B,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,colitis
10010001,0.17,NCT01371981-2,Arm B,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,colonic perforation
D003967,1.57,NCT01371981-2,Arm B,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,diarrhea
D003967,3.03,NCT01371981-4,Arm C (Cohort 2),NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,diarrhea
D004760,0.35,NCT01371981-2,Arm B,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,enterocolitis
D004941,0.17,NCT01371981-2,Arm B,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,esophagitis
10017789,0.17,NCT01371981-2,Arm B,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,gastric hemorrhage
D005756,0.35,NCT01371981-2,Arm B,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,gastritis
10017947,0.52,NCT01371981-2,Arm B,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,gastrointestinal disorders - other specify
D045823,0.17,NCT01371981-2,Arm B,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,ileus
D045823,3.03,NCT01371981-4,Arm C (Cohort 2),NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,ileus
D045823,2.13,NCT01371981-5,Arm C (Cohort 3),NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,ileus
10051746,2.13,NCT01371981-5,Arm C (Cohort 3),NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,lower gastrointestinal hemorrhage
10028130,0.52,NCT01371981-2,Arm B,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,mucositis oral
10028130,8.33,NCT01371981-3,Arm C (Cohort 1),NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,mucositis oral
D009325,0.17,NCT01371981-2,Arm B,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,nausea
D009325,3.03,NCT01371981-4,Arm C (Cohort 2),NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,nausea
10031009,0.35,NCT01371981-2,Arm B,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,oral pain
10031009,3.03,NCT01371981-4,Arm C (Cohort 2),NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,oral pain
D010195,1.39,NCT01371981-2,Arm B,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,pancreatitis
D010195,2.13,NCT01371981-5,Arm C (Cohort 3),NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,pancreatitis
10041101,0.35,NCT01371981-2,Arm B,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,small intestinal obstruction
D053706,0.36,NCT01371981-1,Arm A,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,typhlitis
D053706,4.17,NCT01371981-2,Arm B,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,typhlitis
D053706,3.03,NCT01371981-4,Arm C (Cohort 2),NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,typhlitis
D053706,2.13,NCT01371981-5,Arm C (Cohort 3),NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,typhlitis
10055356,0.17,NCT01371981-2,Arm B,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,upper gastrointestinal hemorrhage
D014839,0.17,NCT01371981-2,Arm B,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,vomiting
D014839,3.03,NCT01371981-4,Arm C (Cohort 2),NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,vomiting
D023341,0.17,NCT01371981-2,Arm B,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,chills
10011914,6.8,NCT01371981-1,Arm A,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,death nos
10011914,6.09,NCT01371981-2,Arm B,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,death nos
10011914,8.33,NCT01371981-3,Arm C (Cohort 1),NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,death nos
10011914,15.15,NCT01371981-4,Arm C (Cohort 2),NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,death nos
10011914,12.77,NCT01371981-5,Arm C (Cohort 3),NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,death nos
10014222,0.17,NCT01371981-2,Arm B,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,edema face
D005334,2.26,NCT01371981-2,Arm B,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,fever
D005334,6.38,NCT01371981-5,Arm C (Cohort 3),NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,fever
10017577,0.17,NCT01371981-2,Arm B,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,gait disturbance
D007035,0.18,NCT01371981-1,Arm A,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,hypothermia
D009102,0.18,NCT01371981-1,Arm A,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,multiple organ failure
D009102,1.39,NCT01371981-2,Arm B,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,multiple organ failure
D009102,4.26,NCT01371981-5,Arm C (Cohort 3),NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,multiple organ failure
10062501,0.35,NCT01371981-2,Arm B,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,non-cardiac chest pain
D010146,0.35,NCT01371981-2,Arm B,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,pain
10051341,0.18,NCT01371981-1,Arm A,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,bile duct stenosis
D002764,0.35,NCT01371981-2,Arm B,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,cholecystitis
D002764,2.13,NCT01371981-5,Arm C (Cohort 3),NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,cholecystitis
D017093,0.36,NCT01371981-1,Arm A,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,hepatic failure
D017093,0.17,NCT01371981-2,Arm B,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,hepatic failure
10019805,0.7,NCT01371981-2,Arm B,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,hepatobiliary disorders - other specify
D006967,0.18,NCT01371981-1,Arm A,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,allergic reaction
D006967,0.35,NCT01371981-2,Arm B,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,allergic reaction
D000707,0.87,NCT01371981-2,Arm B,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,anaphylaxis
10021428,0.18,NCT01371981-1,Arm A,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,immune system disorders - other specify
10061640,0.17,NCT01371981-2,Arm B,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,anorectal infection
D001064,0.17,NCT01371981-2,Arm B,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,appendicitis
10005047,0.17,NCT01371981-2,Arm B,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,bladder infection
10055078,0.17,NCT01371981-2,Arm B,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,bronchial infection
10007810,0.87,NCT01371981-2,Arm B,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,catheter related infection
10065761,0.17,NCT01371981-2,Arm B,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,cecal infection
10065752,0.18,NCT01371981-1,Arm A,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,duodenal infection
D000069544,0.17,NCT01371981-2,Arm B,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,encephalitis infection
10058838,0.18,NCT01371981-1,Arm A,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,enterocolitis infectious
10058838,0.35,NCT01371981-2,Arm B,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,enterocolitis infectious
10058804,0.17,NCT01371981-2,Arm B,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,esophageal infection
10058804,2.13,NCT01371981-5,Arm C (Cohort 3),NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,esophageal infection
10021881,0.36,NCT01371981-1,Arm A,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,infections and infestations - other specify
10021881,2.26,NCT01371981-2,Arm B,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,infections and infestations - other specify
10021881,6.06,NCT01371981-4,Arm C (Cohort 2),NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,infections and infestations - other specify
10061229,0.18,NCT01371981-1,Arm A,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,lung infection
10061229,2.26,NCT01371981-2,Arm B,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,lung infection
10061229,8.33,NCT01371981-3,Arm C (Cohort 1),NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,lung infection
10061229,6.06,NCT01371981-4,Arm C (Cohort 2),NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,lung infection
10050823,0.18,NCT01371981-1,Arm A,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,lymph gland infection
D008581,0.18,NCT01371981-1,Arm A,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,meningitis
10065764,0.52,NCT01371981-2,Arm B,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,mucosal infection
10051472,0.17,NCT01371981-2,Arm B,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,periorbital infection
D018805,3.04,NCT01371981-1,Arm A,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,sepsis
D018805,8.7,NCT01371981-2,Arm B,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,sepsis
D018805,3.03,NCT01371981-4,Arm C (Cohort 2),NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,sepsis
D018805,8.51,NCT01371981-5,Arm C (Cohort 3),NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,sepsis
10040872,0.52,NCT01371981-2,Arm B,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,skin infection
D018461,0.18,NCT01371981-1,Arm A,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,soft tissue infection
D014136,0.17,NCT01371981-2,Arm B,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,tracheitis
10046300,0.18,NCT01371981-1,Arm A,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,upper respiratory infection
10046300,0.52,NCT01371981-2,Arm B,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,upper respiratory infection
D014552,0.18,NCT01371981-1,Arm A,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,urinary tract infection
D014552,0.17,NCT01371981-2,Arm B,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,urinary tract infection
10051792,0.35,NCT01371981-2,Arm B,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,infusion related reaction
D019106,0.18,NCT01371981-1,Arm A,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,postoperative hemorrhage
10062169,0.52,NCT01371981-2,Arm B,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,vascular access complication
10000636,0.7,NCT01371981-2,Arm B,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,activated partial thromboplastin time prolonged
10001551,2.78,NCT01371981-2,Arm B,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,alanine aminotransferase increased
10001551,4.26,NCT01371981-5,Arm C (Cohort 3),NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,alanine aminotransferase increased
10003481,0.18,NCT01371981-1,Arm A,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,aspartate aminotransferase increased
10003481,1.74,NCT01371981-2,Arm B,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,aspartate aminotransferase increased
10003481,2.13,NCT01371981-5,Arm C (Cohort 3),NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,aspartate aminotransferase increased
10005364,0.36,NCT01371981-1,Arm A,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,blood bilirubin increased
10005364,2.78,NCT01371981-2,Arm B,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,blood bilirubin increased
10005364,3.03,NCT01371981-4,Arm C (Cohort 2),NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,blood bilirubin increased
10005364,2.13,NCT01371981-5,Arm C (Cohort 3),NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,blood bilirubin increased
10065906,0.17,NCT01371981-2,Arm B,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,carbon monoxide diffusing capacity decreased
10011368,1.39,NCT01371981-2,Arm B,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,creatinine increased
10011368,3.03,NCT01371981-4,Arm C (Cohort 2),NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,creatinine increased
10050528,0.36,NCT01371981-1,Arm A,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,ejection fraction decreased
10050528,3.13,NCT01371981-2,Arm B,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,ejection fraction decreased
10050528,6.06,NCT01371981-4,Arm C (Cohort 2),NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,ejection fraction decreased
10050528,8.51,NCT01371981-5,Arm C (Cohort 3),NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,ejection fraction decreased
10014383,0.18,NCT01371981-1,Arm A,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,electrocardiogram qt corrected interval prolonged
10014383,0.52,NCT01371981-2,Arm B,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,electrocardiogram qt corrected interval prolonged
10016596,0.18,NCT01371981-1,Arm A,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,fibrinogen decreased
10016596,0.17,NCT01371981-2,Arm B,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,fibrinogen decreased
10056910,0.7,NCT01371981-2,Arm B,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,ggt increased
10056910,3.03,NCT01371981-4,Arm C (Cohort 2),NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,ggt increased
10022891,0.35,NCT01371981-2,Arm B,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,investigations - other specify
10022891,2.13,NCT01371981-5,Arm C (Cohort 3),NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,investigations - other specify
10024574,0.7,NCT01371981-2,Arm B,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,lipase increased
10025256,0.87,NCT01371981-2,Arm B,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,lymphocyte count decreased
10029366,1.39,NCT01371981-2,Arm B,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,neutrophil count decreased
10029366,3.03,NCT01371981-4,Arm C (Cohort 2),NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,neutrophil count decreased
10035528,1.22,NCT01371981-2,Arm B,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,platelet count decreased
10040139,0.52,NCT01371981-2,Arm B,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,serum amylase increased
10059895,0.18,NCT01371981-1,Arm A,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,urine output decreased
10059895,0.17,NCT01371981-2,Arm B,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,urine output decreased
D015431,3.03,NCT01371981-4,Arm C (Cohort 2),NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,weight loss
D015431,2.13,NCT01371981-5,Arm C (Cohort 3),NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,weight loss
10049182,0.87,NCT01371981-2,Arm B,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,white blood cell decreased
D000138,0.7,NCT01371981-2,Arm B,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,acidosis
D000138,3.03,NCT01371981-4,Arm C (Cohort 2),NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,acidosis
D000471,0.17,NCT01371981-2,Arm B,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,alkalosis
D000471,3.03,NCT01371981-4,Arm C (Cohort 2),NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,alkalosis
D000855,0.17,NCT01371981-2,Arm B,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,anorexia
D000855,3.03,NCT01371981-4,Arm C (Cohort 2),NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,anorexia
D003681,0.52,NCT01371981-2,Arm B,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,dehydration
D003681,3.03,NCT01371981-4,Arm C (Cohort 2),NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,dehydration
D006934,0.35,NCT01371981-2,Arm B,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,hypercalcemia
D006943,0.18,NCT01371981-1,Arm A,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,hyperglycemia
D006943,0.35,NCT01371981-2,Arm B,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,hyperglycemia
D006947,0.17,NCT01371981-2,Arm B,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,hyperkalemia
D006947,2.13,NCT01371981-5,Arm C (Cohort 3),NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,hyperkalemia
D006955,0.36,NCT01371981-1,Arm A,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,hypernatremia
D006955,0.52,NCT01371981-2,Arm B,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,hypernatremia
D006955,2.13,NCT01371981-5,Arm C (Cohort 3),NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,hypernatremia
D015228,0.17,NCT01371981-2,Arm B,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,hypertriglyceridemia
D034141,1.04,NCT01371981-2,Arm B,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,hypoalbuminemia
D034141,3.03,NCT01371981-4,Arm C (Cohort 2),NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,hypoalbuminemia
D006996,1.39,NCT01371981-2,Arm B,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,hypocalcemia
D007008,0.18,NCT01371981-1,Arm A,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,hypokalemia
D007008,4.7,NCT01371981-2,Arm B,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,hypokalemia
D007008,6.06,NCT01371981-4,Arm C (Cohort 2),NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,hypokalemia
D007008,2.13,NCT01371981-5,Arm C (Cohort 3),NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,hypokalemia
10021028,0.17,NCT01371981-2,Arm B,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,hypomagnesemia
D007010,1.74,NCT01371981-2,Arm B,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,hyponatremia
D017674,0.18,NCT01371981-1,Arm A,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,hypophosphatemia
D017674,0.52,NCT01371981-2,Arm B,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,hypophosphatemia
10027433,0.36,NCT01371981-1,Arm A,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,metabolism and nutrition disorders - other specify
D015275,0.18,NCT01371981-1,Arm A,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,tumor lysis syndrome
D015275,0.52,NCT01371981-2,Arm B,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,tumor lysis syndrome
D015275,3.03,NCT01371981-4,Arm C (Cohort 2),NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,tumor lysis syndrome
D018771,0.17,NCT01371981-2,Arm B,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,arthralgia
D001416,0.7,NCT01371981-2,Arm B,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,back pain
D019547,0.17,NCT01371981-2,Arm B,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,neck pain
10033425,0.35,NCT01371981-2,Arm B,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,pain in extremity
10033425,3.03,NCT01371981-4,Arm C (Cohort 2),NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,pain in extremity
10029104,0.36,NCT01371981-1,Arm A,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,neoplasms benign malignant and unspecified (incl cysts and polyps) - other specify
10029104,0.17,NCT01371981-2,Arm B,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,neoplasms benign malignant and unspecified (incl cysts and polyps) - other specify
10029104,0.27,NCT01371981-6,Arm D,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,neoplasms benign malignant and unspecified (incl cysts and polyps) - other specify
D001259,0.17,NCT01371981-2,Arm B,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,ataxia
10065784,0.18,NCT01371981-1,Arm A,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,central nervous system necrosis
D065634,0.17,NCT01371981-2,Arm B,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,cerebrospinal fluid leakage
10009845,0.17,NCT01371981-2,Arm B,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,cognitive disturbance
D003244,0.35,NCT01371981-2,Arm B,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,depressed level of consciousness
D004244,0.35,NCT01371981-2,Arm B,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,dizziness
D010292,0.17,NCT01371981-2,Arm B,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,dysesthesia
10014217,0.18,NCT01371981-1,Arm A,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,edema cerebral
10014217,0.7,NCT01371981-2,Arm B,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,edema cerebral
D001927,0.18,NCT01371981-1,Arm A,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,encephalopathy
D001927,0.87,NCT01371981-2,Arm B,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,encephalopathy
D006261,0.7,NCT01371981-2,Arm B,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,headache
D006849,0.18,NCT01371981-1,Arm A,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,hydrocephalus
D006970,0.17,NCT01371981-2,Arm B,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,hypersomnia
D020300,0.36,NCT01371981-1,Arm A,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,intracranial hemorrhage
D020300,0.52,NCT01371981-2,Arm B,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,intracranial hemorrhage
D020300,0.27,NCT01371981-6,Arm D,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,intracranial hemorrhage
D056784,0.17,NCT01371981-2,Arm B,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,leukoencephalopathy
10029205,0.17,NCT01371981-2,Arm B,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,nervous system disorders - other specify
D009437,0.17,NCT01371981-2,Arm B,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,neuralgia
D009437,3.03,NCT01371981-4,Arm C (Cohort 2),NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,neuralgia
D010292,0.35,NCT01371981-2,Arm B,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,paresthesia
10034620,2.43,NCT01371981-2,Arm B,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,peripheral sensory neuropathy
D054038,0.7,NCT01371981-2,Arm B,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,reversible posterior leukoencephalopathy syndrome
D012640,0.18,NCT01371981-1,Arm A,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,seizure
D012640,0.52,NCT01371981-2,Arm B,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,seizure
D012640,2.13,NCT01371981-5,Arm C (Cohort 3),NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,seizure
D000077260,0.7,NCT01371981-2,Arm B,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,somnolence
D013575,0.17,NCT01371981-2,Arm B,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,syncope
10001497,0.35,NCT01371981-2,Arm B,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,agitation
10001497,8.33,NCT01371981-3,Arm C (Cohort 1),NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,agitation
D001007,0.17,NCT01371981-2,Arm B,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,anxiety
D003693,0.17,NCT01371981-2,Arm B,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,delirium
D058186,0.89,NCT01371981-1,Arm A,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,acute kidney injury
D058186,2.61,NCT01371981-2,Arm B,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,acute kidney injury
D058186,9.09,NCT01371981-4,Arm C (Cohort 2),NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,acute kidney injury
D058186,6.38,NCT01371981-5,Arm C (Cohort 3),NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,acute kidney injury
10063057,0.17,NCT01371981-2,Arm B,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,cystitis noninfective
D006417,0.52,NCT01371981-2,Arm B,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,hematuria
D011507,0.17,NCT01371981-2,Arm B,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,proteinuria
10038359,0.18,NCT01371981-1,Arm A,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,renal and urinary disorders - other specify
10038359,0.52,NCT01371981-2,Arm B,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,renal and urinary disorders - other specify
D012128,0.54,NCT01371981-1,Arm A,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,adult respiratory distress syndrome
D012128,2.61,NCT01371981-2,Arm B,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,adult respiratory distress syndrome
D012128,6.06,NCT01371981-4,Arm C (Cohort 2),NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,adult respiratory distress syndrome
D001049,0.18,NCT01371981-1,Arm A,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,apnea
10003504,0.17,NCT01371981-2,Arm B,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,aspiration
D001261,0.35,NCT01371981-2,Arm B,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,atelectasis
10065746,0.54,NCT01371981-1,Arm A,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,bronchopulmonary hemorrhage
10065746,0.17,NCT01371981-2,Arm B,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,bronchopulmonary hemorrhage
D001986,0.17,NCT01371981-2,Arm B,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,bronchospasm
D003371,0.17,NCT01371981-2,Arm B,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,cough
D004417,0.18,NCT01371981-1,Arm A,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,dyspnea
D004417,2.09,NCT01371981-2,Arm B,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,dyspnea
D004417,3.03,NCT01371981-4,Arm C (Cohort 2),NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,dyspnea
D004844,1.22,NCT01371981-2,Arm B,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,epistaxis
D004844,3.03,NCT01371981-4,Arm C (Cohort 2),NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,epistaxis
D000860,0.54,NCT01371981-1,Arm A,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,hypoxia
D000860,9.57,NCT01371981-2,Arm B,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,hypoxia
D000860,8.33,NCT01371981-3,Arm C (Cohort 1),NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,hypoxia
D000860,9.09,NCT01371981-4,Arm C (Cohort 2),NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,hypoxia
D000860,6.38,NCT01371981-5,Arm C (Cohort 3),NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,hypoxia
D007819,0.17,NCT01371981-2,Arm B,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,laryngeal edema
10065880,0.17,NCT01371981-2,Arm B,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,laryngeal mucositis
10056356,0.17,NCT01371981-2,Arm B,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,mediastinal hemorrhage
10065881,0.35,NCT01371981-2,Arm B,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,pharyngeal mucositis
D010996,1.39,NCT01371981-2,Arm B,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,pleural effusion
D010996,3.03,NCT01371981-4,Arm C (Cohort 2),NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,pleural effusion
D011014,1.57,NCT01371981-2,Arm B,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,pneumonitis
10036790,2.13,NCT01371981-5,Arm C (Cohort 3),NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,productive cough
D011654,0.54,NCT01371981-1,Arm A,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,pulmonary edema
D011654,2.09,NCT01371981-2,Arm B,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,pulmonary edema
D011654,4.26,NCT01371981-5,Arm C (Cohort 3),NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,pulmonary edema
D006976,0.18,NCT01371981-1,Arm A,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,pulmonary hypertension
D006976,0.35,NCT01371981-2,Arm B,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,pulmonary hypertension
D012131,1.79,NCT01371981-1,Arm A,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,respiratory failure
D012131,3.83,NCT01371981-2,Arm B,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,respiratory failure
D012131,6.06,NCT01371981-4,Arm C (Cohort 2),NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,respiratory failure
D012131,4.26,NCT01371981-5,Arm C (Cohort 3),NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,respiratory failure
10038738,0.18,NCT01371981-1,Arm A,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,respiratory thoracic and mediastinal disorders - other specify
10038738,1.04,NCT01371981-2,Arm B,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,respiratory thoracic and mediastinal disorders - other specify
D010612,0.17,NCT01371981-2,Arm B,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,sore throat
D010612,8.33,NCT01371981-3,Arm C (Cohort 1),NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,sore throat
D012135,0.17,NCT01371981-2,Arm B,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,stridor
10065900,0.17,NCT01371981-2,Arm B,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,tracheal mucositis
D012135,0.52,NCT01371981-2,Arm B,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,wheezing
D003873,8.33,NCT01371981-3,Arm C (Cohort 1),NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,erythroderma
10033474,0.17,NCT01371981-2,Arm B,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,pain of skin
10033474,2.13,NCT01371981-5,Arm C (Cohort 3),NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,pain of skin
10054524,0.17,NCT01371981-2,Arm B,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,palmar-plantar erythrodysesthesia syndrome
10054524,8.33,NCT01371981-3,Arm C (Cohort 1),NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,palmar-plantar erythrodysesthesia syndrome
10054524,3.03,NCT01371981-4,Arm C (Cohort 2),NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,palmar-plantar erythrodysesthesia syndrome
10054524,2.13,NCT01371981-5,Arm C (Cohort 3),NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,palmar-plantar erythrodysesthesia syndrome
D011537,0.17,NCT01371981-2,Arm B,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,pruritus
D011537,8.33,NCT01371981-3,Arm C (Cohort 1),NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,pruritus
10037868,1.74,NCT01371981-2,Arm B,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,rash maculo-papular
10037868,8.33,NCT01371981-3,Arm C (Cohort 1),NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,rash maculo-papular
10037868,6.06,NCT01371981-4,Arm C (Cohort 2),NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,rash maculo-papular
10037868,6.38,NCT01371981-5,Arm C (Cohort 3),NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,rash maculo-papular
10040785,0.35,NCT01371981-2,Arm B,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,skin and subcutaneous tissue disorders - other specify
D013262,0.17,NCT01371981-2,Arm B,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,toxic epidermal necrolysis
D014581,0.17,NCT01371981-2,Arm B,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,urticaria
D019559,0.87,NCT01371981-2,Arm B,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,capillary leak syndrome
D019559,2.13,NCT01371981-5,Arm C (Cohort 3),NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,capillary leak syndrome
D005483,0.17,NCT01371981-2,Arm B,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,flushing
D006973,1.74,NCT01371981-2,Arm B,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,hypertension
D006973,3.03,NCT01371981-4,Arm C (Cohort 2),NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,hypertension
D006973,2.13,NCT01371981-5,Arm C (Cohort 3),NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,hypertension
D007022,1.25,NCT01371981-1,Arm A,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,hypotension
D007022,8.17,NCT01371981-2,Arm B,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,hypotension
D007022,8.33,NCT01371981-3,Arm C (Cohort 1),NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,hypotension
D007022,9.09,NCT01371981-4,Arm C (Cohort 2),NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,hypotension
D007022,6.38,NCT01371981-5,Arm C (Cohort 3),NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,hypotension
10034578,0.18,NCT01371981-1,Arm A,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,peripheral ischemia
10043565,0.54,NCT01371981-1,Arm A,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,thromboembolic event
10043565,0.52,NCT01371981-2,Arm B,NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,thromboembolic event
10043565,2.13,NCT01371981-5,Arm C (Cohort 3),NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,thromboembolic event
D064420,45.45,NCT01375569-1,TRC105 in Liver Cancer,NCT01375569,TRC105 for Liver Cancer That Has Not Responded to Sorafenib,adverse drug events
D009203,9.09,NCT01375569-1,TRC105 in Liver Cancer,NCT01375569,TRC105 for Liver Cancer That Has Not Responded to Sorafenib,myocardial infarction
D017093,9.09,NCT01375569-1,TRC105 in Liver Cancer,NCT01375569,TRC105 for Liver Cancer That Has Not Responded to Sorafenib,hepatic failure
10061229,9.09,NCT01375569-1,TRC105 in Liver Cancer,NCT01375569,TRC105 for Liver Cancer That Has Not Responded to Sorafenib,lung infection
10003481,9.09,NCT01375569-1,TRC105 in Liver Cancer,NCT01375569,TRC105 for Liver Cancer That Has Not Responded to Sorafenib,aspartate aminotransferase increased
10029104,9.09,NCT01375569-1,TRC105 in Liver Cancer,NCT01375569,TRC105 for Liver Cancer That Has Not Responded to Sorafenib,neoplasms benign malignant and unspecified (incl cysts and polyps) - other specify
D001927,9.09,NCT01375569-1,TRC105 in Liver Cancer,NCT01375569,TRC105 for Liver Cancer That Has Not Responded to Sorafenib,encephalopathy
D064420,30.95,NCT01471353-1,Sorafenib Plus Capecitabine (SorCape),NCT01471353,Sorafenib Plus Capecitabine (SorCape) in Previously Treated Metastatic Colorectal Cancer,adverse drug events
D000740,2.38,NCT01471353-1,Sorafenib Plus Capecitabine (SorCape),NCT01471353,Sorafenib Plus Capecitabine (SorCape) in Previously Treated Metastatic Colorectal Cancer,anemia
D013154,2.38,NCT01471353-1,Sorafenib Plus Capecitabine (SorCape),NCT01471353,Sorafenib Plus Capecitabine (SorCape) in Previously Treated Metastatic Colorectal Cancer,spleen
D013616,2.38,NCT01471353-1,Sorafenib Plus Capecitabine (SorCape),NCT01471353,Sorafenib Plus Capecitabine (SorCape) in Previously Treated Metastatic Colorectal Cancer,sinus tachycardia
D015746,4.76,NCT01471353-1,Sorafenib Plus Capecitabine (SorCape),NCT01471353,Sorafenib Plus Capecitabine (SorCape) in Previously Treated Metastatic Colorectal Cancer,abdominal pain
10010000,2.38,NCT01471353-1,Sorafenib Plus Capecitabine (SorCape),NCT01471353,Sorafenib Plus Capecitabine (SorCape) in Previously Treated Metastatic Colorectal Cancer,colonic obstruction
D005767,2.38,NCT01471353-1,Sorafenib Plus Capecitabine (SorCape),NCT01471353,Sorafenib Plus Capecitabine (SorCape) in Previously Treated Metastatic Colorectal Cancer,gastrointestinal disorders
D005221,2.38,NCT01471353-1,Sorafenib Plus Capecitabine (SorCape),NCT01471353,Sorafenib Plus Capecitabine (SorCape) in Previously Treated Metastatic Colorectal Cancer,fatigue
10018065,2.38,NCT01471353-1,Sorafenib Plus Capecitabine (SorCape),NCT01471353,Sorafenib Plus Capecitabine (SorCape) in Previously Treated Metastatic Colorectal Cancer,general disorders and administration site conditions - other specify
10062501,4.76,NCT01471353-1,Sorafenib Plus Capecitabine (SorCape),NCT01471353,Sorafenib Plus Capecitabine (SorCape) in Previously Treated Metastatic Colorectal Cancer,non-cardiac chest pain
D010146,2.38,NCT01471353-1,Sorafenib Plus Capecitabine (SorCape),NCT01471353,Sorafenib Plus Capecitabine (SorCape) in Previously Treated Metastatic Colorectal Cancer,pain
D004066,2.38,NCT01471353-1,Sorafenib Plus Capecitabine (SorCape),NCT01471353,Sorafenib Plus Capecitabine (SorCape) in Previously Treated Metastatic Colorectal Cancer,hepatobiliary disorders
D018805,2.38,NCT01471353-1,Sorafenib Plus Capecitabine (SorCape),NCT01471353,Sorafenib Plus Capecitabine (SorCape) in Previously Treated Metastatic Colorectal Cancer,sepsis
10011368,2.38,NCT01471353-1,Sorafenib Plus Capecitabine (SorCape),NCT01471353,Sorafenib Plus Capecitabine (SorCape) in Previously Treated Metastatic Colorectal Cancer,creatinine increased
D007010,2.38,NCT01471353-1,Sorafenib Plus Capecitabine (SorCape),NCT01471353,Sorafenib Plus Capecitabine (SorCape) in Previously Treated Metastatic Colorectal Cancer,hyponatremia
D003681,4.76,NCT01471353-1,Sorafenib Plus Capecitabine (SorCape),NCT01471353,Sorafenib Plus Capecitabine (SorCape) in Previously Treated Metastatic Colorectal Cancer,dehydration
10062572,2.38,NCT01471353-1,Sorafenib Plus Capecitabine (SorCape),NCT01471353,Sorafenib Plus Capecitabine (SorCape) in Previously Treated Metastatic Colorectal Cancer,generalized muscle weakness
D013575,2.38,NCT01471353-1,Sorafenib Plus Capecitabine (SorCape),NCT01471353,Sorafenib Plus Capecitabine (SorCape) in Previously Treated Metastatic Colorectal Cancer,syncope
10001497,2.38,NCT01471353-1,Sorafenib Plus Capecitabine (SorCape),NCT01471353,Sorafenib Plus Capecitabine (SorCape) in Previously Treated Metastatic Colorectal Cancer,agitation
D003221,2.38,NCT01471353-1,Sorafenib Plus Capecitabine (SorCape),NCT01471353,Sorafenib Plus Capecitabine (SorCape) in Previously Treated Metastatic Colorectal Cancer,confusion
D003693,4.76,NCT01471353-1,Sorafenib Plus Capecitabine (SorCape),NCT01471353,Sorafenib Plus Capecitabine (SorCape) in Previously Treated Metastatic Colorectal Cancer,delirium
D011030,2.38,NCT01471353-1,Sorafenib Plus Capecitabine (SorCape),NCT01471353,Sorafenib Plus Capecitabine (SorCape) in Previously Treated Metastatic Colorectal Cancer,pneumothorax
D009026,66.67,NCT01498952-1,Phase 1b Cohort A,NCT01498952,MEDI-573 in Combination With SOC in Unresectable or Metastatic HCC.,mortality
D009026,66.67,NCT01498952-2,Phase 1b Cohort B,NCT01498952,MEDI-573 in Combination With SOC in Unresectable or Metastatic HCC.,mortality
D064420,33.33,NCT01498952-1,Phase 1b Cohort A,NCT01498952,MEDI-573 in Combination With SOC in Unresectable or Metastatic HCC.,adverse drug events
D064420,33.33,NCT01498952-2,Phase 1b Cohort B,NCT01498952,MEDI-573 in Combination With SOC in Unresectable or Metastatic HCC.,adverse drug events
D015746,33.33,NCT01498952-1,Phase 1b Cohort A,NCT01498952,MEDI-573 in Combination With SOC in Unresectable or Metastatic HCC.,abdominal pain
D001247,33.33,NCT01498952-1,Phase 1b Cohort A,NCT01498952,MEDI-573 in Combination With SOC in Unresectable or Metastatic HCC.,asthenia
10062501,33.33,NCT01498952-1,Phase 1b Cohort A,NCT01498952,MEDI-573 in Combination With SOC in Unresectable or Metastatic HCC.,non-cardiac chest pain
D017093,33.33,NCT01498952-2,Phase 1b Cohort B,NCT01498952,MEDI-573 in Combination With SOC in Unresectable or Metastatic HCC.,hepatic failure
10024574,33.33,NCT01498952-2,Phase 1b Cohort B,NCT01498952,MEDI-573 in Combination With SOC in Unresectable or Metastatic HCC.,lipase increased
D006501,33.33,NCT01498952-2,Phase 1b Cohort B,NCT01498952,MEDI-573 in Combination With SOC in Unresectable or Metastatic HCC.,hepatic encephalopathy
D011030,33.33,NCT01498952-1,Phase 1b Cohort A,NCT01498952,MEDI-573 in Combination With SOC in Unresectable or Metastatic HCC.,pneumothorax
D064420,25.0,NCT01510756-1,Sorafenib,NCT01510756,Sorafenib for the Treatment of Chronic Lymphocytic Leukemia (CLL),adverse drug events
D001922,25.0,NCT01510756-1,Sorafenib,NCT01510756,Sorafenib for the Treatment of Chronic Lymphocytic Leukemia (CLL),brain abscess
D064420,41.18,NCT01534260-1,Phase I Dose Escalating,NCT01534260,Phase I/II Study of Combination of Sorafenib  Vorinostat  and Bortezomib for the Treatment of Acute Myeloid Leukemia With Complex- or Poor-risk (Monosomy 5/7) Cytogenetics or FLT3-ITD Positive Genotype,adverse drug events
D064420,55.0,NCT01534260-2,Phase II at MTD,NCT01534260,Phase I/II Study of Combination of Sorafenib  Vorinostat  and Bortezomib for the Treatment of Acute Myeloid Leukemia With Complex- or Poor-risk (Monosomy 5/7) Cytogenetics or FLT3-ITD Positive Genotype,adverse drug events
D064147,11.76,NCT01534260-1,Phase I Dose Escalating,NCT01534260,Phase I/II Study of Combination of Sorafenib  Vorinostat  and Bortezomib for the Treatment of Acute Myeloid Leukemia With Complex- or Poor-risk (Monosomy 5/7) Cytogenetics or FLT3-ITD Positive Genotype,febrile neutropenia
D064147,5.0,NCT01534260-2,Phase II at MTD,NCT01534260,Phase I/II Study of Combination of Sorafenib  Vorinostat  and Bortezomib for the Treatment of Acute Myeloid Leukemia With Complex- or Poor-risk (Monosomy 5/7) Cytogenetics or FLT3-ITD Positive Genotype,febrile neutropenia
D009203,5.0,NCT01534260-2,Phase II at MTD,NCT01534260,Phase I/II Study of Combination of Sorafenib  Vorinostat  and Bortezomib for the Treatment of Acute Myeloid Leukemia With Complex- or Poor-risk (Monosomy 5/7) Cytogenetics or FLT3-ITD Positive Genotype,myocardial infarction
D005128,5.0,NCT01534260-2,Phase II at MTD,NCT01534260,Phase I/II Study of Combination of Sorafenib  Vorinostat  and Bortezomib for the Treatment of Acute Myeloid Leukemia With Complex- or Poor-risk (Monosomy 5/7) Cytogenetics or FLT3-ITD Positive Genotype,eye disorders
D003967,10.0,NCT01534260-2,Phase II at MTD,NCT01534260,Phase I/II Study of Combination of Sorafenib  Vorinostat  and Bortezomib for the Treatment of Acute Myeloid Leukemia With Complex- or Poor-risk (Monosomy 5/7) Cytogenetics or FLT3-ITD Positive Genotype,diarrhea
D009325,5.88,NCT01534260-1,Phase I Dose Escalating,NCT01534260,Phase I/II Study of Combination of Sorafenib  Vorinostat  and Bortezomib for the Treatment of Acute Myeloid Leukemia With Complex- or Poor-risk (Monosomy 5/7) Cytogenetics or FLT3-ITD Positive Genotype,nausea
10038064,5.88,NCT01534260-1,Phase I Dose Escalating,NCT01534260,Phase I/II Study of Combination of Sorafenib  Vorinostat  and Bortezomib for the Treatment of Acute Myeloid Leukemia With Complex- or Poor-risk (Monosomy 5/7) Cytogenetics or FLT3-ITD Positive Genotype,rectal hemorrhage
D005334,17.65,NCT01534260-1,Phase I Dose Escalating,NCT01534260,Phase I/II Study of Combination of Sorafenib  Vorinostat  and Bortezomib for the Treatment of Acute Myeloid Leukemia With Complex- or Poor-risk (Monosomy 5/7) Cytogenetics or FLT3-ITD Positive Genotype,fever
D005334,10.0,NCT01534260-2,Phase II at MTD,NCT01534260,Phase I/II Study of Combination of Sorafenib  Vorinostat  and Bortezomib for the Treatment of Acute Myeloid Leukemia With Complex- or Poor-risk (Monosomy 5/7) Cytogenetics or FLT3-ITD Positive Genotype,fever
10061229,5.88,NCT01534260-1,Phase I Dose Escalating,NCT01534260,Phase I/II Study of Combination of Sorafenib  Vorinostat  and Bortezomib for the Treatment of Acute Myeloid Leukemia With Complex- or Poor-risk (Monosomy 5/7) Cytogenetics or FLT3-ITD Positive Genotype,lung infection
10061229,5.0,NCT01534260-2,Phase II at MTD,NCT01534260,Phase I/II Study of Combination of Sorafenib  Vorinostat  and Bortezomib for the Treatment of Acute Myeloid Leukemia With Complex- or Poor-risk (Monosomy 5/7) Cytogenetics or FLT3-ITD Positive Genotype,lung infection
D018805,5.88,NCT01534260-1,Phase I Dose Escalating,NCT01534260,Phase I/II Study of Combination of Sorafenib  Vorinostat  and Bortezomib for the Treatment of Acute Myeloid Leukemia With Complex- or Poor-risk (Monosomy 5/7) Cytogenetics or FLT3-ITD Positive Genotype,sepsis
D018805,10.0,NCT01534260-2,Phase II at MTD,NCT01534260,Phase I/II Study of Combination of Sorafenib  Vorinostat  and Bortezomib for the Treatment of Acute Myeloid Leukemia With Complex- or Poor-risk (Monosomy 5/7) Cytogenetics or FLT3-ITD Positive Genotype,sepsis
10029366,5.0,NCT01534260-2,Phase II at MTD,NCT01534260,Phase I/II Study of Combination of Sorafenib  Vorinostat  and Bortezomib for the Treatment of Acute Myeloid Leukemia With Complex- or Poor-risk (Monosomy 5/7) Cytogenetics or FLT3-ITD Positive Genotype,neutrophil count decreased
10062572,5.0,NCT01534260-2,Phase II at MTD,NCT01534260,Phase I/II Study of Combination of Sorafenib  Vorinostat  and Bortezomib for the Treatment of Acute Myeloid Leukemia With Complex- or Poor-risk (Monosomy 5/7) Cytogenetics or FLT3-ITD Positive Genotype,generalized muscle weakness
D009220,5.0,NCT01534260-2,Phase II at MTD,NCT01534260,Phase I/II Study of Combination of Sorafenib  Vorinostat  and Bortezomib for the Treatment of Acute Myeloid Leukemia With Complex- or Poor-risk (Monosomy 5/7) Cytogenetics or FLT3-ITD Positive Genotype,myositis
D013575,5.0,NCT01534260-2,Phase II at MTD,NCT01534260,Phase I/II Study of Combination of Sorafenib  Vorinostat  and Bortezomib for the Treatment of Acute Myeloid Leukemia With Complex- or Poor-risk (Monosomy 5/7) Cytogenetics or FLT3-ITD Positive Genotype,syncope
D004844,5.88,NCT01534260-1,Phase I Dose Escalating,NCT01534260,Phase I/II Study of Combination of Sorafenib  Vorinostat  and Bortezomib for the Treatment of Acute Myeloid Leukemia With Complex- or Poor-risk (Monosomy 5/7) Cytogenetics or FLT3-ITD Positive Genotype,epistaxis
D012131,10.0,NCT01534260-2,Phase II at MTD,NCT01534260,Phase I/II Study of Combination of Sorafenib  Vorinostat  and Bortezomib for the Treatment of Acute Myeloid Leukemia With Complex- or Poor-risk (Monosomy 5/7) Cytogenetics or FLT3-ITD Positive Genotype,respiratory failure
D064420,34.62,NCT01582009-1,Arm I: Oral Panobinostat and Oral Everolimus,NCT01582009,Panobinostat and Everolimus in Treating Patients With Metastatic or Unresectable Renal Cell Cancer That Does Not Respond to Treatment With Sunitinib Malate or Sorafenib Tosylate,adverse drug events
D013921,3.85,NCT01582009-1,Arm I: Oral Panobinostat and Oral Everolimus,NCT01582009,Panobinostat and Everolimus in Treating Patients With Metastatic or Unresectable Renal Cell Cancer That Does Not Respond to Treatment With Sunitinib Malate or Sorafenib Tosylate,thrombocytopenia
D001281,3.85,NCT01582009-1,Arm I: Oral Panobinostat and Oral Everolimus,NCT01582009,Panobinostat and Everolimus in Treating Patients With Metastatic or Unresectable Renal Cell Cancer That Does Not Respond to Treatment With Sunitinib Malate or Sorafenib Tosylate,atrial fibrillation
D013617,3.85,NCT01582009-1,Arm I: Oral Panobinostat and Oral Everolimus,NCT01582009,Panobinostat and Everolimus in Treating Patients With Metastatic or Unresectable Renal Cell Cancer That Does Not Respond to Treatment With Sunitinib Malate or Sorafenib Tosylate,supraventricular tachycardia
D046449,3.85,NCT01582009-1,Arm I: Oral Panobinostat and Oral Everolimus,NCT01582009,Panobinostat and Everolimus in Treating Patients With Metastatic or Unresectable Renal Cell Cancer That Does Not Respond to Treatment With Sunitinib Malate or Sorafenib Tosylate,abdominal hernia
D015746,3.85,NCT01582009-1,Arm I: Oral Panobinostat and Oral Everolimus,NCT01582009,Panobinostat and Everolimus in Treating Patients With Metastatic or Unresectable Renal Cell Cancer That Does Not Respond to Treatment With Sunitinib Malate or Sorafenib Tosylate,abdominal pain
D018450,3.85,NCT01582009-1,Arm I: Oral Panobinostat and Oral Everolimus,NCT01582009,Panobinostat and Everolimus in Treating Patients With Metastatic or Unresectable Renal Cell Cancer That Does Not Respond to Treatment With Sunitinib Malate or Sorafenib Tosylate,disease progression
D011020,3.85,NCT01582009-1,Arm I: Oral Panobinostat and Oral Everolimus,NCT01582009,Panobinostat and Everolimus in Treating Patients With Metastatic or Unresectable Renal Cell Cancer That Does Not Respond to Treatment With Sunitinib Malate or Sorafenib Tosylate,pneumocystis jirovecii pneumonia
D011014,3.85,NCT01582009-1,Arm I: Oral Panobinostat and Oral Everolimus,NCT01582009,Panobinostat and Everolimus in Treating Patients With Metastatic or Unresectable Renal Cell Cancer That Does Not Respond to Treatment With Sunitinib Malate or Sorafenib Tosylate,pneumonia
D003288,3.85,NCT01582009-1,Arm I: Oral Panobinostat and Oral Everolimus,NCT01582009,Panobinostat and Everolimus in Treating Patients With Metastatic or Unresectable Renal Cell Cancer That Does Not Respond to Treatment With Sunitinib Malate or Sorafenib Tosylate,contusion
D003681,3.85,NCT01582009-1,Arm I: Oral Panobinostat and Oral Everolimus,NCT01582009,Panobinostat and Everolimus in Treating Patients With Metastatic or Unresectable Renal Cell Cancer That Does Not Respond to Treatment With Sunitinib Malate or Sorafenib Tosylate,dehydration
D018908,3.85,NCT01582009-1,Arm I: Oral Panobinostat and Oral Everolimus,NCT01582009,Panobinostat and Everolimus in Treating Patients With Metastatic or Unresectable Renal Cell Cancer That Does Not Respond to Treatment With Sunitinib Malate or Sorafenib Tosylate,muscular weakness
D003221,3.85,NCT01582009-1,Arm I: Oral Panobinostat and Oral Everolimus,NCT01582009,Panobinostat and Everolimus in Treating Patients With Metastatic or Unresectable Renal Cell Cancer That Does Not Respond to Treatment With Sunitinib Malate or Sorafenib Tosylate,confusional state
UNKNOWN-check-for-typo,3.85,NCT01582009-1,Arm I: Oral Panobinostat and Oral Everolimus,NCT01582009,Panobinostat and Everolimus in Treating Patients With Metastatic or Unresectable Renal Cell Cancer That Does Not Respond to Treatment With Sunitinib Malate or Sorafenib Tosylate,D00
D009026,100.0,NCT01752933-1,Guadecitabine 60 mg/m^2,NCT01752933,SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC),mortality
D009026,73.91,NCT01752933-2,Guadecitabine 45 mg/m^2,NCT01752933,SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC),mortality
D064420,25.0,NCT01752933-1,Guadecitabine 60 mg/m^2,NCT01752933,SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC),adverse drug events
D064420,45.65,NCT01752933-2,Guadecitabine 45 mg/m^2,NCT01752933,SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC),adverse drug events
D000741,2.17,NCT01752933-2,Guadecitabine 45 mg/m^2,NCT01752933,SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC),aplastic anaemia
D064147,25.0,NCT01752933-1,Guadecitabine 60 mg/m^2,NCT01752933,SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC),febrile neutropenia
D064147,10.87,NCT01752933-2,Guadecitabine 45 mg/m^2,NCT01752933,SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC),febrile neutropenia
D001281,2.17,NCT01752933-2,Guadecitabine 45 mg/m^2,NCT01752933,SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC),atrial fibrillation
D000308,2.17,NCT01752933-2,Guadecitabine 45 mg/m^2,NCT01752933,SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC),hyperadrenalism
D015746,4.35,NCT01752933-2,Guadecitabine 45 mg/m^2,NCT01752933,SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC),abdominal pain
D001201,2.17,NCT01752933-2,Guadecitabine 45 mg/m^2,NCT01752933,SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC),ascites
UNKNOWN-check-for-typo,2.17,NCT01752933-2,Guadecitabine 45 mg/m^2,NCT01752933,SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC),D00
D000069196,2.17,NCT01752933-2,Guadecitabine 45 mg/m^2,NCT01752933,SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC),gastrointestinal microbiome
D009325,2.17,NCT01752933-2,Guadecitabine 45 mg/m^2,NCT01752933,SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC),nausea
10015461,2.17,NCT01752933-2,Guadecitabine 45 mg/m^2,NCT01752933,SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC),esophagitis
D041742,2.17,NCT01752933-2,Guadecitabine 45 mg/m^2,NCT01752933,SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC),upper gastrointestinal tract
D014839,2.17,NCT01752933-2,Guadecitabine 45 mg/m^2,NCT01752933,SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC),vomiting
UNKNOWN-check-for-typo,2.17,NCT01752933-2,Guadecitabine 45 mg/m^2,NCT01752933,SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC),D00
10036206,2.17,NCT01752933-2,Guadecitabine 45 mg/m^2,NCT01752933,SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC),portal vein thrombosis
D011014,2.17,NCT01752933-2,Guadecitabine 45 mg/m^2,NCT01752933,SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC),pneumonia
D000985,2.17,NCT01752933-2,Guadecitabine 45 mg/m^2,NCT01752933,SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC),antisepsis
D000063,4.35,NCT01752933-2,Guadecitabine 45 mg/m^2,NCT01752933,SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC),accidents traffic
10011368,2.17,NCT01752933-2,Guadecitabine 45 mg/m^2,NCT01752933,SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC),creatinine increased
D007010,2.17,NCT01752933-2,Guadecitabine 45 mg/m^2,NCT01752933,SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC),hyponatremia
10033425,4.35,NCT01752933-2,Guadecitabine 45 mg/m^2,NCT01752933,SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC),pain in extremity
D006501,2.17,NCT01752933-2,Guadecitabine 45 mg/m^2,NCT01752933,SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC),hepatic encephalopathy
D053040,2.17,NCT01752933-2,Guadecitabine 45 mg/m^2,NCT01752933,SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC),nephrolithiasis
D058186,2.17,NCT01752933-2,Guadecitabine 45 mg/m^2,NCT01752933,SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC),acute renal failure
10039757,2.17,NCT01752933-2,Guadecitabine 45 mg/m^2,NCT01752933,SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC),scrotal pain
D000860,2.17,NCT01752933-2,Guadecitabine 45 mg/m^2,NCT01752933,SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC),hypoxia
D012131,2.17,NCT01752933-2,Guadecitabine 45 mg/m^2,NCT01752933,SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC),respiratory failure
D007022,2.17,NCT01752933-2,Guadecitabine 45 mg/m^2,NCT01752933,SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC),hypotension
D064420,20.0,NCT01754987-1,Ascorbic Acid + Sorafenib,NCT01754987,A Study of Vitamin C in the Treatment of Liver Cancer to Determine if it is Safe and Effective,adverse drug events
D003681,20.0,NCT01754987-1,Ascorbic Acid + Sorafenib,NCT01754987,A Study of Vitamin C in the Treatment of Liver Cancer to Determine if it is Safe and Effective,dehydration
D009026,5.0,NCT01775501-1,FOLFOX + Sorafenib,NCT01775501,Sorafenib + mFOLFOX for Hepatocellular Carcinoma,mortality
D064420,80.0,NCT01775501-1,FOLFOX + Sorafenib,NCT01775501,Sorafenib + mFOLFOX for Hepatocellular Carcinoma,adverse drug events
D000740,7.5,NCT01775501-1,FOLFOX + Sorafenib,NCT01775501,Sorafenib + mFOLFOX for Hepatocellular Carcinoma,anemia
10060640,2.5,NCT01775501-1,FOLFOX + Sorafenib,NCT01775501,Sorafenib + mFOLFOX for Hepatocellular Carcinoma,hemorrhoidal hemorrhage
D003967,10.0,NCT01775501-1,FOLFOX + Sorafenib,NCT01775501,Sorafenib + mFOLFOX for Hepatocellular Carcinoma,diarrhea
D003668,2.5,NCT01775501-1,FOLFOX + Sorafenib,NCT01775501,Sorafenib + mFOLFOX for Hepatocellular Carcinoma,bedsores
D010195,2.5,NCT01775501-1,FOLFOX + Sorafenib,NCT01775501,Sorafenib + mFOLFOX for Hepatocellular Carcinoma,pancreatitis
D005221,7.5,NCT01775501-1,FOLFOX + Sorafenib,NCT01775501,Sorafenib + mFOLFOX for Hepatocellular Carcinoma,fatigue
D005334,2.5,NCT01775501-1,FOLFOX + Sorafenib,NCT01775501,Sorafenib + mFOLFOX for Hepatocellular Carcinoma,fever
10062169,2.5,NCT01775501-1,FOLFOX + Sorafenib,NCT01775501,Sorafenib + mFOLFOX for Hepatocellular Carcinoma,vascular access complication
10001551,15.0,NCT01775501-1,FOLFOX + Sorafenib,NCT01775501,Sorafenib + mFOLFOX for Hepatocellular Carcinoma,alanine aminotransferase increased
10001675,5.0,NCT01775501-1,FOLFOX + Sorafenib,NCT01775501,Sorafenib + mFOLFOX for Hepatocellular Carcinoma,alkaline phosphatase increased
10003481,22.5,NCT01775501-1,FOLFOX + Sorafenib,NCT01775501,Sorafenib + mFOLFOX for Hepatocellular Carcinoma,aspartate aminotransferase increased
10005364,10.0,NCT01775501-1,FOLFOX + Sorafenib,NCT01775501,Sorafenib + mFOLFOX for Hepatocellular Carcinoma,blood bilirubin increased
10024574,22.5,NCT01775501-1,FOLFOX + Sorafenib,NCT01775501,Sorafenib + mFOLFOX for Hepatocellular Carcinoma,lipase increased
10025256,17.5,NCT01775501-1,FOLFOX + Sorafenib,NCT01775501,Sorafenib + mFOLFOX for Hepatocellular Carcinoma,lymphocyte count decreased
10029366,7.5,NCT01775501-1,FOLFOX + Sorafenib,NCT01775501,Sorafenib + mFOLFOX for Hepatocellular Carcinoma,neutrophil count decreased
10035528,5.0,NCT01775501-1,FOLFOX + Sorafenib,NCT01775501,Sorafenib + mFOLFOX for Hepatocellular Carcinoma,platelet count decreased
10040139,5.0,NCT01775501-1,FOLFOX + Sorafenib,NCT01775501,Sorafenib + mFOLFOX for Hepatocellular Carcinoma,serum amylase increased
D006943,2.5,NCT01775501-1,FOLFOX + Sorafenib,NCT01775501,Sorafenib + mFOLFOX for Hepatocellular Carcinoma,hyperglycemia
D006955,2.5,NCT01775501-1,FOLFOX + Sorafenib,NCT01775501,Sorafenib + mFOLFOX for Hepatocellular Carcinoma,hypernatremia
D007010,5.0,NCT01775501-1,FOLFOX + Sorafenib,NCT01775501,Sorafenib + mFOLFOX for Hepatocellular Carcinoma,hyponatremia
D017674,32.5,NCT01775501-1,FOLFOX + Sorafenib,NCT01775501,Sorafenib + mFOLFOX for Hepatocellular Carcinoma,hypophosphatemia
D011014,2.5,NCT01775501-1,FOLFOX + Sorafenib,NCT01775501,Sorafenib + mFOLFOX for Hepatocellular Carcinoma,pneumonitis
UNKNOWN-check-for-typo,2.5,NCT01775501-1,FOLFOX + Sorafenib,NCT01775501,Sorafenib + mFOLFOX for Hepatocellular Carcinoma,D00
10054524,7.5,NCT01775501-1,FOLFOX + Sorafenib,NCT01775501,Sorafenib + mFOLFOX for Hepatocellular Carcinoma,palmar-plantar erythrodysesthesia syndrome
D005076,2.5,NCT01775501-1,FOLFOX + Sorafenib,NCT01775501,Sorafenib + mFOLFOX for Hepatocellular Carcinoma,rash
D005483,2.5,NCT01775501-1,FOLFOX + Sorafenib,NCT01775501,Sorafenib + mFOLFOX for Hepatocellular Carcinoma,flushing
D006973,5.0,NCT01775501-1,FOLFOX + Sorafenib,NCT01775501,Sorafenib + mFOLFOX for Hepatocellular Carcinoma,hypertension
D009026,100.0,NCT01887717-1,TheraSphere,NCT01887717,Efficacy Evaluation of TheraSphere to Treat Inoperable Liver Cancer With Blockage of the Portal Vein,mortality
D009026,100.0,NCT01887717-2,Sorafenib,NCT01887717,Efficacy Evaluation of TheraSphere to Treat Inoperable Liver Cancer With Blockage of the Portal Vein,mortality
D064420,75.0,NCT01887717-2,Sorafenib,NCT01887717,Efficacy Evaluation of TheraSphere to Treat Inoperable Liver Cancer With Blockage of the Portal Vein,adverse drug events
UNKNOWN-check-for-typo,6.25,NCT01887717-2,Sorafenib,NCT01887717,Efficacy Evaluation of TheraSphere to Treat Inoperable Liver Cancer With Blockage of the Portal Vein,D00
D000069196,6.25,NCT01887717-2,Sorafenib,NCT01887717,Efficacy Evaluation of TheraSphere to Treat Inoperable Liver Cancer With Blockage of the Portal Vein,gastrointestinal microbiome
D054079,6.25,NCT01887717-2,Sorafenib,NCT01887717,Efficacy Evaluation of TheraSphere to Treat Inoperable Liver Cancer With Blockage of the Portal Vein,vascular malformations
UNKNOWN-check-for-typo,6.25,NCT01887717-2,Sorafenib,NCT01887717,Efficacy Evaluation of TheraSphere to Treat Inoperable Liver Cancer With Blockage of the Portal Vein,D00
D009325,6.25,NCT01887717-2,Sorafenib,NCT01887717,Efficacy Evaluation of TheraSphere to Treat Inoperable Liver Cancer With Blockage of the Portal Vein,nausea
D014839,6.25,NCT01887717-2,Sorafenib,NCT01887717,Efficacy Evaluation of TheraSphere to Treat Inoperable Liver Cancer With Blockage of the Portal Vein,vomiting
D003695,6.25,NCT01887717-2,Sorafenib,NCT01887717,Efficacy Evaluation of TheraSphere to Treat Inoperable Liver Cancer With Blockage of the Portal Vein,healthcare
D007251,6.25,NCT01887717-2,Sorafenib,NCT01887717,Efficacy Evaluation of TheraSphere to Treat Inoperable Liver Cancer With Blockage of the Portal Vein,influenza
D006501,12.5,NCT01887717-2,Sorafenib,NCT01887717,Efficacy Evaluation of TheraSphere to Treat Inoperable Liver Cancer With Blockage of the Portal Vein,hepatic encephalopathy
UNKNOWN-check-for-typo,6.25,NCT01887717-2,Sorafenib,NCT01887717,Efficacy Evaluation of TheraSphere to Treat Inoperable Liver Cancer With Blockage of the Portal Vein,D00
D012131,6.25,NCT01887717-2,Sorafenib,NCT01887717,Efficacy Evaluation of TheraSphere to Treat Inoperable Liver Cancer With Blockage of the Portal Vein,respiratory failure
D009026,100.0,NCT01988493-1,Phase 1b: Tepotinib 300 mg,NCT01988493,Efficacy  Safety  and Pharmacokinetic of MSC2156119J in Asian Participants With Hepatocellular Carcinoma,mortality
D009026,78.57,NCT01988493-2,Phase 1b: Tepotinib 500 mg,NCT01988493,Efficacy  Safety  and Pharmacokinetic of MSC2156119J in Asian Participants With Hepatocellular Carcinoma,mortality
D009026,50.0,NCT01988493-3,Phase 1b: Tepotinib 1000 mg,NCT01988493,Efficacy  Safety  and Pharmacokinetic of MSC2156119J in Asian Participants With Hepatocellular Carcinoma,mortality
D009026,53.33,NCT01988493-4,Phase 2: Tepotinib,NCT01988493,Efficacy  Safety  and Pharmacokinetic of MSC2156119J in Asian Participants With Hepatocellular Carcinoma,mortality
D009026,68.18,NCT01988493-5,Phase 2 Sorafenib,NCT01988493,Efficacy  Safety  and Pharmacokinetic of MSC2156119J in Asian Participants With Hepatocellular Carcinoma,mortality
D064420,28.57,NCT01988493-1,Phase 1b: Tepotinib 300 mg,NCT01988493,Efficacy  Safety  and Pharmacokinetic of MSC2156119J in Asian Participants With Hepatocellular Carcinoma,adverse drug events
D064420,64.29,NCT01988493-2,Phase 1b: Tepotinib 500 mg,NCT01988493,Efficacy  Safety  and Pharmacokinetic of MSC2156119J in Asian Participants With Hepatocellular Carcinoma,adverse drug events
D064420,66.67,NCT01988493-3,Phase 1b: Tepotinib 1000 mg,NCT01988493,Efficacy  Safety  and Pharmacokinetic of MSC2156119J in Asian Participants With Hepatocellular Carcinoma,adverse drug events
D064420,51.11,NCT01988493-4,Phase 2: Tepotinib,NCT01988493,Efficacy  Safety  and Pharmacokinetic of MSC2156119J in Asian Participants With Hepatocellular Carcinoma,adverse drug events
D064420,27.27,NCT01988493-5,Phase 2 Sorafenib,NCT01988493,Efficacy  Safety  and Pharmacokinetic of MSC2156119J in Asian Participants With Hepatocellular Carcinoma,adverse drug events
D013921,2.22,NCT01988493-4,Phase 2: Tepotinib,NCT01988493,Efficacy  Safety  and Pharmacokinetic of MSC2156119J in Asian Participants With Hepatocellular Carcinoma,thrombocytopenia
D013617,2.22,NCT01988493-4,Phase 2: Tepotinib,NCT01988493,Efficacy  Safety  and Pharmacokinetic of MSC2156119J in Asian Participants With Hepatocellular Carcinoma,supraventricular tachycardia
D015746,7.14,NCT01988493-2,Phase 1b: Tepotinib 500 mg,NCT01988493,Efficacy  Safety  and Pharmacokinetic of MSC2156119J in Asian Participants With Hepatocellular Carcinoma,abdominal pain
D015746,16.67,NCT01988493-3,Phase 1b: Tepotinib 1000 mg,NCT01988493,Efficacy  Safety  and Pharmacokinetic of MSC2156119J in Asian Participants With Hepatocellular Carcinoma,abdominal pain
D015746,4.44,NCT01988493-4,Phase 2: Tepotinib,NCT01988493,Efficacy  Safety  and Pharmacokinetic of MSC2156119J in Asian Participants With Hepatocellular Carcinoma,abdominal pain
D015746,4.55,NCT01988493-5,Phase 2 Sorafenib,NCT01988493,Efficacy  Safety  and Pharmacokinetic of MSC2156119J in Asian Participants With Hepatocellular Carcinoma,abdominal pain
D001201,7.14,NCT01988493-2,Phase 1b: Tepotinib 500 mg,NCT01988493,Efficacy  Safety  and Pharmacokinetic of MSC2156119J in Asian Participants With Hepatocellular Carcinoma,ascites
D001201,4.44,NCT01988493-4,Phase 2: Tepotinib,NCT01988493,Efficacy  Safety  and Pharmacokinetic of MSC2156119J in Asian Participants With Hepatocellular Carcinoma,ascites
UNKNOWN-check-for-typo,7.14,NCT01988493-2,Phase 1b: Tepotinib 500 mg,NCT01988493,Efficacy  Safety  and Pharmacokinetic of MSC2156119J in Asian Participants With Hepatocellular Carcinoma,D00
UNKNOWN-check-for-typo,2.22,NCT01988493-4,Phase 2: Tepotinib,NCT01988493,Efficacy  Safety  and Pharmacokinetic of MSC2156119J in Asian Participants With Hepatocellular Carcinoma,D00
UNKNOWN-check-for-typo,2.27,NCT01988493-5,Phase 2 Sorafenib,NCT01988493,Efficacy  Safety  and Pharmacokinetic of MSC2156119J in Asian Participants With Hepatocellular Carcinoma,D00
D004381,7.14,NCT01988493-2,Phase 1b: Tepotinib 500 mg,NCT01988493,Efficacy  Safety  and Pharmacokinetic of MSC2156119J in Asian Participants With Hepatocellular Carcinoma,duodenal ulcer
D056627,7.14,NCT01988493-2,Phase 1b: Tepotinib 500 mg,NCT01988493,Efficacy  Safety  and Pharmacokinetic of MSC2156119J in Asian Participants With Hepatocellular Carcinoma,encapsulating peritoneal sclerosis
D045823,7.14,NCT01988493-2,Phase 1b: Tepotinib 500 mg,NCT01988493,Efficacy  Safety  and Pharmacokinetic of MSC2156119J in Asian Participants With Hepatocellular Carcinoma,ileus
D045823,2.22,NCT01988493-4,Phase 2: Tepotinib,NCT01988493,Efficacy  Safety  and Pharmacokinetic of MSC2156119J in Asian Participants With Hepatocellular Carcinoma,ileus
D050686,7.14,NCT01988493-2,Phase 1b: Tepotinib 500 mg,NCT01988493,Efficacy  Safety  and Pharmacokinetic of MSC2156119J in Asian Participants With Hepatocellular Carcinoma,globicephala melaena
D041742,7.14,NCT01988493-2,Phase 1b: Tepotinib 500 mg,NCT01988493,Efficacy  Safety  and Pharmacokinetic of MSC2156119J in Asian Participants With Hepatocellular Carcinoma,upper gastrointestinal tract
D041742,2.22,NCT01988493-4,Phase 2: Tepotinib,NCT01988493,Efficacy  Safety  and Pharmacokinetic of MSC2156119J in Asian Participants With Hepatocellular Carcinoma,upper gastrointestinal tract
D041742,2.27,NCT01988493-5,Phase 2 Sorafenib,NCT01988493,Efficacy  Safety  and Pharmacokinetic of MSC2156119J in Asian Participants With Hepatocellular Carcinoma,upper gastrointestinal tract
D004381,2.22,NCT01988493-4,Phase 2: Tepotinib,NCT01988493,Efficacy  Safety  and Pharmacokinetic of MSC2156119J in Asian Participants With Hepatocellular Carcinoma,duodenal ulcer
D001202,2.22,NCT01988493-4,Phase 2: Tepotinib,NCT01988493,Efficacy  Safety  and Pharmacokinetic of MSC2156119J in Asian Participants With Hepatocellular Carcinoma,peritoneal fluid
D018450,14.29,NCT01988493-1,Phase 1b: Tepotinib 300 mg,NCT01988493,Efficacy  Safety  and Pharmacokinetic of MSC2156119J in Asian Participants With Hepatocellular Carcinoma,disease progression
D018450,15.56,NCT01988493-4,Phase 2: Tepotinib,NCT01988493,Efficacy  Safety  and Pharmacokinetic of MSC2156119J in Asian Participants With Hepatocellular Carcinoma,disease progression
D018450,4.55,NCT01988493-5,Phase 2 Sorafenib,NCT01988493,Efficacy  Safety  and Pharmacokinetic of MSC2156119J in Asian Participants With Hepatocellular Carcinoma,disease progression
D001247,2.27,NCT01988493-5,Phase 2 Sorafenib,NCT01988493,Efficacy  Safety  and Pharmacokinetic of MSC2156119J in Asian Participants With Hepatocellular Carcinoma,asthenia
D006547,2.22,NCT01988493-4,Phase 2: Tepotinib,NCT01988493,Efficacy  Safety  and Pharmacokinetic of MSC2156119J in Asian Participants With Hepatocellular Carcinoma,hernia
D000799,4.44,NCT01988493-4,Phase 2: Tepotinib,NCT01988493,Efficacy  Safety  and Pharmacokinetic of MSC2156119J in Asian Participants With Hepatocellular Carcinoma,angioedema
D041881,2.27,NCT01988493-5,Phase 2 Sorafenib,NCT01988493,Efficacy  Safety  and Pharmacokinetic of MSC2156119J in Asian Participants With Hepatocellular Carcinoma,acute cholecystitis
D017093,2.22,NCT01988493-4,Phase 2: Tepotinib,NCT01988493,Efficacy  Safety  and Pharmacokinetic of MSC2156119J in Asian Participants With Hepatocellular Carcinoma,hepatic failure
D017093,2.27,NCT01988493-5,Phase 2 Sorafenib,NCT01988493,Efficacy  Safety  and Pharmacokinetic of MSC2156119J in Asian Participants With Hepatocellular Carcinoma,hepatic failure
D011681,2.22,NCT01988493-4,Phase 2: Tepotinib,NCT01988493,Efficacy  Safety  and Pharmacokinetic of MSC2156119J in Asian Participants With Hepatocellular Carcinoma,pupillary functions abnormal
D000069544,16.67,NCT01988493-3,Phase 1b: Tepotinib 1000 mg,NCT01988493,Efficacy  Safety  and Pharmacokinetic of MSC2156119J in Asian Participants With Hepatocellular Carcinoma,encephalitis infection
D002481,2.22,NCT01988493-4,Phase 2: Tepotinib,NCT01988493,Efficacy  Safety  and Pharmacokinetic of MSC2156119J in Asian Participants With Hepatocellular Carcinoma,cellulitis
D005254,2.22,NCT01988493-4,Phase 2: Tepotinib,NCT01988493,Efficacy  Safety  and Pharmacokinetic of MSC2156119J in Asian Participants With Hepatocellular Carcinoma,feline infectious enteritis
D011014,7.14,NCT01988493-2,Phase 1b: Tepotinib 500 mg,NCT01988493,Efficacy  Safety  and Pharmacokinetic of MSC2156119J in Asian Participants With Hepatocellular Carcinoma,pneumonia
10001551,14.29,NCT01988493-1,Phase 1b: Tepotinib 300 mg,NCT01988493,Efficacy  Safety  and Pharmacokinetic of MSC2156119J in Asian Participants With Hepatocellular Carcinoma,alanine aminotransferase increased
10003481,14.29,NCT01988493-1,Phase 1b: Tepotinib 300 mg,NCT01988493,Efficacy  Safety  and Pharmacokinetic of MSC2156119J in Asian Participants With Hepatocellular Carcinoma,aspartate aminotransferase increased
10005364,7.14,NCT01988493-2,Phase 1b: Tepotinib 500 mg,NCT01988493,Efficacy  Safety  and Pharmacokinetic of MSC2156119J in Asian Participants With Hepatocellular Carcinoma,blood bilirubin increased
10005364,2.27,NCT01988493-5,Phase 2 Sorafenib,NCT01988493,Efficacy  Safety  and Pharmacokinetic of MSC2156119J in Asian Participants With Hepatocellular Carcinoma,blood bilirubin increased
10024574,2.27,NCT01988493-5,Phase 2 Sorafenib,NCT01988493,Efficacy  Safety  and Pharmacokinetic of MSC2156119J in Asian Participants With Hepatocellular Carcinoma,lipase increased
D001066,16.67,NCT01988493-3,Phase 1b: Tepotinib 1000 mg,NCT01988493,Efficacy  Safety  and Pharmacokinetic of MSC2156119J in Asian Participants With Hepatocellular Carcinoma,appetite
D001066,2.22,NCT01988493-4,Phase 2: Tepotinib,NCT01988493,Efficacy  Safety  and Pharmacokinetic of MSC2156119J in Asian Participants With Hepatocellular Carcinoma,appetite
UNKNOWN-check-for-typo,2.22,NCT01988493-4,Phase 2: Tepotinib,NCT01988493,Efficacy  Safety  and Pharmacokinetic of MSC2156119J in Asian Participants With Hepatocellular Carcinoma,D00
D018908,16.67,NCT01988493-3,Phase 1b: Tepotinib 1000 mg,NCT01988493,Efficacy  Safety  and Pharmacokinetic of MSC2156119J in Asian Participants With Hepatocellular Carcinoma,muscular weakness
D059352,2.22,NCT01988493-4,Phase 2: Tepotinib,NCT01988493,Efficacy  Safety  and Pharmacokinetic of MSC2156119J in Asian Participants With Hepatocellular Carcinoma,musculoskeletal pain
D015210,2.22,NCT01988493-4,Phase 2: Tepotinib,NCT01988493,Efficacy  Safety  and Pharmacokinetic of MSC2156119J in Asian Participants With Hepatocellular Carcinoma,gouty arthritis
D002490,2.27,NCT01988493-5,Phase 2 Sorafenib,NCT01988493,Efficacy  Safety  and Pharmacokinetic of MSC2156119J in Asian Participants With Hepatocellular Carcinoma,central nervous system
D001749,7.14,NCT01988493-2,Phase 1b: Tepotinib 500 mg,NCT01988493,Efficacy  Safety  and Pharmacokinetic of MSC2156119J in Asian Participants With Hepatocellular Carcinoma,bladder cancer
D020521,7.14,NCT01988493-2,Phase 1b: Tepotinib 500 mg,NCT01988493,Efficacy  Safety  and Pharmacokinetic of MSC2156119J in Asian Participants With Hepatocellular Carcinoma,cerebrovascular accident
D000069280,7.14,NCT01988493-2,Phase 1b: Tepotinib 500 mg,NCT01988493,Efficacy  Safety  and Pharmacokinetic of MSC2156119J in Asian Participants With Hepatocellular Carcinoma,intracranial electroencephalography
D000069280,2.27,NCT01988493-5,Phase 2 Sorafenib,NCT01988493,Efficacy  Safety  and Pharmacokinetic of MSC2156119J in Asian Participants With Hepatocellular Carcinoma,intracranial electroencephalography
D006501,4.44,NCT01988493-4,Phase 2: Tepotinib,NCT01988493,Efficacy  Safety  and Pharmacokinetic of MSC2156119J in Asian Participants With Hepatocellular Carcinoma,hepatic encephalopathy
D006501,2.27,NCT01988493-5,Phase 2 Sorafenib,NCT01988493,Efficacy  Safety  and Pharmacokinetic of MSC2156119J in Asian Participants With Hepatocellular Carcinoma,hepatic encephalopathy
UNKNOWN-check-for-typo,4.44,NCT01988493-4,Phase 2: Tepotinib,NCT01988493,Efficacy  Safety  and Pharmacokinetic of MSC2156119J in Asian Participants With Hepatocellular Carcinoma,D00
D012640,16.67,NCT01988493-3,Phase 1b: Tepotinib 1000 mg,NCT01988493,Efficacy  Safety  and Pharmacokinetic of MSC2156119J in Asian Participants With Hepatocellular Carcinoma,seizure
D051270,14.29,NCT01988493-1,Phase 1b: Tepotinib 300 mg,NCT01988493,Efficacy  Safety  and Pharmacokinetic of MSC2156119J in Asian Participants With Hepatocellular Carcinoma,primary exertional headache
UNKNOWN-check-for-typo,14.29,NCT01988493-1,Phase 1b: Tepotinib 300 mg,NCT01988493,Efficacy  Safety  and Pharmacokinetic of MSC2156119J in Asian Participants With Hepatocellular Carcinoma,D00
D010996,14.29,NCT01988493-1,Phase 1b: Tepotinib 300 mg,NCT01988493,Efficacy  Safety  and Pharmacokinetic of MSC2156119J in Asian Participants With Hepatocellular Carcinoma,pleural effusion
10037868,7.14,NCT01988493-2,Phase 1b: Tepotinib 500 mg,NCT01988493,Efficacy  Safety  and Pharmacokinetic of MSC2156119J in Asian Participants With Hepatocellular Carcinoma,rash maculo-papular
D020246,2.27,NCT01988493-5,Phase 2 Sorafenib,NCT01988493,Efficacy  Safety  and Pharmacokinetic of MSC2156119J in Asian Participants With Hepatocellular Carcinoma,deep vein thrombosis
D006973,14.29,NCT01988493-1,Phase 1b: Tepotinib 300 mg,NCT01988493,Efficacy  Safety  and Pharmacokinetic of MSC2156119J in Asian Participants With Hepatocellular Carcinoma,hypertension
UNKNOWN-check-for-typo,2.22,NCT01988493-4,Phase 2: Tepotinib,NCT01988493,Efficacy  Safety  and Pharmacokinetic of MSC2156119J in Asian Participants With Hepatocellular Carcinoma,D00
D009026,25.0,NCT02050919-1,Treatment (Sorafenib Chemotherapy Radiation Surgery),NCT02050919,Sorafenib Tosylate  Combination Chemotherapy  Radiation Therapy  and Surgery in Treating Patients With High-Risk Stage IIB-IV Soft Tissue Sarcoma,mortality
D064420,90.0,NCT02050919-1,Treatment (Sorafenib Chemotherapy Radiation Surgery),NCT02050919,Sorafenib Tosylate  Combination Chemotherapy  Radiation Therapy  and Surgery in Treating Patients With High-Risk Stage IIB-IV Soft Tissue Sarcoma,adverse drug events
D064147,60.0,NCT02050919-1,Treatment (Sorafenib Chemotherapy Radiation Surgery),NCT02050919,Sorafenib Tosylate  Combination Chemotherapy  Radiation Therapy  and Surgery in Treating Patients With High-Risk Stage IIB-IV Soft Tissue Sarcoma,febrile neutropenia
D003248,5.0,NCT02050919-1,Treatment (Sorafenib Chemotherapy Radiation Surgery),NCT02050919,Sorafenib Tosylate  Combination Chemotherapy  Radiation Therapy  and Surgery in Treating Patients With High-Risk Stage IIB-IV Soft Tissue Sarcoma,constipation
D003967,5.0,NCT02050919-1,Treatment (Sorafenib Chemotherapy Radiation Surgery),NCT02050919,Sorafenib Tosylate  Combination Chemotherapy  Radiation Therapy  and Surgery in Treating Patients With High-Risk Stage IIB-IV Soft Tissue Sarcoma,diarrhea
10007810,5.0,NCT02050919-1,Treatment (Sorafenib Chemotherapy Radiation Surgery),NCT02050919,Sorafenib Tosylate  Combination Chemotherapy  Radiation Therapy  and Surgery in Treating Patients With High-Risk Stage IIB-IV Soft Tissue Sarcoma,catheter related infection
10058838,5.0,NCT02050919-1,Treatment (Sorafenib Chemotherapy Radiation Surgery),NCT02050919,Sorafenib Tosylate  Combination Chemotherapy  Radiation Therapy  and Surgery in Treating Patients With High-Risk Stage IIB-IV Soft Tissue Sarcoma,enterocolitis infectious
D018805,15.0,NCT02050919-1,Treatment (Sorafenib Chemotherapy Radiation Surgery),NCT02050919,Sorafenib Tosylate  Combination Chemotherapy  Radiation Therapy  and Surgery in Treating Patients With High-Risk Stage IIB-IV Soft Tissue Sarcoma,sepsis
D018461,5.0,NCT02050919-1,Treatment (Sorafenib Chemotherapy Radiation Surgery),NCT02050919,Sorafenib Tosylate  Combination Chemotherapy  Radiation Therapy  and Surgery in Treating Patients With High-Risk Stage IIB-IV Soft Tissue Sarcoma,soft tissue infection
D014946,35.0,NCT02050919-1,Treatment (Sorafenib Chemotherapy Radiation Surgery),NCT02050919,Sorafenib Tosylate  Combination Chemotherapy  Radiation Therapy  and Surgery in Treating Patients With High-Risk Stage IIB-IV Soft Tissue Sarcoma,wound infection
10048031,5.0,NCT02050919-1,Treatment (Sorafenib Chemotherapy Radiation Surgery),NCT02050919,Sorafenib Tosylate  Combination Chemotherapy  Radiation Therapy  and Surgery in Treating Patients With High-Risk Stage IIB-IV Soft Tissue Sarcoma,wound dehiscence
10025256,5.0,NCT02050919-1,Treatment (Sorafenib Chemotherapy Radiation Surgery),NCT02050919,Sorafenib Tosylate  Combination Chemotherapy  Radiation Therapy  and Surgery in Treating Patients With High-Risk Stage IIB-IV Soft Tissue Sarcoma,lymphocyte count decreased
10029366,5.0,NCT02050919-1,Treatment (Sorafenib Chemotherapy Radiation Surgery),NCT02050919,Sorafenib Tosylate  Combination Chemotherapy  Radiation Therapy  and Surgery in Treating Patients With High-Risk Stage IIB-IV Soft Tissue Sarcoma,neutrophil count decreased
10035528,10.0,NCT02050919-1,Treatment (Sorafenib Chemotherapy Radiation Surgery),NCT02050919,Sorafenib Tosylate  Combination Chemotherapy  Radiation Therapy  and Surgery in Treating Patients With High-Risk Stage IIB-IV Soft Tissue Sarcoma,platelet count decreased
D007008,5.0,NCT02050919-1,Treatment (Sorafenib Chemotherapy Radiation Surgery),NCT02050919,Sorafenib Tosylate  Combination Chemotherapy  Radiation Therapy  and Surgery in Treating Patients With High-Risk Stage IIB-IV Soft Tissue Sarcoma,hypokalemia
D001927,15.0,NCT02050919-1,Treatment (Sorafenib Chemotherapy Radiation Surgery),NCT02050919,Sorafenib Tosylate  Combination Chemotherapy  Radiation Therapy  and Surgery in Treating Patients With High-Risk Stage IIB-IV Soft Tissue Sarcoma,encephalopathy
D013575,5.0,NCT02050919-1,Treatment (Sorafenib Chemotherapy Radiation Surgery),NCT02050919,Sorafenib Tosylate  Combination Chemotherapy  Radiation Therapy  and Surgery in Treating Patients With High-Risk Stage IIB-IV Soft Tissue Sarcoma,syncope
D003693,5.0,NCT02050919-1,Treatment (Sorafenib Chemotherapy Radiation Surgery),NCT02050919,Sorafenib Tosylate  Combination Chemotherapy  Radiation Therapy  and Surgery in Treating Patients With High-Risk Stage IIB-IV Soft Tissue Sarcoma,delirium
10054524,5.0,NCT02050919-1,Treatment (Sorafenib Chemotherapy Radiation Surgery),NCT02050919,Sorafenib Tosylate  Combination Chemotherapy  Radiation Therapy  and Surgery in Treating Patients With High-Risk Stage IIB-IV Soft Tissue Sarcoma,palmar-plantar erythrodysesthesia syndrome
D009026,2.04,NCT02066181-1,Arm I (Sorafenib Tosylate),NCT02066181,Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis,mortality
D064420,22.45,NCT02066181-1,Arm I (Sorafenib Tosylate),NCT02066181,Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis,adverse drug events
D064420,16.67,NCT02066181-2,Arm II (Placebo),NCT02066181,Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis,adverse drug events
D064420,17.86,NCT02066181-3,Crossover Group,NCT02066181,Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis,adverse drug events
D000740,2.04,NCT02066181-1,Arm I (Sorafenib Tosylate),NCT02066181,Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis,anemia
10005329,2.04,NCT02066181-1,Arm I (Sorafenib Tosylate),NCT02066181,Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis,blood and lymphatic system disorders - other specify
10008481,2.04,NCT02066181-1,Arm I (Sorafenib Tosylate),NCT02066181,Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis,chest pain - cardiac
D006333,2.04,NCT02066181-1,Arm I (Sorafenib Tosylate),NCT02066181,Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis,heart failure
10033557,2.04,NCT02066181-1,Arm I (Sorafenib Tosylate),NCT02066181,Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis,palpitations
D015746,2.78,NCT02066181-2,Arm II (Placebo),NCT02066181,Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis,abdominal pain
D003967,4.08,NCT02066181-1,Arm I (Sorafenib Tosylate),NCT02066181,Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis,diarrhea
10017815,2.04,NCT02066181-1,Arm I (Sorafenib Tosylate),NCT02066181,Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis,gastric perforation
10025476,3.57,NCT02066181-3,Crossover Group,NCT02066181,Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis,malabsorption
D009325,2.04,NCT02066181-1,Arm I (Sorafenib Tosylate),NCT02066181,Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis,nausea
D009325,2.78,NCT02066181-2,Arm II (Placebo),NCT02066181,Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis,nausea
D010195,2.04,NCT02066181-1,Arm I (Sorafenib Tosylate),NCT02066181,Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis,pancreatitis
10041101,5.56,NCT02066181-2,Arm II (Placebo),NCT02066181,Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis,small intestinal obstruction
D014839,2.78,NCT02066181-2,Arm II (Placebo),NCT02066181,Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis,vomiting
D005221,4.08,NCT02066181-1,Arm I (Sorafenib Tosylate),NCT02066181,Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis,fatigue
D005334,2.78,NCT02066181-2,Arm II (Placebo),NCT02066181,Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis,fever
10018065,2.78,NCT02066181-2,Arm II (Placebo),NCT02066181,Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis,general disorders and administration site conditions - other specify
D001064,3.57,NCT02066181-3,Crossover Group,NCT02066181,Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis,appendicitis
D018805,3.57,NCT02066181-3,Crossover Group,NCT02066181,Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis,sepsis
10022117,3.57,NCT02066181-3,Crossover Group,NCT02066181,Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis,injury poisoning and procedural complications - other specify
10001551,3.57,NCT02066181-3,Crossover Group,NCT02066181,Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis,alanine aminotransferase increased
D015228,2.04,NCT02066181-1,Arm I (Sorafenib Tosylate),NCT02066181,Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis,hypertriglyceridemia
D015228,2.78,NCT02066181-2,Arm II (Placebo),NCT02066181,Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis,hypertriglyceridemia
D018771,2.04,NCT02066181-1,Arm I (Sorafenib Tosylate),NCT02066181,Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis,arthralgia
D021501,2.78,NCT02066181-2,Arm II (Placebo),NCT02066181,Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis,flank pain
10036585,2.04,NCT02066181-1,Arm I (Sorafenib Tosylate),NCT02066181,Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis,pregnancy puerperium and perinatal conditions - other specify
D049168,2.04,NCT02066181-1,Arm I (Sorafenib Tosylate),NCT02066181,Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis,unintended pregnancy
D058186,2.04,NCT02066181-1,Arm I (Sorafenib Tosylate),NCT02066181,Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis,acute kidney injury
D004417,2.04,NCT02066181-1,Arm I (Sorafenib Tosylate),NCT02066181,Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis,dyspnea
10054524,4.08,NCT02066181-1,Arm I (Sorafenib Tosylate),NCT02066181,Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis,palmar-plantar erythrodysesthesia syndrome
10040785,2.04,NCT02066181-1,Arm I (Sorafenib Tosylate),NCT02066181,Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis,skin and subcutaneous tissue disorders - other specify
D006973,2.04,NCT02066181-1,Arm I (Sorafenib Tosylate),NCT02066181,Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis,hypertension
D006973,2.78,NCT02066181-2,Arm II (Placebo),NCT02066181,Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis,hypertension
D006973,3.57,NCT02066181-3,Crossover Group,NCT02066181,Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis,hypertension
D009026,75.0,NCT02115373-1,Phase 1b: Tepotinib 300 mg,NCT02115373,c-Met Second-Line Hepatocellular Carcinoma,mortality
D009026,84.62,NCT02115373-2,Phase 1b: Tepotinib 500 mg,NCT02115373,c-Met Second-Line Hepatocellular Carcinoma,mortality
D009026,81.63,NCT02115373-3,Phase 2: Tepotinib 500 mg,NCT02115373,c-Met Second-Line Hepatocellular Carcinoma,mortality
D064420,50.0,NCT02115373-1,Phase 1b: Tepotinib 300 mg,NCT02115373,c-Met Second-Line Hepatocellular Carcinoma,adverse drug events
D064420,38.46,NCT02115373-2,Phase 1b: Tepotinib 500 mg,NCT02115373,c-Met Second-Line Hepatocellular Carcinoma,adverse drug events
D064420,42.86,NCT02115373-3,Phase 2: Tepotinib 500 mg,NCT02115373,c-Met Second-Line Hepatocellular Carcinoma,adverse drug events
D015746,25.0,NCT02115373-1,Phase 1b: Tepotinib 300 mg,NCT02115373,c-Met Second-Line Hepatocellular Carcinoma,abdominal pain
D001201,15.38,NCT02115373-2,Phase 1b: Tepotinib 500 mg,NCT02115373,c-Met Second-Line Hepatocellular Carcinoma,ascites
D001201,6.12,NCT02115373-3,Phase 2: Tepotinib 500 mg,NCT02115373,c-Met Second-Line Hepatocellular Carcinoma,ascites
D000069196,2.04,NCT02115373-3,Phase 2: Tepotinib 500 mg,NCT02115373,c-Met Second-Line Hepatocellular Carcinoma,gastrointestinal microbiome
D018450,25.0,NCT02115373-1,Phase 1b: Tepotinib 300 mg,NCT02115373,c-Met Second-Line Hepatocellular Carcinoma,disease progression
D018450,7.69,NCT02115373-2,Phase 1b: Tepotinib 500 mg,NCT02115373,c-Met Second-Line Hepatocellular Carcinoma,disease progression
D018450,14.29,NCT02115373-3,Phase 2: Tepotinib 500 mg,NCT02115373,c-Met Second-Line Hepatocellular Carcinoma,disease progression
D000799,7.69,NCT02115373-2,Phase 1b: Tepotinib 500 mg,NCT02115373,c-Met Second-Line Hepatocellular Carcinoma,angioedema
D000799,15.38,NCT02115373-2,Phase 1b: Tepotinib 500 mg,NCT02115373,c-Met Second-Line Hepatocellular Carcinoma,angioedema
D000799,2.04,NCT02115373-3,Phase 2: Tepotinib 500 mg,NCT02115373,c-Met Second-Line Hepatocellular Carcinoma,angioedema
UNKNOWN-check-for-typo,2.04,NCT02115373-3,Phase 2: Tepotinib 500 mg,NCT02115373,c-Met Second-Line Hepatocellular Carcinoma,D00
D003695,2.04,NCT02115373-3,Phase 2: Tepotinib 500 mg,NCT02115373,c-Met Second-Line Hepatocellular Carcinoma,healthcare
D005334,2.04,NCT02115373-3,Phase 2: Tepotinib 500 mg,NCT02115373,c-Met Second-Line Hepatocellular Carcinoma,pyrexia
D006083,2.04,NCT02115373-3,Phase 2: Tepotinib 500 mg,NCT02115373,c-Met Second-Line Hepatocellular Carcinoma,vascular graft restenosis
D002761,2.04,NCT02115373-3,Phase 2: Tepotinib 500 mg,NCT02115373,c-Met Second-Line Hepatocellular Carcinoma,cholangitis
D017093,2.04,NCT02115373-3,Phase 2: Tepotinib 500 mg,NCT02115373,c-Met Second-Line Hepatocellular Carcinoma,hepatic failure
D007565,2.04,NCT02115373-3,Phase 2: Tepotinib 500 mg,NCT02115373,c-Met Second-Line Hepatocellular Carcinoma,jaundice
D006530,7.69,NCT02115373-2,Phase 1b: Tepotinib 500 mg,NCT02115373,c-Met Second-Line Hepatocellular Carcinoma,hepatorenal syndrome
10064687,2.04,NCT02115373-3,Phase 2: Tepotinib 500 mg,NCT02115373,c-Met Second-Line Hepatocellular Carcinoma,device related infection
D010538,2.04,NCT02115373-3,Phase 2: Tepotinib 500 mg,NCT02115373,c-Met Second-Line Hepatocellular Carcinoma,peritonitis
D018805,7.69,NCT02115373-2,Phase 1b: Tepotinib 500 mg,NCT02115373,c-Met Second-Line Hepatocellular Carcinoma,sepsis
D018805,2.04,NCT02115373-3,Phase 2: Tepotinib 500 mg,NCT02115373,c-Met Second-Line Hepatocellular Carcinoma,sepsis
D010538,7.69,NCT02115373-2,Phase 1b: Tepotinib 500 mg,NCT02115373,c-Met Second-Line Hepatocellular Carcinoma,peritonitis
D013530,25.0,NCT02115373-1,Phase 1b: Tepotinib 300 mg,NCT02115373,c-Met Second-Line Hepatocellular Carcinoma,wound infection postoperative
10005364,25.0,NCT02115373-1,Phase 1b: Tepotinib 300 mg,NCT02115373,c-Met Second-Line Hepatocellular Carcinoma,blood bilirubin increased
UNKNOWN-check-for-typo,2.04,NCT02115373-3,Phase 2: Tepotinib 500 mg,NCT02115373,c-Met Second-Line Hepatocellular Carcinoma,D00
UNKNOWN-check-for-typo,2.04,NCT02115373-3,Phase 2: Tepotinib 500 mg,NCT02115373,c-Met Second-Line Hepatocellular Carcinoma,D00
UNKNOWN-check-for-typo,2.04,NCT02115373-3,Phase 2: Tepotinib 500 mg,NCT02115373,c-Met Second-Line Hepatocellular Carcinoma,D00
D001066,25.0,NCT02115373-1,Phase 1b: Tepotinib 300 mg,NCT02115373,c-Met Second-Line Hepatocellular Carcinoma,appetite
D012206,2.04,NCT02115373-3,Phase 2: Tepotinib 500 mg,NCT02115373,c-Met Second-Line Hepatocellular Carcinoma,rhabdomyolysis
D000072716,2.04,NCT02115373-3,Phase 2: Tepotinib 500 mg,NCT02115373,c-Met Second-Line Hepatocellular Carcinoma,cancer pain
D000080867,2.04,NCT02115373-3,Phase 2: Tepotinib 500 mg,NCT02115373,c-Met Second-Line Hepatocellular Carcinoma,gingipains
D003128,7.69,NCT02115373-2,Phase 1b: Tepotinib 500 mg,NCT02115373,c-Met Second-Line Hepatocellular Carcinoma,coma
D006501,7.69,NCT02115373-2,Phase 1b: Tepotinib 500 mg,NCT02115373,c-Met Second-Line Hepatocellular Carcinoma,hepatic encephalopathy
D020767,2.04,NCT02115373-3,Phase 2: Tepotinib 500 mg,NCT02115373,c-Met Second-Line Hepatocellular Carcinoma,cerebral thrombosis
D000077276,2.04,NCT02115373-3,Phase 2: Tepotinib 500 mg,NCT02115373,c-Met Second-Line Hepatocellular Carcinoma,lycomato
D058186,25.0,NCT02115373-1,Phase 1b: Tepotinib 300 mg,NCT02115373,c-Met Second-Line Hepatocellular Carcinoma,acute kidney injury
D058186,7.69,NCT02115373-2,Phase 1b: Tepotinib 500 mg,NCT02115373,c-Met Second-Line Hepatocellular Carcinoma,acute kidney injury
D058186,6.12,NCT02115373-3,Phase 2: Tepotinib 500 mg,NCT02115373,c-Met Second-Line Hepatocellular Carcinoma,acute kidney injury
D051436,2.04,NCT02115373-3,Phase 2: Tepotinib 500 mg,NCT02115373,c-Met Second-Line Hepatocellular Carcinoma,chronic kidney disease
D011472,7.69,NCT02115373-2,Phase 1b: Tepotinib 500 mg,NCT02115373,c-Met Second-Line Hepatocellular Carcinoma,prostatitis
D011015,2.04,NCT02115373-3,Phase 2: Tepotinib 500 mg,NCT02115373,c-Met Second-Line Hepatocellular Carcinoma,aspiration pneumonia
D064420,87.5,NCT02196857-1,Azacytidine + Sorafenib,NCT02196857,Sorafenib Plus 5-Azacitidine Initial Therapy of Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MS) With FLT3-ITD Mutation,adverse drug events
D009618,6.25,NCT02196857-1,Azacytidine + Sorafenib,NCT02196857,Sorafenib Plus 5-Azacitidine Initial Therapy of Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MS) With FLT3-ITD Mutation,nocardiaceae
D020300,6.25,NCT02196857-1,Azacytidine + Sorafenib,NCT02196857,Sorafenib Plus 5-Azacitidine Initial Therapy of Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MS) With FLT3-ITD Mutation,intracranial hemorrhage
D013921,6.25,NCT02196857-1,Azacytidine + Sorafenib,NCT02196857,Sorafenib Plus 5-Azacitidine Initial Therapy of Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MS) With FLT3-ITD Mutation,thrombocytopenia
D006333,6.25,NCT02196857-1,Azacytidine + Sorafenib,NCT02196857,Sorafenib Plus 5-Azacitidine Initial Therapy of Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MS) With FLT3-ITD Mutation,heart failure
D003092,12.5,NCT02196857-1,Azacytidine + Sorafenib,NCT02196857,Sorafenib Plus 5-Azacitidine Initial Therapy of Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MS) With FLT3-ITD Mutation,colitis
D003681,6.25,NCT02196857-1,Azacytidine + Sorafenib,NCT02196857,Sorafenib Plus 5-Azacitidine Initial Therapy of Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MS) With FLT3-ITD Mutation,dehydration
D007422,6.25,NCT02196857-1,Azacytidine + Sorafenib,NCT02196857,Sorafenib Plus 5-Azacitidine Initial Therapy of Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MS) With FLT3-ITD Mutation,intestines
D005157,6.25,NCT02196857-1,Azacytidine + Sorafenib,NCT02196857,Sorafenib Plus 5-Azacitidine Initial Therapy of Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MS) With FLT3-ITD Mutation,facial pain
D005221,6.25,NCT02196857-1,Azacytidine + Sorafenib,NCT02196857,Sorafenib Plus 5-Azacitidine Initial Therapy of Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MS) With FLT3-ITD Mutation,fatigue
D005334,6.25,NCT02196857-1,Azacytidine + Sorafenib,NCT02196857,Sorafenib Plus 5-Azacitidine Initial Therapy of Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MS) With FLT3-ITD Mutation,fever
D002481,6.25,NCT02196857-1,Azacytidine + Sorafenib,NCT02196857,Sorafenib Plus 5-Azacitidine Initial Therapy of Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MS) With FLT3-ITD Mutation,cellulitis
D064147,31.25,NCT02196857-1,Azacytidine + Sorafenib,NCT02196857,Sorafenib Plus 5-Azacitidine Initial Therapy of Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MS) With FLT3-ITD Mutation,febrile neutropenia
D014552,12.5,NCT02196857-1,Azacytidine + Sorafenib,NCT02196857,Sorafenib Plus 5-Azacitidine Initial Therapy of Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MS) With FLT3-ITD Mutation,urinary tract infection
D007239,6.25,NCT02196857-1,Azacytidine + Sorafenib,NCT02196857,Sorafenib Plus 5-Azacitidine Initial Therapy of Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MS) With FLT3-ITD Mutation,infection
10061229,31.25,NCT02196857-1,Azacytidine + Sorafenib,NCT02196857,Sorafenib Plus 5-Azacitidine Initial Therapy of Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MS) With FLT3-ITD Mutation,lung infection
D018805,6.25,NCT02196857-1,Azacytidine + Sorafenib,NCT02196857,Sorafenib Plus 5-Azacitidine Initial Therapy of Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MS) With FLT3-ITD Mutation,sepsis
10040872,6.25,NCT02196857-1,Azacytidine + Sorafenib,NCT02196857,Sorafenib Plus 5-Azacitidine Initial Therapy of Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MS) With FLT3-ITD Mutation,skin infection
D001168,6.25,NCT02196857-1,Azacytidine + Sorafenib,NCT02196857,Sorafenib Plus 5-Azacitidine Initial Therapy of Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MS) With FLT3-ITD Mutation,arthritis
D012640,6.25,NCT02196857-1,Azacytidine + Sorafenib,NCT02196857,Sorafenib Plus 5-Azacitidine Initial Therapy of Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MS) With FLT3-ITD Mutation,seizure
D020521,6.25,NCT02196857-1,Azacytidine + Sorafenib,NCT02196857,Sorafenib Plus 5-Azacitidine Initial Therapy of Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MS) With FLT3-ITD Mutation,stroke
D013575,6.25,NCT02196857-1,Azacytidine + Sorafenib,NCT02196857,Sorafenib Plus 5-Azacitidine Initial Therapy of Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MS) With FLT3-ITD Mutation,syncope
D014202,6.25,NCT02196857-1,Azacytidine + Sorafenib,NCT02196857,Sorafenib Plus 5-Azacitidine Initial Therapy of Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MS) With FLT3-ITD Mutation,tremor
D058186,6.25,NCT02196857-1,Azacytidine + Sorafenib,NCT02196857,Sorafenib Plus 5-Azacitidine Initial Therapy of Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MS) With FLT3-ITD Mutation,acute kidney failure
10018112,6.25,NCT02196857-1,Azacytidine + Sorafenib,NCT02196857,Sorafenib Plus 5-Azacitidine Initial Therapy of Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MS) With FLT3-ITD Mutation,generalized edema
D012131,6.25,NCT02196857-1,Azacytidine + Sorafenib,NCT02196857,Sorafenib Plus 5-Azacitidine Initial Therapy of Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MS) With FLT3-ITD Mutation,respiratory failure
D004417,12.5,NCT02196857-1,Azacytidine + Sorafenib,NCT02196857,Sorafenib Plus 5-Azacitidine Initial Therapy of Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MS) With FLT3-ITD Mutation,dyspnea
10065759,6.25,NCT02196857-1,Azacytidine + Sorafenib,NCT02196857,Sorafenib Plus 5-Azacitidine Initial Therapy of Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MS) With FLT3-ITD Mutation,laryngeal hemorrhage
10065735,12.5,NCT02196857-1,Azacytidine + Sorafenib,NCT02196857,Sorafenib Plus 5-Azacitidine Initial Therapy of Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MS) With FLT3-ITD Mutation,laryngeal inflammation
UNKNOWN-check-for-typo,25.0,NCT02196857-1,Azacytidine + Sorafenib,NCT02196857,Sorafenib Plus 5-Azacitidine Initial Therapy of Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MS) With FLT3-ITD Mutation,D00
D064420,50.0,NCT02460991-2,Sorafenib,NCT02460991,A Study of ONCO-DOX in Locally Advanced Hepatocellular Carcinoma,adverse drug events
D000959,50.0,NCT02460991-2,Sorafenib,NCT02460991,A Study of ONCO-DOX in Locally Advanced Hepatocellular Carcinoma,antihypertensives
D064420,3.28,NCT00003896-1,Paclitaxel/CDDP/Liposomal Doxorubicin,NCT00003896,S9912 Combination Chemo in Stage III Ovarian Cancer ,adverse drug events
D013280,1.64,NCT00003896-1,Paclitaxel/CDDP/Liposomal Doxorubicin,NCT00003896,S9912 Combination Chemo in Stage III Ovarian Cancer ,oromucositis
D000069544,1.64,NCT00003896-1,Paclitaxel/CDDP/Liposomal Doxorubicin,NCT00003896,S9912 Combination Chemo in Stage III Ovarian Cancer ,encephalitis infection
D000069544,1.64,NCT00003896-1,Paclitaxel/CDDP/Liposomal Doxorubicin,NCT00003896,S9912 Combination Chemo in Stage III Ovarian Cancer ,encephalitis infection
D007970,1.64,NCT00003896-1,Paclitaxel/CDDP/Liposomal Doxorubicin,NCT00003896,S9912 Combination Chemo in Stage III Ovarian Cancer ,leukopenia
D003681,1.64,NCT00003896-1,Paclitaxel/CDDP/Liposomal Doxorubicin,NCT00003896,S9912 Combination Chemo in Stage III Ovarian Cancer ,dehydration
D064420,96.67,NCT00005908-1,Docetaxel/Capecitabine - A & B,NCT00005908,Primary Chemotherapy With Docetaxel-Capecitabine and Doxorubicin-Cyclophosphamide in Breast Cancer,adverse drug events
D064147,10.0,NCT00005908-1,Docetaxel/Capecitabine - A & B,NCT00005908,Primary Chemotherapy With Docetaxel-Capecitabine and Doxorubicin-Cyclophosphamide in Breast Cancer,febrile neutropenia
UNKNOWN-check-for-typo,3.33,NCT00005908-1,Docetaxel/Capecitabine - A & B,NCT00005908,Primary Chemotherapy With Docetaxel-Capecitabine and Doxorubicin-Cyclophosphamide in Breast Cancer,D00
D000930,16.67,NCT00005908-1,Docetaxel/Capecitabine - A & B,NCT00005908,Primary Chemotherapy With Docetaxel-Capecitabine and Doxorubicin-Cyclophosphamide in Breast Cancer,antidiarrheals
D015746,6.67,NCT00005908-1,Docetaxel/Capecitabine - A & B,NCT00005908,Primary Chemotherapy With Docetaxel-Capecitabine and Doxorubicin-Cyclophosphamide in Breast Cancer,abdominal pain
D003092,3.33,NCT00005908-1,Docetaxel/Capecitabine - A & B,NCT00005908,Primary Chemotherapy With Docetaxel-Capecitabine and Doxorubicin-Cyclophosphamide in Breast Cancer,colitis
D003681,3.33,NCT00005908-1,Docetaxel/Capecitabine - A & B,NCT00005908,Primary Chemotherapy With Docetaxel-Capecitabine and Doxorubicin-Cyclophosphamide in Breast Cancer,dehydration
D009325,3.33,NCT00005908-1,Docetaxel/Capecitabine - A & B,NCT00005908,Primary Chemotherapy With Docetaxel-Capecitabine and Doxorubicin-Cyclophosphamide in Breast Cancer,nausea
D013280,3.33,NCT00005908-1,Docetaxel/Capecitabine - A & B,NCT00005908,Primary Chemotherapy With Docetaxel-Capecitabine and Doxorubicin-Cyclophosphamide in Breast Cancer,oral mucositis
D014839,3.33,NCT00005908-1,Docetaxel/Capecitabine - A & B,NCT00005908,Primary Chemotherapy With Docetaxel-Capecitabine and Doxorubicin-Cyclophosphamide in Breast Cancer,vomiting
D001037,10.0,NCT00005908-1,Docetaxel/Capecitabine - A & B,NCT00005908,Primary Chemotherapy With Docetaxel-Capecitabine and Doxorubicin-Cyclophosphamide in Breast Cancer,logasthenia
D004342,6.67,NCT00005908-1,Docetaxel/Capecitabine - A & B,NCT00005908,Primary Chemotherapy With Docetaxel-Capecitabine and Doxorubicin-Cyclophosphamide in Breast Cancer,drug hypersensitivity
10021881,16.67,NCT00005908-1,Docetaxel/Capecitabine - A & B,NCT00005908,Primary Chemotherapy With Docetaxel-Capecitabine and Doxorubicin-Cyclophosphamide in Breast Cancer,infections and infestations - other specify
D000069544,13.33,NCT00005908-1,Docetaxel/Capecitabine - A & B,NCT00005908,Primary Chemotherapy With Docetaxel-Capecitabine and Doxorubicin-Cyclophosphamide in Breast Cancer,encephalitis infection
D000069544,6.67,NCT00005908-1,Docetaxel/Capecitabine - A & B,NCT00005908,Primary Chemotherapy With Docetaxel-Capecitabine and Doxorubicin-Cyclophosphamide in Breast Cancer,encephalitis infection
D000075662,3.33,NCT00005908-1,Docetaxel/Capecitabine - A & B,NCT00005908,Primary Chemotherapy With Docetaxel-Capecitabine and Doxorubicin-Cyclophosphamide in Breast Cancer,injection site reaction
D014947,3.33,NCT00005908-1,Docetaxel/Capecitabine - A & B,NCT00005908,Primary Chemotherapy With Docetaxel-Capecitabine and Doxorubicin-Cyclophosphamide in Breast Cancer,wounds
D000073296,3.33,NCT00005908-1,Docetaxel/Capecitabine - A & B,NCT00005908,Primary Chemotherapy With Docetaxel-Capecitabine and Doxorubicin-Cyclophosphamide in Breast Cancer,noninfectious diseases
D007962,40.0,NCT00005908-1,Docetaxel/Capecitabine - A & B,NCT00005908,Primary Chemotherapy With Docetaxel-Capecitabine and Doxorubicin-Cyclophosphamide in Breast Cancer,leukocytes
D006098,86.67,NCT00005908-1,Docetaxel/Capecitabine - A & B,NCT00005908,Primary Chemotherapy With Docetaxel-Capecitabine and Doxorubicin-Cyclophosphamide in Breast Cancer,granulocytes
D000068258,3.33,NCT00005908-1,Docetaxel/Capecitabine - A & B,NCT00005908,Primary Chemotherapy With Docetaxel-Capecitabine and Doxorubicin-Cyclophosphamide in Breast Cancer,avastin
D000068736,3.33,NCT00005908-1,Docetaxel/Capecitabine - A & B,NCT00005908,Primary Chemotherapy With Docetaxel-Capecitabine and Doxorubicin-Cyclophosphamide in Breast Cancer,cymbalta
D006943,16.67,NCT00005908-1,Docetaxel/Capecitabine - A & B,NCT00005908,Primary Chemotherapy With Docetaxel-Capecitabine and Doxorubicin-Cyclophosphamide in Breast Cancer,hyperglycemia
D007008,3.33,NCT00005908-1,Docetaxel/Capecitabine - A & B,NCT00005908,Primary Chemotherapy With Docetaxel-Capecitabine and Doxorubicin-Cyclophosphamide in Breast Cancer,hypokalemia
D007010,3.33,NCT00005908-1,Docetaxel/Capecitabine - A & B,NCT00005908,Primary Chemotherapy With Docetaxel-Capecitabine and Doxorubicin-Cyclophosphamide in Breast Cancer,hyponatremia
D017674,3.33,NCT00005908-1,Docetaxel/Capecitabine - A & B,NCT00005908,Primary Chemotherapy With Docetaxel-Capecitabine and Doxorubicin-Cyclophosphamide in Breast Cancer,hypophosphatemia
D000068239,6.67,NCT00005908-1,Docetaxel/Capecitabine - A & B,NCT00005908,Primary Chemotherapy With Docetaxel-Capecitabine and Doxorubicin-Cyclophosphamide in Breast Cancer,peaches
D018771,3.33,NCT00005908-1,Docetaxel/Capecitabine - A & B,NCT00005908,Primary Chemotherapy With Docetaxel-Capecitabine and Doxorubicin-Cyclophosphamide in Breast Cancer,joint pain
10006002,3.33,NCT00005908-1,Docetaxel/Capecitabine - A & B,NCT00005908,Primary Chemotherapy With Docetaxel-Capecitabine and Doxorubicin-Cyclophosphamide in Breast Cancer,bone pain
D002607,3.33,NCT00005908-1,Docetaxel/Capecitabine - A & B,NCT00005908,Primary Chemotherapy With Docetaxel-Capecitabine and Doxorubicin-Cyclophosphamide in Breast Cancer,hereditary type i motor and sensory neuropathy
D006261,3.33,NCT00005908-1,Docetaxel/Capecitabine - A & B,NCT00005908,Primary Chemotherapy With Docetaxel-Capecitabine and Doxorubicin-Cyclophosphamide in Breast Cancer,headache
D013575,3.33,NCT00005908-1,Docetaxel/Capecitabine - A & B,NCT00005908,Primary Chemotherapy With Docetaxel-Capecitabine and Doxorubicin-Cyclophosphamide in Breast Cancer,syncope
D000339,3.33,NCT00005908-1,Docetaxel/Capecitabine - A & B,NCT00005908,Primary Chemotherapy With Docetaxel-Capecitabine and Doxorubicin-Cyclophosphamide in Breast Cancer,mood
10046539,3.33,NCT00005908-1,Docetaxel/Capecitabine - A & B,NCT00005908,Primary Chemotherapy With Docetaxel-Capecitabine and Doxorubicin-Cyclophosphamide in Breast Cancer,urinary frequency
D016066,3.33,NCT00005908-1,Docetaxel/Capecitabine - A & B,NCT00005908,Primary Chemotherapy With Docetaxel-Capecitabine and Doxorubicin-Cyclophosphamide in Breast Cancer,pleural effusion malignant
D060831,43.33,NCT00005908-1,Docetaxel/Capecitabine - A & B,NCT00005908,Primary Chemotherapy With Docetaxel-Capecitabine and Doxorubicin-Cyclophosphamide in Breast Cancer,hand-foot syndrome
D001109,3.33,NCT00005908-1,Docetaxel/Capecitabine - A & B,NCT00005908,Primary Chemotherapy With Docetaxel-Capecitabine and Doxorubicin-Cyclophosphamide in Breast Cancer,archives
D000855,3.33,NCT00005908-1,Docetaxel/Capecitabine - A & B,NCT00005908,Primary Chemotherapy With Docetaxel-Capecitabine and Doxorubicin-Cyclophosphamide in Breast Cancer,anorexia
D002542,6.67,NCT00005908-1,Docetaxel/Capecitabine - A & B,NCT00005908,Primary Chemotherapy With Docetaxel-Capecitabine and Doxorubicin-Cyclophosphamide in Breast Cancer,intracranial embolism and thrombosis
D064420,100.0,NCT00006184-1,Recipient - Chemotherapy Group,NCT00006184,Chemotherapy  Stem Cell Transplantation and Donor and Patient Vaccination for Treatment of Multiple Myeloma,adverse drug events
D064147,10.0,NCT00006184-1,Recipient - Chemotherapy Group,NCT00006184,Chemotherapy  Stem Cell Transplantation and Donor and Patient Vaccination for Treatment of Multiple Myeloma,febrile neutropenia
D015746,10.0,NCT00006184-1,Recipient - Chemotherapy Group,NCT00006184,Chemotherapy  Stem Cell Transplantation and Donor and Patient Vaccination for Treatment of Multiple Myeloma,abdominal pain
D000930,10.0,NCT00006184-1,Recipient - Chemotherapy Group,NCT00006184,Chemotherapy  Stem Cell Transplantation and Donor and Patient Vaccination for Treatment of Multiple Myeloma,antidiarrheals
D020250,10.0,NCT00006184-1,Recipient - Chemotherapy Group,NCT00006184,Chemotherapy  Stem Cell Transplantation and Donor and Patient Vaccination for Treatment of Multiple Myeloma,postoperative nausea and vomiting
D000069544,20.0,NCT00006184-1,Recipient - Chemotherapy Group,NCT00006184,Chemotherapy  Stem Cell Transplantation and Donor and Patient Vaccination for Treatment of Multiple Myeloma,encephalitis infection
D007962,60.0,NCT00006184-1,Recipient - Chemotherapy Group,NCT00006184,Chemotherapy  Stem Cell Transplantation and Donor and Patient Vaccination for Treatment of Multiple Myeloma,leukocytes
D007962,40.0,NCT00006184-1,Recipient - Chemotherapy Group,NCT00006184,Chemotherapy  Stem Cell Transplantation and Donor and Patient Vaccination for Treatment of Multiple Myeloma,leukocytes
D006098,70.0,NCT00006184-1,Recipient - Chemotherapy Group,NCT00006184,Chemotherapy  Stem Cell Transplantation and Donor and Patient Vaccination for Treatment of Multiple Myeloma,granulocytes
D006098,80.0,NCT00006184-1,Recipient - Chemotherapy Group,NCT00006184,Chemotherapy  Stem Cell Transplantation and Donor and Patient Vaccination for Treatment of Multiple Myeloma,granulocytes
D001792,20.0,NCT00006184-1,Recipient - Chemotherapy Group,NCT00006184,Chemotherapy  Stem Cell Transplantation and Donor and Patient Vaccination for Treatment of Multiple Myeloma,platelets
D001792,20.0,NCT00006184-1,Recipient - Chemotherapy Group,NCT00006184,Chemotherapy  Stem Cell Transplantation and Donor and Patient Vaccination for Treatment of Multiple Myeloma,platelets
D000068258,10.0,NCT00006184-1,Recipient - Chemotherapy Group,NCT00006184,Chemotherapy  Stem Cell Transplantation and Donor and Patient Vaccination for Treatment of Multiple Myeloma,avastin
D000068736,20.0,NCT00006184-1,Recipient - Chemotherapy Group,NCT00006184,Chemotherapy  Stem Cell Transplantation and Donor and Patient Vaccination for Treatment of Multiple Myeloma,cymbalta
D001792,10.0,NCT00006184-1,Recipient - Chemotherapy Group,NCT00006184,Chemotherapy  Stem Cell Transplantation and Donor and Patient Vaccination for Treatment of Multiple Myeloma,platelets
D000855,30.0,NCT00006184-1,Recipient - Chemotherapy Group,NCT00006184,Chemotherapy  Stem Cell Transplantation and Donor and Patient Vaccination for Treatment of Multiple Myeloma,anorexia
D006943,10.0,NCT00006184-1,Recipient - Chemotherapy Group,NCT00006184,Chemotherapy  Stem Cell Transplantation and Donor and Patient Vaccination for Treatment of Multiple Myeloma,hyperglycemia
D005723,10.0,NCT00006184-1,Recipient - Chemotherapy Group,NCT00006184,Chemotherapy  Stem Cell Transplantation and Donor and Patient Vaccination for Treatment of Multiple Myeloma,ggtp
D000326,10.0,NCT00006184-1,Recipient - Chemotherapy Group,NCT00006184,Chemotherapy  Stem Cell Transplantation and Donor and Patient Vaccination for Treatment of Multiple Myeloma,adrenomyeloneuropathy
D000339,10.0,NCT00006184-1,Recipient - Chemotherapy Group,NCT00006184,Chemotherapy  Stem Cell Transplantation and Donor and Patient Vaccination for Treatment of Multiple Myeloma,mood
D000860,20.0,NCT00006184-1,Recipient - Chemotherapy Group,NCT00006184,Chemotherapy  Stem Cell Transplantation and Donor and Patient Vaccination for Treatment of Multiple Myeloma,hypoxia
D064420,1.14,NCT00006721-2,CHOP + Rituximab,NCT00006721,S0016 Combination Chemotherapy With Monoclonal Antibody Therapy in Newly Diagnosed Non-Hodgkin's Lymphoma,adverse drug events
D064420,6.08,NCT00006721-3,CHOP + Tositumomab,NCT00006721,S0016 Combination Chemotherapy With Monoclonal Antibody Therapy in Newly Diagnosed Non-Hodgkin's Lymphoma,adverse drug events
D064147,0.76,NCT00006721-3,CHOP + Tositumomab,NCT00006721,S0016 Combination Chemotherapy With Monoclonal Antibody Therapy in Newly Diagnosed Non-Hodgkin's Lymphoma,febrile neutropenia
D006401,1.14,NCT00006721-3,CHOP + Tositumomab,NCT00006721,S0016 Combination Chemotherapy With Monoclonal Antibody Therapy in Newly Diagnosed Non-Hodgkin's Lymphoma,hematologic agents
D017713,0.38,NCT00006721-3,CHOP + Tositumomab,NCT00006721,S0016 Combination Chemotherapy With Monoclonal Antibody Therapy in Newly Diagnosed Non-Hodgkin's Lymphoma,platelet transfusion
D007989,0.38,NCT00006721-3,CHOP + Tositumomab,NCT00006721,S0016 Combination Chemotherapy With Monoclonal Antibody Therapy in Newly Diagnosed Non-Hodgkin's Lymphoma,decreased libido
D010195,0.38,NCT00006721-2,CHOP + Rituximab,NCT00006721,S0016 Combination Chemotherapy With Monoclonal Antibody Therapy in Newly Diagnosed Non-Hodgkin's Lymphoma,pancreatitis
D000069544,0.76,NCT00006721-3,CHOP + Tositumomab,NCT00006721,S0016 Combination Chemotherapy With Monoclonal Antibody Therapy in Newly Diagnosed Non-Hodgkin's Lymphoma,encephalitis infection
D012141,0.38,NCT00006721-3,CHOP + Tositumomab,NCT00006721,S0016 Combination Chemotherapy With Monoclonal Antibody Therapy in Newly Diagnosed Non-Hodgkin's Lymphoma,infections respiratory
D000380,0.38,NCT00006721-3,CHOP + Tositumomab,NCT00006721,S0016 Combination Chemotherapy With Monoclonal Antibody Therapy in Newly Diagnosed Non-Hodgkin's Lymphoma,granulocytopenia
D016609,2.28,NCT00006721-3,CHOP + Tositumomab,NCT00006721,S0016 Combination Chemotherapy With Monoclonal Antibody Therapy in Newly Diagnosed Non-Hodgkin's Lymphoma,neoplasms second primary
10023030,0.38,NCT00006721-2,CHOP + Rituximab,NCT00006721,S0016 Combination Chemotherapy With Monoclonal Antibody Therapy in Newly Diagnosed Non-Hodgkin's Lymphoma,ischemia cerebrovascular
D000069098,0.38,NCT00006721-3,CHOP + Tositumomab,NCT00006721,S0016 Combination Chemotherapy With Monoclonal Antibody Therapy in Newly Diagnosed Non-Hodgkin's Lymphoma,health smart cards
D002542,0.38,NCT00006721-2,CHOP + Rituximab,NCT00006721,S0016 Combination Chemotherapy With Monoclonal Antibody Therapy in Newly Diagnosed Non-Hodgkin's Lymphoma,intracranial embolism and thrombosis
D064420,11.07,NCT00011986-1,Carbo/Taxol,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,adverse drug events
D064420,13.82,NCT00011986-2,Carbo/Taxol/Gemcitabine,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,adverse drug events
D064420,14.99,NCT00011986-3,Carbo/Taxol/Doxil,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,adverse drug events
D064420,10.05,NCT00011986-4,Carbo/Topotecan - Carbo/Taxol,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,adverse drug events
D064420,13.04,NCT00011986-5,Carbo/Gemcitabine - Carbo/Taxol,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,adverse drug events
D006454,0.26,NCT00011986-1,Carbo/Taxol,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,hemoglobin
D006454,0.26,NCT00011986-2,Carbo/Taxol/Gemcitabine,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,hemoglobin
D006454,0.13,NCT00011986-3,Carbo/Taxol/Doxil,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,hemoglobin
D006454,0.39,NCT00011986-5,Carbo/Gemcitabine - Carbo/Taxol,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,hemoglobin
D001792,0.13,NCT00011986-1,Carbo/Taxol,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,platelets
D001792,1.55,NCT00011986-2,Carbo/Taxol/Gemcitabine,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,platelets
D001792,0.26,NCT00011986-3,Carbo/Taxol/Doxil,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,platelets
D001792,1.04,NCT00011986-5,Carbo/Gemcitabine - Carbo/Taxol,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,platelets
D006098,0.13,NCT00011986-1,Carbo/Taxol,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,granulocytes
D006098,0.39,NCT00011986-2,Carbo/Taxol/Gemcitabine,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,granulocytes
D006098,0.39,NCT00011986-3,Carbo/Taxol/Doxil,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,granulocytes
D006098,0.39,NCT00011986-4,Carbo/Topotecan - Carbo/Taxol,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,granulocytes
D006098,0.13,NCT00011986-5,Carbo/Gemcitabine - Carbo/Taxol,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,granulocytes
D007962,0.13,NCT00011986-4,Carbo/Topotecan - Carbo/Taxol,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,leukocytes
D006973,0.13,NCT00011986-1,Carbo/Taxol,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,hypertension
D006973,0.13,NCT00011986-4,Carbo/Topotecan - Carbo/Taxol,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,hypertension
D006973,0.13,NCT00011986-5,Carbo/Gemcitabine - Carbo/Taxol,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,hypertension
D009618,0.13,NCT00011986-3,Carbo/Taxol/Doxil,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,nocardiaceae
D009618,0.13,NCT00011986-5,Carbo/Gemcitabine - Carbo/Taxol,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,nocardiaceae
D016277,0.13,NCT00011986-2,Carbo/Taxol/Gemcitabine,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,ventricular function left
D016277,0.13,NCT00011986-3,Carbo/Taxol/Doxil,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,ventricular function left
D016277,0.13,NCT00011986-5,Carbo/Gemcitabine - Carbo/Taxol,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,ventricular function left
10007612,0.13,NCT00011986-3,Carbo/Taxol/Doxil,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,cardiac troponin i increased
D007022,0.13,NCT00011986-1,Carbo/Taxol,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,hypotension
D013616,0.13,NCT00011986-2,Carbo/Taxol/Gemcitabine,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,sinus tachycardia
D013616,0.26,NCT00011986-3,Carbo/Taxol/Doxil,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,sinus tachycardia
D010689,0.13,NCT00011986-2,Carbo/Taxol/Gemcitabine,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,phlebitis
D010689,0.13,NCT00011986-5,Carbo/Gemcitabine - Carbo/Taxol,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,phlebitis
D013575,0.13,NCT00011986-2,Carbo/Taxol/Gemcitabine,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,syncopal episode
D001919,0.13,NCT00011986-1,Carbo/Taxol,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,bradyarrhythmias
D001919,0.13,NCT00011986-2,Carbo/Taxol/Gemcitabine,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,bradyarrhythmias
D001919,0.13,NCT00011986-3,Carbo/Taxol/Doxil,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,bradyarrhythmias
D001919,0.13,NCT00011986-5,Carbo/Gemcitabine - Carbo/Taxol,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,bradyarrhythmias
D002542,1.29,NCT00011986-1,Carbo/Taxol,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,intracranial embolism and thrombosis
D002542,1.16,NCT00011986-2,Carbo/Taxol/Gemcitabine,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,intracranial embolism and thrombosis
D002542,1.69,NCT00011986-3,Carbo/Taxol/Doxil,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,intracranial embolism and thrombosis
D002542,1.7,NCT00011986-4,Carbo/Topotecan - Carbo/Taxol,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,intracranial embolism and thrombosis
D002542,2.09,NCT00011986-5,Carbo/Gemcitabine - Carbo/Taxol,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,intracranial embolism and thrombosis
D001145,0.13,NCT00011986-3,Carbo/Taxol/Doxil,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,arrhythmia
D001145,0.13,NCT00011986-3,Carbo/Taxol/Doxil,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,arrhythmia
D001145,0.26,NCT00011986-5,Carbo/Gemcitabine - Carbo/Taxol,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,arrhythmia
D006342,0.13,NCT00011986-1,Carbo/Taxol,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,cardiac rupture post-infarction
D006342,0.13,NCT00011986-2,Carbo/Taxol/Gemcitabine,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,cardiac rupture post-infarction
D006342,0.26,NCT00011986-3,Carbo/Taxol/Doxil,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,cardiac rupture post-infarction
D006342,0.13,NCT00011986-4,Carbo/Topotecan - Carbo/Taxol,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,cardiac rupture post-infarction
10040741,0.13,NCT00011986-2,Carbo/Taxol/Gemcitabine,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,sinus bradycardia
D004487,0.13,NCT00011986-2,Carbo/Taxol/Gemcitabine,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,edema
D004487,0.13,NCT00011986-4,Carbo/Topotecan - Carbo/Taxol,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,edema
D004487,0.13,NCT00011986-5,Carbo/Gemcitabine - Carbo/Taxol,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,edema
D006309,0.13,NCT00011986-5,Carbo/Gemcitabine - Carbo/Taxol,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,hearing
D006309,0.13,NCT00011986-2,Carbo/Taxol/Gemcitabine,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,hearing
D005901,0.13,NCT00011986-2,Carbo/Taxol/Gemcitabine,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,glaucoma
D009304,0.13,NCT00011986-3,Carbo/Taxol/Doxil,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,nasopharyngitis
D009304,0.13,NCT00011986-5,Carbo/Gemcitabine - Carbo/Taxol,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,nasopharyngitis
D010195,0.13,NCT00011986-4,Carbo/Topotecan - Carbo/Taxol,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,pancreatitis
D000971,0.13,NCT00011986-1,Carbo/Taxol,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,antineoplastic combined chemotherapy regimens
D000971,0.13,NCT00011986-2,Carbo/Taxol/Gemcitabine,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,antineoplastic combined chemotherapy regimens
D000971,0.13,NCT00011986-4,Carbo/Topotecan - Carbo/Taxol,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,antineoplastic combined chemotherapy regimens
D045823,0.64,NCT00011986-1,Carbo/Taxol,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,ileus
D045823,0.52,NCT00011986-2,Carbo/Taxol/Gemcitabine,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,ileus
D045823,0.26,NCT00011986-3,Carbo/Taxol/Doxil,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,ileus
D045823,0.52,NCT00011986-4,Carbo/Topotecan - Carbo/Taxol,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,ileus
D045823,0.65,NCT00011986-5,Carbo/Gemcitabine - Carbo/Taxol,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,ileus
D005756,0.26,NCT00011986-4,Carbo/Topotecan - Carbo/Taxol,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,gastritis
D000855,0.13,NCT00011986-5,Carbo/Gemcitabine - Carbo/Taxol,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,anorexia
D004415,0.13,NCT00011986-3,Carbo/Taxol/Doxil,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,dyspepsia
D004415,0.13,NCT00011986-4,Carbo/Topotecan - Carbo/Taxol,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,dyspepsia
D013276,0.13,NCT00011986-1,Carbo/Taxol,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,gastric ulcer
D013276,0.13,NCT00011986-3,Carbo/Taxol/Doxil,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,gastric ulcer
D003092,0.13,NCT00011986-2,Carbo/Taxol/Gemcitabine,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,colitis
D003092,0.13,NCT00011986-3,Carbo/Taxol/Doxil,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,colitis
D000068757,0.13,NCT00011986-2,Carbo/Taxol/Gemcitabine,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,ononis
D000068757,0.13,NCT00011986-3,Carbo/Taxol/Doxil,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,ononis
D000068757,0.13,NCT00011986-4,Carbo/Topotecan - Carbo/Taxol,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,ononis
D000068757,0.13,NCT00011986-5,Carbo/Gemcitabine - Carbo/Taxol,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,ononis
D012003,0.13,NCT00011986-4,Carbo/Topotecan - Carbo/Taxol,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,rectal fistula
D003681,0.26,NCT00011986-1,Carbo/Taxol,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,dehydration
D003681,0.39,NCT00011986-2,Carbo/Taxol/Gemcitabine,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,dehydration
D003681,0.26,NCT00011986-3,Carbo/Taxol/Doxil,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,dehydration
D003681,0.26,NCT00011986-4,Carbo/Topotecan - Carbo/Taxol,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,dehydration
D003681,0.13,NCT00011986-5,Carbo/Gemcitabine - Carbo/Taxol,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,dehydration
D003248,0.77,NCT00011986-1,Carbo/Taxol,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,constipation
D003248,0.9,NCT00011986-2,Carbo/Taxol/Gemcitabine,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,constipation
D003248,0.39,NCT00011986-3,Carbo/Taxol/Doxil,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,constipation
D003248,0.65,NCT00011986-4,Carbo/Topotecan - Carbo/Taxol,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,constipation
D003248,0.39,NCT00011986-5,Carbo/Gemcitabine - Carbo/Taxol,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,constipation
D000930,0.13,NCT00011986-1,Carbo/Taxol,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,antidiarrheals
D000930,0.52,NCT00011986-2,Carbo/Taxol/Gemcitabine,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,antidiarrheals
D000930,0.39,NCT00011986-3,Carbo/Taxol/Doxil,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,antidiarrheals
D000930,0.13,NCT00011986-4,Carbo/Topotecan - Carbo/Taxol,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,antidiarrheals
D000930,0.26,NCT00011986-5,Carbo/Gemcitabine - Carbo/Taxol,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,antidiarrheals
D014839,0.9,NCT00011986-1,Carbo/Taxol,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,vomiting
D014839,1.03,NCT00011986-2,Carbo/Taxol/Gemcitabine,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,vomiting
D014839,1.43,NCT00011986-3,Carbo/Taxol/Doxil,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,vomiting
D014839,0.91,NCT00011986-4,Carbo/Topotecan - Carbo/Taxol,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,vomiting
D014839,0.13,NCT00011986-5,Carbo/Gemcitabine - Carbo/Taxol,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,vomiting
D009325,0.26,NCT00011986-3,Carbo/Taxol/Doxil,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,nausea
D009325,0.13,NCT00011986-4,Carbo/Topotecan - Carbo/Taxol,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,nausea
D009325,0.13,NCT00011986-5,Carbo/Gemcitabine - Carbo/Taxol,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,nausea
D000071896,0.13,NCT00011986-1,Carbo/Taxol,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,somatic symptoms
D005334,0.13,NCT00011986-4,Carbo/Topotecan - Carbo/Taxol,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,fever
D005221,0.39,NCT00011986-2,Carbo/Taxol/Gemcitabine,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,fatigue
D005221,0.13,NCT00011986-3,Carbo/Taxol/Doxil,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,fatigue
D005221,0.13,NCT00011986-4,Carbo/Topotecan - Carbo/Taxol,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,fatigue
10062501,0.13,NCT00011986-3,Carbo/Taxol/Doxil,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,non-cardiac chest pain
10062501,0.13,NCT00011986-4,Carbo/Topotecan - Carbo/Taxol,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,non-cardiac chest pain
D006261,0.13,NCT00011986-3,Carbo/Taxol/Doxil,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,headache
D015746,0.51,NCT00011986-1,Carbo/Taxol,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,abdominal pain
D015746,0.39,NCT00011986-2,Carbo/Taxol/Gemcitabine,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,abdominal pain
D015746,0.52,NCT00011986-3,Carbo/Taxol/Doxil,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,abdominal pain
D015746,0.13,NCT00011986-4,Carbo/Topotecan - Carbo/Taxol,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,abdominal pain
D015746,0.13,NCT00011986-5,Carbo/Gemcitabine - Carbo/Taxol,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,abdominal pain
10006002,0.13,NCT00011986-1,Carbo/Taxol,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,bone pain
D018771,0.13,NCT00011986-3,Carbo/Taxol/Doxil,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,arthralgia
D063806,0.13,NCT00011986-1,Carbo/Taxol,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,myalgia
D000080867,0.13,NCT00011986-2,Carbo/Taxol/Gemcitabine,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,gingipains
D000080867,0.13,NCT00011986-3,Carbo/Taxol/Doxil,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,gingipains
D000080867,0.13,NCT00011986-5,Carbo/Gemcitabine - Carbo/Taxol,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,gingipains
D029626,0.13,NCT00011986-4,Carbo/Topotecan - Carbo/Taxol,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,hepatica
D029626,0.13,NCT00011986-5,Carbo/Gemcitabine - Carbo/Taxol,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,hepatica
D000410,0.13,NCT00011986-5,Carbo/Gemcitabine - Carbo/Taxol,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,sgpt
D001219,0.26,NCT00011986-2,Carbo/Taxol/Gemcitabine,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,sgot
D001219,0.13,NCT00011986-4,Carbo/Topotecan - Carbo/Taxol,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,sgot
D001219,0.13,NCT00011986-5,Carbo/Gemcitabine - Carbo/Taxol,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,sgot
D001663,0.13,NCT00011986-3,Carbo/Taxol/Doxil,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,bilirubin
D006967,0.51,NCT00011986-1,Carbo/Taxol,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,allergy
D006967,0.26,NCT00011986-3,Carbo/Taxol/Doxil,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,allergy
D006967,0.13,NCT00011986-4,Carbo/Topotecan - Carbo/Taxol,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,allergy
D006967,1.16,NCT00011986-1,Carbo/Taxol,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,allergic reaction
D006967,0.78,NCT00011986-2,Carbo/Taxol/Gemcitabine,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,allergic reaction
D006967,0.78,NCT00011986-3,Carbo/Taxol/Doxil,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,allergic reaction
D006967,0.39,NCT00011986-4,Carbo/Topotecan - Carbo/Taxol,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,allergic reaction
D006967,0.78,NCT00011986-5,Carbo/Gemcitabine - Carbo/Taxol,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,allergic reaction
10021881,0.13,NCT00011986-1,Carbo/Taxol,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,infections and infestations - other specify
10021881,0.13,NCT00011986-2,Carbo/Taxol/Gemcitabine,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,infections and infestations - other specify
10021881,0.26,NCT00011986-5,Carbo/Gemcitabine - Carbo/Taxol,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,infections and infestations - other specify
10007810,0.13,NCT00011986-2,Carbo/Taxol/Gemcitabine,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,catheter related infection
10007810,0.13,NCT00011986-3,Carbo/Taxol/Doxil,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,catheter related infection
D000069544,0.13,NCT00011986-2,Carbo/Taxol/Gemcitabine,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,encephalitis infection
D000069544,0.13,NCT00011986-3,Carbo/Taxol/Doxil,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,encephalitis infection
D000069544,0.13,NCT00011986-4,Carbo/Topotecan - Carbo/Taxol,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,encephalitis infection
D000069544,0.26,NCT00011986-5,Carbo/Gemcitabine - Carbo/Taxol,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,encephalitis infection
D000069544,0.64,NCT00011986-1,Carbo/Taxol,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,encephalitis infection
D000069544,1.16,NCT00011986-2,Carbo/Taxol/Gemcitabine,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,encephalitis infection
D000069544,1.96,NCT00011986-3,Carbo/Taxol/Doxil,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,encephalitis infection
D000069544,0.91,NCT00011986-4,Carbo/Topotecan - Carbo/Taxol,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,encephalitis infection
D000069544,0.52,NCT00011986-5,Carbo/Gemcitabine - Carbo/Taxol,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,encephalitis infection
D000069544,0.9,NCT00011986-1,Carbo/Taxol,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,encephalitis infection
D000069544,1.03,NCT00011986-2,Carbo/Taxol/Gemcitabine,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,encephalitis infection
D000069544,0.65,NCT00011986-3,Carbo/Taxol/Doxil,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,encephalitis infection
D000069544,0.78,NCT00011986-4,Carbo/Topotecan - Carbo/Taxol,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,encephalitis infection
D000069544,0.78,NCT00011986-5,Carbo/Gemcitabine - Carbo/Taxol,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,encephalitis infection
D064147,1.03,NCT00011986-1,Carbo/Taxol,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,febrile neutropenia
D064147,1.55,NCT00011986-2,Carbo/Taxol/Gemcitabine,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,febrile neutropenia
D064147,1.96,NCT00011986-3,Carbo/Taxol/Doxil,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,febrile neutropenia
D064147,1.31,NCT00011986-4,Carbo/Topotecan - Carbo/Taxol,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,febrile neutropenia
D064147,0.91,NCT00011986-5,Carbo/Gemcitabine - Carbo/Taxol,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,febrile neutropenia
D000138,0.13,NCT00011986-2,Carbo/Taxol/Gemcitabine,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,metabolic acidosis
D000138,0.13,NCT00011986-4,Carbo/Topotecan - Carbo/Taxol,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,metabolic acidosis
D007010,0.13,NCT00011986-2,Carbo/Taxol/Gemcitabine,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,hyponatremia
D007010,0.13,NCT00011986-4,Carbo/Topotecan - Carbo/Taxol,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,hyponatremia
D007010,0.13,NCT00011986-5,Carbo/Gemcitabine - Carbo/Taxol,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,hyponatremia
D006947,0.13,NCT00011986-5,Carbo/Gemcitabine - Carbo/Taxol,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,hyperkalemia
D006943,0.13,NCT00011986-4,Carbo/Topotecan - Carbo/Taxol,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,hyperglycemia
D007008,0.26,NCT00011986-5,Carbo/Gemcitabine - Carbo/Taxol,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,hypokalemia
UNKNOWN-check-for-typo,0.13,NCT00011986-2,Carbo/Taxol/Gemcitabine,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,D00
D000077553,0.13,NCT00011986-3,Carbo/Taxol/Doxil,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,edarabone
D014202,0.26,NCT00011986-2,Carbo/Taxol/Gemcitabine,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,tremor
D001037,0.13,NCT00011986-3,Carbo/Taxol/Doxil,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,aphasia
D003294,0.13,NCT00011986-1,Carbo/Taxol,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,seizures febrile
D003294,0.26,NCT00011986-5,Carbo/Gemcitabine - Carbo/Taxol,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,seizures febrile
D006212,0.13,NCT00011986-5,Carbo/Gemcitabine - Carbo/Taxol,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,hallucinations
10023030,0.52,NCT00011986-3,Carbo/Taxol/Doxil,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,ischemia cerebrovascular
10023030,0.26,NCT00011986-5,Carbo/Gemcitabine - Carbo/Taxol,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,ischemia cerebrovascular
D003221,0.13,NCT00011986-3,Carbo/Taxol/Doxil,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,confusion
D003221,0.13,NCT00011986-4,Carbo/Topotecan - Carbo/Taxol,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,confusion
D003221,0.13,NCT00011986-5,Carbo/Gemcitabine - Carbo/Taxol,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,confusion
D013575,0.77,NCT00011986-1,Carbo/Taxol,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,syncope
D013575,0.26,NCT00011986-2,Carbo/Taxol/Gemcitabine,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,syncope
D013575,0.65,NCT00011986-3,Carbo/Taxol/Doxil,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,syncope
D013575,0.39,NCT00011986-5,Carbo/Gemcitabine - Carbo/Taxol,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,syncope
D000339,0.13,NCT00011986-2,Carbo/Taxol/Gemcitabine,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,mood
D000339,0.13,NCT00011986-4,Carbo/Topotecan - Carbo/Taxol,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,mood
D004244,0.13,NCT00011986-4,Carbo/Topotecan - Carbo/Taxol,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,dizziness
D004244,0.13,NCT00011986-5,Carbo/Gemcitabine - Carbo/Taxol,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,dizziness
D002607,0.13,NCT00011986-1,Carbo/Taxol,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,hereditary type i motor and sensory neuropathy
D002607,0.13,NCT00011986-3,Carbo/Taxol/Doxil,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,hereditary type i motor and sensory neuropathy
D002607,0.13,NCT00011986-1,Carbo/Taxol,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,hereditary type i motor and sensory neuropathy
D002607,0.13,NCT00011986-2,Carbo/Taxol/Gemcitabine,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,hereditary type i motor and sensory neuropathy
D002607,0.13,NCT00011986-3,Carbo/Taxol/Doxil,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,hereditary type i motor and sensory neuropathy
D002607,0.13,NCT00011986-5,Carbo/Gemcitabine - Carbo/Taxol,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,hereditary type i motor and sensory neuropathy
10065826,0.13,NCT00011986-5,Carbo/Gemcitabine - Carbo/Taxol,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,intraoperative arterial injury
D005402,0.26,NCT00011986-3,Carbo/Taxol/Doxil,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,fistula
D051437,0.26,NCT00011986-3,Carbo/Taxol/Doxil,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,renal failure
D051437,0.13,NCT00011986-4,Carbo/Topotecan - Carbo/Taxol,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,renal failure
D051437,0.13,NCT00011986-5,Carbo/Gemcitabine - Carbo/Taxol,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,renal failure
D003404,0.13,NCT00011986-1,Carbo/Taxol,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,creatinine
D003404,0.13,NCT00011986-5,Carbo/Gemcitabine - Carbo/Taxol,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,creatinine
D000071477,0.13,NCT00011986-5,Carbo/Gemcitabine - Carbo/Taxol,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,gubernaculum
D016066,0.13,NCT00011986-1,Carbo/Taxol,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,pleural effusion malignant
D016066,0.26,NCT00011986-2,Carbo/Taxol/Gemcitabine,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,pleural effusion malignant
D016066,0.26,NCT00011986-3,Carbo/Taxol/Doxil,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,pleural effusion malignant
D016066,0.13,NCT00011986-4,Carbo/Topotecan - Carbo/Taxol,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,pleural effusion malignant
D016066,0.39,NCT00011986-5,Carbo/Gemcitabine - Carbo/Taxol,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,pleural effusion malignant
D004417,0.13,NCT00011986-1,Carbo/Taxol,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,dyspnea
D004417,0.39,NCT00011986-2,Carbo/Taxol/Gemcitabine,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,dyspnea
D004417,0.52,NCT00011986-3,Carbo/Taxol/Doxil,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,dyspnea
D004417,0.39,NCT00011986-4,Carbo/Topotecan - Carbo/Taxol,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,dyspnea
D011030,0.13,NCT00011986-5,Carbo/Gemcitabine - Carbo/Taxol,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,pneumothorax
D000860,0.26,NCT00011986-2,Carbo/Taxol/Gemcitabine,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,hypoxia
D012128,0.13,NCT00011986-2,Carbo/Taxol/Gemcitabine,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,adult respiratory distress syndrome
D012128,0.13,NCT00011986-3,Carbo/Taxol/Doxil,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,adult respiratory distress syndrome
D012128,0.13,NCT00011986-5,Carbo/Gemcitabine - Carbo/Taxol,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,adult respiratory distress syndrome
D011537,0.13,NCT00011986-1,Carbo/Taxol,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,pruritus
D014581,0.13,NCT00011986-3,Carbo/Taxol/Doxil,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,urticaria
D014581,0.13,NCT00011986-4,Carbo/Topotecan - Carbo/Taxol,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,urticaria
D014581,0.13,NCT00011986-5,Carbo/Gemcitabine - Carbo/Taxol,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,urticaria
D014947,0.13,NCT00011986-1,Carbo/Taxol,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,wounds
D014947,0.13,NCT00011986-2,Carbo/Taxol/Gemcitabine,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,wounds
D014947,0.13,NCT00011986-4,Carbo/Topotecan - Carbo/Taxol,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,wounds
D014947,0.26,NCT00011986-5,Carbo/Gemcitabine - Carbo/Taxol,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,wounds
D005076,0.13,NCT00011986-2,Carbo/Taxol/Gemcitabine,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,rash
D005076,0.26,NCT00011986-5,Carbo/Gemcitabine - Carbo/Taxol,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,rash
10040785,0.13,NCT00011986-5,Carbo/Gemcitabine - Carbo/Taxol,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,skin and subcutaneous tissue disorders - other specify
D000073296,0.13,NCT00011986-3,Carbo/Taxol/Doxil,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,noninfectious diseases
D004892,0.13,NCT00011986-2,Carbo/Taxol/Gemcitabine,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,erythema multiforme
D006470,0.13,NCT00011986-5,Carbo/Gemcitabine - Carbo/Taxol,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,hemorrhage
D006470,0.13,NCT00011986-2,Carbo/Taxol/Gemcitabine,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,bleeding
D006470,0.13,NCT00011986-5,Carbo/Gemcitabine - Carbo/Taxol,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,bleeding
D003452,0.13,NCT00011986-5,Carbo/Gemcitabine - Carbo/Taxol,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,cryosurgery
D004844,0.13,NCT00011986-4,Carbo/Topotecan - Carbo/Taxol,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,epistaxis
D004844,0.13,NCT00011986-5,Carbo/Gemcitabine - Carbo/Taxol,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,epistaxis
D008796,0.13,NCT00011986-3,Carbo/Taxol/Doxil,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,breakthrough bleeding
D014592,0.13,NCT00011986-1,Carbo/Taxol,NCT00011986,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer,vaginal bleeding
D064420,11.45,NCT00024102-1,Standard Chemotherapy (CMF),NCT00024102,Comparison of Combination Chemotherapy Regimens in Treating Older Women Who Have Undergone Surgery for Breast Cancer,adverse drug events
D064420,9.39,NCT00024102-2,Standard Chemotherapy (AC),NCT00024102,Comparison of Combination Chemotherapy Regimens in Treating Older Women Who Have Undergone Surgery for Breast Cancer,adverse drug events
D064420,8.7,NCT00024102-3,Capecitabine,NCT00024102,Comparison of Combination Chemotherapy Regimens in Treating Older Women Who Have Undergone Surgery for Breast Cancer,adverse drug events
D004211,0.76,NCT00024102-1,Standard Chemotherapy (CMF),NCT00024102,Comparison of Combination Chemotherapy Regimens in Treating Older Women Who Have Undergone Surgery for Breast Cancer,disseminated intravascular coagulation
D064147,3.82,NCT00024102-1,Standard Chemotherapy (CMF),NCT00024102,Comparison of Combination Chemotherapy Regimens in Treating Older Women Who Have Undergone Surgery for Breast Cancer,febrile neutropenia
D064147,0.55,NCT00024102-2,Standard Chemotherapy (AC),NCT00024102,Comparison of Combination Chemotherapy Regimens in Treating Older Women Who Have Undergone Surgery for Breast Cancer,febrile neutropenia
D064147,0.67,NCT00024102-3,Capecitabine,NCT00024102,Comparison of Combination Chemotherapy Regimens in Treating Older Women Who Have Undergone Surgery for Breast Cancer,febrile neutropenia
D002263,5.34,NCT00024102-1,Standard Chemotherapy (CMF),NCT00024102,Comparison of Combination Chemotherapy Regimens in Treating Older Women Who Have Undergone Surgery for Breast Cancer,carboxyhemoglobin
D002263,7.18,NCT00024102-2,Standard Chemotherapy (AC),NCT00024102,Comparison of Combination Chemotherapy Regimens in Treating Older Women Who Have Undergone Surgery for Breast Cancer,carboxyhemoglobin
D002263,2.68,NCT00024102-3,Capecitabine,NCT00024102,Comparison of Combination Chemotherapy Regimens in Treating Older Women Who Have Undergone Surgery for Breast Cancer,carboxyhemoglobin
UNKNOWN-check-for-typo,0.76,NCT00024102-1,Standard Chemotherapy (CMF),NCT00024102,Comparison of Combination Chemotherapy Regimens in Treating Older Women Who Have Undergone Surgery for Breast Cancer,D00
D001804,0.55,NCT00024102-2,Standard Chemotherapy (AC),NCT00024102,Comparison of Combination Chemotherapy Regimens in Treating Older Women Who Have Undergone Surgery for Breast Cancer,autotransfusion
D001145,0.55,NCT00024102-2,Standard Chemotherapy (AC),NCT00024102,Comparison of Combination Chemotherapy Regimens in Treating Older Women Who Have Undergone Surgery for Breast Cancer,arrhythmia
D006331,0.76,NCT00024102-1,Standard Chemotherapy (CMF),NCT00024102,Comparison of Combination Chemotherapy Regimens in Treating Older Women Who Have Undergone Surgery for Breast Cancer,cardiac disorder
D004487,0.33,NCT00024102-3,Capecitabine,NCT00024102,Comparison of Combination Chemotherapy Regimens in Treating Older Women Who Have Undergone Surgery for Breast Cancer,edema
D016277,0.55,NCT00024102-2,Standard Chemotherapy (AC),NCT00024102,Comparison of Combination Chemotherapy Regimens in Treating Older Women Who Have Undergone Surgery for Breast Cancer,ventricular function left
D016277,0.33,NCT00024102-3,Capecitabine,NCT00024102,Comparison of Combination Chemotherapy Regimens in Treating Older Women Who Have Undergone Surgery for Breast Cancer,ventricular function left
D017202,0.76,NCT00024102-1,Standard Chemotherapy (CMF),NCT00024102,Comparison of Combination Chemotherapy Regimens in Treating Older Women Who Have Undergone Surgery for Breast Cancer,myocardial ischemia
D015746,1.0,NCT00024102-3,Capecitabine,NCT00024102,Comparison of Combination Chemotherapy Regimens in Treating Older Women Who Have Undergone Surgery for Breast Cancer,abdominal pain
D003092,0.33,NCT00024102-3,Capecitabine,NCT00024102,Comparison of Combination Chemotherapy Regimens in Treating Older Women Who Have Undergone Surgery for Breast Cancer,colitis
D003967,3.82,NCT00024102-1,Standard Chemotherapy (CMF),NCT00024102,Comparison of Combination Chemotherapy Regimens in Treating Older Women Who Have Undergone Surgery for Breast Cancer,diarrhea
D003967,2.76,NCT00024102-2,Standard Chemotherapy (AC),NCT00024102,Comparison of Combination Chemotherapy Regimens in Treating Older Women Who Have Undergone Surgery for Breast Cancer,diarrhea
D003967,6.02,NCT00024102-3,Capecitabine,NCT00024102,Comparison of Combination Chemotherapy Regimens in Treating Older Women Who Have Undergone Surgery for Breast Cancer,diarrhea
D004941,0.55,NCT00024102-2,Standard Chemotherapy (AC),NCT00024102,Comparison of Combination Chemotherapy Regimens in Treating Older Women Who Have Undergone Surgery for Breast Cancer,esophagitis
D005756,0.55,NCT00024102-2,Standard Chemotherapy (AC),NCT00024102,Comparison of Combination Chemotherapy Regimens in Treating Older Women Who Have Undergone Surgery for Breast Cancer,gastritis
10028130,2.76,NCT00024102-2,Standard Chemotherapy (AC),NCT00024102,Comparison of Combination Chemotherapy Regimens in Treating Older Women Who Have Undergone Surgery for Breast Cancer,mucositis oral
10028130,0.67,NCT00024102-3,Capecitabine,NCT00024102,Comparison of Combination Chemotherapy Regimens in Treating Older Women Who Have Undergone Surgery for Breast Cancer,mucositis oral
D009325,3.82,NCT00024102-1,Standard Chemotherapy (CMF),NCT00024102,Comparison of Combination Chemotherapy Regimens in Treating Older Women Who Have Undergone Surgery for Breast Cancer,nausea
D009325,2.21,NCT00024102-2,Standard Chemotherapy (AC),NCT00024102,Comparison of Combination Chemotherapy Regimens in Treating Older Women Who Have Undergone Surgery for Breast Cancer,nausea
D009325,3.34,NCT00024102-3,Capecitabine,NCT00024102,Comparison of Combination Chemotherapy Regimens in Treating Older Women Who Have Undergone Surgery for Breast Cancer,nausea
D053706,0.67,NCT00024102-3,Capecitabine,NCT00024102,Comparison of Combination Chemotherapy Regimens in Treating Older Women Who Have Undergone Surgery for Breast Cancer,typhlitis
D014839,0.76,NCT00024102-1,Standard Chemotherapy (CMF),NCT00024102,Comparison of Combination Chemotherapy Regimens in Treating Older Women Who Have Undergone Surgery for Breast Cancer,vomiting
D014839,1.1,NCT00024102-2,Standard Chemotherapy (AC),NCT00024102,Comparison of Combination Chemotherapy Regimens in Treating Older Women Who Have Undergone Surgery for Breast Cancer,vomiting
D014839,2.01,NCT00024102-3,Capecitabine,NCT00024102,Comparison of Combination Chemotherapy Regimens in Treating Older Women Who Have Undergone Surgery for Breast Cancer,vomiting
D002637,0.76,NCT00024102-1,Standard Chemotherapy (CMF),NCT00024102,Comparison of Combination Chemotherapy Regimens in Treating Older Women Who Have Undergone Surgery for Breast Cancer,chest pain
D002637,0.33,NCT00024102-3,Capecitabine,NCT00024102,Comparison of Combination Chemotherapy Regimens in Treating Older Women Who Have Undergone Surgery for Breast Cancer,chest pain
D005221,6.11,NCT00024102-1,Standard Chemotherapy (CMF),NCT00024102,Comparison of Combination Chemotherapy Regimens in Treating Older Women Who Have Undergone Surgery for Breast Cancer,fatigue
D005221,4.97,NCT00024102-2,Standard Chemotherapy (AC),NCT00024102,Comparison of Combination Chemotherapy Regimens in Treating Older Women Who Have Undergone Surgery for Breast Cancer,fatigue
D005221,5.35,NCT00024102-3,Capecitabine,NCT00024102,Comparison of Combination Chemotherapy Regimens in Treating Older Women Who Have Undergone Surgery for Breast Cancer,fatigue
10061640,0.76,NCT00024102-1,Standard Chemotherapy (CMF),NCT00024102,Comparison of Combination Chemotherapy Regimens in Treating Older Women Who Have Undergone Surgery for Breast Cancer,anorectal infection
D007239,0.55,NCT00024102-2,Standard Chemotherapy (AC),NCT00024102,Comparison of Combination Chemotherapy Regimens in Treating Older Women Who Have Undergone Surgery for Breast Cancer,infection
D007239,0.33,NCT00024102-3,Capecitabine,NCT00024102,Comparison of Combination Chemotherapy Regimens in Treating Older Women Who Have Undergone Surgery for Breast Cancer,infection
D000069544,0.76,NCT00024102-1,Standard Chemotherapy (CMF),NCT00024102,Comparison of Combination Chemotherapy Regimens in Treating Older Women Who Have Undergone Surgery for Breast Cancer,encephalitis infection
D000069544,0.55,NCT00024102-2,Standard Chemotherapy (AC),NCT00024102,Comparison of Combination Chemotherapy Regimens in Treating Older Women Who Have Undergone Surgery for Breast Cancer,encephalitis infection
D000069544,0.76,NCT00024102-1,Standard Chemotherapy (CMF),NCT00024102,Comparison of Combination Chemotherapy Regimens in Treating Older Women Who Have Undergone Surgery for Breast Cancer,encephalitis infection
D000069544,1.67,NCT00024102-3,Capecitabine,NCT00024102,Comparison of Combination Chemotherapy Regimens in Treating Older Women Who Have Undergone Surgery for Breast Cancer,encephalitis infection
10058838,0.33,NCT00024102-3,Capecitabine,NCT00024102,Comparison of Combination Chemotherapy Regimens in Treating Older Women Who Have Undergone Surgery for Breast Cancer,enterocolitis infectious
10046300,0.33,NCT00024102-3,Capecitabine,NCT00024102,Comparison of Combination Chemotherapy Regimens in Treating Older Women Who Have Undergone Surgery for Breast Cancer,upper respiratory infection
10003481,0.76,NCT00024102-1,Standard Chemotherapy (CMF),NCT00024102,Comparison of Combination Chemotherapy Regimens in Treating Older Women Who Have Undergone Surgery for Breast Cancer,aspartate aminotransferase increased
D004211,0.76,NCT00024102-1,Standard Chemotherapy (CMF),NCT00024102,Comparison of Combination Chemotherapy Regimens in Treating Older Women Who Have Undergone Surgery for Breast Cancer,consumption coagulopathy
10011368,0.76,NCT00024102-1,Standard Chemotherapy (CMF),NCT00024102,Comparison of Combination Chemotherapy Regimens in Treating Older Women Who Have Undergone Surgery for Breast Cancer,creatinine increased
10011368,0.55,NCT00024102-2,Standard Chemotherapy (AC),NCT00024102,Comparison of Combination Chemotherapy Regimens in Treating Older Women Who Have Undergone Surgery for Breast Cancer,creatinine increased
10011368,1.34,NCT00024102-3,Capecitabine,NCT00024102,Comparison of Combination Chemotherapy Regimens in Treating Older Women Who Have Undergone Surgery for Breast Cancer,creatinine increased
10022402,0.76,NCT00024102-1,Standard Chemotherapy (CMF),NCT00024102,Comparison of Combination Chemotherapy Regimens in Treating Older Women Who Have Undergone Surgery for Breast Cancer,inr increased
10022402,0.33,NCT00024102-3,Capecitabine,NCT00024102,Comparison of Combination Chemotherapy Regimens in Treating Older Women Who Have Undergone Surgery for Breast Cancer,inr increased
D007958,9.16,NCT00024102-1,Standard Chemotherapy (CMF),NCT00024102,Comparison of Combination Chemotherapy Regimens in Treating Older Women Who Have Undergone Surgery for Breast Cancer,leukocyte count
D007958,7.18,NCT00024102-2,Standard Chemotherapy (AC),NCT00024102,Comparison of Combination Chemotherapy Regimens in Treating Older Women Who Have Undergone Surgery for Breast Cancer,leukocyte count
D007958,0.67,NCT00024102-3,Capecitabine,NCT00024102,Comparison of Combination Chemotherapy Regimens in Treating Older Women Who Have Undergone Surgery for Breast Cancer,leukocyte count
10025256,1.53,NCT00024102-1,Standard Chemotherapy (CMF),NCT00024102,Comparison of Combination Chemotherapy Regimens in Treating Older Women Who Have Undergone Surgery for Breast Cancer,lymphocyte count decreased
10029366,5.34,NCT00024102-1,Standard Chemotherapy (CMF),NCT00024102,Comparison of Combination Chemotherapy Regimens in Treating Older Women Who Have Undergone Surgery for Breast Cancer,neutrophil count decreased
10029366,5.52,NCT00024102-2,Standard Chemotherapy (AC),NCT00024102,Comparison of Combination Chemotherapy Regimens in Treating Older Women Who Have Undergone Surgery for Breast Cancer,neutrophil count decreased
10029366,0.67,NCT00024102-3,Capecitabine,NCT00024102,Comparison of Combination Chemotherapy Regimens in Treating Older Women Who Have Undergone Surgery for Breast Cancer,neutrophil count decreased
10035528,3.05,NCT00024102-1,Standard Chemotherapy (CMF),NCT00024102,Comparison of Combination Chemotherapy Regimens in Treating Older Women Who Have Undergone Surgery for Breast Cancer,platelet count decreased
10035528,4.42,NCT00024102-2,Standard Chemotherapy (AC),NCT00024102,Comparison of Combination Chemotherapy Regimens in Treating Older Women Who Have Undergone Surgery for Breast Cancer,platelet count decreased
10035528,0.33,NCT00024102-3,Capecitabine,NCT00024102,Comparison of Combination Chemotherapy Regimens in Treating Older Women Who Have Undergone Surgery for Breast Cancer,platelet count decreased
D000855,2.29,NCT00024102-1,Standard Chemotherapy (CMF),NCT00024102,Comparison of Combination Chemotherapy Regimens in Treating Older Women Who Have Undergone Surgery for Breast Cancer,anorexia
D000855,1.66,NCT00024102-2,Standard Chemotherapy (AC),NCT00024102,Comparison of Combination Chemotherapy Regimens in Treating Older Women Who Have Undergone Surgery for Breast Cancer,anorexia
D000855,3.34,NCT00024102-3,Capecitabine,NCT00024102,Comparison of Combination Chemotherapy Regimens in Treating Older Women Who Have Undergone Surgery for Breast Cancer,anorexia
D001786,2.29,NCT00024102-1,Standard Chemotherapy (CMF),NCT00024102,Comparison of Combination Chemotherapy Regimens in Treating Older Women Who Have Undergone Surgery for Breast Cancer,blood glucose
D001786,0.33,NCT00024102-3,Capecitabine,NCT00024102,Comparison of Combination Chemotherapy Regimens in Treating Older Women Who Have Undergone Surgery for Breast Cancer,blood glucose
D000111,0.33,NCT00024102-3,Capecitabine,NCT00024102,Comparison of Combination Chemotherapy Regimens in Treating Older Women Who Have Undergone Surgery for Breast Cancer,mercapturic acid
D003681,0.76,NCT00024102-1,Standard Chemotherapy (CMF),NCT00024102,Comparison of Combination Chemotherapy Regimens in Treating Older Women Who Have Undergone Surgery for Breast Cancer,dehydration
D003681,0.55,NCT00024102-2,Standard Chemotherapy (AC),NCT00024102,Comparison of Combination Chemotherapy Regimens in Treating Older Women Who Have Undergone Surgery for Breast Cancer,dehydration
D003681,2.34,NCT00024102-3,Capecitabine,NCT00024102,Comparison of Combination Chemotherapy Regimens in Treating Older Women Who Have Undergone Surgery for Breast Cancer,dehydration
D012709,0.33,NCT00024102-3,Capecitabine,NCT00024102,Comparison of Combination Chemotherapy Regimens in Treating Older Women Who Have Undergone Surgery for Breast Cancer,serum albumin
D002118,0.67,NCT00024102-3,Capecitabine,NCT00024102,Comparison of Combination Chemotherapy Regimens in Treating Older Women Who Have Undergone Surgery for Breast Cancer,calcium
D003847,0.33,NCT00024102-3,Capecitabine,NCT00024102,Comparison of Combination Chemotherapy Regimens in Treating Older Women Who Have Undergone Surgery for Breast Cancer,deoxyglucose
D008274,0.33,NCT00024102-3,Capecitabine,NCT00024102,Comparison of Combination Chemotherapy Regimens in Treating Older Women Who Have Undergone Surgery for Breast Cancer,magnesium
D011188,0.76,NCT00024102-1,Standard Chemotherapy (CMF),NCT00024102,Comparison of Combination Chemotherapy Regimens in Treating Older Women Who Have Undergone Surgery for Breast Cancer,potassium
D011188,1.0,NCT00024102-3,Capecitabine,NCT00024102,Comparison of Combination Chemotherapy Regimens in Treating Older Women Who Have Undergone Surgery for Breast Cancer,potassium
D012964,0.33,NCT00024102-3,Capecitabine,NCT00024102,Comparison of Combination Chemotherapy Regimens in Treating Older Women Who Have Undergone Surgery for Breast Cancer,sodium
10006002,0.33,NCT00024102-3,Capecitabine,NCT00024102,Comparison of Combination Chemotherapy Regimens in Treating Older Women Who Have Undergone Surgery for Breast Cancer,bone pain
D001259,0.67,NCT00024102-3,Capecitabine,NCT00024102,Comparison of Combination Chemotherapy Regimens in Treating Older Women Who Have Undergone Surgery for Breast Cancer,ataxia
D004244,0.33,NCT00024102-3,Capecitabine,NCT00024102,Comparison of Combination Chemotherapy Regimens in Treating Older Women Who Have Undergone Surgery for Breast Cancer,dizziness
10023030,0.33,NCT00024102-3,Capecitabine,NCT00024102,Comparison of Combination Chemotherapy Regimens in Treating Older Women Who Have Undergone Surgery for Breast Cancer,ischemia cerebrovascular
10034580,0.33,NCT00024102-3,Capecitabine,NCT00024102,Comparison of Combination Chemotherapy Regimens in Treating Older Women Who Have Undergone Surgery for Breast Cancer,peripheral motor neuropathy
D001072,0.67,NCT00024102-3,Capecitabine,NCT00024102,Comparison of Combination Chemotherapy Regimens in Treating Older Women Who Have Undergone Surgery for Breast Cancer,speech-language disorder 1
D013575,0.76,NCT00024102-1,Standard Chemotherapy (CMF),NCT00024102,Comparison of Combination Chemotherapy Regimens in Treating Older Women Who Have Undergone Surgery for Breast Cancer,syncope
10046912,0.76,NCT00024102-1,Standard Chemotherapy (CMF),NCT00024102,Comparison of Combination Chemotherapy Regimens in Treating Older Women Who Have Undergone Surgery for Breast Cancer,vaginal hemorrhage
D012128,0.76,NCT00024102-1,Standard Chemotherapy (CMF),NCT00024102,Comparison of Combination Chemotherapy Regimens in Treating Older Women Who Have Undergone Surgery for Breast Cancer,adult respiratory distress syndrome
D001986,0.55,NCT00024102-2,Standard Chemotherapy (AC),NCT00024102,Comparison of Combination Chemotherapy Regimens in Treating Older Women Who Have Undergone Surgery for Breast Cancer,bronchospasm
D003371,0.55,NCT00024102-2,Standard Chemotherapy (AC),NCT00024102,Comparison of Combination Chemotherapy Regimens in Treating Older Women Who Have Undergone Surgery for Breast Cancer,cough
D003371,0.33,NCT00024102-3,Capecitabine,NCT00024102,Comparison of Combination Chemotherapy Regimens in Treating Older Women Who Have Undergone Surgery for Breast Cancer,cough
D004417,0.76,NCT00024102-1,Standard Chemotherapy (CMF),NCT00024102,Comparison of Combination Chemotherapy Regimens in Treating Older Women Who Have Undergone Surgery for Breast Cancer,dyspnea
D004417,1.0,NCT00024102-3,Capecitabine,NCT00024102,Comparison of Combination Chemotherapy Regimens in Treating Older Women Who Have Undergone Surgery for Breast Cancer,breath shortness
D000860,0.33,NCT00024102-3,Capecitabine,NCT00024102,Comparison of Combination Chemotherapy Regimens in Treating Older Women Who Have Undergone Surgery for Breast Cancer,hypoxia
D010996,0.33,NCT00024102-3,Capecitabine,NCT00024102,Comparison of Combination Chemotherapy Regimens in Treating Older Women Who Have Undergone Surgery for Breast Cancer,pleural effusion
D011014,0.76,NCT00024102-1,Standard Chemotherapy (CMF),NCT00024102,Comparison of Combination Chemotherapy Regimens in Treating Older Women Who Have Undergone Surgery for Breast Cancer,pneumonitis
D000169,0.33,NCT00024102-3,Capecitabine,NCT00024102,Comparison of Combination Chemotherapy Regimens in Treating Older Women Who Have Undergone Surgery for Breast Cancer,acrodermatitis
D060831,2.68,NCT00024102-3,Capecitabine,NCT00024102,Comparison of Combination Chemotherapy Regimens in Treating Older Women Who Have Undergone Surgery for Breast Cancer,hand-foot syndrome
D005076,0.67,NCT00024102-3,Capecitabine,NCT00024102,Comparison of Combination Chemotherapy Regimens in Treating Older Women Who Have Undergone Surgery for Breast Cancer,rash
D006973,0.33,NCT00024102-3,Capecitabine,NCT00024102,Comparison of Combination Chemotherapy Regimens in Treating Older Women Who Have Undergone Surgery for Breast Cancer,hypertension
D007022,0.76,NCT00024102-1,Standard Chemotherapy (CMF),NCT00024102,Comparison of Combination Chemotherapy Regimens in Treating Older Women Who Have Undergone Surgery for Breast Cancer,hypotension
D007022,0.55,NCT00024102-2,Standard Chemotherapy (AC),NCT00024102,Comparison of Combination Chemotherapy Regimens in Treating Older Women Who Have Undergone Surgery for Breast Cancer,hypotension
D007022,1.0,NCT00024102-3,Capecitabine,NCT00024102,Comparison of Combination Chemotherapy Regimens in Treating Older Women Who Have Undergone Surgery for Breast Cancer,hypotension
10034578,0.33,NCT00024102-3,Capecitabine,NCT00024102,Comparison of Combination Chemotherapy Regimens in Treating Older Women Who Have Undergone Surgery for Breast Cancer,peripheral ischemia
D010689,0.76,NCT00024102-1,Standard Chemotherapy (CMF),NCT00024102,Comparison of Combination Chemotherapy Regimens in Treating Older Women Who Have Undergone Surgery for Breast Cancer,phlebitis
D013927,2.29,NCT00024102-1,Standard Chemotherapy (CMF),NCT00024102,Comparison of Combination Chemotherapy Regimens in Treating Older Women Who Have Undergone Surgery for Breast Cancer,thrombosis
D013927,1.66,NCT00024102-2,Standard Chemotherapy (AC),NCT00024102,Comparison of Combination Chemotherapy Regimens in Treating Older Women Who Have Undergone Surgery for Breast Cancer,thrombosis
D013927,0.67,NCT00024102-3,Capecitabine,NCT00024102,Comparison of Combination Chemotherapy Regimens in Treating Older Women Who Have Undergone Surgery for Breast Cancer,thrombosis
D009026,9.72,NCT00026208-1,Stanford V-C + Low-dose Radiotherapy,NCT00026208,Combination Chemotherapy Plus Low-Dose Radiation Therapy in Treating Patients With Stage I or Stage IIA Hodgkin's Lymphoma,mortality
D064420,34.72,NCT00026208-1,Stanford V-C + Low-dose Radiotherapy,NCT00026208,Combination Chemotherapy Plus Low-Dose Radiation Therapy in Treating Patients With Stage I or Stage IIA Hodgkin's Lymphoma,adverse drug events
D064420,50.0,NCT00026208-2,Stanford V-C Only,NCT00026208,Combination Chemotherapy Plus Low-Dose Radiation Therapy in Treating Patients With Stage I or Stage IIA Hodgkin's Lymphoma,adverse drug events
D001281,1.39,NCT00026208-1,Stanford V-C + Low-dose Radiotherapy,NCT00026208,Combination Chemotherapy Plus Low-Dose Radiation Therapy in Treating Patients With Stage I or Stage IIA Hodgkin's Lymphoma,atrial fibrillation
D007037,23.61,NCT00026208-1,Stanford V-C + Low-dose Radiotherapy,NCT00026208,Combination Chemotherapy Plus Low-Dose Radiation Therapy in Treating Patients With Stage I or Stage IIA Hodgkin's Lymphoma,hypothyroidism
D007037,50.0,NCT00026208-2,Stanford V-C Only,NCT00026208,Combination Chemotherapy Plus Low-Dose Radiation Therapy in Treating Patients With Stage I or Stage IIA Hodgkin's Lymphoma,hypothyroidism
D005334,6.94,NCT00026208-1,Stanford V-C + Low-dose Radiotherapy,NCT00026208,Combination Chemotherapy Plus Low-Dose Radiation Therapy in Treating Patients With Stage I or Stage IIA Hodgkin's Lymphoma,fever
D005334,25.0,NCT00026208-2,Stanford V-C Only,NCT00026208,Combination Chemotherapy Plus Low-Dose Radiation Therapy in Treating Patients With Stage I or Stage IIA Hodgkin's Lymphoma,fever
D000071576,1.39,NCT00026208-1,Stanford V-C + Low-dose Radiotherapy,NCT00026208,Combination Chemotherapy Plus Low-Dose Radiation Therapy in Treating Patients With Stage I or Stage IIA Hodgkin's Lymphoma,crush injury
D016609,2.78,NCT00026208-1,Stanford V-C + Low-dose Radiotherapy,NCT00026208,Combination Chemotherapy Plus Low-Dose Radiation Therapy in Treating Patients With Stage I or Stage IIA Hodgkin's Lymphoma,second cancer
D005076,1.39,NCT00026208-1,Stanford V-C + Low-dose Radiotherapy,NCT00026208,Combination Chemotherapy Plus Low-Dose Radiation Therapy in Treating Patients With Stage I or Stage IIA Hodgkin's Lymphoma,rash
D064420,9.89,NCT00041119-1,Arm I (CA for 4 Courses),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,adverse drug events
D064420,13.18,NCT00041119-2,Arm II (CA for 6 Courses [Closed to Accrual 12/15/2007]),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,adverse drug events
D064420,5.13,NCT00041119-3,Arm III (Paclitaxel for 4 Courses),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,adverse drug events
D064420,6.72,NCT00041119-4,Arm IV (Paclitaxel for 6 Courses [Closed 12/15/2007]),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,adverse drug events
D001778,0.13,NCT00041119-2,Arm II (CA for 6 Courses [Closed to Accrual 12/15/2007]),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,blood coagulation disorders
D064147,2.7,NCT00041119-1,Arm I (CA for 4 Courses),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,febrile neutropenia
D064147,3.79,NCT00041119-2,Arm II (CA for 6 Courses [Closed to Accrual 12/15/2007]),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,febrile neutropenia
D064147,0.09,NCT00041119-3,Arm III (Paclitaxel for 4 Courses),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,febrile neutropenia
D002263,7.3,NCT00041119-1,Arm I (CA for 4 Courses),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,carboxyhemoglobin
D002263,8.37,NCT00041119-2,Arm II (CA for 6 Courses [Closed to Accrual 12/15/2007]),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,carboxyhemoglobin
D002263,2.59,NCT00041119-3,Arm III (Paclitaxel for 4 Courses),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,carboxyhemoglobin
D002263,2.49,NCT00041119-4,Arm IV (Paclitaxel for 6 Courses [Closed 12/15/2007]),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,carboxyhemoglobin
D001804,0.27,NCT00041119-1,Arm I (CA for 4 Courses),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,autotransfusion
D001804,0.65,NCT00041119-2,Arm II (CA for 6 Courses [Closed to Accrual 12/15/2007]),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,autotransfusion
D001804,0.18,NCT00041119-3,Arm III (Paclitaxel for 4 Courses),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,autotransfusion
D001804,0.13,NCT00041119-4,Arm IV (Paclitaxel for 6 Courses [Closed 12/15/2007]),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,autotransfusion
D001145,0.54,NCT00041119-1,Arm I (CA for 4 Courses),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,arrhythmia
D001145,0.65,NCT00041119-2,Arm II (CA for 6 Courses [Closed to Accrual 12/15/2007]),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,arrhythmia
D001145,0.63,NCT00041119-3,Arm III (Paclitaxel for 4 Courses),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,arrhythmia
D001145,0.26,NCT00041119-4,Arm IV (Paclitaxel for 6 Courses [Closed 12/15/2007]),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,arrhythmia
D001281,0.09,NCT00041119-1,Arm I (CA for 4 Courses),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,atrial fibrillation
D006331,0.09,NCT00041119-1,Arm I (CA for 4 Courses),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,cardiac disorder
D006331,0.09,NCT00041119-3,Arm III (Paclitaxel for 4 Courses),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,cardiac disorder
D006331,0.13,NCT00041119-4,Arm IV (Paclitaxel for 6 Courses [Closed 12/15/2007]),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,cardiac disorder
10008481,0.09,NCT00041119-1,Arm I (CA for 4 Courses),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,chest pain - cardiac
D004487,0.13,NCT00041119-4,Arm IV (Paclitaxel for 6 Courses [Closed 12/15/2007]),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,edema
D016277,0.09,NCT00041119-1,Arm I (CA for 4 Courses),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,ventricular function left
D016277,0.65,NCT00041119-2,Arm II (CA for 6 Courses [Closed to Accrual 12/15/2007]),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,ventricular function left
D016277,0.09,NCT00041119-3,Arm III (Paclitaxel for 4 Courses),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,ventricular function left
D017202,0.18,NCT00041119-1,Arm I (CA for 4 Courses),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,myocardial ischemia
D017202,0.13,NCT00041119-2,Arm II (CA for 6 Courses [Closed to Accrual 12/15/2007]),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,myocardial ischemia
D014717,0.13,NCT00041119-2,Arm II (CA for 6 Courses [Closed to Accrual 12/15/2007]),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,vertigo
D020795,0.13,NCT00041119-2,Arm II (CA for 6 Courses [Closed to Accrual 12/15/2007]),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,photophobia
10005886,0.09,NCT00041119-1,Arm I (CA for 4 Courses),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,blurred vision
D015746,0.09,NCT00041119-1,Arm I (CA for 4 Courses),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,abdominal pain
D015746,0.36,NCT00041119-3,Arm III (Paclitaxel for 4 Courses),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,abdominal pain
D015746,0.13,NCT00041119-4,Arm IV (Paclitaxel for 6 Courses [Closed 12/15/2007]),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,abdominal pain
D003092,0.18,NCT00041119-1,Arm I (CA for 4 Courses),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,colitis
D003092,0.26,NCT00041119-2,Arm II (CA for 6 Courses [Closed to Accrual 12/15/2007]),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,colitis
D003092,0.09,NCT00041119-3,Arm III (Paclitaxel for 4 Courses),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,colitis
D003248,0.09,NCT00041119-1,Arm I (CA for 4 Courses),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,constipation
D003967,2.43,NCT00041119-1,Arm I (CA for 4 Courses),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,diarrhea
D003967,3.14,NCT00041119-2,Arm II (CA for 6 Courses [Closed to Accrual 12/15/2007]),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,diarrhea
D003967,0.98,NCT00041119-3,Arm III (Paclitaxel for 4 Courses),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,diarrhea
D003967,0.66,NCT00041119-4,Arm IV (Paclitaxel for 6 Courses [Closed 12/15/2007]),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,diarrhea
D004415,0.09,NCT00041119-1,Arm I (CA for 4 Courses),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,dyspepsia
D003680,0.26,NCT00041119-2,Arm II (CA for 6 Courses [Closed to Accrual 12/15/2007]),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,dysphagia
D004941,0.36,NCT00041119-1,Arm I (CA for 4 Courses),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,esophagitis
10017789,0.09,NCT00041119-3,Arm III (Paclitaxel for 4 Courses),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,gastric hemorrhage
D013276,0.13,NCT00041119-4,Arm IV (Paclitaxel for 6 Courses [Closed 12/15/2007]),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,gastric ulcer
D005767,0.13,NCT00041119-2,Arm II (CA for 6 Courses [Closed to Accrual 12/15/2007]),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,gastrointestinal disorder
D005767,0.26,NCT00041119-4,Arm IV (Paclitaxel for 6 Courses [Closed 12/15/2007]),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,gastrointestinal disorder
D006470,0.13,NCT00041119-2,Arm II (CA for 6 Courses [Closed to Accrual 12/15/2007]),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,bleeding
10028130,3.51,NCT00041119-1,Arm I (CA for 4 Courses),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,mucositis oral
10028130,3.92,NCT00041119-2,Arm II (CA for 6 Courses [Closed to Accrual 12/15/2007]),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,mucositis oral
10028130,0.63,NCT00041119-3,Arm III (Paclitaxel for 4 Courses),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,mucositis oral
10028130,0.52,NCT00041119-4,Arm IV (Paclitaxel for 6 Courses [Closed 12/15/2007]),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,mucositis oral
D009325,1.08,NCT00041119-1,Arm I (CA for 4 Courses),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,nausea
D009325,1.05,NCT00041119-2,Arm II (CA for 6 Courses [Closed to Accrual 12/15/2007]),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,nausea
D009325,0.63,NCT00041119-3,Arm III (Paclitaxel for 4 Courses),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,nausea
D009325,0.39,NCT00041119-4,Arm IV (Paclitaxel for 6 Courses [Closed 12/15/2007]),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,nausea
D010195,0.26,NCT00041119-2,Arm II (CA for 6 Courses [Closed to Accrual 12/15/2007]),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,pancreatitis
D006470,0.13,NCT00041119-2,Arm II (CA for 6 Courses [Closed to Accrual 12/15/2007]),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,bleeding
10038064,0.09,NCT00041119-1,Arm I (CA for 4 Courses),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,rectal hemorrhage
10038072,0.18,NCT00041119-1,Arm I (CA for 4 Courses),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,rectal pain
D053706,0.13,NCT00041119-2,Arm II (CA for 6 Courses [Closed to Accrual 12/15/2007]),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,typhlitis
D014839,0.63,NCT00041119-1,Arm I (CA for 4 Courses),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,vomiting
D014839,1.18,NCT00041119-2,Arm II (CA for 6 Courses [Closed to Accrual 12/15/2007]),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,vomiting
D014839,0.45,NCT00041119-3,Arm III (Paclitaxel for 4 Courses),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,vomiting
D014839,0.13,NCT00041119-4,Arm IV (Paclitaxel for 6 Courses [Closed 12/15/2007]),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,vomiting
D002637,0.27,NCT00041119-1,Arm I (CA for 4 Courses),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,chest pain
D002637,0.26,NCT00041119-2,Arm II (CA for 6 Courses [Closed to Accrual 12/15/2007]),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,chest pain
D002637,0.09,NCT00041119-3,Arm III (Paclitaxel for 4 Courses),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,chest pain
D002637,0.39,NCT00041119-4,Arm IV (Paclitaxel for 6 Courses [Closed 12/15/2007]),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,chest pain
D023341,0.13,NCT00041119-4,Arm IV (Paclitaxel for 6 Courses [Closed 12/15/2007]),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,chills
D005221,1.26,NCT00041119-1,Arm I (CA for 4 Courses),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,fatigue
D005221,1.57,NCT00041119-2,Arm II (CA for 6 Courses [Closed to Accrual 12/15/2007]),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,fatigue
D005221,0.36,NCT00041119-3,Arm III (Paclitaxel for 4 Courses),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,fatigue
D005221,0.79,NCT00041119-4,Arm IV (Paclitaxel for 6 Courses [Closed 12/15/2007]),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,fatigue
D005334,0.13,NCT00041119-2,Arm II (CA for 6 Courses [Closed to Accrual 12/15/2007]),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,fever
D005334,0.26,NCT00041119-4,Arm IV (Paclitaxel for 6 Courses [Closed 12/15/2007]),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,fever
D005684,0.13,NCT00041119-4,Arm IV (Paclitaxel for 6 Courses [Closed 12/15/2007]),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,gait
D010146,0.27,NCT00041119-1,Arm I (CA for 4 Courses),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,pain
D010146,0.26,NCT00041119-2,Arm II (CA for 6 Courses [Closed to Accrual 12/15/2007]),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,pain
D010146,0.52,NCT00041119-4,Arm IV (Paclitaxel for 6 Courses [Closed 12/15/2007]),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,pain
D006967,0.09,NCT00041119-1,Arm I (CA for 4 Courses),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,hypersensitivity
D006967,0.26,NCT00041119-2,Arm II (CA for 6 Courses [Closed to Accrual 12/15/2007]),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,hypersensitivity
D006967,0.36,NCT00041119-3,Arm III (Paclitaxel for 4 Courses),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,hypersensitivity
D006967,0.79,NCT00041119-4,Arm IV (Paclitaxel for 6 Courses [Closed 12/15/2007]),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,hypersensitivity
10007810,0.09,NCT00041119-1,Arm I (CA for 4 Courses),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,catheter related infection
10007810,0.13,NCT00041119-2,Arm II (CA for 6 Courses [Closed to Accrual 12/15/2007]),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,catheter related infection
10007810,0.18,NCT00041119-3,Arm III (Paclitaxel for 4 Courses),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,catheter related infection
10007810,0.13,NCT00041119-4,Arm IV (Paclitaxel for 6 Courses [Closed 12/15/2007]),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,catheter related infection
D015817,0.09,NCT00041119-1,Arm I (CA for 4 Courses),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,eye infections
D007239,0.09,NCT00041119-1,Arm I (CA for 4 Courses),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,infection
D000069544,0.9,NCT00041119-1,Arm I (CA for 4 Courses),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,encephalitis infection
D000069544,1.05,NCT00041119-2,Arm II (CA for 6 Courses [Closed to Accrual 12/15/2007]),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,encephalitis infection
D000069544,0.13,NCT00041119-4,Arm IV (Paclitaxel for 6 Courses [Closed 12/15/2007]),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,encephalitis infection
D000069544,0.63,NCT00041119-1,Arm I (CA for 4 Courses),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,encephalitis infection
D000069544,0.65,NCT00041119-2,Arm II (CA for 6 Courses [Closed to Accrual 12/15/2007]),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,encephalitis infection
D000069544,0.63,NCT00041119-3,Arm III (Paclitaxel for 4 Courses),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,encephalitis infection
D000069544,0.39,NCT00041119-4,Arm IV (Paclitaxel for 6 Courses [Closed 12/15/2007]),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,encephalitis infection
10058838,0.09,NCT00041119-1,Arm I (CA for 4 Courses),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,enterocolitis infectious
10065766,0.09,NCT00041119-1,Arm I (CA for 4 Courses),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,peripheral nerve infection
10040872,0.18,NCT00041119-1,Arm I (CA for 4 Courses),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,skin infection
10040872,0.13,NCT00041119-2,Arm II (CA for 6 Courses [Closed to Accrual 12/15/2007]),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,skin infection
D018461,0.09,NCT00041119-1,Arm I (CA for 4 Courses),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,soft tissue infection
10048762,0.09,NCT00041119-1,Arm I (CA for 4 Courses),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,tooth infection
D014552,0.13,NCT00041119-4,Arm IV (Paclitaxel for 6 Courses [Closed 12/15/2007]),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,urinary tract infection
D014946,0.09,NCT00041119-1,Arm I (CA for 4 Courses),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,wound infection
D014946,0.09,NCT00041119-3,Arm III (Paclitaxel for 4 Courses),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,wound infection
D014947,0.18,NCT00041119-1,Arm I (CA for 4 Courses),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,wounds
D014947,0.39,NCT00041119-2,Arm II (CA for 6 Courses [Closed to Accrual 12/15/2007]),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,wounds
10062169,0.09,NCT00041119-3,Arm III (Paclitaxel for 4 Courses),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,vascular access complication
10048031,0.09,NCT00041119-1,Arm I (CA for 4 Courses),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,wound dehiscence
10000636,0.13,NCT00041119-2,Arm II (CA for 6 Courses [Closed to Accrual 12/15/2007]),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,activated partial thromboplastin time prolonged
10000636,0.09,NCT00041119-3,Arm III (Paclitaxel for 4 Courses),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,activated partial thromboplastin time prolonged
10000636,0.13,NCT00041119-4,Arm IV (Paclitaxel for 6 Courses [Closed 12/15/2007]),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,activated partial thromboplastin time prolonged
10001551,0.13,NCT00041119-2,Arm II (CA for 6 Courses [Closed to Accrual 12/15/2007]),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,alanine aminotransferase increased
10001551,0.09,NCT00041119-3,Arm III (Paclitaxel for 4 Courses),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,alanine aminotransferase increased
10001551,0.52,NCT00041119-4,Arm IV (Paclitaxel for 6 Courses [Closed 12/15/2007]),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,alanine aminotransferase increased
D000469,0.13,NCT00041119-4,Arm IV (Paclitaxel for 6 Courses [Closed 12/15/2007]),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,alkaline phosphatase
10040139,0.13,NCT00041119-2,Arm II (CA for 6 Courses [Closed to Accrual 12/15/2007]),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,serum amylase increased
10003481,0.26,NCT00041119-4,Arm IV (Paclitaxel for 6 Courses [Closed 12/15/2007]),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,aspartate aminotransferase increased
10005364,0.13,NCT00041119-4,Arm IV (Paclitaxel for 6 Courses [Closed 12/15/2007]),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,blood bilirubin increased
10007613,0.13,NCT00041119-2,Arm II (CA for 6 Courses [Closed to Accrual 12/15/2007]),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,cardiac troponin t increased
10011368,0.09,NCT00041119-1,Arm I (CA for 4 Courses),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,creatinine increased
10011368,0.13,NCT00041119-2,Arm II (CA for 6 Courses [Closed to Accrual 12/15/2007]),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,creatinine increased
10011368,0.09,NCT00041119-3,Arm III (Paclitaxel for 4 Courses),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,creatinine increased
D000347,0.13,NCT00041119-4,Arm IV (Paclitaxel for 6 Courses [Closed 12/15/2007]),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,afibrinogenemia
10022402,0.09,NCT00041119-1,Arm I (CA for 4 Courses),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,inr increased
10022402,0.13,NCT00041119-4,Arm IV (Paclitaxel for 6 Courses [Closed 12/15/2007]),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,inr increased
D019411,0.09,NCT00041119-1,Arm I (CA for 4 Courses),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,clinical laboratory tests
D007958,6.04,NCT00041119-1,Arm I (CA for 4 Courses),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,leukocyte count
D007958,8.63,NCT00041119-2,Arm II (CA for 6 Courses [Closed to Accrual 12/15/2007]),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,leukocyte count
D007958,0.72,NCT00041119-3,Arm III (Paclitaxel for 4 Courses),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,leukocyte count
D007958,0.26,NCT00041119-4,Arm IV (Paclitaxel for 6 Courses [Closed 12/15/2007]),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,leukocyte count
10024574,0.13,NCT00041119-2,Arm II (CA for 6 Courses [Closed to Accrual 12/15/2007]),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,lipase increased
10025256,0.36,NCT00041119-1,Arm I (CA for 4 Courses),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,lymphocyte count decreased
10025256,0.52,NCT00041119-2,Arm II (CA for 6 Courses [Closed to Accrual 12/15/2007]),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,lymphocyte count decreased
10025256,0.09,NCT00041119-3,Arm III (Paclitaxel for 4 Courses),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,lymphocyte count decreased
10025256,0.13,NCT00041119-4,Arm IV (Paclitaxel for 6 Courses [Closed 12/15/2007]),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,lymphocyte count decreased
10029366,5.95,NCT00041119-1,Arm I (CA for 4 Courses),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,neutrophil count decreased
10029366,7.97,NCT00041119-2,Arm II (CA for 6 Courses [Closed to Accrual 12/15/2007]),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,neutrophil count decreased
10029366,0.89,NCT00041119-3,Arm III (Paclitaxel for 4 Courses),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,neutrophil count decreased
10029366,0.52,NCT00041119-4,Arm IV (Paclitaxel for 6 Courses [Closed 12/15/2007]),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,neutrophil count decreased
10035528,3.6,NCT00041119-1,Arm I (CA for 4 Courses),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,platelet count decreased
10035528,4.71,NCT00041119-2,Arm II (CA for 6 Courses [Closed to Accrual 12/15/2007]),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,platelet count decreased
10035528,0.27,NCT00041119-3,Arm III (Paclitaxel for 4 Courses),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,platelet count decreased
10035528,0.66,NCT00041119-4,Arm IV (Paclitaxel for 6 Courses [Closed 12/15/2007]),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,platelet count decreased
D000855,0.45,NCT00041119-1,Arm I (CA for 4 Courses),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,anorexia
D000855,0.39,NCT00041119-2,Arm II (CA for 6 Courses [Closed to Accrual 12/15/2007]),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,anorexia
D000855,0.09,NCT00041119-3,Arm III (Paclitaxel for 4 Courses),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,anorexia
D001786,0.36,NCT00041119-1,Arm I (CA for 4 Courses),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,blood glucose
D001786,0.26,NCT00041119-2,Arm II (CA for 6 Courses [Closed to Accrual 12/15/2007]),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,blood glucose
D001786,0.36,NCT00041119-3,Arm III (Paclitaxel for 4 Courses),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,blood glucose
D001786,0.66,NCT00041119-4,Arm IV (Paclitaxel for 6 Courses [Closed 12/15/2007]),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,blood glucose
D003681,1.08,NCT00041119-1,Arm I (CA for 4 Courses),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,dehydration
D003681,1.05,NCT00041119-2,Arm II (CA for 6 Courses [Closed to Accrual 12/15/2007]),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,dehydration
D003681,0.27,NCT00041119-3,Arm III (Paclitaxel for 4 Courses),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,dehydration
D003681,0.26,NCT00041119-4,Arm IV (Paclitaxel for 6 Courses [Closed 12/15/2007]),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,dehydration
D012709,0.13,NCT00041119-2,Arm II (CA for 6 Courses [Closed to Accrual 12/15/2007]),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,serum albumin
D002118,0.13,NCT00041119-2,Arm II (CA for 6 Courses [Closed to Accrual 12/15/2007]),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,calcium
D002118,0.09,NCT00041119-3,Arm III (Paclitaxel for 4 Courses),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,calcium
D003847,0.13,NCT00041119-4,Arm IV (Paclitaxel for 6 Courses [Closed 12/15/2007]),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,deoxyglucose
D011188,0.72,NCT00041119-1,Arm I (CA for 4 Courses),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,potassium
D011188,0.26,NCT00041119-2,Arm II (CA for 6 Courses [Closed to Accrual 12/15/2007]),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,potassium
D011188,0.09,NCT00041119-3,Arm III (Paclitaxel for 4 Courses),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,potassium
10040139,0.13,NCT00041119-4,Arm IV (Paclitaxel for 6 Courses [Closed 12/15/2007]),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,serum amylase increased
D012964,0.09,NCT00041119-1,Arm I (CA for 4 Courses),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,sodium
D012964,0.13,NCT00041119-4,Arm IV (Paclitaxel for 6 Courses [Closed 12/15/2007]),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,sodium
D018771,0.09,NCT00041119-1,Arm I (CA for 4 Courses),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,arthralgia
D018771,0.09,NCT00041119-3,Arm III (Paclitaxel for 4 Courses),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,arthralgia
D018771,0.66,NCT00041119-4,Arm IV (Paclitaxel for 6 Courses [Closed 12/15/2007]),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,arthralgia
D001168,0.13,NCT00041119-2,Arm II (CA for 6 Courses [Closed to Accrual 12/15/2007]),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,arthritis
10006002,0.13,NCT00041119-2,Arm II (CA for 6 Courses [Closed to Accrual 12/15/2007]),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,bone pain
10006002,0.27,NCT00041119-3,Arm III (Paclitaxel for 4 Courses),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,bone pain
D018908,0.13,NCT00041119-2,Arm II (CA for 6 Courses [Closed to Accrual 12/15/2007]),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,muscle weakness
D063806,0.13,NCT00041119-2,Arm II (CA for 6 Courses [Closed to Accrual 12/15/2007]),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,myalgia
D063806,0.36,NCT00041119-3,Arm III (Paclitaxel for 4 Courses),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,myalgia
D063806,0.66,NCT00041119-4,Arm IV (Paclitaxel for 6 Courses [Closed 12/15/2007]),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,myalgia
10033425,0.09,NCT00041119-3,Arm III (Paclitaxel for 4 Courses),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,pain in extremity
D001100,0.09,NCT00041119-1,Arm I (CA for 4 Courses),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,arachnoiditis
D001259,0.09,NCT00041119-3,Arm III (Paclitaxel for 4 Courses),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,ataxia
D003244,0.13,NCT00041119-4,Arm IV (Paclitaxel for 6 Courses [Closed 12/15/2007]),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,depressed level of consciousness
D004244,0.09,NCT00041119-1,Arm I (CA for 4 Courses),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,dizziness
D004244,0.13,NCT00041119-2,Arm II (CA for 6 Courses [Closed to Accrual 12/15/2007]),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,dizziness
D004244,0.13,NCT00041119-4,Arm IV (Paclitaxel for 6 Courses [Closed 12/15/2007]),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,dizziness
D004408,0.18,NCT00041119-1,Arm I (CA for 4 Courses),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,dysgeusia
D004408,0.13,NCT00041119-2,Arm II (CA for 6 Courses [Closed to Accrual 12/15/2007]),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,dysgeusia
D006261,0.36,NCT00041119-1,Arm I (CA for 4 Courses),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,headache
D006261,0.13,NCT00041119-2,Arm II (CA for 6 Courses [Closed to Accrual 12/15/2007]),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,headache
D006261,0.52,NCT00041119-4,Arm IV (Paclitaxel for 6 Courses [Closed 12/15/2007]),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,headache
10023030,0.13,NCT00041119-4,Arm IV (Paclitaxel for 6 Courses [Closed 12/15/2007]),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,ischemia cerebrovascular
10027175,0.13,NCT00041119-4,Arm IV (Paclitaxel for 6 Courses [Closed 12/15/2007]),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,memory impairment
D009437,0.09,NCT00041119-1,Arm I (CA for 4 Courses),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,neuralgia
D009437,0.09,NCT00041119-3,Arm III (Paclitaxel for 4 Courses),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,neuralgia
10034580,0.27,NCT00041119-1,Arm I (CA for 4 Courses),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,peripheral motor neuropathy
10034580,0.36,NCT00041119-3,Arm III (Paclitaxel for 4 Courses),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,peripheral motor neuropathy
10034580,0.92,NCT00041119-4,Arm IV (Paclitaxel for 6 Courses [Closed 12/15/2007]),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,peripheral motor neuropathy
10034620,0.81,NCT00041119-1,Arm I (CA for 4 Courses),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,peripheral sensory neuropathy
10034620,0.78,NCT00041119-2,Arm II (CA for 6 Courses [Closed to Accrual 12/15/2007]),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,peripheral sensory neuropathy
10034620,2.06,NCT00041119-3,Arm III (Paclitaxel for 4 Courses),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,peripheral sensory neuropathy
10034620,3.28,NCT00041119-4,Arm IV (Paclitaxel for 6 Courses [Closed 12/15/2007]),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,peripheral sensory neuropathy
D013575,0.27,NCT00041119-1,Arm I (CA for 4 Courses),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,syncope
D013575,0.26,NCT00041119-2,Arm II (CA for 6 Courses [Closed to Accrual 12/15/2007]),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,syncope
D013575,0.52,NCT00041119-4,Arm IV (Paclitaxel for 6 Courses [Closed 12/15/2007]),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,syncope
D014202,0.13,NCT00041119-4,Arm IV (Paclitaxel for 6 Courses [Closed 12/15/2007]),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,tremor
D013575,0.26,NCT00041119-4,Arm IV (Paclitaxel for 6 Courses [Closed 12/15/2007]),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,syncopal episode
D001007,0.13,NCT00041119-2,Arm II (CA for 6 Courses [Closed to Accrual 12/15/2007]),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,anxiety
D003221,0.09,NCT00041119-1,Arm I (CA for 4 Courses),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,confusion
D003221,0.13,NCT00041119-2,Arm II (CA for 6 Courses [Closed to Accrual 12/15/2007]),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,confusion
D003221,0.13,NCT00041119-4,Arm IV (Paclitaxel for 6 Courses [Closed 12/15/2007]),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,confusion
D003863,0.09,NCT00041119-1,Arm I (CA for 4 Courses),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,depression
D003863,0.13,NCT00041119-2,Arm II (CA for 6 Courses [Closed to Accrual 12/15/2007]),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,depression
D003863,0.09,NCT00041119-3,Arm III (Paclitaxel for 4 Courses),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,depression
D003863,0.13,NCT00041119-4,Arm IV (Paclitaxel for 6 Courses [Closed 12/15/2007]),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,depression
D006212,0.09,NCT00041119-1,Arm I (CA for 4 Courses),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,hallucinations
D006212,0.13,NCT00041119-2,Arm II (CA for 6 Courses [Closed to Accrual 12/15/2007]),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,hallucinations
D007319,0.09,NCT00041119-1,Arm I (CA for 4 Courses),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,insomnia
10034719,0.13,NCT00041119-2,Arm II (CA for 6 Courses [Closed to Accrual 12/15/2007]),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,personality change
10034719,0.09,NCT00041119-3,Arm III (Paclitaxel for 4 Courses),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,personality change
D014554,0.13,NCT00041119-2,Arm II (CA for 6 Courses [Closed to Accrual 12/15/2007]),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,urination
D014554,0.09,NCT00041119-3,Arm III (Paclitaxel for 4 Courses),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,urination
D051437,0.09,NCT00041119-3,Arm III (Paclitaxel for 4 Courses),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,renal failure
D000067836,0.09,NCT00041119-1,Arm I (CA for 4 Courses),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,hoarding disorder
D000067836,0.13,NCT00041119-4,Arm IV (Paclitaxel for 6 Courses [Closed 12/15/2007]),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,hoarding disorder
D060737,0.09,NCT00041119-3,Arm III (Paclitaxel for 4 Courses),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,reproductive tract infections
10046912,0.09,NCT00041119-1,Arm I (CA for 4 Courses),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,vaginal hemorrhage
10046912,0.09,NCT00041119-3,Arm III (Paclitaxel for 4 Courses),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,vaginal hemorrhage
10046912,0.13,NCT00041119-4,Arm IV (Paclitaxel for 6 Courses [Closed 12/15/2007]),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,vaginal hemorrhage
D012128,0.13,NCT00041119-2,Arm II (CA for 6 Courses [Closed to Accrual 12/15/2007]),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,adult respiratory distress syndrome
D001049,0.09,NCT00041119-3,Arm III (Paclitaxel for 4 Courses),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,apnea
D001049,0.13,NCT00041119-4,Arm IV (Paclitaxel for 6 Courses [Closed 12/15/2007]),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,apnea
D003371,0.18,NCT00041119-1,Arm I (CA for 4 Courses),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,cough
D003371,0.26,NCT00041119-2,Arm II (CA for 6 Courses [Closed to Accrual 12/15/2007]),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,cough
D004417,0.27,NCT00041119-1,Arm I (CA for 4 Courses),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,dyspnea
D004417,0.13,NCT00041119-2,Arm II (CA for 6 Courses [Closed to Accrual 12/15/2007]),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,dyspnea
D004417,0.09,NCT00041119-3,Arm III (Paclitaxel for 4 Courses),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,dyspnea
D004417,0.45,NCT00041119-1,Arm I (CA for 4 Courses),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,breath shortness
D004417,0.65,NCT00041119-2,Arm II (CA for 6 Courses [Closed to Accrual 12/15/2007]),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,breath shortness
D004417,0.09,NCT00041119-3,Arm III (Paclitaxel for 4 Courses),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,breath shortness
D004417,0.39,NCT00041119-4,Arm IV (Paclitaxel for 6 Courses [Closed 12/15/2007]),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,breath shortness
D004844,0.13,NCT00041119-2,Arm II (CA for 6 Courses [Closed to Accrual 12/15/2007]),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,epistaxis
D006469,0.13,NCT00041119-2,Arm II (CA for 6 Courses [Closed to Accrual 12/15/2007]),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,hemoptysis
D000860,0.09,NCT00041119-1,Arm I (CA for 4 Courses),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,hypoxia
D000860,0.26,NCT00041119-2,Arm II (CA for 6 Courses [Closed to Accrual 12/15/2007]),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,hypoxia
D000860,0.09,NCT00041119-3,Arm III (Paclitaxel for 4 Courses),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,hypoxia
D000860,0.39,NCT00041119-4,Arm IV (Paclitaxel for 6 Courses [Closed 12/15/2007]),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,hypoxia
D000013,0.13,NCT00041119-2,Arm II (CA for 6 Courses [Closed to Accrual 12/15/2007]),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,congenital abnormalities
D011014,0.18,NCT00041119-1,Arm I (CA for 4 Courses),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,pneumonitis
D011014,0.92,NCT00041119-2,Arm II (CA for 6 Courses [Closed to Accrual 12/15/2007]),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,pneumonitis
D011014,0.13,NCT00041119-4,Arm IV (Paclitaxel for 6 Courses [Closed 12/15/2007]),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,pneumonitis
10038738,0.09,NCT00041119-1,Arm I (CA for 4 Courses),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,respiratory thoracic and mediastinal disorders - other specify
10038738,0.26,NCT00041119-2,Arm II (CA for 6 Courses [Closed to Accrual 12/15/2007]),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,respiratory thoracic and mediastinal disorders - other specify
D000505,0.27,NCT00041119-1,Arm I (CA for 4 Courses),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,alopecia
D000505,0.13,NCT00041119-2,Arm II (CA for 6 Courses [Closed to Accrual 12/15/2007]),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,alopecia
D000505,0.27,NCT00041119-3,Arm III (Paclitaxel for 4 Courses),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,alopecia
D000505,0.13,NCT00041119-4,Arm IV (Paclitaxel for 6 Courses [Closed 12/15/2007]),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,alopecia
D060831,0.18,NCT00041119-1,Arm I (CA for 4 Courses),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,hand-foot syndrome
D060831,0.39,NCT00041119-2,Arm II (CA for 6 Courses [Closed to Accrual 12/15/2007]),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,hand-foot syndrome
D009262,0.09,NCT00041119-3,Arm III (Paclitaxel for 4 Courses),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,nails
D011537,0.09,NCT00041119-3,Arm III (Paclitaxel for 4 Courses),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,pruritus
D012871,0.18,NCT00041119-1,Arm I (CA for 4 Courses),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,skin and subcutaneous tissue disorders
D012871,0.09,NCT00041119-3,Arm III (Paclitaxel for 4 Courses),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,skin and subcutaneous tissue disorders
D013546,0.13,NCT00041119-2,Arm II (CA for 6 Courses [Closed to Accrual 12/15/2007]),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,sweating
D019559,0.09,NCT00041119-3,Arm III (Paclitaxel for 4 Courses),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,capillary leak syndrome
D006406,0.09,NCT00041119-3,Arm III (Paclitaxel for 4 Courses),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,hematoma
D006470,0.13,NCT00041119-4,Arm IV (Paclitaxel for 6 Courses [Closed 12/15/2007]),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,hemorrhage
D006470,0.13,NCT00041119-4,Arm IV (Paclitaxel for 6 Courses [Closed 12/15/2007]),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,hemorrhage
D006973,0.27,NCT00041119-3,Arm III (Paclitaxel for 4 Courses),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,hypertension
D006973,0.13,NCT00041119-4,Arm IV (Paclitaxel for 6 Courses [Closed 12/15/2007]),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,hypertension
D007022,0.27,NCT00041119-1,Arm I (CA for 4 Courses),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,hypotension
D007022,0.39,NCT00041119-2,Arm II (CA for 6 Courses [Closed to Accrual 12/15/2007]),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,hypotension
D007022,0.26,NCT00041119-4,Arm IV (Paclitaxel for 6 Courses [Closed 12/15/2007]),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,hypotension
D013927,0.72,NCT00041119-1,Arm I (CA for 4 Courses),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,thrombosis
D013927,0.92,NCT00041119-2,Arm II (CA for 6 Courses [Closed to Accrual 12/15/2007]),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,thrombosis
D013927,0.54,NCT00041119-3,Arm III (Paclitaxel for 4 Courses),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,thrombosis
D013927,0.52,NCT00041119-4,Arm IV (Paclitaxel for 6 Courses [Closed 12/15/2007]),NCT00041119,Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer,thrombosis
D009026,96.67,NCT00043979-1,Arm 2-Recipients,NCT00043979,Stem Cell Transplantation in Patients With High-Risk and Recurrent Pediatric Sarcomas,mortality
D064420,96.67,NCT00043979-1,Arm 2-Recipients,NCT00043979,Stem Cell Transplantation in Patients With High-Risk and Recurrent Pediatric Sarcomas,adverse drug events
D007022,3.33,NCT00043979-1,Arm 2-Recipients,NCT00043979,Stem Cell Transplantation in Patients With High-Risk and Recurrent Pediatric Sarcomas,hypotension
D010490,3.33,NCT00043979-1,Arm 2-Recipients,NCT00043979,Stem Cell Transplantation in Patients With High-Risk and Recurrent Pediatric Sarcomas,pericardial effusion
D013927,6.67,NCT00043979-1,Arm 2-Recipients,NCT00043979,Stem Cell Transplantation in Patients With High-Risk and Recurrent Pediatric Sarcomas,thrombosis
D001146,3.33,NCT00043979-1,Arm 2-Recipients,NCT00043979,Stem Cell Transplantation in Patients With High-Risk and Recurrent Pediatric Sarcomas,arrhythmias sinoatrial
D000930,6.67,NCT00043979-1,Arm 2-Recipients,NCT00043979,Stem Cell Transplantation in Patients With High-Risk and Recurrent Pediatric Sarcomas,antidiarrheals
D003945,3.33,NCT00043979-1,Arm 2-Recipients,NCT00043979,Stem Cell Transplantation in Patients With High-Risk and Recurrent Pediatric Sarcomas,examination oral
D000971,3.33,NCT00043979-1,Arm 2-Recipients,NCT00043979,Stem Cell Transplantation in Patients With High-Risk and Recurrent Pediatric Sarcomas,antineoplastic combined chemotherapy regimens
UNKNOWN-check-for-typo,3.33,NCT00043979-1,Arm 2-Recipients,NCT00043979,Stem Cell Transplantation in Patients With High-Risk and Recurrent Pediatric Sarcomas,D00
D013280,3.33,NCT00043979-1,Arm 2-Recipients,NCT00043979,Stem Cell Transplantation in Patients With High-Risk and Recurrent Pediatric Sarcomas,stomatitis
D005334,3.33,NCT00043979-1,Arm 2-Recipients,NCT00043979,Stem Cell Transplantation in Patients With High-Risk and Recurrent Pediatric Sarcomas,fever
D003643,96.67,NCT00043979-1,Arm 2-Recipients,NCT00043979,Stem Cell Transplantation in Patients With High-Risk and Recurrent Pediatric Sarcomas,death
10008496,3.33,NCT00043979-1,Arm 2-Recipients,NCT00043979,Stem Cell Transplantation in Patients With High-Risk and Recurrent Pediatric Sarcomas,chest wall pain
D000069544,3.33,NCT00043979-1,Arm 2-Recipients,NCT00043979,Stem Cell Transplantation in Patients With High-Risk and Recurrent Pediatric Sarcomas,encephalitis infection
D000069544,3.33,NCT00043979-1,Arm 2-Recipients,NCT00043979,Stem Cell Transplantation in Patients With High-Risk and Recurrent Pediatric Sarcomas,encephalitis infection
D000069544,3.33,NCT00043979-1,Arm 2-Recipients,NCT00043979,Stem Cell Transplantation in Patients With High-Risk and Recurrent Pediatric Sarcomas,encephalitis infection
D006932,3.33,NCT00043979-1,Arm 2-Recipients,NCT00043979,Stem Cell Transplantation in Patients With High-Risk and Recurrent Pediatric Sarcomas,hyperbilirubinemia
D000410,3.33,NCT00043979-1,Arm 2-Recipients,NCT00043979,Stem Cell Transplantation in Patients With High-Risk and Recurrent Pediatric Sarcomas,glutamic-pyruvic transaminase
D001219,3.33,NCT00043979-1,Arm 2-Recipients,NCT00043979,Stem Cell Transplantation in Patients With High-Risk and Recurrent Pediatric Sarcomas,serum glutamic-oxaloacetic transaminase
D000068258,3.33,NCT00043979-1,Arm 2-Recipients,NCT00043979,Stem Cell Transplantation in Patients With High-Risk and Recurrent Pediatric Sarcomas,avastin
D000339,3.33,NCT00043979-1,Arm 2-Recipients,NCT00043979,Stem Cell Transplantation in Patients With High-Risk and Recurrent Pediatric Sarcomas,mood
D000339,3.33,NCT00043979-1,Arm 2-Recipients,NCT00043979,Stem Cell Transplantation in Patients With High-Risk and Recurrent Pediatric Sarcomas,mood
D009462,6.67,NCT00043979-1,Arm 2-Recipients,NCT00043979,Stem Cell Transplantation in Patients With High-Risk and Recurrent Pediatric Sarcomas,neurology
D003404,3.33,NCT00043979-1,Arm 2-Recipients,NCT00043979,Stem Cell Transplantation in Patients With High-Risk and Recurrent Pediatric Sarcomas,creatinine
D014627,3.33,NCT00043979-1,Arm 2-Recipients,NCT00043979,Stem Cell Transplantation in Patients With High-Risk and Recurrent Pediatric Sarcomas,vaginitis
D001261,3.33,NCT00043979-1,Arm 2-Recipients,NCT00043979,Stem Cell Transplantation in Patients With High-Risk and Recurrent Pediatric Sarcomas,pulmonary atelectasis
D011654,3.33,NCT00043979-1,Arm 2-Recipients,NCT00043979,Stem Cell Transplantation in Patients With High-Risk and Recurrent Pediatric Sarcomas,pulmonary edema
D004417,6.67,NCT00043979-1,Arm 2-Recipients,NCT00043979,Stem Cell Transplantation in Patients With High-Risk and Recurrent Pediatric Sarcomas,breath shortness
D012141,6.67,NCT00043979-1,Arm 2-Recipients,NCT00043979,Stem Cell Transplantation in Patients With High-Risk and Recurrent Pediatric Sarcomas,infections upper respiratory
D012131,3.33,NCT00043979-1,Arm 2-Recipients,NCT00043979,Stem Cell Transplantation in Patients With High-Risk and Recurrent Pediatric Sarcomas,respiratory failure
D001261,3.33,NCT00043979-1,Arm 2-Recipients,NCT00043979,Stem Cell Transplantation in Patients With High-Risk and Recurrent Pediatric Sarcomas,pulmonary atelectasis
D011855,3.33,NCT00043979-1,Arm 2-Recipients,NCT00043979,Stem Cell Transplantation in Patients With High-Risk and Recurrent Pediatric Sarcomas,radiation recall reaction
D064420,29.73,NCT00048893-1,Carcinoembryonic Antigen (CEA)-Tricom Vaccines,NCT00048893,Vaccine and Chemotherapy for Previously Untreated Metastatic Breast Cancer,adverse drug events
D007962,2.7,NCT00048893-1,Carcinoembryonic Antigen (CEA)-Tricom Vaccines,NCT00048893,Vaccine and Chemotherapy for Previously Untreated Metastatic Breast Cancer,leukocytes
D006098,13.51,NCT00048893-1,Carcinoembryonic Antigen (CEA)-Tricom Vaccines,NCT00048893,Vaccine and Chemotherapy for Previously Untreated Metastatic Breast Cancer,granulocytes
D001792,2.7,NCT00048893-1,Carcinoembryonic Antigen (CEA)-Tricom Vaccines,NCT00048893,Vaccine and Chemotherapy for Previously Untreated Metastatic Breast Cancer,platelets
D004211,2.7,NCT00048893-1,Carcinoembryonic Antigen (CEA)-Tricom Vaccines,NCT00048893,Vaccine and Chemotherapy for Previously Untreated Metastatic Breast Cancer,disseminated intravascular coagulation
D010314,2.7,NCT00048893-1,Carcinoembryonic Antigen (CEA)-Tricom Vaccines,NCT00048893,Vaccine and Chemotherapy for Previously Untreated Metastatic Breast Cancer,partial thromboplastin time
D008625,5.41,NCT00048893-1,Carcinoembryonic Antigen (CEA)-Tricom Vaccines,NCT00048893,Vaccine and Chemotherapy for Previously Untreated Metastatic Breast Cancer,captimer
D007022,5.41,NCT00048893-1,Carcinoembryonic Antigen (CEA)-Tricom Vaccines,NCT00048893,Vaccine and Chemotherapy for Previously Untreated Metastatic Breast Cancer,hypotension
D002542,2.7,NCT00048893-1,Carcinoembryonic Antigen (CEA)-Tricom Vaccines,NCT00048893,Vaccine and Chemotherapy for Previously Untreated Metastatic Breast Cancer,intracranial embolism and thrombosis
D000930,2.7,NCT00048893-1,Carcinoembryonic Antigen (CEA)-Tricom Vaccines,NCT00048893,Vaccine and Chemotherapy for Previously Untreated Metastatic Breast Cancer,antidiarrheals
D001037,2.7,NCT00048893-1,Carcinoembryonic Antigen (CEA)-Tricom Vaccines,NCT00048893,Vaccine and Chemotherapy for Previously Untreated Metastatic Breast Cancer,logasthenia
D009503,13.51,NCT00048893-1,Carcinoembryonic Antigen (CEA)-Tricom Vaccines,NCT00048893,Vaccine and Chemotherapy for Previously Untreated Metastatic Breast Cancer,neutropenia
D000469,2.7,NCT00048893-1,Carcinoembryonic Antigen (CEA)-Tricom Vaccines,NCT00048893,Vaccine and Chemotherapy for Previously Untreated Metastatic Breast Cancer,alkaline phosphatase
D001663,5.41,NCT00048893-1,Carcinoembryonic Antigen (CEA)-Tricom Vaccines,NCT00048893,Vaccine and Chemotherapy for Previously Untreated Metastatic Breast Cancer,bilirubin
D034141,2.7,NCT00048893-1,Carcinoembryonic Antigen (CEA)-Tricom Vaccines,NCT00048893,Vaccine and Chemotherapy for Previously Untreated Metastatic Breast Cancer,hypoalbuminemia
D008107,2.7,NCT00048893-1,Carcinoembryonic Antigen (CEA)-Tricom Vaccines,NCT00048893,Vaccine and Chemotherapy for Previously Untreated Metastatic Breast Cancer,liver dysfunction
D001219,2.7,NCT00048893-1,Carcinoembryonic Antigen (CEA)-Tricom Vaccines,NCT00048893,Vaccine and Chemotherapy for Previously Untreated Metastatic Breast Cancer,serum glutamic-oxaloacetic transaminase
D000410,2.7,NCT00048893-1,Carcinoembryonic Antigen (CEA)-Tricom Vaccines,NCT00048893,Vaccine and Chemotherapy for Previously Untreated Metastatic Breast Cancer,glutamic-pyruvic transaminase
10007810,13.51,NCT00048893-1,Carcinoembryonic Antigen (CEA)-Tricom Vaccines,NCT00048893,Vaccine and Chemotherapy for Previously Untreated Metastatic Breast Cancer,catheter related infection
D064147,21.62,NCT00048893-1,Carcinoembryonic Antigen (CEA)-Tricom Vaccines,NCT00048893,Vaccine and Chemotherapy for Previously Untreated Metastatic Breast Cancer,febrile neutropenia
D000069544,5.41,NCT00048893-1,Carcinoembryonic Antigen (CEA)-Tricom Vaccines,NCT00048893,Vaccine and Chemotherapy for Previously Untreated Metastatic Breast Cancer,encephalitis infection
D000069544,5.41,NCT00048893-1,Carcinoembryonic Antigen (CEA)-Tricom Vaccines,NCT00048893,Vaccine and Chemotherapy for Previously Untreated Metastatic Breast Cancer,encephalitis infection
D055499,2.7,NCT00048893-1,Carcinoembryonic Antigen (CEA)-Tricom Vaccines,NCT00048893,Vaccine and Chemotherapy for Previously Untreated Metastatic Breast Cancer,catheter-related infections
D000138,2.7,NCT00048893-1,Carcinoembryonic Antigen (CEA)-Tricom Vaccines,NCT00048893,Vaccine and Chemotherapy for Previously Untreated Metastatic Breast Cancer,metabolic acidosis
D007010,5.41,NCT00048893-1,Carcinoembryonic Antigen (CEA)-Tricom Vaccines,NCT00048893,Vaccine and Chemotherapy for Previously Untreated Metastatic Breast Cancer,hyponatremia
D003221,2.7,NCT00048893-1,Carcinoembryonic Antigen (CEA)-Tricom Vaccines,NCT00048893,Vaccine and Chemotherapy for Previously Untreated Metastatic Breast Cancer,confusion
D004244,2.7,NCT00048893-1,Carcinoembryonic Antigen (CEA)-Tricom Vaccines,NCT00048893,Vaccine and Chemotherapy for Previously Untreated Metastatic Breast Cancer,dizziness
D003404,2.7,NCT00048893-1,Carcinoembryonic Antigen (CEA)-Tricom Vaccines,NCT00048893,Vaccine and Chemotherapy for Previously Untreated Metastatic Breast Cancer,creatinine
D004417,2.7,NCT00048893-1,Carcinoembryonic Antigen (CEA)-Tricom Vaccines,NCT00048893,Vaccine and Chemotherapy for Previously Untreated Metastatic Breast Cancer,breath shortness
D000860,5.41,NCT00048893-1,Carcinoembryonic Antigen (CEA)-Tricom Vaccines,NCT00048893,Vaccine and Chemotherapy for Previously Untreated Metastatic Breast Cancer,hypoxia
D064420,87.5,NCT00054665-1,Part A: PS-341 Alone,NCT00054665,PS-341 Alone and PS-341 Plus EPOCH Chemotherapy to Treat Non-Hodgkin's Lymphoma,adverse drug events
D064420,90.91,NCT00054665-2,Part B: PS-341 & EPOCH,NCT00054665,PS-341 Alone and PS-341 Plus EPOCH Chemotherapy to Treat Non-Hodgkin's Lymphoma,adverse drug events
D006454,25.0,NCT00054665-1,Part A: PS-341 Alone,NCT00054665,PS-341 Alone and PS-341 Plus EPOCH Chemotherapy to Treat Non-Hodgkin's Lymphoma,hemoglobin
D006454,38.64,NCT00054665-2,Part B: PS-341 & EPOCH,NCT00054665,PS-341 Alone and PS-341 Plus EPOCH Chemotherapy to Treat Non-Hodgkin's Lymphoma,hemoglobin
D007962,29.17,NCT00054665-1,Part A: PS-341 Alone,NCT00054665,PS-341 Alone and PS-341 Plus EPOCH Chemotherapy to Treat Non-Hodgkin's Lymphoma,leukocytes
D007962,38.64,NCT00054665-2,Part B: PS-341 & EPOCH,NCT00054665,PS-341 Alone and PS-341 Plus EPOCH Chemotherapy to Treat Non-Hodgkin's Lymphoma,leukocytes
D007962,4.17,NCT00054665-1,Part A: PS-341 Alone,NCT00054665,PS-341 Alone and PS-341 Plus EPOCH Chemotherapy to Treat Non-Hodgkin's Lymphoma,leukocytes
D008231,20.83,NCT00054665-1,Part A: PS-341 Alone,NCT00054665,PS-341 Alone and PS-341 Plus EPOCH Chemotherapy to Treat Non-Hodgkin's Lymphoma,lymphopenia
D008231,29.55,NCT00054665-2,Part B: PS-341 & EPOCH,NCT00054665,PS-341 Alone and PS-341 Plus EPOCH Chemotherapy to Treat Non-Hodgkin's Lymphoma,lymphopenia
D006098,20.83,NCT00054665-1,Part A: PS-341 Alone,NCT00054665,PS-341 Alone and PS-341 Plus EPOCH Chemotherapy to Treat Non-Hodgkin's Lymphoma,granulocytes
D006098,47.73,NCT00054665-2,Part B: PS-341 & EPOCH,NCT00054665,PS-341 Alone and PS-341 Plus EPOCH Chemotherapy to Treat Non-Hodgkin's Lymphoma,granulocytes
D001792,50.0,NCT00054665-1,Part A: PS-341 Alone,NCT00054665,PS-341 Alone and PS-341 Plus EPOCH Chemotherapy to Treat Non-Hodgkin's Lymphoma,platelets
D001792,75.0,NCT00054665-2,Part B: PS-341 & EPOCH,NCT00054665,PS-341 Alone and PS-341 Plus EPOCH Chemotherapy to Treat Non-Hodgkin's Lymphoma,platelets
D001792,4.17,NCT00054665-1,Part A: PS-341 Alone,NCT00054665,PS-341 Alone and PS-341 Plus EPOCH Chemotherapy to Treat Non-Hodgkin's Lymphoma,platelets
D001792,27.27,NCT00054665-2,Part B: PS-341 & EPOCH,NCT00054665,PS-341 Alone and PS-341 Plus EPOCH Chemotherapy to Treat Non-Hodgkin's Lymphoma,platelets
D001804,4.17,NCT00054665-1,Part A: PS-341 Alone,NCT00054665,PS-341 Alone and PS-341 Plus EPOCH Chemotherapy to Treat Non-Hodgkin's Lymphoma,autotransfusion
D001804,29.55,NCT00054665-2,Part B: PS-341 & EPOCH,NCT00054665,PS-341 Alone and PS-341 Plus EPOCH Chemotherapy to Treat Non-Hodgkin's Lymphoma,autotransfusion
D013575,4.17,NCT00054665-1,Part A: PS-341 Alone,NCT00054665,PS-341 Alone and PS-341 Plus EPOCH Chemotherapy to Treat Non-Hodgkin's Lymphoma,syncopal episode
D007022,16.67,NCT00054665-1,Part A: PS-341 Alone,NCT00054665,PS-341 Alone and PS-341 Plus EPOCH Chemotherapy to Treat Non-Hodgkin's Lymphoma,hypotension
D007022,25.0,NCT00054665-2,Part B: PS-341 & EPOCH,NCT00054665,PS-341 Alone and PS-341 Plus EPOCH Chemotherapy to Treat Non-Hodgkin's Lymphoma,hypotension
10014383,2.27,NCT00054665-2,Part B: PS-341 & EPOCH,NCT00054665,PS-341 Alone and PS-341 Plus EPOCH Chemotherapy to Treat Non-Hodgkin's Lymphoma,electrocardiogram qt corrected interval prolonged
D013617,2.27,NCT00054665-2,Part B: PS-341 & EPOCH,NCT00054665,PS-341 Alone and PS-341 Plus EPOCH Chemotherapy to Treat Non-Hodgkin's Lymphoma,tachycardia supraventricular
D006309,2.27,NCT00054665-2,Part B: PS-341 & EPOCH,NCT00054665,PS-341 Alone and PS-341 Plus EPOCH Chemotherapy to Treat Non-Hodgkin's Lymphoma,hearing
10054541,4.17,NCT00054665-1,Part A: PS-341 Alone,NCT00054665,PS-341 Alone and PS-341 Plus EPOCH Chemotherapy to Treat Non-Hodgkin's Lymphoma,periorbital edema
D000855,16.67,NCT00054665-1,Part A: PS-341 Alone,NCT00054665,PS-341 Alone and PS-341 Plus EPOCH Chemotherapy to Treat Non-Hodgkin's Lymphoma,anorexia
D000855,18.18,NCT00054665-2,Part B: PS-341 & EPOCH,NCT00054665,PS-341 Alone and PS-341 Plus EPOCH Chemotherapy to Treat Non-Hodgkin's Lymphoma,anorexia
D003248,4.17,NCT00054665-1,Part A: PS-341 Alone,NCT00054665,PS-341 Alone and PS-341 Plus EPOCH Chemotherapy to Treat Non-Hodgkin's Lymphoma,constipation
D003248,13.64,NCT00054665-2,Part B: PS-341 & EPOCH,NCT00054665,PS-341 Alone and PS-341 Plus EPOCH Chemotherapy to Treat Non-Hodgkin's Lymphoma,constipation
D000930,29.17,NCT00054665-1,Part A: PS-341 Alone,NCT00054665,PS-341 Alone and PS-341 Plus EPOCH Chemotherapy to Treat Non-Hodgkin's Lymphoma,antidiarrheals
D000930,25.0,NCT00054665-2,Part B: PS-341 & EPOCH,NCT00054665,PS-341 Alone and PS-341 Plus EPOCH Chemotherapy to Treat Non-Hodgkin's Lymphoma,antidiarrheals
D009325,29.17,NCT00054665-1,Part A: PS-341 Alone,NCT00054665,PS-341 Alone and PS-341 Plus EPOCH Chemotherapy to Treat Non-Hodgkin's Lymphoma,nausea
D009325,27.27,NCT00054665-2,Part B: PS-341 & EPOCH,NCT00054665,PS-341 Alone and PS-341 Plus EPOCH Chemotherapy to Treat Non-Hodgkin's Lymphoma,nausea
D013280,8.33,NCT00054665-1,Part A: PS-341 Alone,NCT00054665,PS-341 Alone and PS-341 Plus EPOCH Chemotherapy to Treat Non-Hodgkin's Lymphoma,oral mucositis
D013280,18.18,NCT00054665-2,Part B: PS-341 & EPOCH,NCT00054665,PS-341 Alone and PS-341 Plus EPOCH Chemotherapy to Treat Non-Hodgkin's Lymphoma,oral mucositis
D000068538,12.5,NCT00054665-1,Part A: PS-341 Alone,NCT00054665,PS-341 Alone and PS-341 Plus EPOCH Chemotherapy to Treat Non-Hodgkin's Lymphoma,dutasteride
D000068538,13.64,NCT00054665-2,Part B: PS-341 & EPOCH,NCT00054665,PS-341 Alone and PS-341 Plus EPOCH Chemotherapy to Treat Non-Hodgkin's Lymphoma,dutasteride
D014839,4.17,NCT00054665-1,Part A: PS-341 Alone,NCT00054665,PS-341 Alone and PS-341 Plus EPOCH Chemotherapy to Treat Non-Hodgkin's Lymphoma,vomiting
D014839,11.36,NCT00054665-2,Part B: PS-341 & EPOCH,NCT00054665,PS-341 Alone and PS-341 Plus EPOCH Chemotherapy to Treat Non-Hodgkin's Lymphoma,vomiting
D015746,12.5,NCT00054665-1,Part A: PS-341 Alone,NCT00054665,PS-341 Alone and PS-341 Plus EPOCH Chemotherapy to Treat Non-Hodgkin's Lymphoma,abdominal pain
D015746,11.36,NCT00054665-2,Part B: PS-341 & EPOCH,NCT00054665,PS-341 Alone and PS-341 Plus EPOCH Chemotherapy to Treat Non-Hodgkin's Lymphoma,abdominal pain
D003681,2.27,NCT00054665-2,Part B: PS-341 & EPOCH,NCT00054665,PS-341 Alone and PS-341 Plus EPOCH Chemotherapy to Treat Non-Hodgkin's Lymphoma,dehydration
D003679,2.27,NCT00054665-2,Part B: PS-341 & EPOCH,NCT00054665,PS-341 Alone and PS-341 Plus EPOCH Chemotherapy to Treat Non-Hodgkin's Lymphoma,swallowing
D005414,2.27,NCT00054665-2,Part B: PS-341 & EPOCH,NCT00054665,PS-341 Alone and PS-341 Plus EPOCH Chemotherapy to Treat Non-Hodgkin's Lymphoma,flatulence
10017947,4.55,NCT00054665-2,Part B: PS-341 & EPOCH,NCT00054665,PS-341 Alone and PS-341 Plus EPOCH Chemotherapy to Treat Non-Hodgkin's Lymphoma,gastrointestinal disorders - other specify
D045823,2.27,NCT00054665-2,Part B: PS-341 & EPOCH,NCT00054665,PS-341 Alone and PS-341 Plus EPOCH Chemotherapy to Treat Non-Hodgkin's Lymphoma,ileus
D006470,4.55,NCT00054665-2,Part B: PS-341 & EPOCH,NCT00054665,PS-341 Alone and PS-341 Plus EPOCH Chemotherapy to Treat Non-Hodgkin's Lymphoma,bleeding
D004487,4.17,NCT00054665-1,Part A: PS-341 Alone,NCT00054665,PS-341 Alone and PS-341 Plus EPOCH Chemotherapy to Treat Non-Hodgkin's Lymphoma,edema
D004487,11.36,NCT00054665-2,Part B: PS-341 & EPOCH,NCT00054665,PS-341 Alone and PS-341 Plus EPOCH Chemotherapy to Treat Non-Hodgkin's Lymphoma,edema
D001037,33.33,NCT00054665-1,Part A: PS-341 Alone,NCT00054665,PS-341 Alone and PS-341 Plus EPOCH Chemotherapy to Treat Non-Hodgkin's Lymphoma,logasthenia
D001037,22.73,NCT00054665-2,Part B: PS-341 & EPOCH,NCT00054665,PS-341 Alone and PS-341 Plus EPOCH Chemotherapy to Treat Non-Hodgkin's Lymphoma,logasthenia
D009503,12.5,NCT00054665-1,Part A: PS-341 Alone,NCT00054665,PS-341 Alone and PS-341 Plus EPOCH Chemotherapy to Treat Non-Hodgkin's Lymphoma,neutropenia
D009503,6.82,NCT00054665-2,Part B: PS-341 & EPOCH,NCT00054665,PS-341 Alone and PS-341 Plus EPOCH Chemotherapy to Treat Non-Hodgkin's Lymphoma,neutropenia
D023341,4.17,NCT00054665-1,Part A: PS-341 Alone,NCT00054665,PS-341 Alone and PS-341 Plus EPOCH Chemotherapy to Treat Non-Hodgkin's Lymphoma,chills
D013546,4.17,NCT00054665-1,Part A: PS-341 Alone,NCT00054665,PS-341 Alone and PS-341 Plus EPOCH Chemotherapy to Treat Non-Hodgkin's Lymphoma,sweating
D015431,4.55,NCT00054665-2,Part B: PS-341 & EPOCH,NCT00054665,PS-341 Alone and PS-341 Plus EPOCH Chemotherapy to Treat Non-Hodgkin's Lymphoma,weight loss
10043345,2.27,NCT00054665-2,Part B: PS-341 & EPOCH,NCT00054665,PS-341 Alone and PS-341 Plus EPOCH Chemotherapy to Treat Non-Hodgkin's Lymphoma,testicular pain
10062572,2.27,NCT00054665-2,Part B: PS-341 & EPOCH,NCT00054665,PS-341 Alone and PS-341 Plus EPOCH Chemotherapy to Treat Non-Hodgkin's Lymphoma,generalized muscle weakness
D000469,4.17,NCT00054665-1,Part A: PS-341 Alone,NCT00054665,PS-341 Alone and PS-341 Plus EPOCH Chemotherapy to Treat Non-Hodgkin's Lymphoma,alkaline phosphatase
D000469,6.82,NCT00054665-2,Part B: PS-341 & EPOCH,NCT00054665,PS-341 Alone and PS-341 Plus EPOCH Chemotherapy to Treat Non-Hodgkin's Lymphoma,alkaline phosphatase
D034141,4.17,NCT00054665-1,Part A: PS-341 Alone,NCT00054665,PS-341 Alone and PS-341 Plus EPOCH Chemotherapy to Treat Non-Hodgkin's Lymphoma,hypoalbuminemia
D034141,20.45,NCT00054665-2,Part B: PS-341 & EPOCH,NCT00054665,PS-341 Alone and PS-341 Plus EPOCH Chemotherapy to Treat Non-Hodgkin's Lymphoma,hypoalbuminemia
D001219,8.33,NCT00054665-1,Part A: PS-341 Alone,NCT00054665,PS-341 Alone and PS-341 Plus EPOCH Chemotherapy to Treat Non-Hodgkin's Lymphoma,serum glutamic-oxaloacetic transaminase
D001219,9.09,NCT00054665-2,Part B: PS-341 & EPOCH,NCT00054665,PS-341 Alone and PS-341 Plus EPOCH Chemotherapy to Treat Non-Hodgkin's Lymphoma,serum glutamic-oxaloacetic transaminase
D000410,12.5,NCT00054665-1,Part A: PS-341 Alone,NCT00054665,PS-341 Alone and PS-341 Plus EPOCH Chemotherapy to Treat Non-Hodgkin's Lymphoma,glutamic-pyruvic transaminase
D000410,6.82,NCT00054665-2,Part B: PS-341 & EPOCH,NCT00054665,PS-341 Alone and PS-341 Plus EPOCH Chemotherapy to Treat Non-Hodgkin's Lymphoma,glutamic-pyruvic transaminase
D001663,6.82,NCT00054665-2,Part B: PS-341 & EPOCH,NCT00054665,PS-341 Alone and PS-341 Plus EPOCH Chemotherapy to Treat Non-Hodgkin's Lymphoma,bilirubin
10036402,4.17,NCT00054665-1,Part A: PS-341 Alone,NCT00054665,PS-341 Alone and PS-341 Plus EPOCH Chemotherapy to Treat Non-Hodgkin's Lymphoma,postnasal drip
D064147,11.36,NCT00054665-2,Part B: PS-341 & EPOCH,NCT00054665,PS-341 Alone and PS-341 Plus EPOCH Chemotherapy to Treat Non-Hodgkin's Lymphoma,febrile neutropenia
D007239,20.45,NCT00054665-2,Part B: PS-341 & EPOCH,NCT00054665,PS-341 Alone and PS-341 Plus EPOCH Chemotherapy to Treat Non-Hodgkin's Lymphoma,infection
D000069544,2.27,NCT00054665-2,Part B: PS-341 & EPOCH,NCT00054665,PS-341 Alone and PS-341 Plus EPOCH Chemotherapy to Treat Non-Hodgkin's Lymphoma,encephalitis infection
D000069544,15.91,NCT00054665-2,Part B: PS-341 & EPOCH,NCT00054665,PS-341 Alone and PS-341 Plus EPOCH Chemotherapy to Treat Non-Hodgkin's Lymphoma,encephalitis infection
D010314,12.5,NCT00054665-1,Part A: PS-341 Alone,NCT00054665,PS-341 Alone and PS-341 Plus EPOCH Chemotherapy to Treat Non-Hodgkin's Lymphoma,partial thromboplastin time
D010314,9.09,NCT00054665-2,Part B: PS-341 & EPOCH,NCT00054665,PS-341 Alone and PS-341 Plus EPOCH Chemotherapy to Treat Non-Hodgkin's Lymphoma,partial thromboplastin time
D008625,4.17,NCT00054665-1,Part A: PS-341 Alone,NCT00054665,PS-341 Alone and PS-341 Plus EPOCH Chemotherapy to Treat Non-Hodgkin's Lymphoma,captimer
D008625,2.27,NCT00054665-2,Part B: PS-341 & EPOCH,NCT00054665,PS-341 Alone and PS-341 Plus EPOCH Chemotherapy to Treat Non-Hodgkin's Lymphoma,captimer
D001457,2.27,NCT00054665-2,Part B: PS-341 & EPOCH,NCT00054665,PS-341 Alone and PS-341 Plus EPOCH Chemotherapy to Treat Non-Hodgkin's Lymphoma,ae1 chloride-bicarbonate exchanger
D006996,4.17,NCT00054665-1,Part A: PS-341 Alone,NCT00054665,PS-341 Alone and PS-341 Plus EPOCH Chemotherapy to Treat Non-Hodgkin's Lymphoma,hypocalcemia
D006996,9.09,NCT00054665-2,Part B: PS-341 & EPOCH,NCT00054665,PS-341 Alone and PS-341 Plus EPOCH Chemotherapy to Treat Non-Hodgkin's Lymphoma,hypocalcemia
D007003,4.17,NCT00054665-1,Part A: PS-341 Alone,NCT00054665,PS-341 Alone and PS-341 Plus EPOCH Chemotherapy to Treat Non-Hodgkin's Lymphoma,hypoglycemia
D007008,4.17,NCT00054665-1,Part A: PS-341 Alone,NCT00054665,PS-341 Alone and PS-341 Plus EPOCH Chemotherapy to Treat Non-Hodgkin's Lymphoma,hypokalemia
D007008,11.36,NCT00054665-2,Part B: PS-341 & EPOCH,NCT00054665,PS-341 Alone and PS-341 Plus EPOCH Chemotherapy to Treat Non-Hodgkin's Lymphoma,hypokalemia
10021028,8.33,NCT00054665-1,Part A: PS-341 Alone,NCT00054665,PS-341 Alone and PS-341 Plus EPOCH Chemotherapy to Treat Non-Hodgkin's Lymphoma,hypomagnesemia
10021028,9.09,NCT00054665-2,Part B: PS-341 & EPOCH,NCT00054665,PS-341 Alone and PS-341 Plus EPOCH Chemotherapy to Treat Non-Hodgkin's Lymphoma,hypomagnesemia
D007010,4.17,NCT00054665-1,Part A: PS-341 Alone,NCT00054665,PS-341 Alone and PS-341 Plus EPOCH Chemotherapy to Treat Non-Hodgkin's Lymphoma,hyponatremia
D007010,9.09,NCT00054665-2,Part B: PS-341 & EPOCH,NCT00054665,PS-341 Alone and PS-341 Plus EPOCH Chemotherapy to Treat Non-Hodgkin's Lymphoma,hyponatremia
D006943,22.73,NCT00054665-2,Part B: PS-341 & EPOCH,NCT00054665,PS-341 Alone and PS-341 Plus EPOCH Chemotherapy to Treat Non-Hodgkin's Lymphoma,hyperglycemia
10020670,2.27,NCT00054665-2,Part B: PS-341 & EPOCH,NCT00054665,PS-341 Alone and PS-341 Plus EPOCH Chemotherapy to Treat Non-Hodgkin's Lymphoma,hypermagnesemia
D033461,6.82,NCT00054665-2,Part B: PS-341 & EPOCH,NCT00054665,PS-341 Alone and PS-341 Plus EPOCH Chemotherapy to Treat Non-Hodgkin's Lymphoma,hyperuricemia
D017674,4.55,NCT00054665-2,Part B: PS-341 & EPOCH,NCT00054665,PS-341 Alone and PS-341 Plus EPOCH Chemotherapy to Treat Non-Hodgkin's Lymphoma,hypophosphatemia
D018771,4.17,NCT00054665-1,Part A: PS-341 Alone,NCT00054665,PS-341 Alone and PS-341 Plus EPOCH Chemotherapy to Treat Non-Hodgkin's Lymphoma,joint pain
D018771,2.27,NCT00054665-2,Part B: PS-341 & EPOCH,NCT00054665,PS-341 Alone and PS-341 Plus EPOCH Chemotherapy to Treat Non-Hodgkin's Lymphoma,joint pain
D063806,12.5,NCT00054665-1,Part A: PS-341 Alone,NCT00054665,PS-341 Alone and PS-341 Plus EPOCH Chemotherapy to Treat Non-Hodgkin's Lymphoma,muscle pain
D063806,2.27,NCT00054665-2,Part B: PS-341 & EPOCH,NCT00054665,PS-341 Alone and PS-341 Plus EPOCH Chemotherapy to Treat Non-Hodgkin's Lymphoma,muscle pain
D018908,15.91,NCT00054665-2,Part B: PS-341 & EPOCH,NCT00054665,PS-341 Alone and PS-341 Plus EPOCH Chemotherapy to Treat Non-Hodgkin's Lymphoma,muscle weakness
10006002,6.82,NCT00054665-2,Part B: PS-341 & EPOCH,NCT00054665,PS-341 Alone and PS-341 Plus EPOCH Chemotherapy to Treat Non-Hodgkin's Lymphoma,bone pain
10062501,2.27,NCT00054665-2,Part B: PS-341 & EPOCH,NCT00054665,PS-341 Alone and PS-341 Plus EPOCH Chemotherapy to Treat Non-Hodgkin's Lymphoma,non-cardiac chest pain
D001259,4.17,NCT00054665-1,Part A: PS-341 Alone,NCT00054665,PS-341 Alone and PS-341 Plus EPOCH Chemotherapy to Treat Non-Hodgkin's Lymphoma,ataxia
D001259,2.27,NCT00054665-2,Part B: PS-341 & EPOCH,NCT00054665,PS-341 Alone and PS-341 Plus EPOCH Chemotherapy to Treat Non-Hodgkin's Lymphoma,ataxia
D004244,8.33,NCT00054665-1,Part A: PS-341 Alone,NCT00054665,PS-341 Alone and PS-341 Plus EPOCH Chemotherapy to Treat Non-Hodgkin's Lymphoma,dizziness
D004244,9.09,NCT00054665-2,Part B: PS-341 & EPOCH,NCT00054665,PS-341 Alone and PS-341 Plus EPOCH Chemotherapy to Treat Non-Hodgkin's Lymphoma,dizziness
D002607,4.17,NCT00054665-1,Part A: PS-341 Alone,NCT00054665,PS-341 Alone and PS-341 Plus EPOCH Chemotherapy to Treat Non-Hodgkin's Lymphoma,hereditary type i motor and sensory neuropathy
D002607,4.55,NCT00054665-2,Part B: PS-341 & EPOCH,NCT00054665,PS-341 Alone and PS-341 Plus EPOCH Chemotherapy to Treat Non-Hodgkin's Lymphoma,hereditary type i motor and sensory neuropathy
D002607,20.83,NCT00054665-1,Part A: PS-341 Alone,NCT00054665,PS-341 Alone and PS-341 Plus EPOCH Chemotherapy to Treat Non-Hodgkin's Lymphoma,hereditary type i motor and sensory neuropathy
D002607,18.18,NCT00054665-2,Part B: PS-341 & EPOCH,NCT00054665,PS-341 Alone and PS-341 Plus EPOCH Chemotherapy to Treat Non-Hodgkin's Lymphoma,hereditary type i motor and sensory neuropathy
D013575,4.17,NCT00054665-1,Part A: PS-341 Alone,NCT00054665,PS-341 Alone and PS-341 Plus EPOCH Chemotherapy to Treat Non-Hodgkin's Lymphoma,syncope
D013575,2.27,NCT00054665-2,Part B: PS-341 & EPOCH,NCT00054665,PS-341 Alone and PS-341 Plus EPOCH Chemotherapy to Treat Non-Hodgkin's Lymphoma,syncope
D006261,4.17,NCT00054665-1,Part A: PS-341 Alone,NCT00054665,PS-341 Alone and PS-341 Plus EPOCH Chemotherapy to Treat Non-Hodgkin's Lymphoma,headache
D006261,2.27,NCT00054665-2,Part B: PS-341 & EPOCH,NCT00054665,PS-341 Alone and PS-341 Plus EPOCH Chemotherapy to Treat Non-Hodgkin's Lymphoma,headache
D009437,4.17,NCT00054665-1,Part A: PS-341 Alone,NCT00054665,PS-341 Alone and PS-341 Plus EPOCH Chemotherapy to Treat Non-Hodgkin's Lymphoma,neuropathic pain
D009437,2.27,NCT00054665-2,Part B: PS-341 & EPOCH,NCT00054665,PS-341 Alone and PS-341 Plus EPOCH Chemotherapy to Treat Non-Hodgkin's Lymphoma,neuropathic pain
D009462,9.09,NCT00054665-2,Part B: PS-341 & EPOCH,NCT00054665,PS-341 Alone and PS-341 Plus EPOCH Chemotherapy to Treat Non-Hodgkin's Lymphoma,neurology
D007319,6.82,NCT00054665-2,Part B: PS-341 & EPOCH,NCT00054665,PS-341 Alone and PS-341 Plus EPOCH Chemotherapy to Treat Non-Hodgkin's Lymphoma,insomnia
D000339,2.27,NCT00054665-2,Part B: PS-341 & EPOCH,NCT00054665,PS-341 Alone and PS-341 Plus EPOCH Chemotherapy to Treat Non-Hodgkin's Lymphoma,mood
D003404,2.27,NCT00054665-2,Part B: PS-341 & EPOCH,NCT00054665,PS-341 Alone and PS-341 Plus EPOCH Chemotherapy to Treat Non-Hodgkin's Lymphoma,creatinine
D004844,2.27,NCT00054665-2,Part B: PS-341 & EPOCH,NCT00054665,PS-341 Alone and PS-341 Plus EPOCH Chemotherapy to Treat Non-Hodgkin's Lymphoma,epistaxis
D004417,9.09,NCT00054665-2,Part B: PS-341 & EPOCH,NCT00054665,PS-341 Alone and PS-341 Plus EPOCH Chemotherapy to Treat Non-Hodgkin's Lymphoma,breath shortness
D006606,2.27,NCT00054665-2,Part B: PS-341 & EPOCH,NCT00054665,PS-341 Alone and PS-341 Plus EPOCH Chemotherapy to Treat Non-Hodgkin's Lymphoma,hiccups
D006685,2.27,NCT00054665-2,Part B: PS-341 & EPOCH,NCT00054665,PS-341 Alone and PS-341 Plus EPOCH Chemotherapy to Treat Non-Hodgkin's Lymphoma,voice hoarseness
D000860,2.27,NCT00054665-2,Part B: PS-341 & EPOCH,NCT00054665,PS-341 Alone and PS-341 Plus EPOCH Chemotherapy to Treat Non-Hodgkin's Lymphoma,hypoxia
D012135,4.55,NCT00054665-2,Part B: PS-341 & EPOCH,NCT00054665,PS-341 Alone and PS-341 Plus EPOCH Chemotherapy to Treat Non-Hodgkin's Lymphoma,wheezing
D013921,4.17,NCT00054665-1,Part A: PS-341 Alone,NCT00054665,PS-341 Alone and PS-341 Plus EPOCH Chemotherapy to Treat Non-Hodgkin's Lymphoma,thrombocytopenia
D005076,12.5,NCT00054665-1,Part A: PS-341 Alone,NCT00054665,PS-341 Alone and PS-341 Plus EPOCH Chemotherapy to Treat Non-Hodgkin's Lymphoma,rash
D001109,4.17,NCT00054665-1,Part A: PS-341 Alone,NCT00054665,PS-341 Alone and PS-341 Plus EPOCH Chemotherapy to Treat Non-Hodgkin's Lymphoma,archives
10028689,2.27,NCT00054665-2,Part B: PS-341 & EPOCH,NCT00054665,PS-341 Alone and PS-341 Plus EPOCH Chemotherapy to Treat Non-Hodgkin's Lymphoma,nail changes
D011537,2.27,NCT00054665-2,Part B: PS-341 & EPOCH,NCT00054665,PS-341 Alone and PS-341 Plus EPOCH Chemotherapy to Treat Non-Hodgkin's Lymphoma,pruritus
D009026,74.19,NCT00069238-1,All Participants,NCT00069238,Campath-1H and EPOCH to Treat Non-Hodgkin's T- and NK-Cell Lymphomas,mortality
D064420,74.19,NCT00069238-1,All Participants,NCT00069238,Campath-1H and EPOCH to Treat Non-Hodgkin's T- and NK-Cell Lymphomas,adverse drug events
10055356,3.23,NCT00069238-1,All Participants,NCT00069238,Campath-1H and EPOCH to Treat Non-Hodgkin's T- and NK-Cell Lymphomas,upper gastrointestinal hemorrhage
D003643,22.58,NCT00069238-1,All Participants,NCT00069238,Campath-1H and EPOCH to Treat Non-Hodgkin's T- and NK-Cell Lymphomas,death
D003643,51.61,NCT00069238-1,All Participants,NCT00069238,Campath-1H and EPOCH to Treat Non-Hodgkin's T- and NK-Cell Lymphomas,death
D000069544,3.23,NCT00069238-1,All Participants,NCT00069238,Campath-1H and EPOCH to Treat Non-Hodgkin's T- and NK-Cell Lymphomas,encephalitis infection
D000069544,3.23,NCT00069238-1,All Participants,NCT00069238,Campath-1H and EPOCH to Treat Non-Hodgkin's T- and NK-Cell Lymphomas,encephalitis infection
D000069544,3.23,NCT00069238-1,All Participants,NCT00069238,Campath-1H and EPOCH to Treat Non-Hodgkin's T- and NK-Cell Lymphomas,encephalitis infection
D000069544,3.23,NCT00069238-1,All Participants,NCT00069238,Campath-1H and EPOCH to Treat Non-Hodgkin's T- and NK-Cell Lymphomas,encephalitis infection
D000069544,3.23,NCT00069238-1,All Participants,NCT00069238,Campath-1H and EPOCH to Treat Non-Hodgkin's T- and NK-Cell Lymphomas,encephalitis infection
D000308,3.23,NCT00069238-1,All Participants,NCT00069238,Campath-1H and EPOCH to Treat Non-Hodgkin's T- and NK-Cell Lymphomas,hyperadrenalism
D014564,3.23,NCT00069238-1,All Participants,NCT00069238,Campath-1H and EPOCH to Treat Non-Hodgkin's T- and NK-Cell Lymphomas,genitourinary abnormalities
D064420,1.53,NCT00070564-1,ARM I,NCT00070564,S0221 Adjuvant Doxorubicin  Cyclophosphamide  and Paclitaxel in Treating Patients With Breast Cancer,adverse drug events
D064420,1.21,NCT00070564-2,ARM II,NCT00070564,S0221 Adjuvant Doxorubicin  Cyclophosphamide  and Paclitaxel in Treating Patients With Breast Cancer,adverse drug events
D064420,2.52,NCT00070564-3,ARM III,NCT00070564,S0221 Adjuvant Doxorubicin  Cyclophosphamide  and Paclitaxel in Treating Patients With Breast Cancer,adverse drug events
D064420,1.44,NCT00070564-4,ARM IV,NCT00070564,S0221 Adjuvant Doxorubicin  Cyclophosphamide  and Paclitaxel in Treating Patients With Breast Cancer,adverse drug events
D064420,1.82,NCT00070564-5,ARM V,NCT00070564,S0221 Adjuvant Doxorubicin  Cyclophosphamide  and Paclitaxel in Treating Patients With Breast Cancer,adverse drug events
D064420,2.75,NCT00070564-6,ARM VI,NCT00070564,S0221 Adjuvant Doxorubicin  Cyclophosphamide  and Paclitaxel in Treating Patients With Breast Cancer,adverse drug events
D001853,0.15,NCT00070564-1,ARM I,NCT00070564,S0221 Adjuvant Doxorubicin  Cyclophosphamide  and Paclitaxel in Treating Patients With Breast Cancer,bone marrow
D004211,0.15,NCT00070564-1,ARM I,NCT00070564,S0221 Adjuvant Doxorubicin  Cyclophosphamide  and Paclitaxel in Treating Patients With Breast Cancer,disseminated intravascular coagulation
D064147,0.36,NCT00070564-5,ARM V,NCT00070564,S0221 Adjuvant Doxorubicin  Cyclophosphamide  and Paclitaxel in Treating Patients With Breast Cancer,febrile neutropenia
D064147,0.69,NCT00070564-6,ARM VI,NCT00070564,S0221 Adjuvant Doxorubicin  Cyclophosphamide  and Paclitaxel in Treating Patients With Breast Cancer,febrile neutropenia
D006342,0.15,NCT00070564-3,ARM III,NCT00070564,S0221 Adjuvant Doxorubicin  Cyclophosphamide  and Paclitaxel in Treating Patients With Breast Cancer,cardiac rupture post-infarction
D001861,0.15,NCT00070564-3,ARM III,NCT00070564,S0221 Adjuvant Doxorubicin  Cyclophosphamide  and Paclitaxel in Treating Patients With Breast Cancer,osteoconduction
D018487,0.15,NCT00070564-1,ARM I,NCT00070564,S0221 Adjuvant Doxorubicin  Cyclophosphamide  and Paclitaxel in Treating Patients With Breast Cancer,ventricular dysfunction left
D018487,0.15,NCT00070564-3,ARM III,NCT00070564,S0221 Adjuvant Doxorubicin  Cyclophosphamide  and Paclitaxel in Treating Patients With Breast Cancer,ventricular dysfunction left
10069501,0.15,NCT00070564-1,ARM I,NCT00070564,S0221 Adjuvant Doxorubicin  Cyclophosphamide  and Paclitaxel in Treating Patients With Breast Cancer,left ventricular systolic dysfunction
10069501,0.36,NCT00070564-5,ARM V,NCT00070564,S0221 Adjuvant Doxorubicin  Cyclophosphamide  and Paclitaxel in Treating Patients With Breast Cancer,left ventricular systolic dysfunction
D009205,0.15,NCT00070564-3,ARM III,NCT00070564,S0221 Adjuvant Doxorubicin  Cyclophosphamide  and Paclitaxel in Treating Patients With Breast Cancer,myocarditis
D010490,0.34,NCT00070564-6,ARM VI,NCT00070564,S0221 Adjuvant Doxorubicin  Cyclophosphamide  and Paclitaxel in Treating Patients With Breast Cancer,pericardial effusion
10047281,0.15,NCT00070564-1,ARM I,NCT00070564,S0221 Adjuvant Doxorubicin  Cyclophosphamide  and Paclitaxel in Treating Patients With Breast Cancer,ventricular arrhythmia
D000071896,0.15,NCT00070564-2,ARM II,NCT00070564,S0221 Adjuvant Doxorubicin  Cyclophosphamide  and Paclitaxel in Treating Patients With Breast Cancer,somatic symptoms
D009102,0.15,NCT00070564-1,ARM I,NCT00070564,S0221 Adjuvant Doxorubicin  Cyclophosphamide  and Paclitaxel in Treating Patients With Breast Cancer,multiple organ failure
D009102,0.15,NCT00070564-3,ARM III,NCT00070564,S0221 Adjuvant Doxorubicin  Cyclophosphamide  and Paclitaxel in Treating Patients With Breast Cancer,multiple organ failure
D003643,0.16,NCT00070564-4,ARM IV,NCT00070564,S0221 Adjuvant Doxorubicin  Cyclophosphamide  and Paclitaxel in Treating Patients With Breast Cancer,death
D003643,0.34,NCT00070564-6,ARM VI,NCT00070564,S0221 Adjuvant Doxorubicin  Cyclophosphamide  and Paclitaxel in Treating Patients With Breast Cancer,death
D008107,0.15,NCT00070564-1,ARM I,NCT00070564,S0221 Adjuvant Doxorubicin  Cyclophosphamide  and Paclitaxel in Treating Patients With Breast Cancer,liver dysfunction
D008107,0.15,NCT00070564-3,ARM III,NCT00070564,S0221 Adjuvant Doxorubicin  Cyclophosphamide  and Paclitaxel in Treating Patients With Breast Cancer,liver dysfunction
D000080104,0.15,NCT00070564-1,ARM I,NCT00070564,S0221 Adjuvant Doxorubicin  Cyclophosphamide  and Paclitaxel in Treating Patients With Breast Cancer,infertility clinics
D000080104,0.15,NCT00070564-2,ARM II,NCT00070564,S0221 Adjuvant Doxorubicin  Cyclophosphamide  and Paclitaxel in Treating Patients With Breast Cancer,infertility clinics
D000080104,0.32,NCT00070564-4,ARM IV,NCT00070564,S0221 Adjuvant Doxorubicin  Cyclophosphamide  and Paclitaxel in Treating Patients With Breast Cancer,infertility clinics
D001788,0.15,NCT00070564-1,ARM I,NCT00070564,S0221 Adjuvant Doxorubicin  Cyclophosphamide  and Paclitaxel in Treating Patients With Breast Cancer,blood grouping
D011014,0.16,NCT00070564-4,ARM IV,NCT00070564,S0221 Adjuvant Doxorubicin  Cyclophosphamide  and Paclitaxel in Treating Patients With Breast Cancer,lung inflammation
D018461,0.15,NCT00070564-3,ARM III,NCT00070564,S0221 Adjuvant Doxorubicin  Cyclophosphamide  and Paclitaxel in Treating Patients With Breast Cancer,soft tissue infections
D000069544,0.34,NCT00070564-6,ARM VI,NCT00070564,S0221 Adjuvant Doxorubicin  Cyclophosphamide  and Paclitaxel in Treating Patients With Breast Cancer,encephalitis infection
10040872,0.34,NCT00070564-6,ARM VI,NCT00070564,S0221 Adjuvant Doxorubicin  Cyclophosphamide  and Paclitaxel in Treating Patients With Breast Cancer,skin infection
D016769,0.15,NCT00070564-2,ARM II,NCT00070564,S0221 Adjuvant Doxorubicin  Cyclophosphamide  and Paclitaxel in Treating Patients With Breast Cancer,embolism and thrombosis
D000410,0.3,NCT00070564-3,ARM III,NCT00070564,S0221 Adjuvant Doxorubicin  Cyclophosphamide  and Paclitaxel in Treating Patients With Breast Cancer,glutamic-pyruvic transaminase
D000068258,0.15,NCT00070564-3,ARM III,NCT00070564,S0221 Adjuvant Doxorubicin  Cyclophosphamide  and Paclitaxel in Treating Patients With Breast Cancer,avastin
D003414,0.15,NCT00070564-3,ARM III,NCT00070564,S0221 Adjuvant Doxorubicin  Cyclophosphamide  and Paclitaxel in Treating Patients With Breast Cancer,familial nonhemolytic unconjugated hyperbilirubinemia
D009618,0.15,NCT00070564-3,ARM III,NCT00070564,S0221 Adjuvant Doxorubicin  Cyclophosphamide  and Paclitaxel in Treating Patients With Breast Cancer,nocardiaceae
D006098,0.15,NCT00070564-3,ARM III,NCT00070564,S0221 Adjuvant Doxorubicin  Cyclophosphamide  and Paclitaxel in Treating Patients With Breast Cancer,granulocytes
D006098,1.09,NCT00070564-5,ARM V,NCT00070564,S0221 Adjuvant Doxorubicin  Cyclophosphamide  and Paclitaxel in Treating Patients With Breast Cancer,granulocytes
D016895,0.34,NCT00070564-6,ARM VI,NCT00070564,S0221 Adjuvant Doxorubicin  Cyclophosphamide  and Paclitaxel in Treating Patients With Breast Cancer,low-serum media
D000074008,0.15,NCT00070564-2,ARM II,NCT00070564,S0221 Adjuvant Doxorubicin  Cyclophosphamide  and Paclitaxel in Treating Patients With Breast Cancer,myelodysplasia syndrome-associated protein 1
D000074008,0.15,NCT00070564-3,ARM III,NCT00070564,S0221 Adjuvant Doxorubicin  Cyclophosphamide  and Paclitaxel in Treating Patients With Breast Cancer,myelodysplasia syndrome-associated protein 1
10049737,0.31,NCT00070564-1,ARM I,NCT00070564,S0221 Adjuvant Doxorubicin  Cyclophosphamide  and Paclitaxel in Treating Patients With Breast Cancer,treatment related secondary malignancy
10049737,0.15,NCT00070564-2,ARM II,NCT00070564,S0221 Adjuvant Doxorubicin  Cyclophosphamide  and Paclitaxel in Treating Patients With Breast Cancer,treatment related secondary malignancy
10049737,0.59,NCT00070564-3,ARM III,NCT00070564,S0221 Adjuvant Doxorubicin  Cyclophosphamide  and Paclitaxel in Treating Patients With Breast Cancer,treatment related secondary malignancy
10049737,0.48,NCT00070564-4,ARM IV,NCT00070564,S0221 Adjuvant Doxorubicin  Cyclophosphamide  and Paclitaxel in Treating Patients With Breast Cancer,treatment related secondary malignancy
10049737,0.36,NCT00070564-5,ARM V,NCT00070564,S0221 Adjuvant Doxorubicin  Cyclophosphamide  and Paclitaxel in Treating Patients With Breast Cancer,treatment related secondary malignancy
10023030,0.16,NCT00070564-4,ARM IV,NCT00070564,S0221 Adjuvant Doxorubicin  Cyclophosphamide  and Paclitaxel in Treating Patients With Breast Cancer,ischemia cerebrovascular
D012640,0.34,NCT00070564-6,ARM VI,NCT00070564,S0221 Adjuvant Doxorubicin  Cyclophosphamide  and Paclitaxel in Treating Patients With Breast Cancer,seizure
D003244,0.34,NCT00070564-6,ARM VI,NCT00070564,S0221 Adjuvant Doxorubicin  Cyclophosphamide  and Paclitaxel in Treating Patients With Breast Cancer,consciousness level depressed
D003221,0.15,NCT00070564-2,ARM II,NCT00070564,S0221 Adjuvant Doxorubicin  Cyclophosphamide  and Paclitaxel in Treating Patients With Breast Cancer,confusion
D012128,0.15,NCT00070564-1,ARM I,NCT00070564,S0221 Adjuvant Doxorubicin  Cyclophosphamide  and Paclitaxel in Treating Patients With Breast Cancer,respiratory distress syndrome adult
D004417,0.15,NCT00070564-3,ARM III,NCT00070564,S0221 Adjuvant Doxorubicin  Cyclophosphamide  and Paclitaxel in Treating Patients With Breast Cancer,breath shortness
D016066,0.15,NCT00070564-2,ARM II,NCT00070564,S0221 Adjuvant Doxorubicin  Cyclophosphamide  and Paclitaxel in Treating Patients With Breast Cancer,pleural effusion malignant
D011014,0.15,NCT00070564-3,ARM III,NCT00070564,S0221 Adjuvant Doxorubicin  Cyclophosphamide  and Paclitaxel in Treating Patients With Breast Cancer,pneumonitis
D012141,0.15,NCT00070564-1,ARM I,NCT00070564,S0221 Adjuvant Doxorubicin  Cyclophosphamide  and Paclitaxel in Treating Patients With Breast Cancer,infections upper respiratory
D012141,0.15,NCT00070564-2,ARM II,NCT00070564,S0221 Adjuvant Doxorubicin  Cyclophosphamide  and Paclitaxel in Treating Patients With Breast Cancer,infections upper respiratory
D012141,0.15,NCT00070564-3,ARM III,NCT00070564,S0221 Adjuvant Doxorubicin  Cyclophosphamide  and Paclitaxel in Treating Patients With Breast Cancer,infections upper respiratory
D007022,0.15,NCT00070564-3,ARM III,NCT00070564,S0221 Adjuvant Doxorubicin  Cyclophosphamide  and Paclitaxel in Treating Patients With Breast Cancer,hypotension
D016769,0.15,NCT00070564-1,ARM I,NCT00070564,S0221 Adjuvant Doxorubicin  Cyclophosphamide  and Paclitaxel in Treating Patients With Breast Cancer,embolism and thrombosis
D016769,0.3,NCT00070564-2,ARM II,NCT00070564,S0221 Adjuvant Doxorubicin  Cyclophosphamide  and Paclitaxel in Treating Patients With Breast Cancer,embolism and thrombosis
D016769,0.3,NCT00070564-3,ARM III,NCT00070564,S0221 Adjuvant Doxorubicin  Cyclophosphamide  and Paclitaxel in Treating Patients With Breast Cancer,embolism and thrombosis
D016769,0.16,NCT00070564-4,ARM IV,NCT00070564,S0221 Adjuvant Doxorubicin  Cyclophosphamide  and Paclitaxel in Treating Patients With Breast Cancer,embolism and thrombosis
D064420,26.0,NCT00071058-1,Surgery Plus Chemothrapy,NCT00071058,Surgery Plus Chemotherapy (Doxorubicin  Vincristine and Etoposide)  Mitotane  and Tariquidar to Treat Adrenocortical Cancer,adverse drug events
D007962,2.0,NCT00071058-1,Surgery Plus Chemothrapy,NCT00071058,Surgery Plus Chemotherapy (Doxorubicin  Vincristine and Etoposide)  Mitotane  and Tariquidar to Treat Adrenocortical Cancer,leukocytes
D006098,6.0,NCT00071058-1,Surgery Plus Chemothrapy,NCT00071058,Surgery Plus Chemotherapy (Doxorubicin  Vincristine and Etoposide)  Mitotane  and Tariquidar to Treat Adrenocortical Cancer,granulocytes
D016277,2.0,NCT00071058-1,Surgery Plus Chemothrapy,NCT00071058,Surgery Plus Chemotherapy (Doxorubicin  Vincristine and Etoposide)  Mitotane  and Tariquidar to Treat Adrenocortical Cancer,ventricular function left
D006342,2.0,NCT00071058-1,Surgery Plus Chemothrapy,NCT00071058,Surgery Plus Chemotherapy (Doxorubicin  Vincristine and Etoposide)  Mitotane  and Tariquidar to Treat Adrenocortical Cancer,cardiac rupture post-infarction
D002542,4.0,NCT00071058-1,Surgery Plus Chemothrapy,NCT00071058,Surgery Plus Chemotherapy (Doxorubicin  Vincristine and Etoposide)  Mitotane  and Tariquidar to Treat Adrenocortical Cancer,intracranial embolism and thrombosis
D000855,2.0,NCT00071058-1,Surgery Plus Chemothrapy,NCT00071058,Surgery Plus Chemotherapy (Doxorubicin  Vincristine and Etoposide)  Mitotane  and Tariquidar to Treat Adrenocortical Cancer,anorexia
D003248,6.0,NCT00071058-1,Surgery Plus Chemothrapy,NCT00071058,Surgery Plus Chemotherapy (Doxorubicin  Vincristine and Etoposide)  Mitotane  and Tariquidar to Treat Adrenocortical Cancer,constipation
D003681,2.0,NCT00071058-1,Surgery Plus Chemothrapy,NCT00071058,Surgery Plus Chemotherapy (Doxorubicin  Vincristine and Etoposide)  Mitotane  and Tariquidar to Treat Adrenocortical Cancer,dehydration
D000930,2.0,NCT00071058-1,Surgery Plus Chemothrapy,NCT00071058,Surgery Plus Chemotherapy (Doxorubicin  Vincristine and Etoposide)  Mitotane  and Tariquidar to Treat Adrenocortical Cancer,antidiarrheals
D003679,2.0,NCT00071058-1,Surgery Plus Chemothrapy,NCT00071058,Surgery Plus Chemotherapy (Doxorubicin  Vincristine and Etoposide)  Mitotane  and Tariquidar to Treat Adrenocortical Cancer,swallowing
D045823,2.0,NCT00071058-1,Surgery Plus Chemothrapy,NCT00071058,Surgery Plus Chemotherapy (Doxorubicin  Vincristine and Etoposide)  Mitotane  and Tariquidar to Treat Adrenocortical Cancer,ileus
D009325,10.0,NCT00071058-1,Surgery Plus Chemothrapy,NCT00071058,Surgery Plus Chemotherapy (Doxorubicin  Vincristine and Etoposide)  Mitotane  and Tariquidar to Treat Adrenocortical Cancer,nausea
D014839,6.0,NCT00071058-1,Surgery Plus Chemothrapy,NCT00071058,Surgery Plus Chemotherapy (Doxorubicin  Vincristine and Etoposide)  Mitotane  and Tariquidar to Treat Adrenocortical Cancer,vomiting
D015746,4.0,NCT00071058-1,Surgery Plus Chemothrapy,NCT00071058,Surgery Plus Chemotherapy (Doxorubicin  Vincristine and Etoposide)  Mitotane  and Tariquidar to Treat Adrenocortical Cancer,abdominal pain
D001037,2.0,NCT00071058-1,Surgery Plus Chemothrapy,NCT00071058,Surgery Plus Chemotherapy (Doxorubicin  Vincristine and Etoposide)  Mitotane  and Tariquidar to Treat Adrenocortical Cancer,logasthenia
D009503,10.0,NCT00071058-1,Surgery Plus Chemothrapy,NCT00071058,Surgery Plus Chemotherapy (Doxorubicin  Vincristine and Etoposide)  Mitotane  and Tariquidar to Treat Adrenocortical Cancer,neutropenia
D023341,2.0,NCT00071058-1,Surgery Plus Chemothrapy,NCT00071058,Surgery Plus Chemotherapy (Doxorubicin  Vincristine and Etoposide)  Mitotane  and Tariquidar to Treat Adrenocortical Cancer,chills
D004342,2.0,NCT00071058-1,Surgery Plus Chemothrapy,NCT00071058,Surgery Plus Chemotherapy (Doxorubicin  Vincristine and Etoposide)  Mitotane  and Tariquidar to Treat Adrenocortical Cancer,drug hypersensitivity
D064147,4.0,NCT00071058-1,Surgery Plus Chemothrapy,NCT00071058,Surgery Plus Chemotherapy (Doxorubicin  Vincristine and Etoposide)  Mitotane  and Tariquidar to Treat Adrenocortical Cancer,febrile neutropenia
D007239,2.0,NCT00071058-1,Surgery Plus Chemothrapy,NCT00071058,Surgery Plus Chemotherapy (Doxorubicin  Vincristine and Etoposide)  Mitotane  and Tariquidar to Treat Adrenocortical Cancer,infection
D000069544,2.0,NCT00071058-1,Surgery Plus Chemothrapy,NCT00071058,Surgery Plus Chemotherapy (Doxorubicin  Vincristine and Etoposide)  Mitotane  and Tariquidar to Treat Adrenocortical Cancer,encephalitis infection
D007010,2.0,NCT00071058-1,Surgery Plus Chemothrapy,NCT00071058,Surgery Plus Chemotherapy (Doxorubicin  Vincristine and Etoposide)  Mitotane  and Tariquidar to Treat Adrenocortical Cancer,hyponatremia
D004417,2.0,NCT00071058-1,Surgery Plus Chemothrapy,NCT00071058,Surgery Plus Chemotherapy (Doxorubicin  Vincristine and Etoposide)  Mitotane  and Tariquidar to Treat Adrenocortical Cancer,breath shortness
D009026,41.18,NCT00074490-2,Arm IVD Cohort 3 (Multiple Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,mortality
D009026,55.0,NCT00074490-3,Arm IVA (12-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,mortality
D009026,54.55,NCT00074490-4,Arm IVB (6-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,mortality
D009026,48.89,NCT00074490-5,Arm IVC (6-day Expanded Th2 DLI and High Dose Sirolimus),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,mortality
D064420,100.0,NCT00074490-1,Arm IVD Cohort 1 (Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,adverse drug events
D064420,64.71,NCT00074490-2,Arm IVD Cohort 3 (Multiple Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,adverse drug events
D064420,92.5,NCT00074490-3,Arm IVA (12-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,adverse drug events
D064420,79.55,NCT00074490-4,Arm IVB (6-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,adverse drug events
D064420,68.89,NCT00074490-5,Arm IVC (6-day Expanded Th2 DLI and High Dose Sirolimus),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,adverse drug events
D000080983,2.22,NCT00074490-5,Arm IVC (6-day Expanded Th2 DLI and High Dose Sirolimus),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,bone marrow failure syndromes
D064147,5.88,NCT00074490-2,Arm IVD Cohort 3 (Multiple Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,febrile neutropenia
D064147,25.0,NCT00074490-3,Arm IVA (12-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,febrile neutropenia
D064147,56.82,NCT00074490-4,Arm IVB (6-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,febrile neutropenia
D064147,11.11,NCT00074490-5,Arm IVC (6-day Expanded Th2 DLI and High Dose Sirolimus),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,febrile neutropenia
D006454,5.88,NCT00074490-2,Arm IVD Cohort 3 (Multiple Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,hemoglobin
D006454,20.0,NCT00074490-3,Arm IVA (12-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,hemoglobin
D006454,22.73,NCT00074490-4,Arm IVB (6-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,hemoglobin
D006454,6.67,NCT00074490-5,Arm IVC (6-day Expanded Th2 DLI and High Dose Sirolimus),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,hemoglobin
D006461,2.5,NCT00074490-3,Arm IVA (12-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,hemolysis
D057049,2.27,NCT00074490-4,Arm IVB (6-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,thrombotic microangiopathy
D001145,2.5,NCT00074490-3,Arm IVA (12-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,arrhythmias cardiac
D006333,2.27,NCT00074490-4,Arm IVB (6-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,congestive heart failure
D006342,2.27,NCT00074490-4,Arm IVB (6-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,cardiac rupture post-infarction
10003674,2.27,NCT00074490-4,Arm IVB (6-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,atrioventricular block first degree
10027786,2.5,NCT00074490-3,Arm IVA (12-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,mobitz (type) ii atrioventricular block
D018487,2.22,NCT00074490-5,Arm IVC (6-day Expanded Th2 DLI and High Dose Sirolimus),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,ventricular dysfunction left
10069501,5.0,NCT00074490-3,Arm IVA (12-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,left ventricular systolic dysfunction
10069501,2.27,NCT00074490-4,Arm IVB (6-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,left ventricular systolic dysfunction
10069501,4.44,NCT00074490-5,Arm IVC (6-day Expanded Th2 DLI and High Dose Sirolimus),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,left ventricular systolic dysfunction
D010490,2.94,NCT00074490-2,Arm IVD Cohort 3 (Multiple Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,pericardial effusion
D010490,2.22,NCT00074490-5,Arm IVC (6-day Expanded Th2 DLI and High Dose Sirolimus),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,pericardial effusion
D002313,2.94,NCT00074490-2,Arm IVD Cohort 3 (Multiple Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,restrictive cardiomyopathy
D001146,2.5,NCT00074490-3,Arm IVA (12-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,sinoatrial arrhythmia
D001146,2.5,NCT00074490-3,Arm IVA (12-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,sinoatrial arrhythmia
D001146,2.5,NCT00074490-3,Arm IVA (12-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,arrhythmia sinus
D013617,2.5,NCT00074490-3,Arm IVA (12-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,tachycardia supraventricular
D013617,4.55,NCT00074490-4,Arm IVB (6-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,tachycardia supraventricular
D018149,5.0,NCT00074490-3,Arm IVA (12-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,glucose intolerance
D018149,11.36,NCT00074490-4,Arm IVB (6-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,glucose intolerance
D006980,2.5,NCT00074490-3,Arm IVA (12-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,hyperthyroidism
D007037,2.5,NCT00074490-3,Arm IVA (12-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,hypothyroidism
D007037,2.27,NCT00074490-4,Arm IVB (6-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,hypothyroidism
D015352,2.5,NCT00074490-3,Arm IVA (12-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,dry eye syndrome
D019252,2.5,NCT00074490-3,Arm IVA (12-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,visualix
D061351,2.5,NCT00074490-3,Arm IVA (12-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,binoculars
D004172,2.27,NCT00074490-4,Arm IVB (6-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,double vision
D003092,5.88,NCT00074490-2,Arm IVD Cohort 3 (Multiple Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,colitis
D003092,2.5,NCT00074490-3,Arm IVA (12-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,colitis
D003092,6.82,NCT00074490-4,Arm IVB (6-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,colitis
D004761,2.94,NCT00074490-2,Arm IVD Cohort 3 (Multiple Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,clostridium enterocolitis
D004761,5.0,NCT00074490-3,Arm IVA (12-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,clostridium enterocolitis
D004761,15.91,NCT00074490-4,Arm IVB (6-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,clostridium enterocolitis
D004761,15.56,NCT00074490-5,Arm IVC (6-day Expanded Th2 DLI and High Dose Sirolimus),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,clostridium enterocolitis
D003967,100.0,NCT00074490-1,Arm IVD Cohort 1 (Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,diarrhea
D003967,11.76,NCT00074490-2,Arm IVD Cohort 3 (Multiple Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,diarrhea
D003967,25.0,NCT00074490-3,Arm IVA (12-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,diarrhea
D003967,36.36,NCT00074490-4,Arm IVB (6-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,diarrhea
D003967,24.44,NCT00074490-5,Arm IVC (6-day Expanded Th2 DLI and High Dose Sirolimus),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,diarrhea
D012469,2.94,NCT00074490-2,Arm IVD Cohort 3 (Multiple Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,salivary glands
D012469,2.27,NCT00074490-4,Arm IVB (6-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,salivary glands
D003679,2.5,NCT00074490-3,Arm IVA (12-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,swallowing
D003679,4.55,NCT00074490-4,Arm IVB (6-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,swallowing
D003679,2.22,NCT00074490-5,Arm IVC (6-day Expanded Th2 DLI and High Dose Sirolimus),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,swallowing
D004941,7.5,NCT00074490-3,Arm IVA (12-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,esophagitis
D004941,2.27,NCT00074490-4,Arm IVB (6-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,esophagitis
D005756,2.27,NCT00074490-4,Arm IVB (6-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,gastritis
D015746,2.5,NCT00074490-3,Arm IVA (12-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,abdominal pain
D015746,2.94,NCT00074490-2,Arm IVD Cohort 3 (Multiple Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,abdominal pain
10051746,5.88,NCT00074490-2,Arm IVD Cohort 3 (Multiple Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,lower gastrointestinal hemorrhage
10051746,2.22,NCT00074490-5,Arm IVC (6-day Expanded Th2 DLI and High Dose Sirolimus),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,lower gastrointestinal hemorrhage
D006471,2.5,NCT00074490-3,Arm IVA (12-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,gastrointestinal hemorrhage
D006471,2.27,NCT00074490-4,Arm IVB (6-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,gastrointestinal hemorrhage
10055356,2.94,NCT00074490-2,Arm IVD Cohort 3 (Multiple Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,upper gastrointestinal hemorrhage
10055356,5.0,NCT00074490-3,Arm IVA (12-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,upper gastrointestinal hemorrhage
10055356,6.67,NCT00074490-5,Arm IVC (6-day Expanded Th2 DLI and High Dose Sirolimus),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,upper gastrointestinal hemorrhage
D005767,2.94,NCT00074490-2,Arm IVD Cohort 3 (Multiple Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,functional gastrointestinal disorders
D005767,7.5,NCT00074490-3,Arm IVA (12-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,functional gastrointestinal disorders
D005767,2.27,NCT00074490-4,Arm IVB (6-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,functional gastrointestinal disorders
D003945,2.94,NCT00074490-2,Arm IVD Cohort 3 (Multiple Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,examination oral
D003945,7.5,NCT00074490-3,Arm IVA (12-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,examination oral
D003945,4.55,NCT00074490-4,Arm IVB (6-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,examination oral
D009055,2.5,NCT00074490-3,Arm IVA (12-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,oral cavity
D009325,5.88,NCT00074490-2,Arm IVD Cohort 3 (Multiple Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,nausea
D009325,7.5,NCT00074490-3,Arm IVA (12-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,nausea
D009325,11.36,NCT00074490-4,Arm IVB (6-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,nausea
D009325,2.22,NCT00074490-5,Arm IVC (6-day Expanded Th2 DLI and High Dose Sirolimus),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,nausea
10017636,2.27,NCT00074490-4,Arm IVB (6-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,gallbladder obstruction
10041101,2.22,NCT00074490-5,Arm IVC (6-day Expanded Th2 DLI and High Dose Sirolimus),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,small intestinal obstruction
D000005,5.88,NCT00074490-2,Arm IVD Cohort 3 (Multiple Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,abdomen
D000005,5.0,NCT00074490-3,Arm IVA (12-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,abdomen
D000005,4.55,NCT00074490-4,Arm IVB (6-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,abdomen
D000005,6.67,NCT00074490-5,Arm IVC (6-day Expanded Th2 DLI and High Dose Sirolimus),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,abdomen
D009055,2.27,NCT00074490-4,Arm IVB (6-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,oral cavity
D009055,2.22,NCT00074490-5,Arm IVC (6-day Expanded Th2 DLI and High Dose Sirolimus),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,oral cavity
10041103,2.94,NCT00074490-2,Arm IVD Cohort 3 (Multiple Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,small intestinal perforation
10041103,2.27,NCT00074490-4,Arm IVB (6-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,small intestinal perforation
D007249,2.94,NCT00074490-2,Arm IVD Cohort 3 (Multiple Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,inflammation
D013276,2.5,NCT00074490-3,Arm IVA (12-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,stomach ulcer
D014839,2.94,NCT00074490-2,Arm IVD Cohort 3 (Multiple Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,vomiting
D014839,7.5,NCT00074490-3,Arm IVA (12-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,vomiting
D014839,2.27,NCT00074490-4,Arm IVB (6-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,vomiting
D014839,2.22,NCT00074490-5,Arm IVC (6-day Expanded Th2 DLI and High Dose Sirolimus),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,vomiting
D003643,2.94,NCT00074490-2,Arm IVD Cohort 3 (Multiple Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,death
D003643,7.5,NCT00074490-3,Arm IVA (12-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,death
D003643,4.55,NCT00074490-4,Arm IVB (6-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,death
D003643,11.11,NCT00074490-5,Arm IVC (6-day Expanded Th2 DLI and High Dose Sirolimus),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,death
D018450,20.59,NCT00074490-2,Arm IVD Cohort 3 (Multiple Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,disease progression
D018450,22.5,NCT00074490-3,Arm IVA (12-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,disease progression
D018450,27.27,NCT00074490-4,Arm IVB (6-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,disease progression
D018450,24.44,NCT00074490-5,Arm IVC (6-day Expanded Th2 DLI and High Dose Sirolimus),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,disease progression
D009102,5.88,NCT00074490-2,Arm IVD Cohort 3 (Multiple Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,multiple organ failure
D003645,4.55,NCT00074490-4,Arm IVB (6-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,death sudden
D009503,2.94,NCT00074490-2,Arm IVD Cohort 3 (Multiple Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,neutropenia
D009503,35.0,NCT00074490-3,Arm IVA (12-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,neutropenia
D009503,22.73,NCT00074490-4,Arm IVB (6-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,neutropenia
D003229,2.5,NCT00074490-3,Arm IVA (12-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,conjunctival diseases
D004342,2.27,NCT00074490-4,Arm IVB (6-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,drug hypersensitivity
D000069544,5.88,NCT00074490-2,Arm IVD Cohort 3 (Multiple Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,encephalitis infection
D000069544,2.27,NCT00074490-4,Arm IVB (6-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,encephalitis infection
D007239,23.53,NCT00074490-2,Arm IVD Cohort 3 (Multiple Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,infection
D007239,12.5,NCT00074490-3,Arm IVA (12-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,infection
D007239,29.55,NCT00074490-4,Arm IVB (6-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,infection
D007239,2.22,NCT00074490-5,Arm IVC (6-day Expanded Th2 DLI and High Dose Sirolimus),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,infection
D007239,2.27,NCT00074490-4,Arm IVB (6-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,infection
D000069544,17.5,NCT00074490-3,Arm IVA (12-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,encephalitis infection
D007239,7.5,NCT00074490-3,Arm IVA (12-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,infection
D007239,6.82,NCT00074490-4,Arm IVB (6-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,infection
D007239,2.94,NCT00074490-2,Arm IVD Cohort 3 (Multiple Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,infection
D007239,2.5,NCT00074490-3,Arm IVA (12-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,infection
D007239,27.27,NCT00074490-4,Arm IVB (6-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,infection
D007239,4.44,NCT00074490-5,Arm IVC (6-day Expanded Th2 DLI and High Dose Sirolimus),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,infection
D007239,2.5,NCT00074490-3,Arm IVA (12-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,infection
D007239,2.27,NCT00074490-4,Arm IVB (6-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,infection
D007239,5.0,NCT00074490-3,Arm IVA (12-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,infection
D007239,7.5,NCT00074490-3,Arm IVA (12-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,infection
D007239,2.27,NCT00074490-4,Arm IVB (6-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,infection
D007239,2.5,NCT00074490-3,Arm IVA (12-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,infection
D007239,4.55,NCT00074490-4,Arm IVB (6-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,infection
D007239,2.94,NCT00074490-2,Arm IVD Cohort 3 (Multiple Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,infection
D007239,2.5,NCT00074490-3,Arm IVA (12-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,infection
D007239,2.22,NCT00074490-5,Arm IVC (6-day Expanded Th2 DLI and High Dose Sirolimus),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,infection
D007239,2.94,NCT00074490-2,Arm IVD Cohort 3 (Multiple Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,infection
D007239,2.27,NCT00074490-4,Arm IVB (6-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,infection
D007239,2.5,NCT00074490-3,Arm IVA (12-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,infection
D007239,2.94,NCT00074490-2,Arm IVD Cohort 3 (Multiple Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,infection
D007239,6.82,NCT00074490-4,Arm IVB (6-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,infection
D007239,2.94,NCT00074490-2,Arm IVD Cohort 3 (Multiple Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,infection
D007239,2.5,NCT00074490-3,Arm IVA (12-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,infection
D007239,4.55,NCT00074490-4,Arm IVB (6-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,infection
D007239,2.22,NCT00074490-5,Arm IVC (6-day Expanded Th2 DLI and High Dose Sirolimus),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,infection
D003015,2.22,NCT00074490-5,Arm IVC (6-day Expanded Th2 DLI and High Dose Sirolimus),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,clostridium difficile infection
10058666,2.5,NCT00074490-3,Arm IVA (12-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,cytomegalovirus infection reactivation
D006192,2.22,NCT00074490-5,Arm IVC (6-day Expanded Th2 DLI and High Dose Sirolimus),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,haemophilus influenzae infection
D000069544,2.27,NCT00074490-4,Arm IVB (6-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,encephalitis infection
D011552,2.94,NCT00074490-2,Arm IVD Cohort 3 (Multiple Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,pseudomonas infections
D000069544,2.27,NCT00074490-4,Arm IVB (6-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,encephalitis infection
D000069544,2.27,NCT00074490-4,Arm IVB (6-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,encephalitis infection
D000069544,100.0,NCT00074490-1,Arm IVD Cohort 1 (Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,encephalitis infection
D000069544,38.24,NCT00074490-2,Arm IVD Cohort 3 (Multiple Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,encephalitis infection
D000069544,25.0,NCT00074490-3,Arm IVA (12-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,encephalitis infection
D000069544,40.91,NCT00074490-4,Arm IVB (6-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,encephalitis infection
D000069544,28.89,NCT00074490-5,Arm IVC (6-day Expanded Th2 DLI and High Dose Sirolimus),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,encephalitis infection
10061017,2.27,NCT00074490-4,Arm IVB (6-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,bone infection
D000069544,9.09,NCT00074490-4,Arm IVB (6-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,encephalitis infection
10014621,2.22,NCT00074490-5,Arm IVC (6-day Expanded Th2 DLI and High Dose Sirolimus),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,encephalomyelitis infection
D000069544,2.27,NCT00074490-4,Arm IVB (6-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,encephalitis infection
D000069544,2.22,NCT00074490-5,Arm IVC (6-day Expanded Th2 DLI and High Dose Sirolimus),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,encephalitis infection
D055499,15.0,NCT00074490-3,Arm IVA (12-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,catheter-related infections
D055499,9.09,NCT00074490-4,Arm IVB (6-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,catheter-related infections
D000069544,100.0,NCT00074490-1,Arm IVD Cohort 1 (Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,encephalitis infection
D000069544,2.94,NCT00074490-2,Arm IVD Cohort 3 (Multiple Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,encephalitis infection
D000069544,17.5,NCT00074490-3,Arm IVA (12-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,encephalitis infection
D000069544,18.18,NCT00074490-4,Arm IVB (6-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,encephalitis infection
D000069544,13.33,NCT00074490-5,Arm IVC (6-day Expanded Th2 DLI and High Dose Sirolimus),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,encephalitis infection
D004431,2.5,NCT00074490-3,Arm IVA (12-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,ear external
10061229,11.76,NCT00074490-2,Arm IVD Cohort 3 (Multiple Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,lung infection
10061229,30.0,NCT00074490-3,Arm IVA (12-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,lung infection
10061229,54.55,NCT00074490-4,Arm IVB (6-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,lung infection
10061229,24.44,NCT00074490-5,Arm IVC (6-day Expanded Th2 DLI and High Dose Sirolimus),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,lung infection
D000069544,4.44,NCT00074490-5,Arm IVC (6-day Expanded Th2 DLI and High Dose Sirolimus),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,encephalitis infection
D000069544,2.22,NCT00074490-5,Arm IVC (6-day Expanded Th2 DLI and High Dose Sirolimus),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,encephalitis infection
10057262,2.27,NCT00074490-4,Arm IVB (6-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,peritoneal infection
D000069544,2.5,NCT00074490-3,Arm IVA (12-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,encephalitis infection
10061351,2.5,NCT00074490-3,Arm IVA (12-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,pleural infection
D000069544,5.0,NCT00074490-3,Arm IVA (12-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,encephalitis infection
D012852,10.0,NCT00074490-3,Arm IVA (12-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,sinus infections
D012852,9.09,NCT00074490-4,Arm IVB (6-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,sinus infections
D012852,4.44,NCT00074490-5,Arm IVC (6-day Expanded Th2 DLI and High Dose Sirolimus),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,sinus infections
10040872,7.5,NCT00074490-3,Arm IVA (12-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,skin infection
10040872,6.82,NCT00074490-4,Arm IVB (6-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,skin infection
10040872,8.89,NCT00074490-5,Arm IVC (6-day Expanded Th2 DLI and High Dose Sirolimus),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,skin infection
D000069544,2.5,NCT00074490-3,Arm IVA (12-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,encephalitis infection
D000069544,2.27,NCT00074490-4,Arm IVB (6-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,encephalitis infection
D000069544,2.22,NCT00074490-5,Arm IVC (6-day Expanded Th2 DLI and High Dose Sirolimus),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,encephalitis infection
D012141,15.0,NCT00074490-3,Arm IVA (12-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,infections upper respiratory
D012141,9.09,NCT00074490-4,Arm IVB (6-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,infections upper respiratory
D012141,13.33,NCT00074490-5,Arm IVC (6-day Expanded Th2 DLI and High Dose Sirolimus),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,infections upper respiratory
D014552,2.94,NCT00074490-2,Arm IVD Cohort 3 (Multiple Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,urinary tract infections
D014552,10.0,NCT00074490-3,Arm IVA (12-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,urinary tract infections
D014552,9.09,NCT00074490-4,Arm IVB (6-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,urinary tract infections
D014552,2.22,NCT00074490-5,Arm IVC (6-day Expanded Th2 DLI and High Dose Sirolimus),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,urinary tract infections
D014946,2.5,NCT00074490-3,Arm IVA (12-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,wound infection
D000069544,2.94,NCT00074490-2,Arm IVD Cohort 3 (Multiple Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,encephalitis infection
D000069544,2.5,NCT00074490-3,Arm IVA (12-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,encephalitis infection
D000069544,2.27,NCT00074490-4,Arm IVB (6-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,encephalitis infection
D000069544,4.44,NCT00074490-5,Arm IVC (6-day Expanded Th2 DLI and High Dose Sirolimus),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,encephalitis infection
10061229,5.0,NCT00074490-3,Arm IVA (12-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,lung infection
10061229,6.82,NCT00074490-4,Arm IVB (6-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,lung infection
10061229,2.22,NCT00074490-5,Arm IVC (6-day Expanded Th2 DLI and High Dose Sirolimus),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,lung infection
D000069544,2.22,NCT00074490-5,Arm IVC (6-day Expanded Th2 DLI and High Dose Sirolimus),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,encephalitis infection
D012852,2.27,NCT00074490-4,Arm IVB (6-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,sinus infections
D012852,2.22,NCT00074490-5,Arm IVC (6-day Expanded Th2 DLI and High Dose Sirolimus),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,sinus infections
D012141,2.27,NCT00074490-4,Arm IVB (6-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,infections upper respiratory
D012141,2.22,NCT00074490-5,Arm IVC (6-day Expanded Th2 DLI and High Dose Sirolimus),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,infections upper respiratory
D014552,2.27,NCT00074490-4,Arm IVB (6-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,urinary tract infections
10019799,2.27,NCT00074490-4,Arm IVB (6-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,hepatitis viral
10017076,6.82,NCT00074490-4,Arm IVB (6-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,fracture
D000410,14.71,NCT00074490-2,Arm IVD Cohort 3 (Multiple Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,glutamic-pyruvic transaminase
D000410,10.0,NCT00074490-3,Arm IVA (12-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,glutamic-pyruvic transaminase
D000410,36.36,NCT00074490-4,Arm IVB (6-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,glutamic-pyruvic transaminase
D000410,11.11,NCT00074490-5,Arm IVC (6-day Expanded Th2 DLI and High Dose Sirolimus),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,glutamic-pyruvic transaminase
D001219,2.94,NCT00074490-2,Arm IVD Cohort 3 (Multiple Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,serum glutamic-oxaloacetic transaminase
D001219,10.0,NCT00074490-3,Arm IVA (12-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,serum glutamic-oxaloacetic transaminase
D001219,27.27,NCT00074490-4,Arm IVB (6-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,serum glutamic-oxaloacetic transaminase
D001219,2.22,NCT00074490-5,Arm IVC (6-day Expanded Th2 DLI and High Dose Sirolimus),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,serum glutamic-oxaloacetic transaminase
D000469,2.5,NCT00074490-3,Arm IVA (12-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,alkaline phosphatase
D000469,2.27,NCT00074490-4,Arm IVB (6-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,alkaline phosphatase
D000681,2.22,NCT00074490-5,Arm IVC (6-day Expanded Th2 DLI and High Dose Sirolimus),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,amylase
D003997,2.94,NCT00074490-2,Arm IVD Cohort 3 (Multiple Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,diethoxycarbonyldihydrocollidine
D009618,2.5,NCT00074490-3,Arm IVA (12-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,nocardiaceae
D009618,2.27,NCT00074490-4,Arm IVB (6-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,nocardiaceae
D003404,7.5,NCT00074490-3,Arm IVA (12-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,creatinine
D003404,9.09,NCT00074490-4,Arm IVB (6-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,creatinine
D007962,5.0,NCT00074490-3,Arm IVA (12-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,leukocytes
D008049,2.22,NCT00074490-5,Arm IVC (6-day Expanded Th2 DLI and High Dose Sirolimus),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,lipase
D006098,8.82,NCT00074490-2,Arm IVD Cohort 3 (Multiple Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,granulocytes
D006098,37.5,NCT00074490-3,Arm IVA (12-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,granulocytes
D006098,29.55,NCT00074490-4,Arm IVB (6-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,granulocytes
D006098,15.56,NCT00074490-5,Arm IVC (6-day Expanded Th2 DLI and High Dose Sirolimus),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,granulocytes
D010314,2.94,NCT00074490-2,Arm IVD Cohort 3 (Multiple Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,partial thromboplastin time
D010314,2.5,NCT00074490-3,Arm IVA (12-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,partial thromboplastin time
D001792,5.88,NCT00074490-2,Arm IVD Cohort 3 (Multiple Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,platelets
D001792,17.5,NCT00074490-3,Arm IVA (12-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,platelets
D001792,15.91,NCT00074490-4,Arm IVB (6-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,platelets
D001792,6.67,NCT00074490-5,Arm IVC (6-day Expanded Th2 DLI and High Dose Sirolimus),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,platelets
10014383,2.5,NCT00074490-3,Arm IVA (12-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,electrocardiogram qt corrected interval prolonged
10014383,2.27,NCT00074490-4,Arm IVB (6-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,electrocardiogram qt corrected interval prolonged
D015431,2.27,NCT00074490-4,Arm IVB (6-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,weight loss
D000138,4.55,NCT00074490-4,Arm IVB (6-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,metabolic acidosis
D034141,2.94,NCT00074490-2,Arm IVD Cohort 3 (Multiple Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,hypoalbuminemia
D034141,2.27,NCT00074490-4,Arm IVB (6-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,hypoalbuminemia
D000472,2.94,NCT00074490-2,Arm IVD Cohort 3 (Multiple Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,alkalosis respiratory
D000855,2.94,NCT00074490-2,Arm IVD Cohort 3 (Multiple Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,anorexia
D000855,2.5,NCT00074490-3,Arm IVA (12-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,anorexia
D000855,4.55,NCT00074490-4,Arm IVB (6-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,anorexia
D016895,2.5,NCT00074490-3,Arm IVA (12-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,low-serum media
D003681,5.0,NCT00074490-3,Arm IVA (12-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,dehydration
D003847,2.5,NCT00074490-3,Arm IVA (12-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,deoxyglucose
D003847,4.55,NCT00074490-4,Arm IVB (6-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,deoxyglucose
D016895,2.5,NCT00074490-3,Arm IVA (12-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,low-serum media
D001928,2.22,NCT00074490-5,Arm IVC (6-day Expanded Th2 DLI and High Dose Sirolimus),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,metabolic encephalopathies
D000081227,2.5,NCT00074490-3,Arm IVA (12-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,neurosteroids
D017674,11.36,NCT00074490-4,Arm IVB (6-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,hypophosphatemia
D017674,2.22,NCT00074490-5,Arm IVC (6-day Expanded Th2 DLI and High Dose Sirolimus),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,hypophosphatemia
D006947,2.5,NCT00074490-3,Arm IVA (12-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,hyperkalemia
D016895,5.0,NCT00074490-3,Arm IVA (12-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,low-serum media
D016895,11.36,NCT00074490-4,Arm IVB (6-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,low-serum media
D004039,5.88,NCT00074490-2,Arm IVD Cohort 3 (Multiple Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,diet low-sodium
D004039,5.0,NCT00074490-3,Arm IVA (12-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,diet low-sodium
D004039,6.82,NCT00074490-4,Arm IVB (6-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,diet low-sodium
D015228,2.27,NCT00074490-4,Arm IVB (6-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,hypertriglyceridemia
D015275,2.27,NCT00074490-4,Arm IVB (6-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,tumor lysis syndrome
D033461,2.27,NCT00074490-4,Arm IVB (6-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,hyperuricemia
D033461,2.22,NCT00074490-5,Arm IVC (6-day Expanded Th2 DLI and High Dose Sirolimus),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,hyperuricemia
D001170,2.5,NCT00074490-3,Arm IVA (12-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,arthritis septic
D001170,4.55,NCT00074490-4,Arm IVB (6-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,arthritis septic
10062572,6.82,NCT00074490-4,Arm IVB (6-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,generalized muscle weakness
10062572,2.22,NCT00074490-5,Arm IVC (6-day Expanded Th2 DLI and High Dose Sirolimus),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,generalized muscle weakness
D010020,2.5,NCT00074490-3,Arm IVA (12-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,osteonecrosis
D001416,2.94,NCT00074490-2,Arm IVD Cohort 3 (Multiple Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,back pain
10006002,2.5,NCT00074490-3,Arm IVA (12-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,bone pain
10008496,4.55,NCT00074490-4,Arm IVB (6-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,chest wall pain
D019547,2.5,NCT00074490-3,Arm IVA (12-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,neck pain
10049737,2.22,NCT00074490-5,Arm IVC (6-day Expanded Th2 DLI and High Dose Sirolimus),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,treatment related secondary malignancy
10049737,2.94,NCT00074490-2,Arm IVD Cohort 3 (Multiple Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,treatment related secondary malignancy
10049737,2.22,NCT00074490-5,Arm IVC (6-day Expanded Th2 DLI and High Dose Sirolimus),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,treatment related secondary malignancy
D003414,8.82,NCT00074490-2,Arm IVD Cohort 3 (Multiple Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,familial nonhemolytic unconjugated hyperbilirubinemia
D003414,15.0,NCT00074490-3,Arm IVA (12-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,familial nonhemolytic unconjugated hyperbilirubinemia
D003414,15.91,NCT00074490-4,Arm IVB (6-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,familial nonhemolytic unconjugated hyperbilirubinemia
10023030,5.0,NCT00074490-3,Arm IVA (12-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,ischemia cerebrovascular
10009845,2.5,NCT00074490-3,Arm IVA (12-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,cognitive disturbance
D004244,2.5,NCT00074490-3,Arm IVA (12-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,dizziness
10054482,2.5,NCT00074490-3,Arm IVA (12-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,neck edema
D001927,7.5,NCT00074490-3,Arm IVA (12-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,encephalopathy
D020300,2.22,NCT00074490-5,Arm IVC (6-day Expanded Th2 DLI and High Dose Sirolimus),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,intracranial hemorrhages
D056784,2.5,NCT00074490-3,Arm IVA (12-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,leukoencephalopathy
D003389,5.0,NCT00074490-3,Arm IVA (12-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,cranial neuropathy
D004948,2.5,NCT00074490-3,Arm IVA (12-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,esodeviation
D002607,2.5,NCT00074490-3,Arm IVA (12-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,hereditary type i motor and sensory neuropathy
D002607,6.82,NCT00074490-4,Arm IVB (6-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,hereditary type i motor and sensory neuropathy
D002607,2.5,NCT00074490-3,Arm IVA (12-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,hereditary type i motor and sensory neuropathy
D002607,4.55,NCT00074490-4,Arm IVB (6-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,hereditary type i motor and sensory neuropathy
D006261,2.27,NCT00074490-4,Arm IVB (6-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,headache
D006261,2.22,NCT00074490-5,Arm IVC (6-day Expanded Th2 DLI and High Dose Sirolimus),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,headache
D012640,5.88,NCT00074490-2,Arm IVD Cohort 3 (Multiple Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,seizure
D012640,2.5,NCT00074490-3,Arm IVA (12-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,seizure
D003244,2.5,NCT00074490-3,Arm IVA (12-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,consciousness level depressed
D003244,2.27,NCT00074490-4,Arm IVB (6-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,consciousness level depressed
D013575,2.22,NCT00074490-5,Arm IVC (6-day Expanded Th2 DLI and High Dose Sirolimus),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,syncope
D003221,5.0,NCT00074490-3,Arm IVA (12-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,confusion
D003221,2.27,NCT00074490-4,Arm IVB (6-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,confusion
D003221,2.22,NCT00074490-5,Arm IVC (6-day Expanded Th2 DLI and High Dose Sirolimus),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,confusion
D000073216,2.27,NCT00074490-4,Arm IVB (6-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,mental status and dementia tests
D003702,2.27,NCT00074490-4,Arm IVB (6-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,delusions
D003702,2.22,NCT00074490-5,Arm IVC (6-day Expanded Th2 DLI and High Dose Sirolimus),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,delusions
D003556,2.94,NCT00074490-2,Arm IVD Cohort 3 (Multiple Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,cystitis
D003556,2.5,NCT00074490-3,Arm IVA (12-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,cystitis
D003556,2.27,NCT00074490-4,Arm IVB (6-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,cystitis
D058734,2.5,NCT00074490-3,Arm IVA (12-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,exsanguinating hemorrhage
D051437,2.94,NCT00074490-2,Arm IVD Cohort 3 (Multiple Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,renal failure
D051437,10.0,NCT00074490-3,Arm IVA (12-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,renal failure
D051437,11.36,NCT00074490-4,Arm IVB (6-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,renal failure
D051437,4.44,NCT00074490-5,Arm IVC (6-day Expanded Th2 DLI and High Dose Sirolimus),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,renal failure
D014525,2.5,NCT00074490-3,Arm IVA (12-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,urethral stricture
D012128,2.94,NCT00074490-2,Arm IVD Cohort 3 (Multiple Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,respiratory distress syndrome adult
D001049,2.5,NCT00074490-3,Arm IVA (12-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,apnea
D003371,2.94,NCT00074490-2,Arm IVD Cohort 3 (Multiple Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,cough
D004417,2.94,NCT00074490-2,Arm IVD Cohort 3 (Multiple Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,breath shortness
D004417,12.5,NCT00074490-3,Arm IVA (12-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,breath shortness
D004417,6.82,NCT00074490-4,Arm IVB (6-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,breath shortness
D004417,2.22,NCT00074490-5,Arm IVC (6-day Expanded Th2 DLI and High Dose Sirolimus),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,breath shortness
D000799,2.22,NCT00074490-5,Arm IVC (6-day Expanded Th2 DLI and High Dose Sirolimus),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,angioedema
10065746,2.27,NCT00074490-4,Arm IVB (6-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,bronchopulmonary hemorrhage
10065746,2.22,NCT00074490-5,Arm IVC (6-day Expanded Th2 DLI and High Dose Sirolimus),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,bronchopulmonary hemorrhage
10065746,2.94,NCT00074490-2,Arm IVD Cohort 3 (Multiple Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,bronchopulmonary hemorrhage
10065746,2.5,NCT00074490-3,Arm IVA (12-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,bronchopulmonary hemorrhage
10065746,2.22,NCT00074490-5,Arm IVC (6-day Expanded Th2 DLI and High Dose Sirolimus),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,bronchopulmonary hemorrhage
D011666,2.27,NCT00074490-4,Arm IVB (6-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,pulmonary stenoses
D011666,2.22,NCT00074490-5,Arm IVC (6-day Expanded Th2 DLI and High Dose Sirolimus),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,pulmonary stenoses
D006470,2.22,NCT00074490-5,Arm IVC (6-day Expanded Th2 DLI and High Dose Sirolimus),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,hemorrhage
D000860,2.94,NCT00074490-2,Arm IVD Cohort 3 (Multiple Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,hypoxia
D000860,30.0,NCT00074490-3,Arm IVA (12-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,hypoxia
D000860,25.0,NCT00074490-4,Arm IVB (6-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,hypoxia
D000860,6.67,NCT00074490-5,Arm IVC (6-day Expanded Th2 DLI and High Dose Sirolimus),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,hypoxia
D000402,2.5,NCT00074490-3,Arm IVA (12-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,airway obstruction
D000402,2.27,NCT00074490-4,Arm IVB (6-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,airway obstruction
D000080867,2.27,NCT00074490-4,Arm IVB (6-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,gingipains
D016066,2.5,NCT00074490-3,Arm IVA (12-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,pleural effusion malignant
D016066,11.36,NCT00074490-4,Arm IVB (6-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,pleural effusion malignant
D016066,2.22,NCT00074490-5,Arm IVC (6-day Expanded Th2 DLI and High Dose Sirolimus),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,pleural effusion malignant
D011014,2.94,NCT00074490-2,Arm IVD Cohort 3 (Multiple Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,pneumonitis
D011014,15.0,NCT00074490-3,Arm IVA (12-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,pneumonitis
D011014,11.36,NCT00074490-4,Arm IVB (6-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,pneumonitis
D003880,2.5,NCT00074490-3,Arm IVA (12-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,dermatology
D011537,2.94,NCT00074490-2,Arm IVD Cohort 3 (Multiple Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,pruritus
D005076,2.94,NCT00074490-2,Arm IVD Cohort 3 (Multiple Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,rash
D005076,27.5,NCT00074490-3,Arm IVA (12-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,rash
D005076,20.45,NCT00074490-4,Arm IVB (6-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,rash
D005076,8.89,NCT00074490-5,Arm IVC (6-day Expanded Th2 DLI and High Dose Sirolimus),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,rash
10037847,5.88,NCT00074490-2,Arm IVD Cohort 3 (Multiple Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,rash acneiform
10037847,2.22,NCT00074490-5,Arm IVC (6-day Expanded Th2 DLI and High Dose Sirolimus),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,rash acneiform
D000071072,2.5,NCT00074490-3,Arm IVA (12-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,acute encephalitis syndrome
D006973,2.94,NCT00074490-2,Arm IVD Cohort 3 (Multiple Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,hypertension
D006973,15.0,NCT00074490-3,Arm IVA (12-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,hypertension
D006973,6.82,NCT00074490-4,Arm IVB (6-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,hypertension
D007022,2.94,NCT00074490-2,Arm IVD Cohort 3 (Multiple Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,hypotension
D007022,15.0,NCT00074490-3,Arm IVA (12-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,hypotension
D007022,4.55,NCT00074490-4,Arm IVB (6-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,hypotension
D007022,2.22,NCT00074490-5,Arm IVC (6-day Expanded Th2 DLI and High Dose Sirolimus),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,hypotension
D016769,5.0,NCT00074490-3,Arm IVA (12-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,embolism and thrombosis
D016769,9.09,NCT00074490-4,Arm IVB (6-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,embolism and thrombosis
D016769,2.22,NCT00074490-5,Arm IVC (6-day Expanded Th2 DLI and High Dose Sirolimus),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,embolism and thrombosis
D016769,2.5,NCT00074490-3,Arm IVA (12-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,embolism and thrombosis
D016769,6.82,NCT00074490-4,Arm IVB (6-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,embolism and thrombosis
D016769,2.22,NCT00074490-5,Arm IVC (6-day Expanded Th2 DLI and High Dose Sirolimus),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,embolism and thrombosis
D014657,2.5,NCT00074490-3,Arm IVA (12-day Expanded Th2 DLI),NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,vasculitis
D064420,4.65,NCT00101101-1,Vaccine and Conventional Therapy,NCT00101101,Universal Granulocyte Macrophage-colony Stimulating Factor (GM-CSF)-Producing and GM.CD40L for Autologous Tumor Vaccine in Mantle Cell Lymphoma,adverse drug events
D007962,2.33,NCT00101101-1,Vaccine and Conventional Therapy,NCT00101101,Universal Granulocyte Macrophage-colony Stimulating Factor (GM-CSF)-Producing and GM.CD40L for Autologous Tumor Vaccine in Mantle Cell Lymphoma,leukocyte
D006098,2.33,NCT00101101-1,Vaccine and Conventional Therapy,NCT00101101,Universal Granulocyte Macrophage-colony Stimulating Factor (GM-CSF)-Producing and GM.CD40L for Autologous Tumor Vaccine in Mantle Cell Lymphoma,granulocyte
D003371,2.33,NCT00101101-1,Vaccine and Conventional Therapy,NCT00101101,Universal Granulocyte Macrophage-colony Stimulating Factor (GM-CSF)-Producing and GM.CD40L for Autologous Tumor Vaccine in Mantle Cell Lymphoma,cough
D064420,33.02,NCT00103506-1,Velcade (Bortezomib) Monotherapy,NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,adverse drug events
D064420,37.74,NCT00103506-2,Doxil/Caelyx Plus Velcade (Bortezomib),NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,adverse drug events
D000741,1.26,NCT00103506-1,Velcade (Bortezomib) Monotherapy,NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,aplastic anaemia
D000741,0.94,NCT00103506-2,Doxil/Caelyx Plus Velcade (Bortezomib),NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,aplastic anaemia
D064147,0.63,NCT00103506-1,Velcade (Bortezomib) Monotherapy,NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,febrile neutropenia
D064147,1.57,NCT00103506-2,Doxil/Caelyx Plus Velcade (Bortezomib),NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,febrile neutropenia
D007970,0.31,NCT00103506-2,Doxil/Caelyx Plus Velcade (Bortezomib),NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,leukopenia
D009503,0.63,NCT00103506-2,Doxil/Caelyx Plus Velcade (Bortezomib),NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,neutropenia
D010198,0.63,NCT00103506-2,Doxil/Caelyx Plus Velcade (Bortezomib),NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,pancytopenia
D013921,2.83,NCT00103506-2,Doxil/Caelyx Plus Velcade (Bortezomib),NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,thrombocytopenia
D056988,0.31,NCT00103506-2,Doxil/Caelyx Plus Velcade (Bortezomib),NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,acute anterior wall myocardial infarction
D000787,0.31,NCT00103506-1,Velcade (Bortezomib) Monotherapy,NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,angina pectoris
D000789,0.31,NCT00103506-1,Velcade (Bortezomib) Monotherapy,NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,unstable angina
D001145,0.31,NCT00103506-1,Velcade (Bortezomib) Monotherapy,NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,arrhythmia
D001281,0.63,NCT00103506-1,Velcade (Bortezomib) Monotherapy,NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,atrial fibrillation
D001282,0.31,NCT00103506-2,Doxil/Caelyx Plus Velcade (Bortezomib),NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,atrial flutter
D006323,0.31,NCT00103506-2,Doxil/Caelyx Plus Velcade (Bortezomib),NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,cardiac arrest
D006333,0.63,NCT00103506-1,Velcade (Bortezomib) Monotherapy,NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,cardiac failure
D006333,0.31,NCT00103506-2,Doxil/Caelyx Plus Velcade (Bortezomib),NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,cardiac failure
D006333,0.63,NCT00103506-1,Velcade (Bortezomib) Monotherapy,NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,cardiac failure
D006333,0.63,NCT00103506-2,Doxil/Caelyx Plus Velcade (Bortezomib),NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,cardiac failure
D000072599,0.31,NCT00103506-1,Velcade (Bortezomib) Monotherapy,NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,cardiorespiratory fitness
D009203,0.31,NCT00103506-1,Velcade (Bortezomib) Monotherapy,NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,myocardial infarction
D009203,0.63,NCT00103506-2,Doxil/Caelyx Plus Velcade (Bortezomib),NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,myocardial infarction
D001145,0.31,NCT00103506-2,Doxil/Caelyx Plus Velcade (Bortezomib),NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,arrhythmia
D016278,0.31,NCT00103506-1,Velcade (Bortezomib) Monotherapy,NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,ventricular function right
D016278,0.31,NCT00103506-2,Doxil/Caelyx Plus Velcade (Bortezomib),NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,ventricular function right
D013610,0.31,NCT00103506-2,Doxil/Caelyx Plus Velcade (Bortezomib),NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,tachyarrhythmia
D003638,0.31,NCT00103506-2,Doxil/Caelyx Plus Velcade (Bortezomib),NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,deafness
D014717,0.94,NCT00103506-1,Velcade (Bortezomib) Monotherapy,NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,vertigo
D000309,0.31,NCT00103506-2,Doxil/Caelyx Plus Velcade (Bortezomib),NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,adrenal insufficiency
UNKNOWN-check-for-typo,0.31,NCT00103506-2,Doxil/Caelyx Plus Velcade (Bortezomib),NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,D00
D007177,0.31,NCT00103506-1,Velcade (Bortezomib) Monotherapy,NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,antidiuretic hormone inappropriate secretion
D002386,0.31,NCT00103506-2,Doxil/Caelyx Plus Velcade (Bortezomib),NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,cataract
D001112,0.31,NCT00103506-2,Doxil/Caelyx Plus Velcade (Bortezomib),NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,corneal arcus
D004172,0.31,NCT00103506-1,Velcade (Bortezomib) Monotherapy,NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,diplopia
D012170,0.31,NCT00103506-1,Velcade (Bortezomib) Monotherapy,NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,retinal vein thrombosis
D015746,0.63,NCT00103506-1,Velcade (Bortezomib) Monotherapy,NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,abdominal pain
D015746,0.63,NCT00103506-2,Doxil/Caelyx Plus Velcade (Bortezomib),NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,abdominal pain
UNKNOWN-check-for-typo,1.89,NCT00103506-1,Velcade (Bortezomib) Monotherapy,NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,D00
UNKNOWN-check-for-typo,2.2,NCT00103506-2,Doxil/Caelyx Plus Velcade (Bortezomib),NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,D00
D004415,0.31,NCT00103506-2,Doxil/Caelyx Plus Velcade (Bortezomib),NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,dyspepsia
D003680,0.63,NCT00103506-2,Doxil/Caelyx Plus Velcade (Bortezomib),NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,dysphagia
UNKNOWN-check-for-typo,0.31,NCT00103506-2,Doxil/Caelyx Plus Velcade (Bortezomib),NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,D00
D005414,0.31,NCT00103506-1,Velcade (Bortezomib) Monotherapy,NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,flatulence
D013276,0.63,NCT00103506-2,Doxil/Caelyx Plus Velcade (Bortezomib),NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,gastric ulcer
D010437,0.31,NCT00103506-2,Doxil/Caelyx Plus Velcade (Bortezomib),NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,gastroduodenal ulcer
D000069196,0.31,NCT00103506-1,Velcade (Bortezomib) Monotherapy,NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,gastrointestinal microbiome
D000069196,0.94,NCT00103506-2,Doxil/Caelyx Plus Velcade (Bortezomib),NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,gastrointestinal microbiome
D005764,0.31,NCT00103506-2,Doxil/Caelyx Plus Velcade (Bortezomib),NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,gastroesophageal reflux disease
UNKNOWN-check-for-typo,0.63,NCT00103506-1,Velcade (Bortezomib) Monotherapy,NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,D00
UNKNOWN-check-for-typo,0.63,NCT00103506-2,Doxil/Caelyx Plus Velcade (Bortezomib),NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,D00
D045823,0.31,NCT00103506-2,Doxil/Caelyx Plus Velcade (Bortezomib),NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,ileus
D007418,0.31,NCT00103506-1,Velcade (Bortezomib) Monotherapy,NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,paralytic ileus
D007418,0.31,NCT00103506-2,Doxil/Caelyx Plus Velcade (Bortezomib),NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,paralytic ileus
D007420,0.31,NCT00103506-2,Doxil/Caelyx Plus Velcade (Bortezomib),NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,intestine large
D008309,0.63,NCT00103506-2,Doxil/Caelyx Plus Velcade (Bortezomib),NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,mallory weiss syndrome
D009325,0.94,NCT00103506-1,Velcade (Bortezomib) Monotherapy,NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,nausea
D009325,2.2,NCT00103506-2,Doxil/Caelyx Plus Velcade (Bortezomib),NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,nausea
D000071056,0.31,NCT00103506-2,Doxil/Caelyx Plus Velcade (Bortezomib),NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,anorectal malformations
D012005,0.31,NCT00103506-1,Velcade (Bortezomib) Monotherapy,NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,rectal prolapse
10041101,0.31,NCT00103506-1,Velcade (Bortezomib) Monotherapy,NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,small intestinal obstruction
10041101,0.31,NCT00103506-2,Doxil/Caelyx Plus Velcade (Bortezomib),NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,small intestinal obstruction
D013280,0.31,NCT00103506-2,Doxil/Caelyx Plus Velcade (Bortezomib),NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,stomatitis
D041742,0.63,NCT00103506-2,Doxil/Caelyx Plus Velcade (Bortezomib),NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,upper gastrointestinal tract
D014839,0.63,NCT00103506-1,Velcade (Bortezomib) Monotherapy,NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,vomiting
D014839,4.09,NCT00103506-2,Doxil/Caelyx Plus Velcade (Bortezomib),NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,vomiting
D001247,0.31,NCT00103506-1,Velcade (Bortezomib) Monotherapy,NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,asthenia
D001247,0.63,NCT00103506-2,Doxil/Caelyx Plus Velcade (Bortezomib),NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,asthenia
D048909,0.31,NCT00103506-1,Velcade (Bortezomib) Monotherapy,NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,diabetes-related complications
D002637,0.94,NCT00103506-1,Velcade (Bortezomib) Monotherapy,NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,chest pain
D023341,0.31,NCT00103506-1,Velcade (Bortezomib) Monotherapy,NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,chills
D003643,0.31,NCT00103506-1,Velcade (Bortezomib) Monotherapy,NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,death
D005221,0.94,NCT00103506-2,Doxil/Caelyx Plus Velcade (Bortezomib),NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,fatigue
D003695,0.31,NCT00103506-2,Doxil/Caelyx Plus Velcade (Bortezomib),NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,healthcare
D005334,0.31,NCT00103506-1,Velcade (Bortezomib) Monotherapy,NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,hyperthermia
D007251,0.31,NCT00103506-2,Doxil/Caelyx Plus Velcade (Bortezomib),NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,influenza
D009102,0.31,NCT00103506-2,Doxil/Caelyx Plus Velcade (Bortezomib),NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,multiple organ failure
D000799,0.31,NCT00103506-1,Velcade (Bortezomib) Monotherapy,NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,angioedema
D010146,0.31,NCT00103506-2,Doxil/Caelyx Plus Velcade (Bortezomib),NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,pain
D005334,2.52,NCT00103506-1,Velcade (Bortezomib) Monotherapy,NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,pyrexia
D005334,4.72,NCT00103506-2,Doxil/Caelyx Plus Velcade (Bortezomib),NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,pyrexia
D016757,0.31,NCT00103506-1,Velcade (Bortezomib) Monotherapy,NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,sudden cardiac death
D003645,0.31,NCT00103506-2,Doxil/Caelyx Plus Velcade (Bortezomib),NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,sudden death
D006967,0.31,NCT00103506-2,Doxil/Caelyx Plus Velcade (Bortezomib),NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,hypersensitivity
10056519,0.31,NCT00103506-2,Doxil/Caelyx Plus Velcade (Bortezomib),NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,abdominal infection
D000985,0.31,NCT00103506-1,Velcade (Bortezomib) Monotherapy,NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,antisepsis
D001991,0.31,NCT00103506-1,Velcade (Bortezomib) Monotherapy,NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,bronchitis
D010223,0.63,NCT00103506-1,Velcade (Bortezomib) Monotherapy,NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,acute laryngotracheo-bronchitis virus
D029481,0.63,NCT00103506-1,Velcade (Bortezomib) Monotherapy,NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,chronic bronchitis
D001996,0.31,NCT00103506-1,Velcade (Bortezomib) Monotherapy,NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,bronchopneumonia
D001996,0.94,NCT00103506-2,Doxil/Caelyx Plus Velcade (Bortezomib),NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,bronchopneumonia
D002177,0.31,NCT00103506-2,Doxil/Caelyx Plus Velcade (Bortezomib),NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,candidiasis
10007810,0.63,NCT00103506-2,Doxil/Caelyx Plus Velcade (Bortezomib),NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,catheter related infection
D002481,0.31,NCT00103506-1,Velcade (Bortezomib) Monotherapy,NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,cellulitis
D002481,0.31,NCT00103506-2,Doxil/Caelyx Plus Velcade (Bortezomib),NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,cellulitis
D000069544,0.31,NCT00103506-1,Velcade (Bortezomib) Monotherapy,NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,infectious encephalitis
D010031,0.31,NCT00103506-2,Doxil/Caelyx Plus Velcade (Bortezomib),NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,ear infection
D005667,0.31,NCT00103506-2,Doxil/Caelyx Plus Velcade (Bortezomib),NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,furuncles
D005759,0.94,NCT00103506-1,Velcade (Bortezomib) Monotherapy,NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,gastroenteritis
D005759,0.31,NCT00103506-2,Doxil/Caelyx Plus Velcade (Bortezomib),NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,gastroenteritis
D012141,0.31,NCT00103506-1,Velcade (Bortezomib) Monotherapy,NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,respiratory tract infections
D006562,0.94,NCT00103506-1,Velcade (Bortezomib) Monotherapy,NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,herpes zoster
D006562,1.57,NCT00103506-2,Doxil/Caelyx Plus Velcade (Bortezomib),NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,herpes zoster
D006562,0.31,NCT00103506-1,Velcade (Bortezomib) Monotherapy,NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,herpes zoster
D006562,0.31,NCT00103506-2,Doxil/Caelyx Plus Velcade (Bortezomib),NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,herpes zoster
D007239,0.31,NCT00103506-1,Velcade (Bortezomib) Monotherapy,NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,infection
D007239,0.31,NCT00103506-2,Doxil/Caelyx Plus Velcade (Bortezomib),NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,infection
D000985,0.31,NCT00103506-1,Velcade (Bortezomib) Monotherapy,NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,antisepsis
D007827,0.31,NCT00103506-1,Velcade (Bortezomib) Monotherapy,NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,laryngitis
D011014,0.31,NCT00103506-1,Velcade (Bortezomib) Monotherapy,NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,lobar pneumonia
D012141,0.94,NCT00103506-1,Velcade (Bortezomib) Monotherapy,NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,respiratory tract infections
D012141,0.94,NCT00103506-2,Doxil/Caelyx Plus Velcade (Bortezomib),NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,respiratory tract infections
D016920,0.31,NCT00103506-1,Velcade (Bortezomib) Monotherapy,NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,bacterial meningitis
D000985,0.31,NCT00103506-2,Doxil/Caelyx Plus Velcade (Bortezomib),NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,antisepsis
D009894,0.31,NCT00103506-2,Doxil/Caelyx Plus Velcade (Bortezomib),NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,opportunistic infection
D009920,0.31,NCT00103506-2,Doxil/Caelyx Plus Velcade (Bortezomib),NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,orchitis
D010019,0.31,NCT00103506-2,Doxil/Caelyx Plus Velcade (Bortezomib),NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,osteomyelitis
D008586,0.31,NCT00103506-2,Doxil/Caelyx Plus Velcade (Bortezomib),NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,meningitis pneumococcal
D000985,0.31,NCT00103506-1,Velcade (Bortezomib) Monotherapy,NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,antisepsis
D000985,0.63,NCT00103506-2,Doxil/Caelyx Plus Velcade (Bortezomib),NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,antisepsis
D011020,0.31,NCT00103506-2,Doxil/Caelyx Plus Velcade (Bortezomib),NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,pneumocystis jirovecii pneumonia
D011014,6.29,NCT00103506-1,Velcade (Bortezomib) Monotherapy,NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,pneumonia
D011014,5.03,NCT00103506-2,Doxil/Caelyx Plus Velcade (Bortezomib),NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,pneumonia
D001230,0.31,NCT00103506-1,Velcade (Bortezomib) Monotherapy,NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,aspergillus
D001996,0.31,NCT00103506-2,Doxil/Caelyx Plus Velcade (Bortezomib),NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,bronchopneumonia
D011018,0.31,NCT00103506-2,Doxil/Caelyx Plus Velcade (Bortezomib),NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,pneumococcal pneumonia
D011552,0.63,NCT00103506-2,Doxil/Caelyx Plus Velcade (Bortezomib),NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,pseudomonas infection
D012141,0.63,NCT00103506-1,Velcade (Bortezomib) Monotherapy,NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,respiratory tract infection
D012141,0.94,NCT00103506-2,Doxil/Caelyx Plus Velcade (Bortezomib),NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,respiratory tract infection
D012141,0.31,NCT00103506-2,Doxil/Caelyx Plus Velcade (Bortezomib),NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,respiratory tract infections
D018805,0.31,NCT00103506-2,Doxil/Caelyx Plus Velcade (Bortezomib),NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,sepsis
D000891,0.31,NCT00103506-2,Doxil/Caelyx Plus Velcade (Bortezomib),NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,antiseptics
D012772,0.31,NCT00103506-1,Velcade (Bortezomib) Monotherapy,NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,septic shock
D012772,0.94,NCT00103506-2,Doxil/Caelyx Plus Velcade (Bortezomib),NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,septic shock
D012852,0.31,NCT00103506-1,Velcade (Bortezomib) Monotherapy,NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,sinusitis
10040872,0.31,NCT00103506-1,Velcade (Bortezomib) Monotherapy,NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,skin infection
D000985,0.63,NCT00103506-2,Doxil/Caelyx Plus Velcade (Bortezomib),NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,antisepsis
D012141,0.63,NCT00103506-1,Velcade (Bortezomib) Monotherapy,NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,upper respiratory tract infections
D012141,1.26,NCT00103506-2,Doxil/Caelyx Plus Velcade (Bortezomib),NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,upper respiratory tract infections
D014552,0.63,NCT00103506-1,Velcade (Bortezomib) Monotherapy,NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,urinary tract infection
10040047,0.31,NCT00103506-1,Velcade (Bortezomib) Monotherapy,NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,sepsis
D064420,0.31,NCT00103506-2,Doxil/Caelyx Plus Velcade (Bortezomib),NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,drug toxicity
10016173,0.31,NCT00103506-1,Velcade (Bortezomib) Monotherapy,NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,fall
10016173,0.31,NCT00103506-2,Doxil/Caelyx Plus Velcade (Bortezomib),NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,fall
10065829,0.31,NCT00103506-2,Doxil/Caelyx Plus Velcade (Bortezomib),NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,intraoperative musculoskeletal injury
D016103,0.31,NCT00103506-2,Doxil/Caelyx Plus Velcade (Bortezomib),NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,spinal fractures
D001468,0.31,NCT00103506-1,Velcade (Bortezomib) Monotherapy,NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,thoracica
10011368,0.63,NCT00103506-1,Velcade (Bortezomib) Monotherapy,NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,creatinine increased
10011368,0.94,NCT00103506-2,Doxil/Caelyx Plus Velcade (Bortezomib),NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,creatinine increased
D001786,0.31,NCT00103506-2,Doxil/Caelyx Plus Velcade (Bortezomib),NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,blood glucose
10050528,0.63,NCT00103506-2,Doxil/Caelyx Plus Velcade (Bortezomib),NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,ejection fraction decreased
10007612,0.31,NCT00103506-1,Velcade (Bortezomib) Monotherapy,NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,cardiac troponin i increased
D000855,0.63,NCT00103506-2,Doxil/Caelyx Plus Velcade (Bortezomib),NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,anorexia
D003681,1.89,NCT00103506-1,Velcade (Bortezomib) Monotherapy,NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,dehydration
D003681,1.89,NCT00103506-2,Doxil/Caelyx Plus Velcade (Bortezomib),NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,dehydration
D006073,0.31,NCT00103506-2,Doxil/Caelyx Plus Velcade (Bortezomib),NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,gout
UNKNOWN-check-for-typo,0.31,NCT00103506-1,Velcade (Bortezomib) Monotherapy,NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,D00
UNKNOWN-check-for-typo,0.31,NCT00103506-2,Doxil/Caelyx Plus Velcade (Bortezomib),NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,D00
UNKNOWN-check-for-typo,0.31,NCT00103506-1,Velcade (Bortezomib) Monotherapy,NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,D00
UNKNOWN-check-for-typo,0.31,NCT00103506-1,Velcade (Bortezomib) Monotherapy,NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,D00
UNKNOWN-check-for-typo,0.31,NCT00103506-2,Doxil/Caelyx Plus Velcade (Bortezomib),NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,D00
UNKNOWN-check-for-typo,0.31,NCT00103506-1,Velcade (Bortezomib) Monotherapy,NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,D00
UNKNOWN-check-for-typo,0.31,NCT00103506-1,Velcade (Bortezomib) Monotherapy,NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,D00
UNKNOWN-check-for-typo,0.94,NCT00103506-2,Doxil/Caelyx Plus Velcade (Bortezomib),NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,D00
UNKNOWN-check-for-typo,0.31,NCT00103506-1,Velcade (Bortezomib) Monotherapy,NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,D00
UNKNOWN-check-for-typo,0.31,NCT00103506-2,Doxil/Caelyx Plus Velcade (Bortezomib),NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,D00
D018771,0.63,NCT00103506-1,Velcade (Bortezomib) Monotherapy,NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,arthralgia
D001416,0.94,NCT00103506-1,Velcade (Bortezomib) Monotherapy,NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,back pain
D000077553,0.31,NCT00103506-1,Velcade (Bortezomib) Monotherapy,NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,edarabone
D000077553,0.31,NCT00103506-2,Doxil/Caelyx Plus Velcade (Bortezomib),NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,edarabone
10006002,0.31,NCT00103506-1,Velcade (Bortezomib) Monotherapy,NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,bone pain
10006002,0.31,NCT00103506-2,Doxil/Caelyx Plus Velcade (Bortezomib),NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,bone pain
D002062,0.31,NCT00103506-2,Doxil/Caelyx Plus Velcade (Bortezomib),NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,bursitis
D007593,0.31,NCT00103506-2,Doxil/Caelyx Plus Velcade (Bortezomib),NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,joint instability
D002637,0.31,NCT00103506-2,Doxil/Caelyx Plus Velcade (Bortezomib),NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,chest pain
D063806,0.31,NCT00103506-1,Velcade (Bortezomib) Monotherapy,NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,myalgia
D010020,0.31,NCT00103506-2,Doxil/Caelyx Plus Velcade (Bortezomib),NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,osteonecrosis
10033425,0.63,NCT00103506-1,Velcade (Bortezomib) Monotherapy,NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,pain in extremity
D005598,0.63,NCT00103506-2,Doxil/Caelyx Plus Velcade (Bortezomib),NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,pathological fracture
D000072716,0.31,NCT00103506-1,Velcade (Bortezomib) Monotherapy,NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,cancer pain
D003110,0.31,NCT00103506-2,Doxil/Caelyx Plus Velcade (Bortezomib),NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,colon cancer
D015275,0.31,NCT00103506-1,Velcade (Bortezomib) Monotherapy,NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,tumour lysis syndrome
D015275,0.63,NCT00103506-2,Doxil/Caelyx Plus Velcade (Bortezomib),NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,tumour lysis syndrome
D003929,0.31,NCT00103506-1,Velcade (Bortezomib) Monotherapy,NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,diabetic autonomic neuropathy
D000067571,0.31,NCT00103506-1,Velcade (Bortezomib) Monotherapy,NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,balance sheet
D000077684,0.63,NCT00103506-1,Velcade (Bortezomib) Monotherapy,NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,cauda equina syndrome
D000077684,0.31,NCT00103506-2,Doxil/Caelyx Plus Velcade (Bortezomib),NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,cauda equina syndrome
D000074042,0.31,NCT00103506-2,Doxil/Caelyx Plus Velcade (Bortezomib),NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,cerebral intraventricular haemorrhage
D002544,0.31,NCT00103506-2,Doxil/Caelyx Plus Velcade (Bortezomib),NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,cerebral infarction
D000070624,0.31,NCT00103506-2,Doxil/Caelyx Plus Velcade (Bortezomib),NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,cerebral contusion
D001259,0.31,NCT00103506-2,Doxil/Caelyx Plus Velcade (Bortezomib),NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,dyscoordination
D004244,0.31,NCT00103506-1,Velcade (Bortezomib) Monotherapy,NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,dizziness
D004244,0.63,NCT00103506-2,Doxil/Caelyx Plus Velcade (Bortezomib),NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,dizziness
D011128,0.31,NCT00103506-1,Velcade (Bortezomib) Monotherapy,NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,polyradiculopathy
D009437,0.31,NCT00103506-1,Velcade (Bortezomib) Monotherapy,NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,neuralgia
D000071075,0.31,NCT00103506-1,Velcade (Bortezomib) Monotherapy,NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,small fiber neuropathy
D010523,0.31,NCT00103506-1,Velcade (Bortezomib) Monotherapy,NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,peripheral neuropathy
D010523,0.63,NCT00103506-2,Doxil/Caelyx Plus Velcade (Bortezomib),NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,peripheral neuropathy
D010243,0.31,NCT00103506-1,Velcade (Bortezomib) Monotherapy,NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,paralysis
D020335,0.31,NCT00103506-1,Velcade (Bortezomib) Monotherapy,NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,paraparesis
D010264,0.31,NCT00103506-1,Velcade (Bortezomib) Monotherapy,NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,paraplegia
D011115,0.31,NCT00103506-1,Velcade (Bortezomib) Monotherapy,NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,polyneuropathy
D011115,0.31,NCT00103506-2,Doxil/Caelyx Plus Velcade (Bortezomib),NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,polyneuropathy
D004194,0.31,NCT00103506-1,Velcade (Bortezomib) Monotherapy,NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,disease
D011782,0.31,NCT00103506-1,Velcade (Bortezomib) Monotherapy,NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,quadriparesis
D013117,0.94,NCT00103506-2,Doxil/Caelyx Plus Velcade (Bortezomib),NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,spinal cord compression
D013575,1.26,NCT00103506-1,Velcade (Bortezomib) Monotherapy,NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,syncope
D013575,1.26,NCT00103506-2,Doxil/Caelyx Plus Velcade (Bortezomib),NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,syncope
D014202,0.31,NCT00103506-2,Doxil/Caelyx Plus Velcade (Bortezomib),NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,tremor
10001497,0.31,NCT00103506-1,Velcade (Bortezomib) Monotherapy,NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,agitation
D001007,0.31,NCT00103506-1,Velcade (Bortezomib) Monotherapy,NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,anxiety
D000081013,0.31,NCT00103506-1,Velcade (Bortezomib) Monotherapy,NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,completed suicide
D001007,0.31,NCT00103506-1,Velcade (Bortezomib) Monotherapy,NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,nervousness
D059020,0.31,NCT00103506-1,Velcade (Bortezomib) Monotherapy,NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,suicidal ideation
D001744,0.31,NCT00103506-2,Doxil/Caelyx Plus Velcade (Bortezomib),NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,bladder calculus
UNKNOWN-check-for-typo,0.31,NCT00103506-2,Doxil/Caelyx Plus Velcade (Bortezomib),NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,D00
D009395,0.31,NCT00103506-1,Velcade (Bortezomib) Monotherapy,NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,interstitial nephritis
D056844,0.31,NCT00103506-2,Doxil/Caelyx Plus Velcade (Bortezomib),NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,renal colic
D051437,0.63,NCT00103506-1,Velcade (Bortezomib) Monotherapy,NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,renal failure
D051437,0.94,NCT00103506-2,Doxil/Caelyx Plus Velcade (Bortezomib),NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,renal failure
D058186,1.57,NCT00103506-1,Velcade (Bortezomib) Monotherapy,NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,acute renal failure
D058186,1.26,NCT00103506-2,Doxil/Caelyx Plus Velcade (Bortezomib),NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,acute renal failure
D007676,0.31,NCT00103506-1,Velcade (Bortezomib) Monotherapy,NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,renal failure chronic
D000308,0.63,NCT00103506-1,Velcade (Bortezomib) Monotherapy,NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,hyperadrenalism
D001743,0.31,NCT00103506-2,Doxil/Caelyx Plus Velcade (Bortezomib),NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,urinary bladder
D016055,0.63,NCT00103506-1,Velcade (Bortezomib) Monotherapy,NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,urinary retention
D016055,0.31,NCT00103506-2,Doxil/Caelyx Plus Velcade (Bortezomib),NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,urinary retention
D011470,0.31,NCT00103506-2,Doxil/Caelyx Plus Velcade (Bortezomib),NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,benign prostatic hyperplasia
D004823,0.31,NCT00103506-1,Velcade (Bortezomib) Monotherapy,NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,epididymitis
D000799,0.31,NCT00103506-1,Velcade (Bortezomib) Monotherapy,NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,angioedema
D000799,0.63,NCT00103506-2,Doxil/Caelyx Plus Velcade (Bortezomib),NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,angioedema
D029424,0.31,NCT00103506-1,Velcade (Bortezomib) Monotherapy,NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,chronic obstructive pulmonary disease
UNKNOWN-check-for-typo,1.89,NCT00103506-1,Velcade (Bortezomib) Monotherapy,NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,D00
UNKNOWN-check-for-typo,0.63,NCT00103506-2,Doxil/Caelyx Plus Velcade (Bortezomib),NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,D00
D051270,0.31,NCT00103506-2,Doxil/Caelyx Plus Velcade (Bortezomib),NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,primary exertional headache
D017563,0.31,NCT00103506-1,Velcade (Bortezomib) Monotherapy,NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,interstitial lung disease
D011014,0.63,NCT00103506-2,Doxil/Caelyx Plus Velcade (Bortezomib),NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,pneumonitis
D011655,0.63,NCT00103506-1,Velcade (Bortezomib) Monotherapy,NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,pulmonary embolism
D011655,0.63,NCT00103506-2,Doxil/Caelyx Plus Velcade (Bortezomib),NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,pulmonary embolism
D011658,0.31,NCT00103506-1,Velcade (Bortezomib) Monotherapy,NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,pulmonary fibrosis
D006976,0.63,NCT00103506-2,Doxil/Caelyx Plus Velcade (Bortezomib),NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,pulmonary hypertension
D000799,0.31,NCT00103506-2,Doxil/Caelyx Plus Velcade (Bortezomib),NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,angioedema
D012131,0.31,NCT00103506-1,Velcade (Bortezomib) Monotherapy,NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,respiratory failure
D012131,0.31,NCT00103506-2,Doxil/Caelyx Plus Velcade (Bortezomib),NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,respiratory failure
D005218,0.31,NCT00103506-2,Doxil/Caelyx Plus Velcade (Bortezomib),NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,steatonecrosis
D000069281,0.31,NCT00103506-1,Velcade (Bortezomib) Monotherapy,NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,hypophysitis lymphocytic
10054524,0.31,NCT00103506-2,Doxil/Caelyx Plus Velcade (Bortezomib),NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,palmar-plantar erythrodysesthesia syndrome
D005076,0.31,NCT00103506-2,Doxil/Caelyx Plus Velcade (Bortezomib),NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,rash
D000077944,0.31,NCT00103506-1,Velcade (Bortezomib) Monotherapy,NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,alefacept
D020246,0.31,NCT00103506-1,Velcade (Bortezomib) Monotherapy,NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,deep vein thrombosis
D007022,0.63,NCT00103506-1,Velcade (Bortezomib) Monotherapy,NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,hypotension
D007022,1.26,NCT00103506-2,Doxil/Caelyx Plus Velcade (Bortezomib),NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,hypotension
D007024,0.63,NCT00103506-1,Velcade (Bortezomib) Monotherapy,NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,orthostatic hypotension
D007024,0.63,NCT00103506-2,Doxil/Caelyx Plus Velcade (Bortezomib),NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,orthostatic hypotension
D010689,0.31,NCT00103506-2,Doxil/Caelyx Plus Velcade (Bortezomib),NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,phlebitis
D013924,0.31,NCT00103506-2,Doxil/Caelyx Plus Velcade (Bortezomib),NCT00103506,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,thrombophlebitis
D064420,9.52,NCT00107380-1,R-CHOP + I-131-tositumomab,NCT00107380,S0433 Iodine I 131 Tositumomab  Rituximab  and Combination Chemotherapy in Treating Older Patients With Stage II  Stage III  or Stage IV Non-Hodgkin's Lymphoma,adverse drug events
D064147,1.19,NCT00107380-1,R-CHOP + I-131-tositumomab,NCT00107380,S0433 Iodine I 131 Tositumomab  Rituximab  and Combination Chemotherapy in Treating Older Patients With Stage II  Stage III  or Stage IV Non-Hodgkin's Lymphoma,febrile neutropenia
D006342,2.38,NCT00107380-1,R-CHOP + I-131-tositumomab,NCT00107380,S0433 Iodine I 131 Tositumomab  Rituximab  and Combination Chemotherapy in Treating Older Patients With Stage II  Stage III  or Stage IV Non-Hodgkin's Lymphoma,cardiac rupture post-infarction
D006471,1.19,NCT00107380-1,R-CHOP + I-131-tositumomab,NCT00107380,S0433 Iodine I 131 Tositumomab  Rituximab  and Combination Chemotherapy in Treating Older Patients With Stage II  Stage III  or Stage IV Non-Hodgkin's Lymphoma,gastrointestinal hemorrhage
10055356,1.19,NCT00107380-1,R-CHOP + I-131-tositumomab,NCT00107380,S0433 Iodine I 131 Tositumomab  Rituximab  and Combination Chemotherapy in Treating Older Patients With Stage II  Stage III  or Stage IV Non-Hodgkin's Lymphoma,upper gastrointestinal hemorrhage
D011014,1.19,NCT00107380-1,R-CHOP + I-131-tositumomab,NCT00107380,S0433 Iodine I 131 Tositumomab  Rituximab  and Combination Chemotherapy in Treating Older Patients With Stage II  Stage III  or Stage IV Non-Hodgkin's Lymphoma,lung inflammation
D001792,1.19,NCT00107380-1,R-CHOP + I-131-tositumomab,NCT00107380,S0433 Iodine I 131 Tositumomab  Rituximab  and Combination Chemotherapy in Treating Older Patients With Stage II  Stage III  or Stage IV Non-Hodgkin's Lymphoma,platelets
10049737,2.38,NCT00107380-1,R-CHOP + I-131-tositumomab,NCT00107380,S0433 Iodine I 131 Tositumomab  Rituximab  and Combination Chemotherapy in Treating Older Patients With Stage II  Stage III  or Stage IV Non-Hodgkin's Lymphoma,treatment related secondary malignancy
D051437,1.19,NCT00107380-1,R-CHOP + I-131-tositumomab,NCT00107380,S0433 Iodine I 131 Tositumomab  Rituximab  and Combination Chemotherapy in Treating Older Patients With Stage II  Stage III  or Stage IV Non-Hodgkin's Lymphoma,renal failure
D064420,2.67,NCT00109837-1,First Induction,NCT00109837,S0333 Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,adverse drug events
D064420,3.57,NCT00109837-2,Second Induction,NCT00109837,S0333 Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,adverse drug events
D064420,3.03,NCT00109837-3,Consolidation,NCT00109837,S0333 Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,adverse drug events
D010195,1.33,NCT00109837-1,First Induction,NCT00109837,S0333 Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,pancreatitis
D009102,1.33,NCT00109837-1,First Induction,NCT00109837,S0333 Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,multiple organ failure
D000069544,1.79,NCT00109837-2,Second Induction,NCT00109837,S0333 Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,encephalitis infection
10061229,1.79,NCT00109837-2,Second Induction,NCT00109837,S0333 Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,lung infection
D019106,1.79,NCT00109837-2,Second Induction,NCT00109837,S0333 Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,postoperative hemorrhage
D007962,3.03,NCT00109837-3,Consolidation,NCT00109837,S0333 Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,leukocytes
D001792,3.03,NCT00109837-3,Consolidation,NCT00109837,S0333 Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,platelets
D015228,1.33,NCT00109837-1,First Induction,NCT00109837,S0333 Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,hypertriglyceridemia
D009026,1.89,NCT00114738-1,EPOCH-R+Bortezomib,NCT00114738,EPOCH-R Chemotherapy Plus Bortezomib to Treat Mantle Cell Lymphoma,mortality
D064420,39.62,NCT00114738-1,EPOCH-R+Bortezomib,NCT00114738,EPOCH-R Chemotherapy Plus Bortezomib to Treat Mantle Cell Lymphoma,adverse drug events
D006454,1.89,NCT00114738-1,EPOCH-R+Bortezomib,NCT00114738,EPOCH-R Chemotherapy Plus Bortezomib to Treat Mantle Cell Lymphoma,hemoglobin
D001792,1.89,NCT00114738-1,EPOCH-R+Bortezomib,NCT00114738,EPOCH-R Chemotherapy Plus Bortezomib to Treat Mantle Cell Lymphoma,platelets
D003248,1.89,NCT00114738-1,EPOCH-R+Bortezomib,NCT00114738,EPOCH-R Chemotherapy Plus Bortezomib to Treat Mantle Cell Lymphoma,constipation
D003967,1.89,NCT00114738-1,EPOCH-R+Bortezomib,NCT00114738,EPOCH-R Chemotherapy Plus Bortezomib to Treat Mantle Cell Lymphoma,diarrhea
D004941,1.89,NCT00114738-1,EPOCH-R+Bortezomib,NCT00114738,EPOCH-R Chemotherapy Plus Bortezomib to Treat Mantle Cell Lymphoma,esophagitis
D006471,1.89,NCT00114738-1,EPOCH-R+Bortezomib,NCT00114738,EPOCH-R Chemotherapy Plus Bortezomib to Treat Mantle Cell Lymphoma,gastrointestinal hemorrhage
D003112,1.89,NCT00114738-1,EPOCH-R+Bortezomib,NCT00114738,EPOCH-R Chemotherapy Plus Bortezomib to Treat Mantle Cell Lymphoma,pseudoobstruction colonic
10041101,1.89,NCT00114738-1,EPOCH-R+Bortezomib,NCT00114738,EPOCH-R Chemotherapy Plus Bortezomib to Treat Mantle Cell Lymphoma,small intestinal obstruction
D000005,1.89,NCT00114738-1,EPOCH-R+Bortezomib,NCT00114738,EPOCH-R Chemotherapy Plus Bortezomib to Treat Mantle Cell Lymphoma,abdomen
10010001,1.89,NCT00114738-1,EPOCH-R+Bortezomib,NCT00114738,EPOCH-R Chemotherapy Plus Bortezomib to Treat Mantle Cell Lymphoma,colonic perforation
D018450,1.89,NCT00114738-1,EPOCH-R+Bortezomib,NCT00114738,EPOCH-R Chemotherapy Plus Bortezomib to Treat Mantle Cell Lymphoma,disease progression
D004342,1.89,NCT00114738-1,EPOCH-R+Bortezomib,NCT00114738,EPOCH-R Chemotherapy Plus Bortezomib to Treat Mantle Cell Lymphoma,drug hypersensitivity
D064147,16.98,NCT00114738-1,EPOCH-R+Bortezomib,NCT00114738,EPOCH-R Chemotherapy Plus Bortezomib to Treat Mantle Cell Lymphoma,febrile neutropenia
10061229,1.89,NCT00114738-1,EPOCH-R+Bortezomib,NCT00114738,EPOCH-R Chemotherapy Plus Bortezomib to Treat Mantle Cell Lymphoma,lung infection
10040872,1.89,NCT00114738-1,EPOCH-R+Bortezomib,NCT00114738,EPOCH-R Chemotherapy Plus Bortezomib to Treat Mantle Cell Lymphoma,skin infection
10061229,1.89,NCT00114738-1,EPOCH-R+Bortezomib,NCT00114738,EPOCH-R Chemotherapy Plus Bortezomib to Treat Mantle Cell Lymphoma,lung infection
D003404,1.89,NCT00114738-1,EPOCH-R+Bortezomib,NCT00114738,EPOCH-R Chemotherapy Plus Bortezomib to Treat Mantle Cell Lymphoma,creatinine
10017076,1.89,NCT00114738-1,EPOCH-R+Bortezomib,NCT00114738,EPOCH-R Chemotherapy Plus Bortezomib to Treat Mantle Cell Lymphoma,fracture
10006002,1.89,NCT00114738-1,EPOCH-R+Bortezomib,NCT00114738,EPOCH-R Chemotherapy Plus Bortezomib to Treat Mantle Cell Lymphoma,bone pain
D004244,1.89,NCT00114738-1,EPOCH-R+Bortezomib,NCT00114738,EPOCH-R Chemotherapy Plus Bortezomib to Treat Mantle Cell Lymphoma,dizziness
D006470,1.89,NCT00114738-1,EPOCH-R+Bortezomib,NCT00114738,EPOCH-R Chemotherapy Plus Bortezomib to Treat Mantle Cell Lymphoma,hemorrhage
D004417,1.89,NCT00114738-1,EPOCH-R+Bortezomib,NCT00114738,EPOCH-R Chemotherapy Plus Bortezomib to Treat Mantle Cell Lymphoma,breath shortness
D064420,42.86,NCT00121199-1,CHOP + Rituximab + Bevacizumab,NCT00121199,Combination Chemo  Rituximab  and Bevacizumab in Older Patients With Stage II-IV Diffuse Large B-Cell Lymphoma,adverse drug events
D064147,4.76,NCT00121199-1,CHOP + Rituximab + Bevacizumab,NCT00121199,Combination Chemo  Rituximab  and Bevacizumab in Older Patients With Stage II-IV Diffuse Large B-Cell Lymphoma,febrile neutropenia
D006454,4.76,NCT00121199-1,CHOP + Rituximab + Bevacizumab,NCT00121199,Combination Chemo  Rituximab  and Bevacizumab in Older Patients With Stage II-IV Diffuse Large B-Cell Lymphoma,hemoglobin
10069501,3.17,NCT00121199-1,CHOP + Rituximab + Bevacizumab,NCT00121199,Combination Chemo  Rituximab  and Bevacizumab in Older Patients With Stage II-IV Diffuse Large B-Cell Lymphoma,left ventricular systolic dysfunction
D003248,3.17,NCT00121199-1,CHOP + Rituximab + Bevacizumab,NCT00121199,Combination Chemo  Rituximab  and Bevacizumab in Older Patients With Stage II-IV Diffuse Large B-Cell Lymphoma,constipation
D003967,1.59,NCT00121199-1,CHOP + Rituximab + Bevacizumab,NCT00121199,Combination Chemo  Rituximab  and Bevacizumab in Older Patients With Stage II-IV Diffuse Large B-Cell Lymphoma,diarrhea
10005265,1.59,NCT00121199-1,CHOP + Rituximab + Bevacizumab,NCT00121199,Combination Chemo  Rituximab  and Bevacizumab in Older Patients With Stage II-IV Diffuse Large B-Cell Lymphoma,bloating
D006471,1.59,NCT00121199-1,CHOP + Rituximab + Bevacizumab,NCT00121199,Combination Chemo  Rituximab  and Bevacizumab in Older Patients With Stage II-IV Diffuse Large B-Cell Lymphoma,gastrointestinal hemorrhage
D000069478,1.59,NCT00121199-1,CHOP + Rituximab + Bevacizumab,NCT00121199,Combination Chemo  Rituximab  and Bevacizumab in Older Patients With Stage II-IV Diffuse Large B-Cell Lymphoma,lisdexamfetamine
D009325,3.17,NCT00121199-1,CHOP + Rituximab + Bevacizumab,NCT00121199,Combination Chemo  Rituximab  and Bevacizumab in Older Patients With Stage II-IV Diffuse Large B-Cell Lymphoma,nausea
D000005,3.17,NCT00121199-1,CHOP + Rituximab + Bevacizumab,NCT00121199,Combination Chemo  Rituximab  and Bevacizumab in Older Patients With Stage II-IV Diffuse Large B-Cell Lymphoma,abdomen
D007583,3.17,NCT00121199-1,CHOP + Rituximab + Bevacizumab,NCT00121199,Combination Chemo  Rituximab  and Bevacizumab in Older Patients With Stage II-IV Diffuse Large B-Cell Lymphoma,jejunum
10041103,1.59,NCT00121199-1,CHOP + Rituximab + Bevacizumab,NCT00121199,Combination Chemo  Rituximab  and Bevacizumab in Older Patients With Stage II-IV Diffuse Large B-Cell Lymphoma,small intestinal perforation
D013270,1.59,NCT00121199-1,CHOP + Rituximab + Bevacizumab,NCT00121199,Combination Chemo  Rituximab  and Bevacizumab in Older Patients With Stage II-IV Diffuse Large B-Cell Lymphoma,stomach
D014839,1.59,NCT00121199-1,CHOP + Rituximab + Bevacizumab,NCT00121199,Combination Chemo  Rituximab  and Bevacizumab in Older Patients With Stage II-IV Diffuse Large B-Cell Lymphoma,vomiting
D001037,4.76,NCT00121199-1,CHOP + Rituximab + Bevacizumab,NCT00121199,Combination Chemo  Rituximab  and Bevacizumab in Older Patients With Stage II-IV Diffuse Large B-Cell Lymphoma,logasthenia
D000080867,1.59,NCT00121199-1,CHOP + Rituximab + Bevacizumab,NCT00121199,Combination Chemo  Rituximab  and Bevacizumab in Older Patients With Stage II-IV Diffuse Large B-Cell Lymphoma,gingipains
D003645,3.17,NCT00121199-1,CHOP + Rituximab + Bevacizumab,NCT00121199,Combination Chemo  Rituximab  and Bevacizumab in Older Patients With Stage II-IV Diffuse Large B-Cell Lymphoma,sudden death
D000080104,1.59,NCT00121199-1,CHOP + Rituximab + Bevacizumab,NCT00121199,Combination Chemo  Rituximab  and Bevacizumab in Older Patients With Stage II-IV Diffuse Large B-Cell Lymphoma,infertility clinics
D000080104,1.59,NCT00121199-1,CHOP + Rituximab + Bevacizumab,NCT00121199,Combination Chemo  Rituximab  and Bevacizumab in Older Patients With Stage II-IV Diffuse Large B-Cell Lymphoma,infertility clinics
D001788,1.59,NCT00121199-1,CHOP + Rituximab + Bevacizumab,NCT00121199,Combination Chemo  Rituximab  and Bevacizumab in Older Patients With Stage II-IV Diffuse Large B-Cell Lymphoma,blood grouping
D011014,3.17,NCT00121199-1,CHOP + Rituximab + Bevacizumab,NCT00121199,Combination Chemo  Rituximab  and Bevacizumab in Older Patients With Stage II-IV Diffuse Large B-Cell Lymphoma,lung inflammation
D044148,1.59,NCT00121199-1,CHOP + Rituximab + Bevacizumab,NCT00121199,Combination Chemo  Rituximab  and Bevacizumab in Older Patients With Stage II-IV Diffuse Large B-Cell Lymphoma,lymphatic abnormalities
D007263,1.59,NCT00121199-1,CHOP + Rituximab + Bevacizumab,NCT00121199,Combination Chemo  Rituximab  and Bevacizumab in Older Patients With Stage II-IV Diffuse Large B-Cell Lymphoma,peritoneal infusions
D001321,1.59,NCT00121199-1,CHOP + Rituximab + Bevacizumab,NCT00121199,Combination Chemo  Rituximab  and Bevacizumab in Older Patients With Stage II-IV Diffuse Large B-Cell Lymphoma,autism infantile
10017076,1.59,NCT00121199-1,CHOP + Rituximab + Bevacizumab,NCT00121199,Combination Chemo  Rituximab  and Bevacizumab in Older Patients With Stage II-IV Diffuse Large B-Cell Lymphoma,fracture
D007962,6.35,NCT00121199-1,CHOP + Rituximab + Bevacizumab,NCT00121199,Combination Chemo  Rituximab  and Bevacizumab in Older Patients With Stage II-IV Diffuse Large B-Cell Lymphoma,leukocytes
D008231,3.17,NCT00121199-1,CHOP + Rituximab + Bevacizumab,NCT00121199,Combination Chemo  Rituximab  and Bevacizumab in Older Patients With Stage II-IV Diffuse Large B-Cell Lymphoma,lymphopenia
D006098,11.11,NCT00121199-1,CHOP + Rituximab + Bevacizumab,NCT00121199,Combination Chemo  Rituximab  and Bevacizumab in Older Patients With Stage II-IV Diffuse Large B-Cell Lymphoma,granulocytes
D001792,4.76,NCT00121199-1,CHOP + Rituximab + Bevacizumab,NCT00121199,Combination Chemo  Rituximab  and Bevacizumab in Older Patients With Stage II-IV Diffuse Large B-Cell Lymphoma,platelets
D000855,3.17,NCT00121199-1,CHOP + Rituximab + Bevacizumab,NCT00121199,Combination Chemo  Rituximab  and Bevacizumab in Older Patients With Stage II-IV Diffuse Large B-Cell Lymphoma,anorexia
D003681,1.59,NCT00121199-1,CHOP + Rituximab + Bevacizumab,NCT00121199,Combination Chemo  Rituximab  and Bevacizumab in Older Patients With Stage II-IV Diffuse Large B-Cell Lymphoma,dehydration
D016895,1.59,NCT00121199-1,CHOP + Rituximab + Bevacizumab,NCT00121199,Combination Chemo  Rituximab  and Bevacizumab in Older Patients With Stage II-IV Diffuse Large B-Cell Lymphoma,low-serum media
D004039,3.17,NCT00121199-1,CHOP + Rituximab + Bevacizumab,NCT00121199,Combination Chemo  Rituximab  and Bevacizumab in Older Patients With Stage II-IV Diffuse Large B-Cell Lymphoma,diet low-sodium
10062572,1.59,NCT00121199-1,CHOP + Rituximab + Bevacizumab,NCT00121199,Combination Chemo  Rituximab  and Bevacizumab in Older Patients With Stage II-IV Diffuse Large B-Cell Lymphoma,generalized muscle weakness
10006002,1.59,NCT00121199-1,CHOP + Rituximab + Bevacizumab,NCT00121199,Combination Chemo  Rituximab  and Bevacizumab in Older Patients With Stage II-IV Diffuse Large B-Cell Lymphoma,bone pain
D018450,1.59,NCT00121199-1,CHOP + Rituximab + Bevacizumab,NCT00121199,Combination Chemo  Rituximab  and Bevacizumab in Older Patients With Stage II-IV Diffuse Large B-Cell Lymphoma,disease progression
D002607,1.59,NCT00121199-1,CHOP + Rituximab + Bevacizumab,NCT00121199,Combination Chemo  Rituximab  and Bevacizumab in Older Patients With Stage II-IV Diffuse Large B-Cell Lymphoma,hereditary type i motor and sensory neuropathy
D006261,1.59,NCT00121199-1,CHOP + Rituximab + Bevacizumab,NCT00121199,Combination Chemo  Rituximab  and Bevacizumab in Older Patients With Stage II-IV Diffuse Large B-Cell Lymphoma,headache
D012128,1.59,NCT00121199-1,CHOP + Rituximab + Bevacizumab,NCT00121199,Combination Chemo  Rituximab  and Bevacizumab in Older Patients With Stage II-IV Diffuse Large B-Cell Lymphoma,respiratory distress syndrome adult
D011666,1.59,NCT00121199-1,CHOP + Rituximab + Bevacizumab,NCT00121199,Combination Chemo  Rituximab  and Bevacizumab in Older Patients With Stage II-IV Diffuse Large B-Cell Lymphoma,pulmonary stenoses
D011014,3.17,NCT00121199-1,CHOP + Rituximab + Bevacizumab,NCT00121199,Combination Chemo  Rituximab  and Bevacizumab in Older Patients With Stage II-IV Diffuse Large B-Cell Lymphoma,pneumonitis
D011030,1.59,NCT00121199-1,CHOP + Rituximab + Bevacizumab,NCT00121199,Combination Chemo  Rituximab  and Bevacizumab in Older Patients With Stage II-IV Diffuse Large B-Cell Lymphoma,pneumothorax
D006973,1.59,NCT00121199-1,CHOP + Rituximab + Bevacizumab,NCT00121199,Combination Chemo  Rituximab  and Bevacizumab in Older Patients With Stage II-IV Diffuse Large B-Cell Lymphoma,hypertension
D007022,1.59,NCT00121199-1,CHOP + Rituximab + Bevacizumab,NCT00121199,Combination Chemo  Rituximab  and Bevacizumab in Older Patients With Stage II-IV Diffuse Large B-Cell Lymphoma,hypotension
D016769,4.76,NCT00121199-1,CHOP + Rituximab + Bevacizumab,NCT00121199,Combination Chemo  Rituximab  and Bevacizumab in Older Patients With Stage II-IV Diffuse Large B-Cell Lymphoma,embolism and thrombosis
D064420,16.67,NCT00147225-3,10 mcg/kg AMG 531 Post Chemotherapy,NCT00147225,AMG 531 in Patients With Advanced Malignancy Receiving Treatment With Carboplatin,adverse drug events
D064420,20.0,NCT00147225-5,5 mcg/kg AMG 531 Pre/Pre/Post/Post Chemotherapy,NCT00147225,AMG 531 in Patients With Advanced Malignancy Receiving Treatment With Carboplatin,adverse drug events
D020246,10.0,NCT00147225-5,5 mcg/kg AMG 531 Pre/Pre/Post/Post Chemotherapy,NCT00147225,AMG 531 in Patients With Advanced Malignancy Receiving Treatment With Carboplatin,deep vein thrombosis
D011655,16.67,NCT00147225-3,10 mcg/kg AMG 531 Post Chemotherapy,NCT00147225,AMG 531 in Patients With Advanced Malignancy Receiving Treatment With Carboplatin,pulmonary embolism
D011655,10.0,NCT00147225-5,5 mcg/kg AMG 531 Pre/Pre/Post/Post Chemotherapy,NCT00147225,AMG 531 in Patients With Advanced Malignancy Receiving Treatment With Carboplatin,pulmonary embolism
D064420,100.0,NCT00182767-1,Ixabepilone 24mg/m2 and Doxorubicin 30mg/m2: Level 1,NCT00182767,Ixabepilone and Liposomal Doxorubicin in Advanced Ovarian Cancer,adverse drug events
D064420,100.0,NCT00182767-2,Ixabepilone 32mg/m2 and Doxorubicin 30mg/m2: Level 2,NCT00182767,Ixabepilone and Liposomal Doxorubicin in Advanced Ovarian Cancer,adverse drug events
D064420,100.0,NCT00182767-3,Ixabepilone 40mg/m2 and Doxorubicin 30mg/m2: Level 3,NCT00182767,Ixabepilone and Liposomal Doxorubicin in Advanced Ovarian Cancer,adverse drug events
D064420,100.0,NCT00182767-4,Ixabepilone 13mg/m2 and Doxorubicin 30mg/m2: Level 4,NCT00182767,Ixabepilone and Liposomal Doxorubicin in Advanced Ovarian Cancer,adverse drug events
D064420,100.0,NCT00182767-5,Ixabepilone 16mg/m2 and Doxorubicin 30mg/m2: Level 5,NCT00182767,Ixabepilone and Liposomal Doxorubicin in Advanced Ovarian Cancer,adverse drug events
D000740,16.67,NCT00182767-1,Ixabepilone 24mg/m2 and Doxorubicin 30mg/m2: Level 1,NCT00182767,Ixabepilone and Liposomal Doxorubicin in Advanced Ovarian Cancer,anemia
D000740,16.67,NCT00182767-5,Ixabepilone 16mg/m2 and Doxorubicin 30mg/m2: Level 5,NCT00182767,Ixabepilone and Liposomal Doxorubicin in Advanced Ovarian Cancer,anemia
D003248,16.67,NCT00182767-1,Ixabepilone 24mg/m2 and Doxorubicin 30mg/m2: Level 1,NCT00182767,Ixabepilone and Liposomal Doxorubicin in Advanced Ovarian Cancer,constipation
D052016,16.67,NCT00182767-1,Ixabepilone 24mg/m2 and Doxorubicin 30mg/m2: Level 1,NCT00182767,Ixabepilone and Liposomal Doxorubicin in Advanced Ovarian Cancer,mucositis
D052016,33.33,NCT00182767-2,Ixabepilone 32mg/m2 and Doxorubicin 30mg/m2: Level 2,NCT00182767,Ixabepilone and Liposomal Doxorubicin in Advanced Ovarian Cancer,mucositis
D052016,16.67,NCT00182767-3,Ixabepilone 40mg/m2 and Doxorubicin 30mg/m2: Level 3,NCT00182767,Ixabepilone and Liposomal Doxorubicin in Advanced Ovarian Cancer,mucositis
D052016,8.33,NCT00182767-5,Ixabepilone 16mg/m2 and Doxorubicin 30mg/m2: Level 5,NCT00182767,Ixabepilone and Liposomal Doxorubicin in Advanced Ovarian Cancer,mucositis
D014839,16.67,NCT00182767-2,Ixabepilone 32mg/m2 and Doxorubicin 30mg/m2: Level 2,NCT00182767,Ixabepilone and Liposomal Doxorubicin in Advanced Ovarian Cancer,vomiting
D003681,16.67,NCT00182767-2,Ixabepilone 32mg/m2 and Doxorubicin 30mg/m2: Level 2,NCT00182767,Ixabepilone and Liposomal Doxorubicin in Advanced Ovarian Cancer,dehydration
D015746,4.17,NCT00182767-5,Ixabepilone 16mg/m2 and Doxorubicin 30mg/m2: Level 5,NCT00182767,Ixabepilone and Liposomal Doxorubicin in Advanced Ovarian Cancer,abdominal pain
10041101,8.33,NCT00182767-5,Ixabepilone 16mg/m2 and Doxorubicin 30mg/m2: Level 5,NCT00182767,Ixabepilone and Liposomal Doxorubicin in Advanced Ovarian Cancer,small intestinal obstruction
D009325,4.17,NCT00182767-5,Ixabepilone 16mg/m2 and Doxorubicin 30mg/m2: Level 5,NCT00182767,Ixabepilone and Liposomal Doxorubicin in Advanced Ovarian Cancer,nausea
D001201,4.17,NCT00182767-5,Ixabepilone 16mg/m2 and Doxorubicin 30mg/m2: Level 5,NCT00182767,Ixabepilone and Liposomal Doxorubicin in Advanced Ovarian Cancer,ascites
D003967,4.17,NCT00182767-5,Ixabepilone 16mg/m2 and Doxorubicin 30mg/m2: Level 5,NCT00182767,Ixabepilone and Liposomal Doxorubicin in Advanced Ovarian Cancer,diarrhea
D005221,33.33,NCT00182767-3,Ixabepilone 40mg/m2 and Doxorubicin 30mg/m2: Level 3,NCT00182767,Ixabepilone and Liposomal Doxorubicin in Advanced Ovarian Cancer,fatigue
D005221,8.33,NCT00182767-5,Ixabepilone 16mg/m2 and Doxorubicin 30mg/m2: Level 5,NCT00182767,Ixabepilone and Liposomal Doxorubicin in Advanced Ovarian Cancer,fatigue
10011914,16.67,NCT00182767-1,Ixabepilone 24mg/m2 and Doxorubicin 30mg/m2: Level 1,NCT00182767,Ixabepilone and Liposomal Doxorubicin in Advanced Ovarian Cancer,death nos
10011914,4.17,NCT00182767-5,Ixabepilone 16mg/m2 and Doxorubicin 30mg/m2: Level 5,NCT00182767,Ixabepilone and Liposomal Doxorubicin in Advanced Ovarian Cancer,death nos
D000069544,16.67,NCT00182767-2,Ixabepilone 32mg/m2 and Doxorubicin 30mg/m2: Level 2,NCT00182767,Ixabepilone and Liposomal Doxorubicin in Advanced Ovarian Cancer,encephalitis infection
D008174,16.67,NCT00182767-1,Ixabepilone 24mg/m2 and Doxorubicin 30mg/m2: Level 1,NCT00182767,Ixabepilone and Liposomal Doxorubicin in Advanced Ovarian Cancer,parasitic infections of lung
10007810,33.33,NCT00182767-4,Ixabepilone 13mg/m2 and Doxorubicin 30mg/m2: Level 4,NCT00182767,Ixabepilone and Liposomal Doxorubicin in Advanced Ovarian Cancer,catheter related infection
10005364,16.67,NCT00182767-1,Ixabepilone 24mg/m2 and Doxorubicin 30mg/m2: Level 1,NCT00182767,Ixabepilone and Liposomal Doxorubicin in Advanced Ovarian Cancer,blood bilirubin increased
D007958,16.67,NCT00182767-1,Ixabepilone 24mg/m2 and Doxorubicin 30mg/m2: Level 1,NCT00182767,Ixabepilone and Liposomal Doxorubicin in Advanced Ovarian Cancer,blood cell count white
D007958,16.67,NCT00182767-2,Ixabepilone 32mg/m2 and Doxorubicin 30mg/m2: Level 2,NCT00182767,Ixabepilone and Liposomal Doxorubicin in Advanced Ovarian Cancer,blood cell count white
D007958,16.67,NCT00182767-3,Ixabepilone 40mg/m2 and Doxorubicin 30mg/m2: Level 3,NCT00182767,Ixabepilone and Liposomal Doxorubicin in Advanced Ovarian Cancer,blood cell count white
D007958,66.67,NCT00182767-4,Ixabepilone 13mg/m2 and Doxorubicin 30mg/m2: Level 4,NCT00182767,Ixabepilone and Liposomal Doxorubicin in Advanced Ovarian Cancer,blood cell count white
D007958,4.17,NCT00182767-5,Ixabepilone 16mg/m2 and Doxorubicin 30mg/m2: Level 5,NCT00182767,Ixabepilone and Liposomal Doxorubicin in Advanced Ovarian Cancer,blood cell count white
10025256,16.67,NCT00182767-1,Ixabepilone 24mg/m2 and Doxorubicin 30mg/m2: Level 1,NCT00182767,Ixabepilone and Liposomal Doxorubicin in Advanced Ovarian Cancer,lymphocyte count decreased
10025256,16.67,NCT00182767-2,Ixabepilone 32mg/m2 and Doxorubicin 30mg/m2: Level 2,NCT00182767,Ixabepilone and Liposomal Doxorubicin in Advanced Ovarian Cancer,lymphocyte count decreased
10025256,16.67,NCT00182767-3,Ixabepilone 40mg/m2 and Doxorubicin 30mg/m2: Level 3,NCT00182767,Ixabepilone and Liposomal Doxorubicin in Advanced Ovarian Cancer,lymphocyte count decreased
10025256,33.33,NCT00182767-4,Ixabepilone 13mg/m2 and Doxorubicin 30mg/m2: Level 4,NCT00182767,Ixabepilone and Liposomal Doxorubicin in Advanced Ovarian Cancer,lymphocyte count decreased
10025256,20.83,NCT00182767-5,Ixabepilone 16mg/m2 and Doxorubicin 30mg/m2: Level 5,NCT00182767,Ixabepilone and Liposomal Doxorubicin in Advanced Ovarian Cancer,lymphocyte count decreased
10035528,8.33,NCT00182767-5,Ixabepilone 16mg/m2 and Doxorubicin 30mg/m2: Level 5,NCT00182767,Ixabepilone and Liposomal Doxorubicin in Advanced Ovarian Cancer,platelet count decreased
D007008,16.67,NCT00182767-1,Ixabepilone 24mg/m2 and Doxorubicin 30mg/m2: Level 1,NCT00182767,Ixabepilone and Liposomal Doxorubicin in Advanced Ovarian Cancer,hypokalemia
D017674,4.17,NCT00182767-5,Ixabepilone 16mg/m2 and Doxorubicin 30mg/m2: Level 5,NCT00182767,Ixabepilone and Liposomal Doxorubicin in Advanced Ovarian Cancer,hypophosphatemia
D006934,4.17,NCT00182767-5,Ixabepilone 16mg/m2 and Doxorubicin 30mg/m2: Level 5,NCT00182767,Ixabepilone and Liposomal Doxorubicin in Advanced Ovarian Cancer,hypercalcemia
10006002,16.67,NCT00182767-2,Ixabepilone 32mg/m2 and Doxorubicin 30mg/m2: Level 2,NCT00182767,Ixabepilone and Liposomal Doxorubicin in Advanced Ovarian Cancer,bone pain
10008496,16.67,NCT00182767-2,Ixabepilone 32mg/m2 and Doxorubicin 30mg/m2: Level 2,NCT00182767,Ixabepilone and Liposomal Doxorubicin in Advanced Ovarian Cancer,chest wall pain
D002607,16.67,NCT00182767-1,Ixabepilone 24mg/m2 and Doxorubicin 30mg/m2: Level 1,NCT00182767,Ixabepilone and Liposomal Doxorubicin in Advanced Ovarian Cancer,hereditary type i motor and sensory neuropathy
D006261,16.67,NCT00182767-1,Ixabepilone 24mg/m2 and Doxorubicin 30mg/m2: Level 1,NCT00182767,Ixabepilone and Liposomal Doxorubicin in Advanced Ovarian Cancer,headache
D001259,4.17,NCT00182767-5,Ixabepilone 16mg/m2 and Doxorubicin 30mg/m2: Level 5,NCT00182767,Ixabepilone and Liposomal Doxorubicin in Advanced Ovarian Cancer,ataxia
D001007,4.17,NCT00182767-5,Ixabepilone 16mg/m2 and Doxorubicin 30mg/m2: Level 5,NCT00182767,Ixabepilone and Liposomal Doxorubicin in Advanced Ovarian Cancer,anxiety
10065746,16.67,NCT00182767-1,Ixabepilone 24mg/m2 and Doxorubicin 30mg/m2: Level 1,NCT00182767,Ixabepilone and Liposomal Doxorubicin in Advanced Ovarian Cancer,bronchopulmonary hemorrhage
D004417,16.67,NCT00182767-2,Ixabepilone 32mg/m2 and Doxorubicin 30mg/m2: Level 2,NCT00182767,Ixabepilone and Liposomal Doxorubicin in Advanced Ovarian Cancer,dyspnea
D004417,16.67,NCT00182767-3,Ixabepilone 40mg/m2 and Doxorubicin 30mg/m2: Level 3,NCT00182767,Ixabepilone and Liposomal Doxorubicin in Advanced Ovarian Cancer,dyspnea
D004417,4.17,NCT00182767-5,Ixabepilone 16mg/m2 and Doxorubicin 30mg/m2: Level 5,NCT00182767,Ixabepilone and Liposomal Doxorubicin in Advanced Ovarian Cancer,dyspnea
D010996,4.17,NCT00182767-5,Ixabepilone 16mg/m2 and Doxorubicin 30mg/m2: Level 5,NCT00182767,Ixabepilone and Liposomal Doxorubicin in Advanced Ovarian Cancer,pleural effusion
D005076,50.0,NCT00182767-3,Ixabepilone 40mg/m2 and Doxorubicin 30mg/m2: Level 3,NCT00182767,Ixabepilone and Liposomal Doxorubicin in Advanced Ovarian Cancer,rash
D005076,4.17,NCT00182767-5,Ixabepilone 16mg/m2 and Doxorubicin 30mg/m2: Level 5,NCT00182767,Ixabepilone and Liposomal Doxorubicin in Advanced Ovarian Cancer,rash
D060831,16.67,NCT00182767-1,Ixabepilone 24mg/m2 and Doxorubicin 30mg/m2: Level 1,NCT00182767,Ixabepilone and Liposomal Doxorubicin in Advanced Ovarian Cancer,hand-foot syndrome
D060831,16.67,NCT00182767-2,Ixabepilone 32mg/m2 and Doxorubicin 30mg/m2: Level 2,NCT00182767,Ixabepilone and Liposomal Doxorubicin in Advanced Ovarian Cancer,hand-foot syndrome
10043565,16.67,NCT00182767-3,Ixabepilone 40mg/m2 and Doxorubicin 30mg/m2: Level 3,NCT00182767,Ixabepilone and Liposomal Doxorubicin in Advanced Ovarian Cancer,thromboembolic event
10043565,33.33,NCT00182767-4,Ixabepilone 13mg/m2 and Doxorubicin 30mg/m2: Level 4,NCT00182767,Ixabepilone and Liposomal Doxorubicin in Advanced Ovarian Cancer,thromboembolic event
10043565,8.33,NCT00182767-5,Ixabepilone 16mg/m2 and Doxorubicin 30mg/m2: Level 5,NCT00182767,Ixabepilone and Liposomal Doxorubicin in Advanced Ovarian Cancer,thromboembolic event
D019584,4.17,NCT00182767-5,Ixabepilone 16mg/m2 and Doxorubicin 30mg/m2: Level 5,NCT00182767,Ixabepilone and Liposomal Doxorubicin in Advanced Ovarian Cancer,hot flashes
D009026,4.41,NCT00184002-1,DR-COP,NCT00184002,Doxorubicin (Doxil) Combined With Rituxan  Cyclophosphamide  Vincristine and Prednisone in Newly Diagnosed Aggressive Non-Hodgkin's Lymphomas,mortality
D064420,51.47,NCT00184002-1,DR-COP,NCT00184002,Doxorubicin (Doxil) Combined With Rituxan  Cyclophosphamide  Vincristine and Prednisone in Newly Diagnosed Aggressive Non-Hodgkin's Lymphomas,adverse drug events
D006098,51.47,NCT00184002-1,DR-COP,NCT00184002,Doxorubicin (Doxil) Combined With Rituxan  Cyclophosphamide  Vincristine and Prednisone in Newly Diagnosed Aggressive Non-Hodgkin's Lymphomas,granulocytes
D006454,16.18,NCT00184002-1,DR-COP,NCT00184002,Doxorubicin (Doxil) Combined With Rituxan  Cyclophosphamide  Vincristine and Prednisone in Newly Diagnosed Aggressive Non-Hodgkin's Lymphomas,hemoglobin
D007962,1.47,NCT00184002-1,DR-COP,NCT00184002,Doxorubicin (Doxil) Combined With Rituxan  Cyclophosphamide  Vincristine and Prednisone in Newly Diagnosed Aggressive Non-Hodgkin's Lymphomas,leukocytes
D001792,7.35,NCT00184002-1,DR-COP,NCT00184002,Doxorubicin (Doxil) Combined With Rituxan  Cyclophosphamide  Vincristine and Prednisone in Newly Diagnosed Aggressive Non-Hodgkin's Lymphomas,platelets
D016277,1.47,NCT00184002-1,DR-COP,NCT00184002,Doxorubicin (Doxil) Combined With Rituxan  Cyclophosphamide  Vincristine and Prednisone in Newly Diagnosed Aggressive Non-Hodgkin's Lymphomas,ventricular function left
D006973,2.94,NCT00184002-1,DR-COP,NCT00184002,Doxorubicin (Doxil) Combined With Rituxan  Cyclophosphamide  Vincristine and Prednisone in Newly Diagnosed Aggressive Non-Hodgkin's Lymphomas,hypertension
D007022,2.94,NCT00184002-1,DR-COP,NCT00184002,Doxorubicin (Doxil) Combined With Rituxan  Cyclophosphamide  Vincristine and Prednisone in Newly Diagnosed Aggressive Non-Hodgkin's Lymphomas,hypotension
D015746,2.94,NCT00184002-1,DR-COP,NCT00184002,Doxorubicin (Doxil) Combined With Rituxan  Cyclophosphamide  Vincristine and Prednisone in Newly Diagnosed Aggressive Non-Hodgkin's Lymphomas,abdominal pain
D000930,1.47,NCT00184002-1,DR-COP,NCT00184002,Doxorubicin (Doxil) Combined With Rituxan  Cyclophosphamide  Vincristine and Prednisone in Newly Diagnosed Aggressive Non-Hodgkin's Lymphomas,antidiarrheals
D045823,2.94,NCT00184002-1,DR-COP,NCT00184002,Doxorubicin (Doxil) Combined With Rituxan  Cyclophosphamide  Vincristine and Prednisone in Newly Diagnosed Aggressive Non-Hodgkin's Lymphomas,ileus
D006470,1.47,NCT00184002-1,DR-COP,NCT00184002,Doxorubicin (Doxil) Combined With Rituxan  Cyclophosphamide  Vincristine and Prednisone in Newly Diagnosed Aggressive Non-Hodgkin's Lymphomas,bleeding
D009325,2.94,NCT00184002-1,DR-COP,NCT00184002,Doxorubicin (Doxil) Combined With Rituxan  Cyclophosphamide  Vincristine and Prednisone in Newly Diagnosed Aggressive Non-Hodgkin's Lymphomas,nausea
D013280,2.94,NCT00184002-1,DR-COP,NCT00184002,Doxorubicin (Doxil) Combined With Rituxan  Cyclophosphamide  Vincristine and Prednisone in Newly Diagnosed Aggressive Non-Hodgkin's Lymphomas,oral mucositis
D014839,2.94,NCT00184002-1,DR-COP,NCT00184002,Doxorubicin (Doxil) Combined With Rituxan  Cyclophosphamide  Vincristine and Prednisone in Newly Diagnosed Aggressive Non-Hodgkin's Lymphomas,vomiting
D001037,1.47,NCT00184002-1,DR-COP,NCT00184002,Doxorubicin (Doxil) Combined With Rituxan  Cyclophosphamide  Vincristine and Prednisone in Newly Diagnosed Aggressive Non-Hodgkin's Lymphomas,logasthenia
D015431,1.47,NCT00184002-1,DR-COP,NCT00184002,Doxorubicin (Doxil) Combined With Rituxan  Cyclophosphamide  Vincristine and Prednisone in Newly Diagnosed Aggressive Non-Hodgkin's Lymphomas,weight loss
D001663,1.47,NCT00184002-1,DR-COP,NCT00184002,Doxorubicin (Doxil) Combined With Rituxan  Cyclophosphamide  Vincristine and Prednisone in Newly Diagnosed Aggressive Non-Hodgkin's Lymphomas,bilirubin
D001219,4.41,NCT00184002-1,DR-COP,NCT00184002,Doxorubicin (Doxil) Combined With Rituxan  Cyclophosphamide  Vincristine and Prednisone in Newly Diagnosed Aggressive Non-Hodgkin's Lymphomas,serum glutamic-oxaloacetic transaminase
D000410,4.41,NCT00184002-1,DR-COP,NCT00184002,Doxorubicin (Doxil) Combined With Rituxan  Cyclophosphamide  Vincristine and Prednisone in Newly Diagnosed Aggressive Non-Hodgkin's Lymphomas,glutamic-pyruvic transaminase
D064147,11.76,NCT00184002-1,DR-COP,NCT00184002,Doxorubicin (Doxil) Combined With Rituxan  Cyclophosphamide  Vincristine and Prednisone in Newly Diagnosed Aggressive Non-Hodgkin's Lymphomas,febrile neutropenia
D007239,11.76,NCT00184002-1,DR-COP,NCT00184002,Doxorubicin (Doxil) Combined With Rituxan  Cyclophosphamide  Vincristine and Prednisone in Newly Diagnosed Aggressive Non-Hodgkin's Lymphomas,infection
D000069544,8.82,NCT00184002-1,DR-COP,NCT00184002,Doxorubicin (Doxil) Combined With Rituxan  Cyclophosphamide  Vincristine and Prednisone in Newly Diagnosed Aggressive Non-Hodgkin's Lymphomas,encephalitis infection
D009618,1.47,NCT00184002-1,DR-COP,NCT00184002,Doxorubicin (Doxil) Combined With Rituxan  Cyclophosphamide  Vincristine and Prednisone in Newly Diagnosed Aggressive Non-Hodgkin's Lymphomas,nocardiaceae
D000855,1.47,NCT00184002-1,DR-COP,NCT00184002,Doxorubicin (Doxil) Combined With Rituxan  Cyclophosphamide  Vincristine and Prednisone in Newly Diagnosed Aggressive Non-Hodgkin's Lymphomas,anorexia
D003681,1.47,NCT00184002-1,DR-COP,NCT00184002,Doxorubicin (Doxil) Combined With Rituxan  Cyclophosphamide  Vincristine and Prednisone in Newly Diagnosed Aggressive Non-Hodgkin's Lymphomas,dehydration
D006943,2.94,NCT00184002-1,DR-COP,NCT00184002,Doxorubicin (Doxil) Combined With Rituxan  Cyclophosphamide  Vincristine and Prednisone in Newly Diagnosed Aggressive Non-Hodgkin's Lymphomas,hyperglycemia
D006996,1.47,NCT00184002-1,DR-COP,NCT00184002,Doxorubicin (Doxil) Combined With Rituxan  Cyclophosphamide  Vincristine and Prednisone in Newly Diagnosed Aggressive Non-Hodgkin's Lymphomas,hypocalcemia
D007008,4.41,NCT00184002-1,DR-COP,NCT00184002,Doxorubicin (Doxil) Combined With Rituxan  Cyclophosphamide  Vincristine and Prednisone in Newly Diagnosed Aggressive Non-Hodgkin's Lymphomas,hypokalemia
D007010,1.47,NCT00184002-1,DR-COP,NCT00184002,Doxorubicin (Doxil) Combined With Rituxan  Cyclophosphamide  Vincristine and Prednisone in Newly Diagnosed Aggressive Non-Hodgkin's Lymphomas,hyponatremia
D017674,1.47,NCT00184002-1,DR-COP,NCT00184002,Doxorubicin (Doxil) Combined With Rituxan  Cyclophosphamide  Vincristine and Prednisone in Newly Diagnosed Aggressive Non-Hodgkin's Lymphomas,hypophosphatemia
D015275,1.47,NCT00184002-1,DR-COP,NCT00184002,Doxorubicin (Doxil) Combined With Rituxan  Cyclophosphamide  Vincristine and Prednisone in Newly Diagnosed Aggressive Non-Hodgkin's Lymphomas,tumor lysis syndrome
D063806,1.47,NCT00184002-1,DR-COP,NCT00184002,Doxorubicin (Doxil) Combined With Rituxan  Cyclophosphamide  Vincristine and Prednisone in Newly Diagnosed Aggressive Non-Hodgkin's Lymphomas,muscle pain
D002607,2.94,NCT00184002-1,DR-COP,NCT00184002,Doxorubicin (Doxil) Combined With Rituxan  Cyclophosphamide  Vincristine and Prednisone in Newly Diagnosed Aggressive Non-Hodgkin's Lymphomas,hereditary type i motor and sensory neuropathy
D005242,1.47,NCT00184002-1,DR-COP,NCT00184002,Doxorubicin (Doxil) Combined With Rituxan  Cyclophosphamide  Vincristine and Prednisone in Newly Diagnosed Aggressive Non-Hodgkin's Lymphomas,fecal incontinence
D014517,1.47,NCT00184002-1,DR-COP,NCT00184002,Doxorubicin (Doxil) Combined With Rituxan  Cyclophosphamide  Vincristine and Prednisone in Newly Diagnosed Aggressive Non-Hodgkin's Lymphomas,ureteral obstruction
D004417,8.82,NCT00184002-1,DR-COP,NCT00184002,Doxorubicin (Doxil) Combined With Rituxan  Cyclophosphamide  Vincristine and Prednisone in Newly Diagnosed Aggressive Non-Hodgkin's Lymphomas,breath shortness
D000860,2.94,NCT00184002-1,DR-COP,NCT00184002,Doxorubicin (Doxil) Combined With Rituxan  Cyclophosphamide  Vincristine and Prednisone in Newly Diagnosed Aggressive Non-Hodgkin's Lymphomas,hypoxia
D016066,1.47,NCT00184002-1,DR-COP,NCT00184002,Doxorubicin (Doxil) Combined With Rituxan  Cyclophosphamide  Vincristine and Prednisone in Newly Diagnosed Aggressive Non-Hodgkin's Lymphomas,pleural effusion malignant
D011014,1.47,NCT00184002-1,DR-COP,NCT00184002,Doxorubicin (Doxil) Combined With Rituxan  Cyclophosphamide  Vincristine and Prednisone in Newly Diagnosed Aggressive Non-Hodgkin's Lymphomas,pneumonitis
D006685,1.47,NCT00184002-1,DR-COP,NCT00184002,Doxorubicin (Doxil) Combined With Rituxan  Cyclophosphamide  Vincristine and Prednisone in Newly Diagnosed Aggressive Non-Hodgkin's Lymphomas,voice hoarseness
D060831,14.71,NCT00184002-1,DR-COP,NCT00184002,Doxorubicin (Doxil) Combined With Rituxan  Cyclophosphamide  Vincristine and Prednisone in Newly Diagnosed Aggressive Non-Hodgkin's Lymphomas,hand-foot syndrome
D064420,100.0,NCT00203502-1,Intervention: Drug:Docetaxel + Cyclophosphamide + Avastin,NCT00203502,Primary Systemic Therapy in Operable/Locally Advanced Breast Cancer,adverse drug events
D064147,2.56,NCT00203502-1,Intervention: Drug:Docetaxel + Cyclophosphamide + Avastin,NCT00203502,Primary Systemic Therapy in Operable/Locally Advanced Breast Cancer,febrile neutropenia
D006333,2.56,NCT00203502-1,Intervention: Drug:Docetaxel + Cyclophosphamide + Avastin,NCT00203502,Primary Systemic Therapy in Operable/Locally Advanced Breast Cancer,heart failure
D003967,7.69,NCT00203502-1,Intervention: Drug:Docetaxel + Cyclophosphamide + Avastin,NCT00203502,Primary Systemic Therapy in Operable/Locally Advanced Breast Cancer,diarrhea
D020250,10.26,NCT00203502-1,Intervention: Drug:Docetaxel + Cyclophosphamide + Avastin,NCT00203502,Primary Systemic Therapy in Operable/Locally Advanced Breast Cancer,postoperative nausea and vomiting
D052016,7.69,NCT00203502-1,Intervention: Drug:Docetaxel + Cyclophosphamide + Avastin,NCT00203502,Primary Systemic Therapy in Operable/Locally Advanced Breast Cancer,mucositis
D005221,10.26,NCT00203502-1,Intervention: Drug:Docetaxel + Cyclophosphamide + Avastin,NCT00203502,Primary Systemic Therapy in Operable/Locally Advanced Breast Cancer,fatigue
D007239,7.69,NCT00203502-1,Intervention: Drug:Docetaxel + Cyclophosphamide + Avastin,NCT00203502,Primary Systemic Therapy in Operable/Locally Advanced Breast Cancer,infection
D014552,5.13,NCT00203502-1,Intervention: Drug:Docetaxel + Cyclophosphamide + Avastin,NCT00203502,Primary Systemic Therapy in Operable/Locally Advanced Breast Cancer,urinary tract infection
D059352,15.38,NCT00203502-1,Intervention: Drug:Docetaxel + Cyclophosphamide + Avastin,NCT00203502,Primary Systemic Therapy in Operable/Locally Advanced Breast Cancer,musculoskeletal pain
D013575,2.56,NCT00203502-1,Intervention: Drug:Docetaxel + Cyclophosphamide + Avastin,NCT00203502,Primary Systemic Therapy in Operable/Locally Advanced Breast Cancer,syncope
D007319,7.69,NCT00203502-1,Intervention: Drug:Docetaxel + Cyclophosphamide + Avastin,NCT00203502,Primary Systemic Therapy in Operable/Locally Advanced Breast Cancer,insomnia
D001007,5.13,NCT00203502-1,Intervention: Drug:Docetaxel + Cyclophosphamide + Avastin,NCT00203502,Primary Systemic Therapy in Operable/Locally Advanced Breast Cancer,anxiety
D003863,5.13,NCT00203502-1,Intervention: Drug:Docetaxel + Cyclophosphamide + Avastin,NCT00203502,Primary Systemic Therapy in Operable/Locally Advanced Breast Cancer,depression
D011655,2.56,NCT00203502-1,Intervention: Drug:Docetaxel + Cyclophosphamide + Avastin,NCT00203502,Primary Systemic Therapy in Operable/Locally Advanced Breast Cancer,pulmonary embolism
D006973,7.69,NCT00203502-1,Intervention: Drug:Docetaxel + Cyclophosphamide + Avastin,NCT00203502,Primary Systemic Therapy in Operable/Locally Advanced Breast Cancer,hypertension
D009026,36.73,NCT00211185-1,Denileukin Diftitox in Combination With CHOP,NCT00211185,A Study of ONTAK and CHOP in Newly Diagnosed  Peripheral T-Cell Lymphoma,mortality
D064420,51.02,NCT00211185-1,Denileukin Diftitox in Combination With CHOP,NCT00211185,A Study of ONTAK and CHOP in Newly Diagnosed  Peripheral T-Cell Lymphoma,adverse drug events
D007962,6.12,NCT00211185-1,Denileukin Diftitox in Combination With CHOP,NCT00211185,A Study of ONTAK and CHOP in Newly Diagnosed  Peripheral T-Cell Lymphoma,leukocytes
D008231,4.08,NCT00211185-1,Denileukin Diftitox in Combination With CHOP,NCT00211185,A Study of ONTAK and CHOP in Newly Diagnosed  Peripheral T-Cell Lymphoma,lymphopenia
D009504,8.16,NCT00211185-1,Denileukin Diftitox in Combination With CHOP,NCT00211185,A Study of ONTAK and CHOP in Newly Diagnosed  Peripheral T-Cell Lymphoma,neutrophils
D001792,6.12,NCT00211185-1,Denileukin Diftitox in Combination With CHOP,NCT00211185,A Study of ONTAK and CHOP in Newly Diagnosed  Peripheral T-Cell Lymphoma,platelets
D013610,2.04,NCT00211185-1,Denileukin Diftitox in Combination With CHOP,NCT00211185,A Study of ONTAK and CHOP in Newly Diagnosed  Peripheral T-Cell Lymphoma,tachyarrhythmia
D006342,4.08,NCT00211185-1,Denileukin Diftitox in Combination With CHOP,NCT00211185,A Study of ONTAK and CHOP in Newly Diagnosed  Peripheral T-Cell Lymphoma,cardiac rupture post-infarction
D006323,2.04,NCT00211185-1,Denileukin Diftitox in Combination With CHOP,NCT00211185,A Study of ONTAK and CHOP in Newly Diagnosed  Peripheral T-Cell Lymphoma,cardiopulmonary arrest
D007022,2.04,NCT00211185-1,Denileukin Diftitox in Combination With CHOP,NCT00211185,A Study of ONTAK and CHOP in Newly Diagnosed  Peripheral T-Cell Lymphoma,hypotension
D018487,2.04,NCT00211185-1,Denileukin Diftitox in Combination With CHOP,NCT00211185,A Study of ONTAK and CHOP in Newly Diagnosed  Peripheral T-Cell Lymphoma,ventricular dysfunction left
D009330,2.04,NCT00211185-1,Denileukin Diftitox in Combination With CHOP,NCT00211185,A Study of ONTAK and CHOP in Newly Diagnosed  Peripheral T-Cell Lymphoma,inhalation devices
10041101,2.04,NCT00211185-1,Denileukin Diftitox in Combination With CHOP,NCT00211185,A Study of ONTAK and CHOP in Newly Diagnosed  Peripheral T-Cell Lymphoma,small intestinal obstruction
D005334,12.24,NCT00211185-1,Denileukin Diftitox in Combination With CHOP,NCT00211185,A Study of ONTAK and CHOP in Newly Diagnosed  Peripheral T-Cell Lymphoma,fever
10011914,2.04,NCT00211185-1,Denileukin Diftitox in Combination With CHOP,NCT00211185,A Study of ONTAK and CHOP in Newly Diagnosed  Peripheral T-Cell Lymphoma,death nos
D018450,4.08,NCT00211185-1,Denileukin Diftitox in Combination With CHOP,NCT00211185,A Study of ONTAK and CHOP in Newly Diagnosed  Peripheral T-Cell Lymphoma,disease progression
D008168,2.04,NCT00211185-1,Denileukin Diftitox in Combination With CHOP,NCT00211185,A Study of ONTAK and CHOP in Newly Diagnosed  Peripheral T-Cell Lymphoma,lung
10050068,2.04,NCT00211185-1,Denileukin Diftitox in Combination With CHOP,NCT00211185,A Study of ONTAK and CHOP in Newly Diagnosed  Peripheral T-Cell Lymphoma,edema limbs
10008481,2.04,NCT00211185-1,Denileukin Diftitox in Combination With CHOP,NCT00211185,A Study of ONTAK and CHOP in Newly Diagnosed  Peripheral T-Cell Lymphoma,chest pain - cardiac
D000005,2.04,NCT00211185-1,Denileukin Diftitox in Combination With CHOP,NCT00211185,A Study of ONTAK and CHOP in Newly Diagnosed  Peripheral T-Cell Lymphoma,abdomen
D000080867,2.04,NCT00211185-1,Denileukin Diftitox in Combination With CHOP,NCT00211185,A Study of ONTAK and CHOP in Newly Diagnosed  Peripheral T-Cell Lymphoma,gingipains
D000377,2.04,NCT00211185-1,Denileukin Diftitox in Combination With CHOP,NCT00211185,A Study of ONTAK and CHOP in Newly Diagnosed  Peripheral T-Cell Lymphoma,agnosia for pain
D015275,2.04,NCT00211185-1,Denileukin Diftitox in Combination With CHOP,NCT00211185,A Study of ONTAK and CHOP in Newly Diagnosed  Peripheral T-Cell Lymphoma,tumor lysis syndrome
D006967,2.04,NCT00211185-1,Denileukin Diftitox in Combination With CHOP,NCT00211185,A Study of ONTAK and CHOP in Newly Diagnosed  Peripheral T-Cell Lymphoma,allergic reaction
D006967,2.04,NCT00211185-1,Denileukin Diftitox in Combination With CHOP,NCT00211185,A Study of ONTAK and CHOP in Newly Diagnosed  Peripheral T-Cell Lymphoma,allergy
D064147,12.24,NCT00211185-1,Denileukin Diftitox in Combination With CHOP,NCT00211185,A Study of ONTAK and CHOP in Newly Diagnosed  Peripheral T-Cell Lymphoma,febrile neutropenia
D055499,2.04,NCT00211185-1,Denileukin Diftitox in Combination With CHOP,NCT00211185,A Study of ONTAK and CHOP in Newly Diagnosed  Peripheral T-Cell Lymphoma,catheter-related infections
D000069285,2.04,NCT00211185-1,Denileukin Diftitox in Combination With CHOP,NCT00211185,A Study of ONTAK and CHOP in Newly Diagnosed  Peripheral T-Cell Lymphoma,infliximab
D055499,2.04,NCT00211185-1,Denileukin Diftitox in Combination With CHOP,NCT00211185,A Study of ONTAK and CHOP in Newly Diagnosed  Peripheral T-Cell Lymphoma,catheter-related infections
10021881,2.04,NCT00211185-1,Denileukin Diftitox in Combination With CHOP,NCT00211185,A Study of ONTAK and CHOP in Newly Diagnosed  Peripheral T-Cell Lymphoma,infections and infestations - other specify
D011014,2.04,NCT00211185-1,Denileukin Diftitox in Combination With CHOP,NCT00211185,A Study of ONTAK and CHOP in Newly Diagnosed  Peripheral T-Cell Lymphoma,lung inflammation
D012885,2.04,NCT00211185-1,Denileukin Diftitox in Combination With CHOP,NCT00211185,A Study of ONTAK and CHOP in Newly Diagnosed  Peripheral T-Cell Lymphoma,skinfold thickness
D000410,2.04,NCT00211185-1,Denileukin Diftitox in Combination With CHOP,NCT00211185,A Study of ONTAK and CHOP in Newly Diagnosed  Peripheral T-Cell Lymphoma,alanine transaminase
D003404,2.04,NCT00211185-1,Denileukin Diftitox in Combination With CHOP,NCT00211185,A Study of ONTAK and CHOP in Newly Diagnosed  Peripheral T-Cell Lymphoma,creatinine
D065634,2.04,NCT00211185-1,Denileukin Diftitox in Combination With CHOP,NCT00211185,A Study of ONTAK and CHOP in Newly Diagnosed  Peripheral T-Cell Lymphoma,cerebrospinal fluid leak
D051437,2.04,NCT00211185-1,Denileukin Diftitox in Combination With CHOP,NCT00211185,A Study of ONTAK and CHOP in Newly Diagnosed  Peripheral T-Cell Lymphoma,renal failure
D004417,2.04,NCT00211185-1,Denileukin Diftitox in Combination With CHOP,NCT00211185,A Study of ONTAK and CHOP in Newly Diagnosed  Peripheral T-Cell Lymphoma,dyspnea
D000860,2.04,NCT00211185-1,Denileukin Diftitox in Combination With CHOP,NCT00211185,A Study of ONTAK and CHOP in Newly Diagnosed  Peripheral T-Cell Lymphoma,hypoxia
D011014,4.08,NCT00211185-1,Denileukin Diftitox in Combination With CHOP,NCT00211185,A Study of ONTAK and CHOP in Newly Diagnosed  Peripheral T-Cell Lymphoma,pneumonitis
D002542,2.04,NCT00211185-1,Denileukin Diftitox in Combination With CHOP,NCT00211185,A Study of ONTAK and CHOP in Newly Diagnosed  Peripheral T-Cell Lymphoma,intracranial embolism and thrombosis
D064420,2.7,NCT00215943-2,Active Comparator: Thalidomide and Dexamethasone Treatment,NCT00215943,Phase III Randomized Trial of Thalidomide/Dexamethasone Versus Vincristine+Adriamycin+Dexamethasone (VAD),adverse drug events
D011014,2.7,NCT00215943-2,Active Comparator: Thalidomide and Dexamethasone Treatment,NCT00215943,Phase III Randomized Trial of Thalidomide/Dexamethasone Versus Vincristine+Adriamycin+Dexamethasone (VAD),pneumonitis
D012141,2.7,NCT00215943-2,Active Comparator: Thalidomide and Dexamethasone Treatment,NCT00215943,Phase III Randomized Trial of Thalidomide/Dexamethasone Versus Vincristine+Adriamycin+Dexamethasone (VAD),infections upper respiratory
D009026,8.0,NCT00222105-1,Arm 1,NCT00222105,A Study Evaluating Efficacy  Toxicity  Harvest Yield and Quality of Life,mortality
D064420,32.0,NCT00222105-1,Arm 1,NCT00222105,A Study Evaluating Efficacy  Toxicity  Harvest Yield and Quality of Life,adverse drug events
D001145,4.0,NCT00222105-1,Arm 1,NCT00222105,A Study Evaluating Efficacy  Toxicity  Harvest Yield and Quality of Life,arrhythmia
D007239,20.0,NCT00222105-1,Arm 1,NCT00222105,A Study Evaluating Efficacy  Toxicity  Harvest Yield and Quality of Life,infection
D003681,4.0,NCT00222105-1,Arm 1,NCT00222105,A Study Evaluating Efficacy  Toxicity  Harvest Yield and Quality of Life,dehydration
D058186,4.0,NCT00222105-1,Arm 1,NCT00222105,A Study Evaluating Efficacy  Toxicity  Harvest Yield and Quality of Life,acute renal failure
D064420,53.33,NCT00245050-1,Pyridoxine,NCT00245050,Pyridoxine in Preventing Hand-Foot Syndrome in Patients Who Are Receiving Liposomal Doxorubicin for Cancer,adverse drug events
D064420,42.86,NCT00245050-2,Placebo,NCT00245050,Pyridoxine in Preventing Hand-Foot Syndrome in Patients Who Are Receiving Liposomal Doxorubicin for Cancer,adverse drug events
D001853,6.67,NCT00245050-1,Pyridoxine,NCT00245050,Pyridoxine in Preventing Hand-Foot Syndrome in Patients Who Are Receiving Liposomal Doxorubicin for Cancer,bone marrow
D001853,14.29,NCT00245050-2,Placebo,NCT00245050,Pyridoxine in Preventing Hand-Foot Syndrome in Patients Who Are Receiving Liposomal Doxorubicin for Cancer,bone marrow
D006470,6.67,NCT00245050-1,Pyridoxine,NCT00245050,Pyridoxine in Preventing Hand-Foot Syndrome in Patients Who Are Receiving Liposomal Doxorubicin for Cancer,hemorrhage
D000069196,13.33,NCT00245050-1,Pyridoxine,NCT00245050,Pyridoxine in Preventing Hand-Foot Syndrome in Patients Who Are Receiving Liposomal Doxorubicin for Cancer,gastrointestinal microbiome
D000071896,7.14,NCT00245050-2,Placebo,NCT00245050,Pyridoxine in Preventing Hand-Foot Syndrome in Patients Who Are Receiving Liposomal Doxorubicin for Cancer,somatic symptoms
D006967,7.14,NCT00245050-2,Placebo,NCT00245050,Pyridoxine in Preventing Hand-Foot Syndrome in Patients Who Are Receiving Liposomal Doxorubicin for Cancer,allergy
D007239,6.67,NCT00245050-1,Pyridoxine,NCT00245050,Pyridoxine in Preventing Hand-Foot Syndrome in Patients Who Are Receiving Liposomal Doxorubicin for Cancer,infection
D007753,7.14,NCT00245050-2,Placebo,NCT00245050,Pyridoxine in Preventing Hand-Foot Syndrome in Patients Who Are Receiving Liposomal Doxorubicin for Cancer,laboratory
D009462,6.67,NCT00245050-1,Pyridoxine,NCT00245050,Pyridoxine in Preventing Hand-Foot Syndrome in Patients Who Are Receiving Liposomal Doxorubicin for Cancer,neurology
D012141,6.67,NCT00245050-1,Pyridoxine,NCT00245050,Pyridoxine in Preventing Hand-Foot Syndrome in Patients Who Are Receiving Liposomal Doxorubicin for Cancer,infections upper respiratory
D000069336,6.67,NCT00245050-1,Pyridoxine,NCT00245050,Pyridoxine in Preventing Hand-Foot Syndrome in Patients Who Are Receiving Liposomal Doxorubicin for Cancer,neurovascular coupling
D000069336,7.14,NCT00245050-2,Placebo,NCT00245050,Pyridoxine in Preventing Hand-Foot Syndrome in Patients Who Are Receiving Liposomal Doxorubicin for Cancer,neurovascular coupling
D064420,1.89,NCT00290433-1,HCVIDDOXIL Regimen,NCT00290433,Efficacy of the HCVIDDOXIL Regimen in Patients With Newly Diagnosed Peripheral T-Cell Lymphoma,adverse drug events
D003586,1.89,NCT00290433-1,HCVIDDOXIL Regimen,NCT00290433,Efficacy of the HCVIDDOXIL Regimen in Patients With Newly Diagnosed Peripheral T-Cell Lymphoma,cytomegalovirus infections
D009026,8.16,NCT00290498-1,RHCVAD,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,mortality
D064420,100.0,NCT00290498-1,RHCVAD,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,adverse drug events
D064420,70.0,NCT00290498-2,RCHOP,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,adverse drug events
D001853,2.04,NCT00290498-1,RHCVAD,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,bone marrow
D064147,55.1,NCT00290498-1,RHCVAD,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,febrile neutropenia
D064147,20.0,NCT00290498-2,RCHOP,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,febrile neutropenia
D006470,16.33,NCT00290498-1,RHCVAD,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,hemorrhage
D006470,10.0,NCT00290498-2,RCHOP,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,hemorrhage
D011693,12.24,NCT00290498-1,RHCVAD,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,petechiae
D010689,2.04,NCT00290498-1,RHCVAD,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,phlebitis
D001281,2.04,NCT00290498-1,RHCVAD,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,atrial fibrillation
D001282,4.08,NCT00290498-1,RHCVAD,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,atrial flutter
D006973,18.37,NCT00290498-1,RHCVAD,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,hypertension
D007022,26.53,NCT00290498-1,RHCVAD,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,hypotension
10033557,2.04,NCT00290498-1,RHCVAD,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,palpitations
10033557,10.0,NCT00290498-2,RCHOP,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,palpitations
D010490,2.04,NCT00290498-1,RHCVAD,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,pericardial effusion
D010490,10.0,NCT00290498-2,RCHOP,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,pericardial effusion
10040741,6.12,NCT00290498-1,RHCVAD,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,sinus bradycardia
D013616,18.37,NCT00290498-1,RHCVAD,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,sinus tachycardia
D013610,4.08,NCT00290498-1,RHCVAD,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,tachycardia
D013610,10.0,NCT00290498-2,RCHOP,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,tachycardia
D000068897,2.04,NCT00290498-1,RHCVAD,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,pearlescence
D014012,8.16,NCT00290498-1,RHCVAD,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,tinnitus
10014698,2.04,NCT00290498-1,RHCVAD,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,endocrine disorders - other specify
D006980,2.04,NCT00290498-1,RHCVAD,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,hyperthyroidism
D007037,2.04,NCT00290498-1,RHCVAD,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,hypothyroidism
10005886,20.0,NCT00290498-2,RCHOP,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,blurred vision
D015352,4.08,NCT00290498-1,RHCVAD,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,dry eye
D019252,2.04,NCT00290498-1,RHCVAD,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,visualix
D058447,2.04,NCT00290498-1,RHCVAD,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,eye pain
D001248,8.16,NCT00290498-1,RHCVAD,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,eyestrain
D001248,20.0,NCT00290498-2,RCHOP,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,eyestrain
D000007,2.04,NCT00290498-1,RHCVAD,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,abdominal injuries
D000007,10.0,NCT00290498-2,RCHOP,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,abdominal injuries
D003248,32.65,NCT00290498-1,RHCVAD,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,constipation
D003967,22.45,NCT00290498-1,RHCVAD,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,diarrhea
D003967,20.0,NCT00290498-2,RCHOP,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,diarrhea
10005265,2.04,NCT00290498-1,RHCVAD,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,bloating
10013781,4.08,NCT00290498-1,RHCVAD,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,dry mouth
10013781,10.0,NCT00290498-2,RCHOP,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,dry mouth
D003680,4.08,NCT00290498-1,RHCVAD,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,dysphagia
D005756,14.29,NCT00290498-1,RHCVAD,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,gastritis
D005764,4.08,NCT00290498-1,RHCVAD,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,gerd
10017947,4.08,NCT00290498-1,RHCVAD,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,gastrointestinal disorders - other specify
10017947,10.0,NCT00290498-2,RCHOP,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,gastrointestinal disorders - other specify
D006356,10.2,NCT00290498-1,RHCVAD,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,heartburn
D006484,12.24,NCT00290498-1,RHCVAD,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,hemorrhoids
D009325,61.22,NCT00290498-1,RHCVAD,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,nausea
D009325,60.0,NCT00290498-2,RCHOP,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,nausea
UNKNOWN-check-for-typo,4.08,NCT00290498-1,RHCVAD,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,D00
D000005,12.24,NCT00290498-1,RHCVAD,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,abdomen
D000005,20.0,NCT00290498-2,RCHOP,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,abdomen
D000080867,10.0,NCT00290498-2,RCHOP,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,gingipains
D000080867,2.04,NCT00290498-1,RHCVAD,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,gingipains
10042112,2.04,NCT00290498-1,RHCVAD,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,stomach pain
D013280,6.12,NCT00290498-1,RHCVAD,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,stomatitis
D013280,20.0,NCT00290498-2,RCHOP,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,stomatitis
D000068538,4.08,NCT00290498-1,RHCVAD,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,dutasteride
D014070,4.08,NCT00290498-1,RHCVAD,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,teeth
D014839,48.98,NCT00290498-1,RHCVAD,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,vomiting
D014839,50.0,NCT00290498-2,RCHOP,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,vomiting
10011914,4.08,NCT00290498-1,RHCVAD,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,death nos
D004364,2.04,NCT00290498-1,RHCVAD,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,drugs
D004487,16.33,NCT00290498-1,RHCVAD,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,edema
D004487,30.0,NCT00290498-2,RCHOP,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,edema
10054482,4.08,NCT00290498-1,RHCVAD,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,neck edema
10050068,26.53,NCT00290498-1,RHCVAD,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,edema limbs
10050068,30.0,NCT00290498-2,RCHOP,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,edema limbs
D003409,4.08,NCT00290498-1,RHCVAD,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,myxedema congenital
D000799,2.04,NCT00290498-1,RHCVAD,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,angioedema
D005221,63.27,NCT00290498-1,RHCVAD,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,fatigue
D005221,20.0,NCT00290498-2,RCHOP,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,fatigue
D005335,4.08,NCT00290498-1,RHCVAD,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,fever of unknown origin
D005335,10.0,NCT00290498-2,RCHOP,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,fever of unknown origin
D005334,28.57,NCT00290498-1,RHCVAD,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,fever
D005334,30.0,NCT00290498-2,RCHOP,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,fever
D003057,2.04,NCT00290498-1,RHCVAD,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,progeria-like syndrome
D003057,10.0,NCT00290498-2,RCHOP,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,progeria-like syndrome
D005684,2.04,NCT00290498-1,RHCVAD,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,gait
D000068882,4.08,NCT00290498-1,RHCVAD,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,paliperidone
D000068882,10.0,NCT00290498-2,RCHOP,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,paliperidone
D000377,8.16,NCT00290498-1,RHCVAD,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,agnosia for pain
D000377,20.0,NCT00290498-2,RCHOP,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,agnosia for pain
D023341,36.73,NCT00290498-1,RHCVAD,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,chills
D023341,10.0,NCT00290498-2,RCHOP,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,chills
D006967,20.41,NCT00290498-1,RHCVAD,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,allergic reaction
D006967,10.0,NCT00290498-2,RCHOP,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,allergic reaction
D006967,2.04,NCT00290498-1,RHCVAD,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,allergy
D006967,10.0,NCT00290498-2,RCHOP,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,allergy
D000035,2.04,NCT00290498-1,RHCVAD,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,abreaction
D002177,6.12,NCT00290498-1,RHCVAD,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,candidiasis
D000069544,95.92,NCT00290498-1,RHCVAD,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,encephalitis infection
D000069544,60.0,NCT00290498-2,RCHOP,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,encephalitis infection
D000068757,2.04,NCT00290498-1,RHCVAD,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,ononis
10001675,8.16,NCT00290498-1,RHCVAD,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,alkaline phosphatase increased
10001675,10.0,NCT00290498-2,RCHOP,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,alkaline phosphatase increased
D014750,34.69,NCT00290498-1,RHCVAD,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,vincristine
D014750,30.0,NCT00290498-2,RCHOP,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,vincristine
D014750,34.69,NCT00290498-1,RHCVAD,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,vincristine
D014750,10.0,NCT00290498-2,RCHOP,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,vincristine
10005364,18.37,NCT00290498-1,RHCVAD,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,blood bilirubin increased
D013848,2.04,NCT00290498-1,RHCVAD,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,thigh
10011368,14.29,NCT00290498-1,RHCVAD,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,creatinine increased
10011368,20.0,NCT00290498-2,RCHOP,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,creatinine increased
D000080864,12.24,NCT00290498-1,RHCVAD,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,ldhm4
D000080864,30.0,NCT00290498-2,RCHOP,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,ldhm4
D000380,10.0,NCT00290498-2,RCHOP,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,granulocytopenia
D002263,97.96,NCT00290498-1,RHCVAD,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,carboxyhemoglobin
D002263,70.0,NCT00290498-2,RCHOP,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,carboxyhemoglobin
D006943,51.02,NCT00290498-1,RHCVAD,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,hyperglycemia
D006943,60.0,NCT00290498-2,RCHOP,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,hyperglycemia
D006947,4.08,NCT00290498-1,RHCVAD,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,hyperkalemia
D033461,8.16,NCT00290498-1,RHCVAD,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,hyperuricemia
D033461,50.0,NCT00290498-2,RCHOP,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,hyperuricemia
D034141,55.1,NCT00290498-1,RHCVAD,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,hypoalbuminemia
D034141,40.0,NCT00290498-2,RCHOP,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,hypoalbuminemia
D006996,30.61,NCT00290498-1,RHCVAD,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,hypocalcemia
D006996,40.0,NCT00290498-2,RCHOP,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,hypocalcemia
D007003,2.04,NCT00290498-1,RHCVAD,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,hypoglycemia
D007003,10.0,NCT00290498-2,RCHOP,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,hypoglycemia
D007008,30.61,NCT00290498-1,RHCVAD,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,hypokalemia
D007008,40.0,NCT00290498-2,RCHOP,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,hypokalemia
10021028,28.57,NCT00290498-1,RHCVAD,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,hypomagnesemia
10021028,60.0,NCT00290498-2,RCHOP,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,hypomagnesemia
D007010,14.29,NCT00290498-1,RHCVAD,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,hyponatremia
D007010,20.0,NCT00290498-2,RCHOP,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,hyponatremia
D017674,4.08,NCT00290498-1,RHCVAD,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,hypophosphatemia
D007970,97.96,NCT00290498-1,RHCVAD,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,leukopenia
D007970,70.0,NCT00290498-2,RCHOP,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,leukopenia
D009503,93.88,NCT00290498-1,RHCVAD,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,neutropenia
D009503,40.0,NCT00290498-2,RCHOP,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,neutropenia
D009846,2.04,NCT00290498-1,RHCVAD,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,oliguria
D001792,79.59,NCT00290498-1,RHCVAD,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,platelets
D001792,30.0,NCT00290498-2,RCHOP,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,platelets
D013921,14.29,NCT00290498-1,RHCVAD,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,thrombocytopenia
D013921,10.0,NCT00290498-2,RCHOP,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,thrombocytopenia
D000855,2.04,NCT00290498-1,RHCVAD,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,anorexia
D000855,10.0,NCT00290498-2,RCHOP,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,anorexia
D003681,4.08,NCT00290498-1,RHCVAD,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,dehydration
D000071698,6.12,NCT00290498-1,RHCVAD,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,latent autoimmune diabetes in adults
D007753,2.04,NCT00290498-1,RHCVAD,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,laboratory
D007753,10.0,NCT00290498-2,RCHOP,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,laboratory
D009765,4.08,NCT00290498-1,RHCVAD,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,obesity
D015430,2.04,NCT00290498-1,RHCVAD,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,weight gain
D015430,10.0,NCT00290498-2,RCHOP,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,weight gain
D015431,2.04,NCT00290498-1,RHCVAD,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,weight loss
D015431,10.0,NCT00290498-2,RCHOP,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,weight loss
D018908,16.33,NCT00290498-1,RHCVAD,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,muscle weakness
D018908,10.0,NCT00290498-2,RCHOP,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,muscle weakness
D063806,6.12,NCT00290498-1,RHCVAD,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,myalgia
D009220,2.04,NCT00290498-1,RHCVAD,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,myositis
D001416,20.41,NCT00290498-1,RHCVAD,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,back pain
D001416,10.0,NCT00290498-2,RCHOP,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,back pain
10006002,10.2,NCT00290498-1,RHCVAD,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,bone pain
10006002,10.0,NCT00290498-2,RCHOP,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,bone pain
D010591,12.24,NCT00290498-1,RHCVAD,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,phantom limb pain
D018771,6.12,NCT00290498-1,RHCVAD,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,joint pain
D063806,14.29,NCT00290498-1,RHCVAD,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,muscle pain
D063806,20.0,NCT00290498-2,RCHOP,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,muscle pain
D019547,10.2,NCT00290498-1,RHCVAD,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,neck pain
D000080867,2.04,NCT00290498-1,RHCVAD,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,gingipains
10009845,2.04,NCT00290498-1,RHCVAD,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,cognitive disturbance
D004244,28.57,NCT00290498-1,RHCVAD,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,dizziness
D004244,30.0,NCT00290498-2,RCHOP,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,dizziness
D006261,2.04,NCT00290498-1,RHCVAD,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,headache
10027175,2.04,NCT00290498-1,RHCVAD,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,memory impairment
D002607,2.04,NCT00290498-1,RHCVAD,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,hereditary type i motor and sensory neuropathy
D002607,30.0,NCT00290498-2,RCHOP,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,hereditary type i motor and sensory neuropathy
D002607,40.82,NCT00290498-1,RHCVAD,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,hereditary type i motor and sensory neuropathy
D002607,40.0,NCT00290498-2,RCHOP,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,hereditary type i motor and sensory neuropathy
D006261,44.9,NCT00290498-1,RHCVAD,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,headache
D006261,30.0,NCT00290498-2,RCHOP,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,headache
D000080867,2.04,NCT00290498-1,RHCVAD,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,gingipains
D000377,4.08,NCT00290498-1,RHCVAD,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,sensory agnosia
D000377,10.0,NCT00290498-2,RCHOP,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,sensory agnosia
D013575,14.29,NCT00290498-1,RHCVAD,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,syncope
D003221,2.04,NCT00290498-1,RHCVAD,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,confusion
D007319,24.49,NCT00290498-1,RHCVAD,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,insomnia
D007319,20.0,NCT00290498-2,RCHOP,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,insomnia
D000339,32.65,NCT00290498-1,RHCVAD,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,mood
D000339,20.0,NCT00290498-2,RCHOP,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,mood
D053159,2.04,NCT00290498-1,RHCVAD,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,dysuria
D053159,10.0,NCT00290498-2,RCHOP,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,dysuria
D006417,2.04,NCT00290498-1,RHCVAD,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,hematuria
D011141,2.04,NCT00290498-1,RHCVAD,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,polyuria
D051437,8.16,NCT00290498-1,RHCVAD,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,renal failure
10046539,2.04,NCT00290498-1,RHCVAD,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,urinary frequency
10046539,10.0,NCT00290498-2,RCHOP,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,urinary frequency
D019584,2.04,NCT00290498-1,RHCVAD,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,hot flashes
D008595,2.04,NCT00290498-1,RHCVAD,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,menorrhagia
D059373,2.04,NCT00290498-1,RHCVAD,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,breast pain
D000080867,4.08,NCT00290498-1,RHCVAD,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,gingipains
10046937,2.04,NCT00290498-1,RHCVAD,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,vaginal pain
10046904,2.04,NCT00290498-1,RHCVAD,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,vaginal dryness
D065631,18.37,NCT00290498-1,RHCVAD,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,allergic rhinitis
D065631,30.0,NCT00290498-2,RCHOP,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,allergic rhinitis
D003371,34.69,NCT00290498-1,RHCVAD,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,cough
D003371,40.0,NCT00290498-2,RCHOP,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,cough
D004417,44.9,NCT00290498-1,RHCVAD,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,dyspnea
D004417,30.0,NCT00290498-2,RCHOP,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,dyspnea
D006469,2.04,NCT00290498-1,RHCVAD,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,hemoptysis
D006469,10.0,NCT00290498-2,RCHOP,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,hemoptysis
UNKNOWN-check-for-typo,10.0,NCT00290498-2,RCHOP,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,D00
D000860,2.04,NCT00290498-1,RHCVAD,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,hypoxia
D000860,10.0,NCT00290498-2,RCHOP,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,hypoxia
D052016,40.82,NCT00290498-1,RHCVAD,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,mucositis
D052016,30.0,NCT00290498-2,RCHOP,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,mucositis
D002637,14.29,NCT00290498-1,RHCVAD,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,chest pain
10035623,10.0,NCT00290498-2,RCHOP,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,pleuritic pain
D000080867,6.12,NCT00290498-1,RHCVAD,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,gingipains
D010996,16.33,NCT00290498-1,RHCVAD,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,pleural effusion
D011014,2.04,NCT00290498-1,RHCVAD,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,pneumonitis
D011030,2.04,NCT00290498-1,RHCVAD,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,pneumothorax
D010547,2.04,NCT00290498-1,RHCVAD,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,alveolar capillary dysplasia with misalignment of pulmonary veins and other congenital anomalies
D010547,10.0,NCT00290498-2,RCHOP,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,alveolar capillary dysplasia with misalignment of pulmonary veins and other congenital anomalies
D012131,2.04,NCT00290498-1,RHCVAD,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,respiratory failure
10039100,12.24,NCT00290498-1,RHCVAD,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,rhinorrhea
D010612,2.04,NCT00290498-1,RHCVAD,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,sore throat
D012141,2.04,NCT00290498-1,RHCVAD,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,upper respiratory tract infections
D014831,6.12,NCT00290498-1,RHCVAD,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,voice
D014831,10.0,NCT00290498-2,RCHOP,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,voice
D000505,40.82,NCT00290498-1,RHCVAD,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,alopecia
D000505,50.0,NCT00290498-2,RCHOP,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,alopecia
D003880,2.04,NCT00290498-1,RHCVAD,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,dermatology
10013786,6.12,NCT00290498-1,RHCVAD,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,dry skin
D004892,10.2,NCT00290498-1,RHCVAD,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,erythema multiforme
D060831,8.16,NCT00290498-1,RHCVAD,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,hand foot syndrome
D017495,2.04,NCT00290498-1,RHCVAD,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,hyperpigmentation
D011537,8.16,NCT00290498-1,RHCVAD,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,pruritus
D011537,2.04,NCT00290498-1,RHCVAD,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,pruritus
D011655,2.04,NCT00290498-1,RHCVAD,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,pulmonary embolism
D005076,28.57,NCT00290498-1,RHCVAD,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,rash
D005076,20.0,NCT00290498-2,RCHOP,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,rash
D013546,14.29,NCT00290498-1,RHCVAD,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,sweating
D013546,10.0,NCT00290498-2,RCHOP,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,sweating
10040947,2.04,NCT00290498-1,RHCVAD,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,skin ulceration
D005483,8.16,NCT00290498-1,RHCVAD,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,flushing
D006406,10.0,NCT00290498-2,RCHOP,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,hematoma
D013577,2.04,NCT00290498-1,RHCVAD,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,syndromes
D016769,24.49,NCT00290498-1,RHCVAD,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,embolism and thrombosis
D016769,10.0,NCT00290498-2,RCHOP,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,embolism and thrombosis
10047065,2.04,NCT00290498-1,RHCVAD,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,vascular disorders - other specify
10047065,10.0,NCT00290498-2,RCHOP,NCT00290498,Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger,vascular disorders - other specify
D064420,2.56,NCT00304070-1,Stratum 3,NCT00304070,Cisplatin-Based Chemotherapy and/or Surgery in Treating Young Patients With Adrenocortical Tumor,adverse drug events
D011014,2.56,NCT00304070-1,Stratum 3,NCT00304070,Cisplatin-Based Chemotherapy and/or Surgery in Treating Young Patients With Adrenocortical Tumor,pneumonitis
D009026,66.67,NCT00305084-1,Cohort 1: NGRhTNF 0.2 μg/m^2+ Doxorubicin 60 mg/m^2,NCT00305084,Study of NGR-hTNF in Combination With Doxorubicin in Solid Tumors,mortality
D009026,33.33,NCT00305084-2,Cohort 2: NGRhTNF 0.2 μg/m^2+ Doxorubicin 75 mg/m^2,NCT00305084,Study of NGR-hTNF in Combination With Doxorubicin in Solid Tumors,mortality
D009026,66.67,NCT00305084-3,Cohort 3: NGR-hTNF 0.4 μg/m^2+ Doxorubicin 75 mg/m^2,NCT00305084,Study of NGR-hTNF in Combination With Doxorubicin in Solid Tumors,mortality
D009026,66.67,NCT00305084-5,Cohort 5: NGR-hTNF: 1.6 μg/m^2 + Doxorubicin 75 mg/m^2,NCT00305084,Study of NGR-hTNF in Combination With Doxorubicin in Solid Tumors,mortality
D064420,66.67,NCT00305084-1,Cohort 1: NGRhTNF 0.2 μg/m^2+ Doxorubicin 60 mg/m^2,NCT00305084,Study of NGR-hTNF in Combination With Doxorubicin in Solid Tumors,adverse drug events
D064420,33.33,NCT00305084-2,Cohort 2: NGRhTNF 0.2 μg/m^2+ Doxorubicin 75 mg/m^2,NCT00305084,Study of NGR-hTNF in Combination With Doxorubicin in Solid Tumors,adverse drug events
D064420,66.67,NCT00305084-3,Cohort 3: NGR-hTNF 0.4 μg/m^2+ Doxorubicin 75 mg/m^2,NCT00305084,Study of NGR-hTNF in Combination With Doxorubicin in Solid Tumors,adverse drug events
D064420,100.0,NCT00305084-4,Cohort 4: NGR-hTNF 0.8 μg/m^2+ Doxorubicin 75 mg/m^2,NCT00305084,Study of NGR-hTNF in Combination With Doxorubicin in Solid Tumors,adverse drug events
D064420,33.33,NCT00305084-5,Cohort 5: NGR-hTNF: 1.6 μg/m^2 + Doxorubicin 75 mg/m^2,NCT00305084,Study of NGR-hTNF in Combination With Doxorubicin in Solid Tumors,adverse drug events
D064147,33.33,NCT00305084-2,Cohort 2: NGRhTNF 0.2 μg/m^2+ Doxorubicin 75 mg/m^2,NCT00305084,Study of NGR-hTNF in Combination With Doxorubicin in Solid Tumors,febrile neutropenia
D007970,33.33,NCT00305084-5,Cohort 5: NGR-hTNF: 1.6 μg/m^2 + Doxorubicin 75 mg/m^2,NCT00305084,Study of NGR-hTNF in Combination With Doxorubicin in Solid Tumors,leukopenia
D000741,33.33,NCT00305084-1,Cohort 1: NGRhTNF 0.2 μg/m^2+ Doxorubicin 60 mg/m^2,NCT00305084,Study of NGR-hTNF in Combination With Doxorubicin in Solid Tumors,aplastic anaemia
D000741,33.33,NCT00305084-5,Cohort 5: NGR-hTNF: 1.6 μg/m^2 + Doxorubicin 75 mg/m^2,NCT00305084,Study of NGR-hTNF in Combination With Doxorubicin in Solid Tumors,aplastic anaemia
D056988,33.33,NCT00305084-3,Cohort 3: NGR-hTNF 0.4 μg/m^2+ Doxorubicin 75 mg/m^2,NCT00305084,Study of NGR-hTNF in Combination With Doxorubicin in Solid Tumors,acute anterior wall myocardial infarction
D014839,33.33,NCT00305084-4,Cohort 4: NGR-hTNF 0.8 μg/m^2+ Doxorubicin 75 mg/m^2,NCT00305084,Study of NGR-hTNF in Combination With Doxorubicin in Solid Tumors,vomiting
UNKNOWN-check-for-typo,33.33,NCT00305084-4,Cohort 4: NGR-hTNF 0.8 μg/m^2+ Doxorubicin 75 mg/m^2,NCT00305084,Study of NGR-hTNF in Combination With Doxorubicin in Solid Tumors,D00
D015746,33.33,NCT00305084-5,Cohort 5: NGR-hTNF: 1.6 μg/m^2 + Doxorubicin 75 mg/m^2,NCT00305084,Study of NGR-hTNF in Combination With Doxorubicin in Solid Tumors,abdominal pain
D003248,33.33,NCT00305084-5,Cohort 5: NGR-hTNF: 1.6 μg/m^2 + Doxorubicin 75 mg/m^2,NCT00305084,Study of NGR-hTNF in Combination With Doxorubicin in Solid Tumors,constipation
D000080867,33.33,NCT00305084-4,Cohort 4: NGR-hTNF 0.8 μg/m^2+ Doxorubicin 75 mg/m^2,NCT00305084,Study of NGR-hTNF in Combination With Doxorubicin in Solid Tumors,gingipains
D020246,33.33,NCT00305084-1,Cohort 1: NGRhTNF 0.2 μg/m^2+ Doxorubicin 60 mg/m^2,NCT00305084,Study of NGR-hTNF in Combination With Doxorubicin in Solid Tumors,deep vein thrombosis
D011655,33.33,NCT00305084-3,Cohort 3: NGR-hTNF 0.4 μg/m^2+ Doxorubicin 75 mg/m^2,NCT00305084,Study of NGR-hTNF in Combination With Doxorubicin in Solid Tumors,pulmonary embolism
D064420,48.11,NCT00327171-1,Aflibercept 2.0 mg/kg,NCT00327171,Study of AVE0005 (VEGF Trap) in Patients With Chemoresistant Advanced Ovarian Cancer,adverse drug events
D064420,51.38,NCT00327171-2,Aflibercept 4.0 mg/kg,NCT00327171,Study of AVE0005 (VEGF Trap) in Patients With Chemoresistant Advanced Ovarian Cancer,adverse drug events
D000741,1.89,NCT00327171-1,Aflibercept 2.0 mg/kg,NCT00327171,Study of AVE0005 (VEGF Trap) in Patients With Chemoresistant Advanced Ovarian Cancer,aplastic anaemia
D000741,0.92,NCT00327171-2,Aflibercept 4.0 mg/kg,NCT00327171,Study of AVE0005 (VEGF Trap) in Patients With Chemoresistant Advanced Ovarian Cancer,aplastic anaemia
D013921,0.94,NCT00327171-1,Aflibercept 2.0 mg/kg,NCT00327171,Study of AVE0005 (VEGF Trap) in Patients With Chemoresistant Advanced Ovarian Cancer,thrombocytopenia
D011697,0.92,NCT00327171-2,Aflibercept 4.0 mg/kg,NCT00327171,Study of AVE0005 (VEGF Trap) in Patients With Chemoresistant Advanced Ovarian Cancer,thrombotic thrombocytopenic purpura
D000787,0.94,NCT00327171-1,Aflibercept 2.0 mg/kg,NCT00327171,Study of AVE0005 (VEGF Trap) in Patients With Chemoresistant Advanced Ovarian Cancer,angina pectoris
D000072599,0.94,NCT00327171-1,Aflibercept 2.0 mg/kg,NCT00327171,Study of AVE0005 (VEGF Trap) in Patients With Chemoresistant Advanced Ovarian Cancer,cardiorespiratory fitness
D002311,0.94,NCT00327171-1,Aflibercept 2.0 mg/kg,NCT00327171,Study of AVE0005 (VEGF Trap) in Patients With Chemoresistant Advanced Ovarian Cancer,congestive cardiomyopathy
D018487,0.92,NCT00327171-2,Aflibercept 4.0 mg/kg,NCT00327171,Study of AVE0005 (VEGF Trap) in Patients With Chemoresistant Advanced Ovarian Cancer,left ventricular dysfunction
D014717,0.92,NCT00327171-2,Aflibercept 4.0 mg/kg,NCT00327171,Study of AVE0005 (VEGF Trap) in Patients With Chemoresistant Advanced Ovarian Cancer,vertigo
D001766,0.92,NCT00327171-2,Aflibercept 4.0 mg/kg,NCT00327171,Study of AVE0005 (VEGF Trap) in Patients With Chemoresistant Advanced Ovarian Cancer,blindness transient
D015746,3.77,NCT00327171-1,Aflibercept 2.0 mg/kg,NCT00327171,Study of AVE0005 (VEGF Trap) in Patients With Chemoresistant Advanced Ovarian Cancer,abdominal pain
D015746,5.5,NCT00327171-2,Aflibercept 4.0 mg/kg,NCT00327171,Study of AVE0005 (VEGF Trap) in Patients With Chemoresistant Advanced Ovarian Cancer,abdominal pain
D001201,0.94,NCT00327171-1,Aflibercept 2.0 mg/kg,NCT00327171,Study of AVE0005 (VEGF Trap) in Patients With Chemoresistant Advanced Ovarian Cancer,ascites
10010000,0.94,NCT00327171-1,Aflibercept 2.0 mg/kg,NCT00327171,Study of AVE0005 (VEGF Trap) in Patients With Chemoresistant Advanced Ovarian Cancer,colonic obstruction
D003424,0.94,NCT00327171-1,Aflibercept 2.0 mg/kg,NCT00327171,Study of AVE0005 (VEGF Trap) in Patients With Chemoresistant Advanced Ovarian Cancer,crohn disease
UNKNOWN-check-for-typo,0.94,NCT00327171-1,Aflibercept 2.0 mg/kg,NCT00327171,Study of AVE0005 (VEGF Trap) in Patients With Chemoresistant Advanced Ovarian Cancer,D00
UNKNOWN-check-for-typo,0.92,NCT00327171-2,Aflibercept 4.0 mg/kg,NCT00327171,Study of AVE0005 (VEGF Trap) in Patients With Chemoresistant Advanced Ovarian Cancer,D00
D000069196,0.92,NCT00327171-2,Aflibercept 4.0 mg/kg,NCT00327171,Study of AVE0005 (VEGF Trap) in Patients With Chemoresistant Advanced Ovarian Cancer,gastrointestinal microbiome
10065712,0.94,NCT00327171-1,Aflibercept 2.0 mg/kg,NCT00327171,Study of AVE0005 (VEGF Trap) in Patients With Chemoresistant Advanced Ovarian Cancer,gastrointestinal stoma necrosis
D000069196,1.89,NCT00327171-1,Aflibercept 2.0 mg/kg,NCT00327171,Study of AVE0005 (VEGF Trap) in Patients With Chemoresistant Advanced Ovarian Cancer,gastrointestinal microbiome
D000069196,0.92,NCT00327171-2,Aflibercept 4.0 mg/kg,NCT00327171,Study of AVE0005 (VEGF Trap) in Patients With Chemoresistant Advanced Ovarian Cancer,gastrointestinal microbiome
D007415,9.43,NCT00327171-1,Aflibercept 2.0 mg/kg,NCT00327171,Study of AVE0005 (VEGF Trap) in Patients With Chemoresistant Advanced Ovarian Cancer,intestinal obstruction
D007415,5.5,NCT00327171-2,Aflibercept 4.0 mg/kg,NCT00327171,Study of AVE0005 (VEGF Trap) in Patients With Chemoresistant Advanced Ovarian Cancer,intestinal obstruction
D007416,0.94,NCT00327171-1,Aflibercept 2.0 mg/kg,NCT00327171,Study of AVE0005 (VEGF Trap) in Patients With Chemoresistant Advanced Ovarian Cancer,intestinal perforation
D007416,1.83,NCT00327171-2,Aflibercept 4.0 mg/kg,NCT00327171,Study of AVE0005 (VEGF Trap) in Patients With Chemoresistant Advanced Ovarian Cancer,intestinal perforation
D050686,0.94,NCT00327171-1,Aflibercept 2.0 mg/kg,NCT00327171,Study of AVE0005 (VEGF Trap) in Patients With Chemoresistant Advanced Ovarian Cancer,globicephala melaena
D009325,2.83,NCT00327171-1,Aflibercept 2.0 mg/kg,NCT00327171,Study of AVE0005 (VEGF Trap) in Patients With Chemoresistant Advanced Ovarian Cancer,nausea
10041101,1.83,NCT00327171-2,Aflibercept 4.0 mg/kg,NCT00327171,Study of AVE0005 (VEGF Trap) in Patients With Chemoresistant Advanced Ovarian Cancer,small intestinal obstruction
10021328,1.83,NCT00327171-2,Aflibercept 4.0 mg/kg,NCT00327171,Study of AVE0005 (VEGF Trap) in Patients With Chemoresistant Advanced Ovarian Cancer,ileus
D014839,1.89,NCT00327171-1,Aflibercept 2.0 mg/kg,NCT00327171,Study of AVE0005 (VEGF Trap) in Patients With Chemoresistant Advanced Ovarian Cancer,vomiting
D014839,1.83,NCT00327171-2,Aflibercept 4.0 mg/kg,NCT00327171,Study of AVE0005 (VEGF Trap) in Patients With Chemoresistant Advanced Ovarian Cancer,vomiting
D001247,0.94,NCT00327171-1,Aflibercept 2.0 mg/kg,NCT00327171,Study of AVE0005 (VEGF Trap) in Patients With Chemoresistant Advanced Ovarian Cancer,asthenia
D001247,1.83,NCT00327171-2,Aflibercept 4.0 mg/kg,NCT00327171,Study of AVE0005 (VEGF Trap) in Patients With Chemoresistant Advanced Ovarian Cancer,asthenia
D018450,2.83,NCT00327171-1,Aflibercept 2.0 mg/kg,NCT00327171,Study of AVE0005 (VEGF Trap) in Patients With Chemoresistant Advanced Ovarian Cancer,disease progression
D018450,6.42,NCT00327171-2,Aflibercept 4.0 mg/kg,NCT00327171,Study of AVE0005 (VEGF Trap) in Patients With Chemoresistant Advanced Ovarian Cancer,disease progression
D005221,0.92,NCT00327171-2,Aflibercept 4.0 mg/kg,NCT00327171,Study of AVE0005 (VEGF Trap) in Patients With Chemoresistant Advanced Ovarian Cancer,fatigue
D003695,1.83,NCT00327171-2,Aflibercept 4.0 mg/kg,NCT00327171,Study of AVE0005 (VEGF Trap) in Patients With Chemoresistant Advanced Ovarian Cancer,healthcare
D005334,1.89,NCT00327171-1,Aflibercept 2.0 mg/kg,NCT00327171,Study of AVE0005 (VEGF Trap) in Patients With Chemoresistant Advanced Ovarian Cancer,pyrexia
D005334,1.83,NCT00327171-2,Aflibercept 4.0 mg/kg,NCT00327171,Study of AVE0005 (VEGF Trap) in Patients With Chemoresistant Advanced Ovarian Cancer,pyrexia
D003645,0.92,NCT00327171-2,Aflibercept 4.0 mg/kg,NCT00327171,Study of AVE0005 (VEGF Trap) in Patients With Chemoresistant Advanced Ovarian Cancer,sudden death
D041781,0.94,NCT00327171-1,Aflibercept 2.0 mg/kg,NCT00327171,Study of AVE0005 (VEGF Trap) in Patients With Chemoresistant Advanced Ovarian Cancer,cholestatic jaundice
D000038,0.92,NCT00327171-2,Aflibercept 4.0 mg/kg,NCT00327171,Study of AVE0005 (VEGF Trap) in Patients With Chemoresistant Advanced Ovarian Cancer,abscess
D001064,0.92,NCT00327171-2,Aflibercept 4.0 mg/kg,NCT00327171,Study of AVE0005 (VEGF Trap) in Patients With Chemoresistant Advanced Ovarian Cancer,appendicitis
D010272,0.92,NCT00327171-2,Aflibercept 4.0 mg/kg,NCT00327171,Study of AVE0005 (VEGF Trap) in Patients With Chemoresistant Advanced Ovarian Cancer,parasite infections
D000069544,0.92,NCT00327171-2,Aflibercept 4.0 mg/kg,NCT00327171,Study of AVE0005 (VEGF Trap) in Patients With Chemoresistant Advanced Ovarian Cancer,encephalitis infection
D004761,0.92,NCT00327171-2,Aflibercept 4.0 mg/kg,NCT00327171,Study of AVE0005 (VEGF Trap) in Patients With Chemoresistant Advanced Ovarian Cancer,clostridium enterocolitis
10064687,0.94,NCT00327171-1,Aflibercept 2.0 mg/kg,NCT00327171,Study of AVE0005 (VEGF Trap) in Patients With Chemoresistant Advanced Ovarian Cancer,device related infection
D000069544,0.94,NCT00327171-1,Aflibercept 2.0 mg/kg,NCT00327171,Study of AVE0005 (VEGF Trap) in Patients With Chemoresistant Advanced Ovarian Cancer,encephalitis infection
D000069544,0.92,NCT00327171-2,Aflibercept 4.0 mg/kg,NCT00327171,Study of AVE0005 (VEGF Trap) in Patients With Chemoresistant Advanced Ovarian Cancer,encephalitis infection
D005759,0.94,NCT00327171-1,Aflibercept 2.0 mg/kg,NCT00327171,Study of AVE0005 (VEGF Trap) in Patients With Chemoresistant Advanced Ovarian Cancer,gastroenteritis
D006506,0.92,NCT00327171-2,Aflibercept 4.0 mg/kg,NCT00327171,Study of AVE0005 (VEGF Trap) in Patients With Chemoresistant Advanced Ovarian Cancer,hepatitis a
D010538,0.92,NCT00327171-2,Aflibercept 4.0 mg/kg,NCT00327171,Study of AVE0005 (VEGF Trap) in Patients With Chemoresistant Advanced Ovarian Cancer,peritonitis
D011014,1.89,NCT00327171-1,Aflibercept 2.0 mg/kg,NCT00327171,Study of AVE0005 (VEGF Trap) in Patients With Chemoresistant Advanced Ovarian Cancer,pneumonia
D011014,1.83,NCT00327171-2,Aflibercept 4.0 mg/kg,NCT00327171,Study of AVE0005 (VEGF Trap) in Patients With Chemoresistant Advanced Ovarian Cancer,pneumonia
D001996,0.94,NCT00327171-1,Aflibercept 2.0 mg/kg,NCT00327171,Study of AVE0005 (VEGF Trap) in Patients With Chemoresistant Advanced Ovarian Cancer,bronchopneumonia
D011704,0.92,NCT00327171-2,Aflibercept 4.0 mg/kg,NCT00327171,Study of AVE0005 (VEGF Trap) in Patients With Chemoresistant Advanced Ovarian Cancer,pyelonephritis
D018805,0.94,NCT00327171-1,Aflibercept 2.0 mg/kg,NCT00327171,Study of AVE0005 (VEGF Trap) in Patients With Chemoresistant Advanced Ovarian Cancer,sepsis
D012772,0.94,NCT00327171-1,Aflibercept 2.0 mg/kg,NCT00327171,Study of AVE0005 (VEGF Trap) in Patients With Chemoresistant Advanced Ovarian Cancer,septic shock
D014552,0.94,NCT00327171-1,Aflibercept 2.0 mg/kg,NCT00327171,Study of AVE0005 (VEGF Trap) in Patients With Chemoresistant Advanced Ovarian Cancer,urinary tract infection
D064386,0.92,NCT00327171-2,Aflibercept 4.0 mg/kg,NCT00327171,Study of AVE0005 (VEGF Trap) in Patients With Chemoresistant Advanced Ovarian Cancer,ankle fracture
D009294,0.92,NCT00327171-2,Aflibercept 4.0 mg/kg,NCT00327171,Study of AVE0005 (VEGF Trap) in Patients With Chemoresistant Advanced Ovarian Cancer,narcotics
10048031,0.92,NCT00327171-2,Aflibercept 4.0 mg/kg,NCT00327171,Study of AVE0005 (VEGF Trap) in Patients With Chemoresistant Advanced Ovarian Cancer,wound dehiscence
10001675,0.94,NCT00327171-1,Aflibercept 2.0 mg/kg,NCT00327171,Study of AVE0005 (VEGF Trap) in Patients With Chemoresistant Advanced Ovarian Cancer,alkaline phosphatase increased
10011368,0.94,NCT00327171-1,Aflibercept 2.0 mg/kg,NCT00327171,Study of AVE0005 (VEGF Trap) in Patients With Chemoresistant Advanced Ovarian Cancer,creatinine increased
D005723,0.94,NCT00327171-1,Aflibercept 2.0 mg/kg,NCT00327171,Study of AVE0005 (VEGF Trap) in Patients With Chemoresistant Advanced Ovarian Cancer,gammaglutamyltransferase
D001051,0.94,NCT00327171-1,Aflibercept 2.0 mg/kg,NCT00327171,Study of AVE0005 (VEGF Trap) in Patients With Chemoresistant Advanced Ovarian Cancer,apoenzymes
D004641,0.92,NCT00327171-2,Aflibercept 4.0 mg/kg,NCT00327171,Study of AVE0005 (VEGF Trap) in Patients With Chemoresistant Advanced Ovarian Cancer,international migration
D001066,1.89,NCT00327171-1,Aflibercept 2.0 mg/kg,NCT00327171,Study of AVE0005 (VEGF Trap) in Patients With Chemoresistant Advanced Ovarian Cancer,appetite
D003681,3.77,NCT00327171-1,Aflibercept 2.0 mg/kg,NCT00327171,Study of AVE0005 (VEGF Trap) in Patients With Chemoresistant Advanced Ovarian Cancer,dehydration
D003681,1.83,NCT00327171-2,Aflibercept 4.0 mg/kg,NCT00327171,Study of AVE0005 (VEGF Trap) in Patients With Chemoresistant Advanced Ovarian Cancer,dehydration
UNKNOWN-check-for-typo,0.94,NCT00327171-1,Aflibercept 2.0 mg/kg,NCT00327171,Study of AVE0005 (VEGF Trap) in Patients With Chemoresistant Advanced Ovarian Cancer,D00
UNKNOWN-check-for-typo,0.94,NCT00327171-1,Aflibercept 2.0 mg/kg,NCT00327171,Study of AVE0005 (VEGF Trap) in Patients With Chemoresistant Advanced Ovarian Cancer,D00
UNKNOWN-check-for-typo,0.92,NCT00327171-2,Aflibercept 4.0 mg/kg,NCT00327171,Study of AVE0005 (VEGF Trap) in Patients With Chemoresistant Advanced Ovarian Cancer,D00
D003922,0.92,NCT00327171-2,Aflibercept 4.0 mg/kg,NCT00327171,Study of AVE0005 (VEGF Trap) in Patients With Chemoresistant Advanced Ovarian Cancer,type 1 diabetes mellitus
D018771,0.92,NCT00327171-2,Aflibercept 4.0 mg/kg,NCT00327171,Study of AVE0005 (VEGF Trap) in Patients With Chemoresistant Advanced Ovarian Cancer,arthralgia
D002637,0.92,NCT00327171-2,Aflibercept 4.0 mg/kg,NCT00327171,Study of AVE0005 (VEGF Trap) in Patients With Chemoresistant Advanced Ovarian Cancer,chest pain
D005350,0.94,NCT00327171-1,Aflibercept 2.0 mg/kg,NCT00327171,Study of AVE0005 (VEGF Trap) in Patients With Chemoresistant Advanced Ovarian Cancer,fibromyxoma
D016066,0.94,NCT00327171-1,Aflibercept 2.0 mg/kg,NCT00327171,Study of AVE0005 (VEGF Trap) in Patients With Chemoresistant Advanced Ovarian Cancer,malignant pleural effusion
D002490,1.83,NCT00327171-2,Aflibercept 4.0 mg/kg,NCT00327171,Study of AVE0005 (VEGF Trap) in Patients With Chemoresistant Advanced Ovarian Cancer,central nervous system
D008198,0.94,NCT00327171-1,Aflibercept 2.0 mg/kg,NCT00327171,Study of AVE0005 (VEGF Trap) in Patients With Chemoresistant Advanced Ovarian Cancer,lymph nodes
D007421,0.92,NCT00327171-2,Aflibercept 4.0 mg/kg,NCT00327171,Study of AVE0005 (VEGF Trap) in Patients With Chemoresistant Advanced Ovarian Cancer,intestine small
D004830,0.92,NCT00327171-2,Aflibercept 4.0 mg/kg,NCT00327171,Study of AVE0005 (VEGF Trap) in Patients With Chemoresistant Advanced Ovarian Cancer,grand mal convulsion
D006261,0.94,NCT00327171-1,Aflibercept 2.0 mg/kg,NCT00327171,Study of AVE0005 (VEGF Trap) in Patients With Chemoresistant Advanced Ovarian Cancer,headache
D006261,1.83,NCT00327171-2,Aflibercept 4.0 mg/kg,NCT00327171,Study of AVE0005 (VEGF Trap) in Patients With Chemoresistant Advanced Ovarian Cancer,headache
D020343,0.92,NCT00327171-2,Aflibercept 4.0 mg/kg,NCT00327171,Study of AVE0005 (VEGF Trap) in Patients With Chemoresistant Advanced Ovarian Cancer,hypertensive encephalopathy
D011115,0.92,NCT00327171-2,Aflibercept 4.0 mg/kg,NCT00327171,Study of AVE0005 (VEGF Trap) in Patients With Chemoresistant Advanced Ovarian Cancer,polyneuropathy
D013575,0.94,NCT00327171-1,Aflibercept 2.0 mg/kg,NCT00327171,Study of AVE0005 (VEGF Trap) in Patients With Chemoresistant Advanced Ovarian Cancer,syncope
D002546,0.94,NCT00327171-1,Aflibercept 2.0 mg/kg,NCT00327171,Study of AVE0005 (VEGF Trap) in Patients With Chemoresistant Advanced Ovarian Cancer,ischemic attack transient
D006869,0.94,NCT00327171-1,Aflibercept 2.0 mg/kg,NCT00327171,Study of AVE0005 (VEGF Trap) in Patients With Chemoresistant Advanced Ovarian Cancer,hydronephrosis
D009404,0.94,NCT00327171-1,Aflibercept 2.0 mg/kg,NCT00327171,Study of AVE0005 (VEGF Trap) in Patients With Chemoresistant Advanced Ovarian Cancer,nephrotic syndrome
D011507,0.94,NCT00327171-1,Aflibercept 2.0 mg/kg,NCT00327171,Study of AVE0005 (VEGF Trap) in Patients With Chemoresistant Advanced Ovarian Cancer,proteinuria
D011507,0.92,NCT00327171-2,Aflibercept 4.0 mg/kg,NCT00327171,Study of AVE0005 (VEGF Trap) in Patients With Chemoresistant Advanced Ovarian Cancer,proteinuria
D051437,2.83,NCT00327171-1,Aflibercept 2.0 mg/kg,NCT00327171,Study of AVE0005 (VEGF Trap) in Patients With Chemoresistant Advanced Ovarian Cancer,renal failure
D051437,2.75,NCT00327171-2,Aflibercept 4.0 mg/kg,NCT00327171,Study of AVE0005 (VEGF Trap) in Patients With Chemoresistant Advanced Ovarian Cancer,renal failure
D058186,0.92,NCT00327171-2,Aflibercept 4.0 mg/kg,NCT00327171,Study of AVE0005 (VEGF Trap) in Patients With Chemoresistant Advanced Ovarian Cancer,acute renal failure
D016055,0.94,NCT00327171-1,Aflibercept 2.0 mg/kg,NCT00327171,Study of AVE0005 (VEGF Trap) in Patients With Chemoresistant Advanced Ovarian Cancer,urinary retention
D012128,0.94,NCT00327171-1,Aflibercept 2.0 mg/kg,NCT00327171,Study of AVE0005 (VEGF Trap) in Patients With Chemoresistant Advanced Ovarian Cancer,acute respiratory distress syndrome
D029424,0.92,NCT00327171-2,Aflibercept 4.0 mg/kg,NCT00327171,Study of AVE0005 (VEGF Trap) in Patients With Chemoresistant Advanced Ovarian Cancer,chronic obstructive pulmonary disease
UNKNOWN-check-for-typo,1.89,NCT00327171-1,Aflibercept 2.0 mg/kg,NCT00327171,Study of AVE0005 (VEGF Trap) in Patients With Chemoresistant Advanced Ovarian Cancer,D00
UNKNOWN-check-for-typo,3.67,NCT00327171-2,Aflibercept 4.0 mg/kg,NCT00327171,Study of AVE0005 (VEGF Trap) in Patients With Chemoresistant Advanced Ovarian Cancer,D00
D000860,0.94,NCT00327171-1,Aflibercept 2.0 mg/kg,NCT00327171,Study of AVE0005 (VEGF Trap) in Patients With Chemoresistant Advanced Ovarian Cancer,hypoxia
D010996,2.83,NCT00327171-1,Aflibercept 2.0 mg/kg,NCT00327171,Study of AVE0005 (VEGF Trap) in Patients With Chemoresistant Advanced Ovarian Cancer,pleural effusion
D010996,0.92,NCT00327171-2,Aflibercept 4.0 mg/kg,NCT00327171,Study of AVE0005 (VEGF Trap) in Patients With Chemoresistant Advanced Ovarian Cancer,pleural effusion
D011015,0.92,NCT00327171-2,Aflibercept 4.0 mg/kg,NCT00327171,Study of AVE0005 (VEGF Trap) in Patients With Chemoresistant Advanced Ovarian Cancer,aspiration pneumonia
D011655,0.94,NCT00327171-1,Aflibercept 2.0 mg/kg,NCT00327171,Study of AVE0005 (VEGF Trap) in Patients With Chemoresistant Advanced Ovarian Cancer,pulmonary embolism
D011655,1.83,NCT00327171-2,Aflibercept 4.0 mg/kg,NCT00327171,Study of AVE0005 (VEGF Trap) in Patients With Chemoresistant Advanced Ovarian Cancer,pulmonary embolism
D000799,0.92,NCT00327171-2,Aflibercept 4.0 mg/kg,NCT00327171,Study of AVE0005 (VEGF Trap) in Patients With Chemoresistant Advanced Ovarian Cancer,angioedema
D012131,0.94,NCT00327171-1,Aflibercept 2.0 mg/kg,NCT00327171,Study of AVE0005 (VEGF Trap) in Patients With Chemoresistant Advanced Ovarian Cancer,respiratory failure
D004890,0.92,NCT00327171-2,Aflibercept 4.0 mg/kg,NCT00327171,Study of AVE0005 (VEGF Trap) in Patients With Chemoresistant Advanced Ovarian Cancer,erythema
D020246,0.92,NCT00327171-2,Aflibercept 4.0 mg/kg,NCT00327171,Study of AVE0005 (VEGF Trap) in Patients With Chemoresistant Advanced Ovarian Cancer,deep vein thrombosis
D006973,3.77,NCT00327171-1,Aflibercept 2.0 mg/kg,NCT00327171,Study of AVE0005 (VEGF Trap) in Patients With Chemoresistant Advanced Ovarian Cancer,hypertension
D006973,5.5,NCT00327171-2,Aflibercept 4.0 mg/kg,NCT00327171,Study of AVE0005 (VEGF Trap) in Patients With Chemoresistant Advanced Ovarian Cancer,hypertension
D010689,0.92,NCT00327171-2,Aflibercept 4.0 mg/kg,NCT00327171,Study of AVE0005 (VEGF Trap) in Patients With Chemoresistant Advanced Ovarian Cancer,phlebitis
D064420,5.88,NCT00346164-2,Arm B: Low Risk; Adjuvant Radiotherapy,NCT00346164,Observation  Radiation Therapy  Combination Chemotherapy  and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma,adverse drug events
D064420,0.91,NCT00346164-3,Arm C: Intermediate & High Risk; Adjuvant Chemoradiotherapy,NCT00346164,Observation  Radiation Therapy  Combination Chemotherapy  and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma,adverse drug events
D064420,1.53,NCT00346164-4,Arm D: Intermediate & High Risk; Neoadjuvant Chemoradiotherapy,NCT00346164,Observation  Radiation Therapy  Combination Chemotherapy  and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma,adverse drug events
10055356,0.91,NCT00346164-3,Arm C: Intermediate & High Risk; Adjuvant Chemoradiotherapy,NCT00346164,Observation  Radiation Therapy  Combination Chemotherapy  and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma,upper gastrointestinal hemorrhage
10011914,0.51,NCT00346164-4,Arm D: Intermediate & High Risk; Neoadjuvant Chemoradiotherapy,NCT00346164,Observation  Radiation Therapy  Combination Chemotherapy  and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma,death nos
10021881,0.51,NCT00346164-4,Arm D: Intermediate & High Risk; Neoadjuvant Chemoradiotherapy,NCT00346164,Observation  Radiation Therapy  Combination Chemotherapy  and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma,infections and infestations - other specify
10029104,0.51,NCT00346164-4,Arm D: Intermediate & High Risk; Neoadjuvant Chemoradiotherapy,NCT00346164,Observation  Radiation Therapy  Combination Chemotherapy  and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma,neoplasms benign malignant and unspecified (incl cysts and polyps) - other specify
10049737,5.88,NCT00346164-2,Arm B: Low Risk; Adjuvant Radiotherapy,NCT00346164,Observation  Radiation Therapy  Combination Chemotherapy  and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma,treatment related secondary malignancy
D064420,1.25,NCT00352027-1,Stanford V Chemotherapy,NCT00352027,Chemotherapy With Low-Dose Radiation for Pediatric Hodgkin Lymphoma,adverse drug events
D016769,1.25,NCT00352027-1,Stanford V Chemotherapy,NCT00352027,Chemotherapy With Low-Dose Radiation for Pediatric Hodgkin Lymphoma,embolism and thrombosis
D064420,3.7,NCT00354744-1,High_Risk_Rhabdomyosarcoma,NCT00354744,High-Dose Combination Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Metastatic Rhabdomyosarcoma or Ectomesenchymoma,adverse drug events
10061640,0.93,NCT00354744-1,High_Risk_Rhabdomyosarcoma,NCT00354744,High-Dose Combination Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Metastatic Rhabdomyosarcoma or Ectomesenchymoma,anorectal infection
10021881,0.93,NCT00354744-1,High_Risk_Rhabdomyosarcoma,NCT00354744,High-Dose Combination Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Metastatic Rhabdomyosarcoma or Ectomesenchymoma,infections and infestations - other specify
D018805,0.93,NCT00354744-1,High_Risk_Rhabdomyosarcoma,NCT00354744,High-Dose Combination Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Metastatic Rhabdomyosarcoma or Ectomesenchymoma,sepsis
10037767,0.93,NCT00354744-1,High_Risk_Rhabdomyosarcoma,NCT00354744,High-Dose Combination Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Metastatic Rhabdomyosarcoma or Ectomesenchymoma,radiation recall reaction (dermatologic)
D064420,29.49,NCT00365365-1,AC->T + Bevacizumab,NCT00365365,Safety & Efficacy of Three Docetaxel-Based Chemotherapy Regimens Plus Bevacizumab With or Without Trastuzumab for Adjuvant Treatment of Patients With Breast Cancer,adverse drug events
D064420,32.0,NCT00365365-2,TAC + Bevacizumab,NCT00365365,Safety & Efficacy of Three Docetaxel-Based Chemotherapy Regimens Plus Bevacizumab With or Without Trastuzumab for Adjuvant Treatment of Patients With Breast Cancer,adverse drug events
D064420,20.34,NCT00365365-3,TCH + Bevacizumab,NCT00365365,Safety & Efficacy of Three Docetaxel-Based Chemotherapy Regimens Plus Bevacizumab With or Without Trastuzumab for Adjuvant Treatment of Patients With Breast Cancer,adverse drug events
D064147,5.13,NCT00365365-1,AC->T + Bevacizumab,NCT00365365,Safety & Efficacy of Three Docetaxel-Based Chemotherapy Regimens Plus Bevacizumab With or Without Trastuzumab for Adjuvant Treatment of Patients With Breast Cancer,febrile neutropenia
D064147,10.67,NCT00365365-2,TAC + Bevacizumab,NCT00365365,Safety & Efficacy of Three Docetaxel-Based Chemotherapy Regimens Plus Bevacizumab With or Without Trastuzumab for Adjuvant Treatment of Patients With Breast Cancer,febrile neutropenia
D009503,1.28,NCT00365365-1,AC->T + Bevacizumab,NCT00365365,Safety & Efficacy of Three Docetaxel-Based Chemotherapy Regimens Plus Bevacizumab With or Without Trastuzumab for Adjuvant Treatment of Patients With Breast Cancer,neutropenia
D009503,4.0,NCT00365365-2,TAC + Bevacizumab,NCT00365365,Safety & Efficacy of Three Docetaxel-Based Chemotherapy Regimens Plus Bevacizumab With or Without Trastuzumab for Adjuvant Treatment of Patients With Breast Cancer,neutropenia
D013921,2.67,NCT00365365-2,TAC + Bevacizumab,NCT00365365,Safety & Efficacy of Three Docetaxel-Based Chemotherapy Regimens Plus Bevacizumab With or Without Trastuzumab for Adjuvant Treatment of Patients With Breast Cancer,thrombocytopenia
D054058,1.28,NCT00365365-1,AC->T + Bevacizumab,NCT00365365,Safety & Efficacy of Three Docetaxel-Based Chemotherapy Regimens Plus Bevacizumab With or Without Trastuzumab for Adjuvant Treatment of Patients With Breast Cancer,acute coronary syndrome
D006333,1.28,NCT00365365-1,AC->T + Bevacizumab,NCT00365365,Safety & Efficacy of Three Docetaxel-Based Chemotherapy Regimens Plus Bevacizumab With or Without Trastuzumab for Adjuvant Treatment of Patients With Breast Cancer,cardiac failure
D006333,2.67,NCT00365365-2,TAC + Bevacizumab,NCT00365365,Safety & Efficacy of Three Docetaxel-Based Chemotherapy Regimens Plus Bevacizumab With or Without Trastuzumab for Adjuvant Treatment of Patients With Breast Cancer,cardiac failure
D009203,1.28,NCT00365365-1,AC->T + Bevacizumab,NCT00365365,Safety & Efficacy of Three Docetaxel-Based Chemotherapy Regimens Plus Bevacizumab With or Without Trastuzumab for Adjuvant Treatment of Patients With Breast Cancer,myocardial infarction
D009202,1.33,NCT00365365-2,TAC + Bevacizumab,NCT00365365,Safety & Efficacy of Three Docetaxel-Based Chemotherapy Regimens Plus Bevacizumab With or Without Trastuzumab for Adjuvant Treatment of Patients With Breast Cancer,cardiomyopathy
D015746,1.28,NCT00365365-1,AC->T + Bevacizumab,NCT00365365,Safety & Efficacy of Three Docetaxel-Based Chemotherapy Regimens Plus Bevacizumab With or Without Trastuzumab for Adjuvant Treatment of Patients With Breast Cancer,abdominal pain
UNKNOWN-check-for-typo,1.28,NCT00365365-1,AC->T + Bevacizumab,NCT00365365,Safety & Efficacy of Three Docetaxel-Based Chemotherapy Regimens Plus Bevacizumab With or Without Trastuzumab for Adjuvant Treatment of Patients With Breast Cancer,D00
UNKNOWN-check-for-typo,1.33,NCT00365365-2,TAC + Bevacizumab,NCT00365365,Safety & Efficacy of Three Docetaxel-Based Chemotherapy Regimens Plus Bevacizumab With or Without Trastuzumab for Adjuvant Treatment of Patients With Breast Cancer,D00
UNKNOWN-check-for-typo,1.69,NCT00365365-3,TCH + Bevacizumab,NCT00365365,Safety & Efficacy of Three Docetaxel-Based Chemotherapy Regimens Plus Bevacizumab With or Without Trastuzumab for Adjuvant Treatment of Patients With Breast Cancer,D00
D041742,1.28,NCT00365365-1,AC->T + Bevacizumab,NCT00365365,Safety & Efficacy of Three Docetaxel-Based Chemotherapy Regimens Plus Bevacizumab With or Without Trastuzumab for Adjuvant Treatment of Patients With Breast Cancer,upper gastrointestinal tract
UNKNOWN-check-for-typo,1.33,NCT00365365-2,TAC + Bevacizumab,NCT00365365,Safety & Efficacy of Three Docetaxel-Based Chemotherapy Regimens Plus Bevacizumab With or Without Trastuzumab for Adjuvant Treatment of Patients With Breast Cancer,D00
D003092,2.67,NCT00365365-2,TAC + Bevacizumab,NCT00365365,Safety & Efficacy of Three Docetaxel-Based Chemotherapy Regimens Plus Bevacizumab With or Without Trastuzumab for Adjuvant Treatment of Patients With Breast Cancer,colitis
D000069196,1.69,NCT00365365-3,TCH + Bevacizumab,NCT00365365,Safety & Efficacy of Three Docetaxel-Based Chemotherapy Regimens Plus Bevacizumab With or Without Trastuzumab for Adjuvant Treatment of Patients With Breast Cancer,gastrointestinal microbiome
D013392,1.33,NCT00365365-2,TAC + Bevacizumab,NCT00365365,Safety & Efficacy of Three Docetaxel-Based Chemotherapy Regimens Plus Bevacizumab With or Without Trastuzumab for Adjuvant Treatment of Patients With Breast Cancer,ulcerban
D043183,1.69,NCT00365365-3,TCH + Bevacizumab,NCT00365365,Safety & Efficacy of Three Docetaxel-Based Chemotherapy Regimens Plus Bevacizumab With or Without Trastuzumab for Adjuvant Treatment of Patients With Breast Cancer,irritable bowel syndrome
10015461,1.33,NCT00365365-2,TAC + Bevacizumab,NCT00365365,Safety & Efficacy of Three Docetaxel-Based Chemotherapy Regimens Plus Bevacizumab With or Without Trastuzumab for Adjuvant Treatment of Patients With Breast Cancer,esophagitis
D003093,1.69,NCT00365365-3,TCH + Bevacizumab,NCT00365365,Safety & Efficacy of Three Docetaxel-Based Chemotherapy Regimens Plus Bevacizumab With or Without Trastuzumab for Adjuvant Treatment of Patients With Breast Cancer,colitis ulcerative
D013280,1.33,NCT00365365-2,TAC + Bevacizumab,NCT00365365,Safety & Efficacy of Three Docetaxel-Based Chemotherapy Regimens Plus Bevacizumab With or Without Trastuzumab for Adjuvant Treatment of Patients With Breast Cancer,stomatitis
D007249,1.28,NCT00365365-1,AC->T + Bevacizumab,NCT00365365,Safety & Efficacy of Three Docetaxel-Based Chemotherapy Regimens Plus Bevacizumab With or Without Trastuzumab for Adjuvant Treatment of Patients With Breast Cancer,inflammation
D002637,1.69,NCT00365365-3,TCH + Bevacizumab,NCT00365365,Safety & Efficacy of Three Docetaxel-Based Chemotherapy Regimens Plus Bevacizumab With or Without Trastuzumab for Adjuvant Treatment of Patients With Breast Cancer,chest pain
10062501,1.33,NCT00365365-2,TAC + Bevacizumab,NCT00365365,Safety & Efficacy of Three Docetaxel-Based Chemotherapy Regimens Plus Bevacizumab With or Without Trastuzumab for Adjuvant Treatment of Patients With Breast Cancer,non-cardiac chest pain
10062501,1.69,NCT00365365-3,TCH + Bevacizumab,NCT00365365,Safety & Efficacy of Three Docetaxel-Based Chemotherapy Regimens Plus Bevacizumab With or Without Trastuzumab for Adjuvant Treatment of Patients With Breast Cancer,non-cardiac chest pain
D005334,1.33,NCT00365365-2,TAC + Bevacizumab,NCT00365365,Safety & Efficacy of Three Docetaxel-Based Chemotherapy Regimens Plus Bevacizumab With or Without Trastuzumab for Adjuvant Treatment of Patients With Breast Cancer,pyrexia
D002769,1.33,NCT00365365-2,TAC + Bevacizumab,NCT00365365,Safety & Efficacy of Three Docetaxel-Based Chemotherapy Regimens Plus Bevacizumab With or Without Trastuzumab for Adjuvant Treatment of Patients With Breast Cancer,cholelithiasis
D001064,1.28,NCT00365365-1,AC->T + Bevacizumab,NCT00365365,Safety & Efficacy of Three Docetaxel-Based Chemotherapy Regimens Plus Bevacizumab With or Without Trastuzumab for Adjuvant Treatment of Patients With Breast Cancer,appendicitis
D001064,1.33,NCT00365365-2,TAC + Bevacizumab,NCT00365365,Safety & Efficacy of Three Docetaxel-Based Chemotherapy Regimens Plus Bevacizumab With or Without Trastuzumab for Adjuvant Treatment of Patients With Breast Cancer,appendicitis
D001991,1.28,NCT00365365-1,AC->T + Bevacizumab,NCT00365365,Safety & Efficacy of Three Docetaxel-Based Chemotherapy Regimens Plus Bevacizumab With or Without Trastuzumab for Adjuvant Treatment of Patients With Breast Cancer,bronchitis
D004238,1.28,NCT00365365-1,AC->T + Bevacizumab,NCT00365365,Safety & Efficacy of Three Docetaxel-Based Chemotherapy Regimens Plus Bevacizumab With or Without Trastuzumab for Adjuvant Treatment of Patients With Breast Cancer,diverticulitis
D004238,1.33,NCT00365365-2,TAC + Bevacizumab,NCT00365365,Safety & Efficacy of Three Docetaxel-Based Chemotherapy Regimens Plus Bevacizumab With or Without Trastuzumab for Adjuvant Treatment of Patients With Breast Cancer,diverticulitis
D006232,1.28,NCT00365365-1,AC->T + Bevacizumab,NCT00365365,Safety & Efficacy of Three Docetaxel-Based Chemotherapy Regimens Plus Bevacizumab With or Without Trastuzumab for Adjuvant Treatment of Patients With Breast Cancer,hand foot and mouth disease
D007251,1.28,NCT00365365-1,AC->T + Bevacizumab,NCT00365365,Safety & Efficacy of Three Docetaxel-Based Chemotherapy Regimens Plus Bevacizumab With or Without Trastuzumab for Adjuvant Treatment of Patients With Breast Cancer,influenza
D000069544,1.28,NCT00365365-1,AC->T + Bevacizumab,NCT00365365,Safety & Efficacy of Three Docetaxel-Based Chemotherapy Regimens Plus Bevacizumab With or Without Trastuzumab for Adjuvant Treatment of Patients With Breast Cancer,encephalitis infection
D000069544,1.33,NCT00365365-2,TAC + Bevacizumab,NCT00365365,Safety & Efficacy of Three Docetaxel-Based Chemotherapy Regimens Plus Bevacizumab With or Without Trastuzumab for Adjuvant Treatment of Patients With Breast Cancer,encephalitis infection
10064687,1.69,NCT00365365-3,TCH + Bevacizumab,NCT00365365,Safety & Efficacy of Three Docetaxel-Based Chemotherapy Regimens Plus Bevacizumab With or Without Trastuzumab for Adjuvant Treatment of Patients With Breast Cancer,device related infection
D006562,1.33,NCT00365365-2,TAC + Bevacizumab,NCT00365365,Safety & Efficacy of Three Docetaxel-Based Chemotherapy Regimens Plus Bevacizumab With or Without Trastuzumab for Adjuvant Treatment of Patients With Breast Cancer,herpes zoster
D000038,1.69,NCT00365365-3,TCH + Bevacizumab,NCT00365365,Safety & Efficacy of Three Docetaxel-Based Chemotherapy Regimens Plus Bevacizumab With or Without Trastuzumab for Adjuvant Treatment of Patients With Breast Cancer,abscess
10061229,1.33,NCT00365365-2,TAC + Bevacizumab,NCT00365365,Safety & Efficacy of Three Docetaxel-Based Chemotherapy Regimens Plus Bevacizumab With or Without Trastuzumab for Adjuvant Treatment of Patients With Breast Cancer,lung infection
D000985,1.33,NCT00365365-2,TAC + Bevacizumab,NCT00365365,Safety & Efficacy of Three Docetaxel-Based Chemotherapy Regimens Plus Bevacizumab With or Without Trastuzumab for Adjuvant Treatment of Patients With Breast Cancer,antisepsis
D000985,1.33,NCT00365365-2,TAC + Bevacizumab,NCT00365365,Safety & Efficacy of Three Docetaxel-Based Chemotherapy Regimens Plus Bevacizumab With or Without Trastuzumab for Adjuvant Treatment of Patients With Breast Cancer,antisepsis
D018805,1.33,NCT00365365-2,TAC + Bevacizumab,NCT00365365,Safety & Efficacy of Three Docetaxel-Based Chemotherapy Regimens Plus Bevacizumab With or Without Trastuzumab for Adjuvant Treatment of Patients With Breast Cancer,sepsis
D012772,1.33,NCT00365365-2,TAC + Bevacizumab,NCT00365365,Safety & Efficacy of Three Docetaxel-Based Chemotherapy Regimens Plus Bevacizumab With or Without Trastuzumab for Adjuvant Treatment of Patients With Breast Cancer,septic shock
D014552,1.69,NCT00365365-3,TCH + Bevacizumab,NCT00365365,Safety & Efficacy of Three Docetaxel-Based Chemotherapy Regimens Plus Bevacizumab With or Without Trastuzumab for Adjuvant Treatment of Patients With Breast Cancer,urinary tract infection
10050528,1.69,NCT00365365-3,TCH + Bevacizumab,NCT00365365,Safety & Efficacy of Three Docetaxel-Based Chemotherapy Regimens Plus Bevacizumab With or Without Trastuzumab for Adjuvant Treatment of Patients With Breast Cancer,ejection fraction decreased
D003681,1.28,NCT00365365-1,AC->T + Bevacizumab,NCT00365365,Safety & Efficacy of Three Docetaxel-Based Chemotherapy Regimens Plus Bevacizumab With or Without Trastuzumab for Adjuvant Treatment of Patients With Breast Cancer,dehydration
D003681,5.33,NCT00365365-2,TAC + Bevacizumab,NCT00365365,Safety & Efficacy of Three Docetaxel-Based Chemotherapy Regimens Plus Bevacizumab With or Without Trastuzumab for Adjuvant Treatment of Patients With Breast Cancer,dehydration
UNKNOWN-check-for-typo,1.33,NCT00365365-2,TAC + Bevacizumab,NCT00365365,Safety & Efficacy of Three Docetaxel-Based Chemotherapy Regimens Plus Bevacizumab With or Without Trastuzumab for Adjuvant Treatment of Patients With Breast Cancer,D00
UNKNOWN-check-for-typo,1.69,NCT00365365-3,TCH + Bevacizumab,NCT00365365,Safety & Efficacy of Three Docetaxel-Based Chemotherapy Regimens Plus Bevacizumab With or Without Trastuzumab for Adjuvant Treatment of Patients With Breast Cancer,D00
UNKNOWN-check-for-typo,1.33,NCT00365365-2,TAC + Bevacizumab,NCT00365365,Safety & Efficacy of Three Docetaxel-Based Chemotherapy Regimens Plus Bevacizumab With or Without Trastuzumab for Adjuvant Treatment of Patients With Breast Cancer,D00
D019534,1.28,NCT00365365-1,AC->T + Bevacizumab,NCT00365365,Safety & Efficacy of Three Docetaxel-Based Chemotherapy Regimens Plus Bevacizumab With or Without Trastuzumab for Adjuvant Treatment of Patients With Breast Cancer,rotator cuff impingement syndrome
D059352,1.69,NCT00365365-3,TCH + Bevacizumab,NCT00365365,Safety & Efficacy of Three Docetaxel-Based Chemotherapy Regimens Plus Bevacizumab With or Without Trastuzumab for Adjuvant Treatment of Patients With Breast Cancer,musculoskeletal pain
D008578,1.28,NCT00365365-1,AC->T + Bevacizumab,NCT00365365,Safety & Efficacy of Three Docetaxel-Based Chemotherapy Regimens Plus Bevacizumab With or Without Trastuzumab for Adjuvant Treatment of Patients With Breast Cancer,meninges
D006261,1.28,NCT00365365-1,AC->T + Bevacizumab,NCT00365365,Safety & Efficacy of Three Docetaxel-Based Chemotherapy Regimens Plus Bevacizumab With or Without Trastuzumab for Adjuvant Treatment of Patients With Breast Cancer,headache
D059409,1.28,NCT00365365-1,AC->T + Bevacizumab,NCT00365365,Safety & Efficacy of Three Docetaxel-Based Chemotherapy Regimens Plus Bevacizumab With or Without Trastuzumab for Adjuvant Treatment of Patients With Breast Cancer,lacunar infarction
D010523,1.28,NCT00365365-1,AC->T + Bevacizumab,NCT00365365,Safety & Efficacy of Three Docetaxel-Based Chemotherapy Regimens Plus Bevacizumab With or Without Trastuzumab for Adjuvant Treatment of Patients With Breast Cancer,peripheral neuropathy
D007427,1.33,NCT00365365-2,TAC + Bevacizumab,NCT00365365,Safety & Efficacy of Three Docetaxel-Based Chemotherapy Regimens Plus Bevacizumab With or Without Trastuzumab for Adjuvant Treatment of Patients With Breast Cancer,subarachnoid pressure
D058186,1.33,NCT00365365-2,TAC + Bevacizumab,NCT00365365,Safety & Efficacy of Three Docetaxel-Based Chemotherapy Regimens Plus Bevacizumab With or Without Trastuzumab for Adjuvant Treatment of Patients With Breast Cancer,acute renal failure
D005836,1.33,NCT00365365-2,TAC + Bevacizumab,NCT00365365,Safety & Efficacy of Three Docetaxel-Based Chemotherapy Regimens Plus Bevacizumab With or Without Trastuzumab for Adjuvant Treatment of Patients With Breast Cancer,genitalia female
D011655,1.28,NCT00365365-1,AC->T + Bevacizumab,NCT00365365,Safety & Efficacy of Three Docetaxel-Based Chemotherapy Regimens Plus Bevacizumab With or Without Trastuzumab for Adjuvant Treatment of Patients With Breast Cancer,pulmonary embolism
D011655,1.69,NCT00365365-3,TCH + Bevacizumab,NCT00365365,Safety & Efficacy of Three Docetaxel-Based Chemotherapy Regimens Plus Bevacizumab With or Without Trastuzumab for Adjuvant Treatment of Patients With Breast Cancer,pulmonary embolism
D012128,1.33,NCT00365365-2,TAC + Bevacizumab,NCT00365365,Safety & Efficacy of Three Docetaxel-Based Chemotherapy Regimens Plus Bevacizumab With or Without Trastuzumab for Adjuvant Treatment of Patients With Breast Cancer,acute respiratory distress syndrome
D005076,1.28,NCT00365365-1,AC->T + Bevacizumab,NCT00365365,Safety & Efficacy of Three Docetaxel-Based Chemotherapy Regimens Plus Bevacizumab With or Without Trastuzumab for Adjuvant Treatment of Patients With Breast Cancer,rash
10054524,1.28,NCT00365365-1,AC->T + Bevacizumab,NCT00365365,Safety & Efficacy of Three Docetaxel-Based Chemotherapy Regimens Plus Bevacizumab With or Without Trastuzumab for Adjuvant Treatment of Patients With Breast Cancer,palmar-plantar erythrodysesthesia syndrome
D020246,2.56,NCT00365365-1,AC->T + Bevacizumab,NCT00365365,Safety & Efficacy of Three Docetaxel-Based Chemotherapy Regimens Plus Bevacizumab With or Without Trastuzumab for Adjuvant Treatment of Patients With Breast Cancer,deep vein thrombosis
D020246,1.33,NCT00365365-2,TAC + Bevacizumab,NCT00365365,Safety & Efficacy of Three Docetaxel-Based Chemotherapy Regimens Plus Bevacizumab With or Without Trastuzumab for Adjuvant Treatment of Patients With Breast Cancer,deep vein thrombosis
D006973,1.28,NCT00365365-1,AC->T + Bevacizumab,NCT00365365,Safety & Efficacy of Three Docetaxel-Based Chemotherapy Regimens Plus Bevacizumab With or Without Trastuzumab for Adjuvant Treatment of Patients With Breast Cancer,hypertension
D006973,1.69,NCT00365365-3,TCH + Bevacizumab,NCT00365365,Safety & Efficacy of Three Docetaxel-Based Chemotherapy Regimens Plus Bevacizumab With or Without Trastuzumab for Adjuvant Treatment of Patients With Breast Cancer,hypertension
D000959,1.69,NCT00365365-3,TCH + Bevacizumab,NCT00365365,Safety & Efficacy of Three Docetaxel-Based Chemotherapy Regimens Plus Bevacizumab With or Without Trastuzumab for Adjuvant Treatment of Patients With Breast Cancer,antihypertensives
D007022,1.33,NCT00365365-2,TAC + Bevacizumab,NCT00365365,Safety & Efficacy of Three Docetaxel-Based Chemotherapy Regimens Plus Bevacizumab With or Without Trastuzumab for Adjuvant Treatment of Patients With Breast Cancer,hypotension
D013479,1.33,NCT00365365-2,TAC + Bevacizumab,NCT00365365,Safety & Efficacy of Three Docetaxel-Based Chemotherapy Regimens Plus Bevacizumab With or Without Trastuzumab for Adjuvant Treatment of Patients With Breast Cancer,superior vena cava syndrome
D064420,31.11,NCT00365417-1,Chemo Plus Bevacizumab,NCT00365417,Therapy With Bevacizumab (BEV)  Doxorubicin  and Cyclophosphamide Followed by BEV  Docetaxel  and Capecitabine Before Surgery Followed by BEV Alone After Surgery for Women With Locally Advanced Breast Cancer,adverse drug events
D006454,2.22,NCT00365417-1,Chemo Plus Bevacizumab,NCT00365417,Therapy With Bevacizumab (BEV)  Doxorubicin  and Cyclophosphamide Followed by BEV  Docetaxel  and Capecitabine Before Surgery Followed by BEV Alone After Surgery for Women With Locally Advanced Breast Cancer,hemoglobin
D003967,2.22,NCT00365417-1,Chemo Plus Bevacizumab,NCT00365417,Therapy With Bevacizumab (BEV)  Doxorubicin  and Cyclophosphamide Followed by BEV  Docetaxel  and Capecitabine Before Surgery Followed by BEV Alone After Surgery for Women With Locally Advanced Breast Cancer,diarrhea
D004941,2.22,NCT00365417-1,Chemo Plus Bevacizumab,NCT00365417,Therapy With Bevacizumab (BEV)  Doxorubicin  and Cyclophosphamide Followed by BEV  Docetaxel  and Capecitabine Before Surgery Followed by BEV Alone After Surgery for Women With Locally Advanced Breast Cancer,esophagitis
D003945,2.22,NCT00365417-1,Chemo Plus Bevacizumab,NCT00365417,Therapy With Bevacizumab (BEV)  Doxorubicin  and Cyclophosphamide Followed by BEV  Docetaxel  and Capecitabine Before Surgery Followed by BEV Alone After Surgery for Women With Locally Advanced Breast Cancer,examination oral
D004931,2.22,NCT00365417-1,Chemo Plus Bevacizumab,NCT00365417,Therapy With Bevacizumab (BEV)  Doxorubicin  and Cyclophosphamide Followed by BEV  Docetaxel  and Capecitabine Before Surgery Followed by BEV Alone After Surgery for Women With Locally Advanced Breast Cancer,megaesophagus
D009055,4.44,NCT00365417-1,Chemo Plus Bevacizumab,NCT00365417,Therapy With Bevacizumab (BEV)  Doxorubicin  and Cyclophosphamide Followed by BEV  Docetaxel  and Capecitabine Before Surgery Followed by BEV Alone After Surgery for Women With Locally Advanced Breast Cancer,oral cavity
D007319,2.22,NCT00365417-1,Chemo Plus Bevacizumab,NCT00365417,Therapy With Bevacizumab (BEV)  Doxorubicin  and Cyclophosphamide Followed by BEV  Docetaxel  and Capecitabine Before Surgery Followed by BEV Alone After Surgery for Women With Locally Advanced Breast Cancer,insomnia
D015746,4.44,NCT00365417-1,Chemo Plus Bevacizumab,NCT00365417,Therapy With Bevacizumab (BEV)  Doxorubicin  and Cyclophosphamide Followed by BEV  Docetaxel  and Capecitabine Before Surgery Followed by BEV Alone After Surgery for Women With Locally Advanced Breast Cancer,abdominal pain
D001416,2.22,NCT00365417-1,Chemo Plus Bevacizumab,NCT00365417,Therapy With Bevacizumab (BEV)  Doxorubicin  and Cyclophosphamide Followed by BEV  Docetaxel  and Capecitabine Before Surgery Followed by BEV Alone After Surgery for Women With Locally Advanced Breast Cancer,back pain
D059352,2.22,NCT00365417-1,Chemo Plus Bevacizumab,NCT00365417,Therapy With Bevacizumab (BEV)  Doxorubicin  and Cyclophosphamide Followed by BEV  Docetaxel  and Capecitabine Before Surgery Followed by BEV Alone After Surgery for Women With Locally Advanced Breast Cancer,musculoskeletal pain
D013575,2.22,NCT00365417-1,Chemo Plus Bevacizumab,NCT00365417,Therapy With Bevacizumab (BEV)  Doxorubicin  and Cyclophosphamide Followed by BEV  Docetaxel  and Capecitabine Before Surgery Followed by BEV Alone After Surgery for Women With Locally Advanced Breast Cancer,syncope
D000069544,2.22,NCT00365417-1,Chemo Plus Bevacizumab,NCT00365417,Therapy With Bevacizumab (BEV)  Doxorubicin  and Cyclophosphamide Followed by BEV  Docetaxel  and Capecitabine Before Surgery Followed by BEV Alone After Surgery for Women With Locally Advanced Breast Cancer,encephalitis infection
D055499,2.22,NCT00365417-1,Chemo Plus Bevacizumab,NCT00365417,Therapy With Bevacizumab (BEV)  Doxorubicin  and Cyclophosphamide Followed by BEV  Docetaxel  and Capecitabine Before Surgery Followed by BEV Alone After Surgery for Women With Locally Advanced Breast Cancer,catheter-related infections
10061229,4.44,NCT00365417-1,Chemo Plus Bevacizumab,NCT00365417,Therapy With Bevacizumab (BEV)  Doxorubicin  and Cyclophosphamide Followed by BEV  Docetaxel  and Capecitabine Before Surgery Followed by BEV Alone After Surgery for Women With Locally Advanced Breast Cancer,lung infection
10040872,6.67,NCT00365417-1,Chemo Plus Bevacizumab,NCT00365417,Therapy With Bevacizumab (BEV)  Doxorubicin  and Cyclophosphamide Followed by BEV  Docetaxel  and Capecitabine Before Surgery Followed by BEV Alone After Surgery for Women With Locally Advanced Breast Cancer,skin infection
D000069544,2.22,NCT00365417-1,Chemo Plus Bevacizumab,NCT00365417,Therapy With Bevacizumab (BEV)  Doxorubicin  and Cyclophosphamide Followed by BEV  Docetaxel  and Capecitabine Before Surgery Followed by BEV Alone After Surgery for Women With Locally Advanced Breast Cancer,encephalitis infection
D014552,2.22,NCT00365417-1,Chemo Plus Bevacizumab,NCT00365417,Therapy With Bevacizumab (BEV)  Doxorubicin  and Cyclophosphamide Followed by BEV  Docetaxel  and Capecitabine Before Surgery Followed by BEV Alone After Surgery for Women With Locally Advanced Breast Cancer,urinary tract infections
D012852,2.22,NCT00365417-1,Chemo Plus Bevacizumab,NCT00365417,Therapy With Bevacizumab (BEV)  Doxorubicin  and Cyclophosphamide Followed by BEV  Docetaxel  and Capecitabine Before Surgery Followed by BEV Alone After Surgery for Women With Locally Advanced Breast Cancer,sinus infections
10040872,4.44,NCT00365417-1,Chemo Plus Bevacizumab,NCT00365417,Therapy With Bevacizumab (BEV)  Doxorubicin  and Cyclophosphamide Followed by BEV  Docetaxel  and Capecitabine Before Surgery Followed by BEV Alone After Surgery for Women With Locally Advanced Breast Cancer,skin infection
D012141,2.22,NCT00365417-1,Chemo Plus Bevacizumab,NCT00365417,Therapy With Bevacizumab (BEV)  Doxorubicin  and Cyclophosphamide Followed by BEV  Docetaxel  and Capecitabine Before Surgery Followed by BEV Alone After Surgery for Women With Locally Advanced Breast Cancer,infections upper respiratory
D014552,2.22,NCT00365417-1,Chemo Plus Bevacizumab,NCT00365417,Therapy With Bevacizumab (BEV)  Doxorubicin  and Cyclophosphamide Followed by BEV  Docetaxel  and Capecitabine Before Surgery Followed by BEV Alone After Surgery for Women With Locally Advanced Breast Cancer,urinary tract infections
D014946,2.22,NCT00365417-1,Chemo Plus Bevacizumab,NCT00365417,Therapy With Bevacizumab (BEV)  Doxorubicin  and Cyclophosphamide Followed by BEV  Docetaxel  and Capecitabine Before Surgery Followed by BEV Alone After Surgery for Women With Locally Advanced Breast Cancer,wound infection
D007008,2.22,NCT00365417-1,Chemo Plus Bevacizumab,NCT00365417,Therapy With Bevacizumab (BEV)  Doxorubicin  and Cyclophosphamide Followed by BEV  Docetaxel  and Capecitabine Before Surgery Followed by BEV Alone After Surgery for Women With Locally Advanced Breast Cancer,hypokalemia
D004417,2.22,NCT00365417-1,Chemo Plus Bevacizumab,NCT00365417,Therapy With Bevacizumab (BEV)  Doxorubicin  and Cyclophosphamide Followed by BEV  Docetaxel  and Capecitabine Before Surgery Followed by BEV Alone After Surgery for Women With Locally Advanced Breast Cancer,dyspnea
D006232,2.22,NCT00365417-1,Chemo Plus Bevacizumab,NCT00365417,Therapy With Bevacizumab (BEV)  Doxorubicin  and Cyclophosphamide Followed by BEV  Docetaxel  and Capecitabine Before Surgery Followed by BEV Alone After Surgery for Women With Locally Advanced Breast Cancer,hand foot and mouth disease
D016769,4.44,NCT00365417-1,Chemo Plus Bevacizumab,NCT00365417,Therapy With Bevacizumab (BEV)  Doxorubicin  and Cyclophosphamide Followed by BEV  Docetaxel  and Capecitabine Before Surgery Followed by BEV Alone After Surgery for Women With Locally Advanced Breast Cancer,embolism and thrombosis
D064420,1.54,NCT00376961-1,Rituximab-CHOP-Bortezomib (R-CHOP-V) Induction,NCT00376961,S0601 Rituximab  Combination Chemotherapy  and Bortezomib Followed by Bortezomib Alone in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma,adverse drug events
D003645,1.54,NCT00376961-1,Rituximab-CHOP-Bortezomib (R-CHOP-V) Induction,NCT00376961,S0601 Rituximab  Combination Chemotherapy  and Bortezomib Followed by Bortezomib Alone in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma,sudden death
D064420,44.9,NCT00379574-1,Bortezomib + CHOP Every 2 Weeks,NCT00379574,Bortezomib Plus CHOP Every 2 Weeks for Advanced Stage DLBCL,adverse drug events
D000740,55.0,NCT00379574-1,Bortezomib + CHOP Every 2 Weeks,NCT00379574,Bortezomib Plus CHOP Every 2 Weeks for Advanced Stage DLBCL,anemia
D009503,35.0,NCT00379574-1,Bortezomib + CHOP Every 2 Weeks,NCT00379574,Bortezomib Plus CHOP Every 2 Weeks for Advanced Stage DLBCL,neutropenia
D009503,17.5,NCT00379574-1,Bortezomib + CHOP Every 2 Weeks,NCT00379574,Bortezomib Plus CHOP Every 2 Weeks for Advanced Stage DLBCL,neutropenia
D013921,32.5,NCT00379574-1,Bortezomib + CHOP Every 2 Weeks,NCT00379574,Bortezomib Plus CHOP Every 2 Weeks for Advanced Stage DLBCL,thrombocytopenia
D006943,10.0,NCT00379574-1,Bortezomib + CHOP Every 2 Weeks,NCT00379574,Bortezomib Plus CHOP Every 2 Weeks for Advanced Stage DLBCL,hyperglycemia
D015746,10.0,NCT00379574-1,Bortezomib + CHOP Every 2 Weeks,NCT00379574,Bortezomib Plus CHOP Every 2 Weeks for Advanced Stage DLBCL,abdominal pain
D003967,10.0,NCT00379574-1,Bortezomib + CHOP Every 2 Weeks,NCT00379574,Bortezomib Plus CHOP Every 2 Weeks for Advanced Stage DLBCL,diarrhea
D014839,10.0,NCT00379574-1,Bortezomib + CHOP Every 2 Weeks,NCT00379574,Bortezomib Plus CHOP Every 2 Weeks for Advanced Stage DLBCL,vomiting
D005221,5.0,NCT00379574-1,Bortezomib + CHOP Every 2 Weeks,NCT00379574,Bortezomib Plus CHOP Every 2 Weeks for Advanced Stage DLBCL,fatigue
D002607,27.5,NCT00379574-1,Bortezomib + CHOP Every 2 Weeks,NCT00379574,Bortezomib Plus CHOP Every 2 Weeks for Advanced Stage DLBCL,hereditary type i motor and sensory neuropathy
D002607,7.5,NCT00379574-1,Bortezomib + CHOP Every 2 Weeks,NCT00379574,Bortezomib Plus CHOP Every 2 Weeks for Advanced Stage DLBCL,hereditary type i motor and sensory neuropathy
D064420,19.7,NCT00381680-1,Regimen A: Standard Vincristine Dosing,NCT00381680,Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia,adverse drug events
D064420,16.18,NCT00381680-2,Arm B: Randomized High Dose Vincristine Regimen,NCT00381680,Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia,adverse drug events
D004211,0.49,NCT00381680-1,Regimen A: Standard Vincristine Dosing,NCT00381680,Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia,disseminated intravascular coagulation
D004211,1.47,NCT00381680-2,Arm B: Randomized High Dose Vincristine Regimen,NCT00381680,Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia,disseminated intravascular coagulation
D064147,1.97,NCT00381680-1,Regimen A: Standard Vincristine Dosing,NCT00381680,Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia,febrile neutropenia
D013616,0.99,NCT00381680-1,Regimen A: Standard Vincristine Dosing,NCT00381680,Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia,sinus tachycardia
10047281,0.49,NCT00381680-1,Regimen A: Standard Vincristine Dosing,NCT00381680,Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia,ventricular arrhythmia
D015746,0.49,NCT00381680-1,Regimen A: Standard Vincristine Dosing,NCT00381680,Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia,abdominal pain
10065722,0.49,NCT00381680-1,Regimen A: Standard Vincristine Dosing,NCT00381680,Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia,anal necrosis
D005401,0.49,NCT00381680-1,Regimen A: Standard Vincristine Dosing,NCT00381680,Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia,anal ulcer
10011914,7.39,NCT00381680-1,Regimen A: Standard Vincristine Dosing,NCT00381680,Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia,death nos
10011914,1.47,NCT00381680-2,Arm B: Randomized High Dose Vincristine Regimen,NCT00381680,Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia,death nos
10014222,0.49,NCT00381680-1,Regimen A: Standard Vincristine Dosing,NCT00381680,Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia,edema face
D005334,0.49,NCT00381680-1,Regimen A: Standard Vincristine Dosing,NCT00381680,Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia,fever
D009102,0.99,NCT00381680-1,Regimen A: Standard Vincristine Dosing,NCT00381680,Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia,multiple organ failure
D009102,1.47,NCT00381680-2,Arm B: Randomized High Dose Vincristine Regimen,NCT00381680,Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia,multiple organ failure
D017093,1.47,NCT00381680-2,Arm B: Randomized High Dose Vincristine Regimen,NCT00381680,Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia,hepatic failure
D001064,0.49,NCT00381680-1,Regimen A: Standard Vincristine Dosing,NCT00381680,Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia,appendicitis
10007810,0.99,NCT00381680-1,Regimen A: Standard Vincristine Dosing,NCT00381680,Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia,catheter related infection
10021881,3.45,NCT00381680-1,Regimen A: Standard Vincristine Dosing,NCT00381680,Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia,infections and infestations - other specify
10021881,8.82,NCT00381680-2,Arm B: Randomized High Dose Vincristine Regimen,NCT00381680,Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia,infections and infestations - other specify
10061229,0.99,NCT00381680-1,Regimen A: Standard Vincristine Dosing,NCT00381680,Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia,lung infection
10061229,1.47,NCT00381680-2,Arm B: Randomized High Dose Vincristine Regimen,NCT00381680,Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia,lung infection
D008581,0.49,NCT00381680-1,Regimen A: Standard Vincristine Dosing,NCT00381680,Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia,meningitis
10065764,0.49,NCT00381680-1,Regimen A: Standard Vincristine Dosing,NCT00381680,Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia,mucosal infection
D018805,3.94,NCT00381680-1,Regimen A: Standard Vincristine Dosing,NCT00381680,Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia,sepsis
D018805,1.47,NCT00381680-2,Arm B: Randomized High Dose Vincristine Regimen,NCT00381680,Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia,sepsis
10046300,0.49,NCT00381680-1,Regimen A: Standard Vincristine Dosing,NCT00381680,Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia,upper respiratory infection
10001551,0.49,NCT00381680-1,Regimen A: Standard Vincristine Dosing,NCT00381680,Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia,alanine aminotransferase increased
10003481,0.49,NCT00381680-1,Regimen A: Standard Vincristine Dosing,NCT00381680,Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia,aspartate aminotransferase increased
10005364,0.99,NCT00381680-1,Regimen A: Standard Vincristine Dosing,NCT00381680,Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia,blood bilirubin increased
10029366,1.48,NCT00381680-1,Regimen A: Standard Vincristine Dosing,NCT00381680,Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia,neutrophil count decreased
10029366,1.47,NCT00381680-2,Arm B: Randomized High Dose Vincristine Regimen,NCT00381680,Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia,neutrophil count decreased
10035528,1.48,NCT00381680-1,Regimen A: Standard Vincristine Dosing,NCT00381680,Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia,platelet count decreased
10035528,2.94,NCT00381680-2,Arm B: Randomized High Dose Vincristine Regimen,NCT00381680,Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia,platelet count decreased
10049182,0.49,NCT00381680-1,Regimen A: Standard Vincristine Dosing,NCT00381680,Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia,white blood cell decreased
D000138,0.49,NCT00381680-1,Regimen A: Standard Vincristine Dosing,NCT00381680,Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia,acidosis
D003681,0.49,NCT00381680-1,Regimen A: Standard Vincristine Dosing,NCT00381680,Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia,dehydration
D006955,0.49,NCT00381680-1,Regimen A: Standard Vincristine Dosing,NCT00381680,Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia,hypernatremia
D007010,0.49,NCT00381680-1,Regimen A: Standard Vincristine Dosing,NCT00381680,Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia,hyponatremia
10048293,0.99,NCT00381680-1,Regimen A: Standard Vincristine Dosing,NCT00381680,Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia,leukemia secondary to oncology chemotherapy
D009190,0.49,NCT00381680-1,Regimen A: Standard Vincristine Dosing,NCT00381680,Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia,myelodysplastic syndrome
D009190,1.47,NCT00381680-2,Arm B: Randomized High Dose Vincristine Regimen,NCT00381680,Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia,myelodysplastic syndrome
10049737,0.49,NCT00381680-1,Regimen A: Standard Vincristine Dosing,NCT00381680,Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia,treatment related secondary malignancy
D020300,2.94,NCT00381680-2,Arm B: Randomized High Dose Vincristine Regimen,NCT00381680,Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia,intracranial hemorrhage
D009187,0.49,NCT00381680-1,Regimen A: Standard Vincristine Dosing,NCT00381680,Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia,myelitis
D012640,1.47,NCT00381680-2,Arm B: Randomized High Dose Vincristine Regimen,NCT00381680,Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia,seizure
D020521,0.49,NCT00381680-1,Regimen A: Standard Vincristine Dosing,NCT00381680,Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia,stroke
D012128,0.49,NCT00381680-1,Regimen A: Standard Vincristine Dosing,NCT00381680,Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia,adult respiratory distress syndrome
10065746,0.99,NCT00381680-1,Regimen A: Standard Vincristine Dosing,NCT00381680,Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia,bronchopulmonary hemorrhage
D000860,0.49,NCT00381680-1,Regimen A: Standard Vincristine Dosing,NCT00381680,Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia,hypoxia
D010996,0.49,NCT00381680-1,Regimen A: Standard Vincristine Dosing,NCT00381680,Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia,pleural effusion
D011014,0.49,NCT00381680-1,Regimen A: Standard Vincristine Dosing,NCT00381680,Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia,pneumonitis
D011030,0.49,NCT00381680-1,Regimen A: Standard Vincristine Dosing,NCT00381680,Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia,pneumothorax
D012131,0.49,NCT00381680-1,Regimen A: Standard Vincristine Dosing,NCT00381680,Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia,respiratory failure
10040785,0.49,NCT00381680-1,Regimen A: Standard Vincristine Dosing,NCT00381680,Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia,skin and subcutaneous tissue disorders - other specify
D007022,1.97,NCT00381680-1,Regimen A: Standard Vincristine Dosing,NCT00381680,Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia,hypotension
D007022,1.47,NCT00381680-2,Arm B: Randomized High Dose Vincristine Regimen,NCT00381680,Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia,hypotension
10043565,0.99,NCT00381680-1,Regimen A: Standard Vincristine Dosing,NCT00381680,Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia,thromboembolic event
D009026,20.0,NCT00392990-1,High Risk - Treated With Alternating R-CODOX-M/R-IVAC Cycles,NCT00392990,Doxorubicin Hydrochloride Liposome and Rituximab With Combination Chemotherapy in Treating Patients With Newly Diagnosed Burkitt's Lymphoma or Burkitt-Like Lymphoma,mortality
D064420,100.0,NCT00392990-1,High Risk - Treated With Alternating R-CODOX-M/R-IVAC Cycles,NCT00392990,Doxorubicin Hydrochloride Liposome and Rituximab With Combination Chemotherapy in Treating Patients With Newly Diagnosed Burkitt's Lymphoma or Burkitt-Like Lymphoma,adverse drug events
D064420,40.0,NCT00392990-2,Low Risk - Treatment With 3 Cycles of R-CODOX-M,NCT00392990,Doxorubicin Hydrochloride Liposome and Rituximab With Combination Chemotherapy in Treating Patients With Newly Diagnosed Burkitt's Lymphoma or Burkitt-Like Lymphoma,adverse drug events
D009190,5.0,NCT00392990-1,High Risk - Treated With Alternating R-CODOX-M/R-IVAC Cycles,NCT00392990,Doxorubicin Hydrochloride Liposome and Rituximab With Combination Chemotherapy in Treating Patients With Newly Diagnosed Burkitt's Lymphoma or Burkitt-Like Lymphoma,myelodysplastic syndrome
D009618,5.0,NCT00392990-1,High Risk - Treated With Alternating R-CODOX-M/R-IVAC Cycles,NCT00392990,Doxorubicin Hydrochloride Liposome and Rituximab With Combination Chemotherapy in Treating Patients With Newly Diagnosed Burkitt's Lymphoma or Burkitt-Like Lymphoma,nocardiaceae
D002637,5.0,NCT00392990-1,High Risk - Treated With Alternating R-CODOX-M/R-IVAC Cycles,NCT00392990,Doxorubicin Hydrochloride Liposome and Rituximab With Combination Chemotherapy in Treating Patients With Newly Diagnosed Burkitt's Lymphoma or Burkitt-Like Lymphoma,chest pain
D052016,5.0,NCT00392990-1,High Risk - Treated With Alternating R-CODOX-M/R-IVAC Cycles,NCT00392990,Doxorubicin Hydrochloride Liposome and Rituximab With Combination Chemotherapy in Treating Patients With Newly Diagnosed Burkitt's Lymphoma or Burkitt-Like Lymphoma,mucositis
D010512,5.0,NCT00392990-1,High Risk - Treated With Alternating R-CODOX-M/R-IVAC Cycles,NCT00392990,Doxorubicin Hydrochloride Liposome and Rituximab With Combination Chemotherapy in Treating Patients With Newly Diagnosed Burkitt's Lymphoma or Burkitt-Like Lymphoma,bleeding on probing gingival
D005334,5.0,NCT00392990-1,High Risk - Treated With Alternating R-CODOX-M/R-IVAC Cycles,NCT00392990,Doxorubicin Hydrochloride Liposome and Rituximab With Combination Chemotherapy in Treating Patients With Newly Diagnosed Burkitt's Lymphoma or Burkitt-Like Lymphoma,fever
D008584,5.0,NCT00392990-1,High Risk - Treated With Alternating R-CODOX-M/R-IVAC Cycles,NCT00392990,Doxorubicin Hydrochloride Liposome and Rituximab With Combination Chemotherapy in Treating Patients With Newly Diagnosed Burkitt's Lymphoma or Burkitt-Like Lymphoma,listeria cerebritis
D000071072,25.0,NCT00392990-1,High Risk - Treated With Alternating R-CODOX-M/R-IVAC Cycles,NCT00392990,Doxorubicin Hydrochloride Liposome and Rituximab With Combination Chemotherapy in Treating Patients With Newly Diagnosed Burkitt's Lymphoma or Burkitt-Like Lymphoma,encephalopathy febrile
D000071072,20.0,NCT00392990-2,Low Risk - Treatment With 3 Cycles of R-CODOX-M,NCT00392990,Doxorubicin Hydrochloride Liposome and Rituximab With Combination Chemotherapy in Treating Patients With Newly Diagnosed Burkitt's Lymphoma or Burkitt-Like Lymphoma,encephalopathy febrile
D007239,10.0,NCT00392990-1,High Risk - Treated With Alternating R-CODOX-M/R-IVAC Cycles,NCT00392990,Doxorubicin Hydrochloride Liposome and Rituximab With Combination Chemotherapy in Treating Patients With Newly Diagnosed Burkitt's Lymphoma or Burkitt-Like Lymphoma,infection
UNKNOWN-check-for-typo,5.0,NCT00392990-1,High Risk - Treated With Alternating R-CODOX-M/R-IVAC Cycles,NCT00392990,Doxorubicin Hydrochloride Liposome and Rituximab With Combination Chemotherapy in Treating Patients With Newly Diagnosed Burkitt's Lymphoma or Burkitt-Like Lymphoma,D00
D010198,15.0,NCT00392990-1,High Risk - Treated With Alternating R-CODOX-M/R-IVAC Cycles,NCT00392990,Doxorubicin Hydrochloride Liposome and Rituximab With Combination Chemotherapy in Treating Patients With Newly Diagnosed Burkitt's Lymphoma or Burkitt-Like Lymphoma,pancytopenia
D010198,20.0,NCT00392990-2,Low Risk - Treatment With 3 Cycles of R-CODOX-M,NCT00392990,Doxorubicin Hydrochloride Liposome and Rituximab With Combination Chemotherapy in Treating Patients With Newly Diagnosed Burkitt's Lymphoma or Burkitt-Like Lymphoma,pancytopenia
D009461,5.0,NCT00392990-1,High Risk - Treated With Alternating R-CODOX-M/R-IVAC Cycles,NCT00392990,Doxorubicin Hydrochloride Liposome and Rituximab With Combination Chemotherapy in Treating Patients With Newly Diagnosed Burkitt's Lymphoma or Burkitt-Like Lymphoma,neurologic symptoms
D006435,5.0,NCT00392990-1,High Risk - Treated With Alternating R-CODOX-M/R-IVAC Cycles,NCT00392990,Doxorubicin Hydrochloride Liposome and Rituximab With Combination Chemotherapy in Treating Patients With Newly Diagnosed Burkitt's Lymphoma or Burkitt-Like Lymphoma,renal dialysis
D006406,20.0,NCT00392990-2,Low Risk - Treatment With 3 Cycles of R-CODOX-M,NCT00392990,Doxorubicin Hydrochloride Liposome and Rituximab With Combination Chemotherapy in Treating Patients With Newly Diagnosed Burkitt's Lymphoma or Burkitt-Like Lymphoma,hematoma
D064420,30.61,NCT00394251-1,AC --> ABI-007,NCT00394251,Study of Dose-dense Adriamycin Plus Cytoxan (AC) Followed by Either ABI-007 (Abraxane) or Taxol With Bevacizumab as Adjuvant Therapy for Patients With Breast Cancer,adverse drug events
D064420,21.21,NCT00394251-2,AC --> Taxol,NCT00394251,Study of Dose-dense Adriamycin Plus Cytoxan (AC) Followed by Either ABI-007 (Abraxane) or Taxol With Bevacizumab as Adjuvant Therapy for Patients With Breast Cancer,adverse drug events
D004211,1.02,NCT00394251-1,AC --> ABI-007,NCT00394251,Study of Dose-dense Adriamycin Plus Cytoxan (AC) Followed by Either ABI-007 (Abraxane) or Taxol With Bevacizumab as Adjuvant Therapy for Patients With Breast Cancer,consumption coagulopathy
D064147,7.14,NCT00394251-1,AC --> ABI-007,NCT00394251,Study of Dose-dense Adriamycin Plus Cytoxan (AC) Followed by Either ABI-007 (Abraxane) or Taxol With Bevacizumab as Adjuvant Therapy for Patients With Breast Cancer,febrile neutropenia
D064147,5.05,NCT00394251-2,AC --> Taxol,NCT00394251,Study of Dose-dense Adriamycin Plus Cytoxan (AC) Followed by Either ABI-007 (Abraxane) or Taxol With Bevacizumab as Adjuvant Therapy for Patients With Breast Cancer,febrile neutropenia
D010198,2.04,NCT00394251-1,AC --> ABI-007,NCT00394251,Study of Dose-dense Adriamycin Plus Cytoxan (AC) Followed by Either ABI-007 (Abraxane) or Taxol With Bevacizumab as Adjuvant Therapy for Patients With Breast Cancer,pancytopenia
D006333,1.01,NCT00394251-2,AC --> Taxol,NCT00394251,Study of Dose-dense Adriamycin Plus Cytoxan (AC) Followed by Either ABI-007 (Abraxane) or Taxol With Bevacizumab as Adjuvant Therapy for Patients With Breast Cancer,cardiac failure
D006333,4.04,NCT00394251-2,AC --> Taxol,NCT00394251,Study of Dose-dense Adriamycin Plus Cytoxan (AC) Followed by Either ABI-007 (Abraxane) or Taxol With Bevacizumab as Adjuvant Therapy for Patients With Breast Cancer,cardiac failure
D010490,1.01,NCT00394251-2,AC --> Taxol,NCT00394251,Study of Dose-dense Adriamycin Plus Cytoxan (AC) Followed by Either ABI-007 (Abraxane) or Taxol With Bevacizumab as Adjuvant Therapy for Patients With Breast Cancer,pericardial effusion
10003012,1.02,NCT00394251-1,AC --> ABI-007,NCT00394251,Study of Dose-dense Adriamycin Plus Cytoxan (AC) Followed by Either ABI-007 (Abraxane) or Taxol With Bevacizumab as Adjuvant Therapy for Patients With Breast Cancer,appendicitis perforated
D003092,1.02,NCT00394251-1,AC --> ABI-007,NCT00394251,Study of Dose-dense Adriamycin Plus Cytoxan (AC) Followed by Either ABI-007 (Abraxane) or Taxol With Bevacizumab as Adjuvant Therapy for Patients With Breast Cancer,colitis
D045823,1.02,NCT00394251-1,AC --> ABI-007,NCT00394251,Study of Dose-dense Adriamycin Plus Cytoxan (AC) Followed by Either ABI-007 (Abraxane) or Taxol With Bevacizumab as Adjuvant Therapy for Patients With Breast Cancer,ileus
D015746,1.02,NCT00394251-1,AC --> ABI-007,NCT00394251,Study of Dose-dense Adriamycin Plus Cytoxan (AC) Followed by Either ABI-007 (Abraxane) or Taxol With Bevacizumab as Adjuvant Therapy for Patients With Breast Cancer,abdominal pain
D000069196,1.01,NCT00394251-2,AC --> Taxol,NCT00394251,Study of Dose-dense Adriamycin Plus Cytoxan (AC) Followed by Either ABI-007 (Abraxane) or Taxol With Bevacizumab as Adjuvant Therapy for Patients With Breast Cancer,gastrointestinal microbiome
D003093,1.01,NCT00394251-2,AC --> Taxol,NCT00394251,Study of Dose-dense Adriamycin Plus Cytoxan (AC) Followed by Either ABI-007 (Abraxane) or Taxol With Bevacizumab as Adjuvant Therapy for Patients With Breast Cancer,colitis ulcerative
D002637,1.02,NCT00394251-1,AC --> ABI-007,NCT00394251,Study of Dose-dense Adriamycin Plus Cytoxan (AC) Followed by Either ABI-007 (Abraxane) or Taxol With Bevacizumab as Adjuvant Therapy for Patients With Breast Cancer,chest pain
D002637,2.02,NCT00394251-2,AC --> Taxol,NCT00394251,Study of Dose-dense Adriamycin Plus Cytoxan (AC) Followed by Either ABI-007 (Abraxane) or Taxol With Bevacizumab as Adjuvant Therapy for Patients With Breast Cancer,chest pain
D005334,2.04,NCT00394251-1,AC --> ABI-007,NCT00394251,Study of Dose-dense Adriamycin Plus Cytoxan (AC) Followed by Either ABI-007 (Abraxane) or Taxol With Bevacizumab as Adjuvant Therapy for Patients With Breast Cancer,pyrexia
10062501,1.02,NCT00394251-1,AC --> ABI-007,NCT00394251,Study of Dose-dense Adriamycin Plus Cytoxan (AC) Followed by Either ABI-007 (Abraxane) or Taxol With Bevacizumab as Adjuvant Therapy for Patients With Breast Cancer,non-cardiac chest pain
D004238,1.02,NCT00394251-1,AC --> ABI-007,NCT00394251,Study of Dose-dense Adriamycin Plus Cytoxan (AC) Followed by Either ABI-007 (Abraxane) or Taxol With Bevacizumab as Adjuvant Therapy for Patients With Breast Cancer,diverticulitis
D004238,1.01,NCT00394251-2,AC --> Taxol,NCT00394251,Study of Dose-dense Adriamycin Plus Cytoxan (AC) Followed by Either ABI-007 (Abraxane) or Taxol With Bevacizumab as Adjuvant Therapy for Patients With Breast Cancer,diverticulitis
D000038,1.02,NCT00394251-1,AC --> ABI-007,NCT00394251,Study of Dose-dense Adriamycin Plus Cytoxan (AC) Followed by Either ABI-007 (Abraxane) or Taxol With Bevacizumab as Adjuvant Therapy for Patients With Breast Cancer,abscess
D011014,1.02,NCT00394251-1,AC --> ABI-007,NCT00394251,Study of Dose-dense Adriamycin Plus Cytoxan (AC) Followed by Either ABI-007 (Abraxane) or Taxol With Bevacizumab as Adjuvant Therapy for Patients With Breast Cancer,pneumonia
D011014,1.01,NCT00394251-2,AC --> Taxol,NCT00394251,Study of Dose-dense Adriamycin Plus Cytoxan (AC) Followed by Either ABI-007 (Abraxane) or Taxol With Bevacizumab as Adjuvant Therapy for Patients With Breast Cancer,pneumonia
D018805,2.04,NCT00394251-1,AC --> ABI-007,NCT00394251,Study of Dose-dense Adriamycin Plus Cytoxan (AC) Followed by Either ABI-007 (Abraxane) or Taxol With Bevacizumab as Adjuvant Therapy for Patients With Breast Cancer,sepsis
D012852,1.02,NCT00394251-1,AC --> ABI-007,NCT00394251,Study of Dose-dense Adriamycin Plus Cytoxan (AC) Followed by Either ABI-007 (Abraxane) or Taxol With Bevacizumab as Adjuvant Therapy for Patients With Breast Cancer,sinusitis
D014946,1.02,NCT00394251-1,AC --> ABI-007,NCT00394251,Study of Dose-dense Adriamycin Plus Cytoxan (AC) Followed by Either ABI-007 (Abraxane) or Taxol With Bevacizumab as Adjuvant Therapy for Patients With Breast Cancer,wound infection
D002481,1.02,NCT00394251-1,AC --> ABI-007,NCT00394251,Study of Dose-dense Adriamycin Plus Cytoxan (AC) Followed by Either ABI-007 (Abraxane) or Taxol With Bevacizumab as Adjuvant Therapy for Patients With Breast Cancer,cellulitis
D002481,1.01,NCT00394251-2,AC --> Taxol,NCT00394251,Study of Dose-dense Adriamycin Plus Cytoxan (AC) Followed by Either ABI-007 (Abraxane) or Taxol With Bevacizumab as Adjuvant Therapy for Patients With Breast Cancer,cellulitis
D001064,1.02,NCT00394251-1,AC --> ABI-007,NCT00394251,Study of Dose-dense Adriamycin Plus Cytoxan (AC) Followed by Either ABI-007 (Abraxane) or Taxol With Bevacizumab as Adjuvant Therapy for Patients With Breast Cancer,appendicitis
D001940,1.01,NCT00394251-2,AC --> Taxol,NCT00394251,Study of Dose-dense Adriamycin Plus Cytoxan (AC) Followed by Either ABI-007 (Abraxane) or Taxol With Bevacizumab as Adjuvant Therapy for Patients With Breast Cancer,breast
10007810,1.01,NCT00394251-2,AC --> Taxol,NCT00394251,Study of Dose-dense Adriamycin Plus Cytoxan (AC) Followed by Either ABI-007 (Abraxane) or Taxol With Bevacizumab as Adjuvant Therapy for Patients With Breast Cancer,catheter related infection
D000077215,1.02,NCT00394251-1,AC --> ABI-007,NCT00394251,Study of Dose-dense Adriamycin Plus Cytoxan (AC) Followed by Either ABI-007 (Abraxane) or Taxol With Bevacizumab as Adjuvant Therapy for Patients With Breast Cancer,halloysite
D005759,1.01,NCT00394251-2,AC --> Taxol,NCT00394251,Study of Dose-dense Adriamycin Plus Cytoxan (AC) Followed by Either ABI-007 (Abraxane) or Taxol With Bevacizumab as Adjuvant Therapy for Patients With Breast Cancer,gastroenteritis
D013530,1.01,NCT00394251-2,AC --> Taxol,NCT00394251,Study of Dose-dense Adriamycin Plus Cytoxan (AC) Followed by Either ABI-007 (Abraxane) or Taxol With Bevacizumab as Adjuvant Therapy for Patients With Breast Cancer,postoperative wound infection
D000985,1.02,NCT00394251-1,AC --> ABI-007,NCT00394251,Study of Dose-dense Adriamycin Plus Cytoxan (AC) Followed by Either ABI-007 (Abraxane) or Taxol With Bevacizumab as Adjuvant Therapy for Patients With Breast Cancer,antisepsis
D014552,1.01,NCT00394251-2,AC --> Taxol,NCT00394251,Study of Dose-dense Adriamycin Plus Cytoxan (AC) Followed by Either ABI-007 (Abraxane) or Taxol With Bevacizumab as Adjuvant Therapy for Patients With Breast Cancer,urinary tract infection
10048031,1.02,NCT00394251-1,AC --> ABI-007,NCT00394251,Study of Dose-dense Adriamycin Plus Cytoxan (AC) Followed by Either ABI-007 (Abraxane) or Taxol With Bevacizumab as Adjuvant Therapy for Patients With Breast Cancer,wound dehiscence
10048031,1.01,NCT00394251-2,AC --> Taxol,NCT00394251,Study of Dose-dense Adriamycin Plus Cytoxan (AC) Followed by Either ABI-007 (Abraxane) or Taxol With Bevacizumab as Adjuvant Therapy for Patients With Breast Cancer,wound dehiscence
D001051,1.01,NCT00394251-2,AC --> Taxol,NCT00394251,Study of Dose-dense Adriamycin Plus Cytoxan (AC) Followed by Either ABI-007 (Abraxane) or Taxol With Bevacizumab as Adjuvant Therapy for Patients With Breast Cancer,apoenzymes
UNKNOWN-check-for-typo,1.02,NCT00394251-1,AC --> ABI-007,NCT00394251,Study of Dose-dense Adriamycin Plus Cytoxan (AC) Followed by Either ABI-007 (Abraxane) or Taxol With Bevacizumab as Adjuvant Therapy for Patients With Breast Cancer,D00
UNKNOWN-check-for-typo,1.02,NCT00394251-1,AC --> ABI-007,NCT00394251,Study of Dose-dense Adriamycin Plus Cytoxan (AC) Followed by Either ABI-007 (Abraxane) or Taxol With Bevacizumab as Adjuvant Therapy for Patients With Breast Cancer,D00
D003681,1.01,NCT00394251-2,AC --> Taxol,NCT00394251,Study of Dose-dense Adriamycin Plus Cytoxan (AC) Followed by Either ABI-007 (Abraxane) or Taxol With Bevacizumab as Adjuvant Therapy for Patients With Breast Cancer,dehydration
D018771,1.02,NCT00394251-1,AC --> ABI-007,NCT00394251,Study of Dose-dense Adriamycin Plus Cytoxan (AC) Followed by Either ABI-007 (Abraxane) or Taxol With Bevacizumab as Adjuvant Therapy for Patients With Breast Cancer,arthralgia
D018771,1.01,NCT00394251-2,AC --> Taxol,NCT00394251,Study of Dose-dense Adriamycin Plus Cytoxan (AC) Followed by Either ABI-007 (Abraxane) or Taxol With Bevacizumab as Adjuvant Therapy for Patients With Breast Cancer,arthralgia
D063806,1.01,NCT00394251-2,AC --> Taxol,NCT00394251,Study of Dose-dense Adriamycin Plus Cytoxan (AC) Followed by Either ABI-007 (Abraxane) or Taxol With Bevacizumab as Adjuvant Therapy for Patients With Breast Cancer,myalgia
10006002,1.02,NCT00394251-1,AC --> ABI-007,NCT00394251,Study of Dose-dense Adriamycin Plus Cytoxan (AC) Followed by Either ABI-007 (Abraxane) or Taxol With Bevacizumab as Adjuvant Therapy for Patients With Breast Cancer,bone pain
D013575,1.02,NCT00394251-1,AC --> ABI-007,NCT00394251,Study of Dose-dense Adriamycin Plus Cytoxan (AC) Followed by Either ABI-007 (Abraxane) or Taxol With Bevacizumab as Adjuvant Therapy for Patients With Breast Cancer,syncope
D013575,2.02,NCT00394251-2,AC --> Taxol,NCT00394251,Study of Dose-dense Adriamycin Plus Cytoxan (AC) Followed by Either ABI-007 (Abraxane) or Taxol With Bevacizumab as Adjuvant Therapy for Patients With Breast Cancer,syncope
D020521,1.02,NCT00394251-1,AC --> ABI-007,NCT00394251,Study of Dose-dense Adriamycin Plus Cytoxan (AC) Followed by Either ABI-007 (Abraxane) or Taxol With Bevacizumab as Adjuvant Therapy for Patients With Breast Cancer,cerebrovascular accident
D001927,1.01,NCT00394251-2,AC --> Taxol,NCT00394251,Study of Dose-dense Adriamycin Plus Cytoxan (AC) Followed by Either ABI-007 (Abraxane) or Taxol With Bevacizumab as Adjuvant Therapy for Patients With Breast Cancer,encephalopathy
UNKNOWN-check-for-typo,1.02,NCT00394251-1,AC --> ABI-007,NCT00394251,Study of Dose-dense Adriamycin Plus Cytoxan (AC) Followed by Either ABI-007 (Abraxane) or Taxol With Bevacizumab as Adjuvant Therapy for Patients With Breast Cancer,D00
D011655,1.02,NCT00394251-1,AC --> ABI-007,NCT00394251,Study of Dose-dense Adriamycin Plus Cytoxan (AC) Followed by Either ABI-007 (Abraxane) or Taxol With Bevacizumab as Adjuvant Therapy for Patients With Breast Cancer,pulmonary embolism
D011655,1.01,NCT00394251-2,AC --> Taxol,NCT00394251,Study of Dose-dense Adriamycin Plus Cytoxan (AC) Followed by Either ABI-007 (Abraxane) or Taxol With Bevacizumab as Adjuvant Therapy for Patients With Breast Cancer,pulmonary embolism
D029424,1.02,NCT00394251-1,AC --> ABI-007,NCT00394251,Study of Dose-dense Adriamycin Plus Cytoxan (AC) Followed by Either ABI-007 (Abraxane) or Taxol With Bevacizumab as Adjuvant Therapy for Patients With Breast Cancer,chronic obstructive pulmonary disease
D029424,1.01,NCT00394251-2,AC --> Taxol,NCT00394251,Study of Dose-dense Adriamycin Plus Cytoxan (AC) Followed by Either ABI-007 (Abraxane) or Taxol With Bevacizumab as Adjuvant Therapy for Patients With Breast Cancer,chronic obstructive pulmonary disease
D012128,1.02,NCT00394251-1,AC --> ABI-007,NCT00394251,Study of Dose-dense Adriamycin Plus Cytoxan (AC) Followed by Either ABI-007 (Abraxane) or Taxol With Bevacizumab as Adjuvant Therapy for Patients With Breast Cancer,acute respiratory distress syndrome
D000035,1.02,NCT00394251-1,AC --> ABI-007,NCT00394251,Study of Dose-dense Adriamycin Plus Cytoxan (AC) Followed by Either ABI-007 (Abraxane) or Taxol With Bevacizumab as Adjuvant Therapy for Patients With Breast Cancer,abreaction
D006973,1.02,NCT00394251-1,AC --> ABI-007,NCT00394251,Study of Dose-dense Adriamycin Plus Cytoxan (AC) Followed by Either ABI-007 (Abraxane) or Taxol With Bevacizumab as Adjuvant Therapy for Patients With Breast Cancer,hypertension
D006973,1.01,NCT00394251-2,AC --> Taxol,NCT00394251,Study of Dose-dense Adriamycin Plus Cytoxan (AC) Followed by Either ABI-007 (Abraxane) or Taxol With Bevacizumab as Adjuvant Therapy for Patients With Breast Cancer,hypertension
D007022,1.02,NCT00394251-1,AC --> ABI-007,NCT00394251,Study of Dose-dense Adriamycin Plus Cytoxan (AC) Followed by Either ABI-007 (Abraxane) or Taxol With Bevacizumab as Adjuvant Therapy for Patients With Breast Cancer,hypotension
D020246,2.04,NCT00394251-1,AC --> ABI-007,NCT00394251,Study of Dose-dense Adriamycin Plus Cytoxan (AC) Followed by Either ABI-007 (Abraxane) or Taxol With Bevacizumab as Adjuvant Therapy for Patients With Breast Cancer,deep vein thrombosis
D064420,9.09,NCT00401817-1,Study Treatment Arm,NCT00401817,Bevacizumab + CHOP-Rituximab in Untreated Mantle Cell Lymphoma,adverse drug events
D011471,9.09,NCT00401817-1,Study Treatment Arm,NCT00401817,Bevacizumab + CHOP-Rituximab in Untreated Mantle Cell Lymphoma,prostate cancer
D064420,2.01,NCT00408408-1,Docetaxel Then AC,NCT00408408,Chemotherapy With or Without Bevacizumab in Treating Women With Stage I  Stage II  or Stage IIIA Breast Cancer That Can Be Removed By Surgery,adverse drug events
D064420,7.65,NCT00408408-2,Docetaxel + Bev Then AC + Bev,NCT00408408,Chemotherapy With or Without Bevacizumab in Treating Women With Stage I  Stage II  or Stage IIIA Breast Cancer That Can Be Removed By Surgery,adverse drug events
D064420,3.94,NCT00408408-3,Docetaxel + Capecitabine Then AC,NCT00408408,Chemotherapy With or Without Bevacizumab in Treating Women With Stage I  Stage II  or Stage IIIA Breast Cancer That Can Be Removed By Surgery,adverse drug events
D064420,15.31,NCT00408408-4,Docetaxel + Cape + Bev Then AC + Bev,NCT00408408,Chemotherapy With or Without Bevacizumab in Treating Women With Stage I  Stage II  or Stage IIIA Breast Cancer That Can Be Removed By Surgery,adverse drug events
D064420,1.03,NCT00408408-5,Docetaxel + Gem Then AC,NCT00408408,Chemotherapy With or Without Bevacizumab in Treating Women With Stage I  Stage II  or Stage IIIA Breast Cancer That Can Be Removed By Surgery,adverse drug events
D064420,7.43,NCT00408408-6,Docetaxel + Gem + Bev Then AC + Bev,NCT00408408,Chemotherapy With or Without Bevacizumab in Treating Women With Stage I  Stage II  or Stage IIIA Breast Cancer That Can Be Removed By Surgery,adverse drug events
D000740,0.51,NCT00408408-4,Docetaxel + Cape + Bev Then AC + Bev,NCT00408408,Chemotherapy With or Without Bevacizumab in Treating Women With Stage I  Stage II  or Stage IIIA Breast Cancer That Can Be Removed By Surgery,anemia
10005329,0.51,NCT00408408-2,Docetaxel + Bev Then AC + Bev,NCT00408408,Chemotherapy With or Without Bevacizumab in Treating Women With Stage I  Stage II  or Stage IIIA Breast Cancer That Can Be Removed By Surgery,blood and lymphatic system disorders - other specify
D006323,0.5,NCT00408408-6,Docetaxel + Gem + Bev Then AC + Bev,NCT00408408,Chemotherapy With or Without Bevacizumab in Treating Women With Stage I  Stage II  or Stage IIIA Breast Cancer That Can Be Removed By Surgery,cardiac arrest
D006333,0.51,NCT00408408-2,Docetaxel + Bev Then AC + Bev,NCT00408408,Chemotherapy With or Without Bevacizumab in Treating Women With Stage I  Stage II  or Stage IIIA Breast Cancer That Can Be Removed By Surgery,heart failure
D006333,0.51,NCT00408408-4,Docetaxel + Cape + Bev Then AC + Bev,NCT00408408,Chemotherapy With or Without Bevacizumab in Treating Women With Stage I  Stage II  or Stage IIIA Breast Cancer That Can Be Removed By Surgery,heart failure
D006333,0.5,NCT00408408-6,Docetaxel + Gem + Bev Then AC + Bev,NCT00408408,Chemotherapy With or Without Bevacizumab in Treating Women With Stage I  Stage II  or Stage IIIA Breast Cancer That Can Be Removed By Surgery,heart failure
D009203,0.51,NCT00408408-4,Docetaxel + Cape + Bev Then AC + Bev,NCT00408408,Chemotherapy With or Without Bevacizumab in Treating Women With Stage I  Stage II  or Stage IIIA Breast Cancer That Can Be Removed By Surgery,myocardial infarction
D009203,0.5,NCT00408408-6,Docetaxel + Gem + Bev Then AC + Bev,NCT00408408,Chemotherapy With or Without Bevacizumab in Treating Women With Stage I  Stage II  or Stage IIIA Breast Cancer That Can Be Removed By Surgery,myocardial infarction
D010490,0.51,NCT00408408-4,Docetaxel + Cape + Bev Then AC + Bev,NCT00408408,Chemotherapy With or Without Bevacizumab in Treating Women With Stage I  Stage II  or Stage IIIA Breast Cancer That Can Be Removed By Surgery,pericardial effusion
10069501,0.51,NCT00408408-2,Docetaxel + Bev Then AC + Bev,NCT00408408,Chemotherapy With or Without Bevacizumab in Treating Women With Stage I  Stage II  or Stage IIIA Breast Cancer That Can Be Removed By Surgery,left ventricular systolic dysfunction
10069501,0.49,NCT00408408-3,Docetaxel + Capecitabine Then AC,NCT00408408,Chemotherapy With or Without Bevacizumab in Treating Women With Stage I  Stage II  or Stage IIIA Breast Cancer That Can Be Removed By Surgery,left ventricular systolic dysfunction
10069501,2.55,NCT00408408-4,Docetaxel + Cape + Bev Then AC + Bev,NCT00408408,Chemotherapy With or Without Bevacizumab in Treating Women With Stage I  Stage II  or Stage IIIA Breast Cancer That Can Be Removed By Surgery,left ventricular systolic dysfunction
10069501,0.99,NCT00408408-6,Docetaxel + Gem + Bev Then AC + Bev,NCT00408408,Chemotherapy With or Without Bevacizumab in Treating Women With Stage I  Stage II  or Stage IIIA Breast Cancer That Can Be Removed By Surgery,left ventricular systolic dysfunction
D015746,0.51,NCT00408408-4,Docetaxel + Cape + Bev Then AC + Bev,NCT00408408,Chemotherapy With or Without Bevacizumab in Treating Women With Stage I  Stage II  or Stage IIIA Breast Cancer That Can Be Removed By Surgery,abdominal pain
10009998,0.51,NCT00408408-4,Docetaxel + Cape + Bev Then AC + Bev,NCT00408408,Chemotherapy With or Without Bevacizumab in Treating Women With Stage I  Stage II  or Stage IIIA Breast Cancer That Can Be Removed By Surgery,colonic hemorrhage
10010001,0.5,NCT00408408-6,Docetaxel + Gem + Bev Then AC + Bev,NCT00408408,Chemotherapy With or Without Bevacizumab in Treating Women With Stage I  Stage II  or Stage IIIA Breast Cancer That Can Be Removed By Surgery,colonic perforation
10041103,0.5,NCT00408408-6,Docetaxel + Gem + Bev Then AC + Bev,NCT00408408,Chemotherapy With or Without Bevacizumab in Treating Women With Stage I  Stage II  or Stage IIIA Breast Cancer That Can Be Removed By Surgery,small intestinal perforation
10051746,0.51,NCT00408408-4,Docetaxel + Cape + Bev Then AC + Bev,NCT00408408,Chemotherapy With or Without Bevacizumab in Treating Women With Stage I  Stage II  or Stage IIIA Breast Cancer That Can Be Removed By Surgery,lower gastrointestinal hemorrhage
10055226,0.5,NCT00408408-6,Docetaxel + Gem + Bev Then AC + Bev,NCT00408408,Chemotherapy With or Without Bevacizumab in Treating Women With Stage I  Stage II  or Stage IIIA Breast Cancer That Can Be Removed By Surgery,anal hemorrhage
10055356,0.51,NCT00408408-4,Docetaxel + Cape + Bev Then AC + Bev,NCT00408408,Chemotherapy With or Without Bevacizumab in Treating Women With Stage I  Stage II  or Stage IIIA Breast Cancer That Can Be Removed By Surgery,upper gastrointestinal hemorrhage
10042435,0.49,NCT00408408-3,Docetaxel + Capecitabine Then AC,NCT00408408,Chemotherapy With or Without Bevacizumab in Treating Women With Stage I  Stage II  or Stage IIIA Breast Cancer That Can Be Removed By Surgery,sudden death nos
D000707,0.51,NCT00408408-4,Docetaxel + Cape + Bev Then AC + Bev,NCT00408408,Chemotherapy With or Without Bevacizumab in Treating Women With Stage I  Stage II  or Stage IIIA Breast Cancer That Can Be Removed By Surgery,anaphylaxis
10014678,0.51,NCT00408408-2,Docetaxel + Bev Then AC + Bev,NCT00408408,Chemotherapy With or Without Bevacizumab in Treating Women With Stage I  Stage II  or Stage IIIA Breast Cancer That Can Be Removed By Surgery,endocarditis infective
10021881,0.52,NCT00408408-5,Docetaxel + Gem Then AC,NCT00408408,Chemotherapy With or Without Bevacizumab in Treating Women With Stage I  Stage II  or Stage IIIA Breast Cancer That Can Be Removed By Surgery,infections and infestations - other specify
D018805,0.51,NCT00408408-2,Docetaxel + Bev Then AC + Bev,NCT00408408,Chemotherapy With or Without Bevacizumab in Treating Women With Stage I  Stage II  or Stage IIIA Breast Cancer That Can Be Removed By Surgery,sepsis
10056519,0.51,NCT00408408-4,Docetaxel + Cape + Bev Then AC + Bev,NCT00408408,Chemotherapy With or Without Bevacizumab in Treating Women With Stage I  Stage II  or Stage IIIA Breast Cancer That Can Be Removed By Surgery,abdominal infection
10061229,0.5,NCT00408408-6,Docetaxel + Gem + Bev Then AC + Bev,NCT00408408,Chemotherapy With or Without Bevacizumab in Treating Women With Stage I  Stage II  or Stage IIIA Breast Cancer That Can Be Removed By Surgery,lung infection
10048031,1.02,NCT00408408-2,Docetaxel + Bev Then AC + Bev,NCT00408408,Chemotherapy With or Without Bevacizumab in Treating Women With Stage I  Stage II  or Stage IIIA Breast Cancer That Can Be Removed By Surgery,wound dehiscence
10048031,1.53,NCT00408408-4,Docetaxel + Cape + Bev Then AC + Bev,NCT00408408,Chemotherapy With or Without Bevacizumab in Treating Women With Stage I  Stage II  or Stage IIIA Breast Cancer That Can Be Removed By Surgery,wound dehiscence
10048031,0.99,NCT00408408-6,Docetaxel + Gem + Bev Then AC + Bev,NCT00408408,Chemotherapy With or Without Bevacizumab in Treating Women With Stage I  Stage II  or Stage IIIA Breast Cancer That Can Be Removed By Surgery,wound dehiscence
10007612,0.49,NCT00408408-3,Docetaxel + Capecitabine Then AC,NCT00408408,Chemotherapy With or Without Bevacizumab in Treating Women With Stage I  Stage II  or Stage IIIA Breast Cancer That Can Be Removed By Surgery,cardiac troponin i increased
10007612,0.51,NCT00408408-4,Docetaxel + Cape + Bev Then AC + Bev,NCT00408408,Chemotherapy With or Without Bevacizumab in Treating Women With Stage I  Stage II  or Stage IIIA Breast Cancer That Can Be Removed By Surgery,cardiac troponin i increased
10007612,0.5,NCT00408408-6,Docetaxel + Gem + Bev Then AC + Bev,NCT00408408,Chemotherapy With or Without Bevacizumab in Treating Women With Stage I  Stage II  or Stage IIIA Breast Cancer That Can Be Removed By Surgery,cardiac troponin i increased
10011368,0.52,NCT00408408-5,Docetaxel + Gem Then AC,NCT00408408,Chemotherapy With or Without Bevacizumab in Treating Women With Stage I  Stage II  or Stage IIIA Breast Cancer That Can Be Removed By Surgery,creatinine increased
10022891,0.49,NCT00408408-3,Docetaxel + Capecitabine Then AC,NCT00408408,Chemotherapy With or Without Bevacizumab in Treating Women With Stage I  Stage II  or Stage IIIA Breast Cancer That Can Be Removed By Surgery,investigations - other specify
D003681,0.99,NCT00408408-6,Docetaxel + Gem + Bev Then AC + Bev,NCT00408408,Chemotherapy With or Without Bevacizumab in Treating Women With Stage I  Stage II  or Stage IIIA Breast Cancer That Can Be Removed By Surgery,dehydration
D006947,0.5,NCT00408408-1,Docetaxel Then AC,NCT00408408,Chemotherapy With or Without Bevacizumab in Treating Women With Stage I  Stage II  or Stage IIIA Breast Cancer That Can Be Removed By Surgery,hyperkalemia
D007008,1.01,NCT00408408-1,Docetaxel Then AC,NCT00408408,Chemotherapy With or Without Bevacizumab in Treating Women With Stage I  Stage II  or Stage IIIA Breast Cancer That Can Be Removed By Surgery,hypokalemia
D007008,1.02,NCT00408408-4,Docetaxel + Cape + Bev Then AC + Bev,NCT00408408,Chemotherapy With or Without Bevacizumab in Treating Women With Stage I  Stage II  or Stage IIIA Breast Cancer That Can Be Removed By Surgery,hypokalemia
D007008,0.52,NCT00408408-5,Docetaxel + Gem Then AC,NCT00408408,Chemotherapy With or Without Bevacizumab in Treating Women With Stage I  Stage II  or Stage IIIA Breast Cancer That Can Be Removed By Surgery,hypokalemia
D007008,0.5,NCT00408408-6,Docetaxel + Gem + Bev Then AC + Bev,NCT00408408,Chemotherapy With or Without Bevacizumab in Treating Women With Stage I  Stage II  or Stage IIIA Breast Cancer That Can Be Removed By Surgery,hypokalemia
D007010,0.5,NCT00408408-6,Docetaxel + Gem + Bev Then AC + Bev,NCT00408408,Chemotherapy With or Without Bevacizumab in Treating Women With Stage I  Stage II  or Stage IIIA Breast Cancer That Can Be Removed By Surgery,hyponatremia
D017674,0.51,NCT00408408-4,Docetaxel + Cape + Bev Then AC + Bev,NCT00408408,Chemotherapy With or Without Bevacizumab in Treating Women With Stage I  Stage II  or Stage IIIA Breast Cancer That Can Be Removed By Surgery,hypophosphatemia
D009220,0.49,NCT00408408-3,Docetaxel + Capecitabine Then AC,NCT00408408,Chemotherapy With or Without Bevacizumab in Treating Women With Stage I  Stage II  or Stage IIIA Breast Cancer That Can Be Removed By Surgery,myositis
10048293,0.51,NCT00408408-4,Docetaxel + Cape + Bev Then AC + Bev,NCT00408408,Chemotherapy With or Without Bevacizumab in Treating Women With Stage I  Stage II  or Stage IIIA Breast Cancer That Can Be Removed By Surgery,leukemia secondary to oncology chemotherapy
10049737,0.51,NCT00408408-4,Docetaxel + Cape + Bev Then AC + Bev,NCT00408408,Chemotherapy With or Without Bevacizumab in Treating Women With Stage I  Stage II  or Stage IIIA Breast Cancer That Can Be Removed By Surgery,treatment related secondary malignancy
D006261,0.51,NCT00408408-2,Docetaxel + Bev Then AC + Bev,NCT00408408,Chemotherapy With or Without Bevacizumab in Treating Women With Stage I  Stage II  or Stage IIIA Breast Cancer That Can Be Removed By Surgery,headache
D006261,0.51,NCT00408408-4,Docetaxel + Cape + Bev Then AC + Bev,NCT00408408,Chemotherapy With or Without Bevacizumab in Treating Women With Stage I  Stage II  or Stage IIIA Breast Cancer That Can Be Removed By Surgery,headache
10029205,0.51,NCT00408408-4,Docetaxel + Cape + Bev Then AC + Bev,NCT00408408,Chemotherapy With or Without Bevacizumab in Treating Women With Stage I  Stage II  or Stage IIIA Breast Cancer That Can Be Removed By Surgery,nervous system disorders - other specify
10029205,0.99,NCT00408408-6,Docetaxel + Gem + Bev Then AC + Bev,NCT00408408,Chemotherapy With or Without Bevacizumab in Treating Women With Stage I  Stage II  or Stage IIIA Breast Cancer That Can Be Removed By Surgery,nervous system disorders - other specify
D001007,0.49,NCT00408408-3,Docetaxel + Capecitabine Then AC,NCT00408408,Chemotherapy With or Without Bevacizumab in Treating Women With Stage I  Stage II  or Stage IIIA Breast Cancer That Can Be Removed By Surgery,anxiety
D001007,0.5,NCT00408408-6,Docetaxel + Gem + Bev Then AC + Bev,NCT00408408,Chemotherapy With or Without Bevacizumab in Treating Women With Stage I  Stage II  or Stage IIIA Breast Cancer That Can Be Removed By Surgery,anxiety
D003863,0.51,NCT00408408-2,Docetaxel + Bev Then AC + Bev,NCT00408408,Chemotherapy With or Without Bevacizumab in Treating Women With Stage I  Stage II  or Stage IIIA Breast Cancer That Can Be Removed By Surgery,depression
D003863,0.49,NCT00408408-3,Docetaxel + Capecitabine Then AC,NCT00408408,Chemotherapy With or Without Bevacizumab in Treating Women With Stage I  Stage II  or Stage IIIA Breast Cancer That Can Be Removed By Surgery,depression
D003863,0.51,NCT00408408-4,Docetaxel + Cape + Bev Then AC + Bev,NCT00408408,Chemotherapy With or Without Bevacizumab in Treating Women With Stage I  Stage II  or Stage IIIA Breast Cancer That Can Be Removed By Surgery,depression
D011507,2.04,NCT00408408-2,Docetaxel + Bev Then AC + Bev,NCT00408408,Chemotherapy With or Without Bevacizumab in Treating Women With Stage I  Stage II  or Stage IIIA Breast Cancer That Can Be Removed By Surgery,proteinuria
D011507,0.5,NCT00408408-6,Docetaxel + Gem + Bev Then AC + Bev,NCT00408408,Chemotherapy With or Without Bevacizumab in Treating Women With Stage I  Stage II  or Stage IIIA Breast Cancer That Can Be Removed By Surgery,proteinuria
D014592,0.51,NCT00408408-2,Docetaxel + Bev Then AC + Bev,NCT00408408,Chemotherapy With or Without Bevacizumab in Treating Women With Stage I  Stage II  or Stage IIIA Breast Cancer That Can Be Removed By Surgery,uterine hemorrhage
D004417,1.02,NCT00408408-4,Docetaxel + Cape + Bev Then AC + Bev,NCT00408408,Chemotherapy With or Without Bevacizumab in Treating Women With Stage I  Stage II  or Stage IIIA Breast Cancer That Can Be Removed By Surgery,dyspnea
D004417,0.5,NCT00408408-6,Docetaxel + Gem + Bev Then AC + Bev,NCT00408408,Chemotherapy With or Without Bevacizumab in Treating Women With Stage I  Stage II  or Stage IIIA Breast Cancer That Can Be Removed By Surgery,dyspnea
D004844,0.51,NCT00408408-2,Docetaxel + Bev Then AC + Bev,NCT00408408,Chemotherapy With or Without Bevacizumab in Treating Women With Stage I  Stage II  or Stage IIIA Breast Cancer That Can Be Removed By Surgery,epistaxis
D004844,0.51,NCT00408408-4,Docetaxel + Cape + Bev Then AC + Bev,NCT00408408,Chemotherapy With or Without Bevacizumab in Treating Women With Stage I  Stage II  or Stage IIIA Breast Cancer That Can Be Removed By Surgery,epistaxis
D004844,0.5,NCT00408408-6,Docetaxel + Gem + Bev Then AC + Bev,NCT00408408,Chemotherapy With or Without Bevacizumab in Treating Women With Stage I  Stage II  or Stage IIIA Breast Cancer That Can Be Removed By Surgery,epistaxis
D011030,0.51,NCT00408408-4,Docetaxel + Cape + Bev Then AC + Bev,NCT00408408,Chemotherapy With or Without Bevacizumab in Treating Women With Stage I  Stage II  or Stage IIIA Breast Cancer That Can Be Removed By Surgery,pneumothorax
10055319,0.51,NCT00408408-4,Docetaxel + Cape + Bev Then AC + Bev,NCT00408408,Chemotherapy With or Without Bevacizumab in Treating Women With Stage I  Stage II  or Stage IIIA Breast Cancer That Can Be Removed By Surgery,pleural hemorrhage
D013262,0.51,NCT00408408-2,Docetaxel + Bev Then AC + Bev,NCT00408408,Chemotherapy With or Without Bevacizumab in Treating Women With Stage I  Stage II  or Stage IIIA Breast Cancer That Can Be Removed By Surgery,stevens johnson syndrome
D013262,0.49,NCT00408408-3,Docetaxel + Capecitabine Then AC,NCT00408408,Chemotherapy With or Without Bevacizumab in Treating Women With Stage I  Stage II  or Stage IIIA Breast Cancer That Can Be Removed By Surgery,stevens johnson syndrome
D006973,0.51,NCT00408408-2,Docetaxel + Bev Then AC + Bev,NCT00408408,Chemotherapy With or Without Bevacizumab in Treating Women With Stage I  Stage II  or Stage IIIA Breast Cancer That Can Be Removed By Surgery,hypertension
D006973,0.51,NCT00408408-4,Docetaxel + Cape + Bev Then AC + Bev,NCT00408408,Chemotherapy With or Without Bevacizumab in Treating Women With Stage I  Stage II  or Stage IIIA Breast Cancer That Can Be Removed By Surgery,hypertension
10043565,0.5,NCT00408408-1,Docetaxel Then AC,NCT00408408,Chemotherapy With or Without Bevacizumab in Treating Women With Stage I  Stage II  or Stage IIIA Breast Cancer That Can Be Removed By Surgery,thromboembolic event
10043565,0.51,NCT00408408-2,Docetaxel + Bev Then AC + Bev,NCT00408408,Chemotherapy With or Without Bevacizumab in Treating Women With Stage I  Stage II  or Stage IIIA Breast Cancer That Can Be Removed By Surgery,thromboembolic event
10043565,0.99,NCT00408408-3,Docetaxel + Capecitabine Then AC,NCT00408408,Chemotherapy With or Without Bevacizumab in Treating Women With Stage I  Stage II  or Stage IIIA Breast Cancer That Can Be Removed By Surgery,thromboembolic event
10043565,2.04,NCT00408408-4,Docetaxel + Cape + Bev Then AC + Bev,NCT00408408,Chemotherapy With or Without Bevacizumab in Treating Women With Stage I  Stage II  or Stage IIIA Breast Cancer That Can Be Removed By Surgery,thromboembolic event
10043565,0.5,NCT00408408-6,Docetaxel + Gem + Bev Then AC + Bev,NCT00408408,Chemotherapy With or Without Bevacizumab in Treating Women With Stage I  Stage II  or Stage IIIA Breast Cancer That Can Be Removed By Surgery,thromboembolic event
10047065,0.49,NCT00408408-3,Docetaxel + Capecitabine Then AC,NCT00408408,Chemotherapy With or Without Bevacizumab in Treating Women With Stage I  Stage II  or Stage IIIA Breast Cancer That Can Be Removed By Surgery,vascular disorders - other specify
10054692,0.5,NCT00408408-1,Docetaxel Then AC,NCT00408408,Chemotherapy With or Without Bevacizumab in Treating Women With Stage I  Stage II  or Stage IIIA Breast Cancer That Can Be Removed By Surgery,visceral arterial ischemia
D064420,15.74,NCT00436566-1,AC/PTL,NCT00436566,Doxorubicin and Cyclophosphamide Followed By Trastuzumab  Paclitaxel  and Lapatinib in Treating Patients With Early-Stage HER2-Positive Breast Cancer That Has Been Removed By Surgery,adverse drug events
D064147,0.93,NCT00436566-1,AC/PTL,NCT00436566,Doxorubicin and Cyclophosphamide Followed By Trastuzumab  Paclitaxel  and Lapatinib in Treating Patients With Early-Stage HER2-Positive Breast Cancer That Has Been Removed By Surgery,febrile neutropenia
D016277,0.93,NCT00436566-1,AC/PTL,NCT00436566,Doxorubicin and Cyclophosphamide Followed By Trastuzumab  Paclitaxel  and Lapatinib in Treating Patients With Early-Stage HER2-Positive Breast Cancer That Has Been Removed By Surgery,ventricular function left
D003967,5.56,NCT00436566-1,AC/PTL,NCT00436566,Doxorubicin and Cyclophosphamide Followed By Trastuzumab  Paclitaxel  and Lapatinib in Treating Patients With Early-Stage HER2-Positive Breast Cancer That Has Been Removed By Surgery,diarrhea
D005221,0.93,NCT00436566-1,AC/PTL,NCT00436566,Doxorubicin and Cyclophosphamide Followed By Trastuzumab  Paclitaxel  and Lapatinib in Treating Patients With Early-Stage HER2-Positive Breast Cancer That Has Been Removed By Surgery,fatigue
D011014,0.93,NCT00436566-1,AC/PTL,NCT00436566,Doxorubicin and Cyclophosphamide Followed By Trastuzumab  Paclitaxel  and Lapatinib in Treating Patients With Early-Stage HER2-Positive Breast Cancer That Has Been Removed By Surgery,pneumonia
10040872,0.93,NCT00436566-1,AC/PTL,NCT00436566,Doxorubicin and Cyclophosphamide Followed By Trastuzumab  Paclitaxel  and Lapatinib in Treating Patients With Early-Stage HER2-Positive Breast Cancer That Has Been Removed By Surgery,skin infection
D014552,0.93,NCT00436566-1,AC/PTL,NCT00436566,Doxorubicin and Cyclophosphamide Followed By Trastuzumab  Paclitaxel  and Lapatinib in Treating Patients With Early-Stage HER2-Positive Breast Cancer That Has Been Removed By Surgery,urinary tract infection
10001551,0.93,NCT00436566-1,AC/PTL,NCT00436566,Doxorubicin and Cyclophosphamide Followed By Trastuzumab  Paclitaxel  and Lapatinib in Treating Patients With Early-Stage HER2-Positive Breast Cancer That Has Been Removed By Surgery,alanine aminotransferase increased
10003481,0.93,NCT00436566-1,AC/PTL,NCT00436566,Doxorubicin and Cyclophosphamide Followed By Trastuzumab  Paclitaxel  and Lapatinib in Treating Patients With Early-Stage HER2-Positive Breast Cancer That Has Been Removed By Surgery,aspartate aminotransferase increased
D007970,1.85,NCT00436566-1,AC/PTL,NCT00436566,Doxorubicin and Cyclophosphamide Followed By Trastuzumab  Paclitaxel  and Lapatinib in Treating Patients With Early-Stage HER2-Positive Breast Cancer That Has Been Removed By Surgery,leukopenia
10029366,3.7,NCT00436566-1,AC/PTL,NCT00436566,Doxorubicin and Cyclophosphamide Followed By Trastuzumab  Paclitaxel  and Lapatinib in Treating Patients With Early-Stage HER2-Positive Breast Cancer That Has Been Removed By Surgery,neutrophil count decreased
D007008,0.93,NCT00436566-1,AC/PTL,NCT00436566,Doxorubicin and Cyclophosphamide Followed By Trastuzumab  Paclitaxel  and Lapatinib in Treating Patients With Early-Stage HER2-Positive Breast Cancer That Has Been Removed By Surgery,hypokalemia
10034620,0.93,NCT00436566-1,AC/PTL,NCT00436566,Doxorubicin and Cyclophosphamide Followed By Trastuzumab  Paclitaxel  and Lapatinib in Treating Patients With Early-Stage HER2-Positive Breast Cancer That Has Been Removed By Surgery,peripheral sensory neuropathy
D003371,0.93,NCT00436566-1,AC/PTL,NCT00436566,Doxorubicin and Cyclophosphamide Followed By Trastuzumab  Paclitaxel  and Lapatinib in Treating Patients With Early-Stage HER2-Positive Breast Cancer That Has Been Removed By Surgery,cough
D000071078,0.93,NCT00436566-1,AC/PTL,NCT00436566,Doxorubicin and Cyclophosphamide Followed By Trastuzumab  Paclitaxel  and Lapatinib in Treating Patients With Early-Stage HER2-Positive Breast Cancer That Has Been Removed By Surgery,stenosis pulmonary vein
D013927,0.93,NCT00436566-1,AC/PTL,NCT00436566,Doxorubicin and Cyclophosphamide Followed By Trastuzumab  Paclitaxel  and Lapatinib in Treating Patients With Early-Stage HER2-Positive Breast Cancer That Has Been Removed By Surgery,thrombosis
D064420,95.45,NCT00450801-1,R-MACLO Cycles,NCT00450801,R-MACLO-IVAM and Thalidomide in Untreated Mantle Cell Lymphoma,adverse drug events
D064420,95.45,NCT00450801-2,R-IVAM Cycles,NCT00450801,R-MACLO-IVAM and Thalidomide in Untreated Mantle Cell Lymphoma,adverse drug events
D064420,95.0,NCT00450801-3,Thalidomide Therapy,NCT00450801,R-MACLO-IVAM and Thalidomide in Untreated Mantle Cell Lymphoma,adverse drug events
D013921,36.36,NCT00450801-1,R-MACLO Cycles,NCT00450801,R-MACLO-IVAM and Thalidomide in Untreated Mantle Cell Lymphoma,thrombocytopenia
D013921,95.45,NCT00450801-2,R-IVAM Cycles,NCT00450801,R-MACLO-IVAM and Thalidomide in Untreated Mantle Cell Lymphoma,thrombocytopenia
D000930,9.09,NCT00450801-1,R-MACLO Cycles,NCT00450801,R-MACLO-IVAM and Thalidomide in Untreated Mantle Cell Lymphoma,antidiarrheals
D000930,4.55,NCT00450801-2,R-IVAM Cycles,NCT00450801,R-MACLO-IVAM and Thalidomide in Untreated Mantle Cell Lymphoma,antidiarrheals
D000930,5.0,NCT00450801-3,Thalidomide Therapy,NCT00450801,R-MACLO-IVAM and Thalidomide in Untreated Mantle Cell Lymphoma,antidiarrheals
D004244,5.0,NCT00450801-3,Thalidomide Therapy,NCT00450801,R-MACLO-IVAM and Thalidomide in Untreated Mantle Cell Lymphoma,dizziness
D009503,54.55,NCT00450801-1,R-MACLO Cycles,NCT00450801,R-MACLO-IVAM and Thalidomide in Untreated Mantle Cell Lymphoma,neutropenia
D009503,59.09,NCT00450801-2,R-IVAM Cycles,NCT00450801,R-MACLO-IVAM and Thalidomide in Untreated Mantle Cell Lymphoma,neutropenia
D009503,35.0,NCT00450801-3,Thalidomide Therapy,NCT00450801,R-MACLO-IVAM and Thalidomide in Untreated Mantle Cell Lymphoma,neutropenia
D064147,40.91,NCT00450801-1,R-MACLO Cycles,NCT00450801,R-MACLO-IVAM and Thalidomide in Untreated Mantle Cell Lymphoma,febrile neutropenia
D064147,90.91,NCT00450801-2,R-IVAM Cycles,NCT00450801,R-MACLO-IVAM and Thalidomide in Untreated Mantle Cell Lymphoma,febrile neutropenia
D000069544,22.73,NCT00450801-1,R-MACLO Cycles,NCT00450801,R-MACLO-IVAM and Thalidomide in Untreated Mantle Cell Lymphoma,encephalitis infection
D000069544,50.0,NCT00450801-2,R-IVAM Cycles,NCT00450801,R-MACLO-IVAM and Thalidomide in Untreated Mantle Cell Lymphoma,encephalitis infection
D000069544,10.0,NCT00450801-3,Thalidomide Therapy,NCT00450801,R-MACLO-IVAM and Thalidomide in Untreated Mantle Cell Lymphoma,encephalitis infection
D016470,9.09,NCT00450801-1,R-MACLO Cycles,NCT00450801,R-MACLO-IVAM and Thalidomide in Untreated Mantle Cell Lymphoma,bacteremia
D016470,54.55,NCT00450801-2,R-IVAM Cycles,NCT00450801,R-MACLO-IVAM and Thalidomide in Untreated Mantle Cell Lymphoma,bacteremia
D013280,4.55,NCT00450801-1,R-MACLO Cycles,NCT00450801,R-MACLO-IVAM and Thalidomide in Untreated Mantle Cell Lymphoma,oromucositis
D000740,31.82,NCT00450801-1,R-MACLO Cycles,NCT00450801,R-MACLO-IVAM and Thalidomide in Untreated Mantle Cell Lymphoma,anemia
D000740,86.36,NCT00450801-2,R-IVAM Cycles,NCT00450801,R-MACLO-IVAM and Thalidomide in Untreated Mantle Cell Lymphoma,anemia
D010523,40.0,NCT00450801-3,Thalidomide Therapy,NCT00450801,R-MACLO-IVAM and Thalidomide in Untreated Mantle Cell Lymphoma,neuropathy peripheral
D004417,4.55,NCT00450801-1,R-MACLO Cycles,NCT00450801,R-MACLO-IVAM and Thalidomide in Untreated Mantle Cell Lymphoma,dyspnea
D004417,4.55,NCT00450801-2,R-IVAM Cycles,NCT00450801,R-MACLO-IVAM and Thalidomide in Untreated Mantle Cell Lymphoma,dyspnea
D010996,4.55,NCT00450801-1,R-MACLO Cycles,NCT00450801,R-MACLO-IVAM and Thalidomide in Untreated Mantle Cell Lymphoma,pleural effusion
D010996,4.55,NCT00450801-2,R-IVAM Cycles,NCT00450801,R-MACLO-IVAM and Thalidomide in Untreated Mantle Cell Lymphoma,pleural effusion
D007172,10.0,NCT00450801-3,Thalidomide Therapy,NCT00450801,R-MACLO-IVAM and Thalidomide in Untreated Mantle Cell Lymphoma,erectile dysfunction
D064420,61.4,NCT00451178-1,R-CHOP and Enzastaurin,NCT00451178,A Study of Participants With Lymphoma Who Take R-CHOP and Enzastaurin Compared to Participants Who Take R-CHOP Only,adverse drug events
D064420,41.86,NCT00451178-2,R-CHOP,NCT00451178,A Study of Participants With Lymphoma Who Take R-CHOP and Enzastaurin Compared to Participants Who Take R-CHOP Only,adverse drug events
D000741,7.02,NCT00451178-1,R-CHOP and Enzastaurin,NCT00451178,A Study of Participants With Lymphoma Who Take R-CHOP and Enzastaurin Compared to Participants Who Take R-CHOP Only,aplastic anaemia
D000741,2.33,NCT00451178-2,R-CHOP,NCT00451178,A Study of Participants With Lymphoma Who Take R-CHOP and Enzastaurin Compared to Participants Who Take R-CHOP Only,aplastic anaemia
D064147,15.79,NCT00451178-1,R-CHOP and Enzastaurin,NCT00451178,A Study of Participants With Lymphoma Who Take R-CHOP and Enzastaurin Compared to Participants Who Take R-CHOP Only,febrile neutropenia
D064147,6.98,NCT00451178-2,R-CHOP,NCT00451178,A Study of Participants With Lymphoma Who Take R-CHOP and Enzastaurin Compared to Participants Who Take R-CHOP Only,febrile neutropenia
D007970,2.33,NCT00451178-2,R-CHOP,NCT00451178,A Study of Participants With Lymphoma Who Take R-CHOP and Enzastaurin Compared to Participants Who Take R-CHOP Only,leukopenia
D009503,3.51,NCT00451178-1,R-CHOP and Enzastaurin,NCT00451178,A Study of Participants With Lymphoma Who Take R-CHOP and Enzastaurin Compared to Participants Who Take R-CHOP Only,neutropenia
D009503,6.98,NCT00451178-2,R-CHOP,NCT00451178,A Study of Participants With Lymphoma Who Take R-CHOP and Enzastaurin Compared to Participants Who Take R-CHOP Only,neutropenia
D013921,1.75,NCT00451178-1,R-CHOP and Enzastaurin,NCT00451178,A Study of Participants With Lymphoma Who Take R-CHOP and Enzastaurin Compared to Participants Who Take R-CHOP Only,thrombocytopenia
D013921,4.65,NCT00451178-2,R-CHOP,NCT00451178,A Study of Participants With Lymphoma Who Take R-CHOP and Enzastaurin Compared to Participants Who Take R-CHOP Only,thrombocytopenia
D000789,2.33,NCT00451178-2,R-CHOP,NCT00451178,A Study of Participants With Lymphoma Who Take R-CHOP and Enzastaurin Compared to Participants Who Take R-CHOP Only,unstable angina
D001281,1.75,NCT00451178-1,R-CHOP and Enzastaurin,NCT00451178,A Study of Participants With Lymphoma Who Take R-CHOP and Enzastaurin Compared to Participants Who Take R-CHOP Only,atrial fibrillation
D001281,4.65,NCT00451178-2,R-CHOP,NCT00451178,A Study of Participants With Lymphoma Who Take R-CHOP and Enzastaurin Compared to Participants Who Take R-CHOP Only,atrial fibrillation
D054537,1.75,NCT00451178-1,R-CHOP and Enzastaurin,NCT00451178,A Study of Participants With Lymphoma Who Take R-CHOP and Enzastaurin Compared to Participants Who Take R-CHOP Only,atrioventricular block
D054537,2.33,NCT00451178-2,R-CHOP,NCT00451178,A Study of Participants With Lymphoma Who Take R-CHOP and Enzastaurin Compared to Participants Who Take R-CHOP Only,atrioventricular block
D000072599,1.75,NCT00451178-1,R-CHOP and Enzastaurin,NCT00451178,A Study of Participants With Lymphoma Who Take R-CHOP and Enzastaurin Compared to Participants Who Take R-CHOP Only,cardiorespiratory fitness
D015746,3.51,NCT00451178-1,R-CHOP and Enzastaurin,NCT00451178,A Study of Participants With Lymphoma Who Take R-CHOP and Enzastaurin Compared to Participants Who Take R-CHOP Only,abdominal pain
D012003,1.75,NCT00451178-1,R-CHOP and Enzastaurin,NCT00451178,A Study of Participants With Lymphoma Who Take R-CHOP and Enzastaurin Compared to Participants Who Take R-CHOP Only,anal fistula
D003248,3.51,NCT00451178-1,R-CHOP and Enzastaurin,NCT00451178,A Study of Participants With Lymphoma Who Take R-CHOP and Enzastaurin Compared to Participants Who Take R-CHOP Only,constipation
UNKNOWN-check-for-typo,1.75,NCT00451178-1,R-CHOP and Enzastaurin,NCT00451178,A Study of Participants With Lymphoma Who Take R-CHOP and Enzastaurin Compared to Participants Who Take R-CHOP Only,D00
D000072663,1.75,NCT00451178-1,R-CHOP and Enzastaurin,NCT00451178,A Study of Participants With Lymphoma Who Take R-CHOP and Enzastaurin Compared to Participants Who Take R-CHOP Only,spontaneous perforation
D003680,1.75,NCT00451178-1,R-CHOP and Enzastaurin,NCT00451178,A Study of Participants With Lymphoma Who Take R-CHOP and Enzastaurin Compared to Participants Who Take R-CHOP Only,dysphagia
D000069196,3.51,NCT00451178-1,R-CHOP and Enzastaurin,NCT00451178,A Study of Participants With Lymphoma Who Take R-CHOP and Enzastaurin Compared to Participants Who Take R-CHOP Only,gastrointestinal microbiome
D009325,1.75,NCT00451178-1,R-CHOP and Enzastaurin,NCT00451178,A Study of Participants With Lymphoma Who Take R-CHOP and Enzastaurin Compared to Participants Who Take R-CHOP Only,nausea
D009325,2.33,NCT00451178-2,R-CHOP,NCT00451178,A Study of Participants With Lymphoma Who Take R-CHOP and Enzastaurin Compared to Participants Who Take R-CHOP Only,nausea
D000067836,2.33,NCT00451178-2,R-CHOP,NCT00451178,A Study of Participants With Lymphoma Who Take R-CHOP and Enzastaurin Compared to Participants Who Take R-CHOP Only,hoarding disorder
D013392,1.75,NCT00451178-1,R-CHOP and Enzastaurin,NCT00451178,A Study of Participants With Lymphoma Who Take R-CHOP and Enzastaurin Compared to Participants Who Take R-CHOP Only,ulcerban
10041101,2.33,NCT00451178-2,R-CHOP,NCT00451178,A Study of Participants With Lymphoma Who Take R-CHOP and Enzastaurin Compared to Participants Who Take R-CHOP Only,small intestinal obstruction
D014839,2.33,NCT00451178-2,R-CHOP,NCT00451178,A Study of Participants With Lymphoma Who Take R-CHOP and Enzastaurin Compared to Participants Who Take R-CHOP Only,vomiting
D001247,1.75,NCT00451178-1,R-CHOP and Enzastaurin,NCT00451178,A Study of Participants With Lymphoma Who Take R-CHOP and Enzastaurin Compared to Participants Who Take R-CHOP Only,asthenia
D005221,1.75,NCT00451178-1,R-CHOP and Enzastaurin,NCT00451178,A Study of Participants With Lymphoma Who Take R-CHOP and Enzastaurin Compared to Participants Who Take R-CHOP Only,fatigue
D005221,2.33,NCT00451178-2,R-CHOP,NCT00451178,A Study of Participants With Lymphoma Who Take R-CHOP and Enzastaurin Compared to Participants Who Take R-CHOP Only,fatigue
D009102,1.75,NCT00451178-1,R-CHOP and Enzastaurin,NCT00451178,A Study of Participants With Lymphoma Who Take R-CHOP and Enzastaurin Compared to Participants Who Take R-CHOP Only,multiple organ failure
D010146,1.75,NCT00451178-1,R-CHOP and Enzastaurin,NCT00451178,A Study of Participants With Lymphoma Who Take R-CHOP and Enzastaurin Compared to Participants Who Take R-CHOP Only,pain
D005334,5.26,NCT00451178-1,R-CHOP and Enzastaurin,NCT00451178,A Study of Participants With Lymphoma Who Take R-CHOP and Enzastaurin Compared to Participants Who Take R-CHOP Only,pyrexia
D005334,9.3,NCT00451178-2,R-CHOP,NCT00451178,A Study of Participants With Lymphoma Who Take R-CHOP and Enzastaurin Compared to Participants Who Take R-CHOP Only,pyrexia
D006967,2.33,NCT00451178-2,R-CHOP,NCT00451178,A Study of Participants With Lymphoma Who Take R-CHOP and Enzastaurin Compared to Participants Who Take R-CHOP Only,hypersensitivity
D013290,1.75,NCT00451178-1,R-CHOP and Enzastaurin,NCT00451178,A Study of Participants With Lymphoma Who Take R-CHOP and Enzastaurin Compared to Participants Who Take R-CHOP Only,streptococcal infections
UNKNOWN-check-for-typo,3.51,NCT00451178-1,R-CHOP and Enzastaurin,NCT00451178,A Study of Participants With Lymphoma Who Take R-CHOP and Enzastaurin Compared to Participants Who Take R-CHOP Only,D00
UNKNOWN-check-for-typo,2.33,NCT00451178-2,R-CHOP,NCT00451178,A Study of Participants With Lymphoma Who Take R-CHOP and Enzastaurin Compared to Participants Who Take R-CHOP Only,D00
D002481,1.75,NCT00451178-1,R-CHOP and Enzastaurin,NCT00451178,A Study of Participants With Lymphoma Who Take R-CHOP and Enzastaurin Compared to Participants Who Take R-CHOP Only,cellulitis
D054517,1.75,NCT00451178-1,R-CHOP and Enzastaurin,NCT00451178,A Study of Participants With Lymphoma Who Take R-CHOP and Enzastaurin Compared to Participants Who Take R-CHOP Only,orbital cellulitis
D007239,1.75,NCT00451178-1,R-CHOP and Enzastaurin,NCT00451178,A Study of Participants With Lymphoma Who Take R-CHOP and Enzastaurin Compared to Participants Who Take R-CHOP Only,infection
D007239,2.33,NCT00451178-2,R-CHOP,NCT00451178,A Study of Participants With Lymphoma Who Take R-CHOP and Enzastaurin Compared to Participants Who Take R-CHOP Only,infection
D000985,1.75,NCT00451178-1,R-CHOP and Enzastaurin,NCT00451178,A Study of Participants With Lymphoma Who Take R-CHOP and Enzastaurin Compared to Participants Who Take R-CHOP Only,antisepsis
D011014,8.77,NCT00451178-1,R-CHOP and Enzastaurin,NCT00451178,A Study of Participants With Lymphoma Who Take R-CHOP and Enzastaurin Compared to Participants Who Take R-CHOP Only,pneumonia
D011014,4.65,NCT00451178-2,R-CHOP,NCT00451178,A Study of Participants With Lymphoma Who Take R-CHOP and Enzastaurin Compared to Participants Who Take R-CHOP Only,pneumonia
D001996,1.75,NCT00451178-1,R-CHOP and Enzastaurin,NCT00451178,A Study of Participants With Lymphoma Who Take R-CHOP and Enzastaurin Compared to Participants Who Take R-CHOP Only,bronchopneumonia
D018805,3.51,NCT00451178-1,R-CHOP and Enzastaurin,NCT00451178,A Study of Participants With Lymphoma Who Take R-CHOP and Enzastaurin Compared to Participants Who Take R-CHOP Only,sepsis
D018805,9.3,NCT00451178-2,R-CHOP,NCT00451178,A Study of Participants With Lymphoma Who Take R-CHOP and Enzastaurin Compared to Participants Who Take R-CHOP Only,sepsis
D012772,1.75,NCT00451178-1,R-CHOP and Enzastaurin,NCT00451178,A Study of Participants With Lymphoma Who Take R-CHOP and Enzastaurin Compared to Participants Who Take R-CHOP Only,septic shock
D012772,2.33,NCT00451178-2,R-CHOP,NCT00451178,A Study of Participants With Lymphoma Who Take R-CHOP and Enzastaurin Compared to Participants Who Take R-CHOP Only,septic shock
D000038,1.75,NCT00451178-1,R-CHOP and Enzastaurin,NCT00451178,A Study of Participants With Lymphoma Who Take R-CHOP and Enzastaurin Compared to Participants Who Take R-CHOP Only,abscess
D014552,3.51,NCT00451178-1,R-CHOP and Enzastaurin,NCT00451178,A Study of Participants With Lymphoma Who Take R-CHOP and Enzastaurin Compared to Participants Who Take R-CHOP Only,urinary tract infection
D014552,4.65,NCT00451178-2,R-CHOP,NCT00451178,A Study of Participants With Lymphoma Who Take R-CHOP and Enzastaurin Compared to Participants Who Take R-CHOP Only,urinary tract infection
10040047,2.33,NCT00451178-2,R-CHOP,NCT00451178,A Study of Participants With Lymphoma Who Take R-CHOP and Enzastaurin Compared to Participants Who Take R-CHOP Only,sepsis
D012141,1.75,NCT00451178-1,R-CHOP and Enzastaurin,NCT00451178,A Study of Participants With Lymphoma Who Take R-CHOP and Enzastaurin Compared to Participants Who Take R-CHOP Only,upper respiratory tract infections
10016173,1.75,NCT00451178-1,R-CHOP and Enzastaurin,NCT00451178,A Study of Participants With Lymphoma Who Take R-CHOP and Enzastaurin Compared to Participants Who Take R-CHOP Only,fall
D005265,1.75,NCT00451178-1,R-CHOP and Enzastaurin,NCT00451178,A Study of Participants With Lymphoma Who Take R-CHOP and Enzastaurin Compared to Participants Who Take R-CHOP Only,femoral neck fracture
D005360,1.75,NCT00451178-1,R-CHOP and Enzastaurin,NCT00451178,A Study of Participants With Lymphoma Who Take R-CHOP and Enzastaurin Compared to Participants Who Take R-CHOP Only,fibula
D013978,1.75,NCT00451178-1,R-CHOP and Enzastaurin,NCT00451178,A Study of Participants With Lymphoma Who Take R-CHOP and Enzastaurin Compared to Participants Who Take R-CHOP Only,tibial fractures
10001551,2.33,NCT00451178-2,R-CHOP,NCT00451178,A Study of Participants With Lymphoma Who Take R-CHOP and Enzastaurin Compared to Participants Who Take R-CHOP Only,alanine aminotransferase increased
10003481,2.33,NCT00451178-2,R-CHOP,NCT00451178,A Study of Participants With Lymphoma Who Take R-CHOP and Enzastaurin Compared to Participants Who Take R-CHOP Only,aspartate aminotransferase increased
10001675,2.33,NCT00451178-2,R-CHOP,NCT00451178,A Study of Participants With Lymphoma Who Take R-CHOP and Enzastaurin Compared to Participants Who Take R-CHOP Only,alkaline phosphatase increased
D007989,1.75,NCT00451178-1,R-CHOP and Enzastaurin,NCT00451178,A Study of Participants With Lymphoma Who Take R-CHOP and Enzastaurin Compared to Participants Who Take R-CHOP Only,decreased libido
D007989,2.33,NCT00451178-2,R-CHOP,NCT00451178,A Study of Participants With Lymphoma Who Take R-CHOP and Enzastaurin Compared to Participants Who Take R-CHOP Only,decreased libido
D013851,1.75,NCT00451178-1,R-CHOP and Enzastaurin,NCT00451178,A Study of Participants With Lymphoma Who Take R-CHOP and Enzastaurin Compared to Participants Who Take R-CHOP Only,underweight
D003681,3.51,NCT00451178-1,R-CHOP and Enzastaurin,NCT00451178,A Study of Participants With Lymphoma Who Take R-CHOP and Enzastaurin Compared to Participants Who Take R-CHOP Only,dehydration
UNKNOWN-check-for-typo,1.75,NCT00451178-1,R-CHOP and Enzastaurin,NCT00451178,A Study of Participants With Lymphoma Who Take R-CHOP and Enzastaurin Compared to Participants Who Take R-CHOP Only,D00
D018908,1.75,NCT00451178-1,R-CHOP and Enzastaurin,NCT00451178,A Study of Participants With Lymphoma Who Take R-CHOP and Enzastaurin Compared to Participants Who Take R-CHOP Only,muscular weakness
D005598,1.75,NCT00451178-1,R-CHOP and Enzastaurin,NCT00451178,A Study of Participants With Lymphoma Who Take R-CHOP and Enzastaurin Compared to Participants Who Take R-CHOP Only,pathological fracture
D008578,1.75,NCT00451178-1,R-CHOP and Enzastaurin,NCT00451178,A Study of Participants With Lymphoma Who Take R-CHOP and Enzastaurin Compared to Participants Who Take R-CHOP Only,meninges
D013964,1.75,NCT00451178-1,R-CHOP and Enzastaurin,NCT00451178,A Study of Participants With Lymphoma Who Take R-CHOP and Enzastaurin Compared to Participants Who Take R-CHOP Only,thyroid cancer
UNKNOWN-check-for-typo,1.75,NCT00451178-1,R-CHOP and Enzastaurin,NCT00451178,A Study of Participants With Lymphoma Who Take R-CHOP and Enzastaurin Compared to Participants Who Take R-CHOP Only,D00
D010523,1.75,NCT00451178-1,R-CHOP and Enzastaurin,NCT00451178,A Study of Participants With Lymphoma Who Take R-CHOP and Enzastaurin Compared to Participants Who Take R-CHOP Only,peripheral neuropathy
D013575,3.51,NCT00451178-1,R-CHOP and Enzastaurin,NCT00451178,A Study of Participants With Lymphoma Who Take R-CHOP and Enzastaurin Compared to Participants Who Take R-CHOP Only,syncope
D003863,2.33,NCT00451178-2,R-CHOP,NCT00451178,A Study of Participants With Lymphoma Who Take R-CHOP and Enzastaurin Compared to Participants Who Take R-CHOP Only,depression
D000073216,1.75,NCT00451178-1,R-CHOP and Enzastaurin,NCT00451178,A Study of Participants With Lymphoma Who Take R-CHOP and Enzastaurin Compared to Participants Who Take R-CHOP Only,mental status tests
D051437,2.33,NCT00451178-2,R-CHOP,NCT00451178,A Study of Participants With Lymphoma Who Take R-CHOP and Enzastaurin Compared to Participants Who Take R-CHOP Only,renal failure
D058186,1.75,NCT00451178-1,R-CHOP and Enzastaurin,NCT00451178,A Study of Participants With Lymphoma Who Take R-CHOP and Enzastaurin Compared to Participants Who Take R-CHOP Only,acute renal failure
D012128,1.75,NCT00451178-1,R-CHOP and Enzastaurin,NCT00451178,A Study of Participants With Lymphoma Who Take R-CHOP and Enzastaurin Compared to Participants Who Take R-CHOP Only,acute respiratory distress syndrome
D004844,1.75,NCT00451178-1,R-CHOP and Enzastaurin,NCT00451178,A Study of Participants With Lymphoma Who Take R-CHOP and Enzastaurin Compared to Participants Who Take R-CHOP Only,epistaxis
D010996,1.75,NCT00451178-1,R-CHOP and Enzastaurin,NCT00451178,A Study of Participants With Lymphoma Who Take R-CHOP and Enzastaurin Compared to Participants Who Take R-CHOP Only,pleural effusion
D011655,3.51,NCT00451178-1,R-CHOP and Enzastaurin,NCT00451178,A Study of Participants With Lymphoma Who Take R-CHOP and Enzastaurin Compared to Participants Who Take R-CHOP Only,pulmonary embolism
D011655,2.33,NCT00451178-2,R-CHOP,NCT00451178,A Study of Participants With Lymphoma Who Take R-CHOP and Enzastaurin Compared to Participants Who Take R-CHOP Only,pulmonary embolism
D003668,2.33,NCT00451178-2,R-CHOP,NCT00451178,A Study of Participants With Lymphoma Who Take R-CHOP and Enzastaurin Compared to Participants Who Take R-CHOP Only,decubitus ulcer
D020246,3.51,NCT00451178-1,R-CHOP and Enzastaurin,NCT00451178,A Study of Participants With Lymphoma Who Take R-CHOP and Enzastaurin Compared to Participants Who Take R-CHOP Only,deep vein thrombosis
D020246,2.33,NCT00451178-2,R-CHOP,NCT00451178,A Study of Participants With Lymphoma Who Take R-CHOP and Enzastaurin Compared to Participants Who Take R-CHOP Only,deep vein thrombosis
D006973,1.75,NCT00451178-1,R-CHOP and Enzastaurin,NCT00451178,A Study of Participants With Lymphoma Who Take R-CHOP and Enzastaurin Compared to Participants Who Take R-CHOP Only,hypertension
D007022,5.26,NCT00451178-1,R-CHOP and Enzastaurin,NCT00451178,A Study of Participants With Lymphoma Who Take R-CHOP and Enzastaurin Compared to Participants Who Take R-CHOP Only,hypotension
D007024,2.33,NCT00451178-2,R-CHOP,NCT00451178,A Study of Participants With Lymphoma Who Take R-CHOP and Enzastaurin Compared to Participants Who Take R-CHOP Only,orthostatic hypotension
D064420,11.72,NCT00455533-1,Ixabepilone,NCT00455533,Study to Assess Effectiveness of Giving Combination of Standard Chemotherapy Drugs Versus Combination of Standard Chemotherapy and New Drug Ixabepilone When Given Before Surgical Removal of Early Stage Breast Cancer,adverse drug events
D064420,7.64,NCT00455533-2,Paclitaxel,NCT00455533,Study to Assess Effectiveness of Giving Combination of Standard Chemotherapy Drugs Versus Combination of Standard Chemotherapy and New Drug Ixabepilone When Given Before Surgical Removal of Early Stage Breast Cancer,adverse drug events
D000741,0.69,NCT00455533-2,Paclitaxel,NCT00455533,Study to Assess Effectiveness of Giving Combination of Standard Chemotherapy Drugs Versus Combination of Standard Chemotherapy and New Drug Ixabepilone When Given Before Surgical Removal of Early Stage Breast Cancer,aplastic anaemia
D007970,1.38,NCT00455533-1,Ixabepilone,NCT00455533,Study to Assess Effectiveness of Giving Combination of Standard Chemotherapy Drugs Versus Combination of Standard Chemotherapy and New Drug Ixabepilone When Given Before Surgical Removal of Early Stage Breast Cancer,leukopenia
D009503,0.69,NCT00455533-1,Ixabepilone,NCT00455533,Study to Assess Effectiveness of Giving Combination of Standard Chemotherapy Drugs Versus Combination of Standard Chemotherapy and New Drug Ixabepilone When Given Before Surgical Removal of Early Stage Breast Cancer,neutropenia
D007964,0.69,NCT00455533-1,Ixabepilone,NCT00455533,Study to Assess Effectiveness of Giving Combination of Standard Chemotherapy Drugs Versus Combination of Standard Chemotherapy and New Drug Ixabepilone When Given Before Surgical Removal of Early Stage Breast Cancer,leukocytosis
D013921,0.69,NCT00455533-1,Ixabepilone,NCT00455533,Study to Assess Effectiveness of Giving Combination of Standard Chemotherapy Drugs Versus Combination of Standard Chemotherapy and New Drug Ixabepilone When Given Before Surgical Removal of Early Stage Breast Cancer,thrombocytopenia
D064147,0.69,NCT00455533-1,Ixabepilone,NCT00455533,Study to Assess Effectiveness of Giving Combination of Standard Chemotherapy Drugs Versus Combination of Standard Chemotherapy and New Drug Ixabepilone When Given Before Surgical Removal of Early Stage Breast Cancer,febrile neutropenia
D064147,0.69,NCT00455533-2,Paclitaxel,NCT00455533,Study to Assess Effectiveness of Giving Combination of Standard Chemotherapy Drugs Versus Combination of Standard Chemotherapy and New Drug Ixabepilone When Given Before Surgical Removal of Early Stage Breast Cancer,febrile neutropenia
D011697,0.69,NCT00455533-2,Paclitaxel,NCT00455533,Study to Assess Effectiveness of Giving Combination of Standard Chemotherapy Drugs Versus Combination of Standard Chemotherapy and New Drug Ixabepilone When Given Before Surgical Removal of Early Stage Breast Cancer,thrombotic thrombocytopenic purpura
D004211,0.69,NCT00455533-2,Paclitaxel,NCT00455533,Study to Assess Effectiveness of Giving Combination of Standard Chemotherapy Drugs Versus Combination of Standard Chemotherapy and New Drug Ixabepilone When Given Before Surgical Removal of Early Stage Breast Cancer,disseminated intravascular coagulation
D006333,0.69,NCT00455533-1,Ixabepilone,NCT00455533,Study to Assess Effectiveness of Giving Combination of Standard Chemotherapy Drugs Versus Combination of Standard Chemotherapy and New Drug Ixabepilone When Given Before Surgical Removal of Early Stage Breast Cancer,cardiac failure
D001281,0.69,NCT00455533-1,Ixabepilone,NCT00455533,Study to Assess Effectiveness of Giving Combination of Standard Chemotherapy Drugs Versus Combination of Standard Chemotherapy and New Drug Ixabepilone When Given Before Surgical Removal of Early Stage Breast Cancer,atrial fibrillation
D000072599,0.69,NCT00455533-2,Paclitaxel,NCT00455533,Study to Assess Effectiveness of Giving Combination of Standard Chemotherapy Drugs Versus Combination of Standard Chemotherapy and New Drug Ixabepilone When Given Before Surgical Removal of Early Stage Breast Cancer,cardiorespiratory fitness
D014839,1.38,NCT00455533-1,Ixabepilone,NCT00455533,Study to Assess Effectiveness of Giving Combination of Standard Chemotherapy Drugs Versus Combination of Standard Chemotherapy and New Drug Ixabepilone When Given Before Surgical Removal of Early Stage Breast Cancer,vomiting
UNKNOWN-check-for-typo,2.76,NCT00455533-1,Ixabepilone,NCT00455533,Study to Assess Effectiveness of Giving Combination of Standard Chemotherapy Drugs Versus Combination of Standard Chemotherapy and New Drug Ixabepilone When Given Before Surgical Removal of Early Stage Breast Cancer,D00
D015746,0.69,NCT00455533-1,Ixabepilone,NCT00455533,Study to Assess Effectiveness of Giving Combination of Standard Chemotherapy Drugs Versus Combination of Standard Chemotherapy and New Drug Ixabepilone When Given Before Surgical Removal of Early Stage Breast Cancer,abdominal pain
D042882,0.69,NCT00455533-2,Paclitaxel,NCT00455533,Study to Assess Effectiveness of Giving Combination of Standard Chemotherapy Drugs Versus Combination of Standard Chemotherapy and New Drug Ixabepilone When Given Before Surgical Removal of Early Stage Breast Cancer,gallstones
D005221,1.38,NCT00455533-1,Ixabepilone,NCT00455533,Study to Assess Effectiveness of Giving Combination of Standard Chemotherapy Drugs Versus Combination of Standard Chemotherapy and New Drug Ixabepilone When Given Before Surgical Removal of Early Stage Breast Cancer,fatigue
D005221,0.69,NCT00455533-2,Paclitaxel,NCT00455533,Study to Assess Effectiveness of Giving Combination of Standard Chemotherapy Drugs Versus Combination of Standard Chemotherapy and New Drug Ixabepilone When Given Before Surgical Removal of Early Stage Breast Cancer,fatigue
D005334,2.08,NCT00455533-2,Paclitaxel,NCT00455533,Study to Assess Effectiveness of Giving Combination of Standard Chemotherapy Drugs Versus Combination of Standard Chemotherapy and New Drug Ixabepilone When Given Before Surgical Removal of Early Stage Breast Cancer,pyrexia
D003645,0.69,NCT00455533-2,Paclitaxel,NCT00455533,Study to Assess Effectiveness of Giving Combination of Standard Chemotherapy Drugs Versus Combination of Standard Chemotherapy and New Drug Ixabepilone When Given Before Surgical Removal of Early Stage Breast Cancer,sudden death
D000799,0.69,NCT00455533-2,Paclitaxel,NCT00455533,Study to Assess Effectiveness of Giving Combination of Standard Chemotherapy Drugs Versus Combination of Standard Chemotherapy and New Drug Ixabepilone When Given Before Surgical Removal of Early Stage Breast Cancer,angioedema
UNKNOWN-check-for-typo,0.69,NCT00455533-2,Paclitaxel,NCT00455533,Study to Assess Effectiveness of Giving Combination of Standard Chemotherapy Drugs Versus Combination of Standard Chemotherapy and New Drug Ixabepilone When Given Before Surgical Removal of Early Stage Breast Cancer,D00
D000707,0.69,NCT00455533-1,Ixabepilone,NCT00455533,Study to Assess Effectiveness of Giving Combination of Standard Chemotherapy Drugs Versus Combination of Standard Chemotherapy and New Drug Ixabepilone When Given Before Surgical Removal of Early Stage Breast Cancer,anaphylactic shock
D000707,0.69,NCT00455533-1,Ixabepilone,NCT00455533,Study to Assess Effectiveness of Giving Combination of Standard Chemotherapy Drugs Versus Combination of Standard Chemotherapy and New Drug Ixabepilone When Given Before Surgical Removal of Early Stage Breast Cancer,anaphylactic reaction
D018805,0.69,NCT00455533-2,Paclitaxel,NCT00455533,Study to Assess Effectiveness of Giving Combination of Standard Chemotherapy Drugs Versus Combination of Standard Chemotherapy and New Drug Ixabepilone When Given Before Surgical Removal of Early Stage Breast Cancer,sepsis
D011014,0.69,NCT00455533-1,Ixabepilone,NCT00455533,Study to Assess Effectiveness of Giving Combination of Standard Chemotherapy Drugs Versus Combination of Standard Chemotherapy and New Drug Ixabepilone When Given Before Surgical Removal of Early Stage Breast Cancer,pneumonia
D011014,0.69,NCT00455533-2,Paclitaxel,NCT00455533,Study to Assess Effectiveness of Giving Combination of Standard Chemotherapy Drugs Versus Combination of Standard Chemotherapy and New Drug Ixabepilone When Given Before Surgical Removal of Early Stage Breast Cancer,pneumonia
D014552,0.69,NCT00455533-2,Paclitaxel,NCT00455533,Study to Assess Effectiveness of Giving Combination of Standard Chemotherapy Drugs Versus Combination of Standard Chemotherapy and New Drug Ixabepilone When Given Before Surgical Removal of Early Stage Breast Cancer,urinary tract infection
D012141,0.69,NCT00455533-2,Paclitaxel,NCT00455533,Study to Assess Effectiveness of Giving Combination of Standard Chemotherapy Drugs Versus Combination of Standard Chemotherapy and New Drug Ixabepilone When Given Before Surgical Removal of Early Stage Breast Cancer,respiratory tract infection
D062787,2.07,NCT00455533-1,Ixabepilone,NCT00455533,Study to Assess Effectiveness of Giving Combination of Standard Chemotherapy Drugs Versus Combination of Standard Chemotherapy and New Drug Ixabepilone When Given Before Surgical Removal of Early Stage Breast Cancer,drug overdose
D008508,0.69,NCT00455533-2,Paclitaxel,NCT00455533,Study to Assess Effectiveness of Giving Combination of Standard Chemotherapy Drugs Versus Combination of Standard Chemotherapy and New Drug Ixabepilone When Given Before Surgical Removal of Early Stage Breast Cancer,medication error
D035002,0.69,NCT00455533-1,Ixabepilone,NCT00455533,Study to Assess Effectiveness of Giving Combination of Standard Chemotherapy Drugs Versus Combination of Standard Chemotherapy and New Drug Ixabepilone When Given Before Surgical Removal of Early Stage Breast Cancer,lower limb
D007989,0.69,NCT00455533-2,Paclitaxel,NCT00455533,Study to Assess Effectiveness of Giving Combination of Standard Chemotherapy Drugs Versus Combination of Standard Chemotherapy and New Drug Ixabepilone When Given Before Surgical Removal of Early Stage Breast Cancer,decreased libido
UNKNOWN-check-for-typo,0.69,NCT00455533-2,Paclitaxel,NCT00455533,Study to Assess Effectiveness of Giving Combination of Standard Chemotherapy Drugs Versus Combination of Standard Chemotherapy and New Drug Ixabepilone When Given Before Surgical Removal of Early Stage Breast Cancer,D00
D063806,0.69,NCT00455533-1,Ixabepilone,NCT00455533,Study to Assess Effectiveness of Giving Combination of Standard Chemotherapy Drugs Versus Combination of Standard Chemotherapy and New Drug Ixabepilone When Given Before Surgical Removal of Early Stage Breast Cancer,myalgia
D063806,0.69,NCT00455533-2,Paclitaxel,NCT00455533,Study to Assess Effectiveness of Giving Combination of Standard Chemotherapy Drugs Versus Combination of Standard Chemotherapy and New Drug Ixabepilone When Given Before Surgical Removal of Early Stage Breast Cancer,myalgia
D006261,0.69,NCT00455533-2,Paclitaxel,NCT00455533,Study to Assess Effectiveness of Giving Combination of Standard Chemotherapy Drugs Versus Combination of Standard Chemotherapy and New Drug Ixabepilone When Given Before Surgical Removal of Early Stage Breast Cancer,headache
D000077260,0.69,NCT00455533-1,Ixabepilone,NCT00455533,Study to Assess Effectiveness of Giving Combination of Standard Chemotherapy Drugs Versus Combination of Standard Chemotherapy and New Drug Ixabepilone When Given Before Surgical Removal of Early Stage Breast Cancer,somnolence
D001927,0.69,NCT00455533-1,Ixabepilone,NCT00455533,Study to Assess Effectiveness of Giving Combination of Standard Chemotherapy Drugs Versus Combination of Standard Chemotherapy and New Drug Ixabepilone When Given Before Surgical Removal of Early Stage Breast Cancer,encephalopathy
D003389,0.69,NCT00455533-2,Paclitaxel,NCT00455533,Study to Assess Effectiveness of Giving Combination of Standard Chemotherapy Drugs Versus Combination of Standard Chemotherapy and New Drug Ixabepilone When Given Before Surgical Removal of Early Stage Breast Cancer,cranial neuropathy
D010523,0.69,NCT00455533-1,Ixabepilone,NCT00455533,Study to Assess Effectiveness of Giving Combination of Standard Chemotherapy Drugs Versus Combination of Standard Chemotherapy and New Drug Ixabepilone When Given Before Surgical Removal of Early Stage Breast Cancer,peripheral neuropathy
D020246,0.69,NCT00455533-2,Paclitaxel,NCT00455533,Study to Assess Effectiveness of Giving Combination of Standard Chemotherapy Drugs Versus Combination of Standard Chemotherapy and New Drug Ixabepilone When Given Before Surgical Removal of Early Stage Breast Cancer,venous thrombosis
10034620,1.38,NCT00455533-1,Ixabepilone,NCT00455533,Study to Assess Effectiveness of Giving Combination of Standard Chemotherapy Drugs Versus Combination of Standard Chemotherapy and New Drug Ixabepilone When Given Before Surgical Removal of Early Stage Breast Cancer,peripheral sensory neuropathy
10034620,0.69,NCT00455533-2,Paclitaxel,NCT00455533,Study to Assess Effectiveness of Giving Combination of Standard Chemotherapy Drugs Versus Combination of Standard Chemotherapy and New Drug Ixabepilone When Given Before Surgical Removal of Early Stage Breast Cancer,peripheral sensory neuropathy
D003244,0.69,NCT00455533-1,Ixabepilone,NCT00455533,Study to Assess Effectiveness of Giving Combination of Standard Chemotherapy Drugs Versus Combination of Standard Chemotherapy and New Drug Ixabepilone When Given Before Surgical Removal of Early Stage Breast Cancer,depressed level of consciousness
D003371,0.69,NCT00455533-1,Ixabepilone,NCT00455533,Study to Assess Effectiveness of Giving Combination of Standard Chemotherapy Drugs Versus Combination of Standard Chemotherapy and New Drug Ixabepilone When Given Before Surgical Removal of Early Stage Breast Cancer,cough
D001249,0.69,NCT00455533-2,Paclitaxel,NCT00455533,Study to Assess Effectiveness of Giving Combination of Standard Chemotherapy Drugs Versus Combination of Standard Chemotherapy and New Drug Ixabepilone When Given Before Surgical Removal of Early Stage Breast Cancer,asthma
D000860,0.69,NCT00455533-2,Paclitaxel,NCT00455533,Study to Assess Effectiveness of Giving Combination of Standard Chemotherapy Drugs Versus Combination of Standard Chemotherapy and New Drug Ixabepilone When Given Before Surgical Removal of Early Stage Breast Cancer,hypoxia
UNKNOWN-check-for-typo,2.08,NCT00455533-2,Paclitaxel,NCT00455533,Study to Assess Effectiveness of Giving Combination of Standard Chemotherapy Drugs Versus Combination of Standard Chemotherapy and New Drug Ixabepilone When Given Before Surgical Removal of Early Stage Breast Cancer,D00
D011014,0.69,NCT00455533-2,Paclitaxel,NCT00455533,Study to Assess Effectiveness of Giving Combination of Standard Chemotherapy Drugs Versus Combination of Standard Chemotherapy and New Drug Ixabepilone When Given Before Surgical Removal of Early Stage Breast Cancer,pneumonitis
10068319,0.69,NCT00455533-2,Paclitaxel,NCT00455533,Study to Assess Effectiveness of Giving Combination of Standard Chemotherapy Drugs Versus Combination of Standard Chemotherapy and New Drug Ixabepilone When Given Before Surgical Removal of Early Stage Breast Cancer,oropharyngeal pain
D011655,0.69,NCT00455533-1,Ixabepilone,NCT00455533,Study to Assess Effectiveness of Giving Combination of Standard Chemotherapy Drugs Versus Combination of Standard Chemotherapy and New Drug Ixabepilone When Given Before Surgical Removal of Early Stage Breast Cancer,pulmonary embolism
D011655,0.69,NCT00455533-2,Paclitaxel,NCT00455533,Study to Assess Effectiveness of Giving Combination of Standard Chemotherapy Drugs Versus Combination of Standard Chemotherapy and New Drug Ixabepilone When Given Before Surgical Removal of Early Stage Breast Cancer,pulmonary embolism
D012143,0.69,NCT00455533-2,Paclitaxel,NCT00455533,Study to Assess Effectiveness of Giving Combination of Standard Chemotherapy Drugs Versus Combination of Standard Chemotherapy and New Drug Ixabepilone When Given Before Surgical Removal of Early Stage Breast Cancer,pulmonary physiological phenomenon
D012128,0.69,NCT00455533-2,Paclitaxel,NCT00455533,Study to Assess Effectiveness of Giving Combination of Standard Chemotherapy Drugs Versus Combination of Standard Chemotherapy and New Drug Ixabepilone When Given Before Surgical Removal of Early Stage Breast Cancer,acute respiratory distress syndrome
D005076,0.69,NCT00455533-1,Ixabepilone,NCT00455533,Study to Assess Effectiveness of Giving Combination of Standard Chemotherapy Drugs Versus Combination of Standard Chemotherapy and New Drug Ixabepilone When Given Before Surgical Removal of Early Stage Breast Cancer,rash
D014581,0.69,NCT00455533-1,Ixabepilone,NCT00455533,Study to Assess Effectiveness of Giving Combination of Standard Chemotherapy Drugs Versus Combination of Standard Chemotherapy and New Drug Ixabepilone When Given Before Surgical Removal of Early Stage Breast Cancer,urticaria
D005076,0.69,NCT00455533-2,Paclitaxel,NCT00455533,Study to Assess Effectiveness of Giving Combination of Standard Chemotherapy Drugs Versus Combination of Standard Chemotherapy and New Drug Ixabepilone When Given Before Surgical Removal of Early Stage Breast Cancer,rash
D007022,0.69,NCT00455533-1,Ixabepilone,NCT00455533,Study to Assess Effectiveness of Giving Combination of Standard Chemotherapy Drugs Versus Combination of Standard Chemotherapy and New Drug Ixabepilone When Given Before Surgical Removal of Early Stage Breast Cancer,hypotension
D007022,0.69,NCT00455533-2,Paclitaxel,NCT00455533,Study to Assess Effectiveness of Giving Combination of Standard Chemotherapy Drugs Versus Combination of Standard Chemotherapy and New Drug Ixabepilone When Given Before Surgical Removal of Early Stage Breast Cancer,hypotension
D002406,0.69,NCT00455533-2,Paclitaxel,NCT00455533,Study to Assess Effectiveness of Giving Combination of Standard Chemotherapy Drugs Versus Combination of Standard Chemotherapy and New Drug Ixabepilone When Given Before Surgical Removal of Early Stage Breast Cancer,catheterization peripheral
D064420,24.21,NCT00482391-1,AC PACLITAXEL  TRASTUZUMAB & LAPATINIB,NCT00482391,Doxorubicin and Cyclophosphamide Followed by Paclitaxel  Trastuzumab  and Lapatinib in Treating Patients With HER2/Neu-Overexpressed Breast Cancer,adverse drug events
10050068,1.05,NCT00482391-1,AC PACLITAXEL  TRASTUZUMAB & LAPATINIB,NCT00482391,Doxorubicin and Cyclophosphamide Followed by Paclitaxel  Trastuzumab  and Lapatinib in Treating Patients With HER2/Neu-Overexpressed Breast Cancer,edema limbs
D006406,1.05,NCT00482391-1,AC PACLITAXEL  TRASTUZUMAB & LAPATINIB,NCT00482391,Doxorubicin and Cyclophosphamide Followed by Paclitaxel  Trastuzumab  and Lapatinib in Treating Patients With HER2/Neu-Overexpressed Breast Cancer,hematoma
D006454,2.11,NCT00482391-1,AC PACLITAXEL  TRASTUZUMAB & LAPATINIB,NCT00482391,Doxorubicin and Cyclophosphamide Followed by Paclitaxel  Trastuzumab  and Lapatinib in Treating Patients With HER2/Neu-Overexpressed Breast Cancer,hemoglobin
D007962,1.05,NCT00482391-1,AC PACLITAXEL  TRASTUZUMAB & LAPATINIB,NCT00482391,Doxorubicin and Cyclophosphamide Followed by Paclitaxel  Trastuzumab  and Lapatinib in Treating Patients With HER2/Neu-Overexpressed Breast Cancer,leukocytes
D006973,1.05,NCT00482391-1,AC PACLITAXEL  TRASTUZUMAB & LAPATINIB,NCT00482391,Doxorubicin and Cyclophosphamide Followed by Paclitaxel  Trastuzumab  and Lapatinib in Treating Patients With HER2/Neu-Overexpressed Breast Cancer,hypertension
D007022,2.11,NCT00482391-1,AC PACLITAXEL  TRASTUZUMAB & LAPATINIB,NCT00482391,Doxorubicin and Cyclophosphamide Followed by Paclitaxel  Trastuzumab  and Lapatinib in Treating Patients With HER2/Neu-Overexpressed Breast Cancer,hypotension
D018487,1.05,NCT00482391-1,AC PACLITAXEL  TRASTUZUMAB & LAPATINIB,NCT00482391,Doxorubicin and Cyclophosphamide Followed by Paclitaxel  Trastuzumab  and Lapatinib in Treating Patients With HER2/Neu-Overexpressed Breast Cancer,ventricular dysfunction left
10014383,1.05,NCT00482391-1,AC PACLITAXEL  TRASTUZUMAB & LAPATINIB,NCT00482391,Doxorubicin and Cyclophosphamide Followed by Paclitaxel  Trastuzumab  and Lapatinib in Treating Patients With HER2/Neu-Overexpressed Breast Cancer,electrocardiogram qt corrected interval prolonged
D013616,1.05,NCT00482391-1,AC PACLITAXEL  TRASTUZUMAB & LAPATINIB,NCT00482391,Doxorubicin and Cyclophosphamide Followed by Paclitaxel  Trastuzumab  and Lapatinib in Treating Patients With HER2/Neu-Overexpressed Breast Cancer,sinus tachycardia
D019252,1.05,NCT00482391-1,AC PACLITAXEL  TRASTUZUMAB & LAPATINIB,NCT00482391,Doxorubicin and Cyclophosphamide Followed by Paclitaxel  Trastuzumab  and Lapatinib in Treating Patients With HER2/Neu-Overexpressed Breast Cancer,visualix
D003681,1.05,NCT00482391-1,AC PACLITAXEL  TRASTUZUMAB & LAPATINIB,NCT00482391,Doxorubicin and Cyclophosphamide Followed by Paclitaxel  Trastuzumab  and Lapatinib in Treating Patients With HER2/Neu-Overexpressed Breast Cancer,dehydration
D003967,3.16,NCT00482391-1,AC PACLITAXEL  TRASTUZUMAB & LAPATINIB,NCT00482391,Doxorubicin and Cyclophosphamide Followed by Paclitaxel  Trastuzumab  and Lapatinib in Treating Patients With HER2/Neu-Overexpressed Breast Cancer,diarrhea
10017947,1.05,NCT00482391-1,AC PACLITAXEL  TRASTUZUMAB & LAPATINIB,NCT00482391,Doxorubicin and Cyclophosphamide Followed by Paclitaxel  Trastuzumab  and Lapatinib in Treating Patients With HER2/Neu-Overexpressed Breast Cancer,gastrointestinal disorders - other specify
D009325,1.05,NCT00482391-1,AC PACLITAXEL  TRASTUZUMAB & LAPATINIB,NCT00482391,Doxorubicin and Cyclophosphamide Followed by Paclitaxel  Trastuzumab  and Lapatinib in Treating Patients With HER2/Neu-Overexpressed Breast Cancer,nausea
D001037,1.05,NCT00482391-1,AC PACLITAXEL  TRASTUZUMAB & LAPATINIB,NCT00482391,Doxorubicin and Cyclophosphamide Followed by Paclitaxel  Trastuzumab  and Lapatinib in Treating Patients With HER2/Neu-Overexpressed Breast Cancer,logasthenia
D005334,4.21,NCT00482391-1,AC PACLITAXEL  TRASTUZUMAB & LAPATINIB,NCT00482391,Doxorubicin and Cyclophosphamide Followed by Paclitaxel  Trastuzumab  and Lapatinib in Treating Patients With HER2/Neu-Overexpressed Breast Cancer,fever
D003057,1.05,NCT00482391-1,AC PACLITAXEL  TRASTUZUMAB & LAPATINIB,NCT00482391,Doxorubicin and Cyclophosphamide Followed by Paclitaxel  Trastuzumab  and Lapatinib in Treating Patients With HER2/Neu-Overexpressed Breast Cancer,progeria-like syndrome
D006261,1.05,NCT00482391-1,AC PACLITAXEL  TRASTUZUMAB & LAPATINIB,NCT00482391,Doxorubicin and Cyclophosphamide Followed by Paclitaxel  Trastuzumab  and Lapatinib in Treating Patients With HER2/Neu-Overexpressed Breast Cancer,headache
D063806,1.05,NCT00482391-1,AC PACLITAXEL  TRASTUZUMAB & LAPATINIB,NCT00482391,Doxorubicin and Cyclophosphamide Followed by Paclitaxel  Trastuzumab  and Lapatinib in Treating Patients With HER2/Neu-Overexpressed Breast Cancer,muscle pain
D000080867,1.05,NCT00482391-1,AC PACLITAXEL  TRASTUZUMAB & LAPATINIB,NCT00482391,Doxorubicin and Cyclophosphamide Followed by Paclitaxel  Trastuzumab  and Lapatinib in Treating Patients With HER2/Neu-Overexpressed Breast Cancer,gingipains
D023341,1.05,NCT00482391-1,AC PACLITAXEL  TRASTUZUMAB & LAPATINIB,NCT00482391,Doxorubicin and Cyclophosphamide Followed by Paclitaxel  Trastuzumab  and Lapatinib in Treating Patients With HER2/Neu-Overexpressed Breast Cancer,chills
D008107,1.05,NCT00482391-1,AC PACLITAXEL  TRASTUZUMAB & LAPATINIB,NCT00482391,Doxorubicin and Cyclophosphamide Followed by Paclitaxel  Trastuzumab  and Lapatinib in Treating Patients With HER2/Neu-Overexpressed Breast Cancer,liver dysfunction
D012868,2.11,NCT00482391-1,AC PACLITAXEL  TRASTUZUMAB & LAPATINIB,NCT00482391,Doxorubicin and Cyclophosphamide Followed by Paclitaxel  Trastuzumab  and Lapatinib in Treating Patients With HER2/Neu-Overexpressed Breast Cancer,skin abnormalities
D000080884,1.05,NCT00482391-1,AC PACLITAXEL  TRASTUZUMAB & LAPATINIB,NCT00482391,Doxorubicin and Cyclophosphamide Followed by Paclitaxel  Trastuzumab  and Lapatinib in Treating Patients With HER2/Neu-Overexpressed Breast Cancer,infratemporal fossa
D012885,1.05,NCT00482391-1,AC PACLITAXEL  TRASTUZUMAB & LAPATINIB,NCT00482391,Doxorubicin and Cyclophosphamide Followed by Paclitaxel  Trastuzumab  and Lapatinib in Treating Patients With HER2/Neu-Overexpressed Breast Cancer,skinfold thickness
D011014,1.05,NCT00482391-1,AC PACLITAXEL  TRASTUZUMAB & LAPATINIB,NCT00482391,Doxorubicin and Cyclophosphamide Followed by Paclitaxel  Trastuzumab  and Lapatinib in Treating Patients With HER2/Neu-Overexpressed Breast Cancer,lung inflammation
D055499,1.05,NCT00482391-1,AC PACLITAXEL  TRASTUZUMAB & LAPATINIB,NCT00482391,Doxorubicin and Cyclophosphamide Followed by Paclitaxel  Trastuzumab  and Lapatinib in Treating Patients With HER2/Neu-Overexpressed Breast Cancer,catheter-related infections
10040872,1.05,NCT00482391-1,AC PACLITAXEL  TRASTUZUMAB & LAPATINIB,NCT00482391,Doxorubicin and Cyclophosphamide Followed by Paclitaxel  Trastuzumab  and Lapatinib in Treating Patients With HER2/Neu-Overexpressed Breast Cancer,skin infection
10021881,2.11,NCT00482391-1,AC PACLITAXEL  TRASTUZUMAB & LAPATINIB,NCT00482391,Doxorubicin and Cyclophosphamide Followed by Paclitaxel  Trastuzumab  and Lapatinib in Treating Patients With HER2/Neu-Overexpressed Breast Cancer,infections and infestations - other specify
D006098,1.05,NCT00482391-1,AC PACLITAXEL  TRASTUZUMAB & LAPATINIB,NCT00482391,Doxorubicin and Cyclophosphamide Followed by Paclitaxel  Trastuzumab  and Lapatinib in Treating Patients With HER2/Neu-Overexpressed Breast Cancer,granulocytes
UNKNOWN-check-for-typo,1.05,NCT00482391-1,AC PACLITAXEL  TRASTUZUMAB & LAPATINIB,NCT00482391,Doxorubicin and Cyclophosphamide Followed by Paclitaxel  Trastuzumab  and Lapatinib in Treating Patients With HER2/Neu-Overexpressed Breast Cancer,D00
D003371,1.05,NCT00482391-1,AC PACLITAXEL  TRASTUZUMAB & LAPATINIB,NCT00482391,Doxorubicin and Cyclophosphamide Followed by Paclitaxel  Trastuzumab  and Lapatinib in Treating Patients With HER2/Neu-Overexpressed Breast Cancer,cough
D004417,6.32,NCT00482391-1,AC PACLITAXEL  TRASTUZUMAB & LAPATINIB,NCT00482391,Doxorubicin and Cyclophosphamide Followed by Paclitaxel  Trastuzumab  and Lapatinib in Treating Patients With HER2/Neu-Overexpressed Breast Cancer,breath shortness
D016066,1.05,NCT00482391-1,AC PACLITAXEL  TRASTUZUMAB & LAPATINIB,NCT00482391,Doxorubicin and Cyclophosphamide Followed by Paclitaxel  Trastuzumab  and Lapatinib in Treating Patients With HER2/Neu-Overexpressed Breast Cancer,pleural effusion malignant
D000072106,1.05,NCT00482391-1,AC PACLITAXEL  TRASTUZUMAB & LAPATINIB,NCT00482391,Doxorubicin and Cyclophosphamide Followed by Paclitaxel  Trastuzumab  and Lapatinib in Treating Patients With HER2/Neu-Overexpressed Breast Cancer,pulmonologists
D016769,1.05,NCT00482391-1,AC PACLITAXEL  TRASTUZUMAB & LAPATINIB,NCT00482391,Doxorubicin and Cyclophosphamide Followed by Paclitaxel  Trastuzumab  and Lapatinib in Treating Patients With HER2/Neu-Overexpressed Breast Cancer,embolism and thrombosis
D009026,100.0,NCT00483509-1,A: NGR-hTNF + Doxorubicin,NCT00483509,Study of NGR-hTNF in Combination With Doxorubicin in Patients Affected by Metastatic Small Cell Lung Carcinoma,mortality
D064420,25.0,NCT00483509-1,A: NGR-hTNF + Doxorubicin,NCT00483509,Study of NGR-hTNF in Combination With Doxorubicin in Patients Affected by Metastatic Small Cell Lung Carcinoma,adverse drug events
D064147,3.57,NCT00483509-1,A: NGR-hTNF + Doxorubicin,NCT00483509,Study of NGR-hTNF in Combination With Doxorubicin in Patients Affected by Metastatic Small Cell Lung Carcinoma,febrile neutropenia
UNKNOWN-check-for-typo,3.57,NCT00483509-1,A: NGR-hTNF + Doxorubicin,NCT00483509,Study of NGR-hTNF in Combination With Doxorubicin in Patients Affected by Metastatic Small Cell Lung Carcinoma,D00
D000741,3.57,NCT00483509-1,A: NGR-hTNF + Doxorubicin,NCT00483509,Study of NGR-hTNF in Combination With Doxorubicin in Patients Affected by Metastatic Small Cell Lung Carcinoma,aplastic anaemia
D004751,3.57,NCT00483509-1,A: NGR-hTNF + Doxorubicin,NCT00483509,Study of NGR-hTNF in Combination With Doxorubicin in Patients Affected by Metastatic Small Cell Lung Carcinoma,enteritis
D013280,3.57,NCT00483509-1,A: NGR-hTNF + Doxorubicin,NCT00483509,Study of NGR-hTNF in Combination With Doxorubicin in Patients Affected by Metastatic Small Cell Lung Carcinoma,stomatitis
D005334,3.57,NCT00483509-1,A: NGR-hTNF + Doxorubicin,NCT00483509,Study of NGR-hTNF in Combination With Doxorubicin in Patients Affected by Metastatic Small Cell Lung Carcinoma,fever
D007249,3.57,NCT00483509-1,A: NGR-hTNF + Doxorubicin,NCT00483509,Study of NGR-hTNF in Combination With Doxorubicin in Patients Affected by Metastatic Small Cell Lung Carcinoma,inflammation
D014946,3.57,NCT00483509-1,A: NGR-hTNF + Doxorubicin,NCT00483509,Study of NGR-hTNF in Combination With Doxorubicin in Patients Affected by Metastatic Small Cell Lung Carcinoma,wound infection
D011014,3.57,NCT00483509-1,A: NGR-hTNF + Doxorubicin,NCT00483509,Study of NGR-hTNF in Combination With Doxorubicin in Patients Affected by Metastatic Small Cell Lung Carcinoma,pneumonia
D018908,3.57,NCT00483509-1,A: NGR-hTNF + Doxorubicin,NCT00483509,Study of NGR-hTNF in Combination With Doxorubicin in Patients Affected by Metastatic Small Cell Lung Carcinoma,muscular weakness
D012640,3.57,NCT00483509-1,A: NGR-hTNF + Doxorubicin,NCT00483509,Study of NGR-hTNF in Combination With Doxorubicin in Patients Affected by Metastatic Small Cell Lung Carcinoma,seizure
D011655,3.57,NCT00483509-1,A: NGR-hTNF + Doxorubicin,NCT00483509,Study of NGR-hTNF in Combination With Doxorubicin in Patients Affected by Metastatic Small Cell Lung Carcinoma,pulmonary embolism
D064420,44.83,NCT00494780-1,500 mg Ofatumumab + CHOP,NCT00494780,Ofatumumab (Humax-CD20) With CHOP (Cyclophosphamide Doxorubicin  Vincristine  Predisolone) in Follicular Lymphoma (FL) Patients,adverse drug events
D064420,37.93,NCT00494780-2,1000 mg Ofatumumab + CHOP,NCT00494780,Ofatumumab (Humax-CD20) With CHOP (Cyclophosphamide Doxorubicin  Vincristine  Predisolone) in Follicular Lymphoma (FL) Patients,adverse drug events
D064420,3.45,NCT00494780-3,500 mg Ofatumumab + CHOP: Extended Follow-up,NCT00494780,Ofatumumab (Humax-CD20) With CHOP (Cyclophosphamide Doxorubicin  Vincristine  Predisolone) in Follicular Lymphoma (FL) Patients,adverse drug events
D064420,20.69,NCT00494780-4,1000 mg Ofatumumab + CHOP: Extended Follow-up,NCT00494780,Ofatumumab (Humax-CD20) With CHOP (Cyclophosphamide Doxorubicin  Vincristine  Predisolone) in Follicular Lymphoma (FL) Patients,adverse drug events
D007970,17.24,NCT00494780-1,500 mg Ofatumumab + CHOP,NCT00494780,Ofatumumab (Humax-CD20) With CHOP (Cyclophosphamide Doxorubicin  Vincristine  Predisolone) in Follicular Lymphoma (FL) Patients,leukopenia
D007970,10.34,NCT00494780-2,1000 mg Ofatumumab + CHOP,NCT00494780,Ofatumumab (Humax-CD20) With CHOP (Cyclophosphamide Doxorubicin  Vincristine  Predisolone) in Follicular Lymphoma (FL) Patients,leukopenia
D009503,13.79,NCT00494780-1,500 mg Ofatumumab + CHOP,NCT00494780,Ofatumumab (Humax-CD20) With CHOP (Cyclophosphamide Doxorubicin  Vincristine  Predisolone) in Follicular Lymphoma (FL) Patients,neutropenia
D009503,10.34,NCT00494780-2,1000 mg Ofatumumab + CHOP,NCT00494780,Ofatumumab (Humax-CD20) With CHOP (Cyclophosphamide Doxorubicin  Vincristine  Predisolone) in Follicular Lymphoma (FL) Patients,neutropenia
D064147,6.9,NCT00494780-1,500 mg Ofatumumab + CHOP,NCT00494780,Ofatumumab (Humax-CD20) With CHOP (Cyclophosphamide Doxorubicin  Vincristine  Predisolone) in Follicular Lymphoma (FL) Patients,febrile neutropenia
D064147,6.9,NCT00494780-2,1000 mg Ofatumumab + CHOP,NCT00494780,Ofatumumab (Humax-CD20) With CHOP (Cyclophosphamide Doxorubicin  Vincristine  Predisolone) in Follicular Lymphoma (FL) Patients,febrile neutropenia
D001201,3.45,NCT00494780-2,1000 mg Ofatumumab + CHOP,NCT00494780,Ofatumumab (Humax-CD20) With CHOP (Cyclophosphamide Doxorubicin  Vincristine  Predisolone) in Follicular Lymphoma (FL) Patients,ascites
D045823,3.45,NCT00494780-2,1000 mg Ofatumumab + CHOP,NCT00494780,Ofatumumab (Humax-CD20) With CHOP (Cyclophosphamide Doxorubicin  Vincristine  Predisolone) in Follicular Lymphoma (FL) Patients,ileus
D009325,3.45,NCT00494780-2,1000 mg Ofatumumab + CHOP,NCT00494780,Ofatumumab (Humax-CD20) With CHOP (Cyclophosphamide Doxorubicin  Vincristine  Predisolone) in Follicular Lymphoma (FL) Patients,nausea
D010538,3.45,NCT00494780-2,1000 mg Ofatumumab + CHOP,NCT00494780,Ofatumumab (Humax-CD20) With CHOP (Cyclophosphamide Doxorubicin  Vincristine  Predisolone) in Follicular Lymphoma (FL) Patients,peritonitis
10041103,3.45,NCT00494780-2,1000 mg Ofatumumab + CHOP,NCT00494780,Ofatumumab (Humax-CD20) With CHOP (Cyclophosphamide Doxorubicin  Vincristine  Predisolone) in Follicular Lymphoma (FL) Patients,small intestinal perforation
D005334,6.9,NCT00494780-1,500 mg Ofatumumab + CHOP,NCT00494780,Ofatumumab (Humax-CD20) With CHOP (Cyclophosphamide Doxorubicin  Vincristine  Predisolone) in Follicular Lymphoma (FL) Patients,pyrexia
D000075662,3.45,NCT00494780-1,500 mg Ofatumumab + CHOP,NCT00494780,Ofatumumab (Humax-CD20) With CHOP (Cyclophosphamide Doxorubicin  Vincristine  Predisolone) in Follicular Lymphoma (FL) Patients,injection site reaction
D018450,3.45,NCT00494780-1,500 mg Ofatumumab + CHOP,NCT00494780,Ofatumumab (Humax-CD20) With CHOP (Cyclophosphamide Doxorubicin  Vincristine  Predisolone) in Follicular Lymphoma (FL) Patients,disease progression
D006547,6.9,NCT00494780-4,1000 mg Ofatumumab + CHOP: Extended Follow-up,NCT00494780,Ofatumumab (Humax-CD20) With CHOP (Cyclophosphamide Doxorubicin  Vincristine  Predisolone) in Follicular Lymphoma (FL) Patients,hernia
D000080424,3.45,NCT00494780-1,500 mg Ofatumumab + CHOP,NCT00494780,Ofatumumab (Humax-CD20) With CHOP (Cyclophosphamide Doxorubicin  Vincristine  Predisolone) in Follicular Lymphoma (FL) Patients,cytokine release syndrome
D006967,3.45,NCT00494780-1,500 mg Ofatumumab + CHOP,NCT00494780,Ofatumumab (Humax-CD20) With CHOP (Cyclophosphamide Doxorubicin  Vincristine  Predisolone) in Follicular Lymphoma (FL) Patients,hypersensitivity
D006967,3.45,NCT00494780-2,1000 mg Ofatumumab + CHOP,NCT00494780,Ofatumumab (Humax-CD20) With CHOP (Cyclophosphamide Doxorubicin  Vincristine  Predisolone) in Follicular Lymphoma (FL) Patients,hypersensitivity
10061229,3.45,NCT00494780-1,500 mg Ofatumumab + CHOP,NCT00494780,Ofatumumab (Humax-CD20) With CHOP (Cyclophosphamide Doxorubicin  Vincristine  Predisolone) in Follicular Lymphoma (FL) Patients,lung infection
D002177,3.45,NCT00494780-1,500 mg Ofatumumab + CHOP,NCT00494780,Ofatumumab (Humax-CD20) With CHOP (Cyclophosphamide Doxorubicin  Vincristine  Predisolone) in Follicular Lymphoma (FL) Patients,candidiasis
D004886,3.45,NCT00494780-4,1000 mg Ofatumumab + CHOP: Extended Follow-up,NCT00494780,Ofatumumab (Humax-CD20) With CHOP (Cyclophosphamide Doxorubicin  Vincristine  Predisolone) in Follicular Lymphoma (FL) Patients,erysipelas
D005360,3.45,NCT00494780-3,500 mg Ofatumumab + CHOP: Extended Follow-up,NCT00494780,Ofatumumab (Humax-CD20) With CHOP (Cyclophosphamide Doxorubicin  Vincristine  Predisolone) in Follicular Lymphoma (FL) Patients,fibula
D000070600,3.45,NCT00494780-4,1000 mg Ofatumumab + CHOP: Extended Follow-up,NCT00494780,Ofatumumab (Humax-CD20) With CHOP (Cyclophosphamide Doxorubicin  Vincristine  Predisolone) in Follicular Lymphoma (FL) Patients,injury tibial meniscus
D013851,3.45,NCT00494780-2,1000 mg Ofatumumab + CHOP,NCT00494780,Ofatumumab (Humax-CD20) With CHOP (Cyclophosphamide Doxorubicin  Vincristine  Predisolone) in Follicular Lymphoma (FL) Patients,underweight
10001551,3.45,NCT00494780-1,500 mg Ofatumumab + CHOP,NCT00494780,Ofatumumab (Humax-CD20) With CHOP (Cyclophosphamide Doxorubicin  Vincristine  Predisolone) in Follicular Lymphoma (FL) Patients,alanine aminotransferase increased
D006943,3.45,NCT00494780-2,1000 mg Ofatumumab + CHOP,NCT00494780,Ofatumumab (Humax-CD20) With CHOP (Cyclophosphamide Doxorubicin  Vincristine  Predisolone) in Follicular Lymphoma (FL) Patients,hyperglycemia
D010522,3.45,NCT00494780-2,1000 mg Ofatumumab + CHOP,NCT00494780,Ofatumumab (Humax-CD20) With CHOP (Cyclophosphamide Doxorubicin  Vincristine  Predisolone) in Follicular Lymphoma (FL) Patients,periostitis
D007403,3.45,NCT00494780-4,1000 mg Ofatumumab + CHOP: Extended Follow-up,NCT00494780,Ofatumumab (Humax-CD20) With CHOP (Cyclophosphamide Doxorubicin  Vincristine  Predisolone) in Follicular Lymphoma (FL) Patients,intervertebral disc
D010051,3.45,NCT00494780-2,1000 mg Ofatumumab + CHOP,NCT00494780,Ofatumumab (Humax-CD20) With CHOP (Cyclophosphamide Doxorubicin  Vincristine  Predisolone) in Follicular Lymphoma (FL) Patients,ovarian cancer
D011471,3.45,NCT00494780-2,1000 mg Ofatumumab + CHOP,NCT00494780,Ofatumumab (Humax-CD20) With CHOP (Cyclophosphamide Doxorubicin  Vincristine  Predisolone) in Follicular Lymphoma (FL) Patients,prostate cancer
D002280,3.45,NCT00494780-2,1000 mg Ofatumumab + CHOP,NCT00494780,Ofatumumab (Humax-CD20) With CHOP (Cyclophosphamide Doxorubicin  Vincristine  Predisolone) in Follicular Lymphoma (FL) Patients,basal cell carcinoma
D009369,3.45,NCT00494780-4,1000 mg Ofatumumab + CHOP: Extended Follow-up,NCT00494780,Ofatumumab (Humax-CD20) With CHOP (Cyclophosphamide Doxorubicin  Vincristine  Predisolone) in Follicular Lymphoma (FL) Patients,cancer
D008881,3.45,NCT00494780-2,1000 mg Ofatumumab + CHOP,NCT00494780,Ofatumumab (Humax-CD20) With CHOP (Cyclophosphamide Doxorubicin  Vincristine  Predisolone) in Follicular Lymphoma (FL) Patients,migraine
D013575,3.45,NCT00494780-2,1000 mg Ofatumumab + CHOP,NCT00494780,Ofatumumab (Humax-CD20) With CHOP (Cyclophosphamide Doxorubicin  Vincristine  Predisolone) in Follicular Lymphoma (FL) Patients,presyncope
D010048,3.45,NCT00494780-2,1000 mg Ofatumumab + CHOP,NCT00494780,Ofatumumab (Humax-CD20) With CHOP (Cyclophosphamide Doxorubicin  Vincristine  Predisolone) in Follicular Lymphoma (FL) Patients,ovarian cyst
D012867,3.45,NCT00494780-2,1000 mg Ofatumumab + CHOP,NCT00494780,Ofatumumab (Humax-CD20) With CHOP (Cyclophosphamide Doxorubicin  Vincristine  Predisolone) in Follicular Lymphoma (FL) Patients,skin
D012393,3.45,NCT00494780-2,1000 mg Ofatumumab + CHOP,NCT00494780,Ofatumumab (Humax-CD20) With CHOP (Cyclophosphamide Doxorubicin  Vincristine  Predisolone) in Follicular Lymphoma (FL) Patients,rosacea
UNKNOWN-check-for-typo,3.45,NCT00494780-2,1000 mg Ofatumumab + CHOP,NCT00494780,Ofatumumab (Humax-CD20) With CHOP (Cyclophosphamide Doxorubicin  Vincristine  Predisolone) in Follicular Lymphoma (FL) Patients,D00
D007238,3.45,NCT00494780-4,1000 mg Ofatumumab + CHOP: Extended Follow-up,NCT00494780,Ofatumumab (Humax-CD20) With CHOP (Cyclophosphamide Doxorubicin  Vincristine  Predisolone) in Follicular Lymphoma (FL) Patients,infarction
D064420,65.85,NCT00499122-1,NOV-002 and Chemotherapy,NCT00499122,NOV-002  Doxorubicin  Cyclophosphamide  and Docetaxel in Women With Newly Diagnosed Stage II or IIIC Breast Cancer,adverse drug events
D064147,9.76,NCT00499122-1,NOV-002 and Chemotherapy,NCT00499122,NOV-002  Doxorubicin  Cyclophosphamide  and Docetaxel in Women With Newly Diagnosed Stage II or IIIC Breast Cancer,febrile neutropenia
D009503,2.44,NCT00499122-1,NOV-002 and Chemotherapy,NCT00499122,NOV-002  Doxorubicin  Cyclophosphamide  and Docetaxel in Women With Newly Diagnosed Stage II or IIIC Breast Cancer,neutropenia
D020246,2.44,NCT00499122-1,NOV-002 and Chemotherapy,NCT00499122,NOV-002  Doxorubicin  Cyclophosphamide  and Docetaxel in Women With Newly Diagnosed Stage II or IIIC Breast Cancer,deep vein thrombosis
D011655,2.44,NCT00499122-1,NOV-002 and Chemotherapy,NCT00499122,NOV-002  Doxorubicin  Cyclophosphamide  and Docetaxel in Women With Newly Diagnosed Stage II or IIIC Breast Cancer,pulmonary embolism
D005263,2.44,NCT00499122-1,NOV-002 and Chemotherapy,NCT00499122,NOV-002  Doxorubicin  Cyclophosphamide  and Docetaxel in Women With Newly Diagnosed Stage II or IIIC Breast Cancer,femoral artery
D015746,4.88,NCT00499122-1,NOV-002 and Chemotherapy,NCT00499122,NOV-002  Doxorubicin  Cyclophosphamide  and Docetaxel in Women With Newly Diagnosed Stage II or IIIC Breast Cancer,abdominal pain
D003248,2.44,NCT00499122-1,NOV-002 and Chemotherapy,NCT00499122,NOV-002  Doxorubicin  Cyclophosphamide  and Docetaxel in Women With Newly Diagnosed Stage II or IIIC Breast Cancer,constipation
D005221,4.88,NCT00499122-1,NOV-002 and Chemotherapy,NCT00499122,NOV-002  Doxorubicin  Cyclophosphamide  and Docetaxel in Women With Newly Diagnosed Stage II or IIIC Breast Cancer,fatigue
D006261,2.44,NCT00499122-1,NOV-002 and Chemotherapy,NCT00499122,NOV-002  Doxorubicin  Cyclophosphamide  and Docetaxel in Women With Newly Diagnosed Stage II or IIIC Breast Cancer,headache
D009325,2.44,NCT00499122-1,NOV-002 and Chemotherapy,NCT00499122,NOV-002  Doxorubicin  Cyclophosphamide  and Docetaxel in Women With Newly Diagnosed Stage II or IIIC Breast Cancer,nausea
D002481,2.44,NCT00499122-1,NOV-002 and Chemotherapy,NCT00499122,NOV-002  Doxorubicin  Cyclophosphamide  and Docetaxel in Women With Newly Diagnosed Stage II or IIIC Breast Cancer,cellulitis
D018908,2.44,NCT00499122-1,NOV-002 and Chemotherapy,NCT00499122,NOV-002  Doxorubicin  Cyclophosphamide  and Docetaxel in Women With Newly Diagnosed Stage II or IIIC Breast Cancer,muscular weakness
D007645,14.63,NCT00499122-1,NOV-002 and Chemotherapy,NCT00499122,NOV-002  Doxorubicin  Cyclophosphamide  and Docetaxel in Women With Newly Diagnosed Stage II or IIIC Breast Cancer,keratosis palmaris et plantaris
D002607,9.76,NCT00499122-1,NOV-002 and Chemotherapy,NCT00499122,NOV-002  Doxorubicin  Cyclophosphamide  and Docetaxel in Women With Newly Diagnosed Stage II or IIIC Breast Cancer,hereditary type i motor and sensory neuropathy
D064420,69.12,NCT00513695-1,Treatment (Neoadjuvant Chemotherapy Before Surgery),NCT00513695,Sunitinib Malate  Paclitaxel  Doxorubicin Hydrochloride  and Cyclophosphamide Before Surgery in Treating Patients With Stage IIB-IIIC Breast Cancer,adverse drug events
D009503,69.12,NCT00513695-1,Treatment (Neoadjuvant Chemotherapy Before Surgery),NCT00513695,Sunitinib Malate  Paclitaxel  Doxorubicin Hydrochloride  and Cyclophosphamide Before Surgery in Treating Patients With Stage IIB-IIIC Breast Cancer,neutropenia
UNKNOWN-check-for-typo,33.82,NCT00513695-1,Treatment (Neoadjuvant Chemotherapy Before Surgery),NCT00513695,Sunitinib Malate  Paclitaxel  Doxorubicin Hydrochloride  and Cyclophosphamide Before Surgery in Treating Patients With Stage IIB-IIIC Breast Cancer,D00
D000740,22.06,NCT00513695-1,Treatment (Neoadjuvant Chemotherapy Before Surgery),NCT00513695,Sunitinib Malate  Paclitaxel  Doxorubicin Hydrochloride  and Cyclophosphamide Before Surgery in Treating Patients With Stage IIB-IIIC Breast Cancer,anemia
D003967,4.41,NCT00513695-1,Treatment (Neoadjuvant Chemotherapy Before Surgery),NCT00513695,Sunitinib Malate  Paclitaxel  Doxorubicin Hydrochloride  and Cyclophosphamide Before Surgery in Treating Patients With Stage IIB-IIIC Breast Cancer,diarrhea
D009325,1.47,NCT00513695-1,Treatment (Neoadjuvant Chemotherapy Before Surgery),NCT00513695,Sunitinib Malate  Paclitaxel  Doxorubicin Hydrochloride  and Cyclophosphamide Before Surgery in Treating Patients With Stage IIB-IIIC Breast Cancer,nausea
D005221,4.41,NCT00513695-1,Treatment (Neoadjuvant Chemotherapy Before Surgery),NCT00513695,Sunitinib Malate  Paclitaxel  Doxorubicin Hydrochloride  and Cyclophosphamide Before Surgery in Treating Patients With Stage IIB-IIIC Breast Cancer,fatigue
D010146,2.94,NCT00513695-1,Treatment (Neoadjuvant Chemotherapy Before Surgery),NCT00513695,Sunitinib Malate  Paclitaxel  Doxorubicin Hydrochloride  and Cyclophosphamide Before Surgery in Treating Patients With Stage IIB-IIIC Breast Cancer,pain
D000068736,5.88,NCT00513695-1,Treatment (Neoadjuvant Chemotherapy Before Surgery),NCT00513695,Sunitinib Malate  Paclitaxel  Doxorubicin Hydrochloride  and Cyclophosphamide Before Surgery in Treating Patients With Stage IIB-IIIC Breast Cancer,cymbalta
D002607,4.41,NCT00513695-1,Treatment (Neoadjuvant Chemotherapy Before Surgery),NCT00513695,Sunitinib Malate  Paclitaxel  Doxorubicin Hydrochloride  and Cyclophosphamide Before Surgery in Treating Patients With Stage IIB-IIIC Breast Cancer,hereditary type i motor and sensory neuropathy
D052016,10.29,NCT00513695-1,Treatment (Neoadjuvant Chemotherapy Before Surgery),NCT00513695,Sunitinib Malate  Paclitaxel  Doxorubicin Hydrochloride  and Cyclophosphamide Before Surgery in Treating Patients With Stage IIB-IIIC Breast Cancer,mucositis
D005076,1.47,NCT00513695-1,Treatment (Neoadjuvant Chemotherapy Before Surgery),NCT00513695,Sunitinib Malate  Paclitaxel  Doxorubicin Hydrochloride  and Cyclophosphamide Before Surgery in Treating Patients With Stage IIB-IIIC Breast Cancer,rash
10028689,2.94,NCT00513695-1,Treatment (Neoadjuvant Chemotherapy Before Surgery),NCT00513695,Sunitinib Malate  Paclitaxel  Doxorubicin Hydrochloride  and Cyclophosphamide Before Surgery in Treating Patients With Stage IIB-IIIC Breast Cancer,nail changes
D009026,18.18,NCT00520130-1,A - Tacrolimus Methotrexate Sirolimus (TMS) Arm,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,mortality
D009026,42.22,NCT00520130-2,B - Cyclosporine (AC) Arm,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,mortality
D064420,81.82,NCT00520130-1,A - Tacrolimus Methotrexate Sirolimus (TMS) Arm,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,adverse drug events
D064420,91.11,NCT00520130-2,B - Cyclosporine (AC) Arm,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,adverse drug events
10050068,2.27,NCT00520130-1,A - Tacrolimus Methotrexate Sirolimus (TMS) Arm,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,edema limbs
D000799,2.27,NCT00520130-1,A - Tacrolimus Methotrexate Sirolimus (TMS) Arm,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,angioedema
D006454,6.82,NCT00520130-1,A - Tacrolimus Methotrexate Sirolimus (TMS) Arm,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,hemoglobin
D006454,4.44,NCT00520130-2,B - Cyclosporine (AC) Arm,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,hemoglobin
D006461,2.22,NCT00520130-2,B - Cyclosporine (AC) Arm,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,hemolysis
D019190,2.22,NCT00520130-2,B - Cyclosporine (AC) Arm,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,iron overload
D007962,4.44,NCT00520130-2,B - Cyclosporine (AC) Arm,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,leukocytes
D008231,2.27,NCT00520130-1,A - Tacrolimus Methotrexate Sirolimus (TMS) Arm,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,lymphopenia
D008231,4.44,NCT00520130-2,B - Cyclosporine (AC) Arm,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,lymphopenia
D006098,6.82,NCT00520130-1,A - Tacrolimus Methotrexate Sirolimus (TMS) Arm,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,granulocytes
D006098,2.22,NCT00520130-2,B - Cyclosporine (AC) Arm,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,granulocytes
D010314,2.27,NCT00520130-1,A - Tacrolimus Methotrexate Sirolimus (TMS) Arm,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,partial thromboplastin time
D001792,2.27,NCT00520130-1,A - Tacrolimus Methotrexate Sirolimus (TMS) Arm,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,platelets
D001792,4.44,NCT00520130-2,B - Cyclosporine (AC) Arm,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,platelets
D057049,4.55,NCT00520130-1,A - Tacrolimus Methotrexate Sirolimus (TMS) Arm,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,thrombotic microangiopathy
D057049,2.22,NCT00520130-2,B - Cyclosporine (AC) Arm,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,thrombotic microangiopathy
D006342,2.27,NCT00520130-1,A - Tacrolimus Methotrexate Sirolimus (TMS) Arm,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,cardiac rupture post-infarction
D006323,2.27,NCT00520130-1,A - Tacrolimus Methotrexate Sirolimus (TMS) Arm,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,cardiopulmonary arrest
D006973,11.11,NCT00520130-2,B - Cyclosporine (AC) Arm,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,hypertension
D007022,6.82,NCT00520130-1,A - Tacrolimus Methotrexate Sirolimus (TMS) Arm,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,hypotension
D007022,11.11,NCT00520130-2,B - Cyclosporine (AC) Arm,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,hypotension
D018487,2.27,NCT00520130-1,A - Tacrolimus Methotrexate Sirolimus (TMS) Arm,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,ventricular dysfunction left
D018487,2.22,NCT00520130-2,B - Cyclosporine (AC) Arm,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,ventricular dysfunction left
10069501,4.55,NCT00520130-1,A - Tacrolimus Methotrexate Sirolimus (TMS) Arm,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,left ventricular systolic dysfunction
10069501,8.89,NCT00520130-2,B - Cyclosporine (AC) Arm,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,left ventricular systolic dysfunction
D018497,2.22,NCT00520130-2,B - Cyclosporine (AC) Arm,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,ventricular dysfunction right
D001146,6.82,NCT00520130-1,A - Tacrolimus Methotrexate Sirolimus (TMS) Arm,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,sinoatrial arrhythmia
D001146,4.44,NCT00520130-2,B - Cyclosporine (AC) Arm,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,arrhythmia sinus
D013617,2.22,NCT00520130-2,B - Cyclosporine (AC) Arm,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,tachycardia supraventricular
D013617,2.22,NCT00520130-2,B - Cyclosporine (AC) Arm,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,tachycardia supraventricular
D000309,2.22,NCT00520130-2,B - Cyclosporine (AC) Arm,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,adrenal insufficiency
D018149,4.55,NCT00520130-1,A - Tacrolimus Methotrexate Sirolimus (TMS) Arm,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,glucose intolerance
D018149,2.22,NCT00520130-2,B - Cyclosporine (AC) Arm,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,glucose intolerance
D015352,6.82,NCT00520130-1,A - Tacrolimus Methotrexate Sirolimus (TMS) Arm,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,dry eye syndrome
D019252,2.22,NCT00520130-2,B - Cyclosporine (AC) Arm,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,visualix
D003092,2.22,NCT00520130-2,B - Cyclosporine (AC) Arm,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,colitis
D004761,11.36,NCT00520130-1,A - Tacrolimus Methotrexate Sirolimus (TMS) Arm,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,clostridium enterocolitis
D004761,15.56,NCT00520130-2,B - Cyclosporine (AC) Arm,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,clostridium enterocolitis
D003967,18.18,NCT00520130-1,A - Tacrolimus Methotrexate Sirolimus (TMS) Arm,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,diarrhea
D003967,17.78,NCT00520130-2,B - Cyclosporine (AC) Arm,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,diarrhea
D003679,2.27,NCT00520130-1,A - Tacrolimus Methotrexate Sirolimus (TMS) Arm,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,swallowing
D003679,4.44,NCT00520130-2,B - Cyclosporine (AC) Arm,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,swallowing
D004941,2.22,NCT00520130-2,B - Cyclosporine (AC) Arm,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,esophagitis
D005756,4.55,NCT00520130-1,A - Tacrolimus Methotrexate Sirolimus (TMS) Arm,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,gastritis
D004415,2.22,NCT00520130-2,B - Cyclosporine (AC) Arm,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,dyspepsia
D006471,2.22,NCT00520130-2,B - Cyclosporine (AC) Arm,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,gastrointestinal hemorrhage
D006471,2.22,NCT00520130-2,B - Cyclosporine (AC) Arm,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,gastrointestinal hemorrhage
10051746,6.67,NCT00520130-2,B - Cyclosporine (AC) Arm,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,lower gastrointestinal hemorrhage
D006471,2.22,NCT00520130-2,B - Cyclosporine (AC) Arm,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,gastrointestinal hemorrhage
10055356,2.22,NCT00520130-2,B - Cyclosporine (AC) Arm,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,upper gastrointestinal hemorrhage
D005767,2.27,NCT00520130-1,A - Tacrolimus Methotrexate Sirolimus (TMS) Arm,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,functional gastrointestinal disorders
D005767,2.22,NCT00520130-2,B - Cyclosporine (AC) Arm,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,functional gastrointestinal disorders
D003945,6.82,NCT00520130-1,A - Tacrolimus Methotrexate Sirolimus (TMS) Arm,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,examination oral
D009055,2.27,NCT00520130-1,A - Tacrolimus Methotrexate Sirolimus (TMS) Arm,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,oral cavity
D009325,2.27,NCT00520130-1,A - Tacrolimus Methotrexate Sirolimus (TMS) Arm,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,nausea
D009325,4.44,NCT00520130-2,B - Cyclosporine (AC) Arm,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,nausea
D000005,2.27,NCT00520130-1,A - Tacrolimus Methotrexate Sirolimus (TMS) Arm,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,abdomen
10041103,2.27,NCT00520130-1,A - Tacrolimus Methotrexate Sirolimus (TMS) Arm,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,small intestinal perforation
10065879,2.27,NCT00520130-1,A - Tacrolimus Methotrexate Sirolimus (TMS) Arm,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,gastrointestinal anastomotic leak
D004386,2.27,NCT00520130-1,A - Tacrolimus Methotrexate Sirolimus (TMS) Arm,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,duodenum
D003643,9.09,NCT00520130-1,A - Tacrolimus Methotrexate Sirolimus (TMS) Arm,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,death
D003643,15.56,NCT00520130-2,B - Cyclosporine (AC) Arm,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,death
D018450,6.82,NCT00520130-1,A - Tacrolimus Methotrexate Sirolimus (TMS) Arm,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,disease progression
D018450,22.22,NCT00520130-2,B - Cyclosporine (AC) Arm,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,disease progression
D009102,2.27,NCT00520130-1,A - Tacrolimus Methotrexate Sirolimus (TMS) Arm,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,multiple organ failure
D009102,4.44,NCT00520130-2,B - Cyclosporine (AC) Arm,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,multiple organ failure
D001037,2.22,NCT00520130-2,B - Cyclosporine (AC) Arm,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,logasthenia
D009503,4.55,NCT00520130-1,A - Tacrolimus Methotrexate Sirolimus (TMS) Arm,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,neutropenia
D009503,2.22,NCT00520130-2,B - Cyclosporine (AC) Arm,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,neutropenia
D015275,2.22,NCT00520130-2,B - Cyclosporine (AC) Arm,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,tumor lysis syndrome
D015430,2.22,NCT00520130-2,B - Cyclosporine (AC) Arm,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,weight gain
D002764,2.27,NCT00520130-1,A - Tacrolimus Methotrexate Sirolimus (TMS) Arm,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,cholecystitis
D002764,2.22,NCT00520130-2,B - Cyclosporine (AC) Arm,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,cholecystitis
D008107,2.27,NCT00520130-1,A - Tacrolimus Methotrexate Sirolimus (TMS) Arm,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,liver dysfunction
D004342,4.55,NCT00520130-1,A - Tacrolimus Methotrexate Sirolimus (TMS) Arm,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,drug hypersensitivity
D000080424,2.22,NCT00520130-2,B - Cyclosporine (AC) Arm,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,cytokine release syndrome
D064147,13.64,NCT00520130-1,A - Tacrolimus Methotrexate Sirolimus (TMS) Arm,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,febrile neutropenia
D064147,13.33,NCT00520130-2,B - Cyclosporine (AC) Arm,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,febrile neutropenia
D000069544,2.22,NCT00520130-2,B - Cyclosporine (AC) Arm,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,encephalitis infection
10005047,2.22,NCT00520130-2,B - Cyclosporine (AC) Arm,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,bladder infection
D000069544,6.82,NCT00520130-1,A - Tacrolimus Methotrexate Sirolimus (TMS) Arm,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,encephalitis infection
D000069544,17.78,NCT00520130-2,B - Cyclosporine (AC) Arm,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,encephalitis infection
D055499,2.27,NCT00520130-1,A - Tacrolimus Methotrexate Sirolimus (TMS) Arm,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,catheter-related infections
D055499,8.89,NCT00520130-2,B - Cyclosporine (AC) Arm,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,catheter-related infections
10065755,2.22,NCT00520130-2,B - Cyclosporine (AC) Arm,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,lip infection
10061229,9.09,NCT00520130-1,A - Tacrolimus Methotrexate Sirolimus (TMS) Arm,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,lung infection
10061229,6.67,NCT00520130-2,B - Cyclosporine (AC) Arm,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,lung infection
D000069544,2.27,NCT00520130-1,A - Tacrolimus Methotrexate Sirolimus (TMS) Arm,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,encephalitis infection
D000069544,2.22,NCT00520130-2,B - Cyclosporine (AC) Arm,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,encephalitis infection
D000069544,2.22,NCT00520130-2,B - Cyclosporine (AC) Arm,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,encephalitis infection
D000069544,2.27,NCT00520130-1,A - Tacrolimus Methotrexate Sirolimus (TMS) Arm,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,encephalitis infection
D012852,4.55,NCT00520130-1,A - Tacrolimus Methotrexate Sirolimus (TMS) Arm,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,sinus infection
D012852,4.44,NCT00520130-2,B - Cyclosporine (AC) Arm,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,sinus infection
D000069544,2.27,NCT00520130-1,A - Tacrolimus Methotrexate Sirolimus (TMS) Arm,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,encephalitis infection
D012141,2.22,NCT00520130-2,B - Cyclosporine (AC) Arm,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,infections upper respiratory
D014552,4.55,NCT00520130-1,A - Tacrolimus Methotrexate Sirolimus (TMS) Arm,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,urinary tract infections
D014552,2.22,NCT00520130-2,B - Cyclosporine (AC) Arm,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,urinary tract infections
10021881,2.27,NCT00520130-1,A - Tacrolimus Methotrexate Sirolimus (TMS) Arm,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,infections and infestations - other specify
10021881,4.44,NCT00520130-2,B - Cyclosporine (AC) Arm,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,infections and infestations - other specify
10005047,2.27,NCT00520130-1,A - Tacrolimus Methotrexate Sirolimus (TMS) Arm,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,bladder infection
10005047,2.22,NCT00520130-2,B - Cyclosporine (AC) Arm,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,bladder infection
D000069544,20.45,NCT00520130-1,A - Tacrolimus Methotrexate Sirolimus (TMS) Arm,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,encephalitis infection
D000069544,46.67,NCT00520130-2,B - Cyclosporine (AC) Arm,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,encephalitis infection
D000069544,6.82,NCT00520130-1,A - Tacrolimus Methotrexate Sirolimus (TMS) Arm,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,encephalitis infection
D000069544,4.55,NCT00520130-1,A - Tacrolimus Methotrexate Sirolimus (TMS) Arm,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,encephalitis infection
D000069544,2.22,NCT00520130-2,B - Cyclosporine (AC) Arm,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,encephalitis infection
D055499,9.09,NCT00520130-1,A - Tacrolimus Methotrexate Sirolimus (TMS) Arm,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,catheter-related infections
D055499,26.67,NCT00520130-2,B - Cyclosporine (AC) Arm,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,catheter-related infections
D000069544,2.22,NCT00520130-2,B - Cyclosporine (AC) Arm,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,encephalitis infection
D000069544,2.27,NCT00520130-1,A - Tacrolimus Methotrexate Sirolimus (TMS) Arm,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,encephalitis infection
D000069544,2.27,NCT00520130-1,A - Tacrolimus Methotrexate Sirolimus (TMS) Arm,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,encephalitis infection
D000069544,2.27,NCT00520130-1,A - Tacrolimus Methotrexate Sirolimus (TMS) Arm,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,encephalitis infection
D000069544,2.22,NCT00520130-2,B - Cyclosporine (AC) Arm,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,encephalitis infection
10061229,22.73,NCT00520130-1,A - Tacrolimus Methotrexate Sirolimus (TMS) Arm,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,lung infection
10061229,28.89,NCT00520130-2,B - Cyclosporine (AC) Arm,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,lung infection
D000069544,2.27,NCT00520130-1,A - Tacrolimus Methotrexate Sirolimus (TMS) Arm,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,encephalitis infection
D000069544,2.27,NCT00520130-1,A - Tacrolimus Methotrexate Sirolimus (TMS) Arm,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,encephalitis infection
D000069544,4.55,NCT00520130-1,A - Tacrolimus Methotrexate Sirolimus (TMS) Arm,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,encephalitis infection
D000069544,2.22,NCT00520130-2,B - Cyclosporine (AC) Arm,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,encephalitis infection
D012852,9.09,NCT00520130-1,A - Tacrolimus Methotrexate Sirolimus (TMS) Arm,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,sinus infections
D012852,13.33,NCT00520130-2,B - Cyclosporine (AC) Arm,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,sinus infections
10040872,4.55,NCT00520130-1,A - Tacrolimus Methotrexate Sirolimus (TMS) Arm,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,skin infection
10040872,8.89,NCT00520130-2,B - Cyclosporine (AC) Arm,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,skin infection
D000069544,2.22,NCT00520130-2,B - Cyclosporine (AC) Arm,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,encephalitis infection
D012141,2.22,NCT00520130-2,B - Cyclosporine (AC) Arm,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,infections upper respiratory
D014552,2.27,NCT00520130-1,A - Tacrolimus Methotrexate Sirolimus (TMS) Arm,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,urinary tract infections
D014552,6.67,NCT00520130-2,B - Cyclosporine (AC) Arm,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,urinary tract infections
D014946,2.27,NCT00520130-1,A - Tacrolimus Methotrexate Sirolimus (TMS) Arm,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,wound infection
D014946,2.22,NCT00520130-2,B - Cyclosporine (AC) Arm,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,wound infection
D000069544,4.55,NCT00520130-1,A - Tacrolimus Methotrexate Sirolimus (TMS) Arm,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,encephalitis infection
D000069544,4.44,NCT00520130-2,B - Cyclosporine (AC) Arm,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,encephalitis infection
D055499,2.27,NCT00520130-1,A - Tacrolimus Methotrexate Sirolimus (TMS) Arm,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,catheter-related infections
D000069544,2.27,NCT00520130-1,A - Tacrolimus Methotrexate Sirolimus (TMS) Arm,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,encephalitis infection
10061229,4.55,NCT00520130-1,A - Tacrolimus Methotrexate Sirolimus (TMS) Arm,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,lung infection
10061229,2.22,NCT00520130-2,B - Cyclosporine (AC) Arm,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,lung infection
D000410,9.09,NCT00520130-1,A - Tacrolimus Methotrexate Sirolimus (TMS) Arm,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,glutamic-pyruvic transaminase
D000410,2.22,NCT00520130-2,B - Cyclosporine (AC) Arm,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,glutamic-pyruvic transaminase
D001219,9.09,NCT00520130-1,A - Tacrolimus Methotrexate Sirolimus (TMS) Arm,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,serum glutamic-oxaloacetic transaminase
D001219,2.22,NCT00520130-2,B - Cyclosporine (AC) Arm,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,serum glutamic-oxaloacetic transaminase
D034141,2.27,NCT00520130-1,A - Tacrolimus Methotrexate Sirolimus (TMS) Arm,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,hypoalbuminemia
D034141,2.22,NCT00520130-2,B - Cyclosporine (AC) Arm,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,hypoalbuminemia
D000469,2.27,NCT00520130-1,A - Tacrolimus Methotrexate Sirolimus (TMS) Arm,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,alkaline phosphatase
D003414,6.82,NCT00520130-1,A - Tacrolimus Methotrexate Sirolimus (TMS) Arm,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,familial nonhemolytic unconjugated hyperbilirubinemia
D003414,4.44,NCT00520130-2,B - Cyclosporine (AC) Arm,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,familial nonhemolytic unconjugated hyperbilirubinemia
D003404,6.82,NCT00520130-1,A - Tacrolimus Methotrexate Sirolimus (TMS) Arm,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,creatinine
D003404,4.44,NCT00520130-2,B - Cyclosporine (AC) Arm,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,creatinine
D016895,2.22,NCT00520130-2,B - Cyclosporine (AC) Arm,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,low-serum media
D017674,2.27,NCT00520130-1,A - Tacrolimus Methotrexate Sirolimus (TMS) Arm,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,hypophosphatemia
D017674,2.22,NCT00520130-2,B - Cyclosporine (AC) Arm,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,hypophosphatemia
D006947,2.22,NCT00520130-2,B - Cyclosporine (AC) Arm,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,hyperkalemia
D016895,2.22,NCT00520130-2,B - Cyclosporine (AC) Arm,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,low-serum media
D004039,2.27,NCT00520130-1,A - Tacrolimus Methotrexate Sirolimus (TMS) Arm,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,diet low-sodium
D033461,2.22,NCT00520130-2,B - Cyclosporine (AC) Arm,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,hyperuricemia
D001170,2.27,NCT00520130-1,A - Tacrolimus Methotrexate Sirolimus (TMS) Arm,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,arthritis septic
10065794,2.22,NCT00520130-2,B - Cyclosporine (AC) Arm,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,muscle weakness right-sided
D012509,2.22,NCT00520130-2,B - Cyclosporine (AC) Arm,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,sarcoma soft tissue
D003882,4.44,NCT00520130-2,B - Cyclosporine (AC) Arm,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,dermatomyositis
D001416,2.22,NCT00520130-2,B - Cyclosporine (AC) Arm,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,back pain
10049737,8.89,NCT00520130-2,B - Cyclosporine (AC) Arm,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,treatment related secondary malignancy
D016609,2.27,NCT00520130-1,A - Tacrolimus Methotrexate Sirolimus (TMS) Arm,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,treatment-related cancer
D001259,2.22,NCT00520130-2,B - Cyclosporine (AC) Arm,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,ataxia
10023030,2.22,NCT00520130-2,B - Cyclosporine (AC) Arm,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,ischemia cerebrovascular
10009845,2.22,NCT00520130-2,B - Cyclosporine (AC) Arm,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,cognitive disturbance
D003221,2.27,NCT00520130-1,A - Tacrolimus Methotrexate Sirolimus (TMS) Arm,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,confusion
D003221,2.22,NCT00520130-2,B - Cyclosporine (AC) Arm,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,confusion
D001927,6.67,NCT00520130-2,B - Cyclosporine (AC) Arm,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,encephalopathy
D006470,4.44,NCT00520130-2,B - Cyclosporine (AC) Arm,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,hemorrhage
D056784,2.22,NCT00520130-2,B - Cyclosporine (AC) Arm,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,leukoencephalopathy
D012640,2.22,NCT00520130-2,B - Cyclosporine (AC) Arm,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,seizure
D003244,2.22,NCT00520130-2,B - Cyclosporine (AC) Arm,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,consciousness level depressed
D003556,2.27,NCT00520130-1,A - Tacrolimus Methotrexate Sirolimus (TMS) Arm,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,cystitis
D051437,22.73,NCT00520130-1,A - Tacrolimus Methotrexate Sirolimus (TMS) Arm,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,renal failure
D051437,13.33,NCT00520130-2,B - Cyclosporine (AC) Arm,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,renal failure
D000073678,2.22,NCT00520130-2,B - Cyclosporine (AC) Arm,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,kayaking
D012128,11.11,NCT00520130-2,B - Cyclosporine (AC) Arm,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,respiratory distress syndrome adult
D003997,2.22,NCT00520130-2,B - Cyclosporine (AC) Arm,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,diethoxycarbonyldihydrocollidine
D004417,9.09,NCT00520130-1,A - Tacrolimus Methotrexate Sirolimus (TMS) Arm,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,breath shortness
D004417,6.67,NCT00520130-2,B - Cyclosporine (AC) Arm,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,breath shortness
10065746,2.27,NCT00520130-1,A - Tacrolimus Methotrexate Sirolimus (TMS) Arm,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,bronchopulmonary hemorrhage
10065746,2.22,NCT00520130-2,B - Cyclosporine (AC) Arm,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,bronchopulmonary hemorrhage
D011666,2.22,NCT00520130-2,B - Cyclosporine (AC) Arm,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,pulmonary stenoses
D000860,15.91,NCT00520130-1,A - Tacrolimus Methotrexate Sirolimus (TMS) Arm,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,hypoxia
D000860,17.78,NCT00520130-2,B - Cyclosporine (AC) Arm,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,hypoxia
D010490,4.55,NCT00520130-1,A - Tacrolimus Methotrexate Sirolimus (TMS) Arm,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,pericardial effusion
D016066,4.55,NCT00520130-1,A - Tacrolimus Methotrexate Sirolimus (TMS) Arm,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,pleural effusion malignant
D016066,4.44,NCT00520130-2,B - Cyclosporine (AC) Arm,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,pleural effusion malignant
D011014,4.55,NCT00520130-1,A - Tacrolimus Methotrexate Sirolimus (TMS) Arm,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,pneumonitis
D011014,11.11,NCT00520130-2,B - Cyclosporine (AC) Arm,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,pneumonitis
D012131,2.27,NCT00520130-1,A - Tacrolimus Methotrexate Sirolimus (TMS) Arm,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,respiratory failure
D012141,2.22,NCT00520130-2,B - Cyclosporine (AC) Arm,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,infections upper respiratory
D010470,2.27,NCT00520130-1,A - Tacrolimus Methotrexate Sirolimus (TMS) Arm,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,perceptual masking
D005076,9.09,NCT00520130-1,A - Tacrolimus Methotrexate Sirolimus (TMS) Arm,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,rash
D005076,15.56,NCT00520130-2,B - Cyclosporine (AC) Arm,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,rash
D005076,2.27,NCT00520130-1,A - Tacrolimus Methotrexate Sirolimus (TMS) Arm,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,skin rash
D016769,4.55,NCT00520130-1,A - Tacrolimus Methotrexate Sirolimus (TMS) Arm,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,embolism and thrombosis
D016769,9.09,NCT00520130-1,A - Tacrolimus Methotrexate Sirolimus (TMS) Arm,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,embolism and thrombosis
D016769,2.22,NCT00520130-2,B - Cyclosporine (AC) Arm,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,embolism and thrombosis
D064420,100.0,NCT00524316-1,Treatment: Sunitinib and Chemoembolization,NCT00524316,Sunitinib and Chemoembolization in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery,adverse drug events
D000741,12.5,NCT00524316-1,Treatment: Sunitinib and Chemoembolization,NCT00524316,Sunitinib and Chemoembolization in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery,aplastic anaemia
D013921,6.25,NCT00524316-1,Treatment: Sunitinib and Chemoembolization,NCT00524316,Sunitinib and Chemoembolization in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery,thrombocytopenia
D015746,12.5,NCT00524316-1,Treatment: Sunitinib and Chemoembolization,NCT00524316,Sunitinib and Chemoembolization in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery,abdominal pain
D003248,6.25,NCT00524316-1,Treatment: Sunitinib and Chemoembolization,NCT00524316,Sunitinib and Chemoembolization in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery,constipation
D003680,6.25,NCT00524316-1,Treatment: Sunitinib and Chemoembolization,NCT00524316,Sunitinib and Chemoembolization in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery,dysphagia
D000069196,12.5,NCT00524316-1,Treatment: Sunitinib and Chemoembolization,NCT00524316,Sunitinib and Chemoembolization in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery,gastrointestinal microbiome
D010195,6.25,NCT00524316-1,Treatment: Sunitinib and Chemoembolization,NCT00524316,Sunitinib and Chemoembolization in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery,pancreatitis
D005221,6.25,NCT00524316-1,Treatment: Sunitinib and Chemoembolization,NCT00524316,Sunitinib and Chemoembolization in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery,fatigue
D005334,6.25,NCT00524316-1,Treatment: Sunitinib and Chemoembolization,NCT00524316,Sunitinib and Chemoembolization in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery,pyrexia
UNKNOWN-check-for-typo,6.25,NCT00524316-1,Treatment: Sunitinib and Chemoembolization,NCT00524316,Sunitinib and Chemoembolization in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery,D00
10024574,6.25,NCT00524316-1,Treatment: Sunitinib and Chemoembolization,NCT00524316,Sunitinib and Chemoembolization in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery,lipase increased
D003681,12.5,NCT00524316-1,Treatment: Sunitinib and Chemoembolization,NCT00524316,Sunitinib and Chemoembolization in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery,dehydration
UNKNOWN-check-for-typo,6.25,NCT00524316-1,Treatment: Sunitinib and Chemoembolization,NCT00524316,Sunitinib and Chemoembolization in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery,D00
D018908,6.25,NCT00524316-1,Treatment: Sunitinib and Chemoembolization,NCT00524316,Sunitinib and Chemoembolization in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery,muscular weakness
D003221,6.25,NCT00524316-1,Treatment: Sunitinib and Chemoembolization,NCT00524316,Sunitinib and Chemoembolization in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery,confusional state
D051437,6.25,NCT00524316-1,Treatment: Sunitinib and Chemoembolization,NCT00524316,Sunitinib and Chemoembolization in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery,renal failure
UNKNOWN-check-for-typo,6.25,NCT00524316-1,Treatment: Sunitinib and Chemoembolization,NCT00524316,Sunitinib and Chemoembolization in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery,D00
D011655,6.25,NCT00524316-1,Treatment: Sunitinib and Chemoembolization,NCT00524316,Sunitinib and Chemoembolization in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery,pulmonary embolism
D009026,35.59,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,mortality
D064420,45.42,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,adverse drug events
D001778,1.36,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,blood coagulation disorders
D004211,0.34,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,disseminated intravascular coagulation
D064147,22.71,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,febrile neutropenia
D002263,43.39,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,carboxyhemoglobin
10025182,0.34,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,lymph node pain
D006425,1.02,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,blood and lymphatic system disorders
D001145,0.34,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,arrhythmia
D001281,1.02,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,atrial fibrillation
D001282,1.02,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,atrial flutter
D013612,0.68,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,tachycardia ectopic atrial
D006331,0.34,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,cardiac disorder
10008481,0.34,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,chest pain - cardiac
10010276,0.34,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,conduction disorder
D018487,0.34,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,left ventricular dysfunction
D016277,0.34,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,ventricular function left
D017202,0.34,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,myocardial ischemia
10033557,1.36,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,palpitations
D010490,0.34,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,pericardial effusion
D018497,0.34,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,right ventricular dysfunction
D001146,0.68,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,sinus arrhythmia
10040741,1.36,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,sinus bradycardia
D013616,10.17,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,sinus tachycardia
D013617,1.36,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,supraventricular tachycardia
D014693,0.34,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,ventricular fibrillation
D017180,1.36,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,ventricular tachycardia
D000067559,0.34,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,specific learning disorder
10014020,2.03,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,ear pain
10019245,0.34,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,hearing impaired
D014012,0.68,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,tinnitus
D000309,0.34,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,adrenal insufficiency
10011655,1.69,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,cushingoid
D015352,0.68,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,dry eye syndrome
10015829,0.68,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,extraocular muscle paresis
D005128,1.36,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,eye disorder
D058447,1.36,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,eye pain
D009934,0.68,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,supervision
D009900,0.34,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,optic nerve
D020795,0.68,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,photophobia
10038923,0.34,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,retinopathy
10005886,4.41,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,blurred vision
10047848,0.34,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,watering eyes
10000060,2.37,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,abdominal distension
D015746,14.92,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,abdominal pain
10055226,0.34,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,anal hemorrhage
10002167,0.34,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,anal pain
D003092,2.03,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,colitis
10009998,1.36,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,colonic hemorrhage
10010001,0.34,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,colonic perforation
D003248,13.22,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,constipation
D003967,16.61,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,diarrhea
D004381,0.34,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,duodenal ulcer
D004415,6.78,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,dyspepsia
D003680,2.03,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,dysphagia
D000068580,0.34,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,varenicline
D013280,0.34,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,oromucositis
10015388,1.69,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,esophageal pain
D005242,0.34,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,fecal incontinence
D005756,1.36,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,gastritis
D005767,1.36,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,gastrointestinal disorder
D006484,1.36,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,hemorrhoids
D045823,0.34,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,ileus
D003945,10.17,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,examination oral
D009325,32.2,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,nausea
D006472,0.68,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,oral hemorrhage
10031009,4.07,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,oral pain
D019283,0.34,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,pancreatic necrosis
D010195,4.41,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,pancreatitis
10038064,1.02,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,rectal hemorrhage
10038072,1.36,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,rectal pain
10042112,0.34,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,stomach pain
10044030,0.34,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,tooth development disorder
D014098,1.36,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,toothache
D053706,1.36,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,typhlitis
10055356,0.34,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,upper gastrointestinal hemorrhage
D014839,21.69,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,vomiting
D002637,4.07,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,chest pain
D023341,10.17,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,chills
D018450,0.34,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,disease progression
10050068,8.81,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,edema limbs
D005157,0.34,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,facial pain
D005221,29.49,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,fatigue
D005334,9.49,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,fever
10016791,0.34,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,flu like symptoms
D005684,1.36,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,gait
D004829,2.03,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,symptomatic generalized epilepsy
D011681,1.36,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,pupillary disorders
D000075662,0.68,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,injection site reaction
10062466,4.75,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,localized edema
D009102,0.34,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,multiple organ failure
D010146,9.83,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,pain
10051341,0.34,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,bile duct stenosis
D002764,0.34,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,cholecystitis
D017093,2.37,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,hepatic failure
D004066,1.69,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,hepatobiliary disease
D000080424,0.34,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,cytokine release syndrome
D006967,7.46,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,hypersensitivity
D007154,0.68,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,immune system disorder
10058838,1.36,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,enterocolitis infectious
D009894,0.34,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,opportunistic infection
D014552,21.36,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,urinary tract infections
10002899,0.34,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,aortic injury
10006504,3.05,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,bruising
10061103,0.34,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,dermatitis radiation
10065826,0.34,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,intraoperative arterial injury
D019106,0.34,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,postoperative hemorrhage
D049291,0.34,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,seroma
10048031,0.34,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,wound dehiscence
10000636,11.86,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,activated partial thromboplastin time prolonged
10001551,42.37,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,alanine aminotransferase increased
10001675,18.98,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,alkaline phosphatase increased
10040139,4.75,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,serum amylase increased
10003481,39.32,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,aspartate aminotransferase increased
10005364,33.56,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,blood bilirubin increased
10005778,0.34,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,blood prolactin abnormal
10007612,0.34,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,cardiac troponin i increased
D004211,1.36,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,consumption coagulopathy
D003402,0.34,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,creatine phosphokinase
10011368,11.19,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,creatinine increased
10014383,0.68,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,electrocardiogram qt corrected interval prolonged
10016596,24.75,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,fibrinogen decreased
D005723,3.05,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,gammaglutamyltransferase
10022402,6.44,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,inr increased
D019411,5.42,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,clinical laboratory tests
D007958,22.37,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,leukocyte count
10024574,6.78,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,lipase increased
10025256,15.25,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,lymphocyte count decreased
10029366,42.71,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,neutrophil count decreased
10035528,42.71,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,platelet count decreased
10040139,5.08,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,serum amylase increased
D015430,2.37,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,weight gain
D015431,6.1,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,weight loss
D000138,1.02,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,acidosis
D000855,12.2,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,anorexia
10005359,2.71,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,blood bicarbonate decreased
D001786,37.63,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,blood glucose
D000111,1.36,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,mercapturic acid
D003681,4.07,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,dehydration
D018149,2.37,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,glucose intolerance
D009765,0.34,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,obesity
D000141,0.34,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,acidosis renal tubular
D012709,23.39,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,serum albumin
D002118,20.68,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,calcium
10040139,2.37,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,serum amylase increased
D003847,10.17,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,deoxyglucose
D008274,11.86,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,magnesium
10040139,9.15,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,serum amylase increased
D000255,6.78,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,adenylpyrophosphate
D011188,20.0,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,potassium
10040139,6.78,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,serum amylase increased
D012964,21.02,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,sodium
10040139,3.73,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,serum amylase increased
10040139,8.14,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,serum amylase increased
D015275,1.02,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,tumor lysis syndrome
D018771,7.12,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,arthralgia
D001416,11.53,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,back pain
10048677,0.68,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,buttock pain
10008496,3.39,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,chest wall pain
D013705,1.02,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,temporomandibular joint disorders
D018908,3.05,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,muscle weakness
10065776,4.07,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,muscle weakness lower limb
10065794,0.68,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,muscle weakness right-sided
10065895,1.36,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,muscle weakness upper limb
D063806,5.76,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,myalgia
D009220,1.02,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,myositis
D019547,3.05,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,neck pain
D010020,5.76,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,osteonecrosis
D010024,1.02,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,osteoporosis
10033425,11.86,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,pain in extremity
10065777,0.34,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,soft tissue necrosis lower limb
10065798,0.34,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,superficial soft tissue fibrosis
10049737,0.34,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,treatment related secondary malignancy
10060929,0.34,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,accessory nerve disorder
D001100,0.68,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,arachnoiditis
D001259,0.68,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,ataxia
10065784,0.34,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,central nervous system necrosis
D065634,1.02,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,cerebrospinal fluid leakage
D003244,1.69,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,depressed level of consciousness
D004244,12.2,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,dizziness
D004408,3.05,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,dysgeusia
D001927,0.68,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,encephalopathy
D001480,0.34,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,extrapyramidal disorder
10051272,0.34,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,facial muscle weakness
D006261,29.15,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,headache
10061212,0.68,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,hypoglossal nerve disorder
D020300,0.68,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,intracranial hemorrhage
10023030,0.68,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,ischemia cerebrovascular
D056784,0.68,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,leukoencephalopathy
10027175,1.36,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,memory impairment
D000073216,0.34,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,mini mental status examination
D009437,0.34,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,neuralgia
D009422,2.71,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,neurological disorders
D015840,0.34,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,oculomotor nerve disorder
10034580,4.75,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,peripheral motor neuropathy
10034620,23.05,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,peripheral sensory neuropathy
D012640,3.39,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,seizure
D001072,2.37,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,speech-language disorder 1
D013575,1.36,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,syncope
D014202,1.69,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,tremor
D020433,0.34,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,trigeminal nerve disorder
10001497,1.36,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,agitation
D001007,7.46,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,anxiety
D003221,3.05,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,confusion
D003863,8.81,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,depression
D005059,0.34,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,euphoria
D007319,13.9,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,insomnia
10024419,0.34,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,libido decreased
D011618,1.69,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,psychosis
10048994,0.34,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,bladder spasm
D003556,0.34,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,cystitis
D005919,0.34,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,glomerular filtration rate
D014551,0.34,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,urinary tract
D000080867,0.34,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,gingipains
D051437,2.71,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,renal failure
D000080867,0.68,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,gingipains
10046539,1.36,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,urinary frequency
D014549,1.02,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,urinary incontinence
10046628,1.69,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,urine discoloration
D000067836,0.68,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,hoarding disorder
D007172,0.34,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,erectile dysfunction
D017699,0.34,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,pelvic pain
D060737,0.34,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,reproductive tract infections
10039757,0.34,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,scrotal pain
10046912,3.05,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,vaginal hemorrhage
D012128,0.68,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,adult respiratory distress syndrome
D065631,3.39,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,allergic rhinitis
10003504,0.34,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,aspiration
D001261,1.02,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,atelectasis
10065746,0.34,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,bronchopulmonary hemorrhage
D001986,0.34,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,bronchospasm
D003371,10.85,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,cough
D004417,10.17,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,dyspnea
D004844,5.08,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,epistaxis
D006606,3.39,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,hiccups
D000860,4.07,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,hypoxia
D007829,0.34,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,laryngeal stenosis
10028735,0.68,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,nasal congestion
10065881,0.68,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,pharyngeal mucositis
10034844,6.1,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,pharyngolaryngeal pain
D010996,1.69,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,pleural effusion
10035623,1.02,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,pleuritic pain
D011014,2.37,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,pneumonitis
D011030,1.02,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,pneumothorax
10038738,2.37,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,respiratory thoracic and mediastinal disorders - other specify
10047681,0.68,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,voice alteration
D000505,6.78,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,alopecia
D003668,0.34,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,decubitus ulcer
10013786,1.02,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,dry skin
D004892,1.02,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,erythema multiforme
D060831,0.34,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,hand-foot syndrome
D009262,0.34,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,nails
D011693,2.71,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,petechiae
10034966,0.34,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,photosensitivity
D011537,2.37,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,pruritus
10037847,2.03,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,rash acneiform
D005076,8.81,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,rash
10049120,0.34,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,scalp pain
D012871,2.03,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,skin and subcutaneous tissue disorders
10040865,0.34,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,skin hyperpigmentation
10040868,0.34,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,skin hypopigmentation
10051837,0.34,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,skin induration
D012867,0.34,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,skin
10040947,2.03,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,skin ulceration
D013546,5.08,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,sweating
D014581,1.36,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,urticaria
D005483,0.34,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,flushing
D006406,2.03,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,hematoma
D006470,1.02,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,hemorrhage
D006973,3.39,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,hypertension
D007022,7.12,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,hypotension
D013927,7.8,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,thrombosis
D002561,0.68,NCT00558519-1,Treatment (Pediatric Regimen),NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,cerebrovascular disorders
D064420,45.61,NCT00617591-1,Induction and Maintenance Therapy,NCT00617591,Pegylated Liposomal Doxorubicin  Low Freq Dexamethasone & Revlimid (Dd-R) in Newly Diagnosed Multiple Myeloma (MM),adverse drug events
D006454,1.75,NCT00617591-1,Induction and Maintenance Therapy,NCT00617591,Pegylated Liposomal Doxorubicin  Low Freq Dexamethasone & Revlimid (Dd-R) in Newly Diagnosed Multiple Myeloma (MM),hemoglobin
D006098,5.26,NCT00617591-1,Induction and Maintenance Therapy,NCT00617591,Pegylated Liposomal Doxorubicin  Low Freq Dexamethasone & Revlimid (Dd-R) in Newly Diagnosed Multiple Myeloma (MM),granulocytes
10050068,1.75,NCT00617591-1,Induction and Maintenance Therapy,NCT00617591,Pegylated Liposomal Doxorubicin  Low Freq Dexamethasone & Revlimid (Dd-R) in Newly Diagnosed Multiple Myeloma (MM),edema limbs
D003409,1.75,NCT00617591-1,Induction and Maintenance Therapy,NCT00617591,Pegylated Liposomal Doxorubicin  Low Freq Dexamethasone & Revlimid (Dd-R) in Newly Diagnosed Multiple Myeloma (MM),myxedema congenital
10033557,1.75,NCT00617591-1,Induction and Maintenance Therapy,NCT00617591,Pegylated Liposomal Doxorubicin  Low Freq Dexamethasone & Revlimid (Dd-R) in Newly Diagnosed Multiple Myeloma (MM),palpitations
D001146,1.75,NCT00617591-1,Induction and Maintenance Therapy,NCT00617591,Pegylated Liposomal Doxorubicin  Low Freq Dexamethasone & Revlimid (Dd-R) in Newly Diagnosed Multiple Myeloma (MM),sinoatrial arrhythmia
D009618,3.51,NCT00617591-1,Induction and Maintenance Therapy,NCT00617591,Pegylated Liposomal Doxorubicin  Low Freq Dexamethasone & Revlimid (Dd-R) in Newly Diagnosed Multiple Myeloma (MM),nocardiaceae
D003681,1.75,NCT00617591-1,Induction and Maintenance Therapy,NCT00617591,Pegylated Liposomal Doxorubicin  Low Freq Dexamethasone & Revlimid (Dd-R) in Newly Diagnosed Multiple Myeloma (MM),dehydration
D003967,1.75,NCT00617591-1,Induction and Maintenance Therapy,NCT00617591,Pegylated Liposomal Doxorubicin  Low Freq Dexamethasone & Revlimid (Dd-R) in Newly Diagnosed Multiple Myeloma (MM),diarrhea
D009325,1.75,NCT00617591-1,Induction and Maintenance Therapy,NCT00617591,Pegylated Liposomal Doxorubicin  Low Freq Dexamethasone & Revlimid (Dd-R) in Newly Diagnosed Multiple Myeloma (MM),nausea
D014839,1.75,NCT00617591-1,Induction and Maintenance Therapy,NCT00617591,Pegylated Liposomal Doxorubicin  Low Freq Dexamethasone & Revlimid (Dd-R) in Newly Diagnosed Multiple Myeloma (MM),vomiting
D000071896,3.51,NCT00617591-1,Induction and Maintenance Therapy,NCT00617591,Pegylated Liposomal Doxorubicin  Low Freq Dexamethasone & Revlimid (Dd-R) in Newly Diagnosed Multiple Myeloma (MM),somatic symptoms
D009503,7.02,NCT00617591-1,Induction and Maintenance Therapy,NCT00617591,Pegylated Liposomal Doxorubicin  Low Freq Dexamethasone & Revlimid (Dd-R) in Newly Diagnosed Multiple Myeloma (MM),neutropenia
D000377,1.75,NCT00617591-1,Induction and Maintenance Therapy,NCT00617591,Pegylated Liposomal Doxorubicin  Low Freq Dexamethasone & Revlimid (Dd-R) in Newly Diagnosed Multiple Myeloma (MM),agnosia for pain
D013577,1.75,NCT00617591-1,Induction and Maintenance Therapy,NCT00617591,Pegylated Liposomal Doxorubicin  Low Freq Dexamethasone & Revlimid (Dd-R) in Newly Diagnosed Multiple Myeloma (MM),syndromes
D064147,3.51,NCT00617591-1,Induction and Maintenance Therapy,NCT00617591,Pegylated Liposomal Doxorubicin  Low Freq Dexamethasone & Revlimid (Dd-R) in Newly Diagnosed Multiple Myeloma (MM),febrile neutropenia
10061229,1.75,NCT00617591-1,Induction and Maintenance Therapy,NCT00617591,Pegylated Liposomal Doxorubicin  Low Freq Dexamethasone & Revlimid (Dd-R) in Newly Diagnosed Multiple Myeloma (MM),lung infection
D012852,1.75,NCT00617591-1,Induction and Maintenance Therapy,NCT00617591,Pegylated Liposomal Doxorubicin  Low Freq Dexamethasone & Revlimid (Dd-R) in Newly Diagnosed Multiple Myeloma (MM),sinus infections
10021881,1.75,NCT00617591-1,Induction and Maintenance Therapy,NCT00617591,Pegylated Liposomal Doxorubicin  Low Freq Dexamethasone & Revlimid (Dd-R) in Newly Diagnosed Multiple Myeloma (MM),infections and infestations - other specify
10005047,1.75,NCT00617591-1,Induction and Maintenance Therapy,NCT00617591,Pegylated Liposomal Doxorubicin  Low Freq Dexamethasone & Revlimid (Dd-R) in Newly Diagnosed Multiple Myeloma (MM),bladder infection
D000069544,1.75,NCT00617591-1,Induction and Maintenance Therapy,NCT00617591,Pegylated Liposomal Doxorubicin  Low Freq Dexamethasone & Revlimid (Dd-R) in Newly Diagnosed Multiple Myeloma (MM),encephalitis infection
D000069544,1.75,NCT00617591-1,Induction and Maintenance Therapy,NCT00617591,Pegylated Liposomal Doxorubicin  Low Freq Dexamethasone & Revlimid (Dd-R) in Newly Diagnosed Multiple Myeloma (MM),encephalitis infection
D000069544,1.75,NCT00617591-1,Induction and Maintenance Therapy,NCT00617591,Pegylated Liposomal Doxorubicin  Low Freq Dexamethasone & Revlimid (Dd-R) in Newly Diagnosed Multiple Myeloma (MM),encephalitis infection
10061229,1.75,NCT00617591-1,Induction and Maintenance Therapy,NCT00617591,Pegylated Liposomal Doxorubicin  Low Freq Dexamethasone & Revlimid (Dd-R) in Newly Diagnosed Multiple Myeloma (MM),lung infection
D016895,1.75,NCT00617591-1,Induction and Maintenance Therapy,NCT00617591,Pegylated Liposomal Doxorubicin  Low Freq Dexamethasone & Revlimid (Dd-R) in Newly Diagnosed Multiple Myeloma (MM),low-serum media
D016895,3.51,NCT00617591-1,Induction and Maintenance Therapy,NCT00617591,Pegylated Liposomal Doxorubicin  Low Freq Dexamethasone & Revlimid (Dd-R) in Newly Diagnosed Multiple Myeloma (MM),low-serum media
10017076,7.02,NCT00617591-1,Induction and Maintenance Therapy,NCT00617591,Pegylated Liposomal Doxorubicin  Low Freq Dexamethasone & Revlimid (Dd-R) in Newly Diagnosed Multiple Myeloma (MM),fracture
10062572,1.75,NCT00617591-1,Induction and Maintenance Therapy,NCT00617591,Pegylated Liposomal Doxorubicin  Low Freq Dexamethasone & Revlimid (Dd-R) in Newly Diagnosed Multiple Myeloma (MM),generalized muscle weakness
D012509,1.75,NCT00617591-1,Induction and Maintenance Therapy,NCT00617591,Pegylated Liposomal Doxorubicin  Low Freq Dexamethasone & Revlimid (Dd-R) in Newly Diagnosed Multiple Myeloma (MM),sarcoma soft tissue
D003221,1.75,NCT00617591-1,Induction and Maintenance Therapy,NCT00617591,Pegylated Liposomal Doxorubicin  Low Freq Dexamethasone & Revlimid (Dd-R) in Newly Diagnosed Multiple Myeloma (MM),confusion
D051437,1.75,NCT00617591-1,Induction and Maintenance Therapy,NCT00617591,Pegylated Liposomal Doxorubicin  Low Freq Dexamethasone & Revlimid (Dd-R) in Newly Diagnosed Multiple Myeloma (MM),renal failure
D004417,5.26,NCT00617591-1,Induction and Maintenance Therapy,NCT00617591,Pegylated Liposomal Doxorubicin  Low Freq Dexamethasone & Revlimid (Dd-R) in Newly Diagnosed Multiple Myeloma (MM),breath shortness
D016066,1.75,NCT00617591-1,Induction and Maintenance Therapy,NCT00617591,Pegylated Liposomal Doxorubicin  Low Freq Dexamethasone & Revlimid (Dd-R) in Newly Diagnosed Multiple Myeloma (MM),pleural effusion malignant
D012141,7.02,NCT00617591-1,Induction and Maintenance Therapy,NCT00617591,Pegylated Liposomal Doxorubicin  Low Freq Dexamethasone & Revlimid (Dd-R) in Newly Diagnosed Multiple Myeloma (MM),infections upper respiratory
D005076,3.51,NCT00617591-1,Induction and Maintenance Therapy,NCT00617591,Pegylated Liposomal Doxorubicin  Low Freq Dexamethasone & Revlimid (Dd-R) in Newly Diagnosed Multiple Myeloma (MM),rash
D016769,7.02,NCT00617591-1,Induction and Maintenance Therapy,NCT00617591,Pegylated Liposomal Doxorubicin  Low Freq Dexamethasone & Revlimid (Dd-R) in Newly Diagnosed Multiple Myeloma (MM),embolism and thrombosis
D064420,50.0,NCT00617890-1,Group 1: 0.3mg/kg,NCT00617890,A Study to Determine the Activity of Robatumumab (SCH 717454) in Participants With Relapsed Osteosarcoma or Ewing's Sarcoma (MK-7454-002/P04720),adverse drug events
D064420,24.24,NCT00617890-2,Group 1: 10mg/kg,NCT00617890,A Study to Determine the Activity of Robatumumab (SCH 717454) in Participants With Relapsed Osteosarcoma or Ewing's Sarcoma (MK-7454-002/P04720),adverse drug events
D064420,35.29,NCT00617890-3,Group 2: 10mg/kg,NCT00617890,A Study to Determine the Activity of Robatumumab (SCH 717454) in Participants With Relapsed Osteosarcoma or Ewing's Sarcoma (MK-7454-002/P04720),adverse drug events
D064420,49.57,NCT00617890-4,Group 3: 10mg/kg,NCT00617890,A Study to Determine the Activity of Robatumumab (SCH 717454) in Participants With Relapsed Osteosarcoma or Ewing's Sarcoma (MK-7454-002/P04720),adverse drug events
D000741,2.61,NCT00617890-4,Group 3: 10mg/kg,NCT00617890,A Study to Determine the Activity of Robatumumab (SCH 717454) in Participants With Relapsed Osteosarcoma or Ewing's Sarcoma (MK-7454-002/P04720),aplastic anaemia
D001853,0.87,NCT00617890-4,Group 3: 10mg/kg,NCT00617890,A Study to Determine the Activity of Robatumumab (SCH 717454) in Participants With Relapsed Osteosarcoma or Ewing's Sarcoma (MK-7454-002/P04720),bone marrow
D064147,5.88,NCT00617890-1,Group 1: 0.3mg/kg,NCT00617890,A Study to Determine the Activity of Robatumumab (SCH 717454) in Participants With Relapsed Osteosarcoma or Ewing's Sarcoma (MK-7454-002/P04720),febrile neutropenia
D013921,2.94,NCT00617890-3,Group 2: 10mg/kg,NCT00617890,A Study to Determine the Activity of Robatumumab (SCH 717454) in Participants With Relapsed Osteosarcoma or Ewing's Sarcoma (MK-7454-002/P04720),thrombocytopenia
D013921,3.48,NCT00617890-4,Group 3: 10mg/kg,NCT00617890,A Study to Determine the Activity of Robatumumab (SCH 717454) in Participants With Relapsed Osteosarcoma or Ewing's Sarcoma (MK-7454-002/P04720),thrombocytopenia
D001281,2.94,NCT00617890-3,Group 2: 10mg/kg,NCT00617890,A Study to Determine the Activity of Robatumumab (SCH 717454) in Participants With Relapsed Osteosarcoma or Ewing's Sarcoma (MK-7454-002/P04720),atrial fibrillation
D006333,0.87,NCT00617890-4,Group 3: 10mg/kg,NCT00617890,A Study to Determine the Activity of Robatumumab (SCH 717454) in Participants With Relapsed Osteosarcoma or Ewing's Sarcoma (MK-7454-002/P04720),cardiac failure
D000072599,2.94,NCT00617890-1,Group 1: 0.3mg/kg,NCT00617890,A Study to Determine the Activity of Robatumumab (SCH 717454) in Participants With Relapsed Osteosarcoma or Ewing's Sarcoma (MK-7454-002/P04720),cardiorespiratory fitness
D000072599,0.87,NCT00617890-4,Group 3: 10mg/kg,NCT00617890,A Study to Determine the Activity of Robatumumab (SCH 717454) in Participants With Relapsed Osteosarcoma or Ewing's Sarcoma (MK-7454-002/P04720),cardiorespiratory fitness
D013610,0.87,NCT00617890-4,Group 3: 10mg/kg,NCT00617890,A Study to Determine the Activity of Robatumumab (SCH 717454) in Participants With Relapsed Osteosarcoma or Ewing's Sarcoma (MK-7454-002/P04720),tachycardia
D000708,0.87,NCT00617890-4,Group 3: 10mg/kg,NCT00617890,A Study to Determine the Activity of Robatumumab (SCH 717454) in Participants With Relapsed Osteosarcoma or Ewing's Sarcoma (MK-7454-002/P04720),anaplasia
D001766,2.94,NCT00617890-3,Group 2: 10mg/kg,NCT00617890,A Study to Determine the Activity of Robatumumab (SCH 717454) in Participants With Relapsed Osteosarcoma or Ewing's Sarcoma (MK-7454-002/P04720),blindness unilateral
D001766,0.87,NCT00617890-4,Group 3: 10mg/kg,NCT00617890,A Study to Determine the Activity of Robatumumab (SCH 717454) in Participants With Relapsed Osteosarcoma or Ewing's Sarcoma (MK-7454-002/P04720),blindness unilateral
10005886,0.87,NCT00617890-4,Group 3: 10mg/kg,NCT00617890,A Study to Determine the Activity of Robatumumab (SCH 717454) in Participants With Relapsed Osteosarcoma or Ewing's Sarcoma (MK-7454-002/P04720),blurred vision
D015746,2.61,NCT00617890-4,Group 3: 10mg/kg,NCT00617890,A Study to Determine the Activity of Robatumumab (SCH 717454) in Participants With Relapsed Osteosarcoma or Ewing's Sarcoma (MK-7454-002/P04720),abdominal pain
D003248,3.03,NCT00617890-2,Group 1: 10mg/kg,NCT00617890,A Study to Determine the Activity of Robatumumab (SCH 717454) in Participants With Relapsed Osteosarcoma or Ewing's Sarcoma (MK-7454-002/P04720),constipation
D003248,1.74,NCT00617890-4,Group 3: 10mg/kg,NCT00617890,A Study to Determine the Activity of Robatumumab (SCH 717454) in Participants With Relapsed Osteosarcoma or Ewing's Sarcoma (MK-7454-002/P04720),constipation
UNKNOWN-check-for-typo,0.87,NCT00617890-4,Group 3: 10mg/kg,NCT00617890,A Study to Determine the Activity of Robatumumab (SCH 717454) in Participants With Relapsed Osteosarcoma or Ewing's Sarcoma (MK-7454-002/P04720),D00
10017999,0.87,NCT00617890-4,Group 3: 10mg/kg,NCT00617890,A Study to Determine the Activity of Robatumumab (SCH 717454) in Participants With Relapsed Osteosarcoma or Ewing's Sarcoma (MK-7454-002/P04720),gastrointestinal pain
D045823,0.87,NCT00617890-4,Group 3: 10mg/kg,NCT00617890,A Study to Determine the Activity of Robatumumab (SCH 717454) in Participants With Relapsed Osteosarcoma or Ewing's Sarcoma (MK-7454-002/P04720),ileus
D009325,0.87,NCT00617890-4,Group 3: 10mg/kg,NCT00617890,A Study to Determine the Activity of Robatumumab (SCH 717454) in Participants With Relapsed Osteosarcoma or Ewing's Sarcoma (MK-7454-002/P04720),nausea
D012185,0.87,NCT00617890-4,Group 3: 10mg/kg,NCT00617890,A Study to Determine the Activity of Robatumumab (SCH 717454) in Participants With Relapsed Osteosarcoma or Ewing's Sarcoma (MK-7454-002/P04720),retroperitoneal fibrosis
D041742,0.87,NCT00617890-4,Group 3: 10mg/kg,NCT00617890,A Study to Determine the Activity of Robatumumab (SCH 717454) in Participants With Relapsed Osteosarcoma or Ewing's Sarcoma (MK-7454-002/P04720),upper gastrointestinal tract
D014839,1.74,NCT00617890-4,Group 3: 10mg/kg,NCT00617890,A Study to Determine the Activity of Robatumumab (SCH 717454) in Participants With Relapsed Osteosarcoma or Ewing's Sarcoma (MK-7454-002/P04720),vomiting
D001247,0.87,NCT00617890-4,Group 3: 10mg/kg,NCT00617890,A Study to Determine the Activity of Robatumumab (SCH 717454) in Participants With Relapsed Osteosarcoma or Ewing's Sarcoma (MK-7454-002/P04720),asthenia
D002637,2.94,NCT00617890-3,Group 2: 10mg/kg,NCT00617890,A Study to Determine the Activity of Robatumumab (SCH 717454) in Participants With Relapsed Osteosarcoma or Ewing's Sarcoma (MK-7454-002/P04720),chest pain
D002637,3.48,NCT00617890-4,Group 3: 10mg/kg,NCT00617890,A Study to Determine the Activity of Robatumumab (SCH 717454) in Participants With Relapsed Osteosarcoma or Ewing's Sarcoma (MK-7454-002/P04720),chest pain
D000389,2.94,NCT00617890-1,Group 1: 0.3mg/kg,NCT00617890,A Study to Determine the Activity of Robatumumab (SCH 717454) in Participants With Relapsed Osteosarcoma or Ewing's Sarcoma (MK-7454-002/P04720),air conditioning
D004864,2.94,NCT00617890-1,Group 1: 0.3mg/kg,NCT00617890,A Study to Determine the Activity of Robatumumab (SCH 717454) in Participants With Relapsed Osteosarcoma or Ewing's Sarcoma (MK-7454-002/P04720),devices
D009357,0.87,NCT00617890-4,Group 3: 10mg/kg,NCT00617890,A Study to Determine the Activity of Robatumumab (SCH 717454) in Participants With Relapsed Osteosarcoma or Ewing's Sarcoma (MK-7454-002/P04720),neonatal withdrawal syndrome
D005221,0.87,NCT00617890-4,Group 3: 10mg/kg,NCT00617890,A Study to Determine the Activity of Robatumumab (SCH 717454) in Participants With Relapsed Osteosarcoma or Ewing's Sarcoma (MK-7454-002/P04720),fatigue
D003695,0.87,NCT00617890-4,Group 3: 10mg/kg,NCT00617890,A Study to Determine the Activity of Robatumumab (SCH 717454) in Participants With Relapsed Osteosarcoma or Ewing's Sarcoma (MK-7454-002/P04720),healthcare
D005334,0.87,NCT00617890-4,Group 3: 10mg/kg,NCT00617890,A Study to Determine the Activity of Robatumumab (SCH 717454) in Participants With Relapsed Osteosarcoma or Ewing's Sarcoma (MK-7454-002/P04720),hyperthermia
D007251,0.87,NCT00617890-4,Group 3: 10mg/kg,NCT00617890,A Study to Determine the Activity of Robatumumab (SCH 717454) in Participants With Relapsed Osteosarcoma or Ewing's Sarcoma (MK-7454-002/P04720),influenza
10025482,0.87,NCT00617890-4,Group 3: 10mg/kg,NCT00617890,A Study to Determine the Activity of Robatumumab (SCH 717454) in Participants With Relapsed Osteosarcoma or Ewing's Sarcoma (MK-7454-002/P04720),malaise
D007249,0.87,NCT00617890-4,Group 3: 10mg/kg,NCT00617890,A Study to Determine the Activity of Robatumumab (SCH 717454) in Participants With Relapsed Osteosarcoma or Ewing's Sarcoma (MK-7454-002/P04720),inflammation
D009102,0.87,NCT00617890-4,Group 3: 10mg/kg,NCT00617890,A Study to Determine the Activity of Robatumumab (SCH 717454) in Participants With Relapsed Osteosarcoma or Ewing's Sarcoma (MK-7454-002/P04720),multiple organ failure
D000799,2.94,NCT00617890-1,Group 1: 0.3mg/kg,NCT00617890,A Study to Determine the Activity of Robatumumab (SCH 717454) in Participants With Relapsed Osteosarcoma or Ewing's Sarcoma (MK-7454-002/P04720),angioedema
D010146,3.03,NCT00617890-2,Group 1: 10mg/kg,NCT00617890,A Study to Determine the Activity of Robatumumab (SCH 717454) in Participants With Relapsed Osteosarcoma or Ewing's Sarcoma (MK-7454-002/P04720),pain
D010146,9.57,NCT00617890-4,Group 3: 10mg/kg,NCT00617890,A Study to Determine the Activity of Robatumumab (SCH 717454) in Participants With Relapsed Osteosarcoma or Ewing's Sarcoma (MK-7454-002/P04720),pain
D017567,0.87,NCT00617890-4,Group 3: 10mg/kg,NCT00617890,A Study to Determine the Activity of Robatumumab (SCH 717454) in Participants With Relapsed Osteosarcoma or Ewing's Sarcoma (MK-7454-002/P04720),karnofsky performance status
D005334,2.94,NCT00617890-1,Group 1: 0.3mg/kg,NCT00617890,A Study to Determine the Activity of Robatumumab (SCH 717454) in Participants With Relapsed Osteosarcoma or Ewing's Sarcoma (MK-7454-002/P04720),pyrexia
D005334,3.03,NCT00617890-2,Group 1: 10mg/kg,NCT00617890,A Study to Determine the Activity of Robatumumab (SCH 717454) in Participants With Relapsed Osteosarcoma or Ewing's Sarcoma (MK-7454-002/P04720),pyrexia
D005334,6.09,NCT00617890-4,Group 3: 10mg/kg,NCT00617890,A Study to Determine the Activity of Robatumumab (SCH 717454) in Participants With Relapsed Osteosarcoma or Ewing's Sarcoma (MK-7454-002/P04720),pyrexia
D029626,0.87,NCT00617890-4,Group 3: 10mg/kg,NCT00617890,A Study to Determine the Activity of Robatumumab (SCH 717454) in Participants With Relapsed Osteosarcoma or Ewing's Sarcoma (MK-7454-002/P04720),hepatica
D007565,0.87,NCT00617890-4,Group 3: 10mg/kg,NCT00617890,A Study to Determine the Activity of Robatumumab (SCH 717454) in Participants With Relapsed Osteosarcoma or Ewing's Sarcoma (MK-7454-002/P04720),jaundice
D001064,0.87,NCT00617890-4,Group 3: 10mg/kg,NCT00617890,A Study to Determine the Activity of Robatumumab (SCH 717454) in Participants With Relapsed Osteosarcoma or Ewing's Sarcoma (MK-7454-002/P04720),appendicitis
D001996,2.94,NCT00617890-1,Group 1: 0.3mg/kg,NCT00617890,A Study to Determine the Activity of Robatumumab (SCH 717454) in Participants With Relapsed Osteosarcoma or Ewing's Sarcoma (MK-7454-002/P04720),bronchopneumonia
D002494,0.87,NCT00617890-4,Group 3: 10mg/kg,NCT00617890,A Study to Determine the Activity of Robatumumab (SCH 717454) in Participants With Relapsed Osteosarcoma or Ewing's Sarcoma (MK-7454-002/P04720),central nervous system infection
D005759,0.87,NCT00617890-4,Group 3: 10mg/kg,NCT00617890,A Study to Determine the Activity of Robatumumab (SCH 717454) in Participants With Relapsed Osteosarcoma or Ewing's Sarcoma (MK-7454-002/P04720),gastroenteritis
D000072139,0.87,NCT00617890-4,Group 3: 10mg/kg,NCT00617890,A Study to Determine the Activity of Robatumumab (SCH 717454) in Participants With Relapsed Osteosarcoma or Ewing's Sarcoma (MK-7454-002/P04720),megavirales
D006562,0.87,NCT00617890-4,Group 3: 10mg/kg,NCT00617890,A Study to Determine the Activity of Robatumumab (SCH 717454) in Participants With Relapsed Osteosarcoma or Ewing's Sarcoma (MK-7454-002/P04720),herpes zoster
D007239,0.87,NCT00617890-4,Group 3: 10mg/kg,NCT00617890,A Study to Determine the Activity of Robatumumab (SCH 717454) in Participants With Relapsed Osteosarcoma or Ewing's Sarcoma (MK-7454-002/P04720),infection
D010033,0.87,NCT00617890-4,Group 3: 10mg/kg,NCT00617890,A Study to Determine the Activity of Robatumumab (SCH 717454) in Participants With Relapsed Osteosarcoma or Ewing's Sarcoma (MK-7454-002/P04720),otitis media
D011014,2.94,NCT00617890-1,Group 1: 0.3mg/kg,NCT00617890,A Study to Determine the Activity of Robatumumab (SCH 717454) in Participants With Relapsed Osteosarcoma or Ewing's Sarcoma (MK-7454-002/P04720),pneumonia
D011014,1.74,NCT00617890-4,Group 3: 10mg/kg,NCT00617890,A Study to Determine the Activity of Robatumumab (SCH 717454) in Participants With Relapsed Osteosarcoma or Ewing's Sarcoma (MK-7454-002/P04720),pneumonia
D011024,0.87,NCT00617890-4,Group 3: 10mg/kg,NCT00617890,A Study to Determine the Activity of Robatumumab (SCH 717454) in Participants With Relapsed Osteosarcoma or Ewing's Sarcoma (MK-7454-002/P04720),viral pneumonia
D013530,3.03,NCT00617890-2,Group 1: 10mg/kg,NCT00617890,A Study to Determine the Activity of Robatumumab (SCH 717454) in Participants With Relapsed Osteosarcoma or Ewing's Sarcoma (MK-7454-002/P04720),wound infection postoperative
D013530,3.03,NCT00617890-2,Group 1: 10mg/kg,NCT00617890,A Study to Determine the Activity of Robatumumab (SCH 717454) in Participants With Relapsed Osteosarcoma or Ewing's Sarcoma (MK-7454-002/P04720),postoperative wound infection
D018805,0.87,NCT00617890-4,Group 3: 10mg/kg,NCT00617890,A Study to Determine the Activity of Robatumumab (SCH 717454) in Participants With Relapsed Osteosarcoma or Ewing's Sarcoma (MK-7454-002/P04720),sepsis
D014552,0.87,NCT00617890-4,Group 3: 10mg/kg,NCT00617890,A Study to Determine the Activity of Robatumumab (SCH 717454) in Participants With Relapsed Osteosarcoma or Ewing's Sarcoma (MK-7454-002/P04720),urinary tract infection
D001621,0.87,NCT00617890-4,Group 3: 10mg/kg,NCT00617890,A Study to Determine the Activity of Robatumumab (SCH 717454) in Participants With Relapsed Osteosarcoma or Ewing's Sarcoma (MK-7454-002/P04720),ribrain
D006811,2.94,NCT00617890-3,Group 2: 10mg/kg,NCT00617890,A Study to Determine the Activity of Robatumumab (SCH 717454) in Participants With Relapsed Osteosarcoma or Ewing's Sarcoma (MK-7454-002/P04720),humerus
D012127,2.94,NCT00617890-1,Group 1: 0.3mg/kg,NCT00617890,A Study to Determine the Activity of Robatumumab (SCH 717454) in Participants With Relapsed Osteosarcoma or Ewing's Sarcoma (MK-7454-002/P04720),respiratory distress syndrome newborn
D007022,2.94,NCT00617890-3,Group 2: 10mg/kg,NCT00617890,A Study to Determine the Activity of Robatumumab (SCH 717454) in Participants With Relapsed Osteosarcoma or Ewing's Sarcoma (MK-7454-002/P04720),hypotension
D012253,0.87,NCT00617890-4,Group 3: 10mg/kg,NCT00617890,A Study to Determine the Activity of Robatumumab (SCH 717454) in Participants With Relapsed Osteosarcoma or Ewing's Sarcoma (MK-7454-002/P04720),rib fracture
D000081015,0.87,NCT00617890-4,Group 3: 10mg/kg,NCT00617890,A Study to Determine the Activity of Robatumumab (SCH 717454) in Participants With Relapsed Osteosarcoma or Ewing's Sarcoma (MK-7454-002/P04720),ototoxicity
D005218,2.94,NCT00617890-1,Group 1: 0.3mg/kg,NCT00617890,A Study to Determine the Activity of Robatumumab (SCH 717454) in Participants With Relapsed Osteosarcoma or Ewing's Sarcoma (MK-7454-002/P04720),steatonecrosis
D000077553,3.03,NCT00617890-2,Group 1: 10mg/kg,NCT00617890,A Study to Determine the Activity of Robatumumab (SCH 717454) in Participants With Relapsed Osteosarcoma or Ewing's Sarcoma (MK-7454-002/P04720),edarabone
10005359,2.94,NCT00617890-3,Group 2: 10mg/kg,NCT00617890,A Study to Determine the Activity of Robatumumab (SCH 717454) in Participants With Relapsed Osteosarcoma or Ewing's Sarcoma (MK-7454-002/P04720),blood bicarbonate decreased
D001066,3.03,NCT00617890-2,Group 1: 10mg/kg,NCT00617890,A Study to Determine the Activity of Robatumumab (SCH 717454) in Participants With Relapsed Osteosarcoma or Ewing's Sarcoma (MK-7454-002/P04720),appetite
D001066,1.74,NCT00617890-4,Group 3: 10mg/kg,NCT00617890,A Study to Determine the Activity of Robatumumab (SCH 717454) in Participants With Relapsed Osteosarcoma or Ewing's Sarcoma (MK-7454-002/P04720),appetite
UNKNOWN-check-for-typo,2.94,NCT00617890-3,Group 2: 10mg/kg,NCT00617890,A Study to Determine the Activity of Robatumumab (SCH 717454) in Participants With Relapsed Osteosarcoma or Ewing's Sarcoma (MK-7454-002/P04720),D00
D018771,1.74,NCT00617890-4,Group 3: 10mg/kg,NCT00617890,A Study to Determine the Activity of Robatumumab (SCH 717454) in Participants With Relapsed Osteosarcoma or Ewing's Sarcoma (MK-7454-002/P04720),arthralgia
D001416,2.61,NCT00617890-4,Group 3: 10mg/kg,NCT00617890,A Study to Determine the Activity of Robatumumab (SCH 717454) in Participants With Relapsed Osteosarcoma or Ewing's Sarcoma (MK-7454-002/P04720),back pain
D002062,2.94,NCT00617890-3,Group 2: 10mg/kg,NCT00617890,A Study to Determine the Activity of Robatumumab (SCH 717454) in Participants With Relapsed Osteosarcoma or Ewing's Sarcoma (MK-7454-002/P04720),bursitis
D021501,0.87,NCT00617890-4,Group 3: 10mg/kg,NCT00617890,A Study to Determine the Activity of Robatumumab (SCH 717454) in Participants With Relapsed Osteosarcoma or Ewing's Sarcoma (MK-7454-002/P04720),flank pain
UNKNOWN-check-for-typo,2.94,NCT00617890-3,Group 2: 10mg/kg,NCT00617890,A Study to Determine the Activity of Robatumumab (SCH 717454) in Participants With Relapsed Osteosarcoma or Ewing's Sarcoma (MK-7454-002/P04720),D00
D059352,0.87,NCT00617890-4,Group 3: 10mg/kg,NCT00617890,A Study to Determine the Activity of Robatumumab (SCH 717454) in Participants With Relapsed Osteosarcoma or Ewing's Sarcoma (MK-7454-002/P04720),musculoskeletal pain
D000072716,0.87,NCT00617890-4,Group 3: 10mg/kg,NCT00617890,A Study to Determine the Activity of Robatumumab (SCH 717454) in Participants With Relapsed Osteosarcoma or Ewing's Sarcoma (MK-7454-002/P04720),cancer pain
D016066,2.94,NCT00617890-3,Group 2: 10mg/kg,NCT00617890,A Study to Determine the Activity of Robatumumab (SCH 717454) in Participants With Relapsed Osteosarcoma or Ewing's Sarcoma (MK-7454-002/P04720),malignant pleural effusion
D008168,2.94,NCT00617890-1,Group 1: 0.3mg/kg,NCT00617890,A Study to Determine the Activity of Robatumumab (SCH 717454) in Participants With Relapsed Osteosarcoma or Ewing's Sarcoma (MK-7454-002/P04720),lung
D012516,3.03,NCT00617890-2,Group 1: 10mg/kg,NCT00617890,A Study to Determine the Activity of Robatumumab (SCH 717454) in Participants With Relapsed Osteosarcoma or Ewing's Sarcoma (MK-7454-002/P04720),osteosarcoma
D000080867,2.61,NCT00617890-4,Group 3: 10mg/kg,NCT00617890,A Study to Determine the Activity of Robatumumab (SCH 717454) in Participants With Relapsed Osteosarcoma or Ewing's Sarcoma (MK-7454-002/P04720),gingipains
D003244,0.87,NCT00617890-4,Group 3: 10mg/kg,NCT00617890,A Study to Determine the Activity of Robatumumab (SCH 717454) in Participants With Relapsed Osteosarcoma or Ewing's Sarcoma (MK-7454-002/P04720),consciousness level altered
D003128,2.94,NCT00617890-3,Group 2: 10mg/kg,NCT00617890,A Study to Determine the Activity of Robatumumab (SCH 717454) in Participants With Relapsed Osteosarcoma or Ewing's Sarcoma (MK-7454-002/P04720),coma
D003128,0.87,NCT00617890-4,Group 3: 10mg/kg,NCT00617890,A Study to Determine the Activity of Robatumumab (SCH 717454) in Participants With Relapsed Osteosarcoma or Ewing's Sarcoma (MK-7454-002/P04720),coma
D012640,2.94,NCT00617890-1,Group 1: 0.3mg/kg,NCT00617890,A Study to Determine the Activity of Robatumumab (SCH 717454) in Participants With Relapsed Osteosarcoma or Ewing's Sarcoma (MK-7454-002/P04720),convulsion
D012640,0.87,NCT00617890-4,Group 3: 10mg/kg,NCT00617890,A Study to Determine the Activity of Robatumumab (SCH 717454) in Participants With Relapsed Osteosarcoma or Ewing's Sarcoma (MK-7454-002/P04720),convulsion
D001927,1.74,NCT00617890-4,Group 3: 10mg/kg,NCT00617890,A Study to Determine the Activity of Robatumumab (SCH 717454) in Participants With Relapsed Osteosarcoma or Ewing's Sarcoma (MK-7454-002/P04720),encephalopathy
D006261,0.87,NCT00617890-4,Group 3: 10mg/kg,NCT00617890,A Study to Determine the Activity of Robatumumab (SCH 717454) in Participants With Relapsed Osteosarcoma or Ewing's Sarcoma (MK-7454-002/P04720),headache
D006501,0.87,NCT00617890-4,Group 3: 10mg/kg,NCT00617890,A Study to Determine the Activity of Robatumumab (SCH 717454) in Participants With Relapsed Osteosarcoma or Ewing's Sarcoma (MK-7454-002/P04720),hepatic encephalopathy
D000067836,0.87,NCT00617890-4,Group 3: 10mg/kg,NCT00617890,A Study to Determine the Activity of Robatumumab (SCH 717454) in Participants With Relapsed Osteosarcoma or Ewing's Sarcoma (MK-7454-002/P04720),hoarding disorder
D009207,0.87,NCT00617890-4,Group 3: 10mg/kg,NCT00617890,A Study to Determine the Activity of Robatumumab (SCH 717454) in Participants With Relapsed Osteosarcoma or Ewing's Sarcoma (MK-7454-002/P04720),myoclonus
D009408,0.87,NCT00617890-4,Group 3: 10mg/kg,NCT00617890,A Study to Determine the Activity of Robatumumab (SCH 717454) in Participants With Relapsed Osteosarcoma or Ewing's Sarcoma (MK-7454-002/P04720),nerve compression syndromes
10034620,0.87,NCT00617890-4,Group 3: 10mg/kg,NCT00617890,A Study to Determine the Activity of Robatumumab (SCH 717454) in Participants With Relapsed Osteosarcoma or Ewing's Sarcoma (MK-7454-002/P04720),peripheral sensory neuropathy
D013117,1.74,NCT00617890-4,Group 3: 10mg/kg,NCT00617890,A Study to Determine the Activity of Robatumumab (SCH 717454) in Participants With Relapsed Osteosarcoma or Ewing's Sarcoma (MK-7454-002/P04720),spinal cord compression
D013575,0.87,NCT00617890-4,Group 3: 10mg/kg,NCT00617890,A Study to Determine the Activity of Robatumumab (SCH 717454) in Participants With Relapsed Osteosarcoma or Ewing's Sarcoma (MK-7454-002/P04720),syncope
D020258,0.87,NCT00617890-4,Group 3: 10mg/kg,NCT00617890,A Study to Determine the Activity of Robatumumab (SCH 717454) in Participants With Relapsed Osteosarcoma or Ewing's Sarcoma (MK-7454-002/P04720),toxic encephalopathy
10001497,2.94,NCT00617890-3,Group 2: 10mg/kg,NCT00617890,A Study to Determine the Activity of Robatumumab (SCH 717454) in Participants With Relapsed Osteosarcoma or Ewing's Sarcoma (MK-7454-002/P04720),agitation
D001007,2.94,NCT00617890-3,Group 2: 10mg/kg,NCT00617890,A Study to Determine the Activity of Robatumumab (SCH 717454) in Participants With Relapsed Osteosarcoma or Ewing's Sarcoma (MK-7454-002/P04720),anxiety
D003221,2.94,NCT00617890-3,Group 2: 10mg/kg,NCT00617890,A Study to Determine the Activity of Robatumumab (SCH 717454) in Participants With Relapsed Osteosarcoma or Ewing's Sarcoma (MK-7454-002/P04720),confusional state
D007319,2.94,NCT00617890-3,Group 2: 10mg/kg,NCT00617890,A Study to Determine the Activity of Robatumumab (SCH 717454) in Participants With Relapsed Osteosarcoma or Ewing's Sarcoma (MK-7454-002/P04720),insomnia
D000073216,0.87,NCT00617890-4,Group 3: 10mg/kg,NCT00617890,A Study to Determine the Activity of Robatumumab (SCH 717454) in Participants With Relapsed Osteosarcoma or Ewing's Sarcoma (MK-7454-002/P04720),mental status tests
D053040,0.87,NCT00617890-4,Group 3: 10mg/kg,NCT00617890,A Study to Determine the Activity of Robatumumab (SCH 717454) in Participants With Relapsed Osteosarcoma or Ewing's Sarcoma (MK-7454-002/P04720),nephrolithiasis
D012128,0.87,NCT00617890-4,Group 3: 10mg/kg,NCT00617890,A Study to Determine the Activity of Robatumumab (SCH 717454) in Participants With Relapsed Osteosarcoma or Ewing's Sarcoma (MK-7454-002/P04720),acute respiratory distress syndrome
D012131,1.74,NCT00617890-4,Group 3: 10mg/kg,NCT00617890,A Study to Determine the Activity of Robatumumab (SCH 717454) in Participants With Relapsed Osteosarcoma or Ewing's Sarcoma (MK-7454-002/P04720),respiratory failure
D000067836,2.94,NCT00617890-1,Group 1: 0.3mg/kg,NCT00617890,A Study to Determine the Activity of Robatumumab (SCH 717454) in Participants With Relapsed Osteosarcoma or Ewing's Sarcoma (MK-7454-002/P04720),hoarding disorder
UNKNOWN-check-for-typo,5.88,NCT00617890-3,Group 2: 10mg/kg,NCT00617890,A Study to Determine the Activity of Robatumumab (SCH 717454) in Participants With Relapsed Osteosarcoma or Ewing's Sarcoma (MK-7454-002/P04720),D00
UNKNOWN-check-for-typo,2.61,NCT00617890-4,Group 3: 10mg/kg,NCT00617890,A Study to Determine the Activity of Robatumumab (SCH 717454) in Participants With Relapsed Osteosarcoma or Ewing's Sarcoma (MK-7454-002/P04720),D00
D000068718,2.94,NCT00617890-3,Group 2: 10mg/kg,NCT00617890,A Study to Determine the Activity of Robatumumab (SCH 717454) in Participants With Relapsed Osteosarcoma or Ewing's Sarcoma (MK-7454-002/P04720),crestor
D051270,0.87,NCT00617890-4,Group 3: 10mg/kg,NCT00617890,A Study to Determine the Activity of Robatumumab (SCH 717454) in Participants With Relapsed Osteosarcoma or Ewing's Sarcoma (MK-7454-002/P04720),primary exertional headache
D004844,1.74,NCT00617890-4,Group 3: 10mg/kg,NCT00617890,A Study to Determine the Activity of Robatumumab (SCH 717454) in Participants With Relapsed Osteosarcoma or Ewing's Sarcoma (MK-7454-002/P04720),epistaxis
UNKNOWN-check-for-typo,2.94,NCT00617890-1,Group 1: 0.3mg/kg,NCT00617890,A Study to Determine the Activity of Robatumumab (SCH 717454) in Participants With Relapsed Osteosarcoma or Ewing's Sarcoma (MK-7454-002/P04720),D00
D000860,2.94,NCT00617890-3,Group 2: 10mg/kg,NCT00617890,A Study to Determine the Activity of Robatumumab (SCH 717454) in Participants With Relapsed Osteosarcoma or Ewing's Sarcoma (MK-7454-002/P04720),hypoxia
D010996,2.94,NCT00617890-1,Group 1: 0.3mg/kg,NCT00617890,A Study to Determine the Activity of Robatumumab (SCH 717454) in Participants With Relapsed Osteosarcoma or Ewing's Sarcoma (MK-7454-002/P04720),pleural effusion
D010996,2.94,NCT00617890-3,Group 2: 10mg/kg,NCT00617890,A Study to Determine the Activity of Robatumumab (SCH 717454) in Participants With Relapsed Osteosarcoma or Ewing's Sarcoma (MK-7454-002/P04720),pleural effusion
D011030,11.76,NCT00617890-1,Group 1: 0.3mg/kg,NCT00617890,A Study to Determine the Activity of Robatumumab (SCH 717454) in Participants With Relapsed Osteosarcoma or Ewing's Sarcoma (MK-7454-002/P04720),pneumothorax
D011030,3.03,NCT00617890-2,Group 1: 10mg/kg,NCT00617890,A Study to Determine the Activity of Robatumumab (SCH 717454) in Participants With Relapsed Osteosarcoma or Ewing's Sarcoma (MK-7454-002/P04720),pneumothorax
D011030,0.87,NCT00617890-4,Group 3: 10mg/kg,NCT00617890,A Study to Determine the Activity of Robatumumab (SCH 717454) in Participants With Relapsed Osteosarcoma or Ewing's Sarcoma (MK-7454-002/P04720),pneumothorax
D011655,0.87,NCT00617890-4,Group 3: 10mg/kg,NCT00617890,A Study to Determine the Activity of Robatumumab (SCH 717454) in Participants With Relapsed Osteosarcoma or Ewing's Sarcoma (MK-7454-002/P04720),pulmonary embolism
D000081015,0.87,NCT00617890-4,Group 3: 10mg/kg,NCT00617890,A Study to Determine the Activity of Robatumumab (SCH 717454) in Participants With Relapsed Osteosarcoma or Ewing's Sarcoma (MK-7454-002/P04720),ototoxicity
D012127,5.22,NCT00617890-4,Group 3: 10mg/kg,NCT00617890,A Study to Determine the Activity of Robatumumab (SCH 717454) in Participants With Relapsed Osteosarcoma or Ewing's Sarcoma (MK-7454-002/P04720),respiratory distress syndrome newborn
D012131,8.82,NCT00617890-1,Group 1: 0.3mg/kg,NCT00617890,A Study to Determine the Activity of Robatumumab (SCH 717454) in Participants With Relapsed Osteosarcoma or Ewing's Sarcoma (MK-7454-002/P04720),respiratory failure
D012131,3.03,NCT00617890-2,Group 1: 10mg/kg,NCT00617890,A Study to Determine the Activity of Robatumumab (SCH 717454) in Participants With Relapsed Osteosarcoma or Ewing's Sarcoma (MK-7454-002/P04720),respiratory failure
D012131,4.35,NCT00617890-4,Group 3: 10mg/kg,NCT00617890,A Study to Determine the Activity of Robatumumab (SCH 717454) in Participants With Relapsed Osteosarcoma or Ewing's Sarcoma (MK-7454-002/P04720),respiratory failure
D011693,0.87,NCT00617890-4,Group 3: 10mg/kg,NCT00617890,A Study to Determine the Activity of Robatumumab (SCH 717454) in Participants With Relapsed Osteosarcoma or Ewing's Sarcoma (MK-7454-002/P04720),petechiae
D000075,2.94,NCT00617890-1,Group 1: 0.3mg/kg,NCT00617890,A Study to Determine the Activity of Robatumumab (SCH 717454) in Participants With Relapsed Osteosarcoma or Ewing's Sarcoma (MK-7454-002/P04720),plegicil
D004864,0.87,NCT00617890-4,Group 3: 10mg/kg,NCT00617890,A Study to Determine the Activity of Robatumumab (SCH 717454) in Participants With Relapsed Osteosarcoma or Ewing's Sarcoma (MK-7454-002/P04720),medical devices
D013908,2.94,NCT00617890-1,Group 1: 0.3mg/kg,NCT00617890,A Study to Determine the Activity of Robatumumab (SCH 717454) in Participants With Relapsed Osteosarcoma or Ewing's Sarcoma (MK-7454-002/P04720),thoracotomy
D000069342,2.94,NCT00617890-1,Group 1: 0.3mg/kg,NCT00617890,A Study to Determine the Activity of Robatumumab (SCH 717454) in Participants With Relapsed Osteosarcoma or Ewing's Sarcoma (MK-7454-002/P04720),overtreatment
D000074042,0.87,NCT00617890-4,Group 3: 10mg/kg,NCT00617890,A Study to Determine the Activity of Robatumumab (SCH 717454) in Participants With Relapsed Osteosarcoma or Ewing's Sarcoma (MK-7454-002/P04720),cerebral intraventricular haemorrhage
D007022,2.94,NCT00617890-1,Group 1: 0.3mg/kg,NCT00617890,A Study to Determine the Activity of Robatumumab (SCH 717454) in Participants With Relapsed Osteosarcoma or Ewing's Sarcoma (MK-7454-002/P04720),hypotension
D004597,2.94,NCT00617890-1,Group 1: 0.3mg/kg,NCT00617890,A Study to Determine the Activity of Robatumumab (SCH 717454) in Participants With Relapsed Osteosarcoma or Ewing's Sarcoma (MK-7454-002/P04720),electroshock
D064420,5.71,NCT00618813-1,Treatment (Combination Chemotherapy),NCT00618813,Two Regimens of Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed Localized Ewing Sarcoma Family of Tumors,adverse drug events
D000740,2.86,NCT00618813-1,Treatment (Combination Chemotherapy),NCT00618813,Two Regimens of Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed Localized Ewing Sarcoma Family of Tumors,anemia
10055356,2.86,NCT00618813-1,Treatment (Combination Chemotherapy),NCT00618813,Two Regimens of Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed Localized Ewing Sarcoma Family of Tumors,upper gastrointestinal hemorrhage
10035528,2.86,NCT00618813-1,Treatment (Combination Chemotherapy),NCT00618813,Two Regimens of Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed Localized Ewing Sarcoma Family of Tumors,platelet count decreased
D001049,2.86,NCT00618813-1,Treatment (Combination Chemotherapy),NCT00618813,Two Regimens of Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed Localized Ewing Sarcoma Family of Tumors,apnea
D064420,3.12,NCT00635050-1,Doxil Paclitaxel Cyclophosphamide + Avastin,NCT00635050,Therapy for Locally Advanced Breast Cancer Using Doxil  Paclitaxel  and Cyclophosphamide With Avastin,adverse drug events
D006760,3.12,NCT00635050-1,Doxil Paclitaxel Cyclophosphamide + Avastin,NCT00635050,Therapy for Locally Advanced Breast Cancer Using Doxil  Paclitaxel  and Cyclophosphamide With Avastin,hospitalization
D064420,33.33,NCT00653328-1,Altrasentan + Doxil,NCT00653328,Ph II Atrasentan + DOXIL in Recurrent Ovarian/Fallopian/Peritoneal Serous Papillary Adenocarcinoma,adverse drug events
D010490,6.67,NCT00653328-1,Altrasentan + Doxil,NCT00653328,Ph II Atrasentan + DOXIL in Recurrent Ovarian/Fallopian/Peritoneal Serous Papillary Adenocarcinoma,pericardial effusion
D009325,13.33,NCT00653328-1,Altrasentan + Doxil,NCT00653328,Ph II Atrasentan + DOXIL in Recurrent Ovarian/Fallopian/Peritoneal Serous Papillary Adenocarcinoma,nausea
D014839,13.33,NCT00653328-1,Altrasentan + Doxil,NCT00653328,Ph II Atrasentan + DOXIL in Recurrent Ovarian/Fallopian/Peritoneal Serous Papillary Adenocarcinoma,vomiting
D000007,6.67,NCT00653328-1,Altrasentan + Doxil,NCT00653328,Ph II Atrasentan + DOXIL in Recurrent Ovarian/Fallopian/Peritoneal Serous Papillary Adenocarcinoma,abdominal injuries
D005221,20.0,NCT00653328-1,Altrasentan + Doxil,NCT00653328,Ph II Atrasentan + DOXIL in Recurrent Ovarian/Fallopian/Peritoneal Serous Papillary Adenocarcinoma,fatigue
D003643,6.67,NCT00653328-1,Altrasentan + Doxil,NCT00653328,Ph II Atrasentan + DOXIL in Recurrent Ovarian/Fallopian/Peritoneal Serous Papillary Adenocarcinoma,death
D004487,6.67,NCT00653328-1,Altrasentan + Doxil,NCT00653328,Ph II Atrasentan + DOXIL in Recurrent Ovarian/Fallopian/Peritoneal Serous Papillary Adenocarcinoma,edema
D005334,13.33,NCT00653328-1,Altrasentan + Doxil,NCT00653328,Ph II Atrasentan + DOXIL in Recurrent Ovarian/Fallopian/Peritoneal Serous Papillary Adenocarcinoma,fever
D005221,13.33,NCT00653328-1,Altrasentan + Doxil,NCT00653328,Ph II Atrasentan + DOXIL in Recurrent Ovarian/Fallopian/Peritoneal Serous Papillary Adenocarcinoma,fatigue
D006454,13.33,NCT00653328-1,Altrasentan + Doxil,NCT00653328,Ph II Atrasentan + DOXIL in Recurrent Ovarian/Fallopian/Peritoneal Serous Papillary Adenocarcinoma,hemoglobin
D003681,6.67,NCT00653328-1,Altrasentan + Doxil,NCT00653328,Ph II Atrasentan + DOXIL in Recurrent Ovarian/Fallopian/Peritoneal Serous Papillary Adenocarcinoma,dehydration
D034141,6.67,NCT00653328-1,Altrasentan + Doxil,NCT00653328,Ph II Atrasentan + DOXIL in Recurrent Ovarian/Fallopian/Peritoneal Serous Papillary Adenocarcinoma,hypoalbuminemia
D007010,6.67,NCT00653328-1,Altrasentan + Doxil,NCT00653328,Ph II Atrasentan + DOXIL in Recurrent Ovarian/Fallopian/Peritoneal Serous Papillary Adenocarcinoma,hyponatremia
10046539,6.67,NCT00653328-1,Altrasentan + Doxil,NCT00653328,Ph II Atrasentan + DOXIL in Recurrent Ovarian/Fallopian/Peritoneal Serous Papillary Adenocarcinoma,urinary frequency
D017699,6.67,NCT00653328-1,Altrasentan + Doxil,NCT00653328,Ph II Atrasentan + DOXIL in Recurrent Ovarian/Fallopian/Peritoneal Serous Papillary Adenocarcinoma,pelvic pain
D004417,13.33,NCT00653328-1,Altrasentan + Doxil,NCT00653328,Ph II Atrasentan + DOXIL in Recurrent Ovarian/Fallopian/Peritoneal Serous Papillary Adenocarcinoma,dyspnea
D000860,6.67,NCT00653328-1,Altrasentan + Doxil,NCT00653328,Ph II Atrasentan + DOXIL in Recurrent Ovarian/Fallopian/Peritoneal Serous Papillary Adenocarcinoma,hypoxia
D010996,13.33,NCT00653328-1,Altrasentan + Doxil,NCT00653328,Ph II Atrasentan + DOXIL in Recurrent Ovarian/Fallopian/Peritoneal Serous Papillary Adenocarcinoma,pleural effusion
D013923,6.67,NCT00653328-1,Altrasentan + Doxil,NCT00653328,Ph II Atrasentan + DOXIL in Recurrent Ovarian/Fallopian/Peritoneal Serous Papillary Adenocarcinoma,thromboembolism
D019584,6.67,NCT00653328-1,Altrasentan + Doxil,NCT00653328,Ph II Atrasentan + DOXIL in Recurrent Ovarian/Fallopian/Peritoneal Serous Papillary Adenocarcinoma,hot flashes
D064420,8.7,NCT00656669-2,Paclitaxel/Sunitinib,NCT00656669,Exploratory Study of Sunitinib Malate as a Component of Neoadjuvant Therapy for Breast Cancer,adverse drug events
D064420,12.5,NCT00656669-3,AC Dosing,NCT00656669,Exploratory Study of Sunitinib Malate as a Component of Neoadjuvant Therapy for Breast Cancer,adverse drug events
10069501,4.35,NCT00656669-2,Paclitaxel/Sunitinib,NCT00656669,Exploratory Study of Sunitinib Malate as a Component of Neoadjuvant Therapy for Breast Cancer,left ventricular systolic dysfunction
D009325,4.35,NCT00656669-2,Paclitaxel/Sunitinib,NCT00656669,Exploratory Study of Sunitinib Malate as a Component of Neoadjuvant Therapy for Breast Cancer,nausea
D014839,4.35,NCT00656669-2,Paclitaxel/Sunitinib,NCT00656669,Exploratory Study of Sunitinib Malate as a Component of Neoadjuvant Therapy for Breast Cancer,vomiting
D003414,4.35,NCT00656669-2,Paclitaxel/Sunitinib,NCT00656669,Exploratory Study of Sunitinib Malate as a Component of Neoadjuvant Therapy for Breast Cancer,familial nonhemolytic unconjugated hyperbilirubinemia
D000069544,4.35,NCT00656669-2,Paclitaxel/Sunitinib,NCT00656669,Exploratory Study of Sunitinib Malate as a Component of Neoadjuvant Therapy for Breast Cancer,encephalitis infection
D006098,6.25,NCT00656669-3,AC Dosing,NCT00656669,Exploratory Study of Sunitinib Malate as a Component of Neoadjuvant Therapy for Breast Cancer,granulocytes
D005335,12.5,NCT00656669-3,AC Dosing,NCT00656669,Exploratory Study of Sunitinib Malate as a Component of Neoadjuvant Therapy for Breast Cancer,unknown origin fever
D064420,33.33,NCT00665457-1,Celecoxib,NCT00665457,Biomarkers in Women Receiving Chemotherapy and Celecoxib for Stage II or Stage III Breast Cancer That Can Be Removed by Surgery,adverse drug events
D005334,33.33,NCT00665457-1,Celecoxib,NCT00665457,Biomarkers in Women Receiving Chemotherapy and Celecoxib for Stage II or Stage III Breast Cancer That Can Be Removed by Surgery,fever
D009026,6.67,NCT00679029-1,Arm I,NCT00679029,Combination Chemotherapy and Bevacizumab in Treating Women With HER2/Neu-Negative Stage II or Stage III Breast Cancer,mortality
D064420,26.67,NCT00679029-1,Arm I,NCT00679029,Combination Chemotherapy and Bevacizumab in Treating Women With HER2/Neu-Negative Stage II or Stage III Breast Cancer,adverse drug events
D064147,6.67,NCT00679029-1,Arm I,NCT00679029,Combination Chemotherapy and Bevacizumab in Treating Women With HER2/Neu-Negative Stage II or Stage III Breast Cancer,febrile neutropenia
D000740,6.67,NCT00679029-1,Arm I,NCT00679029,Combination Chemotherapy and Bevacizumab in Treating Women With HER2/Neu-Negative Stage II or Stage III Breast Cancer,anemia
10010001,6.67,NCT00679029-1,Arm I,NCT00679029,Combination Chemotherapy and Bevacizumab in Treating Women With HER2/Neu-Negative Stage II or Stage III Breast Cancer,colonic perforation
D004751,6.67,NCT00679029-1,Arm I,NCT00679029,Combination Chemotherapy and Bevacizumab in Treating Women With HER2/Neu-Negative Stage II or Stage III Breast Cancer,enteritis
D018908,6.67,NCT00679029-1,Arm I,NCT00679029,Combination Chemotherapy and Bevacizumab in Treating Women With HER2/Neu-Negative Stage II or Stage III Breast Cancer,muscle weakness
10061229,6.67,NCT00679029-1,Arm I,NCT00679029,Combination Chemotherapy and Bevacizumab in Treating Women With HER2/Neu-Negative Stage II or Stage III Breast Cancer,lung infection
10035528,6.67,NCT00679029-1,Arm I,NCT00679029,Combination Chemotherapy and Bevacizumab in Treating Women With HER2/Neu-Negative Stage II or Stage III Breast Cancer,platelet count decreased
10049182,6.67,NCT00679029-1,Arm I,NCT00679029,Combination Chemotherapy and Bevacizumab in Treating Women With HER2/Neu-Negative Stage II or Stage III Breast Cancer,white blood cell decreased
10029366,6.67,NCT00679029-1,Arm I,NCT00679029,Combination Chemotherapy and Bevacizumab in Treating Women With HER2/Neu-Negative Stage II or Stage III Breast Cancer,neutrophil count decreased
D002481,6.67,NCT00679029-1,Arm I,NCT00679029,Combination Chemotherapy and Bevacizumab in Treating Women With HER2/Neu-Negative Stage II or Stage III Breast Cancer,cellulitis
D004417,6.67,NCT00679029-1,Arm I,NCT00679029,Combination Chemotherapy and Bevacizumab in Treating Women With HER2/Neu-Negative Stage II or Stage III Breast Cancer,dyspnea
D006470,6.67,NCT00679029-1,Arm I,NCT00679029,Combination Chemotherapy and Bevacizumab in Treating Women With HER2/Neu-Negative Stage II or Stage III Breast Cancer,hemorrhage
D064420,28.57,NCT00715208-1,VELCADE R-CAP,NCT00715208,Phase 2 Study of VELCADE (Bortezomib) in Patients With Relapsed Follicular Lymphoma,adverse drug events
D064420,25.0,NCT00715208-2,VELCADE R-CP,NCT00715208,Phase 2 Study of VELCADE (Bortezomib) in Patients With Relapsed Follicular Lymphoma,adverse drug events
D064147,14.29,NCT00715208-1,VELCADE R-CAP,NCT00715208,Phase 2 Study of VELCADE (Bortezomib) in Patients With Relapsed Follicular Lymphoma,febrile neutropenia
D064147,2.08,NCT00715208-2,VELCADE R-CP,NCT00715208,Phase 2 Study of VELCADE (Bortezomib) in Patients With Relapsed Follicular Lymphoma,febrile neutropenia
D009503,2.08,NCT00715208-2,VELCADE R-CP,NCT00715208,Phase 2 Study of VELCADE (Bortezomib) in Patients With Relapsed Follicular Lymphoma,neutropenia
D000072281,4.17,NCT00715208-2,VELCADE R-CP,NCT00715208,Phase 2 Study of VELCADE (Bortezomib) in Patients With Relapsed Follicular Lymphoma,lymphadenopathy
D007970,14.29,NCT00715208-1,VELCADE R-CAP,NCT00715208,Phase 2 Study of VELCADE (Bortezomib) in Patients With Relapsed Follicular Lymphoma,leukopenia
D006333,2.08,NCT00715208-2,VELCADE R-CP,NCT00715208,Phase 2 Study of VELCADE (Bortezomib) in Patients With Relapsed Follicular Lymphoma,cardiac failure
D009203,2.08,NCT00715208-2,VELCADE R-CP,NCT00715208,Phase 2 Study of VELCADE (Bortezomib) in Patients With Relapsed Follicular Lymphoma,myocardial infarction
D001281,2.08,NCT00715208-2,VELCADE R-CP,NCT00715208,Phase 2 Study of VELCADE (Bortezomib) in Patients With Relapsed Follicular Lymphoma,atrial fibrillation
10005886,2.08,NCT00715208-2,VELCADE R-CP,NCT00715208,Phase 2 Study of VELCADE (Bortezomib) in Patients With Relapsed Follicular Lymphoma,blurred vision
D001201,2.08,NCT00715208-2,VELCADE R-CP,NCT00715208,Phase 2 Study of VELCADE (Bortezomib) in Patients With Relapsed Follicular Lymphoma,ascites
D015746,2.08,NCT00715208-2,VELCADE R-CP,NCT00715208,Phase 2 Study of VELCADE (Bortezomib) in Patients With Relapsed Follicular Lymphoma,abdominal pain
D005334,14.29,NCT00715208-1,VELCADE R-CAP,NCT00715208,Phase 2 Study of VELCADE (Bortezomib) in Patients With Relapsed Follicular Lymphoma,pyrexia
D005334,6.25,NCT00715208-2,VELCADE R-CP,NCT00715208,Phase 2 Study of VELCADE (Bortezomib) in Patients With Relapsed Follicular Lymphoma,pyrexia
D005221,2.08,NCT00715208-2,VELCADE R-CP,NCT00715208,Phase 2 Study of VELCADE (Bortezomib) in Patients With Relapsed Follicular Lymphoma,fatigue
D018908,2.08,NCT00715208-2,VELCADE R-CP,NCT00715208,Phase 2 Study of VELCADE (Bortezomib) in Patients With Relapsed Follicular Lymphoma,muscle weakness
D001991,2.08,NCT00715208-2,VELCADE R-CP,NCT00715208,Phase 2 Study of VELCADE (Bortezomib) in Patients With Relapsed Follicular Lymphoma,bronchitis
D010223,2.08,NCT00715208-2,VELCADE R-CP,NCT00715208,Phase 2 Study of VELCADE (Bortezomib) in Patients With Relapsed Follicular Lymphoma,acute laryngotracheobronchitis virus
D000077299,2.08,NCT00715208-2,VELCADE R-CP,NCT00715208,Phase 2 Study of VELCADE (Bortezomib) in Patients With Relapsed Follicular Lymphoma,nosocomial pneumonia
UNKNOWN-check-for-typo,2.08,NCT00715208-2,VELCADE R-CP,NCT00715208,Phase 2 Study of VELCADE (Bortezomib) in Patients With Relapsed Follicular Lymphoma,D00
D000985,14.29,NCT00715208-1,VELCADE R-CAP,NCT00715208,Phase 2 Study of VELCADE (Bortezomib) in Patients With Relapsed Follicular Lymphoma,antisepsis
D002177,14.29,NCT00715208-1,VELCADE R-CAP,NCT00715208,Phase 2 Study of VELCADE (Bortezomib) in Patients With Relapsed Follicular Lymphoma,candidiasis
D012141,2.08,NCT00715208-2,VELCADE R-CP,NCT00715208,Phase 2 Study of VELCADE (Bortezomib) in Patients With Relapsed Follicular Lymphoma,respiratory tract infections
D002481,2.08,NCT00715208-2,VELCADE R-CP,NCT00715208,Phase 2 Study of VELCADE (Bortezomib) in Patients With Relapsed Follicular Lymphoma,cellulitis
D014777,2.08,NCT00715208-2,VELCADE R-CP,NCT00715208,Phase 2 Study of VELCADE (Bortezomib) in Patients With Relapsed Follicular Lymphoma,viral infections
D000071997,4.17,NCT00715208-2,VELCADE R-CP,NCT00715208,Phase 2 Study of VELCADE (Bortezomib) in Patients With Relapsed Follicular Lymphoma,blood culture
10050380,2.08,NCT00715208-2,VELCADE R-CP,NCT00715208,Phase 2 Study of VELCADE (Bortezomib) in Patients With Relapsed Follicular Lymphoma,electrocardiogram t wave abnormal
D001416,2.08,NCT00715208-2,VELCADE R-CP,NCT00715208,Phase 2 Study of VELCADE (Bortezomib) in Patients With Relapsed Follicular Lymphoma,back pain
D010591,2.08,NCT00715208-2,VELCADE R-CP,NCT00715208,Phase 2 Study of VELCADE (Bortezomib) in Patients With Relapsed Follicular Lymphoma,phantom limb pain
D013575,2.08,NCT00715208-2,VELCADE R-CP,NCT00715208,Phase 2 Study of VELCADE (Bortezomib) in Patients With Relapsed Follicular Lymphoma,syncope
D006261,2.08,NCT00715208-2,VELCADE R-CP,NCT00715208,Phase 2 Study of VELCADE (Bortezomib) in Patients With Relapsed Follicular Lymphoma,headache
UNKNOWN-check-for-typo,2.08,NCT00715208-2,VELCADE R-CP,NCT00715208,Phase 2 Study of VELCADE (Bortezomib) in Patients With Relapsed Follicular Lymphoma,D00
D029424,2.08,NCT00715208-2,VELCADE R-CP,NCT00715208,Phase 2 Study of VELCADE (Bortezomib) in Patients With Relapsed Follicular Lymphoma,pulmonary disease chronic obstructive
D008168,2.08,NCT00715208-2,VELCADE R-CP,NCT00715208,Phase 2 Study of VELCADE (Bortezomib) in Patients With Relapsed Follicular Lymphoma,lung
D010996,2.08,NCT00715208-2,VELCADE R-CP,NCT00715208,Phase 2 Study of VELCADE (Bortezomib) in Patients With Relapsed Follicular Lymphoma,pleural effusion
D012131,2.08,NCT00715208-2,VELCADE R-CP,NCT00715208,Phase 2 Study of VELCADE (Bortezomib) in Patients With Relapsed Follicular Lymphoma,respiratory failure
D006973,2.08,NCT00715208-2,VELCADE R-CP,NCT00715208,Phase 2 Study of VELCADE (Bortezomib) in Patients With Relapsed Follicular Lymphoma,hypertension
D064420,25.18,NCT00719472-1,Rituximab 375 mg/m^2,NCT00719472,A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-cell or Follicular Non-Hodgkin's Lymphoma (RATE),adverse drug events
D064147,7.76,NCT00719472-1,Rituximab 375 mg/m^2,NCT00719472,A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-cell or Follicular Non-Hodgkin's Lymphoma (RATE),febrile neutropenia
D009503,2.35,NCT00719472-1,Rituximab 375 mg/m^2,NCT00719472,A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-cell or Follicular Non-Hodgkin's Lymphoma (RATE),neutropenia
D010198,1.65,NCT00719472-1,Rituximab 375 mg/m^2,NCT00719472,A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-cell or Follicular Non-Hodgkin's Lymphoma (RATE),pancytopenia
D000741,1.18,NCT00719472-1,Rituximab 375 mg/m^2,NCT00719472,A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-cell or Follicular Non-Hodgkin's Lymphoma (RATE),aplastic anaemia
D007970,0.24,NCT00719472-1,Rituximab 375 mg/m^2,NCT00719472,A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-cell or Follicular Non-Hodgkin's Lymphoma (RATE),leukopenia
D013921,0.24,NCT00719472-1,Rituximab 375 mg/m^2,NCT00719472,A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-cell or Follicular Non-Hodgkin's Lymphoma (RATE),thrombocytopenia
D006323,0.47,NCT00719472-1,Rituximab 375 mg/m^2,NCT00719472,A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-cell or Follicular Non-Hodgkin's Lymphoma (RATE),cardiac arrest
D017180,0.47,NCT00719472-1,Rituximab 375 mg/m^2,NCT00719472,A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-cell or Follicular Non-Hodgkin's Lymphoma (RATE),ventricular tachycardia
D006333,0.71,NCT00719472-1,Rituximab 375 mg/m^2,NCT00719472,A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-cell or Follicular Non-Hodgkin's Lymphoma (RATE),cardiac failure
D001281,0.71,NCT00719472-1,Rituximab 375 mg/m^2,NCT00719472,A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-cell or Follicular Non-Hodgkin's Lymphoma (RATE),atrial fibrillation
D009202,0.24,NCT00719472-1,Rituximab 375 mg/m^2,NCT00719472,A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-cell or Follicular Non-Hodgkin's Lymphoma (RATE),cardiomyopathy
D056988,0.24,NCT00719472-1,Rituximab 375 mg/m^2,NCT00719472,A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-cell or Follicular Non-Hodgkin's Lymphoma (RATE),acute anterior wall myocardial infarction
D015746,1.41,NCT00719472-1,Rituximab 375 mg/m^2,NCT00719472,A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-cell or Follicular Non-Hodgkin's Lymphoma (RATE),abdominal pain
D009325,0.71,NCT00719472-1,Rituximab 375 mg/m^2,NCT00719472,A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-cell or Follicular Non-Hodgkin's Lymphoma (RATE),nausea
D014839,0.71,NCT00719472-1,Rituximab 375 mg/m^2,NCT00719472,A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-cell or Follicular Non-Hodgkin's Lymphoma (RATE),vomiting
D003248,0.71,NCT00719472-1,Rituximab 375 mg/m^2,NCT00719472,A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-cell or Follicular Non-Hodgkin's Lymphoma (RATE),constipation
10041101,0.47,NCT00719472-1,Rituximab 375 mg/m^2,NCT00719472,A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-cell or Follicular Non-Hodgkin's Lymphoma (RATE),small intestinal obstruction
D010195,0.24,NCT00719472-1,Rituximab 375 mg/m^2,NCT00719472,A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-cell or Follicular Non-Hodgkin's Lymphoma (RATE),pancreatitis
D003092,0.24,NCT00719472-1,Rituximab 375 mg/m^2,NCT00719472,A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-cell or Follicular Non-Hodgkin's Lymphoma (RATE),colitis
UNKNOWN-check-for-typo,0.24,NCT00719472-1,Rituximab 375 mg/m^2,NCT00719472,A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-cell or Follicular Non-Hodgkin's Lymphoma (RATE),D00
UNKNOWN-check-for-typo,0.24,NCT00719472-1,Rituximab 375 mg/m^2,NCT00719472,A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-cell or Follicular Non-Hodgkin's Lymphoma (RATE),D00
10017815,0.24,NCT00719472-1,Rituximab 375 mg/m^2,NCT00719472,A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-cell or Follicular Non-Hodgkin's Lymphoma (RATE),gastric perforation
D005756,0.24,NCT00719472-1,Rituximab 375 mg/m^2,NCT00719472,A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-cell or Follicular Non-Hodgkin's Lymphoma (RATE),gastritis
D008404,0.24,NCT00719472-1,Rituximab 375 mg/m^2,NCT00719472,A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-cell or Follicular Non-Hodgkin's Lymphoma (RATE),massachusetts
D003680,0.24,NCT00719472-1,Rituximab 375 mg/m^2,NCT00719472,A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-cell or Follicular Non-Hodgkin's Lymphoma (RATE),dysphagia
UNKNOWN-check-for-typo,0.24,NCT00719472-1,Rituximab 375 mg/m^2,NCT00719472,A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-cell or Follicular Non-Hodgkin's Lymphoma (RATE),D00
10041103,0.24,NCT00719472-1,Rituximab 375 mg/m^2,NCT00719472,A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-cell or Follicular Non-Hodgkin's Lymphoma (RATE),small intestinal perforation
10010000,0.24,NCT00719472-1,Rituximab 375 mg/m^2,NCT00719472,A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-cell or Follicular Non-Hodgkin's Lymphoma (RATE),colonic obstruction
D008531,0.24,NCT00719472-1,Rituximab 375 mg/m^2,NCT00719472,A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-cell or Follicular Non-Hodgkin's Lymphoma (RATE),megacolon
D000069196,0.24,NCT00719472-1,Rituximab 375 mg/m^2,NCT00719472,A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-cell or Follicular Non-Hodgkin's Lymphoma (RATE),gastrointestinal microbiome
D013280,0.24,NCT00719472-1,Rituximab 375 mg/m^2,NCT00719472,A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-cell or Follicular Non-Hodgkin's Lymphoma (RATE),stomatitis
D005334,0.71,NCT00719472-1,Rituximab 375 mg/m^2,NCT00719472,A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-cell or Follicular Non-Hodgkin's Lymphoma (RATE),pyrexia
D002637,0.71,NCT00719472-1,Rituximab 375 mg/m^2,NCT00719472,A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-cell or Follicular Non-Hodgkin's Lymphoma (RATE),chest pain
D001247,0.47,NCT00719472-1,Rituximab 375 mg/m^2,NCT00719472,A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-cell or Follicular Non-Hodgkin's Lymphoma (RATE),asthenia
D017093,0.47,NCT00719472-1,Rituximab 375 mg/m^2,NCT00719472,A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-cell or Follicular Non-Hodgkin's Lymphoma (RATE),hepatic failure
D005234,0.24,NCT00719472-1,Rituximab 375 mg/m^2,NCT00719472,A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-cell or Follicular Non-Hodgkin's Lymphoma (RATE),steatohepatitis
D011014,1.65,NCT00719472-1,Rituximab 375 mg/m^2,NCT00719472,A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-cell or Follicular Non-Hodgkin's Lymphoma (RATE),pneumonia
D001991,0.24,NCT00719472-1,Rituximab 375 mg/m^2,NCT00719472,A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-cell or Follicular Non-Hodgkin's Lymphoma (RATE),bronchitis
10061229,0.24,NCT00719472-1,Rituximab 375 mg/m^2,NCT00719472,A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-cell or Follicular Non-Hodgkin's Lymphoma (RATE),lung infection
D018805,1.18,NCT00719472-1,Rituximab 375 mg/m^2,NCT00719472,A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-cell or Follicular Non-Hodgkin's Lymphoma (RATE),sepsis
10064687,0.24,NCT00719472-1,Rituximab 375 mg/m^2,NCT00719472,A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-cell or Follicular Non-Hodgkin's Lymphoma (RATE),device related infection
D000985,0.24,NCT00719472-1,Rituximab 375 mg/m^2,NCT00719472,A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-cell or Follicular Non-Hodgkin's Lymphoma (RATE),antisepsis
D000985,0.24,NCT00719472-1,Rituximab 375 mg/m^2,NCT00719472,A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-cell or Follicular Non-Hodgkin's Lymphoma (RATE),antisepsis
D012772,0.24,NCT00719472-1,Rituximab 375 mg/m^2,NCT00719472,A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-cell or Follicular Non-Hodgkin's Lymphoma (RATE),septic shock
D013203,0.47,NCT00719472-1,Rituximab 375 mg/m^2,NCT00719472,A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-cell or Follicular Non-Hodgkin's Lymphoma (RATE),staphylococcal infection
D000985,0.24,NCT00719472-1,Rituximab 375 mg/m^2,NCT00719472,A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-cell or Follicular Non-Hodgkin's Lymphoma (RATE),antisepsis
D000985,0.47,NCT00719472-1,Rituximab 375 mg/m^2,NCT00719472,A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-cell or Follicular Non-Hodgkin's Lymphoma (RATE),antisepsis
D005759,0.24,NCT00719472-1,Rituximab 375 mg/m^2,NCT00719472,A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-cell or Follicular Non-Hodgkin's Lymphoma (RATE),gastroenteritis
D002481,0.24,NCT00719472-1,Rituximab 375 mg/m^2,NCT00719472,A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-cell or Follicular Non-Hodgkin's Lymphoma (RATE),cellulitis
D008413,0.24,NCT00719472-1,Rituximab 375 mg/m^2,NCT00719472,A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-cell or Follicular Non-Hodgkin's Lymphoma (RATE),mastitis
D008582,0.24,NCT00719472-1,Rituximab 375 mg/m^2,NCT00719472,A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-cell or Follicular Non-Hodgkin's Lymphoma (RATE),aseptic meningitis
D006509,0.24,NCT00719472-1,Rituximab 375 mg/m^2,NCT00719472,A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-cell or Follicular Non-Hodgkin's Lymphoma (RATE),hepatitis b
D006562,0.24,NCT00719472-1,Rituximab 375 mg/m^2,NCT00719472,A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-cell or Follicular Non-Hodgkin's Lymphoma (RATE),herpes zoster
D010844,0.24,NCT00719472-1,Rituximab 375 mg/m^2,NCT00719472,A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-cell or Follicular Non-Hodgkin's Lymphoma (RATE),streptococcal ok432
D014552,0.24,NCT00719472-1,Rituximab 375 mg/m^2,NCT00719472,A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-cell or Follicular Non-Hodgkin's Lymphoma (RATE),urinary tract infection
10016173,0.24,NCT00719472-1,Rituximab 375 mg/m^2,NCT00719472,A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-cell or Follicular Non-Hodgkin's Lymphoma (RATE),fall
10048031,0.24,NCT00719472-1,Rituximab 375 mg/m^2,NCT00719472,A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-cell or Follicular Non-Hodgkin's Lymphoma (RATE),wound dehiscence
D000058,0.24,NCT00719472-1,Rituximab 375 mg/m^2,NCT00719472,A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-cell or Follicular Non-Hodgkin's Lymphoma (RATE),accidental falls
D003681,2.82,NCT00719472-1,Rituximab 375 mg/m^2,NCT00719472,A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-cell or Follicular Non-Hodgkin's Lymphoma (RATE),dehydration
D005183,0.24,NCT00719472-1,Rituximab 375 mg/m^2,NCT00719472,A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-cell or Follicular Non-Hodgkin's Lymphoma (RATE),failure to thrive
D044342,0.24,NCT00719472-1,Rituximab 375 mg/m^2,NCT00719472,A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-cell or Follicular Non-Hodgkin's Lymphoma (RATE),malnutrition
D001066,0.24,NCT00719472-1,Rituximab 375 mg/m^2,NCT00719472,A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-cell or Follicular Non-Hodgkin's Lymphoma (RATE),appetite
UNKNOWN-check-for-typo,0.24,NCT00719472-1,Rituximab 375 mg/m^2,NCT00719472,A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-cell or Follicular Non-Hodgkin's Lymphoma (RATE),D00
UNKNOWN-check-for-typo,0.24,NCT00719472-1,Rituximab 375 mg/m^2,NCT00719472,A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-cell or Follicular Non-Hodgkin's Lymphoma (RATE),D00
UNKNOWN-check-for-typo,0.24,NCT00719472-1,Rituximab 375 mg/m^2,NCT00719472,A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-cell or Follicular Non-Hodgkin's Lymphoma (RATE),D00
D018908,0.24,NCT00719472-1,Rituximab 375 mg/m^2,NCT00719472,A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-cell or Follicular Non-Hodgkin's Lymphoma (RATE),muscular weakness
D059352,0.24,NCT00719472-1,Rituximab 375 mg/m^2,NCT00719472,A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-cell or Follicular Non-Hodgkin's Lymphoma (RATE),musculoskeletal pain
D001943,0.24,NCT00719472-1,Rituximab 375 mg/m^2,NCT00719472,A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-cell or Follicular Non-Hodgkin's Lymphoma (RATE),breast cancer
D008223,0.24,NCT00719472-1,Rituximab 375 mg/m^2,NCT00719472,A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-cell or Follicular Non-Hodgkin's Lymphoma (RATE),lymphoma
D020521,0.47,NCT00719472-1,Rituximab 375 mg/m^2,NCT00719472,A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-cell or Follicular Non-Hodgkin's Lymphoma (RATE),cerebrovascular accident
D000070624,0.24,NCT00719472-1,Rituximab 375 mg/m^2,NCT00719472,A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-cell or Follicular Non-Hodgkin's Lymphoma (RATE),cerebral contusion
D012640,0.24,NCT00719472-1,Rituximab 375 mg/m^2,NCT00719472,A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-cell or Follicular Non-Hodgkin's Lymphoma (RATE),convulsion
D001007,0.24,NCT00719472-1,Rituximab 375 mg/m^2,NCT00719472,A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-cell or Follicular Non-Hodgkin's Lymphoma (RATE),anxiety
D051437,0.24,NCT00719472-1,Rituximab 375 mg/m^2,NCT00719472,A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-cell or Follicular Non-Hodgkin's Lymphoma (RATE),renal failure
D058186,0.24,NCT00719472-1,Rituximab 375 mg/m^2,NCT00719472,A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-cell or Follicular Non-Hodgkin's Lymphoma (RATE),acute renal failure
UNKNOWN-check-for-typo,0.47,NCT00719472-1,Rituximab 375 mg/m^2,NCT00719472,A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-cell or Follicular Non-Hodgkin's Lymphoma (RATE),D00
D012127,0.24,NCT00719472-1,Rituximab 375 mg/m^2,NCT00719472,A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-cell or Follicular Non-Hodgkin's Lymphoma (RATE),respiratory distress syndrome newborn
D012131,0.47,NCT00719472-1,Rituximab 375 mg/m^2,NCT00719472,A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-cell or Follicular Non-Hodgkin's Lymphoma (RATE),respiratory failure
D012131,0.47,NCT00719472-1,Rituximab 375 mg/m^2,NCT00719472,A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-cell or Follicular Non-Hodgkin's Lymphoma (RATE),respiratory failure
D011015,0.24,NCT00719472-1,Rituximab 375 mg/m^2,NCT00719472,A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-cell or Follicular Non-Hodgkin's Lymphoma (RATE),aspiration pneumonia
D010996,0.24,NCT00719472-1,Rituximab 375 mg/m^2,NCT00719472,A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-cell or Follicular Non-Hodgkin's Lymphoma (RATE),pleural effusion
D020246,0.71,NCT00719472-1,Rituximab 375 mg/m^2,NCT00719472,A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-cell or Follicular Non-Hodgkin's Lymphoma (RATE),deep vein thrombosis
D007601,0.24,NCT00719472-1,Rituximab 375 mg/m^2,NCT00719472,A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-cell or Follicular Non-Hodgkin's Lymphoma (RATE),jugular veins
D020246,0.24,NCT00719472-1,Rituximab 375 mg/m^2,NCT00719472,A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-cell or Follicular Non-Hodgkin's Lymphoma (RATE),venous thrombosis
D007022,0.47,NCT00719472-1,Rituximab 375 mg/m^2,NCT00719472,A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-cell or Follicular Non-Hodgkin's Lymphoma (RATE),hypotension
D007024,0.24,NCT00719472-1,Rituximab 375 mg/m^2,NCT00719472,A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-cell or Follicular Non-Hodgkin's Lymphoma (RATE),orthostatic hypotension
D013927,0.24,NCT00719472-1,Rituximab 375 mg/m^2,NCT00719472,A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-cell or Follicular Non-Hodgkin's Lymphoma (RATE),thrombosis
D013479,0.24,NCT00719472-1,Rituximab 375 mg/m^2,NCT00719472,A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-cell or Follicular Non-Hodgkin's Lymphoma (RATE),superior vena cava syndrome
D064420,29.75,NCT00722137-1,R-CHOP,NCT00722137,Study of the Combination of Rituximab  Cyclophosphamide  Doxorubicin  VELCADE  and Prednisone or Rituximab  Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma,adverse drug events
D064420,37.92,NCT00722137-2,VcR-CAP,NCT00722137,Study of the Combination of Rituximab  Cyclophosphamide  Doxorubicin  VELCADE  and Prednisone or Rituximab  Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma,adverse drug events
D064147,8.26,NCT00722137-1,R-CHOP,NCT00722137,Study of the Combination of Rituximab  Cyclophosphamide  Doxorubicin  VELCADE  and Prednisone or Rituximab  Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma,febrile neutropenia
D064147,10.83,NCT00722137-2,VcR-CAP,NCT00722137,Study of the Combination of Rituximab  Cyclophosphamide  Doxorubicin  VELCADE  and Prednisone or Rituximab  Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma,febrile neutropenia
D009503,5.37,NCT00722137-1,R-CHOP,NCT00722137,Study of the Combination of Rituximab  Cyclophosphamide  Doxorubicin  VELCADE  and Prednisone or Rituximab  Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma,neutropenia
D009503,5.0,NCT00722137-2,VcR-CAP,NCT00722137,Study of the Combination of Rituximab  Cyclophosphamide  Doxorubicin  VELCADE  and Prednisone or Rituximab  Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma,neutropenia
D013921,0.41,NCT00722137-1,R-CHOP,NCT00722137,Study of the Combination of Rituximab  Cyclophosphamide  Doxorubicin  VELCADE  and Prednisone or Rituximab  Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma,thrombocytopenia
D013921,3.33,NCT00722137-2,VcR-CAP,NCT00722137,Study of the Combination of Rituximab  Cyclophosphamide  Doxorubicin  VELCADE  and Prednisone or Rituximab  Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma,thrombocytopenia
D007970,1.24,NCT00722137-1,R-CHOP,NCT00722137,Study of the Combination of Rituximab  Cyclophosphamide  Doxorubicin  VELCADE  and Prednisone or Rituximab  Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma,leukopenia
D007970,2.5,NCT00722137-2,VcR-CAP,NCT00722137,Study of the Combination of Rituximab  Cyclophosphamide  Doxorubicin  VELCADE  and Prednisone or Rituximab  Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma,leukopenia
D000741,2.07,NCT00722137-1,R-CHOP,NCT00722137,Study of the Combination of Rituximab  Cyclophosphamide  Doxorubicin  VELCADE  and Prednisone or Rituximab  Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma,aplastic anaemia
D000741,1.67,NCT00722137-2,VcR-CAP,NCT00722137,Study of the Combination of Rituximab  Cyclophosphamide  Doxorubicin  VELCADE  and Prednisone or Rituximab  Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma,aplastic anaemia
D008231,0.42,NCT00722137-2,VcR-CAP,NCT00722137,Study of the Combination of Rituximab  Cyclophosphamide  Doxorubicin  VELCADE  and Prednisone or Rituximab  Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma,lymphopenia
D000080983,0.42,NCT00722137-2,VcR-CAP,NCT00722137,Study of the Combination of Rituximab  Cyclophosphamide  Doxorubicin  VELCADE  and Prednisone or Rituximab  Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma,bone marrow failure
D018487,1.25,NCT00722137-2,VcR-CAP,NCT00722137,Study of the Combination of Rituximab  Cyclophosphamide  Doxorubicin  VELCADE  and Prednisone or Rituximab  Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma,left ventricular dysfunction
D006333,0.83,NCT00722137-2,VcR-CAP,NCT00722137,Study of the Combination of Rituximab  Cyclophosphamide  Doxorubicin  VELCADE  and Prednisone or Rituximab  Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma,cardiac failure
D001281,0.83,NCT00722137-1,R-CHOP,NCT00722137,Study of the Combination of Rituximab  Cyclophosphamide  Doxorubicin  VELCADE  and Prednisone or Rituximab  Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma,atrial fibrillation
D001281,0.42,NCT00722137-2,VcR-CAP,NCT00722137,Study of the Combination of Rituximab  Cyclophosphamide  Doxorubicin  VELCADE  and Prednisone or Rituximab  Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma,atrial fibrillation
D006333,0.42,NCT00722137-2,VcR-CAP,NCT00722137,Study of the Combination of Rituximab  Cyclophosphamide  Doxorubicin  VELCADE  and Prednisone or Rituximab  Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma,cardiac failure
D012770,0.42,NCT00722137-2,VcR-CAP,NCT00722137,Study of the Combination of Rituximab  Cyclophosphamide  Doxorubicin  VELCADE  and Prednisone or Rituximab  Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma,cardiogenic shock
D000071956,0.41,NCT00722137-1,R-CHOP,NCT00722137,Study of the Combination of Rituximab  Cyclophosphamide  Doxorubicin  VELCADE  and Prednisone or Rituximab  Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma,myocardial contusions
D000071956,0.42,NCT00722137-2,VcR-CAP,NCT00722137,Study of the Combination of Rituximab  Cyclophosphamide  Doxorubicin  VELCADE  and Prednisone or Rituximab  Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma,myocardial contusions
D013616,0.42,NCT00722137-2,VcR-CAP,NCT00722137,Study of the Combination of Rituximab  Cyclophosphamide  Doxorubicin  VELCADE  and Prednisone or Rituximab  Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma,sinus tachycardia
D005117,0.42,NCT00722137-2,VcR-CAP,NCT00722137,Study of the Combination of Rituximab  Cyclophosphamide  Doxorubicin  VELCADE  and Prednisone or Rituximab  Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma,extrasystoles
D016277,0.41,NCT00722137-1,R-CHOP,NCT00722137,Study of the Combination of Rituximab  Cyclophosphamide  Doxorubicin  VELCADE  and Prednisone or Rituximab  Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma,ventricular function left
D056988,0.41,NCT00722137-1,R-CHOP,NCT00722137,Study of the Combination of Rituximab  Cyclophosphamide  Doxorubicin  VELCADE  and Prednisone or Rituximab  Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma,acute anterior wall myocardial infarction
D006323,0.41,NCT00722137-1,R-CHOP,NCT00722137,Study of the Combination of Rituximab  Cyclophosphamide  Doxorubicin  VELCADE  and Prednisone or Rituximab  Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma,cardiac arrest
D006333,0.41,NCT00722137-1,R-CHOP,NCT00722137,Study of the Combination of Rituximab  Cyclophosphamide  Doxorubicin  VELCADE  and Prednisone or Rituximab  Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma,cardiac failure
D000072599,0.83,NCT00722137-1,R-CHOP,NCT00722137,Study of the Combination of Rituximab  Cyclophosphamide  Doxorubicin  VELCADE  and Prednisone or Rituximab  Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma,cardiorespiratory fitness
D009202,0.41,NCT00722137-1,R-CHOP,NCT00722137,Study of the Combination of Rituximab  Cyclophosphamide  Doxorubicin  VELCADE  and Prednisone or Rituximab  Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma,cardiomyopathy
D000028,0.41,NCT00722137-1,R-CHOP,NCT00722137,Study of the Combination of Rituximab  Cyclophosphamide  Doxorubicin  VELCADE  and Prednisone or Rituximab  Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma,abortion failure
D016277,0.41,NCT00722137-1,R-CHOP,NCT00722137,Study of the Combination of Rituximab  Cyclophosphamide  Doxorubicin  VELCADE  and Prednisone or Rituximab  Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma,ventricular function left
D009203,0.83,NCT00722137-1,R-CHOP,NCT00722137,Study of the Combination of Rituximab  Cyclophosphamide  Doxorubicin  VELCADE  and Prednisone or Rituximab  Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma,myocardial infarction
D013610,0.83,NCT00722137-1,R-CHOP,NCT00722137,Study of the Combination of Rituximab  Cyclophosphamide  Doxorubicin  VELCADE  and Prednisone or Rituximab  Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma,tachycardia
UNKNOWN-check-for-typo,1.24,NCT00722137-1,R-CHOP,NCT00722137,Study of the Combination of Rituximab  Cyclophosphamide  Doxorubicin  VELCADE  and Prednisone or Rituximab  Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma,D00
UNKNOWN-check-for-typo,1.67,NCT00722137-2,VcR-CAP,NCT00722137,Study of the Combination of Rituximab  Cyclophosphamide  Doxorubicin  VELCADE  and Prednisone or Rituximab  Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma,D00
D014839,0.41,NCT00722137-1,R-CHOP,NCT00722137,Study of the Combination of Rituximab  Cyclophosphamide  Doxorubicin  VELCADE  and Prednisone or Rituximab  Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma,vomiting
D014839,0.83,NCT00722137-2,VcR-CAP,NCT00722137,Study of the Combination of Rituximab  Cyclophosphamide  Doxorubicin  VELCADE  and Prednisone or Rituximab  Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma,vomiting
D000007,0.42,NCT00722137-2,VcR-CAP,NCT00722137,Study of the Combination of Rituximab  Cyclophosphamide  Doxorubicin  VELCADE  and Prednisone or Rituximab  Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma,abdominal injuries
D003092,0.41,NCT00722137-1,R-CHOP,NCT00722137,Study of the Combination of Rituximab  Cyclophosphamide  Doxorubicin  VELCADE  and Prednisone or Rituximab  Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma,colitis
D003092,0.42,NCT00722137-2,VcR-CAP,NCT00722137,Study of the Combination of Rituximab  Cyclophosphamide  Doxorubicin  VELCADE  and Prednisone or Rituximab  Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma,colitis
D005756,0.42,NCT00722137-2,VcR-CAP,NCT00722137,Study of the Combination of Rituximab  Cyclophosphamide  Doxorubicin  VELCADE  and Prednisone or Rituximab  Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma,gastritis
D000069196,0.42,NCT00722137-2,VcR-CAP,NCT00722137,Study of the Combination of Rituximab  Cyclophosphamide  Doxorubicin  VELCADE  and Prednisone or Rituximab  Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma,gastrointestinal microbiome
D007418,0.42,NCT00722137-2,VcR-CAP,NCT00722137,Study of the Combination of Rituximab  Cyclophosphamide  Doxorubicin  VELCADE  and Prednisone or Rituximab  Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma,paralytic ileus
D050686,0.41,NCT00722137-1,R-CHOP,NCT00722137,Study of the Combination of Rituximab  Cyclophosphamide  Doxorubicin  VELCADE  and Prednisone or Rituximab  Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma,globicephala melaena
D050686,0.42,NCT00722137-2,VcR-CAP,NCT00722137,Study of the Combination of Rituximab  Cyclophosphamide  Doxorubicin  VELCADE  and Prednisone or Rituximab  Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma,globicephala melaena
D009055,0.42,NCT00722137-2,VcR-CAP,NCT00722137,Study of the Combination of Rituximab  Cyclophosphamide  Doxorubicin  VELCADE  and Prednisone or Rituximab  Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma,mouth
10015461,0.42,NCT00722137-2,VcR-CAP,NCT00722137,Study of the Combination of Rituximab  Cyclophosphamide  Doxorubicin  VELCADE  and Prednisone or Rituximab  Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma,esophagitis
D013280,0.83,NCT00722137-1,R-CHOP,NCT00722137,Study of the Combination of Rituximab  Cyclophosphamide  Doxorubicin  VELCADE  and Prednisone or Rituximab  Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma,stomatitis
D013280,0.42,NCT00722137-2,VcR-CAP,NCT00722137,Study of the Combination of Rituximab  Cyclophosphamide  Doxorubicin  VELCADE  and Prednisone or Rituximab  Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma,stomatitis
D005401,0.41,NCT00722137-1,R-CHOP,NCT00722137,Study of the Combination of Rituximab  Cyclophosphamide  Doxorubicin  VELCADE  and Prednisone or Rituximab  Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma,anal fissure
D003248,0.41,NCT00722137-1,R-CHOP,NCT00722137,Study of the Combination of Rituximab  Cyclophosphamide  Doxorubicin  VELCADE  and Prednisone or Rituximab  Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma,constipation
UNKNOWN-check-for-typo,0.41,NCT00722137-1,R-CHOP,NCT00722137,Study of the Combination of Rituximab  Cyclophosphamide  Doxorubicin  VELCADE  and Prednisone or Rituximab  Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma,D00
D010195,0.41,NCT00722137-1,R-CHOP,NCT00722137,Study of the Combination of Rituximab  Cyclophosphamide  Doxorubicin  VELCADE  and Prednisone or Rituximab  Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma,pancreatitis
10036774,0.41,NCT00722137-1,R-CHOP,NCT00722137,Study of the Combination of Rituximab  Cyclophosphamide  Doxorubicin  VELCADE  and Prednisone or Rituximab  Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma,proctitis
10041101,0.41,NCT00722137-1,R-CHOP,NCT00722137,Study of the Combination of Rituximab  Cyclophosphamide  Doxorubicin  VELCADE  and Prednisone or Rituximab  Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma,small intestinal obstruction
D005334,1.65,NCT00722137-1,R-CHOP,NCT00722137,Study of the Combination of Rituximab  Cyclophosphamide  Doxorubicin  VELCADE  and Prednisone or Rituximab  Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma,pyrexia
D005334,4.17,NCT00722137-2,VcR-CAP,NCT00722137,Study of the Combination of Rituximab  Cyclophosphamide  Doxorubicin  VELCADE  and Prednisone or Rituximab  Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma,pyrexia
D000210,0.42,NCT00722137-2,VcR-CAP,NCT00722137,Study of the Combination of Rituximab  Cyclophosphamide  Doxorubicin  VELCADE  and Prednisone or Rituximab  Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma,acute phase reaction
D001247,0.42,NCT00722137-2,VcR-CAP,NCT00722137,Study of the Combination of Rituximab  Cyclophosphamide  Doxorubicin  VELCADE  and Prednisone or Rituximab  Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma,asthenia
D023341,0.41,NCT00722137-1,R-CHOP,NCT00722137,Study of the Combination of Rituximab  Cyclophosphamide  Doxorubicin  VELCADE  and Prednisone or Rituximab  Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma,chills
D023341,0.42,NCT00722137-2,VcR-CAP,NCT00722137,Study of the Combination of Rituximab  Cyclophosphamide  Doxorubicin  VELCADE  and Prednisone or Rituximab  Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma,chills
D003643,0.42,NCT00722137-2,VcR-CAP,NCT00722137,Study of the Combination of Rituximab  Cyclophosphamide  Doxorubicin  VELCADE  and Prednisone or Rituximab  Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma,death
D003643,0.41,NCT00722137-1,R-CHOP,NCT00722137,Study of the Combination of Rituximab  Cyclophosphamide  Doxorubicin  VELCADE  and Prednisone or Rituximab  Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma,cardiac death
D002637,0.41,NCT00722137-1,R-CHOP,NCT00722137,Study of the Combination of Rituximab  Cyclophosphamide  Doxorubicin  VELCADE  and Prednisone or Rituximab  Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma,chest pain
D005221,1.24,NCT00722137-1,R-CHOP,NCT00722137,Study of the Combination of Rituximab  Cyclophosphamide  Doxorubicin  VELCADE  and Prednisone or Rituximab  Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma,fatigue
D000799,0.41,NCT00722137-1,R-CHOP,NCT00722137,Study of the Combination of Rituximab  Cyclophosphamide  Doxorubicin  VELCADE  and Prednisone or Rituximab  Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma,angioedema
D017093,0.42,NCT00722137-2,VcR-CAP,NCT00722137,Study of the Combination of Rituximab  Cyclophosphamide  Doxorubicin  VELCADE  and Prednisone or Rituximab  Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma,hepatic failure
D042882,0.41,NCT00722137-1,R-CHOP,NCT00722137,Study of the Combination of Rituximab  Cyclophosphamide  Doxorubicin  VELCADE  and Prednisone or Rituximab  Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma,gallstones common bile duct
D011681,0.41,NCT00722137-1,R-CHOP,NCT00722137,Study of the Combination of Rituximab  Cyclophosphamide  Doxorubicin  VELCADE  and Prednisone or Rituximab  Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma,pupillary functions abnormal
D011014,2.89,NCT00722137-1,R-CHOP,NCT00722137,Study of the Combination of Rituximab  Cyclophosphamide  Doxorubicin  VELCADE  and Prednisone or Rituximab  Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma,pneumonia
D011014,7.92,NCT00722137-2,VcR-CAP,NCT00722137,Study of the Combination of Rituximab  Cyclophosphamide  Doxorubicin  VELCADE  and Prednisone or Rituximab  Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma,pneumonia
D018805,0.41,NCT00722137-1,R-CHOP,NCT00722137,Study of the Combination of Rituximab  Cyclophosphamide  Doxorubicin  VELCADE  and Prednisone or Rituximab  Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma,sepsis
D018805,1.67,NCT00722137-2,VcR-CAP,NCT00722137,Study of the Combination of Rituximab  Cyclophosphamide  Doxorubicin  VELCADE  and Prednisone or Rituximab  Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma,sepsis
D001991,0.83,NCT00722137-1,R-CHOP,NCT00722137,Study of the Combination of Rituximab  Cyclophosphamide  Doxorubicin  VELCADE  and Prednisone or Rituximab  Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma,bronchitis
D001991,0.83,NCT00722137-2,VcR-CAP,NCT00722137,Study of the Combination of Rituximab  Cyclophosphamide  Doxorubicin  VELCADE  and Prednisone or Rituximab  Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma,bronchitis
D011014,0.41,NCT00722137-1,R-CHOP,NCT00722137,Study of the Combination of Rituximab  Cyclophosphamide  Doxorubicin  VELCADE  and Prednisone or Rituximab  Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma,lobar pneumonia
D011014,0.83,NCT00722137-2,VcR-CAP,NCT00722137,Study of the Combination of Rituximab  Cyclophosphamide  Doxorubicin  VELCADE  and Prednisone or Rituximab  Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma,lobar pneumonia
10061229,0.41,NCT00722137-1,R-CHOP,NCT00722137,Study of the Combination of Rituximab  Cyclophosphamide  Doxorubicin  VELCADE  and Prednisone or Rituximab  Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma,lung infection
10061229,0.83,NCT00722137-2,VcR-CAP,NCT00722137,Study of the Combination of Rituximab  Cyclophosphamide  Doxorubicin  VELCADE  and Prednisone or Rituximab  Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma,lung infection
D001996,0.83,NCT00722137-2,VcR-CAP,NCT00722137,Study of the Combination of Rituximab  Cyclophosphamide  Doxorubicin  VELCADE  and Prednisone or Rituximab  Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma,bronchopneumonia
D012772,0.41,NCT00722137-1,R-CHOP,NCT00722137,Study of the Combination of Rituximab  Cyclophosphamide  Doxorubicin  VELCADE  and Prednisone or Rituximab  Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma,septic shock
D012772,0.83,NCT00722137-2,VcR-CAP,NCT00722137,Study of the Combination of Rituximab  Cyclophosphamide  Doxorubicin  VELCADE  and Prednisone or Rituximab  Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma,septic shock
D000038,0.42,NCT00722137-2,VcR-CAP,NCT00722137,Study of the Combination of Rituximab  Cyclophosphamide  Doxorubicin  VELCADE  and Prednisone or Rituximab  Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma,abscess
D001996,0.41,NCT00722137-1,R-CHOP,NCT00722137,Study of the Combination of Rituximab  Cyclophosphamide  Doxorubicin  VELCADE  and Prednisone or Rituximab  Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma,bronchopneumonia
D001996,0.42,NCT00722137-2,VcR-CAP,NCT00722137,Study of the Combination of Rituximab  Cyclophosphamide  Doxorubicin  VELCADE  and Prednisone or Rituximab  Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma,bronchopneumonia
D002177,0.42,NCT00722137-2,VcR-CAP,NCT00722137,Study of the Combination of Rituximab  Cyclophosphamide  Doxorubicin  VELCADE  and Prednisone or Rituximab  Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma,candidiasis
D002481,0.42,NCT00722137-2,VcR-CAP,NCT00722137,Study of the Combination of Rituximab  Cyclophosphamide  Doxorubicin  VELCADE  and Prednisone or Rituximab  Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma,cellulitis
D004886,0.42,NCT00722137-2,VcR-CAP,NCT00722137,Study of the Combination of Rituximab  Cyclophosphamide  Doxorubicin  VELCADE  and Prednisone or Rituximab  Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma,erysipelas
D006509,0.83,NCT00722137-1,R-CHOP,NCT00722137,Study of the Combination of Rituximab  Cyclophosphamide  Doxorubicin  VELCADE  and Prednisone or Rituximab  Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma,hepatitis b
D006509,0.42,NCT00722137-2,VcR-CAP,NCT00722137,Study of the Combination of Rituximab  Cyclophosphamide  Doxorubicin  VELCADE  and Prednisone or Rituximab  Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma,hepatitis b
D006562,0.41,NCT00722137-1,R-CHOP,NCT00722137,Study of the Combination of Rituximab  Cyclophosphamide  Doxorubicin  VELCADE  and Prednisone or Rituximab  Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma,herpes zoster
D006562,0.42,NCT00722137-2,VcR-CAP,NCT00722137,Study of the Combination of Rituximab  Cyclophosphamide  Doxorubicin  VELCADE  and Prednisone or Rituximab  Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma,herpes zoster
D000985,0.42,NCT00722137-2,VcR-CAP,NCT00722137,Study of the Combination of Rituximab  Cyclophosphamide  Doxorubicin  VELCADE  and Prednisone or Rituximab  Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma,antisepsis
D003428,0.42,NCT00722137-2,VcR-CAP,NCT00722137,Study of the Combination of Rituximab  Cyclophosphamide  Doxorubicin  VELCADE  and Prednisone or Rituximab  Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma,nosocomial infection
D010309,0.42,NCT00722137-2,VcR-CAP,NCT00722137,Study of the Combination of Rituximab  Cyclophosphamide  Doxorubicin  VELCADE  and Prednisone or Rituximab  Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma,parotitis
D018410,0.42,NCT00722137-2,VcR-CAP,NCT00722137,Study of the Combination of Rituximab  Cyclophosphamide  Doxorubicin  VELCADE  and Prednisone or Rituximab  Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma,bacterial pneumonia
D001996,0.42,NCT00722137-2,VcR-CAP,NCT00722137,Study of the Combination of Rituximab  Cyclophosphamide  Doxorubicin  VELCADE  and Prednisone or Rituximab  Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma,bronchopneumonia
D000038,0.42,NCT00722137-2,VcR-CAP,NCT00722137,Study of the Combination of Rituximab  Cyclophosphamide  Doxorubicin  VELCADE  and Prednisone or Rituximab  Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma,abscess
D055744,0.42,NCT00722137-2,VcR-CAP,NCT00722137,Study of the Combination of Rituximab  Cyclophosphamide  Doxorubicin  VELCADE  and Prednisone or Rituximab  Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma,allergic bronchopulmonary mycosis
D012141,0.41,NCT00722137-1,R-CHOP,NCT00722137,Study of the Combination of Rituximab  Cyclophosphamide  Doxorubicin  VELCADE  and Prednisone or Rituximab  Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma,respiratory tract infection
D012141,0.42,NCT00722137-2,VcR-CAP,NCT00722137,Study of the Combination of Rituximab  Cyclophosphamide  Doxorubicin  VELCADE  and Prednisone or Rituximab  Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma,respiratory tract infection
D012480,0.42,NCT00722137-2,VcR-CAP,NCT00722137,Study of the Combination of Rituximab  Cyclophosphamide  Doxorubicin  VELCADE  and Prednisone or Rituximab  Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma,salmonellosis
D012141,0.41,NCT00722137-1,R-CHOP,NCT00722137,Study of the Combination of Rituximab  Cyclophosphamide  Doxorubicin  VELCADE  and Prednisone or Rituximab  Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma,upper respiratory tract infections
D012141,0.42,NCT00722137-2,VcR-CAP,NCT00722137,Study of the Combination of Rituximab  Cyclophosphamide  Doxorubicin  VELCADE  and Prednisone or Rituximab  Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma,upper respiratory tract infections
D014552,0.42,NCT00722137-2,VcR-CAP,NCT00722137,Study of the Combination of Rituximab  Cyclophosphamide  Doxorubicin  VELCADE  and Prednisone or Rituximab  Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma,urinary tract infection
D000038,0.41,NCT00722137-1,R-CHOP,NCT00722137,Study of the Combination of Rituximab  Cyclophosphamide  Doxorubicin  VELCADE  and Prednisone or Rituximab  Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma,abscess
D000985,0.41,NCT00722137-1,R-CHOP,NCT00722137,Study of the Combination of Rituximab  Cyclophosphamide  Doxorubicin  VELCADE  and Prednisone or Rituximab  Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma,antisepsis
D003015,0.41,NCT00722137-1,R-CHOP,NCT00722137,Study of the Combination of Rituximab  Cyclophosphamide  Doxorubicin  VELCADE  and Prednisone or Rituximab  Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma,clostridium difficile infection
D004697,0.41,NCT00722137-1,R-CHOP,NCT00722137,Study of the Combination of Rituximab  Cyclophosphamide  Doxorubicin  VELCADE  and Prednisone or Rituximab  Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma,bacterial endocarditis
D014552,0.41,NCT00722137-1,R-CHOP,NCT00722137,Study of the Combination of Rituximab  Cyclophosphamide  Doxorubicin  VELCADE  and Prednisone or Rituximab  Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma,urinary tract infections
D005759,0.83,NCT00722137-1,R-CHOP,NCT00722137,Study of the Combination of Rituximab  Cyclophosphamide  Doxorubicin  VELCADE  and Prednisone or Rituximab  Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma,gastroenteritis
D009181,0.41,NCT00722137-1,R-CHOP,NCT00722137,Study of the Combination of Rituximab  Cyclophosphamide  Doxorubicin  VELCADE  and Prednisone or Rituximab  Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma,fungal infections
D013283,0.41,NCT00722137-1,R-CHOP,NCT00722137,Study of the Combination of Rituximab  Cyclophosphamide  Doxorubicin  VELCADE  and Prednisone or Rituximab  Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma,herpes simplex oral
D002177,0.41,NCT00722137-1,R-CHOP,NCT00722137,Study of the Combination of Rituximab  Cyclophosphamide  Doxorubicin  VELCADE  and Prednisone or Rituximab  Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma,candidiasis
D010304,0.41,NCT00722137-1,R-CHOP,NCT00722137,Study of the Combination of Rituximab  Cyclophosphamide  Doxorubicin  VELCADE  and Prednisone or Rituximab  Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma,paronychia
D000039,0.41,NCT00722137-1,R-CHOP,NCT00722137,Study of the Combination of Rituximab  Cyclophosphamide  Doxorubicin  VELCADE  and Prednisone or Rituximab  Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma,peritonsillar abscess
D014397,0.41,NCT00722137-1,R-CHOP,NCT00722137,Study of the Combination of Rituximab  Cyclophosphamide  Doxorubicin  VELCADE  and Prednisone or Rituximab  Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma,pulmonary tuberculosis
D000038,0.41,NCT00722137-1,R-CHOP,NCT00722137,Study of the Combination of Rituximab  Cyclophosphamide  Doxorubicin  VELCADE  and Prednisone or Rituximab  Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma,abscess
D002184,0.41,NCT00722137-1,R-CHOP,NCT00722137,Study of the Combination of Rituximab  Cyclophosphamide  Doxorubicin  VELCADE  and Prednisone or Rituximab  Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma,canine tracheobronchitis virus
D005265,0.41,NCT00722137-1,R-CHOP,NCT00722137,Study of the Combination of Rituximab  Cyclophosphamide  Doxorubicin  VELCADE  and Prednisone or Rituximab  Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma,femur neck fractures
D005265,0.42,NCT00722137-2,VcR-CAP,NCT00722137,Study of the Combination of Rituximab  Cyclophosphamide  Doxorubicin  VELCADE  and Prednisone or Rituximab  Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma,femur neck fractures
D050815,0.41,NCT00722137-1,R-CHOP,NCT00722137,Study of the Combination of Rituximab  Cyclophosphamide  Doxorubicin  VELCADE  and Prednisone or Rituximab  Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma,compression fracture
D055370,0.41,NCT00722137-1,R-CHOP,NCT00722137,Study of the Combination of Rituximab  Cyclophosphamide  Doxorubicin  VELCADE  and Prednisone or Rituximab  Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma,lung injury
UNKNOWN-check-for-typo,0.83,NCT00722137-2,VcR-CAP,NCT00722137,Study of the Combination of Rituximab  Cyclophosphamide  Doxorubicin  VELCADE  and Prednisone or Rituximab  Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma,D00
D001066,0.42,NCT00722137-2,VcR-CAP,NCT00722137,Study of the Combination of Rituximab  Cyclophosphamide  Doxorubicin  VELCADE  and Prednisone or Rituximab  Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma,appetite
D011205,0.42,NCT00722137-2,VcR-CAP,NCT00722137,Study of the Combination of Rituximab  Cyclophosphamide  Doxorubicin  VELCADE  and Prednisone or Rituximab  Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma,unifluid
UNKNOWN-check-for-typo,0.42,NCT00722137-2,VcR-CAP,NCT00722137,Study of the Combination of Rituximab  Cyclophosphamide  Doxorubicin  VELCADE  and Prednisone or Rituximab  Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma,D00
D015275,0.83,NCT00722137-1,R-CHOP,NCT00722137,Study of the Combination of Rituximab  Cyclophosphamide  Doxorubicin  VELCADE  and Prednisone or Rituximab  Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma,tumour lysis syndrome
D015275,0.42,NCT00722137-2,VcR-CAP,NCT00722137,Study of the Combination of Rituximab  Cyclophosphamide  Doxorubicin  VELCADE  and Prednisone or Rituximab  Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma,tumour lysis syndrome
D003681,0.41,NCT00722137-1,R-CHOP,NCT00722137,Study of the Combination of Rituximab  Cyclophosphamide  Doxorubicin  VELCADE  and Prednisone or Rituximab  Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma,dehydration
D003920,0.41,NCT00722137-1,R-CHOP,NCT00722137,Study of the Combination of Rituximab  Cyclophosphamide  Doxorubicin  VELCADE  and Prednisone or Rituximab  Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma,diabetes mellitus
10065775,0.41,NCT00722137-1,R-CHOP,NCT00722137,Study of the Combination of Rituximab  Cyclophosphamide  Doxorubicin  VELCADE  and Prednisone or Rituximab  Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma,abdominal soft tissue necrosis
D008545,0.41,NCT00722137-1,R-CHOP,NCT00722137,Study of the Combination of Rituximab  Cyclophosphamide  Doxorubicin  VELCADE  and Prednisone or Rituximab  Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma,malignant melanoma
D013274,0.42,NCT00722137-2,VcR-CAP,NCT00722137,Study of the Combination of Rituximab  Cyclophosphamide  Doxorubicin  VELCADE  and Prednisone or Rituximab  Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma,gastric cancer
D009437,0.83,NCT00722137-2,VcR-CAP,NCT00722137,Study of the Combination of Rituximab  Cyclophosphamide  Doxorubicin  VELCADE  and Prednisone or Rituximab  Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma,neuralgia
D003929,0.42,NCT00722137-2,VcR-CAP,NCT00722137,Study of the Combination of Rituximab  Cyclophosphamide  Doxorubicin  VELCADE  and Prednisone or Rituximab  Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma,diabetic autonomic neuropathy
D000070624,0.42,NCT00722137-2,VcR-CAP,NCT00722137,Study of the Combination of Rituximab  Cyclophosphamide  Doxorubicin  VELCADE  and Prednisone or Rituximab  Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma,cerebral contusion
D003244,0.42,NCT00722137-2,VcR-CAP,NCT00722137,Study of the Combination of Rituximab  Cyclophosphamide  Doxorubicin  VELCADE  and Prednisone or Rituximab  Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma,depressed level of consciousness
D004660,0.42,NCT00722137-2,VcR-CAP,NCT00722137,Study of the Combination of Rituximab  Cyclophosphamide  Doxorubicin  VELCADE  and Prednisone or Rituximab  Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma,encephalitis
D010523,0.42,NCT00722137-2,VcR-CAP,NCT00722137,Study of the Combination of Rituximab  Cyclophosphamide  Doxorubicin  VELCADE  and Prednisone or Rituximab  Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma,neuropathy peripheral
10034620,0.42,NCT00722137-2,VcR-CAP,NCT00722137,Study of the Combination of Rituximab  Cyclophosphamide  Doxorubicin  VELCADE  and Prednisone or Rituximab  Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma,peripheral sensory neuropathy
D013575,0.42,NCT00722137-2,VcR-CAP,NCT00722137,Study of the Combination of Rituximab  Cyclophosphamide  Doxorubicin  VELCADE  and Prednisone or Rituximab  Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma,syncope
D020521,0.41,NCT00722137-1,R-CHOP,NCT00722137,Study of the Combination of Rituximab  Cyclophosphamide  Doxorubicin  VELCADE  and Prednisone or Rituximab  Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma,cerebrovascular accident
D012640,0.41,NCT00722137-1,R-CHOP,NCT00722137,Study of the Combination of Rituximab  Cyclophosphamide  Doxorubicin  VELCADE  and Prednisone or Rituximab  Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma,convulsion
D051437,0.41,NCT00722137-1,R-CHOP,NCT00722137,Study of the Combination of Rituximab  Cyclophosphamide  Doxorubicin  VELCADE  and Prednisone or Rituximab  Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma,renal failure
D000308,0.41,NCT00722137-1,R-CHOP,NCT00722137,Study of the Combination of Rituximab  Cyclophosphamide  Doxorubicin  VELCADE  and Prednisone or Rituximab  Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma,hyperadrenalism
D011655,0.41,NCT00722137-1,R-CHOP,NCT00722137,Study of the Combination of Rituximab  Cyclophosphamide  Doxorubicin  VELCADE  and Prednisone or Rituximab  Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma,pulmonary embolism
D011655,1.67,NCT00722137-2,VcR-CAP,NCT00722137,Study of the Combination of Rituximab  Cyclophosphamide  Doxorubicin  VELCADE  and Prednisone or Rituximab  Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma,pulmonary embolism
D010996,0.41,NCT00722137-1,R-CHOP,NCT00722137,Study of the Combination of Rituximab  Cyclophosphamide  Doxorubicin  VELCADE  and Prednisone or Rituximab  Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma,pleural effusion
D010996,1.25,NCT00722137-2,VcR-CAP,NCT00722137,Study of the Combination of Rituximab  Cyclophosphamide  Doxorubicin  VELCADE  and Prednisone or Rituximab  Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma,pleural effusion
UNKNOWN-check-for-typo,2.07,NCT00722137-1,R-CHOP,NCT00722137,Study of the Combination of Rituximab  Cyclophosphamide  Doxorubicin  VELCADE  and Prednisone or Rituximab  Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma,D00
UNKNOWN-check-for-typo,0.83,NCT00722137-2,VcR-CAP,NCT00722137,Study of the Combination of Rituximab  Cyclophosphamide  Doxorubicin  VELCADE  and Prednisone or Rituximab  Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma,D00
D012128,0.42,NCT00722137-2,VcR-CAP,NCT00722137,Study of the Combination of Rituximab  Cyclophosphamide  Doxorubicin  VELCADE  and Prednisone or Rituximab  Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma,acute respiratory distress syndrome
10003504,0.42,NCT00722137-2,VcR-CAP,NCT00722137,Study of the Combination of Rituximab  Cyclophosphamide  Doxorubicin  VELCADE  and Prednisone or Rituximab  Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma,aspiration
D011015,0.42,NCT00722137-2,VcR-CAP,NCT00722137,Study of the Combination of Rituximab  Cyclophosphamide  Doxorubicin  VELCADE  and Prednisone or Rituximab  Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma,aspiration pneumonia
D006976,0.42,NCT00722137-2,VcR-CAP,NCT00722137,Study of the Combination of Rituximab  Cyclophosphamide  Doxorubicin  VELCADE  and Prednisone or Rituximab  Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma,pulmonary hypertension
D000799,0.42,NCT00722137-2,VcR-CAP,NCT00722137,Study of the Combination of Rituximab  Cyclophosphamide  Doxorubicin  VELCADE  and Prednisone or Rituximab  Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma,angioedema
D012131,0.42,NCT00722137-2,VcR-CAP,NCT00722137,Study of the Combination of Rituximab  Cyclophosphamide  Doxorubicin  VELCADE  and Prednisone or Rituximab  Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma,respiratory failure
D000039,0.42,NCT00722137-2,VcR-CAP,NCT00722137,Study of the Combination of Rituximab  Cyclophosphamide  Doxorubicin  VELCADE  and Prednisone or Rituximab  Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma,peritonsillar abscess
D012131,0.41,NCT00722137-1,R-CHOP,NCT00722137,Study of the Combination of Rituximab  Cyclophosphamide  Doxorubicin  VELCADE  and Prednisone or Rituximab  Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma,respiratory failure
D004844,0.41,NCT00722137-1,R-CHOP,NCT00722137,Study of the Combination of Rituximab  Cyclophosphamide  Doxorubicin  VELCADE  and Prednisone or Rituximab  Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma,epistaxis
D008168,0.41,NCT00722137-1,R-CHOP,NCT00722137,Study of the Combination of Rituximab  Cyclophosphamide  Doxorubicin  VELCADE  and Prednisone or Rituximab  Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma,lung
D012127,0.83,NCT00722137-1,R-CHOP,NCT00722137,Study of the Combination of Rituximab  Cyclophosphamide  Doxorubicin  VELCADE  and Prednisone or Rituximab  Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma,respiratory distress syndrome newborn
D007022,0.41,NCT00722137-1,R-CHOP,NCT00722137,Study of the Combination of Rituximab  Cyclophosphamide  Doxorubicin  VELCADE  and Prednisone or Rituximab  Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma,hypotension
D007022,1.25,NCT00722137-2,VcR-CAP,NCT00722137,Study of the Combination of Rituximab  Cyclophosphamide  Doxorubicin  VELCADE  and Prednisone or Rituximab  Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma,hypotension
D007024,0.83,NCT00722137-2,VcR-CAP,NCT00722137,Study of the Combination of Rituximab  Cyclophosphamide  Doxorubicin  VELCADE  and Prednisone or Rituximab  Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma,orthostatic hypotension
D019022,0.83,NCT00722137-2,VcR-CAP,NCT00722137,Study of the Combination of Rituximab  Cyclophosphamide  Doxorubicin  VELCADE  and Prednisone or Rituximab  Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma,poorhouses
D020246,1.24,NCT00722137-1,R-CHOP,NCT00722137,Study of the Combination of Rituximab  Cyclophosphamide  Doxorubicin  VELCADE  and Prednisone or Rituximab  Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma,deep vein thrombosis
D020246,0.42,NCT00722137-2,VcR-CAP,NCT00722137,Study of the Combination of Rituximab  Cyclophosphamide  Doxorubicin  VELCADE  and Prednisone or Rituximab  Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma,deep vein thrombosis
D006973,0.42,NCT00722137-2,VcR-CAP,NCT00722137,Study of the Combination of Rituximab  Cyclophosphamide  Doxorubicin  VELCADE  and Prednisone or Rituximab  Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma,hypertension
D020246,0.42,NCT00722137-2,VcR-CAP,NCT00722137,Study of the Combination of Rituximab  Cyclophosphamide  Doxorubicin  VELCADE  and Prednisone or Rituximab  Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma,venous thrombosis
D064420,1.45,NCT00770224-2,Rituximab Maintenance,NCT00770224,S0801 Iodine I 131 Tositumomab  Rituximab  and Combination Chemotherapy in Previously Untreated Stage II  Stage III  or Stage IV Follicular Non-Hodgkin Lymphoma,adverse drug events
10049737,1.45,NCT00770224-2,Rituximab Maintenance,NCT00770224,S0801 Iodine I 131 Tositumomab  Rituximab  and Combination Chemotherapy in Previously Untreated Stage II  Stage III  or Stage IV Follicular Non-Hodgkin Lymphoma,treatment related secondary malignancy
D064420,0.3,NCT00822120-1,HIV-negative: Initial ABVD,NCT00822120,S0816 Fludeoxyglucose F 18-PET/CT Imaging and Combination Chemotherapy With or Without Additional Chemotherapy and G-CSF in Treating Patients With Stage III or Stage IV Hodgkin Lymphoma,adverse drug events
D064420,2.22,NCT00822120-2,HIV-negative and PET-negative: Continued ABVD,NCT00822120,S0816 Fludeoxyglucose F 18-PET/CT Imaging and Combination Chemotherapy With or Without Additional Chemotherapy and G-CSF in Treating Patients With Stage III or Stage IV Hodgkin Lymphoma,adverse drug events
D064420,4.08,NCT00822120-3,HIV-negative and PET-positive: BEACOPP Escalated,NCT00822120,S0816 Fludeoxyglucose F 18-PET/CT Imaging and Combination Chemotherapy With or Without Additional Chemotherapy and G-CSF in Treating Patients With Stage III or Stage IV Hodgkin Lymphoma,adverse drug events
D064420,8.33,NCT00822120-4,HIV-positive: Initial ABVD,NCT00822120,S0816 Fludeoxyglucose F 18-PET/CT Imaging and Combination Chemotherapy With or Without Additional Chemotherapy and G-CSF in Treating Patients With Stage III or Stage IV Hodgkin Lymphoma,adverse drug events
D064147,2.04,NCT00822120-3,HIV-negative and PET-positive: BEACOPP Escalated,NCT00822120,S0816 Fludeoxyglucose F 18-PET/CT Imaging and Combination Chemotherapy With or Without Additional Chemotherapy and G-CSF in Treating Patients With Stage III or Stage IV Hodgkin Lymphoma,febrile neutropenia
D006454,0.37,NCT00822120-2,HIV-negative and PET-negative: Continued ABVD,NCT00822120,S0816 Fludeoxyglucose F 18-PET/CT Imaging and Combination Chemotherapy With or Without Additional Chemotherapy and G-CSF in Treating Patients With Stage III or Stage IV Hodgkin Lymphoma,hemoglobin
D003092,0.37,NCT00822120-2,HIV-negative and PET-negative: Continued ABVD,NCT00822120,S0816 Fludeoxyglucose F 18-PET/CT Imaging and Combination Chemotherapy With or Without Additional Chemotherapy and G-CSF in Treating Patients With Stage III or Stage IV Hodgkin Lymphoma,colitis
D000080104,2.04,NCT00822120-3,HIV-negative and PET-positive: BEACOPP Escalated,NCT00822120,S0816 Fludeoxyglucose F 18-PET/CT Imaging and Combination Chemotherapy With or Without Additional Chemotherapy and G-CSF in Treating Patients With Stage III or Stage IV Hodgkin Lymphoma,infertility clinics
10061229,0.37,NCT00822120-2,HIV-negative and PET-negative: Continued ABVD,NCT00822120,S0816 Fludeoxyglucose F 18-PET/CT Imaging and Combination Chemotherapy With or Without Additional Chemotherapy and G-CSF in Treating Patients With Stage III or Stage IV Hodgkin Lymphoma,lung infection
D007962,8.33,NCT00822120-4,HIV-positive: Initial ABVD,NCT00822120,S0816 Fludeoxyglucose F 18-PET/CT Imaging and Combination Chemotherapy With or Without Additional Chemotherapy and G-CSF in Treating Patients With Stage III or Stage IV Hodgkin Lymphoma,leukocytes
D006098,0.37,NCT00822120-2,HIV-negative and PET-negative: Continued ABVD,NCT00822120,S0816 Fludeoxyglucose F 18-PET/CT Imaging and Combination Chemotherapy With or Without Additional Chemotherapy and G-CSF in Treating Patients With Stage III or Stage IV Hodgkin Lymphoma,granulocytes
D006098,8.33,NCT00822120-4,HIV-positive: Initial ABVD,NCT00822120,S0816 Fludeoxyglucose F 18-PET/CT Imaging and Combination Chemotherapy With or Without Additional Chemotherapy and G-CSF in Treating Patients With Stage III or Stage IV Hodgkin Lymphoma,granulocytes
D004039,8.33,NCT00822120-4,HIV-positive: Initial ABVD,NCT00822120,S0816 Fludeoxyglucose F 18-PET/CT Imaging and Combination Chemotherapy With or Without Additional Chemotherapy and G-CSF in Treating Patients With Stage III or Stage IV Hodgkin Lymphoma,diet low-sodium
D000339,0.3,NCT00822120-1,HIV-negative: Initial ABVD,NCT00822120,S0816 Fludeoxyglucose F 18-PET/CT Imaging and Combination Chemotherapy With or Without Additional Chemotherapy and G-CSF in Treating Patients With Stage III or Stage IV Hodgkin Lymphoma,mood
D000339,0.3,NCT00822120-1,HIV-negative: Initial ABVD,NCT00822120,S0816 Fludeoxyglucose F 18-PET/CT Imaging and Combination Chemotherapy With or Without Additional Chemotherapy and G-CSF in Treating Patients With Stage III or Stage IV Hodgkin Lymphoma,mood
D004417,2.04,NCT00822120-3,HIV-negative and PET-positive: BEACOPP Escalated,NCT00822120,S0816 Fludeoxyglucose F 18-PET/CT Imaging and Combination Chemotherapy With or Without Additional Chemotherapy and G-CSF in Treating Patients With Stage III or Stage IV Hodgkin Lymphoma,breath shortness
D011014,0.37,NCT00822120-2,HIV-negative and PET-negative: Continued ABVD,NCT00822120,S0816 Fludeoxyglucose F 18-PET/CT Imaging and Combination Chemotherapy With or Without Additional Chemotherapy and G-CSF in Treating Patients With Stage III or Stage IV Hodgkin Lymphoma,pneumonitis
D011014,2.04,NCT00822120-3,HIV-negative and PET-positive: BEACOPP Escalated,NCT00822120,S0816 Fludeoxyglucose F 18-PET/CT Imaging and Combination Chemotherapy With or Without Additional Chemotherapy and G-CSF in Treating Patients With Stage III or Stage IV Hodgkin Lymphoma,pneumonitis
D016769,0.74,NCT00822120-2,HIV-negative and PET-negative: Continued ABVD,NCT00822120,S0816 Fludeoxyglucose F 18-PET/CT Imaging and Combination Chemotherapy With or Without Additional Chemotherapy and G-CSF in Treating Patients With Stage III or Stage IV Hodgkin Lymphoma,embolism and thrombosis
D009026,1.18,NCT00846742-1,Stanford V Chemotherapy,NCT00846742,Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Favorable-Risk Hodgkin Lymphoma,mortality
D064420,1.18,NCT00846742-1,Stanford V Chemotherapy,NCT00846742,Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Favorable-Risk Hodgkin Lymphoma,adverse drug events
D007962,1.18,NCT00846742-1,Stanford V Chemotherapy,NCT00846742,Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Favorable-Risk Hodgkin Lymphoma,leukocytes
D006098,1.18,NCT00846742-1,Stanford V Chemotherapy,NCT00846742,Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Favorable-Risk Hodgkin Lymphoma,granulocytes
D064420,3.23,NCT00849251-1,Treatment (Chemotherapy and Enzyme Inhibitor),NCT00849251,Pegylated Liposomal Doxorubicin Hydrochloride  Bortezomib  Cyclophosphamide  and Dexamethasone in Treating Patients With Multiple Myeloma,adverse drug events
10043565,3.23,NCT00849251-1,Treatment (Chemotherapy and Enzyme Inhibitor),NCT00849251,Pegylated Liposomal Doxorubicin Hydrochloride  Bortezomib  Cyclophosphamide  and Dexamethasone in Treating Patients With Multiple Myeloma,thromboembolic event
D064420,14.85,NCT00849472-1,AC Followed by Weekly Paclitaxel and Concurrent Pazopanib,NCT00849472,Treatment With Pazopanib for Neoadjuvant Breast Cancer,adverse drug events
D000741,0.99,NCT00849472-1,AC Followed by Weekly Paclitaxel and Concurrent Pazopanib,NCT00849472,Treatment With Pazopanib for Neoadjuvant Breast Cancer,aplastic anaemia
D064147,0.99,NCT00849472-1,AC Followed by Weekly Paclitaxel and Concurrent Pazopanib,NCT00849472,Treatment With Pazopanib for Neoadjuvant Breast Cancer,febrile neutropenia
D000071956,0.99,NCT00849472-1,AC Followed by Weekly Paclitaxel and Concurrent Pazopanib,NCT00849472,Treatment With Pazopanib for Neoadjuvant Breast Cancer,myocardial contusions
D009325,0.99,NCT00849472-1,AC Followed by Weekly Paclitaxel and Concurrent Pazopanib,NCT00849472,Treatment With Pazopanib for Neoadjuvant Breast Cancer,nausea
D014839,0.99,NCT00849472-1,AC Followed by Weekly Paclitaxel and Concurrent Pazopanib,NCT00849472,Treatment With Pazopanib for Neoadjuvant Breast Cancer,vomiting
D005334,1.98,NCT00849472-1,AC Followed by Weekly Paclitaxel and Concurrent Pazopanib,NCT00849472,Treatment With Pazopanib for Neoadjuvant Breast Cancer,pyrexia
D006562,0.99,NCT00849472-1,AC Followed by Weekly Paclitaxel and Concurrent Pazopanib,NCT00849472,Treatment With Pazopanib for Neoadjuvant Breast Cancer,herpes zoster
D007239,1.98,NCT00849472-1,AC Followed by Weekly Paclitaxel and Concurrent Pazopanib,NCT00849472,Treatment With Pazopanib for Neoadjuvant Breast Cancer,infection
D000038,0.99,NCT00849472-1,AC Followed by Weekly Paclitaxel and Concurrent Pazopanib,NCT00849472,Treatment With Pazopanib for Neoadjuvant Breast Cancer,abscess
D002481,0.99,NCT00849472-1,AC Followed by Weekly Paclitaxel and Concurrent Pazopanib,NCT00849472,Treatment With Pazopanib for Neoadjuvant Breast Cancer,cellulitis
D000074766,0.99,NCT00849472-1,AC Followed by Weekly Paclitaxel and Concurrent Pazopanib,NCT00849472,Treatment With Pazopanib for Neoadjuvant Breast Cancer,viburnales
10001551,0.99,NCT00849472-1,AC Followed by Weekly Paclitaxel and Concurrent Pazopanib,NCT00849472,Treatment With Pazopanib for Neoadjuvant Breast Cancer,alanine aminotransferase increased
D012640,0.99,NCT00849472-1,AC Followed by Weekly Paclitaxel and Concurrent Pazopanib,NCT00849472,Treatment With Pazopanib for Neoadjuvant Breast Cancer,convulsion
D003863,0.99,NCT00849472-1,AC Followed by Weekly Paclitaxel and Concurrent Pazopanib,NCT00849472,Treatment With Pazopanib for Neoadjuvant Breast Cancer,depression
D011655,2.97,NCT00849472-1,AC Followed by Weekly Paclitaxel and Concurrent Pazopanib,NCT00849472,Treatment With Pazopanib for Neoadjuvant Breast Cancer,pulmonary embolism
D006973,0.99,NCT00849472-1,AC Followed by Weekly Paclitaxel and Concurrent Pazopanib,NCT00849472,Treatment With Pazopanib for Neoadjuvant Breast Cancer,hypertension
D064420,22.92,NCT00856492-1,Arm I (Nab-Paclitaxel + Bevacizumab - AC+PEG-G)),NCT00856492,S0800  Nab-Paclitaxel  Doxorubicin  Cyclophosphamide  and Pegfilgrastim With or Without Bevacizumab in Treating Women With Inflammatory or Locally Advanced Breast Cancer,adverse drug events
D064420,5.0,NCT00856492-2,Arm II (Nab-Paclitaxel - AC+PEG-G),NCT00856492,S0800  Nab-Paclitaxel  Doxorubicin  Cyclophosphamide  and Pegfilgrastim With or Without Bevacizumab in Treating Women With Inflammatory or Locally Advanced Breast Cancer,adverse drug events
D064420,5.88,NCT00856492-3,Arm III (AC+PEG-G - Nab-Paclitaxel),NCT00856492,S0800  Nab-Paclitaxel  Doxorubicin  Cyclophosphamide  and Pegfilgrastim With or Without Bevacizumab in Treating Women With Inflammatory or Locally Advanced Breast Cancer,adverse drug events
D000740,1.04,NCT00856492-1,Arm I (Nab-Paclitaxel + Bevacizumab - AC+PEG-G)),NCT00856492,S0800  Nab-Paclitaxel  Doxorubicin  Cyclophosphamide  and Pegfilgrastim With or Without Bevacizumab in Treating Women With Inflammatory or Locally Advanced Breast Cancer,anemia
D000740,1.67,NCT00856492-2,Arm II (Nab-Paclitaxel - AC+PEG-G),NCT00856492,S0800  Nab-Paclitaxel  Doxorubicin  Cyclophosphamide  and Pegfilgrastim With or Without Bevacizumab in Treating Women With Inflammatory or Locally Advanced Breast Cancer,anemia
D000740,1.96,NCT00856492-3,Arm III (AC+PEG-G - Nab-Paclitaxel),NCT00856492,S0800  Nab-Paclitaxel  Doxorubicin  Cyclophosphamide  and Pegfilgrastim With or Without Bevacizumab in Treating Women With Inflammatory or Locally Advanced Breast Cancer,anemia
D064147,4.17,NCT00856492-1,Arm I (Nab-Paclitaxel + Bevacizumab - AC+PEG-G)),NCT00856492,S0800  Nab-Paclitaxel  Doxorubicin  Cyclophosphamide  and Pegfilgrastim With or Without Bevacizumab in Treating Women With Inflammatory or Locally Advanced Breast Cancer,febrile neutropenia
D064147,1.67,NCT00856492-2,Arm II (Nab-Paclitaxel - AC+PEG-G),NCT00856492,S0800  Nab-Paclitaxel  Doxorubicin  Cyclophosphamide  and Pegfilgrastim With or Without Bevacizumab in Treating Women With Inflammatory or Locally Advanced Breast Cancer,febrile neutropenia
D006333,1.04,NCT00856492-1,Arm I (Nab-Paclitaxel + Bevacizumab - AC+PEG-G)),NCT00856492,S0800  Nab-Paclitaxel  Doxorubicin  Cyclophosphamide  and Pegfilgrastim With or Without Bevacizumab in Treating Women With Inflammatory or Locally Advanced Breast Cancer,heart failure
D006333,1.67,NCT00856492-2,Arm II (Nab-Paclitaxel - AC+PEG-G),NCT00856492,S0800  Nab-Paclitaxel  Doxorubicin  Cyclophosphamide  and Pegfilgrastim With or Without Bevacizumab in Treating Women With Inflammatory or Locally Advanced Breast Cancer,heart failure
D015746,1.04,NCT00856492-1,Arm I (Nab-Paclitaxel + Bevacizumab - AC+PEG-G)),NCT00856492,S0800  Nab-Paclitaxel  Doxorubicin  Cyclophosphamide  and Pegfilgrastim With or Without Bevacizumab in Treating Women With Inflammatory or Locally Advanced Breast Cancer,abdominal pain
D003680,1.04,NCT00856492-1,Arm I (Nab-Paclitaxel + Bevacizumab - AC+PEG-G)),NCT00856492,S0800  Nab-Paclitaxel  Doxorubicin  Cyclophosphamide  and Pegfilgrastim With or Without Bevacizumab in Treating Women With Inflammatory or Locally Advanced Breast Cancer,dysphagia
10028130,1.04,NCT00856492-1,Arm I (Nab-Paclitaxel + Bevacizumab - AC+PEG-G)),NCT00856492,S0800  Nab-Paclitaxel  Doxorubicin  Cyclophosphamide  and Pegfilgrastim With or Without Bevacizumab in Treating Women With Inflammatory or Locally Advanced Breast Cancer,mucositis oral
D009325,1.04,NCT00856492-1,Arm I (Nab-Paclitaxel + Bevacizumab - AC+PEG-G)),NCT00856492,S0800  Nab-Paclitaxel  Doxorubicin  Cyclophosphamide  and Pegfilgrastim With or Without Bevacizumab in Treating Women With Inflammatory or Locally Advanced Breast Cancer,nausea
D009325,1.96,NCT00856492-3,Arm III (AC+PEG-G - Nab-Paclitaxel),NCT00856492,S0800  Nab-Paclitaxel  Doxorubicin  Cyclophosphamide  and Pegfilgrastim With or Without Bevacizumab in Treating Women With Inflammatory or Locally Advanced Breast Cancer,nausea
D014839,2.08,NCT00856492-1,Arm I (Nab-Paclitaxel + Bevacizumab - AC+PEG-G)),NCT00856492,S0800  Nab-Paclitaxel  Doxorubicin  Cyclophosphamide  and Pegfilgrastim With or Without Bevacizumab in Treating Women With Inflammatory or Locally Advanced Breast Cancer,vomiting
D014839,1.96,NCT00856492-3,Arm III (AC+PEG-G - Nab-Paclitaxel),NCT00856492,S0800  Nab-Paclitaxel  Doxorubicin  Cyclophosphamide  and Pegfilgrastim With or Without Bevacizumab in Treating Women With Inflammatory or Locally Advanced Breast Cancer,vomiting
10011914,1.67,NCT00856492-2,Arm II (Nab-Paclitaxel - AC+PEG-G),NCT00856492,S0800  Nab-Paclitaxel  Doxorubicin  Cyclophosphamide  and Pegfilgrastim With or Without Bevacizumab in Treating Women With Inflammatory or Locally Advanced Breast Cancer,death nos
D010146,1.04,NCT00856492-1,Arm I (Nab-Paclitaxel + Bevacizumab - AC+PEG-G)),NCT00856492,S0800  Nab-Paclitaxel  Doxorubicin  Cyclophosphamide  and Pegfilgrastim With or Without Bevacizumab in Treating Women With Inflammatory or Locally Advanced Breast Cancer,pain
10007810,1.04,NCT00856492-1,Arm I (Nab-Paclitaxel + Bevacizumab - AC+PEG-G)),NCT00856492,S0800  Nab-Paclitaxel  Doxorubicin  Cyclophosphamide  and Pegfilgrastim With or Without Bevacizumab in Treating Women With Inflammatory or Locally Advanced Breast Cancer,catheter related infection
10058838,1.67,NCT00856492-2,Arm II (Nab-Paclitaxel - AC+PEG-G),NCT00856492,S0800  Nab-Paclitaxel  Doxorubicin  Cyclophosphamide  and Pegfilgrastim With or Without Bevacizumab in Treating Women With Inflammatory or Locally Advanced Breast Cancer,enterocolitis infectious
10061229,1.96,NCT00856492-3,Arm III (AC+PEG-G - Nab-Paclitaxel),NCT00856492,S0800  Nab-Paclitaxel  Doxorubicin  Cyclophosphamide  and Pegfilgrastim With or Without Bevacizumab in Treating Women With Inflammatory or Locally Advanced Breast Cancer,lung infection
D018805,2.08,NCT00856492-1,Arm I (Nab-Paclitaxel + Bevacizumab - AC+PEG-G)),NCT00856492,S0800  Nab-Paclitaxel  Doxorubicin  Cyclophosphamide  and Pegfilgrastim With or Without Bevacizumab in Treating Women With Inflammatory or Locally Advanced Breast Cancer,sepsis
D018805,1.67,NCT00856492-2,Arm II (Nab-Paclitaxel - AC+PEG-G),NCT00856492,S0800  Nab-Paclitaxel  Doxorubicin  Cyclophosphamide  and Pegfilgrastim With or Without Bevacizumab in Treating Women With Inflammatory or Locally Advanced Breast Cancer,sepsis
10040872,2.08,NCT00856492-1,Arm I (Nab-Paclitaxel + Bevacizumab - AC+PEG-G)),NCT00856492,S0800  Nab-Paclitaxel  Doxorubicin  Cyclophosphamide  and Pegfilgrastim With or Without Bevacizumab in Treating Women With Inflammatory or Locally Advanced Breast Cancer,skin infection
10040872,1.96,NCT00856492-3,Arm III (AC+PEG-G - Nab-Paclitaxel),NCT00856492,S0800  Nab-Paclitaxel  Doxorubicin  Cyclophosphamide  and Pegfilgrastim With or Without Bevacizumab in Treating Women With Inflammatory or Locally Advanced Breast Cancer,skin infection
D014552,1.04,NCT00856492-1,Arm I (Nab-Paclitaxel + Bevacizumab - AC+PEG-G)),NCT00856492,S0800  Nab-Paclitaxel  Doxorubicin  Cyclophosphamide  and Pegfilgrastim With or Without Bevacizumab in Treating Women With Inflammatory or Locally Advanced Breast Cancer,urinary tract infection
10050528,1.04,NCT00856492-1,Arm I (Nab-Paclitaxel + Bevacizumab - AC+PEG-G)),NCT00856492,S0800  Nab-Paclitaxel  Doxorubicin  Cyclophosphamide  and Pegfilgrastim With or Without Bevacizumab in Treating Women With Inflammatory or Locally Advanced Breast Cancer,ejection fraction decreased
10022891,1.04,NCT00856492-1,Arm I (Nab-Paclitaxel + Bevacizumab - AC+PEG-G)),NCT00856492,S0800  Nab-Paclitaxel  Doxorubicin  Cyclophosphamide  and Pegfilgrastim With or Without Bevacizumab in Treating Women With Inflammatory or Locally Advanced Breast Cancer,investigations - other specify
10029366,5.21,NCT00856492-1,Arm I (Nab-Paclitaxel + Bevacizumab - AC+PEG-G)),NCT00856492,S0800  Nab-Paclitaxel  Doxorubicin  Cyclophosphamide  and Pegfilgrastim With or Without Bevacizumab in Treating Women With Inflammatory or Locally Advanced Breast Cancer,neutrophil count decreased
10029366,3.92,NCT00856492-3,Arm III (AC+PEG-G - Nab-Paclitaxel),NCT00856492,S0800  Nab-Paclitaxel  Doxorubicin  Cyclophosphamide  and Pegfilgrastim With or Without Bevacizumab in Treating Women With Inflammatory or Locally Advanced Breast Cancer,neutrophil count decreased
10035528,1.04,NCT00856492-1,Arm I (Nab-Paclitaxel + Bevacizumab - AC+PEG-G)),NCT00856492,S0800  Nab-Paclitaxel  Doxorubicin  Cyclophosphamide  and Pegfilgrastim With or Without Bevacizumab in Treating Women With Inflammatory or Locally Advanced Breast Cancer,platelet count decreased
10035528,1.67,NCT00856492-2,Arm II (Nab-Paclitaxel - AC+PEG-G),NCT00856492,S0800  Nab-Paclitaxel  Doxorubicin  Cyclophosphamide  and Pegfilgrastim With or Without Bevacizumab in Treating Women With Inflammatory or Locally Advanced Breast Cancer,platelet count decreased
D015430,1.04,NCT00856492-1,Arm I (Nab-Paclitaxel + Bevacizumab - AC+PEG-G)),NCT00856492,S0800  Nab-Paclitaxel  Doxorubicin  Cyclophosphamide  and Pegfilgrastim With or Without Bevacizumab in Treating Women With Inflammatory or Locally Advanced Breast Cancer,weight gain
10049182,4.17,NCT00856492-1,Arm I (Nab-Paclitaxel + Bevacizumab - AC+PEG-G)),NCT00856492,S0800  Nab-Paclitaxel  Doxorubicin  Cyclophosphamide  and Pegfilgrastim With or Without Bevacizumab in Treating Women With Inflammatory or Locally Advanced Breast Cancer,white blood cell decreased
10049182,1.67,NCT00856492-2,Arm II (Nab-Paclitaxel - AC+PEG-G),NCT00856492,S0800  Nab-Paclitaxel  Doxorubicin  Cyclophosphamide  and Pegfilgrastim With or Without Bevacizumab in Treating Women With Inflammatory or Locally Advanced Breast Cancer,white blood cell decreased
10049182,1.96,NCT00856492-3,Arm III (AC+PEG-G - Nab-Paclitaxel),NCT00856492,S0800  Nab-Paclitaxel  Doxorubicin  Cyclophosphamide  and Pegfilgrastim With or Without Bevacizumab in Treating Women With Inflammatory or Locally Advanced Breast Cancer,white blood cell decreased
D003681,1.04,NCT00856492-1,Arm I (Nab-Paclitaxel + Bevacizumab - AC+PEG-G)),NCT00856492,S0800  Nab-Paclitaxel  Doxorubicin  Cyclophosphamide  and Pegfilgrastim With or Without Bevacizumab in Treating Women With Inflammatory or Locally Advanced Breast Cancer,dehydration
D006943,1.04,NCT00856492-1,Arm I (Nab-Paclitaxel + Bevacizumab - AC+PEG-G)),NCT00856492,S0800  Nab-Paclitaxel  Doxorubicin  Cyclophosphamide  and Pegfilgrastim With or Without Bevacizumab in Treating Women With Inflammatory or Locally Advanced Breast Cancer,hyperglycemia
D007008,1.04,NCT00856492-1,Arm I (Nab-Paclitaxel + Bevacizumab - AC+PEG-G)),NCT00856492,S0800  Nab-Paclitaxel  Doxorubicin  Cyclophosphamide  and Pegfilgrastim With or Without Bevacizumab in Treating Women With Inflammatory or Locally Advanced Breast Cancer,hypokalemia
D007010,1.04,NCT00856492-1,Arm I (Nab-Paclitaxel + Bevacizumab - AC+PEG-G)),NCT00856492,S0800  Nab-Paclitaxel  Doxorubicin  Cyclophosphamide  and Pegfilgrastim With or Without Bevacizumab in Treating Women With Inflammatory or Locally Advanced Breast Cancer,hyponatremia
10033425,1.04,NCT00856492-1,Arm I (Nab-Paclitaxel + Bevacizumab - AC+PEG-G)),NCT00856492,S0800  Nab-Paclitaxel  Doxorubicin  Cyclophosphamide  and Pegfilgrastim With or Without Bevacizumab in Treating Women With Inflammatory or Locally Advanced Breast Cancer,pain in extremity
10029104,1.04,NCT00856492-1,Arm I (Nab-Paclitaxel + Bevacizumab - AC+PEG-G)),NCT00856492,S0800  Nab-Paclitaxel  Doxorubicin  Cyclophosphamide  and Pegfilgrastim With or Without Bevacizumab in Treating Women With Inflammatory or Locally Advanced Breast Cancer,neoplasms benign malignant and unspecified (incl cysts and polyps) - other specify
D006261,1.04,NCT00856492-1,Arm I (Nab-Paclitaxel + Bevacizumab - AC+PEG-G)),NCT00856492,S0800  Nab-Paclitaxel  Doxorubicin  Cyclophosphamide  and Pegfilgrastim With or Without Bevacizumab in Treating Women With Inflammatory or Locally Advanced Breast Cancer,headache
10034620,1.04,NCT00856492-1,Arm I (Nab-Paclitaxel + Bevacizumab - AC+PEG-G)),NCT00856492,S0800  Nab-Paclitaxel  Doxorubicin  Cyclophosphamide  and Pegfilgrastim With or Without Bevacizumab in Treating Women With Inflammatory or Locally Advanced Breast Cancer,peripheral sensory neuropathy
D054038,1.04,NCT00856492-1,Arm I (Nab-Paclitaxel + Bevacizumab - AC+PEG-G)),NCT00856492,S0800  Nab-Paclitaxel  Doxorubicin  Cyclophosphamide  and Pegfilgrastim With or Without Bevacizumab in Treating Women With Inflammatory or Locally Advanced Breast Cancer,reversible posterior leukoencephalopathy syndrome
D003221,2.08,NCT00856492-1,Arm I (Nab-Paclitaxel + Bevacizumab - AC+PEG-G)),NCT00856492,S0800  Nab-Paclitaxel  Doxorubicin  Cyclophosphamide  and Pegfilgrastim With or Without Bevacizumab in Treating Women With Inflammatory or Locally Advanced Breast Cancer,confusion
D058186,1.04,NCT00856492-1,Arm I (Nab-Paclitaxel + Bevacizumab - AC+PEG-G)),NCT00856492,S0800  Nab-Paclitaxel  Doxorubicin  Cyclophosphamide  and Pegfilgrastim With or Without Bevacizumab in Treating Women With Inflammatory or Locally Advanced Breast Cancer,acute kidney injury
D012128,1.04,NCT00856492-1,Arm I (Nab-Paclitaxel + Bevacizumab - AC+PEG-G)),NCT00856492,S0800  Nab-Paclitaxel  Doxorubicin  Cyclophosphamide  and Pegfilgrastim With or Without Bevacizumab in Treating Women With Inflammatory or Locally Advanced Breast Cancer,adult respiratory distress syndrome
D004417,1.96,NCT00856492-3,Arm III (AC+PEG-G - Nab-Paclitaxel),NCT00856492,S0800  Nab-Paclitaxel  Doxorubicin  Cyclophosphamide  and Pegfilgrastim With or Without Bevacizumab in Treating Women With Inflammatory or Locally Advanced Breast Cancer,dyspnea
D011014,2.08,NCT00856492-1,Arm I (Nab-Paclitaxel + Bevacizumab - AC+PEG-G)),NCT00856492,S0800  Nab-Paclitaxel  Doxorubicin  Cyclophosphamide  and Pegfilgrastim With or Without Bevacizumab in Treating Women With Inflammatory or Locally Advanced Breast Cancer,pneumonitis
D012131,1.67,NCT00856492-2,Arm II (Nab-Paclitaxel - AC+PEG-G),NCT00856492,S0800  Nab-Paclitaxel  Doxorubicin  Cyclophosphamide  and Pegfilgrastim With or Without Bevacizumab in Treating Women With Inflammatory or Locally Advanced Breast Cancer,respiratory failure
D006973,2.08,NCT00856492-1,Arm I (Nab-Paclitaxel + Bevacizumab - AC+PEG-G)),NCT00856492,S0800  Nab-Paclitaxel  Doxorubicin  Cyclophosphamide  and Pegfilgrastim With or Without Bevacizumab in Treating Women With Inflammatory or Locally Advanced Breast Cancer,hypertension
10043565,2.08,NCT00856492-1,Arm I (Nab-Paclitaxel + Bevacizumab - AC+PEG-G)),NCT00856492,S0800  Nab-Paclitaxel  Doxorubicin  Cyclophosphamide  and Pegfilgrastim With or Without Bevacizumab in Treating Women With Inflammatory or Locally Advanced Breast Cancer,thromboembolic event
D064420,21.43,NCT00862836-1,Vandetanib 100 mg,NCT00862836,Addition of Vandetanib to Standard Therapy Pegliposomal Doxorubicin (PLD),adverse drug events
D001145,7.14,NCT00862836-1,Vandetanib 100 mg,NCT00862836,Addition of Vandetanib to Standard Therapy Pegliposomal Doxorubicin (PLD),arrhythmia
D015746,7.14,NCT00862836-1,Vandetanib 100 mg,NCT00862836,Addition of Vandetanib to Standard Therapy Pegliposomal Doxorubicin (PLD),abdominal pain
D001201,7.14,NCT00862836-1,Vandetanib 100 mg,NCT00862836,Addition of Vandetanib to Standard Therapy Pegliposomal Doxorubicin (PLD),ascites
D045823,7.14,NCT00862836-1,Vandetanib 100 mg,NCT00862836,Addition of Vandetanib to Standard Therapy Pegliposomal Doxorubicin (PLD),ileus
D009325,7.14,NCT00862836-1,Vandetanib 100 mg,NCT00862836,Addition of Vandetanib to Standard Therapy Pegliposomal Doxorubicin (PLD),nausea
D014839,7.14,NCT00862836-1,Vandetanib 100 mg,NCT00862836,Addition of Vandetanib to Standard Therapy Pegliposomal Doxorubicin (PLD),vomiting
D003695,7.14,NCT00862836-1,Vandetanib 100 mg,NCT00862836,Addition of Vandetanib to Standard Therapy Pegliposomal Doxorubicin (PLD),healthcare
UNKNOWN-check-for-typo,7.14,NCT00862836-1,Vandetanib 100 mg,NCT00862836,Addition of Vandetanib to Standard Therapy Pegliposomal Doxorubicin (PLD),D00
D064420,50.0,NCT00873093-1,Pre-B ALL Relapse < 36 Mths From Dx (Chemotherapy) Age >21 Yrs,NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,adverse drug events
D064420,77.05,NCT00873093-2,Pre-B ALL Relapse 18-36 Mths From Dx (Chemotherapy)Age<=21 Yrs,NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,adverse drug events
D064420,81.63,NCT00873093-3,Pre-B ALL Relapse <18 Mths From Dx (Chemotherapy) Age <=21 Yrs,NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,adverse drug events
D064420,81.82,NCT00873093-4,T-cell ALL (Chemotherapy),NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,adverse drug events
D064420,70.0,NCT00873093-5,T-cell Lymphoblastic Lymphoma (LL) (Chemotherapy),NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,adverse drug events
D000740,2.04,NCT00873093-3,Pre-B ALL Relapse <18 Mths From Dx (Chemotherapy) Age <=21 Yrs,NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,anemia
D004211,1.64,NCT00873093-2,Pre-B ALL Relapse 18-36 Mths From Dx (Chemotherapy)Age<=21 Yrs,NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,disseminated intravascular coagulation
D064147,4.92,NCT00873093-2,Pre-B ALL Relapse 18-36 Mths From Dx (Chemotherapy)Age<=21 Yrs,NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,febrile neutropenia
D064147,6.12,NCT00873093-3,Pre-B ALL Relapse <18 Mths From Dx (Chemotherapy) Age <=21 Yrs,NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,febrile neutropenia
D064147,9.09,NCT00873093-4,T-cell ALL (Chemotherapy),NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,febrile neutropenia
D006323,3.28,NCT00873093-2,Pre-B ALL Relapse 18-36 Mths From Dx (Chemotherapy)Age<=21 Yrs,NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,cardiac arrest
D006323,2.04,NCT00873093-3,Pre-B ALL Relapse <18 Mths From Dx (Chemotherapy) Age <=21 Yrs,NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,cardiac arrest
10007541,4.08,NCT00873093-3,Pre-B ALL Relapse <18 Mths From Dx (Chemotherapy) Age <=21 Yrs,NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,cardiac disorders - other specify
D006333,1.64,NCT00873093-2,Pre-B ALL Relapse 18-36 Mths From Dx (Chemotherapy)Age<=21 Yrs,NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,heart failure
D006333,2.04,NCT00873093-3,Pre-B ALL Relapse <18 Mths From Dx (Chemotherapy) Age <=21 Yrs,NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,heart failure
10069501,1.64,NCT00873093-2,Pre-B ALL Relapse 18-36 Mths From Dx (Chemotherapy)Age<=21 Yrs,NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,left ventricular systolic dysfunction
D002305,10.0,NCT00873093-5,T-cell Lymphoblastic Lymphoma (LL) (Chemotherapy),NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,pericardial tamponade
10040741,2.04,NCT00873093-3,Pre-B ALL Relapse <18 Mths From Dx (Chemotherapy) Age <=21 Yrs,NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,sinus bradycardia
D013616,2.04,NCT00873093-3,Pre-B ALL Relapse <18 Mths From Dx (Chemotherapy) Age <=21 Yrs,NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,sinus tachycardia
D017180,1.64,NCT00873093-2,Pre-B ALL Relapse 18-36 Mths From Dx (Chemotherapy)Age<=21 Yrs,NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,ventricular tachycardia
D058447,1.64,NCT00873093-2,Pre-B ALL Relapse 18-36 Mths From Dx (Chemotherapy)Age<=21 Yrs,NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,eye pain
D015746,3.28,NCT00873093-2,Pre-B ALL Relapse 18-36 Mths From Dx (Chemotherapy)Age<=21 Yrs,NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,abdominal pain
D015746,2.04,NCT00873093-3,Pre-B ALL Relapse <18 Mths From Dx (Chemotherapy) Age <=21 Yrs,NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,abdominal pain
D015746,4.55,NCT00873093-4,T-cell ALL (Chemotherapy),NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,abdominal pain
D015746,10.0,NCT00873093-5,T-cell Lymphoblastic Lymphoma (LL) (Chemotherapy),NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,abdominal pain
10002167,1.64,NCT00873093-2,Pre-B ALL Relapse 18-36 Mths From Dx (Chemotherapy)Age<=21 Yrs,NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,anal pain
D003092,1.64,NCT00873093-2,Pre-B ALL Relapse 18-36 Mths From Dx (Chemotherapy)Age<=21 Yrs,NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,colitis
D003731,1.64,NCT00873093-2,Pre-B ALL Relapse 18-36 Mths From Dx (Chemotherapy)Age<=21 Yrs,NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,dental caries
D003967,1.64,NCT00873093-2,Pre-B ALL Relapse 18-36 Mths From Dx (Chemotherapy)Age<=21 Yrs,NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,diarrhea
D003967,2.04,NCT00873093-3,Pre-B ALL Relapse <18 Mths From Dx (Chemotherapy) Age <=21 Yrs,NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,diarrhea
D004760,1.64,NCT00873093-2,Pre-B ALL Relapse 18-36 Mths From Dx (Chemotherapy)Age<=21 Yrs,NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,enterocolitis
D004760,2.04,NCT00873093-3,Pre-B ALL Relapse <18 Mths From Dx (Chemotherapy) Age <=21 Yrs,NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,enterocolitis
D004941,1.64,NCT00873093-2,Pre-B ALL Relapse 18-36 Mths From Dx (Chemotherapy)Age<=21 Yrs,NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,esophagitis
10017789,1.64,NCT00873093-2,Pre-B ALL Relapse 18-36 Mths From Dx (Chemotherapy)Age<=21 Yrs,NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,gastric hemorrhage
D045823,2.04,NCT00873093-3,Pre-B ALL Relapse <18 Mths From Dx (Chemotherapy) Age <=21 Yrs,NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,ileus
D045823,4.55,NCT00873093-4,T-cell ALL (Chemotherapy),NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,ileus
10051746,1.64,NCT00873093-2,Pre-B ALL Relapse 18-36 Mths From Dx (Chemotherapy)Age<=21 Yrs,NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,lower gastrointestinal hemorrhage
10028130,4.92,NCT00873093-2,Pre-B ALL Relapse 18-36 Mths From Dx (Chemotherapy)Age<=21 Yrs,NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,mucositis oral
10028130,2.04,NCT00873093-3,Pre-B ALL Relapse <18 Mths From Dx (Chemotherapy) Age <=21 Yrs,NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,mucositis oral
10028130,4.55,NCT00873093-4,T-cell ALL (Chemotherapy),NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,mucositis oral
D009325,3.28,NCT00873093-2,Pre-B ALL Relapse 18-36 Mths From Dx (Chemotherapy)Age<=21 Yrs,NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,nausea
D009325,2.04,NCT00873093-3,Pre-B ALL Relapse <18 Mths From Dx (Chemotherapy) Age <=21 Yrs,NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,nausea
10031009,1.64,NCT00873093-2,Pre-B ALL Relapse 18-36 Mths From Dx (Chemotherapy)Age<=21 Yrs,NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,oral pain
D019283,10.0,NCT00873093-5,T-cell Lymphoblastic Lymphoma (LL) (Chemotherapy),NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,pancreatic necrosis
D010195,1.64,NCT00873093-2,Pre-B ALL Relapse 18-36 Mths From Dx (Chemotherapy)Age<=21 Yrs,NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,pancreatitis
D010195,6.12,NCT00873093-3,Pre-B ALL Relapse <18 Mths From Dx (Chemotherapy) Age <=21 Yrs,NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,pancreatitis
D010195,13.64,NCT00873093-4,T-cell ALL (Chemotherapy),NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,pancreatitis
D010195,10.0,NCT00873093-5,T-cell Lymphoblastic Lymphoma (LL) (Chemotherapy),NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,pancreatitis
10065704,1.64,NCT00873093-2,Pre-B ALL Relapse 18-36 Mths From Dx (Chemotherapy)Age<=21 Yrs,NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,peritoneal necrosis
D012003,1.64,NCT00873093-2,Pre-B ALL Relapse 18-36 Mths From Dx (Chemotherapy)Age<=21 Yrs,NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,rectal fistula
D053706,6.56,NCT00873093-2,Pre-B ALL Relapse 18-36 Mths From Dx (Chemotherapy)Age<=21 Yrs,NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,typhlitis
D053706,2.04,NCT00873093-3,Pre-B ALL Relapse <18 Mths From Dx (Chemotherapy) Age <=21 Yrs,NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,typhlitis
D053706,9.09,NCT00873093-4,T-cell ALL (Chemotherapy),NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,typhlitis
D053706,10.0,NCT00873093-5,T-cell Lymphoblastic Lymphoma (LL) (Chemotherapy),NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,typhlitis
D014839,2.04,NCT00873093-3,Pre-B ALL Relapse <18 Mths From Dx (Chemotherapy) Age <=21 Yrs,NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,vomiting
D023341,2.04,NCT00873093-3,Pre-B ALL Relapse <18 Mths From Dx (Chemotherapy) Age <=21 Yrs,NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,chills
D023341,4.55,NCT00873093-4,T-cell ALL (Chemotherapy),NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,chills
10011914,50.0,NCT00873093-1,Pre-B ALL Relapse < 36 Mths From Dx (Chemotherapy) Age >21 Yrs,NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,death nos
10011914,39.34,NCT00873093-2,Pre-B ALL Relapse 18-36 Mths From Dx (Chemotherapy)Age<=21 Yrs,NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,death nos
10011914,48.98,NCT00873093-3,Pre-B ALL Relapse <18 Mths From Dx (Chemotherapy) Age <=21 Yrs,NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,death nos
10011914,40.91,NCT00873093-4,T-cell ALL (Chemotherapy),NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,death nos
10011914,50.0,NCT00873093-5,T-cell Lymphoblastic Lymphoma (LL) (Chemotherapy),NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,death nos
D005334,1.64,NCT00873093-2,Pre-B ALL Relapse 18-36 Mths From Dx (Chemotherapy)Age<=21 Yrs,NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,fever
D005334,4.08,NCT00873093-3,Pre-B ALL Relapse <18 Mths From Dx (Chemotherapy) Age <=21 Yrs,NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,fever
10016791,2.04,NCT00873093-3,Pre-B ALL Relapse <18 Mths From Dx (Chemotherapy) Age <=21 Yrs,NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,flu like symptoms
D007035,2.04,NCT00873093-3,Pre-B ALL Relapse <18 Mths From Dx (Chemotherapy) Age <=21 Yrs,NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,hypothermia
D009102,4.92,NCT00873093-2,Pre-B ALL Relapse 18-36 Mths From Dx (Chemotherapy)Age<=21 Yrs,NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,multiple organ failure
D010146,1.64,NCT00873093-2,Pre-B ALL Relapse 18-36 Mths From Dx (Chemotherapy)Age<=21 Yrs,NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,pain
D010146,4.55,NCT00873093-4,T-cell ALL (Chemotherapy),NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,pain
10019805,1.64,NCT00873093-2,Pre-B ALL Relapse 18-36 Mths From Dx (Chemotherapy)Age<=21 Yrs,NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,hepatobiliary disorders - other specify
D006967,3.28,NCT00873093-2,Pre-B ALL Relapse 18-36 Mths From Dx (Chemotherapy)Age<=21 Yrs,NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,allergic reaction
D000080424,1.64,NCT00873093-2,Pre-B ALL Relapse 18-36 Mths From Dx (Chemotherapy)Age<=21 Yrs,NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,cytokine release syndrome
D001064,2.04,NCT00873093-3,Pre-B ALL Relapse <18 Mths From Dx (Chemotherapy) Age <=21 Yrs,NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,appendicitis
10003012,1.64,NCT00873093-2,Pre-B ALL Relapse 18-36 Mths From Dx (Chemotherapy)Age<=21 Yrs,NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,appendicitis perforated
10003012,4.55,NCT00873093-4,T-cell ALL (Chemotherapy),NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,appendicitis perforated
10007810,4.92,NCT00873093-2,Pre-B ALL Relapse 18-36 Mths From Dx (Chemotherapy)Age<=21 Yrs,NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,catheter related infection
10007810,2.04,NCT00873093-3,Pre-B ALL Relapse <18 Mths From Dx (Chemotherapy) Age <=21 Yrs,NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,catheter related infection
D000069544,2.04,NCT00873093-3,Pre-B ALL Relapse <18 Mths From Dx (Chemotherapy) Age <=21 Yrs,NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,encephalitis infection
10058838,1.64,NCT00873093-2,Pre-B ALL Relapse 18-36 Mths From Dx (Chemotherapy)Age<=21 Yrs,NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,enterocolitis infectious
10021881,8.2,NCT00873093-2,Pre-B ALL Relapse 18-36 Mths From Dx (Chemotherapy)Age<=21 Yrs,NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,infections and infestations - other specify
10021881,6.12,NCT00873093-3,Pre-B ALL Relapse <18 Mths From Dx (Chemotherapy) Age <=21 Yrs,NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,infections and infestations - other specify
10021881,9.09,NCT00873093-4,T-cell ALL (Chemotherapy),NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,infections and infestations - other specify
10021881,10.0,NCT00873093-5,T-cell Lymphoblastic Lymphoma (LL) (Chemotherapy),NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,infections and infestations - other specify
10021918,1.64,NCT00873093-2,Pre-B ALL Relapse 18-36 Mths From Dx (Chemotherapy)Age<=21 Yrs,NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,infective myositis
10023216,1.64,NCT00873093-2,Pre-B ALL Relapse 18-36 Mths From Dx (Chemotherapy)Age<=21 Yrs,NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,joint infection
10061229,3.28,NCT00873093-2,Pre-B ALL Relapse 18-36 Mths From Dx (Chemotherapy)Age<=21 Yrs,NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,lung infection
10061229,4.08,NCT00873093-3,Pre-B ALL Relapse <18 Mths From Dx (Chemotherapy) Age <=21 Yrs,NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,lung infection
10061229,10.0,NCT00873093-5,T-cell Lymphoblastic Lymphoma (LL) (Chemotherapy),NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,lung infection
10065764,3.28,NCT00873093-2,Pre-B ALL Relapse 18-36 Mths From Dx (Chemotherapy)Age<=21 Yrs,NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,mucosal infection
10065764,2.04,NCT00873093-3,Pre-B ALL Relapse <18 Mths From Dx (Chemotherapy) Age <=21 Yrs,NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,mucosal infection
10069138,1.64,NCT00873093-2,Pre-B ALL Relapse 18-36 Mths From Dx (Chemotherapy)Age<=21 Yrs,NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,papulopustular rash
D010612,1.64,NCT00873093-2,Pre-B ALL Relapse 18-36 Mths From Dx (Chemotherapy)Age<=21 Yrs,NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,pharyngitis
D018805,13.11,NCT00873093-2,Pre-B ALL Relapse 18-36 Mths From Dx (Chemotherapy)Age<=21 Yrs,NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,sepsis
D018805,16.33,NCT00873093-3,Pre-B ALL Relapse <18 Mths From Dx (Chemotherapy) Age <=21 Yrs,NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,sepsis
D018805,9.09,NCT00873093-4,T-cell ALL (Chemotherapy),NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,sepsis
D018805,10.0,NCT00873093-5,T-cell Lymphoblastic Lymphoma (LL) (Chemotherapy),NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,sepsis
D012852,1.64,NCT00873093-2,Pre-B ALL Relapse 18-36 Mths From Dx (Chemotherapy)Age<=21 Yrs,NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,sinusitis
D018461,2.04,NCT00873093-3,Pre-B ALL Relapse <18 Mths From Dx (Chemotherapy) Age <=21 Yrs,NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,soft tissue infection
D014552,10.0,NCT00873093-5,T-cell Lymphoblastic Lymphoma (LL) (Chemotherapy),NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,urinary tract infection
10001551,1.64,NCT00873093-2,Pre-B ALL Relapse 18-36 Mths From Dx (Chemotherapy)Age<=21 Yrs,NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,alanine aminotransferase increased
10001551,4.55,NCT00873093-4,T-cell ALL (Chemotherapy),NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,alanine aminotransferase increased
10003481,1.64,NCT00873093-2,Pre-B ALL Relapse 18-36 Mths From Dx (Chemotherapy)Age<=21 Yrs,NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,aspartate aminotransferase increased
10005364,25.0,NCT00873093-1,Pre-B ALL Relapse < 36 Mths From Dx (Chemotherapy) Age >21 Yrs,NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,blood bilirubin increased
10005364,9.09,NCT00873093-4,T-cell ALL (Chemotherapy),NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,blood bilirubin increased
10005364,10.0,NCT00873093-5,T-cell Lymphoblastic Lymphoma (LL) (Chemotherapy),NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,blood bilirubin increased
10008661,4.55,NCT00873093-4,T-cell ALL (Chemotherapy),NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,cholesterol high
10011368,2.04,NCT00873093-3,Pre-B ALL Relapse <18 Mths From Dx (Chemotherapy) Age <=21 Yrs,NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,creatinine increased
10022891,10.0,NCT00873093-5,T-cell Lymphoblastic Lymphoma (LL) (Chemotherapy),NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,investigations - other specify
10024574,3.28,NCT00873093-2,Pre-B ALL Relapse 18-36 Mths From Dx (Chemotherapy)Age<=21 Yrs,NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,lipase increased
10024574,13.64,NCT00873093-4,T-cell ALL (Chemotherapy),NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,lipase increased
10024574,10.0,NCT00873093-5,T-cell Lymphoblastic Lymphoma (LL) (Chemotherapy),NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,lipase increased
10029366,1.64,NCT00873093-2,Pre-B ALL Relapse 18-36 Mths From Dx (Chemotherapy)Age<=21 Yrs,NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,neutrophil count decreased
10035528,1.64,NCT00873093-2,Pre-B ALL Relapse 18-36 Mths From Dx (Chemotherapy)Age<=21 Yrs,NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,platelet count decreased
10035528,4.08,NCT00873093-3,Pre-B ALL Relapse <18 Mths From Dx (Chemotherapy) Age <=21 Yrs,NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,platelet count decreased
10040139,4.55,NCT00873093-4,T-cell ALL (Chemotherapy),NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,serum amylase increased
10040139,10.0,NCT00873093-5,T-cell Lymphoblastic Lymphoma (LL) (Chemotherapy),NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,serum amylase increased
10049182,1.64,NCT00873093-2,Pre-B ALL Relapse 18-36 Mths From Dx (Chemotherapy)Age<=21 Yrs,NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,white blood cell decreased
10049182,4.08,NCT00873093-3,Pre-B ALL Relapse <18 Mths From Dx (Chemotherapy) Age <=21 Yrs,NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,white blood cell decreased
D000138,3.28,NCT00873093-2,Pre-B ALL Relapse 18-36 Mths From Dx (Chemotherapy)Age<=21 Yrs,NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,acidosis
D000138,2.04,NCT00873093-3,Pre-B ALL Relapse <18 Mths From Dx (Chemotherapy) Age <=21 Yrs,NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,acidosis
D000855,4.92,NCT00873093-2,Pre-B ALL Relapse 18-36 Mths From Dx (Chemotherapy)Age<=21 Yrs,NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,anorexia
D003681,1.64,NCT00873093-2,Pre-B ALL Relapse 18-36 Mths From Dx (Chemotherapy)Age<=21 Yrs,NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,dehydration
D006943,1.64,NCT00873093-2,Pre-B ALL Relapse 18-36 Mths From Dx (Chemotherapy)Age<=21 Yrs,NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,hyperglycemia
D006943,2.04,NCT00873093-3,Pre-B ALL Relapse <18 Mths From Dx (Chemotherapy) Age <=21 Yrs,NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,hyperglycemia
D006943,4.55,NCT00873093-4,T-cell ALL (Chemotherapy),NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,hyperglycemia
D006947,1.64,NCT00873093-2,Pre-B ALL Relapse 18-36 Mths From Dx (Chemotherapy)Age<=21 Yrs,NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,hyperkalemia
D006947,2.04,NCT00873093-3,Pre-B ALL Relapse <18 Mths From Dx (Chemotherapy) Age <=21 Yrs,NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,hyperkalemia
D006955,1.64,NCT00873093-2,Pre-B ALL Relapse 18-36 Mths From Dx (Chemotherapy)Age<=21 Yrs,NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,hypernatremia
D015228,1.64,NCT00873093-2,Pre-B ALL Relapse 18-36 Mths From Dx (Chemotherapy)Age<=21 Yrs,NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,hypertriglyceridemia
D015228,2.04,NCT00873093-3,Pre-B ALL Relapse <18 Mths From Dx (Chemotherapy) Age <=21 Yrs,NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,hypertriglyceridemia
D015228,4.55,NCT00873093-4,T-cell ALL (Chemotherapy),NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,hypertriglyceridemia
D015228,10.0,NCT00873093-5,T-cell Lymphoblastic Lymphoma (LL) (Chemotherapy),NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,hypertriglyceridemia
D034141,1.64,NCT00873093-2,Pre-B ALL Relapse 18-36 Mths From Dx (Chemotherapy)Age<=21 Yrs,NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,hypoalbuminemia
D034141,2.04,NCT00873093-3,Pre-B ALL Relapse <18 Mths From Dx (Chemotherapy) Age <=21 Yrs,NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,hypoalbuminemia
D034141,9.09,NCT00873093-4,T-cell ALL (Chemotherapy),NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,hypoalbuminemia
D006996,9.09,NCT00873093-4,T-cell ALL (Chemotherapy),NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,hypocalcemia
D007008,13.11,NCT00873093-2,Pre-B ALL Relapse 18-36 Mths From Dx (Chemotherapy)Age<=21 Yrs,NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,hypokalemia
D007008,2.04,NCT00873093-3,Pre-B ALL Relapse <18 Mths From Dx (Chemotherapy) Age <=21 Yrs,NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,hypokalemia
D007008,4.55,NCT00873093-4,T-cell ALL (Chemotherapy),NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,hypokalemia
D007010,6.56,NCT00873093-2,Pre-B ALL Relapse 18-36 Mths From Dx (Chemotherapy)Age<=21 Yrs,NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,hyponatremia
D007010,8.16,NCT00873093-3,Pre-B ALL Relapse <18 Mths From Dx (Chemotherapy) Age <=21 Yrs,NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,hyponatremia
D007010,4.55,NCT00873093-4,T-cell ALL (Chemotherapy),NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,hyponatremia
D007010,10.0,NCT00873093-5,T-cell Lymphoblastic Lymphoma (LL) (Chemotherapy),NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,hyponatremia
D017674,10.0,NCT00873093-5,T-cell Lymphoblastic Lymphoma (LL) (Chemotherapy),NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,hypophosphatemia
D015275,4.55,NCT00873093-4,T-cell ALL (Chemotherapy),NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,tumor lysis syndrome
D018771,1.64,NCT00873093-2,Pre-B ALL Relapse 18-36 Mths From Dx (Chemotherapy)Age<=21 Yrs,NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,arthralgia
D001416,3.28,NCT00873093-2,Pre-B ALL Relapse 18-36 Mths From Dx (Chemotherapy)Age<=21 Yrs,NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,back pain
10023215,1.64,NCT00873093-2,Pre-B ALL Relapse 18-36 Mths From Dx (Chemotherapy)Age<=21 Yrs,NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,joint effusion
10033425,3.28,NCT00873093-2,Pre-B ALL Relapse 18-36 Mths From Dx (Chemotherapy)Age<=21 Yrs,NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,pain in extremity
10029104,4.92,NCT00873093-2,Pre-B ALL Relapse 18-36 Mths From Dx (Chemotherapy)Age<=21 Yrs,NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,neoplasms benign malignant and unspecified (incl cysts and polyps) - other specify
10029104,8.16,NCT00873093-3,Pre-B ALL Relapse <18 Mths From Dx (Chemotherapy) Age <=21 Yrs,NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,neoplasms benign malignant and unspecified (incl cysts and polyps) - other specify
10029104,9.09,NCT00873093-4,T-cell ALL (Chemotherapy),NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,neoplasms benign malignant and unspecified (incl cysts and polyps) - other specify
D011595,4.55,NCT00873093-4,T-cell ALL (Chemotherapy),NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,akathisia
D003244,1.64,NCT00873093-2,Pre-B ALL Relapse 18-36 Mths From Dx (Chemotherapy)Age<=21 Yrs,NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,depressed level of consciousness
D003244,2.04,NCT00873093-3,Pre-B ALL Relapse <18 Mths From Dx (Chemotherapy) Age <=21 Yrs,NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,depressed level of consciousness
D004401,1.64,NCT00873093-2,Pre-B ALL Relapse 18-36 Mths From Dx (Chemotherapy)Age<=21 Yrs,NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,dysarthria
D001927,1.64,NCT00873093-2,Pre-B ALL Relapse 18-36 Mths From Dx (Chemotherapy)Age<=21 Yrs,NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,encephalopathy
D006261,3.28,NCT00873093-2,Pre-B ALL Relapse 18-36 Mths From Dx (Chemotherapy)Age<=21 Yrs,NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,headache
D006261,2.04,NCT00873093-3,Pre-B ALL Relapse <18 Mths From Dx (Chemotherapy) Age <=21 Yrs,NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,headache
10027175,4.55,NCT00873093-4,T-cell ALL (Chemotherapy),NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,memory impairment
10029205,1.64,NCT00873093-2,Pre-B ALL Relapse 18-36 Mths From Dx (Chemotherapy)Age<=21 Yrs,NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,nervous system disorders - other specify
D009437,1.64,NCT00873093-2,Pre-B ALL Relapse 18-36 Mths From Dx (Chemotherapy)Age<=21 Yrs,NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,neuralgia
D010292,4.55,NCT00873093-4,T-cell ALL (Chemotherapy),NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,paresthesia
10034620,25.0,NCT00873093-1,Pre-B ALL Relapse < 36 Mths From Dx (Chemotherapy) Age >21 Yrs,NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,peripheral sensory neuropathy
10034620,2.04,NCT00873093-3,Pre-B ALL Relapse <18 Mths From Dx (Chemotherapy) Age <=21 Yrs,NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,peripheral sensory neuropathy
10034620,4.55,NCT00873093-4,T-cell ALL (Chemotherapy),NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,peripheral sensory neuropathy
D054038,2.04,NCT00873093-3,Pre-B ALL Relapse <18 Mths From Dx (Chemotherapy) Age <=21 Yrs,NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,reversible posterior leukoencephalopathy syndrome
D012640,3.28,NCT00873093-2,Pre-B ALL Relapse 18-36 Mths From Dx (Chemotherapy)Age<=21 Yrs,NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,seizure
D012640,2.04,NCT00873093-3,Pre-B ALL Relapse <18 Mths From Dx (Chemotherapy) Age <=21 Yrs,NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,seizure
D020521,4.08,NCT00873093-3,Pre-B ALL Relapse <18 Mths From Dx (Chemotherapy) Age <=21 Yrs,NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,stroke
D013575,1.64,NCT00873093-2,Pre-B ALL Relapse 18-36 Mths From Dx (Chemotherapy)Age<=21 Yrs,NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,syncope
D001007,4.55,NCT00873093-4,T-cell ALL (Chemotherapy),NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,anxiety
D003221,4.55,NCT00873093-4,T-cell ALL (Chemotherapy),NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,confusion
10037175,4.55,NCT00873093-4,T-cell ALL (Chemotherapy),NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,psychiatric disorders - other specify
D058186,1.64,NCT00873093-2,Pre-B ALL Relapse 18-36 Mths From Dx (Chemotherapy)Age<=21 Yrs,NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,acute kidney injury
D016055,2.04,NCT00873093-3,Pre-B ALL Relapse <18 Mths From Dx (Chemotherapy) Age <=21 Yrs,NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,urinary retention
D012128,3.28,NCT00873093-2,Pre-B ALL Relapse 18-36 Mths From Dx (Chemotherapy)Age<=21 Yrs,NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,adult respiratory distress syndrome
D012128,4.08,NCT00873093-3,Pre-B ALL Relapse <18 Mths From Dx (Chemotherapy) Age <=21 Yrs,NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,adult respiratory distress syndrome
D001261,2.04,NCT00873093-3,Pre-B ALL Relapse <18 Mths From Dx (Chemotherapy) Age <=21 Yrs,NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,atelectasis
10065746,1.64,NCT00873093-2,Pre-B ALL Relapse 18-36 Mths From Dx (Chemotherapy)Age<=21 Yrs,NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,bronchopulmonary hemorrhage
D004417,3.28,NCT00873093-2,Pre-B ALL Relapse 18-36 Mths From Dx (Chemotherapy)Age<=21 Yrs,NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,dyspnea
D004417,6.12,NCT00873093-3,Pre-B ALL Relapse <18 Mths From Dx (Chemotherapy) Age <=21 Yrs,NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,dyspnea
D004844,4.08,NCT00873093-3,Pre-B ALL Relapse <18 Mths From Dx (Chemotherapy) Age <=21 Yrs,NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,epistaxis
D000860,13.11,NCT00873093-2,Pre-B ALL Relapse 18-36 Mths From Dx (Chemotherapy)Age<=21 Yrs,NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,hypoxia
D000860,6.12,NCT00873093-3,Pre-B ALL Relapse <18 Mths From Dx (Chemotherapy) Age <=21 Yrs,NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,hypoxia
10034844,1.64,NCT00873093-2,Pre-B ALL Relapse 18-36 Mths From Dx (Chemotherapy)Age<=21 Yrs,NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,pharyngolaryngeal pain
D010996,3.28,NCT00873093-2,Pre-B ALL Relapse 18-36 Mths From Dx (Chemotherapy)Age<=21 Yrs,NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,pleural effusion
D011014,3.28,NCT00873093-2,Pre-B ALL Relapse 18-36 Mths From Dx (Chemotherapy)Age<=21 Yrs,NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,pneumonitis
D011014,4.08,NCT00873093-3,Pre-B ALL Relapse <18 Mths From Dx (Chemotherapy) Age <=21 Yrs,NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,pneumonitis
D011030,2.04,NCT00873093-3,Pre-B ALL Relapse <18 Mths From Dx (Chemotherapy) Age <=21 Yrs,NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,pneumothorax
D011654,4.92,NCT00873093-2,Pre-B ALL Relapse 18-36 Mths From Dx (Chemotherapy)Age<=21 Yrs,NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,pulmonary edema
D011654,2.04,NCT00873093-3,Pre-B ALL Relapse <18 Mths From Dx (Chemotherapy) Age <=21 Yrs,NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,pulmonary edema
D012131,8.2,NCT00873093-2,Pre-B ALL Relapse 18-36 Mths From Dx (Chemotherapy)Age<=21 Yrs,NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,respiratory failure
D012131,8.16,NCT00873093-3,Pre-B ALL Relapse <18 Mths From Dx (Chemotherapy) Age <=21 Yrs,NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,respiratory failure
D012131,4.55,NCT00873093-4,T-cell ALL (Chemotherapy),NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,respiratory failure
10038738,1.64,NCT00873093-2,Pre-B ALL Relapse 18-36 Mths From Dx (Chemotherapy)Age<=21 Yrs,NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,respiratory thoracic and mediastinal disorders - other specify
10038738,2.04,NCT00873093-3,Pre-B ALL Relapse <18 Mths From Dx (Chemotherapy) Age <=21 Yrs,NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,respiratory thoracic and mediastinal disorders - other specify
D012135,2.04,NCT00873093-3,Pre-B ALL Relapse <18 Mths From Dx (Chemotherapy) Age <=21 Yrs,NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,stridor
D012135,2.04,NCT00873093-3,Pre-B ALL Relapse <18 Mths From Dx (Chemotherapy) Age <=21 Yrs,NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,wheezing
D011537,1.64,NCT00873093-2,Pre-B ALL Relapse 18-36 Mths From Dx (Chemotherapy)Age<=21 Yrs,NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,pruritus
D011537,4.55,NCT00873093-4,T-cell ALL (Chemotherapy),NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,pruritus
10037868,1.64,NCT00873093-2,Pre-B ALL Relapse 18-36 Mths From Dx (Chemotherapy)Age<=21 Yrs,NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,rash maculo-papular
10040947,1.64,NCT00873093-2,Pre-B ALL Relapse 18-36 Mths From Dx (Chemotherapy)Age<=21 Yrs,NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,skin ulceration
10040947,2.04,NCT00873093-3,Pre-B ALL Relapse <18 Mths From Dx (Chemotherapy) Age <=21 Yrs,NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,skin ulceration
D013262,1.64,NCT00873093-2,Pre-B ALL Relapse 18-36 Mths From Dx (Chemotherapy)Age<=21 Yrs,NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,toxic epidermal necrolysis
D019559,2.04,NCT00873093-3,Pre-B ALL Relapse <18 Mths From Dx (Chemotherapy) Age <=21 Yrs,NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,capillary leak syndrome
D019559,10.0,NCT00873093-5,T-cell Lymphoblastic Lymphoma (LL) (Chemotherapy),NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,capillary leak syndrome
D006973,4.92,NCT00873093-2,Pre-B ALL Relapse 18-36 Mths From Dx (Chemotherapy)Age<=21 Yrs,NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,hypertension
D006973,4.08,NCT00873093-3,Pre-B ALL Relapse <18 Mths From Dx (Chemotherapy) Age <=21 Yrs,NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,hypertension
D007022,13.11,NCT00873093-2,Pre-B ALL Relapse 18-36 Mths From Dx (Chemotherapy)Age<=21 Yrs,NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,hypotension
D007022,10.2,NCT00873093-3,Pre-B ALL Relapse <18 Mths From Dx (Chemotherapy) Age <=21 Yrs,NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,hypotension
D007022,13.64,NCT00873093-4,T-cell ALL (Chemotherapy),NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,hypotension
D007022,10.0,NCT00873093-5,T-cell Lymphoblastic Lymphoma (LL) (Chemotherapy),NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,hypotension
D064420,27.15,NCT00877006-1,Bendamustine and Rituximab (BR),NCT00877006,Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study,adverse drug events
D064420,22.79,NCT00877006-2,R-CHOP/CVP,NCT00877006,Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study,adverse drug events
D012010,0.45,NCT00877006-1,Bendamustine and Rituximab (BR),NCT00877006,Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study,aplasia pure red cell
D064147,3.17,NCT00877006-1,Bendamustine and Rituximab (BR),NCT00877006,Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study,febrile neutropenia
D064147,4.19,NCT00877006-2,R-CHOP/CVP,NCT00877006,Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study,febrile neutropenia
D000072281,0.47,NCT00877006-2,R-CHOP/CVP,NCT00877006,Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study,lymphadenopathy
D009503,1.81,NCT00877006-1,Bendamustine and Rituximab (BR),NCT00877006,Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study,neutropenia
D009503,2.33,NCT00877006-2,R-CHOP/CVP,NCT00877006,Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study,neutropenia
D013163,0.45,NCT00877006-1,Bendamustine and Rituximab (BR),NCT00877006,Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study,splenomegaly
D001281,0.47,NCT00877006-2,R-CHOP/CVP,NCT00877006,Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study,atrial fibrillation
10003674,0.45,NCT00877006-1,Bendamustine and Rituximab (BR),NCT00877006,Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study,atrioventricular block first degree
D002037,0.47,NCT00877006-2,R-CHOP/CVP,NCT00877006,Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study,left bundle-branch block
D006323,0.45,NCT00877006-1,Bendamustine and Rituximab (BR),NCT00877006,Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study,cardiac arrest
D006323,0.47,NCT00877006-2,R-CHOP/CVP,NCT00877006,Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study,cardiac arrest
D006333,0.47,NCT00877006-2,R-CHOP/CVP,NCT00877006,Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study,cardiac failure
D018487,0.45,NCT00877006-1,Bendamustine and Rituximab (BR),NCT00877006,Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study,left ventricular dysfunction
D018487,0.47,NCT00877006-2,R-CHOP/CVP,NCT00877006,Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study,left ventricular dysfunction
D009203,0.47,NCT00877006-2,R-CHOP/CVP,NCT00877006,Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study,myocardial infarction
D010490,0.45,NCT00877006-1,Bendamustine and Rituximab (BR),NCT00877006,Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study,pericardial effusion
D013617,0.47,NCT00877006-2,R-CHOP/CVP,NCT00877006,Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study,supraventricular tachycardia
10016778,0.45,NCT00877006-1,Bendamustine and Rituximab (BR),NCT00877006,Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study,floaters
D015746,0.9,NCT00877006-1,Bendamustine and Rituximab (BR),NCT00877006,Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study,abdominal pain
D015746,0.47,NCT00877006-2,R-CHOP/CVP,NCT00877006,Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study,abdominal pain
D001201,0.45,NCT00877006-1,Bendamustine and Rituximab (BR),NCT00877006,Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study,ascites
D003248,0.45,NCT00877006-1,Bendamustine and Rituximab (BR),NCT00877006,Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study,constipation
UNKNOWN-check-for-typo,0.45,NCT00877006-1,Bendamustine and Rituximab (BR),NCT00877006,Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study,D00
D000072663,0.47,NCT00877006-2,R-CHOP/CVP,NCT00877006,Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study,spontaneous perforation
D005764,0.45,NCT00877006-1,Bendamustine and Rituximab (BR),NCT00877006,Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study,gastroesophageal reflux disease
D045823,0.45,NCT00877006-1,Bendamustine and Rituximab (BR),NCT00877006,Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study,ileus
D009325,1.36,NCT00877006-1,Bendamustine and Rituximab (BR),NCT00877006,Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study,nausea
D000071056,0.45,NCT00877006-1,Bendamustine and Rituximab (BR),NCT00877006,Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study,anorectal malformations
10041101,0.45,NCT00877006-1,Bendamustine and Rituximab (BR),NCT00877006,Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study,small intestinal obstruction
10041101,0.47,NCT00877006-2,R-CHOP/CVP,NCT00877006,Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study,small intestinal obstruction
D014839,1.36,NCT00877006-1,Bendamustine and Rituximab (BR),NCT00877006,Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study,vomiting
D023341,0.45,NCT00877006-1,Bendamustine and Rituximab (BR),NCT00877006,Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study,chills
10062501,1.4,NCT00877006-2,R-CHOP/CVP,NCT00877006,Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study,non-cardiac chest pain
D005334,2.26,NCT00877006-1,Bendamustine and Rituximab (BR),NCT00877006,Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study,pyrexia
D005334,1.86,NCT00877006-2,R-CHOP/CVP,NCT00877006,Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study,pyrexia
D002769,0.45,NCT00877006-1,Bendamustine and Rituximab (BR),NCT00877006,Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study,cholelithiasis
10036206,0.45,NCT00877006-1,Bendamustine and Rituximab (BR),NCT00877006,Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study,portal vein thrombosis
D000707,0.45,NCT00877006-1,Bendamustine and Rituximab (BR),NCT00877006,Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study,anaphylactic shock
D004342,1.81,NCT00877006-1,Bendamustine and Rituximab (BR),NCT00877006,Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study,drug hypersensitivity
D000038,0.47,NCT00877006-2,R-CHOP/CVP,NCT00877006,Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study,abscess
D000069544,0.47,NCT00877006-2,R-CHOP/CVP,NCT00877006,Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study,encephalitis infection
UNKNOWN-check-for-typo,0.45,NCT00877006-1,Bendamustine and Rituximab (BR),NCT00877006,Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study,D00
D004761,0.45,NCT00877006-1,Bendamustine and Rituximab (BR),NCT00877006,Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study,clostridium enterocolitis
D004238,0.9,NCT00877006-1,Bendamustine and Rituximab (BR),NCT00877006,Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study,diverticulitis
D004238,0.47,NCT00877006-2,R-CHOP/CVP,NCT00877006,Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study,diverticulitis
D005759,0.45,NCT00877006-1,Bendamustine and Rituximab (BR),NCT00877006,Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study,gastroenteritis
D000069544,0.45,NCT00877006-1,Bendamustine and Rituximab (BR),NCT00877006,Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study,encephalitis infection
D007239,0.45,NCT00877006-1,Bendamustine and Rituximab (BR),NCT00877006,Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study,infection
D029424,0.45,NCT00877006-1,Bendamustine and Rituximab (BR),NCT00877006,Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study,pulmonary disease chronic obstructive
D012141,0.47,NCT00877006-2,R-CHOP/CVP,NCT00877006,Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study,respiratory tract infections
D010612,0.47,NCT00877006-2,R-CHOP/CVP,NCT00877006,Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study,pharyngitis
D016720,0.45,NCT00877006-1,Bendamustine and Rituximab (BR),NCT00877006,Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study,pneumocystis infections
D011020,0.45,NCT00877006-1,Bendamustine and Rituximab (BR),NCT00877006,Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study,pneumocystis jirovecii pneumonia
D011020,0.47,NCT00877006-2,R-CHOP/CVP,NCT00877006,Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study,pneumocystis jirovecii pneumonia
D011014,3.17,NCT00877006-1,Bendamustine and Rituximab (BR),NCT00877006,Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study,pneumonia
D011014,0.47,NCT00877006-2,R-CHOP/CVP,NCT00877006,Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study,pneumonia
D013530,0.47,NCT00877006-2,R-CHOP/CVP,NCT00877006,Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study,postoperative wound infection
D012772,0.45,NCT00877006-1,Bendamustine and Rituximab (BR),NCT00877006,Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study,septic shock
D012772,0.47,NCT00877006-2,R-CHOP/CVP,NCT00877006,Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study,septic shock
D000038,0.45,NCT00877006-1,Bendamustine and Rituximab (BR),NCT00877006,Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study,abscess
10048762,0.47,NCT00877006-2,R-CHOP/CVP,NCT00877006,Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study,tooth infection
D002184,0.45,NCT00877006-1,Bendamustine and Rituximab (BR),NCT00877006,Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study,canine tracheobronchitis virus
D012141,0.45,NCT00877006-1,Bendamustine and Rituximab (BR),NCT00877006,Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study,upper respiratory tract infections
D014552,0.45,NCT00877006-1,Bendamustine and Rituximab (BR),NCT00877006,Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study,urinary tract infection
D014777,0.9,NCT00877006-1,Bendamustine and Rituximab (BR),NCT00877006,Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study,viral infection
D064386,0.47,NCT00877006-2,R-CHOP/CVP,NCT00877006,Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study,ankle fracture
D007714,0.47,NCT00877006-2,R-CHOP/CVP,NCT00877006,Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study,vertebral cervical fusion syndrome
D002968,0.47,NCT00877006-2,R-CHOP/CVP,NCT00877006,Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study,clavicle
10016173,0.47,NCT00877006-2,R-CHOP/CVP,NCT00877006,Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study,fall
10051792,3.62,NCT00877006-1,Bendamustine and Rituximab (BR),NCT00877006,Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study,infusion related reaction
10051792,1.86,NCT00877006-2,R-CHOP/CVP,NCT00877006,Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study,infusion related reaction
10022117,0.47,NCT00877006-2,R-CHOP/CVP,NCT00877006,Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study,injury poisoning and procedural complications - other specify
D012253,0.45,NCT00877006-1,Bendamustine and Rituximab (BR),NCT00877006,Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study,rib fracture
D012253,0.47,NCT00877006-2,R-CHOP/CVP,NCT00877006,Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study,rib fracture
D016103,0.47,NCT00877006-2,R-CHOP/CVP,NCT00877006,Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study,spinal fractures
D000081015,0.45,NCT00877006-1,Bendamustine and Rituximab (BR),NCT00877006,Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study,ototoxicity
D008133,0.47,NCT00877006-2,R-CHOP/CVP,NCT00877006,Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study,electrocardiogram qt prolonged
D003681,0.47,NCT00877006-2,R-CHOP/CVP,NCT00877006,Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study,dehydration
UNKNOWN-check-for-typo,0.47,NCT00877006-2,R-CHOP/CVP,NCT00877006,Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study,D00
D015275,0.45,NCT00877006-1,Bendamustine and Rituximab (BR),NCT00877006,Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study,tumour lysis syndrome
D001416,0.93,NCT00877006-2,R-CHOP/CVP,NCT00877006,Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study,back pain
D008175,0.45,NCT00877006-1,Bendamustine and Rituximab (BR),NCT00877006,Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study,lung neoplasms
D002292,0.47,NCT00877006-2,R-CHOP/CVP,NCT00877006,Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study,renal cell carcinoma
D012509,0.45,NCT00877006-1,Bendamustine and Rituximab (BR),NCT00877006,Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study,sarcoma
D004421,0.47,NCT00877006-2,R-CHOP/CVP,NCT00877006,Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study,dystonia
D006261,0.45,NCT00877006-1,Bendamustine and Rituximab (BR),NCT00877006,Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study,headache
D002532,0.47,NCT00877006-2,R-CHOP/CVP,NCT00877006,Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study,intracranial aneurysm
D010523,0.45,NCT00877006-1,Bendamustine and Rituximab (BR),NCT00877006,Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study,peripheral neuropathy
D013575,0.45,NCT00877006-1,Bendamustine and Rituximab (BR),NCT00877006,Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study,syncope
D013575,0.47,NCT00877006-2,R-CHOP/CVP,NCT00877006,Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study,syncope
D003221,0.45,NCT00877006-1,Bendamustine and Rituximab (BR),NCT00877006,Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study,confusional state
D003863,0.47,NCT00877006-2,R-CHOP/CVP,NCT00877006,Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study,depression
UNKNOWN-check-for-typo,0.45,NCT00877006-1,Bendamustine and Rituximab (BR),NCT00877006,Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study,D00
D058186,0.45,NCT00877006-1,Bendamustine and Rituximab (BR),NCT00877006,Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study,acute renal failure
D000141,0.45,NCT00877006-1,Bendamustine and Rituximab (BR),NCT00877006,Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study,acidosis renal tubular
D016055,0.45,NCT00877006-1,Bendamustine and Rituximab (BR),NCT00877006,Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study,urinary retention
D011472,0.45,NCT00877006-1,Bendamustine and Rituximab (BR),NCT00877006,Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study,prostatitis
D012131,0.45,NCT00877006-1,Bendamustine and Rituximab (BR),NCT00877006,Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study,respiratory failure
D029424,0.9,NCT00877006-1,Bendamustine and Rituximab (BR),NCT00877006,Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study,chronic obstructive pulmonary disease
UNKNOWN-check-for-typo,0.47,NCT00877006-2,R-CHOP/CVP,NCT00877006,Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study,D00
D000860,0.45,NCT00877006-1,Bendamustine and Rituximab (BR),NCT00877006,Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study,hypoxia
D000860,0.47,NCT00877006-2,R-CHOP/CVP,NCT00877006,Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study,hypoxia
D017563,0.45,NCT00877006-1,Bendamustine and Rituximab (BR),NCT00877006,Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study,interstitial lung disease
D010996,0.45,NCT00877006-1,Bendamustine and Rituximab (BR),NCT00877006,Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study,pleural effusion
D011655,0.45,NCT00877006-1,Bendamustine and Rituximab (BR),NCT00877006,Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study,pulmonary embolism
D011655,0.47,NCT00877006-2,R-CHOP/CVP,NCT00877006,Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study,pulmonary embolism
D012131,0.9,NCT00877006-1,Bendamustine and Rituximab (BR),NCT00877006,Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study,respiratory failure
D005076,0.45,NCT00877006-1,Bendamustine and Rituximab (BR),NCT00877006,Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study,rash
10037868,0.47,NCT00877006-2,R-CHOP/CVP,NCT00877006,Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study,rash maculo-papular
D006973,0.47,NCT00877006-2,R-CHOP/CVP,NCT00877006,Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study,hypertension
D007022,0.45,NCT00877006-1,Bendamustine and Rituximab (BR),NCT00877006,Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study,hypotension
D064420,35.89,NCT00883116-1,Ixabepilone 40 mg/m^2 Intravenously (IV),NCT00883116,A Study of Ixabepilone as Second-line Therapy for Locally Advanced  Recurrent  or Metastatic Endometrial Cancer,adverse drug events
D064420,34.5,NCT00883116-2,Control With Chemotherapy (Doxorubicin 60 mg/m^2 IV),NCT00883116,A Study of Ixabepilone as Second-line Therapy for Locally Advanced  Recurrent  or Metastatic Endometrial Cancer,adverse drug events
D064420,16.18,NCT00883116-3,Control With Chemotherapy (Paclitaxel 175 mg/m^2 IV),NCT00883116,A Study of Ixabepilone as Second-line Therapy for Locally Advanced  Recurrent  or Metastatic Endometrial Cancer,adverse drug events
D064147,4.03,NCT00883116-1,Ixabepilone 40 mg/m^2 Intravenously (IV),NCT00883116,A Study of Ixabepilone as Second-line Therapy for Locally Advanced  Recurrent  or Metastatic Endometrial Cancer,febrile neutropenia
D064147,5.85,NCT00883116-2,Control With Chemotherapy (Doxorubicin 60 mg/m^2 IV),NCT00883116,A Study of Ixabepilone as Second-line Therapy for Locally Advanced  Recurrent  or Metastatic Endometrial Cancer,febrile neutropenia
D064147,1.47,NCT00883116-3,Control With Chemotherapy (Paclitaxel 175 mg/m^2 IV),NCT00883116,A Study of Ixabepilone as Second-line Therapy for Locally Advanced  Recurrent  or Metastatic Endometrial Cancer,febrile neutropenia
D007970,1.21,NCT00883116-1,Ixabepilone 40 mg/m^2 Intravenously (IV),NCT00883116,A Study of Ixabepilone as Second-line Therapy for Locally Advanced  Recurrent  or Metastatic Endometrial Cancer,leukopenia
D007970,0.58,NCT00883116-2,Control With Chemotherapy (Doxorubicin 60 mg/m^2 IV),NCT00883116,A Study of Ixabepilone as Second-line Therapy for Locally Advanced  Recurrent  or Metastatic Endometrial Cancer,leukopenia
D009503,2.42,NCT00883116-1,Ixabepilone 40 mg/m^2 Intravenously (IV),NCT00883116,A Study of Ixabepilone as Second-line Therapy for Locally Advanced  Recurrent  or Metastatic Endometrial Cancer,neutropenia
D009503,2.34,NCT00883116-2,Control With Chemotherapy (Doxorubicin 60 mg/m^2 IV),NCT00883116,A Study of Ixabepilone as Second-line Therapy for Locally Advanced  Recurrent  or Metastatic Endometrial Cancer,neutropenia
D013921,0.4,NCT00883116-1,Ixabepilone 40 mg/m^2 Intravenously (IV),NCT00883116,A Study of Ixabepilone as Second-line Therapy for Locally Advanced  Recurrent  or Metastatic Endometrial Cancer,thrombocytopenia
D013921,0.58,NCT00883116-2,Control With Chemotherapy (Doxorubicin 60 mg/m^2 IV),NCT00883116,A Study of Ixabepilone as Second-line Therapy for Locally Advanced  Recurrent  or Metastatic Endometrial Cancer,thrombocytopenia
D013921,1.47,NCT00883116-3,Control With Chemotherapy (Paclitaxel 175 mg/m^2 IV),NCT00883116,A Study of Ixabepilone as Second-line Therapy for Locally Advanced  Recurrent  or Metastatic Endometrial Cancer,thrombocytopenia
D000741,2.02,NCT00883116-1,Ixabepilone 40 mg/m^2 Intravenously (IV),NCT00883116,A Study of Ixabepilone as Second-line Therapy for Locally Advanced  Recurrent  or Metastatic Endometrial Cancer,aplastic anaemia
D000741,4.09,NCT00883116-2,Control With Chemotherapy (Doxorubicin 60 mg/m^2 IV),NCT00883116,A Study of Ixabepilone as Second-line Therapy for Locally Advanced  Recurrent  or Metastatic Endometrial Cancer,aplastic anaemia
D000741,1.47,NCT00883116-3,Control With Chemotherapy (Paclitaxel 175 mg/m^2 IV),NCT00883116,A Study of Ixabepilone as Second-line Therapy for Locally Advanced  Recurrent  or Metastatic Endometrial Cancer,aplastic anaemia
D010198,0.4,NCT00883116-1,Ixabepilone 40 mg/m^2 Intravenously (IV),NCT00883116,A Study of Ixabepilone as Second-line Therapy for Locally Advanced  Recurrent  or Metastatic Endometrial Cancer,pancytopenia
D010198,0.58,NCT00883116-2,Control With Chemotherapy (Doxorubicin 60 mg/m^2 IV),NCT00883116,A Study of Ixabepilone as Second-line Therapy for Locally Advanced  Recurrent  or Metastatic Endometrial Cancer,pancytopenia
D000071956,1.47,NCT00883116-3,Control With Chemotherapy (Paclitaxel 175 mg/m^2 IV),NCT00883116,A Study of Ixabepilone as Second-line Therapy for Locally Advanced  Recurrent  or Metastatic Endometrial Cancer,myocardial contusions
D010490,0.4,NCT00883116-1,Ixabepilone 40 mg/m^2 Intravenously (IV),NCT00883116,A Study of Ixabepilone as Second-line Therapy for Locally Advanced  Recurrent  or Metastatic Endometrial Cancer,pericardial effusion
D016278,0.4,NCT00883116-1,Ixabepilone 40 mg/m^2 Intravenously (IV),NCT00883116,A Study of Ixabepilone as Second-line Therapy for Locally Advanced  Recurrent  or Metastatic Endometrial Cancer,ventricular function right
D002305,0.4,NCT00883116-1,Ixabepilone 40 mg/m^2 Intravenously (IV),NCT00883116,A Study of Ixabepilone as Second-line Therapy for Locally Advanced  Recurrent  or Metastatic Endometrial Cancer,cardiac tamponade
D000072599,0.4,NCT00883116-1,Ixabepilone 40 mg/m^2 Intravenously (IV),NCT00883116,A Study of Ixabepilone as Second-line Therapy for Locally Advanced  Recurrent  or Metastatic Endometrial Cancer,cardiorespiratory fitness
D001281,0.81,NCT00883116-1,Ixabepilone 40 mg/m^2 Intravenously (IV),NCT00883116,A Study of Ixabepilone as Second-line Therapy for Locally Advanced  Recurrent  or Metastatic Endometrial Cancer,atrial fibrillation
D006333,0.4,NCT00883116-1,Ixabepilone 40 mg/m^2 Intravenously (IV),NCT00883116,A Study of Ixabepilone as Second-line Therapy for Locally Advanced  Recurrent  or Metastatic Endometrial Cancer,cardiac failure
D013610,0.58,NCT00883116-2,Control With Chemotherapy (Doxorubicin 60 mg/m^2 IV),NCT00883116,A Study of Ixabepilone as Second-line Therapy for Locally Advanced  Recurrent  or Metastatic Endometrial Cancer,tachycardia
D013927,0.58,NCT00883116-2,Control With Chemotherapy (Doxorubicin 60 mg/m^2 IV),NCT00883116,A Study of Ixabepilone as Second-line Therapy for Locally Advanced  Recurrent  or Metastatic Endometrial Cancer,thrombus
D013610,0.4,NCT00883116-1,Ixabepilone 40 mg/m^2 Intravenously (IV),NCT00883116,A Study of Ixabepilone as Second-line Therapy for Locally Advanced  Recurrent  or Metastatic Endometrial Cancer,tachyarrhythmia
D007037,0.4,NCT00883116-1,Ixabepilone 40 mg/m^2 Intravenously (IV),NCT00883116,A Study of Ixabepilone as Second-line Therapy for Locally Advanced  Recurrent  or Metastatic Endometrial Cancer,hypothyroidism
D004415,0.4,NCT00883116-1,Ixabepilone 40 mg/m^2 Intravenously (IV),NCT00883116,A Study of Ixabepilone as Second-line Therapy for Locally Advanced  Recurrent  or Metastatic Endometrial Cancer,dyspepsia
10065707,0.58,NCT00883116-2,Control With Chemotherapy (Doxorubicin 60 mg/m^2 IV),NCT00883116,A Study of Ixabepilone as Second-line Therapy for Locally Advanced  Recurrent  or Metastatic Endometrial Cancer,rectal obstruction
10041101,0.4,NCT00883116-1,Ixabepilone 40 mg/m^2 Intravenously (IV),NCT00883116,A Study of Ixabepilone as Second-line Therapy for Locally Advanced  Recurrent  or Metastatic Endometrial Cancer,small intestinal obstruction
10041101,1.17,NCT00883116-2,Control With Chemotherapy (Doxorubicin 60 mg/m^2 IV),NCT00883116,A Study of Ixabepilone as Second-line Therapy for Locally Advanced  Recurrent  or Metastatic Endometrial Cancer,small intestinal obstruction
10041101,1.47,NCT00883116-3,Control With Chemotherapy (Paclitaxel 175 mg/m^2 IV),NCT00883116,A Study of Ixabepilone as Second-line Therapy for Locally Advanced  Recurrent  or Metastatic Endometrial Cancer,small intestinal obstruction
D041742,0.4,NCT00883116-1,Ixabepilone 40 mg/m^2 Intravenously (IV),NCT00883116,A Study of Ixabepilone as Second-line Therapy for Locally Advanced  Recurrent  or Metastatic Endometrial Cancer,upper gastrointestinal tract
D041742,0.58,NCT00883116-2,Control With Chemotherapy (Doxorubicin 60 mg/m^2 IV),NCT00883116,A Study of Ixabepilone as Second-line Therapy for Locally Advanced  Recurrent  or Metastatic Endometrial Cancer,upper gastrointestinal tract
D001201,1.21,NCT00883116-1,Ixabepilone 40 mg/m^2 Intravenously (IV),NCT00883116,A Study of Ixabepilone as Second-line Therapy for Locally Advanced  Recurrent  or Metastatic Endometrial Cancer,ascites
D001201,0.58,NCT00883116-2,Control With Chemotherapy (Doxorubicin 60 mg/m^2 IV),NCT00883116,A Study of Ixabepilone as Second-line Therapy for Locally Advanced  Recurrent  or Metastatic Endometrial Cancer,ascites
D007415,0.4,NCT00883116-1,Ixabepilone 40 mg/m^2 Intravenously (IV),NCT00883116,A Study of Ixabepilone as Second-line Therapy for Locally Advanced  Recurrent  or Metastatic Endometrial Cancer,intestinal obstruction
D007415,1.75,NCT00883116-2,Control With Chemotherapy (Doxorubicin 60 mg/m^2 IV),NCT00883116,A Study of Ixabepilone as Second-line Therapy for Locally Advanced  Recurrent  or Metastatic Endometrial Cancer,intestinal obstruction
10015461,0.4,NCT00883116-1,Ixabepilone 40 mg/m^2 Intravenously (IV),NCT00883116,A Study of Ixabepilone as Second-line Therapy for Locally Advanced  Recurrent  or Metastatic Endometrial Cancer,esophagitis
D000069196,0.4,NCT00883116-1,Ixabepilone 40 mg/m^2 Intravenously (IV),NCT00883116,A Study of Ixabepilone as Second-line Therapy for Locally Advanced  Recurrent  or Metastatic Endometrial Cancer,gastrointestinal microbiome
D000071056,0.4,NCT00883116-1,Ixabepilone 40 mg/m^2 Intravenously (IV),NCT00883116,A Study of Ixabepilone as Second-line Therapy for Locally Advanced  Recurrent  or Metastatic Endometrial Cancer,anorectal malformations
D000071056,1.17,NCT00883116-2,Control With Chemotherapy (Doxorubicin 60 mg/m^2 IV),NCT00883116,A Study of Ixabepilone as Second-line Therapy for Locally Advanced  Recurrent  or Metastatic Endometrial Cancer,anorectal malformations
D003680,0.4,NCT00883116-1,Ixabepilone 40 mg/m^2 Intravenously (IV),NCT00883116,A Study of Ixabepilone as Second-line Therapy for Locally Advanced  Recurrent  or Metastatic Endometrial Cancer,dysphagia
D009325,3.23,NCT00883116-1,Ixabepilone 40 mg/m^2 Intravenously (IV),NCT00883116,A Study of Ixabepilone as Second-line Therapy for Locally Advanced  Recurrent  or Metastatic Endometrial Cancer,nausea
D009325,4.09,NCT00883116-2,Control With Chemotherapy (Doxorubicin 60 mg/m^2 IV),NCT00883116,A Study of Ixabepilone as Second-line Therapy for Locally Advanced  Recurrent  or Metastatic Endometrial Cancer,nausea
D015746,1.61,NCT00883116-1,Ixabepilone 40 mg/m^2 Intravenously (IV),NCT00883116,A Study of Ixabepilone as Second-line Therapy for Locally Advanced  Recurrent  or Metastatic Endometrial Cancer,abdominal pain
D015746,3.51,NCT00883116-2,Control With Chemotherapy (Doxorubicin 60 mg/m^2 IV),NCT00883116,A Study of Ixabepilone as Second-line Therapy for Locally Advanced  Recurrent  or Metastatic Endometrial Cancer,abdominal pain
D015746,2.94,NCT00883116-3,Control With Chemotherapy (Paclitaxel 175 mg/m^2 IV),NCT00883116,A Study of Ixabepilone as Second-line Therapy for Locally Advanced  Recurrent  or Metastatic Endometrial Cancer,abdominal pain
UNKNOWN-check-for-typo,0.4,NCT00883116-1,Ixabepilone 40 mg/m^2 Intravenously (IV),NCT00883116,A Study of Ixabepilone as Second-line Therapy for Locally Advanced  Recurrent  or Metastatic Endometrial Cancer,D00
UNKNOWN-check-for-typo,0.58,NCT00883116-2,Control With Chemotherapy (Doxorubicin 60 mg/m^2 IV),NCT00883116,A Study of Ixabepilone as Second-line Therapy for Locally Advanced  Recurrent  or Metastatic Endometrial Cancer,D00
D045823,0.58,NCT00883116-2,Control With Chemotherapy (Doxorubicin 60 mg/m^2 IV),NCT00883116,A Study of Ixabepilone as Second-line Therapy for Locally Advanced  Recurrent  or Metastatic Endometrial Cancer,ileus
10065891,0.4,NCT00883116-1,Ixabepilone 40 mg/m^2 Intravenously (IV),NCT00883116,A Study of Ixabepilone as Second-line Therapy for Locally Advanced  Recurrent  or Metastatic Endometrial Cancer,large intestinal anastomotic leak
D003248,1.61,NCT00883116-1,Ixabepilone 40 mg/m^2 Intravenously (IV),NCT00883116,A Study of Ixabepilone as Second-line Therapy for Locally Advanced  Recurrent  or Metastatic Endometrial Cancer,constipation
D003248,2.34,NCT00883116-2,Control With Chemotherapy (Doxorubicin 60 mg/m^2 IV),NCT00883116,A Study of Ixabepilone as Second-line Therapy for Locally Advanced  Recurrent  or Metastatic Endometrial Cancer,constipation
UNKNOWN-check-for-typo,3.63,NCT00883116-1,Ixabepilone 40 mg/m^2 Intravenously (IV),NCT00883116,A Study of Ixabepilone as Second-line Therapy for Locally Advanced  Recurrent  or Metastatic Endometrial Cancer,D00
UNKNOWN-check-for-typo,1.17,NCT00883116-2,Control With Chemotherapy (Doxorubicin 60 mg/m^2 IV),NCT00883116,A Study of Ixabepilone as Second-line Therapy for Locally Advanced  Recurrent  or Metastatic Endometrial Cancer,D00
UNKNOWN-check-for-typo,1.47,NCT00883116-3,Control With Chemotherapy (Paclitaxel 175 mg/m^2 IV),NCT00883116,A Study of Ixabepilone as Second-line Therapy for Locally Advanced  Recurrent  or Metastatic Endometrial Cancer,D00
D013280,0.58,NCT00883116-2,Control With Chemotherapy (Doxorubicin 60 mg/m^2 IV),NCT00883116,A Study of Ixabepilone as Second-line Therapy for Locally Advanced  Recurrent  or Metastatic Endometrial Cancer,stomatitis
D014839,3.63,NCT00883116-1,Ixabepilone 40 mg/m^2 Intravenously (IV),NCT00883116,A Study of Ixabepilone as Second-line Therapy for Locally Advanced  Recurrent  or Metastatic Endometrial Cancer,vomiting
D014839,2.34,NCT00883116-2,Control With Chemotherapy (Doxorubicin 60 mg/m^2 IV),NCT00883116,A Study of Ixabepilone as Second-line Therapy for Locally Advanced  Recurrent  or Metastatic Endometrial Cancer,vomiting
10000060,0.4,NCT00883116-1,Ixabepilone 40 mg/m^2 Intravenously (IV),NCT00883116,A Study of Ixabepilone as Second-line Therapy for Locally Advanced  Recurrent  or Metastatic Endometrial Cancer,abdominal distension
10000060,0.58,NCT00883116-2,Control With Chemotherapy (Doxorubicin 60 mg/m^2 IV),NCT00883116,A Study of Ixabepilone as Second-line Therapy for Locally Advanced  Recurrent  or Metastatic Endometrial Cancer,abdominal distension
10062570,0.58,NCT00883116-2,Control With Chemotherapy (Doxorubicin 60 mg/m^2 IV),NCT00883116,A Study of Ixabepilone as Second-line Therapy for Locally Advanced  Recurrent  or Metastatic Endometrial Cancer,enterovesical fistula
D007416,0.81,NCT00883116-1,Ixabepilone 40 mg/m^2 Intravenously (IV),NCT00883116,A Study of Ixabepilone as Second-line Therapy for Locally Advanced  Recurrent  or Metastatic Endometrial Cancer,intestinal perforation
D007416,1.17,NCT00883116-2,Control With Chemotherapy (Doxorubicin 60 mg/m^2 IV),NCT00883116,A Study of Ixabepilone as Second-line Therapy for Locally Advanced  Recurrent  or Metastatic Endometrial Cancer,intestinal perforation
D004864,1.47,NCT00883116-3,Control With Chemotherapy (Paclitaxel 175 mg/m^2 IV),NCT00883116,A Study of Ixabepilone as Second-line Therapy for Locally Advanced  Recurrent  or Metastatic Endometrial Cancer,devices
D000799,0.4,NCT00883116-1,Ixabepilone 40 mg/m^2 Intravenously (IV),NCT00883116,A Study of Ixabepilone as Second-line Therapy for Locally Advanced  Recurrent  or Metastatic Endometrial Cancer,angioedema
D003645,0.4,NCT00883116-1,Ixabepilone 40 mg/m^2 Intravenously (IV),NCT00883116,A Study of Ixabepilone as Second-line Therapy for Locally Advanced  Recurrent  or Metastatic Endometrial Cancer,sudden death
D017567,0.58,NCT00883116-2,Control With Chemotherapy (Doxorubicin 60 mg/m^2 IV),NCT00883116,A Study of Ixabepilone as Second-line Therapy for Locally Advanced  Recurrent  or Metastatic Endometrial Cancer,karnofsky performance status
D007249,0.4,NCT00883116-1,Ixabepilone 40 mg/m^2 Intravenously (IV),NCT00883116,A Study of Ixabepilone as Second-line Therapy for Locally Advanced  Recurrent  or Metastatic Endometrial Cancer,inflammation
D005334,1.61,NCT00883116-1,Ixabepilone 40 mg/m^2 Intravenously (IV),NCT00883116,A Study of Ixabepilone as Second-line Therapy for Locally Advanced  Recurrent  or Metastatic Endometrial Cancer,pyrexia
D005334,2.34,NCT00883116-2,Control With Chemotherapy (Doxorubicin 60 mg/m^2 IV),NCT00883116,A Study of Ixabepilone as Second-line Therapy for Locally Advanced  Recurrent  or Metastatic Endometrial Cancer,pyrexia
D001247,1.21,NCT00883116-1,Ixabepilone 40 mg/m^2 Intravenously (IV),NCT00883116,A Study of Ixabepilone as Second-line Therapy for Locally Advanced  Recurrent  or Metastatic Endometrial Cancer,asthenia
D007249,0.58,NCT00883116-2,Control With Chemotherapy (Doxorubicin 60 mg/m^2 IV),NCT00883116,A Study of Ixabepilone as Second-line Therapy for Locally Advanced  Recurrent  or Metastatic Endometrial Cancer,inflammation
D010146,0.4,NCT00883116-1,Ixabepilone 40 mg/m^2 Intravenously (IV),NCT00883116,A Study of Ixabepilone as Second-line Therapy for Locally Advanced  Recurrent  or Metastatic Endometrial Cancer,pain
D010146,1.47,NCT00883116-3,Control With Chemotherapy (Paclitaxel 175 mg/m^2 IV),NCT00883116,A Study of Ixabepilone as Second-line Therapy for Locally Advanced  Recurrent  or Metastatic Endometrial Cancer,pain
D003695,0.4,NCT00883116-1,Ixabepilone 40 mg/m^2 Intravenously (IV),NCT00883116,A Study of Ixabepilone as Second-line Therapy for Locally Advanced  Recurrent  or Metastatic Endometrial Cancer,healthcare
D003695,1.47,NCT00883116-3,Control With Chemotherapy (Paclitaxel 175 mg/m^2 IV),NCT00883116,A Study of Ixabepilone as Second-line Therapy for Locally Advanced  Recurrent  or Metastatic Endometrial Cancer,healthcare
D003643,0.4,NCT00883116-1,Ixabepilone 40 mg/m^2 Intravenously (IV),NCT00883116,A Study of Ixabepilone as Second-line Therapy for Locally Advanced  Recurrent  or Metastatic Endometrial Cancer,death
D005221,1.61,NCT00883116-1,Ixabepilone 40 mg/m^2 Intravenously (IV),NCT00883116,A Study of Ixabepilone as Second-line Therapy for Locally Advanced  Recurrent  or Metastatic Endometrial Cancer,fatigue
D005221,0.58,NCT00883116-2,Control With Chemotherapy (Doxorubicin 60 mg/m^2 IV),NCT00883116,A Study of Ixabepilone as Second-line Therapy for Locally Advanced  Recurrent  or Metastatic Endometrial Cancer,fatigue
UNKNOWN-check-for-typo,0.4,NCT00883116-1,Ixabepilone 40 mg/m^2 Intravenously (IV),NCT00883116,A Study of Ixabepilone as Second-line Therapy for Locally Advanced  Recurrent  or Metastatic Endometrial Cancer,D00
D002764,0.4,NCT00883116-1,Ixabepilone 40 mg/m^2 Intravenously (IV),NCT00883116,A Study of Ixabepilone as Second-line Therapy for Locally Advanced  Recurrent  or Metastatic Endometrial Cancer,cholecystitis
D004696,0.4,NCT00883116-1,Ixabepilone 40 mg/m^2 Intravenously (IV),NCT00883116,A Study of Ixabepilone as Second-line Therapy for Locally Advanced  Recurrent  or Metastatic Endometrial Cancer,endocarditis
D004696,1.47,NCT00883116-3,Control With Chemotherapy (Paclitaxel 175 mg/m^2 IV),NCT00883116,A Study of Ixabepilone as Second-line Therapy for Locally Advanced  Recurrent  or Metastatic Endometrial Cancer,endocarditis
D011704,1.47,NCT00883116-3,Control With Chemotherapy (Paclitaxel 175 mg/m^2 IV),NCT00883116,A Study of Ixabepilone as Second-line Therapy for Locally Advanced  Recurrent  or Metastatic Endometrial Cancer,pyelonephritis
D000985,1.17,NCT00883116-2,Control With Chemotherapy (Doxorubicin 60 mg/m^2 IV),NCT00883116,A Study of Ixabepilone as Second-line Therapy for Locally Advanced  Recurrent  or Metastatic Endometrial Cancer,antisepsis
D011014,1.75,NCT00883116-2,Control With Chemotherapy (Doxorubicin 60 mg/m^2 IV),NCT00883116,A Study of Ixabepilone as Second-line Therapy for Locally Advanced  Recurrent  or Metastatic Endometrial Cancer,pneumonia
D011704,1.47,NCT00883116-3,Control With Chemotherapy (Paclitaxel 175 mg/m^2 IV),NCT00883116,A Study of Ixabepilone as Second-line Therapy for Locally Advanced  Recurrent  or Metastatic Endometrial Cancer,pyelonephritis
D002481,0.81,NCT00883116-1,Ixabepilone 40 mg/m^2 Intravenously (IV),NCT00883116,A Study of Ixabepilone as Second-line Therapy for Locally Advanced  Recurrent  or Metastatic Endometrial Cancer,cellulitis
D003013,0.4,NCT00883116-1,Ixabepilone 40 mg/m^2 Intravenously (IV),NCT00883116,A Study of Ixabepilone as Second-line Therapy for Locally Advanced  Recurrent  or Metastatic Endometrial Cancer,clostridium
10064687,0.81,NCT00883116-1,Ixabepilone 40 mg/m^2 Intravenously (IV),NCT00883116,A Study of Ixabepilone as Second-line Therapy for Locally Advanced  Recurrent  or Metastatic Endometrial Cancer,device related infection
D000069544,0.58,NCT00883116-2,Control With Chemotherapy (Doxorubicin 60 mg/m^2 IV),NCT00883116,A Study of Ixabepilone as Second-line Therapy for Locally Advanced  Recurrent  or Metastatic Endometrial Cancer,encephalitis infection
D012480,0.58,NCT00883116-2,Control With Chemotherapy (Doxorubicin 60 mg/m^2 IV),NCT00883116,A Study of Ixabepilone as Second-line Therapy for Locally Advanced  Recurrent  or Metastatic Endometrial Cancer,salmonellosis
D018805,1.21,NCT00883116-1,Ixabepilone 40 mg/m^2 Intravenously (IV),NCT00883116,A Study of Ixabepilone as Second-line Therapy for Locally Advanced  Recurrent  or Metastatic Endometrial Cancer,sepsis
D018805,1.17,NCT00883116-2,Control With Chemotherapy (Doxorubicin 60 mg/m^2 IV),NCT00883116,A Study of Ixabepilone as Second-line Therapy for Locally Advanced  Recurrent  or Metastatic Endometrial Cancer,sepsis
D018805,1.47,NCT00883116-3,Control With Chemotherapy (Paclitaxel 175 mg/m^2 IV),NCT00883116,A Study of Ixabepilone as Second-line Therapy for Locally Advanced  Recurrent  or Metastatic Endometrial Cancer,sepsis
D012141,0.4,NCT00883116-1,Ixabepilone 40 mg/m^2 Intravenously (IV),NCT00883116,A Study of Ixabepilone as Second-line Therapy for Locally Advanced  Recurrent  or Metastatic Endometrial Cancer,upper respiratory tract infections
D007239,1.47,NCT00883116-3,Control With Chemotherapy (Paclitaxel 175 mg/m^2 IV),NCT00883116,A Study of Ixabepilone as Second-line Therapy for Locally Advanced  Recurrent  or Metastatic Endometrial Cancer,infection
D002177,0.4,NCT00883116-1,Ixabepilone 40 mg/m^2 Intravenously (IV),NCT00883116,A Study of Ixabepilone as Second-line Therapy for Locally Advanced  Recurrent  or Metastatic Endometrial Cancer,moniliasis
D016765,0.58,NCT00883116-2,Control With Chemotherapy (Doxorubicin 60 mg/m^2 IV),NCT00883116,A Study of Ixabepilone as Second-line Therapy for Locally Advanced  Recurrent  or Metastatic Endometrial Cancer,feline infectious peritonitis virus
D012772,0.58,NCT00883116-2,Control With Chemotherapy (Doxorubicin 60 mg/m^2 IV),NCT00883116,A Study of Ixabepilone as Second-line Therapy for Locally Advanced  Recurrent  or Metastatic Endometrial Cancer,septic shock
D002177,0.4,NCT00883116-1,Ixabepilone 40 mg/m^2 Intravenously (IV),NCT00883116,A Study of Ixabepilone as Second-line Therapy for Locally Advanced  Recurrent  or Metastatic Endometrial Cancer,candidiasis
D014552,1.61,NCT00883116-1,Ixabepilone 40 mg/m^2 Intravenously (IV),NCT00883116,A Study of Ixabepilone as Second-line Therapy for Locally Advanced  Recurrent  or Metastatic Endometrial Cancer,urinary tract infection
D014552,1.75,NCT00883116-2,Control With Chemotherapy (Doxorubicin 60 mg/m^2 IV),NCT00883116,A Study of Ixabepilone as Second-line Therapy for Locally Advanced  Recurrent  or Metastatic Endometrial Cancer,urinary tract infection
D006811,0.4,NCT00883116-1,Ixabepilone 40 mg/m^2 Intravenously (IV),NCT00883116,A Study of Ixabepilone as Second-line Therapy for Locally Advanced  Recurrent  or Metastatic Endometrial Cancer,humerus
D062787,0.4,NCT00883116-1,Ixabepilone 40 mg/m^2 Intravenously (IV),NCT00883116,A Study of Ixabepilone as Second-line Therapy for Locally Advanced  Recurrent  or Metastatic Endometrial Cancer,drug overdose
10020100,0.4,NCT00883116-1,Ixabepilone 40 mg/m^2 Intravenously (IV),NCT00883116,A Study of Ixabepilone as Second-line Therapy for Locally Advanced  Recurrent  or Metastatic Endometrial Cancer,hip fracture
D000138,0.4,NCT00883116-1,Ixabepilone 40 mg/m^2 Intravenously (IV),NCT00883116,A Study of Ixabepilone as Second-line Therapy for Locally Advanced  Recurrent  or Metastatic Endometrial Cancer,acidoses
10011368,1.21,NCT00883116-1,Ixabepilone 40 mg/m^2 Intravenously (IV),NCT00883116,A Study of Ixabepilone as Second-line Therapy for Locally Advanced  Recurrent  or Metastatic Endometrial Cancer,creatinine increased
D007958,0.81,NCT00883116-1,Ixabepilone 40 mg/m^2 Intravenously (IV),NCT00883116,A Study of Ixabepilone as Second-line Therapy for Locally Advanced  Recurrent  or Metastatic Endometrial Cancer,blood cell count white
D007958,0.58,NCT00883116-2,Control With Chemotherapy (Doxorubicin 60 mg/m^2 IV),NCT00883116,A Study of Ixabepilone as Second-line Therapy for Locally Advanced  Recurrent  or Metastatic Endometrial Cancer,blood cell count white
D005919,0.4,NCT00883116-1,Ixabepilone 40 mg/m^2 Intravenously (IV),NCT00883116,A Study of Ixabepilone as Second-line Therapy for Locally Advanced  Recurrent  or Metastatic Endometrial Cancer,glomerular filtration rate
D007989,0.81,NCT00883116-1,Ixabepilone 40 mg/m^2 Intravenously (IV),NCT00883116,A Study of Ixabepilone as Second-line Therapy for Locally Advanced  Recurrent  or Metastatic Endometrial Cancer,decreased libido
D004641,1.17,NCT00883116-2,Control With Chemotherapy (Doxorubicin 60 mg/m^2 IV),NCT00883116,A Study of Ixabepilone as Second-line Therapy for Locally Advanced  Recurrent  or Metastatic Endometrial Cancer,international migration
10029366,0.4,NCT00883116-1,Ixabepilone 40 mg/m^2 Intravenously (IV),NCT00883116,A Study of Ixabepilone as Second-line Therapy for Locally Advanced  Recurrent  or Metastatic Endometrial Cancer,neutrophil count decreased
10029366,0.58,NCT00883116-2,Control With Chemotherapy (Doxorubicin 60 mg/m^2 IV),NCT00883116,A Study of Ixabepilone as Second-line Therapy for Locally Advanced  Recurrent  or Metastatic Endometrial Cancer,neutrophil count decreased
10001551,0.4,NCT00883116-1,Ixabepilone 40 mg/m^2 Intravenously (IV),NCT00883116,A Study of Ixabepilone as Second-line Therapy for Locally Advanced  Recurrent  or Metastatic Endometrial Cancer,alanine aminotransferase increased
10035528,0.4,NCT00883116-1,Ixabepilone 40 mg/m^2 Intravenously (IV),NCT00883116,A Study of Ixabepilone as Second-line Therapy for Locally Advanced  Recurrent  or Metastatic Endometrial Cancer,platelet count decreased
10035528,0.58,NCT00883116-2,Control With Chemotherapy (Doxorubicin 60 mg/m^2 IV),NCT00883116,A Study of Ixabepilone as Second-line Therapy for Locally Advanced  Recurrent  or Metastatic Endometrial Cancer,platelet count decreased
UNKNOWN-check-for-typo,0.4,NCT00883116-1,Ixabepilone 40 mg/m^2 Intravenously (IV),NCT00883116,A Study of Ixabepilone as Second-line Therapy for Locally Advanced  Recurrent  or Metastatic Endometrial Cancer,D00
D001066,0.81,NCT00883116-1,Ixabepilone 40 mg/m^2 Intravenously (IV),NCT00883116,A Study of Ixabepilone as Second-line Therapy for Locally Advanced  Recurrent  or Metastatic Endometrial Cancer,appetite
D003924,1.47,NCT00883116-3,Control With Chemotherapy (Paclitaxel 175 mg/m^2 IV),NCT00883116,A Study of Ixabepilone as Second-line Therapy for Locally Advanced  Recurrent  or Metastatic Endometrial Cancer,type 2 diabetes mellitus
UNKNOWN-check-for-typo,0.4,NCT00883116-1,Ixabepilone 40 mg/m^2 Intravenously (IV),NCT00883116,A Study of Ixabepilone as Second-line Therapy for Locally Advanced  Recurrent  or Metastatic Endometrial Cancer,D00
UNKNOWN-check-for-typo,0.4,NCT00883116-1,Ixabepilone 40 mg/m^2 Intravenously (IV),NCT00883116,A Study of Ixabepilone as Second-line Therapy for Locally Advanced  Recurrent  or Metastatic Endometrial Cancer,D00
UNKNOWN-check-for-typo,0.81,NCT00883116-1,Ixabepilone 40 mg/m^2 Intravenously (IV),NCT00883116,A Study of Ixabepilone as Second-line Therapy for Locally Advanced  Recurrent  or Metastatic Endometrial Cancer,D00
D003681,2.02,NCT00883116-1,Ixabepilone 40 mg/m^2 Intravenously (IV),NCT00883116,A Study of Ixabepilone as Second-line Therapy for Locally Advanced  Recurrent  or Metastatic Endometrial Cancer,dehydration
D003681,2.92,NCT00883116-2,Control With Chemotherapy (Doxorubicin 60 mg/m^2 IV),NCT00883116,A Study of Ixabepilone as Second-line Therapy for Locally Advanced  Recurrent  or Metastatic Endometrial Cancer,dehydration
UNKNOWN-check-for-typo,0.4,NCT00883116-1,Ixabepilone 40 mg/m^2 Intravenously (IV),NCT00883116,A Study of Ixabepilone as Second-line Therapy for Locally Advanced  Recurrent  or Metastatic Endometrial Cancer,D00
UNKNOWN-check-for-typo,0.58,NCT00883116-2,Control With Chemotherapy (Doxorubicin 60 mg/m^2 IV),NCT00883116,A Study of Ixabepilone as Second-line Therapy for Locally Advanced  Recurrent  or Metastatic Endometrial Cancer,D00
UNKNOWN-check-for-typo,1.47,NCT00883116-3,Control With Chemotherapy (Paclitaxel 175 mg/m^2 IV),NCT00883116,A Study of Ixabepilone as Second-line Therapy for Locally Advanced  Recurrent  or Metastatic Endometrial Cancer,D00
UNKNOWN-check-for-typo,1.21,NCT00883116-1,Ixabepilone 40 mg/m^2 Intravenously (IV),NCT00883116,A Study of Ixabepilone as Second-line Therapy for Locally Advanced  Recurrent  or Metastatic Endometrial Cancer,D00
10033425,0.4,NCT00883116-1,Ixabepilone 40 mg/m^2 Intravenously (IV),NCT00883116,A Study of Ixabepilone as Second-line Therapy for Locally Advanced  Recurrent  or Metastatic Endometrial Cancer,pain in extremity
D018771,1.47,NCT00883116-3,Control With Chemotherapy (Paclitaxel 175 mg/m^2 IV),NCT00883116,A Study of Ixabepilone as Second-line Therapy for Locally Advanced  Recurrent  or Metastatic Endometrial Cancer,arthralgia
D018908,0.81,NCT00883116-1,Ixabepilone 40 mg/m^2 Intravenously (IV),NCT00883116,A Study of Ixabepilone as Second-line Therapy for Locally Advanced  Recurrent  or Metastatic Endometrial Cancer,muscular weakness
D016889,1.47,NCT00883116-3,Control With Chemotherapy (Paclitaxel 175 mg/m^2 IV),NCT00883116,A Study of Ixabepilone as Second-line Therapy for Locally Advanced  Recurrent  or Metastatic Endometrial Cancer,endometrial cancer
D002490,0.4,NCT00883116-1,Ixabepilone 40 mg/m^2 Intravenously (IV),NCT00883116,A Study of Ixabepilone as Second-line Therapy for Locally Advanced  Recurrent  or Metastatic Endometrial Cancer,central nervous system
D002490,1.47,NCT00883116-3,Control With Chemotherapy (Paclitaxel 175 mg/m^2 IV),NCT00883116,A Study of Ixabepilone as Second-line Therapy for Locally Advanced  Recurrent  or Metastatic Endometrial Cancer,central nervous system
D009369,1.61,NCT00883116-1,Ixabepilone 40 mg/m^2 Intravenously (IV),NCT00883116,A Study of Ixabepilone as Second-line Therapy for Locally Advanced  Recurrent  or Metastatic Endometrial Cancer,malignant neoplasm
D009369,2.92,NCT00883116-2,Control With Chemotherapy (Doxorubicin 60 mg/m^2 IV),NCT00883116,A Study of Ixabepilone as Second-line Therapy for Locally Advanced  Recurrent  or Metastatic Endometrial Cancer,malignant neoplasm
D016066,0.4,NCT00883116-1,Ixabepilone 40 mg/m^2 Intravenously (IV),NCT00883116,A Study of Ixabepilone as Second-line Therapy for Locally Advanced  Recurrent  or Metastatic Endometrial Cancer,malignant pleural effusion
D004244,0.81,NCT00883116-1,Ixabepilone 40 mg/m^2 Intravenously (IV),NCT00883116,A Study of Ixabepilone as Second-line Therapy for Locally Advanced  Recurrent  or Metastatic Endometrial Cancer,dizziness
10034580,1.47,NCT00883116-3,Control With Chemotherapy (Paclitaxel 175 mg/m^2 IV),NCT00883116,A Study of Ixabepilone as Second-line Therapy for Locally Advanced  Recurrent  or Metastatic Endometrial Cancer,peripheral motor neuropathy
D013575,0.81,NCT00883116-1,Ixabepilone 40 mg/m^2 Intravenously (IV),NCT00883116,A Study of Ixabepilone as Second-line Therapy for Locally Advanced  Recurrent  or Metastatic Endometrial Cancer,presyncope
D013575,0.4,NCT00883116-1,Ixabepilone 40 mg/m^2 Intravenously (IV),NCT00883116,A Study of Ixabepilone as Second-line Therapy for Locally Advanced  Recurrent  or Metastatic Endometrial Cancer,syncope
D020521,0.81,NCT00883116-1,Ixabepilone 40 mg/m^2 Intravenously (IV),NCT00883116,A Study of Ixabepilone as Second-line Therapy for Locally Advanced  Recurrent  or Metastatic Endometrial Cancer,cerebrovascular accident
D020521,0.58,NCT00883116-2,Control With Chemotherapy (Doxorubicin 60 mg/m^2 IV),NCT00883116,A Study of Ixabepilone as Second-line Therapy for Locally Advanced  Recurrent  or Metastatic Endometrial Cancer,cerebrovascular accident
D001007,0.4,NCT00883116-1,Ixabepilone 40 mg/m^2 Intravenously (IV),NCT00883116,A Study of Ixabepilone as Second-line Therapy for Locally Advanced  Recurrent  or Metastatic Endometrial Cancer,anxiety
D003221,0.4,NCT00883116-1,Ixabepilone 40 mg/m^2 Intravenously (IV),NCT00883116,A Study of Ixabepilone as Second-line Therapy for Locally Advanced  Recurrent  or Metastatic Endometrial Cancer,confusional state
D003221,0.58,NCT00883116-2,Control With Chemotherapy (Doxorubicin 60 mg/m^2 IV),NCT00883116,A Study of Ixabepilone as Second-line Therapy for Locally Advanced  Recurrent  or Metastatic Endometrial Cancer,confusional state
D003863,1.47,NCT00883116-3,Control With Chemotherapy (Paclitaxel 175 mg/m^2 IV),NCT00883116,A Study of Ixabepilone as Second-line Therapy for Locally Advanced  Recurrent  or Metastatic Endometrial Cancer,depression
D014551,0.58,NCT00883116-2,Control With Chemotherapy (Doxorubicin 60 mg/m^2 IV),NCT00883116,A Study of Ixabepilone as Second-line Therapy for Locally Advanced  Recurrent  or Metastatic Endometrial Cancer,urinary tract
10061574,0.4,NCT00883116-1,Ixabepilone 40 mg/m^2 Intravenously (IV),NCT00883116,A Study of Ixabepilone as Second-line Therapy for Locally Advanced  Recurrent  or Metastatic Endometrial Cancer,urinary tract obstruction
D006869,0.81,NCT00883116-1,Ixabepilone 40 mg/m^2 Intravenously (IV),NCT00883116,A Study of Ixabepilone as Second-line Therapy for Locally Advanced  Recurrent  or Metastatic Endometrial Cancer,hydronephrosis
D051437,0.4,NCT00883116-1,Ixabepilone 40 mg/m^2 Intravenously (IV),NCT00883116,A Study of Ixabepilone as Second-line Therapy for Locally Advanced  Recurrent  or Metastatic Endometrial Cancer,renal failure
D051437,0.58,NCT00883116-2,Control With Chemotherapy (Doxorubicin 60 mg/m^2 IV),NCT00883116,A Study of Ixabepilone as Second-line Therapy for Locally Advanced  Recurrent  or Metastatic Endometrial Cancer,renal failure
UNKNOWN-check-for-typo,0.58,NCT00883116-2,Control With Chemotherapy (Doxorubicin 60 mg/m^2 IV),NCT00883116,A Study of Ixabepilone as Second-line Therapy for Locally Advanced  Recurrent  or Metastatic Endometrial Cancer,D00
UNKNOWN-check-for-typo,0.58,NCT00883116-2,Control With Chemotherapy (Doxorubicin 60 mg/m^2 IV),NCT00883116,A Study of Ixabepilone as Second-line Therapy for Locally Advanced  Recurrent  or Metastatic Endometrial Cancer,D00
D058186,0.81,NCT00883116-1,Ixabepilone 40 mg/m^2 Intravenously (IV),NCT00883116,A Study of Ixabepilone as Second-line Therapy for Locally Advanced  Recurrent  or Metastatic Endometrial Cancer,acute renal failure
D058186,1.17,NCT00883116-2,Control With Chemotherapy (Doxorubicin 60 mg/m^2 IV),NCT00883116,A Study of Ixabepilone as Second-line Therapy for Locally Advanced  Recurrent  or Metastatic Endometrial Cancer,acute renal failure
D058186,1.47,NCT00883116-3,Control With Chemotherapy (Paclitaxel 175 mg/m^2 IV),NCT00883116,A Study of Ixabepilone as Second-line Therapy for Locally Advanced  Recurrent  or Metastatic Endometrial Cancer,acute renal failure
D000402,0.4,NCT00883116-1,Ixabepilone 40 mg/m^2 Intravenously (IV),NCT00883116,A Study of Ixabepilone as Second-line Therapy for Locally Advanced  Recurrent  or Metastatic Endometrial Cancer,airway obstruction
D001002,0.81,NCT00883116-1,Ixabepilone 40 mg/m^2 Intravenously (IV),NCT00883116,A Study of Ixabepilone as Second-line Therapy for Locally Advanced  Recurrent  or Metastatic Endometrial Cancer,anuria
D001743,1.17,NCT00883116-2,Control With Chemotherapy (Doxorubicin 60 mg/m^2 IV),NCT00883116,A Study of Ixabepilone as Second-line Therapy for Locally Advanced  Recurrent  or Metastatic Endometrial Cancer,urinary bladder
D051270,0.58,NCT00883116-2,Control With Chemotherapy (Doxorubicin 60 mg/m^2 IV),NCT00883116,A Study of Ixabepilone as Second-line Therapy for Locally Advanced  Recurrent  or Metastatic Endometrial Cancer,primary exertional headache
D000069339,0.81,NCT00883116-1,Ixabepilone 40 mg/m^2 Intravenously (IV),NCT00883116,A Study of Ixabepilone as Second-line Therapy for Locally Advanced  Recurrent  or Metastatic Endometrial Cancer,vaginal cervicectomy
D000069339,0.58,NCT00883116-2,Control With Chemotherapy (Doxorubicin 60 mg/m^2 IV),NCT00883116,A Study of Ixabepilone as Second-line Therapy for Locally Advanced  Recurrent  or Metastatic Endometrial Cancer,vaginal cervicectomy
D005836,1.47,NCT00883116-3,Control With Chemotherapy (Paclitaxel 175 mg/m^2 IV),NCT00883116,A Study of Ixabepilone as Second-line Therapy for Locally Advanced  Recurrent  or Metastatic Endometrial Cancer,genitalia female
UNKNOWN-check-for-typo,0.4,NCT00883116-1,Ixabepilone 40 mg/m^2 Intravenously (IV),NCT00883116,A Study of Ixabepilone as Second-line Therapy for Locally Advanced  Recurrent  or Metastatic Endometrial Cancer,D00
D011655,1.21,NCT00883116-1,Ixabepilone 40 mg/m^2 Intravenously (IV),NCT00883116,A Study of Ixabepilone as Second-line Therapy for Locally Advanced  Recurrent  or Metastatic Endometrial Cancer,pulmonary embolism
D011655,3.51,NCT00883116-2,Control With Chemotherapy (Doxorubicin 60 mg/m^2 IV),NCT00883116,A Study of Ixabepilone as Second-line Therapy for Locally Advanced  Recurrent  or Metastatic Endometrial Cancer,pulmonary embolism
D012131,0.4,NCT00883116-1,Ixabepilone 40 mg/m^2 Intravenously (IV),NCT00883116,A Study of Ixabepilone as Second-line Therapy for Locally Advanced  Recurrent  or Metastatic Endometrial Cancer,respiratory failure
UNKNOWN-check-for-typo,3.51,NCT00883116-2,Control With Chemotherapy (Doxorubicin 60 mg/m^2 IV),NCT00883116,A Study of Ixabepilone as Second-line Therapy for Locally Advanced  Recurrent  or Metastatic Endometrial Cancer,D00
D011015,0.4,NCT00883116-1,Ixabepilone 40 mg/m^2 Intravenously (IV),NCT00883116,A Study of Ixabepilone as Second-line Therapy for Locally Advanced  Recurrent  or Metastatic Endometrial Cancer,aspiration pneumonia
D000799,0.58,NCT00883116-2,Control With Chemotherapy (Doxorubicin 60 mg/m^2 IV),NCT00883116,A Study of Ixabepilone as Second-line Therapy for Locally Advanced  Recurrent  or Metastatic Endometrial Cancer,angioedema
UNKNOWN-check-for-typo,0.4,NCT00883116-1,Ixabepilone 40 mg/m^2 Intravenously (IV),NCT00883116,A Study of Ixabepilone as Second-line Therapy for Locally Advanced  Recurrent  or Metastatic Endometrial Cancer,D00
D000799,0.4,NCT00883116-1,Ixabepilone 40 mg/m^2 Intravenously (IV),NCT00883116,A Study of Ixabepilone as Second-line Therapy for Locally Advanced  Recurrent  or Metastatic Endometrial Cancer,angioedema
D010996,1.21,NCT00883116-1,Ixabepilone 40 mg/m^2 Intravenously (IV),NCT00883116,A Study of Ixabepilone as Second-line Therapy for Locally Advanced  Recurrent  or Metastatic Endometrial Cancer,pleural effusion
D010996,0.58,NCT00883116-2,Control With Chemotherapy (Doxorubicin 60 mg/m^2 IV),NCT00883116,A Study of Ixabepilone as Second-line Therapy for Locally Advanced  Recurrent  or Metastatic Endometrial Cancer,pleural effusion
D010996,1.47,NCT00883116-3,Control With Chemotherapy (Paclitaxel 175 mg/m^2 IV),NCT00883116,A Study of Ixabepilone as Second-line Therapy for Locally Advanced  Recurrent  or Metastatic Endometrial Cancer,pleural effusion
D007402,0.4,NCT00883116-1,Ixabepilone 40 mg/m^2 Intravenously (IV),NCT00883116,A Study of Ixabepilone as Second-line Therapy for Locally Advanced  Recurrent  or Metastatic Endometrial Cancer,intertrigo
D004617,0.4,NCT00883116-1,Ixabepilone 40 mg/m^2 Intravenously (IV),NCT00883116,A Study of Ixabepilone as Second-line Therapy for Locally Advanced  Recurrent  or Metastatic Endometrial Cancer,embolism
D007024,0.4,NCT00883116-1,Ixabepilone 40 mg/m^2 Intravenously (IV),NCT00883116,A Study of Ixabepilone as Second-line Therapy for Locally Advanced  Recurrent  or Metastatic Endometrial Cancer,orthostatic hypotension
D020246,0.4,NCT00883116-1,Ixabepilone 40 mg/m^2 Intravenously (IV),NCT00883116,A Study of Ixabepilone as Second-line Therapy for Locally Advanced  Recurrent  or Metastatic Endometrial Cancer,deep vein thrombosis
D020246,2.34,NCT00883116-2,Control With Chemotherapy (Doxorubicin 60 mg/m^2 IV),NCT00883116,A Study of Ixabepilone as Second-line Therapy for Locally Advanced  Recurrent  or Metastatic Endometrial Cancer,deep vein thrombosis
D006973,1.47,NCT00883116-3,Control With Chemotherapy (Paclitaxel 175 mg/m^2 IV),NCT00883116,A Study of Ixabepilone as Second-line Therapy for Locally Advanced  Recurrent  or Metastatic Endometrial Cancer,hypertension
D064420,43.55,NCT00913835-1,Olaratumab and Liposomal Doxorubicin,NCT00913835,A Study of Liposomal Doxorubicin With or Without Olaratumab (IMC-3G3) in Platinum-Refractory or Resistant Advanced Ovarian Cancer,adverse drug events
D064420,37.7,NCT00913835-2,Liposomal Doxorubicin,NCT00913835,A Study of Liposomal Doxorubicin With or Without Olaratumab (IMC-3G3) in Platinum-Refractory or Resistant Advanced Ovarian Cancer,adverse drug events
D064420,50.0,NCT00913835-3,Liposomal Doxorubicin: Optional Olaratumab Monotherapy,NCT00913835,A Study of Liposomal Doxorubicin With or Without Olaratumab (IMC-3G3) in Platinum-Refractory or Resistant Advanced Ovarian Cancer,adverse drug events
D000741,1.61,NCT00913835-1,Olaratumab and Liposomal Doxorubicin,NCT00913835,A Study of Liposomal Doxorubicin With or Without Olaratumab (IMC-3G3) in Platinum-Refractory or Resistant Advanced Ovarian Cancer,aplastic anaemia
D000741,1.64,NCT00913835-2,Liposomal Doxorubicin,NCT00913835,A Study of Liposomal Doxorubicin With or Without Olaratumab (IMC-3G3) in Platinum-Refractory or Resistant Advanced Ovarian Cancer,aplastic anaemia
D000741,3.57,NCT00913835-3,Liposomal Doxorubicin: Optional Olaratumab Monotherapy,NCT00913835,A Study of Liposomal Doxorubicin With or Without Olaratumab (IMC-3G3) in Platinum-Refractory or Resistant Advanced Ovarian Cancer,aplastic anaemia
D006333,1.64,NCT00913835-2,Liposomal Doxorubicin,NCT00913835,A Study of Liposomal Doxorubicin With or Without Olaratumab (IMC-3G3) in Platinum-Refractory or Resistant Advanced Ovarian Cancer,cardiac failure
D023921,1.61,NCT00913835-1,Olaratumab and Liposomal Doxorubicin,NCT00913835,A Study of Liposomal Doxorubicin With or Without Olaratumab (IMC-3G3) in Platinum-Refractory or Resistant Advanced Ovarian Cancer,coronary artery stenosis
D011707,1.64,NCT00913835-2,Liposomal Doxorubicin,NCT00913835,A Study of Liposomal Doxorubicin With or Without Olaratumab (IMC-3G3) in Platinum-Refractory or Resistant Advanced Ovarian Cancer,pyloric stenosis
D000007,1.61,NCT00913835-1,Olaratumab and Liposomal Doxorubicin,NCT00913835,A Study of Liposomal Doxorubicin With or Without Olaratumab (IMC-3G3) in Platinum-Refractory or Resistant Advanced Ovarian Cancer,abdominal injuries
10000060,3.23,NCT00913835-1,Olaratumab and Liposomal Doxorubicin,NCT00913835,A Study of Liposomal Doxorubicin With or Without Olaratumab (IMC-3G3) in Platinum-Refractory or Resistant Advanced Ovarian Cancer,abdominal distension
10000060,3.28,NCT00913835-2,Liposomal Doxorubicin,NCT00913835,A Study of Liposomal Doxorubicin With or Without Olaratumab (IMC-3G3) in Platinum-Refractory or Resistant Advanced Ovarian Cancer,abdominal distension
D015746,4.92,NCT00913835-2,Liposomal Doxorubicin,NCT00913835,A Study of Liposomal Doxorubicin With or Without Olaratumab (IMC-3G3) in Platinum-Refractory or Resistant Advanced Ovarian Cancer,abdominal pain
D015746,3.57,NCT00913835-3,Liposomal Doxorubicin: Optional Olaratumab Monotherapy,NCT00913835,A Study of Liposomal Doxorubicin With or Without Olaratumab (IMC-3G3) in Platinum-Refractory or Resistant Advanced Ovarian Cancer,abdominal pain
D001201,4.92,NCT00913835-2,Liposomal Doxorubicin,NCT00913835,A Study of Liposomal Doxorubicin With or Without Olaratumab (IMC-3G3) in Platinum-Refractory or Resistant Advanced Ovarian Cancer,ascites
D003248,1.61,NCT00913835-1,Olaratumab and Liposomal Doxorubicin,NCT00913835,A Study of Liposomal Doxorubicin With or Without Olaratumab (IMC-3G3) in Platinum-Refractory or Resistant Advanced Ovarian Cancer,constipation
D003248,3.28,NCT00913835-2,Liposomal Doxorubicin,NCT00913835,A Study of Liposomal Doxorubicin With or Without Olaratumab (IMC-3G3) in Platinum-Refractory or Resistant Advanced Ovarian Cancer,constipation
UNKNOWN-check-for-typo,1.61,NCT00913835-1,Olaratumab and Liposomal Doxorubicin,NCT00913835,A Study of Liposomal Doxorubicin With or Without Olaratumab (IMC-3G3) in Platinum-Refractory or Resistant Advanced Ovarian Cancer,D00
10050094,3.57,NCT00913835-3,Liposomal Doxorubicin: Optional Olaratumab Monotherapy,NCT00913835,A Study of Liposomal Doxorubicin With or Without Olaratumab (IMC-3G3) in Platinum-Refractory or Resistant Advanced Ovarian Cancer,duodenal stenosis
D000069196,3.57,NCT00913835-3,Liposomal Doxorubicin: Optional Olaratumab Monotherapy,NCT00913835,A Study of Liposomal Doxorubicin With or Without Olaratumab (IMC-3G3) in Platinum-Refractory or Resistant Advanced Ovarian Cancer,gastrointestinal microbiome
D045823,3.28,NCT00913835-2,Liposomal Doxorubicin,NCT00913835,A Study of Liposomal Doxorubicin With or Without Olaratumab (IMC-3G3) in Platinum-Refractory or Resistant Advanced Ovarian Cancer,ileus
D007415,4.84,NCT00913835-1,Olaratumab and Liposomal Doxorubicin,NCT00913835,A Study of Liposomal Doxorubicin With or Without Olaratumab (IMC-3G3) in Platinum-Refractory or Resistant Advanced Ovarian Cancer,intestinal obstruction
D007415,3.28,NCT00913835-2,Liposomal Doxorubicin,NCT00913835,A Study of Liposomal Doxorubicin With or Without Olaratumab (IMC-3G3) in Platinum-Refractory or Resistant Advanced Ovarian Cancer,intestinal obstruction
D007415,3.57,NCT00913835-3,Liposomal Doxorubicin: Optional Olaratumab Monotherapy,NCT00913835,A Study of Liposomal Doxorubicin With or Without Olaratumab (IMC-3G3) in Platinum-Refractory or Resistant Advanced Ovarian Cancer,intestinal obstruction
D009325,1.61,NCT00913835-1,Olaratumab and Liposomal Doxorubicin,NCT00913835,A Study of Liposomal Doxorubicin With or Without Olaratumab (IMC-3G3) in Platinum-Refractory or Resistant Advanced Ovarian Cancer,nausea
D009325,1.64,NCT00913835-2,Liposomal Doxorubicin,NCT00913835,A Study of Liposomal Doxorubicin With or Without Olaratumab (IMC-3G3) in Platinum-Refractory or Resistant Advanced Ovarian Cancer,nausea
D009325,7.14,NCT00913835-3,Liposomal Doxorubicin: Optional Olaratumab Monotherapy,NCT00913835,A Study of Liposomal Doxorubicin With or Without Olaratumab (IMC-3G3) in Platinum-Refractory or Resistant Advanced Ovarian Cancer,nausea
D011349,1.61,NCT00913835-1,Olaratumab and Liposomal Doxorubicin,NCT00913835,A Study of Liposomal Doxorubicin With or Without Olaratumab (IMC-3G3) in Platinum-Refractory or Resistant Advanced Ovarian Cancer,proctitis
D000071056,3.57,NCT00913835-3,Liposomal Doxorubicin: Optional Olaratumab Monotherapy,NCT00913835,A Study of Liposomal Doxorubicin With or Without Olaratumab (IMC-3G3) in Platinum-Refractory or Resistant Advanced Ovarian Cancer,anorectal malformations
10041101,1.61,NCT00913835-1,Olaratumab and Liposomal Doxorubicin,NCT00913835,A Study of Liposomal Doxorubicin With or Without Olaratumab (IMC-3G3) in Platinum-Refractory or Resistant Advanced Ovarian Cancer,small intestinal obstruction
10041101,6.56,NCT00913835-2,Liposomal Doxorubicin,NCT00913835,A Study of Liposomal Doxorubicin With or Without Olaratumab (IMC-3G3) in Platinum-Refractory or Resistant Advanced Ovarian Cancer,small intestinal obstruction
D014839,4.84,NCT00913835-1,Olaratumab and Liposomal Doxorubicin,NCT00913835,A Study of Liposomal Doxorubicin With or Without Olaratumab (IMC-3G3) in Platinum-Refractory or Resistant Advanced Ovarian Cancer,vomiting
D014839,4.92,NCT00913835-2,Liposomal Doxorubicin,NCT00913835,A Study of Liposomal Doxorubicin With or Without Olaratumab (IMC-3G3) in Platinum-Refractory or Resistant Advanced Ovarian Cancer,vomiting
D014839,7.14,NCT00913835-3,Liposomal Doxorubicin: Optional Olaratumab Monotherapy,NCT00913835,A Study of Liposomal Doxorubicin With or Without Olaratumab (IMC-3G3) in Platinum-Refractory or Resistant Advanced Ovarian Cancer,vomiting
D023341,1.61,NCT00913835-1,Olaratumab and Liposomal Doxorubicin,NCT00913835,A Study of Liposomal Doxorubicin With or Without Olaratumab (IMC-3G3) in Platinum-Refractory or Resistant Advanced Ovarian Cancer,chills
D018450,1.64,NCT00913835-2,Liposomal Doxorubicin,NCT00913835,A Study of Liposomal Doxorubicin With or Without Olaratumab (IMC-3G3) in Platinum-Refractory or Resistant Advanced Ovarian Cancer,disease progression
D005119,1.64,NCT00913835-2,Liposomal Doxorubicin,NCT00913835,A Study of Liposomal Doxorubicin With or Without Olaratumab (IMC-3G3) in Platinum-Refractory or Resistant Advanced Ovarian Cancer,extravasation of diagnostic and therapeutic materials
D000075662,1.64,NCT00913835-2,Liposomal Doxorubicin,NCT00913835,A Study of Liposomal Doxorubicin With or Without Olaratumab (IMC-3G3) in Platinum-Refractory or Resistant Advanced Ovarian Cancer,infusion site reaction
D007249,3.57,NCT00913835-3,Liposomal Doxorubicin: Optional Olaratumab Monotherapy,NCT00913835,A Study of Liposomal Doxorubicin With or Without Olaratumab (IMC-3G3) in Platinum-Refractory or Resistant Advanced Ovarian Cancer,inflammation
D005334,3.23,NCT00913835-1,Olaratumab and Liposomal Doxorubicin,NCT00913835,A Study of Liposomal Doxorubicin With or Without Olaratumab (IMC-3G3) in Platinum-Refractory or Resistant Advanced Ovarian Cancer,pyrexia
D005334,7.14,NCT00913835-3,Liposomal Doxorubicin: Optional Olaratumab Monotherapy,NCT00913835,A Study of Liposomal Doxorubicin With or Without Olaratumab (IMC-3G3) in Platinum-Refractory or Resistant Advanced Ovarian Cancer,pyrexia
D002779,3.57,NCT00913835-3,Liposomal Doxorubicin: Optional Olaratumab Monotherapy,NCT00913835,A Study of Liposomal Doxorubicin With or Without Olaratumab (IMC-3G3) in Platinum-Refractory or Resistant Advanced Ovarian Cancer,bile duct obstruction
D006967,3.57,NCT00913835-3,Liposomal Doxorubicin: Optional Olaratumab Monotherapy,NCT00913835,A Study of Liposomal Doxorubicin With or Without Olaratumab (IMC-3G3) in Platinum-Refractory or Resistant Advanced Ovarian Cancer,hypersensitivity
D000189,1.64,NCT00913835-2,Liposomal Doxorubicin,NCT00913835,A Study of Liposomal Doxorubicin With or Without Olaratumab (IMC-3G3) in Platinum-Refractory or Resistant Advanced Ovarian Cancer,actinobacillus infections
D002481,1.64,NCT00913835-2,Liposomal Doxorubicin,NCT00913835,A Study of Liposomal Doxorubicin With or Without Olaratumab (IMC-3G3) in Platinum-Refractory or Resistant Advanced Ovarian Cancer,cellulitis
10064687,3.23,NCT00913835-1,Olaratumab and Liposomal Doxorubicin,NCT00913835,A Study of Liposomal Doxorubicin With or Without Olaratumab (IMC-3G3) in Platinum-Refractory or Resistant Advanced Ovarian Cancer,device related infection
10064687,1.64,NCT00913835-2,Liposomal Doxorubicin,NCT00913835,A Study of Liposomal Doxorubicin With or Without Olaratumab (IMC-3G3) in Platinum-Refractory or Resistant Advanced Ovarian Cancer,device related infection
D000069544,1.64,NCT00913835-2,Liposomal Doxorubicin,NCT00913835,A Study of Liposomal Doxorubicin With or Without Olaratumab (IMC-3G3) in Platinum-Refractory or Resistant Advanced Ovarian Cancer,encephalitis infection
D005759,1.64,NCT00913835-2,Liposomal Doxorubicin,NCT00913835,A Study of Liposomal Doxorubicin With or Without Olaratumab (IMC-3G3) in Platinum-Refractory or Resistant Advanced Ovarian Cancer,gastroenteritis
D007239,3.23,NCT00913835-1,Olaratumab and Liposomal Doxorubicin,NCT00913835,A Study of Liposomal Doxorubicin With or Without Olaratumab (IMC-3G3) in Platinum-Refractory or Resistant Advanced Ovarian Cancer,infection
D007239,1.64,NCT00913835-2,Liposomal Doxorubicin,NCT00913835,A Study of Liposomal Doxorubicin With or Without Olaratumab (IMC-3G3) in Platinum-Refractory or Resistant Advanced Ovarian Cancer,infection
D010612,3.57,NCT00913835-3,Liposomal Doxorubicin: Optional Olaratumab Monotherapy,NCT00913835,A Study of Liposomal Doxorubicin With or Without Olaratumab (IMC-3G3) in Platinum-Refractory or Resistant Advanced Ovarian Cancer,pharyngitis
D011014,1.61,NCT00913835-1,Olaratumab and Liposomal Doxorubicin,NCT00913835,A Study of Liposomal Doxorubicin With or Without Olaratumab (IMC-3G3) in Platinum-Refractory or Resistant Advanced Ovarian Cancer,pneumonia
D014552,3.28,NCT00913835-2,Liposomal Doxorubicin,NCT00913835,A Study of Liposomal Doxorubicin With or Without Olaratumab (IMC-3G3) in Platinum-Refractory or Resistant Advanced Ovarian Cancer,urinary tract infection
D014552,1.64,NCT00913835-2,Liposomal Doxorubicin,NCT00913835,A Study of Liposomal Doxorubicin With or Without Olaratumab (IMC-3G3) in Platinum-Refractory or Resistant Advanced Ovarian Cancer,urinary tract infections
10040047,1.61,NCT00913835-1,Olaratumab and Liposomal Doxorubicin,NCT00913835,A Study of Liposomal Doxorubicin With or Without Olaratumab (IMC-3G3) in Platinum-Refractory or Resistant Advanced Ovarian Cancer,sepsis
D014777,1.61,NCT00913835-1,Olaratumab and Liposomal Doxorubicin,NCT00913835,A Study of Liposomal Doxorubicin With or Without Olaratumab (IMC-3G3) in Platinum-Refractory or Resistant Advanced Ovarian Cancer,viral infection
D005265,1.64,NCT00913835-2,Liposomal Doxorubicin,NCT00913835,A Study of Liposomal Doxorubicin With or Without Olaratumab (IMC-3G3) in Platinum-Refractory or Resistant Advanced Ovarian Cancer,femur neck fractures
D000074381,1.61,NCT00913835-1,Olaratumab and Liposomal Doxorubicin,NCT00913835,A Study of Liposomal Doxorubicin With or Without Olaratumab (IMC-3G3) in Platinum-Refractory or Resistant Advanced Ovarian Cancer,mass drug administration
D008508,1.61,NCT00913835-1,Olaratumab and Liposomal Doxorubicin,NCT00913835,A Study of Liposomal Doxorubicin With or Without Olaratumab (IMC-3G3) in Platinum-Refractory or Resistant Advanced Ovarian Cancer,medication error
D008508,3.57,NCT00913835-3,Liposomal Doxorubicin: Optional Olaratumab Monotherapy,NCT00913835,A Study of Liposomal Doxorubicin With or Without Olaratumab (IMC-3G3) in Platinum-Refractory or Resistant Advanced Ovarian Cancer,medication error
D001066,1.61,NCT00913835-1,Olaratumab and Liposomal Doxorubicin,NCT00913835,A Study of Liposomal Doxorubicin With or Without Olaratumab (IMC-3G3) in Platinum-Refractory or Resistant Advanced Ovarian Cancer,appetite
D001066,1.64,NCT00913835-2,Liposomal Doxorubicin,NCT00913835,A Study of Liposomal Doxorubicin With or Without Olaratumab (IMC-3G3) in Platinum-Refractory or Resistant Advanced Ovarian Cancer,appetite
D003681,4.84,NCT00913835-1,Olaratumab and Liposomal Doxorubicin,NCT00913835,A Study of Liposomal Doxorubicin With or Without Olaratumab (IMC-3G3) in Platinum-Refractory or Resistant Advanced Ovarian Cancer,dehydration
D003681,1.64,NCT00913835-2,Liposomal Doxorubicin,NCT00913835,A Study of Liposomal Doxorubicin With or Without Olaratumab (IMC-3G3) in Platinum-Refractory or Resistant Advanced Ovarian Cancer,dehydration
D021501,3.57,NCT00913835-3,Liposomal Doxorubicin: Optional Olaratumab Monotherapy,NCT00913835,A Study of Liposomal Doxorubicin With or Without Olaratumab (IMC-3G3) in Platinum-Refractory or Resistant Advanced Ovarian Cancer,flank pain
D004244,1.64,NCT00913835-2,Liposomal Doxorubicin,NCT00913835,A Study of Liposomal Doxorubicin With or Without Olaratumab (IMC-3G3) in Platinum-Refractory or Resistant Advanced Ovarian Cancer,dizziness
D000069280,1.61,NCT00913835-1,Olaratumab and Liposomal Doxorubicin,NCT00913835,A Study of Liposomal Doxorubicin With or Without Olaratumab (IMC-3G3) in Platinum-Refractory or Resistant Advanced Ovarian Cancer,intracranial electroencephalography
D013575,1.61,NCT00913835-1,Olaratumab and Liposomal Doxorubicin,NCT00913835,A Study of Liposomal Doxorubicin With or Without Olaratumab (IMC-3G3) in Platinum-Refractory or Resistant Advanced Ovarian Cancer,syncope
UNKNOWN-check-for-typo,1.61,NCT00913835-1,Olaratumab and Liposomal Doxorubicin,NCT00913835,A Study of Liposomal Doxorubicin With or Without Olaratumab (IMC-3G3) in Platinum-Refractory or Resistant Advanced Ovarian Cancer,D00
D006869,1.61,NCT00913835-1,Olaratumab and Liposomal Doxorubicin,NCT00913835,A Study of Liposomal Doxorubicin With or Without Olaratumab (IMC-3G3) in Platinum-Refractory or Resistant Advanced Ovarian Cancer,hydronephrosis
D006869,1.64,NCT00913835-2,Liposomal Doxorubicin,NCT00913835,A Study of Liposomal Doxorubicin With or Without Olaratumab (IMC-3G3) in Platinum-Refractory or Resistant Advanced Ovarian Cancer,hydronephrosis
D006869,3.57,NCT00913835-3,Liposomal Doxorubicin: Optional Olaratumab Monotherapy,NCT00913835,A Study of Liposomal Doxorubicin With or Without Olaratumab (IMC-3G3) in Platinum-Refractory or Resistant Advanced Ovarian Cancer,hydronephrosis
D051437,1.64,NCT00913835-2,Liposomal Doxorubicin,NCT00913835,A Study of Liposomal Doxorubicin With or Without Olaratumab (IMC-3G3) in Platinum-Refractory or Resistant Advanced Ovarian Cancer,renal failure
D058186,1.61,NCT00913835-1,Olaratumab and Liposomal Doxorubicin,NCT00913835,A Study of Liposomal Doxorubicin With or Without Olaratumab (IMC-3G3) in Platinum-Refractory or Resistant Advanced Ovarian Cancer,acute renal failure
UNKNOWN-check-for-typo,3.57,NCT00913835-3,Liposomal Doxorubicin: Optional Olaratumab Monotherapy,NCT00913835,A Study of Liposomal Doxorubicin With or Without Olaratumab (IMC-3G3) in Platinum-Refractory or Resistant Advanced Ovarian Cancer,D00
D017563,1.64,NCT00913835-2,Liposomal Doxorubicin,NCT00913835,A Study of Liposomal Doxorubicin With or Without Olaratumab (IMC-3G3) in Platinum-Refractory or Resistant Advanced Ovarian Cancer,interstitial lung disease
D010996,3.57,NCT00913835-3,Liposomal Doxorubicin: Optional Olaratumab Monotherapy,NCT00913835,A Study of Liposomal Doxorubicin With or Without Olaratumab (IMC-3G3) in Platinum-Refractory or Resistant Advanced Ovarian Cancer,pleural effusion
D011655,3.23,NCT00913835-1,Olaratumab and Liposomal Doxorubicin,NCT00913835,A Study of Liposomal Doxorubicin With or Without Olaratumab (IMC-3G3) in Platinum-Refractory or Resistant Advanced Ovarian Cancer,pulmonary embolism
D011655,6.56,NCT00913835-2,Liposomal Doxorubicin,NCT00913835,A Study of Liposomal Doxorubicin With or Without Olaratumab (IMC-3G3) in Platinum-Refractory or Resistant Advanced Ovarian Cancer,pulmonary embolism
D020246,1.64,NCT00913835-2,Liposomal Doxorubicin,NCT00913835,A Study of Liposomal Doxorubicin With or Without Olaratumab (IMC-3G3) in Platinum-Refractory or Resistant Advanced Ovarian Cancer,venous thrombosis
D064420,16.67,NCT00923936-2,All Other Advanced HIV-associated Kaposi's Sarcoma (KS),NCT00923936,Pilot Study of Liposomal Doxorubicin Combined With Bevacizumab Followed by Bevacizumab Monotherapy in Adults With Advanced Kaposi s Sarcoma,adverse drug events
D006471,16.67,NCT00923936-2,All Other Advanced HIV-associated Kaposi's Sarcoma (KS),NCT00923936,Pilot Study of Liposomal Doxorubicin Combined With Bevacizumab Followed by Bevacizumab Monotherapy in Adults With Advanced Kaposi s Sarcoma,gastrointestinal hemorrhage
D064420,31.0,NCT00931918-1,RCHOP,NCT00931918,Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients,adverse drug events
D064420,33.66,NCT00931918-2,Vc-RCHOP,NCT00931918,Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients,adverse drug events
D064147,8.0,NCT00931918-1,RCHOP,NCT00931918,Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients,febrile neutropenia
D064147,6.93,NCT00931918-2,Vc-RCHOP,NCT00931918,Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients,febrile neutropenia
D009503,5.0,NCT00931918-1,RCHOP,NCT00931918,Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients,neutropenia
D009503,0.99,NCT00931918-2,Vc-RCHOP,NCT00931918,Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients,neutropenia
D010198,2.0,NCT00931918-1,RCHOP,NCT00931918,Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients,pancytopenia
D010198,0.99,NCT00931918-2,Vc-RCHOP,NCT00931918,Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients,pancytopenia
D000080983,1.0,NCT00931918-1,RCHOP,NCT00931918,Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients,bone marrow failure
D000741,2.0,NCT00931918-1,RCHOP,NCT00931918,Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients,aplastic anaemia
D000741,0.99,NCT00931918-2,Vc-RCHOP,NCT00931918,Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients,aplastic anaemia
D007970,2.0,NCT00931918-1,RCHOP,NCT00931918,Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients,leukopenia
D007970,0.99,NCT00931918-2,Vc-RCHOP,NCT00931918,Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients,leukopenia
D013921,1.98,NCT00931918-2,Vc-RCHOP,NCT00931918,Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients,thrombocytopenia
D009203,2.0,NCT00931918-1,RCHOP,NCT00931918,Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients,myocardial infarction
D000789,1.0,NCT00931918-1,RCHOP,NCT00931918,Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients,unstable angina
D001919,0.99,NCT00931918-2,Vc-RCHOP,NCT00931918,Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients,bradycardia
D013610,1.0,NCT00931918-1,RCHOP,NCT00931918,Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients,tachycardia
D010490,1.0,NCT00931918-1,RCHOP,NCT00931918,Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients,pericardial effusion
D001281,1.0,NCT00931918-1,RCHOP,NCT00931918,Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients,atrial fibrillation
D000072599,0.99,NCT00931918-2,Vc-RCHOP,NCT00931918,Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients,cardiorespiratory fitness
D000309,1.0,NCT00931918-1,RCHOP,NCT00931918,Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients,adrenal insufficiency
UNKNOWN-check-for-typo,2.0,NCT00931918-1,RCHOP,NCT00931918,Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients,D00
UNKNOWN-check-for-typo,1.98,NCT00931918-2,Vc-RCHOP,NCT00931918,Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients,D00
D014839,2.0,NCT00931918-1,RCHOP,NCT00931918,Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients,vomiting
D014839,0.99,NCT00931918-2,Vc-RCHOP,NCT00931918,Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients,vomiting
D009325,1.0,NCT00931918-1,RCHOP,NCT00931918,Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients,nausea
D009325,0.99,NCT00931918-2,Vc-RCHOP,NCT00931918,Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients,nausea
D004380,0.99,NCT00931918-2,Vc-RCHOP,NCT00931918,Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients,duodenal obstruction
10041101,0.99,NCT00931918-2,Vc-RCHOP,NCT00931918,Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients,small intestinal obstruction
D000069196,1.98,NCT00931918-2,Vc-RCHOP,NCT00931918,Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients,gastrointestinal microbiome
D050686,0.99,NCT00931918-2,Vc-RCHOP,NCT00931918,Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients,globicephala melaena
D004240,0.99,NCT00931918-2,Vc-RCHOP,NCT00931918,Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients,diverticulum
UNKNOWN-check-for-typo,0.99,NCT00931918-2,Vc-RCHOP,NCT00931918,Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients,D00
D013276,1.0,NCT00931918-1,RCHOP,NCT00931918,Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients,gastric ulcer
D015746,1.0,NCT00931918-1,RCHOP,NCT00931918,Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients,abdominal pain
D003680,0.99,NCT00931918-2,Vc-RCHOP,NCT00931918,Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients,dysphagia
D007415,0.99,NCT00931918-2,Vc-RCHOP,NCT00931918,Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients,intestinal obstruction
D013280,0.99,NCT00931918-2,Vc-RCHOP,NCT00931918,Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients,stomatitis
D005334,4.0,NCT00931918-1,RCHOP,NCT00931918,Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients,pyrexia
D005334,3.96,NCT00931918-2,Vc-RCHOP,NCT00931918,Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients,pyrexia
D001247,1.0,NCT00931918-1,RCHOP,NCT00931918,Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients,asthenia
D001247,1.98,NCT00931918-2,Vc-RCHOP,NCT00931918,Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients,asthenia
D005221,0.99,NCT00931918-2,Vc-RCHOP,NCT00931918,Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients,fatigue
D002637,0.99,NCT00931918-2,Vc-RCHOP,NCT00931918,Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients,chest pain
10062501,0.99,NCT00931918-2,Vc-RCHOP,NCT00931918,Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients,non-cardiac chest pain
D002761,0.99,NCT00931918-2,Vc-RCHOP,NCT00931918,Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients,cholangitis
D006562,1.0,NCT00931918-1,RCHOP,NCT00931918,Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients,herpes zoster
D006562,2.97,NCT00931918-2,Vc-RCHOP,NCT00931918,Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients,herpes zoster
D011014,3.0,NCT00931918-1,RCHOP,NCT00931918,Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients,pneumonia
D011014,0.99,NCT00931918-2,Vc-RCHOP,NCT00931918,Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients,pneumonia
D018805,1.0,NCT00931918-1,RCHOP,NCT00931918,Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients,sepsis
D018805,0.99,NCT00931918-2,Vc-RCHOP,NCT00931918,Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients,sepsis
UNKNOWN-check-for-typo,1.0,NCT00931918-1,RCHOP,NCT00931918,Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients,D00
D012772,1.0,NCT00931918-1,RCHOP,NCT00931918,Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients,septic shock
D005759,1.0,NCT00931918-1,RCHOP,NCT00931918,Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients,gastroenteritis
D002481,0.99,NCT00931918-2,Vc-RCHOP,NCT00931918,Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients,cellulitis
D002177,0.99,NCT00931918-2,Vc-RCHOP,NCT00931918,Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients,candidiasis
D004761,0.99,NCT00931918-2,Vc-RCHOP,NCT00931918,Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients,clostridium enterocolitis
D004925,1.0,NCT00931918-1,RCHOP,NCT00931918,Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients,escherichia
D008100,1.0,NCT00931918-1,RCHOP,NCT00931918,Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients,liver abscess
D002481,0.99,NCT00931918-2,Vc-RCHOP,NCT00931918,Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients,cellulitis
D012141,1.0,NCT00931918-1,RCHOP,NCT00931918,Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients,upper respiratory tract infections
D050815,0.99,NCT00931918-2,Vc-RCHOP,NCT00931918,Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients,compression fracture
D008279,1.0,NCT00931918-1,RCHOP,NCT00931918,Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients,magnetic resonance imaging
D000637,0.99,NCT00931918-2,Vc-RCHOP,NCT00931918,Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients,transaminases
10035528,1.0,NCT00931918-1,RCHOP,NCT00931918,Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients,platelet count decreased
10011368,1.0,NCT00931918-1,RCHOP,NCT00931918,Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients,creatinine increased
10007612,0.99,NCT00931918-2,Vc-RCHOP,NCT00931918,Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients,cardiac troponin i increased
10029366,0.99,NCT00931918-2,Vc-RCHOP,NCT00931918,Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients,neutrophil count decreased
D007958,0.99,NCT00931918-2,Vc-RCHOP,NCT00931918,Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients,blood cell count white
D003681,2.0,NCT00931918-1,RCHOP,NCT00931918,Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients,dehydration
D003681,5.94,NCT00931918-2,Vc-RCHOP,NCT00931918,Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients,dehydration
D015275,0.99,NCT00931918-2,Vc-RCHOP,NCT00931918,Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients,tumour lysis syndrome
D005183,1.0,NCT00931918-1,RCHOP,NCT00931918,Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients,failure to thrive
UNKNOWN-check-for-typo,0.99,NCT00931918-2,Vc-RCHOP,NCT00931918,Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients,D00
UNKNOWN-check-for-typo,0.99,NCT00931918-2,Vc-RCHOP,NCT00931918,Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients,D00
D013575,3.96,NCT00931918-2,Vc-RCHOP,NCT00931918,Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients,syncope
D001928,0.99,NCT00931918-2,Vc-RCHOP,NCT00931918,Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients,metabolic encephalopathy
D013575,1.0,NCT00931918-1,RCHOP,NCT00931918,Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients,presyncope
D051474,0.99,NCT00931918-2,Vc-RCHOP,NCT00931918,Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients,neuralgia postherpetic
D002546,1.0,NCT00931918-1,RCHOP,NCT00931918,Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients,ischemic attack transient
D001007,1.0,NCT00931918-1,RCHOP,NCT00931918,Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients,anxiety
D000073216,1.0,NCT00931918-1,RCHOP,NCT00931918,Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients,mental status tests
D058186,0.99,NCT00931918-2,Vc-RCHOP,NCT00931918,Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients,acute kidney injury
UNKNOWN-check-for-typo,1.0,NCT00931918-1,RCHOP,NCT00931918,Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients,D00
UNKNOWN-check-for-typo,0.99,NCT00931918-2,Vc-RCHOP,NCT00931918,Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients,D00
D011655,1.98,NCT00931918-2,Vc-RCHOP,NCT00931918,Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients,pulmonary embolism
D010996,1.0,NCT00931918-1,RCHOP,NCT00931918,Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients,pleural effusion
D012131,1.0,NCT00931918-1,RCHOP,NCT00931918,Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients,respiratory failure
10003504,0.99,NCT00931918-2,Vc-RCHOP,NCT00931918,Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients,aspiration
D012867,0.99,NCT00931918-2,Vc-RCHOP,NCT00931918,Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients,skin
D011205,0.99,NCT00931918-2,Vc-RCHOP,NCT00931918,Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients,unifluid
D007024,1.0,NCT00931918-1,RCHOP,NCT00931918,Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients,orthostatic hypotension
D007024,2.97,NCT00931918-2,Vc-RCHOP,NCT00931918,Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients,orthostatic hypotension
D007022,1.98,NCT00931918-2,Vc-RCHOP,NCT00931918,Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients,hypotension
D020246,0.99,NCT00931918-2,Vc-RCHOP,NCT00931918,Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients,deep vein thrombosis
D064420,29.17,NCT00949325-1,Temsirolimus Plus Liposomal Doxorubicin,NCT00949325,Safety and Efficacy Study of Torisel and Liposomal Doxorubicin for Patients With Recurrent Sarcoma,adverse drug events
D000855,4.17,NCT00949325-1,Temsirolimus Plus Liposomal Doxorubicin,NCT00949325,Safety and Efficacy Study of Torisel and Liposomal Doxorubicin for Patients With Recurrent Sarcoma,anorexia
D012131,8.33,NCT00949325-1,Temsirolimus Plus Liposomal Doxorubicin,NCT00949325,Safety and Efficacy Study of Torisel and Liposomal Doxorubicin for Patients With Recurrent Sarcoma,respiratory failure
D005334,4.17,NCT00949325-1,Temsirolimus Plus Liposomal Doxorubicin,NCT00949325,Safety and Efficacy Study of Torisel and Liposomal Doxorubicin for Patients With Recurrent Sarcoma,fever
D004417,8.33,NCT00949325-1,Temsirolimus Plus Liposomal Doxorubicin,NCT00949325,Safety and Efficacy Study of Torisel and Liposomal Doxorubicin for Patients With Recurrent Sarcoma,dyspnea
D011030,4.17,NCT00949325-1,Temsirolimus Plus Liposomal Doxorubicin,NCT00949325,Safety and Efficacy Study of Torisel and Liposomal Doxorubicin for Patients With Recurrent Sarcoma,pneumothorax
D018864,8.33,NCT00949325-1,Temsirolimus Plus Liposomal Doxorubicin,NCT00949325,Safety and Efficacy Study of Torisel and Liposomal Doxorubicin for Patients With Recurrent Sarcoma,pluralism
D064420,100.0,NCT00960063-3,Ifosfamide+Etoposide+Robatumumab,NCT00960063,A Study of Robatumumab (SCH 717454  MK-7454) in Combination With Different Treatment Regimens in Pediatric Participants With Advanced Solid Tumors (P05883  MK-7454-006),adverse drug events
D064147,100.0,NCT00960063-3,Ifosfamide+Etoposide+Robatumumab,NCT00960063,A Study of Robatumumab (SCH 717454  MK-7454) in Combination With Different Treatment Regimens in Pediatric Participants With Advanced Solid Tumors (P05883  MK-7454-006),febrile neutropenia
D023341,33.33,NCT00960063-3,Ifosfamide+Etoposide+Robatumumab,NCT00960063,A Study of Robatumumab (SCH 717454  MK-7454) in Combination With Different Treatment Regimens in Pediatric Participants With Advanced Solid Tumors (P05883  MK-7454-006),chills
D005334,33.33,NCT00960063-3,Ifosfamide+Etoposide+Robatumumab,NCT00960063,A Study of Robatumumab (SCH 717454  MK-7454) in Combination With Different Treatment Regimens in Pediatric Participants With Advanced Solid Tumors (P05883  MK-7454-006),pyrexia
D011014,33.33,NCT00960063-3,Ifosfamide+Etoposide+Robatumumab,NCT00960063,A Study of Robatumumab (SCH 717454  MK-7454) in Combination With Different Treatment Regimens in Pediatric Participants With Advanced Solid Tumors (P05883  MK-7454-006),lobar pneumonia
D065227,33.33,NCT00960063-3,Ifosfamide+Etoposide+Robatumumab,NCT00960063,A Study of Robatumumab (SCH 717454  MK-7454) in Combination With Different Treatment Regimens in Pediatric Participants With Advanced Solid Tumors (P05883  MK-7454-006),transfusion reaction
D007958,33.33,NCT00960063-3,Ifosfamide+Etoposide+Robatumumab,NCT00960063,A Study of Robatumumab (SCH 717454  MK-7454) in Combination With Different Treatment Regimens in Pediatric Participants With Advanced Solid Tumors (P05883  MK-7454-006),blood cell count white
D007022,33.33,NCT00960063-3,Ifosfamide+Etoposide+Robatumumab,NCT00960063,A Study of Robatumumab (SCH 717454  MK-7454) in Combination With Different Treatment Regimens in Pediatric Participants With Advanced Solid Tumors (P05883  MK-7454-006),hypotension
D064420,33.33,NCT00968253-1,Phase I: RAD001 5 mg + Combination Chemo,NCT00968253,RAD001 Study in Treatment of Relapsed or Refractory Acute Lymphocytic Leukemia,adverse drug events
D064420,77.78,NCT00968253-2,Phase I: RAD001 10 mg + Combination Chemo,NCT00968253,RAD001 Study in Treatment of Relapsed or Refractory Acute Lymphocytic Leukemia,adverse drug events
D064420,91.67,NCT00968253-3,Phase II: MTD RAD001 + Combination Chemo,NCT00968253,RAD001 Study in Treatment of Relapsed or Refractory Acute Lymphocytic Leukemia,adverse drug events
D064147,55.56,NCT00968253-2,Phase I: RAD001 10 mg + Combination Chemo,NCT00968253,RAD001 Study in Treatment of Relapsed or Refractory Acute Lymphocytic Leukemia,febrile neutropenia
D064147,8.33,NCT00968253-3,Phase II: MTD RAD001 + Combination Chemo,NCT00968253,RAD001 Study in Treatment of Relapsed or Refractory Acute Lymphocytic Leukemia,febrile neutropenia
D005334,33.33,NCT00968253-1,Phase I: RAD001 5 mg + Combination Chemo,NCT00968253,RAD001 Study in Treatment of Relapsed or Refractory Acute Lymphocytic Leukemia,fever
D005334,41.67,NCT00968253-3,Phase II: MTD RAD001 + Combination Chemo,NCT00968253,RAD001 Study in Treatment of Relapsed or Refractory Acute Lymphocytic Leukemia,fever
D010198,8.33,NCT00968253-3,Phase II: MTD RAD001 + Combination Chemo,NCT00968253,RAD001 Study in Treatment of Relapsed or Refractory Acute Lymphocytic Leukemia,pancytopenia
D007010,8.33,NCT00968253-3,Phase II: MTD RAD001 + Combination Chemo,NCT00968253,RAD001 Study in Treatment of Relapsed or Refractory Acute Lymphocytic Leukemia,hyponatremia
D002637,8.33,NCT00968253-3,Phase II: MTD RAD001 + Combination Chemo,NCT00968253,RAD001 Study in Treatment of Relapsed or Refractory Acute Lymphocytic Leukemia,chest pain
D013616,11.11,NCT00968253-2,Phase I: RAD001 10 mg + Combination Chemo,NCT00968253,RAD001 Study in Treatment of Relapsed or Refractory Acute Lymphocytic Leukemia,sinus tachycardia
D013280,44.44,NCT00968253-2,Phase I: RAD001 10 mg + Combination Chemo,NCT00968253,RAD001 Study in Treatment of Relapsed or Refractory Acute Lymphocytic Leukemia,stomatitis
D013280,8.33,NCT00968253-3,Phase II: MTD RAD001 + Combination Chemo,NCT00968253,RAD001 Study in Treatment of Relapsed or Refractory Acute Lymphocytic Leukemia,stomatitis
D009102,8.33,NCT00968253-3,Phase II: MTD RAD001 + Combination Chemo,NCT00968253,RAD001 Study in Treatment of Relapsed or Refractory Acute Lymphocytic Leukemia,multiple organ failure
D003643,22.22,NCT00968253-2,Phase I: RAD001 10 mg + Combination Chemo,NCT00968253,RAD001 Study in Treatment of Relapsed or Refractory Acute Lymphocytic Leukemia,death
D003643,25.0,NCT00968253-3,Phase II: MTD RAD001 + Combination Chemo,NCT00968253,RAD001 Study in Treatment of Relapsed or Refractory Acute Lymphocytic Leukemia,death
D012772,16.67,NCT00968253-3,Phase II: MTD RAD001 + Combination Chemo,NCT00968253,RAD001 Study in Treatment of Relapsed or Refractory Acute Lymphocytic Leukemia,septic shock
D003354,11.11,NCT00968253-2,Phase I: RAD001 10 mg + Combination Chemo,NCT00968253,RAD001 Study in Treatment of Relapsed or Refractory Acute Lymphocytic Leukemia,corynebacterium infections
D003354,8.33,NCT00968253-3,Phase II: MTD RAD001 + Combination Chemo,NCT00968253,RAD001 Study in Treatment of Relapsed or Refractory Acute Lymphocytic Leukemia,corynebacterium infections
D011014,33.33,NCT00968253-2,Phase I: RAD001 10 mg + Combination Chemo,NCT00968253,RAD001 Study in Treatment of Relapsed or Refractory Acute Lymphocytic Leukemia,pneumonia
D011014,16.67,NCT00968253-3,Phase II: MTD RAD001 + Combination Chemo,NCT00968253,RAD001 Study in Treatment of Relapsed or Refractory Acute Lymphocytic Leukemia,pneumonia
10001551,8.33,NCT00968253-3,Phase II: MTD RAD001 + Combination Chemo,NCT00968253,RAD001 Study in Treatment of Relapsed or Refractory Acute Lymphocytic Leukemia,alanine aminotransferase increased
10003481,8.33,NCT00968253-3,Phase II: MTD RAD001 + Combination Chemo,NCT00968253,RAD001 Study in Treatment of Relapsed or Refractory Acute Lymphocytic Leukemia,aspartate aminotransferase increased
D003556,11.11,NCT00968253-2,Phase I: RAD001 10 mg + Combination Chemo,NCT00968253,RAD001 Study in Treatment of Relapsed or Refractory Acute Lymphocytic Leukemia,cystitis
D010996,8.33,NCT00968253-3,Phase II: MTD RAD001 + Combination Chemo,NCT00968253,RAD001 Study in Treatment of Relapsed or Refractory Acute Lymphocytic Leukemia,pleural effusions
D064420,55.56,NCT00972478-1,Ph I: R-CHOP+Vorinostat (400mg D1-9),NCT00972478,Vorinostat  Rituximab  and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II  Stage III  or Stage IV Diffuse Large B-Cell Lymphoma,adverse drug events
D064420,69.84,NCT00972478-2,Ph II: R-CHOP+Vorinostat,NCT00972478,Vorinostat  Rituximab  and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II  Stage III  or Stage IV Diffuse Large B-Cell Lymphoma,adverse drug events
D000740,33.33,NCT00972478-1,Ph I: R-CHOP+Vorinostat (400mg D1-9),NCT00972478,Vorinostat  Rituximab  and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II  Stage III  or Stage IV Diffuse Large B-Cell Lymphoma,anemia
D000740,20.63,NCT00972478-2,Ph II: R-CHOP+Vorinostat,NCT00972478,Vorinostat  Rituximab  and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II  Stage III  or Stage IV Diffuse Large B-Cell Lymphoma,anemia
D004211,11.11,NCT00972478-1,Ph I: R-CHOP+Vorinostat (400mg D1-9),NCT00972478,Vorinostat  Rituximab  and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II  Stage III  or Stage IV Diffuse Large B-Cell Lymphoma,disseminated intravascular coagulation
D064147,33.33,NCT00972478-1,Ph I: R-CHOP+Vorinostat (400mg D1-9),NCT00972478,Vorinostat  Rituximab  and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II  Stage III  or Stage IV Diffuse Large B-Cell Lymphoma,febrile neutropenia
D064147,34.92,NCT00972478-2,Ph II: R-CHOP+Vorinostat,NCT00972478,Vorinostat  Rituximab  and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II  Stage III  or Stage IV Diffuse Large B-Cell Lymphoma,febrile neutropenia
D001281,1.59,NCT00972478-2,Ph II: R-CHOP+Vorinostat,NCT00972478,Vorinostat  Rituximab  and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II  Stage III  or Stage IV Diffuse Large B-Cell Lymphoma,atrial fibrillation
D006323,1.59,NCT00972478-2,Ph II: R-CHOP+Vorinostat,NCT00972478,Vorinostat  Rituximab  and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II  Stage III  or Stage IV Diffuse Large B-Cell Lymphoma,cardiac arrest
10069501,1.59,NCT00972478-2,Ph II: R-CHOP+Vorinostat,NCT00972478,Vorinostat  Rituximab  and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II  Stage III  or Stage IV Diffuse Large B-Cell Lymphoma,left ventricular systolic dysfunction
D009203,4.76,NCT00972478-2,Ph II: R-CHOP+Vorinostat,NCT00972478,Vorinostat  Rituximab  and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II  Stage III  or Stage IV Diffuse Large B-Cell Lymphoma,myocardial infarction
D015746,11.11,NCT00972478-1,Ph I: R-CHOP+Vorinostat (400mg D1-9),NCT00972478,Vorinostat  Rituximab  and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II  Stage III  or Stage IV Diffuse Large B-Cell Lymphoma,abdominal pain
D015746,1.59,NCT00972478-2,Ph II: R-CHOP+Vorinostat,NCT00972478,Vorinostat  Rituximab  and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II  Stage III  or Stage IV Diffuse Large B-Cell Lymphoma,abdominal pain
D003092,11.11,NCT00972478-1,Ph I: R-CHOP+Vorinostat (400mg D1-9),NCT00972478,Vorinostat  Rituximab  and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II  Stage III  or Stage IV Diffuse Large B-Cell Lymphoma,colitis
D003248,1.59,NCT00972478-2,Ph II: R-CHOP+Vorinostat,NCT00972478,Vorinostat  Rituximab  and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II  Stage III  or Stage IV Diffuse Large B-Cell Lymphoma,constipation
D003967,1.59,NCT00972478-2,Ph II: R-CHOP+Vorinostat,NCT00972478,Vorinostat  Rituximab  and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II  Stage III  or Stage IV Diffuse Large B-Cell Lymphoma,diarrhea
D003680,1.59,NCT00972478-2,Ph II: R-CHOP+Vorinostat,NCT00972478,Vorinostat  Rituximab  and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II  Stage III  or Stage IV Diffuse Large B-Cell Lymphoma,dysphagia
D005764,1.59,NCT00972478-2,Ph II: R-CHOP+Vorinostat,NCT00972478,Vorinostat  Rituximab  and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II  Stage III  or Stage IV Diffuse Large B-Cell Lymphoma,gastroesophageal reflux disease
10017947,3.17,NCT00972478-2,Ph II: R-CHOP+Vorinostat,NCT00972478,Vorinostat  Rituximab  and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II  Stage III  or Stage IV Diffuse Large B-Cell Lymphoma,gastrointestinal disorders - other specify
10023174,1.59,NCT00972478-2,Ph II: R-CHOP+Vorinostat,NCT00972478,Vorinostat  Rituximab  and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II  Stage III  or Stage IV Diffuse Large B-Cell Lymphoma,jejunal perforation
10028130,11.11,NCT00972478-1,Ph I: R-CHOP+Vorinostat (400mg D1-9),NCT00972478,Vorinostat  Rituximab  and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II  Stage III  or Stage IV Diffuse Large B-Cell Lymphoma,mucositis oral
D009325,3.17,NCT00972478-2,Ph II: R-CHOP+Vorinostat,NCT00972478,Vorinostat  Rituximab  and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II  Stage III  or Stage IV Diffuse Large B-Cell Lymphoma,nausea
10041101,1.59,NCT00972478-2,Ph II: R-CHOP+Vorinostat,NCT00972478,Vorinostat  Rituximab  and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II  Stage III  or Stage IV Diffuse Large B-Cell Lymphoma,small intestinal obstruction
D014839,3.17,NCT00972478-2,Ph II: R-CHOP+Vorinostat,NCT00972478,Vorinostat  Rituximab  and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II  Stage III  or Stage IV Diffuse Large B-Cell Lymphoma,vomiting
10011914,1.59,NCT00972478-2,Ph II: R-CHOP+Vorinostat,NCT00972478,Vorinostat  Rituximab  and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II  Stage III  or Stage IV Diffuse Large B-Cell Lymphoma,death nos
D005221,11.11,NCT00972478-1,Ph I: R-CHOP+Vorinostat (400mg D1-9),NCT00972478,Vorinostat  Rituximab  and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II  Stage III  or Stage IV Diffuse Large B-Cell Lymphoma,fatigue
D005221,4.76,NCT00972478-2,Ph II: R-CHOP+Vorinostat,NCT00972478,Vorinostat  Rituximab  and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II  Stage III  or Stage IV Diffuse Large B-Cell Lymphoma,fatigue
D005334,3.17,NCT00972478-2,Ph II: R-CHOP+Vorinostat,NCT00972478,Vorinostat  Rituximab  and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II  Stage III  or Stage IV Diffuse Large B-Cell Lymphoma,fever
10025482,1.59,NCT00972478-2,Ph II: R-CHOP+Vorinostat,NCT00972478,Vorinostat  Rituximab  and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II  Stage III  or Stage IV Diffuse Large B-Cell Lymphoma,malaise
D009102,11.11,NCT00972478-1,Ph I: R-CHOP+Vorinostat (400mg D1-9),NCT00972478,Vorinostat  Rituximab  and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II  Stage III  or Stage IV Diffuse Large B-Cell Lymphoma,multiple organ failure
10062501,1.59,NCT00972478-2,Ph II: R-CHOP+Vorinostat,NCT00972478,Vorinostat  Rituximab  and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II  Stage III  or Stage IV Diffuse Large B-Cell Lymphoma,non-cardiac chest pain
D010146,3.17,NCT00972478-2,Ph II: R-CHOP+Vorinostat,NCT00972478,Vorinostat  Rituximab  and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II  Stage III  or Stage IV Diffuse Large B-Cell Lymphoma,pain
10055078,1.59,NCT00972478-2,Ph II: R-CHOP+Vorinostat,NCT00972478,Vorinostat  Rituximab  and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II  Stage III  or Stage IV Diffuse Large B-Cell Lymphoma,bronchial infection
10021881,3.17,NCT00972478-2,Ph II: R-CHOP+Vorinostat,NCT00972478,Vorinostat  Rituximab  and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II  Stage III  or Stage IV Diffuse Large B-Cell Lymphoma,infections and infestations - other specify
10061229,11.11,NCT00972478-1,Ph I: R-CHOP+Vorinostat (400mg D1-9),NCT00972478,Vorinostat  Rituximab  and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II  Stage III  or Stage IV Diffuse Large B-Cell Lymphoma,lung infection
10061229,6.35,NCT00972478-2,Ph II: R-CHOP+Vorinostat,NCT00972478,Vorinostat  Rituximab  and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II  Stage III  or Stage IV Diffuse Large B-Cell Lymphoma,lung infection
D010304,1.59,NCT00972478-2,Ph II: R-CHOP+Vorinostat,NCT00972478,Vorinostat  Rituximab  and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II  Stage III  or Stage IV Diffuse Large B-Cell Lymphoma,paronychia
D018805,33.33,NCT00972478-1,Ph I: R-CHOP+Vorinostat (400mg D1-9),NCT00972478,Vorinostat  Rituximab  and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II  Stage III  or Stage IV Diffuse Large B-Cell Lymphoma,sepsis
D018805,12.7,NCT00972478-2,Ph II: R-CHOP+Vorinostat,NCT00972478,Vorinostat  Rituximab  and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II  Stage III  or Stage IV Diffuse Large B-Cell Lymphoma,sepsis
D012852,1.59,NCT00972478-2,Ph II: R-CHOP+Vorinostat,NCT00972478,Vorinostat  Rituximab  and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II  Stage III  or Stage IV Diffuse Large B-Cell Lymphoma,sinusitis
10064505,1.59,NCT00972478-2,Ph II: R-CHOP+Vorinostat,NCT00972478,Vorinostat  Rituximab  and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II  Stage III  or Stage IV Diffuse Large B-Cell Lymphoma,stoma site infection
D014552,3.17,NCT00972478-2,Ph II: R-CHOP+Vorinostat,NCT00972478,Vorinostat  Rituximab  and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II  Stage III  or Stage IV Diffuse Large B-Cell Lymphoma,urinary tract infection
10003481,1.59,NCT00972478-2,Ph II: R-CHOP+Vorinostat,NCT00972478,Vorinostat  Rituximab  and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II  Stage III  or Stage IV Diffuse Large B-Cell Lymphoma,aspartate aminotransferase increased
10011368,11.11,NCT00972478-1,Ph I: R-CHOP+Vorinostat (400mg D1-9),NCT00972478,Vorinostat  Rituximab  and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II  Stage III  or Stage IV Diffuse Large B-Cell Lymphoma,creatinine increased
10011368,3.17,NCT00972478-2,Ph II: R-CHOP+Vorinostat,NCT00972478,Vorinostat  Rituximab  and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II  Stage III  or Stage IV Diffuse Large B-Cell Lymphoma,creatinine increased
10014383,11.11,NCT00972478-1,Ph I: R-CHOP+Vorinostat (400mg D1-9),NCT00972478,Vorinostat  Rituximab  and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II  Stage III  or Stage IV Diffuse Large B-Cell Lymphoma,electrocardiogram qt corrected interval prolonged
10014383,1.59,NCT00972478-2,Ph II: R-CHOP+Vorinostat,NCT00972478,Vorinostat  Rituximab  and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II  Stage III  or Stage IV Diffuse Large B-Cell Lymphoma,electrocardiogram qt corrected interval prolonged
10025256,11.11,NCT00972478-1,Ph I: R-CHOP+Vorinostat (400mg D1-9),NCT00972478,Vorinostat  Rituximab  and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II  Stage III  or Stage IV Diffuse Large B-Cell Lymphoma,lymphocyte count decreased
10025256,6.35,NCT00972478-2,Ph II: R-CHOP+Vorinostat,NCT00972478,Vorinostat  Rituximab  and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II  Stage III  or Stage IV Diffuse Large B-Cell Lymphoma,lymphocyte count decreased
10029366,33.33,NCT00972478-1,Ph I: R-CHOP+Vorinostat (400mg D1-9),NCT00972478,Vorinostat  Rituximab  and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II  Stage III  or Stage IV Diffuse Large B-Cell Lymphoma,neutrophil count decreased
10029366,25.4,NCT00972478-2,Ph II: R-CHOP+Vorinostat,NCT00972478,Vorinostat  Rituximab  and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II  Stage III  or Stage IV Diffuse Large B-Cell Lymphoma,neutrophil count decreased
10035528,44.44,NCT00972478-1,Ph I: R-CHOP+Vorinostat (400mg D1-9),NCT00972478,Vorinostat  Rituximab  and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II  Stage III  or Stage IV Diffuse Large B-Cell Lymphoma,platelet count decreased
10035528,25.4,NCT00972478-2,Ph II: R-CHOP+Vorinostat,NCT00972478,Vorinostat  Rituximab  and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II  Stage III  or Stage IV Diffuse Large B-Cell Lymphoma,platelet count decreased
D015431,1.59,NCT00972478-2,Ph II: R-CHOP+Vorinostat,NCT00972478,Vorinostat  Rituximab  and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II  Stage III  or Stage IV Diffuse Large B-Cell Lymphoma,weight loss
10049182,22.22,NCT00972478-1,Ph I: R-CHOP+Vorinostat (400mg D1-9),NCT00972478,Vorinostat  Rituximab  and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II  Stage III  or Stage IV Diffuse Large B-Cell Lymphoma,white blood cell decreased
10049182,15.87,NCT00972478-2,Ph II: R-CHOP+Vorinostat,NCT00972478,Vorinostat  Rituximab  and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II  Stage III  or Stage IV Diffuse Large B-Cell Lymphoma,white blood cell decreased
D000855,3.17,NCT00972478-2,Ph II: R-CHOP+Vorinostat,NCT00972478,Vorinostat  Rituximab  and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II  Stage III  or Stage IV Diffuse Large B-Cell Lymphoma,anorexia
D003681,11.11,NCT00972478-1,Ph I: R-CHOP+Vorinostat (400mg D1-9),NCT00972478,Vorinostat  Rituximab  and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II  Stage III  or Stage IV Diffuse Large B-Cell Lymphoma,dehydration
D003681,6.35,NCT00972478-2,Ph II: R-CHOP+Vorinostat,NCT00972478,Vorinostat  Rituximab  and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II  Stage III  or Stage IV Diffuse Large B-Cell Lymphoma,dehydration
D006934,1.59,NCT00972478-2,Ph II: R-CHOP+Vorinostat,NCT00972478,Vorinostat  Rituximab  and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II  Stage III  or Stage IV Diffuse Large B-Cell Lymphoma,hypercalcemia
D034141,1.59,NCT00972478-2,Ph II: R-CHOP+Vorinostat,NCT00972478,Vorinostat  Rituximab  and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II  Stage III  or Stage IV Diffuse Large B-Cell Lymphoma,hypoalbuminemia
D006996,11.11,NCT00972478-1,Ph I: R-CHOP+Vorinostat (400mg D1-9),NCT00972478,Vorinostat  Rituximab  and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II  Stage III  or Stage IV Diffuse Large B-Cell Lymphoma,hypocalcemia
D007008,22.22,NCT00972478-1,Ph I: R-CHOP+Vorinostat (400mg D1-9),NCT00972478,Vorinostat  Rituximab  and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II  Stage III  or Stage IV Diffuse Large B-Cell Lymphoma,hypokalemia
D007008,4.76,NCT00972478-2,Ph II: R-CHOP+Vorinostat,NCT00972478,Vorinostat  Rituximab  and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II  Stage III  or Stage IV Diffuse Large B-Cell Lymphoma,hypokalemia
D017674,11.11,NCT00972478-1,Ph I: R-CHOP+Vorinostat (400mg D1-9),NCT00972478,Vorinostat  Rituximab  and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II  Stage III  or Stage IV Diffuse Large B-Cell Lymphoma,hypophosphatemia
10062572,1.59,NCT00972478-2,Ph II: R-CHOP+Vorinostat,NCT00972478,Vorinostat  Rituximab  and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II  Stage III  or Stage IV Diffuse Large B-Cell Lymphoma,generalized muscle weakness
10029104,1.59,NCT00972478-2,Ph II: R-CHOP+Vorinostat,NCT00972478,Vorinostat  Rituximab  and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II  Stage III  or Stage IV Diffuse Large B-Cell Lymphoma,neoplasms benign malignant and unspecified (incl cysts and polyps) - other specify
10009845,1.59,NCT00972478-2,Ph II: R-CHOP+Vorinostat,NCT00972478,Vorinostat  Rituximab  and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II  Stage III  or Stage IV Diffuse Large B-Cell Lymphoma,cognitive disturbance
D004244,1.59,NCT00972478-2,Ph II: R-CHOP+Vorinostat,NCT00972478,Vorinostat  Rituximab  and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II  Stage III  or Stage IV Diffuse Large B-Cell Lymphoma,dizziness
D014826,1.59,NCT00972478-2,Ph II: R-CHOP+Vorinostat,NCT00972478,Vorinostat  Rituximab  and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II  Stage III  or Stage IV Diffuse Large B-Cell Lymphoma,recurrent laryngeal nerve palsy
D054038,1.59,NCT00972478-2,Ph II: R-CHOP+Vorinostat,NCT00972478,Vorinostat  Rituximab  and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II  Stage III  or Stage IV Diffuse Large B-Cell Lymphoma,reversible posterior leukoencephalopathy syndrome
D013575,4.76,NCT00972478-2,Ph II: R-CHOP+Vorinostat,NCT00972478,Vorinostat  Rituximab  and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II  Stage III  or Stage IV Diffuse Large B-Cell Lymphoma,syncope
D003221,3.17,NCT00972478-2,Ph II: R-CHOP+Vorinostat,NCT00972478,Vorinostat  Rituximab  and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II  Stage III  or Stage IV Diffuse Large B-Cell Lymphoma,confusion
D058186,1.59,NCT00972478-2,Ph II: R-CHOP+Vorinostat,NCT00972478,Vorinostat  Rituximab  and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II  Stage III  or Stage IV Diffuse Large B-Cell Lymphoma,acute kidney injury
10063057,1.59,NCT00972478-2,Ph II: R-CHOP+Vorinostat,NCT00972478,Vorinostat  Rituximab  and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II  Stage III  or Stage IV Diffuse Large B-Cell Lymphoma,cystitis noninfective
10046539,1.59,NCT00972478-2,Ph II: R-CHOP+Vorinostat,NCT00972478,Vorinostat  Rituximab  and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II  Stage III  or Stage IV Diffuse Large B-Cell Lymphoma,urinary frequency
10062225,1.59,NCT00972478-2,Ph II: R-CHOP+Vorinostat,NCT00972478,Vorinostat  Rituximab  and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II  Stage III  or Stage IV Diffuse Large B-Cell Lymphoma,urinary tract pain
D003371,1.59,NCT00972478-2,Ph II: R-CHOP+Vorinostat,NCT00972478,Vorinostat  Rituximab  and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II  Stage III  or Stage IV Diffuse Large B-Cell Lymphoma,cough
D004417,1.59,NCT00972478-2,Ph II: R-CHOP+Vorinostat,NCT00972478,Vorinostat  Rituximab  and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II  Stage III  or Stage IV Diffuse Large B-Cell Lymphoma,dyspnea
D006606,1.59,NCT00972478-2,Ph II: R-CHOP+Vorinostat,NCT00972478,Vorinostat  Rituximab  and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II  Stage III  or Stage IV Diffuse Large B-Cell Lymphoma,hiccups
D011014,3.17,NCT00972478-2,Ph II: R-CHOP+Vorinostat,NCT00972478,Vorinostat  Rituximab  and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II  Stage III  or Stage IV Diffuse Large B-Cell Lymphoma,pneumonitis
D011654,1.59,NCT00972478-2,Ph II: R-CHOP+Vorinostat,NCT00972478,Vorinostat  Rituximab  and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II  Stage III  or Stage IV Diffuse Large B-Cell Lymphoma,pulmonary edema
D012131,1.59,NCT00972478-2,Ph II: R-CHOP+Vorinostat,NCT00972478,Vorinostat  Rituximab  and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II  Stage III  or Stage IV Diffuse Large B-Cell Lymphoma,respiratory failure
D007022,4.76,NCT00972478-2,Ph II: R-CHOP+Vorinostat,NCT00972478,Vorinostat  Rituximab  and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II  Stage III  or Stage IV Diffuse Large B-Cell Lymphoma,hypotension
10043565,3.17,NCT00972478-2,Ph II: R-CHOP+Vorinostat,NCT00972478,Vorinostat  Rituximab  and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II  Stage III  or Stage IV Diffuse Large B-Cell Lymphoma,thromboembolic event
10054692,11.11,NCT00972478-1,Ph I: R-CHOP+Vorinostat (400mg D1-9),NCT00972478,Vorinostat  Rituximab  and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II  Stage III  or Stage IV Diffuse Large B-Cell Lymphoma,visceral arterial ischemia
D009026,15.38,NCT00985907-1,Phase 1 Doxil® + Melphalan + Velcade (DMV),NCT00985907,Doxil® + Melphalan + Velcade (DMV) in Relapsed/Refractory Multiple Myeloma,mortality
D064420,46.15,NCT00985907-1,Phase 1 Doxil® + Melphalan + Velcade (DMV),NCT00985907,Doxil® + Melphalan + Velcade (DMV) in Relapsed/Refractory Multiple Myeloma,adverse drug events
D002764,7.69,NCT00985907-1,Phase 1 Doxil® + Melphalan + Velcade (DMV),NCT00985907,Doxil® + Melphalan + Velcade (DMV) in Relapsed/Refractory Multiple Myeloma,cholecystitis
D007239,7.69,NCT00985907-1,Phase 1 Doxil® + Melphalan + Velcade (DMV),NCT00985907,Doxil® + Melphalan + Velcade (DMV) in Relapsed/Refractory Multiple Myeloma,infection
10061229,7.69,NCT00985907-1,Phase 1 Doxil® + Melphalan + Velcade (DMV),NCT00985907,Doxil® + Melphalan + Velcade (DMV) in Relapsed/Refractory Multiple Myeloma,lung infection
D006932,7.69,NCT00985907-1,Phase 1 Doxil® + Melphalan + Velcade (DMV),NCT00985907,Doxil® + Melphalan + Velcade (DMV) in Relapsed/Refractory Multiple Myeloma,hyperbilirubinemia
D050723,7.69,NCT00985907-1,Phase 1 Doxil® + Melphalan + Velcade (DMV),NCT00985907,Doxil® + Melphalan + Velcade (DMV) in Relapsed/Refractory Multiple Myeloma,bone fracture
D009422,7.69,NCT00985907-1,Phase 1 Doxil® + Melphalan + Velcade (DMV),NCT00985907,Doxil® + Melphalan + Velcade (DMV) in Relapsed/Refractory Multiple Myeloma,neurological disorders
D007022,7.69,NCT00985907-1,Phase 1 Doxil® + Melphalan + Velcade (DMV),NCT00985907,Doxil® + Melphalan + Velcade (DMV) in Relapsed/Refractory Multiple Myeloma,hypotension
D013927,7.69,NCT00985907-1,Phase 1 Doxil® + Melphalan + Velcade (DMV),NCT00985907,Doxil® + Melphalan + Velcade (DMV) in Relapsed/Refractory Multiple Myeloma,thrombosis
D064420,76.0,NCT00992992-1,Iodine I-131 Tositumomab + CHOP,NCT00992992,Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody Plus CHOP For Untreated Mantle Cell Lymphoma,adverse drug events
D064147,28.0,NCT00992992-1,Iodine I-131 Tositumomab + CHOP,NCT00992992,Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody Plus CHOP For Untreated Mantle Cell Lymphoma,febrile neutropenia
D009503,8.0,NCT00992992-1,Iodine I-131 Tositumomab + CHOP,NCT00992992,Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody Plus CHOP For Untreated Mantle Cell Lymphoma,neutropenia
D008199,4.0,NCT00992992-1,Iodine I-131 Tositumomab + CHOP,NCT00992992,Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody Plus CHOP For Untreated Mantle Cell Lymphoma,lymphadenitis
D013921,4.0,NCT00992992-1,Iodine I-131 Tositumomab + CHOP,NCT00992992,Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody Plus CHOP For Untreated Mantle Cell Lymphoma,thrombocytopenia
D006333,4.0,NCT00992992-1,Iodine I-131 Tositumomab + CHOP,NCT00992992,Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody Plus CHOP For Untreated Mantle Cell Lymphoma,cardiac failure
D000072599,4.0,NCT00992992-1,Iodine I-131 Tositumomab + CHOP,NCT00992992,Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody Plus CHOP For Untreated Mantle Cell Lymphoma,cardiorespiratory fitness
D010493,4.0,NCT00992992-1,Iodine I-131 Tositumomab + CHOP,NCT00992992,Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody Plus CHOP For Untreated Mantle Cell Lymphoma,pericarditis
D007443,4.0,NCT00992992-1,Iodine I-131 Tositumomab + CHOP,NCT00992992,Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody Plus CHOP For Untreated Mantle Cell Lymphoma,intussusception
D041742,4.0,NCT00992992-1,Iodine I-131 Tositumomab + CHOP,NCT00992992,Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody Plus CHOP For Untreated Mantle Cell Lymphoma,upper gastrointestinal tract
D005334,4.0,NCT00992992-1,Iodine I-131 Tositumomab + CHOP,NCT00992992,Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody Plus CHOP For Untreated Mantle Cell Lymphoma,pyrexia
D006562,4.0,NCT00992992-1,Iodine I-131 Tositumomab + CHOP,NCT00992992,Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody Plus CHOP For Untreated Mantle Cell Lymphoma,herpes zoster
D011014,4.0,NCT00992992-1,Iodine I-131 Tositumomab + CHOP,NCT00992992,Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody Plus CHOP For Untreated Mantle Cell Lymphoma,pneumonia
D018805,4.0,NCT00992992-1,Iodine I-131 Tositumomab + CHOP,NCT00992992,Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody Plus CHOP For Untreated Mantle Cell Lymphoma,sepsis
D002280,8.0,NCT00992992-1,Iodine I-131 Tositumomab + CHOP,NCT00992992,Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody Plus CHOP For Untreated Mantle Cell Lymphoma,basal cell carcinoma
D009190,8.0,NCT00992992-1,Iodine I-131 Tositumomab + CHOP,NCT00992992,Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody Plus CHOP For Untreated Mantle Cell Lymphoma,myelodysplastic syndrome
D000230,4.0,NCT00992992-1,Iodine I-131 Tositumomab + CHOP,NCT00992992,Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody Plus CHOP For Untreated Mantle Cell Lymphoma,adenocarcinoma
D008545,4.0,NCT00992992-1,Iodine I-131 Tositumomab + CHOP,NCT00992992,Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody Plus CHOP For Untreated Mantle Cell Lymphoma,malignant melanoma
D008545,4.0,NCT00992992-1,Iodine I-131 Tositumomab + CHOP,NCT00992992,Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody Plus CHOP For Untreated Mantle Cell Lymphoma,malignant melanoma
D000230,4.0,NCT00992992-1,Iodine I-131 Tositumomab + CHOP,NCT00992992,Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody Plus CHOP For Untreated Mantle Cell Lymphoma,adenocarcinoma
D009101,4.0,NCT00992992-1,Iodine I-131 Tositumomab + CHOP,NCT00992992,Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody Plus CHOP For Untreated Mantle Cell Lymphoma,plasma cell myeloma
D002294,4.0,NCT00992992-1,Iodine I-131 Tositumomab + CHOP,NCT00992992,Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody Plus CHOP For Untreated Mantle Cell Lymphoma,squamous cell carcinoma
D002294,4.0,NCT00992992-1,Iodine I-131 Tositumomab + CHOP,NCT00992992,Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody Plus CHOP For Untreated Mantle Cell Lymphoma,carcinoma squamous cell
D020521,4.0,NCT00992992-1,Iodine I-131 Tositumomab + CHOP,NCT00992992,Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody Plus CHOP For Untreated Mantle Cell Lymphoma,cerebrovascular accident
D010543,4.0,NCT00992992-1,Iodine I-131 Tositumomab + CHOP,NCT00992992,Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody Plus CHOP For Untreated Mantle Cell Lymphoma,peroneal nerve
D013575,4.0,NCT00992992-1,Iodine I-131 Tositumomab + CHOP,NCT00992992,Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody Plus CHOP For Untreated Mantle Cell Lymphoma,syncope
D051437,4.0,NCT00992992-1,Iodine I-131 Tositumomab + CHOP,NCT00992992,Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody Plus CHOP For Untreated Mantle Cell Lymphoma,renal failure
D058186,4.0,NCT00992992-1,Iodine I-131 Tositumomab + CHOP,NCT00992992,Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody Plus CHOP For Untreated Mantle Cell Lymphoma,acute renal failure
D010998,4.0,NCT00992992-1,Iodine I-131 Tositumomab + CHOP,NCT00992992,Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody Plus CHOP For Untreated Mantle Cell Lymphoma,pleurisy
D011655,4.0,NCT00992992-1,Iodine I-131 Tositumomab + CHOP,NCT00992992,Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody Plus CHOP For Untreated Mantle Cell Lymphoma,pulmonary embolism
D007024,4.0,NCT00992992-1,Iodine I-131 Tositumomab + CHOP,NCT00992992,Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody Plus CHOP For Untreated Mantle Cell Lymphoma,orthostatic hypotension
D064420,5.56,NCT01000285-1,EPOCH Chemotherapy & Bortezomib,NCT01000285,EPOCH Chemotherapy and Bortezomib for Associated T-Cell Leukemia Lymphoma,adverse drug events
D018805,5.56,NCT01000285-1,EPOCH Chemotherapy & Bortezomib,NCT01000285,EPOCH Chemotherapy and Bortezomib for Associated T-Cell Leukemia Lymphoma,sepsis
D064420,16.67,NCT01008150-1,Arm 1: Paclitaxel + Trastuzumab Then A C,NCT01008150,Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer,adverse drug events
D064420,16.67,NCT01008150-2,Arm 2: Paclitaxel + Neratinib Then A C,NCT01008150,Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer,adverse drug events
D064420,23.81,NCT01008150-3,Arm 3: Paclitaxel + Trastuzumab + Neratinib Then A C,NCT01008150,Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer,adverse drug events
D064420,16.67,NCT01008150-4,Arm 3 NR: Paclitaxel + Trastuzumab + Neratinib Then AC,NCT01008150,Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer,adverse drug events
D064147,2.38,NCT01008150-1,Arm 1: Paclitaxel + Trastuzumab Then A C,NCT01008150,Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer,febrile neutropenia
D064147,2.38,NCT01008150-3,Arm 3: Paclitaxel + Trastuzumab + Neratinib Then A C,NCT01008150,Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer,febrile neutropenia
D018487,2.38,NCT01008150-1,Arm 1: Paclitaxel + Trastuzumab Then A C,NCT01008150,Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer,ventricular dysfunction left
D018487,2.38,NCT01008150-2,Arm 2: Paclitaxel + Neratinib Then A C,NCT01008150,Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer,ventricular dysfunction left
D006331,2.38,NCT01008150-1,Arm 1: Paclitaxel + Trastuzumab Then A C,NCT01008150,Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer,cardiac diseases
UNKNOWN-check-for-typo,4.76,NCT01008150-3,Arm 3: Paclitaxel + Trastuzumab + Neratinib Then A C,NCT01008150,Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer,D00
D015746,2.38,NCT01008150-1,Arm 1: Paclitaxel + Trastuzumab Then A C,NCT01008150,Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer,abdominal pain
D003092,2.38,NCT01008150-3,Arm 3: Paclitaxel + Trastuzumab + Neratinib Then A C,NCT01008150,Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer,colitis
D009325,2.38,NCT01008150-3,Arm 3: Paclitaxel + Trastuzumab + Neratinib Then A C,NCT01008150,Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer,nausea
D014839,2.38,NCT01008150-3,Arm 3: Paclitaxel + Trastuzumab + Neratinib Then A C,NCT01008150,Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer,vomiting
D005334,4.76,NCT01008150-2,Arm 2: Paclitaxel + Neratinib Then A C,NCT01008150,Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer,pyrexia
D005334,2.38,NCT01008150-3,Arm 3: Paclitaxel + Trastuzumab + Neratinib Then A C,NCT01008150,Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer,pyrexia
D007251,2.38,NCT01008150-1,Arm 1: Paclitaxel + Trastuzumab Then A C,NCT01008150,Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer,influenza
D000799,2.38,NCT01008150-1,Arm 1: Paclitaxel + Trastuzumab Then A C,NCT01008150,Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer,angioedema
D005221,2.38,NCT01008150-3,Arm 3: Paclitaxel + Trastuzumab + Neratinib Then A C,NCT01008150,Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer,fatigue
D002764,8.33,NCT01008150-4,Arm 3 NR: Paclitaxel + Trastuzumab + Neratinib Then AC,NCT01008150,Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer,cholecystitis
D007239,2.38,NCT01008150-1,Arm 1: Paclitaxel + Trastuzumab Then A C,NCT01008150,Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer,infection
D007239,2.38,NCT01008150-3,Arm 3: Paclitaxel + Trastuzumab + Neratinib Then A C,NCT01008150,Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer,infection
D004886,2.38,NCT01008150-2,Arm 2: Paclitaxel + Neratinib Then A C,NCT01008150,Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer,erysipelas
D004886,2.38,NCT01008150-3,Arm 3: Paclitaxel + Trastuzumab + Neratinib Then A C,NCT01008150,Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer,erysipelas
D002481,2.38,NCT01008150-1,Arm 1: Paclitaxel + Trastuzumab Then A C,NCT01008150,Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer,cellulitis
D002481,8.33,NCT01008150-4,Arm 3 NR: Paclitaxel + Trastuzumab + Neratinib Then AC,NCT01008150,Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer,cellulitis
D000069544,2.38,NCT01008150-1,Arm 1: Paclitaxel + Trastuzumab Then A C,NCT01008150,Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer,encephalitis infection
D010019,2.38,NCT01008150-1,Arm 1: Paclitaxel + Trastuzumab Then A C,NCT01008150,Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer,osteomyelitis
UNKNOWN-check-for-typo,2.38,NCT01008150-2,Arm 2: Paclitaxel + Neratinib Then A C,NCT01008150,Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer,D00
D003556,2.38,NCT01008150-2,Arm 2: Paclitaxel + Neratinib Then A C,NCT01008150,Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer,cystitis
10064687,2.38,NCT01008150-2,Arm 2: Paclitaxel + Neratinib Then A C,NCT01008150,Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer,device related infection
D011832,2.38,NCT01008150-1,Arm 1: Paclitaxel + Trastuzumab Then A C,NCT01008150,Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer,injury radiation
UNKNOWN-check-for-typo,2.38,NCT01008150-3,Arm 3: Paclitaxel + Trastuzumab + Neratinib Then A C,NCT01008150,Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer,D00
UNKNOWN-check-for-typo,2.38,NCT01008150-3,Arm 3: Paclitaxel + Trastuzumab + Neratinib Then A C,NCT01008150,Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer,D00
D013575,2.38,NCT01008150-2,Arm 2: Paclitaxel + Neratinib Then A C,NCT01008150,Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer,syncope
D001007,2.38,NCT01008150-2,Arm 2: Paclitaxel + Neratinib Then A C,NCT01008150,Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer,anxiety
D003863,2.38,NCT01008150-2,Arm 2: Paclitaxel + Neratinib Then A C,NCT01008150,Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer,depression
UNKNOWN-check-for-typo,2.38,NCT01008150-1,Arm 1: Paclitaxel + Trastuzumab Then A C,NCT01008150,Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer,D00
UNKNOWN-check-for-typo,2.38,NCT01008150-2,Arm 2: Paclitaxel + Neratinib Then A C,NCT01008150,Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer,D00
D004617,4.76,NCT01008150-1,Arm 1: Paclitaxel + Trastuzumab Then A C,NCT01008150,Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer,embolism
D004617,2.38,NCT01008150-2,Arm 2: Paclitaxel + Neratinib Then A C,NCT01008150,Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer,embolism
D004617,2.38,NCT01008150-3,Arm 3: Paclitaxel + Trastuzumab + Neratinib Then A C,NCT01008150,Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer,embolism
UNKNOWN-check-for-typo,2.38,NCT01008150-3,Arm 3: Paclitaxel + Trastuzumab + Neratinib Then A C,NCT01008150,Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer,D00
D009026,95.0,NCT01010984-1,Single Arm,NCT01010984,LC Bead Embolization Agent With Doxorubicin in the Treatment Liver Metastasis From Melanoma,mortality
D064420,95.0,NCT01010984-1,Single Arm,NCT01010984,LC Bead Embolization Agent With Doxorubicin in the Treatment Liver Metastasis From Melanoma,adverse drug events
D001919,5.0,NCT01010984-1,Single Arm,NCT01010984,LC Bead Embolization Agent With Doxorubicin in the Treatment Liver Metastasis From Melanoma,bradycardia
D009325,15.0,NCT01010984-1,Single Arm,NCT01010984,LC Bead Embolization Agent With Doxorubicin in the Treatment Liver Metastasis From Melanoma,nausea
D002764,5.0,NCT01010984-1,Single Arm,NCT01010984,LC Bead Embolization Agent With Doxorubicin in the Treatment Liver Metastasis From Melanoma,cholecystitis
D004751,5.0,NCT01010984-1,Single Arm,NCT01010984,LC Bead Embolization Agent With Doxorubicin in the Treatment Liver Metastasis From Melanoma,enteritis
D010195,5.0,NCT01010984-1,Single Arm,NCT01010984,LC Bead Embolization Agent With Doxorubicin in the Treatment Liver Metastasis From Melanoma,pancreatitis
D001064,5.0,NCT01010984-1,Single Arm,NCT01010984,LC Bead Embolization Agent With Doxorubicin in the Treatment Liver Metastasis From Melanoma,perforated appendicitis
D006991,5.0,NCT01010984-1,Single Arm,NCT01010984,LC Bead Embolization Agent With Doxorubicin in the Treatment Liver Metastasis From Melanoma,hypnosedation
D005334,5.0,NCT01010984-1,Single Arm,NCT01010984,LC Bead Embolization Agent With Doxorubicin in the Treatment Liver Metastasis From Melanoma,fever
D001651,15.0,NCT01010984-1,Single Arm,NCT01010984,LC Bead Embolization Agent With Doxorubicin in the Treatment Liver Metastasis From Melanoma,biliary stasis extrahepatic
D029626,5.0,NCT01010984-1,Single Arm,NCT01010984,LC Bead Embolization Agent With Doxorubicin in the Treatment Liver Metastasis From Melanoma,hepatica
D013203,5.0,NCT01010984-1,Single Arm,NCT01010984,LC Bead Embolization Agent With Doxorubicin in the Treatment Liver Metastasis From Melanoma,staphylococcal infections
D020521,5.0,NCT01010984-1,Single Arm,NCT01010984,LC Bead Embolization Agent With Doxorubicin in the Treatment Liver Metastasis From Melanoma,stroke
D014552,5.0,NCT01010984-1,Single Arm,NCT01010984,LC Bead Embolization Agent With Doxorubicin in the Treatment Liver Metastasis From Melanoma,urinary tract infection
D010996,5.0,NCT01010984-1,Single Arm,NCT01010984,LC Bead Embolization Agent With Doxorubicin in the Treatment Liver Metastasis From Melanoma,pleural effusion
D006973,5.0,NCT01010984-1,Single Arm,NCT01010984,LC Bead Embolization Agent With Doxorubicin in the Treatment Liver Metastasis From Melanoma,hypertension
D064420,60.0,NCT01035658-1,Dose Level 1,NCT01035658,Study of Pazopanib and Doxil in Patients With Advanced Relapsed Platinum-Sensitive or Platinum-Resistant Ovarian  Fallopian Tube or Primary Peritoneal Adenocarcinoma,adverse drug events
D064420,12.5,NCT01035658-2,Dose Level -1,NCT01035658,Study of Pazopanib and Doxil in Patients With Advanced Relapsed Platinum-Sensitive or Platinum-Resistant Ovarian  Fallopian Tube or Primary Peritoneal Adenocarcinoma,adverse drug events
D064420,66.67,NCT01035658-3,Dose Level 1 Sequential,NCT01035658,Study of Pazopanib and Doxil in Patients With Advanced Relapsed Platinum-Sensitive or Platinum-Resistant Ovarian  Fallopian Tube or Primary Peritoneal Adenocarcinoma,adverse drug events
D064420,16.67,NCT01035658-4,Dose Level 2 Sequential,NCT01035658,Study of Pazopanib and Doxil in Patients With Advanced Relapsed Platinum-Sensitive or Platinum-Resistant Ovarian  Fallopian Tube or Primary Peritoneal Adenocarcinoma,adverse drug events
D001281,33.33,NCT01035658-3,Dose Level 1 Sequential,NCT01035658,Study of Pazopanib and Doxil in Patients With Advanced Relapsed Platinum-Sensitive or Platinum-Resistant Ovarian  Fallopian Tube or Primary Peritoneal Adenocarcinoma,atrial fibrillation
D015746,20.0,NCT01035658-1,Dose Level 1,NCT01035658,Study of Pazopanib and Doxil in Patients With Advanced Relapsed Platinum-Sensitive or Platinum-Resistant Ovarian  Fallopian Tube or Primary Peritoneal Adenocarcinoma,abdominal pain
D010195,20.0,NCT01035658-1,Dose Level 1,NCT01035658,Study of Pazopanib and Doxil in Patients With Advanced Relapsed Platinum-Sensitive or Platinum-Resistant Ovarian  Fallopian Tube or Primary Peritoneal Adenocarcinoma,pancreatitis
10018065,12.5,NCT01035658-2,Dose Level -1,NCT01035658,Study of Pazopanib and Doxil in Patients With Advanced Relapsed Platinum-Sensitive or Platinum-Resistant Ovarian  Fallopian Tube or Primary Peritoneal Adenocarcinoma,general disorders and administration site conditions - other specify
D014552,12.5,NCT01035658-2,Dose Level -1,NCT01035658,Study of Pazopanib and Doxil in Patients With Advanced Relapsed Platinum-Sensitive or Platinum-Resistant Ovarian  Fallopian Tube or Primary Peritoneal Adenocarcinoma,urinary tract infection
D007239,66.67,NCT01035658-3,Dose Level 1 Sequential,NCT01035658,Study of Pazopanib and Doxil in Patients With Advanced Relapsed Platinum-Sensitive or Platinum-Resistant Ovarian  Fallopian Tube or Primary Peritoneal Adenocarcinoma,infections and infestations
10017076,16.67,NCT01035658-4,Dose Level 2 Sequential,NCT01035658,Study of Pazopanib and Doxil in Patients With Advanced Relapsed Platinum-Sensitive or Platinum-Resistant Ovarian  Fallopian Tube or Primary Peritoneal Adenocarcinoma,fracture
10001551,20.0,NCT01035658-1,Dose Level 1,NCT01035658,Study of Pazopanib and Doxil in Patients With Advanced Relapsed Platinum-Sensitive or Platinum-Resistant Ovarian  Fallopian Tube or Primary Peritoneal Adenocarcinoma,alanine aminotransferase increased
10003481,20.0,NCT01035658-1,Dose Level 1,NCT01035658,Study of Pazopanib and Doxil in Patients With Advanced Relapsed Platinum-Sensitive or Platinum-Resistant Ovarian  Fallopian Tube or Primary Peritoneal Adenocarcinoma,aspartate aminotransferase increased
D003681,20.0,NCT01035658-1,Dose Level 1,NCT01035658,Study of Pazopanib and Doxil in Patients With Advanced Relapsed Platinum-Sensitive or Platinum-Resistant Ovarian  Fallopian Tube or Primary Peritoneal Adenocarcinoma,dehydration
D003681,12.5,NCT01035658-2,Dose Level -1,NCT01035658,Study of Pazopanib and Doxil in Patients With Advanced Relapsed Platinum-Sensitive or Platinum-Resistant Ovarian  Fallopian Tube or Primary Peritoneal Adenocarcinoma,dehydration
10062572,20.0,NCT01035658-1,Dose Level 1,NCT01035658,Study of Pazopanib and Doxil in Patients With Advanced Relapsed Platinum-Sensitive or Platinum-Resistant Ovarian  Fallopian Tube or Primary Peritoneal Adenocarcinoma,generalized muscle weakness
10038738,33.33,NCT01035658-3,Dose Level 1 Sequential,NCT01035658,Study of Pazopanib and Doxil in Patients With Advanced Relapsed Platinum-Sensitive or Platinum-Resistant Ovarian  Fallopian Tube or Primary Peritoneal Adenocarcinoma,respiratory thoracic and mediastinal disorders - other specify
D064420,82.29,NCT01055314-1,Group 1 (Chemotherapy Radiation Therapy Cixutumumab),NCT01055314,Temozolomide  Cixutumumab  and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma,adverse drug events
D064420,57.14,NCT01055314-2,Group 2 (Chemotherapy Radiation Therapy Temozolomide),NCT01055314,Temozolomide  Cixutumumab  and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma,adverse drug events
D000740,4.17,NCT01055314-1,Group 1 (Chemotherapy Radiation Therapy Cixutumumab),NCT01055314,Temozolomide  Cixutumumab  and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma,anemia
D000740,1.43,NCT01055314-2,Group 2 (Chemotherapy Radiation Therapy Temozolomide),NCT01055314,Temozolomide  Cixutumumab  and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma,anemia
10048580,1.04,NCT01055314-1,Group 1 (Chemotherapy Radiation Therapy Cixutumumab),NCT01055314,Temozolomide  Cixutumumab  and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma,bone marrow hypocellular
D004211,1.04,NCT01055314-1,Group 1 (Chemotherapy Radiation Therapy Cixutumumab),NCT01055314,Temozolomide  Cixutumumab  and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma,disseminated intravascular coagulation
D064147,7.29,NCT01055314-1,Group 1 (Chemotherapy Radiation Therapy Cixutumumab),NCT01055314,Temozolomide  Cixutumumab  and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma,febrile neutropenia
D006323,1.43,NCT01055314-2,Group 2 (Chemotherapy Radiation Therapy Temozolomide),NCT01055314,Temozolomide  Cixutumumab  and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma,cardiac arrest
D006333,1.04,NCT01055314-1,Group 1 (Chemotherapy Radiation Therapy Cixutumumab),NCT01055314,Temozolomide  Cixutumumab  and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma,heart failure
10069501,2.08,NCT01055314-1,Group 1 (Chemotherapy Radiation Therapy Cixutumumab),NCT01055314,Temozolomide  Cixutumumab  and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma,left ventricular systolic dysfunction
10069501,1.43,NCT01055314-2,Group 2 (Chemotherapy Radiation Therapy Temozolomide),NCT01055314,Temozolomide  Cixutumumab  and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma,left ventricular systolic dysfunction
D013616,2.08,NCT01055314-1,Group 1 (Chemotherapy Radiation Therapy Cixutumumab),NCT01055314,Temozolomide  Cixutumumab  and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma,sinus tachycardia
10013993,1.04,NCT01055314-1,Group 1 (Chemotherapy Radiation Therapy Cixutumumab),NCT01055314,Temozolomide  Cixutumumab  and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma,ear and labyrinth disorders - other specify
10014698,1.04,NCT01055314-1,Group 1 (Chemotherapy Radiation Therapy Cixutumumab),NCT01055314,Temozolomide  Cixutumumab  and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma,endocrine disorders - other specify
10000060,1.04,NCT01055314-1,Group 1 (Chemotherapy Radiation Therapy Cixutumumab),NCT01055314,Temozolomide  Cixutumumab  and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma,abdominal distension
D015746,5.21,NCT01055314-1,Group 1 (Chemotherapy Radiation Therapy Cixutumumab),NCT01055314,Temozolomide  Cixutumumab  and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma,abdominal pain
D005401,1.04,NCT01055314-1,Group 1 (Chemotherapy Radiation Therapy Cixutumumab),NCT01055314,Temozolomide  Cixutumumab  and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma,anal ulcer
D001201,1.04,NCT01055314-1,Group 1 (Chemotherapy Radiation Therapy Cixutumumab),NCT01055314,Temozolomide  Cixutumumab  and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma,ascites
D003092,5.21,NCT01055314-1,Group 1 (Chemotherapy Radiation Therapy Cixutumumab),NCT01055314,Temozolomide  Cixutumumab  and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma,colitis
D003967,8.33,NCT01055314-1,Group 1 (Chemotherapy Radiation Therapy Cixutumumab),NCT01055314,Temozolomide  Cixutumumab  and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma,diarrhea
D003967,1.43,NCT01055314-2,Group 2 (Chemotherapy Radiation Therapy Temozolomide),NCT01055314,Temozolomide  Cixutumumab  and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma,diarrhea
10015388,1.04,NCT01055314-1,Group 1 (Chemotherapy Radiation Therapy Cixutumumab),NCT01055314,Temozolomide  Cixutumumab  and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma,esophageal pain
D004940,1.04,NCT01055314-1,Group 1 (Chemotherapy Radiation Therapy Cixutumumab),NCT01055314,Temozolomide  Cixutumumab  and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma,esophageal stenosis
D004941,1.04,NCT01055314-1,Group 1 (Chemotherapy Radiation Therapy Cixutumumab),NCT01055314,Temozolomide  Cixutumumab  and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma,esophagitis
10017789,1.04,NCT01055314-1,Group 1 (Chemotherapy Radiation Therapy Cixutumumab),NCT01055314,Temozolomide  Cixutumumab  and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma,gastric hemorrhage
D045823,1.04,NCT01055314-1,Group 1 (Chemotherapy Radiation Therapy Cixutumumab),NCT01055314,Temozolomide  Cixutumumab  and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma,ileus
10028130,7.29,NCT01055314-1,Group 1 (Chemotherapy Radiation Therapy Cixutumumab),NCT01055314,Temozolomide  Cixutumumab  and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma,mucositis oral
D009325,4.17,NCT01055314-1,Group 1 (Chemotherapy Radiation Therapy Cixutumumab),NCT01055314,Temozolomide  Cixutumumab  and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma,nausea
D006472,1.04,NCT01055314-1,Group 1 (Chemotherapy Radiation Therapy Cixutumumab),NCT01055314,Temozolomide  Cixutumumab  and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma,oral hemorrhage
10031009,1.04,NCT01055314-1,Group 1 (Chemotherapy Radiation Therapy Cixutumumab),NCT01055314,Temozolomide  Cixutumumab  and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma,oral pain
D010195,2.08,NCT01055314-1,Group 1 (Chemotherapy Radiation Therapy Cixutumumab),NCT01055314,Temozolomide  Cixutumumab  and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma,pancreatitis
D012003,1.04,NCT01055314-1,Group 1 (Chemotherapy Radiation Therapy Cixutumumab),NCT01055314,Temozolomide  Cixutumumab  and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma,rectal fistula
10038064,2.08,NCT01055314-1,Group 1 (Chemotherapy Radiation Therapy Cixutumumab),NCT01055314,Temozolomide  Cixutumumab  and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma,rectal hemorrhage
10038072,1.04,NCT01055314-1,Group 1 (Chemotherapy Radiation Therapy Cixutumumab),NCT01055314,Temozolomide  Cixutumumab  and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma,rectal pain
D053706,5.21,NCT01055314-1,Group 1 (Chemotherapy Radiation Therapy Cixutumumab),NCT01055314,Temozolomide  Cixutumumab  and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma,typhlitis
10055356,2.08,NCT01055314-1,Group 1 (Chemotherapy Radiation Therapy Cixutumumab),NCT01055314,Temozolomide  Cixutumumab  and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma,upper gastrointestinal hemorrhage
D014839,5.21,NCT01055314-1,Group 1 (Chemotherapy Radiation Therapy Cixutumumab),NCT01055314,Temozolomide  Cixutumumab  and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma,vomiting
10011914,31.25,NCT01055314-1,Group 1 (Chemotherapy Radiation Therapy Cixutumumab),NCT01055314,Temozolomide  Cixutumumab  and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma,death nos
10011914,42.86,NCT01055314-2,Group 2 (Chemotherapy Radiation Therapy Temozolomide),NCT01055314,Temozolomide  Cixutumumab  and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma,death nos
D005334,1.04,NCT01055314-1,Group 1 (Chemotherapy Radiation Therapy Cixutumumab),NCT01055314,Temozolomide  Cixutumumab  and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma,fever
D009102,1.04,NCT01055314-1,Group 1 (Chemotherapy Radiation Therapy Cixutumumab),NCT01055314,Temozolomide  Cixutumumab  and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma,multiple organ failure
D010146,2.08,NCT01055314-1,Group 1 (Chemotherapy Radiation Therapy Cixutumumab),NCT01055314,Temozolomide  Cixutumumab  and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma,pain
10019805,1.04,NCT01055314-1,Group 1 (Chemotherapy Radiation Therapy Cixutumumab),NCT01055314,Temozolomide  Cixutumumab  and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma,hepatobiliary disorders - other specify
D006975,2.08,NCT01055314-1,Group 1 (Chemotherapy Radiation Therapy Cixutumumab),NCT01055314,Temozolomide  Cixutumumab  and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma,portal hypertension
D006967,2.08,NCT01055314-1,Group 1 (Chemotherapy Radiation Therapy Cixutumumab),NCT01055314,Temozolomide  Cixutumumab  and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma,allergic reaction
D001064,1.04,NCT01055314-1,Group 1 (Chemotherapy Radiation Therapy Cixutumumab),NCT01055314,Temozolomide  Cixutumumab  and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma,appendicitis
10007810,2.08,NCT01055314-1,Group 1 (Chemotherapy Radiation Therapy Cixutumumab),NCT01055314,Temozolomide  Cixutumumab  and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma,catheter related infection
10058838,1.04,NCT01055314-1,Group 1 (Chemotherapy Radiation Therapy Cixutumumab),NCT01055314,Temozolomide  Cixutumumab  and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma,enterocolitis infectious
10058804,1.04,NCT01055314-1,Group 1 (Chemotherapy Radiation Therapy Cixutumumab),NCT01055314,Temozolomide  Cixutumumab  and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma,esophageal infection
10018784,1.04,NCT01055314-1,Group 1 (Chemotherapy Radiation Therapy Cixutumumab),NCT01055314,Temozolomide  Cixutumumab  and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma,gum infection
10021881,4.17,NCT01055314-1,Group 1 (Chemotherapy Radiation Therapy Cixutumumab),NCT01055314,Temozolomide  Cixutumumab  and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma,infections and infestations - other specify
10021881,1.43,NCT01055314-2,Group 2 (Chemotherapy Radiation Therapy Temozolomide),NCT01055314,Temozolomide  Cixutumumab  and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma,infections and infestations - other specify
10061229,2.08,NCT01055314-1,Group 1 (Chemotherapy Radiation Therapy Cixutumumab),NCT01055314,Temozolomide  Cixutumumab  and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma,lung infection
10065764,1.43,NCT01055314-2,Group 2 (Chemotherapy Radiation Therapy Temozolomide),NCT01055314,Temozolomide  Cixutumumab  and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma,mucosal infection
D018805,8.33,NCT01055314-1,Group 1 (Chemotherapy Radiation Therapy Cixutumumab),NCT01055314,Temozolomide  Cixutumumab  and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma,sepsis
D012852,1.04,NCT01055314-1,Group 1 (Chemotherapy Radiation Therapy Cixutumumab),NCT01055314,Temozolomide  Cixutumumab  and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma,sinusitis
10040872,4.17,NCT01055314-1,Group 1 (Chemotherapy Radiation Therapy Cixutumumab),NCT01055314,Temozolomide  Cixutumumab  and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma,skin infection
10064505,1.04,NCT01055314-1,Group 1 (Chemotherapy Radiation Therapy Cixutumumab),NCT01055314,Temozolomide  Cixutumumab  and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma,stoma site infection
D014136,1.04,NCT01055314-1,Group 1 (Chemotherapy Radiation Therapy Cixutumumab),NCT01055314,Temozolomide  Cixutumumab  and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma,tracheitis
10061103,1.04,NCT01055314-1,Group 1 (Chemotherapy Radiation Therapy Cixutumumab),NCT01055314,Temozolomide  Cixutumumab  and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma,dermatitis radiation
10017076,1.04,NCT01055314-1,Group 1 (Chemotherapy Radiation Therapy Cixutumumab),NCT01055314,Temozolomide  Cixutumumab  and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma,fracture
10001551,9.38,NCT01055314-1,Group 1 (Chemotherapy Radiation Therapy Cixutumumab),NCT01055314,Temozolomide  Cixutumumab  and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma,alanine aminotransferase increased
10001675,1.04,NCT01055314-1,Group 1 (Chemotherapy Radiation Therapy Cixutumumab),NCT01055314,Temozolomide  Cixutumumab  and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma,alkaline phosphatase increased
10003481,5.21,NCT01055314-1,Group 1 (Chemotherapy Radiation Therapy Cixutumumab),NCT01055314,Temozolomide  Cixutumumab  and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma,aspartate aminotransferase increased
10005364,3.12,NCT01055314-1,Group 1 (Chemotherapy Radiation Therapy Cixutumumab),NCT01055314,Temozolomide  Cixutumumab  and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma,blood bilirubin increased
10050528,1.04,NCT01055314-1,Group 1 (Chemotherapy Radiation Therapy Cixutumumab),NCT01055314,Temozolomide  Cixutumumab  and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma,ejection fraction decreased
10056910,3.12,NCT01055314-1,Group 1 (Chemotherapy Radiation Therapy Cixutumumab),NCT01055314,Temozolomide  Cixutumumab  and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma,ggt increased
10022402,1.04,NCT01055314-1,Group 1 (Chemotherapy Radiation Therapy Cixutumumab),NCT01055314,Temozolomide  Cixutumumab  and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma,inr increased
10024574,3.12,NCT01055314-1,Group 1 (Chemotherapy Radiation Therapy Cixutumumab),NCT01055314,Temozolomide  Cixutumumab  and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma,lipase increased
10025256,2.08,NCT01055314-1,Group 1 (Chemotherapy Radiation Therapy Cixutumumab),NCT01055314,Temozolomide  Cixutumumab  and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma,lymphocyte count decreased
10029366,5.21,NCT01055314-1,Group 1 (Chemotherapy Radiation Therapy Cixutumumab),NCT01055314,Temozolomide  Cixutumumab  and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma,neutrophil count decreased
10029366,1.43,NCT01055314-2,Group 2 (Chemotherapy Radiation Therapy Temozolomide),NCT01055314,Temozolomide  Cixutumumab  and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma,neutrophil count decreased
10035528,8.33,NCT01055314-1,Group 1 (Chemotherapy Radiation Therapy Cixutumumab),NCT01055314,Temozolomide  Cixutumumab  and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma,platelet count decreased
10040139,1.04,NCT01055314-1,Group 1 (Chemotherapy Radiation Therapy Cixutumumab),NCT01055314,Temozolomide  Cixutumumab  and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma,serum amylase increased
D015431,6.25,NCT01055314-1,Group 1 (Chemotherapy Radiation Therapy Cixutumumab),NCT01055314,Temozolomide  Cixutumumab  and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma,weight loss
D015431,1.43,NCT01055314-2,Group 2 (Chemotherapy Radiation Therapy Temozolomide),NCT01055314,Temozolomide  Cixutumumab  and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma,weight loss
10049182,5.21,NCT01055314-1,Group 1 (Chemotherapy Radiation Therapy Cixutumumab),NCT01055314,Temozolomide  Cixutumumab  and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma,white blood cell decreased
D000855,4.17,NCT01055314-1,Group 1 (Chemotherapy Radiation Therapy Cixutumumab),NCT01055314,Temozolomide  Cixutumumab  and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma,anorexia
D000855,1.43,NCT01055314-2,Group 2 (Chemotherapy Radiation Therapy Temozolomide),NCT01055314,Temozolomide  Cixutumumab  and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma,anorexia
D003681,7.29,NCT01055314-1,Group 1 (Chemotherapy Radiation Therapy Cixutumumab),NCT01055314,Temozolomide  Cixutumumab  and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma,dehydration
D006934,1.04,NCT01055314-1,Group 1 (Chemotherapy Radiation Therapy Cixutumumab),NCT01055314,Temozolomide  Cixutumumab  and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma,hypercalcemia
D006943,10.42,NCT01055314-1,Group 1 (Chemotherapy Radiation Therapy Cixutumumab),NCT01055314,Temozolomide  Cixutumumab  and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma,hyperglycemia
D015228,1.04,NCT01055314-1,Group 1 (Chemotherapy Radiation Therapy Cixutumumab),NCT01055314,Temozolomide  Cixutumumab  and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma,hypertriglyceridemia
D034141,1.04,NCT01055314-1,Group 1 (Chemotherapy Radiation Therapy Cixutumumab),NCT01055314,Temozolomide  Cixutumumab  and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma,hypoalbuminemia
D006996,1.04,NCT01055314-1,Group 1 (Chemotherapy Radiation Therapy Cixutumumab),NCT01055314,Temozolomide  Cixutumumab  and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma,hypocalcemia
D007008,5.21,NCT01055314-1,Group 1 (Chemotherapy Radiation Therapy Cixutumumab),NCT01055314,Temozolomide  Cixutumumab  and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma,hypokalemia
D007010,3.12,NCT01055314-1,Group 1 (Chemotherapy Radiation Therapy Cixutumumab),NCT01055314,Temozolomide  Cixutumumab  and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma,hyponatremia
D017674,3.12,NCT01055314-1,Group 1 (Chemotherapy Radiation Therapy Cixutumumab),NCT01055314,Temozolomide  Cixutumumab  and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma,hypophosphatemia
10028395,1.04,NCT01055314-1,Group 1 (Chemotherapy Radiation Therapy Cixutumumab),NCT01055314,Temozolomide  Cixutumumab  and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma,musculoskeletal and connective tissue disorder - other specify
10033425,1.04,NCT01055314-1,Group 1 (Chemotherapy Radiation Therapy Cixutumumab),NCT01055314,Temozolomide  Cixutumumab  and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma,pain in extremity
D009190,1.04,NCT01055314-1,Group 1 (Chemotherapy Radiation Therapy Cixutumumab),NCT01055314,Temozolomide  Cixutumumab  and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma,myelodysplastic syndrome
10029104,7.29,NCT01055314-1,Group 1 (Chemotherapy Radiation Therapy Cixutumumab),NCT01055314,Temozolomide  Cixutumumab  and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma,neoplasms benign malignant and unspecified (incl cysts and polyps) - other specify
10029104,7.14,NCT01055314-2,Group 2 (Chemotherapy Radiation Therapy Temozolomide),NCT01055314,Temozolomide  Cixutumumab  and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma,neoplasms benign malignant and unspecified (incl cysts and polyps) - other specify
D003244,2.08,NCT01055314-1,Group 1 (Chemotherapy Radiation Therapy Cixutumumab),NCT01055314,Temozolomide  Cixutumumab  and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma,depressed level of consciousness
D006849,1.04,NCT01055314-1,Group 1 (Chemotherapy Radiation Therapy Cixutumumab),NCT01055314,Temozolomide  Cixutumumab  and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma,hydrocephalus
10034620,2.08,NCT01055314-1,Group 1 (Chemotherapy Radiation Therapy Cixutumumab),NCT01055314,Temozolomide  Cixutumumab  and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma,peripheral sensory neuropathy
D012640,1.43,NCT01055314-2,Group 2 (Chemotherapy Radiation Therapy Temozolomide),NCT01055314,Temozolomide  Cixutumumab  and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma,seizure
D013575,3.12,NCT01055314-1,Group 1 (Chemotherapy Radiation Therapy Cixutumumab),NCT01055314,Temozolomide  Cixutumumab  and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma,syncope
10047166,1.04,NCT01055314-1,Group 1 (Chemotherapy Radiation Therapy Cixutumumab),NCT01055314,Temozolomide  Cixutumumab  and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma,vasovagal reaction
D003693,1.04,NCT01055314-1,Group 1 (Chemotherapy Radiation Therapy Cixutumumab),NCT01055314,Temozolomide  Cixutumumab  and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma,delirium
D058186,2.08,NCT01055314-1,Group 1 (Chemotherapy Radiation Therapy Cixutumumab),NCT01055314,Temozolomide  Cixutumumab  and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma,acute kidney injury
D006417,2.08,NCT01055314-1,Group 1 (Chemotherapy Radiation Therapy Cixutumumab),NCT01055314,Temozolomide  Cixutumumab  and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma,hematuria
10034310,1.04,NCT01055314-1,Group 1 (Chemotherapy Radiation Therapy Cixutumumab),NCT01055314,Temozolomide  Cixutumumab  and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma,penile pain
D012128,1.43,NCT01055314-2,Group 2 (Chemotherapy Radiation Therapy Temozolomide),NCT01055314,Temozolomide  Cixutumumab  and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma,adult respiratory distress syndrome
D001049,2.08,NCT01055314-1,Group 1 (Chemotherapy Radiation Therapy Cixutumumab),NCT01055314,Temozolomide  Cixutumumab  and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma,apnea
D004844,1.04,NCT01055314-1,Group 1 (Chemotherapy Radiation Therapy Cixutumumab),NCT01055314,Temozolomide  Cixutumumab  and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma,epistaxis
D000860,1.04,NCT01055314-1,Group 1 (Chemotherapy Radiation Therapy Cixutumumab),NCT01055314,Temozolomide  Cixutumumab  and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma,hypoxia
D007819,1.04,NCT01055314-1,Group 1 (Chemotherapy Radiation Therapy Cixutumumab),NCT01055314,Temozolomide  Cixutumumab  and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma,laryngeal edema
D011654,1.04,NCT01055314-1,Group 1 (Chemotherapy Radiation Therapy Cixutumumab),NCT01055314,Temozolomide  Cixutumumab  and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma,pulmonary edema
D012131,1.04,NCT01055314-1,Group 1 (Chemotherapy Radiation Therapy Cixutumumab),NCT01055314,Temozolomide  Cixutumumab  and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma,respiratory failure
D012131,1.43,NCT01055314-2,Group 2 (Chemotherapy Radiation Therapy Temozolomide),NCT01055314,Temozolomide  Cixutumumab  and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma,respiratory failure
D010612,1.04,NCT01055314-1,Group 1 (Chemotherapy Radiation Therapy Cixutumumab),NCT01055314,Temozolomide  Cixutumumab  and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma,sore throat
D012135,2.08,NCT01055314-1,Group 1 (Chemotherapy Radiation Therapy Cixutumumab),NCT01055314,Temozolomide  Cixutumumab  and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma,stridor
10037868,1.04,NCT01055314-1,Group 1 (Chemotherapy Radiation Therapy Cixutumumab),NCT01055314,Temozolomide  Cixutumumab  and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma,rash maculo-papular
D007022,6.25,NCT01055314-1,Group 1 (Chemotherapy Radiation Therapy Cixutumumab),NCT01055314,Temozolomide  Cixutumumab  and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma,hypotension
10043565,2.08,NCT01055314-1,Group 1 (Chemotherapy Radiation Therapy Cixutumumab),NCT01055314,Temozolomide  Cixutumumab  and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma,thromboembolic event
10047065,1.04,NCT01055314-1,Group 1 (Chemotherapy Radiation Therapy Cixutumumab),NCT01055314,Temozolomide  Cixutumumab  and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma,vascular disorders - other specify
D009026,6.22,NCT01098266-1,A: NGR-hTNF + BIC,NCT01098266,NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed,mortality
D009026,6.74,NCT01098266-2,B: Placebo+BIC,NCT01098266,NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed,mortality
D064420,29.02,NCT01098266-1,A: NGR-hTNF + BIC,NCT01098266,NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed,adverse drug events
D064420,27.98,NCT01098266-2,B: Placebo+BIC,NCT01098266,NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed,adverse drug events
D009503,1.04,NCT01098266-1,A: NGR-hTNF + BIC,NCT01098266,NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed,neutropenia
D009503,2.07,NCT01098266-2,B: Placebo+BIC,NCT01098266,NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed,neutropenia
D013921,0.52,NCT01098266-1,A: NGR-hTNF + BIC,NCT01098266,NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed,thrombocytopenia
D007970,0.52,NCT01098266-2,B: Placebo+BIC,NCT01098266,NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed,leukopenia
D005334,1.04,NCT01098266-2,B: Placebo+BIC,NCT01098266,NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed,fever
D000741,0.52,NCT01098266-2,B: Placebo+BIC,NCT01098266,NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed,aplastic anaemia
D010490,0.52,NCT01098266-1,A: NGR-hTNF + BIC,NCT01098266,NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed,pericardial effusion
D010490,1.04,NCT01098266-2,B: Placebo+BIC,NCT01098266,NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed,pericardial effusion
D001281,0.52,NCT01098266-1,A: NGR-hTNF + BIC,NCT01098266,NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed,atrial fibrillation
D001281,0.52,NCT01098266-2,B: Placebo+BIC,NCT01098266,NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed,atrial fibrillation
D006331,0.52,NCT01098266-1,A: NGR-hTNF + BIC,NCT01098266,NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed,cardiac disorder
D006333,0.52,NCT01098266-1,A: NGR-hTNF + BIC,NCT01098266,NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed,cardiac failure
D009203,0.52,NCT01098266-2,B: Placebo+BIC,NCT01098266,NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed,myocardial infarction
D010493,0.52,NCT01098266-2,B: Placebo+BIC,NCT01098266,NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed,pericarditis
D009618,0.52,NCT01098266-2,B: Placebo+BIC,NCT01098266,NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed,nocardiaceae
D007415,0.52,NCT01098266-2,B: Placebo+BIC,NCT01098266,NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed,intestinal obstruction
UNKNOWN-check-for-typo,1.04,NCT01098266-1,A: NGR-hTNF + BIC,NCT01098266,NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed,D00
D010195,0.52,NCT01098266-2,B: Placebo+BIC,NCT01098266,NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed,pancreatitis
D003248,1.04,NCT01098266-1,A: NGR-hTNF + BIC,NCT01098266,NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed,constipation
D003248,0.52,NCT01098266-2,B: Placebo+BIC,NCT01098266,NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed,constipation
D015746,1.04,NCT01098266-2,B: Placebo+BIC,NCT01098266,NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed,abdominal pain
D001201,0.52,NCT01098266-1,A: NGR-hTNF + BIC,NCT01098266,NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed,ascites
D001201,0.52,NCT01098266-2,B: Placebo+BIC,NCT01098266,NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed,ascites
D003680,0.52,NCT01098266-1,A: NGR-hTNF + BIC,NCT01098266,NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed,dysphagia
D014839,1.04,NCT01098266-1,A: NGR-hTNF + BIC,NCT01098266,NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed,vomiting
D023341,1.04,NCT01098266-1,A: NGR-hTNF + BIC,NCT01098266,NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed,chills
D052016,0.52,NCT01098266-2,B: Placebo+BIC,NCT01098266,NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed,mucositis
D005334,1.04,NCT01098266-1,A: NGR-hTNF + BIC,NCT01098266,NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed,pyrexia
D005334,1.04,NCT01098266-2,B: Placebo+BIC,NCT01098266,NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed,pyrexia
D003643,1.55,NCT01098266-1,A: NGR-hTNF + BIC,NCT01098266,NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed,death
D003643,1.04,NCT01098266-2,B: Placebo+BIC,NCT01098266,NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed,death
D008305,0.52,NCT01098266-1,A: NGR-hTNF + BIC,NCT01098266,NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed,hyperpyrexia malignant
D006365,0.52,NCT01098266-2,B: Placebo+BIC,NCT01098266,NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed,heel
D002637,1.55,NCT01098266-1,A: NGR-hTNF + BIC,NCT01098266,NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed,chest pain
D002637,1.55,NCT01098266-2,B: Placebo+BIC,NCT01098266,NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed,chest pain
D000075902,0.52,NCT01098266-1,A: NGR-hTNF + BIC,NCT01098266,NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed,clinical deterioration
D000075902,0.52,NCT01098266-2,B: Placebo+BIC,NCT01098266,NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed,clinical deterioration
D000080867,0.52,NCT01098266-1,A: NGR-hTNF + BIC,NCT01098266,NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed,gingipains
D005221,0.52,NCT01098266-2,B: Placebo+BIC,NCT01098266,NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed,fatigue
D000389,2.07,NCT01098266-1,A: NGR-hTNF + BIC,NCT01098266,NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed,air conditioning
D000389,2.59,NCT01098266-2,B: Placebo+BIC,NCT01098266,NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed,air conditioning
D005234,0.52,NCT01098266-2,B: Placebo+BIC,NCT01098266,NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed,steatohepatitis
D001621,0.52,NCT01098266-1,A: NGR-hTNF + BIC,NCT01098266,NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed,ribrain
D002481,0.52,NCT01098266-2,B: Placebo+BIC,NCT01098266,NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed,cellulitis
D011014,1.55,NCT01098266-2,B: Placebo+BIC,NCT01098266,NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed,pneumonia
D000985,0.52,NCT01098266-1,A: NGR-hTNF + BIC,NCT01098266,NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed,antisepsis
D000985,0.52,NCT01098266-2,B: Placebo+BIC,NCT01098266,NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed,antisepsis
D000038,0.52,NCT01098266-2,B: Placebo+BIC,NCT01098266,NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed,abscess
D018805,1.04,NCT01098266-1,A: NGR-hTNF + BIC,NCT01098266,NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed,sepsis
D018805,0.52,NCT01098266-2,B: Placebo+BIC,NCT01098266,NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed,sepsis
D000069544,0.52,NCT01098266-1,A: NGR-hTNF + BIC,NCT01098266,NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed,encephalitis infection
D000072139,0.52,NCT01098266-1,A: NGR-hTNF + BIC,NCT01098266,NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed,megavirales
D012141,1.04,NCT01098266-1,A: NGR-hTNF + BIC,NCT01098266,NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed,respiratory tract infections
D012141,0.52,NCT01098266-2,B: Placebo+BIC,NCT01098266,NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed,respiratory tract infections
10061229,0.52,NCT01098266-2,B: Placebo+BIC,NCT01098266,NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed,lung infection
D012141,0.52,NCT01098266-2,B: Placebo+BIC,NCT01098266,NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed,respiratory tract infections
D000069342,2.07,NCT01098266-1,A: NGR-hTNF + BIC,NCT01098266,NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed,overmedication
D000069342,4.66,NCT01098266-2,B: Placebo+BIC,NCT01098266,NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed,overmedication
D000075662,1.04,NCT01098266-1,A: NGR-hTNF + BIC,NCT01098266,NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed,infusion site reaction
D062787,0.52,NCT01098266-1,A: NGR-hTNF + BIC,NCT01098266,NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed,drug overdose
D006811,0.52,NCT01098266-1,A: NGR-hTNF + BIC,NCT01098266,NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed,humerus
10020100,0.52,NCT01098266-1,A: NGR-hTNF + BIC,NCT01098266,NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed,hip fracture
D006259,0.52,NCT01098266-1,A: NGR-hTNF + BIC,NCT01098266,NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed,occipital trauma
UNKNOWN-check-for-typo,0.52,NCT01098266-1,A: NGR-hTNF + BIC,NCT01098266,NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed,D00
D002100,0.52,NCT01098266-1,A: NGR-hTNF + BIC,NCT01098266,NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed,cachexia
D002100,0.52,NCT01098266-2,B: Placebo+BIC,NCT01098266,NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed,cachexia
D008654,0.52,NCT01098266-1,A: NGR-hTNF + BIC,NCT01098266,NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed,mesothelioma
D003309,0.52,NCT01098266-2,B: Placebo+BIC,NCT01098266,NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed,copyright
D005334,0.52,NCT01098266-1,A: NGR-hTNF + BIC,NCT01098266,NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed,fever
D001621,0.52,NCT01098266-2,B: Placebo+BIC,NCT01098266,NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed,ribrain
D002546,0.52,NCT01098266-2,B: Placebo+BIC,NCT01098266,NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed,ischemic attack transient
D020225,0.52,NCT01098266-2,B: Placebo+BIC,NCT01098266,NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed,sagittal sinus thrombosis
D020521,0.52,NCT01098266-1,A: NGR-hTNF + BIC,NCT01098266,NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed,cerebrovascular accident
D001927,0.52,NCT01098266-1,A: NGR-hTNF + BIC,NCT01098266,NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed,encephalopathy
D012640,0.52,NCT01098266-1,A: NGR-hTNF + BIC,NCT01098266,NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed,jacksonian seizure
D000308,0.52,NCT01098266-1,A: NGR-hTNF + BIC,NCT01098266,NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed,adrenal gland hyperfunction
D011655,1.04,NCT01098266-1,A: NGR-hTNF + BIC,NCT01098266,NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed,pulmonary embolism
D011655,1.04,NCT01098266-2,B: Placebo+BIC,NCT01098266,NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed,pulmonary embolism
UNKNOWN-check-for-typo,2.07,NCT01098266-1,A: NGR-hTNF + BIC,NCT01098266,NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed,D00
UNKNOWN-check-for-typo,0.52,NCT01098266-2,B: Placebo+BIC,NCT01098266,NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed,D00
D012131,1.04,NCT01098266-1,A: NGR-hTNF + BIC,NCT01098266,NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed,respiratory failure
D012131,1.04,NCT01098266-2,B: Placebo+BIC,NCT01098266,NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed,respiratory failure
D001986,0.52,NCT01098266-1,A: NGR-hTNF + BIC,NCT01098266,NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed,bronchospasm
D011014,0.52,NCT01098266-2,B: Placebo+BIC,NCT01098266,NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed,pneumonitis
D000069544,0.52,NCT01098266-2,B: Placebo+BIC,NCT01098266,NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed,encephalitis infection
D010996,1.04,NCT01098266-1,A: NGR-hTNF + BIC,NCT01098266,NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed,pleural effusion
D000080867,0.52,NCT01098266-2,B: Placebo+BIC,NCT01098266,NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed,gingipains
D011030,0.52,NCT01098266-1,A: NGR-hTNF + BIC,NCT01098266,NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed,pneumothorax
UNKNOWN-check-for-typo,0.52,NCT01098266-2,B: Placebo+BIC,NCT01098266,NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed,D00
D009026,50.0,NCT01100944-1,All Participants,NCT01100944,A Phase 1/2 Study of PXD101 (Belinostat) in Combination With Cisplatin  Doxorubicin and Cyclophosphamide in the First Line Treatment of Advanced or Recurrent Thymic  Malignancies,mortality
D064420,76.92,NCT01100944-1,All Participants,NCT01100944,A Phase 1/2 Study of PXD101 (Belinostat) in Combination With Cisplatin  Doxorubicin and Cyclophosphamide in the First Line Treatment of Advanced or Recurrent Thymic  Malignancies,adverse drug events
D000740,3.85,NCT01100944-1,All Participants,NCT01100944,A Phase 1/2 Study of PXD101 (Belinostat) in Combination With Cisplatin  Doxorubicin and Cyclophosphamide in the First Line Treatment of Advanced or Recurrent Thymic  Malignancies,anemia
D064147,3.85,NCT01100944-1,All Participants,NCT01100944,A Phase 1/2 Study of PXD101 (Belinostat) in Combination With Cisplatin  Doxorubicin and Cyclophosphamide in the First Line Treatment of Advanced or Recurrent Thymic  Malignancies,febrile neutropenia
D001281,3.85,NCT01100944-1,All Participants,NCT01100944,A Phase 1/2 Study of PXD101 (Belinostat) in Combination With Cisplatin  Doxorubicin and Cyclophosphamide in the First Line Treatment of Advanced or Recurrent Thymic  Malignancies,atrial fibrillation
D003967,3.85,NCT01100944-1,All Participants,NCT01100944,A Phase 1/2 Study of PXD101 (Belinostat) in Combination With Cisplatin  Doxorubicin and Cyclophosphamide in the First Line Treatment of Advanced or Recurrent Thymic  Malignancies,diarrhea
10011914,42.31,NCT01100944-1,All Participants,NCT01100944,A Phase 1/2 Study of PXD101 (Belinostat) in Combination With Cisplatin  Doxorubicin and Cyclophosphamide in the First Line Treatment of Advanced or Recurrent Thymic  Malignancies,death nos
10051792,3.85,NCT01100944-1,All Participants,NCT01100944,A Phase 1/2 Study of PXD101 (Belinostat) in Combination With Cisplatin  Doxorubicin and Cyclophosphamide in the First Line Treatment of Advanced or Recurrent Thymic  Malignancies,infusion related reaction
10062466,3.85,NCT01100944-1,All Participants,NCT01100944,A Phase 1/2 Study of PXD101 (Belinostat) in Combination With Cisplatin  Doxorubicin and Cyclophosphamide in the First Line Treatment of Advanced or Recurrent Thymic  Malignancies,localized edema
10007810,7.69,NCT01100944-1,All Participants,NCT01100944,A Phase 1/2 Study of PXD101 (Belinostat) in Combination With Cisplatin  Doxorubicin and Cyclophosphamide in the First Line Treatment of Advanced or Recurrent Thymic  Malignancies,catheter related infection
D007239,3.85,NCT01100944-1,All Participants,NCT01100944,A Phase 1/2 Study of PXD101 (Belinostat) in Combination With Cisplatin  Doxorubicin and Cyclophosphamide in the First Line Treatment of Advanced or Recurrent Thymic  Malignancies,infections and infestations
D000257,3.85,NCT01100944-1,All Participants,NCT01100944,A Phase 1/2 Study of PXD101 (Belinostat) in Combination With Cisplatin  Doxorubicin and Cyclophosphamide in the First Line Treatment of Advanced or Recurrent Thymic  Malignancies,adenovirus infections
10061229,3.85,NCT01100944-1,All Participants,NCT01100944,A Phase 1/2 Study of PXD101 (Belinostat) in Combination With Cisplatin  Doxorubicin and Cyclophosphamide in the First Line Treatment of Advanced or Recurrent Thymic  Malignancies,lung infection
10014383,3.85,NCT01100944-1,All Participants,NCT01100944,A Phase 1/2 Study of PXD101 (Belinostat) in Combination With Cisplatin  Doxorubicin and Cyclophosphamide in the First Line Treatment of Advanced or Recurrent Thymic  Malignancies,electrocardiogram qt corrected interval prolonged
10029366,3.85,NCT01100944-1,All Participants,NCT01100944,A Phase 1/2 Study of PXD101 (Belinostat) in Combination With Cisplatin  Doxorubicin and Cyclophosphamide in the First Line Treatment of Advanced or Recurrent Thymic  Malignancies,neutrophil count decreased
10029104,3.85,NCT01100944-1,All Participants,NCT01100944,A Phase 1/2 Study of PXD101 (Belinostat) in Combination With Cisplatin  Doxorubicin and Cyclophosphamide in the First Line Treatment of Advanced or Recurrent Thymic  Malignancies,neoplasms benign malignant and unspecified (incl cysts and polyps) - other specify
10029104,7.69,NCT01100944-1,All Participants,NCT01100944,A Phase 1/2 Study of PXD101 (Belinostat) in Combination With Cisplatin  Doxorubicin and Cyclophosphamide in the First Line Treatment of Advanced or Recurrent Thymic  Malignancies,neoplasms benign malignant and unspecified (incl cysts and polyps) - other specify
D012131,3.85,NCT01100944-1,All Participants,NCT01100944,A Phase 1/2 Study of PXD101 (Belinostat) in Combination With Cisplatin  Doxorubicin and Cyclophosphamide in the First Line Treatment of Advanced or Recurrent Thymic  Malignancies,respiratory failure
10043565,19.23,NCT01100944-1,All Participants,NCT01100944,A Phase 1/2 Study of PXD101 (Belinostat) in Combination With Cisplatin  Doxorubicin and Cyclophosphamide in the First Line Treatment of Advanced or Recurrent Thymic  Malignancies,thromboembolic event
D064420,44.44,NCT01121406-1,Volasertib (BI 6727),NCT01121406,BI 6727 (Volasertib) Randomised Trial in Ovarian Cancer,adverse drug events
D064420,34.55,NCT01121406-2,Cytotoxic,NCT01121406,BI 6727 (Volasertib) Randomised Trial in Ovarian Cancer,adverse drug events
D064420,50.0,NCT01121406-3,Cytotoxic to Volasertib Switch,NCT01121406,BI 6727 (Volasertib) Randomised Trial in Ovarian Cancer,adverse drug events
D000741,1.85,NCT01121406-1,Volasertib (BI 6727),NCT01121406,BI 6727 (Volasertib) Randomised Trial in Ovarian Cancer,aplastic anaemia
D064147,1.85,NCT01121406-1,Volasertib (BI 6727),NCT01121406,BI 6727 (Volasertib) Randomised Trial in Ovarian Cancer,febrile neutropenia
D009503,8.33,NCT01121406-3,Cytotoxic to Volasertib Switch,NCT01121406,BI 6727 (Volasertib) Randomised Trial in Ovarian Cancer,neutropenia
D013921,3.7,NCT01121406-1,Volasertib (BI 6727),NCT01121406,BI 6727 (Volasertib) Randomised Trial in Ovarian Cancer,thrombocytopenia
D001281,4.17,NCT01121406-3,Cytotoxic to Volasertib Switch,NCT01121406,BI 6727 (Volasertib) Randomised Trial in Ovarian Cancer,atrial fibrillation
10000060,1.85,NCT01121406-1,Volasertib (BI 6727),NCT01121406,BI 6727 (Volasertib) Randomised Trial in Ovarian Cancer,abdominal distension
D015746,7.41,NCT01121406-1,Volasertib (BI 6727),NCT01121406,BI 6727 (Volasertib) Randomised Trial in Ovarian Cancer,abdominal pain
D015746,1.82,NCT01121406-2,Cytotoxic,NCT01121406,BI 6727 (Volasertib) Randomised Trial in Ovarian Cancer,abdominal pain
D015746,8.33,NCT01121406-3,Cytotoxic to Volasertib Switch,NCT01121406,BI 6727 (Volasertib) Randomised Trial in Ovarian Cancer,abdominal pain
D015746,3.7,NCT01121406-1,Volasertib (BI 6727),NCT01121406,BI 6727 (Volasertib) Randomised Trial in Ovarian Cancer,abdominal pain
D001201,1.82,NCT01121406-2,Cytotoxic,NCT01121406,BI 6727 (Volasertib) Randomised Trial in Ovarian Cancer,ascites
D003248,1.82,NCT01121406-2,Cytotoxic,NCT01121406,BI 6727 (Volasertib) Randomised Trial in Ovarian Cancer,constipation
UNKNOWN-check-for-typo,1.85,NCT01121406-1,Volasertib (BI 6727),NCT01121406,BI 6727 (Volasertib) Randomised Trial in Ovarian Cancer,D00
UNKNOWN-check-for-typo,1.82,NCT01121406-2,Cytotoxic,NCT01121406,BI 6727 (Volasertib) Randomised Trial in Ovarian Cancer,D00
D000069196,4.17,NCT01121406-3,Cytotoxic to Volasertib Switch,NCT01121406,BI 6727 (Volasertib) Randomised Trial in Ovarian Cancer,gastrointestinal microbiome
D000069196,1.82,NCT01121406-2,Cytotoxic,NCT01121406,BI 6727 (Volasertib) Randomised Trial in Ovarian Cancer,gastrointestinal microbiome
10021305,1.85,NCT01121406-1,Volasertib (BI 6727),NCT01121406,BI 6727 (Volasertib) Randomised Trial in Ovarian Cancer,ileal perforation
D045823,3.7,NCT01121406-1,Volasertib (BI 6727),NCT01121406,BI 6727 (Volasertib) Randomised Trial in Ovarian Cancer,ileus
D007415,1.85,NCT01121406-1,Volasertib (BI 6727),NCT01121406,BI 6727 (Volasertib) Randomised Trial in Ovarian Cancer,intestinal obstruction
D007415,5.45,NCT01121406-2,Cytotoxic,NCT01121406,BI 6727 (Volasertib) Randomised Trial in Ovarian Cancer,intestinal obstruction
D007415,4.17,NCT01121406-3,Cytotoxic to Volasertib Switch,NCT01121406,BI 6727 (Volasertib) Randomised Trial in Ovarian Cancer,intestinal obstruction
D007420,1.85,NCT01121406-1,Volasertib (BI 6727),NCT01121406,BI 6727 (Volasertib) Randomised Trial in Ovarian Cancer,intestine large
D009325,1.85,NCT01121406-1,Volasertib (BI 6727),NCT01121406,BI 6727 (Volasertib) Randomised Trial in Ovarian Cancer,nausea
D009325,3.64,NCT01121406-2,Cytotoxic,NCT01121406,BI 6727 (Volasertib) Randomised Trial in Ovarian Cancer,nausea
D000071056,1.85,NCT01121406-1,Volasertib (BI 6727),NCT01121406,BI 6727 (Volasertib) Randomised Trial in Ovarian Cancer,anorectal malformations
10041101,1.82,NCT01121406-2,Cytotoxic,NCT01121406,BI 6727 (Volasertib) Randomised Trial in Ovarian Cancer,small intestinal obstruction
10021328,1.82,NCT01121406-2,Cytotoxic,NCT01121406,BI 6727 (Volasertib) Randomised Trial in Ovarian Cancer,ileus
D014839,5.56,NCT01121406-1,Volasertib (BI 6727),NCT01121406,BI 6727 (Volasertib) Randomised Trial in Ovarian Cancer,vomiting
D014839,3.64,NCT01121406-2,Cytotoxic,NCT01121406,BI 6727 (Volasertib) Randomised Trial in Ovarian Cancer,vomiting
D002637,1.85,NCT01121406-1,Volasertib (BI 6727),NCT01121406,BI 6727 (Volasertib) Randomised Trial in Ovarian Cancer,chest pain
D000389,1.85,NCT01121406-1,Volasertib (BI 6727),NCT01121406,BI 6727 (Volasertib) Randomised Trial in Ovarian Cancer,air conditioning
D003643,1.82,NCT01121406-2,Cytotoxic,NCT01121406,BI 6727 (Volasertib) Randomised Trial in Ovarian Cancer,death
D005065,4.17,NCT01121406-3,Cytotoxic to Volasertib Switch,NCT01121406,BI 6727 (Volasertib) Randomised Trial in Ovarian Cancer,euthanasia
D003695,1.82,NCT01121406-2,Cytotoxic,NCT01121406,BI 6727 (Volasertib) Randomised Trial in Ovarian Cancer,healthcare
D009102,1.85,NCT01121406-1,Volasertib (BI 6727),NCT01121406,BI 6727 (Volasertib) Randomised Trial in Ovarian Cancer,multiple organ failure
D000402,3.7,NCT01121406-1,Volasertib (BI 6727),NCT01121406,BI 6727 (Volasertib) Randomised Trial in Ovarian Cancer,airway obstruction
D000402,1.82,NCT01121406-2,Cytotoxic,NCT01121406,BI 6727 (Volasertib) Randomised Trial in Ovarian Cancer,airway obstruction
D005334,3.7,NCT01121406-1,Volasertib (BI 6727),NCT01121406,BI 6727 (Volasertib) Randomised Trial in Ovarian Cancer,pyrexia
D005334,3.64,NCT01121406-2,Cytotoxic,NCT01121406,BI 6727 (Volasertib) Randomised Trial in Ovarian Cancer,pyrexia
D002764,1.82,NCT01121406-2,Cytotoxic,NCT01121406,BI 6727 (Volasertib) Randomised Trial in Ovarian Cancer,cholecystitis
D004342,1.82,NCT01121406-2,Cytotoxic,NCT01121406,BI 6727 (Volasertib) Randomised Trial in Ovarian Cancer,drug hypersensitivity
10064687,4.17,NCT01121406-3,Cytotoxic to Volasertib Switch,NCT01121406,BI 6727 (Volasertib) Randomised Trial in Ovarian Cancer,device related infection
D011014,1.82,NCT01121406-2,Cytotoxic,NCT01121406,BI 6727 (Volasertib) Randomised Trial in Ovarian Cancer,pneumonia
D011704,1.82,NCT01121406-2,Cytotoxic,NCT01121406,BI 6727 (Volasertib) Randomised Trial in Ovarian Cancer,pyelonephritis
D018805,1.85,NCT01121406-1,Volasertib (BI 6727),NCT01121406,BI 6727 (Volasertib) Randomised Trial in Ovarian Cancer,sepsis
D018805,1.82,NCT01121406-2,Cytotoxic,NCT01121406,BI 6727 (Volasertib) Randomised Trial in Ovarian Cancer,sepsis
D018805,4.17,NCT01121406-3,Cytotoxic to Volasertib Switch,NCT01121406,BI 6727 (Volasertib) Randomised Trial in Ovarian Cancer,sepsis
D014552,4.17,NCT01121406-3,Cytotoxic to Volasertib Switch,NCT01121406,BI 6727 (Volasertib) Randomised Trial in Ovarian Cancer,urinary tract infection
10001675,1.85,NCT01121406-1,Volasertib (BI 6727),NCT01121406,BI 6727 (Volasertib) Randomised Trial in Ovarian Cancer,alkaline phosphatase increased
10011368,1.85,NCT01121406-1,Volasertib (BI 6727),NCT01121406,BI 6727 (Volasertib) Randomised Trial in Ovarian Cancer,creatinine increased
D005723,1.85,NCT01121406-1,Volasertib (BI 6727),NCT01121406,BI 6727 (Volasertib) Randomised Trial in Ovarian Cancer,gammaglutamyltransferase
10029366,4.17,NCT01121406-3,Cytotoxic to Volasertib Switch,NCT01121406,BI 6727 (Volasertib) Randomised Trial in Ovarian Cancer,neutrophil count decreased
D001066,1.82,NCT01121406-2,Cytotoxic,NCT01121406,BI 6727 (Volasertib) Randomised Trial in Ovarian Cancer,appetite
D003681,1.85,NCT01121406-1,Volasertib (BI 6727),NCT01121406,BI 6727 (Volasertib) Randomised Trial in Ovarian Cancer,dehydration
D003681,4.17,NCT01121406-3,Cytotoxic to Volasertib Switch,NCT01121406,BI 6727 (Volasertib) Randomised Trial in Ovarian Cancer,dehydration
D018270,4.17,NCT01121406-3,Cytotoxic to Volasertib Switch,NCT01121406,BI 6727 (Volasertib) Randomised Trial in Ovarian Cancer,carcinoma invasive ductal breast
D006321,1.85,NCT01121406-1,Volasertib (BI 6727),NCT01121406,BI 6727 (Volasertib) Randomised Trial in Ovarian Cancer,heart
D009369,1.82,NCT01121406-2,Cytotoxic,NCT01121406,BI 6727 (Volasertib) Randomised Trial in Ovarian Cancer,neoplasms
D009369,4.17,NCT01121406-3,Cytotoxic to Volasertib Switch,NCT01121406,BI 6727 (Volasertib) Randomised Trial in Ovarian Cancer,neoplasms
D009361,4.17,NCT01121406-3,Cytotoxic to Volasertib Switch,NCT01121406,BI 6727 (Volasertib) Randomised Trial in Ovarian Cancer,neoplasm invasion
D020521,1.82,NCT01121406-2,Cytotoxic,NCT01121406,BI 6727 (Volasertib) Randomised Trial in Ovarian Cancer,cerebrovascular accident
D001007,1.82,NCT01121406-2,Cytotoxic,NCT01121406,BI 6727 (Volasertib) Randomised Trial in Ovarian Cancer,anxiety
D000035,1.85,NCT01121406-1,Volasertib (BI 6727),NCT01121406,BI 6727 (Volasertib) Randomised Trial in Ovarian Cancer,abreaction
UNKNOWN-check-for-typo,4.17,NCT01121406-3,Cytotoxic to Volasertib Switch,NCT01121406,BI 6727 (Volasertib) Randomised Trial in Ovarian Cancer,D00
D001261,1.85,NCT01121406-1,Volasertib (BI 6727),NCT01121406,BI 6727 (Volasertib) Randomised Trial in Ovarian Cancer,atelectasis
UNKNOWN-check-for-typo,7.41,NCT01121406-1,Volasertib (BI 6727),NCT01121406,BI 6727 (Volasertib) Randomised Trial in Ovarian Cancer,D00
D010996,1.82,NCT01121406-2,Cytotoxic,NCT01121406,BI 6727 (Volasertib) Randomised Trial in Ovarian Cancer,pleural effusion
D010996,4.17,NCT01121406-3,Cytotoxic to Volasertib Switch,NCT01121406,BI 6727 (Volasertib) Randomised Trial in Ovarian Cancer,pleural effusion
D011655,3.7,NCT01121406-1,Volasertib (BI 6727),NCT01121406,BI 6727 (Volasertib) Randomised Trial in Ovarian Cancer,pulmonary embolism
D012127,1.85,NCT01121406-1,Volasertib (BI 6727),NCT01121406,BI 6727 (Volasertib) Randomised Trial in Ovarian Cancer,respiratory distress syndrome newborn
D006973,1.85,NCT01121406-1,Volasertib (BI 6727),NCT01121406,BI 6727 (Volasertib) Randomised Trial in Ovarian Cancer,hypertension
D019022,1.85,NCT01121406-1,Volasertib (BI 6727),NCT01121406,BI 6727 (Volasertib) Randomised Trial in Ovarian Cancer,poorhouses
D064420,37.5,NCT01167192-1,Neoadjuvant Cisplatin or Carboplatin AUC 6 & Radiation,NCT01167192,Neoadjuvant Platinum-based Chemoradiation Therapy for Locally Advanced Triple Negative Breast Cancer,adverse drug events
D000740,25.0,NCT01167192-1,Neoadjuvant Cisplatin or Carboplatin AUC 6 & Radiation,NCT01167192,Neoadjuvant Platinum-based Chemoradiation Therapy for Locally Advanced Triple Negative Breast Cancer,anemia
D007964,12.5,NCT01167192-1,Neoadjuvant Cisplatin or Carboplatin AUC 6 & Radiation,NCT01167192,Neoadjuvant Platinum-based Chemoradiation Therapy for Locally Advanced Triple Negative Breast Cancer,leukocytosis
D001919,12.5,NCT01167192-1,Neoadjuvant Cisplatin or Carboplatin AUC 6 & Radiation,NCT01167192,Neoadjuvant Platinum-based Chemoradiation Therapy for Locally Advanced Triple Negative Breast Cancer,bradycardia
D006323,12.5,NCT01167192-1,Neoadjuvant Cisplatin or Carboplatin AUC 6 & Radiation,NCT01167192,Neoadjuvant Platinum-based Chemoradiation Therapy for Locally Advanced Triple Negative Breast Cancer,cardiac arrest
D001931,12.5,NCT01167192-1,Neoadjuvant Cisplatin or Carboplatin AUC 6 & Radiation,NCT01167192,Neoadjuvant Platinum-based Chemoradiation Therapy for Locally Advanced Triple Negative Breast Cancer,brain electrical activity mapping
D009325,12.5,NCT01167192-1,Neoadjuvant Cisplatin or Carboplatin AUC 6 & Radiation,NCT01167192,Neoadjuvant Platinum-based Chemoradiation Therapy for Locally Advanced Triple Negative Breast Cancer,nausea
D014839,25.0,NCT01167192-1,Neoadjuvant Cisplatin or Carboplatin AUC 6 & Radiation,NCT01167192,Neoadjuvant Platinum-based Chemoradiation Therapy for Locally Advanced Triple Negative Breast Cancer,vomiting
D023341,25.0,NCT01167192-1,Neoadjuvant Cisplatin or Carboplatin AUC 6 & Radiation,NCT01167192,Neoadjuvant Platinum-based Chemoradiation Therapy for Locally Advanced Triple Negative Breast Cancer,chills
D005334,25.0,NCT01167192-1,Neoadjuvant Cisplatin or Carboplatin AUC 6 & Radiation,NCT01167192,Neoadjuvant Platinum-based Chemoradiation Therapy for Locally Advanced Triple Negative Breast Cancer,fever
D016470,12.5,NCT01167192-1,Neoadjuvant Cisplatin or Carboplatin AUC 6 & Radiation,NCT01167192,Neoadjuvant Platinum-based Chemoradiation Therapy for Locally Advanced Triple Negative Breast Cancer,bacteremia
D014552,12.5,NCT01167192-1,Neoadjuvant Cisplatin or Carboplatin AUC 6 & Radiation,NCT01167192,Neoadjuvant Platinum-based Chemoradiation Therapy for Locally Advanced Triple Negative Breast Cancer,urinary tract infection
10007839,25.0,NCT01167192-1,Neoadjuvant Cisplatin or Carboplatin AUC 6 & Radiation,NCT01167192,Neoadjuvant Platinum-based Chemoradiation Therapy for Locally Advanced Triple Negative Breast Cancer,cd4 lymphocytes decreased
D001792,12.5,NCT01167192-1,Neoadjuvant Cisplatin or Carboplatin AUC 6 & Radiation,NCT01167192,Neoadjuvant Platinum-based Chemoradiation Therapy for Locally Advanced Triple Negative Breast Cancer,platelets
10011368,25.0,NCT01167192-1,Neoadjuvant Cisplatin or Carboplatin AUC 6 & Radiation,NCT01167192,Neoadjuvant Platinum-based Chemoradiation Therapy for Locally Advanced Triple Negative Breast Cancer,creatinine increased
D000547,12.5,NCT01167192-1,Neoadjuvant Cisplatin or Carboplatin AUC 6 & Radiation,NCT01167192,Neoadjuvant Platinum-based Chemoradiation Therapy for Locally Advanced Triple Negative Breast Cancer,amantadinratiopharm
10001675,25.0,NCT01167192-1,Neoadjuvant Cisplatin or Carboplatin AUC 6 & Radiation,NCT01167192,Neoadjuvant Platinum-based Chemoradiation Therapy for Locally Advanced Triple Negative Breast Cancer,alkaline phosphatase increased
D000855,12.5,NCT01167192-1,Neoadjuvant Cisplatin or Carboplatin AUC 6 & Radiation,NCT01167192,Neoadjuvant Platinum-based Chemoradiation Therapy for Locally Advanced Triple Negative Breast Cancer,anorexia
D006934,12.5,NCT01167192-1,Neoadjuvant Cisplatin or Carboplatin AUC 6 & Radiation,NCT01167192,Neoadjuvant Platinum-based Chemoradiation Therapy for Locally Advanced Triple Negative Breast Cancer,hypercalcemia
D006943,12.5,NCT01167192-1,Neoadjuvant Cisplatin or Carboplatin AUC 6 & Radiation,NCT01167192,Neoadjuvant Platinum-based Chemoradiation Therapy for Locally Advanced Triple Negative Breast Cancer,hyperglycemia
D006947,12.5,NCT01167192-1,Neoadjuvant Cisplatin or Carboplatin AUC 6 & Radiation,NCT01167192,Neoadjuvant Platinum-based Chemoradiation Therapy for Locally Advanced Triple Negative Breast Cancer,hyperkalemia
D015228,12.5,NCT01167192-1,Neoadjuvant Cisplatin or Carboplatin AUC 6 & Radiation,NCT01167192,Neoadjuvant Platinum-based Chemoradiation Therapy for Locally Advanced Triple Negative Breast Cancer,hypertriglyceridemia
D034141,25.0,NCT01167192-1,Neoadjuvant Cisplatin or Carboplatin AUC 6 & Radiation,NCT01167192,Neoadjuvant Platinum-based Chemoradiation Therapy for Locally Advanced Triple Negative Breast Cancer,hypoalbuminemia
D006996,12.5,NCT01167192-1,Neoadjuvant Cisplatin or Carboplatin AUC 6 & Radiation,NCT01167192,Neoadjuvant Platinum-based Chemoradiation Therapy for Locally Advanced Triple Negative Breast Cancer,hypocalcemia
D007003,12.5,NCT01167192-1,Neoadjuvant Cisplatin or Carboplatin AUC 6 & Radiation,NCT01167192,Neoadjuvant Platinum-based Chemoradiation Therapy for Locally Advanced Triple Negative Breast Cancer,hypoglycemia
10021028,12.5,NCT01167192-1,Neoadjuvant Cisplatin or Carboplatin AUC 6 & Radiation,NCT01167192,Neoadjuvant Platinum-based Chemoradiation Therapy for Locally Advanced Triple Negative Breast Cancer,hypomagnesemia
D007010,12.5,NCT01167192-1,Neoadjuvant Cisplatin or Carboplatin AUC 6 & Radiation,NCT01167192,Neoadjuvant Platinum-based Chemoradiation Therapy for Locally Advanced Triple Negative Breast Cancer,hyponatremia
D001416,12.5,NCT01167192-1,Neoadjuvant Cisplatin or Carboplatin AUC 6 & Radiation,NCT01167192,Neoadjuvant Platinum-based Chemoradiation Therapy for Locally Advanced Triple Negative Breast Cancer,back pain
D001259,12.5,NCT01167192-1,Neoadjuvant Cisplatin or Carboplatin AUC 6 & Radiation,NCT01167192,Neoadjuvant Platinum-based Chemoradiation Therapy for Locally Advanced Triple Negative Breast Cancer,ataxia
D002548,12.5,NCT01167192-1,Neoadjuvant Cisplatin or Carboplatin AUC 6 & Radiation,NCT01167192,Neoadjuvant Platinum-based Chemoradiation Therapy for Locally Advanced Triple Negative Breast Cancer,cerebral revascularization
UNKNOWN-check-for-typo,12.5,NCT01167192-1,Neoadjuvant Cisplatin or Carboplatin AUC 6 & Radiation,NCT01167192,Neoadjuvant Platinum-based Chemoradiation Therapy for Locally Advanced Triple Negative Breast Cancer,D00
D058186,12.5,NCT01167192-1,Neoadjuvant Cisplatin or Carboplatin AUC 6 & Radiation,NCT01167192,Neoadjuvant Platinum-based Chemoradiation Therapy for Locally Advanced Triple Negative Breast Cancer,acute renal injury
D002481,12.5,NCT01167192-1,Neoadjuvant Cisplatin or Carboplatin AUC 6 & Radiation,NCT01167192,Neoadjuvant Platinum-based Chemoradiation Therapy for Locally Advanced Triple Negative Breast Cancer,cellulitis
D006973,12.5,NCT01167192-1,Neoadjuvant Cisplatin or Carboplatin AUC 6 & Radiation,NCT01167192,Neoadjuvant Platinum-based Chemoradiation Therapy for Locally Advanced Triple Negative Breast Cancer,hypertension
D064420,46.67,NCT01185964-1,Phase 1b: Olaratumab + Doxorubicin,NCT01185964,A Study of Olaratumab in Soft Tissue Sarcoma,adverse drug events
D064420,42.19,NCT01185964-2,Phase 2: Olaratumab + Doxorubicin,NCT01185964,A Study of Olaratumab in Soft Tissue Sarcoma,adverse drug events
D064420,40.0,NCT01185964-3,Phase 2: Doxorubicin,NCT01185964,A Study of Olaratumab in Soft Tissue Sarcoma,adverse drug events
D064420,30.0,NCT01185964-4,Phase 2: Doxorubicin: Optional Olaratumab After Progression,NCT01185964,A Study of Olaratumab in Soft Tissue Sarcoma,adverse drug events
D000741,1.54,NCT01185964-3,Phase 2: Doxorubicin,NCT01185964,A Study of Olaratumab in Soft Tissue Sarcoma,aplastic anaemia
D064147,13.33,NCT01185964-1,Phase 1b: Olaratumab + Doxorubicin,NCT01185964,A Study of Olaratumab in Soft Tissue Sarcoma,febrile neutropenia
D064147,12.5,NCT01185964-2,Phase 2: Olaratumab + Doxorubicin,NCT01185964,A Study of Olaratumab in Soft Tissue Sarcoma,febrile neutropenia
D064147,12.31,NCT01185964-3,Phase 2: Doxorubicin,NCT01185964,A Study of Olaratumab in Soft Tissue Sarcoma,febrile neutropenia
D009503,4.69,NCT01185964-2,Phase 2: Olaratumab + Doxorubicin,NCT01185964,A Study of Olaratumab in Soft Tissue Sarcoma,neutropenia
D009503,4.62,NCT01185964-3,Phase 2: Doxorubicin,NCT01185964,A Study of Olaratumab in Soft Tissue Sarcoma,neutropenia
D013921,3.08,NCT01185964-3,Phase 2: Doxorubicin,NCT01185964,A Study of Olaratumab in Soft Tissue Sarcoma,thrombocytopenia
D006323,3.33,NCT01185964-4,Phase 2: Doxorubicin: Optional Olaratumab After Progression,NCT01185964,A Study of Olaratumab in Soft Tissue Sarcoma,cardiac arrest
10040741,1.56,NCT01185964-2,Phase 2: Olaratumab + Doxorubicin,NCT01185964,A Study of Olaratumab in Soft Tissue Sarcoma,sinus bradycardia
D007177,1.54,NCT01185964-3,Phase 2: Doxorubicin,NCT01185964,A Study of Olaratumab in Soft Tissue Sarcoma,antidiuretic hormone inappropriate secretion
D015746,6.67,NCT01185964-1,Phase 1b: Olaratumab + Doxorubicin,NCT01185964,A Study of Olaratumab in Soft Tissue Sarcoma,abdominal pain
D015746,1.56,NCT01185964-2,Phase 2: Olaratumab + Doxorubicin,NCT01185964,A Study of Olaratumab in Soft Tissue Sarcoma,abdominal pain
D015746,1.54,NCT01185964-3,Phase 2: Doxorubicin,NCT01185964,A Study of Olaratumab in Soft Tissue Sarcoma,abdominal pain
D015746,6.67,NCT01185964-1,Phase 1b: Olaratumab + Doxorubicin,NCT01185964,A Study of Olaratumab in Soft Tissue Sarcoma,abdominal pain
D015746,1.56,NCT01185964-2,Phase 2: Olaratumab + Doxorubicin,NCT01185964,A Study of Olaratumab in Soft Tissue Sarcoma,abdominal pain
D001201,1.54,NCT01185964-3,Phase 2: Doxorubicin,NCT01185964,A Study of Olaratumab in Soft Tissue Sarcoma,ascites
D003248,1.56,NCT01185964-2,Phase 2: Olaratumab + Doxorubicin,NCT01185964,A Study of Olaratumab in Soft Tissue Sarcoma,constipation
D003248,1.54,NCT01185964-3,Phase 2: Doxorubicin,NCT01185964,A Study of Olaratumab in Soft Tissue Sarcoma,constipation
UNKNOWN-check-for-typo,6.67,NCT01185964-1,Phase 1b: Olaratumab + Doxorubicin,NCT01185964,A Study of Olaratumab in Soft Tissue Sarcoma,D00
UNKNOWN-check-for-typo,1.54,NCT01185964-3,Phase 2: Doxorubicin,NCT01185964,A Study of Olaratumab in Soft Tissue Sarcoma,D00
10013781,1.56,NCT01185964-2,Phase 2: Olaratumab + Doxorubicin,NCT01185964,A Study of Olaratumab in Soft Tissue Sarcoma,dry mouth
10017815,1.56,NCT01185964-2,Phase 2: Olaratumab + Doxorubicin,NCT01185964,A Study of Olaratumab in Soft Tissue Sarcoma,gastric perforation
D013276,6.67,NCT01185964-1,Phase 1b: Olaratumab + Doxorubicin,NCT01185964,A Study of Olaratumab in Soft Tissue Sarcoma,gastric ulcer
D000069196,1.54,NCT01185964-3,Phase 2: Doxorubicin,NCT01185964,A Study of Olaratumab in Soft Tissue Sarcoma,gastrointestinal microbiome
D000069196,3.33,NCT01185964-4,Phase 2: Doxorubicin: Optional Olaratumab After Progression,NCT01185964,A Study of Olaratumab in Soft Tissue Sarcoma,gastrointestinal microbiome
D045823,1.56,NCT01185964-2,Phase 2: Olaratumab + Doxorubicin,NCT01185964,A Study of Olaratumab in Soft Tissue Sarcoma,ileus
D009325,13.33,NCT01185964-1,Phase 1b: Olaratumab + Doxorubicin,NCT01185964,A Study of Olaratumab in Soft Tissue Sarcoma,nausea
D009325,1.56,NCT01185964-2,Phase 2: Olaratumab + Doxorubicin,NCT01185964,A Study of Olaratumab in Soft Tissue Sarcoma,nausea
D009325,3.08,NCT01185964-3,Phase 2: Doxorubicin,NCT01185964,A Study of Olaratumab in Soft Tissue Sarcoma,nausea
10041101,6.67,NCT01185964-1,Phase 1b: Olaratumab + Doxorubicin,NCT01185964,A Study of Olaratumab in Soft Tissue Sarcoma,small intestinal obstruction
10041101,1.56,NCT01185964-2,Phase 2: Olaratumab + Doxorubicin,NCT01185964,A Study of Olaratumab in Soft Tissue Sarcoma,small intestinal obstruction
10041101,3.08,NCT01185964-3,Phase 2: Doxorubicin,NCT01185964,A Study of Olaratumab in Soft Tissue Sarcoma,small intestinal obstruction
D041742,3.33,NCT01185964-4,Phase 2: Doxorubicin: Optional Olaratumab After Progression,NCT01185964,A Study of Olaratumab in Soft Tissue Sarcoma,upper gastrointestinal tract
D014839,20.0,NCT01185964-1,Phase 1b: Olaratumab + Doxorubicin,NCT01185964,A Study of Olaratumab in Soft Tissue Sarcoma,vomiting
D014839,1.56,NCT01185964-2,Phase 2: Olaratumab + Doxorubicin,NCT01185964,A Study of Olaratumab in Soft Tissue Sarcoma,vomiting
D001247,1.56,NCT01185964-2,Phase 2: Olaratumab + Doxorubicin,NCT01185964,A Study of Olaratumab in Soft Tissue Sarcoma,asthenia
D003643,6.67,NCT01185964-1,Phase 1b: Olaratumab + Doxorubicin,NCT01185964,A Study of Olaratumab in Soft Tissue Sarcoma,death
D004864,1.56,NCT01185964-2,Phase 2: Olaratumab + Doxorubicin,NCT01185964,A Study of Olaratumab in Soft Tissue Sarcoma,devices
D018450,3.33,NCT01185964-4,Phase 2: Doxorubicin: Optional Olaratumab After Progression,NCT01185964,A Study of Olaratumab in Soft Tissue Sarcoma,disease progression
10062501,6.67,NCT01185964-1,Phase 1b: Olaratumab + Doxorubicin,NCT01185964,A Study of Olaratumab in Soft Tissue Sarcoma,non-cardiac chest pain
10062501,1.56,NCT01185964-2,Phase 2: Olaratumab + Doxorubicin,NCT01185964,A Study of Olaratumab in Soft Tissue Sarcoma,non-cardiac chest pain
10062501,1.54,NCT01185964-3,Phase 2: Doxorubicin,NCT01185964,A Study of Olaratumab in Soft Tissue Sarcoma,non-cardiac chest pain
D005334,1.54,NCT01185964-3,Phase 2: Doxorubicin,NCT01185964,A Study of Olaratumab in Soft Tissue Sarcoma,pyrexia
D029626,1.56,NCT01185964-2,Phase 2: Olaratumab + Doxorubicin,NCT01185964,A Study of Olaratumab in Soft Tissue Sarcoma,hepatica
D006967,3.12,NCT01185964-2,Phase 2: Olaratumab + Doxorubicin,NCT01185964,A Study of Olaratumab in Soft Tissue Sarcoma,hypersensitivity
10040872,1.56,NCT01185964-2,Phase 2: Olaratumab + Doxorubicin,NCT01185964,A Study of Olaratumab in Soft Tissue Sarcoma,skin infection
D002481,1.56,NCT01185964-2,Phase 2: Olaratumab + Doxorubicin,NCT01185964,A Study of Olaratumab in Soft Tissue Sarcoma,cellulitis
D002481,3.08,NCT01185964-3,Phase 2: Doxorubicin,NCT01185964,A Study of Olaratumab in Soft Tissue Sarcoma,cellulitis
D004761,1.56,NCT01185964-2,Phase 2: Olaratumab + Doxorubicin,NCT01185964,A Study of Olaratumab in Soft Tissue Sarcoma,clostridium enterocolitis
D007251,3.33,NCT01185964-4,Phase 2: Doxorubicin: Optional Olaratumab After Progression,NCT01185964,A Study of Olaratumab in Soft Tissue Sarcoma,influenza
D000985,3.08,NCT01185964-3,Phase 2: Doxorubicin,NCT01185964,A Study of Olaratumab in Soft Tissue Sarcoma,antisepsis
D018805,1.54,NCT01185964-3,Phase 2: Doxorubicin,NCT01185964,A Study of Olaratumab in Soft Tissue Sarcoma,sepsis
D012772,1.54,NCT01185964-3,Phase 2: Doxorubicin,NCT01185964,A Study of Olaratumab in Soft Tissue Sarcoma,septic shock
D012852,1.56,NCT01185964-2,Phase 2: Olaratumab + Doxorubicin,NCT01185964,A Study of Olaratumab in Soft Tissue Sarcoma,sinusitis
10040872,1.54,NCT01185964-3,Phase 2: Doxorubicin,NCT01185964,A Study of Olaratumab in Soft Tissue Sarcoma,skin infection
D004768,1.56,NCT01185964-2,Phase 2: Olaratumab + Doxorubicin,NCT01185964,A Study of Olaratumab in Soft Tissue Sarcoma,staphylococcal enterotoxins
D014552,1.56,NCT01185964-2,Phase 2: Olaratumab + Doxorubicin,NCT01185964,A Study of Olaratumab in Soft Tissue Sarcoma,urinary tract infection
D014552,4.62,NCT01185964-3,Phase 2: Doxorubicin,NCT01185964,A Study of Olaratumab in Soft Tissue Sarcoma,urinary tract infection
D013392,1.54,NCT01185964-3,Phase 2: Doxorubicin,NCT01185964,A Study of Olaratumab in Soft Tissue Sarcoma,ulcerban
10017076,6.67,NCT01185964-1,Phase 1b: Olaratumab + Doxorubicin,NCT01185964,A Study of Olaratumab in Soft Tissue Sarcoma,fracture
10051792,3.33,NCT01185964-4,Phase 2: Doxorubicin: Optional Olaratumab After Progression,NCT01185964,A Study of Olaratumab in Soft Tissue Sarcoma,infusion related reaction
D000073818,1.54,NCT01185964-3,Phase 2: Doxorubicin,NCT01185964,A Study of Olaratumab in Soft Tissue Sarcoma,procedural pain
D005218,1.56,NCT01185964-2,Phase 2: Olaratumab + Doxorubicin,NCT01185964,A Study of Olaratumab in Soft Tissue Sarcoma,steatonecrosis
10011368,1.54,NCT01185964-3,Phase 2: Doxorubicin,NCT01185964,A Study of Olaratumab in Soft Tissue Sarcoma,creatinine increased
10007612,1.56,NCT01185964-2,Phase 2: Olaratumab + Doxorubicin,NCT01185964,A Study of Olaratumab in Soft Tissue Sarcoma,cardiac troponin i increased
D007958,1.56,NCT01185964-2,Phase 2: Olaratumab + Doxorubicin,NCT01185964,A Study of Olaratumab in Soft Tissue Sarcoma,blood cell count white
D001066,1.56,NCT01185964-2,Phase 2: Olaratumab + Doxorubicin,NCT01185964,A Study of Olaratumab in Soft Tissue Sarcoma,appetite
D003681,1.56,NCT01185964-2,Phase 2: Olaratumab + Doxorubicin,NCT01185964,A Study of Olaratumab in Soft Tissue Sarcoma,dehydration
UNKNOWN-check-for-typo,1.56,NCT01185964-2,Phase 2: Olaratumab + Doxorubicin,NCT01185964,A Study of Olaratumab in Soft Tissue Sarcoma,D00
UNKNOWN-check-for-typo,1.56,NCT01185964-2,Phase 2: Olaratumab + Doxorubicin,NCT01185964,A Study of Olaratumab in Soft Tissue Sarcoma,D00
UNKNOWN-check-for-typo,1.54,NCT01185964-3,Phase 2: Doxorubicin,NCT01185964,A Study of Olaratumab in Soft Tissue Sarcoma,D00
UNKNOWN-check-for-typo,1.56,NCT01185964-2,Phase 2: Olaratumab + Doxorubicin,NCT01185964,A Study of Olaratumab in Soft Tissue Sarcoma,D00
D018771,1.56,NCT01185964-2,Phase 2: Olaratumab + Doxorubicin,NCT01185964,A Study of Olaratumab in Soft Tissue Sarcoma,arthralgia
D001416,13.33,NCT01185964-1,Phase 1b: Olaratumab + Doxorubicin,NCT01185964,A Study of Olaratumab in Soft Tissue Sarcoma,back pain
D001416,3.12,NCT01185964-2,Phase 2: Olaratumab + Doxorubicin,NCT01185964,A Study of Olaratumab in Soft Tissue Sarcoma,back pain
D001416,6.67,NCT01185964-4,Phase 2: Doxorubicin: Optional Olaratumab After Progression,NCT01185964,A Study of Olaratumab in Soft Tissue Sarcoma,back pain
D002637,1.54,NCT01185964-3,Phase 2: Doxorubicin,NCT01185964,A Study of Olaratumab in Soft Tissue Sarcoma,chest pain
10033425,1.56,NCT01185964-2,Phase 2: Olaratumab + Doxorubicin,NCT01185964,A Study of Olaratumab in Soft Tissue Sarcoma,pain in extremity
10033425,3.33,NCT01185964-4,Phase 2: Doxorubicin: Optional Olaratumab After Progression,NCT01185964,A Study of Olaratumab in Soft Tissue Sarcoma,pain in extremity
D000080867,3.33,NCT01185964-4,Phase 2: Doxorubicin: Optional Olaratumab After Progression,NCT01185964,A Study of Olaratumab in Soft Tissue Sarcoma,gingipains
D020521,1.54,NCT01185964-3,Phase 2: Doxorubicin,NCT01185964,A Study of Olaratumab in Soft Tissue Sarcoma,cerebrovascular accident
D012640,1.54,NCT01185964-3,Phase 2: Doxorubicin,NCT01185964,A Study of Olaratumab in Soft Tissue Sarcoma,convulsion
D013575,1.54,NCT01185964-3,Phase 2: Doxorubicin,NCT01185964,A Study of Olaratumab in Soft Tissue Sarcoma,syncope
D058186,1.54,NCT01185964-3,Phase 2: Doxorubicin,NCT01185964,A Study of Olaratumab in Soft Tissue Sarcoma,acute renal failure
UNKNOWN-check-for-typo,1.54,NCT01185964-3,Phase 2: Doxorubicin,NCT01185964,A Study of Olaratumab in Soft Tissue Sarcoma,D00
UNKNOWN-check-for-typo,3.33,NCT01185964-4,Phase 2: Doxorubicin: Optional Olaratumab After Progression,NCT01185964,A Study of Olaratumab in Soft Tissue Sarcoma,D00
D000067836,1.54,NCT01185964-3,Phase 2: Doxorubicin,NCT01185964,A Study of Olaratumab in Soft Tissue Sarcoma,hoarding disorder
D010996,6.67,NCT01185964-1,Phase 1b: Olaratumab + Doxorubicin,NCT01185964,A Study of Olaratumab in Soft Tissue Sarcoma,pleural effusion
D010996,1.56,NCT01185964-2,Phase 2: Olaratumab + Doxorubicin,NCT01185964,A Study of Olaratumab in Soft Tissue Sarcoma,pleural effusion
D010996,1.54,NCT01185964-3,Phase 2: Doxorubicin,NCT01185964,A Study of Olaratumab in Soft Tissue Sarcoma,pleural effusion
10035623,1.56,NCT01185964-2,Phase 2: Olaratumab + Doxorubicin,NCT01185964,A Study of Olaratumab in Soft Tissue Sarcoma,pleuritic pain
D011015,1.54,NCT01185964-3,Phase 2: Doxorubicin,NCT01185964,A Study of Olaratumab in Soft Tissue Sarcoma,aspiration pneumonia
D011030,3.12,NCT01185964-2,Phase 2: Olaratumab + Doxorubicin,NCT01185964,A Study of Olaratumab in Soft Tissue Sarcoma,pneumothorax
D011030,3.08,NCT01185964-3,Phase 2: Doxorubicin,NCT01185964,A Study of Olaratumab in Soft Tissue Sarcoma,pneumothorax
D011655,6.67,NCT01185964-1,Phase 1b: Olaratumab + Doxorubicin,NCT01185964,A Study of Olaratumab in Soft Tissue Sarcoma,pulmonary embolism
D011655,1.54,NCT01185964-3,Phase 2: Doxorubicin,NCT01185964,A Study of Olaratumab in Soft Tissue Sarcoma,pulmonary embolism
D012131,1.56,NCT01185964-2,Phase 2: Olaratumab + Doxorubicin,NCT01185964,A Study of Olaratumab in Soft Tissue Sarcoma,respiratory failure
D012131,1.54,NCT01185964-3,Phase 2: Doxorubicin,NCT01185964,A Study of Olaratumab in Soft Tissue Sarcoma,respiratory failure
D007022,1.54,NCT01185964-3,Phase 2: Doxorubicin,NCT01185964,A Study of Olaratumab in Soft Tissue Sarcoma,hypotension
D064420,37.5,NCT01188499-1,Arm 1: Carboplatin/Paclitaxel + Birinapant,NCT01188499,Dose Escalation  Combination Chemotherapy Safety Study of Birinapant (TL32711)  in Subjects With Advanced or Metastatic Solid Tumors,adverse drug events
D064420,49.4,NCT01188499-2,Arm 2: Irinotecan + Birinapant,NCT01188499,Dose Escalation  Combination Chemotherapy Safety Study of Birinapant (TL32711)  in Subjects With Advanced or Metastatic Solid Tumors,adverse drug events
D064420,48.48,NCT01188499-3,Arm 3: Docetaxel + Birinapant,NCT01188499,Dose Escalation  Combination Chemotherapy Safety Study of Birinapant (TL32711)  in Subjects With Advanced or Metastatic Solid Tumors,adverse drug events
D064420,72.22,NCT01188499-4,Arm 4: Gemcitabine + Birinapant,NCT01188499,Dose Escalation  Combination Chemotherapy Safety Study of Birinapant (TL32711)  in Subjects With Advanced or Metastatic Solid Tumors,adverse drug events
D064420,50.0,NCT01188499-5,Arm 5: Liposomal Doxorubicin + Birinapant,NCT01188499,Dose Escalation  Combination Chemotherapy Safety Study of Birinapant (TL32711)  in Subjects With Advanced or Metastatic Solid Tumors,adverse drug events
D000741,8.33,NCT01188499-1,Arm 1: Carboplatin/Paclitaxel + Birinapant,NCT01188499,Dose Escalation  Combination Chemotherapy Safety Study of Birinapant (TL32711)  in Subjects With Advanced or Metastatic Solid Tumors,aplastic anaemia
D000741,3.61,NCT01188499-2,Arm 2: Irinotecan + Birinapant,NCT01188499,Dose Escalation  Combination Chemotherapy Safety Study of Birinapant (TL32711)  in Subjects With Advanced or Metastatic Solid Tumors,aplastic anaemia
D000741,6.06,NCT01188499-3,Arm 3: Docetaxel + Birinapant,NCT01188499,Dose Escalation  Combination Chemotherapy Safety Study of Birinapant (TL32711)  in Subjects With Advanced or Metastatic Solid Tumors,aplastic anaemia
D000741,5.56,NCT01188499-4,Arm 4: Gemcitabine + Birinapant,NCT01188499,Dose Escalation  Combination Chemotherapy Safety Study of Birinapant (TL32711)  in Subjects With Advanced or Metastatic Solid Tumors,aplastic anaemia
D000741,5.56,NCT01188499-5,Arm 5: Liposomal Doxorubicin + Birinapant,NCT01188499,Dose Escalation  Combination Chemotherapy Safety Study of Birinapant (TL32711)  in Subjects With Advanced or Metastatic Solid Tumors,aplastic anaemia
D004211,1.2,NCT01188499-2,Arm 2: Irinotecan + Birinapant,NCT01188499,Dose Escalation  Combination Chemotherapy Safety Study of Birinapant (TL32711)  in Subjects With Advanced or Metastatic Solid Tumors,consumption coagulopathy
D004211,5.56,NCT01188499-4,Arm 4: Gemcitabine + Birinapant,NCT01188499,Dose Escalation  Combination Chemotherapy Safety Study of Birinapant (TL32711)  in Subjects With Advanced or Metastatic Solid Tumors,consumption coagulopathy
D004211,5.56,NCT01188499-5,Arm 5: Liposomal Doxorubicin + Birinapant,NCT01188499,Dose Escalation  Combination Chemotherapy Safety Study of Birinapant (TL32711)  in Subjects With Advanced or Metastatic Solid Tumors,disseminated intravascular coagulation
D064147,8.43,NCT01188499-2,Arm 2: Irinotecan + Birinapant,NCT01188499,Dose Escalation  Combination Chemotherapy Safety Study of Birinapant (TL32711)  in Subjects With Advanced or Metastatic Solid Tumors,febrile neutropenia
D064147,3.03,NCT01188499-3,Arm 3: Docetaxel + Birinapant,NCT01188499,Dose Escalation  Combination Chemotherapy Safety Study of Birinapant (TL32711)  in Subjects With Advanced or Metastatic Solid Tumors,febrile neutropenia
D009503,6.02,NCT01188499-2,Arm 2: Irinotecan + Birinapant,NCT01188499,Dose Escalation  Combination Chemotherapy Safety Study of Birinapant (TL32711)  in Subjects With Advanced or Metastatic Solid Tumors,neutropenia
D009503,3.03,NCT01188499-3,Arm 3: Docetaxel + Birinapant,NCT01188499,Dose Escalation  Combination Chemotherapy Safety Study of Birinapant (TL32711)  in Subjects With Advanced or Metastatic Solid Tumors,neutropenia
D007964,4.17,NCT01188499-1,Arm 1: Carboplatin/Paclitaxel + Birinapant,NCT01188499,Dose Escalation  Combination Chemotherapy Safety Study of Birinapant (TL32711)  in Subjects With Advanced or Metastatic Solid Tumors,leukocytosis
D013921,3.61,NCT01188499-2,Arm 2: Irinotecan + Birinapant,NCT01188499,Dose Escalation  Combination Chemotherapy Safety Study of Birinapant (TL32711)  in Subjects With Advanced or Metastatic Solid Tumors,thrombocytopenia
D013921,3.03,NCT01188499-3,Arm 3: Docetaxel + Birinapant,NCT01188499,Dose Escalation  Combination Chemotherapy Safety Study of Birinapant (TL32711)  in Subjects With Advanced or Metastatic Solid Tumors,thrombocytopenia
D010198,3.61,NCT01188499-2,Arm 2: Irinotecan + Birinapant,NCT01188499,Dose Escalation  Combination Chemotherapy Safety Study of Birinapant (TL32711)  in Subjects With Advanced or Metastatic Solid Tumors,pancytopenia
D002305,5.56,NCT01188499-5,Arm 5: Liposomal Doxorubicin + Birinapant,NCT01188499,Dose Escalation  Combination Chemotherapy Safety Study of Birinapant (TL32711)  in Subjects With Advanced or Metastatic Solid Tumors,cardiac tamponade
D054549,5.56,NCT01188499-4,Arm 4: Gemcitabine + Birinapant,NCT01188499,Dose Escalation  Combination Chemotherapy Safety Study of Birinapant (TL32711)  in Subjects With Advanced or Metastatic Solid Tumors,stress cardiomyopathy
D011707,3.03,NCT01188499-3,Arm 3: Docetaxel + Birinapant,NCT01188499,Dose Escalation  Combination Chemotherapy Safety Study of Birinapant (TL32711)  in Subjects With Advanced or Metastatic Solid Tumors,pyloric stenosis
D015746,4.82,NCT01188499-2,Arm 2: Irinotecan + Birinapant,NCT01188499,Dose Escalation  Combination Chemotherapy Safety Study of Birinapant (TL32711)  in Subjects With Advanced or Metastatic Solid Tumors,abdominal pain
D015746,3.03,NCT01188499-3,Arm 3: Docetaxel + Birinapant,NCT01188499,Dose Escalation  Combination Chemotherapy Safety Study of Birinapant (TL32711)  in Subjects With Advanced or Metastatic Solid Tumors,abdominal pain
D015746,11.11,NCT01188499-5,Arm 5: Liposomal Doxorubicin + Birinapant,NCT01188499,Dose Escalation  Combination Chemotherapy Safety Study of Birinapant (TL32711)  in Subjects With Advanced or Metastatic Solid Tumors,abdominal pain
D015746,4.17,NCT01188499-1,Arm 1: Carboplatin/Paclitaxel + Birinapant,NCT01188499,Dose Escalation  Combination Chemotherapy Safety Study of Birinapant (TL32711)  in Subjects With Advanced or Metastatic Solid Tumors,abdominal pain
D015746,1.2,NCT01188499-2,Arm 2: Irinotecan + Birinapant,NCT01188499,Dose Escalation  Combination Chemotherapy Safety Study of Birinapant (TL32711)  in Subjects With Advanced or Metastatic Solid Tumors,abdominal pain
D005401,1.2,NCT01188499-2,Arm 2: Irinotecan + Birinapant,NCT01188499,Dose Escalation  Combination Chemotherapy Safety Study of Birinapant (TL32711)  in Subjects With Advanced or Metastatic Solid Tumors,anal fissure
D001201,3.03,NCT01188499-3,Arm 3: Docetaxel + Birinapant,NCT01188499,Dose Escalation  Combination Chemotherapy Safety Study of Birinapant (TL32711)  in Subjects With Advanced or Metastatic Solid Tumors,ascites
D003092,3.61,NCT01188499-2,Arm 2: Irinotecan + Birinapant,NCT01188499,Dose Escalation  Combination Chemotherapy Safety Study of Birinapant (TL32711)  in Subjects With Advanced or Metastatic Solid Tumors,colitis
D003248,8.33,NCT01188499-1,Arm 1: Carboplatin/Paclitaxel + Birinapant,NCT01188499,Dose Escalation  Combination Chemotherapy Safety Study of Birinapant (TL32711)  in Subjects With Advanced or Metastatic Solid Tumors,constipation
UNKNOWN-check-for-typo,7.23,NCT01188499-2,Arm 2: Irinotecan + Birinapant,NCT01188499,Dose Escalation  Combination Chemotherapy Safety Study of Birinapant (TL32711)  in Subjects With Advanced or Metastatic Solid Tumors,D00
D000069196,2.41,NCT01188499-2,Arm 2: Irinotecan + Birinapant,NCT01188499,Dose Escalation  Combination Chemotherapy Safety Study of Birinapant (TL32711)  in Subjects With Advanced or Metastatic Solid Tumors,gastrointestinal microbiome
D000069196,3.03,NCT01188499-3,Arm 3: Docetaxel + Birinapant,NCT01188499,Dose Escalation  Combination Chemotherapy Safety Study of Birinapant (TL32711)  in Subjects With Advanced or Metastatic Solid Tumors,gastrointestinal microbiome
D007415,3.03,NCT01188499-3,Arm 3: Docetaxel + Birinapant,NCT01188499,Dose Escalation  Combination Chemotherapy Safety Study of Birinapant (TL32711)  in Subjects With Advanced or Metastatic Solid Tumors,intestinal obstruction
D007416,3.03,NCT01188499-3,Arm 3: Docetaxel + Birinapant,NCT01188499,Dose Escalation  Combination Chemotherapy Safety Study of Birinapant (TL32711)  in Subjects With Advanced or Metastatic Solid Tumors,intestinal perforation
D041741,3.03,NCT01188499-3,Arm 3: Docetaxel + Birinapant,NCT01188499,Dose Escalation  Combination Chemotherapy Safety Study of Birinapant (TL32711)  in Subjects With Advanced or Metastatic Solid Tumors,lower gastrointestinal tract
D009325,4.17,NCT01188499-1,Arm 1: Carboplatin/Paclitaxel + Birinapant,NCT01188499,Dose Escalation  Combination Chemotherapy Safety Study of Birinapant (TL32711)  in Subjects With Advanced or Metastatic Solid Tumors,nausea
D009325,2.41,NCT01188499-2,Arm 2: Irinotecan + Birinapant,NCT01188499,Dose Escalation  Combination Chemotherapy Safety Study of Birinapant (TL32711)  in Subjects With Advanced or Metastatic Solid Tumors,nausea
D009325,5.56,NCT01188499-4,Arm 4: Gemcitabine + Birinapant,NCT01188499,Dose Escalation  Combination Chemotherapy Safety Study of Birinapant (TL32711)  in Subjects With Advanced or Metastatic Solid Tumors,nausea
D009325,5.56,NCT01188499-5,Arm 5: Liposomal Doxorubicin + Birinapant,NCT01188499,Dose Escalation  Combination Chemotherapy Safety Study of Birinapant (TL32711)  in Subjects With Advanced or Metastatic Solid Tumors,nausea
10015461,5.56,NCT01188499-5,Arm 5: Liposomal Doxorubicin + Birinapant,NCT01188499,Dose Escalation  Combination Chemotherapy Safety Study of Birinapant (TL32711)  in Subjects With Advanced or Metastatic Solid Tumors,esophagitis
D005756,5.56,NCT01188499-5,Arm 5: Liposomal Doxorubicin + Birinapant,NCT01188499,Dose Escalation  Combination Chemotherapy Safety Study of Birinapant (TL32711)  in Subjects With Advanced or Metastatic Solid Tumors,gastritis
10041101,4.17,NCT01188499-1,Arm 1: Carboplatin/Paclitaxel + Birinapant,NCT01188499,Dose Escalation  Combination Chemotherapy Safety Study of Birinapant (TL32711)  in Subjects With Advanced or Metastatic Solid Tumors,small intestinal obstruction
10041101,3.61,NCT01188499-2,Arm 2: Irinotecan + Birinapant,NCT01188499,Dose Escalation  Combination Chemotherapy Safety Study of Birinapant (TL32711)  in Subjects With Advanced or Metastatic Solid Tumors,small intestinal obstruction
10041101,3.03,NCT01188499-3,Arm 3: Docetaxel + Birinapant,NCT01188499,Dose Escalation  Combination Chemotherapy Safety Study of Birinapant (TL32711)  in Subjects With Advanced or Metastatic Solid Tumors,small intestinal obstruction
D041742,1.2,NCT01188499-2,Arm 2: Irinotecan + Birinapant,NCT01188499,Dose Escalation  Combination Chemotherapy Safety Study of Birinapant (TL32711)  in Subjects With Advanced or Metastatic Solid Tumors,upper gastrointestinal tract
D014839,4.17,NCT01188499-1,Arm 1: Carboplatin/Paclitaxel + Birinapant,NCT01188499,Dose Escalation  Combination Chemotherapy Safety Study of Birinapant (TL32711)  in Subjects With Advanced or Metastatic Solid Tumors,vomiting
D014839,6.02,NCT01188499-2,Arm 2: Irinotecan + Birinapant,NCT01188499,Dose Escalation  Combination Chemotherapy Safety Study of Birinapant (TL32711)  in Subjects With Advanced or Metastatic Solid Tumors,vomiting
D014839,11.11,NCT01188499-4,Arm 4: Gemcitabine + Birinapant,NCT01188499,Dose Escalation  Combination Chemotherapy Safety Study of Birinapant (TL32711)  in Subjects With Advanced or Metastatic Solid Tumors,vomiting
D014839,11.11,NCT01188499-5,Arm 5: Liposomal Doxorubicin + Birinapant,NCT01188499,Dose Escalation  Combination Chemotherapy Safety Study of Birinapant (TL32711)  in Subjects With Advanced or Metastatic Solid Tumors,vomiting
UNKNOWN-check-for-typo,2.41,NCT01188499-2,Arm 2: Irinotecan + Birinapant,NCT01188499,Dose Escalation  Combination Chemotherapy Safety Study of Birinapant (TL32711)  in Subjects With Advanced or Metastatic Solid Tumors,D00
D013276,1.2,NCT01188499-2,Arm 2: Irinotecan + Birinapant,NCT01188499,Dose Escalation  Combination Chemotherapy Safety Study of Birinapant (TL32711)  in Subjects With Advanced or Metastatic Solid Tumors,gastric ulcer
D005756,1.2,NCT01188499-2,Arm 2: Irinotecan + Birinapant,NCT01188499,Dose Escalation  Combination Chemotherapy Safety Study of Birinapant (TL32711)  in Subjects With Advanced or Metastatic Solid Tumors,gastritis
UNKNOWN-check-for-typo,1.2,NCT01188499-2,Arm 2: Irinotecan + Birinapant,NCT01188499,Dose Escalation  Combination Chemotherapy Safety Study of Birinapant (TL32711)  in Subjects With Advanced or Metastatic Solid Tumors,D00
D014648,1.2,NCT01188499-2,Arm 2: Irinotecan + Birinapant,NCT01188499,Dose Escalation  Combination Chemotherapy Safety Study of Birinapant (TL32711)  in Subjects With Advanced or Metastatic Solid Tumors,varices
D002637,5.56,NCT01188499-5,Arm 5: Liposomal Doxorubicin + Birinapant,NCT01188499,Dose Escalation  Combination Chemotherapy Safety Study of Birinapant (TL32711)  in Subjects With Advanced or Metastatic Solid Tumors,chest pain
D003643,4.17,NCT01188499-1,Arm 1: Carboplatin/Paclitaxel + Birinapant,NCT01188499,Dose Escalation  Combination Chemotherapy Safety Study of Birinapant (TL32711)  in Subjects With Advanced or Metastatic Solid Tumors,death
D018450,4.82,NCT01188499-2,Arm 2: Irinotecan + Birinapant,NCT01188499,Dose Escalation  Combination Chemotherapy Safety Study of Birinapant (TL32711)  in Subjects With Advanced or Metastatic Solid Tumors,disease progression
D018450,15.15,NCT01188499-3,Arm 3: Docetaxel + Birinapant,NCT01188499,Dose Escalation  Combination Chemotherapy Safety Study of Birinapant (TL32711)  in Subjects With Advanced or Metastatic Solid Tumors,disease progression
D018450,5.56,NCT01188499-4,Arm 4: Gemcitabine + Birinapant,NCT01188499,Dose Escalation  Combination Chemotherapy Safety Study of Birinapant (TL32711)  in Subjects With Advanced or Metastatic Solid Tumors,disease progression
D018450,5.56,NCT01188499-5,Arm 5: Liposomal Doxorubicin + Birinapant,NCT01188499,Dose Escalation  Combination Chemotherapy Safety Study of Birinapant (TL32711)  in Subjects With Advanced or Metastatic Solid Tumors,disease progression
D000799,3.03,NCT01188499-3,Arm 3: Docetaxel + Birinapant,NCT01188499,Dose Escalation  Combination Chemotherapy Safety Study of Birinapant (TL32711)  in Subjects With Advanced or Metastatic Solid Tumors,angioedema
D000799,4.17,NCT01188499-1,Arm 1: Carboplatin/Paclitaxel + Birinapant,NCT01188499,Dose Escalation  Combination Chemotherapy Safety Study of Birinapant (TL32711)  in Subjects With Advanced or Metastatic Solid Tumors,angioedema
D010146,5.56,NCT01188499-4,Arm 4: Gemcitabine + Birinapant,NCT01188499,Dose Escalation  Combination Chemotherapy Safety Study of Birinapant (TL32711)  in Subjects With Advanced or Metastatic Solid Tumors,pain
D005334,1.2,NCT01188499-2,Arm 2: Irinotecan + Birinapant,NCT01188499,Dose Escalation  Combination Chemotherapy Safety Study of Birinapant (TL32711)  in Subjects With Advanced or Metastatic Solid Tumors,pyrexia
D005334,6.06,NCT01188499-3,Arm 3: Docetaxel + Birinapant,NCT01188499,Dose Escalation  Combination Chemotherapy Safety Study of Birinapant (TL32711)  in Subjects With Advanced or Metastatic Solid Tumors,pyrexia
D005334,16.67,NCT01188499-4,Arm 4: Gemcitabine + Birinapant,NCT01188499,Dose Escalation  Combination Chemotherapy Safety Study of Birinapant (TL32711)  in Subjects With Advanced or Metastatic Solid Tumors,pyrexia
D005334,5.56,NCT01188499-5,Arm 5: Liposomal Doxorubicin + Birinapant,NCT01188499,Dose Escalation  Combination Chemotherapy Safety Study of Birinapant (TL32711)  in Subjects With Advanced or Metastatic Solid Tumors,pyrexia
D001247,1.2,NCT01188499-2,Arm 2: Irinotecan + Birinapant,NCT01188499,Dose Escalation  Combination Chemotherapy Safety Study of Birinapant (TL32711)  in Subjects With Advanced or Metastatic Solid Tumors,asthenia
D005221,1.2,NCT01188499-2,Arm 2: Irinotecan + Birinapant,NCT01188499,Dose Escalation  Combination Chemotherapy Safety Study of Birinapant (TL32711)  in Subjects With Advanced or Metastatic Solid Tumors,fatigue
10051341,3.03,NCT01188499-3,Arm 3: Docetaxel + Birinapant,NCT01188499,Dose Escalation  Combination Chemotherapy Safety Study of Birinapant (TL32711)  in Subjects With Advanced or Metastatic Solid Tumors,bile duct stenosis
D002769,5.56,NCT01188499-5,Arm 5: Liposomal Doxorubicin + Birinapant,NCT01188499,Dose Escalation  Combination Chemotherapy Safety Study of Birinapant (TL32711)  in Subjects With Advanced or Metastatic Solid Tumors,cholelithiasis
D041781,5.56,NCT01188499-4,Arm 4: Gemcitabine + Birinapant,NCT01188499,Dose Escalation  Combination Chemotherapy Safety Study of Birinapant (TL32711)  in Subjects With Advanced or Metastatic Solid Tumors,cholestatic jaundice
D001991,3.03,NCT01188499-3,Arm 3: Docetaxel + Birinapant,NCT01188499,Dose Escalation  Combination Chemotherapy Safety Study of Birinapant (TL32711)  in Subjects With Advanced or Metastatic Solid Tumors,bronchitis
D008105,3.03,NCT01188499-3,Arm 3: Docetaxel + Birinapant,NCT01188499,Dose Escalation  Combination Chemotherapy Safety Study of Birinapant (TL32711)  in Subjects With Advanced or Metastatic Solid Tumors,cholangitis chronic nonsuppurative destructive
D003556,5.56,NCT01188499-4,Arm 4: Gemcitabine + Birinapant,NCT01188499,Dose Escalation  Combination Chemotherapy Safety Study of Birinapant (TL32711)  in Subjects With Advanced or Metastatic Solid Tumors,cystitis
10064687,5.56,NCT01188499-4,Arm 4: Gemcitabine + Birinapant,NCT01188499,Dose Escalation  Combination Chemotherapy Safety Study of Birinapant (TL32711)  in Subjects With Advanced or Metastatic Solid Tumors,device related infection
D004653,5.56,NCT01188499-4,Arm 4: Gemcitabine + Birinapant,NCT01188499,Dose Escalation  Combination Chemotherapy Safety Study of Birinapant (TL32711)  in Subjects With Advanced or Metastatic Solid Tumors,empyema
D004925,3.03,NCT01188499-3,Arm 3: Docetaxel + Birinapant,NCT01188499,Dose Escalation  Combination Chemotherapy Safety Study of Birinapant (TL32711)  in Subjects With Advanced or Metastatic Solid Tumors,escherichia
10023424,11.11,NCT01188499-4,Arm 4: Gemcitabine + Birinapant,NCT01188499,Dose Escalation  Combination Chemotherapy Safety Study of Birinapant (TL32711)  in Subjects With Advanced or Metastatic Solid Tumors,kidney infection
D011014,12.5,NCT01188499-1,Arm 1: Carboplatin/Paclitaxel + Birinapant,NCT01188499,Dose Escalation  Combination Chemotherapy Safety Study of Birinapant (TL32711)  in Subjects With Advanced or Metastatic Solid Tumors,pneumonia
D011014,2.41,NCT01188499-2,Arm 2: Irinotecan + Birinapant,NCT01188499,Dose Escalation  Combination Chemotherapy Safety Study of Birinapant (TL32711)  in Subjects With Advanced or Metastatic Solid Tumors,pneumonia
D011014,15.15,NCT01188499-3,Arm 3: Docetaxel + Birinapant,NCT01188499,Dose Escalation  Combination Chemotherapy Safety Study of Birinapant (TL32711)  in Subjects With Advanced or Metastatic Solid Tumors,pneumonia
D011014,11.11,NCT01188499-4,Arm 4: Gemcitabine + Birinapant,NCT01188499,Dose Escalation  Combination Chemotherapy Safety Study of Birinapant (TL32711)  in Subjects With Advanced or Metastatic Solid Tumors,pneumonia
D011014,5.56,NCT01188499-5,Arm 5: Liposomal Doxorubicin + Birinapant,NCT01188499,Dose Escalation  Combination Chemotherapy Safety Study of Birinapant (TL32711)  in Subjects With Advanced or Metastatic Solid Tumors,pneumonia
D018805,4.17,NCT01188499-1,Arm 1: Carboplatin/Paclitaxel + Birinapant,NCT01188499,Dose Escalation  Combination Chemotherapy Safety Study of Birinapant (TL32711)  in Subjects With Advanced or Metastatic Solid Tumors,sepsis
D018805,4.82,NCT01188499-2,Arm 2: Irinotecan + Birinapant,NCT01188499,Dose Escalation  Combination Chemotherapy Safety Study of Birinapant (TL32711)  in Subjects With Advanced or Metastatic Solid Tumors,sepsis
D018805,3.03,NCT01188499-3,Arm 3: Docetaxel + Birinapant,NCT01188499,Dose Escalation  Combination Chemotherapy Safety Study of Birinapant (TL32711)  in Subjects With Advanced or Metastatic Solid Tumors,sepsis
D012772,5.56,NCT01188499-5,Arm 5: Liposomal Doxorubicin + Birinapant,NCT01188499,Dose Escalation  Combination Chemotherapy Safety Study of Birinapant (TL32711)  in Subjects With Advanced or Metastatic Solid Tumors,septic shock
D012141,5.56,NCT01188499-5,Arm 5: Liposomal Doxorubicin + Birinapant,NCT01188499,Dose Escalation  Combination Chemotherapy Safety Study of Birinapant (TL32711)  in Subjects With Advanced or Metastatic Solid Tumors,upper respiratory tract infections
D014552,6.02,NCT01188499-2,Arm 2: Irinotecan + Birinapant,NCT01188499,Dose Escalation  Combination Chemotherapy Safety Study of Birinapant (TL32711)  in Subjects With Advanced or Metastatic Solid Tumors,urinary tract infection
D000985,1.2,NCT01188499-2,Arm 2: Irinotecan + Birinapant,NCT01188499,Dose Escalation  Combination Chemotherapy Safety Study of Birinapant (TL32711)  in Subjects With Advanced or Metastatic Solid Tumors,antisepsis
10016173,4.17,NCT01188499-1,Arm 1: Carboplatin/Paclitaxel + Birinapant,NCT01188499,Dose Escalation  Combination Chemotherapy Safety Study of Birinapant (TL32711)  in Subjects With Advanced or Metastatic Solid Tumors,fall
D005265,1.2,NCT01188499-2,Arm 2: Irinotecan + Birinapant,NCT01188499,Dose Escalation  Combination Chemotherapy Safety Study of Birinapant (TL32711)  in Subjects With Advanced or Metastatic Solid Tumors,femoral neck fracture
D008133,5.56,NCT01188499-4,Arm 4: Gemcitabine + Birinapant,NCT01188499,Dose Escalation  Combination Chemotherapy Safety Study of Birinapant (TL32711)  in Subjects With Advanced or Metastatic Solid Tumors,electrocardiogram qt prolonged
D004641,1.2,NCT01188499-2,Arm 2: Irinotecan + Birinapant,NCT01188499,Dose Escalation  Combination Chemotherapy Safety Study of Birinapant (TL32711)  in Subjects With Advanced or Metastatic Solid Tumors,international migration
D003681,4.17,NCT01188499-1,Arm 1: Carboplatin/Paclitaxel + Birinapant,NCT01188499,Dose Escalation  Combination Chemotherapy Safety Study of Birinapant (TL32711)  in Subjects With Advanced or Metastatic Solid Tumors,dehydration
D003681,9.64,NCT01188499-2,Arm 2: Irinotecan + Birinapant,NCT01188499,Dose Escalation  Combination Chemotherapy Safety Study of Birinapant (TL32711)  in Subjects With Advanced or Metastatic Solid Tumors,dehydration
D003681,3.03,NCT01188499-3,Arm 3: Docetaxel + Birinapant,NCT01188499,Dose Escalation  Combination Chemotherapy Safety Study of Birinapant (TL32711)  in Subjects With Advanced or Metastatic Solid Tumors,dehydration
D003681,5.56,NCT01188499-4,Arm 4: Gemcitabine + Birinapant,NCT01188499,Dose Escalation  Combination Chemotherapy Safety Study of Birinapant (TL32711)  in Subjects With Advanced or Metastatic Solid Tumors,dehydration
D003681,5.56,NCT01188499-5,Arm 5: Liposomal Doxorubicin + Birinapant,NCT01188499,Dose Escalation  Combination Chemotherapy Safety Study of Birinapant (TL32711)  in Subjects With Advanced or Metastatic Solid Tumors,dehydration
D005183,6.06,NCT01188499-3,Arm 3: Docetaxel + Birinapant,NCT01188499,Dose Escalation  Combination Chemotherapy Safety Study of Birinapant (TL32711)  in Subjects With Advanced or Metastatic Solid Tumors,failure to thrive
D011205,3.03,NCT01188499-3,Arm 3: Docetaxel + Birinapant,NCT01188499,Dose Escalation  Combination Chemotherapy Safety Study of Birinapant (TL32711)  in Subjects With Advanced or Metastatic Solid Tumors,unifluid
UNKNOWN-check-for-typo,3.03,NCT01188499-3,Arm 3: Docetaxel + Birinapant,NCT01188499,Dose Escalation  Combination Chemotherapy Safety Study of Birinapant (TL32711)  in Subjects With Advanced or Metastatic Solid Tumors,D00
UNKNOWN-check-for-typo,3.03,NCT01188499-3,Arm 3: Docetaxel + Birinapant,NCT01188499,Dose Escalation  Combination Chemotherapy Safety Study of Birinapant (TL32711)  in Subjects With Advanced or Metastatic Solid Tumors,D00
D000138,1.2,NCT01188499-2,Arm 2: Irinotecan + Birinapant,NCT01188499,Dose Escalation  Combination Chemotherapy Safety Study of Birinapant (TL32711)  in Subjects With Advanced or Metastatic Solid Tumors,metabolic acidosis
UNKNOWN-check-for-typo,1.2,NCT01188499-2,Arm 2: Irinotecan + Birinapant,NCT01188499,Dose Escalation  Combination Chemotherapy Safety Study of Birinapant (TL32711)  in Subjects With Advanced or Metastatic Solid Tumors,D00
UNKNOWN-check-for-typo,1.2,NCT01188499-2,Arm 2: Irinotecan + Birinapant,NCT01188499,Dose Escalation  Combination Chemotherapy Safety Study of Birinapant (TL32711)  in Subjects With Advanced or Metastatic Solid Tumors,D00
D001416,11.11,NCT01188499-4,Arm 4: Gemcitabine + Birinapant,NCT01188499,Dose Escalation  Combination Chemotherapy Safety Study of Birinapant (TL32711)  in Subjects With Advanced or Metastatic Solid Tumors,back pain
D000069280,4.17,NCT01188499-1,Arm 1: Carboplatin/Paclitaxel + Birinapant,NCT01188499,Dose Escalation  Combination Chemotherapy Safety Study of Birinapant (TL32711)  in Subjects With Advanced or Metastatic Solid Tumors,intracranial electroencephalography
D000073116,1.2,NCT01188499-2,Arm 2: Irinotecan + Birinapant,NCT01188499,Dose Escalation  Combination Chemotherapy Safety Study of Birinapant (TL32711)  in Subjects With Advanced or Metastatic Solid Tumors,cancer survivors
D013117,4.17,NCT01188499-1,Arm 1: Carboplatin/Paclitaxel + Birinapant,NCT01188499,Dose Escalation  Combination Chemotherapy Safety Study of Birinapant (TL32711)  in Subjects With Advanced or Metastatic Solid Tumors,spinal cord compression
D003221,4.17,NCT01188499-1,Arm 1: Carboplatin/Paclitaxel + Birinapant,NCT01188499,Dose Escalation  Combination Chemotherapy Safety Study of Birinapant (TL32711)  in Subjects With Advanced or Metastatic Solid Tumors,confusional state
D003221,1.2,NCT01188499-2,Arm 2: Irinotecan + Birinapant,NCT01188499,Dose Escalation  Combination Chemotherapy Safety Study of Birinapant (TL32711)  in Subjects With Advanced or Metastatic Solid Tumors,confusional state
D000073216,5.56,NCT01188499-5,Arm 5: Liposomal Doxorubicin + Birinapant,NCT01188499,Dose Escalation  Combination Chemotherapy Safety Study of Birinapant (TL32711)  in Subjects With Advanced or Metastatic Solid Tumors,mental status tests
D006869,1.2,NCT01188499-2,Arm 2: Irinotecan + Birinapant,NCT01188499,Dose Escalation  Combination Chemotherapy Safety Study of Birinapant (TL32711)  in Subjects With Advanced or Metastatic Solid Tumors,hydronephrosis
D006869,5.56,NCT01188499-5,Arm 5: Liposomal Doxorubicin + Birinapant,NCT01188499,Dose Escalation  Combination Chemotherapy Safety Study of Birinapant (TL32711)  in Subjects With Advanced or Metastatic Solid Tumors,hydronephrosis
D058186,4.82,NCT01188499-2,Arm 2: Irinotecan + Birinapant,NCT01188499,Dose Escalation  Combination Chemotherapy Safety Study of Birinapant (TL32711)  in Subjects With Advanced or Metastatic Solid Tumors,acute renal failure
D058186,5.56,NCT01188499-5,Arm 5: Liposomal Doxorubicin + Birinapant,NCT01188499,Dose Escalation  Combination Chemotherapy Safety Study of Birinapant (TL32711)  in Subjects With Advanced or Metastatic Solid Tumors,acute renal failure
D014549,1.2,NCT01188499-2,Arm 2: Irinotecan + Birinapant,NCT01188499,Dose Escalation  Combination Chemotherapy Safety Study of Birinapant (TL32711)  in Subjects With Advanced or Metastatic Solid Tumors,urinary incontinence
D012131,2.41,NCT01188499-2,Arm 2: Irinotecan + Birinapant,NCT01188499,Dose Escalation  Combination Chemotherapy Safety Study of Birinapant (TL32711)  in Subjects With Advanced or Metastatic Solid Tumors,respiratory failure
D012131,3.03,NCT01188499-3,Arm 3: Docetaxel + Birinapant,NCT01188499,Dose Escalation  Combination Chemotherapy Safety Study of Birinapant (TL32711)  in Subjects With Advanced or Metastatic Solid Tumors,respiratory failure
D001983,5.56,NCT01188499-4,Arm 4: Gemcitabine + Birinapant,NCT01188499,Dose Escalation  Combination Chemotherapy Safety Study of Birinapant (TL32711)  in Subjects With Advanced or Metastatic Solid Tumors,bronchial fistula
UNKNOWN-check-for-typo,3.03,NCT01188499-3,Arm 3: Docetaxel + Birinapant,NCT01188499,Dose Escalation  Combination Chemotherapy Safety Study of Birinapant (TL32711)  in Subjects With Advanced or Metastatic Solid Tumors,D00
UNKNOWN-check-for-typo,5.56,NCT01188499-5,Arm 5: Liposomal Doxorubicin + Birinapant,NCT01188499,Dose Escalation  Combination Chemotherapy Safety Study of Birinapant (TL32711)  in Subjects With Advanced or Metastatic Solid Tumors,D00
D010996,16.67,NCT01188499-4,Arm 4: Gemcitabine + Birinapant,NCT01188499,Dose Escalation  Combination Chemotherapy Safety Study of Birinapant (TL32711)  in Subjects With Advanced or Metastatic Solid Tumors,pleural effusion
D010996,5.56,NCT01188499-5,Arm 5: Liposomal Doxorubicin + Birinapant,NCT01188499,Dose Escalation  Combination Chemotherapy Safety Study of Birinapant (TL32711)  in Subjects With Advanced or Metastatic Solid Tumors,pleural effusion
D010998,4.17,NCT01188499-1,Arm 1: Carboplatin/Paclitaxel + Birinapant,NCT01188499,Dose Escalation  Combination Chemotherapy Safety Study of Birinapant (TL32711)  in Subjects With Advanced or Metastatic Solid Tumors,pleurisy
D011014,5.56,NCT01188499-4,Arm 4: Gemcitabine + Birinapant,NCT01188499,Dose Escalation  Combination Chemotherapy Safety Study of Birinapant (TL32711)  in Subjects With Advanced or Metastatic Solid Tumors,pneumonitis
D011655,4.82,NCT01188499-2,Arm 2: Irinotecan + Birinapant,NCT01188499,Dose Escalation  Combination Chemotherapy Safety Study of Birinapant (TL32711)  in Subjects With Advanced or Metastatic Solid Tumors,pulmonary embolism
D011655,3.03,NCT01188499-3,Arm 3: Docetaxel + Birinapant,NCT01188499,Dose Escalation  Combination Chemotherapy Safety Study of Birinapant (TL32711)  in Subjects With Advanced or Metastatic Solid Tumors,pulmonary embolism
D011655,5.56,NCT01188499-4,Arm 4: Gemcitabine + Birinapant,NCT01188499,Dose Escalation  Combination Chemotherapy Safety Study of Birinapant (TL32711)  in Subjects With Advanced or Metastatic Solid Tumors,pulmonary embolism
D001261,5.56,NCT01188499-4,Arm 4: Gemcitabine + Birinapant,NCT01188499,Dose Escalation  Combination Chemotherapy Safety Study of Birinapant (TL32711)  in Subjects With Advanced or Metastatic Solid Tumors,pulmonary atelectasis
D000799,1.2,NCT01188499-2,Arm 2: Irinotecan + Birinapant,NCT01188499,Dose Escalation  Combination Chemotherapy Safety Study of Birinapant (TL32711)  in Subjects With Advanced or Metastatic Solid Tumors,angioedema
D012131,5.56,NCT01188499-5,Arm 5: Liposomal Doxorubicin + Birinapant,NCT01188499,Dose Escalation  Combination Chemotherapy Safety Study of Birinapant (TL32711)  in Subjects With Advanced or Metastatic Solid Tumors,respiratory failure
10003504,1.2,NCT01188499-2,Arm 2: Irinotecan + Birinapant,NCT01188499,Dose Escalation  Combination Chemotherapy Safety Study of Birinapant (TL32711)  in Subjects With Advanced or Metastatic Solid Tumors,aspiration
D012127,1.2,NCT01188499-2,Arm 2: Irinotecan + Birinapant,NCT01188499,Dose Escalation  Combination Chemotherapy Safety Study of Birinapant (TL32711)  in Subjects With Advanced or Metastatic Solid Tumors,respiratory distress syndrome newborn
D020246,1.2,NCT01188499-2,Arm 2: Irinotecan + Birinapant,NCT01188499,Dose Escalation  Combination Chemotherapy Safety Study of Birinapant (TL32711)  in Subjects With Advanced or Metastatic Solid Tumors,deep vein thrombosis
D020246,3.03,NCT01188499-3,Arm 3: Docetaxel + Birinapant,NCT01188499,Dose Escalation  Combination Chemotherapy Safety Study of Birinapant (TL32711)  in Subjects With Advanced or Metastatic Solid Tumors,deep vein thrombosis
D020246,5.56,NCT01188499-4,Arm 4: Gemcitabine + Birinapant,NCT01188499,Dose Escalation  Combination Chemotherapy Safety Study of Birinapant (TL32711)  in Subjects With Advanced or Metastatic Solid Tumors,deep vein thrombosis
D020246,11.11,NCT01188499-5,Arm 5: Liposomal Doxorubicin + Birinapant,NCT01188499,Dose Escalation  Combination Chemotherapy Safety Study of Birinapant (TL32711)  in Subjects With Advanced or Metastatic Solid Tumors,deep vein thrombosis
D020246,1.2,NCT01188499-2,Arm 2: Irinotecan + Birinapant,NCT01188499,Dose Escalation  Combination Chemotherapy Safety Study of Birinapant (TL32711)  in Subjects With Advanced or Metastatic Solid Tumors,venous thrombosis
D007022,6.02,NCT01188499-2,Arm 2: Irinotecan + Birinapant,NCT01188499,Dose Escalation  Combination Chemotherapy Safety Study of Birinapant (TL32711)  in Subjects With Advanced or Metastatic Solid Tumors,hypotension
D009026,28.57,NCT01193842-1,Phase I: VR-DA-EPOCH Dose Level 1,NCT01193842,Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas,mortality
D009026,14.29,NCT01193842-2,Phase I: VR-DA-EPOCH Dose Level 2,NCT01193842,Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas,mortality
D009026,28.89,NCT01193842-4,Phase II: VR-DA-EPOCH,NCT01193842,Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas,mortality
D009026,19.57,NCT01193842-5,Phase II: DA-R-EPOCH,NCT01193842,Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas,mortality
D064420,71.43,NCT01193842-1,Phase I: VR-DA-EPOCH Dose Level 1,NCT01193842,Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas,adverse drug events
D064420,42.86,NCT01193842-2,Phase I: VR-DA-EPOCH Dose Level 2,NCT01193842,Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas,adverse drug events
D064420,55.56,NCT01193842-4,Phase II: VR-DA-EPOCH,NCT01193842,Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas,adverse drug events
D064420,45.65,NCT01193842-5,Phase II: DA-R-EPOCH,NCT01193842,Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas,adverse drug events
D064147,14.29,NCT01193842-1,Phase I: VR-DA-EPOCH Dose Level 1,NCT01193842,Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas,febrile neutropenia
D064147,22.22,NCT01193842-4,Phase II: VR-DA-EPOCH,NCT01193842,Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas,febrile neutropenia
D064147,17.39,NCT01193842-5,Phase II: DA-R-EPOCH,NCT01193842,Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas,febrile neutropenia
D000740,14.29,NCT01193842-1,Phase I: VR-DA-EPOCH Dose Level 1,NCT01193842,Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas,anemia
D000740,2.22,NCT01193842-4,Phase II: VR-DA-EPOCH,NCT01193842,Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas,anemia
D000740,4.35,NCT01193842-5,Phase II: DA-R-EPOCH,NCT01193842,Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas,anemia
D001281,2.22,NCT01193842-4,Phase II: VR-DA-EPOCH,NCT01193842,Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas,atrial fibrillation
D006323,14.29,NCT01193842-2,Phase I: VR-DA-EPOCH Dose Level 2,NCT01193842,Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas,cardiac arrest
D006323,6.67,NCT01193842-4,Phase II: VR-DA-EPOCH,NCT01193842,Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas,cardiac arrest
D006323,4.35,NCT01193842-5,Phase II: DA-R-EPOCH,NCT01193842,Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas,cardiac arrest
10007541,2.22,NCT01193842-4,Phase II: VR-DA-EPOCH,NCT01193842,Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas,cardiac disorders - other specify
D010490,14.29,NCT01193842-1,Phase I: VR-DA-EPOCH Dose Level 1,NCT01193842,Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas,pericardial effusion
D015746,28.57,NCT01193842-1,Phase I: VR-DA-EPOCH Dose Level 1,NCT01193842,Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas,abdominal pain
D015746,4.44,NCT01193842-4,Phase II: VR-DA-EPOCH,NCT01193842,Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas,abdominal pain
D015746,2.17,NCT01193842-5,Phase II: DA-R-EPOCH,NCT01193842,Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas,abdominal pain
D003092,28.57,NCT01193842-1,Phase I: VR-DA-EPOCH Dose Level 1,NCT01193842,Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas,colitis
D003092,2.17,NCT01193842-5,Phase II: DA-R-EPOCH,NCT01193842,Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas,colitis
D003967,28.57,NCT01193842-1,Phase I: VR-DA-EPOCH Dose Level 1,NCT01193842,Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas,diarrhea
10015451,2.17,NCT01193842-5,Phase II: DA-R-EPOCH,NCT01193842,Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas,esophageal ulcer
D004941,14.29,NCT01193842-1,Phase I: VR-DA-EPOCH Dose Level 1,NCT01193842,Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas,esophagitis
D004941,2.17,NCT01193842-5,Phase II: DA-R-EPOCH,NCT01193842,Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas,esophagitis
10017789,2.17,NCT01193842-5,Phase II: DA-R-EPOCH,NCT01193842,Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas,gastric hemorrhage
10055291,14.29,NCT01193842-1,Phase I: VR-DA-EPOCH Dose Level 1,NCT01193842,Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas,intra-abdominal hemorrhage
10028130,2.22,NCT01193842-4,Phase II: VR-DA-EPOCH,NCT01193842,Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas,mucositis oral
D009325,2.22,NCT01193842-4,Phase II: VR-DA-EPOCH,NCT01193842,Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas,nausea
D009325,2.17,NCT01193842-5,Phase II: DA-R-EPOCH,NCT01193842,Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas,nausea
10038072,2.17,NCT01193842-5,Phase II: DA-R-EPOCH,NCT01193842,Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas,rectal pain
10041101,2.22,NCT01193842-4,Phase II: VR-DA-EPOCH,NCT01193842,Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas,small intestinal obstruction
D014839,14.29,NCT01193842-1,Phase I: VR-DA-EPOCH Dose Level 1,NCT01193842,Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas,vomiting
D014839,2.22,NCT01193842-4,Phase II: VR-DA-EPOCH,NCT01193842,Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas,vomiting
D014839,6.52,NCT01193842-5,Phase II: DA-R-EPOCH,NCT01193842,Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas,vomiting
10011914,14.29,NCT01193842-1,Phase I: VR-DA-EPOCH Dose Level 1,NCT01193842,Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas,death nos
10011914,2.22,NCT01193842-4,Phase II: VR-DA-EPOCH,NCT01193842,Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas,death nos
D005221,14.29,NCT01193842-2,Phase I: VR-DA-EPOCH Dose Level 2,NCT01193842,Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas,fatigue
D009102,2.22,NCT01193842-4,Phase II: VR-DA-EPOCH,NCT01193842,Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas,multiple organ failure
10062501,2.17,NCT01193842-5,Phase II: DA-R-EPOCH,NCT01193842,Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas,non-cardiac chest pain
10058838,2.17,NCT01193842-5,Phase II: DA-R-EPOCH,NCT01193842,Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas,enterocolitis infectious
10021881,2.22,NCT01193842-4,Phase II: VR-DA-EPOCH,NCT01193842,Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas,infections and infestations - other specify
10023424,2.17,NCT01193842-5,Phase II: DA-R-EPOCH,NCT01193842,Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas,kidney infection
10061229,14.29,NCT01193842-1,Phase I: VR-DA-EPOCH Dose Level 1,NCT01193842,Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas,lung infection
10061229,2.22,NCT01193842-4,Phase II: VR-DA-EPOCH,NCT01193842,Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas,lung infection
10061229,4.35,NCT01193842-5,Phase II: DA-R-EPOCH,NCT01193842,Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas,lung infection
D018805,14.29,NCT01193842-1,Phase I: VR-DA-EPOCH Dose Level 1,NCT01193842,Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas,sepsis
D018805,6.67,NCT01193842-4,Phase II: VR-DA-EPOCH,NCT01193842,Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas,sepsis
D018805,6.52,NCT01193842-5,Phase II: DA-R-EPOCH,NCT01193842,Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas,sepsis
D018461,2.22,NCT01193842-4,Phase II: VR-DA-EPOCH,NCT01193842,Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas,soft tissue infection
10048762,14.29,NCT01193842-1,Phase I: VR-DA-EPOCH Dose Level 1,NCT01193842,Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas,tooth infection
D014552,2.17,NCT01193842-5,Phase II: DA-R-EPOCH,NCT01193842,Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas,urinary tract infection
D016103,2.17,NCT01193842-5,Phase II: DA-R-EPOCH,NCT01193842,Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas,spinal fracture
10001551,2.22,NCT01193842-4,Phase II: VR-DA-EPOCH,NCT01193842,Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas,alanine aminotransferase increased
10025256,4.44,NCT01193842-4,Phase II: VR-DA-EPOCH,NCT01193842,Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas,lymphocyte count decreased
10029366,71.43,NCT01193842-1,Phase I: VR-DA-EPOCH Dose Level 1,NCT01193842,Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas,neutrophil count decreased
10029366,28.57,NCT01193842-2,Phase I: VR-DA-EPOCH Dose Level 2,NCT01193842,Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas,neutrophil count decreased
10029366,26.67,NCT01193842-4,Phase II: VR-DA-EPOCH,NCT01193842,Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas,neutrophil count decreased
10029366,4.35,NCT01193842-5,Phase II: DA-R-EPOCH,NCT01193842,Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas,neutrophil count decreased
10035528,42.86,NCT01193842-2,Phase I: VR-DA-EPOCH Dose Level 2,NCT01193842,Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas,platelet count decreased
10035528,24.44,NCT01193842-4,Phase II: VR-DA-EPOCH,NCT01193842,Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas,platelet count decreased
10049182,71.43,NCT01193842-1,Phase I: VR-DA-EPOCH Dose Level 1,NCT01193842,Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas,white blood cell decreased
10049182,11.11,NCT01193842-4,Phase II: VR-DA-EPOCH,NCT01193842,Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas,white blood cell decreased
10049182,2.17,NCT01193842-5,Phase II: DA-R-EPOCH,NCT01193842,Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas,white blood cell decreased
D003681,14.29,NCT01193842-1,Phase I: VR-DA-EPOCH Dose Level 1,NCT01193842,Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas,dehydration
D003681,14.29,NCT01193842-2,Phase I: VR-DA-EPOCH Dose Level 2,NCT01193842,Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas,dehydration
D003681,2.17,NCT01193842-5,Phase II: DA-R-EPOCH,NCT01193842,Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas,dehydration
D006943,2.22,NCT01193842-4,Phase II: VR-DA-EPOCH,NCT01193842,Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas,hyperglycemia
10029104,15.56,NCT01193842-4,Phase II: VR-DA-EPOCH,NCT01193842,Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas,neoplasms benign malignant and unspecified (incl cysts and polyps) - other specify
10029104,8.7,NCT01193842-5,Phase II: DA-R-EPOCH,NCT01193842,Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas,neoplasms benign malignant and unspecified (incl cysts and polyps) - other specify
D001927,4.44,NCT01193842-4,Phase II: VR-DA-EPOCH,NCT01193842,Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas,encephalopathy
D006261,2.22,NCT01193842-4,Phase II: VR-DA-EPOCH,NCT01193842,Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas,headache
10029205,2.22,NCT01193842-4,Phase II: VR-DA-EPOCH,NCT01193842,Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas,nervous system disorders - other specify
D003693,2.22,NCT01193842-4,Phase II: VR-DA-EPOCH,NCT01193842,Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas,delirium
D058186,2.17,NCT01193842-5,Phase II: DA-R-EPOCH,NCT01193842,Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas,acute kidney injury
10038359,2.17,NCT01193842-5,Phase II: DA-R-EPOCH,NCT01193842,Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas,renal and urinary disorders - other specify
D056844,2.17,NCT01193842-5,Phase II: DA-R-EPOCH,NCT01193842,Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas,renal colic
D004417,4.44,NCT01193842-4,Phase II: VR-DA-EPOCH,NCT01193842,Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas,dyspnea
D011014,2.22,NCT01193842-4,Phase II: VR-DA-EPOCH,NCT01193842,Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas,pneumonitis
D012131,2.22,NCT01193842-4,Phase II: VR-DA-EPOCH,NCT01193842,Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas,respiratory failure
10042613,2.17,NCT01193842-5,Phase II: DA-R-EPOCH,NCT01193842,Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas,surgical and medical procedures - other specify
10043565,14.29,NCT01193842-1,Phase I: VR-DA-EPOCH Dose Level 1,NCT01193842,Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas,thromboembolic event
10043565,2.22,NCT01193842-4,Phase II: VR-DA-EPOCH,NCT01193842,Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas,thromboembolic event
D064420,50.0,NCT01214668-1,LY 300 μg/mL + Dox,NCT01214668,Dose-Escalation Study of LY573636-sodium and Liposomal Doxorubicin in Patients With Advanced Solid Tumors,adverse drug events
D064420,83.33,NCT01214668-3,LY 340 μg/mL + Dox,NCT01214668,Dose-Escalation Study of LY573636-sodium and Liposomal Doxorubicin in Patients With Advanced Solid Tumors,adverse drug events
D064420,50.0,NCT01214668-4,LY 360 μg/mL + Dox,NCT01214668,Dose-Escalation Study of LY573636-sodium and Liposomal Doxorubicin in Patients With Advanced Solid Tumors,adverse drug events
D064420,50.0,NCT01214668-5,LY 380 μg/mL + Dox,NCT01214668,Dose-Escalation Study of LY573636-sodium and Liposomal Doxorubicin in Patients With Advanced Solid Tumors,adverse drug events
D064420,50.0,NCT01214668-6,LY Albumin and Day 15 PK Tailored + Dox,NCT01214668,Dose-Escalation Study of LY573636-sodium and Liposomal Doxorubicin in Patients With Advanced Solid Tumors,adverse drug events
D000741,25.0,NCT01214668-1,LY 300 μg/mL + Dox,NCT01214668,Dose-Escalation Study of LY573636-sodium and Liposomal Doxorubicin in Patients With Advanced Solid Tumors,aplastic anaemia
D009503,25.0,NCT01214668-1,LY 300 μg/mL + Dox,NCT01214668,Dose-Escalation Study of LY573636-sodium and Liposomal Doxorubicin in Patients With Advanced Solid Tumors,neutropenia
D009503,16.67,NCT01214668-3,LY 340 μg/mL + Dox,NCT01214668,Dose-Escalation Study of LY573636-sodium and Liposomal Doxorubicin in Patients With Advanced Solid Tumors,neutropenia
D013921,25.0,NCT01214668-1,LY 300 μg/mL + Dox,NCT01214668,Dose-Escalation Study of LY573636-sodium and Liposomal Doxorubicin in Patients With Advanced Solid Tumors,thrombocytopenia
D013921,33.33,NCT01214668-3,LY 340 μg/mL + Dox,NCT01214668,Dose-Escalation Study of LY573636-sodium and Liposomal Doxorubicin in Patients With Advanced Solid Tumors,thrombocytopenia
D013921,16.67,NCT01214668-6,LY Albumin and Day 15 PK Tailored + Dox,NCT01214668,Dose-Escalation Study of LY573636-sodium and Liposomal Doxorubicin in Patients With Advanced Solid Tumors,thrombocytopenia
D006323,16.67,NCT01214668-3,LY 340 μg/mL + Dox,NCT01214668,Dose-Escalation Study of LY573636-sodium and Liposomal Doxorubicin in Patients With Advanced Solid Tumors,cardiac arrest
D014717,16.67,NCT01214668-6,LY Albumin and Day 15 PK Tailored + Dox,NCT01214668,Dose-Escalation Study of LY573636-sodium and Liposomal Doxorubicin in Patients With Advanced Solid Tumors,vertigo
D015746,16.67,NCT01214668-4,LY 360 μg/mL + Dox,NCT01214668,Dose-Escalation Study of LY573636-sodium and Liposomal Doxorubicin in Patients With Advanced Solid Tumors,abdominal pain
D015746,16.67,NCT01214668-6,LY Albumin and Day 15 PK Tailored + Dox,NCT01214668,Dose-Escalation Study of LY573636-sodium and Liposomal Doxorubicin in Patients With Advanced Solid Tumors,abdominal pain
D003248,16.67,NCT01214668-4,LY 360 μg/mL + Dox,NCT01214668,Dose-Escalation Study of LY573636-sodium and Liposomal Doxorubicin in Patients With Advanced Solid Tumors,constipation
D003248,16.67,NCT01214668-6,LY Albumin and Day 15 PK Tailored + Dox,NCT01214668,Dose-Escalation Study of LY573636-sodium and Liposomal Doxorubicin in Patients With Advanced Solid Tumors,constipation
D003680,33.33,NCT01214668-3,LY 340 μg/mL + Dox,NCT01214668,Dose-Escalation Study of LY573636-sodium and Liposomal Doxorubicin in Patients With Advanced Solid Tumors,dysphagia
D000069196,16.67,NCT01214668-3,LY 340 μg/mL + Dox,NCT01214668,Dose-Escalation Study of LY573636-sodium and Liposomal Doxorubicin in Patients With Advanced Solid Tumors,gastrointestinal microbiome
D005746,16.67,NCT01214668-4,LY 360 μg/mL + Dox,NCT01214668,Dose-Escalation Study of LY573636-sodium and Liposomal Doxorubicin in Patients With Advanced Solid Tumors,gastric emptying
D007415,16.67,NCT01214668-6,LY Albumin and Day 15 PK Tailored + Dox,NCT01214668,Dose-Escalation Study of LY573636-sodium and Liposomal Doxorubicin in Patients With Advanced Solid Tumors,intestinal obstruction
D007415,25.0,NCT01214668-1,LY 300 μg/mL + Dox,NCT01214668,Dose-Escalation Study of LY573636-sodium and Liposomal Doxorubicin in Patients With Advanced Solid Tumors,intestinal obstruction
D009325,16.67,NCT01214668-4,LY 360 μg/mL + Dox,NCT01214668,Dose-Escalation Study of LY573636-sodium and Liposomal Doxorubicin in Patients With Advanced Solid Tumors,nausea
10015461,33.33,NCT01214668-3,LY 340 μg/mL + Dox,NCT01214668,Dose-Escalation Study of LY573636-sodium and Liposomal Doxorubicin in Patients With Advanced Solid Tumors,esophagitis
10041101,33.33,NCT01214668-6,LY Albumin and Day 15 PK Tailored + Dox,NCT01214668,Dose-Escalation Study of LY573636-sodium and Liposomal Doxorubicin in Patients With Advanced Solid Tumors,small intestinal obstruction
D013280,16.67,NCT01214668-3,LY 340 μg/mL + Dox,NCT01214668,Dose-Escalation Study of LY573636-sodium and Liposomal Doxorubicin in Patients With Advanced Solid Tumors,stomatitis
D014839,16.67,NCT01214668-4,LY 360 μg/mL + Dox,NCT01214668,Dose-Escalation Study of LY573636-sodium and Liposomal Doxorubicin in Patients With Advanced Solid Tumors,vomiting
D007249,16.67,NCT01214668-3,LY 340 μg/mL + Dox,NCT01214668,Dose-Escalation Study of LY573636-sodium and Liposomal Doxorubicin in Patients With Advanced Solid Tumors,inflammation
D001653,16.67,NCT01214668-5,LY 380 μg/mL + Dox,NCT01214668,Dose-Escalation Study of LY573636-sodium and Liposomal Doxorubicin in Patients With Advanced Solid Tumors,bile ducts intrahepatic
D004342,16.67,NCT01214668-3,LY 340 μg/mL + Dox,NCT01214668,Dose-Escalation Study of LY573636-sodium and Liposomal Doxorubicin in Patients With Advanced Solid Tumors,drug hypersensitivity
D053118,16.67,NCT01214668-3,LY 340 μg/mL + Dox,NCT01214668,Dose-Escalation Study of LY573636-sodium and Liposomal Doxorubicin in Patients With Advanced Solid Tumors,influenza a virus h1n1 subtype
D013530,16.67,NCT01214668-6,LY Albumin and Day 15 PK Tailored + Dox,NCT01214668,Dose-Escalation Study of LY573636-sodium and Liposomal Doxorubicin in Patients With Advanced Solid Tumors,postoperative wound infection
D018746,16.67,NCT01214668-5,LY 380 μg/mL + Dox,NCT01214668,Dose-Escalation Study of LY573636-sodium and Liposomal Doxorubicin in Patients With Advanced Solid Tumors,sepsis syndrome
D014946,16.67,NCT01214668-6,LY Albumin and Day 15 PK Tailored + Dox,NCT01214668,Dose-Escalation Study of LY573636-sodium and Liposomal Doxorubicin in Patients With Advanced Solid Tumors,wound infection
10011368,25.0,NCT01214668-1,LY 300 μg/mL + Dox,NCT01214668,Dose-Escalation Study of LY573636-sodium and Liposomal Doxorubicin in Patients With Advanced Solid Tumors,creatinine increased
D007958,16.67,NCT01214668-3,LY 340 μg/mL + Dox,NCT01214668,Dose-Escalation Study of LY573636-sodium and Liposomal Doxorubicin in Patients With Advanced Solid Tumors,blood cell count white
D003681,16.67,NCT01214668-3,LY 340 μg/mL + Dox,NCT01214668,Dose-Escalation Study of LY573636-sodium and Liposomal Doxorubicin in Patients With Advanced Solid Tumors,dehydration
D003681,16.67,NCT01214668-4,LY 360 μg/mL + Dox,NCT01214668,Dose-Escalation Study of LY573636-sodium and Liposomal Doxorubicin in Patients With Advanced Solid Tumors,dehydration
UNKNOWN-check-for-typo,25.0,NCT01214668-1,LY 300 μg/mL + Dox,NCT01214668,Dose-Escalation Study of LY573636-sodium and Liposomal Doxorubicin in Patients With Advanced Solid Tumors,D00
D018908,16.67,NCT01214668-4,LY 360 μg/mL + Dox,NCT01214668,Dose-Escalation Study of LY573636-sodium and Liposomal Doxorubicin in Patients With Advanced Solid Tumors,muscular weakness
D018908,16.67,NCT01214668-6,LY Albumin and Day 15 PK Tailored + Dox,NCT01214668,Dose-Escalation Study of LY573636-sodium and Liposomal Doxorubicin in Patients With Advanced Solid Tumors,muscular weakness
D007427,16.67,NCT01214668-6,LY Albumin and Day 15 PK Tailored + Dox,NCT01214668,Dose-Escalation Study of LY573636-sodium and Liposomal Doxorubicin in Patients With Advanced Solid Tumors,subarachnoid pressure
D014826,16.67,NCT01214668-4,LY 360 μg/mL + Dox,NCT01214668,Dose-Escalation Study of LY573636-sodium and Liposomal Doxorubicin in Patients With Advanced Solid Tumors,vocal cord paralysis
D003221,25.0,NCT01214668-1,LY 300 μg/mL + Dox,NCT01214668,Dose-Escalation Study of LY573636-sodium and Liposomal Doxorubicin in Patients With Advanced Solid Tumors,confusional state
D001249,16.67,NCT01214668-4,LY 360 μg/mL + Dox,NCT01214668,Dose-Escalation Study of LY573636-sodium and Liposomal Doxorubicin in Patients With Advanced Solid Tumors,asthma
D011015,16.67,NCT01214668-4,LY 360 μg/mL + Dox,NCT01214668,Dose-Escalation Study of LY573636-sodium and Liposomal Doxorubicin in Patients With Advanced Solid Tumors,aspiration pneumonia
D011014,16.67,NCT01214668-5,LY 380 μg/mL + Dox,NCT01214668,Dose-Escalation Study of LY573636-sodium and Liposomal Doxorubicin in Patients With Advanced Solid Tumors,pneumonitis
D005076,16.67,NCT01214668-3,LY 340 μg/mL + Dox,NCT01214668,Dose-Escalation Study of LY573636-sodium and Liposomal Doxorubicin in Patients With Advanced Solid Tumors,rash
D007022,25.0,NCT01214668-1,LY 300 μg/mL + Dox,NCT01214668,Dose-Escalation Study of LY573636-sodium and Liposomal Doxorubicin in Patients With Advanced Solid Tumors,hypotension
D064420,20.0,NCT01220128-1,Cohort A-GSK2302024A Group,NCT01220128,Evaluation of an Anti-cancer Immunotherapy Combined With Standard Neoadjuvant Treatment in Patients With WT1-positive Primary Invasive Breast Cancer,adverse drug events
D064420,44.44,NCT01220128-3,Cohort B-GSK2302024A Group,NCT01220128,Evaluation of an Anti-cancer Immunotherapy Combined With Standard Neoadjuvant Treatment in Patients With WT1-positive Primary Invasive Breast Cancer,adverse drug events
D064420,33.33,NCT01220128-4,Cohort B-Placebo Group,NCT01220128,Evaluation of an Anti-cancer Immunotherapy Combined With Standard Neoadjuvant Treatment in Patients With WT1-positive Primary Invasive Breast Cancer,adverse drug events
D064420,45.45,NCT01220128-5,Cohort C-GSK2302024A Group,NCT01220128,Evaluation of an Anti-cancer Immunotherapy Combined With Standard Neoadjuvant Treatment in Patients With WT1-positive Primary Invasive Breast Cancer,adverse drug events
D064420,25.0,NCT01220128-6,Cohort C-Placebo Group,NCT01220128,Evaluation of an Anti-cancer Immunotherapy Combined With Standard Neoadjuvant Treatment in Patients With WT1-positive Primary Invasive Breast Cancer,adverse drug events
D064420,62.5,NCT01220128-7,Cohort D-GSK2302024A-D14 Group,NCT01220128,Evaluation of an Anti-cancer Immunotherapy Combined With Standard Neoadjuvant Treatment in Patients With WT1-positive Primary Invasive Breast Cancer,adverse drug events
D009503,11.11,NCT01220128-3,Cohort B-GSK2302024A Group,NCT01220128,Evaluation of an Anti-cancer Immunotherapy Combined With Standard Neoadjuvant Treatment in Patients With WT1-positive Primary Invasive Breast Cancer,neutropenia
D009503,16.67,NCT01220128-4,Cohort B-Placebo Group,NCT01220128,Evaluation of an Anti-cancer Immunotherapy Combined With Standard Neoadjuvant Treatment in Patients With WT1-positive Primary Invasive Breast Cancer,neutropenia
D009503,36.36,NCT01220128-5,Cohort C-GSK2302024A Group,NCT01220128,Evaluation of an Anti-cancer Immunotherapy Combined With Standard Neoadjuvant Treatment in Patients With WT1-positive Primary Invasive Breast Cancer,neutropenia
D009503,37.5,NCT01220128-7,Cohort D-GSK2302024A-D14 Group,NCT01220128,Evaluation of an Anti-cancer Immunotherapy Combined With Standard Neoadjuvant Treatment in Patients With WT1-positive Primary Invasive Breast Cancer,neutropenia
D064147,11.11,NCT01220128-3,Cohort B-GSK2302024A Group,NCT01220128,Evaluation of an Anti-cancer Immunotherapy Combined With Standard Neoadjuvant Treatment in Patients With WT1-positive Primary Invasive Breast Cancer,febrile neutropenia
D064147,16.67,NCT01220128-4,Cohort B-Placebo Group,NCT01220128,Evaluation of an Anti-cancer Immunotherapy Combined With Standard Neoadjuvant Treatment in Patients With WT1-positive Primary Invasive Breast Cancer,febrile neutropenia
D064147,9.09,NCT01220128-5,Cohort C-GSK2302024A Group,NCT01220128,Evaluation of an Anti-cancer Immunotherapy Combined With Standard Neoadjuvant Treatment in Patients With WT1-positive Primary Invasive Breast Cancer,febrile neutropenia
D064147,25.0,NCT01220128-6,Cohort C-Placebo Group,NCT01220128,Evaluation of an Anti-cancer Immunotherapy Combined With Standard Neoadjuvant Treatment in Patients With WT1-positive Primary Invasive Breast Cancer,febrile neutropenia
D064147,25.0,NCT01220128-7,Cohort D-GSK2302024A-D14 Group,NCT01220128,Evaluation of an Anti-cancer Immunotherapy Combined With Standard Neoadjuvant Treatment in Patients With WT1-positive Primary Invasive Breast Cancer,febrile neutropenia
D007970,11.11,NCT01220128-3,Cohort B-GSK2302024A Group,NCT01220128,Evaluation of an Anti-cancer Immunotherapy Combined With Standard Neoadjuvant Treatment in Patients With WT1-positive Primary Invasive Breast Cancer,leukopenia
D007970,9.09,NCT01220128-5,Cohort C-GSK2302024A Group,NCT01220128,Evaluation of an Anti-cancer Immunotherapy Combined With Standard Neoadjuvant Treatment in Patients With WT1-positive Primary Invasive Breast Cancer,leukopenia
D007970,12.5,NCT01220128-7,Cohort D-GSK2302024A-D14 Group,NCT01220128,Evaluation of an Anti-cancer Immunotherapy Combined With Standard Neoadjuvant Treatment in Patients With WT1-positive Primary Invasive Breast Cancer,leukopenia
10047386,6.67,NCT01220128-1,Cohort A-GSK2302024A Group,NCT01220128,Evaluation of an Anti-cancer Immunotherapy Combined With Standard Neoadjuvant Treatment in Patients With WT1-positive Primary Invasive Breast Cancer,vestibular disorder
UNKNOWN-check-for-typo,18.18,NCT01220128-5,Cohort C-GSK2302024A Group,NCT01220128,Evaluation of an Anti-cancer Immunotherapy Combined With Standard Neoadjuvant Treatment in Patients With WT1-positive Primary Invasive Breast Cancer,D00
D000074042,6.67,NCT01220128-1,Cohort A-GSK2302024A Group,NCT01220128,Evaluation of an Anti-cancer Immunotherapy Combined With Standard Neoadjuvant Treatment in Patients With WT1-positive Primary Invasive Breast Cancer,cerebral intraventricular haemorrhage
D009325,9.09,NCT01220128-5,Cohort C-GSK2302024A Group,NCT01220128,Evaluation of an Anti-cancer Immunotherapy Combined With Standard Neoadjuvant Treatment in Patients With WT1-positive Primary Invasive Breast Cancer,nausea
D013280,12.5,NCT01220128-7,Cohort D-GSK2302024A-D14 Group,NCT01220128,Evaluation of an Anti-cancer Immunotherapy Combined With Standard Neoadjuvant Treatment in Patients With WT1-positive Primary Invasive Breast Cancer,stomatitis
D014839,9.09,NCT01220128-5,Cohort C-GSK2302024A Group,NCT01220128,Evaluation of an Anti-cancer Immunotherapy Combined With Standard Neoadjuvant Treatment in Patients With WT1-positive Primary Invasive Breast Cancer,vomiting
D003643,11.11,NCT01220128-3,Cohort B-GSK2302024A Group,NCT01220128,Evaluation of an Anti-cancer Immunotherapy Combined With Standard Neoadjuvant Treatment in Patients With WT1-positive Primary Invasive Breast Cancer,death
D002764,11.11,NCT01220128-3,Cohort B-GSK2302024A Group,NCT01220128,Evaluation of an Anti-cancer Immunotherapy Combined With Standard Neoadjuvant Treatment in Patients With WT1-positive Primary Invasive Breast Cancer,cholecystitis
D003681,9.09,NCT01220128-5,Cohort C-GSK2302024A Group,NCT01220128,Evaluation of an Anti-cancer Immunotherapy Combined With Standard Neoadjuvant Treatment in Patients With WT1-positive Primary Invasive Breast Cancer,dehydration
UNKNOWN-check-for-typo,11.11,NCT01220128-3,Cohort B-GSK2302024A Group,NCT01220128,Evaluation of an Anti-cancer Immunotherapy Combined With Standard Neoadjuvant Treatment in Patients With WT1-positive Primary Invasive Breast Cancer,D00
D063806,12.5,NCT01220128-7,Cohort D-GSK2302024A-D14 Group,NCT01220128,Evaluation of an Anti-cancer Immunotherapy Combined With Standard Neoadjuvant Treatment in Patients With WT1-positive Primary Invasive Breast Cancer,myalgia
D011111,6.67,NCT01220128-1,Cohort A-GSK2302024A Group,NCT01220128,Evaluation of an Anti-cancer Immunotherapy Combined With Standard Neoadjuvant Treatment in Patients With WT1-positive Primary Invasive Breast Cancer,polymyalgia rheumatica
D007680,6.67,NCT01220128-1,Cohort A-GSK2302024A Group,NCT01220128,Evaluation of an Anti-cancer Immunotherapy Combined With Standard Neoadjuvant Treatment in Patients With WT1-positive Primary Invasive Breast Cancer,renal cancer
D009026,2.96,NCT01275677-1,Arm I (Chemotherapy),NCT01275677,Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer,mortality
D009026,3.75,NCT01275677-2,Arm II (Chemotherapy Trastuzumab),NCT01275677,Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer,mortality
D064420,1.92,NCT01275677-1,Arm I (Chemotherapy),NCT01275677,Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer,adverse drug events
D064420,5.91,NCT01275677-2,Arm II (Chemotherapy Trastuzumab),NCT01275677,Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer,adverse drug events
10005329,0.06,NCT01275677-2,Arm II (Chemotherapy Trastuzumab),NCT01275677,Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer,blood and lymphatic system disorders - other specify
D004211,0.06,NCT01275677-2,Arm II (Chemotherapy Trastuzumab),NCT01275677,Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer,disseminated intravascular coagulation
D006323,0.06,NCT01275677-2,Arm II (Chemotherapy Trastuzumab),NCT01275677,Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer,asystole
D006333,0.06,NCT01275677-1,Arm I (Chemotherapy),NCT01275677,Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer,heart failure
D006333,1.11,NCT01275677-2,Arm II (Chemotherapy Trastuzumab),NCT01275677,Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer,heart failure
D009203,0.12,NCT01275677-1,Arm I (Chemotherapy),NCT01275677,Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer,myocardial infarction
D009203,0.12,NCT01275677-2,Arm II (Chemotherapy Trastuzumab),NCT01275677,Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer,myocardial infarction
D010490,0.06,NCT01275677-1,Arm I (Chemotherapy),NCT01275677,Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer,pericardial effusion
D013617,0.18,NCT01275677-2,Arm II (Chemotherapy Trastuzumab),NCT01275677,Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer,supraventricular tachycardia
D017180,0.06,NCT01275677-2,Arm II (Chemotherapy Trastuzumab),NCT01275677,Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer,ventricular tachycardia
D054058,0.06,NCT01275677-1,Arm I (Chemotherapy),NCT01275677,Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer,acute coronary syndrome
10061389,0.06,NCT01275677-2,Arm II (Chemotherapy Trastuzumab),NCT01275677,Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer,tricuspid valve disease
10061532,0.06,NCT01275677-2,Arm II (Chemotherapy Trastuzumab),NCT01275677,Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer,mitral valve disease
10061589,0.06,NCT01275677-2,Arm II (Chemotherapy Trastuzumab),NCT01275677,Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer,aortic valve disease
10069501,0.31,NCT01275677-1,Arm I (Chemotherapy),NCT01275677,Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer,left ventricular systolic dysfunction
10069501,1.78,NCT01275677-2,Arm II (Chemotherapy Trastuzumab),NCT01275677,Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer,left ventricular systolic dysfunction
10010001,0.06,NCT01275677-1,Arm I (Chemotherapy),NCT01275677,Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer,colonic perforation
D003967,0.06,NCT01275677-2,Arm II (Chemotherapy Trastuzumab),NCT01275677,Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer,diarrhea
D053706,0.06,NCT01275677-2,Arm II (Chemotherapy Trastuzumab),NCT01275677,Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer,typhlitis
10055356,0.06,NCT01275677-2,Arm II (Chemotherapy Trastuzumab),NCT01275677,Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer,upper gastrointestinal hemorrhage
D009102,0.06,NCT01275677-1,Arm I (Chemotherapy),NCT01275677,Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer,multiple organ failure
D009102,0.06,NCT01275677-2,Arm II (Chemotherapy Trastuzumab),NCT01275677,Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer,multiple organ failure
D017093,0.06,NCT01275677-2,Arm II (Chemotherapy Trastuzumab),NCT01275677,Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer,hepatic failure
10007810,0.06,NCT01275677-2,Arm II (Chemotherapy Trastuzumab),NCT01275677,Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer,catheter related infection
10019799,0.06,NCT01275677-2,Arm II (Chemotherapy Trastuzumab),NCT01275677,Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer,hepatitis viral
D018805,0.12,NCT01275677-1,Arm I (Chemotherapy),NCT01275677,Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer,sepsis
D018805,0.43,NCT01275677-2,Arm II (Chemotherapy Trastuzumab),NCT01275677,Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer,sepsis
10058838,0.12,NCT01275677-2,Arm II (Chemotherapy Trastuzumab),NCT01275677,Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer,enterocolitis infectious
10061229,0.06,NCT01275677-1,Arm I (Chemotherapy),NCT01275677,Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer,lung infection
10061229,0.06,NCT01275677-2,Arm II (Chemotherapy Trastuzumab),NCT01275677,Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer,lung infection
10065771,0.06,NCT01275677-1,Arm I (Chemotherapy),NCT01275677,Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer,small intestine infection
10022117,0.06,NCT01275677-2,Arm II (Chemotherapy Trastuzumab),NCT01275677,Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer,injury poisoning and procedural complications - other specify
10062169,0.06,NCT01275677-1,Arm I (Chemotherapy),NCT01275677,Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer,vascular access complication
10001551,0.06,NCT01275677-2,Arm II (Chemotherapy Trastuzumab),NCT01275677,Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer,alanine aminotransferase increased
10003481,0.06,NCT01275677-2,Arm II (Chemotherapy Trastuzumab),NCT01275677,Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer,aspartate aminotransferase increased
10024574,0.06,NCT01275677-1,Arm I (Chemotherapy),NCT01275677,Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer,lipase increased
10050528,0.06,NCT01275677-1,Arm I (Chemotherapy),NCT01275677,Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer,ejection fraction decreased
10050528,0.62,NCT01275677-2,Arm II (Chemotherapy Trastuzumab),NCT01275677,Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer,ejection fraction decreased
D006934,0.06,NCT01275677-1,Arm I (Chemotherapy),NCT01275677,Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer,hypercalcemia
D006943,0.12,NCT01275677-1,Arm I (Chemotherapy),NCT01275677,Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer,hyperglycemia
D006943,0.25,NCT01275677-2,Arm II (Chemotherapy Trastuzumab),NCT01275677,Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer,hyperglycemia
D015228,0.06,NCT01275677-2,Arm II (Chemotherapy Trastuzumab),NCT01275677,Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer,hypertriglyceridemia
D033461,0.06,NCT01275677-1,Arm I (Chemotherapy),NCT01275677,Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer,hyperuricemia
D006996,0.06,NCT01275677-2,Arm II (Chemotherapy Trastuzumab),NCT01275677,Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer,hypocalcemia
D007008,0.12,NCT01275677-1,Arm I (Chemotherapy),NCT01275677,Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer,hypokalemia
D007008,0.37,NCT01275677-2,Arm II (Chemotherapy Trastuzumab),NCT01275677,Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer,hypokalemia
10021028,0.06,NCT01275677-2,Arm II (Chemotherapy Trastuzumab),NCT01275677,Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer,hypomagnesemia
D007010,0.06,NCT01275677-2,Arm II (Chemotherapy Trastuzumab),NCT01275677,Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer,hyponatremia
D009190,0.12,NCT01275677-1,Arm I (Chemotherapy),NCT01275677,Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer,myelodysplastic syndrome
10048293,0.06,NCT01275677-1,Arm I (Chemotherapy),NCT01275677,Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer,leukemia secondary to oncology chemotherapy
10048293,0.06,NCT01275677-2,Arm II (Chemotherapy Trastuzumab),NCT01275677,Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer,leukemia secondary to oncology chemotherapy
D020300,0.06,NCT01275677-2,Arm II (Chemotherapy Trastuzumab),NCT01275677,Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer,intracranial hemorrhage
D020521,0.06,NCT01275677-2,Arm II (Chemotherapy Trastuzumab),NCT01275677,Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer,stroke
D013575,0.12,NCT01275677-2,Arm II (Chemotherapy Trastuzumab),NCT01275677,Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer,syncope
10036585,0.12,NCT01275677-2,Arm II (Chemotherapy Trastuzumab),NCT01275677,Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer,pregnancy puerperium and perinatal conditions - other specify
D003693,0.06,NCT01275677-1,Arm I (Chemotherapy),NCT01275677,Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer,delirium
D003693,0.06,NCT01275677-2,Arm II (Chemotherapy Trastuzumab),NCT01275677,Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer,delirium
D003863,0.19,NCT01275677-1,Arm I (Chemotherapy),NCT01275677,Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer,depression
D003863,0.25,NCT01275677-2,Arm II (Chemotherapy Trastuzumab),NCT01275677,Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer,depression
D011618,0.06,NCT01275677-2,Arm II (Chemotherapy Trastuzumab),NCT01275677,Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer,psychosis
10042464,0.06,NCT01275677-2,Arm II (Chemotherapy Trastuzumab),NCT01275677,Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer,suicide attempt
D058186,0.06,NCT01275677-2,Arm II (Chemotherapy Trastuzumab),NCT01275677,Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer,acute kidney injury
10046904,0.06,NCT01275677-2,Arm II (Chemotherapy Trastuzumab),NCT01275677,Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer,vaginal dryness
D012128,0.06,NCT01275677-2,Arm II (Chemotherapy Trastuzumab),NCT01275677,Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer,adult respiratory distress syndrome
D004417,0.06,NCT01275677-2,Arm II (Chemotherapy Trastuzumab),NCT01275677,Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer,dyspnea
D000860,0.06,NCT01275677-1,Arm I (Chemotherapy),NCT01275677,Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer,hypoxia
D011014,0.43,NCT01275677-1,Arm I (Chemotherapy),NCT01275677,Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer,pneumonitis
D011014,0.31,NCT01275677-2,Arm II (Chemotherapy Trastuzumab),NCT01275677,Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer,pneumonitis
D011030,0.06,NCT01275677-2,Arm II (Chemotherapy Trastuzumab),NCT01275677,Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer,pneumothorax
D012131,0.06,NCT01275677-1,Arm I (Chemotherapy),NCT01275677,Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer,respiratory failure
D004892,0.06,NCT01275677-2,Arm II (Chemotherapy Trastuzumab),NCT01275677,Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer,erythema multiforme
D006973,0.12,NCT01275677-2,Arm II (Chemotherapy Trastuzumab),NCT01275677,Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer,hypertension
D007022,0.06,NCT01275677-2,Arm II (Chemotherapy Trastuzumab),NCT01275677,Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer,hypotension
10043565,0.06,NCT01275677-1,Arm I (Chemotherapy),NCT01275677,Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer,thromboembolic event
D064420,38.37,NCT01287741-1,Rituximab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),adverse drug events
D064420,44.44,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),adverse drug events
D000741,0.86,NCT01287741-1,Rituximab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),aplastic anaemia
D000741,1.28,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),aplastic anaemia
D064147,10.13,NCT01287741-1,Rituximab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),febrile neutropenia
D064147,12.11,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),febrile neutropenia
D000743,0.14,NCT01287741-1,Rituximab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),haemolytic anaemia
D015614,0.14,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),histiocytosis
D016553,0.14,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),immune thrombocytopenic purpura
D007970,0.86,NCT01287741-1,Rituximab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),leukopenia
D007970,1.99,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),leukopenia
D009503,5.42,NCT01287741-1,Rituximab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),neutropenia
D009503,7.69,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),neutropenia
D006971,0.14,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),anemia splenic
D013921,0.29,NCT01287741-1,Rituximab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),thrombocytopenia
D013921,1.71,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),thrombocytopenia
D000080983,0.14,NCT01287741-1,Rituximab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),bone marrow failure
D054058,0.14,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),acute coronary syndrome
D056988,0.71,NCT01287741-1,Rituximab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),acute anterior wall myocardial infarction
D056988,0.28,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),acute anterior wall myocardial infarction
D000787,0.29,NCT01287741-1,Rituximab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),angina pectoris
D001281,0.57,NCT01287741-1,Rituximab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),atrial fibrillation
D001281,1.28,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),atrial fibrillation
D001282,0.14,NCT01287741-1,Rituximab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),atrial flutter
D001282,0.14,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),atrial flutter
D001919,0.14,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),bradycardia
D006323,0.14,NCT01287741-1,Rituximab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),cardiac arrest
D006323,0.14,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),cardiac arrest
D006333,0.43,NCT01287741-1,Rituximab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),cardiac failure
D006333,1.0,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),cardiac failure
D006333,0.14,NCT01287741-1,Rituximab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),cardiac failure
D006333,0.43,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),cardiac failure
D009618,0.14,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),nocardiaceae
D009202,0.14,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),cardiomyopathy
D000028,0.14,NCT01287741-1,Rituximab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),abortion failure
D002311,0.14,NCT01287741-1,Rituximab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),congestive cardiomyopathy
D003324,0.14,NCT01287741-1,Rituximab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),coronary artery disease
D003328,0.14,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),coronary thrombosis
D004184,0.14,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),heartworm disease
D018487,0.14,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),left ventricular dysfunction
10061532,0.14,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),mitral valve disease
D009203,0.29,NCT01287741-1,Rituximab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),myocardial infarction
D009203,0.43,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),myocardial infarction
D000071956,0.14,NCT01287741-1,Rituximab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),myocardial contusions
D010490,0.14,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),pericardial effusion
D013617,0.14,NCT01287741-1,Rituximab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),supraventricular tachycardia
D054141,0.14,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),ventricular flutter
D014717,0.14,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),positional vertigo
D000075262,0.14,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),familial x-linked addison disease
UNKNOWN-check-for-typo,0.14,NCT01287741-1,Rituximab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),D00
D002386,0.29,NCT01287741-1,Rituximab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),cataract
D007989,0.14,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),increased libido
D015746,0.86,NCT01287741-1,Rituximab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),abdominal pain
D015746,0.57,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),abdominal pain
D015746,0.14,NCT01287741-1,Rituximab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),abdominal pain
D015746,0.28,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),abdominal pain
D012003,0.14,NCT01287741-1,Rituximab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),anal fistula
D003092,0.29,NCT01287741-1,Rituximab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),colitis
D003092,0.28,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),colitis
D003248,0.14,NCT01287741-1,Rituximab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),constipation
UNKNOWN-check-for-typo,0.86,NCT01287741-1,Rituximab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),D00
UNKNOWN-check-for-typo,0.71,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),D00
D003680,0.14,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),dysphagia
D020115,0.29,NCT01287741-1,Rituximab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),progastricsin
D020115,0.14,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),progastricsin
10017815,0.43,NCT01287741-1,Rituximab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),gastric perforation
10017815,0.14,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),gastric perforation
D013276,0.14,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),gastric ulcer
D005756,0.14,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),gastritis
D005756,0.14,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),gastritis
D000069196,0.43,NCT01287741-1,Rituximab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),gastrointestinal microbiome
D000069196,0.28,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),gastrointestinal microbiome
UNKNOWN-check-for-typo,0.14,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),D00
UNKNOWN-check-for-typo,0.14,NCT01287741-1,Rituximab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),D00
UNKNOWN-check-for-typo,0.28,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),D00
10021305,0.14,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),ileal perforation
D045823,0.29,NCT01287741-1,Rituximab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),ileus
D045823,0.14,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),ileus
D007418,0.14,NCT01287741-1,Rituximab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),paralytic ileus
D005746,0.14,NCT01287741-1,Rituximab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),gastric emptying
D006552,0.14,NCT01287741-1,Rituximab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),inguinal hernia
D006552,0.14,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),inguinal hernia
D000069196,0.14,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),gastrointestinal microbiome
D007415,0.71,NCT01287741-1,Rituximab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),intestinal obstruction
D007415,0.28,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),intestinal obstruction
D007416,0.43,NCT01287741-1,Rituximab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),intestinal perforation
D007416,0.43,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),intestinal perforation
D007420,0.28,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),intestine large
D041741,0.14,NCT01287741-1,Rituximab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),lower gastrointestinal tract
D050686,0.14,NCT01287741-1,Rituximab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),globicephala melaena
D009325,0.29,NCT01287741-1,Rituximab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),nausea
D009325,0.14,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),nausea
D010195,0.14,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),acute pancreatitis
D011027,0.14,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),pneumoperitoneum
10041101,0.14,NCT01287741-1,Rituximab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),small intestinal obstruction
10041101,0.28,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),small intestinal obstruction
10041103,0.14,NCT01287741-1,Rituximab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),small intestinal perforation
10041103,0.14,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),small intestinal perforation
D013280,0.14,NCT01287741-1,Rituximab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),stomatitis
10021328,0.14,NCT01287741-1,Rituximab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),ileus
10021328,0.14,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),ileus
D041742,0.14,NCT01287741-1,Rituximab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),upper gastrointestinal tract
D041742,0.43,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),upper gastrointestinal tract
D014839,0.29,NCT01287741-1,Rituximab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),vomiting
D014839,0.28,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),vomiting
D001247,0.57,NCT01287741-1,Rituximab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),asthenia
D001247,0.28,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),asthenia
D000080867,0.14,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),gingipains
D002637,0.29,NCT01287741-1,Rituximab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),chest pain
D023341,0.14,NCT01287741-1,Rituximab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),chills
D023341,0.28,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),chills
D003643,0.29,NCT01287741-1,Rituximab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),death
D003643,0.43,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),death
D005119,0.14,NCT01287741-1,Rituximab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),extravasation of diagnostic and therapeutic materials
D005221,0.71,NCT01287741-1,Rituximab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),fatigue
D005221,0.57,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),fatigue
D003695,0.14,NCT01287741-1,Rituximab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),healthcare
D003695,0.28,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),healthcare
D006547,0.14,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),hernia
D008305,0.14,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),hyperpyrexia malignant
D006547,0.14,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),hernia
10025482,0.28,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),malaise
D007249,0.14,NCT01287741-1,Rituximab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),inflammation
D007249,0.14,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),inflammation
10062501,0.29,NCT01287741-1,Rituximab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),non-cardiac chest pain
D000799,0.28,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),angioedema
D010146,0.14,NCT01287741-1,Rituximab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),pain
D001929,0.14,NCT01287741-1,Rituximab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),brain swelling
D005334,1.57,NCT01287741-1,Rituximab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),pyrexia
D005334,2.42,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),pyrexia
D003645,0.14,NCT01287741-1,Rituximab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),sudden death
D003645,0.14,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),sudden death
D002779,0.14,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),bile duct obstruction
D002764,0.29,NCT01287741-1,Rituximab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),cholecystitis
D002764,0.14,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),cholecystitis
D041881,0.14,NCT01287741-1,Rituximab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),acute cholecystitis
D041881,0.14,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),acute cholecystitis
D002769,0.14,NCT01287741-1,Rituximab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),cholelithiasis
D011681,0.14,NCT01287741-1,Rituximab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),pupillary functions abnormal
D000038,0.28,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),abscess
D000038,0.14,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),abscess
D001064,0.43,NCT01287741-1,Rituximab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),appendicitis
D001064,0.14,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),appendicitis
D011016,0.29,NCT01287741-1,Rituximab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),pneumonia atypical interstitial of cattle
D001424,0.14,NCT01287741-1,Rituximab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),bacterial infection
D000985,0.14,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),antisepsis
D001991,0.57,NCT01287741-1,Rituximab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),bronchitis
D001991,0.14,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),bronchitis
D055732,0.14,NCT01287741-1,Rituximab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),bronchopulmonary aspergillosis
D055732,0.14,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),bronchopulmonary aspergillosis
D000985,0.14,NCT01287741-1,Rituximab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),antisepsis
D002481,0.29,NCT01287741-1,Rituximab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),cellulitis
D002481,0.28,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),cellulitis
D002764,0.14,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),cholecystitis
D004761,0.14,NCT01287741-1,Rituximab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),clostridium enterocolitis
D004761,0.14,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),clostridium enterocolitis
D003015,0.14,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),clostridium difficile infection
D002825,0.14,NCT01287741-1,Rituximab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),chorioretinitis
D002825,0.43,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),chorioretinitis
D003092,0.14,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),colitis
D003586,0.29,NCT01287741-1,Rituximab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),cytomegalovirus infection
10064687,0.29,NCT01287741-1,Rituximab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),device related infection
10064687,0.14,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),device related infection
10064687,0.14,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),device related infection
D000069544,0.14,NCT01287741-1,Rituximab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),encephalitis infection
D000069544,0.28,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),infectious encephalitis
D004238,0.14,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),diverticulitis
D004756,0.14,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),enterobacteriaceae infections
10058838,0.14,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),enterocolitis infectious
D000985,0.14,NCT01287741-1,Rituximab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),antisepsis
D009181,0.14,NCT01287741-1,Rituximab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),fungal infection
D005759,0.43,NCT01287741-1,Rituximab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),gastroenteritis
D005759,0.28,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),gastroenteritis
D053118,0.14,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),influenza a virus h1n1 subtype
10058827,0.14,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),hepatitis b reactivation
D006561,0.14,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),herpes simplex
D006558,0.28,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),herpes simplex virus genital infection
D006562,0.43,NCT01287741-1,Rituximab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),herpes zoster
D006562,0.57,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),herpes zoster
D006562,0.14,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),herpes zoster
D008210,0.14,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),lymphocele
D007239,0.28,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),infection
D010996,0.28,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),pleural effusion
D005928,0.14,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),glossitis
D007251,0.29,NCT01287741-1,Rituximab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),influenza
D007251,0.14,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),influenza
D000985,0.14,NCT01287741-1,Rituximab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),antisepsis
D000985,0.14,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),antisepsis
D007827,0.14,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),laryngitis
D000069544,0.14,NCT01287741-1,Rituximab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),encephalitis infection
D012141,0.14,NCT01287741-1,Rituximab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),respiratory tract infections
D012141,0.43,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),respiratory tract infections
10061229,0.43,NCT01287741-1,Rituximab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),lung infection
10061229,0.85,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),lung infection
D008457,0.14,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),measles
D008581,0.14,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),meningitis
D016919,0.14,NCT01287741-1,Rituximab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),cryptococcal meningitis
D008587,0.14,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),viral meningitis
D009304,0.29,NCT01287741-1,Rituximab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),nasopharyngitis
D005208,0.14,NCT01287741-1,Rituximab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),fasciitis
D000069544,0.14,NCT01287741-1,Rituximab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),encephalitis infection
D000069544,0.14,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),encephalitis infection
D000985,0.43,NCT01287741-1,Rituximab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),antisepsis
D000985,0.43,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),antisepsis
D000069544,0.29,NCT01287741-1,Rituximab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),encephalitis infection
D009920,0.14,NCT01287741-1,Rituximab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),orchitis
D010019,0.14,NCT01287741-1,Rituximab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),osteomyelitis
D010019,0.14,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),osteomyelitis
D010538,0.29,NCT01287741-1,Rituximab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),peritonitis
D010538,0.28,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),peritonitis
D009304,0.14,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),nasopharyngitis
D011020,0.43,NCT01287741-1,Rituximab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),pneumocystis jirovecii pneumonia
D011020,0.14,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),pneumocystis jirovecii pneumonia
D011014,4.71,NCT01287741-1,Rituximab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),pneumonia
D011014,6.13,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),pneumonia
D018410,0.14,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),bacterial pneumonia
D007968,0.14,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),progressive multifocal leukoencephalopathy
D000038,0.14,NCT01287741-1,Rituximab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),abscess
D000985,0.14,NCT01287741-1,Rituximab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),antisepsis
D000985,0.14,NCT01287741-1,Rituximab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),antisepsis
D000038,0.14,NCT01287741-1,Rituximab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),abscess
D000038,0.14,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),abscess
D012141,0.28,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),respiratory tract infection
D000038,0.14,NCT01287741-1,Rituximab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),abscess
D018805,1.43,NCT01287741-1,Rituximab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),sepsis
D018805,2.28,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),sepsis
D018746,0.14,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),sepsis syndrome
D012772,0.43,NCT01287741-1,Rituximab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),septic shock
D012772,1.71,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),septic shock
D012852,0.14,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),sinusitis
D018461,0.14,NCT01287741-1,Rituximab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),soft tissue infection
D000038,0.14,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),abscess
D014376,0.14,NCT01287741-1,Rituximab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),tuberculosis
D020306,0.14,NCT01287741-1,Rituximab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),tuberculosis central nervous system
D012141,0.14,NCT01287741-1,Rituximab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),upper respiratory tract infections
D012141,0.14,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),upper respiratory tract infections
D014552,0.43,NCT01287741-1,Rituximab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),urinary tract infection
D014552,0.43,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),urinary tract infection
10040047,0.14,NCT01287741-1,Rituximab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),sepsis
10040047,0.14,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),sepsis
D002644,0.14,NCT01287741-1,Rituximab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),varicella
D002644,0.14,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),varicella
D014777,0.14,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),viral infection
D000072139,0.14,NCT01287741-1,Rituximab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),megavirales
D014946,0.14,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),wound infection
D002481,0.14,NCT01287741-1,Rituximab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),cellulitis
D000069544,0.14,NCT01287741-1,Rituximab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),encephalitis infection
10048031,0.14,NCT01287741-1,Rituximab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),wound dehiscence
D005147,0.14,NCT01287741-1,Rituximab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),facial bones
10016173,0.14,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),fall
D005265,0.14,NCT01287741-1,Rituximab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),femoral neck fracture
D005265,0.29,NCT01287741-1,Rituximab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),femur neck fractures
D005265,0.14,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),femur neck fractures
10017076,0.14,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),fracture
10020100,0.14,NCT01287741-1,Rituximab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),hip fracture
10020100,0.14,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),hip fracture
10051792,0.14,NCT01287741-1,Rituximab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),infusion related reaction
10051792,1.14,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),infusion related reaction
D007668,0.14,NCT01287741-1,Rituximab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),kidney
D015775,0.14,NCT01287741-1,Rituximab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),microfractures
D000080902,0.14,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),injury mandibular nerve
D015775,0.14,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),microfractures
D012131,0.14,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),respiratory failure
10022117,0.14,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),injury poisoning and procedural complications - other specify
D016103,0.14,NCT01287741-1,Rituximab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),spinal fractures
D006408,0.43,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),hematoma subdural
D000081015,0.14,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),ototoxicity
D017541,0.14,NCT01287741-1,Rituximab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),pseudoaneurysm
D014947,0.14,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),wounds
D050815,0.14,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),compression fracture
10050528,0.14,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),ejection fraction decreased
D006679,0.14,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),hiv antibody positivity
D006899,0.14,NCT01287741-1,Rituximab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),monooxygenases
D002100,0.14,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),cachexia
D001066,0.14,NCT01287741-1,Rituximab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),appetite
D001066,0.28,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),appetite
D003681,0.57,NCT01287741-1,Rituximab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),dehydration
D003681,0.71,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),dehydration
D003920,0.14,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),diabetes mellitus
D005183,0.43,NCT01287741-1,Rituximab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),failure to thrive
UNKNOWN-check-for-typo,0.14,NCT01287741-1,Rituximab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),D00
UNKNOWN-check-for-typo,0.14,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),D00
UNKNOWN-check-for-typo,0.29,NCT01287741-1,Rituximab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),D00
UNKNOWN-check-for-typo,0.28,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),D00
UNKNOWN-check-for-typo,0.29,NCT01287741-1,Rituximab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),D00
UNKNOWN-check-for-typo,0.14,NCT01287741-1,Rituximab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),D00
D044342,0.29,NCT01287741-1,Rituximab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),malnutrition
D044342,0.14,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),malnutrition
D015275,0.29,NCT01287741-1,Rituximab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),tumour lysis syndrome
D015275,0.14,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),tumour lysis syndrome
D018771,0.29,NCT01287741-1,Rituximab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),arthralgia
D018771,0.14,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),arthralgia
D001416,0.14,NCT01287741-1,Rituximab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),back pain
D001416,0.28,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),back pain
UNKNOWN-check-for-typo,0.14,NCT01287741-1,Rituximab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),D00
D007403,0.14,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),intervertebral disc
D007596,0.14,NCT01287741-1,Rituximab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),joints
D063806,0.14,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),myalgia
D010003,0.14,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),osteoarthritis
10033425,0.14,NCT01287741-1,Rituximab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),pain in extremity
D015470,0.29,NCT01287741-1,Rituximab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),leukemia myeloid acute
D015470,0.14,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),leukemia myeloid acute
D000230,0.29,NCT01287741-1,Rituximab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),adenocarcinoma
D016393,0.14,NCT01287741-1,Rituximab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),b cell lymphoma
D001943,0.43,NCT01287741-1,Rituximab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),breast cancer
D001943,0.14,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),breast cancer
D011125,0.14,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),adenomatous polyposis of the colon
D003110,0.29,NCT01287741-1,Rituximab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),colon cancer
D015179,0.14,NCT01287741-1,Rituximab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),colorectal cancer
D015179,0.14,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),colorectal cancer
D006528,0.14,NCT01287741-1,Rituximab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),hepatocellular carcinoma
D006528,0.28,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),hepatocellular carcinoma
D008080,0.14,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),liposarcoma
D000077192,0.29,NCT01287741-1,Rituximab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),lung adenocarcinoma
D000077192,0.43,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),lung adenocarcinoma
D018442,0.14,NCT01287741-1,Rituximab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),lymphoma b-cell marginal zone
D000230,0.14,NCT01287741-1,Rituximab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),adenocarcinoma
D000235,0.14,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),papillary cystadenoma lymphomatosum
D011471,0.29,NCT01287741-1,Rituximab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),prostate cancer
D011471,0.28,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),prostate cancer
D002289,0.14,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),nonsmall cell lung cancer
D000072663,0.14,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),spontaneous perforation
D008228,0.14,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),lymphoma mixed-cell
D009190,0.14,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),myelodysplastic syndrome
D004847,0.14,NCT01287741-1,Rituximab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),squamous cells
D008175,0.14,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),lung neoplasms
D009101,0.14,NCT01287741-1,Rituximab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),plasma cell myeloma
D000690,0.14,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),amyotrophic lateral sclerosis
D000074042,0.14,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),cerebral intraventricular haemorrhage
D002544,0.14,NCT01287741-1,Rituximab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),cerebral infarction
D000070624,0.14,NCT01287741-1,Rituximab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),cerebral contusion
D000070624,0.14,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),cerebral contusion
D020521,0.29,NCT01287741-1,Rituximab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),cerebrovascular accident
D020521,0.43,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),cerebrovascular accident
D003244,0.14,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),depressed level of consciousness
D004244,0.28,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),dizziness
D013474,0.14,NCT01287741-1,Rituximab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),sunstroke
D004827,0.14,NCT01287741-1,Rituximab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),epilepsy
D006261,0.29,NCT01287741-1,Rituximab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),headache
D006261,0.43,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),headache
D010291,0.14,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),hemiparesis
D015840,0.14,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),oculomotor nerve paralysis
D013474,0.14,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),sunstroke
D014474,0.14,NCT01287741-1,Rituximab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),loss of consciousness
D010523,0.14,NCT01287741-1,Rituximab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),peripheral neuropathy
D010523,0.14,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),peripheral neuropathy
10034580,0.14,NCT01287741-1,Rituximab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),peripheral motor neuropathy
10034620,0.14,NCT01287741-1,Rituximab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),peripheral sensory neuropathy
D011115,0.14,NCT01287741-1,Rituximab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),polyneuropathy
D013575,0.14,NCT01287741-1,Rituximab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),presyncope
D013575,0.28,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),presyncope
D013474,0.14,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),sunstroke
D013575,0.43,NCT01287741-1,Rituximab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),syncope
D020258,0.14,NCT01287741-1,Rituximab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),toxic encephalopathy
D002546,0.14,NCT01287741-1,Rituximab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),ischemic attack transient
D014826,0.14,NCT01287741-1,Rituximab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),vocal cord paralysis
D012640,0.14,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),seizure
D001007,0.14,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),anxiety
D000081013,0.14,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),completed suicide
D003693,0.14,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),delirium
D003863,0.14,NCT01287741-1,Rituximab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),depression
D000079225,0.14,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),emotional distress
D000073216,0.14,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),mental status tests
D058186,0.29,NCT01287741-1,Rituximab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),acute kidney injury
D058186,0.28,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),acute kidney injury
D002764,0.14,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),cholecystitis
UNKNOWN-check-for-typo,0.28,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),D00
D056844,0.14,NCT01287741-1,Rituximab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),renal colic
D051437,0.14,NCT01287741-1,Rituximab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),renal failure
D051437,0.14,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),renal failure
D000308,0.14,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),hyperadrenalism
D016055,0.14,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),urinary retention
D000290,0.14,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),uterine appendages
D014138,0.14,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),tracheoesophageal fistula
D000799,0.14,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),angioedema
D012128,0.14,NCT01287741-1,Rituximab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),acute respiratory distress syndrome
D012128,0.14,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),acute respiratory distress syndrome
D012131,0.43,NCT01287741-1,Rituximab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),respiratory failure
D012131,0.14,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),respiratory failure
D000542,0.14,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),alveolitis extrinsic allergic
D001249,0.14,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),asthma
10006440,0.14,NCT01287741-1,Rituximab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),bronchial obstruction
D001986,0.14,NCT01287741-1,Rituximab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),bronchospasm
D001986,0.14,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),bronchospasm
D029424,0.14,NCT01287741-1,Rituximab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),chronic obstructive pulmonary disease
D029424,0.28,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),chronic obstructive pulmonary disease
UNKNOWN-check-for-typo,0.14,NCT01287741-1,Rituximab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),D00
UNKNOWN-check-for-typo,0.28,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),D00
D051270,0.14,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),primary exertional headache
D004646,0.28,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),emphysema
UNKNOWN-check-for-typo,0.14,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),D00
UNKNOWN-check-for-typo,0.14,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),D00
D000860,0.14,NCT01287741-1,Rituximab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),hypoxia
D000860,0.14,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),hypoxia
D017563,0.86,NCT01287741-1,Rituximab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),interstitial lung disease
D017563,0.43,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),interstitial lung disease
D008168,0.14,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),lung
D001996,0.14,NCT01287741-1,Rituximab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),bronchopneumonia
D010996,0.29,NCT01287741-1,Rituximab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),pleural effusion
D010996,0.57,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),pleural effusion
D011015,0.14,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),aspiration pneumonia
D011014,0.14,NCT01287741-1,Rituximab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),pneumonitis
D011014,0.71,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),pneumonitis
D011030,0.14,NCT01287741-1,Rituximab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),pneumothorax
D011030,0.14,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),pneumothorax
D011655,0.57,NCT01287741-1,Rituximab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),pulmonary embolism
D011655,0.57,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),pulmonary embolism
D011658,0.14,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),pulmonary fibrosis
D000799,0.14,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),angioedema
D012131,0.29,NCT01287741-1,Rituximab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),respiratory failure
D003371,0.14,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),cough
D017719,0.14,NCT01287741-1,Rituximab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),diabetic foot
D012883,0.14,NCT01287741-1,Rituximab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),skin ulcer
D012883,0.28,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),skin ulcer
D020246,0.28,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),deep vein thrombosis
D000074042,0.14,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),cerebral intraventricular haemorrhage
D006973,0.14,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),hypertension
D007022,0.29,NCT01287741-1,Rituximab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),hypotension
D007022,0.43,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),hypotension
D007024,0.14,NCT01287741-1,Rituximab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),orthostatic hypotension
D010689,0.14,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),phlebitis
D013924,0.29,NCT01287741-1,Rituximab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),thrombophlebitis
10042554,0.14,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),superficial thrombophlebitis
D008310,0.14,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),malocclusion
D020246,0.14,NCT01287741-2,Obinutuzumab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),venous thrombosis
D001367,0.14,NCT01287741-1,Rituximab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),axillary vein
D007601,0.14,NCT01287741-1,Rituximab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),jugular veins
D013350,0.14,NCT01287741-1,Rituximab+Chemotherapy,NCT01287741,A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA),subclavian vein
D064420,42.86,NCT01314105-1,Nintedanib 150mg,NCT01314105,BIBF 1120 + Carboplatin/Pegylated Liposomal Doxorubicin (PLD) in Patients With Advanced Ovarian Cancer  Fallopian Tube Carcinoma or Primary Peritoneal Cancer,adverse drug events
D064420,33.33,NCT01314105-2,Nintedanib 200mg,NCT01314105,BIBF 1120 + Carboplatin/Pegylated Liposomal Doxorubicin (PLD) in Patients With Advanced Ovarian Cancer  Fallopian Tube Carcinoma or Primary Peritoneal Cancer,adverse drug events
D045823,8.33,NCT01314105-2,Nintedanib 200mg,NCT01314105,BIBF 1120 + Carboplatin/Pegylated Liposomal Doxorubicin (PLD) in Patients With Advanced Ovarian Cancer  Fallopian Tube Carcinoma or Primary Peritoneal Cancer,ileus
D007415,8.33,NCT01314105-2,Nintedanib 200mg,NCT01314105,BIBF 1120 + Carboplatin/Pegylated Liposomal Doxorubicin (PLD) in Patients With Advanced Ovarian Cancer  Fallopian Tube Carcinoma or Primary Peritoneal Cancer,intestinal obstruction
10041101,8.33,NCT01314105-2,Nintedanib 200mg,NCT01314105,BIBF 1120 + Carboplatin/Pegylated Liposomal Doxorubicin (PLD) in Patients With Advanced Ovarian Cancer  Fallopian Tube Carcinoma or Primary Peritoneal Cancer,small intestinal obstruction
D006967,14.29,NCT01314105-1,Nintedanib 150mg,NCT01314105,BIBF 1120 + Carboplatin/Pegylated Liposomal Doxorubicin (PLD) in Patients With Advanced Ovarian Cancer  Fallopian Tube Carcinoma or Primary Peritoneal Cancer,hypersensitivity
10001551,14.29,NCT01314105-1,Nintedanib 150mg,NCT01314105,BIBF 1120 + Carboplatin/Pegylated Liposomal Doxorubicin (PLD) in Patients With Advanced Ovarian Cancer  Fallopian Tube Carcinoma or Primary Peritoneal Cancer,alanine aminotransferase increased
10035528,14.29,NCT01314105-1,Nintedanib 150mg,NCT01314105,BIBF 1120 + Carboplatin/Pegylated Liposomal Doxorubicin (PLD) in Patients With Advanced Ovarian Cancer  Fallopian Tube Carcinoma or Primary Peritoneal Cancer,platelet count decreased
D011655,8.33,NCT01314105-2,Nintedanib 200mg,NCT01314105,BIBF 1120 + Carboplatin/Pegylated Liposomal Doxorubicin (PLD) in Patients With Advanced Ovarian Cancer  Fallopian Tube Carcinoma or Primary Peritoneal Cancer,pulmonary embolism
D009026,5.45,NCT01328249-1,Cohort 1: Eribulin Mesylate With Filgrastim as Needed,NCT01328249,Dose Dense Doxorubucin and Cyclophosphamide Followed by Eribulin Mesylate for the Adjuvant Treatment of Early Stage Breast Cancer,mortality
D064420,10.91,NCT01328249-1,Cohort 1: Eribulin Mesylate With Filgrastim as Needed,NCT01328249,Dose Dense Doxorubucin and Cyclophosphamide Followed by Eribulin Mesylate for the Adjuvant Treatment of Early Stage Breast Cancer,adverse drug events
D064420,15.38,NCT01328249-2,Cohort 2: Eribulin Mesylate With Prophylactic Filgrastim,NCT01328249,Dose Dense Doxorubucin and Cyclophosphamide Followed by Eribulin Mesylate for the Adjuvant Treatment of Early Stage Breast Cancer,adverse drug events
D064147,3.64,NCT01328249-1,Cohort 1: Eribulin Mesylate With Filgrastim as Needed,NCT01328249,Dose Dense Doxorubucin and Cyclophosphamide Followed by Eribulin Mesylate for the Adjuvant Treatment of Early Stage Breast Cancer,febrile neutropenia
D064147,3.85,NCT01328249-2,Cohort 2: Eribulin Mesylate With Prophylactic Filgrastim,NCT01328249,Dose Dense Doxorubucin and Cyclophosphamide Followed by Eribulin Mesylate for the Adjuvant Treatment of Early Stage Breast Cancer,febrile neutropenia
D009325,3.64,NCT01328249-1,Cohort 1: Eribulin Mesylate With Filgrastim as Needed,NCT01328249,Dose Dense Doxorubucin and Cyclophosphamide Followed by Eribulin Mesylate for the Adjuvant Treatment of Early Stage Breast Cancer,nausea
10015461,3.64,NCT01328249-1,Cohort 1: Eribulin Mesylate With Filgrastim as Needed,NCT01328249,Dose Dense Doxorubucin and Cyclophosphamide Followed by Eribulin Mesylate for the Adjuvant Treatment of Early Stage Breast Cancer,esophagitis
D014839,3.64,NCT01328249-1,Cohort 1: Eribulin Mesylate With Filgrastim as Needed,NCT01328249,Dose Dense Doxorubucin and Cyclophosphamide Followed by Eribulin Mesylate for the Adjuvant Treatment of Early Stage Breast Cancer,vomiting
D007249,3.85,NCT01328249-2,Cohort 2: Eribulin Mesylate With Prophylactic Filgrastim,NCT01328249,Dose Dense Doxorubucin and Cyclophosphamide Followed by Eribulin Mesylate for the Adjuvant Treatment of Early Stage Breast Cancer,inflammation
D005334,3.64,NCT01328249-1,Cohort 1: Eribulin Mesylate With Filgrastim as Needed,NCT01328249,Dose Dense Doxorubucin and Cyclophosphamide Followed by Eribulin Mesylate for the Adjuvant Treatment of Early Stage Breast Cancer,pyrexia
D005334,3.85,NCT01328249-2,Cohort 2: Eribulin Mesylate With Prophylactic Filgrastim,NCT01328249,Dose Dense Doxorubucin and Cyclophosphamide Followed by Eribulin Mesylate for the Adjuvant Treatment of Early Stage Breast Cancer,pyrexia
D000038,3.85,NCT01328249-2,Cohort 2: Eribulin Mesylate With Prophylactic Filgrastim,NCT01328249,Dose Dense Doxorubucin and Cyclophosphamide Followed by Eribulin Mesylate for the Adjuvant Treatment of Early Stage Breast Cancer,abscess
D000077215,3.85,NCT01328249-2,Cohort 2: Eribulin Mesylate With Prophylactic Filgrastim,NCT01328249,Dose Dense Doxorubucin and Cyclophosphamide Followed by Eribulin Mesylate for the Adjuvant Treatment of Early Stage Breast Cancer,halloysite
D006558,1.82,NCT01328249-1,Cohort 1: Eribulin Mesylate With Filgrastim as Needed,NCT01328249,Dose Dense Doxorubucin and Cyclophosphamide Followed by Eribulin Mesylate for the Adjuvant Treatment of Early Stage Breast Cancer,genital herpes
10061229,3.85,NCT01328249-2,Cohort 2: Eribulin Mesylate With Prophylactic Filgrastim,NCT01328249,Dose Dense Doxorubucin and Cyclophosphamide Followed by Eribulin Mesylate for the Adjuvant Treatment of Early Stage Breast Cancer,lung infection
D012141,1.82,NCT01328249-1,Cohort 1: Eribulin Mesylate With Filgrastim as Needed,NCT01328249,Dose Dense Doxorubucin and Cyclophosphamide Followed by Eribulin Mesylate for the Adjuvant Treatment of Early Stage Breast Cancer,upper respiratory tract infections
D013851,1.82,NCT01328249-1,Cohort 1: Eribulin Mesylate With Filgrastim as Needed,NCT01328249,Dose Dense Doxorubucin and Cyclophosphamide Followed by Eribulin Mesylate for the Adjuvant Treatment of Early Stage Breast Cancer,underweight
D003681,3.64,NCT01328249-1,Cohort 1: Eribulin Mesylate With Filgrastim as Needed,NCT01328249,Dose Dense Doxorubucin and Cyclophosphamide Followed by Eribulin Mesylate for the Adjuvant Treatment of Early Stage Breast Cancer,dehydration
D013575,1.82,NCT01328249-1,Cohort 1: Eribulin Mesylate With Filgrastim as Needed,NCT01328249,Dose Dense Doxorubucin and Cyclophosphamide Followed by Eribulin Mesylate for the Adjuvant Treatment of Early Stage Breast Cancer,syncope
D064420,41.33,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),adverse drug events
D064420,48.71,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),adverse drug events
D000741,0.72,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),aplastic anaemia
D000744,0.14,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),autoimmune haemolytic anaemia
D000080983,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),bone marrow failure
D004211,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),disseminated intravascular coagulation
D064147,3.47,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),febrile neutropenia
D064147,4.87,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),febrile neutropenia
D006461,0.14,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),haemolysis
D000743,0.14,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),haemolytic anaemia
D015614,0.14,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),histiocytosis
D016553,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),immune thrombocytopenic purpura
D007970,0.72,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),leukopenia
D007970,0.43,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),leukopenia
D009503,4.34,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),neutropenia
D009503,3.58,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),neutropenia
D013163,0.14,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),splenomegaly
D013163,0.29,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),splenomegaly
D013921,0.29,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),thrombocytopenia
D013921,0.72,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),thrombocytopenia
D056988,0.57,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),acute anterior wall myocardial infarction
D000787,0.14,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),angina pectoris
D000787,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),angina pectoris
D001024,0.14,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),aortic valve stenosis
D001145,0.29,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),arrhythmia
D001281,0.29,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),atrial fibrillation
D001281,1.29,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),atrial fibrillation
D001282,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),atrial flutter
D001919,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),bradycardia
D006323,0.14,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),cardiac arrest
D006323,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),cardiac arrest
D006333,0.43,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),cardiac failure
D006333,0.29,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),cardiac failure
D006333,0.29,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),cardiac failure
D000072599,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),cardiorespiratory fitness
D012770,0.14,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),cardiogenic shock
D012770,0.29,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),cardiogenic shock
D003324,0.29,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),coronary artery disease
D023921,0.14,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),coronary artery stenosis
D009203,0.14,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),myocardial infarction
D009203,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),myocardial infarction
D000071956,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),myocardial contusions
10033557,0.14,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),palpitations
D016278,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),ventricular function right
10040741,0.72,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),sinus bradycardia
D013616,0.43,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),sinus tachycardia
D001919,0.14,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),bradycardia
D001919,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),bradycardia
D013610,0.43,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),tachycardia
D017180,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),ventricular tachycardia
D002607,0.14,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),peroneal muscular atrophy
D003638,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),deafness
10014020,0.14,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),ear pain
D003318,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),corneal opacity
D015746,0.72,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),abdominal pain
D015746,1.43,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),abdominal pain
D015746,0.29,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),abdominal pain
D001201,0.29,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),ascites
D001201,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),ascites
D003092,0.29,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),colitis
D003092,0.43,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),colitis
D003248,0.14,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),constipation
D003248,0.43,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),constipation
UNKNOWN-check-for-typo,1.01,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),D00
UNKNOWN-check-for-typo,1.58,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),D00
D004415,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),dyspepsia
D003680,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),dysphagia
10062570,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),enterovesical fistula
UNKNOWN-check-for-typo,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),D00
D020115,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),progastricsin
D013276,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),gastric ulcer
D005756,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),gastritis
D005756,0.14,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),gastritis
D005759,0.14,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),gastroenteritis
D005764,0.14,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),gastroesophageal reflux disease
UNKNOWN-check-for-typo,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),D00
UNKNOWN-check-for-typo,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),D00
D006551,0.14,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),hiatus hernia
D045823,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),ileus
D006552,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),inguinal hernia
D000069196,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),gastrointestinal microbiome
D007415,0.43,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),intestinal obstruction
D001284,0.14,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),atrophy
D007415,0.14,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),intestinal obstruction
D007420,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),intestine large
D050686,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),globicephala melaena
D013577,0.14,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),syndrome
D009055,0.14,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),mouth
D009055,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),mouth
D009325,0.43,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),nausea
D009325,0.86,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),nausea
D010195,0.14,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),pancreatitis
D010195,0.72,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),pancreatitis
D010195,0.14,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),acute pancreatitis
D010195,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),acute pancreatitis
D000071056,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),anorectal malformations
10041101,0.29,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),small intestinal obstruction
D013280,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),stomatitis
D041742,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),upper gastrointestinal tract
D014839,1.3,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),vomiting
D014839,0.86,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),vomiting
D064420,0.14,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),adverse drug reaction
D013909,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),chest
D002637,0.58,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),chest pain
D002637,0.29,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),chest pain
D023341,0.43,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),chills
D023341,0.57,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),chills
D000070621,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),cystography
D003643,0.29,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),death
D003643,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),death
D003695,0.29,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),healthcare
D003695,0.43,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),healthcare
D005334,0.14,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),hyperthermia
D011681,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),pupillary disorders
D007251,0.14,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),influenza
D007251,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),influenza
D000075662,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),injection site reaction
D007249,0.14,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),inflammation
D007249,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),inflammation
D009102,0.43,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),multiple organ failure
10062501,0.29,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),non-cardiac chest pain
D000799,0.14,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),angioedema
D010146,0.43,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),pain
D005334,3.47,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),pyrexia
D005334,5.3,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),pyrexia
D001964,0.14,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),hustentabsratiopharm
D004864,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),devices
10051341,0.14,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),bile duct stenosis
D042882,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),gallstones common bile duct
D000923,0.14,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),scolicides
D000923,0.29,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),scolicides
D002761,0.14,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),cholangitis
D002764,0.87,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),cholecystitis
D002764,0.57,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),cholecystitis
D041881,0.14,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),acute cholecystitis
D002769,0.14,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),cholelithiasis
D002769,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),cholelithiasis
D056486,0.29,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),drug induced liver injury
10017638,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),gallbladder pain
D011681,0.14,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),pupillary functions abnormal
D005234,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),steatohepatitis
D001181,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),arthropods
D000707,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),anaphylactic reaction
D000707,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),anaphylactic shock
D000080424,0.29,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),cytokine release syndrome
D004342,0.14,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),drug hypersensitivity
D006967,0.43,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),hypersensitivity
UNKNOWN-check-for-typo,0.14,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),D00
D018784,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),abdominal abscess
D000038,0.14,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),abscess
D000038,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),abscess
D001064,0.58,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),appendicitis
D001064,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),appendicitis
D001170,0.14,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),bacterial arthritis
D001168,0.14,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),arthritis
D011016,0.43,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),pneumonia atypical interstitial of cattle
D011016,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),pneumonia atypical interstitial of cattle
UNKNOWN-check-for-typo,0.14,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),D00
UNKNOWN-check-for-typo,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),D00
D014136,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),tracheitis
D000257,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),adenovirus infections
D000038,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),abscess
D001991,0.43,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),bronchitis
D001991,1.0,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),bronchitis
D002169,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),campylobacter infection
D000077215,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),halloysite
D002481,0.43,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),cellulitis
D002481,0.43,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),cellulitis
D012852,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),sinusitis
D004761,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),clostridium enterocolitis
D003556,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),cystitis
D003586,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),cytomegalovirus infection
10064687,0.43,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),device related infection
10064687,0.29,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),device related infection
10064687,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),device related infection
D004238,0.14,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),diverticulitis
D004660,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),encephalitis
D000069544,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),encephalitis infection
D004826,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),epiglottitis
D004927,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),escherichia coli infections
D014552,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),urinary tract infections
D000069544,0.14,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),encephalitis infection
D005759,0.14,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),gastroenteritis
D005759,1.0,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),gastroenteritis
D004926,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),escherichia coli
D000072139,0.14,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),megavirales
D006562,1.16,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),herpes zoster
D006562,1.0,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),herpes zoster
D006562,0.29,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),herpes zoster
D006566,0.14,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),herpesviridae infections
D016697,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),herpes zoster oticus
D000070621,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),cystography
D007239,1.16,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),infection
D007239,0.86,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),infection
D029424,0.57,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),pulmonary disease chronic obstructive
D007251,0.43,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),influenza
D015299,0.14,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),discitis
D012141,1.01,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),respiratory tract infections
D012141,1.72,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),respiratory tract infections
10061229,0.87,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),lung infection
10061229,1.15,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),lung infection
D008417,0.14,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),mastoiditis
D008580,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),pseudomeningitis
10065764,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),mucosal infection
D020852,0.14,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),lyme neuroborreliosis
D000069544,0.14,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),encephalitis infection
D000069544,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),encephalitis infection
D000985,0.72,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),antisepsis
D000985,0.72,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),antisepsis
D002177,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),candidiasis
D000069544,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),encephalitis infection
D013283,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),herpes simplex oral
D001424,0.14,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),bacterial infections
D000038,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),abscess
D010518,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),periodontitis
D000039,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),peritonsillar abscess
D017703,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),retropharyngeal abscess
D000069544,0.14,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),encephalitis infection
D011020,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),pneumocystis jirovecii pneumonia
D011014,4.34,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),pneumonia
D011014,6.02,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),pneumonia
D018410,0.14,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),bacterial pneumonia
D018410,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),bacterial pneumonia
D001996,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),bronchopneumonia
D011018,0.14,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),pneumococcal pneumonia
D013530,0.14,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),wound infection postoperative
D000985,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),antisepsis
D011704,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),pyelonephritis
D012141,0.58,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),respiratory tract infection
D012141,0.72,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),respiratory tract infection
D012220,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),rhinitis
D000069544,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),encephalitis infection
D018805,0.87,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),sepsis
D018805,1.86,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),sepsis
D012772,0.29,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),septic shock
D012852,0.29,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),sinusitis
D012852,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),sinusitis
D012852,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),sinusitis
D012852,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),sinusitis
D004768,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),staphylococcal enterotoxins
D013203,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),staphylococcal infection
D000038,0.29,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),abscess
D014376,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),tuberculosis
D000038,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),abscess
D012141,0.43,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),upper respiratory tract infections
D012141,0.86,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),upper respiratory tract infections
D014552,0.87,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),urinary tract infection
D014552,1.29,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),urinary tract infection
10040047,0.43,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),sepsis
10040047,0.43,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),sepsis
D014777,0.43,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),viral infection
D014777,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),viral infection
D000072139,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),megavirales
D000059,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),accident
D000437,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),alcoholism
D003251,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),stenosis
D064386,0.29,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),ankle fracture
D064386,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),ankle fracture
D000070624,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),brain contusion
D002356,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),cartilage
D050815,0.14,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),compression fracture
D005147,0.14,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),facial bones
10016173,0.14,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),fall
10016173,0.43,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),fall
D005265,0.14,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),femur neck fractures
D005265,0.29,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),femur neck fractures
D000068636,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),bigfoot
D006811,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),humerus
10051792,2.6,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),infusion related reaction
10051792,5.16,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),infusion related reaction
D008022,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),ligaments
D015775,0.14,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),microfractures
D008508,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),medication error
D000070600,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),injury tibial meniscus
D000069076,0.14,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),multiple fractures
D006468,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),hemopneumothorax
D049291,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),seroma
D016103,0.14,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),spinal fractures
D016103,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),spinal fractures
D016103,0.14,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),spinal fracture
D034941,0.43,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),upper limb
D034941,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),upper limb
10011368,0.14,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),creatinine increased
10011368,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),creatinine increased
D017567,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),karnofsky performance status
D001051,0.14,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),apoenzymes
D004641,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),international migration
D008111,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),liver function tests
D003681,0.29,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),dehydration
D003681,0.43,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),dehydration
D003920,0.29,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),diabetes mellitus
D011205,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),unifluid
UNKNOWN-check-for-typo,0.29,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),D00
UNKNOWN-check-for-typo,0.29,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),D00
UNKNOWN-check-for-typo,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),D00
UNKNOWN-check-for-typo,0.14,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),D00
UNKNOWN-check-for-typo,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),D00
UNKNOWN-check-for-typo,0.14,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),D00
UNKNOWN-check-for-typo,0.57,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),D00
D015275,0.14,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),tumour lysis syndrome
D015275,0.43,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),tumour lysis syndrome
D007592,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),arthropathy
D001416,0.43,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),back pain
D001416,0.29,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),back pain
D021501,0.14,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),flank pain
D021501,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),flank pain
UNKNOWN-check-for-typo,0.14,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),D00
D007403,0.14,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),intervertebral disc
D007403,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),intervertebral disc
D018908,0.14,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),muscular weakness
D009135,0.14,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),myopathy
D009135,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),myopathy
D009220,0.14,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),myositis
D009220,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),myositis
D019547,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),neck pain
D010001,0.14,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),osteitis deformans
D010003,0.43,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),osteoarthritis
D010003,0.29,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),osteoarthritis
10033425,0.14,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),pain in extremity
D005598,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),pathological fracture
D019534,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),rotator cuff impingement syndrome
D013130,0.29,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),spinal stenosis
D000080867,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),gingipains
D013585,0.14,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),synovitis
D013706,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),temporomandibular joint syndrome
D009464,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),acoustic neuroma
D015470,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),leukemia nonlymphocytic acute
D015470,0.29,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),leukemia myeloid acute
D000230,0.14,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),adenocarcinoma
D000230,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),adenocarcinoma
D000236,0.14,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),adenoma
D002280,0.29,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),basal cell carcinoma
D002280,0.72,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),basal cell carcinoma
D009369,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),benign neoplasm
D001943,0.57,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),breast cancer
D000072716,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),cancer pain
D003110,0.29,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),colon cancer
D003110,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),colon cancer
D015179,0.14,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),colorectal cancer
D000230,0.14,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),adenocarcinoma
D013274,0.14,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),gastric cancer
D008113,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),hepatic neoplasm
D006689,0.29,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),hodgkin disease
D003928,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),nodular glomerulosclerosis
D001940,0.14,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),breast
D008545,0.14,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),melanoma
D018270,0.14,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),carcinoma invasive ductal breast
D018270,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),carcinoma invasive ductal breast
D007636,0.14,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),keratoacanthoma
D000077192,0.14,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),lung adenocarcinoma
D008175,0.14,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),lung neoplasms
D008545,0.29,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),malignant melanoma
D008545,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),malignant melanoma
D008579,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),meningioma
D009190,0.29,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),myelodysplastic syndrome
D018278,0.14,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),carcinoma neuroendocrine
D002289,0.29,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),nonsmall cell lung cancer
D002289,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),nonsmall cell lung cancer
D000230,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),adenocarcinoma
D001943,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),breast cancer
D000077273,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),papillary thyroid cancer
D011471,0.43,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),prostate cancer
D011471,0.43,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),prostate cancer
D000230,0.14,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),adenocarcinoma
D000230,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),adenocarcinoma
D007680,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),renal cancer
D002292,0.14,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),renal cell carcinoma
D009442,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),schwannoma
D002294,0.29,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),squamous cell carcinoma
D002294,0.57,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),squamous cell carcinoma
D002294,0.14,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),carcinoma squamous cell
D002294,0.29,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),carcinoma squamous cell
D013964,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),thyroid cancer
D002295,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),transitional cell carcinoma
D000067251,0.14,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),symptom flareup
D014860,0.14,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),warts
D001259,0.14,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),ataxia
D020516,0.14,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),brachial plexopathy
D016893,0.14,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),carotid artery stenosis
D002526,0.14,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),cerebellar syndrome
D000067836,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),hoarding disorder
D000070624,0.14,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),cerebral contusion
D000070624,0.14,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),cerebral contusion
D000070624,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),cerebral contusion
D020521,0.14,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),cerebrovascular accident
D003704,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),dementia
D004244,0.29,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),dizziness
D004244,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),dizziness
D004244,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),dizziness
D001927,0.14,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),encephalopathy
D004827,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),epilepsy
D000069280,0.14,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),intracranial electroencephalography
D013474,0.14,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),sunstroke
D009123,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),hypotonia
D013474,0.14,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),sunstroke
D013474,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),sunstroke
D053609,0.29,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),lethargy
D000072676,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),ankyloglossia
D010291,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),monoparesis
D009422,0.14,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),nervous system disorder
D009437,0.14,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),neuralgia
D009437,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),neuralgia
D010523,0.14,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),peripheral neuropathy
D054971,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),orthostatic intolerance
D010095,0.14,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),oxotremorine
D000070579,0.14,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),parkinson disease associated proteins
D011115,0.14,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),polyneuropathy
D013575,0.43,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),presyncope
D012640,0.14,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),seizure
D012640,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),seizure
D013117,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),spinal cord compression
D013575,0.43,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),syncope
D013575,0.43,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),syncope
D002546,0.14,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),ischemic attack transient
D002546,0.57,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),ischemic attack transient
D014202,0.14,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),tremor
D007427,0.14,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),subarachnoid pressure
D015840,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),oculomotor nerve paralysis
D000022,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),abortion spontaneous
D000437,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),alcoholism
D001007,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),anxiety
D003221,0.14,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),confusional state
D003221,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),confusional state
D003863,0.29,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),depression
D003863,0.29,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),depression
D000066498,0.14,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),emotional adjustment
D000073216,0.29,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),mental status tests
D011618,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),psychotic disorder
D011618,0.14,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),psychotic disorders
10042464,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),suicide attempt
D058186,0.14,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),acute kidney injury
D058186,0.43,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),acute kidney injury
D017114,0.14,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),liver failure acute
D053159,0.14,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),dysuria
D053040,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),nephrolithiasis
D056844,0.14,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),renal colic
D051437,0.29,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),renal failure
D051437,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),renal failure
D000308,0.14,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),hyperadrenalism
D000402,0.14,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),airway obstruction
D000402,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),airway obstruction
D006869,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),hydronephrosis
D010048,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),ovarian cyst
D008404,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),massachusetts
D011472,0.29,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),prostatitis
D011472,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),prostatitis
D000069339,0.14,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),vaginal cervicectomy
D000080867,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),gingipains
D055371,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),acute lung injury
D012128,0.29,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),acute respiratory distress syndrome
D012131,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),respiratory failure
D001249,0.29,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),asthma
D001249,0.29,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),asthma
D001986,0.14,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),bronchospasm
D001986,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),bronchospasm
D029424,0.43,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),chronic obstructive pulmonary disease
D029424,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),chronic obstructive pulmonary disease
D003371,0.29,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),cough
UNKNOWN-check-for-typo,1.16,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),D00
UNKNOWN-check-for-typo,1.43,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),D00
D051270,0.14,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),primary exertional headache
D004646,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),emphysema
D004844,0.14,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),epistaxis
D004844,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),epistaxis
UNKNOWN-check-for-typo,0.14,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),D00
D000860,0.29,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),hypoxia
D017563,0.58,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),interstitial lung disease
D017563,0.29,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),interstitial lung disease
D008168,0.14,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),lung
D008168,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),lung
10068319,0.14,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),oropharyngeal pain
D000070621,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),cystography
D007249,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),inflammation
D000077274,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),nasopharyngeal carcinoma
D010996,0.72,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),pleural effusion
D010996,0.72,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),pleural effusion
D010998,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),pleurisy
10035623,0.29,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),pleuritic pain
10035623,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),pleuritic pain
D011015,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),aspiration pneumonia
D011014,0.14,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),pneumonitis
D011014,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),pneumonitis
D011030,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),pneumothorax
10036790,0.14,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),productive cough
D000081029,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),pulmonary arterial hypertension
D001261,0.14,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),pulmonary atelectasis
D011655,0.29,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),pulmonary embolism
D011655,1.15,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),pulmonary embolism
D019390,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),arrestins
10038738,0.14,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),respiratory thoracic and mediastinal disorders - other specify
D012131,0.29,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),respiratory failure
D012131,0.43,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),respiratory failure
D014827,0.14,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),vocal cords
D000799,0.29,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),angioedema
D003877,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),contact dermatitis
D003873,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),dermatitis exfoliative
D005076,0.29,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),rash
D005076,0.72,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),rash
10037868,0.14,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),rash maculo-papular
10037868,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),rash maculo-papular
D000077944,0.14,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),alefacept
D014581,0.14,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),urticaria
D014581,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),urticaria
D003452,0.14,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),cryosurgery
UNKNOWN-check-for-typo,0.14,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),D00
D013965,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),thyroidectomy
D001367,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),axillary vein
D012769,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),circulatory collapse
D020246,0.29,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),deep vein thrombosis
D020246,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),deep vein thrombosis
D004617,0.43,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),embolism
D000959,0.14,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),antihypertensives
D000959,0.29,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),antihypertensives
D007022,0.29,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),hypotension
D007022,1.0,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),hypotension
D002532,0.14,NCT01332968-1,Rituximab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),aneurysm basilar artery
D002406,0.14,NCT01332968-2,Obinutuzumab+Chemotherapy,NCT01332968,A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM),catheterization peripheral
D064420,3.85,NCT01412879-3,Stem Cell Transplant (Consolidation Therapy),NCT01412879,S1106 Rituximab With Combination Chemotherapy or Bendamustine Hydrochloride Followed by Consolidation Chemotherapy and Stem Cell Transplantation in Older Patients With Previously Untreated Mantle Cell Lymphoma,adverse drug events
D003967,3.85,NCT01412879-3,Stem Cell Transplant (Consolidation Therapy),NCT01412879,S1106 Rituximab With Combination Chemotherapy or Bendamustine Hydrochloride Followed by Consolidation Chemotherapy and Stem Cell Transplantation in Older Patients With Previously Untreated Mantle Cell Lymphoma,diarrhea
10058838,3.85,NCT01412879-3,Stem Cell Transplant (Consolidation Therapy),NCT01412879,S1106 Rituximab With Combination Chemotherapy or Bendamustine Hydrochloride Followed by Consolidation Chemotherapy and Stem Cell Transplantation in Older Patients With Previously Untreated Mantle Cell Lymphoma,enterocolitis infectious
D012128,3.85,NCT01412879-3,Stem Cell Transplant (Consolidation Therapy),NCT01412879,S1106 Rituximab With Combination Chemotherapy or Bendamustine Hydrochloride Followed by Consolidation Chemotherapy and Stem Cell Transplantation in Older Patients With Previously Untreated Mantle Cell Lymphoma,adult respiratory distress syndrome
D064420,38.0,NCT01414855-1,Obinutuzumab + CHOP,NCT01414855,A Study of Obinutuzumab [RO5072759 (GA101)] in Combination With CHOP Chemotherapy in Patients With Previously Untreated Advanced Diffuse Large B-Cell Lymphoma (GATHER),adverse drug events
D064147,14.0,NCT01414855-1,Obinutuzumab + CHOP,NCT01414855,A Study of Obinutuzumab [RO5072759 (GA101)] in Combination With CHOP Chemotherapy in Patients With Previously Untreated Advanced Diffuse Large B-Cell Lymphoma (GATHER),febrile neutropenia
D000741,1.0,NCT01414855-1,Obinutuzumab + CHOP,NCT01414855,A Study of Obinutuzumab [RO5072759 (GA101)] in Combination With CHOP Chemotherapy in Patients With Previously Untreated Advanced Diffuse Large B-Cell Lymphoma (GATHER),aplastic anaemia
D009503,1.0,NCT01414855-1,Obinutuzumab + CHOP,NCT01414855,A Study of Obinutuzumab [RO5072759 (GA101)] in Combination With CHOP Chemotherapy in Patients With Previously Untreated Advanced Diffuse Large B-Cell Lymphoma (GATHER),neutropenia
D010198,1.0,NCT01414855-1,Obinutuzumab + CHOP,NCT01414855,A Study of Obinutuzumab [RO5072759 (GA101)] in Combination With CHOP Chemotherapy in Patients With Previously Untreated Advanced Diffuse Large B-Cell Lymphoma (GATHER),pancytopenia
D006333,1.0,NCT01414855-1,Obinutuzumab + CHOP,NCT01414855,A Study of Obinutuzumab [RO5072759 (GA101)] in Combination With CHOP Chemotherapy in Patients With Previously Untreated Advanced Diffuse Large B-Cell Lymphoma (GATHER),cardiac failure
D016277,1.0,NCT01414855-1,Obinutuzumab + CHOP,NCT01414855,A Study of Obinutuzumab [RO5072759 (GA101)] in Combination With CHOP Chemotherapy in Patients With Previously Untreated Advanced Diffuse Large B-Cell Lymphoma (GATHER),ventricular function left
D000067836,1.0,NCT01414855-1,Obinutuzumab + CHOP,NCT01414855,A Study of Obinutuzumab [RO5072759 (GA101)] in Combination With CHOP Chemotherapy in Patients With Previously Untreated Advanced Diffuse Large B-Cell Lymphoma (GATHER),hoarding disorder
D018487,1.0,NCT01414855-1,Obinutuzumab + CHOP,NCT01414855,A Study of Obinutuzumab [RO5072759 (GA101)] in Combination With CHOP Chemotherapy in Patients With Previously Untreated Advanced Diffuse Large B-Cell Lymphoma (GATHER),left ventricular dysfunction
UNKNOWN-check-for-typo,2.0,NCT01414855-1,Obinutuzumab + CHOP,NCT01414855,A Study of Obinutuzumab [RO5072759 (GA101)] in Combination With CHOP Chemotherapy in Patients With Previously Untreated Advanced Diffuse Large B-Cell Lymphoma (GATHER),D00
D015746,1.0,NCT01414855-1,Obinutuzumab + CHOP,NCT01414855,A Study of Obinutuzumab [RO5072759 (GA101)] in Combination With CHOP Chemotherapy in Patients With Previously Untreated Advanced Diffuse Large B-Cell Lymphoma (GATHER),abdominal pain
D015746,1.0,NCT01414855-1,Obinutuzumab + CHOP,NCT01414855,A Study of Obinutuzumab [RO5072759 (GA101)] in Combination With CHOP Chemotherapy in Patients With Previously Untreated Advanced Diffuse Large B-Cell Lymphoma (GATHER),abdominal pain
D007416,1.0,NCT01414855-1,Obinutuzumab + CHOP,NCT01414855,A Study of Obinutuzumab [RO5072759 (GA101)] in Combination With CHOP Chemotherapy in Patients With Previously Untreated Advanced Diffuse Large B-Cell Lymphoma (GATHER),intestinal perforation
D059325,1.0,NCT01414855-1,Obinutuzumab + CHOP,NCT01414855,A Study of Obinutuzumab [RO5072759 (GA101)] in Combination With CHOP Chemotherapy in Patients With Previously Untreated Advanced Diffuse Large B-Cell Lymphoma (GATHER),intraabdominal hypertension
D000071056,1.0,NCT01414855-1,Obinutuzumab + CHOP,NCT01414855,A Study of Obinutuzumab [RO5072759 (GA101)] in Combination With CHOP Chemotherapy in Patients With Previously Untreated Advanced Diffuse Large B-Cell Lymphoma (GATHER),anorectal malformations
10041101,1.0,NCT01414855-1,Obinutuzumab + CHOP,NCT01414855,A Study of Obinutuzumab [RO5072759 (GA101)] in Combination With CHOP Chemotherapy in Patients With Previously Untreated Advanced Diffuse Large B-Cell Lymphoma (GATHER),small intestinal obstruction
D041742,1.0,NCT01414855-1,Obinutuzumab + CHOP,NCT01414855,A Study of Obinutuzumab [RO5072759 (GA101)] in Combination With CHOP Chemotherapy in Patients With Previously Untreated Advanced Diffuse Large B-Cell Lymphoma (GATHER),upper gastrointestinal tract
D001247,1.0,NCT01414855-1,Obinutuzumab + CHOP,NCT01414855,A Study of Obinutuzumab [RO5072759 (GA101)] in Combination With CHOP Chemotherapy in Patients With Previously Untreated Advanced Diffuse Large B-Cell Lymphoma (GATHER),asthenia
D002637,1.0,NCT01414855-1,Obinutuzumab + CHOP,NCT01414855,A Study of Obinutuzumab [RO5072759 (GA101)] in Combination With CHOP Chemotherapy in Patients With Previously Untreated Advanced Diffuse Large B-Cell Lymphoma (GATHER),chest pain
D003643,1.0,NCT01414855-1,Obinutuzumab + CHOP,NCT01414855,A Study of Obinutuzumab [RO5072759 (GA101)] in Combination With CHOP Chemotherapy in Patients With Previously Untreated Advanced Diffuse Large B-Cell Lymphoma (GATHER),death
D011014,6.0,NCT01414855-1,Obinutuzumab + CHOP,NCT01414855,A Study of Obinutuzumab [RO5072759 (GA101)] in Combination With CHOP Chemotherapy in Patients With Previously Untreated Advanced Diffuse Large B-Cell Lymphoma (GATHER),pneumonia
D018805,2.0,NCT01414855-1,Obinutuzumab + CHOP,NCT01414855,A Study of Obinutuzumab [RO5072759 (GA101)] in Combination With CHOP Chemotherapy in Patients With Previously Untreated Advanced Diffuse Large B-Cell Lymphoma (GATHER),sepsis
D000077215,1.0,NCT01414855-1,Obinutuzumab + CHOP,NCT01414855,A Study of Obinutuzumab [RO5072759 (GA101)] in Combination With CHOP Chemotherapy in Patients With Previously Untreated Advanced Diffuse Large B-Cell Lymphoma (GATHER),halloysite
D002481,1.0,NCT01414855-1,Obinutuzumab + CHOP,NCT01414855,A Study of Obinutuzumab [RO5072759 (GA101)] in Combination With CHOP Chemotherapy in Patients With Previously Untreated Advanced Diffuse Large B-Cell Lymphoma (GATHER),cellulitis
D003015,1.0,NCT01414855-1,Obinutuzumab + CHOP,NCT01414855,A Study of Obinutuzumab [RO5072759 (GA101)] in Combination With CHOP Chemotherapy in Patients With Previously Untreated Advanced Diffuse Large B-Cell Lymphoma (GATHER),clostridium difficile infection
D001996,1.0,NCT01414855-1,Obinutuzumab + CHOP,NCT01414855,A Study of Obinutuzumab [RO5072759 (GA101)] in Combination With CHOP Chemotherapy in Patients With Previously Untreated Advanced Diffuse Large B-Cell Lymphoma (GATHER),bronchopneumonia
10064687,1.0,NCT01414855-1,Obinutuzumab + CHOP,NCT01414855,A Study of Obinutuzumab [RO5072759 (GA101)] in Combination With CHOP Chemotherapy in Patients With Previously Untreated Advanced Diffuse Large B-Cell Lymphoma (GATHER),device related infection
D004660,1.0,NCT01414855-1,Obinutuzumab + CHOP,NCT01414855,A Study of Obinutuzumab [RO5072759 (GA101)] in Combination With CHOP Chemotherapy in Patients With Previously Untreated Advanced Diffuse Large B-Cell Lymphoma (GATHER),encephalitis
D000069544,1.0,NCT01414855-1,Obinutuzumab + CHOP,NCT01414855,A Study of Obinutuzumab [RO5072759 (GA101)] in Combination With CHOP Chemotherapy in Patients With Previously Untreated Advanced Diffuse Large B-Cell Lymphoma (GATHER),encephalitis infection
D006562,1.0,NCT01414855-1,Obinutuzumab + CHOP,NCT01414855,A Study of Obinutuzumab [RO5072759 (GA101)] in Combination With CHOP Chemotherapy in Patients With Previously Untreated Advanced Diffuse Large B-Cell Lymphoma (GATHER),herpes zoster
D006562,1.0,NCT01414855-1,Obinutuzumab + CHOP,NCT01414855,A Study of Obinutuzumab [RO5072759 (GA101)] in Combination With CHOP Chemotherapy in Patients With Previously Untreated Advanced Diffuse Large B-Cell Lymphoma (GATHER),herpes zoster
D000038,1.0,NCT01414855-1,Obinutuzumab + CHOP,NCT01414855,A Study of Obinutuzumab [RO5072759 (GA101)] in Combination With CHOP Chemotherapy in Patients With Previously Untreated Advanced Diffuse Large B-Cell Lymphoma (GATHER),abscess
D000069544,1.0,NCT01414855-1,Obinutuzumab + CHOP,NCT01414855,A Study of Obinutuzumab [RO5072759 (GA101)] in Combination With CHOP Chemotherapy in Patients With Previously Untreated Advanced Diffuse Large B-Cell Lymphoma (GATHER),encephalitis infection
D001996,1.0,NCT01414855-1,Obinutuzumab + CHOP,NCT01414855,A Study of Obinutuzumab [RO5072759 (GA101)] in Combination With CHOP Chemotherapy in Patients With Previously Untreated Advanced Diffuse Large B-Cell Lymphoma (GATHER),bronchopneumonia
D012772,1.0,NCT01414855-1,Obinutuzumab + CHOP,NCT01414855,A Study of Obinutuzumab [RO5072759 (GA101)] in Combination With CHOP Chemotherapy in Patients With Previously Untreated Advanced Diffuse Large B-Cell Lymphoma (GATHER),septic shock
D014552,1.0,NCT01414855-1,Obinutuzumab + CHOP,NCT01414855,A Study of Obinutuzumab [RO5072759 (GA101)] in Combination With CHOP Chemotherapy in Patients With Previously Untreated Advanced Diffuse Large B-Cell Lymphoma (GATHER),urinary tract infection
D005265,1.0,NCT01414855-1,Obinutuzumab + CHOP,NCT01414855,A Study of Obinutuzumab [RO5072759 (GA101)] in Combination With CHOP Chemotherapy in Patients With Previously Untreated Advanced Diffuse Large B-Cell Lymphoma (GATHER),femur neck fractures
10020100,1.0,NCT01414855-1,Obinutuzumab + CHOP,NCT01414855,A Study of Obinutuzumab [RO5072759 (GA101)] in Combination With CHOP Chemotherapy in Patients With Previously Untreated Advanced Diffuse Large B-Cell Lymphoma (GATHER),hip fracture
D003681,2.0,NCT01414855-1,Obinutuzumab + CHOP,NCT01414855,A Study of Obinutuzumab [RO5072759 (GA101)] in Combination With CHOP Chemotherapy in Patients With Previously Untreated Advanced Diffuse Large B-Cell Lymphoma (GATHER),dehydration
UNKNOWN-check-for-typo,1.0,NCT01414855-1,Obinutuzumab + CHOP,NCT01414855,A Study of Obinutuzumab [RO5072759 (GA101)] in Combination With CHOP Chemotherapy in Patients With Previously Untreated Advanced Diffuse Large B-Cell Lymphoma (GATHER),D00
D018771,1.0,NCT01414855-1,Obinutuzumab + CHOP,NCT01414855,A Study of Obinutuzumab [RO5072759 (GA101)] in Combination With CHOP Chemotherapy in Patients With Previously Untreated Advanced Diffuse Large B-Cell Lymphoma (GATHER),arthralgia
D005598,1.0,NCT01414855-1,Obinutuzumab + CHOP,NCT01414855,A Study of Obinutuzumab [RO5072759 (GA101)] in Combination With CHOP Chemotherapy in Patients With Previously Untreated Advanced Diffuse Large B-Cell Lymphoma (GATHER),pathological fracture
D020521,1.0,NCT01414855-1,Obinutuzumab + CHOP,NCT01414855,A Study of Obinutuzumab [RO5072759 (GA101)] in Combination With CHOP Chemotherapy in Patients With Previously Untreated Advanced Diffuse Large B-Cell Lymphoma (GATHER),cerebrovascular accident
D010291,1.0,NCT01414855-1,Obinutuzumab + CHOP,NCT01414855,A Study of Obinutuzumab [RO5072759 (GA101)] in Combination With CHOP Chemotherapy in Patients With Previously Untreated Advanced Diffuse Large B-Cell Lymphoma (GATHER),hemiparesis
D013575,1.0,NCT01414855-1,Obinutuzumab + CHOP,NCT01414855,A Study of Obinutuzumab [RO5072759 (GA101)] in Combination With CHOP Chemotherapy in Patients With Previously Untreated Advanced Diffuse Large B-Cell Lymphoma (GATHER),presyncope
D013118,1.0,NCT01414855-1,Obinutuzumab + CHOP,NCT01414855,A Study of Obinutuzumab [RO5072759 (GA101)] in Combination With CHOP Chemotherapy in Patients With Previously Untreated Advanced Diffuse Large B-Cell Lymphoma (GATHER),myelopathy
D013575,1.0,NCT01414855-1,Obinutuzumab + CHOP,NCT01414855,A Study of Obinutuzumab [RO5072759 (GA101)] in Combination With CHOP Chemotherapy in Patients With Previously Untreated Advanced Diffuse Large B-Cell Lymphoma (GATHER),syncope
D000073216,2.0,NCT01414855-1,Obinutuzumab + CHOP,NCT01414855,A Study of Obinutuzumab [RO5072759 (GA101)] in Combination With CHOP Chemotherapy in Patients With Previously Untreated Advanced Diffuse Large B-Cell Lymphoma (GATHER),mental status tests
D003693,1.0,NCT01414855-1,Obinutuzumab + CHOP,NCT01414855,A Study of Obinutuzumab [RO5072759 (GA101)] in Combination With CHOP Chemotherapy in Patients With Previously Untreated Advanced Diffuse Large B-Cell Lymphoma (GATHER),delirium
10042464,1.0,NCT01414855-1,Obinutuzumab + CHOP,NCT01414855,A Study of Obinutuzumab [RO5072759 (GA101)] in Combination With CHOP Chemotherapy in Patients With Previously Untreated Advanced Diffuse Large B-Cell Lymphoma (GATHER),suicide attempt
D000860,2.0,NCT01414855-1,Obinutuzumab + CHOP,NCT01414855,A Study of Obinutuzumab [RO5072759 (GA101)] in Combination With CHOP Chemotherapy in Patients With Previously Untreated Advanced Diffuse Large B-Cell Lymphoma (GATHER),hypoxia
D011655,2.0,NCT01414855-1,Obinutuzumab + CHOP,NCT01414855,A Study of Obinutuzumab [RO5072759 (GA101)] in Combination With CHOP Chemotherapy in Patients With Previously Untreated Advanced Diffuse Large B-Cell Lymphoma (GATHER),pulmonary embolism
UNKNOWN-check-for-typo,1.0,NCT01414855-1,Obinutuzumab + CHOP,NCT01414855,A Study of Obinutuzumab [RO5072759 (GA101)] in Combination With CHOP Chemotherapy in Patients With Previously Untreated Advanced Diffuse Large B-Cell Lymphoma (GATHER),D00
D004438,1.0,NCT01414855-1,Obinutuzumab + CHOP,NCT01414855,A Study of Obinutuzumab [RO5072759 (GA101)] in Combination With CHOP Chemotherapy in Patients With Previously Untreated Advanced Diffuse Large B-Cell Lymphoma (GATHER),ecchymosis
D009026,66.67,NCT01445535-1,Cohort 1 - 3.4 mg/kg,NCT01445535,Phase 1 Trial of Siplizumab and Dose-Adjusted EPOCH-Rituximab in T- and NK-Cell Lymphomas,mortality
D009026,100.0,NCT01445535-2,Cohort 2 - 4.8 mg/kg,NCT01445535,Phase 1 Trial of Siplizumab and Dose-Adjusted EPOCH-Rituximab in T- and NK-Cell Lymphomas,mortality
D009026,100.0,NCT01445535-3,Cohort 3 - 8.5 mg/kg,NCT01445535,Phase 1 Trial of Siplizumab and Dose-Adjusted EPOCH-Rituximab in T- and NK-Cell Lymphomas,mortality
D009026,66.67,NCT01445535-4,Cohort 4 - 15 mg/kg,NCT01445535,Phase 1 Trial of Siplizumab and Dose-Adjusted EPOCH-Rituximab in T- and NK-Cell Lymphomas,mortality
D064420,66.67,NCT01445535-2,Cohort 2 - 4.8 mg/kg,NCT01445535,Phase 1 Trial of Siplizumab and Dose-Adjusted EPOCH-Rituximab in T- and NK-Cell Lymphomas,adverse drug events
D064420,66.67,NCT01445535-3,Cohort 3 - 8.5 mg/kg,NCT01445535,Phase 1 Trial of Siplizumab and Dose-Adjusted EPOCH-Rituximab in T- and NK-Cell Lymphomas,adverse drug events
D064420,16.67,NCT01445535-4,Cohort 4 - 15 mg/kg,NCT01445535,Phase 1 Trial of Siplizumab and Dose-Adjusted EPOCH-Rituximab in T- and NK-Cell Lymphomas,adverse drug events
D009503,33.33,NCT01445535-2,Cohort 2 - 4.8 mg/kg,NCT01445535,Phase 1 Trial of Siplizumab and Dose-Adjusted EPOCH-Rituximab in T- and NK-Cell Lymphomas,neutropenia
D007239,33.33,NCT01445535-2,Cohort 2 - 4.8 mg/kg,NCT01445535,Phase 1 Trial of Siplizumab and Dose-Adjusted EPOCH-Rituximab in T- and NK-Cell Lymphomas,infection
D064147,66.67,NCT01445535-3,Cohort 3 - 8.5 mg/kg,NCT01445535,Phase 1 Trial of Siplizumab and Dose-Adjusted EPOCH-Rituximab in T- and NK-Cell Lymphomas,febrile neutropenia
10017076,16.67,NCT01445535-4,Cohort 4 - 15 mg/kg,NCT01445535,Phase 1 Trial of Siplizumab and Dose-Adjusted EPOCH-Rituximab in T- and NK-Cell Lymphomas,fracture
D064420,10.81,NCT01490060-1,Control Cycle (Arm A/Arm B),NCT01490060,Fosaprepitant in Patients Receiving Ifosfamide-based Regimen,adverse drug events
D064420,4.55,NCT01490060-2,Arm A: Single Dose Day 1,NCT01490060,Fosaprepitant in Patients Receiving Ifosfamide-based Regimen,adverse drug events
D064420,5.88,NCT01490060-3,Arm B: Two Doses Day 1 + Day 4,NCT01490060,Fosaprepitant in Patients Receiving Ifosfamide-based Regimen,adverse drug events
D005334,10.81,NCT01490060-1,Control Cycle (Arm A/Arm B),NCT01490060,Fosaprepitant in Patients Receiving Ifosfamide-based Regimen,fever
D005334,4.55,NCT01490060-2,Arm A: Single Dose Day 1,NCT01490060,Fosaprepitant in Patients Receiving Ifosfamide-based Regimen,fever
D005334,5.88,NCT01490060-3,Arm B: Two Doses Day 1 + Day 4,NCT01490060,Fosaprepitant in Patients Receiving Ifosfamide-based Regimen,fever
D009026,43.24,NCT01527149-1,Treatment (Monoclonal Antibody and Combination Chemotherapy),NCT01527149,Ofatumumab in Combination With Cyclophosphamide  Doxorubicin Hydrochloride  Vincristine Sulfate  and Dexamethasone Alternating With Ofatumumab in Combination With Cytarabine and Methotrexate in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma,mortality
D064420,51.35,NCT01527149-1,Treatment (Monoclonal Antibody and Combination Chemotherapy),NCT01527149,Ofatumumab in Combination With Cyclophosphamide  Doxorubicin Hydrochloride  Vincristine Sulfate  and Dexamethasone Alternating With Ofatumumab in Combination With Cytarabine and Methotrexate in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma,adverse drug events
D054058,2.7,NCT01527149-1,Treatment (Monoclonal Antibody and Combination Chemotherapy),NCT01527149,Ofatumumab in Combination With Cyclophosphamide  Doxorubicin Hydrochloride  Vincristine Sulfate  and Dexamethasone Alternating With Ofatumumab in Combination With Cytarabine and Methotrexate in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma,acute coronary syndrome
D000799,2.7,NCT01527149-1,Treatment (Monoclonal Antibody and Combination Chemotherapy),NCT01527149,Ofatumumab in Combination With Cyclophosphamide  Doxorubicin Hydrochloride  Vincristine Sulfate  and Dexamethasone Alternating With Ofatumumab in Combination With Cytarabine and Methotrexate in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma,angioedema
UNKNOWN-check-for-typo,2.7,NCT01527149-1,Treatment (Monoclonal Antibody and Combination Chemotherapy),NCT01527149,Ofatumumab in Combination With Cyclophosphamide  Doxorubicin Hydrochloride  Vincristine Sulfate  and Dexamethasone Alternating With Ofatumumab in Combination With Cytarabine and Methotrexate in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma,D00
D005334,2.7,NCT01527149-1,Treatment (Monoclonal Antibody and Combination Chemotherapy),NCT01527149,Ofatumumab in Combination With Cyclophosphamide  Doxorubicin Hydrochloride  Vincristine Sulfate  and Dexamethasone Alternating With Ofatumumab in Combination With Cytarabine and Methotrexate in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma,pyrexia
D004238,2.7,NCT01527149-1,Treatment (Monoclonal Antibody and Combination Chemotherapy),NCT01527149,Ofatumumab in Combination With Cyclophosphamide  Doxorubicin Hydrochloride  Vincristine Sulfate  and Dexamethasone Alternating With Ofatumumab in Combination With Cytarabine and Methotrexate in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma,diverticulitis
10058838,2.7,NCT01527149-1,Treatment (Monoclonal Antibody and Combination Chemotherapy),NCT01527149,Ofatumumab in Combination With Cyclophosphamide  Doxorubicin Hydrochloride  Vincristine Sulfate  and Dexamethasone Alternating With Ofatumumab in Combination With Cytarabine and Methotrexate in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma,enterocolitis infectious
D010272,8.11,NCT01527149-1,Treatment (Monoclonal Antibody and Combination Chemotherapy),NCT01527149,Ofatumumab in Combination With Cyclophosphamide  Doxorubicin Hydrochloride  Vincristine Sulfate  and Dexamethasone Alternating With Ofatumumab in Combination With Cytarabine and Methotrexate in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma,parasite infections
10061229,5.41,NCT01527149-1,Treatment (Monoclonal Antibody and Combination Chemotherapy),NCT01527149,Ofatumumab in Combination With Cyclophosphamide  Doxorubicin Hydrochloride  Vincristine Sulfate  and Dexamethasone Alternating With Ofatumumab in Combination With Cytarabine and Methotrexate in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma,lung infection
D000985,2.7,NCT01527149-1,Treatment (Monoclonal Antibody and Combination Chemotherapy),NCT01527149,Ofatumumab in Combination With Cyclophosphamide  Doxorubicin Hydrochloride  Vincristine Sulfate  and Dexamethasone Alternating With Ofatumumab in Combination With Cytarabine and Methotrexate in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma,antisepsis
D000257,2.7,NCT01527149-1,Treatment (Monoclonal Antibody and Combination Chemotherapy),NCT01527149,Ofatumumab in Combination With Cyclophosphamide  Doxorubicin Hydrochloride  Vincristine Sulfate  and Dexamethasone Alternating With Ofatumumab in Combination With Cytarabine and Methotrexate in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma,adenovirus infections
D011014,2.7,NCT01527149-1,Treatment (Monoclonal Antibody and Combination Chemotherapy),NCT01527149,Ofatumumab in Combination With Cyclophosphamide  Doxorubicin Hydrochloride  Vincristine Sulfate  and Dexamethasone Alternating With Ofatumumab in Combination With Cytarabine and Methotrexate in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma,pneumonia
D018805,21.62,NCT01527149-1,Treatment (Monoclonal Antibody and Combination Chemotherapy),NCT01527149,Ofatumumab in Combination With Cyclophosphamide  Doxorubicin Hydrochloride  Vincristine Sulfate  and Dexamethasone Alternating With Ofatumumab in Combination With Cytarabine and Methotrexate in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma,sepsis
10029366,2.7,NCT01527149-1,Treatment (Monoclonal Antibody and Combination Chemotherapy),NCT01527149,Ofatumumab in Combination With Cyclophosphamide  Doxorubicin Hydrochloride  Vincristine Sulfate  and Dexamethasone Alternating With Ofatumumab in Combination With Cytarabine and Methotrexate in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma,neutrophil count decreased
D003561,2.7,NCT01527149-1,Treatment (Monoclonal Antibody and Combination Chemotherapy),NCT01527149,Ofatumumab in Combination With Cyclophosphamide  Doxorubicin Hydrochloride  Vincristine Sulfate  and Dexamethasone Alternating With Ofatumumab in Combination With Cytarabine and Methotrexate in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma,cytarabine
10033425,2.7,NCT01527149-1,Treatment (Monoclonal Antibody and Combination Chemotherapy),NCT01527149,Ofatumumab in Combination With Cyclophosphamide  Doxorubicin Hydrochloride  Vincristine Sulfate  and Dexamethasone Alternating With Ofatumumab in Combination With Cytarabine and Methotrexate in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma,pain in extremity
D000075722,2.7,NCT01527149-1,Treatment (Monoclonal Antibody and Combination Chemotherapy),NCT01527149,Ofatumumab in Combination With Cyclophosphamide  Doxorubicin Hydrochloride  Vincristine Sulfate  and Dexamethasone Alternating With Ofatumumab in Combination With Cytarabine and Methotrexate in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma,promyelocytic leukaemia zinc finger protein
D008545,2.7,NCT01527149-1,Treatment (Monoclonal Antibody and Combination Chemotherapy),NCT01527149,Ofatumumab in Combination With Cyclophosphamide  Doxorubicin Hydrochloride  Vincristine Sulfate  and Dexamethasone Alternating With Ofatumumab in Combination With Cytarabine and Methotrexate in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma,malignant melanoma
D001100,2.7,NCT01527149-1,Treatment (Monoclonal Antibody and Combination Chemotherapy),NCT01527149,Ofatumumab in Combination With Cyclophosphamide  Doxorubicin Hydrochloride  Vincristine Sulfate  and Dexamethasone Alternating With Ofatumumab in Combination With Cytarabine and Methotrexate in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma,arachnoiditis
D006261,2.7,NCT01527149-1,Treatment (Monoclonal Antibody and Combination Chemotherapy),NCT01527149,Ofatumumab in Combination With Cyclophosphamide  Doxorubicin Hydrochloride  Vincristine Sulfate  and Dexamethasone Alternating With Ofatumumab in Combination With Cytarabine and Methotrexate in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma,headache
UNKNOWN-check-for-typo,2.7,NCT01527149-1,Treatment (Monoclonal Antibody and Combination Chemotherapy),NCT01527149,Ofatumumab in Combination With Cyclophosphamide  Doxorubicin Hydrochloride  Vincristine Sulfate  and Dexamethasone Alternating With Ofatumumab in Combination With Cytarabine and Methotrexate in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma,D00
D011655,2.7,NCT01527149-1,Treatment (Monoclonal Antibody and Combination Chemotherapy),NCT01527149,Ofatumumab in Combination With Cyclophosphamide  Doxorubicin Hydrochloride  Vincristine Sulfate  and Dexamethasone Alternating With Ofatumumab in Combination With Cytarabine and Methotrexate in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma,pulmonary embolism
D001768,2.7,NCT01527149-1,Treatment (Monoclonal Antibody and Combination Chemotherapy),NCT01527149,Ofatumumab in Combination With Cyclophosphamide  Doxorubicin Hydrochloride  Vincristine Sulfate  and Dexamethasone Alternating With Ofatumumab in Combination With Cytarabine and Methotrexate in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma,blister
D007022,2.7,NCT01527149-1,Treatment (Monoclonal Antibody and Combination Chemotherapy),NCT01527149,Ofatumumab in Combination With Cyclophosphamide  Doxorubicin Hydrochloride  Vincristine Sulfate  and Dexamethasone Alternating With Ofatumumab in Combination With Cytarabine and Methotrexate in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma,hypotension
D009026,25.0,NCT01533207-1,Regimen 1,NCT01533207,Gemcitabine Hydrochloride and Docetaxel Followed by Doxorubicin Hydrochloride or Observation in Treating Patients With High-Risk Uterine Leiomyosarcoma Previously Removed by Surgery,mortality
D009026,5.56,NCT01533207-2,Regimen II,NCT01533207,Gemcitabine Hydrochloride and Docetaxel Followed by Doxorubicin Hydrochloride or Observation in Treating Patients With High-Risk Uterine Leiomyosarcoma Previously Removed by Surgery,mortality
D064420,25.0,NCT01533207-1,Regimen 1,NCT01533207,Gemcitabine Hydrochloride and Docetaxel Followed by Doxorubicin Hydrochloride or Observation in Treating Patients With High-Risk Uterine Leiomyosarcoma Previously Removed by Surgery,adverse drug events
10028130,5.0,NCT01533207-1,Regimen 1,NCT01533207,Gemcitabine Hydrochloride and Docetaxel Followed by Doxorubicin Hydrochloride or Observation in Treating Patients With High-Risk Uterine Leiomyosarcoma Previously Removed by Surgery,mucositis oral
D014946,5.0,NCT01533207-1,Regimen 1,NCT01533207,Gemcitabine Hydrochloride and Docetaxel Followed by Doxorubicin Hydrochloride or Observation in Treating Patients With High-Risk Uterine Leiomyosarcoma Previously Removed by Surgery,wound infection
10040872,5.0,NCT01533207-1,Regimen 1,NCT01533207,Gemcitabine Hydrochloride and Docetaxel Followed by Doxorubicin Hydrochloride or Observation in Treating Patients With High-Risk Uterine Leiomyosarcoma Previously Removed by Surgery,skin infection
10007810,5.0,NCT01533207-1,Regimen 1,NCT01533207,Gemcitabine Hydrochloride and Docetaxel Followed by Doxorubicin Hydrochloride or Observation in Treating Patients With High-Risk Uterine Leiomyosarcoma Previously Removed by Surgery,catheter related infection
10062169,5.0,NCT01533207-1,Regimen 1,NCT01533207,Gemcitabine Hydrochloride and Docetaxel Followed by Doxorubicin Hydrochloride or Observation in Treating Patients With High-Risk Uterine Leiomyosarcoma Previously Removed by Surgery,vascular access complication
10029366,5.0,NCT01533207-1,Regimen 1,NCT01533207,Gemcitabine Hydrochloride and Docetaxel Followed by Doxorubicin Hydrochloride or Observation in Treating Patients With High-Risk Uterine Leiomyosarcoma Previously Removed by Surgery,neutrophil count decreased
10040785,5.0,NCT01533207-1,Regimen 1,NCT01533207,Gemcitabine Hydrochloride and Docetaxel Followed by Doxorubicin Hydrochloride or Observation in Treating Patients With High-Risk Uterine Leiomyosarcoma Previously Removed by Surgery,skin and subcutaneous tissue disorders - other specify
D009026,2.94,NCT01534078-1,Treatment Arm,NCT01534078,Brentuximab Vedotin Plus AVD in Limited-stage Hodgkin Lymphoma,mortality
D064420,44.12,NCT01534078-1,Treatment Arm,NCT01534078,Brentuximab Vedotin Plus AVD in Limited-stage Hodgkin Lymphoma,adverse drug events
D064147,23.53,NCT01534078-1,Treatment Arm,NCT01534078,Brentuximab Vedotin Plus AVD in Limited-stage Hodgkin Lymphoma,febrile neutropenia
10008481,2.94,NCT01534078-1,Treatment Arm,NCT01534078,Brentuximab Vedotin Plus AVD in Limited-stage Hodgkin Lymphoma,chest pain - cardiac
D000072139,2.94,NCT01534078-1,Treatment Arm,NCT01534078,Brentuximab Vedotin Plus AVD in Limited-stage Hodgkin Lymphoma,megavirales
D015746,5.88,NCT01534078-1,Treatment Arm,NCT01534078,Brentuximab Vedotin Plus AVD in Limited-stage Hodgkin Lymphoma,abdominal pain
10017789,2.94,NCT01534078-1,Treatment Arm,NCT01534078,Brentuximab Vedotin Plus AVD in Limited-stage Hodgkin Lymphoma,gastric hemorrhage
D045823,2.94,NCT01534078-1,Treatment Arm,NCT01534078,Brentuximab Vedotin Plus AVD in Limited-stage Hodgkin Lymphoma,ileus
D003681,2.94,NCT01534078-1,Treatment Arm,NCT01534078,Brentuximab Vedotin Plus AVD in Limited-stage Hodgkin Lymphoma,dehydration
D000855,2.94,NCT01534078-1,Treatment Arm,NCT01534078,Brentuximab Vedotin Plus AVD in Limited-stage Hodgkin Lymphoma,anorexia
D000930,2.94,NCT01534078-1,Treatment Arm,NCT01534078,Brentuximab Vedotin Plus AVD in Limited-stage Hodgkin Lymphoma,antidiarrheals
D007958,2.94,NCT01534078-1,Treatment Arm,NCT01534078,Brentuximab Vedotin Plus AVD in Limited-stage Hodgkin Lymphoma,blood cell count white
D005334,2.94,NCT01534078-1,Treatment Arm,NCT01534078,Brentuximab Vedotin Plus AVD in Limited-stage Hodgkin Lymphoma,fever
D002196,2.94,NCT01534078-1,Treatment Arm,NCT01534078,Brentuximab Vedotin Plus AVD in Limited-stage Hodgkin Lymphoma,sinusoids
D018805,2.94,NCT01534078-1,Treatment Arm,NCT01534078,Brentuximab Vedotin Plus AVD in Limited-stage Hodgkin Lymphoma,sepsis
10055078,2.94,NCT01534078-1,Treatment Arm,NCT01534078,Brentuximab Vedotin Plus AVD in Limited-stage Hodgkin Lymphoma,bronchial infection
D009889,2.94,NCT01534078-1,Treatment Arm,NCT01534078,Brentuximab Vedotin Plus AVD in Limited-stage Hodgkin Lymphoma,opisthorchis felineus infection
D018461,2.94,NCT01534078-1,Treatment Arm,NCT01534078,Brentuximab Vedotin Plus AVD in Limited-stage Hodgkin Lymphoma,soft tissue infection
10029366,5.88,NCT01534078-1,Treatment Arm,NCT01534078,Brentuximab Vedotin Plus AVD in Limited-stage Hodgkin Lymphoma,neutrophil count decreased
10049182,2.94,NCT01534078-1,Treatment Arm,NCT01534078,Brentuximab Vedotin Plus AVD in Limited-stage Hodgkin Lymphoma,white blood cell decreased
D003681,2.94,NCT01534078-1,Treatment Arm,NCT01534078,Brentuximab Vedotin Plus AVD in Limited-stage Hodgkin Lymphoma,dehydration
D000855,2.94,NCT01534078-1,Treatment Arm,NCT01534078,Brentuximab Vedotin Plus AVD in Limited-stage Hodgkin Lymphoma,anorexia
D001416,2.94,NCT01534078-1,Treatment Arm,NCT01534078,Brentuximab Vedotin Plus AVD in Limited-stage Hodgkin Lymphoma,back pain
D003221,2.94,NCT01534078-1,Treatment Arm,NCT01534078,Brentuximab Vedotin Plus AVD in Limited-stage Hodgkin Lymphoma,confusion
10003504,2.94,NCT01534078-1,Treatment Arm,NCT01534078,Brentuximab Vedotin Plus AVD in Limited-stage Hodgkin Lymphoma,aspiration
D017497,2.94,NCT01534078-1,Treatment Arm,NCT01534078,Brentuximab Vedotin Plus AVD in Limited-stage Hodgkin Lymphoma,hidradenitis suppurativa
D009026,15.79,NCT01548573-1,Tandem Transplant in MM <12 Mos of Prior Treatment,NCT01548573,Tandem Auto Transplantation in Myeloma Patients With <12 Months of Prior Treatment,mortality
D064420,68.42,NCT01548573-1,Tandem Transplant in MM <12 Mos of Prior Treatment,NCT01548573,Tandem Auto Transplantation in Myeloma Patients With <12 Months of Prior Treatment,adverse drug events
D020246,5.26,NCT01548573-1,Tandem Transplant in MM <12 Mos of Prior Treatment,NCT01548573,Tandem Auto Transplantation in Myeloma Patients With <12 Months of Prior Treatment,deep vein thrombosis
D002637,5.26,NCT01548573-1,Tandem Transplant in MM <12 Mos of Prior Treatment,NCT01548573,Tandem Auto Transplantation in Myeloma Patients With <12 Months of Prior Treatment,chest pain
D009203,5.26,NCT01548573-1,Tandem Transplant in MM <12 Mos of Prior Treatment,NCT01548573,Tandem Auto Transplantation in Myeloma Patients With <12 Months of Prior Treatment,myocardial infarction
D001281,10.53,NCT01548573-1,Tandem Transplant in MM <12 Mos of Prior Treatment,NCT01548573,Tandem Auto Transplantation in Myeloma Patients With <12 Months of Prior Treatment,atrial fibrillation
D001281,5.26,NCT01548573-1,Tandem Transplant in MM <12 Mos of Prior Treatment,NCT01548573,Tandem Auto Transplantation in Myeloma Patients With <12 Months of Prior Treatment,atrial fibrillation
D002764,5.26,NCT01548573-1,Tandem Transplant in MM <12 Mos of Prior Treatment,NCT01548573,Tandem Auto Transplantation in Myeloma Patients With <12 Months of Prior Treatment,cholecystitis
D015746,5.26,NCT01548573-1,Tandem Transplant in MM <12 Mos of Prior Treatment,NCT01548573,Tandem Auto Transplantation in Myeloma Patients With <12 Months of Prior Treatment,abdominal pain
D005334,10.53,NCT01548573-1,Tandem Transplant in MM <12 Mos of Prior Treatment,NCT01548573,Tandem Auto Transplantation in Myeloma Patients With <12 Months of Prior Treatment,fever
D005334,10.53,NCT01548573-1,Tandem Transplant in MM <12 Mos of Prior Treatment,NCT01548573,Tandem Auto Transplantation in Myeloma Patients With <12 Months of Prior Treatment,fever
D005334,15.79,NCT01548573-1,Tandem Transplant in MM <12 Mos of Prior Treatment,NCT01548573,Tandem Auto Transplantation in Myeloma Patients With <12 Months of Prior Treatment,fever
D002637,5.26,NCT01548573-1,Tandem Transplant in MM <12 Mos of Prior Treatment,NCT01548573,Tandem Auto Transplantation in Myeloma Patients With <12 Months of Prior Treatment,chest pain
D015746,5.26,NCT01548573-1,Tandem Transplant in MM <12 Mos of Prior Treatment,NCT01548573,Tandem Auto Transplantation in Myeloma Patients With <12 Months of Prior Treatment,abdominal pain
D003074,5.26,NCT01548573-1,Tandem Transplant in MM <12 Mos of Prior Treatment,NCT01548573,Tandem Auto Transplantation in Myeloma Patients With <12 Months of Prior Treatment,solitary pulmonary nodules
D001416,5.26,NCT01548573-1,Tandem Transplant in MM <12 Mos of Prior Treatment,NCT01548573,Tandem Auto Transplantation in Myeloma Patients With <12 Months of Prior Treatment,vertebrogenic pain syndrome
D018805,5.26,NCT01548573-1,Tandem Transplant in MM <12 Mos of Prior Treatment,NCT01548573,Tandem Auto Transplantation in Myeloma Patients With <12 Months of Prior Treatment,sepsis
D011024,5.26,NCT01548573-1,Tandem Transplant in MM <12 Mos of Prior Treatment,NCT01548573,Tandem Auto Transplantation in Myeloma Patients With <12 Months of Prior Treatment,viral pneumonia
10006002,5.26,NCT01548573-1,Tandem Transplant in MM <12 Mos of Prior Treatment,NCT01548573,Tandem Auto Transplantation in Myeloma Patients With <12 Months of Prior Treatment,bone pain
D001416,5.26,NCT01548573-1,Tandem Transplant in MM <12 Mos of Prior Treatment,NCT01548573,Tandem Auto Transplantation in Myeloma Patients With <12 Months of Prior Treatment,back pain
D009202,5.26,NCT01548573-1,Tandem Transplant in MM <12 Mos of Prior Treatment,NCT01548573,Tandem Auto Transplantation in Myeloma Patients With <12 Months of Prior Treatment,cardiomyopathies secondary
D058186,5.26,NCT01548573-1,Tandem Transplant in MM <12 Mos of Prior Treatment,NCT01548573,Tandem Auto Transplantation in Myeloma Patients With <12 Months of Prior Treatment,acute kidney injury
D011014,5.26,NCT01548573-1,Tandem Transplant in MM <12 Mos of Prior Treatment,NCT01548573,Tandem Auto Transplantation in Myeloma Patients With <12 Months of Prior Treatment,pneumonia
D001996,5.26,NCT01548573-1,Tandem Transplant in MM <12 Mos of Prior Treatment,NCT01548573,Tandem Auto Transplantation in Myeloma Patients With <12 Months of Prior Treatment,bronchopneumonia
D009026,2.44,NCT01578967-1,ABVD Followed by Brentuximab Vedotin,NCT01578967,Induction Chemo w/ABVD Followed by Brentuximab Vedotin Consolidation in Newly Diagnosed  Non-Bulky Stage I/II Hodgkin Lymphoma,mortality
D064420,14.63,NCT01578967-1,ABVD Followed by Brentuximab Vedotin,NCT01578967,Induction Chemo w/ABVD Followed by Brentuximab Vedotin Consolidation in Newly Diagnosed  Non-Bulky Stage I/II Hodgkin Lymphoma,adverse drug events
D002764,2.44,NCT01578967-1,ABVD Followed by Brentuximab Vedotin,NCT01578967,Induction Chemo w/ABVD Followed by Brentuximab Vedotin Consolidation in Newly Diagnosed  Non-Bulky Stage I/II Hodgkin Lymphoma,cholecystitis
10007810,2.44,NCT01578967-1,ABVD Followed by Brentuximab Vedotin,NCT01578967,Induction Chemo w/ABVD Followed by Brentuximab Vedotin Consolidation in Newly Diagnosed  Non-Bulky Stage I/II Hodgkin Lymphoma,catheter related infection
10061229,4.88,NCT01578967-1,ABVD Followed by Brentuximab Vedotin,NCT01578967,Induction Chemo w/ABVD Followed by Brentuximab Vedotin Consolidation in Newly Diagnosed  Non-Bulky Stage I/II Hodgkin Lymphoma,lung infection
D008581,2.44,NCT01578967-1,ABVD Followed by Brentuximab Vedotin,NCT01578967,Induction Chemo w/ABVD Followed by Brentuximab Vedotin Consolidation in Newly Diagnosed  Non-Bulky Stage I/II Hodgkin Lymphoma,meningitis
10001551,2.44,NCT01578967-1,ABVD Followed by Brentuximab Vedotin,NCT01578967,Induction Chemo w/ABVD Followed by Brentuximab Vedotin Consolidation in Newly Diagnosed  Non-Bulky Stage I/II Hodgkin Lymphoma,alanine aminotransferase increased
10003481,2.44,NCT01578967-1,ABVD Followed by Brentuximab Vedotin,NCT01578967,Induction Chemo w/ABVD Followed by Brentuximab Vedotin Consolidation in Newly Diagnosed  Non-Bulky Stage I/II Hodgkin Lymphoma,aspartate aminotransferase increased
D020300,2.44,NCT01578967-1,ABVD Followed by Brentuximab Vedotin,NCT01578967,Induction Chemo w/ABVD Followed by Brentuximab Vedotin Consolidation in Newly Diagnosed  Non-Bulky Stage I/II Hodgkin Lymphoma,intracranial hemorrhage
D002546,2.44,NCT01578967-1,ABVD Followed by Brentuximab Vedotin,NCT01578967,Induction Chemo w/ABVD Followed by Brentuximab Vedotin Consolidation in Newly Diagnosed  Non-Bulky Stage I/II Hodgkin Lymphoma,transient ischemic attacks
D011654,2.44,NCT01578967-1,ABVD Followed by Brentuximab Vedotin,NCT01578967,Induction Chemo w/ABVD Followed by Brentuximab Vedotin Consolidation in Newly Diagnosed  Non-Bulky Stage I/II Hodgkin Lymphoma,pulmonary edema
D007022,2.44,NCT01578967-1,ABVD Followed by Brentuximab Vedotin,NCT01578967,Induction Chemo w/ABVD Followed by Brentuximab Vedotin Consolidation in Newly Diagnosed  Non-Bulky Stage I/II Hodgkin Lymphoma,hypotension
D064420,25.0,NCT01659554-1,Intraoperative Cisplatin Followed by IP Chemotherapy,NCT01659554,A Phase II Combined Modality Protocol of Debulking Surgery With HIPEC Followed by Intraperitoneal Chemotherapy for the Treatment of Recurrent Ovarian  Primary Peritoneal & Fallopian Tube Cancers,adverse drug events
D045823,25.0,NCT01659554-1,Intraoperative Cisplatin Followed by IP Chemotherapy,NCT01659554,A Phase II Combined Modality Protocol of Debulking Surgery With HIPEC Followed by Intraperitoneal Chemotherapy for the Treatment of Recurrent Ovarian  Primary Peritoneal & Fallopian Tube Cancers,ileus
D020250,25.0,NCT01659554-1,Intraoperative Cisplatin Followed by IP Chemotherapy,NCT01659554,A Phase II Combined Modality Protocol of Debulking Surgery With HIPEC Followed by Intraperitoneal Chemotherapy for the Treatment of Recurrent Ovarian  Primary Peritoneal & Fallopian Tube Cancers,postoperative nausea and vomiting
D015746,25.0,NCT01659554-1,Intraoperative Cisplatin Followed by IP Chemotherapy,NCT01659554,A Phase II Combined Modality Protocol of Debulking Surgery With HIPEC Followed by Intraperitoneal Chemotherapy for the Treatment of Recurrent Ovarian  Primary Peritoneal & Fallopian Tube Cancers,abdominal pain
D004154,25.0,NCT01659554-1,Intraoperative Cisplatin Followed by IP Chemotherapy,NCT01659554,A Phase II Combined Modality Protocol of Debulking Surgery With HIPEC Followed by Intraperitoneal Chemotherapy for the Treatment of Recurrent Ovarian  Primary Peritoneal & Fallopian Tube Cancers,dipetalonema infections
D002481,25.0,NCT01659554-1,Intraoperative Cisplatin Followed by IP Chemotherapy,NCT01659554,A Phase II Combined Modality Protocol of Debulking Surgery With HIPEC Followed by Intraperitoneal Chemotherapy for the Treatment of Recurrent Ovarian  Primary Peritoneal & Fallopian Tube Cancers,cellulitis
D055499,25.0,NCT01659554-1,Intraoperative Cisplatin Followed by IP Chemotherapy,NCT01659554,A Phase II Combined Modality Protocol of Debulking Surgery With HIPEC Followed by Intraperitoneal Chemotherapy for the Treatment of Recurrent Ovarian  Primary Peritoneal & Fallopian Tube Cancers,catheter-related infections
D058186,25.0,NCT01659554-1,Intraoperative Cisplatin Followed by IP Chemotherapy,NCT01659554,A Phase II Combined Modality Protocol of Debulking Surgery With HIPEC Followed by Intraperitoneal Chemotherapy for the Treatment of Recurrent Ovarian  Primary Peritoneal & Fallopian Tube Cancers,acute renal injury
D014552,25.0,NCT01659554-1,Intraoperative Cisplatin Followed by IP Chemotherapy,NCT01659554,A Phase II Combined Modality Protocol of Debulking Surgery With HIPEC Followed by Intraperitoneal Chemotherapy for the Treatment of Recurrent Ovarian  Primary Peritoneal & Fallopian Tube Cancers,urinary tract infections
D064420,20.41,NCT01666444-1,Pegylated Liposomal Doxorubicin (PLD) + Placebo,NCT01666444,VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian  Fallopian Tube or Primary Peritoneal Cancer,adverse drug events
D064420,24.49,NCT01666444-2,Pegylated Liposomal Doxorubicin (PLD)+VTX-2337 (VTX),NCT01666444,VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian  Fallopian Tube or Primary Peritoneal Cancer,adverse drug events
D000740,2.04,NCT01666444-1,Pegylated Liposomal Doxorubicin (PLD) + Placebo,NCT01666444,VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian  Fallopian Tube or Primary Peritoneal Cancer,anemia
D000740,1.36,NCT01666444-2,Pegylated Liposomal Doxorubicin (PLD)+VTX-2337 (VTX),NCT01666444,VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian  Fallopian Tube or Primary Peritoneal Cancer,anemia
D001281,0.68,NCT01666444-1,Pegylated Liposomal Doxorubicin (PLD) + Placebo,NCT01666444,VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian  Fallopian Tube or Primary Peritoneal Cancer,atrial fibrillation
D001281,0.68,NCT01666444-2,Pegylated Liposomal Doxorubicin (PLD)+VTX-2337 (VTX),NCT01666444,VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian  Fallopian Tube or Primary Peritoneal Cancer,atrial fibrillation
D003248,1.36,NCT01666444-2,Pegylated Liposomal Doxorubicin (PLD)+VTX-2337 (VTX),NCT01666444,VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian  Fallopian Tube or Primary Peritoneal Cancer,constipation
D003967,0.68,NCT01666444-1,Pegylated Liposomal Doxorubicin (PLD) + Placebo,NCT01666444,VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian  Fallopian Tube or Primary Peritoneal Cancer,diarrhea
D003967,2.72,NCT01666444-2,Pegylated Liposomal Doxorubicin (PLD)+VTX-2337 (VTX),NCT01666444,VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian  Fallopian Tube or Primary Peritoneal Cancer,diarrhea
D014839,3.4,NCT01666444-1,Pegylated Liposomal Doxorubicin (PLD) + Placebo,NCT01666444,VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian  Fallopian Tube or Primary Peritoneal Cancer,vomiting
D014839,4.76,NCT01666444-2,Pegylated Liposomal Doxorubicin (PLD)+VTX-2337 (VTX),NCT01666444,VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian  Fallopian Tube or Primary Peritoneal Cancer,vomiting
10055356,0.68,NCT01666444-2,Pegylated Liposomal Doxorubicin (PLD)+VTX-2337 (VTX),NCT01666444,VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian  Fallopian Tube or Primary Peritoneal Cancer,upper gastrointestinal hemorrhage
10005265,0.68,NCT01666444-2,Pegylated Liposomal Doxorubicin (PLD)+VTX-2337 (VTX),NCT01666444,VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian  Fallopian Tube or Primary Peritoneal Cancer,bloating
10041101,2.04,NCT01666444-1,Pegylated Liposomal Doxorubicin (PLD) + Placebo,NCT01666444,VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian  Fallopian Tube or Primary Peritoneal Cancer,small intestinal obstruction
D015746,2.04,NCT01666444-1,Pegylated Liposomal Doxorubicin (PLD) + Placebo,NCT01666444,VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian  Fallopian Tube or Primary Peritoneal Cancer,abdominal pain
D015746,4.08,NCT01666444-2,Pegylated Liposomal Doxorubicin (PLD)+VTX-2337 (VTX),NCT01666444,VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian  Fallopian Tube or Primary Peritoneal Cancer,abdominal pain
10028130,0.68,NCT01666444-1,Pegylated Liposomal Doxorubicin (PLD) + Placebo,NCT01666444,VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian  Fallopian Tube or Primary Peritoneal Cancer,mucositis oral
10017947,0.68,NCT01666444-1,Pegylated Liposomal Doxorubicin (PLD) + Placebo,NCT01666444,VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian  Fallopian Tube or Primary Peritoneal Cancer,gastrointestinal disorders - other specify
10017947,0.68,NCT01666444-2,Pegylated Liposomal Doxorubicin (PLD)+VTX-2337 (VTX),NCT01666444,VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian  Fallopian Tube or Primary Peritoneal Cancer,gastrointestinal disorders - other specify
D045823,0.68,NCT01666444-2,Pegylated Liposomal Doxorubicin (PLD)+VTX-2337 (VTX),NCT01666444,VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian  Fallopian Tube or Primary Peritoneal Cancer,ileus
10000060,0.68,NCT01666444-1,Pegylated Liposomal Doxorubicin (PLD) + Placebo,NCT01666444,VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian  Fallopian Tube or Primary Peritoneal Cancer,abdominal distension
10000060,1.36,NCT01666444-2,Pegylated Liposomal Doxorubicin (PLD)+VTX-2337 (VTX),NCT01666444,VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian  Fallopian Tube or Primary Peritoneal Cancer,abdominal distension
D009325,5.44,NCT01666444-1,Pegylated Liposomal Doxorubicin (PLD) + Placebo,NCT01666444,VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian  Fallopian Tube or Primary Peritoneal Cancer,nausea
D009325,6.12,NCT01666444-2,Pegylated Liposomal Doxorubicin (PLD)+VTX-2337 (VTX),NCT01666444,VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian  Fallopian Tube or Primary Peritoneal Cancer,nausea
10015451,0.68,NCT01666444-2,Pegylated Liposomal Doxorubicin (PLD)+VTX-2337 (VTX),NCT01666444,VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian  Fallopian Tube or Primary Peritoneal Cancer,esophageal ulcer
D004941,0.68,NCT01666444-1,Pegylated Liposomal Doxorubicin (PLD) + Placebo,NCT01666444,VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian  Fallopian Tube or Primary Peritoneal Cancer,esophagitis
D001201,1.36,NCT01666444-1,Pegylated Liposomal Doxorubicin (PLD) + Placebo,NCT01666444,VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian  Fallopian Tube or Primary Peritoneal Cancer,ascites
D001201,0.68,NCT01666444-2,Pegylated Liposomal Doxorubicin (PLD)+VTX-2337 (VTX),NCT01666444,VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian  Fallopian Tube or Primary Peritoneal Cancer,ascites
D010146,1.36,NCT01666444-2,Pegylated Liposomal Doxorubicin (PLD)+VTX-2337 (VTX),NCT01666444,VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian  Fallopian Tube or Primary Peritoneal Cancer,pain
10025482,0.68,NCT01666444-1,Pegylated Liposomal Doxorubicin (PLD) + Placebo,NCT01666444,VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian  Fallopian Tube or Primary Peritoneal Cancer,malaise
10025482,0.68,NCT01666444-2,Pegylated Liposomal Doxorubicin (PLD)+VTX-2337 (VTX),NCT01666444,VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian  Fallopian Tube or Primary Peritoneal Cancer,malaise
D000075662,0.68,NCT01666444-2,Pegylated Liposomal Doxorubicin (PLD)+VTX-2337 (VTX),NCT01666444,VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian  Fallopian Tube or Primary Peritoneal Cancer,injection site reaction
10062501,0.68,NCT01666444-1,Pegylated Liposomal Doxorubicin (PLD) + Placebo,NCT01666444,VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian  Fallopian Tube or Primary Peritoneal Cancer,non-cardiac chest pain
10050068,0.68,NCT01666444-2,Pegylated Liposomal Doxorubicin (PLD)+VTX-2337 (VTX),NCT01666444,VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian  Fallopian Tube or Primary Peritoneal Cancer,edema limbs
D005221,1.36,NCT01666444-1,Pegylated Liposomal Doxorubicin (PLD) + Placebo,NCT01666444,VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian  Fallopian Tube or Primary Peritoneal Cancer,fatigue
D005221,2.72,NCT01666444-2,Pegylated Liposomal Doxorubicin (PLD)+VTX-2337 (VTX),NCT01666444,VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian  Fallopian Tube or Primary Peritoneal Cancer,fatigue
10011914,0.68,NCT01666444-2,Pegylated Liposomal Doxorubicin (PLD)+VTX-2337 (VTX),NCT01666444,VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian  Fallopian Tube or Primary Peritoneal Cancer,death nos
D005334,0.68,NCT01666444-1,Pegylated Liposomal Doxorubicin (PLD) + Placebo,NCT01666444,VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian  Fallopian Tube or Primary Peritoneal Cancer,fever
D005334,2.04,NCT01666444-2,Pegylated Liposomal Doxorubicin (PLD)+VTX-2337 (VTX),NCT01666444,VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian  Fallopian Tube or Primary Peritoneal Cancer,fever
D023341,0.68,NCT01666444-2,Pegylated Liposomal Doxorubicin (PLD)+VTX-2337 (VTX),NCT01666444,VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian  Fallopian Tube or Primary Peritoneal Cancer,chills
D012852,0.68,NCT01666444-1,Pegylated Liposomal Doxorubicin (PLD) + Placebo,NCT01666444,VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian  Fallopian Tube or Primary Peritoneal Cancer,sinusitis
D018805,3.4,NCT01666444-1,Pegylated Liposomal Doxorubicin (PLD) + Placebo,NCT01666444,VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian  Fallopian Tube or Primary Peritoneal Cancer,sepsis
D018805,0.68,NCT01666444-2,Pegylated Liposomal Doxorubicin (PLD)+VTX-2337 (VTX),NCT01666444,VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian  Fallopian Tube or Primary Peritoneal Cancer,sepsis
10061229,0.68,NCT01666444-2,Pegylated Liposomal Doxorubicin (PLD)+VTX-2337 (VTX),NCT01666444,VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian  Fallopian Tube or Primary Peritoneal Cancer,lung infection
10065761,0.68,NCT01666444-2,Pegylated Liposomal Doxorubicin (PLD)+VTX-2337 (VTX),NCT01666444,VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian  Fallopian Tube or Primary Peritoneal Cancer,cecal infection
D014552,1.36,NCT01666444-1,Pegylated Liposomal Doxorubicin (PLD) + Placebo,NCT01666444,VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian  Fallopian Tube or Primary Peritoneal Cancer,urinary tract infection
D014552,1.36,NCT01666444-2,Pegylated Liposomal Doxorubicin (PLD)+VTX-2337 (VTX),NCT01666444,VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian  Fallopian Tube or Primary Peritoneal Cancer,urinary tract infection
10058838,0.68,NCT01666444-1,Pegylated Liposomal Doxorubicin (PLD) + Placebo,NCT01666444,VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian  Fallopian Tube or Primary Peritoneal Cancer,enterocolitis infectious
10061695,0.68,NCT01666444-1,Pegylated Liposomal Doxorubicin (PLD) + Placebo,NCT01666444,VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian  Fallopian Tube or Primary Peritoneal Cancer,biliary tract infection
D016103,0.68,NCT01666444-1,Pegylated Liposomal Doxorubicin (PLD) + Placebo,NCT01666444,VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian  Fallopian Tube or Primary Peritoneal Cancer,spinal fracture
10025256,0.68,NCT01666444-1,Pegylated Liposomal Doxorubicin (PLD) + Placebo,NCT01666444,VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian  Fallopian Tube or Primary Peritoneal Cancer,lymphocyte count decreased
10022402,0.68,NCT01666444-2,Pegylated Liposomal Doxorubicin (PLD)+VTX-2337 (VTX),NCT01666444,VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian  Fallopian Tube or Primary Peritoneal Cancer,inr increased
10011368,2.72,NCT01666444-1,Pegylated Liposomal Doxorubicin (PLD) + Placebo,NCT01666444,VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian  Fallopian Tube or Primary Peritoneal Cancer,creatinine increased
10029366,0.68,NCT01666444-1,Pegylated Liposomal Doxorubicin (PLD) + Placebo,NCT01666444,VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian  Fallopian Tube or Primary Peritoneal Cancer,neutrophil count decreased
10029366,1.36,NCT01666444-2,Pegylated Liposomal Doxorubicin (PLD)+VTX-2337 (VTX),NCT01666444,VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian  Fallopian Tube or Primary Peritoneal Cancer,neutrophil count decreased
10005364,0.68,NCT01666444-2,Pegylated Liposomal Doxorubicin (PLD)+VTX-2337 (VTX),NCT01666444,VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian  Fallopian Tube or Primary Peritoneal Cancer,blood bilirubin increased
10049182,0.68,NCT01666444-2,Pegylated Liposomal Doxorubicin (PLD)+VTX-2337 (VTX),NCT01666444,VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian  Fallopian Tube or Primary Peritoneal Cancer,white blood cell decreased
10003481,0.68,NCT01666444-2,Pegylated Liposomal Doxorubicin (PLD)+VTX-2337 (VTX),NCT01666444,VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian  Fallopian Tube or Primary Peritoneal Cancer,aspartate aminotransferase increased
10001675,0.68,NCT01666444-2,Pegylated Liposomal Doxorubicin (PLD)+VTX-2337 (VTX),NCT01666444,VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian  Fallopian Tube or Primary Peritoneal Cancer,alkaline phosphatase increased
10001551,0.68,NCT01666444-2,Pegylated Liposomal Doxorubicin (PLD)+VTX-2337 (VTX),NCT01666444,VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian  Fallopian Tube or Primary Peritoneal Cancer,alanine aminotransferase increased
D007010,0.68,NCT01666444-1,Pegylated Liposomal Doxorubicin (PLD) + Placebo,NCT01666444,VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian  Fallopian Tube or Primary Peritoneal Cancer,hyponatremia
D007010,0.68,NCT01666444-2,Pegylated Liposomal Doxorubicin (PLD)+VTX-2337 (VTX),NCT01666444,VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian  Fallopian Tube or Primary Peritoneal Cancer,hyponatremia
10021028,0.68,NCT01666444-1,Pegylated Liposomal Doxorubicin (PLD) + Placebo,NCT01666444,VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian  Fallopian Tube or Primary Peritoneal Cancer,hypomagnesemia
D007008,0.68,NCT01666444-1,Pegylated Liposomal Doxorubicin (PLD) + Placebo,NCT01666444,VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian  Fallopian Tube or Primary Peritoneal Cancer,hypokalemia
D006996,0.68,NCT01666444-2,Pegylated Liposomal Doxorubicin (PLD)+VTX-2337 (VTX),NCT01666444,VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian  Fallopian Tube or Primary Peritoneal Cancer,hypocalcemia
D034141,0.68,NCT01666444-2,Pegylated Liposomal Doxorubicin (PLD)+VTX-2337 (VTX),NCT01666444,VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian  Fallopian Tube or Primary Peritoneal Cancer,hypoalbuminemia
D006943,0.68,NCT01666444-1,Pegylated Liposomal Doxorubicin (PLD) + Placebo,NCT01666444,VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian  Fallopian Tube or Primary Peritoneal Cancer,hyperglycemia
D003681,0.68,NCT01666444-1,Pegylated Liposomal Doxorubicin (PLD) + Placebo,NCT01666444,VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian  Fallopian Tube or Primary Peritoneal Cancer,dehydration
D003681,1.36,NCT01666444-2,Pegylated Liposomal Doxorubicin (PLD)+VTX-2337 (VTX),NCT01666444,VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian  Fallopian Tube or Primary Peritoneal Cancer,dehydration
D000855,2.04,NCT01666444-2,Pegylated Liposomal Doxorubicin (PLD)+VTX-2337 (VTX),NCT01666444,VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian  Fallopian Tube or Primary Peritoneal Cancer,anorexia
10033425,0.68,NCT01666444-1,Pegylated Liposomal Doxorubicin (PLD) + Placebo,NCT01666444,VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian  Fallopian Tube or Primary Peritoneal Cancer,pain in extremity
10033425,0.68,NCT01666444-2,Pegylated Liposomal Doxorubicin (PLD)+VTX-2337 (VTX),NCT01666444,VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian  Fallopian Tube or Primary Peritoneal Cancer,pain in extremity
10062572,1.36,NCT01666444-2,Pegylated Liposomal Doxorubicin (PLD)+VTX-2337 (VTX),NCT01666444,VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian  Fallopian Tube or Primary Peritoneal Cancer,generalized muscle weakness
10029104,0.68,NCT01666444-2,Pegylated Liposomal Doxorubicin (PLD)+VTX-2337 (VTX),NCT01666444,VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian  Fallopian Tube or Primary Peritoneal Cancer,neoplasms benign malignant and unspecified (incl cysts and polyps) - other specify
D020521,0.68,NCT01666444-2,Pegylated Liposomal Doxorubicin (PLD)+VTX-2337 (VTX),NCT01666444,VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian  Fallopian Tube or Primary Peritoneal Cancer,stroke
D004401,0.68,NCT01666444-2,Pegylated Liposomal Doxorubicin (PLD)+VTX-2337 (VTX),NCT01666444,VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian  Fallopian Tube or Primary Peritoneal Cancer,dysarthria
10009845,0.68,NCT01666444-2,Pegylated Liposomal Doxorubicin (PLD)+VTX-2337 (VTX),NCT01666444,VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian  Fallopian Tube or Primary Peritoneal Cancer,cognitive disturbance
D003221,0.68,NCT01666444-2,Pegylated Liposomal Doxorubicin (PLD)+VTX-2337 (VTX),NCT01666444,VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian  Fallopian Tube or Primary Peritoneal Cancer,confusion
10061574,0.68,NCT01666444-1,Pegylated Liposomal Doxorubicin (PLD) + Placebo,NCT01666444,VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian  Fallopian Tube or Primary Peritoneal Cancer,urinary tract obstruction
10061574,0.68,NCT01666444-2,Pegylated Liposomal Doxorubicin (PLD)+VTX-2337 (VTX),NCT01666444,VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian  Fallopian Tube or Primary Peritoneal Cancer,urinary tract obstruction
D058186,1.36,NCT01666444-2,Pegylated Liposomal Doxorubicin (PLD)+VTX-2337 (VTX),NCT01666444,VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian  Fallopian Tube or Primary Peritoneal Cancer,acute kidney injury
10038738,0.68,NCT01666444-1,Pegylated Liposomal Doxorubicin (PLD) + Placebo,NCT01666444,VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian  Fallopian Tube or Primary Peritoneal Cancer,respiratory thoracic and mediastinal disorders - other specify
D012131,0.68,NCT01666444-1,Pegylated Liposomal Doxorubicin (PLD) + Placebo,NCT01666444,VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian  Fallopian Tube or Primary Peritoneal Cancer,respiratory failure
D012131,0.68,NCT01666444-2,Pegylated Liposomal Doxorubicin (PLD)+VTX-2337 (VTX),NCT01666444,VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian  Fallopian Tube or Primary Peritoneal Cancer,respiratory failure
D010996,2.04,NCT01666444-1,Pegylated Liposomal Doxorubicin (PLD) + Placebo,NCT01666444,VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian  Fallopian Tube or Primary Peritoneal Cancer,pleural effusion
D010996,2.04,NCT01666444-2,Pegylated Liposomal Doxorubicin (PLD)+VTX-2337 (VTX),NCT01666444,VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian  Fallopian Tube or Primary Peritoneal Cancer,pleural effusion
D000860,0.68,NCT01666444-1,Pegylated Liposomal Doxorubicin (PLD) + Placebo,NCT01666444,VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian  Fallopian Tube or Primary Peritoneal Cancer,hypoxia
D004417,2.04,NCT01666444-2,Pegylated Liposomal Doxorubicin (PLD)+VTX-2337 (VTX),NCT01666444,VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian  Fallopian Tube or Primary Peritoneal Cancer,dyspnea
10003504,0.68,NCT01666444-2,Pegylated Liposomal Doxorubicin (PLD)+VTX-2337 (VTX),NCT01666444,VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian  Fallopian Tube or Primary Peritoneal Cancer,aspiration
10043565,0.68,NCT01666444-1,Pegylated Liposomal Doxorubicin (PLD) + Placebo,NCT01666444,VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian  Fallopian Tube or Primary Peritoneal Cancer,thromboembolic event
D007022,0.68,NCT01666444-2,Pegylated Liposomal Doxorubicin (PLD)+VTX-2337 (VTX),NCT01666444,VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian  Fallopian Tube or Primary Peritoneal Cancer,hypotension
D006973,0.68,NCT01666444-1,Pegylated Liposomal Doxorubicin (PLD) + Placebo,NCT01666444,VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian  Fallopian Tube or Primary Peritoneal Cancer,hypertension
D064420,10.53,NCT01670500-1,Doxorubicin-Cyclophosphamide,NCT01670500,Cisplatin vs. Doxorubicin/Cyclophosphamide in BrCa,adverse drug events
D064420,8.33,NCT01670500-2,Cisplatin,NCT01670500,Cisplatin vs. Doxorubicin/Cyclophosphamide in BrCa,adverse drug events
D064147,1.75,NCT01670500-1,Doxorubicin-Cyclophosphamide,NCT01670500,Cisplatin vs. Doxorubicin/Cyclophosphamide in BrCa,febrile neutropenia
10062501,1.67,NCT01670500-2,Cisplatin,NCT01670500,Cisplatin vs. Doxorubicin/Cyclophosphamide in BrCa,non-cardiac chest pain
D006967,1.75,NCT01670500-1,Doxorubicin-Cyclophosphamide,NCT01670500,Cisplatin vs. Doxorubicin/Cyclophosphamide in BrCa,allergic reaction
10006259,1.67,NCT01670500-2,Cisplatin,NCT01670500,Cisplatin vs. Doxorubicin/Cyclophosphamide in BrCa,breast infection
10029366,7.02,NCT01670500-1,Doxorubicin-Cyclophosphamide,NCT01670500,Cisplatin vs. Doxorubicin/Cyclophosphamide in BrCa,neutrophil count decreased
10011368,3.33,NCT01670500-2,Cisplatin,NCT01670500,Cisplatin vs. Doxorubicin/Cyclophosphamide in BrCa,creatinine increased
D003681,1.67,NCT01670500-2,Cisplatin,NCT01670500,Cisplatin vs. Doxorubicin/Cyclophosphamide in BrCa,dehydration
10043565,3.33,NCT01670500-2,Cisplatin,NCT01670500,Cisplatin vs. Doxorubicin/Cyclophosphamide in BrCa,thromboembolic event
D064420,15.79,NCT01705691-1,Arm 1: Paclitaxel Then AC,NCT01705691,Comparison of Neoadjuvant Chemotherapy With Weekly Paclitaxel or Eribulin Followed by A/C in Women With Locally Advanced HER2-Negative Breast Cancer,adverse drug events
D064420,13.33,NCT01705691-2,Arm 2: Eribulin Then AC,NCT01705691,Comparison of Neoadjuvant Chemotherapy With Weekly Paclitaxel or Eribulin Followed by A/C in Women With Locally Advanced HER2-Negative Breast Cancer,adverse drug events
D064147,5.26,NCT01705691-1,Arm 1: Paclitaxel Then AC,NCT01705691,Comparison of Neoadjuvant Chemotherapy With Weekly Paclitaxel or Eribulin Followed by A/C in Women With Locally Advanced HER2-Negative Breast Cancer,febrile neutropenia
D064147,3.33,NCT01705691-2,Arm 2: Eribulin Then AC,NCT01705691,Comparison of Neoadjuvant Chemotherapy With Weekly Paclitaxel or Eribulin Followed by A/C in Women With Locally Advanced HER2-Negative Breast Cancer,febrile neutropenia
D003092,5.26,NCT01705691-1,Arm 1: Paclitaxel Then AC,NCT01705691,Comparison of Neoadjuvant Chemotherapy With Weekly Paclitaxel or Eribulin Followed by A/C in Women With Locally Advanced HER2-Negative Breast Cancer,colitis
10033425,3.33,NCT01705691-2,Arm 2: Eribulin Then AC,NCT01705691,Comparison of Neoadjuvant Chemotherapy With Weekly Paclitaxel or Eribulin Followed by A/C in Women With Locally Advanced HER2-Negative Breast Cancer,pain in extremity
D053040,3.33,NCT01705691-2,Arm 2: Eribulin Then AC,NCT01705691,Comparison of Neoadjuvant Chemotherapy With Weekly Paclitaxel or Eribulin Followed by A/C in Women With Locally Advanced HER2-Negative Breast Cancer,nephrolithiasis
D011655,5.26,NCT01705691-1,Arm 1: Paclitaxel Then AC,NCT01705691,Comparison of Neoadjuvant Chemotherapy With Weekly Paclitaxel or Eribulin Followed by A/C in Women With Locally Advanced HER2-Negative Breast Cancer,pulmonary embolism
UNKNOWN-check-for-typo,3.33,NCT01705691-2,Arm 2: Eribulin Then AC,NCT01705691,Comparison of Neoadjuvant Chemotherapy With Weekly Paclitaxel or Eribulin Followed by A/C in Women With Locally Advanced HER2-Negative Breast Cancer,D00
UNKNOWN-check-for-typo,3.33,NCT01705691-2,Arm 2: Eribulin Then AC,NCT01705691,Comparison of Neoadjuvant Chemotherapy With Weekly Paclitaxel or Eribulin Followed by A/C in Women With Locally Advanced HER2-Negative Breast Cancer,D00
D009026,1.36,NCT01712490-1,A+AVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,mortality
D009026,1.97,NCT01712490-2,ABVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,mortality
D064420,42.9,NCT01712490-1,A+AVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,adverse drug events
D064420,27.01,NCT01712490-2,ABVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,adverse drug events
D064147,17.22,NCT01712490-1,A+AVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,febrile neutropenia
D064147,6.53,NCT01712490-2,ABVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,febrile neutropenia
D009503,2.87,NCT01712490-1,A+AVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,neutropenia
D009503,0.61,NCT01712490-2,ABVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,neutropenia
D000741,1.06,NCT01712490-1,A+AVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,aplastic anaemia
D000741,0.46,NCT01712490-2,ABVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,aplastic anaemia
D008199,0.15,NCT01712490-2,ABVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,lymphadenitis
D000072281,0.15,NCT01712490-1,A+AVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,lymphadenopathy
D010198,0.3,NCT01712490-1,A+AVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,pancytopenia
D013921,0.15,NCT01712490-1,A+AVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,thrombocytopenia
D013921,0.15,NCT01712490-2,ABVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,thrombocytopenia
D015614,0.15,NCT01712490-1,A+AVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,histiocytosis
D009203,0.45,NCT01712490-1,A+AVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,myocardial infarction
D009203,0.15,NCT01712490-2,ABVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,myocardial infarction
D056988,0.15,NCT01712490-2,ABVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,acute anterior wall myocardial infarction
D000787,0.15,NCT01712490-1,A+AVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,angina pectoris
D003324,0.15,NCT01712490-2,ABVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,coronary artery disease
D013617,0.3,NCT01712490-1,A+AVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,supraventricular tachycardia
D013617,0.15,NCT01712490-2,ABVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,supraventricular tachycardia
D001281,0.3,NCT01712490-1,A+AVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,atrial fibrillation
D013616,0.15,NCT01712490-1,A+AVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,sinus tachycardia
D013616,0.15,NCT01712490-2,ABVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,sinus tachycardia
D013610,0.3,NCT01712490-1,A+AVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,tachycardia
D013610,0.15,NCT01712490-2,ABVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,tachycardia
D006323,0.3,NCT01712490-2,ABVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,cardiac arrest
D000072599,0.15,NCT01712490-1,A+AVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,cardiorespiratory fitness
D006333,0.15,NCT01712490-1,A+AVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,cardiac failure
D000028,0.15,NCT01712490-2,ABVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,abortion failure
D010493,0.15,NCT01712490-1,A+AVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,pericarditis
D010493,0.15,NCT01712490-2,ABVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,pericarditis
D013927,0.15,NCT01712490-1,A+AVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,thrombosis
D001935,0.15,NCT01712490-1,A+AVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,branchial cyst
D003480,0.15,NCT01712490-2,ABVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,cushing syndrome
10005886,0.15,NCT01712490-2,ABVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,blurred vision
D015746,2.11,NCT01712490-1,A+AVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,abdominal pain
D015746,0.61,NCT01712490-2,ABVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,abdominal pain
D015746,0.15,NCT01712490-1,A+AVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,abdominal pain
D014839,1.66,NCT01712490-1,A+AVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,vomiting
D014839,0.46,NCT01712490-2,ABVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,vomiting
D009325,1.06,NCT01712490-1,A+AVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,nausea
D009325,0.46,NCT01712490-2,ABVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,nausea
D003248,1.66,NCT01712490-1,A+AVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,constipation
D003248,0.91,NCT01712490-2,ABVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,constipation
UNKNOWN-check-for-typo,1.66,NCT01712490-1,A+AVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,D00
UNKNOWN-check-for-typo,0.15,NCT01712490-2,ABVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,D00
D003092,0.6,NCT01712490-1,A+AVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,colitis
D044504,0.15,NCT01712490-1,A+AVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,enterocolitis neutropenic
D005756,0.3,NCT01712490-1,A+AVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,gastritis
D005756,0.46,NCT01712490-2,ABVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,gastritis
D045823,0.45,NCT01712490-1,A+AVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,ileus
D045823,0.15,NCT01712490-2,ABVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,ileus
D007418,0.6,NCT01712490-1,A+AVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,paralytic ileus
D010195,0.15,NCT01712490-1,A+AVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,pancreatitis
D010195,0.15,NCT01712490-1,A+AVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,acute pancreatitis
D004760,0.15,NCT01712490-1,A+AVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,enterocolitis
D004760,0.15,NCT01712490-2,ABVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,enterocolitis
D009055,0.15,NCT01712490-2,ABVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,mouth
D013280,0.15,NCT01712490-2,ABVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,stomatitis
D005401,0.15,NCT01712490-2,ABVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,anal ulcer
D005767,0.15,NCT01712490-1,A+AVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,gastrointestinal disorder
UNKNOWN-check-for-typo,0.15,NCT01712490-1,A+AVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,D00
D005334,6.65,NCT01712490-1,A+AVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,pyrexia
D005334,4.25,NCT01712490-2,ABVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,pyrexia
10062501,0.15,NCT01712490-1,A+AVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,non-cardiac chest pain
10062501,0.3,NCT01712490-2,ABVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,non-cardiac chest pain
D010146,0.15,NCT01712490-1,A+AVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,pain
D010146,0.15,NCT01712490-2,ABVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,pain
D002637,0.15,NCT01712490-2,ABVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,chest pain
D005221,0.3,NCT01712490-1,A+AVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,fatigue
D001247,0.15,NCT01712490-1,A+AVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,asthenia
10025482,0.15,NCT01712490-1,A+AVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,malaise
D009102,0.15,NCT01712490-1,A+AVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,multiple organ dysfunction syndrome
D009102,0.15,NCT01712490-2,ABVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,multiple organ dysfunction syndrome
D007251,0.15,NCT01712490-1,A+AVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,influenza
D001929,0.15,NCT01712490-2,ABVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,brain swelling
D023341,0.15,NCT01712490-1,A+AVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,chills
D023341,0.3,NCT01712490-2,ABVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,chills
D003643,0.15,NCT01712490-1,A+AVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,death
D003643,0.15,NCT01712490-2,ABVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,death
D000077215,0.15,NCT01712490-2,ABVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,halloysite
D000077215,0.15,NCT01712490-2,ABVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,halloysite
10064774,0.15,NCT01712490-1,A+AVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,infusion site extravasation
10064774,0.15,NCT01712490-2,ABVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,infusion site extravasation
D004864,0.15,NCT01712490-2,ABVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,devices
D000799,0.15,NCT01712490-1,A+AVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,angioedema
D064420,0.15,NCT01712490-2,ABVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,adverse drug reaction
10064687,0.15,NCT01712490-2,ABVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,device related infection
D041881,0.15,NCT01712490-1,A+AVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,acute cholecystitis
D041881,0.15,NCT01712490-2,ABVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,acute cholecystitis
D002769,0.15,NCT01712490-1,A+AVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,cholelithiasis
UNKNOWN-check-for-typo,0.3,NCT01712490-1,A+AVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,D00
10017636,0.15,NCT01712490-1,A+AVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,gallbladder obstruction
D001664,0.15,NCT01712490-2,ABVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,biliverdine
D011681,0.15,NCT01712490-1,A+AVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,pupillary functions abnormal
D017093,0.15,NCT01712490-1,A+AVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,hepatic failure
D004342,0.15,NCT01712490-1,A+AVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,drug hypersensitivity
D004342,0.15,NCT01712490-2,ABVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,drug hypersensitivity
D011014,2.72,NCT01712490-1,A+AVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,pneumonia
D011014,2.28,NCT01712490-2,ABVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,pneumonia
10061229,0.6,NCT01712490-1,A+AVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,lung infection
10061229,0.3,NCT01712490-2,ABVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,lung infection
D012141,0.3,NCT01712490-1,A+AVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,respiratory tract infections
D012141,0.46,NCT01712490-2,ABVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,respiratory tract infections
D001991,0.15,NCT01712490-1,A+AVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,bronchitis
D001991,0.3,NCT01712490-2,ABVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,bronchitis
D011016,0.15,NCT01712490-2,ABVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,pneumonia atypical interstitial of cattle
D018805,2.11,NCT01712490-1,A+AVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,sepsis
D018805,0.61,NCT01712490-2,ABVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,sepsis
D000985,1.21,NCT01712490-1,A+AVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,antisepsis
D000985,0.3,NCT01712490-2,ABVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,antisepsis
UNKNOWN-check-for-typo,0.15,NCT01712490-1,A+AVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,D00
UNKNOWN-check-for-typo,0.61,NCT01712490-2,ABVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,D00
D012772,0.6,NCT01712490-1,A+AVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,septic shock
D000891,0.15,NCT01712490-2,ABVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,antiseptics
10064687,1.06,NCT01712490-1,A+AVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,device related infection
10064687,0.3,NCT01712490-2,ABVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,device related infection
D012141,0.15,NCT01712490-1,A+AVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,respiratory tract infection
D012141,0.3,NCT01712490-2,ABVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,respiratory tract infection
D007239,0.15,NCT01712490-1,A+AVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,infection
D007239,0.15,NCT01712490-2,ABVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,infection
D010272,0.15,NCT01712490-1,A+AVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,parasite infections
10050823,0.15,NCT01712490-2,ABVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,lymph gland infection
D034161,0.15,NCT01712490-2,ABVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,pelvic infection
D014946,0.15,NCT01712490-2,ABVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,wound infection
D012141,0.45,NCT01712490-1,A+AVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,upper respiratory tract infections
D012141,0.3,NCT01712490-2,ABVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,upper respiratory tract infections
D014069,0.15,NCT01712490-1,A+AVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,tonsillitis
D014069,0.15,NCT01712490-2,ABVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,tonsillitis
D007827,0.15,NCT01712490-2,ABVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,laryngitis
D017703,0.15,NCT01712490-1,A+AVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,retropharyngeal abscess
D010612,0.15,NCT01712490-1,A+AVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,pharyngitis
D012852,0.15,NCT01712490-1,A+AVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,sinusitis
D002481,0.76,NCT01712490-1,A+AVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,cellulitis
D002481,0.3,NCT01712490-2,ABVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,cellulitis
D001424,0.15,NCT01712490-2,ABVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,bacterial infection
D054517,0.15,NCT01712490-1,A+AVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,orbital cellulitis
D005734,0.15,NCT01712490-2,ABVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,gangrene
D011020,0.76,NCT01712490-1,A+AVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,pneumocystis jirovecii pneumonia
D011020,0.3,NCT01712490-2,ABVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,pneumocystis jirovecii pneumonia
D016720,0.15,NCT01712490-1,A+AVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,pneumocystis infections
D000038,0.3,NCT01712490-1,A+AVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,abscess
D018784,0.15,NCT01712490-2,ABVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,abdominal abscess
D001064,0.15,NCT01712490-1,A+AVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,appendicitis
D004238,0.15,NCT01712490-1,A+AVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,diverticulitis
D005254,0.15,NCT01712490-2,ABVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,feline infectious enteritis
10040872,0.3,NCT01712490-1,A+AVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,skin infection
10040872,0.15,NCT01712490-2,ABVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,skin infection
D000038,0.15,NCT01712490-1,A+AVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,abscess
D000038,0.15,NCT01712490-2,ABVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,abscess
D005499,0.15,NCT01712490-1,A+AVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,folliculitis
D000072139,0.15,NCT01712490-1,A+AVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,megavirales
D000072139,0.3,NCT01712490-2,ABVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,megavirales
D011024,0.3,NCT01712490-1,A+AVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,viral pneumonia
D014777,0.15,NCT01712490-1,A+AVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,viral infection
D004761,0.3,NCT01712490-1,A+AVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,clostridium enterocolitis
D004761,0.15,NCT01712490-2,ABVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,clostridium enterocolitis
D003015,0.15,NCT01712490-1,A+AVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,clostridium difficile infection
D000038,0.3,NCT01712490-1,A+AVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,abscess
D010497,0.15,NCT01712490-1,A+AVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,pericoronitis
D010518,0.15,NCT01712490-2,ABVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,periodontitis
D013203,0.15,NCT01712490-1,A+AVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,staphylococcal infection
D013203,0.15,NCT01712490-2,ABVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,staphylococcal infection
D004768,0.15,NCT01712490-2,ABVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,staphylococcal enterotoxins
D000985,0.15,NCT01712490-1,A+AVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,antisepsis
D014552,0.3,NCT01712490-1,A+AVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,urinary tract infection
D014552,0.15,NCT01712490-2,ABVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,urinary tract infection
D011704,0.15,NCT01712490-2,ABVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,pyelonephritis
D018461,0.15,NCT01712490-1,A+AVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,soft tissue infection
D018461,0.3,NCT01712490-2,ABVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,soft tissue infection
D001228,0.15,NCT01712490-2,ABVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,aspergillus infection
D055732,0.15,NCT01712490-1,A+AVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,bronchopulmonary aspergillosis
D014125,0.15,NCT01712490-2,ABVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,toxoplasma infections congenital
D014847,0.15,NCT01712490-1,A+AVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,vulvitis
D000985,0.15,NCT01712490-2,ABVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,antisepsis
D001996,0.15,NCT01712490-2,ABVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,bronchopneumonia
D006558,0.15,NCT01712490-1,A+AVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,herpes simplex virus genital infection
D006562,0.15,NCT01712490-2,ABVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,herpes zoster
D006563,0.15,NCT01712490-2,ABVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,herpes zoster ophthalmicus
D008210,0.15,NCT01712490-1,A+AVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,lymphocele
10056627,0.15,NCT01712490-2,ABVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,phlebitis infective
D004696,0.15,NCT01712490-2,ABVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,endocarditis
D004660,0.15,NCT01712490-1,A+AVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,encephalitis
D018177,0.15,NCT01712490-1,A+AVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,flavivirus infection
D006509,0.15,NCT01712490-2,ABVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,hepatitis b
D007251,0.15,NCT01712490-1,A+AVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,influenza
D045828,0.15,NCT01712490-2,ABVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,moraxella infection
D000257,0.15,NCT01712490-2,ABVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,adenovirus infections
D001996,0.15,NCT01712490-1,A+AVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,bronchopneumonia
10020100,0.3,NCT01712490-1,A+AVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,hip fracture
D064386,0.15,NCT01712490-1,A+AVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,ankle fracture
D005265,0.15,NCT01712490-1,A+AVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,femur neck fractures
10051792,0.15,NCT01712490-1,A+AVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,infusion related reaction
10051792,0.15,NCT01712490-2,ABVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,infusion related reaction
10016173,0.15,NCT01712490-2,ABVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,fall
10029366,0.45,NCT01712490-1,A+AVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,neutrophil count decreased
10029366,0.15,NCT01712490-2,ABVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,neutrophil count decreased
D020604,0.15,NCT01712490-2,ABVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,pseudomonas testosteroni
D004845,0.15,NCT01712490-2,ABVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,epitestosterone
D001786,0.15,NCT01712490-1,A+AVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,blood glucose
10040139,0.15,NCT01712490-1,A+AVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,serum amylase increased
10024574,0.15,NCT01712490-1,A+AVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,lipase increased
D008133,0.15,NCT01712490-1,A+AVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,electrocardiogram qt prolonged
10005364,0.15,NCT01712490-1,A+AVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,blood bilirubin increased
D001831,0.15,NCT01712490-2,ABVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,body temperature
D003681,1.51,NCT01712490-1,A+AVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,dehydration
D003681,0.46,NCT01712490-2,ABVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,dehydration
UNKNOWN-check-for-typo,0.6,NCT01712490-1,A+AVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,D00
UNKNOWN-check-for-typo,0.46,NCT01712490-2,ABVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,D00
UNKNOWN-check-for-typo,0.45,NCT01712490-1,A+AVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,D00
UNKNOWN-check-for-typo,0.15,NCT01712490-2,ABVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,D00
UNKNOWN-check-for-typo,0.3,NCT01712490-1,A+AVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,D00
UNKNOWN-check-for-typo,0.15,NCT01712490-2,ABVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,D00
UNKNOWN-check-for-typo,0.15,NCT01712490-2,ABVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,D00
D005183,0.15,NCT01712490-1,A+AVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,failure to thrive
D044342,0.15,NCT01712490-1,A+AVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,malnutrition
UNKNOWN-check-for-typo,0.3,NCT01712490-1,A+AVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,D00
D003924,0.15,NCT01712490-1,A+AVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,type 2 diabetes mellitus
UNKNOWN-check-for-typo,0.15,NCT01712490-1,A+AVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,D00
10033425,0.3,NCT01712490-1,A+AVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,pain in extremity
10033425,0.15,NCT01712490-2,ABVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,pain in extremity
D001416,0.3,NCT01712490-1,A+AVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,back pain
D021501,0.3,NCT01712490-1,A+AVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,flank pain
D059352,0.15,NCT01712490-1,A+AVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,musculoskeletal pain
D063806,0.15,NCT01712490-1,A+AVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,myalgia
D063806,0.15,NCT01712490-2,ABVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,myalgia
10006002,0.15,NCT01712490-1,A+AVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,bone pain
D018771,0.15,NCT01712490-2,ABVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,arthralgia
D018908,0.15,NCT01712490-2,ABVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,muscular weakness
D009490,0.15,NCT01712490-2,ABVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,neuroendocrine system
D004393,0.15,NCT01712490-1,A+AVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,dwarfism pituitary
D016399,0.15,NCT01712490-2,ABVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,t cell lymphoma
D001650,0.15,NCT01712490-2,ABVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,bile duct cancer
D046152,0.15,NCT01712490-1,A+AVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,gastrointestinal stromal tumors
D005207,0.15,NCT01712490-2,ABVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,fasciculation benign
D009101,0.15,NCT01712490-1,A+AVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,plasma cell myeloma
D013575,0.3,NCT01712490-1,A+AVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,syncope
D013575,0.3,NCT01712490-2,ABVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,syncope
D053609,0.3,NCT01712490-1,A+AVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,lethargy
D053609,0.15,NCT01712490-2,ABVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,lethargy
D000077260,0.15,NCT01712490-2,ABVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,somnolence
D006261,0.45,NCT01712490-1,A+AVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,headache
D006261,0.46,NCT01712490-2,ABVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,headache
10034580,0.45,NCT01712490-1,A+AVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,peripheral motor neuropathy
10034620,0.3,NCT01712490-1,A+AVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,peripheral sensory neuropathy
D011115,0.15,NCT01712490-1,A+AVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,polyneuropathy
D011115,0.15,NCT01712490-2,ABVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,polyneuropathy
D020521,0.15,NCT01712490-1,A+AVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,cerebrovascular accident
D020521,0.15,NCT01712490-2,ABVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,cerebrovascular accident
D059409,0.15,NCT01712490-2,ABVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,lacunar infarction
D003929,0.15,NCT01712490-2,ABVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,diabetic autonomic neuropathy
D005158,0.15,NCT01712490-1,A+AVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,facial paralysis
UNKNOWN-check-for-typo,0.15,NCT01712490-1,A+AVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,D00
D010291,0.15,NCT01712490-1,A+AVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,hemiparesis
D009437,0.15,NCT01712490-1,A+AVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,neuralgia
D013116,0.15,NCT01712490-1,A+AVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,spinal cord
D001007,0.3,NCT01712490-1,A+AVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,anxiety
D001007,0.15,NCT01712490-2,ABVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,anxiety
10001497,0.15,NCT01712490-2,ABVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,agitation
D003693,0.3,NCT01712490-1,A+AVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,delirium
D001714,0.15,NCT01712490-2,ABVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,bipolar disorder
D059020,0.15,NCT01712490-1,A+AVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,suicidal ideation
D058186,0.45,NCT01712490-1,A+AVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,acute kidney injury
D001002,0.15,NCT01712490-1,A+AVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,anuria
D000402,0.15,NCT01712490-1,A+AVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,airway obstruction
D000402,0.15,NCT01712490-2,ABVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,airway obstruction
UNKNOWN-check-for-typo,0.15,NCT01712490-2,ABVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,D00
D008796,0.15,NCT01712490-2,ABVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,metrorrhagia
D000069339,0.15,NCT01712490-2,ABVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,vaginal cervicectomy
D011655,1.66,NCT01712490-1,A+AVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,pulmonary embolism
D011655,1.37,NCT01712490-2,ABVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,pulmonary embolism
D013927,0.15,NCT01712490-1,A+AVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,thrombosis
D011014,0.3,NCT01712490-1,A+AVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,pneumonitis
D011014,1.82,NCT01712490-2,ABVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,pneumonitis
D000081015,0.76,NCT01712490-2,ABVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,ototoxicity
D017563,0.15,NCT01712490-1,A+AVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,interstitial lung disease
D017563,0.3,NCT01712490-2,ABVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,interstitial lung disease
D008168,0.3,NCT01712490-1,A+AVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,lung
D001996,0.15,NCT01712490-2,ABVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,bronchopneumonia
UNKNOWN-check-for-typo,0.45,NCT01712490-1,A+AVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,D00
UNKNOWN-check-for-typo,0.76,NCT01712490-2,ABVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,D00
D012131,0.3,NCT01712490-1,A+AVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,respiratory failure
D012131,0.61,NCT01712490-2,ABVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,respiratory failure
D000860,0.15,NCT01712490-1,A+AVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,hypoxia
D000860,0.3,NCT01712490-2,ABVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,hypoxia
D003371,0.15,NCT01712490-1,A+AVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,cough
D003371,0.15,NCT01712490-2,ABVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,cough
D000799,0.15,NCT01712490-1,A+AVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,angioedema
D012128,0.15,NCT01712490-2,ABVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,acute respiratory distress syndrome
D008168,0.15,NCT01712490-1,A+AVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,lung
10038738,0.15,NCT01712490-2,ABVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,respiratory thoracic and mediastinal disorders - other specify
D029424,0.15,NCT01712490-1,A+AVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,chronic obstructive pulmonary disease
D012135,0.15,NCT01712490-1,A+AVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,stridor
10035623,0.15,NCT01712490-2,ABVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,pleuritic pain
D010998,0.15,NCT01712490-1,A+AVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,pleurisy
D011030,0.15,NCT01712490-1,A+AVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,pneumothorax
D005076,0.15,NCT01712490-1,A+AVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,rash
10037868,0.15,NCT01712490-1,A+AVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,rash maculo-papular
D016575,0.15,NCT01712490-2,ABVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,hidradenitis
D003875,0.15,NCT01712490-2,ABVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,drug eruption
D012883,0.15,NCT01712490-2,ABVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,skin ulcer
D020246,0.76,NCT01712490-1,A+AVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,deep vein thrombosis
D020246,0.3,NCT01712490-2,ABVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,deep vein thrombosis
10042554,0.15,NCT01712490-1,A+AVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,superficial thrombophlebitis
10042554,0.15,NCT01712490-2,ABVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,superficial thrombophlebitis
D007601,0.15,NCT01712490-2,ABVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,jugular veins
D020246,0.15,NCT01712490-1,A+AVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,venous thrombosis
D002341,0.15,NCT01712490-1,A+AVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,carotid artery thrombosis
D020246,0.15,NCT01712490-2,ABVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,venous thrombosis
D007022,0.6,NCT01712490-1,A+AVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,hypotension
D007022,0.15,NCT01712490-2,ABVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,hypotension
D007024,0.15,NCT01712490-2,ABVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,orthostatic hypotension
D004617,0.61,NCT01712490-2,ABVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,embolism
D020246,0.15,NCT01712490-1,A+AVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,venous thrombosis
D016121,0.15,NCT01712490-2,ABVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,brachiocephalic veins
D013479,0.15,NCT01712490-1,A+AVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,superior vena cava syndrome
D010689,0.15,NCT01712490-1,A+AVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,phlebitis
D013479,0.15,NCT01712490-2,ABVD,NCT01712490,A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma,superior vena cava thrombosis
D064420,33.96,NCT01724021-1,Arm A,NCT01724021,A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1  2 or 3a,adverse drug events
D064420,31.44,NCT01724021-2,Arm B,NCT01724021,A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1  2 or 3a,adverse drug events
D064147,8.36,NCT01724021-1,Arm A,NCT01724021,A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1  2 or 3a,febrile neutropenia
D064147,8.13,NCT01724021-2,Arm B,NCT01724021,A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1  2 or 3a,febrile neutropenia
D009503,4.31,NCT01724021-1,Arm A,NCT01724021,A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1  2 or 3a,neutropenia
D009503,3.52,NCT01724021-2,Arm B,NCT01724021,A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1  2 or 3a,neutropenia
D000741,0.81,NCT01724021-1,Arm A,NCT01724021,A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1  2 or 3a,aplastic anaemia
D000741,1.36,NCT01724021-2,Arm B,NCT01724021,A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1  2 or 3a,aplastic anaemia
D007970,1.35,NCT01724021-1,Arm A,NCT01724021,A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1  2 or 3a,leukopenia
D007970,0.27,NCT01724021-2,Arm B,NCT01724021,A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1  2 or 3a,leukopenia
D010198,0.27,NCT01724021-1,Arm A,NCT01724021,A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1  2 or 3a,pancytopenia
D010198,0.54,NCT01724021-2,Arm B,NCT01724021,A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1  2 or 3a,pancytopenia
D008231,0.27,NCT01724021-2,Arm B,NCT01724021,A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1  2 or 3a,lymphopenia
D001281,0.54,NCT01724021-1,Arm A,NCT01724021,A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1  2 or 3a,atrial fibrillation
D001281,0.27,NCT01724021-2,Arm B,NCT01724021,A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1  2 or 3a,atrial fibrillation
D006333,0.27,NCT01724021-1,Arm A,NCT01724021,A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1  2 or 3a,cardiac failure
D006333,0.54,NCT01724021-2,Arm B,NCT01724021,A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1  2 or 3a,cardiac failure
D054058,0.27,NCT01724021-1,Arm A,NCT01724021,A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1  2 or 3a,acute coronary syndrome
D000787,0.27,NCT01724021-2,Arm B,NCT01724021,A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1  2 or 3a,angina pectoris
D001919,0.27,NCT01724021-2,Arm B,NCT01724021,A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1  2 or 3a,bradycardia
D009203,0.27,NCT01724021-2,Arm B,NCT01724021,A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1  2 or 3a,myocardial infarction
D003919,0.27,NCT01724021-1,Arm A,NCT01724021,A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1  2 or 3a,diabetes insipidus
D006980,0.27,NCT01724021-2,Arm B,NCT01724021,A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1  2 or 3a,hyperthyroidism
UNKNOWN-check-for-typo,0.27,NCT01724021-1,Arm A,NCT01724021,A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1  2 or 3a,D00
UNKNOWN-check-for-typo,0.81,NCT01724021-2,Arm B,NCT01724021,A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1  2 or 3a,D00
D014839,0.54,NCT01724021-1,Arm A,NCT01724021,A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1  2 or 3a,vomiting
D014839,0.54,NCT01724021-2,Arm B,NCT01724021,A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1  2 or 3a,vomiting
D015746,0.54,NCT01724021-1,Arm A,NCT01724021,A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1  2 or 3a,abdominal pain
D015746,0.27,NCT01724021-2,Arm B,NCT01724021,A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1  2 or 3a,abdominal pain
D003248,0.54,NCT01724021-1,Arm A,NCT01724021,A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1  2 or 3a,constipation
D003248,0.27,NCT01724021-2,Arm B,NCT01724021,A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1  2 or 3a,constipation
D007416,0.27,NCT01724021-1,Arm A,NCT01724021,A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1  2 or 3a,intestinal perforation
D007416,0.54,NCT01724021-2,Arm B,NCT01724021,A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1  2 or 3a,intestinal perforation
D015746,0.27,NCT01724021-2,Arm B,NCT01724021,A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1  2 or 3a,abdominal pain
D034861,0.27,NCT01724021-2,Arm B,NCT01724021,A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1  2 or 3a,abdominal wall
D012003,0.27,NCT01724021-2,Arm B,NCT01724021,A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1  2 or 3a,anal fistula
D004760,0.27,NCT01724021-2,Arm B,NCT01724021,A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1  2 or 3a,enterocolitis
D000069196,0.27,NCT01724021-2,Arm B,NCT01724021,A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1  2 or 3a,gastrointestinal microbiome
10021305,0.27,NCT01724021-1,Arm A,NCT01724021,A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1  2 or 3a,ileal perforation
D045823,0.27,NCT01724021-2,Arm B,NCT01724021,A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1  2 or 3a,ileus
D007418,0.27,NCT01724021-2,Arm B,NCT01724021,A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1  2 or 3a,paralytic ileus
D059325,0.27,NCT01724021-1,Arm A,NCT01724021,A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1  2 or 3a,intraabdominal hypertension
10015461,0.27,NCT01724021-1,Arm A,NCT01724021,A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1  2 or 3a,esophagitis
10041103,0.27,NCT01724021-1,Arm A,NCT01724021,A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1  2 or 3a,small intestinal perforation
10021328,0.27,NCT01724021-2,Arm B,NCT01724021,A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1  2 or 3a,ileus
D041742,0.27,NCT01724021-2,Arm B,NCT01724021,A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1  2 or 3a,upper gastrointestinal tract
D005334,2.7,NCT01724021-1,Arm A,NCT01724021,A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1  2 or 3a,pyrexia
D005334,0.81,NCT01724021-2,Arm B,NCT01724021,A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1  2 or 3a,pyrexia
D001247,1.08,NCT01724021-1,Arm A,NCT01724021,A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1  2 or 3a,asthenia
D001247,0.27,NCT01724021-2,Arm B,NCT01724021,A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1  2 or 3a,asthenia
D003695,0.81,NCT01724021-1,Arm A,NCT01724021,A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1  2 or 3a,healthcare
D002637,0.27,NCT01724021-1,Arm A,NCT01724021,A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1  2 or 3a,chest pain
D000075662,0.27,NCT01724021-1,Arm A,NCT01724021,A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1  2 or 3a,injection site reaction
D064420,0.27,NCT01724021-1,Arm A,NCT01724021,A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1  2 or 3a,adverse drug reaction
D041881,0.27,NCT01724021-2,Arm B,NCT01724021,A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1  2 or 3a,acute cholecystitis
D002779,0.27,NCT01724021-1,Arm A,NCT01724021,A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1  2 or 3a,cholestasis
D006967,0.54,NCT01724021-2,Arm B,NCT01724021,A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1  2 or 3a,hypersensitivity
D000707,0.27,NCT01724021-1,Arm A,NCT01724021,A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1  2 or 3a,anaphylactic reaction
D000080424,0.27,NCT01724021-2,Arm B,NCT01724021,A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1  2 or 3a,cytokine release syndrome
D011014,3.23,NCT01724021-1,Arm A,NCT01724021,A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1  2 or 3a,pneumonia
D011014,2.44,NCT01724021-2,Arm B,NCT01724021,A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1  2 or 3a,pneumonia
D018805,0.81,NCT01724021-1,Arm A,NCT01724021,A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1  2 or 3a,sepsis
D018805,1.36,NCT01724021-2,Arm B,NCT01724021,A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1  2 or 3a,sepsis
10061229,0.81,NCT01724021-1,Arm A,NCT01724021,A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1  2 or 3a,lung infection
10061229,0.81,NCT01724021-2,Arm B,NCT01724021,A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1  2 or 3a,lung infection
D006562,0.27,NCT01724021-1,Arm A,NCT01724021,A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1  2 or 3a,herpes zoster
D006562,0.81,NCT01724021-2,Arm B,NCT01724021,A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1  2 or 3a,herpes zoster
D014552,0.81,NCT01724021-1,Arm A,NCT01724021,A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1  2 or 3a,urinary tract infection
D014552,0.81,NCT01724021-2,Arm B,NCT01724021,A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1  2 or 3a,urinary tract infection
D012772,0.54,NCT01724021-1,Arm A,NCT01724021,A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1  2 or 3a,septic shock
D012772,0.54,NCT01724021-2,Arm B,NCT01724021,A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1  2 or 3a,septic shock
D011016,0.27,NCT01724021-1,Arm A,NCT01724021,A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1  2 or 3a,pneumonia atypical interstitial of cattle
D011016,0.54,NCT01724021-2,Arm B,NCT01724021,A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1  2 or 3a,pneumonia atypical interstitial of cattle
D001991,0.27,NCT01724021-1,Arm A,NCT01724021,A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1  2 or 3a,bronchitis
D001991,0.81,NCT01724021-2,Arm B,NCT01724021,A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1  2 or 3a,bronchitis
D007239,0.81,NCT01724021-1,Arm A,NCT01724021,A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1  2 or 3a,infection
D012141,0.27,NCT01724021-1,Arm A,NCT01724021,A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1  2 or 3a,upper respiratory tract infections
D012141,0.54,NCT01724021-2,Arm B,NCT01724021,A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1  2 or 3a,upper respiratory tract infections
D002481,0.27,NCT01724021-1,Arm A,NCT01724021,A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1  2 or 3a,cellulitis
D002481,0.27,NCT01724021-2,Arm B,NCT01724021,A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1  2 or 3a,cellulitis
D004886,0.27,NCT01724021-1,Arm A,NCT01724021,A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1  2 or 3a,erysipelas
D004886,0.27,NCT01724021-2,Arm B,NCT01724021,A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1  2 or 3a,erysipelas
D005759,0.27,NCT01724021-1,Arm A,NCT01724021,A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1  2 or 3a,gastroenteritis
D005759,0.27,NCT01724021-2,Arm B,NCT01724021,A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1  2 or 3a,gastroenteritis
D007251,0.54,NCT01724021-1,Arm A,NCT01724021,A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1  2 or 3a,influenza
D000985,0.27,NCT01724021-2,Arm B,NCT01724021,A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1  2 or 3a,antisepsis
D011020,0.54,NCT01724021-1,Arm A,NCT01724021,A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1  2 or 3a,pneumocystis jirovecii pneumonia
D011024,0.27,NCT01724021-1,Arm A,NCT01724021,A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1  2 or 3a,viral pneumonia
D011024,0.27,NCT01724021-2,Arm B,NCT01724021,A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1  2 or 3a,viral pneumonia
D012141,0.54,NCT01724021-2,Arm B,NCT01724021,A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1  2 or 3a,respiratory tract infection
D018461,0.54,NCT01724021-2,Arm B,NCT01724021,A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1  2 or 3a,soft tissue infection
D000038,0.27,NCT01724021-1,Arm A,NCT01724021,A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1  2 or 3a,abscess
D001064,0.27,NCT01724021-1,Arm A,NCT01724021,A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1  2 or 3a,appendicitis
D055732,0.54,NCT01724021-2,Arm B,NCT01724021,A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1  2 or 3a,bronchopulmonary aspergillosis
D003556,0.27,NCT01724021-1,Arm A,NCT01724021,A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1  2 or 3a,cystitis
D004238,0.27,NCT01724021-1,Arm A,NCT01724021,A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1  2 or 3a,diverticulitis
D009181,0.27,NCT01724021-1,Arm A,NCT01724021,A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1  2 or 3a,fungal infection
D005759,0.27,NCT01724021-2,Arm B,NCT01724021,A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1  2 or 3a,gastroenteritis
D000075662,0.27,NCT01724021-2,Arm B,NCT01724021,A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1  2 or 3a,injection site reaction
10023424,0.27,NCT01724021-1,Arm A,NCT01724021,A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1  2 or 3a,kidney infection
D000069544,0.27,NCT01724021-2,Arm B,NCT01724021,A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1  2 or 3a,encephalitis infection
D012141,0.27,NCT01724021-1,Arm A,NCT01724021,A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1  2 or 3a,respiratory tract infections
D008198,0.27,NCT01724021-2,Arm B,NCT01724021,A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1  2 or 3a,lymph nodes
10065764,0.27,NCT01724021-2,Arm B,NCT01724021,A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1  2 or 3a,mucosal infection
D009181,0.27,NCT01724021-1,Arm A,NCT01724021,A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1  2 or 3a,fungal infections
D002177,0.27,NCT01724021-2,Arm B,NCT01724021,A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1  2 or 3a,candidiasis
UNKNOWN-check-for-typo,0.27,NCT01724021-2,Arm B,NCT01724021,A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1  2 or 3a,D00
D013530,0.27,NCT01724021-2,Arm B,NCT01724021,A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1  2 or 3a,wound infection postoperative
D007968,0.27,NCT01724021-1,Arm A,NCT01724021,A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1  2 or 3a,progressive multifocal leukoencephalopathy
D011711,0.27,NCT01724021-1,Arm A,NCT01724021,A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1  2 or 3a,pyoderma
10040872,0.27,NCT01724021-1,Arm A,NCT01724021,A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1  2 or 3a,skin infection
D000985,0.27,NCT01724021-1,Arm A,NCT01724021,A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1  2 or 3a,antisepsis
D000038,0.27,NCT01724021-2,Arm B,NCT01724021,A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1  2 or 3a,abscess
10048762,0.27,NCT01724021-1,Arm A,NCT01724021,A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1  2 or 3a,tooth infection
D014777,0.27,NCT01724021-2,Arm B,NCT01724021,A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1  2 or 3a,viral infection
UNKNOWN-check-for-typo,0.27,NCT01724021-2,Arm B,NCT01724021,A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1  2 or 3a,D00
D001424,0.27,NCT01724021-2,Arm B,NCT01724021,A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1  2 or 3a,bacterial infections
D002180,0.27,NCT01724021-1,Arm A,NCT01724021,A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1  2 or 3a,oral candidiasis
D000069544,0.27,NCT01724021-1,Arm A,NCT01724021,A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1  2 or 3a,encephalitis infection
D000073618,0.27,NCT01724021-1,Arm A,NCT01724021,A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1  2 or 3a,varicella zoster virus infection
10016173,0.54,NCT01724021-1,Arm A,NCT01724021,A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1  2 or 3a,fall
10016173,0.27,NCT01724021-2,Arm B,NCT01724021,A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1  2 or 3a,fall
D062787,0.27,NCT01724021-2,Arm B,NCT01724021,A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1  2 or 3a,drug overdose
D011885,0.27,NCT01724021-1,Arm A,NCT01724021,A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1  2 or 3a,radius fracture
D016103,0.27,NCT01724021-2,Arm B,NCT01724021,A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1  2 or 3a,spinal fracture
D016103,0.27,NCT01724021-1,Arm A,NCT01724021,A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1  2 or 3a,spinal fractures
10029366,2.96,NCT01724021-1,Arm A,NCT01724021,A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1  2 or 3a,neutrophil count decreased
10029366,2.71,NCT01724021-2,Arm B,NCT01724021,A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1  2 or 3a,neutrophil count decreased
D007958,0.81,NCT01724021-1,Arm A,NCT01724021,A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1  2 or 3a,blood cell count white
D007958,0.81,NCT01724021-2,Arm B,NCT01724021,A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1  2 or 3a,blood cell count white
10001551,0.27,NCT01724021-1,Arm A,NCT01724021,A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1  2 or 3a,alanine aminotransferase increased
10035528,0.27,NCT01724021-1,Arm A,NCT01724021,A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1  2 or 3a,platelet count decreased
D001831,0.27,NCT01724021-1,Arm A,NCT01724021,A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1  2 or 3a,body temperature
D003681,0.27,NCT01724021-1,Arm A,NCT01724021,A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1  2 or 3a,dehydration
D003681,0.27,NCT01724021-2,Arm B,NCT01724021,A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1  2 or 3a,dehydration
UNKNOWN-check-for-typo,0.54,NCT01724021-2,Arm B,NCT01724021,A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1  2 or 3a,D00
D001066,0.27,NCT01724021-2,Arm B,NCT01724021,A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1  2 or 3a,appetite
D006073,0.27,NCT01724021-1,Arm A,NCT01724021,A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1  2 or 3a,gout
UNKNOWN-check-for-typo,0.27,NCT01724021-2,Arm B,NCT01724021,A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1  2 or 3a,D00
UNKNOWN-check-for-typo,0.27,NCT01724021-2,Arm B,NCT01724021,A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1  2 or 3a,D00
D015275,0.27,NCT01724021-1,Arm A,NCT01724021,A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1  2 or 3a,tumor lysis syndrome
D001416,0.27,NCT01724021-1,Arm A,NCT01724021,A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1  2 or 3a,back pain
10006002,0.27,NCT01724021-1,Arm A,NCT01724021,A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1  2 or 3a,bone pain
D015210,0.27,NCT01724021-2,Arm B,NCT01724021,A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1  2 or 3a,gouty arthritis
D009209,0.27,NCT01724021-1,Arm A,NCT01724021,A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1  2 or 3a,myofascial pain syndrome
D009135,0.27,NCT01724021-2,Arm B,NCT01724021,A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1  2 or 3a,myopathy
D000077273,0.27,NCT01724021-2,Arm B,NCT01724021,A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1  2 or 3a,papillary thyroid cancer
D002292,0.27,NCT01724021-2,Arm B,NCT01724021,A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1  2 or 3a,renal cell cancer
D000077192,0.27,NCT01724021-2,Arm B,NCT01724021,A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1  2 or 3a,lung adenocarcinoma
D009369,0.27,NCT01724021-1,Arm A,NCT01724021,A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1  2 or 3a,neoplasm
D004244,0.54,NCT01724021-1,Arm A,NCT01724021,A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1  2 or 3a,dizziness
D013575,0.54,NCT01724021-1,Arm A,NCT01724021,A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1  2 or 3a,syncope
D013575,0.27,NCT01724021-2,Arm B,NCT01724021,A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1  2 or 3a,syncope
D003244,0.27,NCT01724021-2,Arm B,NCT01724021,A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1  2 or 3a,depressed level of consciousness
D000069280,0.27,NCT01724021-1,Arm A,NCT01724021,A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1  2 or 3a,intracranial electroencephalography
D006261,0.27,NCT01724021-1,Arm A,NCT01724021,A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1  2 or 3a,headache
D010291,0.27,NCT01724021-2,Arm B,NCT01724021,A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1  2 or 3a,hemiparesis
D020343,0.27,NCT01724021-2,Arm B,NCT01724021,A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1  2 or 3a,hypertensive encephalopathy
D010523,0.27,NCT01724021-2,Arm B,NCT01724021,A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1  2 or 3a,peripheral neuropathy
D020335,0.27,NCT01724021-2,Arm B,NCT01724021,A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1  2 or 3a,paraparesis
10034620,0.27,NCT01724021-2,Arm B,NCT01724021,A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1  2 or 3a,peripheral sensory neuropathy
D002546,0.27,NCT01724021-2,Arm B,NCT01724021,A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1  2 or 3a,ischemic attack transient
D015840,0.27,NCT01724021-1,Arm A,NCT01724021,A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1  2 or 3a,oculomotor nerve paralysis
D001927,0.27,NCT01724021-2,Arm B,NCT01724021,A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1  2 or 3a,encephalopathy
D001007,0.27,NCT01724021-2,Arm B,NCT01724021,A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1  2 or 3a,anxiety
D003863,0.27,NCT01724021-1,Arm A,NCT01724021,A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1  2 or 3a,depression
D003863,0.27,NCT01724021-2,Arm B,NCT01724021,A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1  2 or 3a,depression
10042464,0.27,NCT01724021-2,Arm B,NCT01724021,A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1  2 or 3a,suicide attempt
D000081015,0.27,NCT01724021-1,Arm A,NCT01724021,A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1  2 or 3a,ototoxicity
10062225,0.27,NCT01724021-2,Arm B,NCT01724021,A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1  2 or 3a,urinary tract pain
D058186,0.27,NCT01724021-1,Arm A,NCT01724021,A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1  2 or 3a,acute kidney injury
D058186,0.54,NCT01724021-2,Arm B,NCT01724021,A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1  2 or 3a,acute kidney injury
D011655,0.81,NCT01724021-1,Arm A,NCT01724021,A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1  2 or 3a,pulmonary embolism
D011655,0.27,NCT01724021-2,Arm B,NCT01724021,A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1  2 or 3a,pulmonary embolism
UNKNOWN-check-for-typo,0.54,NCT01724021-1,Arm A,NCT01724021,A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1  2 or 3a,D00
D017563,0.54,NCT01724021-1,Arm A,NCT01724021,A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1  2 or 3a,interstitial lung disease
D012128,0.27,NCT01724021-1,Arm A,NCT01724021,A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1  2 or 3a,acute respiratory distress syndrome
D001986,0.27,NCT01724021-1,Arm A,NCT01724021,A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1  2 or 3a,bronchospasm
D010996,0.27,NCT01724021-2,Arm B,NCT01724021,A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1  2 or 3a,pleural effusion
D012131,0.27,NCT01724021-2,Arm B,NCT01724021,A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1  2 or 3a,respiratory failure
D005076,0.54,NCT01724021-1,Arm A,NCT01724021,A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1  2 or 3a,rash
D005076,0.27,NCT01724021-2,Arm B,NCT01724021,A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1  2 or 3a,rash
D000799,0.27,NCT01724021-1,Arm A,NCT01724021,A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1  2 or 3a,angioedema
D011693,0.27,NCT01724021-1,Arm A,NCT01724021,A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1  2 or 3a,purpura
D013262,0.27,NCT01724021-2,Arm B,NCT01724021,A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1  2 or 3a,stevens johnson syndrome
D020246,0.81,NCT01724021-2,Arm B,NCT01724021,A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1  2 or 3a,deep vein thrombosis
D012769,0.27,NCT01724021-2,Arm B,NCT01724021,A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1  2 or 3a,circulatory collapse
D007024,0.27,NCT01724021-1,Arm A,NCT01724021,A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1  2 or 3a,orthostatic hypotension
D014657,0.27,NCT01724021-2,Arm B,NCT01724021,A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1  2 or 3a,vasculitis
D020246,0.27,NCT01724021-2,Arm B,NCT01724021,A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1  2 or 3a,venous thrombosis
D020246,0.27,NCT01724021-2,Arm B,NCT01724021,A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1  2 or 3a,venous thrombosis
D009026,72.22,NCT01769209-1,Bortezomib + Chemotherapy,NCT01769209,Bortezomib and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia,mortality
D064420,55.56,NCT01769209-1,Bortezomib + Chemotherapy,NCT01769209,Bortezomib and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia,adverse drug events
D064147,5.56,NCT01769209-1,Bortezomib + Chemotherapy,NCT01769209,Bortezomib and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia,febrile neutropenia
D004211,5.56,NCT01769209-1,Bortezomib + Chemotherapy,NCT01769209,Bortezomib and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia,disseminated intravascular coagulation
D003092,5.56,NCT01769209-1,Bortezomib + Chemotherapy,NCT01769209,Bortezomib and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia,colitis
D011668,5.56,NCT01769209-1,Bortezomib + Chemotherapy,NCT01769209,Bortezomib and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia,pulmonary venoocclusive disease
D012772,27.78,NCT01769209-1,Bortezomib + Chemotherapy,NCT01769209,Bortezomib and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia,shock septic
D020300,5.56,NCT01769209-1,Bortezomib + Chemotherapy,NCT01769209,Bortezomib and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia,intracranial hemorrhage
D009026,22.42,NCT01777152-1,A+CHP,NCT01777152,ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas,mortality
D009026,32.3,NCT01777152-2,CHOP,NCT01777152,ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas,mortality
D064420,39.01,NCT01777152-1,A+CHP,NCT01777152,ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas,adverse drug events
D064420,38.5,NCT01777152-2,CHOP,NCT01777152,ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas,adverse drug events
D064147,13.9,NCT01777152-1,A+CHP,NCT01777152,ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas,febrile neutropenia
D064147,11.5,NCT01777152-2,CHOP,NCT01777152,ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas,febrile neutropenia
D009503,3.59,NCT01777152-1,A+CHP,NCT01777152,ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas,neutropenia
D009503,2.65,NCT01777152-2,CHOP,NCT01777152,ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas,neutropenia
D000741,0.45,NCT01777152-1,A+CHP,NCT01777152,ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas,aplastic anaemia
D000741,0.44,NCT01777152-2,CHOP,NCT01777152,ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas,aplastic anaemia
D007970,0.45,NCT01777152-1,A+CHP,NCT01777152,ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas,leukopenia
D007970,1.33,NCT01777152-2,CHOP,NCT01777152,ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas,leukopenia
D000072281,0.45,NCT01777152-1,A+CHP,NCT01777152,ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas,lymphadenopathy
D008231,0.45,NCT01777152-1,A+CHP,NCT01777152,ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas,lymphopenia
D013921,0.45,NCT01777152-1,A+CHP,NCT01777152,ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas,thrombocytopenia
D013921,0.44,NCT01777152-2,CHOP,NCT01777152,ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas,thrombocytopenia
D010198,0.44,NCT01777152-2,CHOP,NCT01777152,ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas,pancytopenia
D001281,0.45,NCT01777152-1,A+CHP,NCT01777152,ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas,atrial fibrillation
D001281,0.44,NCT01777152-2,CHOP,NCT01777152,ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas,atrial fibrillation
D006323,0.45,NCT01777152-1,A+CHP,NCT01777152,ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas,cardiac arrest
D006323,0.44,NCT01777152-2,CHOP,NCT01777152,ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas,cardiac arrest
D013616,0.45,NCT01777152-1,A+CHP,NCT01777152,ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas,sinus tachycardia
D013617,0.45,NCT01777152-1,A+CHP,NCT01777152,ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas,supraventricular tachycardia
D013610,0.45,NCT01777152-1,A+CHP,NCT01777152,ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas,tachycardia
D013610,0.88,NCT01777152-2,CHOP,NCT01777152,ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas,tachycardia
D014693,0.45,NCT01777152-1,A+CHP,NCT01777152,ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas,ventricular fibrillation
D001145,0.44,NCT01777152-2,CHOP,NCT01777152,ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas,arrhythmia
D006333,0.44,NCT01777152-2,CHOP,NCT01777152,ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas,cardiac failure
UNKNOWN-check-for-typo,1.79,NCT01777152-1,A+CHP,NCT01777152,ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas,D00
UNKNOWN-check-for-typo,1.33,NCT01777152-2,CHOP,NCT01777152,ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas,D00
D015746,0.45,NCT01777152-1,A+CHP,NCT01777152,ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas,abdominal pain
D015746,0.44,NCT01777152-2,CHOP,NCT01777152,ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas,abdominal pain
D003248,0.45,NCT01777152-1,A+CHP,NCT01777152,ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas,constipation
D003248,0.44,NCT01777152-2,CHOP,NCT01777152,ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas,constipation
D004381,0.45,NCT01777152-1,A+CHP,NCT01777152,ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas,duodenal ulcer
D004382,0.45,NCT01777152-1,A+CHP,NCT01777152,ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas,duodenitis
D004760,0.45,NCT01777152-1,A+CHP,NCT01777152,ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas,enterocolitis
D004760,0.44,NCT01777152-2,CHOP,NCT01777152,ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas,enterocolitis
D006552,0.45,NCT01777152-1,A+CHP,NCT01777152,ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas,hernia inguinal
D007416,0.45,NCT01777152-1,A+CHP,NCT01777152,ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas,intestinal perforation
D009325,0.45,NCT01777152-1,A+CHP,NCT01777152,ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas,nausea
D009325,1.77,NCT01777152-2,CHOP,NCT01777152,ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas,nausea
D041742,0.45,NCT01777152-1,A+CHP,NCT01777152,ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas,upper gastrointestinal tract
D014839,0.45,NCT01777152-1,A+CHP,NCT01777152,ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas,vomiting
D014839,1.33,NCT01777152-2,CHOP,NCT01777152,ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas,vomiting
D003092,0.44,NCT01777152-2,CHOP,NCT01777152,ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas,colitis
D013276,0.88,NCT01777152-2,CHOP,NCT01777152,ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas,gastric ulcer
UNKNOWN-check-for-typo,0.44,NCT01777152-2,CHOP,NCT01777152,ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas,D00
D007415,0.44,NCT01777152-2,CHOP,NCT01777152,ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas,intestinal obstruction
D041741,0.44,NCT01777152-2,CHOP,NCT01777152,ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas,lower gastrointestinal tract
UNKNOWN-check-for-typo,0.44,NCT01777152-2,CHOP,NCT01777152,ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas,D00
10015461,0.44,NCT01777152-2,CHOP,NCT01777152,ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas,esophagitis
10041101,0.44,NCT01777152-2,CHOP,NCT01777152,ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas,small intestinal obstruction
D013280,0.88,NCT01777152-2,CHOP,NCT01777152,ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas,stomatitis
10021328,0.44,NCT01777152-2,CHOP,NCT01777152,ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas,ileus
D005334,4.04,NCT01777152-1,A+CHP,NCT01777152,ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas,pyrexia
D005334,3.1,NCT01777152-2,CHOP,NCT01777152,ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas,pyrexia
D001247,0.45,NCT01777152-1,A+CHP,NCT01777152,ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas,asthenia
D005119,0.45,NCT01777152-1,A+CHP,NCT01777152,ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas,extravasation of diagnostic and therapeutic materials
D005334,0.45,NCT01777152-1,A+CHP,NCT01777152,ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas,hyperthermia
D007249,0.45,NCT01777152-1,A+CHP,NCT01777152,ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas,inflammation
D007249,0.44,NCT01777152-2,CHOP,NCT01777152,ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas,inflammation
10062501,0.45,NCT01777152-1,A+CHP,NCT01777152,ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas,non-cardiac chest pain
D003643,0.44,NCT01777152-2,CHOP,NCT01777152,ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas,death
D009102,1.33,NCT01777152-2,CHOP,NCT01777152,ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas,multiple organ dysfunction syndrome
D011681,0.45,NCT01777152-1,A+CHP,NCT01777152,ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas,pupillary functions abnormal
D002761,0.44,NCT01777152-2,CHOP,NCT01777152,ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas,cholangitis
D011014,4.93,NCT01777152-1,A+CHP,NCT01777152,ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas,pneumonia
D011014,1.33,NCT01777152-2,CHOP,NCT01777152,ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas,pneumonia
D018805,2.24,NCT01777152-1,A+CHP,NCT01777152,ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas,sepsis
D018805,1.77,NCT01777152-2,CHOP,NCT01777152,ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas,sepsis
D002481,0.9,NCT01777152-1,A+CHP,NCT01777152,ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas,cellulitis
D004761,0.9,NCT01777152-1,A+CHP,NCT01777152,ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas,clostridium enterocolitis
10064687,0.9,NCT01777152-1,A+CHP,NCT01777152,ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas,device related infection
D007251,0.9,NCT01777152-1,A+CHP,NCT01777152,ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas,influenza
D000069544,0.9,NCT01777152-1,A+CHP,NCT01777152,ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas,encephalitis infection
D000069544,0.44,NCT01777152-2,CHOP,NCT01777152,ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas,encephalitis infection
D011020,0.9,NCT01777152-1,A+CHP,NCT01777152,ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas,pneumocystis jirovecii pneumonia
D014552,0.9,NCT01777152-1,A+CHP,NCT01777152,ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas,urinary tract infection
D012509,0.45,NCT01777152-1,A+CHP,NCT01777152,ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas,sarcoma soft tissue
D000069544,0.45,NCT01777152-1,A+CHP,NCT01777152,ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas,encephalitis infection
D011704,0.45,NCT01777152-1,A+CHP,NCT01777152,ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas,pyelonephritis
D000985,0.45,NCT01777152-1,A+CHP,NCT01777152,ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas,antisepsis
D055732,0.45,NCT01777152-1,A+CHP,NCT01777152,ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas,bronchopulmonary aspergillosis
D000077215,0.45,NCT01777152-1,A+CHP,NCT01777152,ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas,halloysite
D003015,0.45,NCT01777152-1,A+CHP,NCT01777152,ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas,clostridium difficile infection
D003586,0.45,NCT01777152-1,A+CHP,NCT01777152,ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas,cytomegalovirus infection
10058838,0.45,NCT01777152-1,A+CHP,NCT01777152,ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas,enterocolitis infectious
D020031,0.45,NCT01777152-1,A+CHP,NCT01777152,ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas,epstein barr virus infection
D053118,0.45,NCT01777152-1,A+CHP,NCT01777152,ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas,influenza a virus h1n1 subtype
D012883,0.45,NCT01777152-1,A+CHP,NCT01777152,ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas,skin ulcer
D007239,0.45,NCT01777152-1,A+CHP,NCT01777152,ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas,infection
D007239,0.44,NCT01777152-2,CHOP,NCT01777152,ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas,infection
D010272,0.45,NCT01777152-1,A+CHP,NCT01777152,ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas,parasite infections
10050823,0.45,NCT01777152-1,A+CHP,NCT01777152,ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas,lymph gland infection
D010032,0.45,NCT01777152-1,A+CHP,NCT01777152,ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas,otitis externa
D000038,0.45,NCT01777152-1,A+CHP,NCT01777152,ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas,abscess
D018357,0.45,NCT01777152-1,A+CHP,NCT01777152,ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas,respiratory syncytial virus infection
D012772,0.45,NCT01777152-1,A+CHP,NCT01777152,ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas,septic shock
D012772,0.88,NCT01777152-2,CHOP,NCT01777152,ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas,septic shock
D018461,0.45,NCT01777152-1,A+CHP,NCT01777152,ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas,soft tissue infection
D018461,0.44,NCT01777152-2,CHOP,NCT01777152,ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas,soft tissue infection
D013203,0.45,NCT01777152-1,A+CHP,NCT01777152,ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas,staphylococcal infection
D013203,0.88,NCT01777152-2,CHOP,NCT01777152,ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas,staphylococcal infection
D004886,0.44,NCT01777152-2,CHOP,NCT01777152,ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas,erysipelas
D000985,0.88,NCT01777152-2,CHOP,NCT01777152,ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas,antisepsis
D000038,0.44,NCT01777152-2,CHOP,NCT01777152,ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas,abscess
D007827,0.44,NCT01777152-2,CHOP,NCT01777152,ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas,laryngitis
D000985,1.33,NCT01777152-2,CHOP,NCT01777152,ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas,antisepsis
D000069544,0.44,NCT01777152-2,CHOP,NCT01777152,ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas,encephalitis infection
10040872,0.88,NCT01777152-2,CHOP,NCT01777152,ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas,skin infection
D000985,0.44,NCT01777152-2,CHOP,NCT01777152,ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas,antisepsis
D000985,0.44,NCT01777152-2,CHOP,NCT01777152,ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas,antisepsis
D012141,0.44,NCT01777152-2,CHOP,NCT01777152,ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas,upper respiratory tract infections
D013161,0.45,NCT01777152-1,A+CHP,NCT01777152,ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas,splenic rupture
10020100,0.44,NCT01777152-2,CHOP,NCT01777152,ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas,hip fracture
D016103,0.44,NCT01777152-2,CHOP,NCT01777152,ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas,spinal fractures
D013851,0.45,NCT01777152-1,A+CHP,NCT01777152,ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas,underweight
10016987,0.44,NCT01777152-2,CHOP,NCT01777152,ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas,forced expiratory volume decreased
D015275,1.35,NCT01777152-1,A+CHP,NCT01777152,ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas,tumour lysis syndrome
D003681,0.9,NCT01777152-1,A+CHP,NCT01777152,ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas,dehydration
D003681,1.33,NCT01777152-2,CHOP,NCT01777152,ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas,dehydration
D001066,0.45,NCT01777152-1,A+CHP,NCT01777152,ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas,appetite
D011205,0.45,NCT01777152-1,A+CHP,NCT01777152,ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas,unifluid
UNKNOWN-check-for-typo,0.45,NCT01777152-1,A+CHP,NCT01777152,ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas,D00
UNKNOWN-check-for-typo,0.44,NCT01777152-2,CHOP,NCT01777152,ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas,D00
UNKNOWN-check-for-typo,0.44,NCT01777152-2,CHOP,NCT01777152,ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas,D00
10006002,0.45,NCT01777152-1,A+CHP,NCT01777152,ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas,bone pain
10033425,0.45,NCT01777152-1,A+CHP,NCT01777152,ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas,pain in extremity
D018908,0.44,NCT01777152-2,CHOP,NCT01777152,ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas,muscular weakness
D013131,0.44,NCT01777152-2,CHOP,NCT01777152,ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas,vertebral column
D009182,0.45,NCT01777152-1,A+CHP,NCT01777152,ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas,mycosis fungoides
D000077273,0.45,NCT01777152-1,A+CHP,NCT01777152,ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas,papillary thyroid cancer
D016411,0.45,NCT01777152-1,A+CHP,NCT01777152,ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas,lymphoma t-cell peripheral
D018365,0.45,NCT01777152-1,A+CHP,NCT01777152,ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas,residual tumour
D017728,4.87,NCT01777152-2,CHOP,NCT01777152,ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas,lymphoma large-cell anaplastic
D000072716,0.44,NCT01777152-2,CHOP,NCT01777152,ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas,cancer pain
D002490,0.88,NCT01777152-2,CHOP,NCT01777152,ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas,central nervous system
D002295,0.44,NCT01777152-2,CHOP,NCT01777152,ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas,transitional cell carcinoma
D005334,0.44,NCT01777152-2,CHOP,NCT01777152,ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas,fever
10034620,0.9,NCT01777152-1,A+CHP,NCT01777152,ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas,peripheral sensory neuropathy
D004244,0.45,NCT01777152-1,A+CHP,NCT01777152,ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas,dizziness
D006261,0.45,NCT01777152-1,A+CHP,NCT01777152,ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas,headache
10034580,0.45,NCT01777152-1,A+CHP,NCT01777152,ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas,peripheral motor neuropathy
D012640,0.45,NCT01777152-1,A+CHP,NCT01777152,ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas,seizure
D012640,0.44,NCT01777152-2,CHOP,NCT01777152,ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas,seizure
D013575,0.45,NCT01777152-1,A+CHP,NCT01777152,ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas,syncope
D003929,0.44,NCT01777152-2,CHOP,NCT01777152,ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas,diabetic autonomic neuropathy
D002544,0.44,NCT01777152-2,CHOP,NCT01777152,ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas,cerebral infarction
D006849,0.44,NCT01777152-2,CHOP,NCT01777152,ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas,hydrocephalus
D019585,0.44,NCT01777152-2,CHOP,NCT01777152,ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas,intracranial hypotension
UNKNOWN-check-for-typo,0.44,NCT01777152-2,CHOP,NCT01777152,ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas,D00
D015625,0.44,NCT01777152-2,CHOP,NCT01777152,ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas,tissue expansion devices
D000073216,0.45,NCT01777152-1,A+CHP,NCT01777152,ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas,mental status tests
D003221,0.44,NCT01777152-2,CHOP,NCT01777152,ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas,confusional state
D058186,1.35,NCT01777152-1,A+CHP,NCT01777152,ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas,acute kidney injury
UNKNOWN-check-for-typo,0.45,NCT01777152-1,A+CHP,NCT01777152,ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas,D00
UNKNOWN-check-for-typo,0.44,NCT01777152-2,CHOP,NCT01777152,ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas,D00
D051437,0.45,NCT01777152-1,A+CHP,NCT01777152,ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas,renal failure
D051437,0.44,NCT01777152-2,CHOP,NCT01777152,ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas,renal failure
D016055,0.45,NCT01777152-1,A+CHP,NCT01777152,ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas,urinary retention
D009846,0.44,NCT01777152-2,CHOP,NCT01777152,ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas,oliguria
D011014,2.24,NCT01777152-1,A+CHP,NCT01777152,ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas,pneumonitis
D012131,1.35,NCT01777152-1,A+CHP,NCT01777152,ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas,respiratory failure
D012131,0.88,NCT01777152-2,CHOP,NCT01777152,ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas,respiratory failure
D011655,0.9,NCT01777152-1,A+CHP,NCT01777152,ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas,pulmonary embolism
D011655,2.21,NCT01777152-2,CHOP,NCT01777152,ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas,pulmonary embolism
D012131,0.45,NCT01777152-1,A+CHP,NCT01777152,ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas,respiratory failure
D003371,0.45,NCT01777152-1,A+CHP,NCT01777152,ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas,cough
UNKNOWN-check-for-typo,0.45,NCT01777152-1,A+CHP,NCT01777152,ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas,D00
UNKNOWN-check-for-typo,0.45,NCT01777152-1,A+CHP,NCT01777152,ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas,D00
D010996,0.45,NCT01777152-1,A+CHP,NCT01777152,ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas,pleural effusion
D011015,0.45,NCT01777152-1,A+CHP,NCT01777152,ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas,aspiration pneumonia
D001261,0.45,NCT01777152-1,A+CHP,NCT01777152,ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas,pulmonary atelectasis
D012128,0.44,NCT01777152-2,CHOP,NCT01777152,ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas,acute respiratory distress syndrome
D005076,0.45,NCT01777152-1,A+CHP,NCT01777152,ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas,rash
10037868,0.45,NCT01777152-1,A+CHP,NCT01777152,ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas,rash maculo-papular
D001768,0.44,NCT01777152-2,CHOP,NCT01777152,ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas,blister
D020246,1.35,NCT01777152-1,A+CHP,NCT01777152,ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas,deep vein thrombosis
D020246,0.88,NCT01777152-2,CHOP,NCT01777152,ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas,deep vein thrombosis
D004617,0.45,NCT01777152-1,A+CHP,NCT01777152,ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas,embolism
D007022,0.45,NCT01777152-1,A+CHP,NCT01777152,ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas,hypotension
D007022,0.44,NCT01777152-2,CHOP,NCT01777152,ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas,hypotension
10042554,0.44,NCT01777152-2,CHOP,NCT01777152,ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas,superficial thrombophlebitis
D064420,40.0,NCT01798134-1,DEB-TACE,NCT01798134,Microparticle Enhanced Cytotoxic Transarterial Embolization Therapy in Hepatocellular Carcinoma,adverse drug events
D000741,4.0,NCT01798134-1,DEB-TACE,NCT01798134,Microparticle Enhanced Cytotoxic Transarterial Embolization Therapy in Hepatocellular Carcinoma,aplastic anaemia
D000787,4.0,NCT01798134-1,DEB-TACE,NCT01798134,Microparticle Enhanced Cytotoxic Transarterial Embolization Therapy in Hepatocellular Carcinoma,angina pectoris
D006333,4.0,NCT01798134-1,DEB-TACE,NCT01798134,Microparticle Enhanced Cytotoxic Transarterial Embolization Therapy in Hepatocellular Carcinoma,cardiac failure
D005756,4.0,NCT01798134-1,DEB-TACE,NCT01798134,Microparticle Enhanced Cytotoxic Transarterial Embolization Therapy in Hepatocellular Carcinoma,gastritis
D000074042,4.0,NCT01798134-1,DEB-TACE,NCT01798134,Microparticle Enhanced Cytotoxic Transarterial Embolization Therapy in Hepatocellular Carcinoma,cerebral intraventricular haemorrhage
D050686,4.0,NCT01798134-1,DEB-TACE,NCT01798134,Microparticle Enhanced Cytotoxic Transarterial Embolization Therapy in Hepatocellular Carcinoma,globicephala melaena
D001201,4.0,NCT01798134-1,DEB-TACE,NCT01798134,Microparticle Enhanced Cytotoxic Transarterial Embolization Therapy in Hepatocellular Carcinoma,ascites
D017093,4.0,NCT01798134-1,DEB-TACE,NCT01798134,Microparticle Enhanced Cytotoxic Transarterial Embolization Therapy in Hepatocellular Carcinoma,hepatic failure
10019692,4.0,NCT01798134-1,DEB-TACE,NCT01798134,Microparticle Enhanced Cytotoxic Transarterial Embolization Therapy in Hepatocellular Carcinoma,hepatic necrosis
D008100,4.0,NCT01798134-1,DEB-TACE,NCT01798134,Microparticle Enhanced Cytotoxic Transarterial Embolization Therapy in Hepatocellular Carcinoma,liver abscess
D018805,4.0,NCT01798134-1,DEB-TACE,NCT01798134,Microparticle Enhanced Cytotoxic Transarterial Embolization Therapy in Hepatocellular Carcinoma,sepsis
D010538,4.0,NCT01798134-1,DEB-TACE,NCT01798134,Microparticle Enhanced Cytotoxic Transarterial Embolization Therapy in Hepatocellular Carcinoma,peritonitis
D014552,4.0,NCT01798134-1,DEB-TACE,NCT01798134,Microparticle Enhanced Cytotoxic Transarterial Embolization Therapy in Hepatocellular Carcinoma,urinary tract infection
D013124,4.0,NCT01798134-1,DEB-TACE,NCT01798134,Microparticle Enhanced Cytotoxic Transarterial Embolization Therapy in Hepatocellular Carcinoma,injury spinal
D007989,4.0,NCT01798134-1,DEB-TACE,NCT01798134,Microparticle Enhanced Cytotoxic Transarterial Embolization Therapy in Hepatocellular Carcinoma,decreased libido
D006501,4.0,NCT01798134-1,DEB-TACE,NCT01798134,Microparticle Enhanced Cytotoxic Transarterial Embolization Therapy in Hepatocellular Carcinoma,hepatic encephalopathy
D001259,4.0,NCT01798134-1,DEB-TACE,NCT01798134,Microparticle Enhanced Cytotoxic Transarterial Embolization Therapy in Hepatocellular Carcinoma,ataxia
D003221,4.0,NCT01798134-1,DEB-TACE,NCT01798134,Microparticle Enhanced Cytotoxic Transarterial Embolization Therapy in Hepatocellular Carcinoma,confusional state
UNKNOWN-check-for-typo,4.0,NCT01798134-1,DEB-TACE,NCT01798134,Microparticle Enhanced Cytotoxic Transarterial Embolization Therapy in Hepatocellular Carcinoma,D00
D012883,4.0,NCT01798134-1,DEB-TACE,NCT01798134,Microparticle Enhanced Cytotoxic Transarterial Embolization Therapy in Hepatocellular Carcinoma,skin ulcer
D007022,4.0,NCT01798134-1,DEB-TACE,NCT01798134,Microparticle Enhanced Cytotoxic Transarterial Embolization Therapy in Hepatocellular Carcinoma,hypotension
D064420,7.14,NCT01840943-1,CAELYX,NCT01840943,A Study to Compare CAELYX With Topotecan HCL in Patients With Recurrent Epithelial Ovarian Carcinoma Following Failure of First-Line  Platinum-Based Chemotherapy,adverse drug events
D064420,8.33,NCT01840943-2,Topotecan Hydrocloride (HCl),NCT01840943,A Study to Compare CAELYX With Topotecan HCL in Patients With Recurrent Epithelial Ovarian Carcinoma Following Failure of First-Line  Platinum-Based Chemotherapy,adverse drug events
D014397,7.14,NCT01840943-1,CAELYX,NCT01840943,A Study to Compare CAELYX With Topotecan HCL in Patients With Recurrent Epithelial Ovarian Carcinoma Following Failure of First-Line  Platinum-Based Chemotherapy,pulmonary tuberculosis
10035528,8.33,NCT01840943-2,Topotecan Hydrocloride (HCl),NCT01840943,A Study to Compare CAELYX With Topotecan HCL in Patients With Recurrent Epithelial Ovarian Carcinoma Following Failure of First-Line  Platinum-Based Chemotherapy,platelet count decreased
D009026,20.0,NCT01887587-1,(Modified VXLD) Plus MLN9708,NCT01887587,Vincristine  Doxorubicin  And Dexamethasone + Ixazomib in Acute Lymphoblastic Leukemia (ALL)  Lymphoblastic Lymphoma Or Mixed Phenotype Acute Leukemia,mortality
D064420,80.0,NCT01887587-1,(Modified VXLD) Plus MLN9708,NCT01887587,Vincristine  Doxorubicin  And Dexamethasone + Ixazomib in Acute Lymphoblastic Leukemia (ALL)  Lymphoblastic Lymphoma Or Mixed Phenotype Acute Leukemia,adverse drug events
D064147,20.0,NCT01887587-1,(Modified VXLD) Plus MLN9708,NCT01887587,Vincristine  Doxorubicin  And Dexamethasone + Ixazomib in Acute Lymphoblastic Leukemia (ALL)  Lymphoblastic Lymphoma Or Mixed Phenotype Acute Leukemia,febrile neutropenia
D013616,20.0,NCT01887587-1,(Modified VXLD) Plus MLN9708,NCT01887587,Vincristine  Doxorubicin  And Dexamethasone + Ixazomib in Acute Lymphoblastic Leukemia (ALL)  Lymphoblastic Lymphoma Or Mixed Phenotype Acute Leukemia,sinus tachycardia
D000140,20.0,NCT01887587-1,(Modified VXLD) Plus MLN9708,NCT01887587,Vincristine  Doxorubicin  And Dexamethasone + Ixazomib in Acute Lymphoblastic Leukemia (ALL)  Lymphoblastic Lymphoma Or Mixed Phenotype Acute Leukemia,lactic acidosis
10005364,20.0,NCT01887587-1,(Modified VXLD) Plus MLN9708,NCT01887587,Vincristine  Doxorubicin  And Dexamethasone + Ixazomib in Acute Lymphoblastic Leukemia (ALL)  Lymphoblastic Lymphoma Or Mixed Phenotype Acute Leukemia,blood bilirubin increased
D018805,60.0,NCT01887587-1,(Modified VXLD) Plus MLN9708,NCT01887587,Vincristine  Doxorubicin  And Dexamethasone + Ixazomib in Acute Lymphoblastic Leukemia (ALL)  Lymphoblastic Lymphoma Or Mixed Phenotype Acute Leukemia,sepsis
D008708,20.0,NCT01887587-1,(Modified VXLD) Plus MLN9708,NCT01887587,Vincristine  Doxorubicin  And Dexamethasone + Ixazomib in Acute Lymphoblastic Leukemia (ALL)  Lymphoblastic Lymphoma Or Mixed Phenotype Acute Leukemia,methemoglobinemia
D007022,20.0,NCT01887587-1,(Modified VXLD) Plus MLN9708,NCT01887587,Vincristine  Doxorubicin  And Dexamethasone + Ixazomib in Acute Lymphoblastic Leukemia (ALL)  Lymphoblastic Lymphoma Or Mixed Phenotype Acute Leukemia,hypotension
D009026,19.44,NCT01889069-1,Diffuse Large B-Cell Lymphoma (DLBCL),NCT01889069,A Study to Evaluate Safety  Efficacy and Pharmacokinetics of Rituximab (MabThera/Rituxan) in Participants With Diffuse Large B Cell Lymphoma (DLBCL) or Follicular Lymphoma (FL),mortality
D009026,4.65,NCT01889069-2,Follicular Lymphoma (FL),NCT01889069,A Study to Evaluate Safety  Efficacy and Pharmacokinetics of Rituximab (MabThera/Rituxan) in Participants With Diffuse Large B Cell Lymphoma (DLBCL) or Follicular Lymphoma (FL),mortality
D064420,36.11,NCT01889069-1,Diffuse Large B-Cell Lymphoma (DLBCL),NCT01889069,A Study to Evaluate Safety  Efficacy and Pharmacokinetics of Rituximab (MabThera/Rituxan) in Participants With Diffuse Large B Cell Lymphoma (DLBCL) or Follicular Lymphoma (FL),adverse drug events
D064420,26.74,NCT01889069-2,Follicular Lymphoma (FL),NCT01889069,A Study to Evaluate Safety  Efficacy and Pharmacokinetics of Rituximab (MabThera/Rituxan) in Participants With Diffuse Large B Cell Lymphoma (DLBCL) or Follicular Lymphoma (FL),adverse drug events
D009503,20.83,NCT01889069-1,Diffuse Large B-Cell Lymphoma (DLBCL),NCT01889069,A Study to Evaluate Safety  Efficacy and Pharmacokinetics of Rituximab (MabThera/Rituxan) in Participants With Diffuse Large B Cell Lymphoma (DLBCL) or Follicular Lymphoma (FL),neutropenia
D009503,15.12,NCT01889069-2,Follicular Lymphoma (FL),NCT01889069,A Study to Evaluate Safety  Efficacy and Pharmacokinetics of Rituximab (MabThera/Rituxan) in Participants With Diffuse Large B Cell Lymphoma (DLBCL) or Follicular Lymphoma (FL),neutropenia
D064147,5.56,NCT01889069-1,Diffuse Large B-Cell Lymphoma (DLBCL),NCT01889069,A Study to Evaluate Safety  Efficacy and Pharmacokinetics of Rituximab (MabThera/Rituxan) in Participants With Diffuse Large B Cell Lymphoma (DLBCL) or Follicular Lymphoma (FL),febrile neutropenia
D064147,2.33,NCT01889069-2,Follicular Lymphoma (FL),NCT01889069,A Study to Evaluate Safety  Efficacy and Pharmacokinetics of Rituximab (MabThera/Rituxan) in Participants With Diffuse Large B Cell Lymphoma (DLBCL) or Follicular Lymphoma (FL),febrile neutropenia
D007970,1.39,NCT01889069-1,Diffuse Large B-Cell Lymphoma (DLBCL),NCT01889069,A Study to Evaluate Safety  Efficacy and Pharmacokinetics of Rituximab (MabThera/Rituxan) in Participants With Diffuse Large B Cell Lymphoma (DLBCL) or Follicular Lymphoma (FL),leukopenia
D007970,1.16,NCT01889069-2,Follicular Lymphoma (FL),NCT01889069,A Study to Evaluate Safety  Efficacy and Pharmacokinetics of Rituximab (MabThera/Rituxan) in Participants With Diffuse Large B Cell Lymphoma (DLBCL) or Follicular Lymphoma (FL),leukopenia
D008231,2.33,NCT01889069-2,Follicular Lymphoma (FL),NCT01889069,A Study to Evaluate Safety  Efficacy and Pharmacokinetics of Rituximab (MabThera/Rituxan) in Participants With Diffuse Large B Cell Lymphoma (DLBCL) or Follicular Lymphoma (FL),lymphopenia
D013921,2.33,NCT01889069-2,Follicular Lymphoma (FL),NCT01889069,A Study to Evaluate Safety  Efficacy and Pharmacokinetics of Rituximab (MabThera/Rituxan) in Participants With Diffuse Large B Cell Lymphoma (DLBCL) or Follicular Lymphoma (FL),thrombocytopenia
D054058,1.39,NCT01889069-1,Diffuse Large B-Cell Lymphoma (DLBCL),NCT01889069,A Study to Evaluate Safety  Efficacy and Pharmacokinetics of Rituximab (MabThera/Rituxan) in Participants With Diffuse Large B Cell Lymphoma (DLBCL) or Follicular Lymphoma (FL),acute coronary syndrome
D054058,1.16,NCT01889069-2,Follicular Lymphoma (FL),NCT01889069,A Study to Evaluate Safety  Efficacy and Pharmacokinetics of Rituximab (MabThera/Rituxan) in Participants With Diffuse Large B Cell Lymphoma (DLBCL) or Follicular Lymphoma (FL),acute coronary syndrome
D006333,1.39,NCT01889069-1,Diffuse Large B-Cell Lymphoma (DLBCL),NCT01889069,A Study to Evaluate Safety  Efficacy and Pharmacokinetics of Rituximab (MabThera/Rituxan) in Participants With Diffuse Large B Cell Lymphoma (DLBCL) or Follicular Lymphoma (FL),cardiac failure
D009205,1.16,NCT01889069-2,Follicular Lymphoma (FL),NCT01889069,A Study to Evaluate Safety  Efficacy and Pharmacokinetics of Rituximab (MabThera/Rituxan) in Participants With Diffuse Large B Cell Lymphoma (DLBCL) or Follicular Lymphoma (FL),myocarditis
D013616,1.39,NCT01889069-1,Diffuse Large B-Cell Lymphoma (DLBCL),NCT01889069,A Study to Evaluate Safety  Efficacy and Pharmacokinetics of Rituximab (MabThera/Rituxan) in Participants With Diffuse Large B Cell Lymphoma (DLBCL) or Follicular Lymphoma (FL),sinus tachycardia
10021328,1.39,NCT01889069-1,Diffuse Large B-Cell Lymphoma (DLBCL),NCT01889069,A Study to Evaluate Safety  Efficacy and Pharmacokinetics of Rituximab (MabThera/Rituxan) in Participants With Diffuse Large B Cell Lymphoma (DLBCL) or Follicular Lymphoma (FL),ileus
D002637,1.16,NCT01889069-2,Follicular Lymphoma (FL),NCT01889069,A Study to Evaluate Safety  Efficacy and Pharmacokinetics of Rituximab (MabThera/Rituxan) in Participants With Diffuse Large B Cell Lymphoma (DLBCL) or Follicular Lymphoma (FL),chest pain
D041881,2.33,NCT01889069-2,Follicular Lymphoma (FL),NCT01889069,A Study to Evaluate Safety  Efficacy and Pharmacokinetics of Rituximab (MabThera/Rituxan) in Participants With Diffuse Large B Cell Lymphoma (DLBCL) or Follicular Lymphoma (FL),acute cholecystitis
D002769,2.33,NCT01889069-2,Follicular Lymphoma (FL),NCT01889069,A Study to Evaluate Safety  Efficacy and Pharmacokinetics of Rituximab (MabThera/Rituxan) in Participants With Diffuse Large B Cell Lymphoma (DLBCL) or Follicular Lymphoma (FL),cholelithiasis
D011014,2.78,NCT01889069-1,Diffuse Large B-Cell Lymphoma (DLBCL),NCT01889069,A Study to Evaluate Safety  Efficacy and Pharmacokinetics of Rituximab (MabThera/Rituxan) in Participants With Diffuse Large B Cell Lymphoma (DLBCL) or Follicular Lymphoma (FL),pneumonia
D007710,1.39,NCT01889069-1,Diffuse Large B-Cell Lymphoma (DLBCL),NCT01889069,A Study to Evaluate Safety  Efficacy and Pharmacokinetics of Rituximab (MabThera/Rituxan) in Participants With Diffuse Large B Cell Lymphoma (DLBCL) or Follicular Lymphoma (FL),klebsiella infection
D000069544,1.39,NCT01889069-1,Diffuse Large B-Cell Lymphoma (DLBCL),NCT01889069,A Study to Evaluate Safety  Efficacy and Pharmacokinetics of Rituximab (MabThera/Rituxan) in Participants With Diffuse Large B Cell Lymphoma (DLBCL) or Follicular Lymphoma (FL),encephalitis infection
D011020,1.16,NCT01889069-2,Follicular Lymphoma (FL),NCT01889069,A Study to Evaluate Safety  Efficacy and Pharmacokinetics of Rituximab (MabThera/Rituxan) in Participants With Diffuse Large B Cell Lymphoma (DLBCL) or Follicular Lymphoma (FL),pneumocystis jirovecii pneumonia
D012772,1.39,NCT01889069-1,Diffuse Large B-Cell Lymphoma (DLBCL),NCT01889069,A Study to Evaluate Safety  Efficacy and Pharmacokinetics of Rituximab (MabThera/Rituxan) in Participants With Diffuse Large B Cell Lymphoma (DLBCL) or Follicular Lymphoma (FL),septic shock
D013203,1.39,NCT01889069-1,Diffuse Large B-Cell Lymphoma (DLBCL),NCT01889069,A Study to Evaluate Safety  Efficacy and Pharmacokinetics of Rituximab (MabThera/Rituxan) in Participants With Diffuse Large B Cell Lymphoma (DLBCL) or Follicular Lymphoma (FL),staphylococcal infection
D000070600,1.16,NCT01889069-2,Follicular Lymphoma (FL),NCT01889069,A Study to Evaluate Safety  Efficacy and Pharmacokinetics of Rituximab (MabThera/Rituxan) in Participants With Diffuse Large B Cell Lymphoma (DLBCL) or Follicular Lymphoma (FL),injury tibial meniscus
10029366,6.94,NCT01889069-1,Diffuse Large B-Cell Lymphoma (DLBCL),NCT01889069,A Study to Evaluate Safety  Efficacy and Pharmacokinetics of Rituximab (MabThera/Rituxan) in Participants With Diffuse Large B Cell Lymphoma (DLBCL) or Follicular Lymphoma (FL),neutrophil count decreased
10029366,1.16,NCT01889069-2,Follicular Lymphoma (FL),NCT01889069,A Study to Evaluate Safety  Efficacy and Pharmacokinetics of Rituximab (MabThera/Rituxan) in Participants With Diffuse Large B Cell Lymphoma (DLBCL) or Follicular Lymphoma (FL),neutrophil count decreased
D007958,2.78,NCT01889069-1,Diffuse Large B-Cell Lymphoma (DLBCL),NCT01889069,A Study to Evaluate Safety  Efficacy and Pharmacokinetics of Rituximab (MabThera/Rituxan) in Participants With Diffuse Large B Cell Lymphoma (DLBCL) or Follicular Lymphoma (FL),blood cell count white
D003920,1.16,NCT01889069-2,Follicular Lymphoma (FL),NCT01889069,A Study to Evaluate Safety  Efficacy and Pharmacokinetics of Rituximab (MabThera/Rituxan) in Participants With Diffuse Large B Cell Lymphoma (DLBCL) or Follicular Lymphoma (FL),diabetes mellitus
UNKNOWN-check-for-typo,1.39,NCT01889069-1,Diffuse Large B-Cell Lymphoma (DLBCL),NCT01889069,A Study to Evaluate Safety  Efficacy and Pharmacokinetics of Rituximab (MabThera/Rituxan) in Participants With Diffuse Large B Cell Lymphoma (DLBCL) or Follicular Lymphoma (FL),D00
D018771,1.39,NCT01889069-1,Diffuse Large B-Cell Lymphoma (DLBCL),NCT01889069,A Study to Evaluate Safety  Efficacy and Pharmacokinetics of Rituximab (MabThera/Rituxan) in Participants With Diffuse Large B Cell Lymphoma (DLBCL) or Follicular Lymphoma (FL),arthralgia
D011470,1.16,NCT01889069-2,Follicular Lymphoma (FL),NCT01889069,A Study to Evaluate Safety  Efficacy and Pharmacokinetics of Rituximab (MabThera/Rituxan) in Participants With Diffuse Large B Cell Lymphoma (DLBCL) or Follicular Lymphoma (FL),prostatic adenoma
D010291,1.16,NCT01889069-2,Follicular Lymphoma (FL),NCT01889069,A Study to Evaluate Safety  Efficacy and Pharmacokinetics of Rituximab (MabThera/Rituxan) in Participants With Diffuse Large B Cell Lymphoma (DLBCL) or Follicular Lymphoma (FL),monoparesis
D013575,1.39,NCT01889069-1,Diffuse Large B-Cell Lymphoma (DLBCL),NCT01889069,A Study to Evaluate Safety  Efficacy and Pharmacokinetics of Rituximab (MabThera/Rituxan) in Participants With Diffuse Large B Cell Lymphoma (DLBCL) or Follicular Lymphoma (FL),syncope
D000400,1.16,NCT01889069-2,Follicular Lymphoma (FL),NCT01889069,A Study to Evaluate Safety  Efficacy and Pharmacokinetics of Rituximab (MabThera/Rituxan) in Participants With Diffuse Large B Cell Lymphoma (DLBCL) or Follicular Lymphoma (FL),swimbladder
D002916,1.39,NCT01889069-1,Diffuse Large B-Cell Lymphoma (DLBCL),NCT01889069,A Study to Evaluate Safety  Efficacy and Pharmacokinetics of Rituximab (MabThera/Rituxan) in Participants With Diffuse Large B Cell Lymphoma (DLBCL) or Follicular Lymphoma (FL),chylothorax
D011014,1.39,NCT01889069-1,Diffuse Large B-Cell Lymphoma (DLBCL),NCT01889069,A Study to Evaluate Safety  Efficacy and Pharmacokinetics of Rituximab (MabThera/Rituxan) in Participants With Diffuse Large B Cell Lymphoma (DLBCL) or Follicular Lymphoma (FL),pneumonitis
D012131,1.39,NCT01889069-1,Diffuse Large B-Cell Lymphoma (DLBCL),NCT01889069,A Study to Evaluate Safety  Efficacy and Pharmacokinetics of Rituximab (MabThera/Rituxan) in Participants With Diffuse Large B Cell Lymphoma (DLBCL) or Follicular Lymphoma (FL),respiratory failure
D006973,1.39,NCT01889069-1,Diffuse Large B-Cell Lymphoma (DLBCL),NCT01889069,A Study to Evaluate Safety  Efficacy and Pharmacokinetics of Rituximab (MabThera/Rituxan) in Participants With Diffuse Large B Cell Lymphoma (DLBCL) or Follicular Lymphoma (FL),hypertension
D009026,3.45,NCT01925612-1,Part 1: BV(1.2 mg/kg) + RCHOP,NCT01925612,Study of Brentuximab Vedotin Combined With RCHOP or RCHP in Front-line Treatment of Patients With Diffuse Large B-cell Lymphoma (DLBCL),mortality
D009026,9.09,NCT01925612-2,Part 1: BV(1.8 mg/kg) + RCHOP,NCT01925612,Study of Brentuximab Vedotin Combined With RCHOP or RCHP in Front-line Treatment of Patients With Diffuse Large B-cell Lymphoma (DLBCL),mortality
D009026,9.09,NCT01925612-4,Part 3: BV(1.8 mg/kg) + RCHP,NCT01925612,Study of Brentuximab Vedotin Combined With RCHOP or RCHP in Front-line Treatment of Patients With Diffuse Large B-cell Lymphoma (DLBCL),mortality
D009026,16.67,NCT01925612-5,Part 3: RCHOP,NCT01925612,Study of Brentuximab Vedotin Combined With RCHOP or RCHP in Front-line Treatment of Patients With Diffuse Large B-cell Lymphoma (DLBCL),mortality
D064420,55.17,NCT01925612-1,Part 1: BV(1.2 mg/kg) + RCHOP,NCT01925612,Study of Brentuximab Vedotin Combined With RCHOP or RCHP in Front-line Treatment of Patients With Diffuse Large B-cell Lymphoma (DLBCL),adverse drug events
D064420,63.64,NCT01925612-2,Part 1: BV(1.8 mg/kg) + RCHOP,NCT01925612,Study of Brentuximab Vedotin Combined With RCHOP or RCHP in Front-line Treatment of Patients With Diffuse Large B-cell Lymphoma (DLBCL),adverse drug events
D064420,45.45,NCT01925612-3,Part 2: BV(1.8 mg/kg) + RCHP,NCT01925612,Study of Brentuximab Vedotin Combined With RCHOP or RCHP in Front-line Treatment of Patients With Diffuse Large B-cell Lymphoma (DLBCL),adverse drug events
D064420,36.36,NCT01925612-4,Part 3: BV(1.8 mg/kg) + RCHP,NCT01925612,Study of Brentuximab Vedotin Combined With RCHOP or RCHP in Front-line Treatment of Patients With Diffuse Large B-cell Lymphoma (DLBCL),adverse drug events
D064420,33.33,NCT01925612-5,Part 3: RCHOP,NCT01925612,Study of Brentuximab Vedotin Combined With RCHOP or RCHP in Front-line Treatment of Patients With Diffuse Large B-cell Lymphoma (DLBCL),adverse drug events
D064147,27.59,NCT01925612-1,Part 1: BV(1.2 mg/kg) + RCHOP,NCT01925612,Study of Brentuximab Vedotin Combined With RCHOP or RCHP in Front-line Treatment of Patients With Diffuse Large B-cell Lymphoma (DLBCL),febrile neutropenia
D064147,36.36,NCT01925612-2,Part 1: BV(1.8 mg/kg) + RCHOP,NCT01925612,Study of Brentuximab Vedotin Combined With RCHOP or RCHP in Front-line Treatment of Patients With Diffuse Large B-cell Lymphoma (DLBCL),febrile neutropenia
D064147,18.18,NCT01925612-3,Part 2: BV(1.8 mg/kg) + RCHP,NCT01925612,Study of Brentuximab Vedotin Combined With RCHOP or RCHP in Front-line Treatment of Patients With Diffuse Large B-cell Lymphoma (DLBCL),febrile neutropenia
D064147,8.33,NCT01925612-5,Part 3: RCHOP,NCT01925612,Study of Brentuximab Vedotin Combined With RCHOP or RCHP in Front-line Treatment of Patients With Diffuse Large B-cell Lymphoma (DLBCL),febrile neutropenia
D009503,6.9,NCT01925612-1,Part 1: BV(1.2 mg/kg) + RCHOP,NCT01925612,Study of Brentuximab Vedotin Combined With RCHOP or RCHP in Front-line Treatment of Patients With Diffuse Large B-cell Lymphoma (DLBCL),neutropenia
D009503,4.55,NCT01925612-2,Part 1: BV(1.8 mg/kg) + RCHOP,NCT01925612,Study of Brentuximab Vedotin Combined With RCHOP or RCHP in Front-line Treatment of Patients With Diffuse Large B-cell Lymphoma (DLBCL),neutropenia
D000741,8.33,NCT01925612-5,Part 3: RCHOP,NCT01925612,Study of Brentuximab Vedotin Combined With RCHOP or RCHP in Front-line Treatment of Patients With Diffuse Large B-cell Lymphoma (DLBCL),aplastic anaemia
D010198,3.45,NCT01925612-1,Part 1: BV(1.2 mg/kg) + RCHOP,NCT01925612,Study of Brentuximab Vedotin Combined With RCHOP or RCHP in Front-line Treatment of Patients With Diffuse Large B-cell Lymphoma (DLBCL),pancytopenia
D010198,9.09,NCT01925612-4,Part 3: BV(1.8 mg/kg) + RCHP,NCT01925612,Study of Brentuximab Vedotin Combined With RCHOP or RCHP in Front-line Treatment of Patients With Diffuse Large B-cell Lymphoma (DLBCL),pancytopenia
D001281,9.09,NCT01925612-4,Part 3: BV(1.8 mg/kg) + RCHP,NCT01925612,Study of Brentuximab Vedotin Combined With RCHOP or RCHP in Front-line Treatment of Patients With Diffuse Large B-cell Lymphoma (DLBCL),atrial fibrillation
D006323,9.09,NCT01925612-4,Part 3: BV(1.8 mg/kg) + RCHP,NCT01925612,Study of Brentuximab Vedotin Combined With RCHOP or RCHP in Front-line Treatment of Patients With Diffuse Large B-cell Lymphoma (DLBCL),cardiac arrest
D006333,6.9,NCT01925612-1,Part 1: BV(1.2 mg/kg) + RCHOP,NCT01925612,Study of Brentuximab Vedotin Combined With RCHOP or RCHP in Front-line Treatment of Patients With Diffuse Large B-cell Lymphoma (DLBCL),cardiac failure
D009202,3.45,NCT01925612-1,Part 1: BV(1.2 mg/kg) + RCHOP,NCT01925612,Study of Brentuximab Vedotin Combined With RCHOP or RCHP in Front-line Treatment of Patients With Diffuse Large B-cell Lymphoma (DLBCL),cardiomyopathy
D018487,3.45,NCT01925612-1,Part 1: BV(1.2 mg/kg) + RCHOP,NCT01925612,Study of Brentuximab Vedotin Combined With RCHOP or RCHP in Front-line Treatment of Patients With Diffuse Large B-cell Lymphoma (DLBCL),left ventricular dysfunction
D014786,3.45,NCT01925612-1,Part 1: BV(1.2 mg/kg) + RCHOP,NCT01925612,Study of Brentuximab Vedotin Combined With RCHOP or RCHP in Front-line Treatment of Patients With Diffuse Large B-cell Lymphoma (DLBCL),visual impairment
UNKNOWN-check-for-typo,18.18,NCT01925612-4,Part 3: BV(1.8 mg/kg) + RCHP,NCT01925612,Study of Brentuximab Vedotin Combined With RCHOP or RCHP in Front-line Treatment of Patients With Diffuse Large B-cell Lymphoma (DLBCL),D00
D009325,9.09,NCT01925612-3,Part 2: BV(1.8 mg/kg) + RCHP,NCT01925612,Study of Brentuximab Vedotin Combined With RCHOP or RCHP in Front-line Treatment of Patients With Diffuse Large B-cell Lymphoma (DLBCL),nausea
D009325,9.09,NCT01925612-4,Part 3: BV(1.8 mg/kg) + RCHP,NCT01925612,Study of Brentuximab Vedotin Combined With RCHOP or RCHP in Front-line Treatment of Patients With Diffuse Large B-cell Lymphoma (DLBCL),nausea
D014839,9.09,NCT01925612-3,Part 2: BV(1.8 mg/kg) + RCHP,NCT01925612,Study of Brentuximab Vedotin Combined With RCHOP or RCHP in Front-line Treatment of Patients With Diffuse Large B-cell Lymphoma (DLBCL),vomiting
D014839,9.09,NCT01925612-4,Part 3: BV(1.8 mg/kg) + RCHP,NCT01925612,Study of Brentuximab Vedotin Combined With RCHOP or RCHP in Front-line Treatment of Patients With Diffuse Large B-cell Lymphoma (DLBCL),vomiting
D013276,9.09,NCT01925612-4,Part 3: BV(1.8 mg/kg) + RCHP,NCT01925612,Study of Brentuximab Vedotin Combined With RCHOP or RCHP in Front-line Treatment of Patients With Diffuse Large B-cell Lymphoma (DLBCL),gastric ulcer
D000069196,3.45,NCT01925612-1,Part 1: BV(1.2 mg/kg) + RCHOP,NCT01925612,Study of Brentuximab Vedotin Combined With RCHOP or RCHP in Front-line Treatment of Patients With Diffuse Large B-cell Lymphoma (DLBCL),gastrointestinal microbiome
D000069196,4.55,NCT01925612-2,Part 1: BV(1.8 mg/kg) + RCHOP,NCT01925612,Study of Brentuximab Vedotin Combined With RCHOP or RCHP in Front-line Treatment of Patients With Diffuse Large B-cell Lymphoma (DLBCL),gastrointestinal microbiome
D045823,3.45,NCT01925612-1,Part 1: BV(1.2 mg/kg) + RCHOP,NCT01925612,Study of Brentuximab Vedotin Combined With RCHOP or RCHP in Front-line Treatment of Patients With Diffuse Large B-cell Lymphoma (DLBCL),ileus
D007416,3.45,NCT01925612-1,Part 1: BV(1.2 mg/kg) + RCHOP,NCT01925612,Study of Brentuximab Vedotin Combined With RCHOP or RCHP in Front-line Treatment of Patients With Diffuse Large B-cell Lymphoma (DLBCL),intestinal perforation
D007415,4.55,NCT01925612-2,Part 1: BV(1.8 mg/kg) + RCHOP,NCT01925612,Study of Brentuximab Vedotin Combined With RCHOP or RCHP in Front-line Treatment of Patients With Diffuse Large B-cell Lymphoma (DLBCL),intestinal obstruction
D044504,3.45,NCT01925612-1,Part 1: BV(1.2 mg/kg) + RCHOP,NCT01925612,Study of Brentuximab Vedotin Combined With RCHOP or RCHP in Front-line Treatment of Patients With Diffuse Large B-cell Lymphoma (DLBCL),enterocolitis neutropenic
D013280,3.45,NCT01925612-1,Part 1: BV(1.2 mg/kg) + RCHOP,NCT01925612,Study of Brentuximab Vedotin Combined With RCHOP or RCHP in Front-line Treatment of Patients With Diffuse Large B-cell Lymphoma (DLBCL),stomatitis
D001247,8.33,NCT01925612-5,Part 3: RCHOP,NCT01925612,Study of Brentuximab Vedotin Combined With RCHOP or RCHP in Front-line Treatment of Patients With Diffuse Large B-cell Lymphoma (DLBCL),asthenia
D002637,8.33,NCT01925612-5,Part 3: RCHOP,NCT01925612,Study of Brentuximab Vedotin Combined With RCHOP or RCHP in Front-line Treatment of Patients With Diffuse Large B-cell Lymphoma (DLBCL),chest pain
UNKNOWN-check-for-typo,6.9,NCT01925612-1,Part 1: BV(1.2 mg/kg) + RCHOP,NCT01925612,Study of Brentuximab Vedotin Combined With RCHOP or RCHP in Front-line Treatment of Patients With Diffuse Large B-cell Lymphoma (DLBCL),D00
UNKNOWN-check-for-typo,9.09,NCT01925612-3,Part 2: BV(1.8 mg/kg) + RCHP,NCT01925612,Study of Brentuximab Vedotin Combined With RCHOP or RCHP in Front-line Treatment of Patients With Diffuse Large B-cell Lymphoma (DLBCL),D00
D011020,9.09,NCT01925612-3,Part 2: BV(1.8 mg/kg) + RCHP,NCT01925612,Study of Brentuximab Vedotin Combined With RCHOP or RCHP in Front-line Treatment of Patients With Diffuse Large B-cell Lymphoma (DLBCL),pneumocystis jirovecii pneumonia
D011014,3.45,NCT01925612-1,Part 1: BV(1.2 mg/kg) + RCHOP,NCT01925612,Study of Brentuximab Vedotin Combined With RCHOP or RCHP in Front-line Treatment of Patients With Diffuse Large B-cell Lymphoma (DLBCL),pneumonia
D011014,9.09,NCT01925612-2,Part 1: BV(1.8 mg/kg) + RCHOP,NCT01925612,Study of Brentuximab Vedotin Combined With RCHOP or RCHP in Front-line Treatment of Patients With Diffuse Large B-cell Lymphoma (DLBCL),pneumonia
D000985,9.09,NCT01925612-4,Part 3: BV(1.8 mg/kg) + RCHP,NCT01925612,Study of Brentuximab Vedotin Combined With RCHOP or RCHP in Front-line Treatment of Patients With Diffuse Large B-cell Lymphoma (DLBCL),antisepsis
D018805,4.55,NCT01925612-2,Part 1: BV(1.8 mg/kg) + RCHOP,NCT01925612,Study of Brentuximab Vedotin Combined With RCHOP or RCHP in Front-line Treatment of Patients With Diffuse Large B-cell Lymphoma (DLBCL),sepsis
D018805,8.33,NCT01925612-5,Part 3: RCHOP,NCT01925612,Study of Brentuximab Vedotin Combined With RCHOP or RCHP in Front-line Treatment of Patients With Diffuse Large B-cell Lymphoma (DLBCL),sepsis
D001988,4.55,NCT01925612-2,Part 1: BV(1.8 mg/kg) + RCHOP,NCT01925612,Study of Brentuximab Vedotin Combined With RCHOP or RCHP in Front-line Treatment of Patients With Diffuse Large B-cell Lymphoma (DLBCL),bronchiolitis
D004761,4.55,NCT01925612-2,Part 1: BV(1.8 mg/kg) + RCHOP,NCT01925612,Study of Brentuximab Vedotin Combined With RCHOP or RCHP in Front-line Treatment of Patients With Diffuse Large B-cell Lymphoma (DLBCL),clostridium enterocolitis
D004927,3.45,NCT01925612-1,Part 1: BV(1.2 mg/kg) + RCHOP,NCT01925612,Study of Brentuximab Vedotin Combined With RCHOP or RCHP in Front-line Treatment of Patients With Diffuse Large B-cell Lymphoma (DLBCL),escherichia coli infections
D000069544,3.45,NCT01925612-1,Part 1: BV(1.2 mg/kg) + RCHOP,NCT01925612,Study of Brentuximab Vedotin Combined With RCHOP or RCHP in Front-line Treatment of Patients With Diffuse Large B-cell Lymphoma (DLBCL),encephalitis infection
D014552,4.55,NCT01925612-2,Part 1: BV(1.8 mg/kg) + RCHOP,NCT01925612,Study of Brentuximab Vedotin Combined With RCHOP or RCHP in Front-line Treatment of Patients With Diffuse Large B-cell Lymphoma (DLBCL),urinary tract infection
10029366,9.09,NCT01925612-4,Part 3: BV(1.8 mg/kg) + RCHP,NCT01925612,Study of Brentuximab Vedotin Combined With RCHOP or RCHP in Front-line Treatment of Patients With Diffuse Large B-cell Lymphoma (DLBCL),neutrophil count decreased
D003587,3.45,NCT01925612-1,Part 1: BV(1.2 mg/kg) + RCHOP,NCT01925612,Study of Brentuximab Vedotin Combined With RCHOP or RCHP in Front-line Treatment of Patients With Diffuse Large B-cell Lymphoma (DLBCL),cytomegalovirus
10035528,3.45,NCT01925612-1,Part 1: BV(1.2 mg/kg) + RCHOP,NCT01925612,Study of Brentuximab Vedotin Combined With RCHOP or RCHP in Front-line Treatment of Patients With Diffuse Large B-cell Lymphoma (DLBCL),platelet count decreased
D007958,3.45,NCT01925612-1,Part 1: BV(1.2 mg/kg) + RCHOP,NCT01925612,Study of Brentuximab Vedotin Combined With RCHOP or RCHP in Front-line Treatment of Patients With Diffuse Large B-cell Lymphoma (DLBCL),blood cell count white
D003681,4.55,NCT01925612-2,Part 1: BV(1.8 mg/kg) + RCHOP,NCT01925612,Study of Brentuximab Vedotin Combined With RCHOP or RCHP in Front-line Treatment of Patients With Diffuse Large B-cell Lymphoma (DLBCL),dehydration
D003681,8.33,NCT01925612-5,Part 3: RCHOP,NCT01925612,Study of Brentuximab Vedotin Combined With RCHOP or RCHP in Front-line Treatment of Patients With Diffuse Large B-cell Lymphoma (DLBCL),dehydration
D059352,3.45,NCT01925612-1,Part 1: BV(1.2 mg/kg) + RCHOP,NCT01925612,Study of Brentuximab Vedotin Combined With RCHOP or RCHP in Front-line Treatment of Patients With Diffuse Large B-cell Lymphoma (DLBCL),musculoskeletal pain
D015179,8.33,NCT01925612-5,Part 3: RCHOP,NCT01925612,Study of Brentuximab Vedotin Combined With RCHOP or RCHP in Front-line Treatment of Patients With Diffuse Large B-cell Lymphoma (DLBCL),colorectal cancer
D002490,4.55,NCT01925612-2,Part 1: BV(1.8 mg/kg) + RCHOP,NCT01925612,Study of Brentuximab Vedotin Combined With RCHOP or RCHP in Front-line Treatment of Patients With Diffuse Large B-cell Lymphoma (DLBCL),central nervous system
D009190,4.55,NCT01925612-2,Part 1: BV(1.8 mg/kg) + RCHOP,NCT01925612,Study of Brentuximab Vedotin Combined With RCHOP or RCHP in Front-line Treatment of Patients With Diffuse Large B-cell Lymphoma (DLBCL),myelodysplastic syndrome
D020521,8.33,NCT01925612-5,Part 3: RCHOP,NCT01925612,Study of Brentuximab Vedotin Combined With RCHOP or RCHP in Front-line Treatment of Patients With Diffuse Large B-cell Lymphoma (DLBCL),cerebrovascular accident
D020275,3.45,NCT01925612-1,Part 1: BV(1.2 mg/kg) + RCHOP,NCT01925612,Study of Brentuximab Vedotin Combined With RCHOP or RCHP in Front-line Treatment of Patients With Diffuse Large B-cell Lymphoma (DLBCL),guillain barre syndrome
D012640,3.45,NCT01925612-1,Part 1: BV(1.2 mg/kg) + RCHOP,NCT01925612,Study of Brentuximab Vedotin Combined With RCHOP or RCHP in Front-line Treatment of Patients With Diffuse Large B-cell Lymphoma (DLBCL),seizure
D058186,8.33,NCT01925612-5,Part 3: RCHOP,NCT01925612,Study of Brentuximab Vedotin Combined With RCHOP or RCHP in Front-line Treatment of Patients With Diffuse Large B-cell Lymphoma (DLBCL),acute kidney injury
D051437,4.55,NCT01925612-2,Part 1: BV(1.8 mg/kg) + RCHOP,NCT01925612,Study of Brentuximab Vedotin Combined With RCHOP or RCHP in Front-line Treatment of Patients With Diffuse Large B-cell Lymphoma (DLBCL),renal failure
D011655,9.09,NCT01925612-3,Part 2: BV(1.8 mg/kg) + RCHP,NCT01925612,Study of Brentuximab Vedotin Combined With RCHOP or RCHP in Front-line Treatment of Patients With Diffuse Large B-cell Lymphoma (DLBCL),pulmonary embolism
D012131,3.45,NCT01925612-1,Part 1: BV(1.2 mg/kg) + RCHOP,NCT01925612,Study of Brentuximab Vedotin Combined With RCHOP or RCHP in Front-line Treatment of Patients With Diffuse Large B-cell Lymphoma (DLBCL),respiratory failure
D012131,9.09,NCT01925612-4,Part 3: BV(1.8 mg/kg) + RCHP,NCT01925612,Study of Brentuximab Vedotin Combined With RCHOP or RCHP in Front-line Treatment of Patients With Diffuse Large B-cell Lymphoma (DLBCL),respiratory failure
D051270,8.33,NCT01925612-5,Part 3: RCHOP,NCT01925612,Study of Brentuximab Vedotin Combined With RCHOP or RCHP in Front-line Treatment of Patients With Diffuse Large B-cell Lymphoma (DLBCL),primary exertional headache
D012131,4.55,NCT01925612-2,Part 1: BV(1.8 mg/kg) + RCHOP,NCT01925612,Study of Brentuximab Vedotin Combined With RCHOP or RCHP in Front-line Treatment of Patients With Diffuse Large B-cell Lymphoma (DLBCL),respiratory failure
D012131,8.33,NCT01925612-5,Part 3: RCHOP,NCT01925612,Study of Brentuximab Vedotin Combined With RCHOP or RCHP in Front-line Treatment of Patients With Diffuse Large B-cell Lymphoma (DLBCL),respiratory failure
D012128,4.55,NCT01925612-2,Part 1: BV(1.8 mg/kg) + RCHOP,NCT01925612,Study of Brentuximab Vedotin Combined With RCHOP or RCHP in Front-line Treatment of Patients With Diffuse Large B-cell Lymphoma (DLBCL),acute respiratory distress syndrome
UNKNOWN-check-for-typo,4.55,NCT01925612-2,Part 1: BV(1.8 mg/kg) + RCHOP,NCT01925612,Study of Brentuximab Vedotin Combined With RCHOP or RCHP in Front-line Treatment of Patients With Diffuse Large B-cell Lymphoma (DLBCL),D00
D000799,4.55,NCT01925612-2,Part 1: BV(1.8 mg/kg) + RCHOP,NCT01925612,Study of Brentuximab Vedotin Combined With RCHOP or RCHP in Front-line Treatment of Patients With Diffuse Large B-cell Lymphoma (DLBCL),angioedema
D013262,4.55,NCT01925612-2,Part 1: BV(1.8 mg/kg) + RCHOP,NCT01925612,Study of Brentuximab Vedotin Combined With RCHOP or RCHP in Front-line Treatment of Patients With Diffuse Large B-cell Lymphoma (DLBCL),stevens johnson syndrome
D004597,3.45,NCT01925612-1,Part 1: BV(1.2 mg/kg) + RCHOP,NCT01925612,Study of Brentuximab Vedotin Combined With RCHOP or RCHP in Front-line Treatment of Patients With Diffuse Large B-cell Lymphoma (DLBCL),electroshock
D009026,5.26,NCT01940497-1,Trastuzumab (Vial): Adjuvant,NCT01940497,A Study of the Safety of Subcutaneously Administered Trastuzumab (Herceptin) in Participants With Early and Locally Advanced Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer,mortality
D009026,5.0,NCT01940497-2,Trastuzumab (Vial): Neoadjuvant,NCT01940497,A Study of the Safety of Subcutaneously Administered Trastuzumab (Herceptin) in Participants With Early and Locally Advanced Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer,mortality
D009026,4.76,NCT01940497-4,Trastuzumab (SID) Neoadjuvant,NCT01940497,A Study of the Safety of Subcutaneously Administered Trastuzumab (Herceptin) in Participants With Early and Locally Advanced Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer,mortality
D064420,5.26,NCT01940497-1,Trastuzumab (Vial): Adjuvant,NCT01940497,A Study of the Safety of Subcutaneously Administered Trastuzumab (Herceptin) in Participants With Early and Locally Advanced Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer,adverse drug events
D064420,15.0,NCT01940497-2,Trastuzumab (Vial): Neoadjuvant,NCT01940497,A Study of the Safety of Subcutaneously Administered Trastuzumab (Herceptin) in Participants With Early and Locally Advanced Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer,adverse drug events
D064420,7.61,NCT01940497-3,Trastuzumab (SID) Adjuvant,NCT01940497,A Study of the Safety of Subcutaneously Administered Trastuzumab (Herceptin) in Participants With Early and Locally Advanced Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer,adverse drug events
D064420,9.52,NCT01940497-4,Trastuzumab (SID) Neoadjuvant,NCT01940497,A Study of the Safety of Subcutaneously Administered Trastuzumab (Herceptin) in Participants With Early and Locally Advanced Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer,adverse drug events
D064147,1.09,NCT01940497-3,Trastuzumab (SID) Adjuvant,NCT01940497,A Study of the Safety of Subcutaneously Administered Trastuzumab (Herceptin) in Participants With Early and Locally Advanced Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer,febrile neutropenia
D009503,4.76,NCT01940497-4,Trastuzumab (SID) Neoadjuvant,NCT01940497,A Study of the Safety of Subcutaneously Administered Trastuzumab (Herceptin) in Participants With Early and Locally Advanced Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer,neutropenia
D001281,5.0,NCT01940497-2,Trastuzumab (Vial): Neoadjuvant,NCT01940497,A Study of the Safety of Subcutaneously Administered Trastuzumab (Herceptin) in Participants With Early and Locally Advanced Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer,atrial fibrillation
D010493,5.0,NCT01940497-2,Trastuzumab (Vial): Neoadjuvant,NCT01940497,A Study of the Safety of Subcutaneously Administered Trastuzumab (Herceptin) in Participants With Early and Locally Advanced Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer,pleuropericarditis
D014839,4.76,NCT01940497-4,Trastuzumab (SID) Neoadjuvant,NCT01940497,A Study of the Safety of Subcutaneously Administered Trastuzumab (Herceptin) in Participants With Early and Locally Advanced Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer,vomiting
UNKNOWN-check-for-typo,1.09,NCT01940497-3,Trastuzumab (SID) Adjuvant,NCT01940497,A Study of the Safety of Subcutaneously Administered Trastuzumab (Herceptin) in Participants With Early and Locally Advanced Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer,D00
D000707,1.05,NCT01940497-1,Trastuzumab (Vial): Adjuvant,NCT01940497,A Study of the Safety of Subcutaneously Administered Trastuzumab (Herceptin) in Participants With Early and Locally Advanced Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer,anaphylactic shock
D000707,1.09,NCT01940497-3,Trastuzumab (SID) Adjuvant,NCT01940497,A Study of the Safety of Subcutaneously Administered Trastuzumab (Herceptin) in Participants With Early and Locally Advanced Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer,anaphylactic shock
D005759,5.0,NCT01940497-2,Trastuzumab (Vial): Neoadjuvant,NCT01940497,A Study of the Safety of Subcutaneously Administered Trastuzumab (Herceptin) in Participants With Early and Locally Advanced Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer,gastroenteritis
D005360,1.05,NCT01940497-1,Trastuzumab (Vial): Adjuvant,NCT01940497,A Study of the Safety of Subcutaneously Administered Trastuzumab (Herceptin) in Participants With Early and Locally Advanced Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer,fibula
D013978,1.05,NCT01940497-1,Trastuzumab (Vial): Adjuvant,NCT01940497,A Study of the Safety of Subcutaneously Administered Trastuzumab (Herceptin) in Participants With Early and Locally Advanced Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer,tibial fractures
D007403,5.0,NCT01940497-2,Trastuzumab (Vial): Neoadjuvant,NCT01940497,A Study of the Safety of Subcutaneously Administered Trastuzumab (Herceptin) in Participants With Early and Locally Advanced Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer,intervertebral disc
D002295,1.09,NCT01940497-3,Trastuzumab (SID) Adjuvant,NCT01940497,A Study of the Safety of Subcutaneously Administered Trastuzumab (Herceptin) in Participants With Early and Locally Advanced Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer,carcinoma transitional cell
D000069280,1.05,NCT01940497-1,Trastuzumab (Vial): Adjuvant,NCT01940497,A Study of the Safety of Subcutaneously Administered Trastuzumab (Herceptin) in Participants With Early and Locally Advanced Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer,intracranial electroencephalography
D000077216,1.05,NCT01940497-1,Trastuzumab (Vial): Adjuvant,NCT01940497,A Study of the Safety of Subcutaneously Administered Trastuzumab (Herceptin) in Participants With Early and Locally Advanced Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer,epithelial ovarian cancer
D000230,1.09,NCT01940497-3,Trastuzumab (SID) Adjuvant,NCT01940497,A Study of the Safety of Subcutaneously Administered Trastuzumab (Herceptin) in Participants With Early and Locally Advanced Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer,adenocarcinoma
D013575,1.05,NCT01940497-1,Trastuzumab (Vial): Adjuvant,NCT01940497,A Study of the Safety of Subcutaneously Administered Trastuzumab (Herceptin) in Participants With Early and Locally Advanced Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer,syncope
D000073222,1.09,NCT01940497-3,Trastuzumab (SID) Adjuvant,NCT01940497,A Study of the Safety of Subcutaneously Administered Trastuzumab (Herceptin) in Participants With Early and Locally Advanced Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer,two-item generalised anxiety disorder scale
D058186,1.09,NCT01940497-3,Trastuzumab (SID) Adjuvant,NCT01940497,A Study of the Safety of Subcutaneously Administered Trastuzumab (Herceptin) in Participants With Early and Locally Advanced Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer,acute kidney injury
D009026,33.33,NCT01964755-1,Chemotherapy + Antiviral-Based Therapy,NCT01964755,Chemotherapy for Relapsed Epstein Barr Virus Associated Lymphoma,mortality
D064420,33.33,NCT01964755-1,Chemotherapy + Antiviral-Based Therapy,NCT01964755,Chemotherapy for Relapsed Epstein Barr Virus Associated Lymphoma,adverse drug events
D064147,16.67,NCT01964755-1,Chemotherapy + Antiviral-Based Therapy,NCT01964755,Chemotherapy for Relapsed Epstein Barr Virus Associated Lymphoma,febrile neutropenia
10035528,16.67,NCT01964755-1,Chemotherapy + Antiviral-Based Therapy,NCT01964755,Chemotherapy for Relapsed Epstein Barr Virus Associated Lymphoma,platelet count decreased
D003681,16.67,NCT01964755-1,Chemotherapy + Antiviral-Based Therapy,NCT01964755,Chemotherapy for Relapsed Epstein Barr Virus Associated Lymphoma,dehydration
D017674,16.67,NCT01964755-1,Chemotherapy + Antiviral-Based Therapy,NCT01964755,Chemotherapy for Relapsed Epstein Barr Virus Associated Lymphoma,hypophosphatemia
D000860,16.67,NCT01964755-1,Chemotherapy + Antiviral-Based Therapy,NCT01964755,Chemotherapy for Relapsed Epstein Barr Virus Associated Lymphoma,hypoxia
D011014,16.67,NCT01964755-1,Chemotherapy + Antiviral-Based Therapy,NCT01964755,Chemotherapy for Relapsed Epstein Barr Virus Associated Lymphoma,pneumonitis
D012128,16.67,NCT01964755-1,Chemotherapy + Antiviral-Based Therapy,NCT01964755,Chemotherapy for Relapsed Epstein Barr Virus Associated Lymphoma,adult respiratory distress syndrome
D009026,16.67,NCT01992653-3,Polatuzumab Vedotin (1.8mg) + R-CHP,NCT01992653,A Study of Polatuzumab Vedotin in Combination With Rituximab or Obinutuzumab  Cyclophosphamide  Doxorubicin  and Prednisone in Participants With B-Cell Non-Hodgkin's Lymphoma,mortality
D009026,16.67,NCT01992653-5,Polatuzumab Vedotin (1.4mg) + G-CHP,NCT01992653,A Study of Polatuzumab Vedotin in Combination With Rituximab or Obinutuzumab  Cyclophosphamide  Doxorubicin  and Prednisone in Participants With B-Cell Non-Hodgkin's Lymphoma,mortality
D009026,10.0,NCT01992653-7,Expansion: Polatuzumab Vedotin (1.8mg) + R-CHP,NCT01992653,A Study of Polatuzumab Vedotin in Combination With Rituximab or Obinutuzumab  Cyclophosphamide  Doxorubicin  and Prednisone in Participants With B-Cell Non-Hodgkin's Lymphoma,mortality
D009026,11.76,NCT01992653-8,Expansion: Polatuzumab Vedotin (1.8mg) + G-CHP,NCT01992653,A Study of Polatuzumab Vedotin in Combination With Rituximab or Obinutuzumab  Cyclophosphamide  Doxorubicin  and Prednisone in Participants With B-Cell Non-Hodgkin's Lymphoma,mortality
D064420,33.33,NCT01992653-1,Polatuzumab Vedotin (1.0mg) + R-CHP,NCT01992653,A Study of Polatuzumab Vedotin in Combination With Rituximab or Obinutuzumab  Cyclophosphamide  Doxorubicin  and Prednisone in Participants With B-Cell Non-Hodgkin's Lymphoma,adverse drug events
D064420,33.33,NCT01992653-2,Polatuzumab Vedotin (1.4mg) + R-CHP,NCT01992653,A Study of Polatuzumab Vedotin in Combination With Rituximab or Obinutuzumab  Cyclophosphamide  Doxorubicin  and Prednisone in Participants With B-Cell Non-Hodgkin's Lymphoma,adverse drug events
D064420,66.67,NCT01992653-3,Polatuzumab Vedotin (1.8mg) + R-CHP,NCT01992653,A Study of Polatuzumab Vedotin in Combination With Rituximab or Obinutuzumab  Cyclophosphamide  Doxorubicin  and Prednisone in Participants With B-Cell Non-Hodgkin's Lymphoma,adverse drug events
D064420,16.67,NCT01992653-5,Polatuzumab Vedotin (1.4mg) + G-CHP,NCT01992653,A Study of Polatuzumab Vedotin in Combination With Rituximab or Obinutuzumab  Cyclophosphamide  Doxorubicin  and Prednisone in Participants With B-Cell Non-Hodgkin's Lymphoma,adverse drug events
D064420,50.0,NCT01992653-6,Polatuzumab Vedotin (1.8mg) + G-CHP,NCT01992653,A Study of Polatuzumab Vedotin in Combination With Rituximab or Obinutuzumab  Cyclophosphamide  Doxorubicin  and Prednisone in Participants With B-Cell Non-Hodgkin's Lymphoma,adverse drug events
D064420,37.5,NCT01992653-7,Expansion: Polatuzumab Vedotin (1.8mg) + R-CHP,NCT01992653,A Study of Polatuzumab Vedotin in Combination With Rituximab or Obinutuzumab  Cyclophosphamide  Doxorubicin  and Prednisone in Participants With B-Cell Non-Hodgkin's Lymphoma,adverse drug events
D064420,35.29,NCT01992653-8,Expansion: Polatuzumab Vedotin (1.8mg) + G-CHP,NCT01992653,A Study of Polatuzumab Vedotin in Combination With Rituximab or Obinutuzumab  Cyclophosphamide  Doxorubicin  and Prednisone in Participants With B-Cell Non-Hodgkin's Lymphoma,adverse drug events
D064147,33.33,NCT01992653-2,Polatuzumab Vedotin (1.4mg) + R-CHP,NCT01992653,A Study of Polatuzumab Vedotin in Combination With Rituximab or Obinutuzumab  Cyclophosphamide  Doxorubicin  and Prednisone in Participants With B-Cell Non-Hodgkin's Lymphoma,febrile neutropenia
D064147,16.67,NCT01992653-5,Polatuzumab Vedotin (1.4mg) + G-CHP,NCT01992653,A Study of Polatuzumab Vedotin in Combination With Rituximab or Obinutuzumab  Cyclophosphamide  Doxorubicin  and Prednisone in Participants With B-Cell Non-Hodgkin's Lymphoma,febrile neutropenia
D064147,33.33,NCT01992653-6,Polatuzumab Vedotin (1.8mg) + G-CHP,NCT01992653,A Study of Polatuzumab Vedotin in Combination With Rituximab or Obinutuzumab  Cyclophosphamide  Doxorubicin  and Prednisone in Participants With B-Cell Non-Hodgkin's Lymphoma,febrile neutropenia
D064147,7.5,NCT01992653-7,Expansion: Polatuzumab Vedotin (1.8mg) + R-CHP,NCT01992653,A Study of Polatuzumab Vedotin in Combination With Rituximab or Obinutuzumab  Cyclophosphamide  Doxorubicin  and Prednisone in Participants With B-Cell Non-Hodgkin's Lymphoma,febrile neutropenia
D064147,23.53,NCT01992653-8,Expansion: Polatuzumab Vedotin (1.8mg) + G-CHP,NCT01992653,A Study of Polatuzumab Vedotin in Combination With Rituximab or Obinutuzumab  Cyclophosphamide  Doxorubicin  and Prednisone in Participants With B-Cell Non-Hodgkin's Lymphoma,febrile neutropenia
D009503,33.33,NCT01992653-3,Polatuzumab Vedotin (1.8mg) + R-CHP,NCT01992653,A Study of Polatuzumab Vedotin in Combination With Rituximab or Obinutuzumab  Cyclophosphamide  Doxorubicin  and Prednisone in Participants With B-Cell Non-Hodgkin's Lymphoma,neutropenia
D009503,16.67,NCT01992653-6,Polatuzumab Vedotin (1.8mg) + G-CHP,NCT01992653,A Study of Polatuzumab Vedotin in Combination With Rituximab or Obinutuzumab  Cyclophosphamide  Doxorubicin  and Prednisone in Participants With B-Cell Non-Hodgkin's Lymphoma,neutropenia
D009503,5.88,NCT01992653-8,Expansion: Polatuzumab Vedotin (1.8mg) + G-CHP,NCT01992653,A Study of Polatuzumab Vedotin in Combination With Rituximab or Obinutuzumab  Cyclophosphamide  Doxorubicin  and Prednisone in Participants With B-Cell Non-Hodgkin's Lymphoma,neutropenia
D013921,16.67,NCT01992653-5,Polatuzumab Vedotin (1.4mg) + G-CHP,NCT01992653,A Study of Polatuzumab Vedotin in Combination With Rituximab or Obinutuzumab  Cyclophosphamide  Doxorubicin  and Prednisone in Participants With B-Cell Non-Hodgkin's Lymphoma,thrombocytopenia
D001281,16.67,NCT01992653-5,Polatuzumab Vedotin (1.4mg) + G-CHP,NCT01992653,A Study of Polatuzumab Vedotin in Combination With Rituximab or Obinutuzumab  Cyclophosphamide  Doxorubicin  and Prednisone in Participants With B-Cell Non-Hodgkin's Lymphoma,atrial fibrillation
D001281,5.0,NCT01992653-7,Expansion: Polatuzumab Vedotin (1.8mg) + R-CHP,NCT01992653,A Study of Polatuzumab Vedotin in Combination With Rituximab or Obinutuzumab  Cyclophosphamide  Doxorubicin  and Prednisone in Participants With B-Cell Non-Hodgkin's Lymphoma,atrial fibrillation
D003324,16.67,NCT01992653-6,Polatuzumab Vedotin (1.8mg) + G-CHP,NCT01992653,A Study of Polatuzumab Vedotin in Combination With Rituximab or Obinutuzumab  Cyclophosphamide  Doxorubicin  and Prednisone in Participants With B-Cell Non-Hodgkin's Lymphoma,coronary artery disease
D013617,16.67,NCT01992653-6,Polatuzumab Vedotin (1.8mg) + G-CHP,NCT01992653,A Study of Polatuzumab Vedotin in Combination With Rituximab or Obinutuzumab  Cyclophosphamide  Doxorubicin  and Prednisone in Participants With B-Cell Non-Hodgkin's Lymphoma,supraventricular tachycardia
UNKNOWN-check-for-typo,2.5,NCT01992653-7,Expansion: Polatuzumab Vedotin (1.8mg) + R-CHP,NCT01992653,A Study of Polatuzumab Vedotin in Combination With Rituximab or Obinutuzumab  Cyclophosphamide  Doxorubicin  and Prednisone in Participants With B-Cell Non-Hodgkin's Lymphoma,D00
D003680,16.67,NCT01992653-3,Polatuzumab Vedotin (1.8mg) + R-CHP,NCT01992653,A Study of Polatuzumab Vedotin in Combination With Rituximab or Obinutuzumab  Cyclophosphamide  Doxorubicin  and Prednisone in Participants With B-Cell Non-Hodgkin's Lymphoma,dysphagia
D014839,5.88,NCT01992653-8,Expansion: Polatuzumab Vedotin (1.8mg) + G-CHP,NCT01992653,A Study of Polatuzumab Vedotin in Combination With Rituximab or Obinutuzumab  Cyclophosphamide  Doxorubicin  and Prednisone in Participants With B-Cell Non-Hodgkin's Lymphoma,vomiting
D001247,5.88,NCT01992653-8,Expansion: Polatuzumab Vedotin (1.8mg) + G-CHP,NCT01992653,A Study of Polatuzumab Vedotin in Combination With Rituximab or Obinutuzumab  Cyclophosphamide  Doxorubicin  and Prednisone in Participants With B-Cell Non-Hodgkin's Lymphoma,asthenia
D018746,2.5,NCT01992653-7,Expansion: Polatuzumab Vedotin (1.8mg) + R-CHP,NCT01992653,A Study of Polatuzumab Vedotin in Combination With Rituximab or Obinutuzumab  Cyclophosphamide  Doxorubicin  and Prednisone in Participants With B-Cell Non-Hodgkin's Lymphoma,systemic inflammatory response syndrome
D003015,16.67,NCT01992653-6,Polatuzumab Vedotin (1.8mg) + G-CHP,NCT01992653,A Study of Polatuzumab Vedotin in Combination With Rituximab or Obinutuzumab  Cyclophosphamide  Doxorubicin  and Prednisone in Participants With B-Cell Non-Hodgkin's Lymphoma,clostridium difficile infection
D014552,2.5,NCT01992653-7,Expansion: Polatuzumab Vedotin (1.8mg) + R-CHP,NCT01992653,A Study of Polatuzumab Vedotin in Combination With Rituximab or Obinutuzumab  Cyclophosphamide  Doxorubicin  and Prednisone in Participants With B-Cell Non-Hodgkin's Lymphoma,urinary tract infections
10061229,2.5,NCT01992653-7,Expansion: Polatuzumab Vedotin (1.8mg) + R-CHP,NCT01992653,A Study of Polatuzumab Vedotin in Combination With Rituximab or Obinutuzumab  Cyclophosphamide  Doxorubicin  and Prednisone in Participants With B-Cell Non-Hodgkin's Lymphoma,lung infection
D009181,2.5,NCT01992653-7,Expansion: Polatuzumab Vedotin (1.8mg) + R-CHP,NCT01992653,A Study of Polatuzumab Vedotin in Combination With Rituximab or Obinutuzumab  Cyclophosphamide  Doxorubicin  and Prednisone in Participants With B-Cell Non-Hodgkin's Lymphoma,fungal infections
D011014,33.33,NCT01992653-3,Polatuzumab Vedotin (1.8mg) + R-CHP,NCT01992653,A Study of Polatuzumab Vedotin in Combination With Rituximab or Obinutuzumab  Cyclophosphamide  Doxorubicin  and Prednisone in Participants With B-Cell Non-Hodgkin's Lymphoma,pneumonia
D011014,16.67,NCT01992653-6,Polatuzumab Vedotin (1.8mg) + G-CHP,NCT01992653,A Study of Polatuzumab Vedotin in Combination With Rituximab or Obinutuzumab  Cyclophosphamide  Doxorubicin  and Prednisone in Participants With B-Cell Non-Hodgkin's Lymphoma,pneumonia
D011014,5.88,NCT01992653-8,Expansion: Polatuzumab Vedotin (1.8mg) + G-CHP,NCT01992653,A Study of Polatuzumab Vedotin in Combination With Rituximab or Obinutuzumab  Cyclophosphamide  Doxorubicin  and Prednisone in Participants With B-Cell Non-Hodgkin's Lymphoma,pneumonia
D018805,16.67,NCT01992653-6,Polatuzumab Vedotin (1.8mg) + G-CHP,NCT01992653,A Study of Polatuzumab Vedotin in Combination With Rituximab or Obinutuzumab  Cyclophosphamide  Doxorubicin  and Prednisone in Participants With B-Cell Non-Hodgkin's Lymphoma,sepsis
D012772,5.88,NCT01992653-8,Expansion: Polatuzumab Vedotin (1.8mg) + G-CHP,NCT01992653,A Study of Polatuzumab Vedotin in Combination With Rituximab or Obinutuzumab  Cyclophosphamide  Doxorubicin  and Prednisone in Participants With B-Cell Non-Hodgkin's Lymphoma,septic shock
D005265,2.5,NCT01992653-7,Expansion: Polatuzumab Vedotin (1.8mg) + R-CHP,NCT01992653,A Study of Polatuzumab Vedotin in Combination With Rituximab or Obinutuzumab  Cyclophosphamide  Doxorubicin  and Prednisone in Participants With B-Cell Non-Hodgkin's Lymphoma,femur neck fractures
10051792,33.33,NCT01992653-1,Polatuzumab Vedotin (1.0mg) + R-CHP,NCT01992653,A Study of Polatuzumab Vedotin in Combination With Rituximab or Obinutuzumab  Cyclophosphamide  Doxorubicin  and Prednisone in Participants With B-Cell Non-Hodgkin's Lymphoma,infusion related reaction
D015775,2.5,NCT01992653-7,Expansion: Polatuzumab Vedotin (1.8mg) + R-CHP,NCT01992653,A Study of Polatuzumab Vedotin in Combination With Rituximab or Obinutuzumab  Cyclophosphamide  Doxorubicin  and Prednisone in Participants With B-Cell Non-Hodgkin's Lymphoma,microfractures
D007252,5.0,NCT01992653-7,Expansion: Polatuzumab Vedotin (1.8mg) + R-CHP,NCT01992653,A Study of Polatuzumab Vedotin in Combination With Rituximab or Obinutuzumab  Cyclophosphamide  Doxorubicin  and Prednisone in Participants With B-Cell Non-Hodgkin's Lymphoma,influenzavirus vaccines
UNKNOWN-check-for-typo,5.88,NCT01992653-8,Expansion: Polatuzumab Vedotin (1.8mg) + G-CHP,NCT01992653,A Study of Polatuzumab Vedotin in Combination With Rituximab or Obinutuzumab  Cyclophosphamide  Doxorubicin  and Prednisone in Participants With B-Cell Non-Hodgkin's Lymphoma,D00
UNKNOWN-check-for-typo,2.5,NCT01992653-7,Expansion: Polatuzumab Vedotin (1.8mg) + R-CHP,NCT01992653,A Study of Polatuzumab Vedotin in Combination With Rituximab or Obinutuzumab  Cyclophosphamide  Doxorubicin  and Prednisone in Participants With B-Cell Non-Hodgkin's Lymphoma,D00
D044342,2.5,NCT01992653-7,Expansion: Polatuzumab Vedotin (1.8mg) + R-CHP,NCT01992653,A Study of Polatuzumab Vedotin in Combination With Rituximab or Obinutuzumab  Cyclophosphamide  Doxorubicin  and Prednisone in Participants With B-Cell Non-Hodgkin's Lymphoma,malnutrition
D001168,2.5,NCT01992653-7,Expansion: Polatuzumab Vedotin (1.8mg) + R-CHP,NCT01992653,A Study of Polatuzumab Vedotin in Combination With Rituximab or Obinutuzumab  Cyclophosphamide  Doxorubicin  and Prednisone in Participants With B-Cell Non-Hodgkin's Lymphoma,arthritis
D001172,2.5,NCT01992653-7,Expansion: Polatuzumab Vedotin (1.8mg) + R-CHP,NCT01992653,A Study of Polatuzumab Vedotin in Combination With Rituximab or Obinutuzumab  Cyclophosphamide  Doxorubicin  and Prednisone in Participants With B-Cell Non-Hodgkin's Lymphoma,rheumatoid arthritis
D013575,16.67,NCT01992653-6,Polatuzumab Vedotin (1.8mg) + G-CHP,NCT01992653,A Study of Polatuzumab Vedotin in Combination With Rituximab or Obinutuzumab  Cyclophosphamide  Doxorubicin  and Prednisone in Participants With B-Cell Non-Hodgkin's Lymphoma,syncope
D013575,2.5,NCT01992653-7,Expansion: Polatuzumab Vedotin (1.8mg) + R-CHP,NCT01992653,A Study of Polatuzumab Vedotin in Combination With Rituximab or Obinutuzumab  Cyclophosphamide  Doxorubicin  and Prednisone in Participants With B-Cell Non-Hodgkin's Lymphoma,syncope
D001007,2.5,NCT01992653-7,Expansion: Polatuzumab Vedotin (1.8mg) + R-CHP,NCT01992653,A Study of Polatuzumab Vedotin in Combination With Rituximab or Obinutuzumab  Cyclophosphamide  Doxorubicin  and Prednisone in Participants With B-Cell Non-Hodgkin's Lymphoma,anxiety
D000073216,5.88,NCT01992653-8,Expansion: Polatuzumab Vedotin (1.8mg) + G-CHP,NCT01992653,A Study of Polatuzumab Vedotin in Combination With Rituximab or Obinutuzumab  Cyclophosphamide  Doxorubicin  and Prednisone in Participants With B-Cell Non-Hodgkin's Lymphoma,mental status tests
D058186,16.67,NCT01992653-6,Polatuzumab Vedotin (1.8mg) + G-CHP,NCT01992653,A Study of Polatuzumab Vedotin in Combination With Rituximab or Obinutuzumab  Cyclophosphamide  Doxorubicin  and Prednisone in Participants With B-Cell Non-Hodgkin's Lymphoma,acute kidney injury
D002916,2.5,NCT01992653-7,Expansion: Polatuzumab Vedotin (1.8mg) + R-CHP,NCT01992653,A Study of Polatuzumab Vedotin in Combination With Rituximab or Obinutuzumab  Cyclophosphamide  Doxorubicin  and Prednisone in Participants With B-Cell Non-Hodgkin's Lymphoma,chylothorax
D011655,16.67,NCT01992653-3,Polatuzumab Vedotin (1.8mg) + R-CHP,NCT01992653,A Study of Polatuzumab Vedotin in Combination With Rituximab or Obinutuzumab  Cyclophosphamide  Doxorubicin  and Prednisone in Participants With B-Cell Non-Hodgkin's Lymphoma,pulmonary embolism
D011655,2.5,NCT01992653-7,Expansion: Polatuzumab Vedotin (1.8mg) + R-CHP,NCT01992653,A Study of Polatuzumab Vedotin in Combination With Rituximab or Obinutuzumab  Cyclophosphamide  Doxorubicin  and Prednisone in Participants With B-Cell Non-Hodgkin's Lymphoma,pulmonary embolism
D009026,4.17,NCT02007954-1,DEBDOX,NCT02007954,Doxorubicin-eluting LC Bead M1 for Patients With Hepatocellular Carcinoma,mortality
D064420,16.67,NCT02007954-1,DEBDOX,NCT02007954,Doxorubicin-eluting LC Bead M1 for Patients With Hepatocellular Carcinoma,adverse drug events
D006323,4.17,NCT02007954-1,DEBDOX,NCT02007954,Doxorubicin-eluting LC Bead M1 for Patients With Hepatocellular Carcinoma,cardiac arrest
10055356,4.17,NCT02007954-1,DEBDOX,NCT02007954,Doxorubicin-eluting LC Bead M1 for Patients With Hepatocellular Carcinoma,upper gastrointestinal hemorrhage
D051437,4.17,NCT02007954-1,DEBDOX,NCT02007954,Doxorubicin-eluting LC Bead M1 for Patients With Hepatocellular Carcinoma,renal failure
D000860,4.17,NCT02007954-1,DEBDOX,NCT02007954,Doxorubicin-eluting LC Bead M1 for Patients With Hepatocellular Carcinoma,hypoxia
D012131,4.17,NCT02007954-1,DEBDOX,NCT02007954,Doxorubicin-eluting LC Bead M1 for Patients With Hepatocellular Carcinoma,respiratory failure
10043565,4.17,NCT02007954-1,DEBDOX,NCT02007954,Doxorubicin-eluting LC Bead M1 for Patients With Hepatocellular Carcinoma,thromboembolic event
D009026,40.0,NCT02018458-1,LA TNBC: DC Vaccine+Preop Chemo,NCT02018458,Safety Study Of Chemotherapy Combined With Dendritic Cell Vaccine to Treat Breast Cancer,mortality
D064420,30.0,NCT02018458-1,LA TNBC: DC Vaccine+Preop Chemo,NCT02018458,Safety Study Of Chemotherapy Combined With Dendritic Cell Vaccine to Treat Breast Cancer,adverse drug events
D016280,10.0,NCT02018458-1,LA TNBC: DC Vaccine+Preop Chemo,NCT02018458,Safety Study Of Chemotherapy Combined With Dendritic Cell Vaccine to Treat Breast Cancer,atrial function right
D003643,10.0,NCT02018458-1,LA TNBC: DC Vaccine+Preop Chemo,NCT02018458,Safety Study Of Chemotherapy Combined With Dendritic Cell Vaccine to Treat Breast Cancer,death
D011655,10.0,NCT02018458-1,LA TNBC: DC Vaccine+Preop Chemo,NCT02018458,Safety Study Of Chemotherapy Combined With Dendritic Cell Vaccine to Treat Breast Cancer,pulmonary embolism
D004417,10.0,NCT02018458-1,LA TNBC: DC Vaccine+Preop Chemo,NCT02018458,Safety Study Of Chemotherapy Combined With Dendritic Cell Vaccine to Treat Breast Cancer,dyspnea
D000069584,10.0,NCT02018458-1,LA TNBC: DC Vaccine+Preop Chemo,NCT02018458,Safety Study Of Chemotherapy Combined With Dendritic Cell Vaccine to Treat Breast Cancer,right-sided breast neoplasms
D009026,14.29,NCT02055820-1,Venetoclax 200 mg +R-CHOP,NCT02055820,A Study Evaluating the Safety  Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL,mortality
D009026,12.5,NCT02055820-3,Venetoclax 600 mg +R-CHOP,NCT02055820,A Study Evaluating the Safety  Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL,mortality
D009026,66.67,NCT02055820-4,Venetoclax 800 mg +R-CHOP,NCT02055820,A Study Evaluating the Safety  Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL,mortality
D009026,15.87,NCT02055820-5,Venetoclax 800 mg +R-CHOP Phase II,NCT02055820,A Study Evaluating the Safety  Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL,mortality
D009026,14.29,NCT02055820-6,Venetoclax 200 mg +G-CHOP,NCT02055820,A Study Evaluating the Safety  Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL,mortality
D009026,14.29,NCT02055820-7,Venetoclax 400 mg +G-CHOP,NCT02055820,A Study Evaluating the Safety  Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL,mortality
D064420,71.43,NCT02055820-1,Venetoclax 200 mg +R-CHOP,NCT02055820,A Study Evaluating the Safety  Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL,adverse drug events
D064420,66.67,NCT02055820-2,Venetoclax 400 mg +R-CHOP,NCT02055820,A Study Evaluating the Safety  Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL,adverse drug events
D064420,50.0,NCT02055820-3,Venetoclax 600 mg +R-CHOP,NCT02055820,A Study Evaluating the Safety  Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL,adverse drug events
D064420,50.0,NCT02055820-4,Venetoclax 800 mg +R-CHOP,NCT02055820,A Study Evaluating the Safety  Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL,adverse drug events
D064420,55.77,NCT02055820-5,Venetoclax 800 mg +R-CHOP Phase II,NCT02055820,A Study Evaluating the Safety  Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL,adverse drug events
D064420,71.43,NCT02055820-6,Venetoclax 200 mg +G-CHOP,NCT02055820,A Study Evaluating the Safety  Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL,adverse drug events
D064420,57.14,NCT02055820-7,Venetoclax 400 mg +G-CHOP,NCT02055820,A Study Evaluating the Safety  Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL,adverse drug events
D064420,50.0,NCT02055820-8,Venetoclax 600 mg +G-CHOP,NCT02055820,A Study Evaluating the Safety  Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL,adverse drug events
D064420,83.33,NCT02055820-9,Venetoclax 800 mg + G-CHOP A,NCT02055820,A Study Evaluating the Safety  Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL,adverse drug events
D064420,83.33,NCT02055820-10,Venetoclax 800 mg +G-CHOP B,NCT02055820,A Study Evaluating the Safety  Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL,adverse drug events
D000380,0.48,NCT02055820-5,Venetoclax 800 mg +R-CHOP Phase II,NCT02055820,A Study Evaluating the Safety  Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL,agranulocytosis
D000741,33.33,NCT02055820-2,Venetoclax 400 mg +R-CHOP,NCT02055820,A Study Evaluating the Safety  Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL,aplastic anaemia
D000741,1.92,NCT02055820-5,Venetoclax 800 mg +R-CHOP Phase II,NCT02055820,A Study Evaluating the Safety  Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL,aplastic anaemia
D064147,42.86,NCT02055820-1,Venetoclax 200 mg +R-CHOP,NCT02055820,A Study Evaluating the Safety  Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL,febrile neutropenia
D064147,12.5,NCT02055820-3,Venetoclax 600 mg +R-CHOP,NCT02055820,A Study Evaluating the Safety  Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL,febrile neutropenia
D064147,33.33,NCT02055820-4,Venetoclax 800 mg +R-CHOP,NCT02055820,A Study Evaluating the Safety  Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL,febrile neutropenia
D064147,27.4,NCT02055820-5,Venetoclax 800 mg +R-CHOP Phase II,NCT02055820,A Study Evaluating the Safety  Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL,febrile neutropenia
D064147,14.29,NCT02055820-6,Venetoclax 200 mg +G-CHOP,NCT02055820,A Study Evaluating the Safety  Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL,febrile neutropenia
D064147,28.57,NCT02055820-7,Venetoclax 400 mg +G-CHOP,NCT02055820,A Study Evaluating the Safety  Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL,febrile neutropenia
D064147,16.67,NCT02055820-10,Venetoclax 800 mg +G-CHOP B,NCT02055820,A Study Evaluating the Safety  Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL,febrile neutropenia
D000743,14.29,NCT02055820-1,Venetoclax 200 mg +R-CHOP,NCT02055820,A Study Evaluating the Safety  Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL,haemolytic anaemia
D007970,0.48,NCT02055820-5,Venetoclax 800 mg +R-CHOP Phase II,NCT02055820,A Study Evaluating the Safety  Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL,leukopenia
D009503,9.13,NCT02055820-5,Venetoclax 800 mg +R-CHOP Phase II,NCT02055820,A Study Evaluating the Safety  Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL,neutropenia
D009503,14.29,NCT02055820-6,Venetoclax 200 mg +G-CHOP,NCT02055820,A Study Evaluating the Safety  Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL,neutropenia
D009503,16.67,NCT02055820-10,Venetoclax 800 mg +G-CHOP B,NCT02055820,A Study Evaluating the Safety  Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL,neutropenia
D013921,0.96,NCT02055820-5,Venetoclax 800 mg +R-CHOP Phase II,NCT02055820,A Study Evaluating the Safety  Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL,thrombocytopenia
D013921,33.33,NCT02055820-9,Venetoclax 800 mg + G-CHOP A,NCT02055820,A Study Evaluating the Safety  Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL,thrombocytopenia
D054058,14.29,NCT02055820-6,Venetoclax 200 mg +G-CHOP,NCT02055820,A Study Evaluating the Safety  Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL,acute coronary syndrome
D001281,14.29,NCT02055820-1,Venetoclax 200 mg +R-CHOP,NCT02055820,A Study Evaluating the Safety  Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL,atrial fibrillation
D001281,33.33,NCT02055820-2,Venetoclax 400 mg +R-CHOP,NCT02055820,A Study Evaluating the Safety  Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL,atrial fibrillation
D001281,2.88,NCT02055820-5,Venetoclax 800 mg +R-CHOP Phase II,NCT02055820,A Study Evaluating the Safety  Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL,atrial fibrillation
D054537,0.96,NCT02055820-5,Venetoclax 800 mg +R-CHOP Phase II,NCT02055820,A Study Evaluating the Safety  Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL,atrioventricular block
D006323,16.67,NCT02055820-10,Venetoclax 800 mg +G-CHOP B,NCT02055820,A Study Evaluating the Safety  Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL,cardiac arrest
D006333,0.48,NCT02055820-5,Venetoclax 800 mg +R-CHOP Phase II,NCT02055820,A Study Evaluating the Safety  Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL,cardiac failure
D006333,0.48,NCT02055820-5,Venetoclax 800 mg +R-CHOP Phase II,NCT02055820,A Study Evaluating the Safety  Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL,cardiac failure
D012770,0.48,NCT02055820-5,Venetoclax 800 mg +R-CHOP Phase II,NCT02055820,A Study Evaluating the Safety  Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL,cardiogenic shock
D009202,33.33,NCT02055820-2,Venetoclax 400 mg +R-CHOP,NCT02055820,A Study Evaluating the Safety  Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL,cardiomyopathy
D016277,0.48,NCT02055820-5,Venetoclax 800 mg +R-CHOP Phase II,NCT02055820,A Study Evaluating the Safety  Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL,ventricular function left
D000071956,0.48,NCT02055820-5,Venetoclax 800 mg +R-CHOP Phase II,NCT02055820,A Study Evaluating the Safety  Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL,myocardial contusions
D013616,0.48,NCT02055820-5,Venetoclax 800 mg +R-CHOP Phase II,NCT02055820,A Study Evaluating the Safety  Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL,sinus tachycardia
D013617,0.48,NCT02055820-5,Venetoclax 800 mg +R-CHOP Phase II,NCT02055820,A Study Evaluating the Safety  Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL,supraventricular tachycardia
D013610,0.48,NCT02055820-5,Venetoclax 800 mg +R-CHOP Phase II,NCT02055820,A Study Evaluating the Safety  Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL,tachycardia
D013610,16.67,NCT02055820-10,Venetoclax 800 mg +G-CHOP B,NCT02055820,A Study Evaluating the Safety  Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL,tachycardia
D009901,0.48,NCT02055820-5,Venetoclax 800 mg +R-CHOP Phase II,NCT02055820,A Study Evaluating the Safety  Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL,optic neuropathy
UNKNOWN-check-for-typo,1.92,NCT02055820-5,Venetoclax 800 mg +R-CHOP Phase II,NCT02055820,A Study Evaluating the Safety  Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL,D00
D000072663,0.48,NCT02055820-5,Venetoclax 800 mg +R-CHOP Phase II,NCT02055820,A Study Evaluating the Safety  Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL,spontaneous perforation
10050094,0.48,NCT02055820-5,Venetoclax 800 mg +R-CHOP Phase II,NCT02055820,A Study Evaluating the Safety  Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL,duodenal stenosis
D003680,16.67,NCT02055820-8,Venetoclax 600 mg +G-CHOP,NCT02055820,A Study Evaluating the Safety  Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL,dysphagia
D004760,0.48,NCT02055820-5,Venetoclax 800 mg +R-CHOP Phase II,NCT02055820,A Study Evaluating the Safety  Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL,enterocolitis
D013271,0.48,NCT02055820-5,Venetoclax 800 mg +R-CHOP Phase II,NCT02055820,A Study Evaluating the Safety  Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL,gastric dilatation
10017815,0.48,NCT02055820-5,Venetoclax 800 mg +R-CHOP Phase II,NCT02055820,A Study Evaluating the Safety  Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL,gastric perforation
10061970,0.48,NCT02055820-5,Venetoclax 800 mg +R-CHOP Phase II,NCT02055820,A Study Evaluating the Safety  Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL,gastric stenosis
D013276,0.48,NCT02055820-5,Venetoclax 800 mg +R-CHOP Phase II,NCT02055820,A Study Evaluating the Safety  Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL,gastric ulcer
D013276,16.67,NCT02055820-9,Venetoclax 800 mg + G-CHOP A,NCT02055820,A Study Evaluating the Safety  Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL,gastric ulcer
10017999,0.48,NCT02055820-5,Venetoclax 800 mg +R-CHOP Phase II,NCT02055820,A Study Evaluating the Safety  Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL,gastrointestinal pain
UNKNOWN-check-for-typo,0.48,NCT02055820-5,Venetoclax 800 mg +R-CHOP Phase II,NCT02055820,A Study Evaluating the Safety  Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL,D00
10021305,0.48,NCT02055820-5,Venetoclax 800 mg +R-CHOP Phase II,NCT02055820,A Study Evaluating the Safety  Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL,ileal perforation
D045823,16.67,NCT02055820-8,Venetoclax 600 mg +G-CHOP,NCT02055820,A Study Evaluating the Safety  Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL,ileus
D009325,0.48,NCT02055820-5,Venetoclax 800 mg +R-CHOP Phase II,NCT02055820,A Study Evaluating the Safety  Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL,nausea
10029957,0.48,NCT02055820-5,Venetoclax 800 mg +R-CHOP Phase II,NCT02055820,A Study Evaluating the Safety  Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL,obstruction gastric
D003251,14.29,NCT02055820-6,Venetoclax 200 mg +G-CHOP,NCT02055820,A Study Evaluating the Safety  Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL,stenosis
D010195,0.96,NCT02055820-5,Venetoclax 800 mg +R-CHOP Phase II,NCT02055820,A Study Evaluating the Safety  Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL,pancreatitis
D000071056,0.48,NCT02055820-5,Venetoclax 800 mg +R-CHOP Phase II,NCT02055820,A Study Evaluating the Safety  Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL,anorectal malformations
10041101,0.48,NCT02055820-5,Venetoclax 800 mg +R-CHOP Phase II,NCT02055820,A Study Evaluating the Safety  Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL,small intestinal obstruction
D013280,0.48,NCT02055820-5,Venetoclax 800 mg +R-CHOP Phase II,NCT02055820,A Study Evaluating the Safety  Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL,stomatitis
D041742,0.48,NCT02055820-5,Venetoclax 800 mg +R-CHOP Phase II,NCT02055820,A Study Evaluating the Safety  Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL,upper gastrointestinal tract
D014839,33.33,NCT02055820-2,Venetoclax 400 mg +R-CHOP,NCT02055820,A Study Evaluating the Safety  Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL,vomiting
D014839,2.4,NCT02055820-5,Venetoclax 800 mg +R-CHOP Phase II,NCT02055820,A Study Evaluating the Safety  Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL,vomiting
D001247,16.67,NCT02055820-9,Venetoclax 800 mg + G-CHOP A,NCT02055820,A Study Evaluating the Safety  Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL,asthenia
D005221,0.96,NCT02055820-5,Venetoclax 800 mg +R-CHOP Phase II,NCT02055820,A Study Evaluating the Safety  Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL,fatigue
D007249,0.48,NCT02055820-5,Venetoclax 800 mg +R-CHOP Phase II,NCT02055820,A Study Evaluating the Safety  Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL,inflammation
D005334,3.37,NCT02055820-5,Venetoclax 800 mg +R-CHOP Phase II,NCT02055820,A Study Evaluating the Safety  Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL,pyrexia
D005334,14.29,NCT02055820-6,Venetoclax 200 mg +G-CHOP,NCT02055820,A Study Evaluating the Safety  Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL,pyrexia
D016757,0.48,NCT02055820-5,Venetoclax 800 mg +R-CHOP Phase II,NCT02055820,A Study Evaluating the Safety  Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL,sudden cardiac death
D042882,0.48,NCT02055820-5,Venetoclax 800 mg +R-CHOP Phase II,NCT02055820,A Study Evaluating the Safety  Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL,gallstones common bile duct
D002764,16.67,NCT02055820-10,Venetoclax 800 mg +G-CHOP B,NCT02055820,A Study Evaluating the Safety  Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL,cholecystitis
D041881,0.48,NCT02055820-5,Venetoclax 800 mg +R-CHOP Phase II,NCT02055820,A Study Evaluating the Safety  Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL,acute cholecystitis
D056486,14.29,NCT02055820-6,Venetoclax 200 mg +G-CHOP,NCT02055820,A Study Evaluating the Safety  Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL,drug induced liver injury
UNKNOWN-check-for-typo,0.48,NCT02055820-5,Venetoclax 800 mg +R-CHOP Phase II,NCT02055820,A Study Evaluating the Safety  Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL,D00
D012852,0.48,NCT02055820-5,Venetoclax 800 mg +R-CHOP Phase II,NCT02055820,A Study Evaluating the Safety  Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL,sinusitis
D011016,0.96,NCT02055820-5,Venetoclax 800 mg +R-CHOP Phase II,NCT02055820,A Study Evaluating the Safety  Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL,pneumonia atypical interstitial of cattle
D000985,0.48,NCT02055820-5,Venetoclax 800 mg +R-CHOP Phase II,NCT02055820,A Study Evaluating the Safety  Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL,antisepsis
D001991,0.48,NCT02055820-5,Venetoclax 800 mg +R-CHOP Phase II,NCT02055820,A Study Evaluating the Safety  Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL,bronchitis
D002481,0.48,NCT02055820-5,Venetoclax 800 mg +R-CHOP Phase II,NCT02055820,A Study Evaluating the Safety  Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL,cellulitis
D004761,0.48,NCT02055820-5,Venetoclax 800 mg +R-CHOP Phase II,NCT02055820,A Study Evaluating the Safety  Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL,clostridium enterocolitis
D003015,0.48,NCT02055820-5,Venetoclax 800 mg +R-CHOP Phase II,NCT02055820,A Study Evaluating the Safety  Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL,clostridium difficile infection
10064687,14.29,NCT02055820-1,Venetoclax 200 mg +R-CHOP,NCT02055820,A Study Evaluating the Safety  Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL,device related infection
D004238,16.67,NCT02055820-9,Venetoclax 800 mg + G-CHOP A,NCT02055820,A Study Evaluating the Safety  Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL,diverticulitis
D004653,14.29,NCT02055820-7,Venetoclax 400 mg +G-CHOP,NCT02055820,A Study Evaluating the Safety  Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL,empyema
D004925,0.48,NCT02055820-5,Venetoclax 800 mg +R-CHOP Phase II,NCT02055820,A Study Evaluating the Safety  Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL,escherichia
D014552,0.48,NCT02055820-5,Venetoclax 800 mg +R-CHOP Phase II,NCT02055820,A Study Evaluating the Safety  Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL,urinary tract infections
D005759,0.48,NCT02055820-5,Venetoclax 800 mg +R-CHOP Phase II,NCT02055820,A Study Evaluating the Safety  Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL,gastroenteritis
D005759,16.67,NCT02055820-4,Venetoclax 800 mg +R-CHOP,NCT02055820,A Study Evaluating the Safety  Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL,gastroenteritis
D006561,0.48,NCT02055820-5,Venetoclax 800 mg +R-CHOP Phase II,NCT02055820,A Study Evaluating the Safety  Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL,herpes simplex
D007239,1.92,NCT02055820-5,Venetoclax 800 mg +R-CHOP Phase II,NCT02055820,A Study Evaluating the Safety  Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL,infection
D007239,14.29,NCT02055820-6,Venetoclax 200 mg +G-CHOP,NCT02055820,A Study Evaluating the Safety  Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL,infection
D007251,0.96,NCT02055820-5,Venetoclax 800 mg +R-CHOP Phase II,NCT02055820,A Study Evaluating the Safety  Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL,influenza
D012141,0.96,NCT02055820-5,Venetoclax 800 mg +R-CHOP Phase II,NCT02055820,A Study Evaluating the Safety  Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL,respiratory tract infections
10061229,1.44,NCT02055820-5,Venetoclax 800 mg +R-CHOP Phase II,NCT02055820,A Study Evaluating the Safety  Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL,lung infection
10061229,14.29,NCT02055820-7,Venetoclax 400 mg +G-CHOP,NCT02055820,A Study Evaluating the Safety  Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL,lung infection
10061229,16.67,NCT02055820-9,Venetoclax 800 mg + G-CHOP A,NCT02055820,A Study Evaluating the Safety  Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL,lung infection
D008587,16.67,NCT02055820-4,Venetoclax 800 mg +R-CHOP,NCT02055820,A Study Evaluating the Safety  Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL,viral meningitis
D009304,0.48,NCT02055820-5,Venetoclax 800 mg +R-CHOP Phase II,NCT02055820,A Study Evaluating the Safety  Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL,nasopharyngitis
D009869,14.29,NCT02055820-7,Venetoclax 400 mg +G-CHOP,NCT02055820,A Study Evaluating the Safety  Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL,oophoritis
D002180,0.48,NCT02055820-5,Venetoclax 800 mg +R-CHOP Phase II,NCT02055820,A Study Evaluating the Safety  Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL,oral candidiasis
D013283,0.48,NCT02055820-5,Venetoclax 800 mg +R-CHOP Phase II,NCT02055820,A Study Evaluating the Safety  Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL,herpes simplex oral
D016720,0.48,NCT02055820-5,Venetoclax 800 mg +R-CHOP Phase II,NCT02055820,A Study Evaluating the Safety  Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL,pneumocystis infections
D011020,0.96,NCT02055820-5,Venetoclax 800 mg +R-CHOP Phase II,NCT02055820,A Study Evaluating the Safety  Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL,pneumocystis jirovecii pneumonia
D011020,16.67,NCT02055820-10,Venetoclax 800 mg +G-CHOP B,NCT02055820,A Study Evaluating the Safety  Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL,pneumocystis jirovecii pneumonia
D011014,4.33,NCT02055820-5,Venetoclax 800 mg +R-CHOP Phase II,NCT02055820,A Study Evaluating the Safety  Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL,pneumonia
D011014,14.29,NCT02055820-6,Venetoclax 200 mg +G-CHOP,NCT02055820,A Study Evaluating the Safety  Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL,pneumonia
D011024,14.29,NCT02055820-1,Venetoclax 200 mg +R-CHOP,NCT02055820,A Study Evaluating the Safety  Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL,pneumonia viral
D000985,0.96,NCT02055820-5,Venetoclax 800 mg +R-CHOP Phase II,NCT02055820,A Study Evaluating the Safety  Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL,antisepsis
D000038,0.48,NCT02055820-5,Venetoclax 800 mg +R-CHOP Phase II,NCT02055820,A Study Evaluating the Safety  Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL,abscess
D012141,0.48,NCT02055820-5,Venetoclax 800 mg +R-CHOP Phase II,NCT02055820,A Study Evaluating the Safety  Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL,respiratory tract infection
D000069544,14.29,NCT02055820-1,Venetoclax 200 mg +R-CHOP,NCT02055820,A Study Evaluating the Safety  Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL,encephalitis infection
D000069544,12.5,NCT02055820-3,Venetoclax 600 mg +R-CHOP,NCT02055820,A Study Evaluating the Safety  Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL,encephalitis infection
D018805,16.67,NCT02055820-4,Venetoclax 800 mg +R-CHOP,NCT02055820,A Study Evaluating the Safety  Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL,sepsis
D018805,2.88,NCT02055820-5,Venetoclax 800 mg +R-CHOP Phase II,NCT02055820,A Study Evaluating the Safety  Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL,sepsis
D018805,16.67,NCT02055820-8,Venetoclax 600 mg +G-CHOP,NCT02055820,A Study Evaluating the Safety  Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL,sepsis
D012793,0.48,NCT02055820-5,Venetoclax 800 mg +R-CHOP Phase II,NCT02055820,A Study Evaluating the Safety  Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL,sialoadenitis
D012852,0.48,NCT02055820-5,Venetoclax 800 mg +R-CHOP Phase II,NCT02055820,A Study Evaluating the Safety  Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL,sinusitis
10040872,0.48,NCT02055820-5,Venetoclax 800 mg +R-CHOP Phase II,NCT02055820,A Study Evaluating the Safety  Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL,skin infection
D000985,0.48,NCT02055820-5,Venetoclax 800 mg +R-CHOP Phase II,NCT02055820,A Study Evaluating the Safety  Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL,antisepsis
D012141,0.48,NCT02055820-5,Venetoclax 800 mg +R-CHOP Phase II,NCT02055820,A Study Evaluating the Safety  Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL,upper respiratory tract infections
D014552,0.96,NCT02055820-5,Venetoclax 800 mg +R-CHOP Phase II,NCT02055820,A Study Evaluating the Safety  Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL,urinary tract infection
D014552,0.48,NCT02055820-5,Venetoclax 800 mg +R-CHOP Phase II,NCT02055820,A Study Evaluating the Safety  Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL,urinary tract infections
D053821,0.96,NCT02055820-5,Venetoclax 800 mg +R-CHOP Phase II,NCT02055820,A Study Evaluating the Safety  Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL,cardiovascular infections
D003288,0.48,NCT02055820-5,Venetoclax 800 mg +R-CHOP Phase II,NCT02055820,A Study Evaluating the Safety  Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL,contusion
10051792,12.5,NCT02055820-3,Venetoclax 600 mg +R-CHOP,NCT02055820,A Study Evaluating the Safety  Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL,infusion related reaction
10051792,0.48,NCT02055820-5,Venetoclax 800 mg +R-CHOP Phase II,NCT02055820,A Study Evaluating the Safety  Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL,infusion related reaction
D008022,12.5,NCT02055820-3,Venetoclax 600 mg +R-CHOP,NCT02055820,A Study Evaluating the Safety  Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL,ligaments
D051299,0.48,NCT02055820-5,Venetoclax 800 mg +R-CHOP Phase II,NCT02055820,A Study Evaluating the Safety  Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL,post-lumbar puncture headache
D051299,14.29,NCT02055820-6,Venetoclax 200 mg +G-CHOP,NCT02055820,A Study Evaluating the Safety  Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL,post-lumbar puncture headache
D016103,0.48,NCT02055820-5,Venetoclax 800 mg +R-CHOP Phase II,NCT02055820,A Study Evaluating the Safety  Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL,spinal fracture
D000081015,0.48,NCT02055820-5,Venetoclax 800 mg +R-CHOP Phase II,NCT02055820,A Study Evaluating the Safety  Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL,ototoxicity
10005364,14.29,NCT02055820-6,Venetoclax 200 mg +G-CHOP,NCT02055820,A Study Evaluating the Safety  Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL,blood bilirubin increased
D002097,0.48,NCT02055820-5,Venetoclax 800 mg +R-CHOP Phase II,NCT02055820,A Study Evaluating the Safety  Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL,c-reactive protein
D001066,0.48,NCT02055820-5,Venetoclax 800 mg +R-CHOP Phase II,NCT02055820,A Study Evaluating the Safety  Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL,appetite
D003681,14.29,NCT02055820-1,Venetoclax 200 mg +R-CHOP,NCT02055820,A Study Evaluating the Safety  Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL,dehydration
D003681,0.48,NCT02055820-5,Venetoclax 800 mg +R-CHOP Phase II,NCT02055820,A Study Evaluating the Safety  Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL,dehydration
D003920,0.96,NCT02055820-5,Venetoclax 800 mg +R-CHOP Phase II,NCT02055820,A Study Evaluating the Safety  Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL,diabetes mellitus
UNKNOWN-check-for-typo,16.67,NCT02055820-9,Venetoclax 800 mg + G-CHOP A,NCT02055820,A Study Evaluating the Safety  Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL,D00
UNKNOWN-check-for-typo,16.67,NCT02055820-10,Venetoclax 800 mg +G-CHOP B,NCT02055820,A Study Evaluating the Safety  Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL,D00
UNKNOWN-check-for-typo,0.48,NCT02055820-5,Venetoclax 800 mg +R-CHOP Phase II,NCT02055820,A Study Evaluating the Safety  Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL,D00
UNKNOWN-check-for-typo,0.48,NCT02055820-5,Venetoclax 800 mg +R-CHOP Phase II,NCT02055820,A Study Evaluating the Safety  Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL,D00
D015275,12.5,NCT02055820-3,Venetoclax 600 mg +R-CHOP,NCT02055820,A Study Evaluating the Safety  Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL,tumour lysis syndrome
D001416,0.48,NCT02055820-5,Venetoclax 800 mg +R-CHOP Phase II,NCT02055820,A Study Evaluating the Safety  Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL,back pain
D007596,0.48,NCT02055820-5,Venetoclax 800 mg +R-CHOP Phase II,NCT02055820,A Study Evaluating the Safety  Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL,joints
10033425,0.96,NCT02055820-5,Venetoclax 800 mg +R-CHOP Phase II,NCT02055820,A Study Evaluating the Safety  Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL,pain in extremity
D013168,0.48,NCT02055820-5,Venetoclax 800 mg +R-CHOP Phase II,NCT02055820,A Study Evaluating the Safety  Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL,spondylolisthesis
D015470,1.44,NCT02055820-5,Venetoclax 800 mg +R-CHOP Phase II,NCT02055820,A Study Evaluating the Safety  Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL,leukemia myeloid acute
D000235,0.48,NCT02055820-5,Venetoclax 800 mg +R-CHOP Phase II,NCT02055820,A Study Evaluating the Safety  Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL,adenolymphoma
D005909,0.48,NCT02055820-5,Venetoclax 800 mg +R-CHOP Phase II,NCT02055820,A Study Evaluating the Safety  Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL,glioblastoma
D015614,16.67,NCT02055820-8,Venetoclax 600 mg +G-CHOP,NCT02055820,A Study Evaluating the Safety  Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL,histiocytosis
D008175,14.29,NCT02055820-6,Venetoclax 200 mg +G-CHOP,NCT02055820,A Study Evaluating the Safety  Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL,lung neoplasms
D009190,12.5,NCT02055820-3,Venetoclax 600 mg +R-CHOP,NCT02055820,A Study Evaluating the Safety  Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL,myelodysplastic syndrome
D009190,0.96,NCT02055820-5,Venetoclax 800 mg +R-CHOP Phase II,NCT02055820,A Study Evaluating the Safety  Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL,myelodysplastic syndrome
D002346,14.29,NCT02055820-1,Venetoclax 200 mg +R-CHOP,NCT02055820,A Study Evaluating the Safety  Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL,carotid sinus
D004827,0.48,NCT02055820-5,Venetoclax 800 mg +R-CHOP Phase II,NCT02055820,A Study Evaluating the Safety  Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL,epilepsy
D007002,0.48,NCT02055820-5,Venetoclax 800 mg +R-CHOP Phase II,NCT02055820,A Study Evaluating the Safety  Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL,hypoglossal nerve
D011115,0.48,NCT02055820-5,Venetoclax 800 mg +R-CHOP Phase II,NCT02055820,A Study Evaluating the Safety  Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL,polyneuropathy
D013575,0.48,NCT02055820-5,Venetoclax 800 mg +R-CHOP Phase II,NCT02055820,A Study Evaluating the Safety  Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL,presyncope
D013575,0.96,NCT02055820-5,Venetoclax 800 mg +R-CHOP Phase II,NCT02055820,A Study Evaluating the Safety  Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL,syncope
D002546,0.48,NCT02055820-5,Venetoclax 800 mg +R-CHOP Phase II,NCT02055820,A Study Evaluating the Safety  Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL,ischemic attack transient
D003221,16.67,NCT02055820-9,Venetoclax 800 mg + G-CHOP A,NCT02055820,A Study Evaluating the Safety  Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL,confusional state
D011618,14.29,NCT02055820-6,Venetoclax 200 mg +G-CHOP,NCT02055820,A Study Evaluating the Safety  Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL,psychotic disorder
D058186,0.96,NCT02055820-5,Venetoclax 800 mg +R-CHOP Phase II,NCT02055820,A Study Evaluating the Safety  Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL,acute kidney injury
D029424,0.48,NCT02055820-5,Venetoclax 800 mg +R-CHOP Phase II,NCT02055820,A Study Evaluating the Safety  Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL,chronic obstructive pulmonary disease
D003371,0.48,NCT02055820-5,Venetoclax 800 mg +R-CHOP Phase II,NCT02055820,A Study Evaluating the Safety  Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL,cough
UNKNOWN-check-for-typo,0.96,NCT02055820-5,Venetoclax 800 mg +R-CHOP Phase II,NCT02055820,A Study Evaluating the Safety  Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL,D00
UNKNOWN-check-for-typo,0.48,NCT02055820-5,Venetoclax 800 mg +R-CHOP Phase II,NCT02055820,A Study Evaluating the Safety  Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL,D00
D017563,12.5,NCT02055820-3,Venetoclax 600 mg +R-CHOP,NCT02055820,A Study Evaluating the Safety  Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL,interstitial lung disease
D001996,0.48,NCT02055820-5,Venetoclax 800 mg +R-CHOP Phase II,NCT02055820,A Study Evaluating the Safety  Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL,bronchopneumonia
D001996,14.29,NCT02055820-7,Venetoclax 400 mg +G-CHOP,NCT02055820,A Study Evaluating the Safety  Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL,bronchopneumonia
D010996,0.48,NCT02055820-5,Venetoclax 800 mg +R-CHOP Phase II,NCT02055820,A Study Evaluating the Safety  Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL,pleural effusion
D011030,0.48,NCT02055820-5,Venetoclax 800 mg +R-CHOP Phase II,NCT02055820,A Study Evaluating the Safety  Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL,pneumothorax
10036790,0.48,NCT02055820-5,Venetoclax 800 mg +R-CHOP Phase II,NCT02055820,A Study Evaluating the Safety  Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL,productive cough
D011655,0.48,NCT02055820-5,Venetoclax 800 mg +R-CHOP Phase II,NCT02055820,A Study Evaluating the Safety  Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL,pulmonary embolism
D011655,14.29,NCT02055820-7,Venetoclax 400 mg +G-CHOP,NCT02055820,A Study Evaluating the Safety  Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL,pulmonary embolism
10037868,0.48,NCT02055820-5,Venetoclax 800 mg +R-CHOP Phase II,NCT02055820,A Study Evaluating the Safety  Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL,rash maculo-papular
D004617,14.29,NCT02055820-7,Venetoclax 400 mg +G-CHOP,NCT02055820,A Study Evaluating the Safety  Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL,embolism
D007022,14.29,NCT02055820-1,Venetoclax 200 mg +R-CHOP,NCT02055820,A Study Evaluating the Safety  Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL,hypotension
D007022,0.96,NCT02055820-5,Venetoclax 800 mg +R-CHOP Phase II,NCT02055820,A Study Evaluating the Safety  Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL,hypotension
D009026,6.67,NCT02096588-1,Simvastatin,NCT02096588,Detection and Prevention of Anthracycline-Related Cardiac Toxicity With Concurrent Simvastatin,mortality
D064420,6.67,NCT02096588-1,Simvastatin,NCT02096588,Detection and Prevention of Anthracycline-Related Cardiac Toxicity With Concurrent Simvastatin,adverse drug events
10011268,6.67,NCT02096588-1,Simvastatin,NCT02096588,Detection and Prevention of Anthracycline-Related Cardiac Toxicity With Concurrent Simvastatin,cpk increased
D009026,47.24,NCT02101788-1,Arm A - Control Arm,NCT02101788,Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer,mortality
D009026,40.16,NCT02101788-2,Arm B - Experimental Arm,NCT02101788,Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer,mortality
D009026,3.41,NCT02101788-3,Crossover From Control to Experimental Arm,NCT02101788,Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer,mortality
D064420,33.86,NCT02101788-1,Arm A - Control Arm,NCT02101788,Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer,adverse drug events
D064420,35.43,NCT02101788-2,Arm B - Experimental Arm,NCT02101788,Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer,adverse drug events
D064420,28.41,NCT02101788-3,Crossover From Control to Experimental Arm,NCT02101788,Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer,adverse drug events
D000740,0.79,NCT02101788-1,Arm A - Control Arm,NCT02101788,Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer,anemia
D000740,3.15,NCT02101788-2,Arm B - Experimental Arm,NCT02101788,Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer,anemia
D000740,1.14,NCT02101788-3,Crossover From Control to Experimental Arm,NCT02101788,Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer,anemia
D006323,1.14,NCT02101788-3,Crossover From Control to Experimental Arm,NCT02101788,Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer,cardiac arrest
10015919,1.57,NCT02101788-1,Arm A - Control Arm,NCT02101788,Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer,eye disorders - other specify
10015919,1.57,NCT02101788-2,Arm B - Experimental Arm,NCT02101788,Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer,eye disorders - other specify
10038901,0.79,NCT02101788-2,Arm B - Experimental Arm,NCT02101788,Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer,retinal vascular disorder
10010000,3.15,NCT02101788-1,Arm A - Control Arm,NCT02101788,Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer,colonic obstruction
10010000,5.68,NCT02101788-3,Crossover From Control to Experimental Arm,NCT02101788,Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer,colonic obstruction
10010004,0.79,NCT02101788-2,Arm B - Experimental Arm,NCT02101788,Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer,colonic stenosis
10010004,1.14,NCT02101788-3,Crossover From Control to Experimental Arm,NCT02101788,Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer,colonic stenosis
10010001,0.79,NCT02101788-1,Arm A - Control Arm,NCT02101788,Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer,colonic perforation
D003967,1.57,NCT02101788-1,Arm A - Control Arm,NCT02101788,Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer,diarrhea
D003967,0.79,NCT02101788-2,Arm B - Experimental Arm,NCT02101788,Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer,diarrhea
D014839,0.79,NCT02101788-1,Arm A - Control Arm,NCT02101788,Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer,vomiting
D014839,2.36,NCT02101788-2,Arm B - Experimental Arm,NCT02101788,Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer,vomiting
D014839,1.14,NCT02101788-3,Crossover From Control to Experimental Arm,NCT02101788,Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer,vomiting
10041101,1.57,NCT02101788-1,Arm A - Control Arm,NCT02101788,Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer,small intestinal obstruction
10041101,8.66,NCT02101788-2,Arm B - Experimental Arm,NCT02101788,Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer,small intestinal obstruction
10041101,3.41,NCT02101788-3,Crossover From Control to Experimental Arm,NCT02101788,Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer,small intestinal obstruction
D015746,7.87,NCT02101788-1,Arm A - Control Arm,NCT02101788,Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer,abdominal pain
D015746,1.57,NCT02101788-2,Arm B - Experimental Arm,NCT02101788,Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer,abdominal pain
D015746,2.27,NCT02101788-3,Crossover From Control to Experimental Arm,NCT02101788,Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer,abdominal pain
10028130,0.79,NCT02101788-1,Arm A - Control Arm,NCT02101788,Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer,mucositis oral
10028130,0.79,NCT02101788-2,Arm B - Experimental Arm,NCT02101788,Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer,mucositis oral
10051746,0.79,NCT02101788-2,Arm B - Experimental Arm,NCT02101788,Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer,lower gastrointestinal hemorrhage
10017947,0.79,NCT02101788-1,Arm A - Control Arm,NCT02101788,Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer,gastrointestinal disorders - other specify
D009325,3.94,NCT02101788-1,Arm A - Control Arm,NCT02101788,Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer,nausea
D009325,0.79,NCT02101788-2,Arm B - Experimental Arm,NCT02101788,Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer,nausea
D001201,0.79,NCT02101788-1,Arm A - Control Arm,NCT02101788,Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer,ascites
10065732,0.79,NCT02101788-2,Arm B - Experimental Arm,NCT02101788,Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer,jejunal obstruction
10029957,2.27,NCT02101788-3,Crossover From Control to Experimental Arm,NCT02101788,Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer,obstruction gastric
D045823,1.14,NCT02101788-3,Crossover From Control to Experimental Arm,NCT02101788,Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer,ileus
D010146,0.79,NCT02101788-1,Arm A - Control Arm,NCT02101788,Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer,pain
D010146,1.14,NCT02101788-3,Crossover From Control to Experimental Arm,NCT02101788,Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer,pain
10016791,0.79,NCT02101788-2,Arm B - Experimental Arm,NCT02101788,Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer,flu like symptoms
10062501,0.79,NCT02101788-1,Arm A - Control Arm,NCT02101788,Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer,non-cardiac chest pain
10050068,0.79,NCT02101788-1,Arm A - Control Arm,NCT02101788,Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer,edema limbs
10011914,0.79,NCT02101788-1,Arm A - Control Arm,NCT02101788,Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer,death nos
10011914,1.57,NCT02101788-2,Arm B - Experimental Arm,NCT02101788,Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer,death nos
D002764,0.79,NCT02101788-1,Arm A - Control Arm,NCT02101788,Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer,cholecystitis
10021881,0.79,NCT02101788-1,Arm A - Control Arm,NCT02101788,Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer,infections and infestations - other specify
10021881,0.79,NCT02101788-2,Arm B - Experimental Arm,NCT02101788,Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer,infections and infestations - other specify
10046300,0.79,NCT02101788-2,Arm B - Experimental Arm,NCT02101788,Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer,upper respiratory infection
D018461,0.79,NCT02101788-2,Arm B - Experimental Arm,NCT02101788,Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer,soft tissue infection
D018805,0.79,NCT02101788-1,Arm A - Control Arm,NCT02101788,Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer,sepsis
D018805,1.57,NCT02101788-2,Arm B - Experimental Arm,NCT02101788,Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer,sepsis
D018805,1.14,NCT02101788-3,Crossover From Control to Experimental Arm,NCT02101788,Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer,sepsis
10061229,0.79,NCT02101788-1,Arm A - Control Arm,NCT02101788,Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer,lung infection
10061229,1.57,NCT02101788-2,Arm B - Experimental Arm,NCT02101788,Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer,lung infection
10023424,1.57,NCT02101788-1,Arm A - Control Arm,NCT02101788,Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer,kidney infection
10023424,0.79,NCT02101788-2,Arm B - Experimental Arm,NCT02101788,Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer,kidney infection
10064687,0.79,NCT02101788-2,Arm B - Experimental Arm,NCT02101788,Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer,device related infection
D014552,3.15,NCT02101788-1,Arm A - Control Arm,NCT02101788,Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer,urinary tract infection
D014552,4.72,NCT02101788-2,Arm B - Experimental Arm,NCT02101788,Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer,urinary tract infection
D014552,2.27,NCT02101788-3,Crossover From Control to Experimental Arm,NCT02101788,Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer,urinary tract infection
10040872,1.14,NCT02101788-3,Crossover From Control to Experimental Arm,NCT02101788,Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer,skin infection
10061229,1.14,NCT02101788-3,Crossover From Control to Experimental Arm,NCT02101788,Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer,lung infection
10059094,0.79,NCT02101788-1,Arm A - Control Arm,NCT02101788,Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer,intestinal stoma obstruction
10050528,0.79,NCT02101788-1,Arm A - Control Arm,NCT02101788,Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer,ejection fraction decreased
10050528,1.57,NCT02101788-2,Arm B - Experimental Arm,NCT02101788,Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer,ejection fraction decreased
10029366,0.79,NCT02101788-1,Arm A - Control Arm,NCT02101788,Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer,neutrophil count decreased
10001675,0.79,NCT02101788-2,Arm B - Experimental Arm,NCT02101788,Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer,alkaline phosphatase increased
10001551,0.79,NCT02101788-2,Arm B - Experimental Arm,NCT02101788,Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer,alanine aminotransferase increased
D007010,1.57,NCT02101788-1,Arm A - Control Arm,NCT02101788,Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer,hyponatremia
D007010,1.14,NCT02101788-3,Crossover From Control to Experimental Arm,NCT02101788,Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer,hyponatremia
D007008,0.79,NCT02101788-2,Arm B - Experimental Arm,NCT02101788,Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer,hypokalemia
D003681,1.57,NCT02101788-1,Arm A - Control Arm,NCT02101788,Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer,dehydration
D000855,0.79,NCT02101788-2,Arm B - Experimental Arm,NCT02101788,Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer,anorexia
D034141,1.14,NCT02101788-3,Crossover From Control to Experimental Arm,NCT02101788,Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer,hypoalbuminemia
D003693,1.14,NCT02101788-3,Crossover From Control to Experimental Arm,NCT02101788,Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer,delirium
10038359,0.79,NCT02101788-2,Arm B - Experimental Arm,NCT02101788,Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer,renal and urinary disorders - other specify
10038359,1.14,NCT02101788-3,Crossover From Control to Experimental Arm,NCT02101788,Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer,renal and urinary disorders - other specify
10061574,0.79,NCT02101788-2,Arm B - Experimental Arm,NCT02101788,Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer,urinary tract obstruction
10061574,1.14,NCT02101788-3,Crossover From Control to Experimental Arm,NCT02101788,Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer,urinary tract obstruction
D006417,0.79,NCT02101788-2,Arm B - Experimental Arm,NCT02101788,Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer,hematuria
D058186,0.79,NCT02101788-1,Arm A - Control Arm,NCT02101788,Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer,acute kidney injury
D058186,1.14,NCT02101788-3,Crossover From Control to Experimental Arm,NCT02101788,Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer,acute kidney injury
D016055,1.14,NCT02101788-3,Crossover From Control to Experimental Arm,NCT02101788,Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer,urinary retention
10046912,2.36,NCT02101788-1,Arm A - Control Arm,NCT02101788,Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer,vaginal hemorrhage
10046912,1.14,NCT02101788-3,Crossover From Control to Experimental Arm,NCT02101788,Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer,vaginal hemorrhage
D012131,0.79,NCT02101788-2,Arm B - Experimental Arm,NCT02101788,Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer,respiratory failure
D011014,0.79,NCT02101788-2,Arm B - Experimental Arm,NCT02101788,Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer,pneumonitis
D011014,1.14,NCT02101788-3,Crossover From Control to Experimental Arm,NCT02101788,Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer,pneumonitis
D010996,0.79,NCT02101788-1,Arm A - Control Arm,NCT02101788,Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer,pleural effusion
D010996,1.57,NCT02101788-2,Arm B - Experimental Arm,NCT02101788,Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer,pleural effusion
D010996,2.27,NCT02101788-3,Crossover From Control to Experimental Arm,NCT02101788,Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer,pleural effusion
D004417,1.57,NCT02101788-1,Arm A - Control Arm,NCT02101788,Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer,dyspnea
D004417,1.57,NCT02101788-2,Arm B - Experimental Arm,NCT02101788,Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer,dyspnea
D002916,0.79,NCT02101788-2,Arm B - Experimental Arm,NCT02101788,Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer,chylothorax
10065746,0.79,NCT02101788-2,Arm B - Experimental Arm,NCT02101788,Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer,bronchopulmonary hemorrhage
10040785,0.79,NCT02101788-2,Arm B - Experimental Arm,NCT02101788,Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer,skin and subcutaneous tissue disorders - other specify
10037868,0.79,NCT02101788-2,Arm B - Experimental Arm,NCT02101788,Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer,rash maculo-papular
10043565,0.79,NCT02101788-1,Arm A - Control Arm,NCT02101788,Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer,thromboembolic event
10043565,3.15,NCT02101788-2,Arm B - Experimental Arm,NCT02101788,Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer,thromboembolic event
D007022,0.79,NCT02101788-1,Arm A - Control Arm,NCT02101788,Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer,hypotension
D006973,0.79,NCT02101788-2,Arm B - Experimental Arm,NCT02101788,Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer,hypertension
D009026,100.0,NCT02142049-1,Part 1: Dose Level 1,NCT02142049,Ibrutinib and Lenalidomide With Dose Adjusted EPOCH-R in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma,mortality
D009026,100.0,NCT02142049-2,Part 1: Dose Level 2,NCT02142049,Ibrutinib and Lenalidomide With Dose Adjusted EPOCH-R in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma,mortality
D009026,100.0,NCT02142049-3,Part 1: Dose Level 3,NCT02142049,Ibrutinib and Lenalidomide With Dose Adjusted EPOCH-R in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma,mortality
D009026,83.33,NCT02142049-4,Part 1: Dose Level 4,NCT02142049,Ibrutinib and Lenalidomide With Dose Adjusted EPOCH-R in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma,mortality
D009026,11.54,NCT02142049-5,All Subjects Treated at RP2D,NCT02142049,Ibrutinib and Lenalidomide With Dose Adjusted EPOCH-R in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma,mortality
D064420,100.0,NCT02142049-1,Part 1: Dose Level 1,NCT02142049,Ibrutinib and Lenalidomide With Dose Adjusted EPOCH-R in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma,adverse drug events
D064420,100.0,NCT02142049-2,Part 1: Dose Level 2,NCT02142049,Ibrutinib and Lenalidomide With Dose Adjusted EPOCH-R in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma,adverse drug events
D064420,100.0,NCT02142049-3,Part 1: Dose Level 3,NCT02142049,Ibrutinib and Lenalidomide With Dose Adjusted EPOCH-R in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma,adverse drug events
D064420,83.33,NCT02142049-4,Part 1: Dose Level 4,NCT02142049,Ibrutinib and Lenalidomide With Dose Adjusted EPOCH-R in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma,adverse drug events
D064420,73.08,NCT02142049-5,All Subjects Treated at RP2D,NCT02142049,Ibrutinib and Lenalidomide With Dose Adjusted EPOCH-R in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma,adverse drug events
D064147,33.33,NCT02142049-1,Part 1: Dose Level 1,NCT02142049,Ibrutinib and Lenalidomide With Dose Adjusted EPOCH-R in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma,febrile neutropenia
D064147,33.33,NCT02142049-2,Part 1: Dose Level 2,NCT02142049,Ibrutinib and Lenalidomide With Dose Adjusted EPOCH-R in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma,febrile neutropenia
D064147,33.33,NCT02142049-3,Part 1: Dose Level 3,NCT02142049,Ibrutinib and Lenalidomide With Dose Adjusted EPOCH-R in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma,febrile neutropenia
D064147,23.08,NCT02142049-5,All Subjects Treated at RP2D,NCT02142049,Ibrutinib and Lenalidomide With Dose Adjusted EPOCH-R in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma,febrile neutropenia
D000741,33.33,NCT02142049-3,Part 1: Dose Level 3,NCT02142049,Ibrutinib and Lenalidomide With Dose Adjusted EPOCH-R in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma,aplastic anaemia
D000741,33.33,NCT02142049-4,Part 1: Dose Level 4,NCT02142049,Ibrutinib and Lenalidomide With Dose Adjusted EPOCH-R in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma,aplastic anaemia
D000741,7.69,NCT02142049-5,All Subjects Treated at RP2D,NCT02142049,Ibrutinib and Lenalidomide With Dose Adjusted EPOCH-R in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma,aplastic anaemia
D013921,33.33,NCT02142049-1,Part 1: Dose Level 1,NCT02142049,Ibrutinib and Lenalidomide With Dose Adjusted EPOCH-R in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma,thrombocytopenia
D013921,33.33,NCT02142049-3,Part 1: Dose Level 3,NCT02142049,Ibrutinib and Lenalidomide With Dose Adjusted EPOCH-R in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma,thrombocytopenia
D013921,3.85,NCT02142049-5,All Subjects Treated at RP2D,NCT02142049,Ibrutinib and Lenalidomide With Dose Adjusted EPOCH-R in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma,thrombocytopenia
D001281,33.33,NCT02142049-2,Part 1: Dose Level 2,NCT02142049,Ibrutinib and Lenalidomide With Dose Adjusted EPOCH-R in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma,atrial fibrillation
D001281,33.33,NCT02142049-3,Part 1: Dose Level 3,NCT02142049,Ibrutinib and Lenalidomide With Dose Adjusted EPOCH-R in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma,atrial fibrillation
D001281,3.85,NCT02142049-5,All Subjects Treated at RP2D,NCT02142049,Ibrutinib and Lenalidomide With Dose Adjusted EPOCH-R in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma,atrial fibrillation
D015746,16.67,NCT02142049-4,Part 1: Dose Level 4,NCT02142049,Ibrutinib and Lenalidomide With Dose Adjusted EPOCH-R in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma,abdominal pain
D015746,3.85,NCT02142049-5,All Subjects Treated at RP2D,NCT02142049,Ibrutinib and Lenalidomide With Dose Adjusted EPOCH-R in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma,abdominal pain
D003092,16.67,NCT02142049-4,Part 1: Dose Level 4,NCT02142049,Ibrutinib and Lenalidomide With Dose Adjusted EPOCH-R in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma,colitis
D003092,7.69,NCT02142049-5,All Subjects Treated at RP2D,NCT02142049,Ibrutinib and Lenalidomide With Dose Adjusted EPOCH-R in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma,colitis
D000069196,33.33,NCT02142049-3,Part 1: Dose Level 3,NCT02142049,Ibrutinib and Lenalidomide With Dose Adjusted EPOCH-R in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma,gastrointestinal microbiome
D044504,16.67,NCT02142049-4,Part 1: Dose Level 4,NCT02142049,Ibrutinib and Lenalidomide With Dose Adjusted EPOCH-R in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma,enterocolitis neutropenic
D044504,3.85,NCT02142049-5,All Subjects Treated at RP2D,NCT02142049,Ibrutinib and Lenalidomide With Dose Adjusted EPOCH-R in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma,enterocolitis neutropenic
D014839,33.33,NCT02142049-1,Part 1: Dose Level 1,NCT02142049,Ibrutinib and Lenalidomide With Dose Adjusted EPOCH-R in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma,vomiting
D014839,3.85,NCT02142049-5,All Subjects Treated at RP2D,NCT02142049,Ibrutinib and Lenalidomide With Dose Adjusted EPOCH-R in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma,vomiting
D003643,33.33,NCT02142049-1,Part 1: Dose Level 1,NCT02142049,Ibrutinib and Lenalidomide With Dose Adjusted EPOCH-R in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma,death
D005334,16.67,NCT02142049-4,Part 1: Dose Level 4,NCT02142049,Ibrutinib and Lenalidomide With Dose Adjusted EPOCH-R in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma,pyrexia
D005334,11.54,NCT02142049-5,All Subjects Treated at RP2D,NCT02142049,Ibrutinib and Lenalidomide With Dose Adjusted EPOCH-R in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma,pyrexia
D018784,16.67,NCT02142049-4,Part 1: Dose Level 4,NCT02142049,Ibrutinib and Lenalidomide With Dose Adjusted EPOCH-R in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma,abdominal abscess
D018784,3.85,NCT02142049-5,All Subjects Treated at RP2D,NCT02142049,Ibrutinib and Lenalidomide With Dose Adjusted EPOCH-R in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma,abdominal abscess
D003015,16.67,NCT02142049-4,Part 1: Dose Level 4,NCT02142049,Ibrutinib and Lenalidomide With Dose Adjusted EPOCH-R in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma,clostridium difficile infection
D003015,3.85,NCT02142049-5,All Subjects Treated at RP2D,NCT02142049,Ibrutinib and Lenalidomide With Dose Adjusted EPOCH-R in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma,clostridium difficile infection
D000985,16.67,NCT02142049-4,Part 1: Dose Level 4,NCT02142049,Ibrutinib and Lenalidomide With Dose Adjusted EPOCH-R in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma,antisepsis
D000985,3.85,NCT02142049-5,All Subjects Treated at RP2D,NCT02142049,Ibrutinib and Lenalidomide With Dose Adjusted EPOCH-R in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma,antisepsis
D011014,33.33,NCT02142049-2,Part 1: Dose Level 2,NCT02142049,Ibrutinib and Lenalidomide With Dose Adjusted EPOCH-R in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma,pneumonia
D011014,7.69,NCT02142049-5,All Subjects Treated at RP2D,NCT02142049,Ibrutinib and Lenalidomide With Dose Adjusted EPOCH-R in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma,pneumonia
D000985,33.33,NCT02142049-2,Part 1: Dose Level 2,NCT02142049,Ibrutinib and Lenalidomide With Dose Adjusted EPOCH-R in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma,antisepsis
D012772,33.33,NCT02142049-1,Part 1: Dose Level 1,NCT02142049,Ibrutinib and Lenalidomide With Dose Adjusted EPOCH-R in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma,septic shock
10016173,16.67,NCT02142049-4,Part 1: Dose Level 4,NCT02142049,Ibrutinib and Lenalidomide With Dose Adjusted EPOCH-R in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma,fall
10016173,3.85,NCT02142049-5,All Subjects Treated at RP2D,NCT02142049,Ibrutinib and Lenalidomide With Dose Adjusted EPOCH-R in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma,fall
D003681,33.33,NCT02142049-1,Part 1: Dose Level 1,NCT02142049,Ibrutinib and Lenalidomide With Dose Adjusted EPOCH-R in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma,dehydration
D003681,16.67,NCT02142049-4,Part 1: Dose Level 4,NCT02142049,Ibrutinib and Lenalidomide With Dose Adjusted EPOCH-R in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma,dehydration
D003681,3.85,NCT02142049-5,All Subjects Treated at RP2D,NCT02142049,Ibrutinib and Lenalidomide With Dose Adjusted EPOCH-R in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma,dehydration
UNKNOWN-check-for-typo,16.67,NCT02142049-4,Part 1: Dose Level 4,NCT02142049,Ibrutinib and Lenalidomide With Dose Adjusted EPOCH-R in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma,D00
UNKNOWN-check-for-typo,3.85,NCT02142049-5,All Subjects Treated at RP2D,NCT02142049,Ibrutinib and Lenalidomide With Dose Adjusted EPOCH-R in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma,D00
D013575,33.33,NCT02142049-4,Part 1: Dose Level 4,NCT02142049,Ibrutinib and Lenalidomide With Dose Adjusted EPOCH-R in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma,syncope
D013575,7.69,NCT02142049-5,All Subjects Treated at RP2D,NCT02142049,Ibrutinib and Lenalidomide With Dose Adjusted EPOCH-R in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma,syncope
D058186,16.67,NCT02142049-4,Part 1: Dose Level 4,NCT02142049,Ibrutinib and Lenalidomide With Dose Adjusted EPOCH-R in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma,acute kidney injury
D058186,3.85,NCT02142049-5,All Subjects Treated at RP2D,NCT02142049,Ibrutinib and Lenalidomide With Dose Adjusted EPOCH-R in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma,acute kidney injury
D006869,16.67,NCT02142049-4,Part 1: Dose Level 4,NCT02142049,Ibrutinib and Lenalidomide With Dose Adjusted EPOCH-R in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma,hydronephrosis
D006869,3.85,NCT02142049-5,All Subjects Treated at RP2D,NCT02142049,Ibrutinib and Lenalidomide With Dose Adjusted EPOCH-R in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma,hydronephrosis
10061574,16.67,NCT02142049-4,Part 1: Dose Level 4,NCT02142049,Ibrutinib and Lenalidomide With Dose Adjusted EPOCH-R in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma,urinary tract obstruction
10061574,3.85,NCT02142049-5,All Subjects Treated at RP2D,NCT02142049,Ibrutinib and Lenalidomide With Dose Adjusted EPOCH-R in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma,urinary tract obstruction
D000539,16.67,NCT02142049-4,Part 1: Dose Level 4,NCT02142049,Ibrutinib and Lenalidomide With Dose Adjusted EPOCH-R in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma,alveolar process
D000539,3.85,NCT02142049-5,All Subjects Treated at RP2D,NCT02142049,Ibrutinib and Lenalidomide With Dose Adjusted EPOCH-R in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma,alveolar process
D007022,33.33,NCT02142049-1,Part 1: Dose Level 1,NCT02142049,Ibrutinib and Lenalidomide With Dose Adjusted EPOCH-R in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma,hypotension
D007022,33.33,NCT02142049-2,Part 1: Dose Level 2,NCT02142049,Ibrutinib and Lenalidomide With Dose Adjusted EPOCH-R in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma,hypotension
D007022,16.67,NCT02142049-4,Part 1: Dose Level 4,NCT02142049,Ibrutinib and Lenalidomide With Dose Adjusted EPOCH-R in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma,hypotension
D007022,7.69,NCT02142049-5,All Subjects Treated at RP2D,NCT02142049,Ibrutinib and Lenalidomide With Dose Adjusted EPOCH-R in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma,hypotension
D007024,33.33,NCT02142049-2,Part 1: Dose Level 2,NCT02142049,Ibrutinib and Lenalidomide With Dose Adjusted EPOCH-R in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma,orthostatic hypotension
D009026,70.59,NCT02147301-1,DEB-TACE,NCT02147301,TACE Using Doxorubicin-eluting Beads for Patients With HCC and Marginal Hepatic Reserve,mortality
D064420,76.47,NCT02147301-1,DEB-TACE,NCT02147301,TACE Using Doxorubicin-eluting Beads for Patients With HCC and Marginal Hepatic Reserve,adverse drug events
D000740,11.76,NCT02147301-1,DEB-TACE,NCT02147301,TACE Using Doxorubicin-eluting Beads for Patients With HCC and Marginal Hepatic Reserve,anemia
D013921,17.65,NCT02147301-1,DEB-TACE,NCT02147301,TACE Using Doxorubicin-eluting Beads for Patients With HCC and Marginal Hepatic Reserve,thrombocytopenia
D017093,23.53,NCT02147301-1,DEB-TACE,NCT02147301,TACE Using Doxorubicin-eluting Beads for Patients With HCC and Marginal Hepatic Reserve,hepatic failure
D001201,5.88,NCT02147301-1,DEB-TACE,NCT02147301,TACE Using Doxorubicin-eluting Beads for Patients With HCC and Marginal Hepatic Reserve,ascites
D006932,17.65,NCT02147301-1,DEB-TACE,NCT02147301,TACE Using Doxorubicin-eluting Beads for Patients With HCC and Marginal Hepatic Reserve,hyperbilirubinemia
D000068258,17.65,NCT02147301-1,DEB-TACE,NCT02147301,TACE Using Doxorubicin-eluting Beads for Patients With HCC and Marginal Hepatic Reserve,avastin
D000799,11.76,NCT02147301-1,DEB-TACE,NCT02147301,TACE Using Doxorubicin-eluting Beads for Patients With HCC and Marginal Hepatic Reserve,angioedema
D007010,23.53,NCT02147301-1,DEB-TACE,NCT02147301,TACE Using Doxorubicin-eluting Beads for Patients With HCC and Marginal Hepatic Reserve,hyponatremia
D009026,11.11,NCT02180867-1,Dose-Finding Level 1 CR,NCT02180867,Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery,mortality
D009026,44.44,NCT02180867-2,Dose-Finding Level 1 RT,NCT02180867,Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery,mortality
D009026,30.0,NCT02180867-3,Dose-Finding Level 2 RT,NCT02180867,Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery,mortality
D009026,10.87,NCT02180867-4,Regimen A,NCT02180867,Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery,mortality
D009026,20.93,NCT02180867-5,Regimen B,NCT02180867,Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery,mortality
D009026,33.33,NCT02180867-7,Regimen D,NCT02180867,Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery,mortality
D064420,66.67,NCT02180867-1,Dose-Finding Level 1 CR,NCT02180867,Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery,adverse drug events
D064420,66.67,NCT02180867-2,Dose-Finding Level 1 RT,NCT02180867,Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery,adverse drug events
D064420,20.0,NCT02180867-3,Dose-Finding Level 2 RT,NCT02180867,Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery,adverse drug events
D064420,71.74,NCT02180867-4,Regimen A,NCT02180867,Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery,adverse drug events
D064420,18.6,NCT02180867-5,Regimen B,NCT02180867,Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery,adverse drug events
D064420,16.67,NCT02180867-6,Regimen C,NCT02180867,Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery,adverse drug events
D064147,20.0,NCT02180867-1,Dose-Finding Level 1 CR,NCT02180867,Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery,febrile neutropenia
D064147,43.75,NCT02180867-4,Regimen A,NCT02180867,Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery,febrile neutropenia
D000740,16.67,NCT02180867-2,Dose-Finding Level 1 RT,NCT02180867,Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery,anemia
D000740,6.67,NCT02180867-4,Regimen A,NCT02180867,Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery,anemia
D000740,4.0,NCT02180867-5,Regimen B,NCT02180867,Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery,anemia
10005329,3.33,NCT02180867-4,Regimen A,NCT02180867,Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery,blood and lymphatic system disorders - other specify
D064147,25.0,NCT02180867-1,Dose-Finding Level 1 CR,NCT02180867,Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery,febrile neutropenia
D064147,36.67,NCT02180867-4,Regimen A,NCT02180867,Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery,febrile neutropenia
D064147,4.0,NCT02180867-5,Regimen B,NCT02180867,Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery,febrile neutropenia
D001281,3.33,NCT02180867-4,Regimen A,NCT02180867,Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery,atrial fibrillation
D001282,3.33,NCT02180867-4,Regimen A,NCT02180867,Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery,atrial flutter
D013616,3.33,NCT02180867-4,Regimen A,NCT02180867,Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery,sinus tachycardia
10005886,3.33,NCT02180867-4,Regimen A,NCT02180867,Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery,blurred vision
D020795,14.29,NCT02180867-3,Dose-Finding Level 2 RT,NCT02180867,Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery,photophobia
D003967,33.33,NCT02180867-3,Dose-Finding Level 2 RT,NCT02180867,Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery,diarrhea
D045823,6.25,NCT02180867-4,Regimen A,NCT02180867,Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery,ileus
10028130,18.75,NCT02180867-4,Regimen A,NCT02180867,Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery,mucositis oral
D014839,12.5,NCT02180867-4,Regimen A,NCT02180867,Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery,vomiting
D003967,14.29,NCT02180867-3,Dose-Finding Level 2 RT,NCT02180867,Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery,diarrhea
D003967,3.33,NCT02180867-4,Regimen A,NCT02180867,Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery,diarrhea
D004941,3.33,NCT02180867-4,Regimen A,NCT02180867,Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery,esophagitis
10028130,3.33,NCT02180867-4,Regimen A,NCT02180867,Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery,mucositis oral
D009325,25.0,NCT02180867-1,Dose-Finding Level 1 CR,NCT02180867,Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery,nausea
D009325,3.33,NCT02180867-4,Regimen A,NCT02180867,Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery,nausea
D009325,20.0,NCT02180867-6,Regimen C,NCT02180867,Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery,nausea
D014839,25.0,NCT02180867-1,Dose-Finding Level 1 CR,NCT02180867,Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery,vomiting
D014839,14.29,NCT02180867-3,Dose-Finding Level 2 RT,NCT02180867,Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery,vomiting
D014839,6.67,NCT02180867-4,Regimen A,NCT02180867,Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery,vomiting
D005334,6.25,NCT02180867-4,Regimen A,NCT02180867,Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery,fever
D010146,6.25,NCT02180867-4,Regimen A,NCT02180867,Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery,pain
D023341,3.33,NCT02180867-4,Regimen A,NCT02180867,Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery,chills
D023341,20.0,NCT02180867-6,Regimen C,NCT02180867,Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery,chills
10011914,4.0,NCT02180867-5,Regimen B,NCT02180867,Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery,death nos
D005221,6.67,NCT02180867-4,Regimen A,NCT02180867,Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery,fatigue
D005221,20.0,NCT02180867-6,Regimen C,NCT02180867,Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery,fatigue
D005334,6.67,NCT02180867-4,Regimen A,NCT02180867,Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery,fever
D005334,8.0,NCT02180867-5,Regimen B,NCT02180867,Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery,fever
D005334,20.0,NCT02180867-6,Regimen C,NCT02180867,Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery,fever
10017577,16.67,NCT02180867-2,Dose-Finding Level 1 RT,NCT02180867,Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery,gait disturbance
10018065,3.33,NCT02180867-4,Regimen A,NCT02180867,Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery,general disorders and administration site conditions - other specify
D009102,4.0,NCT02180867-5,Regimen B,NCT02180867,Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery,multiple organ failure
10062501,3.33,NCT02180867-4,Regimen A,NCT02180867,Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery,non-cardiac chest pain
10034405,6.25,NCT02180867-4,Regimen A,NCT02180867,Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery,perforation bile duct
D018805,5.56,NCT02180867-5,Regimen B,NCT02180867,Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery,sepsis
10040872,6.25,NCT02180867-4,Regimen A,NCT02180867,Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery,skin infection
D014946,33.33,NCT02180867-2,Dose-Finding Level 1 RT,NCT02180867,Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery,wound infection
D014946,6.25,NCT02180867-4,Regimen A,NCT02180867,Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery,wound infection
D018805,13.33,NCT02180867-4,Regimen A,NCT02180867,Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery,sepsis
D018805,4.0,NCT02180867-5,Regimen B,NCT02180867,Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery,sepsis
10040872,6.67,NCT02180867-4,Regimen A,NCT02180867,Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery,skin infection
10040872,4.0,NCT02180867-5,Regimen B,NCT02180867,Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery,skin infection
10046300,4.0,NCT02180867-5,Regimen B,NCT02180867,Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery,upper respiratory infection
D014552,3.33,NCT02180867-4,Regimen A,NCT02180867,Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery,urinary tract infection
D014946,25.0,NCT02180867-1,Dose-Finding Level 1 CR,NCT02180867,Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery,wound infection
D014946,50.0,NCT02180867-2,Dose-Finding Level 1 RT,NCT02180867,Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery,wound infection
D014946,14.29,NCT02180867-3,Dose-Finding Level 2 RT,NCT02180867,Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery,wound infection
D014946,3.33,NCT02180867-4,Regimen A,NCT02180867,Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery,wound infection
D014946,4.0,NCT02180867-5,Regimen B,NCT02180867,Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery,wound infection
10061229,4.0,NCT02180867-5,Regimen B,NCT02180867,Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery,lung infection
D018461,16.67,NCT02180867-2,Dose-Finding Level 1 RT,NCT02180867,Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery,soft tissue infection
10064687,3.33,NCT02180867-4,Regimen A,NCT02180867,Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery,device related infection
10064687,4.0,NCT02180867-5,Regimen B,NCT02180867,Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery,device related infection
10048031,33.33,NCT02180867-2,Dose-Finding Level 1 RT,NCT02180867,Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery,wound dehiscence
10048031,6.25,NCT02180867-4,Regimen A,NCT02180867,Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery,wound dehiscence
10048031,5.56,NCT02180867-5,Regimen B,NCT02180867,Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery,wound dehiscence
10053692,6.25,NCT02180867-4,Regimen A,NCT02180867,Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery,wound complication
10048031,50.0,NCT02180867-1,Dose-Finding Level 1 CR,NCT02180867,Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery,wound dehiscence
10048031,13.33,NCT02180867-4,Regimen A,NCT02180867,Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery,wound dehiscence
10053692,6.67,NCT02180867-4,Regimen A,NCT02180867,Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery,wound complication
10053692,4.0,NCT02180867-5,Regimen B,NCT02180867,Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery,wound complication
D019106,3.33,NCT02180867-4,Regimen A,NCT02180867,Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery,postoperative hemorrhage
10061103,14.29,NCT02180867-3,Dose-Finding Level 2 RT,NCT02180867,Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery,dermatitis radiation
10061103,3.33,NCT02180867-4,Regimen A,NCT02180867,Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery,dermatitis radiation
10011368,33.33,NCT02180867-2,Dose-Finding Level 1 RT,NCT02180867,Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery,creatinine increased
10001551,3.33,NCT02180867-4,Regimen A,NCT02180867,Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery,alanine aminotransferase increased
10005364,3.33,NCT02180867-4,Regimen A,NCT02180867,Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery,blood bilirubin increased
10014383,3.33,NCT02180867-4,Regimen A,NCT02180867,Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery,electrocardiogram qt corrected interval prolonged
10025256,6.67,NCT02180867-4,Regimen A,NCT02180867,Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery,lymphocyte count decreased
10025256,4.0,NCT02180867-5,Regimen B,NCT02180867,Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery,lymphocyte count decreased
10029366,16.67,NCT02180867-4,Regimen A,NCT02180867,Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery,neutrophil count decreased
10035528,16.67,NCT02180867-4,Regimen A,NCT02180867,Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery,platelet count decreased
10049182,26.67,NCT02180867-4,Regimen A,NCT02180867,Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery,white blood cell decreased
10050528,3.33,NCT02180867-4,Regimen A,NCT02180867,Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery,ejection fraction decreased
D000855,12.5,NCT02180867-4,Regimen A,NCT02180867,Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery,anorexia
D003681,12.5,NCT02180867-4,Regimen A,NCT02180867,Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery,dehydration
D006947,33.33,NCT02180867-3,Dose-Finding Level 2 RT,NCT02180867,Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery,hyperkalemia
D003681,25.0,NCT02180867-1,Dose-Finding Level 1 CR,NCT02180867,Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery,dehydration
D003681,14.29,NCT02180867-3,Dose-Finding Level 2 RT,NCT02180867,Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery,dehydration
D006943,16.67,NCT02180867-2,Dose-Finding Level 1 RT,NCT02180867,Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery,hyperglycemia
D006943,4.0,NCT02180867-5,Regimen B,NCT02180867,Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery,hyperglycemia
D007008,16.67,NCT02180867-2,Dose-Finding Level 1 RT,NCT02180867,Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery,hypokalemia
D007008,6.67,NCT02180867-4,Regimen A,NCT02180867,Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery,hypokalemia
D007010,10.0,NCT02180867-4,Regimen A,NCT02180867,Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery,hyponatremia
D007010,4.0,NCT02180867-5,Regimen B,NCT02180867,Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery,hyponatremia
D007010,20.0,NCT02180867-6,Regimen C,NCT02180867,Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery,hyponatremia
D017674,10.0,NCT02180867-4,Regimen A,NCT02180867,Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery,hypophosphatemia
D017674,20.0,NCT02180867-6,Regimen C,NCT02180867,Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery,hypophosphatemia
10033425,6.25,NCT02180867-4,Regimen A,NCT02180867,Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery,pain in extremity
10033425,16.67,NCT02180867-2,Dose-Finding Level 1 RT,NCT02180867,Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery,pain in extremity
10033425,3.33,NCT02180867-4,Regimen A,NCT02180867,Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery,pain in extremity
10009845,3.33,NCT02180867-4,Regimen A,NCT02180867,Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery,cognitive disturbance
D004244,3.33,NCT02180867-4,Regimen A,NCT02180867,Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery,dizziness
D001927,3.33,NCT02180867-4,Regimen A,NCT02180867,Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery,encephalopathy
D006261,14.29,NCT02180867-3,Dose-Finding Level 2 RT,NCT02180867,Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery,headache
D020521,3.33,NCT02180867-4,Regimen A,NCT02180867,Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery,stroke
D013575,25.0,NCT02180867-1,Dose-Finding Level 1 CR,NCT02180867,Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery,syncope
D006212,6.25,NCT02180867-4,Regimen A,NCT02180867,Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery,hallucinations
D003693,10.0,NCT02180867-4,Regimen A,NCT02180867,Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery,delirium
D003863,14.29,NCT02180867-3,Dose-Finding Level 2 RT,NCT02180867,Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery,depression
D003863,3.33,NCT02180867-4,Regimen A,NCT02180867,Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery,depression
D058186,33.33,NCT02180867-2,Dose-Finding Level 1 RT,NCT02180867,Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery,acute kidney injury
10038359,4.0,NCT02180867-5,Regimen B,NCT02180867,Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery,renal and urinary disorders - other specify
D014592,3.33,NCT02180867-4,Regimen A,NCT02180867,Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery,uterine hemorrhage
D000860,6.25,NCT02180867-4,Regimen A,NCT02180867,Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery,hypoxia
D004417,3.33,NCT02180867-4,Regimen A,NCT02180867,Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery,dyspnea
D004417,4.0,NCT02180867-5,Regimen B,NCT02180867,Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery,dyspnea
D000860,3.33,NCT02180867-4,Regimen A,NCT02180867,Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery,hypoxia
D007826,3.33,NCT02180867-4,Regimen A,NCT02180867,Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery,laryngospasm
D010996,4.0,NCT02180867-5,Regimen B,NCT02180867,Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery,pleural effusion
D011030,3.33,NCT02180867-4,Regimen A,NCT02180867,Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery,pneumothorax
D011654,6.67,NCT02180867-4,Regimen A,NCT02180867,Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery,pulmonary edema
10040868,14.29,NCT02180867-3,Dose-Finding Level 2 RT,NCT02180867,Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery,skin hypopigmentation
10043565,20.0,NCT02180867-1,Dose-Finding Level 1 CR,NCT02180867,Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery,thromboembolic event
10043565,6.25,NCT02180867-4,Regimen A,NCT02180867,Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery,thromboembolic event
10043565,25.0,NCT02180867-1,Dose-Finding Level 1 CR,NCT02180867,Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery,thromboembolic event
10043565,16.67,NCT02180867-2,Dose-Finding Level 1 RT,NCT02180867,Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery,thromboembolic event
10043565,13.33,NCT02180867-4,Regimen A,NCT02180867,Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery,thromboembolic event
D064420,50.0,NCT02181075-1,Part I (Patients Enrolled Between March 2015-April 2017),NCT02181075,Targeted Chemotherapy Using Focused Ultrasound for Liver Tumours,adverse drug events
D064420,75.0,NCT02181075-2,Part II (Patients Enrolled Between June 2016-Feb 2017),NCT02181075,Targeted Chemotherapy Using Focused Ultrasound for Liver Tumours,adverse drug events
D009503,50.0,NCT02181075-1,Part I (Patients Enrolled Between March 2015-April 2017),NCT02181075,Targeted Chemotherapy Using Focused Ultrasound for Liver Tumours,neutropenia
D009503,50.0,NCT02181075-2,Part II (Patients Enrolled Between June 2016-Feb 2017),NCT02181075,Targeted Chemotherapy Using Focused Ultrasound for Liver Tumours,neutropenia
D003221,25.0,NCT02181075-2,Part II (Patients Enrolled Between June 2016-Feb 2017),NCT02181075,Targeted Chemotherapy Using Focused Ultrasound for Liver Tumours,confusion
D009026,9.52,NCT02181738-1,COHORT A,NCT02181738,Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational),mortality
D009026,12.5,NCT02181738-2,COHORT B,NCT02181738,Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational),mortality
D009026,13.0,NCT02181738-3,COHORT C,NCT02181738,Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational),mortality
D009026,1.96,NCT02181738-4,Cohort D,NCT02181738,Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational),mortality
D064420,14.29,NCT02181738-1,COHORT A,NCT02181738,Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational),adverse drug events
D064420,31.25,NCT02181738-2,COHORT B,NCT02181738,Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational),adverse drug events
D064420,32.0,NCT02181738-3,COHORT C,NCT02181738,Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational),adverse drug events
D064420,23.53,NCT02181738-4,Cohort D,NCT02181738,Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational),adverse drug events
D064147,1.25,NCT02181738-2,COHORT B,NCT02181738,Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational),febrile neutropenia
D064147,3.92,NCT02181738-4,Cohort D,NCT02181738,Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational),febrile neutropenia
D056988,1.25,NCT02181738-2,COHORT B,NCT02181738,Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational),acute anterior wall myocardial infarction
D001145,2.5,NCT02181738-2,COHORT B,NCT02181738,Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational),arrhythmia
D006323,1.0,NCT02181738-3,COHORT C,NCT02181738,Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational),cardiac arrest
D006333,1.25,NCT02181738-2,COHORT B,NCT02181738,Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational),cardiac failure
D006333,1.96,NCT02181738-4,Cohort D,NCT02181738,Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational),cardiac failure
D010490,1.25,NCT02181738-2,COHORT B,NCT02181738,Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational),pericardial effusion
D010490,1.0,NCT02181738-3,COHORT C,NCT02181738,Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational),pericardial effusion
D014138,1.0,NCT02181738-3,COHORT C,NCT02181738,Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational),tracheoesophageal fistula
D006980,1.96,NCT02181738-4,Cohort D,NCT02181738,Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational),hyperthyroidism
D015746,1.0,NCT02181738-3,COHORT C,NCT02181738,Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational),abdominal pain
D003092,2.0,NCT02181738-3,COHORT C,NCT02181738,Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational),colitis
D003092,1.96,NCT02181738-4,Cohort D,NCT02181738,Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational),colitis
UNKNOWN-check-for-typo,1.59,NCT02181738-1,COHORT A,NCT02181738,Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational),D00
UNKNOWN-check-for-typo,1.0,NCT02181738-3,COHORT C,NCT02181738,Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational),D00
D005756,1.59,NCT02181738-1,COHORT A,NCT02181738,Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational),gastritis
D009325,1.0,NCT02181738-3,COHORT C,NCT02181738,Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational),nausea
D010195,1.0,NCT02181738-3,COHORT C,NCT02181738,Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational),pancreatitis
D014839,1.0,NCT02181738-3,COHORT C,NCT02181738,Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational),vomiting
D000799,1.25,NCT02181738-2,COHORT B,NCT02181738,Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational),angioedema
D009102,1.25,NCT02181738-2,COHORT B,NCT02181738,Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational),multiple organ dysfunction syndrome
D005334,3.75,NCT02181738-2,COHORT B,NCT02181738,Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational),pyrexia
D005334,1.0,NCT02181738-3,COHORT C,NCT02181738,Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational),pyrexia
D005334,5.88,NCT02181738-4,Cohort D,NCT02181738,Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational),pyrexia
D018746,1.59,NCT02181738-1,COHORT A,NCT02181738,Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational),systemic inflammatory response syndrome
D019693,1.0,NCT02181738-3,COHORT C,NCT02181738,Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational),autoimmune hepatitis
D002769,1.59,NCT02181738-1,COHORT A,NCT02181738,Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational),cholelithiasis
UNKNOWN-check-for-typo,1.0,NCT02181738-3,COHORT C,NCT02181738,Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational),D00
D001168,1.59,NCT02181738-1,COHORT A,NCT02181738,Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational),arthritis
D011016,1.59,NCT02181738-1,COHORT A,NCT02181738,Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational),pneumonia atypical interstitial of cattle
UNKNOWN-check-for-typo,1.0,NCT02181738-3,COHORT C,NCT02181738,Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational),D00
D003556,1.25,NCT02181738-2,COHORT B,NCT02181738,Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational),cystitis
10064687,1.59,NCT02181738-1,COHORT A,NCT02181738,Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational),device related infection
D004886,2.0,NCT02181738-3,COHORT C,NCT02181738,Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational),erysipelas
D005759,1.59,NCT02181738-1,COHORT A,NCT02181738,Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational),gastroenteritis
D005759,1.96,NCT02181738-4,Cohort D,NCT02181738,Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational),gastroenteritis
D007239,1.25,NCT02181738-2,COHORT B,NCT02181738,Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational),infection
D007251,1.25,NCT02181738-2,COHORT B,NCT02181738,Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational),influenza
D007251,1.0,NCT02181738-3,COHORT C,NCT02181738,Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational),influenza
D007251,3.92,NCT02181738-4,Cohort D,NCT02181738,Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational),influenza
10061229,1.25,NCT02181738-2,COHORT B,NCT02181738,Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational),lung infection
10061229,1.96,NCT02181738-4,Cohort D,NCT02181738,Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational),lung infection
D008193,1.0,NCT02181738-3,COHORT C,NCT02181738,Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational),lyme disease
D008581,2.5,NCT02181738-2,COHORT B,NCT02181738,Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational),meningitis
D000257,1.0,NCT02181738-3,COHORT C,NCT02181738,Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational),adenovirus infections
D010612,1.96,NCT02181738-4,Cohort D,NCT02181738,Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational),pharyngitis
D011020,1.59,NCT02181738-1,COHORT A,NCT02181738,Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational),pneumocystis jirovecii pneumonia
D011014,3.75,NCT02181738-2,COHORT B,NCT02181738,Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational),pneumonia
D011014,3.0,NCT02181738-3,COHORT C,NCT02181738,Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational),pneumonia
D011704,1.0,NCT02181738-3,COHORT C,NCT02181738,Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational),pyelonephritis
D012141,1.0,NCT02181738-3,COHORT C,NCT02181738,Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational),respiratory tract infection
D012141,1.96,NCT02181738-4,Cohort D,NCT02181738,Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational),respiratory tract infection
D018805,1.0,NCT02181738-3,COHORT C,NCT02181738,Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational),sepsis
D012141,1.25,NCT02181738-2,COHORT B,NCT02181738,Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational),upper respiratory tract infections
D012141,1.59,NCT02181738-1,COHORT A,NCT02181738,Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational),upper respiratory tract infections
10051792,1.59,NCT02181738-1,COHORT A,NCT02181738,Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational),infusion related reaction
10051792,2.5,NCT02181738-2,COHORT B,NCT02181738,Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational),infusion related reaction
10051792,2.0,NCT02181738-3,COHORT C,NCT02181738,Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational),infusion related reaction
D016103,1.25,NCT02181738-2,COHORT B,NCT02181738,Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational),spinal fractures
10001551,1.0,NCT02181738-3,COHORT C,NCT02181738,Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational),alanine aminotransferase increased
10001551,1.96,NCT02181738-4,Cohort D,NCT02181738,Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational),alanine aminotransferase increased
10003481,1.25,NCT02181738-2,COHORT B,NCT02181738,Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational),aspartate aminotransferase increased
10003481,1.96,NCT02181738-4,Cohort D,NCT02181738,Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational),aspartate aminotransferase increased
D001999,1.25,NCT02181738-2,COHORT B,NCT02181738,Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational),bronchoscopy
10035528,1.25,NCT02181738-2,COHORT B,NCT02181738,Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational),platelet count decreased
D008826,1.25,NCT02181738-2,COHORT B,NCT02181738,Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational),viral drug sensitivity tests
D003681,1.0,NCT02181738-3,COHORT C,NCT02181738,Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational),dehydration
D003681,1.96,NCT02181738-4,Cohort D,NCT02181738,Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational),dehydration
D016883,1.0,NCT02181738-3,COHORT C,NCT02181738,Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational),diabetic ketoacidosis
D018149,1.0,NCT02181738-3,COHORT C,NCT02181738,Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational),impaired glucose tolerance
UNKNOWN-check-for-typo,1.25,NCT02181738-2,COHORT B,NCT02181738,Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational),D00
UNKNOWN-check-for-typo,1.0,NCT02181738-3,COHORT C,NCT02181738,Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational),D00
UNKNOWN-check-for-typo,1.25,NCT02181738-2,COHORT B,NCT02181738,Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational),D00
UNKNOWN-check-for-typo,1.0,NCT02181738-3,COHORT C,NCT02181738,Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational),D00
D010020,1.25,NCT02181738-2,COHORT B,NCT02181738,Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational),osteonecrosis
10033425,1.25,NCT02181738-2,COHORT B,NCT02181738,Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational),pain in extremity
10033425,1.0,NCT02181738-3,COHORT C,NCT02181738,Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational),pain in extremity
D001168,1.25,NCT02181738-2,COHORT B,NCT02181738,Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational),polyarthritis
D012509,1.59,NCT02181738-1,COHORT A,NCT02181738,Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational),sarcoma soft tissue
D046152,1.25,NCT02181738-2,COHORT B,NCT02181738,Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational),gastrointestinal stromal tumors
D009369,2.5,NCT02181738-2,COHORT B,NCT02181738,Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational),malignant neoplasms
D009369,3.0,NCT02181738-3,COHORT C,NCT02181738,Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational),malignant neoplasms
D016411,1.25,NCT02181738-2,COHORT B,NCT02181738,Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational),lymphoma t-cell peripheral
D016893,1.25,NCT02181738-2,COHORT B,NCT02181738,Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational),carotid artery stenosis
D011115,1.96,NCT02181738-4,Cohort D,NCT02181738,Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational),polyneuropathy
D012640,2.0,NCT02181738-3,COHORT C,NCT02181738,Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational),seizure
D013575,1.25,NCT02181738-2,COHORT B,NCT02181738,Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational),syncope
10042464,1.0,NCT02181738-3,COHORT C,NCT02181738,Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational),suicide attempt
D058186,1.25,NCT02181738-2,COHORT B,NCT02181738,Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational),acute kidney injury
UNKNOWN-check-for-typo,1.25,NCT02181738-2,COHORT B,NCT02181738,Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational),D00
UNKNOWN-check-for-typo,1.0,NCT02181738-3,COHORT C,NCT02181738,Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational),D00
D010996,1.59,NCT02181738-1,COHORT A,NCT02181738,Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational),pleural effusion
D010996,3.0,NCT02181738-3,COHORT C,NCT02181738,Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational),pleural effusion
D011014,1.59,NCT02181738-1,COHORT A,NCT02181738,Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational),pneumonitis
D011014,2.0,NCT02181738-3,COHORT C,NCT02181738,Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational),pneumonitis
D011030,1.0,NCT02181738-3,COHORT C,NCT02181738,Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational),pneumothorax
D011655,1.0,NCT02181738-3,COHORT C,NCT02181738,Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational),pulmonary embolism
D005076,1.25,NCT02181738-2,COHORT B,NCT02181738,Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational),rash
D005076,1.0,NCT02181738-3,COHORT C,NCT02181738,Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational),rash
10037868,1.25,NCT02181738-2,COHORT B,NCT02181738,Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational),rash maculo-papular
10037868,1.0,NCT02181738-3,COHORT C,NCT02181738,Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational),rash maculo-papular
D000028,1.0,NCT02181738-3,COHORT C,NCT02181738,Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational),induced abortion
D004617,1.25,NCT02181738-2,COHORT B,NCT02181738,Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational),embolism
D002406,1.25,NCT02181738-2,COHORT B,NCT02181738,Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational),catheterization peripheral
D064420,66.67,NCT02255110-1,TH-302 and Doxorubicin,NCT02255110,A Japanese Trial of TH-302 in Subjects With Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma,adverse drug events
D064147,16.67,NCT02255110-1,TH-302 and Doxorubicin,NCT02255110,A Japanese Trial of TH-302 in Subjects With Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma,febrile neutropenia
D015746,16.67,NCT02255110-1,TH-302 and Doxorubicin,NCT02255110,A Japanese Trial of TH-302 in Subjects With Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma,abdominal pain
D009325,16.67,NCT02255110-1,TH-302 and Doxorubicin,NCT02255110,A Japanese Trial of TH-302 in Subjects With Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma,nausea
D011014,16.67,NCT02255110-1,TH-302 and Doxorubicin,NCT02255110,A Japanese Trial of TH-302 in Subjects With Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma,pneumonia
D018365,16.67,NCT02255110-1,TH-302 and Doxorubicin,NCT02255110,A Japanese Trial of TH-302 in Subjects With Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma,residual tumour
D009026,9.09,NCT02267083-1,GPX-150,NCT02267083,Efficacy and Safety Study of GPX-150 to Treat Soft Tissue Sarcoma,mortality
D064420,100.0,NCT02267083-1,GPX-150,NCT02267083,Efficacy and Safety Study of GPX-150 to Treat Soft Tissue Sarcoma,adverse drug events
D064147,4.55,NCT02267083-1,GPX-150,NCT02267083,Efficacy and Safety Study of GPX-150 to Treat Soft Tissue Sarcoma,febrile neutropenia
D000741,4.55,NCT02267083-1,GPX-150,NCT02267083,Efficacy and Safety Study of GPX-150 to Treat Soft Tissue Sarcoma,aplastic anaemia
D009203,4.55,NCT02267083-1,GPX-150,NCT02267083,Efficacy and Safety Study of GPX-150 to Treat Soft Tissue Sarcoma,myocardial infarction
D015746,4.55,NCT02267083-1,GPX-150,NCT02267083,Efficacy and Safety Study of GPX-150 to Treat Soft Tissue Sarcoma,abdominal pain
UNKNOWN-check-for-typo,4.55,NCT02267083-1,GPX-150,NCT02267083,Efficacy and Safety Study of GPX-150 to Treat Soft Tissue Sarcoma,D00
D045823,4.55,NCT02267083-1,GPX-150,NCT02267083,Efficacy and Safety Study of GPX-150 to Treat Soft Tissue Sarcoma,ileus
D009325,4.55,NCT02267083-1,GPX-150,NCT02267083,Efficacy and Safety Study of GPX-150 to Treat Soft Tissue Sarcoma,nausea
D007421,4.55,NCT02267083-1,GPX-150,NCT02267083,Efficacy and Safety Study of GPX-150 to Treat Soft Tissue Sarcoma,intestine small
D014839,9.09,NCT02267083-1,GPX-150,NCT02267083,Efficacy and Safety Study of GPX-150 to Treat Soft Tissue Sarcoma,vomiting
D002764,4.55,NCT02267083-1,GPX-150,NCT02267083,Efficacy and Safety Study of GPX-150 to Treat Soft Tissue Sarcoma,cholecystitis
D007251,4.55,NCT02267083-1,GPX-150,NCT02267083,Efficacy and Safety Study of GPX-150 to Treat Soft Tissue Sarcoma,influenza
D018461,4.55,NCT02267083-1,GPX-150,NCT02267083,Efficacy and Safety Study of GPX-150 to Treat Soft Tissue Sarcoma,soft tissue infection
10017076,4.55,NCT02267083-1,GPX-150,NCT02267083,Efficacy and Safety Study of GPX-150 to Treat Soft Tissue Sarcoma,fracture
10025256,4.55,NCT02267083-1,GPX-150,NCT02267083,Efficacy and Safety Study of GPX-150 to Treat Soft Tissue Sarcoma,lymphocyte count decreased
D007958,4.55,NCT02267083-1,GPX-150,NCT02267083,Efficacy and Safety Study of GPX-150 to Treat Soft Tissue Sarcoma,blood cell count white
D003681,4.55,NCT02267083-1,GPX-150,NCT02267083,Efficacy and Safety Study of GPX-150 to Treat Soft Tissue Sarcoma,dehydration
D008080,4.55,NCT02267083-1,GPX-150,NCT02267083,Efficacy and Safety Study of GPX-150 to Treat Soft Tissue Sarcoma,liposarcoma
D018223,4.55,NCT02267083-1,GPX-150,NCT02267083,Efficacy and Safety Study of GPX-150 to Treat Soft Tissue Sarcoma,metastatic dermatofibrosarcoma protuberans
D002490,4.55,NCT02267083-1,GPX-150,NCT02267083,Efficacy and Safety Study of GPX-150 to Treat Soft Tissue Sarcoma,central nervous system
D004244,4.55,NCT02267083-1,GPX-150,NCT02267083,Efficacy and Safety Study of GPX-150 to Treat Soft Tissue Sarcoma,dizziness
D013117,4.55,NCT02267083-1,GPX-150,NCT02267083,Efficacy and Safety Study of GPX-150 to Treat Soft Tissue Sarcoma,spinal cord compression
D012131,4.55,NCT02267083-1,GPX-150,NCT02267083,Efficacy and Safety Study of GPX-150 to Treat Soft Tissue Sarcoma,respiratory failure
D009026,5.88,NCT02268045-1,RTXM83-CHOP,NCT02268045,Study of RTXM83 Plus CHOP Chemotherapy Versus a Rituximab Plus CHOP Therapy in Patients With Non Hodgkin's Lymphoma,mortality
D009026,8.82,NCT02268045-2,MabThera-CHOP,NCT02268045,Study of RTXM83 Plus CHOP Chemotherapy Versus a Rituximab Plus CHOP Therapy in Patients With Non Hodgkin's Lymphoma,mortality
D064420,34.56,NCT02268045-1,RTXM83-CHOP,NCT02268045,Study of RTXM83 Plus CHOP Chemotherapy Versus a Rituximab Plus CHOP Therapy in Patients With Non Hodgkin's Lymphoma,adverse drug events
D064420,33.09,NCT02268045-2,MabThera-CHOP,NCT02268045,Study of RTXM83 Plus CHOP Chemotherapy Versus a Rituximab Plus CHOP Therapy in Patients With Non Hodgkin's Lymphoma,adverse drug events
D009503,7.35,NCT02268045-1,RTXM83-CHOP,NCT02268045,Study of RTXM83 Plus CHOP Chemotherapy Versus a Rituximab Plus CHOP Therapy in Patients With Non Hodgkin's Lymphoma,neutropenia
D009503,5.88,NCT02268045-2,MabThera-CHOP,NCT02268045,Study of RTXM83 Plus CHOP Chemotherapy Versus a Rituximab Plus CHOP Therapy in Patients With Non Hodgkin's Lymphoma,neutropenia
D007970,4.41,NCT02268045-1,RTXM83-CHOP,NCT02268045,Study of RTXM83 Plus CHOP Chemotherapy Versus a Rituximab Plus CHOP Therapy in Patients With Non Hodgkin's Lymphoma,leukopenia
D007970,3.68,NCT02268045-2,MabThera-CHOP,NCT02268045,Study of RTXM83 Plus CHOP Chemotherapy Versus a Rituximab Plus CHOP Therapy in Patients With Non Hodgkin's Lymphoma,leukopenia
D064147,13.97,NCT02268045-1,RTXM83-CHOP,NCT02268045,Study of RTXM83 Plus CHOP Chemotherapy Versus a Rituximab Plus CHOP Therapy in Patients With Non Hodgkin's Lymphoma,febrile neutropenia
D064147,5.15,NCT02268045-2,MabThera-CHOP,NCT02268045,Study of RTXM83 Plus CHOP Chemotherapy Versus a Rituximab Plus CHOP Therapy in Patients With Non Hodgkin's Lymphoma,febrile neutropenia
UNKNOWN-check-for-typo,2.94,NCT02268045-1,RTXM83-CHOP,NCT02268045,Study of RTXM83 Plus CHOP Chemotherapy Versus a Rituximab Plus CHOP Therapy in Patients With Non Hodgkin's Lymphoma,D00
UNKNOWN-check-for-typo,2.21,NCT02268045-2,MabThera-CHOP,NCT02268045,Study of RTXM83 Plus CHOP Chemotherapy Versus a Rituximab Plus CHOP Therapy in Patients With Non Hodgkin's Lymphoma,D00
D005334,3.68,NCT02268045-1,RTXM83-CHOP,NCT02268045,Study of RTXM83 Plus CHOP Chemotherapy Versus a Rituximab Plus CHOP Therapy in Patients With Non Hodgkin's Lymphoma,pyrexia
D005334,3.68,NCT02268045-2,MabThera-CHOP,NCT02268045,Study of RTXM83 Plus CHOP Chemotherapy Versus a Rituximab Plus CHOP Therapy in Patients With Non Hodgkin's Lymphoma,pyrexia
D011014,4.41,NCT02268045-1,RTXM83-CHOP,NCT02268045,Study of RTXM83 Plus CHOP Chemotherapy Versus a Rituximab Plus CHOP Therapy in Patients With Non Hodgkin's Lymphoma,pneumonia
D011014,3.68,NCT02268045-2,MabThera-CHOP,NCT02268045,Study of RTXM83 Plus CHOP Chemotherapy Versus a Rituximab Plus CHOP Therapy in Patients With Non Hodgkin's Lymphoma,pneumonia
D012772,2.21,NCT02268045-1,RTXM83-CHOP,NCT02268045,Study of RTXM83 Plus CHOP Chemotherapy Versus a Rituximab Plus CHOP Therapy in Patients With Non Hodgkin's Lymphoma,septic shock
D012772,2.21,NCT02268045-2,MabThera-CHOP,NCT02268045,Study of RTXM83 Plus CHOP Chemotherapy Versus a Rituximab Plus CHOP Therapy in Patients With Non Hodgkin's Lymphoma,septic shock
10061229,1.47,NCT02268045-1,RTXM83-CHOP,NCT02268045,Study of RTXM83 Plus CHOP Chemotherapy Versus a Rituximab Plus CHOP Therapy in Patients With Non Hodgkin's Lymphoma,lung infection
10061229,0.74,NCT02268045-2,MabThera-CHOP,NCT02268045,Study of RTXM83 Plus CHOP Chemotherapy Versus a Rituximab Plus CHOP Therapy in Patients With Non Hodgkin's Lymphoma,lung infection
D003681,2.21,NCT02268045-1,RTXM83-CHOP,NCT02268045,Study of RTXM83 Plus CHOP Chemotherapy Versus a Rituximab Plus CHOP Therapy in Patients With Non Hodgkin's Lymphoma,dehydration
D003681,2.21,NCT02268045-2,MabThera-CHOP,NCT02268045,Study of RTXM83 Plus CHOP Chemotherapy Versus a Rituximab Plus CHOP Therapy in Patients With Non Hodgkin's Lymphoma,dehydration
D007010,2.21,NCT02268045-1,RTXM83-CHOP,NCT02268045,Study of RTXM83 Plus CHOP Chemotherapy Versus a Rituximab Plus CHOP Therapy in Patients With Non Hodgkin's Lymphoma,hyponatremia
D007010,2.21,NCT02268045-2,MabThera-CHOP,NCT02268045,Study of RTXM83 Plus CHOP Chemotherapy Versus a Rituximab Plus CHOP Therapy in Patients With Non Hodgkin's Lymphoma,hyponatremia
D007249,1.47,NCT02268045-1,RTXM83-CHOP,NCT02268045,Study of RTXM83 Plus CHOP Chemotherapy Versus a Rituximab Plus CHOP Therapy in Patients With Non Hodgkin's Lymphoma,inflammation
D007249,1.47,NCT02268045-2,MabThera-CHOP,NCT02268045,Study of RTXM83 Plus CHOP Chemotherapy Versus a Rituximab Plus CHOP Therapy in Patients With Non Hodgkin's Lymphoma,inflammation
D009026,55.56,NCT02272790-1,Arm A,NCT02272790,Adavosertib Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian  Fallopian Tube  or Primary Peritoneal Cancer,mortality
D009026,31.58,NCT02272790-2,Arm B,NCT02272790,Adavosertib Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian  Fallopian Tube  or Primary Peritoneal Cancer,mortality
D009026,39.13,NCT02272790-3,Arm C,NCT02272790,Adavosertib Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian  Fallopian Tube  or Primary Peritoneal Cancer,mortality
D009026,16.67,NCT02272790-4,Arm C2,NCT02272790,Adavosertib Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian  Fallopian Tube  or Primary Peritoneal Cancer,mortality
D009026,50.0,NCT02272790-5,Arm D-175 mg,NCT02272790,Adavosertib Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian  Fallopian Tube  or Primary Peritoneal Cancer,mortality
D064420,44.44,NCT02272790-1,Arm A,NCT02272790,Adavosertib Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian  Fallopian Tube  or Primary Peritoneal Cancer,adverse drug events
D064420,44.74,NCT02272790-2,Arm B,NCT02272790,Adavosertib Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian  Fallopian Tube  or Primary Peritoneal Cancer,adverse drug events
D064420,52.17,NCT02272790-3,Arm C,NCT02272790,Adavosertib Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian  Fallopian Tube  or Primary Peritoneal Cancer,adverse drug events
D064420,66.67,NCT02272790-4,Arm C2,NCT02272790,Adavosertib Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian  Fallopian Tube  or Primary Peritoneal Cancer,adverse drug events
D064420,33.33,NCT02272790-5,Arm D-175 mg,NCT02272790,Adavosertib Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian  Fallopian Tube  or Primary Peritoneal Cancer,adverse drug events
D064420,16.67,NCT02272790-6,Arm D-225 mg,NCT02272790,Adavosertib Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian  Fallopian Tube  or Primary Peritoneal Cancer,adverse drug events
D000741,17.39,NCT02272790-3,Arm C,NCT02272790,Adavosertib Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian  Fallopian Tube  or Primary Peritoneal Cancer,aplastic anaemia
D064147,7.89,NCT02272790-2,Arm B,NCT02272790,Adavosertib Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian  Fallopian Tube  or Primary Peritoneal Cancer,febrile neutropenia
D064147,8.7,NCT02272790-3,Arm C,NCT02272790,Adavosertib Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian  Fallopian Tube  or Primary Peritoneal Cancer,febrile neutropenia
D064147,8.33,NCT02272790-4,Arm C2,NCT02272790,Adavosertib Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian  Fallopian Tube  or Primary Peritoneal Cancer,febrile neutropenia
D007970,4.35,NCT02272790-3,Arm C,NCT02272790,Adavosertib Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian  Fallopian Tube  or Primary Peritoneal Cancer,leukopenia
D009503,2.63,NCT02272790-2,Arm B,NCT02272790,Adavosertib Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian  Fallopian Tube  or Primary Peritoneal Cancer,neutropenia
D009503,16.67,NCT02272790-4,Arm C2,NCT02272790,Adavosertib Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian  Fallopian Tube  or Primary Peritoneal Cancer,neutropenia
D009503,16.67,NCT02272790-6,Arm D-225 mg,NCT02272790,Adavosertib Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian  Fallopian Tube  or Primary Peritoneal Cancer,neutropenia
D010198,2.63,NCT02272790-2,Arm B,NCT02272790,Adavosertib Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian  Fallopian Tube  or Primary Peritoneal Cancer,pancytopenia
D013921,13.04,NCT02272790-3,Arm C,NCT02272790,Adavosertib Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian  Fallopian Tube  or Primary Peritoneal Cancer,thrombocytopenia
D013921,41.67,NCT02272790-4,Arm C2,NCT02272790,Adavosertib Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian  Fallopian Tube  or Primary Peritoneal Cancer,thrombocytopenia
D001281,2.63,NCT02272790-2,Arm B,NCT02272790,Adavosertib Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian  Fallopian Tube  or Primary Peritoneal Cancer,atrial fibrillation
D015746,4.35,NCT02272790-3,Arm C,NCT02272790,Adavosertib Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian  Fallopian Tube  or Primary Peritoneal Cancer,abdominal pain
D003092,2.63,NCT02272790-2,Arm B,NCT02272790,Adavosertib Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian  Fallopian Tube  or Primary Peritoneal Cancer,colitis
UNKNOWN-check-for-typo,8.7,NCT02272790-3,Arm C,NCT02272790,Adavosertib Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian  Fallopian Tube  or Primary Peritoneal Cancer,D00
D045823,2.63,NCT02272790-2,Arm B,NCT02272790,Adavosertib Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian  Fallopian Tube  or Primary Peritoneal Cancer,ileus
D007415,2.63,NCT02272790-2,Arm B,NCT02272790,Adavosertib Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian  Fallopian Tube  or Primary Peritoneal Cancer,intestinal obstruction
D007415,8.33,NCT02272790-4,Arm C2,NCT02272790,Adavosertib Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian  Fallopian Tube  or Primary Peritoneal Cancer,intestinal obstruction
D009325,11.11,NCT02272790-1,Arm A,NCT02272790,Adavosertib Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian  Fallopian Tube  or Primary Peritoneal Cancer,nausea
D009325,2.63,NCT02272790-2,Arm B,NCT02272790,Adavosertib Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian  Fallopian Tube  or Primary Peritoneal Cancer,nausea
D009325,8.7,NCT02272790-3,Arm C,NCT02272790,Adavosertib Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian  Fallopian Tube  or Primary Peritoneal Cancer,nausea
D009325,16.67,NCT02272790-5,Arm D-175 mg,NCT02272790,Adavosertib Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian  Fallopian Tube  or Primary Peritoneal Cancer,nausea
10041101,22.22,NCT02272790-1,Arm A,NCT02272790,Adavosertib Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian  Fallopian Tube  or Primary Peritoneal Cancer,small intestinal obstruction
10041101,7.89,NCT02272790-2,Arm B,NCT02272790,Adavosertib Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian  Fallopian Tube  or Primary Peritoneal Cancer,small intestinal obstruction
10041101,4.35,NCT02272790-3,Arm C,NCT02272790,Adavosertib Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian  Fallopian Tube  or Primary Peritoneal Cancer,small intestinal obstruction
D014839,11.11,NCT02272790-1,Arm A,NCT02272790,Adavosertib Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian  Fallopian Tube  or Primary Peritoneal Cancer,vomiting
D014839,2.63,NCT02272790-2,Arm B,NCT02272790,Adavosertib Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian  Fallopian Tube  or Primary Peritoneal Cancer,vomiting
D014839,8.7,NCT02272790-3,Arm C,NCT02272790,Adavosertib Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian  Fallopian Tube  or Primary Peritoneal Cancer,vomiting
D014839,8.33,NCT02272790-4,Arm C2,NCT02272790,Adavosertib Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian  Fallopian Tube  or Primary Peritoneal Cancer,vomiting
D014839,16.67,NCT02272790-5,Arm D-175 mg,NCT02272790,Adavosertib Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian  Fallopian Tube  or Primary Peritoneal Cancer,vomiting
D005221,11.11,NCT02272790-1,Arm A,NCT02272790,Adavosertib Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian  Fallopian Tube  or Primary Peritoneal Cancer,fatigue
D005334,11.11,NCT02272790-1,Arm A,NCT02272790,Adavosertib Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian  Fallopian Tube  or Primary Peritoneal Cancer,pyrexia
D005334,2.63,NCT02272790-2,Arm B,NCT02272790,Adavosertib Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian  Fallopian Tube  or Primary Peritoneal Cancer,pyrexia
D005334,16.67,NCT02272790-5,Arm D-175 mg,NCT02272790,Adavosertib Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian  Fallopian Tube  or Primary Peritoneal Cancer,pyrexia
D000707,8.33,NCT02272790-4,Arm C2,NCT02272790,Adavosertib Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian  Fallopian Tube  or Primary Peritoneal Cancer,anaphylactic reaction
D002637,4.35,NCT02272790-3,Arm C,NCT02272790,Adavosertib Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian  Fallopian Tube  or Primary Peritoneal Cancer,chest pain
D002637,8.33,NCT02272790-4,Arm C2,NCT02272790,Adavosertib Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian  Fallopian Tube  or Primary Peritoneal Cancer,chest pain
UNKNOWN-check-for-typo,7.89,NCT02272790-2,Arm B,NCT02272790,Adavosertib Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian  Fallopian Tube  or Primary Peritoneal Cancer,D00
UNKNOWN-check-for-typo,8.33,NCT02272790-4,Arm C2,NCT02272790,Adavosertib Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian  Fallopian Tube  or Primary Peritoneal Cancer,D00
D002481,11.11,NCT02272790-1,Arm A,NCT02272790,Adavosertib Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian  Fallopian Tube  or Primary Peritoneal Cancer,cellulitis
D002481,2.63,NCT02272790-2,Arm B,NCT02272790,Adavosertib Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian  Fallopian Tube  or Primary Peritoneal Cancer,cellulitis
10023424,16.67,NCT02272790-5,Arm D-175 mg,NCT02272790,Adavosertib Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian  Fallopian Tube  or Primary Peritoneal Cancer,kidney infection
D008100,2.63,NCT02272790-2,Arm B,NCT02272790,Adavosertib Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian  Fallopian Tube  or Primary Peritoneal Cancer,liver abscess
D000985,2.63,NCT02272790-2,Arm B,NCT02272790,Adavosertib Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian  Fallopian Tube  or Primary Peritoneal Cancer,antisepsis
D000038,2.63,NCT02272790-2,Arm B,NCT02272790,Adavosertib Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian  Fallopian Tube  or Primary Peritoneal Cancer,abscess
D018805,11.11,NCT02272790-1,Arm A,NCT02272790,Adavosertib Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian  Fallopian Tube  or Primary Peritoneal Cancer,sepsis
D018805,8.33,NCT02272790-4,Arm C2,NCT02272790,Adavosertib Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian  Fallopian Tube  or Primary Peritoneal Cancer,sepsis
D012772,2.63,NCT02272790-2,Arm B,NCT02272790,Adavosertib Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian  Fallopian Tube  or Primary Peritoneal Cancer,septic shock
D014552,2.63,NCT02272790-2,Arm B,NCT02272790,Adavosertib Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian  Fallopian Tube  or Primary Peritoneal Cancer,urinary tract infection
D053821,2.63,NCT02272790-2,Arm B,NCT02272790,Adavosertib Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian  Fallopian Tube  or Primary Peritoneal Cancer,cardiovascular infections
10065712,4.35,NCT02272790-3,Arm C,NCT02272790,Adavosertib Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian  Fallopian Tube  or Primary Peritoneal Cancer,gastrointestinal stoma necrosis
10051792,8.7,NCT02272790-3,Arm C,NCT02272790,Adavosertib Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian  Fallopian Tube  or Primary Peritoneal Cancer,infusion related reaction
10029366,4.35,NCT02272790-3,Arm C,NCT02272790,Adavosertib Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian  Fallopian Tube  or Primary Peritoneal Cancer,neutrophil count decreased
10035528,8.7,NCT02272790-3,Arm C,NCT02272790,Adavosertib Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian  Fallopian Tube  or Primary Peritoneal Cancer,platelet count decreased
D003924,8.33,NCT02272790-4,Arm C2,NCT02272790,Adavosertib Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian  Fallopian Tube  or Primary Peritoneal Cancer,type 2 diabetes mellitus
D021501,11.11,NCT02272790-1,Arm A,NCT02272790,Adavosertib Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian  Fallopian Tube  or Primary Peritoneal Cancer,flank pain
D002546,2.63,NCT02272790-2,Arm B,NCT02272790,Adavosertib Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian  Fallopian Tube  or Primary Peritoneal Cancer,ischemic attack transient
UNKNOWN-check-for-typo,8.33,NCT02272790-4,Arm C2,NCT02272790,Adavosertib Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian  Fallopian Tube  or Primary Peritoneal Cancer,D00
D011655,2.63,NCT02272790-2,Arm B,NCT02272790,Adavosertib Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian  Fallopian Tube  or Primary Peritoneal Cancer,pulmonary embolism
D011655,4.35,NCT02272790-3,Arm C,NCT02272790,Adavosertib Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian  Fallopian Tube  or Primary Peritoneal Cancer,pulmonary embolism
D011655,16.67,NCT02272790-4,Arm C2,NCT02272790,Adavosertib Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian  Fallopian Tube  or Primary Peritoneal Cancer,pulmonary embolism
D012135,16.67,NCT02272790-5,Arm D-175 mg,NCT02272790,Adavosertib Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian  Fallopian Tube  or Primary Peritoneal Cancer,wheezing
D012883,8.33,NCT02272790-4,Arm C2,NCT02272790,Adavosertib Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian  Fallopian Tube  or Primary Peritoneal Cancer,skin ulcer
D009026,31.46,NCT02282020-1,Olaparib 300mg BID,NCT02282020,Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments,mortality
D009026,23.86,NCT02282020-2,Selected Chemotherapy,NCT02282020,Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments,mortality
D064420,23.6,NCT02282020-1,Olaparib 300mg BID,NCT02282020,Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments,adverse drug events
D064420,18.42,NCT02282020-2,Selected Chemotherapy,NCT02282020,Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments,adverse drug events
D000741,2.81,NCT02282020-1,Olaparib 300mg BID,NCT02282020,Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments,aplastic anaemia
D010198,1.12,NCT02282020-1,Olaparib 300mg BID,NCT02282020,Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments,pancytopenia
D000028,0.56,NCT02282020-1,Olaparib 300mg BID,NCT02282020,Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments,abortion failure
D014012,0.56,NCT02282020-1,Olaparib 300mg BID,NCT02282020,Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments,tinnitus
D014717,0.56,NCT02282020-1,Olaparib 300mg BID,NCT02282020,Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments,vertigo
D015746,0.56,NCT02282020-1,Olaparib 300mg BID,NCT02282020,Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments,abdominal pain
D015746,1.32,NCT02282020-2,Selected Chemotherapy,NCT02282020,Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments,abdominal pain
D000069282,1.32,NCT02282020-2,Selected Chemotherapy,NCT02282020,Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments,canaliculitis
D001201,0.56,NCT02282020-1,Olaparib 300mg BID,NCT02282020,Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments,ascites
D045823,1.12,NCT02282020-1,Olaparib 300mg BID,NCT02282020,Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments,ileus
D007415,1.12,NCT02282020-1,Olaparib 300mg BID,NCT02282020,Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments,intestinal obstruction
D007415,1.32,NCT02282020-2,Selected Chemotherapy,NCT02282020,Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments,intestinal obstruction
D008642,1.32,NCT02282020-2,Selected Chemotherapy,NCT02282020,Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments,mesenteric veins
D009325,1.12,NCT02282020-1,Olaparib 300mg BID,NCT02282020,Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments,nausea
D009325,2.63,NCT02282020-2,Selected Chemotherapy,NCT02282020,Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments,nausea
10015461,0.56,NCT02282020-1,Olaparib 300mg BID,NCT02282020,Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments,esophagitis
10041101,1.12,NCT02282020-1,Olaparib 300mg BID,NCT02282020,Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments,small intestinal obstruction
D014839,1.69,NCT02282020-1,Olaparib 300mg BID,NCT02282020,Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments,vomiting
D014839,3.95,NCT02282020-2,Selected Chemotherapy,NCT02282020,Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments,vomiting
D001247,1.12,NCT02282020-1,Olaparib 300mg BID,NCT02282020,Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments,asthenia
D001247,1.32,NCT02282020-2,Selected Chemotherapy,NCT02282020,Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments,asthenia
D002637,0.56,NCT02282020-1,Olaparib 300mg BID,NCT02282020,Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments,chest pain
10025482,1.32,NCT02282020-2,Selected Chemotherapy,NCT02282020,Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments,malaise
D000799,1.32,NCT02282020-2,Selected Chemotherapy,NCT02282020,Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments,angioedema
D005334,1.12,NCT02282020-1,Olaparib 300mg BID,NCT02282020,Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments,pyrexia
D005334,2.63,NCT02282020-2,Selected Chemotherapy,NCT02282020,Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments,pyrexia
D002764,0.56,NCT02282020-1,Olaparib 300mg BID,NCT02282020,Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments,cholecystitis
D000707,0.56,NCT02282020-1,Olaparib 300mg BID,NCT02282020,Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments,anaphylactic reaction
D000038,0.56,NCT02282020-1,Olaparib 300mg BID,NCT02282020,Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments,abscess
10064687,1.32,NCT02282020-2,Selected Chemotherapy,NCT02282020,Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments,device related infection
D005759,1.12,NCT02282020-1,Olaparib 300mg BID,NCT02282020,Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments,gastroenteritis
D006562,0.56,NCT02282020-1,Olaparib 300mg BID,NCT02282020,Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments,herpes zoster
D011014,1.12,NCT02282020-1,Olaparib 300mg BID,NCT02282020,Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments,pneumonia
D011014,1.32,NCT02282020-2,Selected Chemotherapy,NCT02282020,Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments,pneumonia
D018805,1.12,NCT02282020-1,Olaparib 300mg BID,NCT02282020,Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments,sepsis
D000073818,0.56,NCT02282020-1,Olaparib 300mg BID,NCT02282020,Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments,procedural pain
D011885,0.56,NCT02282020-1,Olaparib 300mg BID,NCT02282020,Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments,radius fracture
D011885,1.32,NCT02282020-2,Selected Chemotherapy,NCT02282020,Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments,radius fracture
D016103,0.56,NCT02282020-1,Olaparib 300mg BID,NCT02282020,Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments,spinal fractures
D007427,0.56,NCT02282020-1,Olaparib 300mg BID,NCT02282020,Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments,subarachnoid pressure
10011368,0.56,NCT02282020-1,Olaparib 300mg BID,NCT02282020,Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments,creatinine increased
D014883,0.56,NCT02282020-1,Olaparib 300mg BID,NCT02282020,Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments,water-electrolyte imbalance
10033425,1.32,NCT02282020-2,Selected Chemotherapy,NCT02282020,Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments,pain in extremity
D019534,0.56,NCT02282020-1,Olaparib 300mg BID,NCT02282020,Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments,rotator cuff impingement syndrome
D015470,0.56,NCT02282020-1,Olaparib 300mg BID,NCT02282020,Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments,leukemia myeloid acute
D015470,1.32,NCT02282020-2,Selected Chemotherapy,NCT02282020,Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments,leukemia myeloid acute
D001943,0.56,NCT02282020-1,Olaparib 300mg BID,NCT02282020,Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments,breast cancer
D013274,0.56,NCT02282020-1,Olaparib 300mg BID,NCT02282020,Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments,gastric cancer
D008175,0.56,NCT02282020-1,Olaparib 300mg BID,NCT02282020,Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments,lung neoplasms
D008198,0.56,NCT02282020-1,Olaparib 300mg BID,NCT02282020,Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments,lymph nodes
D009190,1.12,NCT02282020-1,Olaparib 300mg BID,NCT02282020,Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments,myelodysplastic syndrome
D013474,0.56,NCT02282020-1,Olaparib 300mg BID,NCT02282020,Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments,sunstroke
D013575,1.12,NCT02282020-1,Olaparib 300mg BID,NCT02282020,Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments,syncope
D051437,0.56,NCT02282020-1,Olaparib 300mg BID,NCT02282020,Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments,renal failure
D010996,1.69,NCT02282020-1,Olaparib 300mg BID,NCT02282020,Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments,pleural effusion
D010996,2.63,NCT02282020-2,Selected Chemotherapy,NCT02282020,Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments,pleural effusion
D011655,1.12,NCT02282020-1,Olaparib 300mg BID,NCT02282020,Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments,pulmonary embolism
D020246,1.69,NCT02282020-1,Olaparib 300mg BID,NCT02282020,Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments,deep vein thrombosis
D004617,0.56,NCT02282020-1,Olaparib 300mg BID,NCT02282020,Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments,embolism
D009026,20.35,NCT02285062-1,Lenalidomide Plus R-CHOP (R2-CHOP),NCT02285062,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,mortality
D009026,21.75,NCT02285062-2,Placebo Plus R-CHOP,NCT02285062,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,mortality
D064420,36.75,NCT02285062-1,Lenalidomide Plus R-CHOP (R2-CHOP),NCT02285062,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,adverse drug events
D064420,30.99,NCT02285062-2,Placebo Plus R-CHOP,NCT02285062,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,adverse drug events
D000380,0.35,NCT02285062-1,Lenalidomide Plus R-CHOP (R2-CHOP),NCT02285062,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,agranulocytosis
D000380,0.35,NCT02285062-2,Placebo Plus R-CHOP,NCT02285062,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,agranulocytosis
D000741,2.12,NCT02285062-1,Lenalidomide Plus R-CHOP (R2-CHOP),NCT02285062,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,aplastic anaemia
D000741,2.11,NCT02285062-2,Placebo Plus R-CHOP,NCT02285062,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,aplastic anaemia
D000380,0.35,NCT02285062-1,Lenalidomide Plus R-CHOP (R2-CHOP),NCT02285062,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,granulocytopenia
D064147,10.95,NCT02285062-1,Lenalidomide Plus R-CHOP (R2-CHOP),NCT02285062,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,febrile neutropenia
D064147,4.93,NCT02285062-2,Placebo Plus R-CHOP,NCT02285062,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,febrile neutropenia
D007970,0.71,NCT02285062-1,Lenalidomide Plus R-CHOP (R2-CHOP),NCT02285062,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,leukopenia
D000072281,0.35,NCT02285062-2,Placebo Plus R-CHOP,NCT02285062,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,lymphadenopathy
D009503,6.71,NCT02285062-1,Lenalidomide Plus R-CHOP (R2-CHOP),NCT02285062,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,neutropenia
D009503,4.58,NCT02285062-2,Placebo Plus R-CHOP,NCT02285062,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,neutropenia
D005218,0.35,NCT02285062-2,Placebo Plus R-CHOP,NCT02285062,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,steatonecrosis
D013921,5.65,NCT02285062-1,Lenalidomide Plus R-CHOP (R2-CHOP),NCT02285062,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,thrombocytopenia
D013921,0.35,NCT02285062-2,Placebo Plus R-CHOP,NCT02285062,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,thrombocytopenia
D054058,0.35,NCT02285062-1,Lenalidomide Plus R-CHOP (R2-CHOP),NCT02285062,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,acute coronary syndrome
D056988,0.71,NCT02285062-1,Lenalidomide Plus R-CHOP (R2-CHOP),NCT02285062,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,acute anterior wall myocardial infarction
D001145,0.35,NCT02285062-1,Lenalidomide Plus R-CHOP (R2-CHOP),NCT02285062,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,arrhythmia
D001281,0.71,NCT02285062-1,Lenalidomide Plus R-CHOP (R2-CHOP),NCT02285062,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,atrial fibrillation
D001281,1.41,NCT02285062-2,Placebo Plus R-CHOP,NCT02285062,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,atrial fibrillation
D001282,0.35,NCT02285062-2,Placebo Plus R-CHOP,NCT02285062,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,atrial flutter
D006323,0.35,NCT02285062-2,Placebo Plus R-CHOP,NCT02285062,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,cardiac arrest
D006331,0.35,NCT02285062-2,Placebo Plus R-CHOP,NCT02285062,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,cardiac disorder
D006333,1.06,NCT02285062-2,Placebo Plus R-CHOP,NCT02285062,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,cardiac failure
D006333,0.35,NCT02285062-2,Placebo Plus R-CHOP,NCT02285062,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,cardiac failure
D003324,0.35,NCT02285062-2,Placebo Plus R-CHOP,NCT02285062,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,coronary artery disease
D013616,0.35,NCT02285062-2,Placebo Plus R-CHOP,NCT02285062,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,sinus tachycardia
10000060,0.35,NCT02285062-1,Lenalidomide Plus R-CHOP (R2-CHOP),NCT02285062,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,abdominal distension
D015746,1.41,NCT02285062-1,Lenalidomide Plus R-CHOP (R2-CHOP),NCT02285062,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,abdominal pain
D003731,0.35,NCT02285062-2,Placebo Plus R-CHOP,NCT02285062,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,dental caries
UNKNOWN-check-for-typo,2.12,NCT02285062-1,Lenalidomide Plus R-CHOP (R2-CHOP),NCT02285062,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,D00
UNKNOWN-check-for-typo,1.41,NCT02285062-2,Placebo Plus R-CHOP,NCT02285062,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,D00
D000072663,0.35,NCT02285062-2,Placebo Plus R-CHOP,NCT02285062,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,spontaneous perforation
D007412,0.35,NCT02285062-2,Placebo Plus R-CHOP,NCT02285062,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,enterocutaneous fistula
D005414,0.35,NCT02285062-1,Lenalidomide Plus R-CHOP (R2-CHOP),NCT02285062,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,flatulence
D020115,0.71,NCT02285062-1,Lenalidomide Plus R-CHOP (R2-CHOP),NCT02285062,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,progastricsin
D020115,0.35,NCT02285062-2,Placebo Plus R-CHOP,NCT02285062,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,progastricsin
D010437,0.35,NCT02285062-2,Placebo Plus R-CHOP,NCT02285062,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,gastroduodenal ulcer
D000069196,0.35,NCT02285062-1,Lenalidomide Plus R-CHOP (R2-CHOP),NCT02285062,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,gastrointestinal microbiome
UNKNOWN-check-for-typo,0.35,NCT02285062-1,Lenalidomide Plus R-CHOP (R2-CHOP),NCT02285062,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,D00
D007415,0.35,NCT02285062-1,Lenalidomide Plus R-CHOP (R2-CHOP),NCT02285062,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,intestinal obstruction
D007420,0.35,NCT02285062-2,Placebo Plus R-CHOP,NCT02285062,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,intestine large
D009325,0.71,NCT02285062-1,Lenalidomide Plus R-CHOP (R2-CHOP),NCT02285062,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,nausea
D009325,0.7,NCT02285062-2,Placebo Plus R-CHOP,NCT02285062,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,nausea
D044504,0.35,NCT02285062-2,Placebo Plus R-CHOP,NCT02285062,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,enterocolitis neutropenic
D013280,0.71,NCT02285062-1,Lenalidomide Plus R-CHOP (R2-CHOP),NCT02285062,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,stomatitis
D014839,1.06,NCT02285062-1,Lenalidomide Plus R-CHOP (R2-CHOP),NCT02285062,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,vomiting
D014839,0.35,NCT02285062-2,Placebo Plus R-CHOP,NCT02285062,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,vomiting
D001247,0.71,NCT02285062-1,Lenalidomide Plus R-CHOP (R2-CHOP),NCT02285062,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,asthenia
D001247,0.35,NCT02285062-2,Placebo Plus R-CHOP,NCT02285062,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,asthenia
D003643,0.35,NCT02285062-1,Lenalidomide Plus R-CHOP (R2-CHOP),NCT02285062,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,death
D005119,0.35,NCT02285062-1,Lenalidomide Plus R-CHOP (R2-CHOP),NCT02285062,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,extravasation of diagnostic and therapeutic materials
D000077944,0.35,NCT02285062-1,Lenalidomide Plus R-CHOP (R2-CHOP),NCT02285062,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,alefacept
D003695,0.35,NCT02285062-1,Lenalidomide Plus R-CHOP (R2-CHOP),NCT02285062,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,healthcare
D007035,0.35,NCT02285062-1,Lenalidomide Plus R-CHOP (R2-CHOP),NCT02285062,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,hypothermia
10025482,0.35,NCT02285062-1,Lenalidomide Plus R-CHOP (R2-CHOP),NCT02285062,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,malaise
10062501,0.35,NCT02285062-2,Placebo Plus R-CHOP,NCT02285062,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,non-cardiac chest pain
D000799,0.35,NCT02285062-1,Lenalidomide Plus R-CHOP (R2-CHOP),NCT02285062,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,angioedema
D005334,2.47,NCT02285062-1,Lenalidomide Plus R-CHOP (R2-CHOP),NCT02285062,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,pyrexia
D005334,3.17,NCT02285062-2,Placebo Plus R-CHOP,NCT02285062,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,pyrexia
D016757,0.35,NCT02285062-1,Lenalidomide Plus R-CHOP (R2-CHOP),NCT02285062,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,sudden cardiac death
D042882,0.35,NCT02285062-1,Lenalidomide Plus R-CHOP (R2-CHOP),NCT02285062,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,gallstones common bile duct
D056486,0.35,NCT02285062-1,Lenalidomide Plus R-CHOP (R2-CHOP),NCT02285062,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,drug induced liver injury
D011681,0.35,NCT02285062-2,Placebo Plus R-CHOP,NCT02285062,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,pupillary functions abnormal
D006505,0.35,NCT02285062-2,Placebo Plus R-CHOP,NCT02285062,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,hepatitis
D041781,0.35,NCT02285062-1,Lenalidomide Plus R-CHOP (R2-CHOP),NCT02285062,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,cholestatic jaundice
D056486,0.35,NCT02285062-2,Placebo Plus R-CHOP,NCT02285062,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,chemical and drug induced liver injury
D003287,0.35,NCT02285062-2,Placebo Plus R-CHOP,NCT02285062,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,contrast media
10056519,0.35,NCT02285062-2,Placebo Plus R-CHOP,NCT02285062,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,abdominal infection
D000038,0.35,NCT02285062-1,Lenalidomide Plus R-CHOP (R2-CHOP),NCT02285062,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,abscess
D001064,0.35,NCT02285062-1,Lenalidomide Plus R-CHOP (R2-CHOP),NCT02285062,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,appendicitis
D001064,0.35,NCT02285062-2,Placebo Plus R-CHOP,NCT02285062,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,appendicitis
D001170,0.35,NCT02285062-1,Lenalidomide Plus R-CHOP (R2-CHOP),NCT02285062,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,bacterial arthritis
D001424,0.35,NCT02285062-1,Lenalidomide Plus R-CHOP (R2-CHOP),NCT02285062,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,bacterial infection
D001991,0.35,NCT02285062-2,Placebo Plus R-CHOP,NCT02285062,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,bronchitis
D000073557,0.35,NCT02285062-1,Lenalidomide Plus R-CHOP (R2-CHOP),NCT02285062,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,campylobacteraceae
D002481,1.06,NCT02285062-1,Lenalidomide Plus R-CHOP (R2-CHOP),NCT02285062,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,cellulitis
D004761,0.35,NCT02285062-1,Lenalidomide Plus R-CHOP (R2-CHOP),NCT02285062,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,clostridium enterocolitis
D004761,0.35,NCT02285062-2,Placebo Plus R-CHOP,NCT02285062,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,clostridium enterocolitis
D003586,0.35,NCT02285062-1,Lenalidomide Plus R-CHOP (R2-CHOP),NCT02285062,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,cytomegalovirus infection
D003586,0.35,NCT02285062-2,Placebo Plus R-CHOP,NCT02285062,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,cytomegalovirus infection
10064687,0.35,NCT02285062-1,Lenalidomide Plus R-CHOP (R2-CHOP),NCT02285062,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,device related infection
10064687,0.7,NCT02285062-2,Placebo Plus R-CHOP,NCT02285062,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,device related infection
10064687,0.71,NCT02285062-1,Lenalidomide Plus R-CHOP (R2-CHOP),NCT02285062,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,device related infection
D000985,0.35,NCT02285062-1,Lenalidomide Plus R-CHOP (R2-CHOP),NCT02285062,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,antisepsis
D014552,0.35,NCT02285062-1,Lenalidomide Plus R-CHOP (R2-CHOP),NCT02285062,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,urinary tract infections
D000038,0.35,NCT02285062-1,Lenalidomide Plus R-CHOP (R2-CHOP),NCT02285062,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,abscess
D006509,0.35,NCT02285062-2,Placebo Plus R-CHOP,NCT02285062,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,hepatitis b
D006562,0.35,NCT02285062-2,Placebo Plus R-CHOP,NCT02285062,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,herpes zoster
D007251,0.35,NCT02285062-1,Lenalidomide Plus R-CHOP (R2-CHOP),NCT02285062,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,influenza
D007710,0.35,NCT02285062-1,Lenalidomide Plus R-CHOP (R2-CHOP),NCT02285062,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,klebsiella infection
D012141,0.35,NCT02285062-2,Placebo Plus R-CHOP,NCT02285062,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,respiratory tract infections
D012141,0.35,NCT02285062-1,Lenalidomide Plus R-CHOP (R2-CHOP),NCT02285062,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,respiratory tract infections
10061229,1.41,NCT02285062-1,Lenalidomide Plus R-CHOP (R2-CHOP),NCT02285062,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,lung infection
10061229,0.7,NCT02285062-2,Placebo Plus R-CHOP,NCT02285062,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,lung infection
D000985,0.35,NCT02285062-1,Lenalidomide Plus R-CHOP (R2-CHOP),NCT02285062,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,antisepsis
D010019,0.35,NCT02285062-2,Placebo Plus R-CHOP,NCT02285062,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,osteomyelitis
D000257,0.35,NCT02285062-1,Lenalidomide Plus R-CHOP (R2-CHOP),NCT02285062,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,adenovirus infections
D010612,0.35,NCT02285062-2,Placebo Plus R-CHOP,NCT02285062,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,pharyngitis
D011020,0.35,NCT02285062-2,Placebo Plus R-CHOP,NCT02285062,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,pneumocystis jirovecii pneumonia
D011014,3.89,NCT02285062-1,Lenalidomide Plus R-CHOP (R2-CHOP),NCT02285062,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,pneumonia
D011014,2.46,NCT02285062-2,Placebo Plus R-CHOP,NCT02285062,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,pneumonia
D000985,0.35,NCT02285062-1,Lenalidomide Plus R-CHOP (R2-CHOP),NCT02285062,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,antisepsis
D012480,0.35,NCT02285062-1,Lenalidomide Plus R-CHOP (R2-CHOP),NCT02285062,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,salmonellosis
D018805,0.71,NCT02285062-1,Lenalidomide Plus R-CHOP (R2-CHOP),NCT02285062,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,sepsis
D018805,0.7,NCT02285062-2,Placebo Plus R-CHOP,NCT02285062,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,sepsis
D012772,0.71,NCT02285062-1,Lenalidomide Plus R-CHOP (R2-CHOP),NCT02285062,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,septic shock
D012772,0.35,NCT02285062-2,Placebo Plus R-CHOP,NCT02285062,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,septic shock
D018461,0.35,NCT02285062-2,Placebo Plus R-CHOP,NCT02285062,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,soft tissue infection
D002184,0.35,NCT02285062-2,Placebo Plus R-CHOP,NCT02285062,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,canine tracheobronchitis virus
D012141,0.71,NCT02285062-1,Lenalidomide Plus R-CHOP (R2-CHOP),NCT02285062,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,upper respiratory tract infections
D012141,0.35,NCT02285062-2,Placebo Plus R-CHOP,NCT02285062,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,upper respiratory tract infections
D014552,1.41,NCT02285062-2,Placebo Plus R-CHOP,NCT02285062,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,urinary tract infection
D002644,0.35,NCT02285062-1,Lenalidomide Plus R-CHOP (R2-CHOP),NCT02285062,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,varicella
D015775,0.35,NCT02285062-2,Placebo Plus R-CHOP,NCT02285062,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,microfractures
D005265,0.35,NCT02285062-2,Placebo Plus R-CHOP,NCT02285062,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,femur neck fractures
10051792,0.35,NCT02285062-1,Lenalidomide Plus R-CHOP (R2-CHOP),NCT02285062,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,infusion related reaction
10051792,1.06,NCT02285062-2,Placebo Plus R-CHOP,NCT02285062,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,infusion related reaction
D035002,0.35,NCT02285062-1,Lenalidomide Plus R-CHOP (R2-CHOP),NCT02285062,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,lower limb
D015775,0.35,NCT02285062-1,Lenalidomide Plus R-CHOP (R2-CHOP),NCT02285062,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,microfractures
D006261,0.35,NCT02285062-1,Lenalidomide Plus R-CHOP (R2-CHOP),NCT02285062,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,headache
D009325,0.35,NCT02285062-1,Lenalidomide Plus R-CHOP (R2-CHOP),NCT02285062,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,nausea
D014839,0.35,NCT02285062-1,Lenalidomide Plus R-CHOP (R2-CHOP),NCT02285062,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,vomiting
D016103,0.35,NCT02285062-1,Lenalidomide Plus R-CHOP (R2-CHOP),NCT02285062,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,spinal fractures
D016103,0.35,NCT02285062-2,Placebo Plus R-CHOP,NCT02285062,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,spinal fractures
D016103,0.35,NCT02285062-2,Placebo Plus R-CHOP,NCT02285062,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,spinal fracture
D020198,0.35,NCT02285062-2,Placebo Plus R-CHOP,NCT02285062,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,intracranial hemorrhage traumatic
10029366,0.7,NCT02285062-2,Placebo Plus R-CHOP,NCT02285062,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,neutrophil count decreased
10035528,0.35,NCT02285062-2,Placebo Plus R-CHOP,NCT02285062,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,platelet count decreased
D007958,0.35,NCT02285062-1,Lenalidomide Plus R-CHOP (R2-CHOP),NCT02285062,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,blood cell count white
D003681,0.7,NCT02285062-2,Placebo Plus R-CHOP,NCT02285062,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,dehydration
D014883,0.35,NCT02285062-1,Lenalidomide Plus R-CHOP (R2-CHOP),NCT02285062,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,water-electrolyte imbalance
UNKNOWN-check-for-typo,0.71,NCT02285062-1,Lenalidomide Plus R-CHOP (R2-CHOP),NCT02285062,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,D00
UNKNOWN-check-for-typo,0.35,NCT02285062-1,Lenalidomide Plus R-CHOP (R2-CHOP),NCT02285062,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,D00
UNKNOWN-check-for-typo,0.35,NCT02285062-2,Placebo Plus R-CHOP,NCT02285062,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,D00
UNKNOWN-check-for-typo,0.35,NCT02285062-2,Placebo Plus R-CHOP,NCT02285062,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,D00
UNKNOWN-check-for-typo,0.35,NCT02285062-1,Lenalidomide Plus R-CHOP (R2-CHOP),NCT02285062,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,D00
D015275,0.35,NCT02285062-1,Lenalidomide Plus R-CHOP (R2-CHOP),NCT02285062,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,tumour lysis syndrome
D015275,0.35,NCT02285062-2,Placebo Plus R-CHOP,NCT02285062,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,tumour lysis syndrome
D001416,0.35,NCT02285062-1,Lenalidomide Plus R-CHOP (R2-CHOP),NCT02285062,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,back pain
D001416,0.35,NCT02285062-2,Placebo Plus R-CHOP,NCT02285062,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,back pain
D002295,0.35,NCT02285062-2,Placebo Plus R-CHOP,NCT02285062,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,carcinoma transitional cell
D002490,0.35,NCT02285062-1,Lenalidomide Plus R-CHOP (R2-CHOP),NCT02285062,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,central nervous system
D000069293,1.06,NCT02285062-1,Lenalidomide Plus R-CHOP (R2-CHOP),NCT02285062,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,plasmablasts diffuse large b-cell lymphoma
D000077192,0.35,NCT02285062-2,Placebo Plus R-CHOP,NCT02285062,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,lung adenocarcinoma
D008545,0.35,NCT02285062-1,Lenalidomide Plus R-CHOP (R2-CHOP),NCT02285062,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,malignant melanoma
D018365,0.35,NCT02285062-2,Placebo Plus R-CHOP,NCT02285062,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,residual tumour
D003244,0.35,NCT02285062-1,Lenalidomide Plus R-CHOP (R2-CHOP),NCT02285062,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,consciousness level altered
D000647,0.35,NCT02285062-1,Lenalidomide Plus R-CHOP (R2-CHOP),NCT02285062,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,amnesia
D001037,0.35,NCT02285062-1,Lenalidomide Plus R-CHOP (R2-CHOP),NCT02285062,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,aphasia
D020521,0.7,NCT02285062-2,Placebo Plus R-CHOP,NCT02285062,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,cerebrovascular accident
D008569,0.35,NCT02285062-1,Lenalidomide Plus R-CHOP (R2-CHOP),NCT02285062,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,retention disorders cognitive
D004244,0.35,NCT02285062-1,Lenalidomide Plus R-CHOP (R2-CHOP),NCT02285062,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,dizziness
D004401,0.35,NCT02285062-1,Lenalidomide Plus R-CHOP (R2-CHOP),NCT02285062,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,dysarthria
D004827,0.35,NCT02285062-1,Lenalidomide Plus R-CHOP (R2-CHOP),NCT02285062,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,epilepsy
D020275,0.35,NCT02285062-2,Placebo Plus R-CHOP,NCT02285062,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,guillain barre syndrome
D000069280,0.35,NCT02285062-2,Placebo Plus R-CHOP,NCT02285062,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,intracranial electroencephalography
D010291,0.35,NCT02285062-1,Lenalidomide Plus R-CHOP (R2-CHOP),NCT02285062,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,hemiparesis
D010291,0.7,NCT02285062-2,Placebo Plus R-CHOP,NCT02285062,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,hemiparesis
D053609,0.35,NCT02285062-2,Placebo Plus R-CHOP,NCT02285062,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,lethargy
10027175,0.35,NCT02285062-1,Lenalidomide Plus R-CHOP (R2-CHOP),NCT02285062,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,memory impairment
D009422,0.35,NCT02285062-1,Lenalidomide Plus R-CHOP (R2-CHOP),NCT02285062,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,nervous system disorder
D009437,0.35,NCT02285062-2,Placebo Plus R-CHOP,NCT02285062,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,neuralgia
D013575,0.35,NCT02285062-1,Lenalidomide Plus R-CHOP (R2-CHOP),NCT02285062,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,presyncope
D013575,0.71,NCT02285062-1,Lenalidomide Plus R-CHOP (R2-CHOP),NCT02285062,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,syncope
D013575,0.7,NCT02285062-2,Placebo Plus R-CHOP,NCT02285062,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,syncope
D014826,0.35,NCT02285062-1,Lenalidomide Plus R-CHOP (R2-CHOP),NCT02285062,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,vocal cord paralysis
D003221,0.35,NCT02285062-1,Lenalidomide Plus R-CHOP (R2-CHOP),NCT02285062,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,confusional state
D011618,0.35,NCT02285062-1,Lenalidomide Plus R-CHOP (R2-CHOP),NCT02285062,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,psychotic disorder
D020323,0.35,NCT02285062-2,Placebo Plus R-CHOP,NCT02285062,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,tic
D058186,0.71,NCT02285062-1,Lenalidomide Plus R-CHOP (R2-CHOP),NCT02285062,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,acute kidney injury
D058186,0.35,NCT02285062-2,Placebo Plus R-CHOP,NCT02285062,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,acute kidney injury
D016055,0.35,NCT02285062-1,Lenalidomide Plus R-CHOP (R2-CHOP),NCT02285062,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,urinary retention
D012131,0.35,NCT02285062-2,Placebo Plus R-CHOP,NCT02285062,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,respiratory failure
D003371,0.35,NCT02285062-1,Lenalidomide Plus R-CHOP (R2-CHOP),NCT02285062,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,cough
UNKNOWN-check-for-typo,0.7,NCT02285062-2,Placebo Plus R-CHOP,NCT02285062,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,D00
D017563,0.35,NCT02285062-1,Lenalidomide Plus R-CHOP (R2-CHOP),NCT02285062,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,interstitial lung disease
D017563,1.41,NCT02285062-2,Placebo Plus R-CHOP,NCT02285062,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,interstitial lung disease
D010996,0.35,NCT02285062-1,Lenalidomide Plus R-CHOP (R2-CHOP),NCT02285062,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,pleural effusion
10035623,0.35,NCT02285062-1,Lenalidomide Plus R-CHOP (R2-CHOP),NCT02285062,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,pleuritic pain
D011014,0.35,NCT02285062-2,Placebo Plus R-CHOP,NCT02285062,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,pneumonitis
D011655,1.77,NCT02285062-1,Lenalidomide Plus R-CHOP (R2-CHOP),NCT02285062,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,pulmonary embolism
D011655,1.06,NCT02285062-2,Placebo Plus R-CHOP,NCT02285062,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,pulmonary embolism
D000799,0.7,NCT02285062-2,Placebo Plus R-CHOP,NCT02285062,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,angioedema
D012131,0.35,NCT02285062-1,Lenalidomide Plus R-CHOP (R2-CHOP),NCT02285062,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,respiratory failure
D012131,1.06,NCT02285062-2,Placebo Plus R-CHOP,NCT02285062,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,respiratory failure
D003668,0.35,NCT02285062-1,Lenalidomide Plus R-CHOP (R2-CHOP),NCT02285062,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,decubitus ulcer
D003875,0.35,NCT02285062-1,Lenalidomide Plus R-CHOP (R2-CHOP),NCT02285062,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,drug eruption
D005076,0.35,NCT02285062-1,Lenalidomide Plus R-CHOP (R2-CHOP),NCT02285062,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,rash
D020246,0.71,NCT02285062-1,Lenalidomide Plus R-CHOP (R2-CHOP),NCT02285062,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,deep vein thrombosis
D020246,0.35,NCT02285062-2,Placebo Plus R-CHOP,NCT02285062,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,deep vein thrombosis
D006973,0.35,NCT02285062-1,Lenalidomide Plus R-CHOP (R2-CHOP),NCT02285062,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,hypertension
D006973,0.35,NCT02285062-2,Placebo Plus R-CHOP,NCT02285062,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,hypertension
D007022,0.35,NCT02285062-2,Placebo Plus R-CHOP,NCT02285062,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,hypotension
D007601,0.35,NCT02285062-1,Lenalidomide Plus R-CHOP (R2-CHOP),NCT02285062,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,jugular veins
10042554,0.35,NCT02285062-2,Placebo Plus R-CHOP,NCT02285062,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,superficial thrombophlebitis
D009026,5.0,NCT02431559-4,Phase 2,NCT02431559,Phase 1/2 Study of Motolimod  Doxorubicin  and Durvalumab in Recurrent  Platinum-Resistant Ovarian Cancer,mortality
D064420,50.0,NCT02431559-2,Phase 1 Dose Level 0b,NCT02431559,Phase 1/2 Study of Motolimod  Doxorubicin  and Durvalumab in Recurrent  Platinum-Resistant Ovarian Cancer,adverse drug events
D064420,16.67,NCT02431559-3,Phase 1 Dose Level +1,NCT02431559,Phase 1/2 Study of Motolimod  Doxorubicin  and Durvalumab in Recurrent  Platinum-Resistant Ovarian Cancer,adverse drug events
D064420,57.5,NCT02431559-4,Phase 2,NCT02431559,Phase 1/2 Study of Motolimod  Doxorubicin  and Durvalumab in Recurrent  Platinum-Resistant Ovarian Cancer,adverse drug events
10005886,2.5,NCT02431559-4,Phase 2,NCT02431559,Phase 1/2 Study of Motolimod  Doxorubicin  and Durvalumab in Recurrent  Platinum-Resistant Ovarian Cancer,blurred vision
D015746,7.5,NCT02431559-4,Phase 2,NCT02431559,Phase 1/2 Study of Motolimod  Doxorubicin  and Durvalumab in Recurrent  Platinum-Resistant Ovarian Cancer,abdominal pain
D001201,2.5,NCT02431559-4,Phase 2,NCT02431559,Phase 1/2 Study of Motolimod  Doxorubicin  and Durvalumab in Recurrent  Platinum-Resistant Ovarian Cancer,ascites
UNKNOWN-check-for-typo,2.5,NCT02431559-4,Phase 2,NCT02431559,Phase 1/2 Study of Motolimod  Doxorubicin  and Durvalumab in Recurrent  Platinum-Resistant Ovarian Cancer,D00
D045823,16.67,NCT02431559-3,Phase 1 Dose Level +1,NCT02431559,Phase 1/2 Study of Motolimod  Doxorubicin  and Durvalumab in Recurrent  Platinum-Resistant Ovarian Cancer,ileus
D045823,5.0,NCT02431559-4,Phase 2,NCT02431559,Phase 1/2 Study of Motolimod  Doxorubicin  and Durvalumab in Recurrent  Platinum-Resistant Ovarian Cancer,ileus
D010195,2.5,NCT02431559-4,Phase 2,NCT02431559,Phase 1/2 Study of Motolimod  Doxorubicin  and Durvalumab in Recurrent  Platinum-Resistant Ovarian Cancer,pancreatitis
10065707,2.5,NCT02431559-4,Phase 2,NCT02431559,Phase 1/2 Study of Motolimod  Doxorubicin  and Durvalumab in Recurrent  Platinum-Resistant Ovarian Cancer,rectal obstruction
10041101,2.5,NCT02431559-4,Phase 2,NCT02431559,Phase 1/2 Study of Motolimod  Doxorubicin  and Durvalumab in Recurrent  Platinum-Resistant Ovarian Cancer,small intestinal obstruction
D013280,25.0,NCT02431559-2,Phase 1 Dose Level 0b,NCT02431559,Phase 1/2 Study of Motolimod  Doxorubicin  and Durvalumab in Recurrent  Platinum-Resistant Ovarian Cancer,stomatitis
D013280,2.5,NCT02431559-4,Phase 2,NCT02431559,Phase 1/2 Study of Motolimod  Doxorubicin  and Durvalumab in Recurrent  Platinum-Resistant Ovarian Cancer,stomatitis
10021328,2.5,NCT02431559-4,Phase 2,NCT02431559,Phase 1/2 Study of Motolimod  Doxorubicin  and Durvalumab in Recurrent  Platinum-Resistant Ovarian Cancer,ileus
D003695,2.5,NCT02431559-4,Phase 2,NCT02431559,Phase 1/2 Study of Motolimod  Doxorubicin  and Durvalumab in Recurrent  Platinum-Resistant Ovarian Cancer,healthcare
D005334,7.5,NCT02431559-4,Phase 2,NCT02431559,Phase 1/2 Study of Motolimod  Doxorubicin  and Durvalumab in Recurrent  Platinum-Resistant Ovarian Cancer,pyrexia
D007249,2.5,NCT02431559-4,Phase 2,NCT02431559,Phase 1/2 Study of Motolimod  Doxorubicin  and Durvalumab in Recurrent  Platinum-Resistant Ovarian Cancer,inflammation
UNKNOWN-check-for-typo,2.5,NCT02431559-4,Phase 2,NCT02431559,Phase 1/2 Study of Motolimod  Doxorubicin  and Durvalumab in Recurrent  Platinum-Resistant Ovarian Cancer,D00
D018988,2.5,NCT02431559-4,Phase 2,NCT02431559,Phase 1/2 Study of Motolimod  Doxorubicin  and Durvalumab in Recurrent  Platinum-Resistant Ovarian Cancer,bacterial translocation
10061229,5.0,NCT02431559-4,Phase 2,NCT02431559,Phase 1/2 Study of Motolimod  Doxorubicin  and Durvalumab in Recurrent  Platinum-Resistant Ovarian Cancer,lung infection
D018805,2.5,NCT02431559-4,Phase 2,NCT02431559,Phase 1/2 Study of Motolimod  Doxorubicin  and Durvalumab in Recurrent  Platinum-Resistant Ovarian Cancer,sepsis
10016173,2.5,NCT02431559-4,Phase 2,NCT02431559,Phase 1/2 Study of Motolimod  Doxorubicin  and Durvalumab in Recurrent  Platinum-Resistant Ovarian Cancer,fall
10017076,5.0,NCT02431559-4,Phase 2,NCT02431559,Phase 1/2 Study of Motolimod  Doxorubicin  and Durvalumab in Recurrent  Platinum-Resistant Ovarian Cancer,fracture
10020100,2.5,NCT02431559-4,Phase 2,NCT02431559,Phase 1/2 Study of Motolimod  Doxorubicin  and Durvalumab in Recurrent  Platinum-Resistant Ovarian Cancer,hip fracture
10051792,2.5,NCT02431559-4,Phase 2,NCT02431559,Phase 1/2 Study of Motolimod  Doxorubicin  and Durvalumab in Recurrent  Platinum-Resistant Ovarian Cancer,infusion related reaction
10048031,2.5,NCT02431559-4,Phase 2,NCT02431559,Phase 1/2 Study of Motolimod  Doxorubicin  and Durvalumab in Recurrent  Platinum-Resistant Ovarian Cancer,wound dehiscence
D000013,2.5,NCT02431559-4,Phase 2,NCT02431559,Phase 1/2 Study of Motolimod  Doxorubicin  and Durvalumab in Recurrent  Platinum-Resistant Ovarian Cancer,congenital abnormalities
UNKNOWN-check-for-typo,25.0,NCT02431559-2,Phase 1 Dose Level 0b,NCT02431559,Phase 1/2 Study of Motolimod  Doxorubicin  and Durvalumab in Recurrent  Platinum-Resistant Ovarian Cancer,D00
D001416,2.5,NCT02431559-4,Phase 2,NCT02431559,Phase 1/2 Study of Motolimod  Doxorubicin  and Durvalumab in Recurrent  Platinum-Resistant Ovarian Cancer,back pain
D018908,2.5,NCT02431559-4,Phase 2,NCT02431559,Phase 1/2 Study of Motolimod  Doxorubicin  and Durvalumab in Recurrent  Platinum-Resistant Ovarian Cancer,muscular weakness
D009369,7.5,NCT02431559-4,Phase 2,NCT02431559,Phase 1/2 Study of Motolimod  Doxorubicin  and Durvalumab in Recurrent  Platinum-Resistant Ovarian Cancer,malignant neoplasms
D001037,2.5,NCT02431559-4,Phase 2,NCT02431559,Phase 1/2 Study of Motolimod  Doxorubicin  and Durvalumab in Recurrent  Platinum-Resistant Ovarian Cancer,aphasia
D002546,2.5,NCT02431559-4,Phase 2,NCT02431559,Phase 1/2 Study of Motolimod  Doxorubicin  and Durvalumab in Recurrent  Platinum-Resistant Ovarian Cancer,ischemic attack transient
10061574,25.0,NCT02431559-2,Phase 1 Dose Level 0b,NCT02431559,Phase 1/2 Study of Motolimod  Doxorubicin  and Durvalumab in Recurrent  Platinum-Resistant Ovarian Cancer,urinary tract obstruction
10006440,25.0,NCT02431559-2,Phase 1 Dose Level 0b,NCT02431559,Phase 1/2 Study of Motolimod  Doxorubicin  and Durvalumab in Recurrent  Platinum-Resistant Ovarian Cancer,bronchial obstruction
D010996,5.0,NCT02431559-4,Phase 2,NCT02431559,Phase 1/2 Study of Motolimod  Doxorubicin  and Durvalumab in Recurrent  Platinum-Resistant Ovarian Cancer,pleural effusion
D005355,2.5,NCT02431559-4,Phase 2,NCT02431559,Phase 1/2 Study of Motolimod  Doxorubicin  and Durvalumab in Recurrent  Platinum-Resistant Ovarian Cancer,fibrosis
10006556,25.0,NCT02431559-2,Phase 1 Dose Level 0b,NCT02431559,Phase 1/2 Study of Motolimod  Doxorubicin  and Durvalumab in Recurrent  Platinum-Resistant Ovarian Cancer,bullous dermatitis
10054524,25.0,NCT02431559-2,Phase 1 Dose Level 0b,NCT02431559,Phase 1/2 Study of Motolimod  Doxorubicin  and Durvalumab in Recurrent  Platinum-Resistant Ovarian Cancer,palmar-plantar erythrodysesthesia syndrome
D008197,2.5,NCT02431559-4,Phase 2,NCT02431559,Phase 1/2 Study of Motolimod  Doxorubicin  and Durvalumab in Recurrent  Platinum-Resistant Ovarian Cancer,lymphadenectomy
D064420,30.0,NCT02448537-1,Stratum A,NCT02448537,A Phase II Multi-Strata Study of PM01183 as a Single Agent or in Combination With Conventional Chemotherapy in Metastatic and/or Unresectable Sarcomas,adverse drug events
D064420,60.0,NCT02448537-2,Stratum B,NCT02448537,A Phase II Multi-Strata Study of PM01183 as a Single Agent or in Combination With Conventional Chemotherapy in Metastatic and/or Unresectable Sarcomas,adverse drug events
D064420,33.33,NCT02448537-3,Stratum C,NCT02448537,A Phase II Multi-Strata Study of PM01183 as a Single Agent or in Combination With Conventional Chemotherapy in Metastatic and/or Unresectable Sarcomas,adverse drug events
D000740,10.0,NCT02448537-2,Stratum B,NCT02448537,A Phase II Multi-Strata Study of PM01183 as a Single Agent or in Combination With Conventional Chemotherapy in Metastatic and/or Unresectable Sarcomas,anemia
D064147,5.0,NCT02448537-1,Stratum A,NCT02448537,A Phase II Multi-Strata Study of PM01183 as a Single Agent or in Combination With Conventional Chemotherapy in Metastatic and/or Unresectable Sarcomas,febrile neutropenia
D064147,10.0,NCT02448537-2,Stratum B,NCT02448537,A Phase II Multi-Strata Study of PM01183 as a Single Agent or in Combination With Conventional Chemotherapy in Metastatic and/or Unresectable Sarcomas,febrile neutropenia
10047281,5.0,NCT02448537-1,Stratum A,NCT02448537,A Phase II Multi-Strata Study of PM01183 as a Single Agent or in Combination With Conventional Chemotherapy in Metastatic and/or Unresectable Sarcomas,ventricular arrhythmia
D003248,8.33,NCT02448537-3,Stratum C,NCT02448537,A Phase II Multi-Strata Study of PM01183 as a Single Agent or in Combination With Conventional Chemotherapy in Metastatic and/or Unresectable Sarcomas,constipation
D003967,5.0,NCT02448537-1,Stratum A,NCT02448537,A Phase II Multi-Strata Study of PM01183 as a Single Agent or in Combination With Conventional Chemotherapy in Metastatic and/or Unresectable Sarcomas,diarrhea
D003967,8.33,NCT02448537-3,Stratum C,NCT02448537,A Phase II Multi-Strata Study of PM01183 as a Single Agent or in Combination With Conventional Chemotherapy in Metastatic and/or Unresectable Sarcomas,diarrhea
D045823,5.0,NCT02448537-1,Stratum A,NCT02448537,A Phase II Multi-Strata Study of PM01183 as a Single Agent or in Combination With Conventional Chemotherapy in Metastatic and/or Unresectable Sarcomas,ileus
D009325,5.0,NCT02448537-1,Stratum A,NCT02448537,A Phase II Multi-Strata Study of PM01183 as a Single Agent or in Combination With Conventional Chemotherapy in Metastatic and/or Unresectable Sarcomas,nausea
D009325,8.33,NCT02448537-3,Stratum C,NCT02448537,A Phase II Multi-Strata Study of PM01183 as a Single Agent or in Combination With Conventional Chemotherapy in Metastatic and/or Unresectable Sarcomas,nausea
10041101,5.0,NCT02448537-1,Stratum A,NCT02448537,A Phase II Multi-Strata Study of PM01183 as a Single Agent or in Combination With Conventional Chemotherapy in Metastatic and/or Unresectable Sarcomas,small intestinal obstruction
10041101,8.33,NCT02448537-3,Stratum C,NCT02448537,A Phase II Multi-Strata Study of PM01183 as a Single Agent or in Combination With Conventional Chemotherapy in Metastatic and/or Unresectable Sarcomas,small intestinal obstruction
D014839,5.0,NCT02448537-1,Stratum A,NCT02448537,A Phase II Multi-Strata Study of PM01183 as a Single Agent or in Combination With Conventional Chemotherapy in Metastatic and/or Unresectable Sarcomas,vomiting
D014839,8.33,NCT02448537-3,Stratum C,NCT02448537,A Phase II Multi-Strata Study of PM01183 as a Single Agent or in Combination With Conventional Chemotherapy in Metastatic and/or Unresectable Sarcomas,vomiting
D000076263,10.0,NCT02448537-2,Stratum B,NCT02448537,A Phase II Multi-Strata Study of PM01183 as a Single Agent or in Combination With Conventional Chemotherapy in Metastatic and/or Unresectable Sarcomas,imported infections
D001424,5.0,NCT02448537-1,Stratum A,NCT02448537,A Phase II Multi-Strata Study of PM01183 as a Single Agent or in Combination With Conventional Chemotherapy in Metastatic and/or Unresectable Sarcomas,bacterial infections
10025256,10.0,NCT02448537-1,Stratum A,NCT02448537,A Phase II Multi-Strata Study of PM01183 as a Single Agent or in Combination With Conventional Chemotherapy in Metastatic and/or Unresectable Sarcomas,lymphocyte count decreased
10025256,10.0,NCT02448537-2,Stratum B,NCT02448537,A Phase II Multi-Strata Study of PM01183 as a Single Agent or in Combination With Conventional Chemotherapy in Metastatic and/or Unresectable Sarcomas,lymphocyte count decreased
10029366,20.0,NCT02448537-1,Stratum A,NCT02448537,A Phase II Multi-Strata Study of PM01183 as a Single Agent or in Combination With Conventional Chemotherapy in Metastatic and/or Unresectable Sarcomas,neutrophil count decreased
10029366,40.0,NCT02448537-2,Stratum B,NCT02448537,A Phase II Multi-Strata Study of PM01183 as a Single Agent or in Combination With Conventional Chemotherapy in Metastatic and/or Unresectable Sarcomas,neutrophil count decreased
10029366,8.33,NCT02448537-3,Stratum C,NCT02448537,A Phase II Multi-Strata Study of PM01183 as a Single Agent or in Combination With Conventional Chemotherapy in Metastatic and/or Unresectable Sarcomas,neutrophil count decreased
10035528,5.0,NCT02448537-1,Stratum A,NCT02448537,A Phase II Multi-Strata Study of PM01183 as a Single Agent or in Combination With Conventional Chemotherapy in Metastatic and/or Unresectable Sarcomas,platelet count decreased
10035528,10.0,NCT02448537-2,Stratum B,NCT02448537,A Phase II Multi-Strata Study of PM01183 as a Single Agent or in Combination With Conventional Chemotherapy in Metastatic and/or Unresectable Sarcomas,platelet count decreased
10049182,15.0,NCT02448537-1,Stratum A,NCT02448537,A Phase II Multi-Strata Study of PM01183 as a Single Agent or in Combination With Conventional Chemotherapy in Metastatic and/or Unresectable Sarcomas,white blood cell decreased
10049182,10.0,NCT02448537-2,Stratum B,NCT02448537,A Phase II Multi-Strata Study of PM01183 as a Single Agent or in Combination With Conventional Chemotherapy in Metastatic and/or Unresectable Sarcomas,white blood cell decreased
D020300,10.0,NCT02448537-2,Stratum B,NCT02448537,A Phase II Multi-Strata Study of PM01183 as a Single Agent or in Combination With Conventional Chemotherapy in Metastatic and/or Unresectable Sarcomas,intracranial hemorrhage
D014549,5.0,NCT02448537-1,Stratum A,NCT02448537,A Phase II Multi-Strata Study of PM01183 as a Single Agent or in Combination With Conventional Chemotherapy in Metastatic and/or Unresectable Sarcomas,urinary incontinence
D010996,8.33,NCT02448537-3,Stratum C,NCT02448537,A Phase II Multi-Strata Study of PM01183 as a Single Agent or in Combination With Conventional Chemotherapy in Metastatic and/or Unresectable Sarcomas,pleural effusion
D019299,5.0,NCT02448537-1,Stratum A,NCT02448537,A Phase II Multi-Strata Study of PM01183 as a Single Agent or in Combination With Conventional Chemotherapy in Metastatic and/or Unresectable Sarcomas,decompression surgical
D009026,33.33,NCT02495454-1,Single Arm,NCT02495454,GA101-miniCHOP Regimen for the Treatment of Elderly Unfit Patients With Diffuse Large B-cell Non-Hodgkin's Lymphoma,mortality
D064420,18.18,NCT02495454-1,Single Arm,NCT02495454,GA101-miniCHOP Regimen for the Treatment of Elderly Unfit Patients With Diffuse Large B-cell Non-Hodgkin's Lymphoma,adverse drug events
D006333,6.06,NCT02495454-1,Single Arm,NCT02495454,GA101-miniCHOP Regimen for the Treatment of Elderly Unfit Patients With Diffuse Large B-cell Non-Hodgkin's Lymphoma,congestive heart failure
D006333,3.03,NCT02495454-1,Single Arm,NCT02495454,GA101-miniCHOP Regimen for the Treatment of Elderly Unfit Patients With Diffuse Large B-cell Non-Hodgkin's Lymphoma,heart failure
D001281,3.03,NCT02495454-1,Single Arm,NCT02495454,GA101-miniCHOP Regimen for the Treatment of Elderly Unfit Patients With Diffuse Large B-cell Non-Hodgkin's Lymphoma,atrial fibrillation
D009325,3.03,NCT02495454-1,Single Arm,NCT02495454,GA101-miniCHOP Regimen for the Treatment of Elderly Unfit Patients With Diffuse Large B-cell Non-Hodgkin's Lymphoma,nausea
D005265,6.06,NCT02495454-1,Single Arm,NCT02495454,GA101-miniCHOP Regimen for the Treatment of Elderly Unfit Patients With Diffuse Large B-cell Non-Hodgkin's Lymphoma,femur neck fractures
D000071074,12.12,NCT02495454-1,Single Arm,NCT02495454,GA101-miniCHOP Regimen for the Treatment of Elderly Unfit Patients With Diffuse Large B-cell Non-Hodgkin's Lymphoma,neonatal sepsis
D000080867,3.03,NCT02495454-1,Single Arm,NCT02495454,GA101-miniCHOP Regimen for the Treatment of Elderly Unfit Patients With Diffuse Large B-cell Non-Hodgkin's Lymphoma,gingipains
D001943,9.09,NCT02495454-1,Single Arm,NCT02495454,GA101-miniCHOP Regimen for the Treatment of Elderly Unfit Patients With Diffuse Large B-cell Non-Hodgkin's Lymphoma,breast cancer
D002289,9.09,NCT02495454-1,Single Arm,NCT02495454,GA101-miniCHOP Regimen for the Treatment of Elderly Unfit Patients With Diffuse Large B-cell Non-Hodgkin's Lymphoma,nonsmall cell lung cancer
D064420,14.71,NCT02505269-1,Brentuximab Vedotin,NCT02505269,Brentuximab Vedotin Plus AD in Non-bulky Limited Stage Hodgkin Lymphoma,adverse drug events
D003092,2.94,NCT02505269-1,Brentuximab Vedotin,NCT02505269,Brentuximab Vedotin Plus AD in Non-bulky Limited Stage Hodgkin Lymphoma,colitis
D009325,2.94,NCT02505269-1,Brentuximab Vedotin,NCT02505269,Brentuximab Vedotin Plus AD in Non-bulky Limited Stage Hodgkin Lymphoma,nausea
D014839,2.94,NCT02505269-1,Brentuximab Vedotin,NCT02505269,Brentuximab Vedotin Plus AD in Non-bulky Limited Stage Hodgkin Lymphoma,vomiting
D003967,2.94,NCT02505269-1,Brentuximab Vedotin,NCT02505269,Brentuximab Vedotin Plus AD in Non-bulky Limited Stage Hodgkin Lymphoma,diarrhea
10046300,2.94,NCT02505269-1,Brentuximab Vedotin,NCT02505269,Brentuximab Vedotin Plus AD in Non-bulky Limited Stage Hodgkin Lymphoma,upper respiratory infection
D018771,2.94,NCT02505269-1,Brentuximab Vedotin,NCT02505269,Brentuximab Vedotin Plus AD in Non-bulky Limited Stage Hodgkin Lymphoma,arthralgia
10043565,2.94,NCT02505269-1,Brentuximab Vedotin,NCT02505269,Brentuximab Vedotin Plus AD in Non-bulky Limited Stage Hodgkin Lymphoma,thromboembolic event
D009026,3.33,NCT02541565-1,Treatment (Pembrolizumab Combination Chemotherapy),NCT02541565,Pembrolizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Diffuse Large B-cell Lymphoma or Grade 3b Follicular Lymphoma,mortality
D064420,43.33,NCT02541565-1,Treatment (Pembrolizumab Combination Chemotherapy),NCT02541565,Pembrolizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Diffuse Large B-cell Lymphoma or Grade 3b Follicular Lymphoma,adverse drug events
D064147,13.33,NCT02541565-1,Treatment (Pembrolizumab Combination Chemotherapy),NCT02541565,Pembrolizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Diffuse Large B-cell Lymphoma or Grade 3b Follicular Lymphoma,febrile neutropenia
10069501,3.33,NCT02541565-1,Treatment (Pembrolizumab Combination Chemotherapy),NCT02541565,Pembrolizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Diffuse Large B-cell Lymphoma or Grade 3b Follicular Lymphoma,left ventricular systolic dysfunction
D041742,3.33,NCT02541565-1,Treatment (Pembrolizumab Combination Chemotherapy),NCT02541565,Pembrolizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Diffuse Large B-cell Lymphoma or Grade 3b Follicular Lymphoma,upper gastrointestinal tract
D015746,3.33,NCT02541565-1,Treatment (Pembrolizumab Combination Chemotherapy),NCT02541565,Pembrolizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Diffuse Large B-cell Lymphoma or Grade 3b Follicular Lymphoma,abdominal pain
D003248,3.33,NCT02541565-1,Treatment (Pembrolizumab Combination Chemotherapy),NCT02541565,Pembrolizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Diffuse Large B-cell Lymphoma or Grade 3b Follicular Lymphoma,constipation
D003967,3.33,NCT02541565-1,Treatment (Pembrolizumab Combination Chemotherapy),NCT02541565,Pembrolizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Diffuse Large B-cell Lymphoma or Grade 3b Follicular Lymphoma,diarrhea
D005334,3.33,NCT02541565-1,Treatment (Pembrolizumab Combination Chemotherapy),NCT02541565,Pembrolizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Diffuse Large B-cell Lymphoma or Grade 3b Follicular Lymphoma,fever
UNKNOWN-check-for-typo,3.33,NCT02541565-1,Treatment (Pembrolizumab Combination Chemotherapy),NCT02541565,Pembrolizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Diffuse Large B-cell Lymphoma or Grade 3b Follicular Lymphoma,D00
D000069544,3.33,NCT02541565-1,Treatment (Pembrolizumab Combination Chemotherapy),NCT02541565,Pembrolizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Diffuse Large B-cell Lymphoma or Grade 3b Follicular Lymphoma,encephalitis infection
D000860,3.33,NCT02541565-1,Treatment (Pembrolizumab Combination Chemotherapy),NCT02541565,Pembrolizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Diffuse Large B-cell Lymphoma or Grade 3b Follicular Lymphoma,hypoxia
D011014,3.33,NCT02541565-1,Treatment (Pembrolizumab Combination Chemotherapy),NCT02541565,Pembrolizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Diffuse Large B-cell Lymphoma or Grade 3b Follicular Lymphoma,pneumonitis
D064420,50.0,NCT02560051-1,Definitive Local Therapy,NCT02560051,Hormone Therapy Plus Chemotherapy as Initial Treatment for Local Failures or Advanced Prostate Cancer,adverse drug events
D064420,25.0,NCT02560051-2,Nodal Only/Low-volume Bone,NCT02560051,Hormone Therapy Plus Chemotherapy as Initial Treatment for Local Failures or Advanced Prostate Cancer,adverse drug events
D000740,12.5,NCT02560051-2,Nodal Only/Low-volume Bone,NCT02560051,Hormone Therapy Plus Chemotherapy as Initial Treatment for Local Failures or Advanced Prostate Cancer,anemia
D013616,12.5,NCT02560051-2,Nodal Only/Low-volume Bone,NCT02560051,Hormone Therapy Plus Chemotherapy as Initial Treatment for Local Failures or Advanced Prostate Cancer,sinus tachycardia
D015746,12.5,NCT02560051-2,Nodal Only/Low-volume Bone,NCT02560051,Hormone Therapy Plus Chemotherapy as Initial Treatment for Local Failures or Advanced Prostate Cancer,abdominal pain
D003967,12.5,NCT02560051-2,Nodal Only/Low-volume Bone,NCT02560051,Hormone Therapy Plus Chemotherapy as Initial Treatment for Local Failures or Advanced Prostate Cancer,diarrhea
D009325,12.5,NCT02560051-2,Nodal Only/Low-volume Bone,NCT02560051,Hormone Therapy Plus Chemotherapy as Initial Treatment for Local Failures or Advanced Prostate Cancer,nausea
D014839,12.5,NCT02560051-2,Nodal Only/Low-volume Bone,NCT02560051,Hormone Therapy Plus Chemotherapy as Initial Treatment for Local Failures or Advanced Prostate Cancer,vomiting
D005334,50.0,NCT02560051-1,Definitive Local Therapy,NCT02560051,Hormone Therapy Plus Chemotherapy as Initial Treatment for Local Failures or Advanced Prostate Cancer,fever
D005334,25.0,NCT02560051-2,Nodal Only/Low-volume Bone,NCT02560051,Hormone Therapy Plus Chemotherapy as Initial Treatment for Local Failures or Advanced Prostate Cancer,fever
D023341,12.5,NCT02560051-2,Nodal Only/Low-volume Bone,NCT02560051,Hormone Therapy Plus Chemotherapy as Initial Treatment for Local Failures or Advanced Prostate Cancer,chills
D005221,16.67,NCT02560051-1,Definitive Local Therapy,NCT02560051,Hormone Therapy Plus Chemotherapy as Initial Treatment for Local Failures or Advanced Prostate Cancer,fatigue
D014552,12.5,NCT02560051-2,Nodal Only/Low-volume Bone,NCT02560051,Hormone Therapy Plus Chemotherapy as Initial Treatment for Local Failures or Advanced Prostate Cancer,urinary tract infection
D018805,12.5,NCT02560051-2,Nodal Only/Low-volume Bone,NCT02560051,Hormone Therapy Plus Chemotherapy as Initial Treatment for Local Failures or Advanced Prostate Cancer,sepsis
10011368,12.5,NCT02560051-2,Nodal Only/Low-volume Bone,NCT02560051,Hormone Therapy Plus Chemotherapy as Initial Treatment for Local Failures or Advanced Prostate Cancer,creatinine increased
10049182,25.0,NCT02560051-2,Nodal Only/Low-volume Bone,NCT02560051,Hormone Therapy Plus Chemotherapy as Initial Treatment for Local Failures or Advanced Prostate Cancer,white blood cell decreased
D007008,12.5,NCT02560051-2,Nodal Only/Low-volume Bone,NCT02560051,Hormone Therapy Plus Chemotherapy as Initial Treatment for Local Failures or Advanced Prostate Cancer,hypokalemia
D034141,25.0,NCT02560051-2,Nodal Only/Low-volume Bone,NCT02560051,Hormone Therapy Plus Chemotherapy as Initial Treatment for Local Failures or Advanced Prostate Cancer,hypoalbuminemia
D000855,25.0,NCT02560051-2,Nodal Only/Low-volume Bone,NCT02560051,Hormone Therapy Plus Chemotherapy as Initial Treatment for Local Failures or Advanced Prostate Cancer,anorexia
D017674,12.5,NCT02560051-2,Nodal Only/Low-volume Bone,NCT02560051,Hormone Therapy Plus Chemotherapy as Initial Treatment for Local Failures or Advanced Prostate Cancer,hypophosphatemia
D003371,16.67,NCT02560051-1,Definitive Local Therapy,NCT02560051,Hormone Therapy Plus Chemotherapy as Initial Treatment for Local Failures or Advanced Prostate Cancer,cough
D003371,12.5,NCT02560051-2,Nodal Only/Low-volume Bone,NCT02560051,Hormone Therapy Plus Chemotherapy as Initial Treatment for Local Failures or Advanced Prostate Cancer,cough
10036402,12.5,NCT02560051-2,Nodal Only/Low-volume Bone,NCT02560051,Hormone Therapy Plus Chemotherapy as Initial Treatment for Local Failures or Advanced Prostate Cancer,postnasal drip
D004417,25.0,NCT02560051-2,Nodal Only/Low-volume Bone,NCT02560051,Hormone Therapy Plus Chemotherapy as Initial Treatment for Local Failures or Advanced Prostate Cancer,dyspnea
D000860,12.5,NCT02560051-2,Nodal Only/Low-volume Bone,NCT02560051,Hormone Therapy Plus Chemotherapy as Initial Treatment for Local Failures or Advanced Prostate Cancer,hypoxia
10038738,16.67,NCT02560051-1,Definitive Local Therapy,NCT02560051,Hormone Therapy Plus Chemotherapy as Initial Treatment for Local Failures or Advanced Prostate Cancer,respiratory thoracic and mediastinal disorders - other specify
10043565,16.67,NCT02560051-1,Definitive Local Therapy,NCT02560051,Hormone Therapy Plus Chemotherapy as Initial Treatment for Local Failures or Advanced Prostate Cancer,thromboembolic event
D009026,57.98,NCT02580058-1,Avelumab,NCT02580058,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),mortality
D009026,54.26,NCT02580058-2,Avelumab + PLD,NCT02580058,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),mortality
D009026,54.74,NCT02580058-3,Pegylated Liposomal Doxorubicin (PLD),NCT02580058,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),mortality
D064420,37.97,NCT02580058-1,Avelumab,NCT02580058,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),adverse drug events
D064420,41.21,NCT02580058-2,Avelumab + PLD,NCT02580058,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),adverse drug events
D064420,28.81,NCT02580058-3,Pegylated Liposomal Doxorubicin (PLD),NCT02580058,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),adverse drug events
D000741,0.56,NCT02580058-3,Pegylated Liposomal Doxorubicin (PLD),NCT02580058,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),aplastic anaemia
D064147,0.55,NCT02580058-2,Avelumab + PLD,NCT02580058,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),febrile neutropenia
D064147,1.69,NCT02580058-3,Pegylated Liposomal Doxorubicin (PLD),NCT02580058,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),febrile neutropenia
D009503,0.56,NCT02580058-3,Pegylated Liposomal Doxorubicin (PLD),NCT02580058,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),neutropenia
D013921,0.55,NCT02580058-2,Avelumab + PLD,NCT02580058,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),thrombocytopenia
D013921,0.56,NCT02580058-3,Pegylated Liposomal Doxorubicin (PLD),NCT02580058,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),thrombocytopenia
D001281,0.53,NCT02580058-1,Avelumab,NCT02580058,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),atrial fibrillation
D009203,0.55,NCT02580058-2,Avelumab + PLD,NCT02580058,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),myocardial infarction
D013610,0.55,NCT02580058-2,Avelumab + PLD,NCT02580058,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),tachycardia
D000309,0.55,NCT02580058-2,Avelumab + PLD,NCT02580058,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),adrenal insufficiency
D006111,0.55,NCT02580058-2,Avelumab + PLD,NCT02580058,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),basedow disease
D007018,1.1,NCT02580058-2,Avelumab + PLD,NCT02580058,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),hypopituitarism
D012163,0.53,NCT02580058-1,Avelumab,NCT02580058,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),retinal detachment
10000060,1.6,NCT02580058-1,Avelumab,NCT02580058,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),abdominal distension
10000060,0.55,NCT02580058-2,Avelumab + PLD,NCT02580058,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),abdominal distension
10000060,0.56,NCT02580058-3,Pegylated Liposomal Doxorubicin (PLD),NCT02580058,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),abdominal distension
D015746,4.81,NCT02580058-1,Avelumab,NCT02580058,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),abdominal pain
D015746,3.3,NCT02580058-2,Avelumab + PLD,NCT02580058,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),abdominal pain
D015746,3.39,NCT02580058-3,Pegylated Liposomal Doxorubicin (PLD),NCT02580058,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),abdominal pain
D015746,0.53,NCT02580058-1,Avelumab,NCT02580058,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),abdominal pain
D015746,0.56,NCT02580058-3,Pegylated Liposomal Doxorubicin (PLD),NCT02580058,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),abdominal pain
D001201,1.07,NCT02580058-1,Avelumab,NCT02580058,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),ascites
D001201,0.55,NCT02580058-2,Avelumab + PLD,NCT02580058,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),ascites
D001201,0.56,NCT02580058-3,Pegylated Liposomal Doxorubicin (PLD),NCT02580058,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),ascites
D003092,0.55,NCT02580058-2,Avelumab + PLD,NCT02580058,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),colitis
D003248,1.07,NCT02580058-1,Avelumab,NCT02580058,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),constipation
D003248,2.75,NCT02580058-2,Avelumab + PLD,NCT02580058,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),constipation
D003248,0.56,NCT02580058-3,Pegylated Liposomal Doxorubicin (PLD),NCT02580058,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),constipation
UNKNOWN-check-for-typo,2.14,NCT02580058-1,Avelumab,NCT02580058,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),D00
UNKNOWN-check-for-typo,0.55,NCT02580058-2,Avelumab + PLD,NCT02580058,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),D00
UNKNOWN-check-for-typo,0.56,NCT02580058-3,Pegylated Liposomal Doxorubicin (PLD),NCT02580058,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),D00
UNKNOWN-check-for-typo,0.55,NCT02580058-2,Avelumab + PLD,NCT02580058,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),D00
UNKNOWN-check-for-typo,0.56,NCT02580058-3,Pegylated Liposomal Doxorubicin (PLD),NCT02580058,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),D00
D045823,0.53,NCT02580058-1,Avelumab,NCT02580058,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),ileus
D045823,2.2,NCT02580058-2,Avelumab + PLD,NCT02580058,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),ileus
D045823,1.13,NCT02580058-3,Pegylated Liposomal Doxorubicin (PLD),NCT02580058,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),ileus
D007415,5.88,NCT02580058-1,Avelumab,NCT02580058,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),intestinal obstruction
D007415,4.95,NCT02580058-2,Avelumab + PLD,NCT02580058,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),intestinal obstruction
D007415,3.39,NCT02580058-3,Pegylated Liposomal Doxorubicin (PLD),NCT02580058,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),intestinal obstruction
D007418,0.56,NCT02580058-3,Pegylated Liposomal Doxorubicin (PLD),NCT02580058,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),intestinal pseudo obstruction
D007443,0.55,NCT02580058-2,Avelumab + PLD,NCT02580058,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),intussusception
D007415,0.55,NCT02580058-2,Avelumab + PLD,NCT02580058,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),intestinal obstruction
D000230,0.53,NCT02580058-1,Avelumab,NCT02580058,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),adenoma malignant
D000230,0.55,NCT02580058-2,Avelumab + PLD,NCT02580058,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),adenoma malignant
D000230,0.56,NCT02580058-3,Pegylated Liposomal Doxorubicin (PLD),NCT02580058,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),adenoma malignant
D045823,0.53,NCT02580058-1,Avelumab,NCT02580058,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),ileus
D009325,3.74,NCT02580058-1,Avelumab,NCT02580058,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),nausea
D009325,2.2,NCT02580058-2,Avelumab + PLD,NCT02580058,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),nausea
D009325,0.56,NCT02580058-3,Pegylated Liposomal Doxorubicin (PLD),NCT02580058,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),nausea
10029957,0.53,NCT02580058-1,Avelumab,NCT02580058,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),obstruction gastric
10015461,0.53,NCT02580058-1,Avelumab,NCT02580058,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),esophagitis
D010195,0.53,NCT02580058-1,Avelumab,NCT02580058,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),acute pancreatitis
10041101,2.67,NCT02580058-1,Avelumab,NCT02580058,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),small intestinal obstruction
10041101,2.2,NCT02580058-2,Avelumab + PLD,NCT02580058,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),small intestinal obstruction
10041101,1.13,NCT02580058-3,Pegylated Liposomal Doxorubicin (PLD),NCT02580058,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),small intestinal obstruction
D013280,1.1,NCT02580058-2,Avelumab + PLD,NCT02580058,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),stomatitis
D013280,0.56,NCT02580058-3,Pegylated Liposomal Doxorubicin (PLD),NCT02580058,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),stomatitis
10021328,0.53,NCT02580058-1,Avelumab,NCT02580058,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),ileus
10021328,0.55,NCT02580058-2,Avelumab + PLD,NCT02580058,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),ileus
10021328,1.13,NCT02580058-3,Pegylated Liposomal Doxorubicin (PLD),NCT02580058,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),ileus
D006554,0.56,NCT02580058-3,Pegylated Liposomal Doxorubicin (PLD),NCT02580058,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),umbilical hernia
D014839,3.74,NCT02580058-1,Avelumab,NCT02580058,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),vomiting
D014839,2.2,NCT02580058-2,Avelumab + PLD,NCT02580058,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),vomiting
D014839,1.69,NCT02580058-3,Pegylated Liposomal Doxorubicin (PLD),NCT02580058,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),vomiting
10064774,0.56,NCT02580058-3,Pegylated Liposomal Doxorubicin (PLD),NCT02580058,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),infusion site extravasation
D001247,1.1,NCT02580058-2,Avelumab + PLD,NCT02580058,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),asthenia
D013909,0.53,NCT02580058-1,Avelumab,NCT02580058,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),chest
D023341,0.53,NCT02580058-1,Avelumab,NCT02580058,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),chills
D023341,0.55,NCT02580058-2,Avelumab + PLD,NCT02580058,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),chills
D004864,0.56,NCT02580058-3,Pegylated Liposomal Doxorubicin (PLD),NCT02580058,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),devices
D018450,4.81,NCT02580058-1,Avelumab,NCT02580058,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),disease progression
D018450,2.75,NCT02580058-2,Avelumab + PLD,NCT02580058,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),disease progression
D018450,1.13,NCT02580058-3,Pegylated Liposomal Doxorubicin (PLD),NCT02580058,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),disease progression
D005221,1.1,NCT02580058-2,Avelumab + PLD,NCT02580058,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),fatigue
D003695,1.07,NCT02580058-1,Avelumab,NCT02580058,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),healthcare
D003695,1.1,NCT02580058-2,Avelumab + PLD,NCT02580058,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),healthcare
D007251,0.53,NCT02580058-1,Avelumab,NCT02580058,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),influenza
D000799,0.55,NCT02580058-2,Avelumab + PLD,NCT02580058,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),angioedema
10025482,1.1,NCT02580058-2,Avelumab + PLD,NCT02580058,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),malaise
D007249,0.55,NCT02580058-2,Avelumab + PLD,NCT02580058,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),inflammation
D000799,0.55,NCT02580058-2,Avelumab + PLD,NCT02580058,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),angioedema
D010146,0.55,NCT02580058-2,Avelumab + PLD,NCT02580058,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),pain
D005334,3.74,NCT02580058-1,Avelumab,NCT02580058,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),pyrexia
D005334,4.95,NCT02580058-2,Avelumab + PLD,NCT02580058,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),pyrexia
D005334,0.56,NCT02580058-3,Pegylated Liposomal Doxorubicin (PLD),NCT02580058,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),pyrexia
D019693,0.53,NCT02580058-1,Avelumab,NCT02580058,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),autoimmune hepatitis
D056486,0.53,NCT02580058-1,Avelumab,NCT02580058,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),drug induced liver injury
D017093,0.56,NCT02580058-3,Pegylated Liposomal Doxorubicin (PLD),NCT02580058,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),hepatic failure
D000707,0.56,NCT02580058-3,Pegylated Liposomal Doxorubicin (PLD),NCT02580058,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),anaphylactic reaction
D000080424,0.55,NCT02580058-2,Avelumab + PLD,NCT02580058,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),cytokine release syndrome
D006967,0.55,NCT02580058-2,Avelumab + PLD,NCT02580058,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),hypersensitivity
D007104,0.53,NCT02580058-1,Avelumab,NCT02580058,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),immune adherence reaction
UNKNOWN-check-for-typo,0.53,NCT02580058-1,Avelumab,NCT02580058,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),D00
UNKNOWN-check-for-typo,0.55,NCT02580058-2,Avelumab + PLD,NCT02580058,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),D00
D002481,0.53,NCT02580058-1,Avelumab,NCT02580058,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),cellulitis
D002761,0.53,NCT02580058-1,Avelumab,NCT02580058,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),cholangitis
D003556,0.53,NCT02580058-1,Avelumab,NCT02580058,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),cystitis
10064687,0.53,NCT02580058-1,Avelumab,NCT02580058,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),device related infection
10064687,0.55,NCT02580058-2,Avelumab + PLD,NCT02580058,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),device related infection
10064687,0.56,NCT02580058-3,Pegylated Liposomal Doxorubicin (PLD),NCT02580058,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),device related infection
D004886,0.56,NCT02580058-3,Pegylated Liposomal Doxorubicin (PLD),NCT02580058,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),erysipelas
D005759,0.53,NCT02580058-1,Avelumab,NCT02580058,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),gastroenteritis
D005759,0.56,NCT02580058-3,Pegylated Liposomal Doxorubicin (PLD),NCT02580058,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),gastroenteritis
D010996,0.56,NCT02580058-3,Pegylated Liposomal Doxorubicin (PLD),NCT02580058,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),pleural effusion
D007251,0.55,NCT02580058-2,Avelumab + PLD,NCT02580058,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),influenza
D007251,1.13,NCT02580058-3,Pegylated Liposomal Doxorubicin (PLD),NCT02580058,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),influenza
10050823,0.55,NCT02580058-2,Avelumab + PLD,NCT02580058,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),lymph gland infection
D010272,0.55,NCT02580058-2,Avelumab + PLD,NCT02580058,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),parasite infections
D008581,0.55,NCT02580058-2,Avelumab + PLD,NCT02580058,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),meningitis
10061304,0.56,NCT02580058-3,Pegylated Liposomal Doxorubicin (PLD),NCT02580058,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),nail infection
D009181,0.55,NCT02580058-2,Avelumab + PLD,NCT02580058,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),fungal infections
D010538,0.53,NCT02580058-1,Avelumab,NCT02580058,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),peritonitis
D010538,0.55,NCT02580058-2,Avelumab + PLD,NCT02580058,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),peritonitis
D011014,1.6,NCT02580058-1,Avelumab,NCT02580058,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),pneumonia
D011014,1.65,NCT02580058-2,Avelumab + PLD,NCT02580058,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),pneumonia
D011704,0.53,NCT02580058-1,Avelumab,NCT02580058,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),pyelonephritis
D011704,0.56,NCT02580058-3,Pegylated Liposomal Doxorubicin (PLD),NCT02580058,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),pyelonephritis
D012141,0.56,NCT02580058-3,Pegylated Liposomal Doxorubicin (PLD),NCT02580058,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),respiratory tract infection
D018805,1.13,NCT02580058-3,Pegylated Liposomal Doxorubicin (PLD),NCT02580058,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),sepsis
D000891,0.56,NCT02580058-3,Pegylated Liposomal Doxorubicin (PLD),NCT02580058,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),antiseptics
D012772,0.56,NCT02580058-3,Pegylated Liposomal Doxorubicin (PLD),NCT02580058,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),septic shock
D012852,0.55,NCT02580058-2,Avelumab + PLD,NCT02580058,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),sinusitis
D013203,0.55,NCT02580058-2,Avelumab + PLD,NCT02580058,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),staphylococcal infection
D013203,0.56,NCT02580058-3,Pegylated Liposomal Doxorubicin (PLD),NCT02580058,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),staphylococcal infection
D014552,0.53,NCT02580058-1,Avelumab,NCT02580058,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),urinary tract infection
D014552,0.55,NCT02580058-2,Avelumab + PLD,NCT02580058,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),urinary tract infection
D014552,1.13,NCT02580058-3,Pegylated Liposomal Doxorubicin (PLD),NCT02580058,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),urinary tract infection
10040047,0.55,NCT02580058-2,Avelumab + PLD,NCT02580058,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),sepsis
D012141,0.55,NCT02580058-2,Avelumab + PLD,NCT02580058,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),upper respiratory tract infections
10051792,0.53,NCT02580058-1,Avelumab,NCT02580058,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),infusion related reaction
10051792,1.65,NCT02580058-2,Avelumab + PLD,NCT02580058,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),infusion related reaction
10051792,0.56,NCT02580058-3,Pegylated Liposomal Doxorubicin (PLD),NCT02580058,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),infusion related reaction
D010329,0.53,NCT02580058-1,Avelumab,NCT02580058,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),patella
D000557,0.53,NCT02580058-1,Avelumab,NCT02580058,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),ambystoma
D034941,0.55,NCT02580058-2,Avelumab + PLD,NCT02580058,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),upper limb
10062169,0.55,NCT02580058-2,Avelumab + PLD,NCT02580058,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),vascular access complication
10003481,0.55,NCT02580058-2,Avelumab + PLD,NCT02580058,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),aspartate aminotransferase increased
D003402,0.55,NCT02580058-2,Avelumab + PLD,NCT02580058,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),creatine phosphokinase
D007989,0.53,NCT02580058-1,Avelumab,NCT02580058,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),decreased libido
10029366,0.56,NCT02580058-3,Pegylated Liposomal Doxorubicin (PLD),NCT02580058,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),neutrophil count decreased
10059895,0.56,NCT02580058-3,Pegylated Liposomal Doxorubicin (PLD),NCT02580058,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),urine output decreased
D007958,0.56,NCT02580058-3,Pegylated Liposomal Doxorubicin (PLD),NCT02580058,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),blood cell count white
D001066,1.6,NCT02580058-1,Avelumab,NCT02580058,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),appetite
D001066,0.55,NCT02580058-2,Avelumab + PLD,NCT02580058,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),appetite
D001066,0.56,NCT02580058-3,Pegylated Liposomal Doxorubicin (PLD),NCT02580058,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),appetite
D003681,1.07,NCT02580058-1,Avelumab,NCT02580058,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),dehydration
D003681,0.55,NCT02580058-2,Avelumab + PLD,NCT02580058,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),dehydration
D003681,0.56,NCT02580058-3,Pegylated Liposomal Doxorubicin (PLD),NCT02580058,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),dehydration
UNKNOWN-check-for-typo,2.75,NCT02580058-2,Avelumab + PLD,NCT02580058,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),D00
UNKNOWN-check-for-typo,0.56,NCT02580058-3,Pegylated Liposomal Doxorubicin (PLD),NCT02580058,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),D00
UNKNOWN-check-for-typo,0.55,NCT02580058-2,Avelumab + PLD,NCT02580058,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),D00
UNKNOWN-check-for-typo,0.55,NCT02580058-2,Avelumab + PLD,NCT02580058,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),D00
UNKNOWN-check-for-typo,1.13,NCT02580058-3,Pegylated Liposomal Doxorubicin (PLD),NCT02580058,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),D00
D001416,1.13,NCT02580058-3,Pegylated Liposomal Doxorubicin (PLD),NCT02580058,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),back pain
D009369,0.55,NCT02580058-2,Avelumab + PLD,NCT02580058,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),malignant neoplasms
D001037,0.53,NCT02580058-1,Avelumab,NCT02580058,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),aphasia
D004830,0.56,NCT02580058-3,Pegylated Liposomal Doxorubicin (PLD),NCT02580058,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),tonic clonic convulsions
D014202,0.53,NCT02580058-1,Avelumab,NCT02580058,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),tremor
D004864,0.53,NCT02580058-1,Avelumab,NCT02580058,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),devices
D003221,0.55,NCT02580058-2,Avelumab + PLD,NCT02580058,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),confusional state
D003221,0.56,NCT02580058-3,Pegylated Liposomal Doxorubicin (PLD),NCT02580058,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),confusional state
D000073216,0.53,NCT02580058-1,Avelumab,NCT02580058,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),mental status tests
D058186,0.53,NCT02580058-1,Avelumab,NCT02580058,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),acute kidney injury
D051436,0.55,NCT02580058-2,Avelumab + PLD,NCT02580058,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),chronic kidney disease
UNKNOWN-check-for-typo,0.53,NCT02580058-1,Avelumab,NCT02580058,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),D00
D001449,0.55,NCT02580058-2,Avelumab + PLD,NCT02580058,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),balkan nephropathy
D051437,0.53,NCT02580058-1,Avelumab,NCT02580058,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),renal failure
10061574,0.55,NCT02580058-2,Avelumab + PLD,NCT02580058,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),urinary tract obstruction
D000069339,0.53,NCT02580058-1,Avelumab,NCT02580058,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),vaginal cervicectomy
D003371,0.55,NCT02580058-2,Avelumab + PLD,NCT02580058,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),cough
UNKNOWN-check-for-typo,2.14,NCT02580058-1,Avelumab,NCT02580058,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),D00
UNKNOWN-check-for-typo,2.75,NCT02580058-2,Avelumab + PLD,NCT02580058,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),D00
D008168,0.56,NCT02580058-3,Pegylated Liposomal Doxorubicin (PLD),NCT02580058,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),lung
10068319,0.55,NCT02580058-2,Avelumab + PLD,NCT02580058,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),oropharyngeal pain
D010996,1.07,NCT02580058-1,Avelumab,NCT02580058,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),pleural effusion
D011015,0.53,NCT02580058-1,Avelumab,NCT02580058,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),aspiration pneumonia
D011014,0.53,NCT02580058-1,Avelumab,NCT02580058,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),pneumonitis
D011014,0.55,NCT02580058-2,Avelumab + PLD,NCT02580058,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),pneumonitis
D011014,0.56,NCT02580058-3,Pegylated Liposomal Doxorubicin (PLD),NCT02580058,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),pneumonitis
10036790,0.53,NCT02580058-1,Avelumab,NCT02580058,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),productive cough
D011655,1.07,NCT02580058-1,Avelumab,NCT02580058,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),pulmonary embolism
D011655,2.2,NCT02580058-2,Avelumab + PLD,NCT02580058,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),pulmonary embolism
D011655,1.13,NCT02580058-3,Pegylated Liposomal Doxorubicin (PLD),NCT02580058,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),pulmonary embolism
D012131,0.53,NCT02580058-1,Avelumab,NCT02580058,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),respiratory failure
D003873,0.56,NCT02580058-3,Pegylated Liposomal Doxorubicin (PLD),NCT02580058,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),dermatitis exfoliative generalised
10054524,1.1,NCT02580058-2,Avelumab + PLD,NCT02580058,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),palmar-plantar erythrodysesthesia syndrome
10054524,0.56,NCT02580058-3,Pegylated Liposomal Doxorubicin (PLD),NCT02580058,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),palmar-plantar erythrodysesthesia syndrome
D013392,0.55,NCT02580058-2,Avelumab + PLD,NCT02580058,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),ulcerban
D020246,0.55,NCT02580058-2,Avelumab + PLD,NCT02580058,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),deep vein thrombosis
D004617,1.69,NCT02580058-3,Pegylated Liposomal Doxorubicin (PLD),NCT02580058,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),embolism
D054556,0.55,NCT02580058-2,Avelumab + PLD,NCT02580058,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),venous thromboembolism
D007022,0.53,NCT02580058-1,Avelumab,NCT02580058,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200),hypotension
D009026,4.76,NCT02596971-1,Atezo-G-Benda Cohort (Safety Run-In and Expansion Phases),NCT02596971,A Study of Atezolizumab in Combination With Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus (+) Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone (CHOP) in Participants With Follicular Lymphoma (FL) or Rituximab + CHOP in Participants With Diffuse Large B-Cell Lymphoma (DLBCL),mortality
D064420,28.57,NCT02596971-1,Atezo-G-Benda Cohort (Safety Run-In and Expansion Phases),NCT02596971,A Study of Atezolizumab in Combination With Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus (+) Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone (CHOP) in Participants With Follicular Lymphoma (FL) or Rituximab + CHOP in Participants With Diffuse Large B-Cell Lymphoma (DLBCL),adverse drug events
D064420,28.57,NCT02596971-2,Atezo-G-CHOP Cohort (Safety Run-In Phase),NCT02596971,A Study of Atezolizumab in Combination With Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus (+) Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone (CHOP) in Participants With Follicular Lymphoma (FL) or Rituximab + CHOP in Participants With Diffuse Large B-Cell Lymphoma (DLBCL),adverse drug events
D064420,38.1,NCT02596971-3,Atezo-R-CHOP Cohort (Expansion Phase),NCT02596971,A Study of Atezolizumab in Combination With Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus (+) Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone (CHOP) in Participants With Follicular Lymphoma (FL) or Rituximab + CHOP in Participants With Diffuse Large B-Cell Lymphoma (DLBCL),adverse drug events
D009503,14.29,NCT02596971-2,Atezo-G-CHOP Cohort (Safety Run-In Phase),NCT02596971,A Study of Atezolizumab in Combination With Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus (+) Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone (CHOP) in Participants With Follicular Lymphoma (FL) or Rituximab + CHOP in Participants With Diffuse Large B-Cell Lymphoma (DLBCL),neutropenia
D064147,11.9,NCT02596971-3,Atezo-R-CHOP Cohort (Expansion Phase),NCT02596971,A Study of Atezolizumab in Combination With Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus (+) Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone (CHOP) in Participants With Follicular Lymphoma (FL) or Rituximab + CHOP in Participants With Diffuse Large B-Cell Lymphoma (DLBCL),febrile neutropenia
D010198,2.38,NCT02596971-3,Atezo-R-CHOP Cohort (Expansion Phase),NCT02596971,A Study of Atezolizumab in Combination With Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus (+) Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone (CHOP) in Participants With Follicular Lymphoma (FL) or Rituximab + CHOP in Participants With Diffuse Large B-Cell Lymphoma (DLBCL),pancytopenia
D013921,2.38,NCT02596971-3,Atezo-R-CHOP Cohort (Expansion Phase),NCT02596971,A Study of Atezolizumab in Combination With Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus (+) Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone (CHOP) in Participants With Follicular Lymphoma (FL) or Rituximab + CHOP in Participants With Diffuse Large B-Cell Lymphoma (DLBCL),thrombocytopenia
D006323,2.38,NCT02596971-1,Atezo-G-Benda Cohort (Safety Run-In and Expansion Phases),NCT02596971,A Study of Atezolizumab in Combination With Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus (+) Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone (CHOP) in Participants With Follicular Lymphoma (FL) or Rituximab + CHOP in Participants With Diffuse Large B-Cell Lymphoma (DLBCL),cardiac arrest
D009205,2.38,NCT02596971-1,Atezo-G-Benda Cohort (Safety Run-In and Expansion Phases),NCT02596971,A Study of Atezolizumab in Combination With Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus (+) Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone (CHOP) in Participants With Follicular Lymphoma (FL) or Rituximab + CHOP in Participants With Diffuse Large B-Cell Lymphoma (DLBCL),myocarditis
D001281,2.38,NCT02596971-3,Atezo-R-CHOP Cohort (Expansion Phase),NCT02596971,A Study of Atezolizumab in Combination With Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus (+) Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone (CHOP) in Participants With Follicular Lymphoma (FL) or Rituximab + CHOP in Participants With Diffuse Large B-Cell Lymphoma (DLBCL),atrial fibrillation
D004172,2.38,NCT02596971-3,Atezo-R-CHOP Cohort (Expansion Phase),NCT02596971,A Study of Atezolizumab in Combination With Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus (+) Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone (CHOP) in Participants With Follicular Lymphoma (FL) or Rituximab + CHOP in Participants With Diffuse Large B-Cell Lymphoma (DLBCL),diplopia
D009325,2.38,NCT02596971-1,Atezo-G-Benda Cohort (Safety Run-In and Expansion Phases),NCT02596971,A Study of Atezolizumab in Combination With Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus (+) Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone (CHOP) in Participants With Follicular Lymphoma (FL) or Rituximab + CHOP in Participants With Diffuse Large B-Cell Lymphoma (DLBCL),nausea
10041101,2.38,NCT02596971-1,Atezo-G-Benda Cohort (Safety Run-In and Expansion Phases),NCT02596971,A Study of Atezolizumab in Combination With Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus (+) Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone (CHOP) in Participants With Follicular Lymphoma (FL) or Rituximab + CHOP in Participants With Diffuse Large B-Cell Lymphoma (DLBCL),small intestinal obstruction
D015746,2.38,NCT02596971-3,Atezo-R-CHOP Cohort (Expansion Phase),NCT02596971,A Study of Atezolizumab in Combination With Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus (+) Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone (CHOP) in Participants With Follicular Lymphoma (FL) or Rituximab + CHOP in Participants With Diffuse Large B-Cell Lymphoma (DLBCL),abdominal pain
D007415,2.38,NCT02596971-3,Atezo-R-CHOP Cohort (Expansion Phase),NCT02596971,A Study of Atezolizumab in Combination With Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus (+) Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone (CHOP) in Participants With Follicular Lymphoma (FL) or Rituximab + CHOP in Participants With Diffuse Large B-Cell Lymphoma (DLBCL),intestinal obstruction
D005334,7.14,NCT02596971-1,Atezo-G-Benda Cohort (Safety Run-In and Expansion Phases),NCT02596971,A Study of Atezolizumab in Combination With Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus (+) Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone (CHOP) in Participants With Follicular Lymphoma (FL) or Rituximab + CHOP in Participants With Diffuse Large B-Cell Lymphoma (DLBCL),pyrexia
D005334,2.38,NCT02596971-3,Atezo-R-CHOP Cohort (Expansion Phase),NCT02596971,A Study of Atezolizumab in Combination With Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus (+) Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone (CHOP) in Participants With Follicular Lymphoma (FL) or Rituximab + CHOP in Participants With Diffuse Large B-Cell Lymphoma (DLBCL),pyrexia
D003645,2.38,NCT02596971-1,Atezo-G-Benda Cohort (Safety Run-In and Expansion Phases),NCT02596971,A Study of Atezolizumab in Combination With Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus (+) Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone (CHOP) in Participants With Follicular Lymphoma (FL) or Rituximab + CHOP in Participants With Diffuse Large B-Cell Lymphoma (DLBCL),sudden death
D011014,2.38,NCT02596971-1,Atezo-G-Benda Cohort (Safety Run-In and Expansion Phases),NCT02596971,A Study of Atezolizumab in Combination With Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus (+) Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone (CHOP) in Participants With Follicular Lymphoma (FL) or Rituximab + CHOP in Participants With Diffuse Large B-Cell Lymphoma (DLBCL),pneumonia
D011014,2.38,NCT02596971-3,Atezo-R-CHOP Cohort (Expansion Phase),NCT02596971,A Study of Atezolizumab in Combination With Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus (+) Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone (CHOP) in Participants With Follicular Lymphoma (FL) or Rituximab + CHOP in Participants With Diffuse Large B-Cell Lymphoma (DLBCL),pneumonia
10040872,2.38,NCT02596971-1,Atezo-G-Benda Cohort (Safety Run-In and Expansion Phases),NCT02596971,A Study of Atezolizumab in Combination With Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus (+) Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone (CHOP) in Participants With Follicular Lymphoma (FL) or Rituximab + CHOP in Participants With Diffuse Large B-Cell Lymphoma (DLBCL),skin infection
D012141,2.38,NCT02596971-1,Atezo-G-Benda Cohort (Safety Run-In and Expansion Phases),NCT02596971,A Study of Atezolizumab in Combination With Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus (+) Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone (CHOP) in Participants With Follicular Lymphoma (FL) or Rituximab + CHOP in Participants With Diffuse Large B-Cell Lymphoma (DLBCL),upper respiratory tract infections
D014552,2.38,NCT02596971-1,Atezo-G-Benda Cohort (Safety Run-In and Expansion Phases),NCT02596971,A Study of Atezolizumab in Combination With Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus (+) Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone (CHOP) in Participants With Follicular Lymphoma (FL) or Rituximab + CHOP in Participants With Diffuse Large B-Cell Lymphoma (DLBCL),urinary tract infections
10023424,14.29,NCT02596971-2,Atezo-G-CHOP Cohort (Safety Run-In Phase),NCT02596971,A Study of Atezolizumab in Combination With Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus (+) Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone (CHOP) in Participants With Follicular Lymphoma (FL) or Rituximab + CHOP in Participants With Diffuse Large B-Cell Lymphoma (DLBCL),kidney infection
D004238,2.38,NCT02596971-3,Atezo-R-CHOP Cohort (Expansion Phase),NCT02596971,A Study of Atezolizumab in Combination With Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus (+) Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone (CHOP) in Participants With Follicular Lymphoma (FL) or Rituximab + CHOP in Participants With Diffuse Large B-Cell Lymphoma (DLBCL),diverticulitis
D020031,2.38,NCT02596971-3,Atezo-R-CHOP Cohort (Expansion Phase),NCT02596971,A Study of Atezolizumab in Combination With Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus (+) Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone (CHOP) in Participants With Follicular Lymphoma (FL) or Rituximab + CHOP in Participants With Diffuse Large B-Cell Lymphoma (DLBCL),epstein barr virus infection
10061229,2.38,NCT02596971-3,Atezo-R-CHOP Cohort (Expansion Phase),NCT02596971,A Study of Atezolizumab in Combination With Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus (+) Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone (CHOP) in Participants With Follicular Lymphoma (FL) or Rituximab + CHOP in Participants With Diffuse Large B-Cell Lymphoma (DLBCL),lung infection
D018805,2.38,NCT02596971-3,Atezo-R-CHOP Cohort (Expansion Phase),NCT02596971,A Study of Atezolizumab in Combination With Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus (+) Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone (CHOP) in Participants With Follicular Lymphoma (FL) or Rituximab + CHOP in Participants With Diffuse Large B-Cell Lymphoma (DLBCL),sepsis
D012852,2.38,NCT02596971-3,Atezo-R-CHOP Cohort (Expansion Phase),NCT02596971,A Study of Atezolizumab in Combination With Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus (+) Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone (CHOP) in Participants With Follicular Lymphoma (FL) or Rituximab + CHOP in Participants With Diffuse Large B-Cell Lymphoma (DLBCL),sinusitis
10051792,4.76,NCT02596971-1,Atezo-G-Benda Cohort (Safety Run-In and Expansion Phases),NCT02596971,A Study of Atezolizumab in Combination With Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus (+) Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone (CHOP) in Participants With Follicular Lymphoma (FL) or Rituximab + CHOP in Participants With Diffuse Large B-Cell Lymphoma (DLBCL),infusion related reaction
D003110,2.38,NCT02596971-1,Atezo-G-Benda Cohort (Safety Run-In and Expansion Phases),NCT02596971,A Study of Atezolizumab in Combination With Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus (+) Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone (CHOP) in Participants With Follicular Lymphoma (FL) or Rituximab + CHOP in Participants With Diffuse Large B-Cell Lymphoma (DLBCL),colon cancer
D008881,2.38,NCT02596971-1,Atezo-G-Benda Cohort (Safety Run-In and Expansion Phases),NCT02596971,A Study of Atezolizumab in Combination With Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus (+) Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone (CHOP) in Participants With Follicular Lymphoma (FL) or Rituximab + CHOP in Participants With Diffuse Large B-Cell Lymphoma (DLBCL),migraine
D013575,2.38,NCT02596971-1,Atezo-G-Benda Cohort (Safety Run-In and Expansion Phases),NCT02596971,A Study of Atezolizumab in Combination With Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus (+) Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone (CHOP) in Participants With Follicular Lymphoma (FL) or Rituximab + CHOP in Participants With Diffuse Large B-Cell Lymphoma (DLBCL),syncope
D013575,2.38,NCT02596971-3,Atezo-R-CHOP Cohort (Expansion Phase),NCT02596971,A Study of Atezolizumab in Combination With Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus (+) Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone (CHOP) in Participants With Follicular Lymphoma (FL) or Rituximab + CHOP in Participants With Diffuse Large B-Cell Lymphoma (DLBCL),syncope
UNKNOWN-check-for-typo,2.38,NCT02596971-1,Atezo-G-Benda Cohort (Safety Run-In and Expansion Phases),NCT02596971,A Study of Atezolizumab in Combination With Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus (+) Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone (CHOP) in Participants With Follicular Lymphoma (FL) or Rituximab + CHOP in Participants With Diffuse Large B-Cell Lymphoma (DLBCL),D00
D001988,2.38,NCT02596971-1,Atezo-G-Benda Cohort (Safety Run-In and Expansion Phases),NCT02596971,A Study of Atezolizumab in Combination With Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus (+) Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone (CHOP) in Participants With Follicular Lymphoma (FL) or Rituximab + CHOP in Participants With Diffuse Large B-Cell Lymphoma (DLBCL),bronchiolitis
D011655,2.38,NCT02596971-1,Atezo-G-Benda Cohort (Safety Run-In and Expansion Phases),NCT02596971,A Study of Atezolizumab in Combination With Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus (+) Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone (CHOP) in Participants With Follicular Lymphoma (FL) or Rituximab + CHOP in Participants With Diffuse Large B-Cell Lymphoma (DLBCL),pulmonary embolism
10065735,2.38,NCT02596971-3,Atezo-R-CHOP Cohort (Expansion Phase),NCT02596971,A Study of Atezolizumab in Combination With Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus (+) Cyclophosphamide  Doxorubicin  Vincristine  and Prednisone (CHOP) in Participants With Follicular Lymphoma (FL) or Rituximab + CHOP in Participants With Diffuse Large B-Cell Lymphoma (DLBCL),laryngeal inflammation
D009026,40.0,NCT02622074-1,Cohort A: KNp / KAC,NCT02622074,Safety and Efficacy Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy as Neoadjuvant Treatment for Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-173/KEYNOTE-173),mortality
D009026,10.0,NCT02622074-4,Cohort D: KNpCb (Regimen 3) / KAC,NCT02622074,Safety and Efficacy Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy as Neoadjuvant Treatment for Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-173/KEYNOTE-173),mortality
D009026,10.0,NCT02622074-5,Cohort E: KTCb (Regimen 1) / KAC,NCT02622074,Safety and Efficacy Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy as Neoadjuvant Treatment for Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-173/KEYNOTE-173),mortality
D064420,50.0,NCT02622074-1,Cohort A: KNp / KAC,NCT02622074,Safety and Efficacy Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy as Neoadjuvant Treatment for Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-173/KEYNOTE-173),adverse drug events
D064420,40.0,NCT02622074-2,Cohort B: KNpCb (Regimen 1) / KAC,NCT02622074,Safety and Efficacy Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy as Neoadjuvant Treatment for Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-173/KEYNOTE-173),adverse drug events
D064420,80.0,NCT02622074-3,Cohort C: KNpCb (Regimen 2) / KAC,NCT02622074,Safety and Efficacy Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy as Neoadjuvant Treatment for Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-173/KEYNOTE-173),adverse drug events
D064420,70.0,NCT02622074-4,Cohort D: KNpCb (Regimen 3) / KAC,NCT02622074,Safety and Efficacy Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy as Neoadjuvant Treatment for Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-173/KEYNOTE-173),adverse drug events
D064420,30.0,NCT02622074-5,Cohort E: KTCb (Regimen 1) / KAC,NCT02622074,Safety and Efficacy Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy as Neoadjuvant Treatment for Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-173/KEYNOTE-173),adverse drug events
D064420,40.0,NCT02622074-6,Cohort F: KTCb (Regimen 2) / KAC,NCT02622074,Safety and Efficacy Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy as Neoadjuvant Treatment for Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-173/KEYNOTE-173),adverse drug events
D000741,10.0,NCT02622074-6,Cohort F: KTCb (Regimen 2) / KAC,NCT02622074,Safety and Efficacy Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy as Neoadjuvant Treatment for Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-173/KEYNOTE-173),aplastic anaemia
D064147,10.0,NCT02622074-1,Cohort A: KNp / KAC,NCT02622074,Safety and Efficacy Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy as Neoadjuvant Treatment for Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-173/KEYNOTE-173),febrile neutropenia
D064147,20.0,NCT02622074-2,Cohort B: KNpCb (Regimen 1) / KAC,NCT02622074,Safety and Efficacy Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy as Neoadjuvant Treatment for Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-173/KEYNOTE-173),febrile neutropenia
D064147,40.0,NCT02622074-3,Cohort C: KNpCb (Regimen 2) / KAC,NCT02622074,Safety and Efficacy Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy as Neoadjuvant Treatment for Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-173/KEYNOTE-173),febrile neutropenia
D064147,40.0,NCT02622074-4,Cohort D: KNpCb (Regimen 3) / KAC,NCT02622074,Safety and Efficacy Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy as Neoadjuvant Treatment for Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-173/KEYNOTE-173),febrile neutropenia
D008199,10.0,NCT02622074-3,Cohort C: KNpCb (Regimen 2) / KAC,NCT02622074,Safety and Efficacy Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy as Neoadjuvant Treatment for Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-173/KEYNOTE-173),lymphadenitis
D009503,10.0,NCT02622074-2,Cohort B: KNpCb (Regimen 1) / KAC,NCT02622074,Safety and Efficacy Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy as Neoadjuvant Treatment for Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-173/KEYNOTE-173),neutropenia
D009503,10.0,NCT02622074-6,Cohort F: KTCb (Regimen 2) / KAC,NCT02622074,Safety and Efficacy Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy as Neoadjuvant Treatment for Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-173/KEYNOTE-173),neutropenia
D015746,10.0,NCT02622074-5,Cohort E: KTCb (Regimen 1) / KAC,NCT02622074,Safety and Efficacy Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy as Neoadjuvant Treatment for Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-173/KEYNOTE-173),abdominal pain
D003092,10.0,NCT02622074-3,Cohort C: KNpCb (Regimen 2) / KAC,NCT02622074,Safety and Efficacy Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy as Neoadjuvant Treatment for Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-173/KEYNOTE-173),colitis
D003092,10.0,NCT02622074-6,Cohort F: KTCb (Regimen 2) / KAC,NCT02622074,Safety and Efficacy Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy as Neoadjuvant Treatment for Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-173/KEYNOTE-173),colitis
UNKNOWN-check-for-typo,10.0,NCT02622074-4,Cohort D: KNpCb (Regimen 3) / KAC,NCT02622074,Safety and Efficacy Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy as Neoadjuvant Treatment for Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-173/KEYNOTE-173),D00
D009325,10.0,NCT02622074-1,Cohort A: KNp / KAC,NCT02622074,Safety and Efficacy Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy as Neoadjuvant Treatment for Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-173/KEYNOTE-173),nausea
10015461,10.0,NCT02622074-3,Cohort C: KNpCb (Regimen 2) / KAC,NCT02622074,Safety and Efficacy Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy as Neoadjuvant Treatment for Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-173/KEYNOTE-173),esophagitis
D005334,10.0,NCT02622074-2,Cohort B: KNpCb (Regimen 1) / KAC,NCT02622074,Safety and Efficacy Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy as Neoadjuvant Treatment for Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-173/KEYNOTE-173),pyrexia
D005334,10.0,NCT02622074-3,Cohort C: KNpCb (Regimen 2) / KAC,NCT02622074,Safety and Efficacy Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy as Neoadjuvant Treatment for Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-173/KEYNOTE-173),pyrexia
D005334,10.0,NCT02622074-5,Cohort E: KTCb (Regimen 1) / KAC,NCT02622074,Safety and Efficacy Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy as Neoadjuvant Treatment for Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-173/KEYNOTE-173),pyrexia
D005334,10.0,NCT02622074-6,Cohort F: KTCb (Regimen 2) / KAC,NCT02622074,Safety and Efficacy Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy as Neoadjuvant Treatment for Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-173/KEYNOTE-173),pyrexia
D019693,10.0,NCT02622074-4,Cohort D: KNpCb (Regimen 3) / KAC,NCT02622074,Safety and Efficacy Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy as Neoadjuvant Treatment for Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-173/KEYNOTE-173),autoimmune hepatitis
D007251,10.0,NCT02622074-3,Cohort C: KNpCb (Regimen 2) / KAC,NCT02622074,Safety and Efficacy Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy as Neoadjuvant Treatment for Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-173/KEYNOTE-173),influenza
D000985,10.0,NCT02622074-6,Cohort F: KTCb (Regimen 2) / KAC,NCT02622074,Safety and Efficacy Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy as Neoadjuvant Treatment for Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-173/KEYNOTE-173),antisepsis
D011020,10.0,NCT02622074-4,Cohort D: KNpCb (Regimen 3) / KAC,NCT02622074,Safety and Efficacy Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy as Neoadjuvant Treatment for Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-173/KEYNOTE-173),pneumocystis jirovecii pneumonia
D011014,10.0,NCT02622074-1,Cohort A: KNp / KAC,NCT02622074,Safety and Efficacy Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy as Neoadjuvant Treatment for Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-173/KEYNOTE-173),pneumonia
D011014,10.0,NCT02622074-4,Cohort D: KNpCb (Regimen 3) / KAC,NCT02622074,Safety and Efficacy Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy as Neoadjuvant Treatment for Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-173/KEYNOTE-173),pneumonia
D011014,10.0,NCT02622074-6,Cohort F: KTCb (Regimen 2) / KAC,NCT02622074,Safety and Efficacy Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy as Neoadjuvant Treatment for Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-173/KEYNOTE-173),pneumonia
D012141,10.0,NCT02622074-6,Cohort F: KTCb (Regimen 2) / KAC,NCT02622074,Safety and Efficacy Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy as Neoadjuvant Treatment for Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-173/KEYNOTE-173),respiratory tract infection
D012772,10.0,NCT02622074-4,Cohort D: KNpCb (Regimen 3) / KAC,NCT02622074,Safety and Efficacy Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy as Neoadjuvant Treatment for Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-173/KEYNOTE-173),septic shock
10048762,10.0,NCT02622074-2,Cohort B: KNpCb (Regimen 1) / KAC,NCT02622074,Safety and Efficacy Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy as Neoadjuvant Treatment for Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-173/KEYNOTE-173),tooth infection
D014552,10.0,NCT02622074-3,Cohort C: KNpCb (Regimen 2) / KAC,NCT02622074,Safety and Efficacy Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy as Neoadjuvant Treatment for Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-173/KEYNOTE-173),urinary tract infection
D012421,10.0,NCT02622074-3,Cohort C: KNpCb (Regimen 2) / KAC,NCT02622074,Safety and Efficacy Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy as Neoadjuvant Treatment for Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-173/KEYNOTE-173),rupture
10001551,10.0,NCT02622074-1,Cohort A: KNp / KAC,NCT02622074,Safety and Efficacy Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy as Neoadjuvant Treatment for Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-173/KEYNOTE-173),alanine aminotransferase increased
10003481,10.0,NCT02622074-1,Cohort A: KNp / KAC,NCT02622074,Safety and Efficacy Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy as Neoadjuvant Treatment for Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-173/KEYNOTE-173),aspartate aminotransferase increased
10011368,10.0,NCT02622074-4,Cohort D: KNpCb (Regimen 3) / KAC,NCT02622074,Safety and Efficacy Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy as Neoadjuvant Treatment for Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-173/KEYNOTE-173),creatinine increased
D007958,10.0,NCT02622074-4,Cohort D: KNpCb (Regimen 3) / KAC,NCT02622074,Safety and Efficacy Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy as Neoadjuvant Treatment for Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-173/KEYNOTE-173),blood cell count white
D001066,10.0,NCT02622074-1,Cohort A: KNp / KAC,NCT02622074,Safety and Efficacy Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy as Neoadjuvant Treatment for Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-173/KEYNOTE-173),appetite
D001416,10.0,NCT02622074-5,Cohort E: KTCb (Regimen 1) / KAC,NCT02622074,Safety and Efficacy Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy as Neoadjuvant Treatment for Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-173/KEYNOTE-173),back pain
D003929,10.0,NCT02622074-3,Cohort C: KNpCb (Regimen 2) / KAC,NCT02622074,Safety and Efficacy Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy as Neoadjuvant Treatment for Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-173/KEYNOTE-173),diabetic autonomic neuropathy
D020516,10.0,NCT02622074-5,Cohort E: KTCb (Regimen 1) / KAC,NCT02622074,Safety and Efficacy Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy as Neoadjuvant Treatment for Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-173/KEYNOTE-173),brachial plexopathy
D013474,10.0,NCT02622074-4,Cohort D: KNpCb (Regimen 3) / KAC,NCT02622074,Safety and Efficacy Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy as Neoadjuvant Treatment for Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-173/KEYNOTE-173),sunstroke
D008178,10.0,NCT02622074-4,Cohort D: KNpCb (Regimen 3) / KAC,NCT02622074,Safety and Efficacy Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy as Neoadjuvant Treatment for Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-173/KEYNOTE-173),lupus erythematosus subacute cutaneous
D020246,10.0,NCT02622074-2,Cohort B: KNpCb (Regimen 1) / KAC,NCT02622074,Safety and Efficacy Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy as Neoadjuvant Treatment for Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-173/KEYNOTE-173),deep vein thrombosis
D007024,10.0,NCT02622074-3,Cohort C: KNpCb (Regimen 2) / KAC,NCT02622074,Safety and Efficacy Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy as Neoadjuvant Treatment for Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-173/KEYNOTE-173),orthostatic hypotension
D009026,39.51,NCT02631876-1,Mirvetuximab Soravtansine,NCT02631876,A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC)  Primary Peritoneal or Fallopian Tube Cancer,mortality
D009026,45.87,NCT02631876-2,Investigator's Choice (IC) Chemotherapy,NCT02631876,A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC)  Primary Peritoneal or Fallopian Tube Cancer,mortality
D064420,27.57,NCT02631876-1,Mirvetuximab Soravtansine,NCT02631876,A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC)  Primary Peritoneal or Fallopian Tube Cancer,adverse drug events
D064420,28.44,NCT02631876-2,Investigator's Choice (IC) Chemotherapy,NCT02631876,A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC)  Primary Peritoneal or Fallopian Tube Cancer,adverse drug events
D000741,0.92,NCT02631876-2,Investigator's Choice (IC) Chemotherapy,NCT02631876,A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC)  Primary Peritoneal or Fallopian Tube Cancer,aplastic anaemia
D064147,0.92,NCT02631876-2,Investigator's Choice (IC) Chemotherapy,NCT02631876,A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC)  Primary Peritoneal or Fallopian Tube Cancer,febrile neutropenia
D006323,0.82,NCT02631876-1,Mirvetuximab Soravtansine,NCT02631876,A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC)  Primary Peritoneal or Fallopian Tube Cancer,cardiac arrest
D058447,0.41,NCT02631876-1,Mirvetuximab Soravtansine,NCT02631876,A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC)  Primary Peritoneal or Fallopian Tube Cancer,eye pain
D007634,0.41,NCT02631876-1,Mirvetuximab Soravtansine,NCT02631876,A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC)  Primary Peritoneal or Fallopian Tube Cancer,keratitis
D007415,4.12,NCT02631876-1,Mirvetuximab Soravtansine,NCT02631876,A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC)  Primary Peritoneal or Fallopian Tube Cancer,intestinal obstruction
D007415,2.75,NCT02631876-2,Investigator's Choice (IC) Chemotherapy,NCT02631876,A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC)  Primary Peritoneal or Fallopian Tube Cancer,intestinal obstruction
10041101,2.06,NCT02631876-1,Mirvetuximab Soravtansine,NCT02631876,A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC)  Primary Peritoneal or Fallopian Tube Cancer,small intestinal obstruction
10041101,3.67,NCT02631876-2,Investigator's Choice (IC) Chemotherapy,NCT02631876,A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC)  Primary Peritoneal or Fallopian Tube Cancer,small intestinal obstruction
D003248,1.65,NCT02631876-1,Mirvetuximab Soravtansine,NCT02631876,A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC)  Primary Peritoneal or Fallopian Tube Cancer,constipation
D003248,0.92,NCT02631876-2,Investigator's Choice (IC) Chemotherapy,NCT02631876,A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC)  Primary Peritoneal or Fallopian Tube Cancer,constipation
D007415,1.65,NCT02631876-1,Mirvetuximab Soravtansine,NCT02631876,A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC)  Primary Peritoneal or Fallopian Tube Cancer,intestinal obstruction
D007415,1.83,NCT02631876-2,Investigator's Choice (IC) Chemotherapy,NCT02631876,A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC)  Primary Peritoneal or Fallopian Tube Cancer,intestinal obstruction
D015746,0.82,NCT02631876-1,Mirvetuximab Soravtansine,NCT02631876,A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC)  Primary Peritoneal or Fallopian Tube Cancer,abdominal pain
D015746,1.83,NCT02631876-2,Investigator's Choice (IC) Chemotherapy,NCT02631876,A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC)  Primary Peritoneal or Fallopian Tube Cancer,abdominal pain
D009325,0.82,NCT02631876-1,Mirvetuximab Soravtansine,NCT02631876,A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC)  Primary Peritoneal or Fallopian Tube Cancer,nausea
D009325,0.92,NCT02631876-2,Investigator's Choice (IC) Chemotherapy,NCT02631876,A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC)  Primary Peritoneal or Fallopian Tube Cancer,nausea
D014839,0.82,NCT02631876-1,Mirvetuximab Soravtansine,NCT02631876,A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC)  Primary Peritoneal or Fallopian Tube Cancer,vomiting
D014839,1.83,NCT02631876-2,Investigator's Choice (IC) Chemotherapy,NCT02631876,A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC)  Primary Peritoneal or Fallopian Tube Cancer,vomiting
D046449,0.41,NCT02631876-1,Mirvetuximab Soravtansine,NCT02631876,A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC)  Primary Peritoneal or Fallopian Tube Cancer,hernia abdominal
D015746,0.41,NCT02631876-1,Mirvetuximab Soravtansine,NCT02631876,A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC)  Primary Peritoneal or Fallopian Tube Cancer,abdominal pain
D001201,0.41,NCT02631876-1,Mirvetuximab Soravtansine,NCT02631876,A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC)  Primary Peritoneal or Fallopian Tube Cancer,ascites
D001201,1.83,NCT02631876-2,Investigator's Choice (IC) Chemotherapy,NCT02631876,A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC)  Primary Peritoneal or Fallopian Tube Cancer,ascites
D005756,0.41,NCT02631876-1,Mirvetuximab Soravtansine,NCT02631876,A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC)  Primary Peritoneal or Fallopian Tube Cancer,gastritis
D007416,0.41,NCT02631876-1,Mirvetuximab Soravtansine,NCT02631876,A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC)  Primary Peritoneal or Fallopian Tube Cancer,intestinal perforation
D001247,0.41,NCT02631876-1,Mirvetuximab Soravtansine,NCT02631876,A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC)  Primary Peritoneal or Fallopian Tube Cancer,asthenia
D004864,0.41,NCT02631876-1,Mirvetuximab Soravtansine,NCT02631876,A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC)  Primary Peritoneal or Fallopian Tube Cancer,devices
D018746,0.41,NCT02631876-1,Mirvetuximab Soravtansine,NCT02631876,A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC)  Primary Peritoneal or Fallopian Tube Cancer,systemic inflammatory response syndrome
D018746,0.92,NCT02631876-2,Investigator's Choice (IC) Chemotherapy,NCT02631876,A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC)  Primary Peritoneal or Fallopian Tube Cancer,systemic inflammatory response syndrome
D005221,0.92,NCT02631876-2,Investigator's Choice (IC) Chemotherapy,NCT02631876,A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC)  Primary Peritoneal or Fallopian Tube Cancer,fatigue
D003695,0.92,NCT02631876-2,Investigator's Choice (IC) Chemotherapy,NCT02631876,A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC)  Primary Peritoneal or Fallopian Tube Cancer,healthcare
D005334,2.75,NCT02631876-2,Investigator's Choice (IC) Chemotherapy,NCT02631876,A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC)  Primary Peritoneal or Fallopian Tube Cancer,pyrexia
D041881,0.92,NCT02631876-2,Investigator's Choice (IC) Chemotherapy,NCT02631876,A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC)  Primary Peritoneal or Fallopian Tube Cancer,acute cholecystitis
D018805,1.23,NCT02631876-1,Mirvetuximab Soravtansine,NCT02631876,A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC)  Primary Peritoneal or Fallopian Tube Cancer,sepsis
D018805,2.75,NCT02631876-2,Investigator's Choice (IC) Chemotherapy,NCT02631876,A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC)  Primary Peritoneal or Fallopian Tube Cancer,sepsis
D014552,0.82,NCT02631876-1,Mirvetuximab Soravtansine,NCT02631876,A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC)  Primary Peritoneal or Fallopian Tube Cancer,urinary tract infection
D014552,0.92,NCT02631876-2,Investigator's Choice (IC) Chemotherapy,NCT02631876,A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC)  Primary Peritoneal or Fallopian Tube Cancer,urinary tract infection
D000073557,0.41,NCT02631876-1,Mirvetuximab Soravtansine,NCT02631876,A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC)  Primary Peritoneal or Fallopian Tube Cancer,campylobacteraceae
D000072139,0.41,NCT02631876-1,Mirvetuximab Soravtansine,NCT02631876,A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC)  Primary Peritoneal or Fallopian Tube Cancer,megavirales
D007251,0.41,NCT02631876-1,Mirvetuximab Soravtansine,NCT02631876,A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC)  Primary Peritoneal or Fallopian Tube Cancer,influenza
D000069544,0.41,NCT02631876-1,Mirvetuximab Soravtansine,NCT02631876,A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC)  Primary Peritoneal or Fallopian Tube Cancer,encephalitis infection
D011704,0.41,NCT02631876-1,Mirvetuximab Soravtansine,NCT02631876,A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC)  Primary Peritoneal or Fallopian Tube Cancer,pyelonephritis
D000069544,0.41,NCT02631876-1,Mirvetuximab Soravtansine,NCT02631876,A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC)  Primary Peritoneal or Fallopian Tube Cancer,encephalitis infection
D012141,0.41,NCT02631876-1,Mirvetuximab Soravtansine,NCT02631876,A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC)  Primary Peritoneal or Fallopian Tube Cancer,upper respiratory tract infections
10040047,0.41,NCT02631876-1,Mirvetuximab Soravtansine,NCT02631876,A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC)  Primary Peritoneal or Fallopian Tube Cancer,sepsis
10040047,0.92,NCT02631876-2,Investigator's Choice (IC) Chemotherapy,NCT02631876,A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC)  Primary Peritoneal or Fallopian Tube Cancer,sepsis
D020338,0.41,NCT02631876-1,Mirvetuximab Soravtansine,NCT02631876,A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC)  Primary Peritoneal or Fallopian Tube Cancer,vestibular neuronitis
D012480,0.92,NCT02631876-2,Investigator's Choice (IC) Chemotherapy,NCT02631876,A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC)  Primary Peritoneal or Fallopian Tube Cancer,salmonellosis
D000077,0.41,NCT02631876-1,Mirvetuximab Soravtansine,NCT02631876,A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC)  Primary Peritoneal or Fallopian Tube Cancer,acetabulum
D005147,0.41,NCT02631876-1,Mirvetuximab Soravtansine,NCT02631876,A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC)  Primary Peritoneal or Fallopian Tube Cancer,facial bones
10051792,0.41,NCT02631876-1,Mirvetuximab Soravtansine,NCT02631876,A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC)  Primary Peritoneal or Fallopian Tube Cancer,infusion related reaction
D015775,0.41,NCT02631876-1,Mirvetuximab Soravtansine,NCT02631876,A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC)  Primary Peritoneal or Fallopian Tube Cancer,microfractures
D012253,0.41,NCT02631876-1,Mirvetuximab Soravtansine,NCT02631876,A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC)  Primary Peritoneal or Fallopian Tube Cancer,rib fracture
D006408,0.41,NCT02631876-1,Mirvetuximab Soravtansine,NCT02631876,A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC)  Primary Peritoneal or Fallopian Tube Cancer,hematoma subdural
10020100,0.92,NCT02631876-2,Investigator's Choice (IC) Chemotherapy,NCT02631876,A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC)  Primary Peritoneal or Fallopian Tube Cancer,hip fracture
D003681,1.65,NCT02631876-1,Mirvetuximab Soravtansine,NCT02631876,A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC)  Primary Peritoneal or Fallopian Tube Cancer,dehydration
D005183,0.41,NCT02631876-1,Mirvetuximab Soravtansine,NCT02631876,A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC)  Primary Peritoneal or Fallopian Tube Cancer,failure to thrive
UNKNOWN-check-for-typo,0.41,NCT02631876-1,Mirvetuximab Soravtansine,NCT02631876,A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC)  Primary Peritoneal or Fallopian Tube Cancer,D00
UNKNOWN-check-for-typo,0.41,NCT02631876-1,Mirvetuximab Soravtansine,NCT02631876,A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC)  Primary Peritoneal or Fallopian Tube Cancer,D00
UNKNOWN-check-for-typo,0.41,NCT02631876-1,Mirvetuximab Soravtansine,NCT02631876,A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC)  Primary Peritoneal or Fallopian Tube Cancer,D00
D001066,0.92,NCT02631876-2,Investigator's Choice (IC) Chemotherapy,NCT02631876,A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC)  Primary Peritoneal or Fallopian Tube Cancer,appetite
D016066,0.41,NCT02631876-1,Mirvetuximab Soravtansine,NCT02631876,A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC)  Primary Peritoneal or Fallopian Tube Cancer,malignant pleural effusion
D000402,0.41,NCT02631876-1,Mirvetuximab Soravtansine,NCT02631876,A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC)  Primary Peritoneal or Fallopian Tube Cancer,airway obstruction
D013575,0.82,NCT02631876-1,Mirvetuximab Soravtansine,NCT02631876,A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC)  Primary Peritoneal or Fallopian Tube Cancer,syncope
D006261,0.41,NCT02631876-1,Mirvetuximab Soravtansine,NCT02631876,A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC)  Primary Peritoneal or Fallopian Tube Cancer,headache
D013575,0.41,NCT02631876-1,Mirvetuximab Soravtansine,NCT02631876,A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC)  Primary Peritoneal or Fallopian Tube Cancer,presyncope
D020521,0.92,NCT02631876-2,Investigator's Choice (IC) Chemotherapy,NCT02631876,A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC)  Primary Peritoneal or Fallopian Tube Cancer,cerebrovascular accident
D001714,0.92,NCT02631876-2,Investigator's Choice (IC) Chemotherapy,NCT02631876,A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC)  Primary Peritoneal or Fallopian Tube Cancer,mania
D006869,0.41,NCT02631876-1,Mirvetuximab Soravtansine,NCT02631876,A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC)  Primary Peritoneal or Fallopian Tube Cancer,hydronephrosis
10061574,0.92,NCT02631876-2,Investigator's Choice (IC) Chemotherapy,NCT02631876,A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC)  Primary Peritoneal or Fallopian Tube Cancer,urinary tract obstruction
D011014,2.88,NCT02631876-1,Mirvetuximab Soravtansine,NCT02631876,A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC)  Primary Peritoneal or Fallopian Tube Cancer,pneumonitis
D011014,1.83,NCT02631876-2,Investigator's Choice (IC) Chemotherapy,NCT02631876,A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC)  Primary Peritoneal or Fallopian Tube Cancer,pneumonitis
D010996,2.06,NCT02631876-1,Mirvetuximab Soravtansine,NCT02631876,A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC)  Primary Peritoneal or Fallopian Tube Cancer,pleural effusion
D010996,2.75,NCT02631876-2,Investigator's Choice (IC) Chemotherapy,NCT02631876,A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC)  Primary Peritoneal or Fallopian Tube Cancer,pleural effusion
D011655,1.23,NCT02631876-1,Mirvetuximab Soravtansine,NCT02631876,A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC)  Primary Peritoneal or Fallopian Tube Cancer,pulmonary embolism
UNKNOWN-check-for-typo,0.82,NCT02631876-1,Mirvetuximab Soravtansine,NCT02631876,A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC)  Primary Peritoneal or Fallopian Tube Cancer,D00
UNKNOWN-check-for-typo,1.83,NCT02631876-2,Investigator's Choice (IC) Chemotherapy,NCT02631876,A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC)  Primary Peritoneal or Fallopian Tube Cancer,D00
D011015,0.41,NCT02631876-1,Mirvetuximab Soravtansine,NCT02631876,A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC)  Primary Peritoneal or Fallopian Tube Cancer,aspiration pneumonia
D011030,0.41,NCT02631876-1,Mirvetuximab Soravtansine,NCT02631876,A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC)  Primary Peritoneal or Fallopian Tube Cancer,pneumothorax
D004617,0.41,NCT02631876-1,Mirvetuximab Soravtansine,NCT02631876,A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC)  Primary Peritoneal or Fallopian Tube Cancer,embolism
D009026,33.33,NCT02644278-3,VX-984 480 mg + PLD 40 mg/m^2,NCT02644278,First-in-Human Study of the Safety  Tolerability  and Pharmacokinetic/Pharmacodynamic Profile of VX-984 in Combination With Chemotherapy,mortality
D064420,66.67,NCT02644278-1,VX-984 120 mg + PLD 40 mg/m^2,NCT02644278,First-in-Human Study of the Safety  Tolerability  and Pharmacokinetic/Pharmacodynamic Profile of VX-984 in Combination With Chemotherapy,adverse drug events
D064420,50.0,NCT02644278-3,VX-984 480 mg + PLD 40 mg/m^2,NCT02644278,First-in-Human Study of the Safety  Tolerability  and Pharmacokinetic/Pharmacodynamic Profile of VX-984 in Combination With Chemotherapy,adverse drug events
D064420,33.33,NCT02644278-4,VX-984 720 mg + PLD 40 mg/m^2,NCT02644278,First-in-Human Study of the Safety  Tolerability  and Pharmacokinetic/Pharmacodynamic Profile of VX-984 in Combination With Chemotherapy,adverse drug events
D015746,66.67,NCT02644278-1,VX-984 120 mg + PLD 40 mg/m^2,NCT02644278,First-in-Human Study of the Safety  Tolerability  and Pharmacokinetic/Pharmacodynamic Profile of VX-984 in Combination With Chemotherapy,abdominal pain
D009325,33.33,NCT02644278-1,VX-984 120 mg + PLD 40 mg/m^2,NCT02644278,First-in-Human Study of the Safety  Tolerability  and Pharmacokinetic/Pharmacodynamic Profile of VX-984 in Combination With Chemotherapy,nausea
D009325,16.67,NCT02644278-3,VX-984 480 mg + PLD 40 mg/m^2,NCT02644278,First-in-Human Study of the Safety  Tolerability  and Pharmacokinetic/Pharmacodynamic Profile of VX-984 in Combination With Chemotherapy,nausea
10041101,33.33,NCT02644278-1,VX-984 120 mg + PLD 40 mg/m^2,NCT02644278,First-in-Human Study of the Safety  Tolerability  and Pharmacokinetic/Pharmacodynamic Profile of VX-984 in Combination With Chemotherapy,small intestinal obstruction
10041101,33.33,NCT02644278-4,VX-984 720 mg + PLD 40 mg/m^2,NCT02644278,First-in-Human Study of the Safety  Tolerability  and Pharmacokinetic/Pharmacodynamic Profile of VX-984 in Combination With Chemotherapy,small intestinal obstruction
10061229,16.67,NCT02644278-3,VX-984 480 mg + PLD 40 mg/m^2,NCT02644278,First-in-Human Study of the Safety  Tolerability  and Pharmacokinetic/Pharmacodynamic Profile of VX-984 in Combination With Chemotherapy,lung infection
D018805,16.67,NCT02644278-3,VX-984 480 mg + PLD 40 mg/m^2,NCT02644278,First-in-Human Study of the Safety  Tolerability  and Pharmacokinetic/Pharmacodynamic Profile of VX-984 in Combination With Chemotherapy,sepsis
D000072716,33.33,NCT02644278-1,VX-984 120 mg + PLD 40 mg/m^2,NCT02644278,First-in-Human Study of the Safety  Tolerability  and Pharmacokinetic/Pharmacodynamic Profile of VX-984 in Combination With Chemotherapy,cancer pain
D010996,16.67,NCT02644278-3,VX-984 480 mg + PLD 40 mg/m^2,NCT02644278,First-in-Human Study of the Safety  Tolerability  and Pharmacokinetic/Pharmacodynamic Profile of VX-984 in Combination With Chemotherapy,pleural effusion
D011655,16.67,NCT02644278-3,VX-984 480 mg + PLD 40 mg/m^2,NCT02644278,First-in-Human Study of the Safety  Tolerability  and Pharmacokinetic/Pharmacodynamic Profile of VX-984 in Combination With Chemotherapy,pulmonary embolism
D020246,16.67,NCT02644278-3,VX-984 480 mg + PLD 40 mg/m^2,NCT02644278,First-in-Human Study of the Safety  Tolerability  and Pharmacokinetic/Pharmacodynamic Profile of VX-984 in Combination With Chemotherapy,deep vein thrombosis
D009026,20.0,NCT02677116-1,Olaratumab + Vincristine + Irinotecan (Part A),NCT02677116,A Study of Olaratumab Alone and in Combination With Standard Chemotherapies in Children With Cancer,mortality
D009026,11.11,NCT02677116-2,Olaratumab + Ifosfamide (Part A),NCT02677116,A Study of Olaratumab Alone and in Combination With Standard Chemotherapies in Children With Cancer,mortality
D009026,18.18,NCT02677116-3,Olaratumab + Doxorubicin (Part A),NCT02677116,A Study of Olaratumab Alone and in Combination With Standard Chemotherapies in Children With Cancer,mortality
D009026,20.0,NCT02677116-4,Olaratumab + Vincristine + Irinotecan (Part B),NCT02677116,A Study of Olaratumab Alone and in Combination With Standard Chemotherapies in Children With Cancer,mortality
D009026,15.38,NCT02677116-5,Olaratumab + Ifosfamide (Part B),NCT02677116,A Study of Olaratumab Alone and in Combination With Standard Chemotherapies in Children With Cancer,mortality
D064420,30.0,NCT02677116-1,Olaratumab + Vincristine + Irinotecan (Part A),NCT02677116,A Study of Olaratumab Alone and in Combination With Standard Chemotherapies in Children With Cancer,adverse drug events
D064420,44.44,NCT02677116-2,Olaratumab + Ifosfamide (Part A),NCT02677116,A Study of Olaratumab Alone and in Combination With Standard Chemotherapies in Children With Cancer,adverse drug events
D064420,18.18,NCT02677116-3,Olaratumab + Doxorubicin (Part A),NCT02677116,A Study of Olaratumab Alone and in Combination With Standard Chemotherapies in Children With Cancer,adverse drug events
D064420,50.0,NCT02677116-4,Olaratumab + Vincristine + Irinotecan (Part B),NCT02677116,A Study of Olaratumab Alone and in Combination With Standard Chemotherapies in Children With Cancer,adverse drug events
D064420,53.85,NCT02677116-5,Olaratumab + Ifosfamide (Part B),NCT02677116,A Study of Olaratumab Alone and in Combination With Standard Chemotherapies in Children With Cancer,adverse drug events
D064420,33.33,NCT02677116-7,Olaratumab + Vincristine + Irinotecan (Part C),NCT02677116,A Study of Olaratumab Alone and in Combination With Standard Chemotherapies in Children With Cancer,adverse drug events
D064420,25.0,NCT02677116-8,Olaratumab + Ifosfamide (Part C),NCT02677116,A Study of Olaratumab Alone and in Combination With Standard Chemotherapies in Children With Cancer,adverse drug events
D064420,100.0,NCT02677116-9,Olaratumab + Doxorubicin (Part C),NCT02677116,A Study of Olaratumab Alone and in Combination With Standard Chemotherapies in Children With Cancer,adverse drug events
D000741,22.22,NCT02677116-2,Olaratumab + Ifosfamide (Part A),NCT02677116,A Study of Olaratumab Alone and in Combination With Standard Chemotherapies in Children With Cancer,aplastic anaemia
D064147,10.0,NCT02677116-4,Olaratumab + Vincristine + Irinotecan (Part B),NCT02677116,A Study of Olaratumab Alone and in Combination With Standard Chemotherapies in Children With Cancer,febrile neutropenia
D064147,46.15,NCT02677116-5,Olaratumab + Ifosfamide (Part B),NCT02677116,A Study of Olaratumab Alone and in Combination With Standard Chemotherapies in Children With Cancer,febrile neutropenia
D064147,16.67,NCT02677116-7,Olaratumab + Vincristine + Irinotecan (Part C),NCT02677116,A Study of Olaratumab Alone and in Combination With Standard Chemotherapies in Children With Cancer,febrile neutropenia
D064147,25.0,NCT02677116-8,Olaratumab + Ifosfamide (Part C),NCT02677116,A Study of Olaratumab Alone and in Combination With Standard Chemotherapies in Children With Cancer,febrile neutropenia
D064147,50.0,NCT02677116-9,Olaratumab + Doxorubicin (Part C),NCT02677116,A Study of Olaratumab Alone and in Combination With Standard Chemotherapies in Children With Cancer,febrile neutropenia
UNKNOWN-check-for-typo,10.0,NCT02677116-1,Olaratumab + Vincristine + Irinotecan (Part A),NCT02677116,A Study of Olaratumab Alone and in Combination With Standard Chemotherapies in Children With Cancer,D00
D015746,9.09,NCT02677116-3,Olaratumab + Doxorubicin (Part A),NCT02677116,A Study of Olaratumab Alone and in Combination With Standard Chemotherapies in Children With Cancer,abdominal pain
UNKNOWN-check-for-typo,30.0,NCT02677116-4,Olaratumab + Vincristine + Irinotecan (Part B),NCT02677116,A Study of Olaratumab Alone and in Combination With Standard Chemotherapies in Children With Cancer,D00
UNKNOWN-check-for-typo,16.67,NCT02677116-7,Olaratumab + Vincristine + Irinotecan (Part C),NCT02677116,A Study of Olaratumab Alone and in Combination With Standard Chemotherapies in Children With Cancer,D00
D009325,7.69,NCT02677116-5,Olaratumab + Ifosfamide (Part B),NCT02677116,A Study of Olaratumab Alone and in Combination With Standard Chemotherapies in Children With Cancer,nausea
D014839,10.0,NCT02677116-4,Olaratumab + Vincristine + Irinotecan (Part B),NCT02677116,A Study of Olaratumab Alone and in Combination With Standard Chemotherapies in Children With Cancer,vomiting
D010146,10.0,NCT02677116-4,Olaratumab + Vincristine + Irinotecan (Part B),NCT02677116,A Study of Olaratumab Alone and in Combination With Standard Chemotherapies in Children With Cancer,pain
10056519,25.0,NCT02677116-9,Olaratumab + Doxorubicin (Part C),NCT02677116,A Study of Olaratumab Alone and in Combination With Standard Chemotherapies in Children With Cancer,abdominal infection
D007251,9.09,NCT02677116-3,Olaratumab + Doxorubicin (Part A),NCT02677116,A Study of Olaratumab Alone and in Combination With Standard Chemotherapies in Children With Cancer,influenza
10061229,10.0,NCT02677116-1,Olaratumab + Vincristine + Irinotecan (Part A),NCT02677116,A Study of Olaratumab Alone and in Combination With Standard Chemotherapies in Children With Cancer,lung infection
10061229,10.0,NCT02677116-4,Olaratumab + Vincristine + Irinotecan (Part B),NCT02677116,A Study of Olaratumab Alone and in Combination With Standard Chemotherapies in Children With Cancer,lung infection
10061912,14.29,NCT02677116-2,Olaratumab + Ifosfamide (Part A),NCT02677116,A Study of Olaratumab Alone and in Combination With Standard Chemotherapies in Children With Cancer,penile infection
D014552,11.11,NCT02677116-2,Olaratumab + Ifosfamide (Part A),NCT02677116,A Study of Olaratumab Alone and in Combination With Standard Chemotherapies in Children With Cancer,urinary tract infection
D008310,10.0,NCT02677116-1,Olaratumab + Vincristine + Irinotecan (Part A),NCT02677116,A Study of Olaratumab Alone and in Combination With Standard Chemotherapies in Children With Cancer,malocclusion
D013978,10.0,NCT02677116-4,Olaratumab + Vincristine + Irinotecan (Part B),NCT02677116,A Study of Olaratumab Alone and in Combination With Standard Chemotherapies in Children With Cancer,tibial fractures
10001551,11.11,NCT02677116-2,Olaratumab + Ifosfamide (Part A),NCT02677116,A Study of Olaratumab Alone and in Combination With Standard Chemotherapies in Children With Cancer,alanine aminotransferase increased
10003481,11.11,NCT02677116-2,Olaratumab + Ifosfamide (Part A),NCT02677116,A Study of Olaratumab Alone and in Combination With Standard Chemotherapies in Children With Cancer,aspartate aminotransferase increased
10029366,11.11,NCT02677116-2,Olaratumab + Ifosfamide (Part A),NCT02677116,A Study of Olaratumab Alone and in Combination With Standard Chemotherapies in Children With Cancer,neutrophil count decreased
10029366,9.09,NCT02677116-3,Olaratumab + Doxorubicin (Part A),NCT02677116,A Study of Olaratumab Alone and in Combination With Standard Chemotherapies in Children With Cancer,neutrophil count decreased
D004845,16.67,NCT02677116-7,Olaratumab + Vincristine + Irinotecan (Part C),NCT02677116,A Study of Olaratumab Alone and in Combination With Standard Chemotherapies in Children With Cancer,epitestosterone
D003681,20.0,NCT02677116-4,Olaratumab + Vincristine + Irinotecan (Part B),NCT02677116,A Study of Olaratumab Alone and in Combination With Standard Chemotherapies in Children With Cancer,dehydration
D018771,9.09,NCT02677116-3,Olaratumab + Doxorubicin (Part A),NCT02677116,A Study of Olaratumab Alone and in Combination With Standard Chemotherapies in Children With Cancer,arthralgia
D018771,10.0,NCT02677116-4,Olaratumab + Vincristine + Irinotecan (Part B),NCT02677116,A Study of Olaratumab Alone and in Combination With Standard Chemotherapies in Children With Cancer,arthralgia
10033425,10.0,NCT02677116-4,Olaratumab + Vincristine + Irinotecan (Part B),NCT02677116,A Study of Olaratumab Alone and in Combination With Standard Chemotherapies in Children With Cancer,pain in extremity
D000080867,7.69,NCT02677116-5,Olaratumab + Ifosfamide (Part B),NCT02677116,A Study of Olaratumab Alone and in Combination With Standard Chemotherapies in Children With Cancer,gingipains
D006849,11.11,NCT02677116-2,Olaratumab + Ifosfamide (Part A),NCT02677116,A Study of Olaratumab Alone and in Combination With Standard Chemotherapies in Children With Cancer,hydrocephalus
D012640,11.11,NCT02677116-2,Olaratumab + Ifosfamide (Part A),NCT02677116,A Study of Olaratumab Alone and in Combination With Standard Chemotherapies in Children With Cancer,seizure
D058186,10.0,NCT02677116-4,Olaratumab + Vincristine + Irinotecan (Part B),NCT02677116,A Study of Olaratumab Alone and in Combination With Standard Chemotherapies in Children With Cancer,acute kidney injury
D016055,25.0,NCT02677116-9,Olaratumab + Doxorubicin (Part C),NCT02677116,A Study of Olaratumab Alone and in Combination With Standard Chemotherapies in Children With Cancer,urinary retention
10003504,11.11,NCT02677116-2,Olaratumab + Ifosfamide (Part A),NCT02677116,A Study of Olaratumab Alone and in Combination With Standard Chemotherapies in Children With Cancer,aspiration
D000860,11.11,NCT02677116-2,Olaratumab + Ifosfamide (Part A),NCT02677116,A Study of Olaratumab Alone and in Combination With Standard Chemotherapies in Children With Cancer,hypoxia
D000860,7.69,NCT02677116-5,Olaratumab + Ifosfamide (Part B),NCT02677116,A Study of Olaratumab Alone and in Combination With Standard Chemotherapies in Children With Cancer,hypoxia
D011030,7.69,NCT02677116-5,Olaratumab + Ifosfamide (Part B),NCT02677116,A Study of Olaratumab Alone and in Combination With Standard Chemotherapies in Children With Cancer,pneumothorax
D013479,16.67,NCT02677116-7,Olaratumab + Vincristine + Irinotecan (Part C),NCT02677116,A Study of Olaratumab Alone and in Combination With Standard Chemotherapies in Children With Cancer,superior vena cava thrombosis
D009026,10.0,NCT02753881-1,Superselective cTACE Doxorubicin (One Segment),NCT02753881,Pharmacokinetics of Doxorubicin in cTACE of Liver Cancer,mortality
D064420,10.0,NCT02753881-1,Superselective cTACE Doxorubicin (One Segment),NCT02753881,Pharmacokinetics of Doxorubicin in cTACE of Liver Cancer,adverse drug events
D064420,10.0,NCT02753881-2,Superselective cTACE (2+ Segments),NCT02753881,Pharmacokinetics of Doxorubicin in cTACE of Liver Cancer,adverse drug events
D006323,10.0,NCT02753881-1,Superselective cTACE Doxorubicin (One Segment),NCT02753881,Pharmacokinetics of Doxorubicin in cTACE of Liver Cancer,cardiac arrest
D007010,10.0,NCT02753881-2,Superselective cTACE (2+ Segments),NCT02753881,Pharmacokinetics of Doxorubicin in cTACE of Liver Cancer,hyponatremia
D009026,100.0,NCT02788201-1,Doxorubicin 75mg/m^2,NCT02788201,Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma,mortality
D009026,100.0,NCT02788201-2,Paclitaxel 100 mg/m^2 and Erlotinib 150 mg,NCT02788201,Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma,mortality
D009026,100.0,NCT02788201-3,Paclitaxel 135mg/m^2 and Doxorubicin 40mg/m^2,NCT02788201,Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma,mortality
D009026,100.0,NCT02788201-4,Sunitinib 50mg,NCT02788201,Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma,mortality
D009026,100.0,NCT02788201-6,Participants Who Were Enrolled But Not Treated,NCT02788201,Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma,mortality
D064420,100.0,NCT02788201-1,Doxorubicin 75mg/m^2,NCT02788201,Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma,adverse drug events
D064420,100.0,NCT02788201-2,Paclitaxel 100 mg/m^2 and Erlotinib 150 mg,NCT02788201,Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma,adverse drug events
D064420,100.0,NCT02788201-3,Paclitaxel 135mg/m^2 and Doxorubicin 40mg/m^2,NCT02788201,Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma,adverse drug events
D064420,100.0,NCT02788201-4,Sunitinib 50mg,NCT02788201,Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma,adverse drug events
D064420,100.0,NCT02788201-5,Vorinostat 500mg and Etoposide 100mg/m^2 and 60mg/m^2,NCT02788201,Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma,adverse drug events
D064147,100.0,NCT02788201-5,Vorinostat 500mg and Etoposide 100mg/m^2 and 60mg/m^2,NCT02788201,Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma,febrile neutropenia
10011914,100.0,NCT02788201-1,Doxorubicin 75mg/m^2,NCT02788201,Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma,death nos
10011914,100.0,NCT02788201-2,Paclitaxel 100 mg/m^2 and Erlotinib 150 mg,NCT02788201,Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma,death nos
10011914,100.0,NCT02788201-3,Paclitaxel 135mg/m^2 and Doxorubicin 40mg/m^2,NCT02788201,Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma,death nos
10011914,100.0,NCT02788201-4,Sunitinib 50mg,NCT02788201,Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma,death nos
D009026,18.18,NCT02855359-1,Denintuzumab Mafodotin + RCHP,NCT02855359,Denintuzumab Mafodotin (SGN-CD19A) Combined With RCHOP or RCHP Versus RCHOP Alone in Diffuse Large B-Cell Lymphoma or Follicular Lymphoma,mortality
D009026,15.38,NCT02855359-2,Denintuzumab Mafodotin + RCHOP,NCT02855359,Denintuzumab Mafodotin (SGN-CD19A) Combined With RCHOP or RCHP Versus RCHOP Alone in Diffuse Large B-Cell Lymphoma or Follicular Lymphoma,mortality
D064420,45.45,NCT02855359-1,Denintuzumab Mafodotin + RCHP,NCT02855359,Denintuzumab Mafodotin (SGN-CD19A) Combined With RCHOP or RCHP Versus RCHOP Alone in Diffuse Large B-Cell Lymphoma or Follicular Lymphoma,adverse drug events
D064420,30.77,NCT02855359-2,Denintuzumab Mafodotin + RCHOP,NCT02855359,Denintuzumab Mafodotin (SGN-CD19A) Combined With RCHOP or RCHP Versus RCHOP Alone in Diffuse Large B-Cell Lymphoma or Follicular Lymphoma,adverse drug events
D064147,18.18,NCT02855359-1,Denintuzumab Mafodotin + RCHP,NCT02855359,Denintuzumab Mafodotin (SGN-CD19A) Combined With RCHOP or RCHP Versus RCHOP Alone in Diffuse Large B-Cell Lymphoma or Follicular Lymphoma,febrile neutropenia
D064147,23.08,NCT02855359-2,Denintuzumab Mafodotin + RCHOP,NCT02855359,Denintuzumab Mafodotin (SGN-CD19A) Combined With RCHOP or RCHP Versus RCHOP Alone in Diffuse Large B-Cell Lymphoma or Follicular Lymphoma,febrile neutropenia
D009503,7.69,NCT02855359-2,Denintuzumab Mafodotin + RCHOP,NCT02855359,Denintuzumab Mafodotin (SGN-CD19A) Combined With RCHOP or RCHP Versus RCHOP Alone in Diffuse Large B-Cell Lymphoma or Follicular Lymphoma,neutropenia
D013921,7.69,NCT02855359-2,Denintuzumab Mafodotin + RCHOP,NCT02855359,Denintuzumab Mafodotin (SGN-CD19A) Combined With RCHOP or RCHP Versus RCHOP Alone in Diffuse Large B-Cell Lymphoma or Follicular Lymphoma,thrombocytopenia
D003324,7.69,NCT02855359-2,Denintuzumab Mafodotin + RCHOP,NCT02855359,Denintuzumab Mafodotin (SGN-CD19A) Combined With RCHOP or RCHP Versus RCHOP Alone in Diffuse Large B-Cell Lymphoma or Follicular Lymphoma,coronary artery disease
10033557,9.09,NCT02855359-1,Denintuzumab Mafodotin + RCHP,NCT02855359,Denintuzumab Mafodotin (SGN-CD19A) Combined With RCHOP or RCHP Versus RCHOP Alone in Diffuse Large B-Cell Lymphoma or Follicular Lymphoma,palpitations
D001247,9.09,NCT02855359-1,Denintuzumab Mafodotin + RCHP,NCT02855359,Denintuzumab Mafodotin (SGN-CD19A) Combined With RCHOP or RCHP Versus RCHOP Alone in Diffuse Large B-Cell Lymphoma or Follicular Lymphoma,asthenia
D005221,7.69,NCT02855359-2,Denintuzumab Mafodotin + RCHOP,NCT02855359,Denintuzumab Mafodotin (SGN-CD19A) Combined With RCHOP or RCHP Versus RCHOP Alone in Diffuse Large B-Cell Lymphoma or Follicular Lymphoma,fatigue
D005334,7.69,NCT02855359-2,Denintuzumab Mafodotin + RCHOP,NCT02855359,Denintuzumab Mafodotin (SGN-CD19A) Combined With RCHOP or RCHP Versus RCHOP Alone in Diffuse Large B-Cell Lymphoma or Follicular Lymphoma,pyrexia
D011020,7.69,NCT02855359-2,Denintuzumab Mafodotin + RCHOP,NCT02855359,Denintuzumab Mafodotin (SGN-CD19A) Combined With RCHOP or RCHP Versus RCHOP Alone in Diffuse Large B-Cell Lymphoma or Follicular Lymphoma,pneumocystis jirovecii pneumonia
D018410,9.09,NCT02855359-1,Denintuzumab Mafodotin + RCHP,NCT02855359,Denintuzumab Mafodotin (SGN-CD19A) Combined With RCHOP or RCHP Versus RCHOP Alone in Diffuse Large B-Cell Lymphoma or Follicular Lymphoma,bacterial pneumonia
D012772,7.69,NCT02855359-2,Denintuzumab Mafodotin + RCHOP,NCT02855359,Denintuzumab Mafodotin (SGN-CD19A) Combined With RCHOP or RCHP Versus RCHOP Alone in Diffuse Large B-Cell Lymphoma or Follicular Lymphoma,septic shock
D004768,7.69,NCT02855359-2,Denintuzumab Mafodotin + RCHOP,NCT02855359,Denintuzumab Mafodotin (SGN-CD19A) Combined With RCHOP or RCHP Versus RCHOP Alone in Diffuse Large B-Cell Lymphoma or Follicular Lymphoma,staphylococcal enterotoxins
D015275,9.09,NCT02855359-1,Denintuzumab Mafodotin + RCHP,NCT02855359,Denintuzumab Mafodotin (SGN-CD19A) Combined With RCHOP or RCHP Versus RCHOP Alone in Diffuse Large B-Cell Lymphoma or Follicular Lymphoma,tumour lysis syndrome
D018771,7.69,NCT02855359-2,Denintuzumab Mafodotin + RCHOP,NCT02855359,Denintuzumab Mafodotin (SGN-CD19A) Combined With RCHOP or RCHP Versus RCHOP Alone in Diffuse Large B-Cell Lymphoma or Follicular Lymphoma,arthralgia
D020521,9.09,NCT02855359-1,Denintuzumab Mafodotin + RCHP,NCT02855359,Denintuzumab Mafodotin (SGN-CD19A) Combined With RCHOP or RCHP Versus RCHOP Alone in Diffuse Large B-Cell Lymphoma or Follicular Lymphoma,cerebrovascular accident
D058186,9.09,NCT02855359-1,Denintuzumab Mafodotin + RCHP,NCT02855359,Denintuzumab Mafodotin (SGN-CD19A) Combined With RCHOP or RCHP Versus RCHOP Alone in Diffuse Large B-Cell Lymphoma or Follicular Lymphoma,acute kidney injury
D011015,9.09,NCT02855359-1,Denintuzumab Mafodotin + RCHP,NCT02855359,Denintuzumab Mafodotin (SGN-CD19A) Combined With RCHOP or RCHP Versus RCHOP Alone in Diffuse Large B-Cell Lymphoma or Follicular Lymphoma,aspiration pneumonia
D011655,7.69,NCT02855359-2,Denintuzumab Mafodotin + RCHOP,NCT02855359,Denintuzumab Mafodotin (SGN-CD19A) Combined With RCHOP or RCHP Versus RCHOP Alone in Diffuse Large B-Cell Lymphoma or Follicular Lymphoma,pulmonary embolism
D012131,7.69,NCT02855359-2,Denintuzumab Mafodotin + RCHOP,NCT02855359,Denintuzumab Mafodotin (SGN-CD19A) Combined With RCHOP or RCHP Versus RCHOP Alone in Diffuse Large B-Cell Lymphoma or Follicular Lymphoma,respiratory failure
D007022,9.09,NCT02855359-1,Denintuzumab Mafodotin + RCHP,NCT02855359,Denintuzumab Mafodotin (SGN-CD19A) Combined With RCHOP or RCHP Versus RCHOP Alone in Diffuse Large B-Cell Lymphoma or Follicular Lymphoma,hypotension
D007022,7.69,NCT02855359-2,Denintuzumab Mafodotin + RCHOP,NCT02855359,Denintuzumab Mafodotin (SGN-CD19A) Combined With RCHOP or RCHP Versus RCHOP Alone in Diffuse Large B-Cell Lymphoma or Follicular Lymphoma,hypotension
D009026,4.65,NCT03003520-1,DUR + R-CHOP,NCT03003520,A Study of Durvalumab in Combination With R-CHOP or Lenalidomide Plus R-CHOP in Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma,mortality
D009026,33.33,NCT03003520-2,DUR + R2-CHOP,NCT03003520,A Study of Durvalumab in Combination With R-CHOP or Lenalidomide Plus R-CHOP in Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma,mortality
D064420,51.16,NCT03003520-1,DUR + R-CHOP,NCT03003520,A Study of Durvalumab in Combination With R-CHOP or Lenalidomide Plus R-CHOP in Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma,adverse drug events
D064420,33.33,NCT03003520-2,DUR + R2-CHOP,NCT03003520,A Study of Durvalumab in Combination With R-CHOP or Lenalidomide Plus R-CHOP in Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma,adverse drug events
D000741,2.33,NCT03003520-1,DUR + R-CHOP,NCT03003520,A Study of Durvalumab in Combination With R-CHOP or Lenalidomide Plus R-CHOP in Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma,aplastic anaemia
D064147,13.95,NCT03003520-1,DUR + R-CHOP,NCT03003520,A Study of Durvalumab in Combination With R-CHOP or Lenalidomide Plus R-CHOP in Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma,febrile neutropenia
D064147,33.33,NCT03003520-2,DUR + R2-CHOP,NCT03003520,A Study of Durvalumab in Combination With R-CHOP or Lenalidomide Plus R-CHOP in Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma,febrile neutropenia
D015614,2.33,NCT03003520-1,DUR + R-CHOP,NCT03003520,A Study of Durvalumab in Combination With R-CHOP or Lenalidomide Plus R-CHOP in Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma,histiocytosis
D007970,2.33,NCT03003520-1,DUR + R-CHOP,NCT03003520,A Study of Durvalumab in Combination With R-CHOP or Lenalidomide Plus R-CHOP in Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma,leukopenia
D009503,2.33,NCT03003520-1,DUR + R-CHOP,NCT03003520,A Study of Durvalumab in Combination With R-CHOP or Lenalidomide Plus R-CHOP in Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma,neutropenia
D010198,2.33,NCT03003520-1,DUR + R-CHOP,NCT03003520,A Study of Durvalumab in Combination With R-CHOP or Lenalidomide Plus R-CHOP in Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma,pancytopenia
D001281,4.65,NCT03003520-1,DUR + R-CHOP,NCT03003520,A Study of Durvalumab in Combination With R-CHOP or Lenalidomide Plus R-CHOP in Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma,atrial fibrillation
D006323,2.33,NCT03003520-1,DUR + R-CHOP,NCT03003520,A Study of Durvalumab in Combination With R-CHOP or Lenalidomide Plus R-CHOP in Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma,cardiac arrest
D000071956,2.33,NCT03003520-1,DUR + R-CHOP,NCT03003520,A Study of Durvalumab in Combination With R-CHOP or Lenalidomide Plus R-CHOP in Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma,myocardial contusions
D009325,4.65,NCT03003520-1,DUR + R-CHOP,NCT03003520,A Study of Durvalumab in Combination With R-CHOP or Lenalidomide Plus R-CHOP in Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma,nausea
D014839,2.33,NCT03003520-1,DUR + R-CHOP,NCT03003520,A Study of Durvalumab in Combination With R-CHOP or Lenalidomide Plus R-CHOP in Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma,vomiting
D005221,2.33,NCT03003520-1,DUR + R-CHOP,NCT03003520,A Study of Durvalumab in Combination With R-CHOP or Lenalidomide Plus R-CHOP in Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma,fatigue
D003695,4.65,NCT03003520-1,DUR + R-CHOP,NCT03003520,A Study of Durvalumab in Combination With R-CHOP or Lenalidomide Plus R-CHOP in Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma,healthcare
D005334,6.98,NCT03003520-1,DUR + R-CHOP,NCT03003520,A Study of Durvalumab in Combination With R-CHOP or Lenalidomide Plus R-CHOP in Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma,pyrexia
D019693,2.33,NCT03003520-1,DUR + R-CHOP,NCT03003520,A Study of Durvalumab in Combination With R-CHOP or Lenalidomide Plus R-CHOP in Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma,autoimmune hepatitis
10064687,2.33,NCT03003520-1,DUR + R-CHOP,NCT03003520,A Study of Durvalumab in Combination With R-CHOP or Lenalidomide Plus R-CHOP in Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma,device related infection
D007239,4.65,NCT03003520-1,DUR + R-CHOP,NCT03003520,A Study of Durvalumab in Combination With R-CHOP or Lenalidomide Plus R-CHOP in Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma,infection
D007251,4.65,NCT03003520-1,DUR + R-CHOP,NCT03003520,A Study of Durvalumab in Combination With R-CHOP or Lenalidomide Plus R-CHOP in Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma,influenza
D000038,2.33,NCT03003520-1,DUR + R-CHOP,NCT03003520,A Study of Durvalumab in Combination With R-CHOP or Lenalidomide Plus R-CHOP in Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma,abscess
D011014,4.65,NCT03003520-1,DUR + R-CHOP,NCT03003520,A Study of Durvalumab in Combination With R-CHOP or Lenalidomide Plus R-CHOP in Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma,pneumonia
D000072139,2.33,NCT03003520-1,DUR + R-CHOP,NCT03003520,A Study of Durvalumab in Combination With R-CHOP or Lenalidomide Plus R-CHOP in Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma,megavirales
10051792,2.33,NCT03003520-1,DUR + R-CHOP,NCT03003520,A Study of Durvalumab in Combination With R-CHOP or Lenalidomide Plus R-CHOP in Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma,infusion related reaction
UNKNOWN-check-for-typo,2.33,NCT03003520-1,DUR + R-CHOP,NCT03003520,A Study of Durvalumab in Combination With R-CHOP or Lenalidomide Plus R-CHOP in Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma,D00
D000080867,2.33,NCT03003520-1,DUR + R-CHOP,NCT03003520,A Study of Durvalumab in Combination With R-CHOP or Lenalidomide Plus R-CHOP in Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma,gingipains
D002292,2.33,NCT03003520-1,DUR + R-CHOP,NCT03003520,A Study of Durvalumab in Combination With R-CHOP or Lenalidomide Plus R-CHOP in Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma,clear cell renal cell carcinoma
D008223,2.33,NCT03003520-1,DUR + R-CHOP,NCT03003520,A Study of Durvalumab in Combination With R-CHOP or Lenalidomide Plus R-CHOP in Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma,lymphoma
D000080867,2.33,NCT03003520-1,DUR + R-CHOP,NCT03003520,A Study of Durvalumab in Combination With R-CHOP or Lenalidomide Plus R-CHOP in Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma,gingipains
D020521,2.33,NCT03003520-1,DUR + R-CHOP,NCT03003520,A Study of Durvalumab in Combination With R-CHOP or Lenalidomide Plus R-CHOP in Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma,cerebrovascular accident
D058186,2.33,NCT03003520-1,DUR + R-CHOP,NCT03003520,A Study of Durvalumab in Combination With R-CHOP or Lenalidomide Plus R-CHOP in Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma,acute kidney injury
D000169,2.33,NCT03003520-1,DUR + R-CHOP,NCT03003520,A Study of Durvalumab in Combination With R-CHOP or Lenalidomide Plus R-CHOP in Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma,acrodermatitis
D020246,2.33,NCT03003520-1,DUR + R-CHOP,NCT03003520,A Study of Durvalumab in Combination With R-CHOP or Lenalidomide Plus R-CHOP in Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma,deep vein thrombosis
D020246,2.33,NCT03003520-1,DUR + R-CHOP,NCT03003520,A Study of Durvalumab in Combination With R-CHOP or Lenalidomide Plus R-CHOP in Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma,venous thrombosis
D009026,6.38,NCT03023878-1,Blinatumomab,NCT03023878,Safety and Efficacy of Blinatumomab in Adults With Newly Diagnosed High-risk Diffuse Large B-Cell Lymphoma,mortality
D064420,25.0,NCT03023878-1,Blinatumomab,NCT03023878,Safety and Efficacy of Blinatumomab in Adults With Newly Diagnosed High-risk Diffuse Large B-Cell Lymphoma,adverse drug events
D009503,3.57,NCT03023878-1,Blinatumomab,NCT03023878,Safety and Efficacy of Blinatumomab in Adults With Newly Diagnosed High-risk Diffuse Large B-Cell Lymphoma,neutropenia
D005334,7.14,NCT03023878-1,Blinatumomab,NCT03023878,Safety and Efficacy of Blinatumomab in Adults With Newly Diagnosed High-risk Diffuse Large B-Cell Lymphoma,pyrexia
UNKNOWN-check-for-typo,3.57,NCT03023878-1,Blinatumomab,NCT03023878,Safety and Efficacy of Blinatumomab in Adults With Newly Diagnosed High-risk Diffuse Large B-Cell Lymphoma,D00
D011014,3.57,NCT03023878-1,Blinatumomab,NCT03023878,Safety and Efficacy of Blinatumomab in Adults With Newly Diagnosed High-risk Diffuse Large B-Cell Lymphoma,pneumonia
D018805,3.57,NCT03023878-1,Blinatumomab,NCT03023878,Safety and Efficacy of Blinatumomab in Adults With Newly Diagnosed High-risk Diffuse Large B-Cell Lymphoma,sepsis
D001037,3.57,NCT03023878-1,Blinatumomab,NCT03023878,Safety and Efficacy of Blinatumomab in Adults With Newly Diagnosed High-risk Diffuse Large B-Cell Lymphoma,aphasia
D020149,3.57,NCT03023878-1,Blinatumomab,NCT03023878,Safety and Efficacy of Blinatumomab in Adults With Newly Diagnosed High-risk Diffuse Large B-Cell Lymphoma,neurotoxicity syndrome manganese
D009026,100.0,NCT03211117-1,Cohort B (Pembrolizumab Chemoradiation),NCT03211117,Pembrolizumab  Chemotherapy  and Radiation Therapy With or Without Surgery in Treating Patients With Anaplastic Thyroid Cancer,mortality
D064420,100.0,NCT03211117-1,Cohort B (Pembrolizumab Chemoradiation),NCT03211117,Pembrolizumab  Chemotherapy  and Radiation Therapy With or Without Surgery in Treating Patients With Anaplastic Thyroid Cancer,adverse drug events
D000740,33.33,NCT03211117-1,Cohort B (Pembrolizumab Chemoradiation),NCT03211117,Pembrolizumab  Chemotherapy  and Radiation Therapy With or Without Surgery in Treating Patients With Anaplastic Thyroid Cancer,anemia
D004760,33.33,NCT03211117-1,Cohort B (Pembrolizumab Chemoradiation),NCT03211117,Pembrolizumab  Chemotherapy  and Radiation Therapy With or Without Surgery in Treating Patients With Anaplastic Thyroid Cancer,enterocolitis
D009325,33.33,NCT03211117-1,Cohort B (Pembrolizumab Chemoradiation),NCT03211117,Pembrolizumab  Chemotherapy  and Radiation Therapy With or Without Surgery in Treating Patients With Anaplastic Thyroid Cancer,nausea
D014839,33.33,NCT03211117-1,Cohort B (Pembrolizumab Chemoradiation),NCT03211117,Pembrolizumab  Chemotherapy  and Radiation Therapy With or Without Surgery in Treating Patients With Anaplastic Thyroid Cancer,vomiting
D005334,33.33,NCT03211117-1,Cohort B (Pembrolizumab Chemoradiation),NCT03211117,Pembrolizumab  Chemotherapy  and Radiation Therapy With or Without Surgery in Treating Patients With Anaplastic Thyroid Cancer,fever
10021881,33.33,NCT03211117-1,Cohort B (Pembrolizumab Chemoradiation),NCT03211117,Pembrolizumab  Chemotherapy  and Radiation Therapy With or Without Surgery in Treating Patients With Anaplastic Thyroid Cancer,infections and infestations - other specify
10061229,33.33,NCT03211117-1,Cohort B (Pembrolizumab Chemoradiation),NCT03211117,Pembrolizumab  Chemotherapy  and Radiation Therapy With or Without Surgery in Treating Patients With Anaplastic Thyroid Cancer,lung infection
D018805,33.33,NCT03211117-1,Cohort B (Pembrolizumab Chemoradiation),NCT03211117,Pembrolizumab  Chemotherapy  and Radiation Therapy With or Without Surgery in Treating Patients With Anaplastic Thyroid Cancer,sepsis
D014552,33.33,NCT03211117-1,Cohort B (Pembrolizumab Chemoradiation),NCT03211117,Pembrolizumab  Chemotherapy  and Radiation Therapy With or Without Surgery in Treating Patients With Anaplastic Thyroid Cancer,urinary tract infection
D003681,33.33,NCT03211117-1,Cohort B (Pembrolizumab Chemoradiation),NCT03211117,Pembrolizumab  Chemotherapy  and Radiation Therapy With or Without Surgery in Treating Patients With Anaplastic Thyroid Cancer,dehydration
D006943,33.33,NCT03211117-1,Cohort B (Pembrolizumab Chemoradiation),NCT03211117,Pembrolizumab  Chemotherapy  and Radiation Therapy With or Without Surgery in Treating Patients With Anaplastic Thyroid Cancer,hyperglycemia
D017674,33.33,NCT03211117-1,Cohort B (Pembrolizumab Chemoradiation),NCT03211117,Pembrolizumab  Chemotherapy  and Radiation Therapy With or Without Surgery in Treating Patients With Anaplastic Thyroid Cancer,hypophosphatemia
10062572,33.33,NCT03211117-1,Cohort B (Pembrolizumab Chemoradiation),NCT03211117,Pembrolizumab  Chemotherapy  and Radiation Therapy With or Without Surgery in Treating Patients With Anaplastic Thyroid Cancer,generalized muscle weakness
D004417,33.33,NCT03211117-1,Cohort B (Pembrolizumab Chemoradiation),NCT03211117,Pembrolizumab  Chemotherapy  and Radiation Therapy With or Without Surgery in Treating Patients With Anaplastic Thyroid Cancer,dyspnea
D007819,33.33,NCT03211117-1,Cohort B (Pembrolizumab Chemoradiation),NCT03211117,Pembrolizumab  Chemotherapy  and Radiation Therapy With or Without Surgery in Treating Patients With Anaplastic Thyroid Cancer,laryngeal edema
D011014,66.67,NCT03211117-1,Cohort B (Pembrolizumab Chemoradiation),NCT03211117,Pembrolizumab  Chemotherapy  and Radiation Therapy With or Without Surgery in Treating Patients With Anaplastic Thyroid Cancer,pneumonitis
D012131,66.67,NCT03211117-1,Cohort B (Pembrolizumab Chemoradiation),NCT03211117,Pembrolizumab  Chemotherapy  and Radiation Therapy With or Without Surgery in Treating Patients With Anaplastic Thyroid Cancer,respiratory failure
D007022,33.33,NCT03211117-1,Cohort B (Pembrolizumab Chemoradiation),NCT03211117,Pembrolizumab  Chemotherapy  and Radiation Therapy With or Without Surgery in Treating Patients With Anaplastic Thyroid Cancer,hypotension
D064420,20.0,NCT03226249-1,Treatment: Pembrolizumab and AVD Chemotherapy Guided by PET-CT,NCT03226249,PET-Directed Therapy With Pembrolizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Classical Hodgkin Lymphoma,adverse drug events
D064147,3.33,NCT03226249-1,Treatment: Pembrolizumab and AVD Chemotherapy Guided by PET-CT,NCT03226249,PET-Directed Therapy With Pembrolizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Classical Hodgkin Lymphoma,febrile neutropenia
D064147,6.67,NCT03226249-1,Treatment: Pembrolizumab and AVD Chemotherapy Guided by PET-CT,NCT03226249,PET-Directed Therapy With Pembrolizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Classical Hodgkin Lymphoma,febrile neutropenia
D010493,3.33,NCT03226249-1,Treatment: Pembrolizumab and AVD Chemotherapy Guided by PET-CT,NCT03226249,PET-Directed Therapy With Pembrolizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Classical Hodgkin Lymphoma,pericarditis
D005334,3.33,NCT03226249-1,Treatment: Pembrolizumab and AVD Chemotherapy Guided by PET-CT,NCT03226249,PET-Directed Therapy With Pembrolizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Classical Hodgkin Lymphoma,fever
D005155,3.33,NCT03226249-1,Treatment: Pembrolizumab and AVD Chemotherapy Guided by PET-CT,NCT03226249,PET-Directed Therapy With Pembrolizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Classical Hodgkin Lymphoma,facial nerve disorder
D009026,43.75,NCT03283696-1,Olaratumab 15 mg/kg + Doxorubicin + Ifosfamide,NCT03283696,A Study of Olaratumab (LY3012207)  Doxorubicin  and Ifosfamide in Participants With Advanced or Metastatic Soft Tissue Sarcoma,mortality
D009026,25.0,NCT03283696-2,Olaratumab 20 mg/kg + Doxorubicin + Ifosfamide,NCT03283696,A Study of Olaratumab (LY3012207)  Doxorubicin  and Ifosfamide in Participants With Advanced or Metastatic Soft Tissue Sarcoma,mortality
D064420,56.25,NCT03283696-1,Olaratumab 15 mg/kg + Doxorubicin + Ifosfamide,NCT03283696,A Study of Olaratumab (LY3012207)  Doxorubicin  and Ifosfamide in Participants With Advanced or Metastatic Soft Tissue Sarcoma,adverse drug events
D064420,87.5,NCT03283696-2,Olaratumab 20 mg/kg + Doxorubicin + Ifosfamide,NCT03283696,A Study of Olaratumab (LY3012207)  Doxorubicin  and Ifosfamide in Participants With Advanced or Metastatic Soft Tissue Sarcoma,adverse drug events
D000741,12.5,NCT03283696-1,Olaratumab 15 mg/kg + Doxorubicin + Ifosfamide,NCT03283696,A Study of Olaratumab (LY3012207)  Doxorubicin  and Ifosfamide in Participants With Advanced or Metastatic Soft Tissue Sarcoma,aplastic anaemia
D000741,12.5,NCT03283696-2,Olaratumab 20 mg/kg + Doxorubicin + Ifosfamide,NCT03283696,A Study of Olaratumab (LY3012207)  Doxorubicin  and Ifosfamide in Participants With Advanced or Metastatic Soft Tissue Sarcoma,aplastic anaemia
D064147,37.5,NCT03283696-1,Olaratumab 15 mg/kg + Doxorubicin + Ifosfamide,NCT03283696,A Study of Olaratumab (LY3012207)  Doxorubicin  and Ifosfamide in Participants With Advanced or Metastatic Soft Tissue Sarcoma,febrile neutropenia
D064147,50.0,NCT03283696-2,Olaratumab 20 mg/kg + Doxorubicin + Ifosfamide,NCT03283696,A Study of Olaratumab (LY3012207)  Doxorubicin  and Ifosfamide in Participants With Advanced or Metastatic Soft Tissue Sarcoma,febrile neutropenia
D009503,6.25,NCT03283696-1,Olaratumab 15 mg/kg + Doxorubicin + Ifosfamide,NCT03283696,A Study of Olaratumab (LY3012207)  Doxorubicin  and Ifosfamide in Participants With Advanced or Metastatic Soft Tissue Sarcoma,neutropenia
D001281,12.5,NCT03283696-2,Olaratumab 20 mg/kg + Doxorubicin + Ifosfamide,NCT03283696,A Study of Olaratumab (LY3012207)  Doxorubicin  and Ifosfamide in Participants With Advanced or Metastatic Soft Tissue Sarcoma,atrial fibrillation
UNKNOWN-check-for-typo,6.25,NCT03283696-1,Olaratumab 15 mg/kg + Doxorubicin + Ifosfamide,NCT03283696,A Study of Olaratumab (LY3012207)  Doxorubicin  and Ifosfamide in Participants With Advanced or Metastatic Soft Tissue Sarcoma,D00
D009325,6.25,NCT03283696-1,Olaratumab 15 mg/kg + Doxorubicin + Ifosfamide,NCT03283696,A Study of Olaratumab (LY3012207)  Doxorubicin  and Ifosfamide in Participants With Advanced or Metastatic Soft Tissue Sarcoma,nausea
10015461,6.25,NCT03283696-1,Olaratumab 15 mg/kg + Doxorubicin + Ifosfamide,NCT03283696,A Study of Olaratumab (LY3012207)  Doxorubicin  and Ifosfamide in Participants With Advanced or Metastatic Soft Tissue Sarcoma,esophagitis
D014839,6.25,NCT03283696-1,Olaratumab 15 mg/kg + Doxorubicin + Ifosfamide,NCT03283696,A Study of Olaratumab (LY3012207)  Doxorubicin  and Ifosfamide in Participants With Advanced or Metastatic Soft Tissue Sarcoma,vomiting
D005221,12.5,NCT03283696-1,Olaratumab 15 mg/kg + Doxorubicin + Ifosfamide,NCT03283696,A Study of Olaratumab (LY3012207)  Doxorubicin  and Ifosfamide in Participants With Advanced or Metastatic Soft Tissue Sarcoma,fatigue
D007249,6.25,NCT03283696-1,Olaratumab 15 mg/kg + Doxorubicin + Ifosfamide,NCT03283696,A Study of Olaratumab (LY3012207)  Doxorubicin  and Ifosfamide in Participants With Advanced or Metastatic Soft Tissue Sarcoma,inflammation
10064687,6.25,NCT03283696-1,Olaratumab 15 mg/kg + Doxorubicin + Ifosfamide,NCT03283696,A Study of Olaratumab (LY3012207)  Doxorubicin  and Ifosfamide in Participants With Advanced or Metastatic Soft Tissue Sarcoma,device related infection
D011014,25.0,NCT03283696-2,Olaratumab 20 mg/kg + Doxorubicin + Ifosfamide,NCT03283696,A Study of Olaratumab (LY3012207)  Doxorubicin  and Ifosfamide in Participants With Advanced or Metastatic Soft Tissue Sarcoma,pneumonia
10017076,12.5,NCT03283696-2,Olaratumab 20 mg/kg + Doxorubicin + Ifosfamide,NCT03283696,A Study of Olaratumab (LY3012207)  Doxorubicin  and Ifosfamide in Participants With Advanced or Metastatic Soft Tissue Sarcoma,fracture
10011368,12.5,NCT03283696-2,Olaratumab 20 mg/kg + Doxorubicin + Ifosfamide,NCT03283696,A Study of Olaratumab (LY3012207)  Doxorubicin  and Ifosfamide in Participants With Advanced or Metastatic Soft Tissue Sarcoma,creatinine increased
10035528,12.5,NCT03283696-1,Olaratumab 15 mg/kg + Doxorubicin + Ifosfamide,NCT03283696,A Study of Olaratumab (LY3012207)  Doxorubicin  and Ifosfamide in Participants With Advanced or Metastatic Soft Tissue Sarcoma,platelet count decreased
10035528,25.0,NCT03283696-2,Olaratumab 20 mg/kg + Doxorubicin + Ifosfamide,NCT03283696,A Study of Olaratumab (LY3012207)  Doxorubicin  and Ifosfamide in Participants With Advanced or Metastatic Soft Tissue Sarcoma,platelet count decreased
D007958,12.5,NCT03283696-2,Olaratumab 20 mg/kg + Doxorubicin + Ifosfamide,NCT03283696,A Study of Olaratumab (LY3012207)  Doxorubicin  and Ifosfamide in Participants With Advanced or Metastatic Soft Tissue Sarcoma,blood cell count white
D003681,6.25,NCT03283696-1,Olaratumab 15 mg/kg + Doxorubicin + Ifosfamide,NCT03283696,A Study of Olaratumab (LY3012207)  Doxorubicin  and Ifosfamide in Participants With Advanced or Metastatic Soft Tissue Sarcoma,dehydration
UNKNOWN-check-for-typo,6.25,NCT03283696-1,Olaratumab 15 mg/kg + Doxorubicin + Ifosfamide,NCT03283696,A Study of Olaratumab (LY3012207)  Doxorubicin  and Ifosfamide in Participants With Advanced or Metastatic Soft Tissue Sarcoma,D00
D018908,6.25,NCT03283696-1,Olaratumab 15 mg/kg + Doxorubicin + Ifosfamide,NCT03283696,A Study of Olaratumab (LY3012207)  Doxorubicin  and Ifosfamide in Participants With Advanced or Metastatic Soft Tissue Sarcoma,muscular weakness
D009369,6.25,NCT03283696-1,Olaratumab 15 mg/kg + Doxorubicin + Ifosfamide,NCT03283696,A Study of Olaratumab (LY3012207)  Doxorubicin  and Ifosfamide in Participants With Advanced or Metastatic Soft Tissue Sarcoma,neoplasms
D018365,6.25,NCT03283696-1,Olaratumab 15 mg/kg + Doxorubicin + Ifosfamide,NCT03283696,A Study of Olaratumab (LY3012207)  Doxorubicin  and Ifosfamide in Participants With Advanced or Metastatic Soft Tissue Sarcoma,residual tumour
D000080867,6.25,NCT03283696-1,Olaratumab 15 mg/kg + Doxorubicin + Ifosfamide,NCT03283696,A Study of Olaratumab (LY3012207)  Doxorubicin  and Ifosfamide in Participants With Advanced or Metastatic Soft Tissue Sarcoma,gingipains
D004864,12.5,NCT03283696-2,Olaratumab 20 mg/kg + Doxorubicin + Ifosfamide,NCT03283696,A Study of Olaratumab (LY3012207)  Doxorubicin  and Ifosfamide in Participants With Advanced or Metastatic Soft Tissue Sarcoma,devices
D011655,6.25,NCT03283696-1,Olaratumab 15 mg/kg + Doxorubicin + Ifosfamide,NCT03283696,A Study of Olaratumab (LY3012207)  Doxorubicin  and Ifosfamide in Participants With Advanced or Metastatic Soft Tissue Sarcoma,pulmonary embolism
D007593,6.25,NCT03283696-1,Olaratumab 15 mg/kg + Doxorubicin + Ifosfamide,NCT03283696,A Study of Olaratumab (LY3012207)  Doxorubicin  and Ifosfamide in Participants With Advanced or Metastatic Soft Tissue Sarcoma,joint instability
D007022,6.25,NCT03283696-1,Olaratumab 15 mg/kg + Doxorubicin + Ifosfamide,NCT03283696,A Study of Olaratumab (LY3012207)  Doxorubicin  and Ifosfamide in Participants With Advanced or Metastatic Soft Tissue Sarcoma,hypotension
D009026,0.4,NCT03493854-1,Arm A: Pertuzumab IV + Trastuzumab IV + Chemotherapy,NCT03493854,A Study to Evaluate the Pharmacokinetics  Efficacy  and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer,mortality
D009026,0.4,NCT03493854-2,Arm B: Pertuzumab and Trastuzumab FDC SC + Chemotherapy,NCT03493854,A Study to Evaluate the Pharmacokinetics  Efficacy  and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer,mortality
D064420,17.86,NCT03493854-1,Arm A: Pertuzumab IV + Trastuzumab IV + Chemotherapy,NCT03493854,A Study to Evaluate the Pharmacokinetics  Efficacy  and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer,adverse drug events
D064420,16.13,NCT03493854-2,Arm B: Pertuzumab and Trastuzumab FDC SC + Chemotherapy,NCT03493854,A Study to Evaluate the Pharmacokinetics  Efficacy  and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer,adverse drug events
D000741,0.4,NCT03493854-1,Arm A: Pertuzumab IV + Trastuzumab IV + Chemotherapy,NCT03493854,A Study to Evaluate the Pharmacokinetics  Efficacy  and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer,aplastic anaemia
D000741,0.4,NCT03493854-2,Arm B: Pertuzumab and Trastuzumab FDC SC + Chemotherapy,NCT03493854,A Study to Evaluate the Pharmacokinetics  Efficacy  and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer,aplastic anaemia
D064147,3.97,NCT03493854-1,Arm A: Pertuzumab IV + Trastuzumab IV + Chemotherapy,NCT03493854,A Study to Evaluate the Pharmacokinetics  Efficacy  and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer,febrile neutropenia
D064147,3.63,NCT03493854-2,Arm B: Pertuzumab and Trastuzumab FDC SC + Chemotherapy,NCT03493854,A Study to Evaluate the Pharmacokinetics  Efficacy  and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer,febrile neutropenia
D009503,1.19,NCT03493854-1,Arm A: Pertuzumab IV + Trastuzumab IV + Chemotherapy,NCT03493854,A Study to Evaluate the Pharmacokinetics  Efficacy  and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer,neutropenia
D009503,0.4,NCT03493854-2,Arm B: Pertuzumab and Trastuzumab FDC SC + Chemotherapy,NCT03493854,A Study to Evaluate the Pharmacokinetics  Efficacy  and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer,neutropenia
D056988,0.4,NCT03493854-2,Arm B: Pertuzumab and Trastuzumab FDC SC + Chemotherapy,NCT03493854,A Study to Evaluate the Pharmacokinetics  Efficacy  and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer,acute anterior wall myocardial infarction
D001145,0.4,NCT03493854-2,Arm B: Pertuzumab and Trastuzumab FDC SC + Chemotherapy,NCT03493854,A Study to Evaluate the Pharmacokinetics  Efficacy  and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer,arrhythmia
D006333,0.79,NCT03493854-1,Arm A: Pertuzumab IV + Trastuzumab IV + Chemotherapy,NCT03493854,A Study to Evaluate the Pharmacokinetics  Efficacy  and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer,cardiac failure
D006333,0.81,NCT03493854-2,Arm B: Pertuzumab and Trastuzumab FDC SC + Chemotherapy,NCT03493854,A Study to Evaluate the Pharmacokinetics  Efficacy  and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer,cardiac failure
UNKNOWN-check-for-typo,0.4,NCT03493854-1,Arm A: Pertuzumab IV + Trastuzumab IV + Chemotherapy,NCT03493854,A Study to Evaluate the Pharmacokinetics  Efficacy  and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer,D00
D015746,0.4,NCT03493854-2,Arm B: Pertuzumab and Trastuzumab FDC SC + Chemotherapy,NCT03493854,A Study to Evaluate the Pharmacokinetics  Efficacy  and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer,abdominal pain
D000069282,0.4,NCT03493854-2,Arm B: Pertuzumab and Trastuzumab FDC SC + Chemotherapy,NCT03493854,A Study to Evaluate the Pharmacokinetics  Efficacy  and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer,canaliculitis
D003092,0.4,NCT03493854-1,Arm A: Pertuzumab IV + Trastuzumab IV + Chemotherapy,NCT03493854,A Study to Evaluate the Pharmacokinetics  Efficacy  and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer,colitis
D003092,0.4,NCT03493854-2,Arm B: Pertuzumab and Trastuzumab FDC SC + Chemotherapy,NCT03493854,A Study to Evaluate the Pharmacokinetics  Efficacy  and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer,colitis
UNKNOWN-check-for-typo,0.79,NCT03493854-1,Arm A: Pertuzumab IV + Trastuzumab IV + Chemotherapy,NCT03493854,A Study to Evaluate the Pharmacokinetics  Efficacy  and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer,D00
UNKNOWN-check-for-typo,0.4,NCT03493854-2,Arm B: Pertuzumab and Trastuzumab FDC SC + Chemotherapy,NCT03493854,A Study to Evaluate the Pharmacokinetics  Efficacy  and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer,D00
D005756,0.4,NCT03493854-2,Arm B: Pertuzumab and Trastuzumab FDC SC + Chemotherapy,NCT03493854,A Study to Evaluate the Pharmacokinetics  Efficacy  and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer,gastritis
D000081015,0.4,NCT03493854-2,Arm B: Pertuzumab and Trastuzumab FDC SC + Chemotherapy,NCT03493854,A Study to Evaluate the Pharmacokinetics  Efficacy  and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer,ototoxicity
D010195,0.4,NCT03493854-2,Arm B: Pertuzumab and Trastuzumab FDC SC + Chemotherapy,NCT03493854,A Study to Evaluate the Pharmacokinetics  Efficacy  and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer,pancreatitis
D014839,0.4,NCT03493854-1,Arm A: Pertuzumab IV + Trastuzumab IV + Chemotherapy,NCT03493854,A Study to Evaluate the Pharmacokinetics  Efficacy  and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer,vomiting
D002637,0.4,NCT03493854-1,Arm A: Pertuzumab IV + Trastuzumab IV + Chemotherapy,NCT03493854,A Study to Evaluate the Pharmacokinetics  Efficacy  and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer,chest pain
D005221,0.4,NCT03493854-1,Arm A: Pertuzumab IV + Trastuzumab IV + Chemotherapy,NCT03493854,A Study to Evaluate the Pharmacokinetics  Efficacy  and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer,fatigue
D020347,0.4,NCT03493854-2,Arm B: Pertuzumab and Trastuzumab FDC SC + Chemotherapy,NCT03493854,A Study to Evaluate the Pharmacokinetics  Efficacy  and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer,lithiasis
D007249,0.4,NCT03493854-1,Arm A: Pertuzumab IV + Trastuzumab IV + Chemotherapy,NCT03493854,A Study to Evaluate the Pharmacokinetics  Efficacy  and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer,inflammation
D005334,1.59,NCT03493854-1,Arm A: Pertuzumab IV + Trastuzumab IV + Chemotherapy,NCT03493854,A Study to Evaluate the Pharmacokinetics  Efficacy  and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer,pyrexia
D005334,0.81,NCT03493854-2,Arm B: Pertuzumab and Trastuzumab FDC SC + Chemotherapy,NCT03493854,A Study to Evaluate the Pharmacokinetics  Efficacy  and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer,pyrexia
D000038,0.4,NCT03493854-1,Arm A: Pertuzumab IV + Trastuzumab IV + Chemotherapy,NCT03493854,A Study to Evaluate the Pharmacokinetics  Efficacy  and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer,abscess
D001064,0.4,NCT03493854-1,Arm A: Pertuzumab IV + Trastuzumab IV + Chemotherapy,NCT03493854,A Study to Evaluate the Pharmacokinetics  Efficacy  and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer,appendicitis
D001064,0.4,NCT03493854-2,Arm B: Pertuzumab and Trastuzumab FDC SC + Chemotherapy,NCT03493854,A Study to Evaluate the Pharmacokinetics  Efficacy  and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer,appendicitis
D002481,0.4,NCT03493854-1,Arm A: Pertuzumab IV + Trastuzumab IV + Chemotherapy,NCT03493854,A Study to Evaluate the Pharmacokinetics  Efficacy  and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer,cellulitis
D004761,0.4,NCT03493854-1,Arm A: Pertuzumab IV + Trastuzumab IV + Chemotherapy,NCT03493854,A Study to Evaluate the Pharmacokinetics  Efficacy  and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer,clostridium enterocolitis
D004925,0.4,NCT03493854-2,Arm B: Pertuzumab and Trastuzumab FDC SC + Chemotherapy,NCT03493854,A Study to Evaluate the Pharmacokinetics  Efficacy  and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer,escherichia
D005759,0.4,NCT03493854-1,Arm A: Pertuzumab IV + Trastuzumab IV + Chemotherapy,NCT03493854,A Study to Evaluate the Pharmacokinetics  Efficacy  and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer,gastroenteritis
D005759,0.4,NCT03493854-2,Arm B: Pertuzumab and Trastuzumab FDC SC + Chemotherapy,NCT03493854,A Study to Evaluate the Pharmacokinetics  Efficacy  and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer,gastroenteritis
D007251,0.4,NCT03493854-2,Arm B: Pertuzumab and Trastuzumab FDC SC + Chemotherapy,NCT03493854,A Study to Evaluate the Pharmacokinetics  Efficacy  and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer,influenza
D012141,0.4,NCT03493854-2,Arm B: Pertuzumab and Trastuzumab FDC SC + Chemotherapy,NCT03493854,A Study to Evaluate the Pharmacokinetics  Efficacy  and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer,respiratory tract infections
D008413,0.79,NCT03493854-1,Arm A: Pertuzumab IV + Trastuzumab IV + Chemotherapy,NCT03493854,A Study to Evaluate the Pharmacokinetics  Efficacy  and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer,mastitis
D008413,0.4,NCT03493854-2,Arm B: Pertuzumab and Trastuzumab FDC SC + Chemotherapy,NCT03493854,A Study to Evaluate the Pharmacokinetics  Efficacy  and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer,mastitis
D000985,0.4,NCT03493854-1,Arm A: Pertuzumab IV + Trastuzumab IV + Chemotherapy,NCT03493854,A Study to Evaluate the Pharmacokinetics  Efficacy  and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer,antisepsis
D000985,1.21,NCT03493854-2,Arm B: Pertuzumab and Trastuzumab FDC SC + Chemotherapy,NCT03493854,A Study to Evaluate the Pharmacokinetics  Efficacy  and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer,antisepsis
D010612,0.4,NCT03493854-1,Arm A: Pertuzumab IV + Trastuzumab IV + Chemotherapy,NCT03493854,A Study to Evaluate the Pharmacokinetics  Efficacy  and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer,pharyngitis
D011014,0.4,NCT03493854-1,Arm A: Pertuzumab IV + Trastuzumab IV + Chemotherapy,NCT03493854,A Study to Evaluate the Pharmacokinetics  Efficacy  and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer,pneumonia
D013530,0.79,NCT03493854-1,Arm A: Pertuzumab IV + Trastuzumab IV + Chemotherapy,NCT03493854,A Study to Evaluate the Pharmacokinetics  Efficacy  and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer,postoperative wound infection
D011552,0.4,NCT03493854-2,Arm B: Pertuzumab and Trastuzumab FDC SC + Chemotherapy,NCT03493854,A Study to Evaluate the Pharmacokinetics  Efficacy  and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer,pseudomonas infection
D011704,0.4,NCT03493854-1,Arm A: Pertuzumab IV + Trastuzumab IV + Chemotherapy,NCT03493854,A Study to Evaluate the Pharmacokinetics  Efficacy  and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer,pyelonephritis acute necrotizing
D012141,0.4,NCT03493854-1,Arm A: Pertuzumab IV + Trastuzumab IV + Chemotherapy,NCT03493854,A Study to Evaluate the Pharmacokinetics  Efficacy  and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer,respiratory tract infection
D018805,0.79,NCT03493854-1,Arm A: Pertuzumab IV + Trastuzumab IV + Chemotherapy,NCT03493854,A Study to Evaluate the Pharmacokinetics  Efficacy  and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer,sepsis
D018805,0.4,NCT03493854-2,Arm B: Pertuzumab and Trastuzumab FDC SC + Chemotherapy,NCT03493854,A Study to Evaluate the Pharmacokinetics  Efficacy  and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer,sepsis
10040047,0.4,NCT03493854-1,Arm A: Pertuzumab IV + Trastuzumab IV + Chemotherapy,NCT03493854,A Study to Evaluate the Pharmacokinetics  Efficacy  and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer,sepsis
D005265,0.4,NCT03493854-2,Arm B: Pertuzumab and Trastuzumab FDC SC + Chemotherapy,NCT03493854,A Study to Evaluate the Pharmacokinetics  Efficacy  and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer,femur neck fractures
D005218,0.4,NCT03493854-2,Arm B: Pertuzumab and Trastuzumab FDC SC + Chemotherapy,NCT03493854,A Study to Evaluate the Pharmacokinetics  Efficacy  and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer,steatonecrosis
10051792,1.19,NCT03493854-1,Arm A: Pertuzumab IV + Trastuzumab IV + Chemotherapy,NCT03493854,A Study to Evaluate the Pharmacokinetics  Efficacy  and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer,infusion related reaction
D000076282,0.4,NCT03493854-2,Arm B: Pertuzumab and Trastuzumab FDC SC + Chemotherapy,NCT03493854,A Study to Evaluate the Pharmacokinetics  Efficacy  and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer,composting
D000076282,0.4,NCT03493854-2,Arm B: Pertuzumab and Trastuzumab FDC SC + Chemotherapy,NCT03493854,A Study to Evaluate the Pharmacokinetics  Efficacy  and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer,composting
D003013,0.4,NCT03493854-1,Arm A: Pertuzumab IV + Trastuzumab IV + Chemotherapy,NCT03493854,A Study to Evaluate the Pharmacokinetics  Efficacy  and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer,clostridium
10029366,0.4,NCT03493854-1,Arm A: Pertuzumab IV + Trastuzumab IV + Chemotherapy,NCT03493854,A Study to Evaluate the Pharmacokinetics  Efficacy  and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer,neutrophil count decreased
10029366,1.21,NCT03493854-2,Arm B: Pertuzumab and Trastuzumab FDC SC + Chemotherapy,NCT03493854,A Study to Evaluate the Pharmacokinetics  Efficacy  and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer,neutrophil count decreased
D007958,0.4,NCT03493854-2,Arm B: Pertuzumab and Trastuzumab FDC SC + Chemotherapy,NCT03493854,A Study to Evaluate the Pharmacokinetics  Efficacy  and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer,blood cell count white
D010522,0.4,NCT03493854-1,Arm A: Pertuzumab IV + Trastuzumab IV + Chemotherapy,NCT03493854,A Study to Evaluate the Pharmacokinetics  Efficacy  and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer,periostitis
D002292,0.4,NCT03493854-1,Arm A: Pertuzumab IV + Trastuzumab IV + Chemotherapy,NCT03493854,A Study to Evaluate the Pharmacokinetics  Efficacy  and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer,renal cell carcinoma
D012640,0.4,NCT03493854-1,Arm A: Pertuzumab IV + Trastuzumab IV + Chemotherapy,NCT03493854,A Study to Evaluate the Pharmacokinetics  Efficacy  and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer,seizure
D012640,0.4,NCT03493854-2,Arm B: Pertuzumab and Trastuzumab FDC SC + Chemotherapy,NCT03493854,A Study to Evaluate the Pharmacokinetics  Efficacy  and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer,seizure
D003863,0.4,NCT03493854-1,Arm A: Pertuzumab IV + Trastuzumab IV + Chemotherapy,NCT03493854,A Study to Evaluate the Pharmacokinetics  Efficacy  and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer,depression
D051437,0.4,NCT03493854-2,Arm B: Pertuzumab and Trastuzumab FDC SC + Chemotherapy,NCT03493854,A Study to Evaluate the Pharmacokinetics  Efficacy  and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer,renal failure
D001940,0.4,NCT03493854-1,Arm A: Pertuzumab IV + Trastuzumab IV + Chemotherapy,NCT03493854,A Study to Evaluate the Pharmacokinetics  Efficacy  and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer,breast
D001940,0.4,NCT03493854-2,Arm B: Pertuzumab and Trastuzumab FDC SC + Chemotherapy,NCT03493854,A Study to Evaluate the Pharmacokinetics  Efficacy  and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer,breast
D008796,0.4,NCT03493854-1,Arm A: Pertuzumab IV + Trastuzumab IV + Chemotherapy,NCT03493854,A Study to Evaluate the Pharmacokinetics  Efficacy  and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer,metrorrhagia
UNKNOWN-check-for-typo,0.4,NCT03493854-2,Arm B: Pertuzumab and Trastuzumab FDC SC + Chemotherapy,NCT03493854,A Study to Evaluate the Pharmacokinetics  Efficacy  and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer,D00
D000860,0.4,NCT03493854-1,Arm A: Pertuzumab IV + Trastuzumab IV + Chemotherapy,NCT03493854,A Study to Evaluate the Pharmacokinetics  Efficacy  and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer,hypoxia
D011014,0.4,NCT03493854-1,Arm A: Pertuzumab IV + Trastuzumab IV + Chemotherapy,NCT03493854,A Study to Evaluate the Pharmacokinetics  Efficacy  and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer,pneumonitis
D011014,0.81,NCT03493854-2,Arm B: Pertuzumab and Trastuzumab FDC SC + Chemotherapy,NCT03493854,A Study to Evaluate the Pharmacokinetics  Efficacy  and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer,pneumonitis
D011030,0.4,NCT03493854-1,Arm A: Pertuzumab IV + Trastuzumab IV + Chemotherapy,NCT03493854,A Study to Evaluate the Pharmacokinetics  Efficacy  and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer,pneumothorax
D011655,0.4,NCT03493854-1,Arm A: Pertuzumab IV + Trastuzumab IV + Chemotherapy,NCT03493854,A Study to Evaluate the Pharmacokinetics  Efficacy  and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer,pulmonary embolism
D011655,0.81,NCT03493854-2,Arm B: Pertuzumab and Trastuzumab FDC SC + Chemotherapy,NCT03493854,A Study to Evaluate the Pharmacokinetics  Efficacy  and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer,pulmonary embolism
D000799,0.4,NCT03493854-2,Arm B: Pertuzumab and Trastuzumab FDC SC + Chemotherapy,NCT03493854,A Study to Evaluate the Pharmacokinetics  Efficacy  and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer,angioedema
D004890,0.4,NCT03493854-2,Arm B: Pertuzumab and Trastuzumab FDC SC + Chemotherapy,NCT03493854,A Study to Evaluate the Pharmacokinetics  Efficacy  and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer,erythema
D004617,0.4,NCT03493854-2,Arm B: Pertuzumab and Trastuzumab FDC SC + Chemotherapy,NCT03493854,A Study to Evaluate the Pharmacokinetics  Efficacy  and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer,embolism
UNKNOWN-check-for-typo,0.4,NCT03493854-1,Arm A: Pertuzumab IV + Trastuzumab IV + Chemotherapy,NCT03493854,A Study to Evaluate the Pharmacokinetics  Efficacy  and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer,D00
D006973,0.4,NCT03493854-2,Arm B: Pertuzumab and Trastuzumab FDC SC + Chemotherapy,NCT03493854,A Study to Evaluate the Pharmacokinetics  Efficacy  and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer,hypertension
D007083,0.4,NCT03493854-1,Arm A: Pertuzumab IV + Trastuzumab IV + Chemotherapy,NCT03493854,A Study to Evaluate the Pharmacokinetics  Efficacy  and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer,iliac artery
D064420,33.33,NCT00054327-3,Regimen B-2,NCT00054327,Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer,adverse drug events
D064420,50.0,NCT00054327-4,Regimen B-3,NCT00054327,Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer,adverse drug events
D064420,20.0,NCT00054327-5,Regimen C,NCT00054327,Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer,adverse drug events
D006470,33.33,NCT00054327-3,Regimen B-2,NCT00054327,Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer,bleeding
D013280,25.0,NCT00054327-4,Regimen B-3,NCT00054327,Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer,oral mucositis
D006470,25.0,NCT00054327-4,Regimen B-3,NCT00054327,Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer,hemorrhage
D004487,33.33,NCT00054327-3,Regimen B-2,NCT00054327,Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer,edema
D009102,10.0,NCT00054327-5,Regimen C,NCT00054327,Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer,multiple organ failure
D006086,33.33,NCT00054327-3,Regimen B-2,NCT00054327,Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer,graft-versus-host disease
D008569,33.33,NCT00054327-3,Regimen B-2,NCT00054327,Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer,memory loss
D000339,25.0,NCT00054327-4,Regimen B-3,NCT00054327,Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer,mood
D003221,25.0,NCT00054327-4,Regimen B-3,NCT00054327,Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer,confusion
D006417,25.0,NCT00054327-4,Regimen B-3,NCT00054327,Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer,hematuria
D016066,25.0,NCT00054327-4,Regimen B-3,NCT00054327,Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer,pleural effusion malignant
D004417,25.0,NCT00054327-4,Regimen B-3,NCT00054327,Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer,breath shortness
D004417,10.0,NCT00054327-5,Regimen C,NCT00054327,Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer,breath shortness
D000860,10.0,NCT00054327-5,Regimen C,NCT00054327,Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer,hypoxia
D000138,25.0,NCT00054327-4,Regimen B-3,NCT00054327,Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer,acidoses
D006973,25.0,NCT00054327-4,Regimen B-3,NCT00054327,Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer,hypertension
D064420,65.14,NCT00071799-1,Azacitidine,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,adverse drug events
D064420,69.61,NCT00071799-2,Best Supportive Care Only,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,adverse drug events
D064420,61.36,NCT00071799-3,Low-dose Cytarabine,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,adverse drug events
D064420,73.68,NCT00071799-4,Standard Chemotherapy,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,adverse drug events
D000741,6.86,NCT00071799-1,Azacitidine,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,aplastic anaemia
D000741,2.94,NCT00071799-2,Best Supportive Care Only,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,aplastic anaemia
D000741,4.55,NCT00071799-3,Low-dose Cytarabine,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,aplastic anaemia
D000080983,1.14,NCT00071799-1,Azacitidine,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,bone marrow failure
D000080983,5.26,NCT00071799-4,Standard Chemotherapy,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,bone marrow failure
D001853,4.55,NCT00071799-3,Low-dose Cytarabine,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,bone marrow
D064147,10.86,NCT00071799-1,Azacitidine,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,febrile neutropenia
D064147,2.94,NCT00071799-2,Best Supportive Care Only,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,febrile neutropenia
D064147,2.27,NCT00071799-3,Low-dose Cytarabine,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,febrile neutropenia
D064147,26.32,NCT00071799-4,Standard Chemotherapy,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,febrile neutropenia
D006461,0.98,NCT00071799-2,Best Supportive Care Only,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,haemolysis
D004198,5.26,NCT00071799-4,Standard Chemotherapy,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,diathesis
D007964,2.27,NCT00071799-3,Low-dose Cytarabine,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,leukocytosis
D007970,0.57,NCT00071799-1,Azacitidine,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,leukopenia
D009503,2.86,NCT00071799-1,Azacitidine,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,neutropenia
D009503,5.26,NCT00071799-4,Standard Chemotherapy,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,neutropenia
D010198,1.14,NCT00071799-1,Azacitidine,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,pancytopenia
D013921,4.57,NCT00071799-1,Azacitidine,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,thrombocytopenia
D013921,1.96,NCT00071799-2,Best Supportive Care Only,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,thrombocytopenia
D013921,4.55,NCT00071799-3,Low-dose Cytarabine,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,thrombocytopenia
D013921,5.26,NCT00071799-4,Standard Chemotherapy,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,thrombocytopenia
D056988,0.98,NCT00071799-2,Best Supportive Care Only,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,acute anterior wall myocardial infarction
D000787,1.14,NCT00071799-1,Azacitidine,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,angina pectoris
D000787,0.98,NCT00071799-2,Best Supportive Care Only,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,angina pectoris
D001281,0.57,NCT00071799-1,Azacitidine,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,atrial fibrillation
D001281,0.98,NCT00071799-2,Best Supportive Care Only,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,atrial fibrillation
D001281,5.26,NCT00071799-4,Standard Chemotherapy,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,atrial fibrillation
D006333,1.71,NCT00071799-1,Azacitidine,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,cardiac failure
D006333,1.96,NCT00071799-2,Best Supportive Care Only,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,cardiac failure
D006333,2.27,NCT00071799-3,Low-dose Cytarabine,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,cardiac failure
D006333,1.14,NCT00071799-1,Azacitidine,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,cardiac failure
D006333,0.98,NCT00071799-2,Best Supportive Care Only,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,cardiac failure
D006333,1.96,NCT00071799-2,Best Supportive Care Only,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,cardiac failure
D009202,0.98,NCT00071799-2,Best Supportive Care Only,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,cardiomyopathy
D003324,5.26,NCT00071799-4,Standard Chemotherapy,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,coronary artery disease
D003331,0.98,NCT00071799-2,Best Supportive Care Only,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,artery coronary
D016277,0.98,NCT00071799-2,Best Supportive Care Only,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,ventricular function left
D009203,1.14,NCT00071799-1,Azacitidine,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,myocardial infarction
D009203,5.26,NCT00071799-4,Standard Chemotherapy,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,myocardial infarction
D010490,0.57,NCT00071799-1,Azacitidine,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,pericardial effusion
D017180,0.57,NCT00071799-1,Azacitidine,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,ventricular tachycardia
D014717,0.57,NCT00071799-1,Azacitidine,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,vertigo
D014717,1.96,NCT00071799-2,Best Supportive Care Only,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,vertigo
10047386,0.98,NCT00071799-2,Best Supportive Care Only,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,vestibular disorder
D007037,0.57,NCT00071799-1,Azacitidine,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,hypothyroidism
D015812,0.57,NCT00071799-1,Azacitidine,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,angle closure glaucoma
D009877,0.57,NCT00071799-1,Azacitidine,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,endophthalmitis
D001248,1.14,NCT00071799-1,Azacitidine,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,eyestrain
D009216,0.57,NCT00071799-1,Azacitidine,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,myopia
D015356,0.57,NCT00071799-1,Azacitidine,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,retinal artery occlusion
D012172,0.57,NCT00071799-1,Azacitidine,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,retinaldehyde
D012167,0.57,NCT00071799-1,Azacitidine,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,retinal tear
D013285,0.57,NCT00071799-1,Azacitidine,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,strabismus
D015746,1.14,NCT00071799-1,Azacitidine,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,abdominal pain
D005401,0.98,NCT00071799-2,Best Supportive Care Only,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,anal fissure
D012003,2.27,NCT00071799-3,Low-dose Cytarabine,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,anal fistula
UNKNOWN-check-for-typo,2.27,NCT00071799-3,Low-dose Cytarabine,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,D00
D003093,0.57,NCT00071799-1,Azacitidine,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,ulcerative colitis
D003248,0.57,NCT00071799-1,Azacitidine,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,constipation
UNKNOWN-check-for-typo,0.98,NCT00071799-2,Best Supportive Care Only,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,D00
D003680,5.26,NCT00071799-4,Standard Chemotherapy,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,dysphagia
D005517,0.57,NCT00071799-1,Azacitidine,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,food poisoning
D005756,0.98,NCT00071799-2,Best Supportive Care Only,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,gastritis
D005756,0.98,NCT00071799-2,Best Supportive Care Only,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,gastritis
D000069196,0.57,NCT00071799-1,Azacitidine,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,gastrointestinal microbiome
D000069196,0.98,NCT00071799-2,Best Supportive Care Only,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,gastrointestinal microbiome
D010512,1.14,NCT00071799-1,Azacitidine,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,bleeding on probing gingival
UNKNOWN-check-for-typo,0.57,NCT00071799-1,Azacitidine,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,D00
D000074042,0.57,NCT00071799-1,Azacitidine,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,cerebral intraventricular haemorrhage
D007079,2.27,NCT00071799-3,Low-dose Cytarabine,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,ileitis
D000069196,0.57,NCT00071799-1,Azacitidine,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,gastrointestinal microbiome
10065891,0.98,NCT00071799-2,Best Supportive Care Only,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,large intestinal anastomotic leak
D050686,1.96,NCT00071799-2,Best Supportive Care Only,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,globicephala melaena
D009055,0.57,NCT00071799-1,Azacitidine,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,mouth
D044504,10.53,NCT00071799-4,Standard Chemotherapy,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,enterocolitis neutropenic
D000071056,1.14,NCT00071799-1,Azacitidine,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,anorectal malformations
D013280,0.57,NCT00071799-1,Azacitidine,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,stomatitis
10021328,0.57,NCT00071799-1,Azacitidine,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,ileus
10044030,0.57,NCT00071799-1,Azacitidine,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,tooth development disorder
D001247,0.57,NCT00071799-1,Azacitidine,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,asthenia
D001247,2.27,NCT00071799-3,Low-dose Cytarabine,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,asthenia
D000077215,2.27,NCT00071799-3,Low-dose Cytarabine,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,halloysite
D002637,0.57,NCT00071799-1,Azacitidine,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,chest pain
D003643,1.96,NCT00071799-2,Best Supportive Care Only,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,death
D005157,0.98,NCT00071799-2,Best Supportive Care Only,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,facial pain
D005221,0.98,NCT00071799-2,Best Supportive Care Only,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,fatigue
D003695,1.14,NCT00071799-1,Azacitidine,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,healthcare
D000075662,0.57,NCT00071799-1,Azacitidine,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,injection site reaction
D000075662,0.57,NCT00071799-1,Azacitidine,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,injection site reaction
D007249,2.27,NCT00071799-3,Low-dose Cytarabine,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,inflammation
D007249,5.26,NCT00071799-4,Standard Chemotherapy,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,inflammation
D010146,2.27,NCT00071799-3,Low-dose Cytarabine,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,pain
D005334,5.71,NCT00071799-1,Azacitidine,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,pyrexia
D005334,2.94,NCT00071799-2,Best Supportive Care Only,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,pyrexia
D005334,11.36,NCT00071799-3,Low-dose Cytarabine,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,pyrexia
D042882,0.57,NCT00071799-1,Azacitidine,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,gallstones common bile duct
D011681,0.57,NCT00071799-1,Azacitidine,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,pupillary functions abnormal
D004342,0.98,NCT00071799-2,Best Supportive Care Only,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,drug hypersensitivity
D018784,0.57,NCT00071799-1,Azacitidine,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,abdominal abscess
D000038,0.57,NCT00071799-1,Azacitidine,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,abscess
D000069544,2.27,NCT00071799-3,Low-dose Cytarabine,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,encephalitis infection
D001228,5.26,NCT00071799-4,Standard Chemotherapy,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,aspergillosis
UNKNOWN-check-for-typo,1.14,NCT00071799-1,Azacitidine,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,D00
UNKNOWN-check-for-typo,10.53,NCT00071799-4,Standard Chemotherapy,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,D00
D001991,0.57,NCT00071799-1,Azacitidine,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,bronchitis
D001991,2.27,NCT00071799-3,Low-dose Cytarabine,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,bronchitis
D001996,1.71,NCT00071799-1,Azacitidine,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,bronchopneumonia
D001996,2.94,NCT00071799-2,Best Supportive Care Only,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,bronchopneumonia
D002177,2.27,NCT00071799-3,Low-dose Cytarabine,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,candidiasis
D002481,1.14,NCT00071799-1,Azacitidine,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,cellulitis
D002481,1.96,NCT00071799-2,Best Supportive Care Only,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,cellulitis
D002481,4.55,NCT00071799-3,Low-dose Cytarabine,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,cellulitis
D004761,0.57,NCT00071799-1,Azacitidine,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,clostridium enterocolitis
D003354,0.57,NCT00071799-1,Azacitidine,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,corynebacterium infection
D010283,2.27,NCT00071799-3,Low-dose Cytarabine,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,paratuberculosis
D004238,5.26,NCT00071799-4,Standard Chemotherapy,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,diverticulitis
D010031,0.57,NCT00071799-1,Azacitidine,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,ear infection
D004754,0.57,NCT00071799-1,Azacitidine,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,enterobacter
D000985,1.96,NCT00071799-2,Best Supportive Care Only,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,antisepsis
D014552,0.98,NCT00071799-2,Best Supportive Care Only,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,urinary tract infections
D000985,0.57,NCT00071799-1,Azacitidine,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,antisepsis
D000985,2.27,NCT00071799-3,Low-dose Cytarabine,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,antisepsis
UNKNOWN-check-for-typo,0.57,NCT00071799-1,Azacitidine,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,D00
UNKNOWN-check-for-typo,0.98,NCT00071799-2,Best Supportive Care Only,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,D00
D012475,0.57,NCT00071799-1,Azacitidine,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,salmonella
D000069544,0.98,NCT00071799-2,Best Supportive Care Only,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,encephalitis infection
D006562,0.57,NCT00071799-1,Azacitidine,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,herpes zoster
D007239,0.98,NCT00071799-2,Best Supportive Care Only,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,infection
D007239,5.26,NCT00071799-4,Standard Chemotherapy,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,infection
D007709,5.26,NCT00071799-4,Standard Chemotherapy,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,klebsiella
10034835,0.57,NCT00071799-1,Azacitidine,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,pharyngitis
D011014,0.57,NCT00071799-1,Azacitidine,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,lobar pneumonia
D012141,1.14,NCT00071799-1,Azacitidine,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,respiratory tract infections
10061229,1.14,NCT00071799-1,Azacitidine,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,lung infection
D008581,0.57,NCT00071799-1,Azacitidine,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,meningitis
D009091,0.57,NCT00071799-1,Azacitidine,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,mucormycosis
D000069544,0.57,NCT00071799-1,Azacitidine,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,encephalitis infection
D000985,2.29,NCT00071799-1,Azacitidine,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,antisepsis
D000985,0.98,NCT00071799-2,Best Supportive Care Only,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,antisepsis
D000985,2.27,NCT00071799-3,Low-dose Cytarabine,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,antisepsis
D000985,10.53,NCT00071799-4,Standard Chemotherapy,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,antisepsis
D013283,0.57,NCT00071799-1,Azacitidine,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,herpes simplex oral
D013283,2.27,NCT00071799-3,Low-dose Cytarabine,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,herpes simplex oral
D010309,0.57,NCT00071799-1,Azacitidine,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,parotitis
D000038,1.14,NCT00071799-1,Azacitidine,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,abscess
D011014,11.43,NCT00071799-1,Azacitidine,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,pneumonia
D011014,11.76,NCT00071799-2,Best Supportive Care Only,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,pneumonia
D011014,4.55,NCT00071799-3,Low-dose Cytarabine,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,pneumonia
D011014,15.79,NCT00071799-4,Standard Chemotherapy,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,pneumonia
D018410,0.98,NCT00071799-2,Best Supportive Care Only,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,bacterial pneumonia
D001996,0.57,NCT00071799-1,Azacitidine,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,bronchopneumonia
D001996,10.53,NCT00071799-4,Standard Chemotherapy,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,bronchopneumonia
D004761,0.98,NCT00071799-2,Best Supportive Care Only,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,pseudomembranous colitis
D000985,0.98,NCT00071799-2,Best Supportive Care Only,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,antisepsis
D014397,0.57,NCT00071799-1,Azacitidine,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,pulmonary tuberculosis
D000038,0.98,NCT00071799-2,Best Supportive Care Only,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,abscess
D012141,0.57,NCT00071799-1,Azacitidine,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,respiratory tract infection
D012141,0.98,NCT00071799-2,Best Supportive Care Only,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,respiratory tract infection
D000985,0.57,NCT00071799-1,Azacitidine,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,antisepsis
D018805,3.43,NCT00071799-1,Azacitidine,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,sepsis
D018805,2.94,NCT00071799-2,Best Supportive Care Only,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,sepsis
D018805,4.55,NCT00071799-3,Low-dose Cytarabine,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,sepsis
D012772,1.71,NCT00071799-1,Azacitidine,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,septic shock
D012772,0.98,NCT00071799-2,Best Supportive Care Only,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,septic shock
D012772,4.55,NCT00071799-3,Low-dose Cytarabine,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,septic shock
D012793,0.57,NCT00071799-1,Azacitidine,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,sialoadenitis
D000038,0.57,NCT00071799-1,Azacitidine,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,abscess
D004768,0.57,NCT00071799-1,Azacitidine,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,staphylococcal enterotoxins
D000038,0.57,NCT00071799-1,Azacitidine,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,abscess
D013369,0.57,NCT00071799-1,Azacitidine,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,subdiaphragmatic abscess
D000038,0.57,NCT00071799-1,Azacitidine,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,abscess
D014376,0.98,NCT00071799-2,Best Supportive Care Only,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,tuberculosis
D012141,1.14,NCT00071799-1,Azacitidine,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,upper respiratory tract infections
D014552,2.86,NCT00071799-1,Azacitidine,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,urinary tract infection
D014552,4.55,NCT00071799-3,Low-dose Cytarabine,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,urinary tract infection
D014552,5.26,NCT00071799-4,Standard Chemotherapy,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,urinary tract infection
D055732,1.14,NCT00071799-1,Azacitidine,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,bronchopulmonary aspergillosis
D002968,0.57,NCT00071799-1,Azacitidine,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,clavicle
10020100,0.57,NCT00071799-1,Azacitidine,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,hip fracture
D006408,2.27,NCT00071799-3,Low-dose Cytarabine,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,hematoma subdural
D012421,0.57,NCT00071799-1,Azacitidine,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,rupture
D065227,1.71,NCT00071799-1,Azacitidine,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,transfusion reaction
D065227,2.27,NCT00071799-3,Low-dose Cytarabine,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,transfusion reaction
D020198,0.57,NCT00071799-1,Azacitidine,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,intracranial hemorrhage traumatic
D034941,0.98,NCT00071799-2,Best Supportive Care Only,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,upper limb
D003920,0.57,NCT00071799-1,Azacitidine,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,diabetes mellitus
UNKNOWN-check-for-typo,0.98,NCT00071799-2,Best Supportive Care Only,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,D00
UNKNOWN-check-for-typo,0.98,NCT00071799-2,Best Supportive Care Only,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,D00
UNKNOWN-check-for-typo,0.98,NCT00071799-2,Best Supportive Care Only,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,D00
D018771,0.98,NCT00071799-2,Best Supportive Care Only,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,arthralgia
D001168,0.98,NCT00071799-2,Best Supportive Care Only,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,arthritis
D001416,0.98,NCT00071799-2,Best Supportive Care Only,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,back pain
D002062,0.98,NCT00071799-2,Best Supportive Care Only,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,bursitis
D000255,5.26,NCT00071799-4,Standard Chemotherapy,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,adenylpyrophosphate
D010024,0.57,NCT00071799-1,Azacitidine,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,osteoporosis
10033425,0.98,NCT00071799-2,Best Supportive Care Only,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,pain in extremity
D005598,0.98,NCT00071799-2,Best Supportive Care Only,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,pathological fracture
D015470,17.14,NCT00071799-1,Azacitidine,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,leukemia myeloid acute
D015470,34.31,NCT00071799-2,Best Supportive Care Only,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,leukemia myeloid acute
D015470,13.64,NCT00071799-3,Low-dose Cytarabine,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,leukemia myeloid acute
D015470,5.26,NCT00071799-4,Standard Chemotherapy,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,leukemia myeloid acute
D003110,0.57,NCT00071799-1,Azacitidine,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,colon cancer
D000077192,0.57,NCT00071799-1,Azacitidine,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,lung adenocarcinoma
D009190,2.29,NCT00071799-1,Azacitidine,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,myelodysplastic syndrome
D009190,1.96,NCT00071799-2,Best Supportive Care Only,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,myelodysplastic syndrome
D009190,2.27,NCT00071799-3,Low-dose Cytarabine,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,myelodysplastic syndrome
D055728,0.57,NCT00071799-1,Azacitidine,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,myelofibrosis
D011471,0.57,NCT00071799-1,Azacitidine,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,prostate neoplasm
D000230,0.57,NCT00071799-1,Azacitidine,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,adenocarcinoma
D002294,0.57,NCT00071799-1,Azacitidine,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,carcinoma squamous cell
D014571,0.57,NCT00071799-1,Azacitidine,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,urinary tract neoplasm
D000074042,2.29,NCT00071799-1,Azacitidine,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,cerebral intraventricular haemorrhage
D000074042,2.94,NCT00071799-2,Best Supportive Care Only,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,cerebral intraventricular haemorrhage
D000070624,2.27,NCT00071799-3,Low-dose Cytarabine,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,cerebral contusion
D003128,0.57,NCT00071799-1,Azacitidine,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,coma
D012640,0.98,NCT00071799-2,Best Supportive Care Only,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,convulsion
D004244,5.26,NCT00071799-4,Standard Chemotherapy,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,dizziness
D004830,0.98,NCT00071799-2,Best Supportive Care Only,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,grand mal convulsion
D000069280,0.57,NCT00071799-1,Azacitidine,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,intracranial electroencephalography
D000069280,0.98,NCT00071799-2,Best Supportive Care Only,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,intracranial electroencephalography
D006261,0.98,NCT00071799-2,Best Supportive Care Only,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,headache
D000069280,0.98,NCT00071799-2,Best Supportive Care Only,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,intracranial electroencephalography
D014474,0.57,NCT00071799-1,Azacitidine,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,loss of consciousness
D000077260,2.27,NCT00071799-3,Low-dose Cytarabine,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,somnolence
D013575,1.14,NCT00071799-1,Azacitidine,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,syncope
D002546,0.57,NCT00071799-1,Azacitidine,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,ischemic attack transient
D003221,0.57,NCT00071799-1,Azacitidine,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,confusional state
D003693,0.57,NCT00071799-1,Azacitidine,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,delirium
D003863,0.57,NCT00071799-1,Azacitidine,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,depression
D011618,0.57,NCT00071799-1,Azacitidine,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,psychotic disorder
UNKNOWN-check-for-typo,1.14,NCT00071799-1,Azacitidine,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,D00
UNKNOWN-check-for-typo,0.98,NCT00071799-2,Best Supportive Care Only,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,D00
D053040,0.98,NCT00071799-2,Best Supportive Care Only,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,nephrolithiasis
D056844,0.57,NCT00071799-1,Azacitidine,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,renal colic
D051437,0.57,NCT00071799-1,Azacitidine,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,renal failure
D051437,0.98,NCT00071799-2,Best Supportive Care Only,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,renal failure
D058186,1.96,NCT00071799-2,Best Supportive Care Only,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,acute renal failure
D000308,0.98,NCT00071799-2,Best Supportive Care Only,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,hyperadrenalism
D014525,0.57,NCT00071799-1,Azacitidine,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,urethral stenosis
D016055,0.57,NCT00071799-1,Azacitidine,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,urinary retention
D011470,0.57,NCT00071799-1,Azacitidine,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,benign prostatic hyperplasia
D008796,0.98,NCT00071799-2,Best Supportive Care Only,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,metrorrhagia
D011472,0.98,NCT00071799-2,Best Supportive Care Only,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,prostatitis
D000069339,0.98,NCT00071799-2,Best Supportive Care Only,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,vaginal cervicectomy
D000799,0.57,NCT00071799-1,Azacitidine,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,angioedema
D012131,0.57,NCT00071799-1,Azacitidine,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,respiratory failure
D029481,0.98,NCT00071799-2,Best Supportive Care Only,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,chronic bronchitis
D029424,0.98,NCT00071799-2,Best Supportive Care Only,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,chronic obstructive pulmonary disease
D004844,2.29,NCT00071799-1,Azacitidine,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,epistaxis
D004844,2.94,NCT00071799-2,Best Supportive Care Only,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,epistaxis
D004844,4.55,NCT00071799-3,Low-dose Cytarabine,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,epistaxis
UNKNOWN-check-for-typo,0.57,NCT00071799-1,Azacitidine,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,D00
UNKNOWN-check-for-typo,2.27,NCT00071799-3,Low-dose Cytarabine,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,D00
D008168,0.57,NCT00071799-1,Azacitidine,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,lung
D010996,1.14,NCT00071799-1,Azacitidine,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,pleural effusion
D010996,0.98,NCT00071799-2,Best Supportive Care Only,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,pleural effusion
10035623,0.98,NCT00071799-2,Best Supportive Care Only,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,pleuritic pain
D011014,0.57,NCT00071799-1,Azacitidine,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,pneumonitis
D011655,0.57,NCT00071799-1,Azacitidine,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,pulmonary embolism
D011655,5.26,NCT00071799-4,Standard Chemotherapy,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,pulmonary embolism
D011658,0.57,NCT00071799-1,Azacitidine,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,pulmonary fibrosis
D006976,0.98,NCT00071799-2,Best Supportive Care Only,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,pulmonary hypertension
D012131,0.57,NCT00071799-1,Azacitidine,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,respiratory failure
D012131,0.98,NCT00071799-2,Best Supportive Care Only,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,respiratory failure
D055623,0.57,NCT00071799-1,Azacitidine,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,actinic keratosis
D011537,0.57,NCT00071799-1,Azacitidine,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,pruritus
D011693,2.27,NCT00071799-3,Low-dose Cytarabine,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,purpura
D001014,0.57,NCT00071799-1,Azacitidine,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,aortic aneurysm
D012769,0.57,NCT00071799-1,Azacitidine,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,circulatory collapse
D007022,0.98,NCT00071799-2,Best Supportive Care Only,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,hypotension
D012769,0.98,NCT00071799-2,Best Supportive Care Only,NCT00071799,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,shock
D009026,57.1,NCT00078949-1,Salvage GDP,NCT00078949,Chemotherapy Before Autologous Stem Cell Transplantation +/- Rituximab in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma,mortality
D009026,58.58,NCT00078949-2,Salvage DHAP,NCT00078949,Chemotherapy Before Autologous Stem Cell Transplantation +/- Rituximab in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma,mortality
D009026,33.91,NCT00078949-3,Maintenance,NCT00078949,Chemotherapy Before Autologous Stem Cell Transplantation +/- Rituximab in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma,mortality
D009026,36.52,NCT00078949-4,Observation,NCT00078949,Chemotherapy Before Autologous Stem Cell Transplantation +/- Rituximab in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma,mortality
D064420,11.76,NCT00078949-1,Salvage GDP,NCT00078949,Chemotherapy Before Autologous Stem Cell Transplantation +/- Rituximab in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma,adverse drug events
D064420,8.55,NCT00078949-2,Salvage DHAP,NCT00078949,Chemotherapy Before Autologous Stem Cell Transplantation +/- Rituximab in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma,adverse drug events
D064420,14.29,NCT00078949-3,Maintenance,NCT00078949,Chemotherapy Before Autologous Stem Cell Transplantation +/- Rituximab in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma,adverse drug events
D064420,7.14,NCT00078949-4,Observation,NCT00078949,Chemotherapy Before Autologous Stem Cell Transplantation +/- Rituximab in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma,adverse drug events
D006454,0.33,NCT00078949-1,Salvage GDP,NCT00078949,Chemotherapy Before Autologous Stem Cell Transplantation +/- Rituximab in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma,hemoglobin
D003606,0.33,NCT00078949-1,Salvage GDP,NCT00078949,Chemotherapy Before Autologous Stem Cell Transplantation +/- Rituximab in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma,dic
D064147,0.98,NCT00078949-1,Salvage GDP,NCT00078949,Chemotherapy Before Autologous Stem Cell Transplantation +/- Rituximab in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma,febrile neutropenia
D064147,3.62,NCT00078949-2,Salvage DHAP,NCT00078949,Chemotherapy Before Autologous Stem Cell Transplantation +/- Rituximab in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma,febrile neutropenia
D064147,2.68,NCT00078949-3,Maintenance,NCT00078949,Chemotherapy Before Autologous Stem Cell Transplantation +/- Rituximab in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma,febrile neutropenia
D064147,0.89,NCT00078949-4,Observation,NCT00078949,Chemotherapy Before Autologous Stem Cell Transplantation +/- Rituximab in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma,febrile neutropenia
D004487,0.33,NCT00078949-1,Salvage GDP,NCT00078949,Chemotherapy Before Autologous Stem Cell Transplantation +/- Rituximab in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma,edema
D007238,0.33,NCT00078949-1,Salvage GDP,NCT00078949,Chemotherapy Before Autologous Stem Cell Transplantation +/- Rituximab in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma,infarction
D007238,0.33,NCT00078949-2,Salvage DHAP,NCT00078949,Chemotherapy Before Autologous Stem Cell Transplantation +/- Rituximab in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma,infarction
D010490,0.33,NCT00078949-2,Salvage DHAP,NCT00078949,Chemotherapy Before Autologous Stem Cell Transplantation +/- Rituximab in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma,pericardial effusion
D013616,0.33,NCT00078949-2,Salvage DHAP,NCT00078949,Chemotherapy Before Autologous Stem Cell Transplantation +/- Rituximab in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma,sinus tachycardia
D003092,0.66,NCT00078949-2,Salvage DHAP,NCT00078949,Chemotherapy Before Autologous Stem Cell Transplantation +/- Rituximab in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma,colitis
D003092,0.89,NCT00078949-3,Maintenance,NCT00078949,Chemotherapy Before Autologous Stem Cell Transplantation +/- Rituximab in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma,colitis
D003092,0.89,NCT00078949-4,Observation,NCT00078949,Chemotherapy Before Autologous Stem Cell Transplantation +/- Rituximab in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma,colitis
D003248,0.89,NCT00078949-3,Maintenance,NCT00078949,Chemotherapy Before Autologous Stem Cell Transplantation +/- Rituximab in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma,constipation
D003967,0.65,NCT00078949-1,Salvage GDP,NCT00078949,Chemotherapy Before Autologous Stem Cell Transplantation +/- Rituximab in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma,diarrhea
D003967,0.66,NCT00078949-2,Salvage DHAP,NCT00078949,Chemotherapy Before Autologous Stem Cell Transplantation +/- Rituximab in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma,diarrhea
D003967,2.68,NCT00078949-3,Maintenance,NCT00078949,Chemotherapy Before Autologous Stem Cell Transplantation +/- Rituximab in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma,diarrhea
D003680,0.33,NCT00078949-1,Salvage GDP,NCT00078949,Chemotherapy Before Autologous Stem Cell Transplantation +/- Rituximab in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma,dysphagia
D009325,1.31,NCT00078949-1,Salvage GDP,NCT00078949,Chemotherapy Before Autologous Stem Cell Transplantation +/- Rituximab in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma,nausea
D009325,1.79,NCT00078949-3,Maintenance,NCT00078949,Chemotherapy Before Autologous Stem Cell Transplantation +/- Rituximab in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma,nausea
D009325,0.89,NCT00078949-4,Observation,NCT00078949,Chemotherapy Before Autologous Stem Cell Transplantation +/- Rituximab in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma,nausea
D004381,0.33,NCT00078949-1,Salvage GDP,NCT00078949,Chemotherapy Before Autologous Stem Cell Transplantation +/- Rituximab in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma,duodenal ulcer
D013276,0.33,NCT00078949-1,Salvage GDP,NCT00078949,Chemotherapy Before Autologous Stem Cell Transplantation +/- Rituximab in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma,gastric ulcer
D013276,0.89,NCT00078949-3,Maintenance,NCT00078949,Chemotherapy Before Autologous Stem Cell Transplantation +/- Rituximab in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma,gastric ulcer
D014839,0.65,NCT00078949-1,Salvage GDP,NCT00078949,Chemotherapy Before Autologous Stem Cell Transplantation +/- Rituximab in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma,vomiting
D014839,0.66,NCT00078949-2,Salvage DHAP,NCT00078949,Chemotherapy Before Autologous Stem Cell Transplantation +/- Rituximab in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma,vomiting
D014839,1.79,NCT00078949-3,Maintenance,NCT00078949,Chemotherapy Before Autologous Stem Cell Transplantation +/- Rituximab in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma,vomiting
D006470,0.33,NCT00078949-1,Salvage GDP,NCT00078949,Chemotherapy Before Autologous Stem Cell Transplantation +/- Rituximab in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma,bleeding
D006470,0.33,NCT00078949-1,Salvage GDP,NCT00078949,Chemotherapy Before Autologous Stem Cell Transplantation +/- Rituximab in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma,bleeding
D006470,0.33,NCT00078949-2,Salvage DHAP,NCT00078949,Chemotherapy Before Autologous Stem Cell Transplantation +/- Rituximab in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma,bleeding
D006396,0.33,NCT00078949-1,Salvage GDP,NCT00078949,Chemotherapy Before Autologous Stem Cell Transplantation +/- Rituximab in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma,hematemesis
D015746,1.31,NCT00078949-1,Salvage GDP,NCT00078949,Chemotherapy Before Autologous Stem Cell Transplantation +/- Rituximab in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma,abdominal pain
D015746,0.66,NCT00078949-2,Salvage DHAP,NCT00078949,Chemotherapy Before Autologous Stem Cell Transplantation +/- Rituximab in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma,abdominal pain
D015746,0.89,NCT00078949-3,Maintenance,NCT00078949,Chemotherapy Before Autologous Stem Cell Transplantation +/- Rituximab in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma,abdominal pain
D015746,0.89,NCT00078949-4,Observation,NCT00078949,Chemotherapy Before Autologous Stem Cell Transplantation +/- Rituximab in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma,abdominal pain
D005221,0.33,NCT00078949-2,Salvage DHAP,NCT00078949,Chemotherapy Before Autologous Stem Cell Transplantation +/- Rituximab in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma,fatigue
D000080867,0.65,NCT00078949-1,Salvage GDP,NCT00078949,Chemotherapy Before Autologous Stem Cell Transplantation +/- Rituximab in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma,gingipains
D000080867,0.89,NCT00078949-3,Maintenance,NCT00078949,Chemotherapy Before Autologous Stem Cell Transplantation +/- Rituximab in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma,gingipains
D000080867,0.89,NCT00078949-4,Observation,NCT00078949,Chemotherapy Before Autologous Stem Cell Transplantation +/- Rituximab in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma,gingipains
D000066502,0.33,NCT00078949-1,Salvage GDP,NCT00078949,Chemotherapy Before Autologous Stem Cell Transplantation +/- Rituximab in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma,grandmother
D000066502,0.33,NCT00078949-2,Salvage DHAP,NCT00078949,Chemotherapy Before Autologous Stem Cell Transplantation +/- Rituximab in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma,grandmother
D000066502,0.98,NCT00078949-1,Salvage GDP,NCT00078949,Chemotherapy Before Autologous Stem Cell Transplantation +/- Rituximab in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma,grandmother
D000066502,0.89,NCT00078949-4,Observation,NCT00078949,Chemotherapy Before Autologous Stem Cell Transplantation +/- Rituximab in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma,grandmother
D005334,0.98,NCT00078949-1,Salvage GDP,NCT00078949,Chemotherapy Before Autologous Stem Cell Transplantation +/- Rituximab in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma,fever
D005334,0.99,NCT00078949-2,Salvage DHAP,NCT00078949,Chemotherapy Before Autologous Stem Cell Transplantation +/- Rituximab in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma,fever
D005334,1.79,NCT00078949-3,Maintenance,NCT00078949,Chemotherapy Before Autologous Stem Cell Transplantation +/- Rituximab in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma,fever
D000066502,0.33,NCT00078949-1,Salvage GDP,NCT00078949,Chemotherapy Before Autologous Stem Cell Transplantation +/- Rituximab in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma,grandmother
D000066502,0.89,NCT00078949-3,Maintenance,NCT00078949,Chemotherapy Before Autologous Stem Cell Transplantation +/- Rituximab in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma,grandmother
D000066502,0.33,NCT00078949-1,Salvage GDP,NCT00078949,Chemotherapy Before Autologous Stem Cell Transplantation +/- Rituximab in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma,grandmother
D014947,0.33,NCT00078949-1,Salvage GDP,NCT00078949,Chemotherapy Before Autologous Stem Cell Transplantation +/- Rituximab in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma,wounds
D006098,0.65,NCT00078949-1,Salvage GDP,NCT00078949,Chemotherapy Before Autologous Stem Cell Transplantation +/- Rituximab in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma,granulocytes
D006098,0.89,NCT00078949-3,Maintenance,NCT00078949,Chemotherapy Before Autologous Stem Cell Transplantation +/- Rituximab in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma,granulocytes
D008231,0.33,NCT00078949-1,Salvage GDP,NCT00078949,Chemotherapy Before Autologous Stem Cell Transplantation +/- Rituximab in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma,lymphopenia
D001792,0.33,NCT00078949-2,Salvage DHAP,NCT00078949,Chemotherapy Before Autologous Stem Cell Transplantation +/- Rituximab in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma,platelets
D007962,0.33,NCT00078949-1,Salvage GDP,NCT00078949,Chemotherapy Before Autologous Stem Cell Transplantation +/- Rituximab in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma,leukocytes
D007962,0.33,NCT00078949-2,Salvage DHAP,NCT00078949,Chemotherapy Before Autologous Stem Cell Transplantation +/- Rituximab in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma,leukocytes
10007612,0.33,NCT00078949-2,Salvage DHAP,NCT00078949,Chemotherapy Before Autologous Stem Cell Transplantation +/- Rituximab in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma,cardiac troponin i increased
D003404,0.33,NCT00078949-1,Salvage GDP,NCT00078949,Chemotherapy Before Autologous Stem Cell Transplantation +/- Rituximab in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma,creatinine
D003404,0.66,NCT00078949-2,Salvage DHAP,NCT00078949,Chemotherapy Before Autologous Stem Cell Transplantation +/- Rituximab in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma,creatinine
D003404,0.89,NCT00078949-3,Maintenance,NCT00078949,Chemotherapy Before Autologous Stem Cell Transplantation +/- Rituximab in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma,creatinine
D000068736,0.33,NCT00078949-1,Salvage GDP,NCT00078949,Chemotherapy Before Autologous Stem Cell Transplantation +/- Rituximab in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma,cymbalta
D000068258,0.33,NCT00078949-1,Salvage GDP,NCT00078949,Chemotherapy Before Autologous Stem Cell Transplantation +/- Rituximab in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma,avastin
D001663,0.33,NCT00078949-1,Salvage GDP,NCT00078949,Chemotherapy Before Autologous Stem Cell Transplantation +/- Rituximab in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma,bilirubin
D015431,0.33,NCT00078949-1,Salvage GDP,NCT00078949,Chemotherapy Before Autologous Stem Cell Transplantation +/- Rituximab in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma,weight loss
D015431,0.89,NCT00078949-3,Maintenance,NCT00078949,Chemotherapy Before Autologous Stem Cell Transplantation +/- Rituximab in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma,weight loss
D003681,0.33,NCT00078949-1,Salvage GDP,NCT00078949,Chemotherapy Before Autologous Stem Cell Transplantation +/- Rituximab in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma,dehydration
D003681,0.33,NCT00078949-2,Salvage DHAP,NCT00078949,Chemotherapy Before Autologous Stem Cell Transplantation +/- Rituximab in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma,dehydration
D003681,0.89,NCT00078949-3,Maintenance,NCT00078949,Chemotherapy Before Autologous Stem Cell Transplantation +/- Rituximab in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma,dehydration
10049737,0.65,NCT00078949-1,Salvage GDP,NCT00078949,Chemotherapy Before Autologous Stem Cell Transplantation +/- Rituximab in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma,treatment related secondary malignancy
10049737,1.32,NCT00078949-2,Salvage DHAP,NCT00078949,Chemotherapy Before Autologous Stem Cell Transplantation +/- Rituximab in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma,treatment related secondary malignancy
10049737,2.68,NCT00078949-3,Maintenance,NCT00078949,Chemotherapy Before Autologous Stem Cell Transplantation +/- Rituximab in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma,treatment related secondary malignancy
10049737,2.68,NCT00078949-4,Observation,NCT00078949,Chemotherapy Before Autologous Stem Cell Transplantation +/- Rituximab in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma,treatment related secondary malignancy
D006470,0.33,NCT00078949-1,Salvage GDP,NCT00078949,Chemotherapy Before Autologous Stem Cell Transplantation +/- Rituximab in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma,hemorrhage
D008085,0.65,NCT00078949-1,Salvage GDP,NCT00078949,Chemotherapy Before Autologous Stem Cell Transplantation +/- Rituximab in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma,speechreading
D002607,0.33,NCT00078949-1,Salvage GDP,NCT00078949,Chemotherapy Before Autologous Stem Cell Transplantation +/- Rituximab in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma,hereditary type i motor and sensory neuropathy
D013575,0.33,NCT00078949-1,Salvage GDP,NCT00078949,Chemotherapy Before Autologous Stem Cell Transplantation +/- Rituximab in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma,syncope
D013575,0.89,NCT00078949-3,Maintenance,NCT00078949,Chemotherapy Before Autologous Stem Cell Transplantation +/- Rituximab in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma,syncope
D006261,0.33,NCT00078949-1,Salvage GDP,NCT00078949,Chemotherapy Before Autologous Stem Cell Transplantation +/- Rituximab in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma,headache
D006261,0.89,NCT00078949-3,Maintenance,NCT00078949,Chemotherapy Before Autologous Stem Cell Transplantation +/- Rituximab in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma,headache
D003221,0.33,NCT00078949-2,Salvage DHAP,NCT00078949,Chemotherapy Before Autologous Stem Cell Transplantation +/- Rituximab in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma,confusion
D051437,0.33,NCT00078949-2,Salvage DHAP,NCT00078949,Chemotherapy Before Autologous Stem Cell Transplantation +/- Rituximab in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma,renal failure
D053159,0.33,NCT00078949-1,Salvage GDP,NCT00078949,Chemotherapy Before Autologous Stem Cell Transplantation +/- Rituximab in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma,dysuria
D006417,0.65,NCT00078949-1,Salvage GDP,NCT00078949,Chemotherapy Before Autologous Stem Cell Transplantation +/- Rituximab in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma,hematuria
D000069098,0.33,NCT00078949-2,Salvage DHAP,NCT00078949,Chemotherapy Before Autologous Stem Cell Transplantation +/- Rituximab in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma,health smart cards
D003371,0.33,NCT00078949-2,Salvage DHAP,NCT00078949,Chemotherapy Before Autologous Stem Cell Transplantation +/- Rituximab in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma,cough
D010996,0.33,NCT00078949-1,Salvage GDP,NCT00078949,Chemotherapy Before Autologous Stem Cell Transplantation +/- Rituximab in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma,pleural effusion
D004417,0.65,NCT00078949-1,Salvage GDP,NCT00078949,Chemotherapy Before Autologous Stem Cell Transplantation +/- Rituximab in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma,dyspnea
D004417,0.99,NCT00078949-2,Salvage DHAP,NCT00078949,Chemotherapy Before Autologous Stem Cell Transplantation +/- Rituximab in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma,dyspnea
D004417,1.79,NCT00078949-3,Maintenance,NCT00078949,Chemotherapy Before Autologous Stem Cell Transplantation +/- Rituximab in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma,dyspnea
D006973,0.33,NCT00078949-2,Salvage DHAP,NCT00078949,Chemotherapy Before Autologous Stem Cell Transplantation +/- Rituximab in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma,hypertension
D007022,0.33,NCT00078949-1,Salvage GDP,NCT00078949,Chemotherapy Before Autologous Stem Cell Transplantation +/- Rituximab in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma,hypotension
D007022,0.33,NCT00078949-2,Salvage DHAP,NCT00078949,Chemotherapy Before Autologous Stem Cell Transplantation +/- Rituximab in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma,hypotension
D007022,0.89,NCT00078949-3,Maintenance,NCT00078949,Chemotherapy Before Autologous Stem Cell Transplantation +/- Rituximab in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma,hypotension
D002542,1.63,NCT00078949-1,Salvage GDP,NCT00078949,Chemotherapy Before Autologous Stem Cell Transplantation +/- Rituximab in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma,intracranial embolism and thrombosis
D002542,0.66,NCT00078949-2,Salvage DHAP,NCT00078949,Chemotherapy Before Autologous Stem Cell Transplantation +/- Rituximab in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma,intracranial embolism and thrombosis
D002542,2.68,NCT00078949-3,Maintenance,NCT00078949,Chemotherapy Before Autologous Stem Cell Transplantation +/- Rituximab in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma,intracranial embolism and thrombosis
D002542,0.89,NCT00078949-4,Observation,NCT00078949,Chemotherapy Before Autologous Stem Cell Transplantation +/- Rituximab in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma,intracranial embolism and thrombosis
D064420,16.04,NCT00085709-1,Induction 7 + 3 + G.O.,NCT00085709,S0106 Cytarabine and Daunorubicin w/ or w/o Gemtuzumab Followed By HD Cytarabine and Either Gemtuzumab or Nothing in de Novo AML,adverse drug events
D064420,3.07,NCT00085709-2,Induction 7 + 3,NCT00085709,S0106 Cytarabine and Daunorubicin w/ or w/o Gemtuzumab Followed By HD Cytarabine and Either Gemtuzumab or Nothing in de Novo AML,adverse drug events
D064420,3.47,NCT00085709-3,Ara-C Consolidation,NCT00085709,S0106 Cytarabine and Daunorubicin w/ or w/o Gemtuzumab Followed By HD Cytarabine and Either Gemtuzumab or Nothing in de Novo AML,adverse drug events
D064420,24.36,NCT00085709-4,Post-consolidation G.O.,NCT00085709,S0106 Cytarabine and Daunorubicin w/ or w/o Gemtuzumab Followed By HD Cytarabine and Either Gemtuzumab or Nothing in de Novo AML,adverse drug events
D004211,0.34,NCT00085709-1,Induction 7 + 3 + G.O.,NCT00085709,S0106 Cytarabine and Daunorubicin w/ or w/o Gemtuzumab Followed By HD Cytarabine and Either Gemtuzumab or Nothing in de Novo AML,disseminated intravascular coagulation
D064147,2.39,NCT00085709-1,Induction 7 + 3 + G.O.,NCT00085709,S0106 Cytarabine and Daunorubicin w/ or w/o Gemtuzumab Followed By HD Cytarabine and Either Gemtuzumab or Nothing in de Novo AML,febrile neutropenia
D064147,0.34,NCT00085709-2,Induction 7 + 3,NCT00085709,S0106 Cytarabine and Daunorubicin w/ or w/o Gemtuzumab Followed By HD Cytarabine and Either Gemtuzumab or Nothing in de Novo AML,febrile neutropenia
D064147,1.07,NCT00085709-3,Ara-C Consolidation,NCT00085709,S0106 Cytarabine and Daunorubicin w/ or w/o Gemtuzumab Followed By HD Cytarabine and Either Gemtuzumab or Nothing in de Novo AML,febrile neutropenia
D064147,11.54,NCT00085709-4,Post-consolidation G.O.,NCT00085709,S0106 Cytarabine and Daunorubicin w/ or w/o Gemtuzumab Followed By HD Cytarabine and Either Gemtuzumab or Nothing in de Novo AML,febrile neutropenia
D006454,0.34,NCT00085709-1,Induction 7 + 3 + G.O.,NCT00085709,S0106 Cytarabine and Daunorubicin w/ or w/o Gemtuzumab Followed By HD Cytarabine and Either Gemtuzumab or Nothing in de Novo AML,hemoglobin
D006342,0.34,NCT00085709-1,Induction 7 + 3 + G.O.,NCT00085709,S0106 Cytarabine and Daunorubicin w/ or w/o Gemtuzumab Followed By HD Cytarabine and Either Gemtuzumab or Nothing in de Novo AML,cardiac rupture post-infarction
D010490,0.34,NCT00085709-1,Induction 7 + 3 + G.O.,NCT00085709,S0106 Cytarabine and Daunorubicin w/ or w/o Gemtuzumab Followed By HD Cytarabine and Either Gemtuzumab or Nothing in de Novo AML,pericardial effusion
D010493,0.34,NCT00085709-1,Induction 7 + 3 + G.O.,NCT00085709,S0106 Cytarabine and Daunorubicin w/ or w/o Gemtuzumab Followed By HD Cytarabine and Either Gemtuzumab or Nothing in de Novo AML,pericarditis
D003092,0.34,NCT00085709-2,Induction 7 + 3,NCT00085709,S0106 Cytarabine and Daunorubicin w/ or w/o Gemtuzumab Followed By HD Cytarabine and Either Gemtuzumab or Nothing in de Novo AML,colitis
D003945,1.28,NCT00085709-4,Post-consolidation G.O.,NCT00085709,S0106 Cytarabine and Daunorubicin w/ or w/o Gemtuzumab Followed By HD Cytarabine and Either Gemtuzumab or Nothing in de Novo AML,examination oral
D009325,1.28,NCT00085709-4,Post-consolidation G.O.,NCT00085709,S0106 Cytarabine and Daunorubicin w/ or w/o Gemtuzumab Followed By HD Cytarabine and Either Gemtuzumab or Nothing in de Novo AML,nausea
D000080867,1.28,NCT00085709-4,Post-consolidation G.O.,NCT00085709,S0106 Cytarabine and Daunorubicin w/ or w/o Gemtuzumab Followed By HD Cytarabine and Either Gemtuzumab or Nothing in de Novo AML,gingipains
10010001,0.34,NCT00085709-2,Induction 7 + 3,NCT00085709,S0106 Cytarabine and Daunorubicin w/ or w/o Gemtuzumab Followed By HD Cytarabine and Either Gemtuzumab or Nothing in de Novo AML,colonic perforation
D007249,0.34,NCT00085709-1,Induction 7 + 3 + G.O.,NCT00085709,S0106 Cytarabine and Daunorubicin w/ or w/o Gemtuzumab Followed By HD Cytarabine and Either Gemtuzumab or Nothing in de Novo AML,inflammation
D007249,0.34,NCT00085709-2,Induction 7 + 3,NCT00085709,S0106 Cytarabine and Daunorubicin w/ or w/o Gemtuzumab Followed By HD Cytarabine and Either Gemtuzumab or Nothing in de Novo AML,inflammation
D014839,1.28,NCT00085709-4,Post-consolidation G.O.,NCT00085709,S0106 Cytarabine and Daunorubicin w/ or w/o Gemtuzumab Followed By HD Cytarabine and Either Gemtuzumab or Nothing in de Novo AML,vomiting
D009102,0.34,NCT00085709-1,Induction 7 + 3 + G.O.,NCT00085709,S0106 Cytarabine and Daunorubicin w/ or w/o Gemtuzumab Followed By HD Cytarabine and Either Gemtuzumab or Nothing in de Novo AML,multiple organ failure
D001037,0.34,NCT00085709-1,Induction 7 + 3 + G.O.,NCT00085709,S0106 Cytarabine and Daunorubicin w/ or w/o Gemtuzumab Followed By HD Cytarabine and Either Gemtuzumab or Nothing in de Novo AML,logasthenia
D013577,0.27,NCT00085709-3,Ara-C Consolidation,NCT00085709,S0106 Cytarabine and Daunorubicin w/ or w/o Gemtuzumab Followed By HD Cytarabine and Either Gemtuzumab or Nothing in de Novo AML,syndromes
D010179,0.34,NCT00085709-1,Induction 7 + 3 + G.O.,NCT00085709,S0106 Cytarabine and Daunorubicin w/ or w/o Gemtuzumab Followed By HD Cytarabine and Either Gemtuzumab or Nothing in de Novo AML,pancreas
D008107,1.37,NCT00085709-1,Induction 7 + 3 + G.O.,NCT00085709,S0106 Cytarabine and Daunorubicin w/ or w/o Gemtuzumab Followed By HD Cytarabine and Either Gemtuzumab or Nothing in de Novo AML,liver dysfunction
D011169,0.34,NCT00085709-1,Induction 7 + 3 + G.O.,NCT00085709,S0106 Cytarabine and Daunorubicin w/ or w/o Gemtuzumab Followed By HD Cytarabine and Either Gemtuzumab or Nothing in de Novo AML,portal vein
D004342,0.68,NCT00085709-1,Induction 7 + 3 + G.O.,NCT00085709,S0106 Cytarabine and Daunorubicin w/ or w/o Gemtuzumab Followed By HD Cytarabine and Either Gemtuzumab or Nothing in de Novo AML,drug hypersensitivity
D004761,0.34,NCT00085709-1,Induction 7 + 3 + G.O.,NCT00085709,S0106 Cytarabine and Daunorubicin w/ or w/o Gemtuzumab Followed By HD Cytarabine and Either Gemtuzumab or Nothing in de Novo AML,clostridium enterocolitis
D000069544,2.73,NCT00085709-1,Induction 7 + 3 + G.O.,NCT00085709,S0106 Cytarabine and Daunorubicin w/ or w/o Gemtuzumab Followed By HD Cytarabine and Either Gemtuzumab or Nothing in de Novo AML,encephalitis infection
D000069544,0.68,NCT00085709-2,Induction 7 + 3,NCT00085709,S0106 Cytarabine and Daunorubicin w/ or w/o Gemtuzumab Followed By HD Cytarabine and Either Gemtuzumab or Nothing in de Novo AML,encephalitis infection
D000069544,0.27,NCT00085709-3,Ara-C Consolidation,NCT00085709,S0106 Cytarabine and Daunorubicin w/ or w/o Gemtuzumab Followed By HD Cytarabine and Either Gemtuzumab or Nothing in de Novo AML,encephalitis infection
D000069544,3.85,NCT00085709-4,Post-consolidation G.O.,NCT00085709,S0106 Cytarabine and Daunorubicin w/ or w/o Gemtuzumab Followed By HD Cytarabine and Either Gemtuzumab or Nothing in de Novo AML,encephalitis infection
D000069544,0.34,NCT00085709-1,Induction 7 + 3 + G.O.,NCT00085709,S0106 Cytarabine and Daunorubicin w/ or w/o Gemtuzumab Followed By HD Cytarabine and Either Gemtuzumab or Nothing in de Novo AML,encephalitis infection
D000069544,0.34,NCT00085709-1,Induction 7 + 3 + G.O.,NCT00085709,S0106 Cytarabine and Daunorubicin w/ or w/o Gemtuzumab Followed By HD Cytarabine and Either Gemtuzumab or Nothing in de Novo AML,encephalitis infection
10061229,1.02,NCT00085709-1,Induction 7 + 3 + G.O.,NCT00085709,S0106 Cytarabine and Daunorubicin w/ or w/o Gemtuzumab Followed By HD Cytarabine and Either Gemtuzumab or Nothing in de Novo AML,lung infection
10061229,0.34,NCT00085709-2,Induction 7 + 3,NCT00085709,S0106 Cytarabine and Daunorubicin w/ or w/o Gemtuzumab Followed By HD Cytarabine and Either Gemtuzumab or Nothing in de Novo AML,lung infection
10061229,0.27,NCT00085709-3,Ara-C Consolidation,NCT00085709,S0106 Cytarabine and Daunorubicin w/ or w/o Gemtuzumab Followed By HD Cytarabine and Either Gemtuzumab or Nothing in de Novo AML,lung infection
D000069544,0.34,NCT00085709-1,Induction 7 + 3 + G.O.,NCT00085709,S0106 Cytarabine and Daunorubicin w/ or w/o Gemtuzumab Followed By HD Cytarabine and Either Gemtuzumab or Nothing in de Novo AML,encephalitis infection
10040872,0.34,NCT00085709-1,Induction 7 + 3 + G.O.,NCT00085709,S0106 Cytarabine and Daunorubicin w/ or w/o Gemtuzumab Followed By HD Cytarabine and Either Gemtuzumab or Nothing in de Novo AML,skin infection
10040872,1.28,NCT00085709-4,Post-consolidation G.O.,NCT00085709,S0106 Cytarabine and Daunorubicin w/ or w/o Gemtuzumab Followed By HD Cytarabine and Either Gemtuzumab or Nothing in de Novo AML,skin infection
10021881,1.28,NCT00085709-4,Post-consolidation G.O.,NCT00085709,S0106 Cytarabine and Daunorubicin w/ or w/o Gemtuzumab Followed By HD Cytarabine and Either Gemtuzumab or Nothing in de Novo AML,infections and infestations - other specify
D000410,1.71,NCT00085709-1,Induction 7 + 3 + G.O.,NCT00085709,S0106 Cytarabine and Daunorubicin w/ or w/o Gemtuzumab Followed By HD Cytarabine and Either Gemtuzumab or Nothing in de Novo AML,glutamic-pyruvic transaminase
D000410,0.27,NCT00085709-3,Ara-C Consolidation,NCT00085709,S0106 Cytarabine and Daunorubicin w/ or w/o Gemtuzumab Followed By HD Cytarabine and Either Gemtuzumab or Nothing in de Novo AML,glutamic-pyruvic transaminase
D000410,1.28,NCT00085709-4,Post-consolidation G.O.,NCT00085709,S0106 Cytarabine and Daunorubicin w/ or w/o Gemtuzumab Followed By HD Cytarabine and Either Gemtuzumab or Nothing in de Novo AML,glutamic-pyruvic transaminase
D001219,1.37,NCT00085709-1,Induction 7 + 3 + G.O.,NCT00085709,S0106 Cytarabine and Daunorubicin w/ or w/o Gemtuzumab Followed By HD Cytarabine and Either Gemtuzumab or Nothing in de Novo AML,serum glutamic-oxaloacetic transaminase
D001219,0.27,NCT00085709-3,Ara-C Consolidation,NCT00085709,S0106 Cytarabine and Daunorubicin w/ or w/o Gemtuzumab Followed By HD Cytarabine and Either Gemtuzumab or Nothing in de Novo AML,serum glutamic-oxaloacetic transaminase
D001219,1.28,NCT00085709-4,Post-consolidation G.O.,NCT00085709,S0106 Cytarabine and Daunorubicin w/ or w/o Gemtuzumab Followed By HD Cytarabine and Either Gemtuzumab or Nothing in de Novo AML,serum glutamic-oxaloacetic transaminase
D000469,0.27,NCT00085709-3,Ara-C Consolidation,NCT00085709,S0106 Cytarabine and Daunorubicin w/ or w/o Gemtuzumab Followed By HD Cytarabine and Either Gemtuzumab or Nothing in de Novo AML,alkaline phosphatase
D003414,1.02,NCT00085709-1,Induction 7 + 3 + G.O.,NCT00085709,S0106 Cytarabine and Daunorubicin w/ or w/o Gemtuzumab Followed By HD Cytarabine and Either Gemtuzumab or Nothing in de Novo AML,familial nonhemolytic unconjugated hyperbilirubinemia
D003404,0.34,NCT00085709-1,Induction 7 + 3 + G.O.,NCT00085709,S0106 Cytarabine and Daunorubicin w/ or w/o Gemtuzumab Followed By HD Cytarabine and Either Gemtuzumab or Nothing in de Novo AML,creatinine
D007962,1.71,NCT00085709-1,Induction 7 + 3 + G.O.,NCT00085709,S0106 Cytarabine and Daunorubicin w/ or w/o Gemtuzumab Followed By HD Cytarabine and Either Gemtuzumab or Nothing in de Novo AML,leukocytes
D007962,0.27,NCT00085709-3,Ara-C Consolidation,NCT00085709,S0106 Cytarabine and Daunorubicin w/ or w/o Gemtuzumab Followed By HD Cytarabine and Either Gemtuzumab or Nothing in de Novo AML,leukocytes
D007962,2.56,NCT00085709-4,Post-consolidation G.O.,NCT00085709,S0106 Cytarabine and Daunorubicin w/ or w/o Gemtuzumab Followed By HD Cytarabine and Either Gemtuzumab or Nothing in de Novo AML,leukocytes
D007753,0.27,NCT00085709-3,Ara-C Consolidation,NCT00085709,S0106 Cytarabine and Daunorubicin w/ or w/o Gemtuzumab Followed By HD Cytarabine and Either Gemtuzumab or Nothing in de Novo AML,laboratory
D006098,1.02,NCT00085709-1,Induction 7 + 3 + G.O.,NCT00085709,S0106 Cytarabine and Daunorubicin w/ or w/o Gemtuzumab Followed By HD Cytarabine and Either Gemtuzumab or Nothing in de Novo AML,granulocytes
D006098,0.27,NCT00085709-3,Ara-C Consolidation,NCT00085709,S0106 Cytarabine and Daunorubicin w/ or w/o Gemtuzumab Followed By HD Cytarabine and Either Gemtuzumab or Nothing in de Novo AML,granulocytes
D006098,6.41,NCT00085709-4,Post-consolidation G.O.,NCT00085709,S0106 Cytarabine and Daunorubicin w/ or w/o Gemtuzumab Followed By HD Cytarabine and Either Gemtuzumab or Nothing in de Novo AML,granulocytes
D001792,3.07,NCT00085709-1,Induction 7 + 3 + G.O.,NCT00085709,S0106 Cytarabine and Daunorubicin w/ or w/o Gemtuzumab Followed By HD Cytarabine and Either Gemtuzumab or Nothing in de Novo AML,platelets
D001792,0.34,NCT00085709-2,Induction 7 + 3,NCT00085709,S0106 Cytarabine and Daunorubicin w/ or w/o Gemtuzumab Followed By HD Cytarabine and Either Gemtuzumab or Nothing in de Novo AML,platelets
D001792,0.27,NCT00085709-3,Ara-C Consolidation,NCT00085709,S0106 Cytarabine and Daunorubicin w/ or w/o Gemtuzumab Followed By HD Cytarabine and Either Gemtuzumab or Nothing in de Novo AML,platelets
D001792,2.56,NCT00085709-4,Post-consolidation G.O.,NCT00085709,S0106 Cytarabine and Daunorubicin w/ or w/o Gemtuzumab Followed By HD Cytarabine and Either Gemtuzumab or Nothing in de Novo AML,platelets
D016895,1.02,NCT00085709-1,Induction 7 + 3 + G.O.,NCT00085709,S0106 Cytarabine and Daunorubicin w/ or w/o Gemtuzumab Followed By HD Cytarabine and Either Gemtuzumab or Nothing in de Novo AML,low-serum media
D003681,1.28,NCT00085709-4,Post-consolidation G.O.,NCT00085709,S0106 Cytarabine and Daunorubicin w/ or w/o Gemtuzumab Followed By HD Cytarabine and Either Gemtuzumab or Nothing in de Novo AML,dehydration
D003847,1.28,NCT00085709-4,Post-consolidation G.O.,NCT00085709,S0106 Cytarabine and Daunorubicin w/ or w/o Gemtuzumab Followed By HD Cytarabine and Either Gemtuzumab or Nothing in de Novo AML,deoxyglucose
D016895,0.34,NCT00085709-1,Induction 7 + 3 + G.O.,NCT00085709,S0106 Cytarabine and Daunorubicin w/ or w/o Gemtuzumab Followed By HD Cytarabine and Either Gemtuzumab or Nothing in de Novo AML,low-serum media
D018149,0.34,NCT00085709-1,Induction 7 + 3 + G.O.,NCT00085709,S0106 Cytarabine and Daunorubicin w/ or w/o Gemtuzumab Followed By HD Cytarabine and Either Gemtuzumab or Nothing in de Novo AML,glucose intolerance
D016895,0.34,NCT00085709-1,Induction 7 + 3 + G.O.,NCT00085709,S0106 Cytarabine and Daunorubicin w/ or w/o Gemtuzumab Followed By HD Cytarabine and Either Gemtuzumab or Nothing in de Novo AML,low-serum media
D016895,0.34,NCT00085709-2,Induction 7 + 3,NCT00085709,S0106 Cytarabine and Daunorubicin w/ or w/o Gemtuzumab Followed By HD Cytarabine and Either Gemtuzumab or Nothing in de Novo AML,low-serum media
D033461,0.34,NCT00085709-1,Induction 7 + 3 + G.O.,NCT00085709,S0106 Cytarabine and Daunorubicin w/ or w/o Gemtuzumab Followed By HD Cytarabine and Either Gemtuzumab or Nothing in de Novo AML,hyperuricemia
D018771,0.34,NCT00085709-1,Induction 7 + 3 + G.O.,NCT00085709,S0106 Cytarabine and Daunorubicin w/ or w/o Gemtuzumab Followed By HD Cytarabine and Either Gemtuzumab or Nothing in de Novo AML,joint pain
D006470,1.71,NCT00085709-1,Induction 7 + 3 + G.O.,NCT00085709,S0106 Cytarabine and Daunorubicin w/ or w/o Gemtuzumab Followed By HD Cytarabine and Either Gemtuzumab or Nothing in de Novo AML,hemorrhage
D006470,0.34,NCT00085709-2,Induction 7 + 3,NCT00085709,S0106 Cytarabine and Daunorubicin w/ or w/o Gemtuzumab Followed By HD Cytarabine and Either Gemtuzumab or Nothing in de Novo AML,hemorrhage
D056784,0.27,NCT00085709-3,Ara-C Consolidation,NCT00085709,S0106 Cytarabine and Daunorubicin w/ or w/o Gemtuzumab Followed By HD Cytarabine and Either Gemtuzumab or Nothing in de Novo AML,leukoencephalopathy
D009462,0.34,NCT00085709-1,Induction 7 + 3 + G.O.,NCT00085709,S0106 Cytarabine and Daunorubicin w/ or w/o Gemtuzumab Followed By HD Cytarabine and Either Gemtuzumab or Nothing in de Novo AML,neurology
D009462,0.34,NCT00085709-2,Induction 7 + 3,NCT00085709,S0106 Cytarabine and Daunorubicin w/ or w/o Gemtuzumab Followed By HD Cytarabine and Either Gemtuzumab or Nothing in de Novo AML,neurology
D058734,0.34,NCT00085709-1,Induction 7 + 3 + G.O.,NCT00085709,S0106 Cytarabine and Daunorubicin w/ or w/o Gemtuzumab Followed By HD Cytarabine and Either Gemtuzumab or Nothing in de Novo AML,exsanguinating hemorrhage
D058734,0.68,NCT00085709-1,Induction 7 + 3 + G.O.,NCT00085709,S0106 Cytarabine and Daunorubicin w/ or w/o Gemtuzumab Followed By HD Cytarabine and Either Gemtuzumab or Nothing in de Novo AML,exsanguinating hemorrhage
D012128,1.71,NCT00085709-1,Induction 7 + 3 + G.O.,NCT00085709,S0106 Cytarabine and Daunorubicin w/ or w/o Gemtuzumab Followed By HD Cytarabine and Either Gemtuzumab or Nothing in de Novo AML,respiratory distress syndrome adult
D012128,0.27,NCT00085709-3,Ara-C Consolidation,NCT00085709,S0106 Cytarabine and Daunorubicin w/ or w/o Gemtuzumab Followed By HD Cytarabine and Either Gemtuzumab or Nothing in de Novo AML,respiratory distress syndrome adult
D004417,0.34,NCT00085709-1,Induction 7 + 3 + G.O.,NCT00085709,S0106 Cytarabine and Daunorubicin w/ or w/o Gemtuzumab Followed By HD Cytarabine and Either Gemtuzumab or Nothing in de Novo AML,breath shortness
10065746,1.71,NCT00085709-1,Induction 7 + 3 + G.O.,NCT00085709,S0106 Cytarabine and Daunorubicin w/ or w/o Gemtuzumab Followed By HD Cytarabine and Either Gemtuzumab or Nothing in de Novo AML,bronchopulmonary hemorrhage
D000860,1.37,NCT00085709-1,Induction 7 + 3 + G.O.,NCT00085709,S0106 Cytarabine and Daunorubicin w/ or w/o Gemtuzumab Followed By HD Cytarabine and Either Gemtuzumab or Nothing in de Novo AML,hypoxia
D000860,0.27,NCT00085709-3,Ara-C Consolidation,NCT00085709,S0106 Cytarabine and Daunorubicin w/ or w/o Gemtuzumab Followed By HD Cytarabine and Either Gemtuzumab or Nothing in de Novo AML,hypoxia
D016066,0.68,NCT00085709-1,Induction 7 + 3 + G.O.,NCT00085709,S0106 Cytarabine and Daunorubicin w/ or w/o Gemtuzumab Followed By HD Cytarabine and Either Gemtuzumab or Nothing in de Novo AML,pleural effusion malignant
D011014,0.68,NCT00085709-1,Induction 7 + 3 + G.O.,NCT00085709,S0106 Cytarabine and Daunorubicin w/ or w/o Gemtuzumab Followed By HD Cytarabine and Either Gemtuzumab or Nothing in de Novo AML,pneumonitis
D011014,0.27,NCT00085709-3,Ara-C Consolidation,NCT00085709,S0106 Cytarabine and Daunorubicin w/ or w/o Gemtuzumab Followed By HD Cytarabine and Either Gemtuzumab or Nothing in de Novo AML,pneumonitis
D012141,0.27,NCT00085709-3,Ara-C Consolidation,NCT00085709,S0106 Cytarabine and Daunorubicin w/ or w/o Gemtuzumab Followed By HD Cytarabine and Either Gemtuzumab or Nothing in de Novo AML,infections upper respiratory
D005076,0.34,NCT00085709-1,Induction 7 + 3 + G.O.,NCT00085709,S0106 Cytarabine and Daunorubicin w/ or w/o Gemtuzumab Followed By HD Cytarabine and Either Gemtuzumab or Nothing in de Novo AML,rash
D006470,0.27,NCT00085709-3,Ara-C Consolidation,NCT00085709,S0106 Cytarabine and Daunorubicin w/ or w/o Gemtuzumab Followed By HD Cytarabine and Either Gemtuzumab or Nothing in de Novo AML,hemorrhage
D007022,0.34,NCT00085709-1,Induction 7 + 3 + G.O.,NCT00085709,S0106 Cytarabine and Daunorubicin w/ or w/o Gemtuzumab Followed By HD Cytarabine and Either Gemtuzumab or Nothing in de Novo AML,hypotension
D007022,0.27,NCT00085709-3,Ara-C Consolidation,NCT00085709,S0106 Cytarabine and Daunorubicin w/ or w/o Gemtuzumab Followed By HD Cytarabine and Either Gemtuzumab or Nothing in de Novo AML,hypotension
10042554,0.34,NCT00085709-1,Induction 7 + 3 + G.O.,NCT00085709,S0106 Cytarabine and Daunorubicin w/ or w/o Gemtuzumab Followed By HD Cytarabine and Either Gemtuzumab or Nothing in de Novo AML,superficial thrombophlebitis
D016769,0.27,NCT00085709-3,Ara-C Consolidation,NCT00085709,S0106 Cytarabine and Daunorubicin w/ or w/o Gemtuzumab Followed By HD Cytarabine and Either Gemtuzumab or Nothing in de Novo AML,embolism and thrombosis
D009026,42.86,NCT00133991-1,R-CVP + HiCy,NCT00133991,Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed Burkitt's Lymphoma or Leukemia,mortality
D064420,57.14,NCT00133991-1,R-CVP + HiCy,NCT00133991,Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed Burkitt's Lymphoma or Leukemia,adverse drug events
D001281,4.76,NCT00133991-1,R-CVP + HiCy,NCT00133991,Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed Burkitt's Lymphoma or Leukemia,atrial fibrillation
D007022,4.76,NCT00133991-1,R-CVP + HiCy,NCT00133991,Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed Burkitt's Lymphoma or Leukemia,hypotension
D010493,4.76,NCT00133991-1,R-CVP + HiCy,NCT00133991,Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed Burkitt's Lymphoma or Leukemia,pericarditis
D003092,4.76,NCT00133991-1,R-CVP + HiCy,NCT00133991,Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed Burkitt's Lymphoma or Leukemia,colitis
D000077260,4.76,NCT00133991-1,R-CVP + HiCy,NCT00133991,Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed Burkitt's Lymphoma or Leukemia,somnolence
D001201,4.76,NCT00133991-1,R-CVP + HiCy,NCT00133991,Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed Burkitt's Lymphoma or Leukemia,ascites
D000069544,4.76,NCT00133991-1,R-CVP + HiCy,NCT00133991,Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed Burkitt's Lymphoma or Leukemia,encephalitis infection
D004660,4.76,NCT00133991-1,R-CVP + HiCy,NCT00133991,Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed Burkitt's Lymphoma or Leukemia,encephalitis
D064147,9.52,NCT00133991-1,R-CVP + HiCy,NCT00133991,Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed Burkitt's Lymphoma or Leukemia,febrile neutropenia
D011014,4.76,NCT00133991-1,R-CVP + HiCy,NCT00133991,Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed Burkitt's Lymphoma or Leukemia,pneumonia
D018805,4.76,NCT00133991-1,R-CVP + HiCy,NCT00133991,Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed Burkitt's Lymphoma or Leukemia,sepsis
D015275,4.76,NCT00133991-1,R-CVP + HiCy,NCT00133991,Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed Burkitt's Lymphoma or Leukemia,tumor lysis syndrome
D002637,4.76,NCT00133991-1,R-CVP + HiCy,NCT00133991,Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed Burkitt's Lymphoma or Leukemia,chest pain
10053692,4.76,NCT00133991-1,R-CVP + HiCy,NCT00133991,Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed Burkitt's Lymphoma or Leukemia,wound complication
D020521,4.76,NCT00133991-1,R-CVP + HiCy,NCT00133991,Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed Burkitt's Lymphoma or Leukemia,stroke
D006408,4.76,NCT00133991-1,R-CVP + HiCy,NCT00133991,Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed Burkitt's Lymphoma or Leukemia,subdural hematoma
D012128,4.76,NCT00133991-1,R-CVP + HiCy,NCT00133991,Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed Burkitt's Lymphoma or Leukemia,acute respiratory distress syndrome
D004417,4.76,NCT00133991-1,R-CVP + HiCy,NCT00133991,Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed Burkitt's Lymphoma or Leukemia,dyspnea
D000860,4.76,NCT00133991-1,R-CVP + HiCy,NCT00133991,Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed Burkitt's Lymphoma or Leukemia,hypoxia
D064420,23.08,NCT00186875-1,Standard Risk,NCT00186875,Therapy for Pediatric Relapsed or Refractory Acute Lymphoblastic Leukemia,adverse drug events
D064420,14.29,NCT00186875-2,High Risk,NCT00186875,Therapy for Pediatric Relapsed or Refractory Acute Lymphoblastic Leukemia,adverse drug events
D019190,7.14,NCT00186875-2,High Risk,NCT00186875,Therapy for Pediatric Relapsed or Refractory Acute Lymphoblastic Leukemia,iron overload
D006471,3.85,NCT00186875-1,Standard Risk,NCT00186875,Therapy for Pediatric Relapsed or Refractory Acute Lymphoblastic Leukemia,gastrointestinal hemorrhage
10014383,3.85,NCT00186875-1,Standard Risk,NCT00186875,Therapy for Pediatric Relapsed or Refractory Acute Lymphoblastic Leukemia,electrocardiogram qt corrected interval prolonged
D013617,7.14,NCT00186875-2,High Risk,NCT00186875,Therapy for Pediatric Relapsed or Refractory Acute Lymphoblastic Leukemia,tachycardia supraventricular
10047281,7.14,NCT00186875-2,High Risk,NCT00186875,Therapy for Pediatric Relapsed or Refractory Acute Lymphoblastic Leukemia,ventricular arrhythmia
D007022,3.85,NCT00186875-1,Standard Risk,NCT00186875,Therapy for Pediatric Relapsed or Refractory Acute Lymphoblastic Leukemia,hypotension
D007022,7.14,NCT00186875-2,High Risk,NCT00186875,Therapy for Pediatric Relapsed or Refractory Acute Lymphoblastic Leukemia,hypotension
D007249,3.85,NCT00186875-1,Standard Risk,NCT00186875,Therapy for Pediatric Relapsed or Refractory Acute Lymphoblastic Leukemia,inflammation
D013276,3.85,NCT00186875-1,Standard Risk,NCT00186875,Therapy for Pediatric Relapsed or Refractory Acute Lymphoblastic Leukemia,stomach ulcer
D004342,3.85,NCT00186875-1,Standard Risk,NCT00186875,Therapy for Pediatric Relapsed or Refractory Acute Lymphoblastic Leukemia,drug hypersensitivity
D000069544,3.85,NCT00186875-1,Standard Risk,NCT00186875,Therapy for Pediatric Relapsed or Refractory Acute Lymphoblastic Leukemia,encephalitis infection
D000069544,7.14,NCT00186875-2,High Risk,NCT00186875,Therapy for Pediatric Relapsed or Refractory Acute Lymphoblastic Leukemia,encephalitis infection
D000069544,3.85,NCT00186875-1,Standard Risk,NCT00186875,Therapy for Pediatric Relapsed or Refractory Acute Lymphoblastic Leukemia,encephalitis infection
D000069544,7.14,NCT00186875-2,High Risk,NCT00186875,Therapy for Pediatric Relapsed or Refractory Acute Lymphoblastic Leukemia,encephalitis infection
D055499,3.85,NCT00186875-1,Standard Risk,NCT00186875,Therapy for Pediatric Relapsed or Refractory Acute Lymphoblastic Leukemia,catheter-related infections
D051437,7.14,NCT00186875-2,High Risk,NCT00186875,Therapy for Pediatric Relapsed or Refractory Acute Lymphoblastic Leukemia,renal failure
D000860,7.14,NCT00186875-2,High Risk,NCT00186875,Therapy for Pediatric Relapsed or Refractory Acute Lymphoblastic Leukemia,hypoxia
D064420,64.0,NCT00288626-1,HDIT and HCT,NCT00288626,High-Dose Immunosuppression and Autologous Transplantation for Multiple Sclerosis (HALT MS) Study,adverse drug events
D007970,8.0,NCT00288626-1,HDIT and HCT,NCT00288626,High-Dose Immunosuppression and Autologous Transplantation for Multiple Sclerosis (HALT MS) Study,leukopenia
D008231,12.0,NCT00288626-1,HDIT and HCT,NCT00288626,High-Dose Immunosuppression and Autologous Transplantation for Multiple Sclerosis (HALT MS) Study,lymphopenia
D054537,4.0,NCT00288626-1,HDIT and HCT,NCT00288626,High-Dose Immunosuppression and Autologous Transplantation for Multiple Sclerosis (HALT MS) Study,atrioventricular block
D000072599,4.0,NCT00288626-1,HDIT and HCT,NCT00288626,High-Dose Immunosuppression and Autologous Transplantation for Multiple Sclerosis (HALT MS) Study,cardiorespiratory fitness
D001165,4.0,NCT00288626-1,HDIT and HCT,NCT00288626,High-Dose Immunosuppression and Autologous Transplantation for Multiple Sclerosis (HALT MS) Study,arteriovenous malformation
10005886,4.0,NCT00288626-1,HDIT and HCT,NCT00288626,High-Dose Immunosuppression and Autologous Transplantation for Multiple Sclerosis (HALT MS) Study,blurred vision
D003248,4.0,NCT00288626-1,HDIT and HCT,NCT00288626,High-Dose Immunosuppression and Autologous Transplantation for Multiple Sclerosis (HALT MS) Study,constipation
D002637,4.0,NCT00288626-1,HDIT and HCT,NCT00288626,High-Dose Immunosuppression and Autologous Transplantation for Multiple Sclerosis (HALT MS) Study,chest pain
D005221,4.0,NCT00288626-1,HDIT and HCT,NCT00288626,High-Dose Immunosuppression and Autologous Transplantation for Multiple Sclerosis (HALT MS) Study,fatigue
D005334,8.0,NCT00288626-1,HDIT and HCT,NCT00288626,High-Dose Immunosuppression and Autologous Transplantation for Multiple Sclerosis (HALT MS) Study,pyrexia
10017636,4.0,NCT00288626-1,HDIT and HCT,NCT00288626,High-Dose Immunosuppression and Autologous Transplantation for Multiple Sclerosis (HALT MS) Study,gallbladder obstruction
D013577,4.0,NCT00288626-1,HDIT and HCT,NCT00288626,High-Dose Immunosuppression and Autologous Transplantation for Multiple Sclerosis (HALT MS) Study,syndrome
D000151,4.0,NCT00288626-1,HDIT and HCT,NCT00288626,High-Dose Immunosuppression and Autologous Transplantation for Multiple Sclerosis (HALT MS) Study,acinetobacter infection
UNKNOWN-check-for-typo,4.0,NCT00288626-1,HDIT and HCT,NCT00288626,High-Dose Immunosuppression and Autologous Transplantation for Multiple Sclerosis (HALT MS) Study,D00
D002481,4.0,NCT00288626-1,HDIT and HCT,NCT00288626,High-Dose Immunosuppression and Autologous Transplantation for Multiple Sclerosis (HALT MS) Study,cellulitis
D012852,4.0,NCT00288626-1,HDIT and HCT,NCT00288626,High-Dose Immunosuppression and Autologous Transplantation for Multiple Sclerosis (HALT MS) Study,sinusitis
D020031,4.0,NCT00288626-1,HDIT and HCT,NCT00288626,High-Dose Immunosuppression and Autologous Transplantation for Multiple Sclerosis (HALT MS) Study,epstein barr virus infection
D008582,4.0,NCT00288626-1,HDIT and HCT,NCT00288626,High-Dose Immunosuppression and Autologous Transplantation for Multiple Sclerosis (HALT MS) Study,aseptic meningitis
D011014,4.0,NCT00288626-1,HDIT and HCT,NCT00288626,High-Dose Immunosuppression and Autologous Transplantation for Multiple Sclerosis (HALT MS) Study,pneumonia
D018805,4.0,NCT00288626-1,HDIT and HCT,NCT00288626,High-Dose Immunosuppression and Autologous Transplantation for Multiple Sclerosis (HALT MS) Study,sepsis
D014552,4.0,NCT00288626-1,HDIT and HCT,NCT00288626,High-Dose Immunosuppression and Autologous Transplantation for Multiple Sclerosis (HALT MS) Study,urinary tract infection
10001551,4.0,NCT00288626-1,HDIT and HCT,NCT00288626,High-Dose Immunosuppression and Autologous Transplantation for Multiple Sclerosis (HALT MS) Study,alanine aminotransferase increased
D003681,4.0,NCT00288626-1,HDIT and HCT,NCT00288626,High-Dose Immunosuppression and Autologous Transplantation for Multiple Sclerosis (HALT MS) Study,dehydration
UNKNOWN-check-for-typo,4.0,NCT00288626-1,HDIT and HCT,NCT00288626,High-Dose Immunosuppression and Autologous Transplantation for Multiple Sclerosis (HALT MS) Study,D00
UNKNOWN-check-for-typo,8.0,NCT00288626-1,HDIT and HCT,NCT00288626,High-Dose Immunosuppression and Autologous Transplantation for Multiple Sclerosis (HALT MS) Study,D00
D001416,4.0,NCT00288626-1,HDIT and HCT,NCT00288626,High-Dose Immunosuppression and Autologous Transplantation for Multiple Sclerosis (HALT MS) Study,back pain
10033425,8.0,NCT00288626-1,HDIT and HCT,NCT00288626,High-Dose Immunosuppression and Autologous Transplantation for Multiple Sclerosis (HALT MS) Study,pain in extremity
D001943,4.0,NCT00288626-1,HDIT and HCT,NCT00288626,High-Dose Immunosuppression and Autologous Transplantation for Multiple Sclerosis (HALT MS) Study,breast cancer
D002534,4.0,NCT00288626-1,HDIT and HCT,NCT00288626,High-Dose Immunosuppression and Autologous Transplantation for Multiple Sclerosis (HALT MS) Study,anoxic encephalopathy
D006261,4.0,NCT00288626-1,HDIT and HCT,NCT00288626,High-Dose Immunosuppression and Autologous Transplantation for Multiple Sclerosis (HALT MS) Study,headache
D010291,8.0,NCT00288626-1,HDIT and HCT,NCT00288626,High-Dose Immunosuppression and Autologous Transplantation for Multiple Sclerosis (HALT MS) Study,hemiparesis
D009049,4.0,NCT00288626-1,HDIT and HCT,NCT00288626,High-Dose Immunosuppression and Autologous Transplantation for Multiple Sclerosis (HALT MS) Study,motorcycles
D009103,12.0,NCT00288626-1,HDIT and HCT,NCT00288626,High-Dose Immunosuppression and Autologous Transplantation for Multiple Sclerosis (HALT MS) Study,multiple sclerosis
D000066530,4.0,NCT00288626-1,HDIT and HCT,NCT00288626,High-Dose Immunosuppression and Autologous Transplantation for Multiple Sclerosis (HALT MS) Study,neurological rehabilitation
D011247,4.0,NCT00288626-1,HDIT and HCT,NCT00288626,High-Dose Immunosuppression and Autologous Transplantation for Multiple Sclerosis (HALT MS) Study,pregnancy
D003863,4.0,NCT00288626-1,HDIT and HCT,NCT00288626,High-Dose Immunosuppression and Autologous Transplantation for Multiple Sclerosis (HALT MS) Study,depression
D001714,4.0,NCT00288626-1,HDIT and HCT,NCT00288626,High-Dose Immunosuppression and Autologous Transplantation for Multiple Sclerosis (HALT MS) Study,mania
10042464,8.0,NCT00288626-1,HDIT and HCT,NCT00288626,High-Dose Immunosuppression and Autologous Transplantation for Multiple Sclerosis (HALT MS) Study,suicide attempt
D001249,4.0,NCT00288626-1,HDIT and HCT,NCT00288626,High-Dose Immunosuppression and Autologous Transplantation for Multiple Sclerosis (HALT MS) Study,asthma
UNKNOWN-check-for-typo,4.0,NCT00288626-1,HDIT and HCT,NCT00288626,High-Dose Immunosuppression and Autologous Transplantation for Multiple Sclerosis (HALT MS) Study,D00
D011014,4.0,NCT00288626-1,HDIT and HCT,NCT00288626,High-Dose Immunosuppression and Autologous Transplantation for Multiple Sclerosis (HALT MS) Study,pneumonitis
D011655,8.0,NCT00288626-1,HDIT and HCT,NCT00288626,High-Dose Immunosuppression and Autologous Transplantation for Multiple Sclerosis (HALT MS) Study,pulmonary embolism
D019390,4.0,NCT00288626-1,HDIT and HCT,NCT00288626,High-Dose Immunosuppression and Autologous Transplantation for Multiple Sclerosis (HALT MS) Study,arrestins
D012131,4.0,NCT00288626-1,HDIT and HCT,NCT00288626,High-Dose Immunosuppression and Autologous Transplantation for Multiple Sclerosis (HALT MS) Study,respiratory failure
D020246,4.0,NCT00288626-1,HDIT and HCT,NCT00288626,High-Dose Immunosuppression and Autologous Transplantation for Multiple Sclerosis (HALT MS) Study,deep vein thrombosis
D007601,4.0,NCT00288626-1,HDIT and HCT,NCT00288626,High-Dose Immunosuppression and Autologous Transplantation for Multiple Sclerosis (HALT MS) Study,jugular veins
D064420,60.25,NCT00317642-1,Clofarabine (IV Formulation) and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),adverse drug events
D064420,49.03,NCT00317642-2,Placebo and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),adverse drug events
D064420,54.75,NCT00317642-3,Overall,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),adverse drug events
D000080983,0.62,NCT00317642-1,Clofarabine (IV Formulation) and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),bone marrow failure
D000080983,0.32,NCT00317642-3,Overall,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),bone marrow failure
D064147,15.53,NCT00317642-1,Clofarabine (IV Formulation) and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),febrile neutropenia
D064147,12.26,NCT00317642-2,Placebo and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),febrile neutropenia
D064147,13.92,NCT00317642-3,Overall,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),febrile neutropenia
D007970,0.62,NCT00317642-1,Clofarabine (IV Formulation) and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),leukopenia
D007970,1.29,NCT00317642-2,Placebo and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),leukopenia
D007970,0.95,NCT00317642-3,Overall,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),leukopenia
D008199,0.65,NCT00317642-2,Placebo and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),lymphadenitis
D008199,0.32,NCT00317642-3,Overall,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),lymphadenitis
D009503,1.24,NCT00317642-1,Clofarabine (IV Formulation) and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),neutropenia
D009503,2.58,NCT00317642-2,Placebo and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),neutropenia
D009503,1.9,NCT00317642-3,Overall,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),neutropenia
D010198,1.29,NCT00317642-2,Placebo and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),pancytopenia
D010198,0.63,NCT00317642-3,Overall,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),pancytopenia
D013921,1.24,NCT00317642-1,Clofarabine (IV Formulation) and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),thrombocytopenia
D013921,1.94,NCT00317642-2,Placebo and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),thrombocytopenia
D013921,1.58,NCT00317642-3,Overall,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),thrombocytopenia
D056988,1.86,NCT00317642-1,Clofarabine (IV Formulation) and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),acute anterior wall myocardial infarction
D056988,0.95,NCT00317642-3,Overall,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),acute anterior wall myocardial infarction
D000787,0.62,NCT00317642-1,Clofarabine (IV Formulation) and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),angina pectoris
D000787,0.32,NCT00317642-3,Overall,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),angina pectoris
D001281,1.24,NCT00317642-1,Clofarabine (IV Formulation) and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),atrial fibrillation
D001281,0.65,NCT00317642-2,Placebo and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),atrial fibrillation
D001281,0.95,NCT00317642-3,Overall,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),atrial fibrillation
D001282,0.65,NCT00317642-2,Placebo and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),atrial flutter
D001282,0.32,NCT00317642-3,Overall,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),atrial flutter
D001919,0.62,NCT00317642-1,Clofarabine (IV Formulation) and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),bradycardia
D001919,0.32,NCT00317642-3,Overall,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),bradycardia
D006323,0.62,NCT00317642-1,Clofarabine (IV Formulation) and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),cardiac arrest
D006323,0.65,NCT00317642-2,Placebo and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),cardiac arrest
D006323,0.63,NCT00317642-3,Overall,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),cardiac arrest
D006333,0.62,NCT00317642-1,Clofarabine (IV Formulation) and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),cardiac failure
D006333,0.32,NCT00317642-3,Overall,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),cardiac failure
D006333,0.62,NCT00317642-1,Clofarabine (IV Formulation) and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),cardiac failure
D006333,1.29,NCT00317642-2,Placebo and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),cardiac failure
D006333,0.95,NCT00317642-3,Overall,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),cardiac failure
D000072599,0.62,NCT00317642-1,Clofarabine (IV Formulation) and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),cardiorespiratory fitness
D000072599,0.65,NCT00317642-2,Placebo and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),cardiorespiratory fitness
D000072599,0.63,NCT00317642-3,Overall,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),cardiorespiratory fitness
D012770,0.62,NCT00317642-1,Clofarabine (IV Formulation) and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),cardiogenic shock
D012770,0.32,NCT00317642-3,Overall,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),cardiogenic shock
D009203,1.24,NCT00317642-1,Clofarabine (IV Formulation) and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),myocardial infarction
D009203,0.63,NCT00317642-3,Overall,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),myocardial infarction
D000071956,0.62,NCT00317642-1,Clofarabine (IV Formulation) and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),myocardial contusions
D000071956,0.32,NCT00317642-3,Overall,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),myocardial contusions
D010493,0.62,NCT00317642-1,Clofarabine (IV Formulation) and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),pericarditis
D010493,0.32,NCT00317642-3,Overall,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),pericarditis
D054549,0.62,NCT00317642-1,Clofarabine (IV Formulation) and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),stress cardiomyopathy
D054549,0.32,NCT00317642-3,Overall,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),stress cardiomyopathy
D013617,0.62,NCT00317642-1,Clofarabine (IV Formulation) and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),supraventricular tachycardia
D013617,0.32,NCT00317642-3,Overall,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),supraventricular tachycardia
D013610,0.65,NCT00317642-2,Placebo and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),tachycardia
D013610,0.32,NCT00317642-3,Overall,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),tachycardia
D001766,0.62,NCT00317642-1,Clofarabine (IV Formulation) and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),blindness unilateral
D001766,0.32,NCT00317642-3,Overall,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),blindness unilateral
D015746,0.62,NCT00317642-1,Clofarabine (IV Formulation) and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),abdominal pain
D015746,0.65,NCT00317642-2,Placebo and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),abdominal pain
D015746,0.63,NCT00317642-3,Overall,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),abdominal pain
UNKNOWN-check-for-typo,1.29,NCT00317642-2,Placebo and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),D00
UNKNOWN-check-for-typo,0.63,NCT00317642-3,Overall,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),D00
D003092,0.65,NCT00317642-2,Placebo and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),colitis
D003092,0.32,NCT00317642-3,Overall,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),colitis
UNKNOWN-check-for-typo,1.24,NCT00317642-1,Clofarabine (IV Formulation) and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),D00
UNKNOWN-check-for-typo,0.65,NCT00317642-2,Placebo and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),D00
UNKNOWN-check-for-typo,0.95,NCT00317642-3,Overall,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),D00
D000069196,1.24,NCT00317642-1,Clofarabine (IV Formulation) and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),gastrointestinal microbiome
D000069196,0.65,NCT00317642-2,Placebo and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),gastrointestinal microbiome
D000069196,0.95,NCT00317642-3,Overall,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),gastrointestinal microbiome
D041741,0.65,NCT00317642-2,Placebo and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),lower gastrointestinal tract
D041741,0.32,NCT00317642-3,Overall,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),lower gastrointestinal tract
D050686,0.62,NCT00317642-1,Clofarabine (IV Formulation) and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),globicephala melaena
D050686,0.32,NCT00317642-3,Overall,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),globicephala melaena
D001247,1.86,NCT00317642-1,Clofarabine (IV Formulation) and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),asthenia
D001247,0.65,NCT00317642-2,Placebo and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),asthenia
D001247,1.27,NCT00317642-3,Overall,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),asthenia
D003643,0.62,NCT00317642-1,Clofarabine (IV Formulation) and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),death
D003643,0.32,NCT00317642-3,Overall,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),death
D005221,0.62,NCT00317642-1,Clofarabine (IV Formulation) and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),fatigue
D005221,0.32,NCT00317642-3,Overall,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),fatigue
D000799,0.62,NCT00317642-1,Clofarabine (IV Formulation) and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),angioedema
D000799,0.32,NCT00317642-3,Overall,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),angioedema
D007035,0.65,NCT00317642-2,Placebo and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),hypothermia
D007035,0.32,NCT00317642-3,Overall,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),hypothermia
D007249,0.65,NCT00317642-2,Placebo and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),inflammation
D007249,0.32,NCT00317642-3,Overall,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),inflammation
D009102,1.86,NCT00317642-1,Clofarabine (IV Formulation) and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),multiple organ failure
D009102,0.65,NCT00317642-2,Placebo and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),multiple organ failure
D009102,1.27,NCT00317642-3,Overall,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),multiple organ failure
D000799,0.62,NCT00317642-1,Clofarabine (IV Formulation) and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),angioedema
D000799,0.32,NCT00317642-3,Overall,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),angioedema
D010146,0.62,NCT00317642-1,Clofarabine (IV Formulation) and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),pain
D010146,0.32,NCT00317642-3,Overall,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),pain
D005334,4.35,NCT00317642-1,Clofarabine (IV Formulation) and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),pyrexia
D005334,5.81,NCT00317642-2,Placebo and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),pyrexia
D005334,5.06,NCT00317642-3,Overall,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),pyrexia
D008107,0.62,NCT00317642-1,Clofarabine (IV Formulation) and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),liver diseases
D008107,0.32,NCT00317642-3,Overall,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),liver diseases
D000707,0.65,NCT00317642-2,Placebo and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),anaphylactic reaction
D000707,0.32,NCT00317642-3,Overall,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),anaphylactic reaction
D006086,0.65,NCT00317642-2,Placebo and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),graft versus host disease
D006086,0.32,NCT00317642-3,Overall,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),graft versus host disease
D013290,0.65,NCT00317642-2,Placebo and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),streptococcal infections
D013290,0.32,NCT00317642-3,Overall,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),streptococcal infections
D001064,0.65,NCT00317642-2,Placebo and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),appendicitis
D001064,0.32,NCT00317642-3,Overall,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),appendicitis
UNKNOWN-check-for-typo,4.35,NCT00317642-1,Clofarabine (IV Formulation) and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),D00
UNKNOWN-check-for-typo,1.94,NCT00317642-2,Placebo and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),D00
UNKNOWN-check-for-typo,3.16,NCT00317642-3,Overall,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),D00
D001424,0.65,NCT00317642-2,Placebo and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),bacterial infection
D001424,0.32,NCT00317642-3,Overall,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),bacterial infection
D000985,0.62,NCT00317642-1,Clofarabine (IV Formulation) and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),antisepsis
D000985,0.32,NCT00317642-3,Overall,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),antisepsis
D055732,1.24,NCT00317642-1,Clofarabine (IV Formulation) and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),bronchopulmonary aspergillosis
D055732,0.65,NCT00317642-2,Placebo and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),bronchopulmonary aspergillosis
D055732,0.95,NCT00317642-3,Overall,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),bronchopulmonary aspergillosis
D002481,1.94,NCT00317642-2,Placebo and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),cellulitis
D002481,0.95,NCT00317642-3,Overall,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),cellulitis
D000069544,0.62,NCT00317642-1,Clofarabine (IV Formulation) and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),encephalitis infection
D000069544,0.32,NCT00317642-3,Overall,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),encephalitis infection
D004761,1.86,NCT00317642-1,Clofarabine (IV Formulation) and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),clostridium enterocolitis
D004761,1.29,NCT00317642-2,Placebo and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),clostridium enterocolitis
D004761,1.58,NCT00317642-3,Overall,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),clostridium enterocolitis
D000985,0.62,NCT00317642-1,Clofarabine (IV Formulation) and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),antisepsis
D000985,0.32,NCT00317642-3,Overall,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),antisepsis
10064687,0.62,NCT00317642-1,Clofarabine (IV Formulation) and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),device related infection
10064687,0.32,NCT00317642-3,Overall,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),device related infection
D004238,0.65,NCT00317642-2,Placebo and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),diverticulitis
D004238,0.32,NCT00317642-3,Overall,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),diverticulitis
D004754,1.29,NCT00317642-2,Placebo and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),enterobacter
D004754,0.63,NCT00317642-3,Overall,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),enterobacter
D000985,0.62,NCT00317642-1,Clofarabine (IV Formulation) and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),antisepsis
D000985,0.32,NCT00317642-3,Overall,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),antisepsis
UNKNOWN-check-for-typo,3.73,NCT00317642-1,Clofarabine (IV Formulation) and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),D00
UNKNOWN-check-for-typo,0.65,NCT00317642-2,Placebo and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),D00
UNKNOWN-check-for-typo,2.22,NCT00317642-3,Overall,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),D00
D000985,1.86,NCT00317642-1,Clofarabine (IV Formulation) and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),antisepsis
D000985,0.95,NCT00317642-3,Overall,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),antisepsis
D004925,2.48,NCT00317642-1,Clofarabine (IV Formulation) and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),escherichia
D004925,1.27,NCT00317642-3,Overall,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),escherichia
D004927,0.65,NCT00317642-2,Placebo and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),escherichia coli infections
D004927,0.32,NCT00317642-3,Overall,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),escherichia coli infections
D000985,1.24,NCT00317642-1,Clofarabine (IV Formulation) and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),antisepsis
D000985,0.63,NCT00317642-3,Overall,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),antisepsis
D009181,0.62,NCT00317642-1,Clofarabine (IV Formulation) and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),fungal infection
D009181,0.32,NCT00317642-3,Overall,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),fungal infection
D000069544,0.62,NCT00317642-1,Clofarabine (IV Formulation) and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),encephalitis infection
D000069544,0.32,NCT00317642-3,Overall,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),encephalitis infection
D006562,0.65,NCT00317642-2,Placebo and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),herpes zoster
D006562,0.32,NCT00317642-3,Overall,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),herpes zoster
D016849,0.62,NCT00317642-1,Clofarabine (IV Formulation) and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),herpetic keratitis
D016849,0.32,NCT00317642-3,Overall,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),herpetic keratitis
D007709,0.62,NCT00317642-1,Clofarabine (IV Formulation) and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),klebsiella
D007709,0.32,NCT00317642-3,Overall,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),klebsiella
D000985,1.29,NCT00317642-2,Placebo and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),antisepsis
D000985,0.63,NCT00317642-3,Overall,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),antisepsis
D011014,0.65,NCT00317642-2,Placebo and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),lobar pneumonia
D011014,0.32,NCT00317642-3,Overall,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),lobar pneumonia
D000985,2.48,NCT00317642-1,Clofarabine (IV Formulation) and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),antisepsis
D000985,1.27,NCT00317642-3,Overall,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),antisepsis
D013283,0.62,NCT00317642-1,Clofarabine (IV Formulation) and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),herpes simplex oral
D013283,0.32,NCT00317642-3,Overall,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),herpes simplex oral
D000257,0.62,NCT00317642-1,Clofarabine (IV Formulation) and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),adenovirus infections
D000257,0.32,NCT00317642-3,Overall,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),adenovirus infections
D011014,8.07,NCT00317642-1,Clofarabine (IV Formulation) and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),pneumonia
D011014,7.74,NCT00317642-2,Placebo and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),pneumonia
D011014,7.91,NCT00317642-3,Overall,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),pneumonia
D018410,1.86,NCT00317642-1,Clofarabine (IV Formulation) and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),bacterial pneumonia
D018410,0.95,NCT00317642-3,Overall,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),bacterial pneumonia
D001996,3.11,NCT00317642-1,Clofarabine (IV Formulation) and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),bronchopneumonia
D001996,1.58,NCT00317642-3,Overall,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),bronchopneumonia
D011024,0.65,NCT00317642-2,Placebo and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),viral pneumonia
D011024,0.32,NCT00317642-3,Overall,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),viral pneumonia
UNKNOWN-check-for-typo,0.62,NCT00317642-1,Clofarabine (IV Formulation) and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),D00
UNKNOWN-check-for-typo,0.65,NCT00317642-2,Placebo and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),D00
UNKNOWN-check-for-typo,0.63,NCT00317642-3,Overall,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),D00
D018805,4.97,NCT00317642-1,Clofarabine (IV Formulation) and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),sepsis
D018805,1.94,NCT00317642-2,Placebo and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),sepsis
D018805,3.48,NCT00317642-3,Overall,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),sepsis
D018746,0.62,NCT00317642-1,Clofarabine (IV Formulation) and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),sepsis syndrome
D018746,0.32,NCT00317642-3,Overall,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),sepsis syndrome
D012772,3.73,NCT00317642-1,Clofarabine (IV Formulation) and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),septic shock
D012772,1.9,NCT00317642-3,Overall,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),septic shock
D000985,0.62,NCT00317642-1,Clofarabine (IV Formulation) and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),antisepsis
D000985,0.32,NCT00317642-3,Overall,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),antisepsis
D012852,0.62,NCT00317642-1,Clofarabine (IV Formulation) and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),sinusitis
D012852,0.32,NCT00317642-3,Overall,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),sinusitis
D004768,1.24,NCT00317642-1,Clofarabine (IV Formulation) and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),staphylococcal enterotoxins
D004768,1.29,NCT00317642-2,Placebo and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),staphylococcal enterotoxins
D004768,1.27,NCT00317642-3,Overall,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),staphylococcal enterotoxins
D013203,0.62,NCT00317642-1,Clofarabine (IV Formulation) and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),staphylococcal infection
D013203,0.65,NCT00317642-2,Placebo and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),staphylococcal infection
D013203,0.63,NCT00317642-3,Overall,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),staphylococcal infection
D013206,0.62,NCT00317642-1,Clofarabine (IV Formulation) and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),staphylococcal scalded skin syndrome
D013206,0.32,NCT00317642-3,Overall,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),staphylococcal scalded skin syndrome
D000985,1.24,NCT00317642-1,Clofarabine (IV Formulation) and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),antisepsis
D000985,0.63,NCT00317642-3,Overall,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),antisepsis
D010844,2.48,NCT00317642-1,Clofarabine (IV Formulation) and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),streptococcal ok432
D010844,1.27,NCT00317642-3,Overall,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),streptococcal ok432
D000985,1.24,NCT00317642-1,Clofarabine (IV Formulation) and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),antisepsis
D000985,0.63,NCT00317642-3,Overall,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),antisepsis
D002175,0.62,NCT00317642-1,Clofarabine (IV Formulation) and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),candida
D002175,0.32,NCT00317642-3,Overall,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),candida
D012141,0.62,NCT00317642-1,Clofarabine (IV Formulation) and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),infections upper respiratory
D012141,0.32,NCT00317642-3,Overall,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),infections upper respiratory
D014552,0.65,NCT00317642-2,Placebo and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),urinary tract infection
D014552,0.32,NCT00317642-3,Overall,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),urinary tract infection
D014552,0.62,NCT00317642-1,Clofarabine (IV Formulation) and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),urinary tract infections
D014552,1.29,NCT00317642-2,Placebo and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),urinary tract infections
D014552,0.95,NCT00317642-3,Overall,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),urinary tract infections
D014552,0.62,NCT00317642-1,Clofarabine (IV Formulation) and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),urinary tract infections
D014552,0.32,NCT00317642-3,Overall,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),urinary tract infections
D020096,0.65,NCT00317642-2,Placebo and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),zygomycosis
D020096,0.32,NCT00317642-3,Overall,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),zygomycosis
D005265,0.62,NCT00317642-1,Clofarabine (IV Formulation) and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),femoral neck fracture
D005265,0.32,NCT00317642-3,Overall,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),femoral neck fracture
D017713,0.62,NCT00317642-1,Clofarabine (IV Formulation) and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),platelet transfusion
D017713,0.32,NCT00317642-3,Overall,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),platelet transfusion
D006408,1.86,NCT00317642-1,Clofarabine (IV Formulation) and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),hematoma subdural
D006408,0.65,NCT00317642-2,Placebo and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),hematoma subdural
D006408,1.27,NCT00317642-3,Overall,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),hematoma subdural
10003481,0.62,NCT00317642-1,Clofarabine (IV Formulation) and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),aspartate aminotransferase increased
10003481,0.32,NCT00317642-3,Overall,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),aspartate aminotransferase increased
10005364,0.62,NCT00317642-1,Clofarabine (IV Formulation) and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),blood bilirubin increased
10005364,0.32,NCT00317642-3,Overall,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),blood bilirubin increased
10005359,0.62,NCT00317642-1,Clofarabine (IV Formulation) and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),blood bicarbonate decreased
10005359,0.32,NCT00317642-3,Overall,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),blood bicarbonate decreased
10050528,0.62,NCT00317642-1,Clofarabine (IV Formulation) and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),ejection fraction decreased
10050528,0.32,NCT00317642-3,Overall,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),ejection fraction decreased
D008133,0.62,NCT00317642-1,Clofarabine (IV Formulation) and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),electrocardiogram qt prolonged
D008133,0.32,NCT00317642-3,Overall,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),electrocardiogram qt prolonged
10024574,0.62,NCT00317642-1,Clofarabine (IV Formulation) and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),lipase increased
10024574,0.32,NCT00317642-3,Overall,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),lipase increased
10007612,0.62,NCT00317642-1,Clofarabine (IV Formulation) and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),cardiac troponin i increased
10007612,0.32,NCT00317642-3,Overall,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),cardiac troponin i increased
D007958,0.62,NCT00317642-1,Clofarabine (IV Formulation) and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),blood cell count white
D007958,0.32,NCT00317642-3,Overall,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),blood cell count white
D000138,0.65,NCT00317642-2,Placebo and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),acidosis
D000138,0.32,NCT00317642-3,Overall,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),acidosis
D003681,0.62,NCT00317642-1,Clofarabine (IV Formulation) and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),dehydration
D003681,0.32,NCT00317642-3,Overall,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),dehydration
D011205,0.62,NCT00317642-1,Clofarabine (IV Formulation) and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),unifluid
D011205,0.32,NCT00317642-3,Overall,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),unifluid
UNKNOWN-check-for-typo,0.62,NCT00317642-1,Clofarabine (IV Formulation) and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),D00
UNKNOWN-check-for-typo,0.32,NCT00317642-3,Overall,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),D00
UNKNOWN-check-for-typo,0.62,NCT00317642-1,Clofarabine (IV Formulation) and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),D00
UNKNOWN-check-for-typo,0.65,NCT00317642-2,Placebo and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),D00
UNKNOWN-check-for-typo,0.63,NCT00317642-3,Overall,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),D00
D000138,0.62,NCT00317642-1,Clofarabine (IV Formulation) and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),metabolic acidosis
D000138,0.32,NCT00317642-3,Overall,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),metabolic acidosis
D015275,0.62,NCT00317642-1,Clofarabine (IV Formulation) and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),tumour lysis syndrome
D015275,0.32,NCT00317642-3,Overall,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),tumour lysis syndrome
D001416,0.62,NCT00317642-1,Clofarabine (IV Formulation) and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),back pain
D001416,0.32,NCT00317642-3,Overall,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),back pain
D009135,0.62,NCT00317642-1,Clofarabine (IV Formulation) and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),muscle disorder
D009135,0.32,NCT00317642-3,Overall,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),muscle disorder
D010003,0.65,NCT00317642-2,Placebo and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),osteoarthritis
D010003,0.32,NCT00317642-3,Overall,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),osteoarthritis
D015470,2.48,NCT00317642-1,Clofarabine (IV Formulation) and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),leukemia myeloid acute
D015470,3.23,NCT00317642-2,Placebo and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),leukemia myeloid acute
D015470,2.85,NCT00317642-3,Overall,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),leukemia myeloid acute
D000075722,0.62,NCT00317642-1,Clofarabine (IV Formulation) and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),promyelocytic leukaemia zinc finger protein
D000075722,0.32,NCT00317642-3,Overall,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),promyelocytic leukaemia zinc finger protein
D009369,1.24,NCT00317642-1,Clofarabine (IV Formulation) and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),malignant neoplasm
D009369,2.58,NCT00317642-2,Placebo and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),malignant neoplasm
D009369,1.9,NCT00317642-3,Overall,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),malignant neoplasm
D000074042,1.24,NCT00317642-1,Clofarabine (IV Formulation) and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),cerebral intraventricular haemorrhage
D000074042,1.29,NCT00317642-2,Placebo and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),cerebral intraventricular haemorrhage
D000074042,1.27,NCT00317642-3,Overall,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),cerebral intraventricular haemorrhage
D002544,0.65,NCT00317642-2,Placebo and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),cerebral infarction
D002544,0.32,NCT00317642-3,Overall,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),cerebral infarction
D020521,0.62,NCT00317642-1,Clofarabine (IV Formulation) and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),cerebrovascular accident
D020521,0.65,NCT00317642-2,Placebo and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),cerebrovascular accident
D020521,0.63,NCT00317642-3,Overall,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),cerebrovascular accident
D012640,0.62,NCT00317642-1,Clofarabine (IV Formulation) and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),convulsion
D012640,0.65,NCT00317642-2,Placebo and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),convulsion
D012640,0.63,NCT00317642-3,Overall,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),convulsion
D001927,0.62,NCT00317642-1,Clofarabine (IV Formulation) and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),encephalopathy
D001927,0.65,NCT00317642-2,Placebo and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),encephalopathy
D001927,0.63,NCT00317642-3,Overall,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),encephalopathy
D002534,0.62,NCT00317642-1,Clofarabine (IV Formulation) and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),hypoxic encephalopathy
D002534,0.32,NCT00317642-3,Overall,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),hypoxic encephalopathy
D010523,0.62,NCT00317642-1,Clofarabine (IV Formulation) and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),peripheral neuropathy
D010523,0.32,NCT00317642-3,Overall,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),peripheral neuropathy
D020149,0.65,NCT00317642-2,Placebo and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),neurotoxicity syndrome manganese
D020149,0.32,NCT00317642-3,Overall,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),neurotoxicity syndrome manganese
D010523,0.62,NCT00317642-1,Clofarabine (IV Formulation) and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),neuropathy peripheral
D010523,0.32,NCT00317642-3,Overall,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),neuropathy peripheral
D000077260,0.65,NCT00317642-2,Placebo and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),somnolence
D000077260,0.32,NCT00317642-3,Overall,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),somnolence
D013226,0.62,NCT00317642-1,Clofarabine (IV Formulation) and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),status epilepticus
D013226,0.32,NCT00317642-3,Overall,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),status epilepticus
D013575,1.24,NCT00317642-1,Clofarabine (IV Formulation) and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),syncope
D013575,0.63,NCT00317642-3,Overall,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),syncope
10001497,0.62,NCT00317642-1,Clofarabine (IV Formulation) and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),agitation
10001497,0.65,NCT00317642-2,Placebo and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),agitation
10001497,0.63,NCT00317642-3,Overall,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),agitation
D003221,1.29,NCT00317642-2,Placebo and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),confusional state
D003221,0.63,NCT00317642-3,Overall,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),confusional state
D000073216,0.62,NCT00317642-1,Clofarabine (IV Formulation) and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),mental status tests
D000073216,0.65,NCT00317642-2,Placebo and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),mental status tests
D000073216,0.63,NCT00317642-3,Overall,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),mental status tests
D001002,0.65,NCT00317642-2,Placebo and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),anuria
D001002,0.32,NCT00317642-3,Overall,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),anuria
UNKNOWN-check-for-typo,0.65,NCT00317642-2,Placebo and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),D00
UNKNOWN-check-for-typo,0.32,NCT00317642-3,Overall,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),D00
D051437,0.62,NCT00317642-1,Clofarabine (IV Formulation) and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),renal failure
D051437,0.32,NCT00317642-3,Overall,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),renal failure
D058186,3.11,NCT00317642-1,Clofarabine (IV Formulation) and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),acute renal failure
D058186,0.65,NCT00317642-2,Placebo and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),acute renal failure
D058186,1.9,NCT00317642-3,Overall,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),acute renal failure
D007676,0.62,NCT00317642-1,Clofarabine (IV Formulation) and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),renal failure chronic
D007676,0.32,NCT00317642-3,Overall,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),renal failure chronic
D000308,0.65,NCT00317642-2,Placebo and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),hyperadrenalism
D000308,0.32,NCT00317642-3,Overall,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),hyperadrenalism
D012128,2.48,NCT00317642-1,Clofarabine (IV Formulation) and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),acute respiratory distress syndrome
D012128,1.27,NCT00317642-3,Overall,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),acute respiratory distress syndrome
D012131,1.24,NCT00317642-1,Clofarabine (IV Formulation) and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),respiratory failure
D012131,0.63,NCT00317642-3,Overall,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),respiratory failure
UNKNOWN-check-for-typo,0.62,NCT00317642-1,Clofarabine (IV Formulation) and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),D00
UNKNOWN-check-for-typo,1.94,NCT00317642-2,Placebo and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),D00
UNKNOWN-check-for-typo,1.27,NCT00317642-3,Overall,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),D00
D004844,0.62,NCT00317642-1,Clofarabine (IV Formulation) and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),epistaxis
D004844,0.32,NCT00317642-3,Overall,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),epistaxis
UNKNOWN-check-for-typo,1.29,NCT00317642-2,Placebo and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),D00
UNKNOWN-check-for-typo,0.63,NCT00317642-3,Overall,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),D00
D000860,0.65,NCT00317642-2,Placebo and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),hypoxia
D000860,0.32,NCT00317642-3,Overall,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),hypoxia
D017563,0.62,NCT00317642-1,Clofarabine (IV Formulation) and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),interstitial lung disease
D017563,0.32,NCT00317642-3,Overall,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),interstitial lung disease
D008168,1.29,NCT00317642-2,Placebo and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),lung
D008168,0.63,NCT00317642-3,Overall,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),lung
D011015,0.65,NCT00317642-2,Placebo and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),aspiration pneumonia
D011015,0.32,NCT00317642-3,Overall,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),aspiration pneumonia
D011649,0.62,NCT00317642-1,Clofarabine (IV Formulation) and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),pulmonary alveolar proteinosis
D011649,0.32,NCT00317642-3,Overall,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),pulmonary alveolar proteinosis
D001261,1.24,NCT00317642-1,Clofarabine (IV Formulation) and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),pulmonary atelectasis
D001261,0.63,NCT00317642-3,Overall,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),pulmonary atelectasis
D000799,0.62,NCT00317642-1,Clofarabine (IV Formulation) and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),angioedema
D000799,0.32,NCT00317642-3,Overall,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),angioedema
D012127,0.62,NCT00317642-1,Clofarabine (IV Formulation) and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),respiratory distress syndrome newborn
D012127,1.29,NCT00317642-2,Placebo and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),respiratory distress syndrome newborn
D012127,0.95,NCT00317642-3,Overall,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),respiratory distress syndrome newborn
D012131,0.62,NCT00317642-1,Clofarabine (IV Formulation) and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),respiratory failure
D012131,2.58,NCT00317642-2,Placebo and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),respiratory failure
D012131,1.58,NCT00317642-3,Overall,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),respiratory failure
D003875,0.62,NCT00317642-1,Clofarabine (IV Formulation) and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),drug eruption
D003875,0.32,NCT00317642-3,Overall,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),drug eruption
D005076,0.62,NCT00317642-1,Clofarabine (IV Formulation) and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),rash
D005076,0.32,NCT00317642-3,Overall,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),rash
D004890,0.62,NCT00317642-1,Clofarabine (IV Formulation) and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),erythema
D004890,0.32,NCT00317642-3,Overall,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),erythema
10054524,0.62,NCT00317642-1,Clofarabine (IV Formulation) and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),palmar-plantar erythrodysesthesia syndrome
10054524,0.32,NCT00317642-3,Overall,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),palmar-plantar erythrodysesthesia syndrome
D005076,0.62,NCT00317642-1,Clofarabine (IV Formulation) and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),rash
D005076,0.32,NCT00317642-3,Overall,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),rash
D013262,0.62,NCT00317642-1,Clofarabine (IV Formulation) and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),toxic epidermal necrolysis
D013262,0.32,NCT00317642-3,Overall,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),toxic epidermal necrolysis
D020246,1.24,NCT00317642-1,Clofarabine (IV Formulation) and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),deep vein thrombosis
D020246,0.65,NCT00317642-2,Placebo and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),deep vein thrombosis
D020246,0.95,NCT00317642-3,Overall,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),deep vein thrombosis
D006973,1.29,NCT00317642-2,Placebo and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),hypertension
D006973,0.63,NCT00317642-3,Overall,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),hypertension
D007022,2.48,NCT00317642-1,Clofarabine (IV Formulation) and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),hypotension
D007022,2.58,NCT00317642-2,Placebo and Cytarabine,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),hypotension
D007022,2.53,NCT00317642-3,Overall,NCT00317642,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),hypotension
D064420,41.02,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,adverse drug events
D064420,30.58,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,adverse drug events
D064420,14.29,NCT00333840-3,Imatinib to IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,adverse drug events
D064420,44.08,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,adverse drug events
D014842,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,von willebrand diseases
D000741,1.09,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,aplastic anaemia
D000741,1.88,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,aplastic anaemia
D000741,1.38,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,aplastic anaemia
D016553,0.19,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,autoimmune thrombocytopenia
D004211,0.19,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,disseminated intravascular coagulation
D064147,0.36,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,febrile neutropenia
D064147,0.55,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,febrile neutropenia
UNKNOWN-check-for-typo,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,D00
UNKNOWN-check-for-typo,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,D00
D006461,0.19,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,haemolysis
D000081032,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,haemorrhagic pancreatitis
D018798,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,anemia iron-deficiency
D007964,0.56,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,leukocytosis
D007970,0.19,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,leukopenia
10025182,0.19,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,lymph node pain
D000072281,0.19,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,lymphadenopathy
D009503,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,neutropenia
D009503,0.56,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,neutropenia
D009503,1.1,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,neutropenia
D010198,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,pancytopenia
D010198,0.83,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,pancytopenia
D013159,0.19,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,splenic infarction
D013163,0.38,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,splenomegaly
D013921,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,thrombocytopenia
D013921,1.88,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,thrombocytopenia
D013921,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,thrombocytopenia
D013922,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,thrombocytosis
D013922,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,thrombocytosis
D056988,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,acute anterior wall myocardial infarction
D056988,0.19,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,acute anterior wall myocardial infarction
D056988,0.55,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,acute anterior wall myocardial infarction
D000787,0.36,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,angina pectoris
D000787,0.19,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,angina pectoris
D000787,0.55,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,angina pectoris
D000789,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,unstable angina
D000789,0.19,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,unstable angina
10061589,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,aortic valve disease
D001024,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,aortic valve stenosis
D001145,0.73,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,arrhythmia
D001145,0.19,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,arrhythmia
D001145,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,arrhythmia
D003324,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,coronary arteriosclerosis
D001281,0.91,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,atrial fibrillation
D001281,0.56,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,atrial fibrillation
D001281,0.83,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,atrial fibrillation
D001919,0.36,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,bradycardia
D002037,0.19,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,left bundle-branch block
D006323,0.91,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,cardiac arrest
D006323,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,cardiac arrest
D006333,0.36,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,cardiac failure
D006333,0.55,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,cardiac failure
D006333,0.73,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,cardiac failure
D006333,0.75,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,cardiac failure
D006333,0.55,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,cardiac failure
D002305,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,cardiac tamponade
D000072599,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,cardiorespiratory fitness
D000072599,0.19,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,cardiorespiratory fitness
D000072599,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,cardiorespiratory fitness
D006332,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,cardiomegaly
D009202,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,cardiomyopathy
D009202,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,cardiomyopathy
D000067836,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,hoarding disorder
10010276,0.19,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,conduction disorder
D003324,1.27,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,coronary artery disease
D003324,0.19,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,coronary artery disease
D003324,0.55,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,coronary artery disease
D006351,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,heart valves
D004184,0.19,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,heartworm disease
D009202,0.19,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,cardiomyopathy
D018487,0.36,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,left ventricular dysfunction
D018487,0.19,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,left ventricular dysfunction
D018487,0.83,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,left ventricular dysfunction
D016277,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,ventricular function left
D008946,0.19,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,mitral valve stenosis
D009203,1.27,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,myocardial infarction
D009203,0.94,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,myocardial infarction
D009203,0.55,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,myocardial infarction
D001145,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,arrhythmia
10033557,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,palpitations
10033557,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,palpitations
D010490,0.36,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,pericardial effusion
D010493,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,pericarditis
D012804,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,sick sinus syndrome
D001146,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,sinus arrhythmia
D013617,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,supraventricular tachycardia
D013610,0.19,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,tachycardia
D016171,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,torsade de pointes
D018879,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,ventricular extrasystoles
D014693,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,ventricular fibrillation
D014693,0.19,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,ventricular fibrillation
D017180,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,ventricular tachycardia
D017180,0.19,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,ventricular tachycardia
D016153,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,genes nonsense mutation suppressor
D016153,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,genes nonsense mutation suppressor
D002607,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,hereditary type i motor and sensory neuropathy
D003638,0.19,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,deafness
D014717,0.19,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,vertigo
UNKNOWN-check-for-typo,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,D00
UNKNOWN-check-for-typo,0.55,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,D00
D006961,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,hyperparathyroidism
D007018,0.19,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,hypopituitarism
D007037,0.19,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,hypothyroidism
D001766,0.19,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,blindness
D001766,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,blindness unilateral
D001766,0.19,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,blindness unilateral
D003229,0.36,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,conjunctival diseases
D003930,0.19,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,diabetic retinopathy
D004172,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,diplopia
D000799,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,angioedema
D005901,0.36,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,glaucoma
D005902,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,open angle glaucoma
UNKNOWN-check-for-typo,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,D00
D012163,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,retinal detachment
D012163,0.19,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,retinal detachment
D012172,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,retinaldehyde
D012172,0.19,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,retinaldehyde
D012170,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,retinal vein thrombosis
10005886,0.19,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,blurred vision
D002244,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,vitreous carbon
D002244,0.19,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,vitreous carbon
D000007,0.19,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,abdominal injuries
10000060,0.36,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,abdominal distension
D008404,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,massachusetts
D015746,2.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,abdominal pain
D015746,0.19,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,abdominal pain
D015746,1.38,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,abdominal pain
D015746,0.73,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,abdominal pain
D015746,0.19,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,abdominal pain
D015746,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,abdominal pain
D015746,1.27,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,abdominal pain
D015746,0.56,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,abdominal pain
D015746,0.55,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,abdominal pain
D000007,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,abdominal injuries
D000006,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,acute abdomen
D005401,0.19,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,anal fissure
D012003,0.36,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,anal fistula
D001471,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,barrett esophagus
D003092,0.36,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,colitis
D003092,0.19,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,colitis
D003248,0.54,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,constipation
D003248,0.55,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,constipation
D003424,0.54,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,crohn disease
UNKNOWN-check-for-typo,1.63,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,D00
UNKNOWN-check-for-typo,0.38,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,D00
UNKNOWN-check-for-typo,1.38,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,D00
D000081032,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,haemorrhagic pancreatitis
D000072663,0.36,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,spontaneous perforation
D004381,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,duodenal ulcer
D004382,0.36,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,duodenitis
D004382,0.19,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,duodenitis
D004415,0.19,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,dyspepsia
D003680,0.36,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,dysphagia
D000070036,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,faecalibacterium
UNKNOWN-check-for-typo,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,D00
D005414,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,flatulence
D013276,0.36,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,gastric ulcer
D013276,0.19,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,gastric ulcer
D013276,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,gastric ulcer
D005756,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,gastritis
D005756,0.83,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,gastritis
D005756,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,gastritis
D005756,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,gastritis
D005767,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,gastrointestinal disorder
D000069196,0.54,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,gastrointestinal microbiome
D000069196,0.55,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,gastrointestinal microbiome
D013392,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,ulcerban
D010512,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,bleeding on probing gingival
10018286,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,gingival pain
UNKNOWN-check-for-typo,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,D00
D006551,0.36,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,hiatus hernia
D045823,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,ileus
D005746,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,gastric emptying
D015212,0.36,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,inflammatory bowel disease
D006552,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,inguinal hernia
D006552,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,inguinal hernia
D000069196,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,gastrointestinal microbiome
D007415,0.55,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,intestinal obstruction
D007416,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,intestinal perforation
D007420,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,intestine large
D008309,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,mallory weiss syndrome
D050686,0.36,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,globicephala melaena
D050686,0.38,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,globicephala melaena
D050686,0.55,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,globicephala melaena
D009055,0.19,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,mouth
D009325,1.27,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,nausea
D009325,1.5,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,nausea
D009325,1.1,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,nausea
UNKNOWN-check-for-typo,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,D00
D010195,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,pancreatitis
D004412,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,menstruation painful
D010192,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,pancreatic pseudocyst
D010195,0.54,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,pancreatitis
D010195,0.38,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,pancreatitis
D010195,0.55,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,pancreatitis
D010195,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,acute pancreatitis
D010195,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,acute pancreatitis
UNKNOWN-check-for-typo,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,D00
D011349,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,proctitis
D000071056,0.36,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,anorectal malformations
D000071056,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,anorectal malformations
D011350,0.36,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,proctosigmoiditis
D011350,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,proctosigmoiditis
10041101,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,small intestinal obstruction
10041101,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,small intestinal obstruction
10021328,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,ileus
D000070621,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,cystography
D041742,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,upper gastrointestinal tract
D041742,0.55,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,upper gastrointestinal tract
D014839,2.0,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,vomiting
D014839,1.31,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,vomiting
D014839,0.55,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,vomiting
D003291,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,astasia-abasia
D003291,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,astasia-abasia
D064420,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,adverse drug reaction
D001247,0.36,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,asthenia
D001247,0.75,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,asthenia
D001247,0.83,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,asthenia
D003643,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,cardiac death
D013909,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,chest
D013909,0.19,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,chest
D013909,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,chest
D002637,2.54,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,chest pain
D002637,0.75,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,chest pain
D002637,1.93,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,chest pain
D023341,1.27,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,chills
D023341,0.75,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,chills
D023341,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,chills
D000389,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,air conditioning
UNKNOWN-check-for-typo,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,D00
D004864,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,devices
D004364,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,drugs
D004364,0.19,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,drugs
D004364,0.55,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,drugs
D004347,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,drug interaction
D004364,0.19,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,drugs
D005221,0.54,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,fatigue
D005221,1.31,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,fatigue
D005221,7.14,NCT00333840-3,Imatinib to IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,fatigue
D005221,0.83,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,fatigue
10017577,0.19,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,gait disturbance
D003695,0.38,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,healthcare
D003695,0.83,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,healthcare
D000799,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,angioedema
D006099,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,granuloma
D006547,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,hernia
D006965,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,hyperplasia
D005334,0.19,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,hyperthermia
D006987,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,impaired sensation
D007251,0.36,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,influenza
D007251,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,influenza
10025482,0.73,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,malaise
10025482,0.38,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,malaise
D001284,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,atrophy
D009102,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,multiple organ failure
D009336,0.19,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,necrosis
10062501,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,non-cardiac chest pain
D000799,0.54,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,angioedema
D000799,0.19,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,angioedema
D010146,0.73,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,pain
D010146,0.19,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,pain
D010146,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,pain
D017567,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,karnofsky performance status
D017567,0.38,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,karnofsky performance status
D017567,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,karnofsky performance status
D005334,3.45,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,pyrexia
D005334,3.75,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,pyrexia
D005334,7.14,NCT00333840-3,Imatinib to IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,pyrexia
D005334,3.31,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,pyrexia
D012509,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,sarcoma soft tissue
D000080867,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,gingipains
D016757,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,sudden cardiac death
D018746,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,systemic inflammatory response syndrome
D042882,0.36,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,gallstones common bile duct
D001659,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,biliary tract
D002761,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,cholangitis
D002764,1.09,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,cholecystitis
D002764,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,cholecystitis
D041881,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,acute cholecystitis
D041881,0.55,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,acute cholecystitis
D002769,0.73,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,cholelithiasis
D002769,0.38,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,cholelithiasis
D002769,0.55,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,cholelithiasis
D005234,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,steatohepatitis
D056486,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,drug induced liver injury
10017639,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,gallbladder perforation
D008107,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,liver diseases
D017093,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,hepatic failure
D011681,0.19,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,pupillary functions abnormal
10019692,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,hepatic necrosis
D006505,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,hepatitis
D005234,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,steatohepatitis
D006529,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,hepatomegaly
UNKNOWN-check-for-typo,0.19,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,D00
UNKNOWN-check-for-typo,0.55,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,D00
UNKNOWN-check-for-typo,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,D00
D007565,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,jaundice
D007565,0.19,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,jaundice
D007565,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,jaundice
D000707,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,anaphylactic shock
D004342,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,drug hypersensitivity
D006084,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,transplant rejection
D000038,0.36,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,abscess
D000038,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,abscess
D000562,0.19,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,amoebiasis
D000038,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,abscess
10061640,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,anorectal infection
D001064,0.73,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,appendicitis
D001064,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,appendicitis
D001170,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,bacterial arthritis
UNKNOWN-check-for-typo,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,D00
D001424,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,bacterial infection
D014394,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,bone tuberculosis
D001991,0.36,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,bronchitis
D001991,0.38,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,bronchitis
D001991,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,bronchitis
D000072139,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,megavirales
D001996,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,bronchopneumonia
D055732,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,bronchopulmonary aspergillosis
D002481,1.09,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,cellulitis
D002481,0.56,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,cellulitis
D002481,0.55,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,cellulitis
D004761,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,clostridium enterocolitis
D004238,0.54,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,diverticulitis
D010031,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,ear infection
D020031,0.19,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,epstein barr virus infection
D004925,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,escherichia
D000985,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,antisepsis
D014552,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,urinary tract infections
D005499,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,folliculitis
D005734,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,gangrene
D000072139,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,megavirales
D005759,0.54,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,gastroenteritis
D005759,0.83,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,gastroenteritis
D005759,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,gastroenteritis
D005759,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,gastroenteritis
D000072139,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,megavirales
D000069544,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,encephalitis infection
D006192,0.19,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,haemophilus infection
D006509,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,hepatitis b
D006562,0.19,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,herpes zoster
D006562,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,herpes zoster
D010272,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,parasite infections
D007239,0.19,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,infection
D007239,0.55,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,infection
D007251,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,influenza
D007251,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,influenza
D011014,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,lobar pneumonia
D011014,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,lobar pneumonia
D000069544,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,encephalitis infection
D012141,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,respiratory tract infections
D012141,0.55,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,respiratory tract infections
10061229,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,lung infection
10061229,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,lung infection
D008288,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,malaria
D008581,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,meningitis
D008586,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,pneumococcal meningitis
D020803,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,herpetic meningoencephalitis
D000038,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,abscess
D000038,0.19,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,abscess
D009175,0.19,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,mycoplasma infection
D005208,0.19,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,fasciitis
D000985,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,antisepsis
D009920,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,orchitis
D010019,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,osteomyelitis
D010309,0.19,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,parotitis
D000038,0.36,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,abscess
D000038,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,abscess
D000038,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,abscess
D010612,0.36,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,pharyngitis
D010612,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,pharyngitis
D000985,0.19,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,antisepsis
D011020,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,pneumocystis jirovecii pneumonia
D011014,2.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,pneumonia
D011014,1.31,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,pneumonia
D011014,3.86,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,pneumonia
D001996,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,bronchopneumonia
D013530,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,wound infection postoperative
D013530,0.19,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,wound infection postoperative
10050662,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,prostate infection
D004761,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,pseudomembranous colitis
D011704,0.38,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,pyelonephritis
D000038,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,abscess
D000038,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,abscess
D012141,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,respiratory tract infection
D012141,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,respiratory tract infections
D012141,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,respiratory tract infections
D012220,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,rhinitis
D012480,0.55,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,salmonellosis
D012488,0.19,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,salpingitis
D000038,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,abscess
D005734,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,gangrene
D018805,0.54,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,sepsis
D018805,0.19,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,sepsis
D018805,0.55,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,sepsis
D012772,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,septic shock
D012772,0.19,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,septic shock
D012852,0.36,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,sinusitis
D012852,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,sinusitis
D013203,0.36,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,staphylococcal infection
D013203,0.19,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,staphylococcal infection
D013290,0.19,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,streptococcal infection
D000038,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,abscess
D002175,0.19,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,candida
D014069,0.36,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,tonsillitis
D000038,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,abscess
D002184,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,canine tracheobronchitis virus
D002490,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,central nervous system
D012141,0.73,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,upper respiratory tract infections
D014552,0.73,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,urinary tract infection
D014552,0.75,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,urinary tract infection
D014552,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,urinary tract infection
10040047,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,sepsis
10040047,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,sepsis
D014777,0.54,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,viral infection
D014777,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,viral infection
D012141,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,upper respiratory tract infections
D014847,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,vulvitis
D014946,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,wound infection
D014946,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,wound infection
D013203,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,staphylococcal infections
D000058,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,accidental falls
D000818,0.19,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,animals
D064386,0.36,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,ankle fracture
D001181,0.19,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,arthropods
D007714,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,vertebral cervical fusion syndrome
D050815,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,compression fracture
D001924,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,brain concussion
D003288,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,contusion
D000066502,0.19,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,grandfather
D005147,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,facial bones
10016173,0.54,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,fall
10016173,0.19,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,fall
10016173,0.55,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,fall
D005265,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,femoral neck fracture
D005265,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,femur neck fractures
D005360,0.36,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,fibula
D005360,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,fibula
10017076,0.19,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,fracture
D055031,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,primary graft dysfunction
D006259,0.36,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,head injury
10020100,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,hip fracture
10020100,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,hip fracture
D006811,0.36,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,humerus
D004204,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,joint dislocation
D004204,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,joint dislocation
D005121,0.55,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,limbs
D015775,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,microfractures
D000072600,0.36,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,meniscus
D000072600,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,meniscus
D062787,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,drug overdose
D062787,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,drug overdose
D011183,0.36,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,postoperative complications
D000076282,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,composting
D012253,0.36,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,rib fracture
D012253,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,rib fracture
D000063,0.36,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,accidents traffic
D000063,0.19,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,accidents traffic
D019291,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,skull base
D006408,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,hematoma subdural
D012421,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,rupture
D000074766,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,viburnales
D001468,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,thoracica
D014082,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,tooth fracture
D000081015,0.56,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,ototoxicity
D034941,0.36,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,upper limb
D014525,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,urethral stricture
D006083,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,vascular graft occlusion
D057772,0.19,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,vascular injury
D017541,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,pseudoaneurysm
D009489,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,neurosecretion
10001551,0.36,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,alanine aminotransferase increased
10001551,0.19,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,alanine aminotransferase increased
10001551,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,alanine aminotransferase increased
10040139,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,serum amylase increased
D001219,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,aspartate aminotransferases
10003481,0.36,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,aspartate aminotransferase increased
10003481,0.19,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,aspartate aminotransferase increased
10003481,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,aspartate aminotransferase increased
D014747,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,cellblastin
D000938,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,antigen-presenting cells
10001675,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,alkaline phosphatase increased
10001675,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,alkaline phosphatase increased
10005364,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,blood bilirubin increased
10005364,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,blood bilirubin increased
D003402,0.54,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,creatine phosphokinase
D003402,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,creatine phosphokinase
10011368,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,creatinine increased
10011368,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,creatinine increased
D000071997,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,blood culture
D010281,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,parathyroid hormone
D001794,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,blood pressure
D001831,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,body temperature
D001831,0.19,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,body temperature
D000308,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,hyperadrenalism
D000013,0.19,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,congenital abnormalities
D000013,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,congenital abnormalities
D005723,0.19,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,gammaglutamyltransferase
D005723,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,gammaglutamyltransferase
D007989,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,decreased libido
D007989,0.55,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,decreased libido
D006339,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,heart rate
D001051,0.36,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,apoenzymes
10024574,0.36,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,lipase increased
D008111,0.55,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,liver function tests
D000015,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,abnormalities multiple
D000069597,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,presenteeism
D010976,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,platelet count
D000939,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,antigenic specificity
D000939,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,antigenic specificity
10007612,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,cardiac troponin i increased
D013851,0.36,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,underweight
D013851,0.19,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,underweight
D013851,0.55,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,underweight
D007958,0.75,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,blood cell count white
D007958,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,blood cell count white
D002100,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,cachexia
D001066,0.56,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,appetite
D001066,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,appetite
D003681,0.91,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,dehydration
D003681,0.94,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,dehydration
D003681,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,dehydration
D003920,0.19,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,diabetes mellitus
D014883,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,water-electrolyte imbalance
D000073923,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,food intolerance
D006073,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,gout
UNKNOWN-check-for-typo,0.36,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,D00
UNKNOWN-check-for-typo,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,D00
UNKNOWN-check-for-typo,0.38,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,D00
UNKNOWN-check-for-typo,0.36,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,D00
UNKNOWN-check-for-typo,0.38,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,D00
UNKNOWN-check-for-typo,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,D00
UNKNOWN-check-for-typo,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,D00
UNKNOWN-check-for-typo,0.36,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,D00
UNKNOWN-check-for-typo,0.19,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,D00
UNKNOWN-check-for-typo,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,D00
UNKNOWN-check-for-typo,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,D00
D018771,0.73,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,arthralgia
D018771,2.06,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,arthralgia
D018771,7.14,NCT00333840-3,Imatinib to IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,arthralgia
D018771,0.55,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,arthralgia
D001168,0.36,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,arthritis
D001168,0.19,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,arthritis
D001416,0.73,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,back pain
D001416,1.13,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,back pain
D001416,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,back pain
D000080983,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,bone marrow failure disorders
10006002,0.36,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,bone pain
10006002,1.13,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,bone pain
10006002,7.14,NCT00333840-3,Imatinib to IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,bone pain
10006002,0.55,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,bone pain
D003161,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,compartment syndrome
D021501,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,flank pain
D000080867,0.19,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,gingipains
D018979,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,inclusion body myositis
D018979,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,inclusion body myositis
D007403,0.73,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,intervertebral disc
D007403,0.19,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,intervertebral disc
D007403,0.83,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,intervertebral disc
D007596,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,joints
D008947,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,mixed connective tissue disease
D009133,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,muscle atrophy
D013035,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,muscle spasms
D018908,0.36,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,muscular weakness
D002637,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,chest pain
D002637,1.1,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,chest pain
D059352,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,musculoskeletal pain
D059352,0.56,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,musculoskeletal pain
D059352,0.55,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,musculoskeletal pain
D063806,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,myalgia
D063806,1.88,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,myalgia
D063806,0.55,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,myalgia
D009220,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,myositis
D008404,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,massachusetts
D019547,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,neck pain
D010000,0.19,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,osteitis
D010003,0.91,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,osteoarthritis
D010003,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,osteoarthritis
D010014,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,osteolysis
D010020,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,osteonecrosis
D010020,0.56,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,osteonecrosis
D010020,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,osteonecrosis
D058866,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,osteoporotic fracture
10033425,0.73,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,pain in extremity
10033425,0.94,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,pain in extremity
10033425,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,pain in extremity
D000080867,0.36,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,gingipains
D001168,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,polyarthritis
D001168,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,polyarthritis
D001172,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,rheumatoid arthritis
D001172,0.19,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,rheumatoid arthritis
D019534,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,rotator cuff impingement syndrome
D013130,0.36,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,spinal stenosis
D013130,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,spinal stenosis
D013168,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,spondylolisthesis
D008180,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,systemic lupus erythematosus
D052256,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,tendonitis
D000069472,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,cholestagel
D000006,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,abdomen acute
D015470,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,leukemia myeloid acute
D015470,0.83,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,leukemia myeloid acute
D000230,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,adenocarcinoma
D002280,1.09,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,basal cell carcinoma
D002280,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,basal cell carcinoma
D009369,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,benign neoplasms
D001749,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,bladder cancer
D014747,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,cellblastin
D014747,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,cellblastin
D001752,0.73,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,blast crisis
D001752,0.94,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,blast crisis
D001752,3.31,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,blast crisis
D001859,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,bone neoplasm
D001932,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,brain neoplasm
D001943,0.54,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,breast cancer
D001943,0.19,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,breast cancer
D001943,0.83,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,breast cancer
D001943,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,breast neoplasm
D002282,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,bronchioloalveolar carcinoma
D002282,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,bronchioloalveolar carcinoma
D000071960,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,breast carcinoma in situ
D000230,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,adenocarcinoma
D023981,0.19,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,chloroma
D023981,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,chloroma
D002781,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,cholesteatoma
D015451,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,lymphocytic leukemia chronic
D015464,0.36,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,leukemia chronic myeloid
D015464,0.83,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,leukemia chronic myeloid
D003110,0.36,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,colon cancer
D003110,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,colon cancer
D016889,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,endometrial cancer
UNKNOWN-check-for-typo,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,D00
D008998,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,monoclonal gammopathies benign
D007822,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,laryngeal cancer
D002026,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,gliporal
D000077192,0.36,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,lung adenocarcinoma
D008175,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,lung neoplasms
D008223,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,lymphoma
D008545,0.54,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,malignant melanoma
D008545,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,malignant melanoma
D008545,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,malignant melanoma
D009362,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,metastases
D000077553,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,edarabone
D007420,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,intestine large
D001664,0.55,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,biliverdine
D009369,0.36,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,neoplasms
D002292,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,carcinoma renal cell
D009101,0.73,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,multiple myeloma
D009101,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,multiple myeloma
D009190,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,myelodysplastic syndrome
D009190,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,myelodysplastic syndrome
D055728,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,myelofibrosis
D009369,0.73,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,malignant neoplasm
D009369,0.38,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,malignant neoplasm
D009369,7.14,NCT00333840-3,Imatinib to IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,malignant neoplasm
D009369,0.83,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,malignant neoplasm
D001065,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,appendix
D009396,0.19,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,nephroblastoma
D009490,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,neuroendocrine system
D008228,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,lymphoma nonhodgkins
D008228,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,lymphoma nonhodgkins
D000230,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,adenocarcinoma
D010190,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,pancreatic neoplasm
D010190,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,pancreatic neoplasm
D010257,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,paraneoplastic syndrome
D006961,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,hyperparathyroidism
D011471,2.0,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,prostate cancer
D011471,0.19,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,prostate cancer
D011471,2.48,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,prostate cancer
D011471,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,prostate cancer
D011470,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,prostatic adenoma
D012004,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,rectal cancer
D012004,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,rectal cancer
D007680,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,renal cancer
D002292,0.54,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,renal cell carcinoma
D018279,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,signet ring cell carcinoma
D002289,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,nonsmall cell lung cancer
D002294,1.09,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,squamous cell carcinoma
D002294,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,squamous cell carcinoma
D002294,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,carcinoma squamous cell
D013964,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,thyroid adenoma
D013964,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,thyroid cancer
D009369,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,malignant neoplasms
D002295,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,transitional cell carcinoma
D000690,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,amyotrophic lateral sclerosis
D000690,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,amyotrophic lateral sclerosis
D001037,0.19,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,aphasia
D000071699,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,vestibular areflexia
D001259,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,ataxia
D001259,0.56,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,ataxia
D000067571,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,balance sheet
D001621,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,ribrain
D000799,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,angioedema
D002339,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,artery carotid
D002339,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,artery carotid
D016893,0.36,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,carotid artery stenosis
D016893,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,carotid artery stenosis
D002349,0.19,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,carpal tunnel syndrome
D002526,0.19,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,cerebellar syndrome
D020244,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,middle cerebral artery occlusion
D002544,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,cerebral infarction
D020521,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,cerebrovascular accident
D020521,0.38,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,cerebrovascular accident
D020521,0.55,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,cerebrovascular accident
D013577,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,syndrome
D008569,0.19,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,retention disorders cognitive
D003128,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,coma
D020918,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,complex regional pain syndrome
D020325,0.19,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,complicated migraine
D012640,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,convulsion
D012640,0.19,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,convulsion
D012640,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,convulsion
D003704,0.38,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,dementia
D000544,0.19,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,alzheimer type senile dementia
D003711,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,demyelination
D003929,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,diabetic neuropathy
D001288,0.19,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,attention
D004244,1.27,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,dizziness
D004244,0.94,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,dizziness
D004244,7.14,NCT00333840-3,Imatinib to IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,dizziness
D004244,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,dizziness
D004827,0.38,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,epilepsy
D001480,0.38,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,extrapyramidal disorder
D004830,0.19,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,grand mal convulsion
D006261,0.54,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,headache
D006261,0.56,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,headache
D006261,0.55,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,headache
D010291,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,hemiparesis
D010291,0.19,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,hemiparesis
D002534,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,hypoxic encephalopathy
D009437,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,neuralgia
D010211,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,papilledema associated with increased intracranial pressure
D013474,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,sunstroke
D014474,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,loss of consciousness
D014474,0.19,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,loss of consciousness
D008881,0.38,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,migraine
D010291,0.19,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,monoparesis
D009103,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,multiple sclerosis
D000066530,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,neurological rehabilitation
D020149,0.38,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,neurotoxicity syndrome manganese
UNKNOWN-check-for-typo,0.19,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,D00
D010264,0.19,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,paraplegia
D000070579,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,parkinson disease associated proteins
10034620,0.19,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,peripheral sensory neuropathy
D010543,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,peroneal nerve
D055958,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,piriformis syndrome
D011115,0.19,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,polyneuropathy
D013575,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,presyncope
D013575,0.19,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,presyncope
D011843,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,radiculopathy
D012585,0.36,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,sciatica
D012585,0.38,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,sciatica
D004828,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,simple partial seizures
D000077260,0.19,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,somnolence
D001072,0.38,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,speech-language disorder 1
D007427,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,subarachnoid pressure
D013575,1.45,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,syncope
D013575,0.75,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,syncope
D013575,0.55,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,syncope
D004833,0.19,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,temporal lobe epilepsy
D020236,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,transient global amnesia
D002546,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,ischemic attack transient
D002546,0.56,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,ischemic attack transient
D002546,0.83,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,ischemic attack transient
D014202,0.19,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,tremor
D015840,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,oculomotor nerve paralysis
D000022,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,spontaneous abortion
D011247,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,pregnancy
D000374,0.19,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,aggression
10001497,0.38,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,agitation
D001007,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,anxiety
D001007,0.56,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,anxiety
D000081013,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,completed suicide
D003221,0.56,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,confusional state
D003693,0.19,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,delirium
D003863,0.36,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,depression
D003863,2.81,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,depression
D003863,0.55,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,depression
D003863,0.38,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,depression
D003221,0.19,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,disorientation
D000377,0.19,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,ideational agnosia
D001714,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,mania
D000073216,0.19,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,mental status tests
D000339,0.19,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,mood
D010259,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,paranoia
D011618,0.19,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,psychotic disorder
D011618,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,psychotic disorder
D059020,0.94,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,suicidal ideation
D017114,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,liver failure acute
D002137,0.19,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,calculus
D002137,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,calculus
D002137,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,calculus
D053159,0.38,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,dysuria
UNKNOWN-check-for-typo,0.36,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,D00
UNKNOWN-check-for-typo,0.19,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,D00
UNKNOWN-check-for-typo,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,D00
D053040,1.09,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,nephrolithiasis
D053040,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,nephrolithiasis
D009404,0.19,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,nephrotic syndrome
D009846,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,oliguria
UNKNOWN-check-for-typo,0.19,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,D00
D011507,0.19,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,proteinuria
D056844,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,renal colic
D056844,0.19,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,renal colic
D051437,0.91,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,renal failure
D051437,0.38,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,renal failure
D051437,0.83,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,renal failure
D058186,0.91,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,acute renal failure
D058186,0.55,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,acute renal failure
D007676,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,renal failure chronic
D014525,0.36,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,urethral stenosis
10061574,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,urinary tract obstruction
10061574,0.19,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,urinary tract obstruction
D011470,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,benign prostatic hyperplasia
D011470,0.19,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,benign prostatic hyperplasia
D001940,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,breast
D004823,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,epididymitis
D008595,0.38,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,menorrhagia
D008595,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,menorrhagia
D008796,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,metrorrhagia
D010048,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,ovarian cyst
D010048,0.19,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,ovarian cyst
D010048,0.55,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,ovarian cyst
D010413,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,penis
D007917,0.36,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,leprostatics
D011472,0.19,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,prostatitis
D001929,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,brain swelling
D000070621,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,cystography
D014648,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,varicose veins
D012128,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,acute respiratory distress syndrome
10003504,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,aspiration
D001249,0.36,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,asthma
D001261,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,atelectasis
D016535,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,bronchial hyperreactivity
D029481,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,chronic bronchitis
D029424,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,chronic obstructive pulmonary disease
D029424,0.55,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,chronic obstructive pulmonary disease
D012131,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,respiratory failure
D003371,0.54,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,cough
D003371,0.19,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,cough
D003371,0.83,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,cough
UNKNOWN-check-for-typo,2.0,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,D00
UNKNOWN-check-for-typo,0.75,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,D00
UNKNOWN-check-for-typo,1.65,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,D00
D051270,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,primary exertional headache
D004844,0.36,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,epistaxis
D004844,0.19,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,epistaxis
D004844,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,epistaxis
UNKNOWN-check-for-typo,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,D00
UNKNOWN-check-for-typo,0.19,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,D00
D006606,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,hiccups
D006935,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,hypercapnia
D006985,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,hyperventilation
D000860,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,hypoxia
D017563,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,interstitial lung disease
D008168,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,lung
D008168,0.38,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,lung
D008168,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,lung
D008168,0.19,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,lung
D008168,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,lung
D015508,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,nasal obstruction
10068319,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,oropharyngeal pain
D004890,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,erythema
10050028,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,pharyngeal stenosis
D010845,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,pickwickian syndrome
D010996,0.91,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,pleural effusion
D010996,0.38,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,pleural effusion
D010996,0.55,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,pleural effusion
D010998,0.54,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,pleurisy
D011015,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,aspiration pneumonia
D011014,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,pneumonitis
D011030,0.36,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,pneumothorax
10036790,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,productive cough
10036790,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,productive cough
D011655,0.54,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,pulmonary embolism
D011655,0.19,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,pulmonary embolism
D011655,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,pulmonary embolism
D000799,0.54,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,angioedema
D000799,0.19,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,angioedema
D000799,0.83,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,angioedema
D012127,0.36,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,respiratory distress syndrome newborn
D012131,0.73,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,respiratory failure
D012131,0.38,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,respiratory failure
D012891,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,sleep apnea syndromes
D012141,0.19,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,upper respiratory tract infections
D012135,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,wheezing
D016463,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,acute febrile neutrophilic dermatosis
D000505,0.19,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,alopecia
D000799,0.55,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,angioedema
D018366,0.19,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,vasculitis leukocytoclastic cutaneous
D004814,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,epidermal cyst
D003875,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,drug eruption
D004892,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,erythema multiforme
D004893,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,erythema nodosum
D006945,0.19,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,hyperhidrosis
D006945,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,hyperhidrosis
D003288,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,bruise
D011693,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,petechiae
D004244,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,lightheadedness
D011537,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,pruritus
D005076,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,rash
D005076,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,rash
10037868,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,rash maculo-papular
10037868,0.19,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,rash maculo-papular
D002615,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,chemexfoliation
D012867,0.55,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,skin
D005218,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,steatonecrosis
D013262,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,stevens johnson syndrome
D000077944,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,alefacept
D014581,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,urticaria
D002064,0.19,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,buserelin
D000077109,0.19,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,disability studies
D000022,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,miscarriage
D000028,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,induced abortion
D000028,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,induced abortion
D000038,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,abscess
D016026,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,bone marrow transplantation
D001964,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,hustentabsratiopharm
D018380,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,hematopoietic stem cell transplantation
D000783,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,aneurysm
D001014,0.19,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,aortic aneurysm
D001024,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,aortic stenosis
D001157,0.36,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,arterial occlusive disease
D001161,0.36,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,arteriosclerosis
D012769,0.36,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,circulatory collapse
D020246,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,deep vein thrombosis
D020246,0.19,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,deep vein thrombosis
D020246,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,deep vein thrombosis
D005263,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,femoral artery
UNKNOWN-check-for-typo,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,D00
UNKNOWN-check-for-typo,0.19,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,D00
D000074042,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,cerebral intraventricular haemorrhage
D006973,0.91,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,hypertension
D006973,0.19,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,hypertension
D006973,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,hypertension
D000959,0.19,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,antihypertensives
D007022,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,hypotension
D007022,0.75,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,hypotension
D007083,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,iliac artery
D007083,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,iliac artery
D007238,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,infarction
UNKNOWN-check-for-typo,0.83,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,D00
UNKNOWN-check-for-typo,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,D00
D007024,0.38,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,orthostatic hypotension
D007024,0.28,NCT00333840-4,IFN-a + Ara-C to Imatinib,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,orthostatic hypotension
D001157,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,arterial occlusive diseases
D002561,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,cerebrovascular disorders
D010689,0.19,NCT00333840-2,IFN-a + Ara-C,NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,phlebitis
10034879,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,phlebitis
D002561,0.18,NCT00333840-1,Imatinib (STI571),NCT00333840,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,cerebrovascular occlusion
D064420,100.0,NCT00334074-1,Clofarabine and Cytarabine,NCT00334074,Clofarabine and Ara-C for the Treatment of Relapsed AML and Untreated MDS,adverse drug events
D015430,10.0,NCT00334074-1,Clofarabine and Cytarabine,NCT00334074,Clofarabine and Ara-C for the Treatment of Relapsed AML and Untreated MDS,weight gain
D010198,80.0,NCT00334074-1,Clofarabine and Cytarabine,NCT00334074,Clofarabine and Ara-C for the Treatment of Relapsed AML and Untreated MDS,pancytopenia
D001792,3.33,NCT00334074-1,Clofarabine and Cytarabine,NCT00334074,Clofarabine and Ara-C for the Treatment of Relapsed AML and Untreated MDS,platelets
D013921,3.33,NCT00334074-1,Clofarabine and Cytarabine,NCT00334074,Clofarabine and Ara-C for the Treatment of Relapsed AML and Untreated MDS,thrombocytopenia
D001810,3.33,NCT00334074-1,Clofarabine and Cytarabine,NCT00334074,Clofarabine and Ara-C for the Treatment of Relapsed AML and Untreated MDS,blood volume
D001281,10.0,NCT00334074-1,Clofarabine and Cytarabine,NCT00334074,Clofarabine and Ara-C for the Treatment of Relapsed AML and Untreated MDS,atrial fibrillation
D009203,3.33,NCT00334074-1,Clofarabine and Cytarabine,NCT00334074,Clofarabine and Ara-C for the Treatment of Relapsed AML and Untreated MDS,myocardial infarction
D009325,3.33,NCT00334074-1,Clofarabine and Cytarabine,NCT00334074,Clofarabine and Ara-C for the Treatment of Relapsed AML and Untreated MDS,nausea
10041101,3.33,NCT00334074-1,Clofarabine and Cytarabine,NCT00334074,Clofarabine and Ara-C for the Treatment of Relapsed AML and Untreated MDS,small intestinal obstruction
D010481,3.33,NCT00334074-1,Clofarabine and Cytarabine,NCT00334074,Clofarabine and Ara-C for the Treatment of Relapsed AML and Untreated MDS,perianal glands
D064147,6.67,NCT00334074-1,Clofarabine and Cytarabine,NCT00334074,Clofarabine and Ara-C for the Treatment of Relapsed AML and Untreated MDS,febrile neutropenia
D005334,10.0,NCT00334074-1,Clofarabine and Cytarabine,NCT00334074,Clofarabine and Ara-C for the Treatment of Relapsed AML and Untreated MDS,fever
D001996,6.67,NCT00334074-1,Clofarabine and Cytarabine,NCT00334074,Clofarabine and Ara-C for the Treatment of Relapsed AML and Untreated MDS,bronchopneumonia
D018805,16.67,NCT00334074-1,Clofarabine and Cytarabine,NCT00334074,Clofarabine and Ara-C for the Treatment of Relapsed AML and Untreated MDS,sepsis
D003030,3.33,NCT00334074-1,Clofarabine and Cytarabine,NCT00334074,Clofarabine and Ara-C for the Treatment of Relapsed AML and Untreated MDS,staphylocoagulase
D003030,3.33,NCT00334074-1,Clofarabine and Cytarabine,NCT00334074,Clofarabine and Ara-C for the Treatment of Relapsed AML and Untreated MDS,staphylocoagulase
D010032,3.33,NCT00334074-1,Clofarabine and Cytarabine,NCT00334074,Clofarabine and Ara-C for the Treatment of Relapsed AML and Untreated MDS,external otitis
D009102,20.0,NCT00334074-1,Clofarabine and Cytarabine,NCT00334074,Clofarabine and Ara-C for the Treatment of Relapsed AML and Untreated MDS,multiple organ failure
D042742,3.33,NCT00334074-1,Clofarabine and Cytarabine,NCT00334074,Clofarabine and Ara-C for the Treatment of Relapsed AML and Untreated MDS,delftia
D006943,3.33,NCT00334074-1,Clofarabine and Cytarabine,NCT00334074,Clofarabine and Ara-C for the Treatment of Relapsed AML and Untreated MDS,hyperglycemia
D003693,3.33,NCT00334074-1,Clofarabine and Cytarabine,NCT00334074,Clofarabine and Ara-C for the Treatment of Relapsed AML and Untreated MDS,delirium
D000309,10.0,NCT00334074-1,Clofarabine and Cytarabine,NCT00334074,Clofarabine and Ara-C for the Treatment of Relapsed AML and Untreated MDS,adrenal insufficiency
D001261,3.33,NCT00334074-1,Clofarabine and Cytarabine,NCT00334074,Clofarabine and Ara-C for the Treatment of Relapsed AML and Untreated MDS,pulmonary atelectasis
D012131,10.0,NCT00334074-1,Clofarabine and Cytarabine,NCT00334074,Clofarabine and Ara-C for the Treatment of Relapsed AML and Untreated MDS,respiratory failure
D012127,6.67,NCT00334074-1,Clofarabine and Cytarabine,NCT00334074,Clofarabine and Ara-C for the Treatment of Relapsed AML and Untreated MDS,respiratory distress syndrome newborn
D011014,6.67,NCT00334074-1,Clofarabine and Cytarabine,NCT00334074,Clofarabine and Ara-C for the Treatment of Relapsed AML and Untreated MDS,pneumonia
D060831,10.0,NCT00334074-1,Clofarabine and Cytarabine,NCT00334074,Clofarabine and Ara-C for the Treatment of Relapsed AML and Untreated MDS,hand-foot syndrome
D064420,3.85,NCT00336583-1,ESHAOx,NCT00336583,Etoposide  Methylprednisolone  High-dose Cytarabine and Oxaliplatin as 2nd Line Therapy for Non-Hodgkin's Lymphoma (NHL),adverse drug events
D064147,3.85,NCT00336583-1,ESHAOx,NCT00336583,Etoposide  Methylprednisolone  High-dose Cytarabine and Oxaliplatin as 2nd Line Therapy for Non-Hodgkin's Lymphoma (NHL),febrile neutropenia
D064420,13.89,NCT00337168-1,Induction,NCT00337168,S0530 Cytarabine and Clofarabine in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia,adverse drug events
D064147,2.78,NCT00337168-1,Induction,NCT00337168,S0530 Cytarabine and Clofarabine in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia,febrile neutropenia
D003092,2.78,NCT00337168-1,Induction,NCT00337168,S0530 Cytarabine and Clofarabine in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia,colitis
D009102,2.78,NCT00337168-1,Induction,NCT00337168,S0530 Cytarabine and Clofarabine in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia,multiple organ failure
D000069544,2.78,NCT00337168-1,Induction,NCT00337168,S0530 Cytarabine and Clofarabine in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia,encephalitis infection
D051437,2.78,NCT00337168-1,Induction,NCT00337168,S0530 Cytarabine and Clofarabine in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia,renal failure
D007022,2.78,NCT00337168-1,Induction,NCT00337168,S0530 Cytarabine and Clofarabine in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia,hypotension
D009026,11.11,NCT00368355-1,CLINIMACS Device,NCT00368355,T Cell Depletion for Recipients of HLA Haploidentical Related Donor Stem Cell Grafts,mortality
D009026,14.29,NCT00368355-2,ISOLEX Device,NCT00368355,T Cell Depletion for Recipients of HLA Haploidentical Related Donor Stem Cell Grafts,mortality
D064420,77.78,NCT00368355-1,CLINIMACS Device,NCT00368355,T Cell Depletion for Recipients of HLA Haploidentical Related Donor Stem Cell Grafts,adverse drug events
D064420,53.57,NCT00368355-2,ISOLEX Device,NCT00368355,T Cell Depletion for Recipients of HLA Haploidentical Related Donor Stem Cell Grafts,adverse drug events
D006470,11.11,NCT00368355-1,CLINIMACS Device,NCT00368355,T Cell Depletion for Recipients of HLA Haploidentical Related Donor Stem Cell Grafts,hemorrhage
D007022,3.57,NCT00368355-2,ISOLEX Device,NCT00368355,T Cell Depletion for Recipients of HLA Haploidentical Related Donor Stem Cell Grafts,hypotension
D013616,3.57,NCT00368355-2,ISOLEX Device,NCT00368355,T Cell Depletion for Recipients of HLA Haploidentical Related Donor Stem Cell Grafts,sinus tachycardia
10047281,3.57,NCT00368355-2,ISOLEX Device,NCT00368355,T Cell Depletion for Recipients of HLA Haploidentical Related Donor Stem Cell Grafts,ventricular arrhythmia
D003092,5.56,NCT00368355-1,CLINIMACS Device,NCT00368355,T Cell Depletion for Recipients of HLA Haploidentical Related Donor Stem Cell Grafts,colitis
D001064,3.57,NCT00368355-2,ISOLEX Device,NCT00368355,T Cell Depletion for Recipients of HLA Haploidentical Related Donor Stem Cell Grafts,appendicitis
D013280,3.57,NCT00368355-2,ISOLEX Device,NCT00368355,T Cell Depletion for Recipients of HLA Haploidentical Related Donor Stem Cell Grafts,oral mucositis
D014456,3.57,NCT00368355-2,ISOLEX Device,NCT00368355,T Cell Depletion for Recipients of HLA Haploidentical Related Donor Stem Cell Grafts,ulcers
D008107,3.57,NCT00368355-2,ISOLEX Device,NCT00368355,T Cell Depletion for Recipients of HLA Haploidentical Related Donor Stem Cell Grafts,liver dysfunction
D001219,7.14,NCT00368355-2,ISOLEX Device,NCT00368355,T Cell Depletion for Recipients of HLA Haploidentical Related Donor Stem Cell Grafts,serum glutamic-oxaloacetic transaminase
D000410,3.57,NCT00368355-2,ISOLEX Device,NCT00368355,T Cell Depletion for Recipients of HLA Haploidentical Related Donor Stem Cell Grafts,glutamic-pyruvic transaminase
10007810,11.11,NCT00368355-1,CLINIMACS Device,NCT00368355,T Cell Depletion for Recipients of HLA Haploidentical Related Donor Stem Cell Grafts,catheter related infection
10007810,7.14,NCT00368355-2,ISOLEX Device,NCT00368355,T Cell Depletion for Recipients of HLA Haploidentical Related Donor Stem Cell Grafts,catheter related infection
D000069544,5.56,NCT00368355-1,CLINIMACS Device,NCT00368355,T Cell Depletion for Recipients of HLA Haploidentical Related Donor Stem Cell Grafts,encephalitis infection
D000069544,3.57,NCT00368355-2,ISOLEX Device,NCT00368355,T Cell Depletion for Recipients of HLA Haploidentical Related Donor Stem Cell Grafts,encephalitis infection
D000069544,55.56,NCT00368355-1,CLINIMACS Device,NCT00368355,T Cell Depletion for Recipients of HLA Haploidentical Related Donor Stem Cell Grafts,encephalitis infection
D000069544,21.43,NCT00368355-2,ISOLEX Device,NCT00368355,T Cell Depletion for Recipients of HLA Haploidentical Related Donor Stem Cell Grafts,encephalitis infection
D006943,3.57,NCT00368355-2,ISOLEX Device,NCT00368355,T Cell Depletion for Recipients of HLA Haploidentical Related Donor Stem Cell Grafts,hyperglycemia
D007008,7.14,NCT00368355-2,ISOLEX Device,NCT00368355,T Cell Depletion for Recipients of HLA Haploidentical Related Donor Stem Cell Grafts,hypokalemia
D001259,3.57,NCT00368355-2,ISOLEX Device,NCT00368355,T Cell Depletion for Recipients of HLA Haploidentical Related Donor Stem Cell Grafts,ataxia
D002607,5.56,NCT00368355-1,CLINIMACS Device,NCT00368355,T Cell Depletion for Recipients of HLA Haploidentical Related Donor Stem Cell Grafts,hereditary type i motor and sensory neuropathy
D014592,5.56,NCT00368355-1,CLINIMACS Device,NCT00368355,T Cell Depletion for Recipients of HLA Haploidentical Related Donor Stem Cell Grafts,vaginal bleeding
D014884,7.14,NCT00368355-2,ISOLEX Device,NCT00368355,T Cell Depletion for Recipients of HLA Haploidentical Related Donor Stem Cell Grafts,meningococcal hemorrhagic adrenalitis
D000308,5.56,NCT00368355-1,CLINIMACS Device,NCT00368355,T Cell Depletion for Recipients of HLA Haploidentical Related Donor Stem Cell Grafts,hyperadrenalism
D000308,3.57,NCT00368355-2,ISOLEX Device,NCT00368355,T Cell Depletion for Recipients of HLA Haploidentical Related Donor Stem Cell Grafts,hyperadrenalism
D051437,3.57,NCT00368355-2,ISOLEX Device,NCT00368355,T Cell Depletion for Recipients of HLA Haploidentical Related Donor Stem Cell Grafts,renal failure
D012128,3.57,NCT00368355-2,ISOLEX Device,NCT00368355,T Cell Depletion for Recipients of HLA Haploidentical Related Donor Stem Cell Grafts,respiratory distress syndrome adult
D000860,3.57,NCT00368355-2,ISOLEX Device,NCT00368355,T Cell Depletion for Recipients of HLA Haploidentical Related Donor Stem Cell Grafts,hypoxia
D011030,3.57,NCT00368355-2,ISOLEX Device,NCT00368355,T Cell Depletion for Recipients of HLA Haploidentical Related Donor Stem Cell Grafts,pneumothorax
D012131,5.56,NCT00368355-1,CLINIMACS Device,NCT00368355,T Cell Depletion for Recipients of HLA Haploidentical Related Donor Stem Cell Grafts,respiratory failure
D064807,5.56,NCT00368355-1,CLINIMACS Device,NCT00368355,T Cell Depletion for Recipients of HLA Haploidentical Related Donor Stem Cell Grafts,central anticholinergic syndrome
D012131,3.57,NCT00368355-2,ISOLEX Device,NCT00368355,T Cell Depletion for Recipients of HLA Haploidentical Related Donor Stem Cell Grafts,respiratory failure
D064420,1.47,NCT00369317-1,Treatment (Combination Chemotherapy),NCT00369317,Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes,adverse drug events
D001201,0.49,NCT00369317-1,Treatment (Combination Chemotherapy),NCT00369317,Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes,ascites
D053706,0.49,NCT00369317-1,Treatment (Combination Chemotherapy),NCT00369317,Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes,typhlitis
D017093,0.49,NCT00369317-1,Treatment (Combination Chemotherapy),NCT00369317,Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes,hepatic failure
10021428,0.49,NCT00369317-1,Treatment (Combination Chemotherapy),NCT00369317,Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes,immune system disorders - other specify
D000860,0.49,NCT00369317-1,Treatment (Combination Chemotherapy),NCT00369317,Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes,hypoxia
10038738,0.49,NCT00369317-1,Treatment (Combination Chemotherapy),NCT00369317,Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes,respiratory thoracic and mediastinal disorders - other specify
D064420,5.09,NCT00372593-1,Arm A: Standard Arm - No GMTZ AML Pts w/Out Down Syndrome,NCT00372593,Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia,adverse drug events
D064420,6.26,NCT00372593-2,Arm B: Experimental - With GMTZ AML Pts w/Out Down Syndrome,NCT00372593,Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia,adverse drug events
D064420,33.33,NCT00372593-3,Arm A: Standard Arm - No GMTZ AML Patients With Down Syndrome,NCT00372593,Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia,adverse drug events
D004211,0.39,NCT00372593-1,Arm A: Standard Arm - No GMTZ AML Pts w/Out Down Syndrome,NCT00372593,Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia,disseminated intravascular coagulation
D004211,0.39,NCT00372593-2,Arm B: Experimental - With GMTZ AML Pts w/Out Down Syndrome,NCT00372593,Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia,disseminated intravascular coagulation
D064147,0.39,NCT00372593-2,Arm B: Experimental - With GMTZ AML Pts w/Out Down Syndrome,NCT00372593,Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia,febrile neutropenia
D001282,0.2,NCT00372593-1,Arm A: Standard Arm - No GMTZ AML Pts w/Out Down Syndrome,NCT00372593,Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia,atrial flutter
10007541,0.59,NCT00372593-1,Arm A: Standard Arm - No GMTZ AML Pts w/Out Down Syndrome,NCT00372593,Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia,cardiac disorders - other specify
10007541,0.78,NCT00372593-2,Arm B: Experimental - With GMTZ AML Pts w/Out Down Syndrome,NCT00372593,Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia,cardiac disorders - other specify
D006333,0.2,NCT00372593-1,Arm A: Standard Arm - No GMTZ AML Pts w/Out Down Syndrome,NCT00372593,Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia,heart failure
10069501,0.39,NCT00372593-1,Arm A: Standard Arm - No GMTZ AML Pts w/Out Down Syndrome,NCT00372593,Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia,left ventricular systolic dysfunction
10069501,0.98,NCT00372593-2,Arm B: Experimental - With GMTZ AML Pts w/Out Down Syndrome,NCT00372593,Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia,left ventricular systolic dysfunction
D010490,0.2,NCT00372593-1,Arm A: Standard Arm - No GMTZ AML Pts w/Out Down Syndrome,NCT00372593,Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia,pericardial effusion
D010490,0.2,NCT00372593-2,Arm B: Experimental - With GMTZ AML Pts w/Out Down Syndrome,NCT00372593,Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia,pericardial effusion
D010493,0.2,NCT00372593-1,Arm A: Standard Arm - No GMTZ AML Pts w/Out Down Syndrome,NCT00372593,Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia,pericarditis
D002313,0.2,NCT00372593-1,Arm A: Standard Arm - No GMTZ AML Pts w/Out Down Syndrome,NCT00372593,Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia,restrictive cardiomyopathy
D018497,0.2,NCT00372593-1,Arm A: Standard Arm - No GMTZ AML Pts w/Out Down Syndrome,NCT00372593,Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia,right ventricular dysfunction
D001201,0.2,NCT00372593-1,Arm A: Standard Arm - No GMTZ AML Pts w/Out Down Syndrome,NCT00372593,Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia,ascites
D005756,0.2,NCT00372593-1,Arm A: Standard Arm - No GMTZ AML Pts w/Out Down Syndrome,NCT00372593,Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia,gastritis
10028130,0.2,NCT00372593-1,Arm A: Standard Arm - No GMTZ AML Pts w/Out Down Syndrome,NCT00372593,Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia,mucositis oral
10011914,0.59,NCT00372593-1,Arm A: Standard Arm - No GMTZ AML Pts w/Out Down Syndrome,NCT00372593,Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia,death nos
10011914,0.59,NCT00372593-2,Arm B: Experimental - With GMTZ AML Pts w/Out Down Syndrome,NCT00372593,Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia,death nos
10011914,16.67,NCT00372593-3,Arm A: Standard Arm - No GMTZ AML Patients With Down Syndrome,NCT00372593,Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia,death nos
D009102,1.17,NCT00372593-1,Arm A: Standard Arm - No GMTZ AML Pts w/Out Down Syndrome,NCT00372593,Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia,multiple organ failure
D009102,0.39,NCT00372593-2,Arm B: Experimental - With GMTZ AML Pts w/Out Down Syndrome,NCT00372593,Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia,multiple organ failure
10042435,0.2,NCT00372593-1,Arm A: Standard Arm - No GMTZ AML Pts w/Out Down Syndrome,NCT00372593,Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia,sudden death nos
10042435,0.2,NCT00372593-2,Arm B: Experimental - With GMTZ AML Pts w/Out Down Syndrome,NCT00372593,Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia,sudden death nos
D017093,0.2,NCT00372593-2,Arm B: Experimental - With GMTZ AML Pts w/Out Down Syndrome,NCT00372593,Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia,hepatic failure
D006975,0.2,NCT00372593-1,Arm A: Standard Arm - No GMTZ AML Pts w/Out Down Syndrome,NCT00372593,Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia,portal hypertension
10058838,16.67,NCT00372593-3,Arm A: Standard Arm - No GMTZ AML Patients With Down Syndrome,NCT00372593,Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia,enterocolitis infectious
10021881,2.74,NCT00372593-1,Arm A: Standard Arm - No GMTZ AML Pts w/Out Down Syndrome,NCT00372593,Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia,infections and infestations - other specify
10021881,2.94,NCT00372593-2,Arm B: Experimental - With GMTZ AML Pts w/Out Down Syndrome,NCT00372593,Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia,infections and infestations - other specify
10021881,16.67,NCT00372593-3,Arm A: Standard Arm - No GMTZ AML Patients With Down Syndrome,NCT00372593,Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia,infections and infestations - other specify
10061229,16.67,NCT00372593-3,Arm A: Standard Arm - No GMTZ AML Patients With Down Syndrome,NCT00372593,Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia,lung infection
D018805,0.2,NCT00372593-1,Arm A: Standard Arm - No GMTZ AML Pts w/Out Down Syndrome,NCT00372593,Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia,sepsis
D018805,0.39,NCT00372593-2,Arm B: Experimental - With GMTZ AML Pts w/Out Down Syndrome,NCT00372593,Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia,sepsis
10001551,0.39,NCT00372593-2,Arm B: Experimental - With GMTZ AML Pts w/Out Down Syndrome,NCT00372593,Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia,alanine aminotransferase increased
10003481,0.2,NCT00372593-1,Arm A: Standard Arm - No GMTZ AML Pts w/Out Down Syndrome,NCT00372593,Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia,aspartate aminotransferase increased
10003481,0.39,NCT00372593-2,Arm B: Experimental - With GMTZ AML Pts w/Out Down Syndrome,NCT00372593,Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia,aspartate aminotransferase increased
10005364,0.39,NCT00372593-1,Arm A: Standard Arm - No GMTZ AML Pts w/Out Down Syndrome,NCT00372593,Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia,blood bilirubin increased
10005364,0.2,NCT00372593-2,Arm B: Experimental - With GMTZ AML Pts w/Out Down Syndrome,NCT00372593,Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia,blood bilirubin increased
10011368,0.2,NCT00372593-2,Arm B: Experimental - With GMTZ AML Pts w/Out Down Syndrome,NCT00372593,Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia,creatinine increased
10014383,0.2,NCT00372593-2,Arm B: Experimental - With GMTZ AML Pts w/Out Down Syndrome,NCT00372593,Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia,electrocardiogram qt corrected interval prolonged
10016596,0.2,NCT00372593-1,Arm A: Standard Arm - No GMTZ AML Pts w/Out Down Syndrome,NCT00372593,Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia,fibrinogen decreased
10022891,0.2,NCT00372593-1,Arm A: Standard Arm - No GMTZ AML Pts w/Out Down Syndrome,NCT00372593,Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia,investigations - other specify
10022891,0.2,NCT00372593-2,Arm B: Experimental - With GMTZ AML Pts w/Out Down Syndrome,NCT00372593,Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia,investigations - other specify
10024574,0.2,NCT00372593-2,Arm B: Experimental - With GMTZ AML Pts w/Out Down Syndrome,NCT00372593,Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia,lipase increased
10040139,0.2,NCT00372593-2,Arm B: Experimental - With GMTZ AML Pts w/Out Down Syndrome,NCT00372593,Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia,serum amylase increased
D000138,0.59,NCT00372593-1,Arm A: Standard Arm - No GMTZ AML Pts w/Out Down Syndrome,NCT00372593,Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia,acidosis
D000138,0.59,NCT00372593-2,Arm B: Experimental - With GMTZ AML Pts w/Out Down Syndrome,NCT00372593,Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia,acidosis
D006943,0.2,NCT00372593-1,Arm A: Standard Arm - No GMTZ AML Pts w/Out Down Syndrome,NCT00372593,Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia,hyperglycemia
D006943,0.39,NCT00372593-2,Arm B: Experimental - With GMTZ AML Pts w/Out Down Syndrome,NCT00372593,Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia,hyperglycemia
D006947,0.2,NCT00372593-1,Arm A: Standard Arm - No GMTZ AML Pts w/Out Down Syndrome,NCT00372593,Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia,hyperkalemia
D006947,0.2,NCT00372593-2,Arm B: Experimental - With GMTZ AML Pts w/Out Down Syndrome,NCT00372593,Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia,hyperkalemia
D006996,0.2,NCT00372593-1,Arm A: Standard Arm - No GMTZ AML Pts w/Out Down Syndrome,NCT00372593,Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia,hypocalcemia
D007003,0.2,NCT00372593-1,Arm A: Standard Arm - No GMTZ AML Pts w/Out Down Syndrome,NCT00372593,Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia,hypoglycemia
D007003,0.2,NCT00372593-2,Arm B: Experimental - With GMTZ AML Pts w/Out Down Syndrome,NCT00372593,Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia,hypoglycemia
D007008,0.39,NCT00372593-1,Arm A: Standard Arm - No GMTZ AML Pts w/Out Down Syndrome,NCT00372593,Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia,hypokalemia
D007010,0.2,NCT00372593-1,Arm A: Standard Arm - No GMTZ AML Pts w/Out Down Syndrome,NCT00372593,Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia,hyponatremia
10033425,0.2,NCT00372593-2,Arm B: Experimental - With GMTZ AML Pts w/Out Down Syndrome,NCT00372593,Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia,pain in extremity
10049737,0.2,NCT00372593-2,Arm B: Experimental - With GMTZ AML Pts w/Out Down Syndrome,NCT00372593,Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia,treatment related secondary malignancy
D001927,0.2,NCT00372593-2,Arm B: Experimental - With GMTZ AML Pts w/Out Down Syndrome,NCT00372593,Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia,encephalopathy
D020300,1.17,NCT00372593-2,Arm B: Experimental - With GMTZ AML Pts w/Out Down Syndrome,NCT00372593,Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia,intracranial hemorrhage
10029205,0.2,NCT00372593-1,Arm A: Standard Arm - No GMTZ AML Pts w/Out Down Syndrome,NCT00372593,Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia,nervous system disorders - other specify
D012640,0.2,NCT00372593-1,Arm A: Standard Arm - No GMTZ AML Pts w/Out Down Syndrome,NCT00372593,Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia,seizure
D012640,0.2,NCT00372593-2,Arm B: Experimental - With GMTZ AML Pts w/Out Down Syndrome,NCT00372593,Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia,seizure
D012640,16.67,NCT00372593-3,Arm A: Standard Arm - No GMTZ AML Patients With Down Syndrome,NCT00372593,Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia,seizure
D003221,0.2,NCT00372593-2,Arm B: Experimental - With GMTZ AML Pts w/Out Down Syndrome,NCT00372593,Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia,confusion
D058186,1.57,NCT00372593-1,Arm A: Standard Arm - No GMTZ AML Pts w/Out Down Syndrome,NCT00372593,Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia,acute kidney injury
D058186,0.39,NCT00372593-2,Arm B: Experimental - With GMTZ AML Pts w/Out Down Syndrome,NCT00372593,Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia,acute kidney injury
D012128,0.78,NCT00372593-1,Arm A: Standard Arm - No GMTZ AML Pts w/Out Down Syndrome,NCT00372593,Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia,adult respiratory distress syndrome
D012128,1.57,NCT00372593-2,Arm B: Experimental - With GMTZ AML Pts w/Out Down Syndrome,NCT00372593,Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia,adult respiratory distress syndrome
D001261,0.2,NCT00372593-2,Arm B: Experimental - With GMTZ AML Pts w/Out Down Syndrome,NCT00372593,Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia,atelectasis
10065746,0.39,NCT00372593-1,Arm A: Standard Arm - No GMTZ AML Pts w/Out Down Syndrome,NCT00372593,Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia,bronchopulmonary hemorrhage
10065746,0.2,NCT00372593-2,Arm B: Experimental - With GMTZ AML Pts w/Out Down Syndrome,NCT00372593,Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia,bronchopulmonary hemorrhage
D001986,0.2,NCT00372593-2,Arm B: Experimental - With GMTZ AML Pts w/Out Down Syndrome,NCT00372593,Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia,bronchospasm
D004417,0.39,NCT00372593-2,Arm B: Experimental - With GMTZ AML Pts w/Out Down Syndrome,NCT00372593,Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia,dyspnea
D000860,1.37,NCT00372593-1,Arm A: Standard Arm - No GMTZ AML Pts w/Out Down Syndrome,NCT00372593,Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia,hypoxia
D000860,1.37,NCT00372593-2,Arm B: Experimental - With GMTZ AML Pts w/Out Down Syndrome,NCT00372593,Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia,hypoxia
D000860,33.33,NCT00372593-3,Arm A: Standard Arm - No GMTZ AML Patients With Down Syndrome,NCT00372593,Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia,hypoxia
D010996,0.39,NCT00372593-2,Arm B: Experimental - With GMTZ AML Pts w/Out Down Syndrome,NCT00372593,Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia,pleural effusion
10055319,0.2,NCT00372593-2,Arm B: Experimental - With GMTZ AML Pts w/Out Down Syndrome,NCT00372593,Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia,pleural hemorrhage
D011014,0.39,NCT00372593-1,Arm A: Standard Arm - No GMTZ AML Pts w/Out Down Syndrome,NCT00372593,Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia,pneumonitis
D011014,0.39,NCT00372593-2,Arm B: Experimental - With GMTZ AML Pts w/Out Down Syndrome,NCT00372593,Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia,pneumonitis
10038738,0.39,NCT00372593-1,Arm A: Standard Arm - No GMTZ AML Pts w/Out Down Syndrome,NCT00372593,Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia,respiratory thoracic and mediastinal disorders - other specify
10038738,0.2,NCT00372593-2,Arm B: Experimental - With GMTZ AML Pts w/Out Down Syndrome,NCT00372593,Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia,respiratory thoracic and mediastinal disorders - other specify
D007022,1.17,NCT00372593-1,Arm A: Standard Arm - No GMTZ AML Pts w/Out Down Syndrome,NCT00372593,Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia,hypotension
D007022,0.78,NCT00372593-2,Arm B: Experimental - With GMTZ AML Pts w/Out Down Syndrome,NCT00372593,Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia,hypotension
D007022,16.67,NCT00372593-3,Arm A: Standard Arm - No GMTZ AML Patients With Down Syndrome,NCT00372593,Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia,hypotension
10047065,0.2,NCT00372593-2,Arm B: Experimental - With GMTZ AML Pts w/Out Down Syndrome,NCT00372593,Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia,vascular disorders - other specify
D064420,62.5,NCT00372619-1,Clofarabine 40 mg/m² to Assess Feasibility in ALL Patients.,NCT00372619,Clofarabine and Cytarabine in Treating Young Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia,adverse drug events
D064420,100.0,NCT00372619-2,Clofarabine 40 mg/m² to Assess Feasibility in AML Patients.,NCT00372619,Clofarabine and Cytarabine in Treating Young Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia,adverse drug events
D064420,66.67,NCT00372619-3,Clofarabine 52 mg/m² to Assess Feasibility in ALL Patients.,NCT00372619,Clofarabine and Cytarabine in Treating Young Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia,adverse drug events
D064420,70.0,NCT00372619-4,Clofarabine 52 mg/m² to Assess Efficacy in ALL Patients.,NCT00372619,Clofarabine and Cytarabine in Treating Young Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia,adverse drug events
D064420,42.86,NCT00372619-5,Clofarabine 52 mg/m² to Assess Feasibility in AML Patients.,NCT00372619,Clofarabine and Cytarabine in Treating Young Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia,adverse drug events
D064420,35.0,NCT00372619-6,Clofarabine 52 mg/m² to Assess Efficacy in AML Patients,NCT00372619,Clofarabine and Cytarabine in Treating Young Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia,adverse drug events
D064420,100.0,NCT00372619-7,Clofarabine 52 mg/m² to Assess Efficacy - Ambiguous Lineage pt,NCT00372619,Clofarabine and Cytarabine in Treating Young Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia,adverse drug events
D064147,25.0,NCT00372619-1,Clofarabine 40 mg/m² to Assess Feasibility in ALL Patients.,NCT00372619,Clofarabine and Cytarabine in Treating Young Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia,febrile neutropenia
D064147,50.0,NCT00372619-2,Clofarabine 40 mg/m² to Assess Feasibility in AML Patients.,NCT00372619,Clofarabine and Cytarabine in Treating Young Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia,febrile neutropenia
D064147,10.0,NCT00372619-4,Clofarabine 52 mg/m² to Assess Efficacy in ALL Patients.,NCT00372619,Clofarabine and Cytarabine in Treating Young Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia,febrile neutropenia
D064147,14.29,NCT00372619-5,Clofarabine 52 mg/m² to Assess Feasibility in AML Patients.,NCT00372619,Clofarabine and Cytarabine in Treating Young Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia,febrile neutropenia
D064147,15.0,NCT00372619-6,Clofarabine 52 mg/m² to Assess Efficacy in AML Patients,NCT00372619,Clofarabine and Cytarabine in Treating Young Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia,febrile neutropenia
10069501,2.5,NCT00372619-6,Clofarabine 52 mg/m² to Assess Efficacy in AML Patients,NCT00372619,Clofarabine and Cytarabine in Treating Young Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia,left ventricular systolic dysfunction
D018497,2.5,NCT00372619-6,Clofarabine 52 mg/m² to Assess Efficacy in AML Patients,NCT00372619,Clofarabine and Cytarabine in Treating Young Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia,right ventricular dysfunction
D013616,14.29,NCT00372619-5,Clofarabine 52 mg/m² to Assess Feasibility in AML Patients.,NCT00372619,Clofarabine and Cytarabine in Treating Young Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia,sinus tachycardia
D015746,25.0,NCT00372619-1,Clofarabine 40 mg/m² to Assess Feasibility in ALL Patients.,NCT00372619,Clofarabine and Cytarabine in Treating Young Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia,abdominal pain
D003092,2.5,NCT00372619-6,Clofarabine 52 mg/m² to Assess Efficacy in AML Patients,NCT00372619,Clofarabine and Cytarabine in Treating Young Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia,colitis
D003967,25.0,NCT00372619-1,Clofarabine 40 mg/m² to Assess Feasibility in ALL Patients.,NCT00372619,Clofarabine and Cytarabine in Treating Young Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia,diarrhea
D045823,10.0,NCT00372619-4,Clofarabine 52 mg/m² to Assess Efficacy in ALL Patients.,NCT00372619,Clofarabine and Cytarabine in Treating Young Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia,ileus
D009325,12.5,NCT00372619-1,Clofarabine 40 mg/m² to Assess Feasibility in ALL Patients.,NCT00372619,Clofarabine and Cytarabine in Treating Young Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia,nausea
D010195,12.5,NCT00372619-1,Clofarabine 40 mg/m² to Assess Feasibility in ALL Patients.,NCT00372619,Clofarabine and Cytarabine in Treating Young Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia,pancreatitis
D010195,2.5,NCT00372619-6,Clofarabine 52 mg/m² to Assess Efficacy in AML Patients,NCT00372619,Clofarabine and Cytarabine in Treating Young Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia,pancreatitis
10065710,10.0,NCT00372619-4,Clofarabine 52 mg/m² to Assess Efficacy in ALL Patients.,NCT00372619,Clofarabine and Cytarabine in Treating Young Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia,small intestinal mucositis
D014839,12.5,NCT00372619-1,Clofarabine 40 mg/m² to Assess Feasibility in ALL Patients.,NCT00372619,Clofarabine and Cytarabine in Treating Young Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia,vomiting
D023341,14.29,NCT00372619-5,Clofarabine 52 mg/m² to Assess Feasibility in AML Patients.,NCT00372619,Clofarabine and Cytarabine in Treating Young Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia,chills
D005221,14.29,NCT00372619-5,Clofarabine 52 mg/m² to Assess Feasibility in AML Patients.,NCT00372619,Clofarabine and Cytarabine in Treating Young Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia,fatigue
10062501,12.5,NCT00372619-1,Clofarabine 40 mg/m² to Assess Feasibility in ALL Patients.,NCT00372619,Clofarabine and Cytarabine in Treating Young Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia,non-cardiac chest pain
10005047,12.5,NCT00372619-1,Clofarabine 40 mg/m² to Assess Feasibility in ALL Patients.,NCT00372619,Clofarabine and Cytarabine in Treating Young Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia,bladder infection
10021881,50.0,NCT00372619-1,Clofarabine 40 mg/m² to Assess Feasibility in ALL Patients.,NCT00372619,Clofarabine and Cytarabine in Treating Young Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia,infections and infestations - other specify
10021881,33.33,NCT00372619-3,Clofarabine 52 mg/m² to Assess Feasibility in ALL Patients.,NCT00372619,Clofarabine and Cytarabine in Treating Young Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia,infections and infestations - other specify
10021881,30.0,NCT00372619-4,Clofarabine 52 mg/m² to Assess Efficacy in ALL Patients.,NCT00372619,Clofarabine and Cytarabine in Treating Young Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia,infections and infestations - other specify
10021881,28.57,NCT00372619-5,Clofarabine 52 mg/m² to Assess Feasibility in AML Patients.,NCT00372619,Clofarabine and Cytarabine in Treating Young Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia,infections and infestations - other specify
10021881,20.0,NCT00372619-6,Clofarabine 52 mg/m² to Assess Efficacy in AML Patients,NCT00372619,Clofarabine and Cytarabine in Treating Young Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia,infections and infestations - other specify
D018805,2.5,NCT00372619-6,Clofarabine 52 mg/m² to Assess Efficacy in AML Patients,NCT00372619,Clofarabine and Cytarabine in Treating Young Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia,sepsis
10001551,12.5,NCT00372619-1,Clofarabine 40 mg/m² to Assess Feasibility in ALL Patients.,NCT00372619,Clofarabine and Cytarabine in Treating Young Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia,alanine aminotransferase increased
10001551,10.0,NCT00372619-4,Clofarabine 52 mg/m² to Assess Efficacy in ALL Patients.,NCT00372619,Clofarabine and Cytarabine in Treating Young Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia,alanine aminotransferase increased
10001551,2.5,NCT00372619-6,Clofarabine 52 mg/m² to Assess Efficacy in AML Patients,NCT00372619,Clofarabine and Cytarabine in Treating Young Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia,alanine aminotransferase increased
10003481,12.5,NCT00372619-1,Clofarabine 40 mg/m² to Assess Feasibility in ALL Patients.,NCT00372619,Clofarabine and Cytarabine in Treating Young Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia,aspartate aminotransferase increased
10003481,20.0,NCT00372619-4,Clofarabine 52 mg/m² to Assess Efficacy in ALL Patients.,NCT00372619,Clofarabine and Cytarabine in Treating Young Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia,aspartate aminotransferase increased
10003481,2.5,NCT00372619-6,Clofarabine 52 mg/m² to Assess Efficacy in AML Patients,NCT00372619,Clofarabine and Cytarabine in Treating Young Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia,aspartate aminotransferase increased
10005364,12.5,NCT00372619-1,Clofarabine 40 mg/m² to Assess Feasibility in ALL Patients.,NCT00372619,Clofarabine and Cytarabine in Treating Young Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia,blood bilirubin increased
10016596,2.5,NCT00372619-6,Clofarabine 52 mg/m² to Assess Efficacy in AML Patients,NCT00372619,Clofarabine and Cytarabine in Treating Young Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia,fibrinogen decreased
10056910,10.0,NCT00372619-4,Clofarabine 52 mg/m² to Assess Efficacy in ALL Patients.,NCT00372619,Clofarabine and Cytarabine in Treating Young Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia,ggt increased
10024574,12.5,NCT00372619-1,Clofarabine 40 mg/m² to Assess Feasibility in ALL Patients.,NCT00372619,Clofarabine and Cytarabine in Treating Young Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia,lipase increased
10024574,33.33,NCT00372619-3,Clofarabine 52 mg/m² to Assess Feasibility in ALL Patients.,NCT00372619,Clofarabine and Cytarabine in Treating Young Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia,lipase increased
10024574,7.5,NCT00372619-6,Clofarabine 52 mg/m² to Assess Efficacy in AML Patients,NCT00372619,Clofarabine and Cytarabine in Treating Young Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia,lipase increased
10024574,50.0,NCT00372619-7,Clofarabine 52 mg/m² to Assess Efficacy - Ambiguous Lineage pt,NCT00372619,Clofarabine and Cytarabine in Treating Young Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia,lipase increased
10040139,5.0,NCT00372619-6,Clofarabine 52 mg/m² to Assess Efficacy in AML Patients,NCT00372619,Clofarabine and Cytarabine in Treating Young Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia,serum amylase increased
D000855,12.5,NCT00372619-1,Clofarabine 40 mg/m² to Assess Feasibility in ALL Patients.,NCT00372619,Clofarabine and Cytarabine in Treating Young Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia,anorexia
D006934,5.0,NCT00372619-6,Clofarabine 52 mg/m² to Assess Efficacy in AML Patients,NCT00372619,Clofarabine and Cytarabine in Treating Young Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia,hypercalcemia
D006934,50.0,NCT00372619-7,Clofarabine 52 mg/m² to Assess Efficacy - Ambiguous Lineage pt,NCT00372619,Clofarabine and Cytarabine in Treating Young Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia,hypercalcemia
D006943,50.0,NCT00372619-7,Clofarabine 52 mg/m² to Assess Efficacy - Ambiguous Lineage pt,NCT00372619,Clofarabine and Cytarabine in Treating Young Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia,hyperglycemia
10020670,50.0,NCT00372619-2,Clofarabine 40 mg/m² to Assess Feasibility in AML Patients.,NCT00372619,Clofarabine and Cytarabine in Treating Young Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia,hypermagnesemia
D034141,50.0,NCT00372619-7,Clofarabine 52 mg/m² to Assess Efficacy - Ambiguous Lineage pt,NCT00372619,Clofarabine and Cytarabine in Treating Young Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia,hypoalbuminemia
D007008,25.0,NCT00372619-1,Clofarabine 40 mg/m² to Assess Feasibility in ALL Patients.,NCT00372619,Clofarabine and Cytarabine in Treating Young Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia,hypokalemia
D007008,50.0,NCT00372619-2,Clofarabine 40 mg/m² to Assess Feasibility in AML Patients.,NCT00372619,Clofarabine and Cytarabine in Treating Young Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia,hypokalemia
D007008,20.0,NCT00372619-4,Clofarabine 52 mg/m² to Assess Efficacy in ALL Patients.,NCT00372619,Clofarabine and Cytarabine in Treating Young Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia,hypokalemia
D007008,5.0,NCT00372619-6,Clofarabine 52 mg/m² to Assess Efficacy in AML Patients,NCT00372619,Clofarabine and Cytarabine in Treating Young Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia,hypokalemia
D007010,50.0,NCT00372619-7,Clofarabine 52 mg/m² to Assess Efficacy - Ambiguous Lineage pt,NCT00372619,Clofarabine and Cytarabine in Treating Young Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia,hyponatremia
D017674,33.33,NCT00372619-3,Clofarabine 52 mg/m² to Assess Feasibility in ALL Patients.,NCT00372619,Clofarabine and Cytarabine in Treating Young Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia,hypophosphatemia
D017674,2.5,NCT00372619-6,Clofarabine 52 mg/m² to Assess Efficacy in AML Patients,NCT00372619,Clofarabine and Cytarabine in Treating Young Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia,hypophosphatemia
D015275,2.5,NCT00372619-6,Clofarabine 52 mg/m² to Assess Efficacy in AML Patients,NCT00372619,Clofarabine and Cytarabine in Treating Young Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia,tumor lysis syndrome
D001416,12.5,NCT00372619-1,Clofarabine 40 mg/m² to Assess Feasibility in ALL Patients.,NCT00372619,Clofarabine and Cytarabine in Treating Young Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia,back pain
10006002,12.5,NCT00372619-1,Clofarabine 40 mg/m² to Assess Feasibility in ALL Patients.,NCT00372619,Clofarabine and Cytarabine in Treating Young Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia,bone pain
10008496,12.5,NCT00372619-1,Clofarabine 40 mg/m² to Assess Feasibility in ALL Patients.,NCT00372619,Clofarabine and Cytarabine in Treating Young Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia,chest wall pain
D006261,12.5,NCT00372619-1,Clofarabine 40 mg/m² to Assess Feasibility in ALL Patients.,NCT00372619,Clofarabine and Cytarabine in Treating Young Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia,headache
D009437,12.5,NCT00372619-1,Clofarabine 40 mg/m² to Assess Feasibility in ALL Patients.,NCT00372619,Clofarabine and Cytarabine in Treating Young Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia,neuralgia
10034580,12.5,NCT00372619-1,Clofarabine 40 mg/m² to Assess Feasibility in ALL Patients.,NCT00372619,Clofarabine and Cytarabine in Treating Young Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia,peripheral motor neuropathy
10034580,2.5,NCT00372619-6,Clofarabine 52 mg/m² to Assess Efficacy in AML Patients,NCT00372619,Clofarabine and Cytarabine in Treating Young Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia,peripheral motor neuropathy
10034620,2.5,NCT00372619-6,Clofarabine 52 mg/m² to Assess Efficacy in AML Patients,NCT00372619,Clofarabine and Cytarabine in Treating Young Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia,peripheral sensory neuropathy
D011507,33.33,NCT00372619-3,Clofarabine 52 mg/m² to Assess Feasibility in ALL Patients.,NCT00372619,Clofarabine and Cytarabine in Treating Young Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia,proteinuria
D003371,12.5,NCT00372619-1,Clofarabine 40 mg/m² to Assess Feasibility in ALL Patients.,NCT00372619,Clofarabine and Cytarabine in Treating Young Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia,cough
D004417,12.5,NCT00372619-1,Clofarabine 40 mg/m² to Assess Feasibility in ALL Patients.,NCT00372619,Clofarabine and Cytarabine in Treating Young Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia,dyspnea
D000860,25.0,NCT00372619-1,Clofarabine 40 mg/m² to Assess Feasibility in ALL Patients.,NCT00372619,Clofarabine and Cytarabine in Treating Young Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia,hypoxia
D000860,5.0,NCT00372619-6,Clofarabine 52 mg/m² to Assess Efficacy in AML Patients,NCT00372619,Clofarabine and Cytarabine in Treating Young Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia,hypoxia
D011014,25.0,NCT00372619-1,Clofarabine 40 mg/m² to Assess Feasibility in ALL Patients.,NCT00372619,Clofarabine and Cytarabine in Treating Young Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia,pneumonitis
D000505,33.33,NCT00372619-3,Clofarabine 52 mg/m² to Assess Feasibility in ALL Patients.,NCT00372619,Clofarabine and Cytarabine in Treating Young Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia,alopecia
10054524,10.0,NCT00372619-4,Clofarabine 52 mg/m² to Assess Efficacy in ALL Patients.,NCT00372619,Clofarabine and Cytarabine in Treating Young Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia,palmar-plantar erythrodysesthesia syndrome
10037868,14.29,NCT00372619-5,Clofarabine 52 mg/m² to Assess Feasibility in AML Patients.,NCT00372619,Clofarabine and Cytarabine in Treating Young Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia,rash maculo-papular
10037868,2.5,NCT00372619-6,Clofarabine 52 mg/m² to Assess Efficacy in AML Patients,NCT00372619,Clofarabine and Cytarabine in Treating Young Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia,rash maculo-papular
D019559,10.0,NCT00372619-4,Clofarabine 52 mg/m² to Assess Efficacy in ALL Patients.,NCT00372619,Clofarabine and Cytarabine in Treating Young Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia,capillary leak syndrome
D019559,7.5,NCT00372619-6,Clofarabine 52 mg/m² to Assess Efficacy in AML Patients,NCT00372619,Clofarabine and Cytarabine in Treating Young Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia,capillary leak syndrome
D006973,12.5,NCT00372619-1,Clofarabine 40 mg/m² to Assess Feasibility in ALL Patients.,NCT00372619,Clofarabine and Cytarabine in Treating Young Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia,hypertension
D007022,12.5,NCT00372619-1,Clofarabine 40 mg/m² to Assess Feasibility in ALL Patients.,NCT00372619,Clofarabine and Cytarabine in Treating Young Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia,hypotension
D007022,14.29,NCT00372619-5,Clofarabine 52 mg/m² to Assess Feasibility in AML Patients.,NCT00372619,Clofarabine and Cytarabine in Treating Young Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia,hypotension
D007022,5.0,NCT00372619-6,Clofarabine 52 mg/m² to Assess Efficacy in AML Patients,NCT00372619,Clofarabine and Cytarabine in Treating Young Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia,hypotension
D064420,71.43,NCT00429416-1,LLME to Decrease GVHD Following HSC T,NCT00429416,Research Study to Determine if an Experimental Agent  LLME Can Decrease the Incidence and Severity of Graft-Versus-Host-Disease (GVHD) Following Blood (Hematopoietic) Stem Cell Transplantation,adverse drug events
D003967,14.29,NCT00429416-1,LLME to Decrease GVHD Following HSC T,NCT00429416,Research Study to Determine if an Experimental Agent  LLME Can Decrease the Incidence and Severity of Graft-Versus-Host-Disease (GVHD) Following Blood (Hematopoietic) Stem Cell Transplantation,diarrhea
D001853,7.14,NCT00429416-1,LLME to Decrease GVHD Following HSC T,NCT00429416,Research Study to Determine if an Experimental Agent  LLME Can Decrease the Incidence and Severity of Graft-Versus-Host-Disease (GVHD) Following Blood (Hematopoietic) Stem Cell Transplantation,bone marrow
D007239,21.43,NCT00429416-1,LLME to Decrease GVHD Following HSC T,NCT00429416,Research Study to Determine if an Experimental Agent  LLME Can Decrease the Incidence and Severity of Graft-Versus-Host-Disease (GVHD) Following Blood (Hematopoietic) Stem Cell Transplantation,infection
UNKNOWN-check-for-typo,7.14,NCT00429416-1,LLME to Decrease GVHD Following HSC T,NCT00429416,Research Study to Determine if an Experimental Agent  LLME Can Decrease the Incidence and Severity of Graft-Versus-Host-Disease (GVHD) Following Blood (Hematopoietic) Stem Cell Transplantation,D00
D006406,7.14,NCT00429416-1,LLME to Decrease GVHD Following HSC T,NCT00429416,Research Study to Determine if an Experimental Agent  LLME Can Decrease the Incidence and Severity of Graft-Versus-Host-Disease (GVHD) Following Blood (Hematopoietic) Stem Cell Transplantation,hematoma
D003643,50.0,NCT00429416-1,LLME to Decrease GVHD Following HSC T,NCT00429416,Research Study to Determine if an Experimental Agent  LLME Can Decrease the Incidence and Severity of Graft-Versus-Host-Disease (GVHD) Following Blood (Hematopoietic) Stem Cell Transplantation,death
D006967,7.14,NCT00429416-1,LLME to Decrease GVHD Following HSC T,NCT00429416,Research Study to Determine if an Experimental Agent  LLME Can Decrease the Incidence and Severity of Graft-Versus-Host-Disease (GVHD) Following Blood (Hematopoietic) Stem Cell Transplantation,hypersensitivity
D002637,14.29,NCT00429416-1,LLME to Decrease GVHD Following HSC T,NCT00429416,Research Study to Determine if an Experimental Agent  LLME Can Decrease the Incidence and Severity of Graft-Versus-Host-Disease (GVHD) Following Blood (Hematopoietic) Stem Cell Transplantation,chest pain
D002549,7.14,NCT00429416-1,LLME to Decrease GVHD Following HSC T,NCT00429416,Research Study to Determine if an Experimental Agent  LLME Can Decrease the Incidence and Severity of Graft-Versus-Host-Disease (GVHD) Following Blood (Hematopoietic) Stem Cell Transplantation,neuronal degeneration of childhood with liver disease progressive
D009325,21.43,NCT00429416-1,LLME to Decrease GVHD Following HSC T,NCT00429416,Research Study to Determine if an Experimental Agent  LLME Can Decrease the Incidence and Severity of Graft-Versus-Host-Disease (GVHD) Following Blood (Hematopoietic) Stem Cell Transplantation,nausea
D014839,14.29,NCT00429416-1,LLME to Decrease GVHD Following HSC T,NCT00429416,Research Study to Determine if an Experimental Agent  LLME Can Decrease the Incidence and Severity of Graft-Versus-Host-Disease (GVHD) Following Blood (Hematopoietic) Stem Cell Transplantation,vomiting
D005334,7.14,NCT00429416-1,LLME to Decrease GVHD Following HSC T,NCT00429416,Research Study to Determine if an Experimental Agent  LLME Can Decrease the Incidence and Severity of Graft-Versus-Host-Disease (GVHD) Following Blood (Hematopoietic) Stem Cell Transplantation,fevers
D005076,7.14,NCT00429416-1,LLME to Decrease GVHD Following HSC T,NCT00429416,Research Study to Determine if an Experimental Agent  LLME Can Decrease the Incidence and Severity of Graft-Versus-Host-Disease (GVHD) Following Blood (Hematopoietic) Stem Cell Transplantation,rash
10055026,7.14,NCT00429416-1,LLME to Decrease GVHD Following HSC T,NCT00429416,Research Study to Determine if an Experimental Agent  LLME Can Decrease the Incidence and Severity of Graft-Versus-Host-Disease (GVHD) Following Blood (Hematopoietic) Stem Cell Transplantation,prostatic obstruction
D010490,7.14,NCT00429416-1,LLME to Decrease GVHD Following HSC T,NCT00429416,Research Study to Determine if an Experimental Agent  LLME Can Decrease the Incidence and Severity of Graft-Versus-Host-Disease (GVHD) Following Blood (Hematopoietic) Stem Cell Transplantation,pericardial effusion
D009894,21.43,NCT00429416-1,LLME to Decrease GVHD Following HSC T,NCT00429416,Research Study to Determine if an Experimental Agent  LLME Can Decrease the Incidence and Severity of Graft-Versus-Host-Disease (GVHD) Following Blood (Hematopoietic) Stem Cell Transplantation,opportunistic infection
D001748,7.14,NCT00429416-1,LLME to Decrease GVHD Following HSC T,NCT00429416,Research Study to Determine if an Experimental Agent  LLME Can Decrease the Incidence and Severity of Graft-Versus-Host-Disease (GVHD) Following Blood (Hematopoietic) Stem Cell Transplantation,urinary bladder neck obstruction
D017093,7.14,NCT00429416-1,LLME to Decrease GVHD Following HSC T,NCT00429416,Research Study to Determine if an Experimental Agent  LLME Can Decrease the Incidence and Severity of Graft-Versus-Host-Disease (GVHD) Following Blood (Hematopoietic) Stem Cell Transplantation,hepatic failure
D051437,7.14,NCT00429416-1,LLME to Decrease GVHD Following HSC T,NCT00429416,Research Study to Determine if an Experimental Agent  LLME Can Decrease the Incidence and Severity of Graft-Versus-Host-Disease (GVHD) Following Blood (Hematopoietic) Stem Cell Transplantation,renal insufficiency
D051437,7.14,NCT00429416-1,LLME to Decrease GVHD Following HSC T,NCT00429416,Research Study to Determine if an Experimental Agent  LLME Can Decrease the Incidence and Severity of Graft-Versus-Host-Disease (GVHD) Following Blood (Hematopoietic) Stem Cell Transplantation,renal failure
D009026,16.67,NCT00439556-1,Velcade Dose Level 1,NCT00439556,Bortezomib and Chemotherapy in Treating Participants With Lymphoid Malignancies Undergoing Stem Cell Transplant,mortality
D009026,66.67,NCT00439556-2,Velcade Dose Level 2,NCT00439556,Bortezomib and Chemotherapy in Treating Participants With Lymphoid Malignancies Undergoing Stem Cell Transplant,mortality
D064420,16.67,NCT00439556-1,Velcade Dose Level 1,NCT00439556,Bortezomib and Chemotherapy in Treating Participants With Lymphoid Malignancies Undergoing Stem Cell Transplant,adverse drug events
D064420,66.67,NCT00439556-2,Velcade Dose Level 2,NCT00439556,Bortezomib and Chemotherapy in Treating Participants With Lymphoid Malignancies Undergoing Stem Cell Transplant,adverse drug events
D006086,5.56,NCT00439556-1,Velcade Dose Level 1,NCT00439556,Bortezomib and Chemotherapy in Treating Participants With Lymphoid Malignancies Undergoing Stem Cell Transplant,graft vs host disease
D007239,11.11,NCT00439556-1,Velcade Dose Level 1,NCT00439556,Bortezomib and Chemotherapy in Treating Participants With Lymphoid Malignancies Undergoing Stem Cell Transplant,infection
D007239,66.67,NCT00439556-2,Velcade Dose Level 2,NCT00439556,Bortezomib and Chemotherapy in Treating Participants With Lymphoid Malignancies Undergoing Stem Cell Transplant,infection
D064420,66.67,NCT00472849-1,OFAR (Phase I),NCT00472849,Oxaliplatin  Fludarabine  Cytarabine  and Rituximab in Patients With Richter's Transformation and Leukemias,adverse drug events
D064420,19.23,NCT00472849-2,OFAR MTD (Phase II),NCT00472849,Oxaliplatin  Fludarabine  Cytarabine  and Rituximab in Patients With Richter's Transformation and Leukemias,adverse drug events
D006461,1.28,NCT00472849-2,OFAR MTD (Phase II),NCT00472849,Oxaliplatin  Fludarabine  Cytarabine  and Rituximab in Patients With Richter's Transformation and Leukemias,hemolysis
D006470,1.28,NCT00472849-2,OFAR MTD (Phase II),NCT00472849,Oxaliplatin  Fludarabine  Cytarabine  and Rituximab in Patients With Richter's Transformation and Leukemias,hemorrhage
D000744,8.33,NCT00472849-1,OFAR (Phase I),NCT00472849,Oxaliplatin  Fludarabine  Cytarabine  and Rituximab in Patients With Richter's Transformation and Leukemias,anemia hemolytic autoimmune
D007022,1.28,NCT00472849-2,OFAR MTD (Phase II),NCT00472849,Oxaliplatin  Fludarabine  Cytarabine  and Rituximab in Patients With Richter's Transformation and Leukemias,hypotension
D020250,1.28,NCT00472849-2,OFAR MTD (Phase II),NCT00472849,Oxaliplatin  Fludarabine  Cytarabine  and Rituximab in Patients With Richter's Transformation and Leukemias,postoperative nausea and vomiting
D015746,1.28,NCT00472849-2,OFAR MTD (Phase II),NCT00472849,Oxaliplatin  Fludarabine  Cytarabine  and Rituximab in Patients With Richter's Transformation and Leukemias,abdominal pain
D003681,8.33,NCT00472849-1,OFAR (Phase I),NCT00472849,Oxaliplatin  Fludarabine  Cytarabine  and Rituximab in Patients With Richter's Transformation and Leukemias,dehydration
D003681,3.85,NCT00472849-2,OFAR MTD (Phase II),NCT00472849,Oxaliplatin  Fludarabine  Cytarabine  and Rituximab in Patients With Richter's Transformation and Leukemias,dehydration
D003967,16.67,NCT00472849-1,OFAR (Phase I),NCT00472849,Oxaliplatin  Fludarabine  Cytarabine  and Rituximab in Patients With Richter's Transformation and Leukemias,diarrhea
D003967,1.28,NCT00472849-2,OFAR MTD (Phase II),NCT00472849,Oxaliplatin  Fludarabine  Cytarabine  and Rituximab in Patients With Richter's Transformation and Leukemias,diarrhea
D003643,8.33,NCT00472849-1,OFAR (Phase I),NCT00472849,Oxaliplatin  Fludarabine  Cytarabine  and Rituximab in Patients With Richter's Transformation and Leukemias,death
D003643,6.41,NCT00472849-2,OFAR MTD (Phase II),NCT00472849,Oxaliplatin  Fludarabine  Cytarabine  and Rituximab in Patients With Richter's Transformation and Leukemias,death
D004417,8.33,NCT00472849-1,OFAR (Phase I),NCT00472849,Oxaliplatin  Fludarabine  Cytarabine  and Rituximab in Patients With Richter's Transformation and Leukemias,dyspnea
D004417,1.28,NCT00472849-2,OFAR MTD (Phase II),NCT00472849,Oxaliplatin  Fludarabine  Cytarabine  and Rituximab in Patients With Richter's Transformation and Leukemias,dyspnea
D007239,16.67,NCT00472849-1,OFAR (Phase I),NCT00472849,Oxaliplatin  Fludarabine  Cytarabine  and Rituximab in Patients With Richter's Transformation and Leukemias,infection
D007239,3.85,NCT00472849-2,OFAR MTD (Phase II),NCT00472849,Oxaliplatin  Fludarabine  Cytarabine  and Rituximab in Patients With Richter's Transformation and Leukemias,infection
D005334,25.0,NCT00472849-1,OFAR (Phase I),NCT00472849,Oxaliplatin  Fludarabine  Cytarabine  and Rituximab in Patients With Richter's Transformation and Leukemias,fever
D007010,8.33,NCT00472849-1,OFAR (Phase I),NCT00472849,Oxaliplatin  Fludarabine  Cytarabine  and Rituximab in Patients With Richter's Transformation and Leukemias,hyponatremia
10049737,2.56,NCT00472849-2,OFAR MTD (Phase II),NCT00472849,Oxaliplatin  Fludarabine  Cytarabine  and Rituximab in Patients With Richter's Transformation and Leukemias,treatment related secondary malignancy
D051437,1.28,NCT00472849-2,OFAR MTD (Phase II),NCT00472849,Oxaliplatin  Fludarabine  Cytarabine  and Rituximab in Patients With Richter's Transformation and Leukemias,renal failure
D010996,8.33,NCT00472849-1,OFAR (Phase I),NCT00472849,Oxaliplatin  Fludarabine  Cytarabine  and Rituximab in Patients With Richter's Transformation and Leukemias,pleural effusion
D009026,2.86,NCT00557193-1,Induction (All Patients),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,mortality
D009026,50.0,NCT00557193-2,Post Induction (Follow-up Only),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,mortality
D009026,5.0,NCT00557193-3,Arm A (Standard Risk MLL-G),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,mortality
D009026,57.41,NCT00557193-4,Arm B (IR/HR MLL-R Chemotherapy),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,mortality
D009026,54.55,NCT00557193-5,Arm C (Safety/ Dose Level 1),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,mortality
D009026,45.45,NCT00557193-6,Arm C (Safety/ Dose Level 2),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,mortality
D009026,50.0,NCT00557193-7,Arm C (Efficacy/ Dose Level 2),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,mortality
D064420,4.29,NCT00557193-1,Induction (All Patients),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,adverse drug events
D064420,3.33,NCT00557193-3,Arm A (Standard Risk MLL-G),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,adverse drug events
D064420,16.67,NCT00557193-4,Arm B (IR/HR MLL-R Chemotherapy),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,adverse drug events
D064420,72.73,NCT00557193-5,Arm C (Safety/ Dose Level 1),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,adverse drug events
D064420,63.64,NCT00557193-6,Arm C (Safety/ Dose Level 2),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,adverse drug events
D064420,73.21,NCT00557193-7,Arm C (Efficacy/ Dose Level 2),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,adverse drug events
D000740,1.85,NCT00557193-4,Arm B (IR/HR MLL-R Chemotherapy),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,anemia
D000740,9.09,NCT00557193-6,Arm C (Safety/ Dose Level 2),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,anemia
D000740,3.57,NCT00557193-7,Arm C (Efficacy/ Dose Level 2),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,anemia
10005329,1.67,NCT00557193-3,Arm A (Standard Risk MLL-G),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,blood and lymphatic system disorders - other specify
D064147,54.55,NCT00557193-5,Arm C (Safety/ Dose Level 1),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,febrile neutropenia
D064147,9.09,NCT00557193-6,Arm C (Safety/ Dose Level 2),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,febrile neutropenia
D064147,39.29,NCT00557193-7,Arm C (Efficacy/ Dose Level 2),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,febrile neutropenia
D006463,1.79,NCT00557193-7,Arm C (Efficacy/ Dose Level 2),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,hemolytic uremic syndrome
D011697,9.09,NCT00557193-5,Arm C (Safety/ Dose Level 1),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,thrombotic thrombocytopenic purpura
D006323,9.09,NCT00557193-6,Arm C (Safety/ Dose Level 2),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,cardiac arrest
D006323,1.79,NCT00557193-7,Arm C (Efficacy/ Dose Level 2),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,cardiac arrest
D006333,1.79,NCT00557193-7,Arm C (Efficacy/ Dose Level 2),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,heart failure
10069501,9.09,NCT00557193-5,Arm C (Safety/ Dose Level 1),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,left ventricular systolic dysfunction
10069501,3.57,NCT00557193-7,Arm C (Efficacy/ Dose Level 2),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,left ventricular systolic dysfunction
D009205,1.79,NCT00557193-7,Arm C (Efficacy/ Dose Level 2),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,myocarditis
D013616,3.57,NCT00557193-7,Arm C (Efficacy/ Dose Level 2),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,sinus tachycardia
D001201,1.85,NCT00557193-4,Arm B (IR/HR MLL-R Chemotherapy),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,ascites
D001201,9.09,NCT00557193-6,Arm C (Safety/ Dose Level 2),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,ascites
D001201,1.79,NCT00557193-7,Arm C (Efficacy/ Dose Level 2),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,ascites
D003092,18.18,NCT00557193-5,Arm C (Safety/ Dose Level 1),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,colitis
D003092,5.36,NCT00557193-7,Arm C (Efficacy/ Dose Level 2),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,colitis
D003967,45.45,NCT00557193-5,Arm C (Safety/ Dose Level 1),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,diarrhea
D003967,27.27,NCT00557193-6,Arm C (Safety/ Dose Level 2),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,diarrhea
D003967,19.64,NCT00557193-7,Arm C (Efficacy/ Dose Level 2),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,diarrhea
D004760,1.79,NCT00557193-7,Arm C (Efficacy/ Dose Level 2),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,enterocolitis
10017789,1.79,NCT00557193-7,Arm C (Efficacy/ Dose Level 2),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,gastric hemorrhage
10017947,0.48,NCT00557193-1,Induction (All Patients),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,gastrointestinal disorders - other specify
10017947,8.93,NCT00557193-7,Arm C (Efficacy/ Dose Level 2),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,gastrointestinal disorders - other specify
10017877,9.09,NCT00557193-6,Arm C (Safety/ Dose Level 2),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,gastrointestinal fistula
10051746,3.57,NCT00557193-7,Arm C (Efficacy/ Dose Level 2),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,lower gastrointestinal hemorrhage
10028130,1.67,NCT00557193-3,Arm A (Standard Risk MLL-G),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,mucositis oral
10028130,9.09,NCT00557193-5,Arm C (Safety/ Dose Level 1),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,mucositis oral
10028130,18.18,NCT00557193-6,Arm C (Safety/ Dose Level 2),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,mucositis oral
10028130,16.07,NCT00557193-7,Arm C (Efficacy/ Dose Level 2),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,mucositis oral
10031009,1.79,NCT00557193-7,Arm C (Efficacy/ Dose Level 2),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,oral pain
10041103,9.09,NCT00557193-6,Arm C (Safety/ Dose Level 2),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,small intestinal perforation
D053706,9.09,NCT00557193-6,Arm C (Safety/ Dose Level 2),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,typhlitis
D014839,9.09,NCT00557193-5,Arm C (Safety/ Dose Level 1),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,vomiting
D014839,3.57,NCT00557193-7,Arm C (Efficacy/ Dose Level 2),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,vomiting
10011914,0.48,NCT00557193-1,Induction (All Patients),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,death nos
10011914,5.36,NCT00557193-7,Arm C (Efficacy/ Dose Level 2),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,death nos
D005221,9.09,NCT00557193-5,Arm C (Safety/ Dose Level 1),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,fatigue
D005334,9.09,NCT00557193-5,Arm C (Safety/ Dose Level 1),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,fever
D005334,18.18,NCT00557193-6,Arm C (Safety/ Dose Level 2),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,fever
D005334,5.36,NCT00557193-7,Arm C (Efficacy/ Dose Level 2),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,fever
10018065,9.09,NCT00557193-6,Arm C (Safety/ Dose Level 2),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,general disorders and administration site conditions - other specify
10022998,1.79,NCT00557193-7,Arm C (Efficacy/ Dose Level 2),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,irritability
D009102,1.85,NCT00557193-4,Arm B (IR/HR MLL-R Chemotherapy),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,multiple organ failure
D000707,1.79,NCT00557193-7,Arm C (Efficacy/ Dose Level 2),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,anaphylaxis
10021428,1.85,NCT00557193-4,Arm B (IR/HR MLL-R Chemotherapy),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,immune system disorders - other specify
10056519,9.09,NCT00557193-5,Arm C (Safety/ Dose Level 1),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,abdominal infection
10061640,9.09,NCT00557193-5,Arm C (Safety/ Dose Level 1),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,anorectal infection
10061640,1.79,NCT00557193-7,Arm C (Efficacy/ Dose Level 2),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,anorectal infection
10055078,1.85,NCT00557193-4,Arm B (IR/HR MLL-R Chemotherapy),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,bronchial infection
10007810,18.18,NCT00557193-5,Arm C (Safety/ Dose Level 1),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,catheter related infection
10007810,18.18,NCT00557193-6,Arm C (Safety/ Dose Level 2),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,catheter related infection
10007810,10.71,NCT00557193-7,Arm C (Efficacy/ Dose Level 2),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,catheter related infection
10014678,1.79,NCT00557193-7,Arm C (Efficacy/ Dose Level 2),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,endocarditis infective
10058838,1.85,NCT00557193-4,Arm B (IR/HR MLL-R Chemotherapy),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,enterocolitis infectious
10058838,5.36,NCT00557193-7,Arm C (Efficacy/ Dose Level 2),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,enterocolitis infectious
10056522,1.85,NCT00557193-4,Arm B (IR/HR MLL-R Chemotherapy),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,hepatic infection
10021881,2.38,NCT00557193-1,Induction (All Patients),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,infections and infestations - other specify
10021881,3.7,NCT00557193-4,Arm B (IR/HR MLL-R Chemotherapy),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,infections and infestations - other specify
10021881,54.55,NCT00557193-5,Arm C (Safety/ Dose Level 1),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,infections and infestations - other specify
10021881,45.45,NCT00557193-6,Arm C (Safety/ Dose Level 2),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,infections and infestations - other specify
10021881,41.07,NCT00557193-7,Arm C (Efficacy/ Dose Level 2),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,infections and infestations - other specify
10061229,3.7,NCT00557193-4,Arm B (IR/HR MLL-R Chemotherapy),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,lung infection
10061229,27.27,NCT00557193-5,Arm C (Safety/ Dose Level 1),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,lung infection
10061229,9.09,NCT00557193-6,Arm C (Safety/ Dose Level 2),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,lung infection
10061229,1.79,NCT00557193-7,Arm C (Efficacy/ Dose Level 2),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,lung infection
10065764,1.79,NCT00557193-7,Arm C (Efficacy/ Dose Level 2),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,mucosal infection
10057262,9.09,NCT00557193-6,Arm C (Safety/ Dose Level 2),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,peritoneal infection
D018805,3.7,NCT00557193-4,Arm B (IR/HR MLL-R Chemotherapy),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,sepsis
D018805,9.09,NCT00557193-5,Arm C (Safety/ Dose Level 1),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,sepsis
D018805,9.09,NCT00557193-6,Arm C (Safety/ Dose Level 2),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,sepsis
D018805,19.64,NCT00557193-7,Arm C (Efficacy/ Dose Level 2),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,sepsis
10040872,5.36,NCT00557193-7,Arm C (Efficacy/ Dose Level 2),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,skin infection
10065771,9.09,NCT00557193-6,Arm C (Safety/ Dose Level 2),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,small intestine infection
10065771,3.57,NCT00557193-7,Arm C (Efficacy/ Dose Level 2),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,small intestine infection
D018461,3.57,NCT00557193-7,Arm C (Efficacy/ Dose Level 2),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,soft tissue infection
D014136,9.09,NCT00557193-6,Arm C (Safety/ Dose Level 2),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,tracheitis
10046300,9.09,NCT00557193-5,Arm C (Safety/ Dose Level 1),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,upper respiratory infection
D014552,9.09,NCT00557193-5,Arm C (Safety/ Dose Level 1),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,urinary tract infection
D014552,18.18,NCT00557193-6,Arm C (Safety/ Dose Level 2),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,urinary tract infection
D014552,5.36,NCT00557193-7,Arm C (Efficacy/ Dose Level 2),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,urinary tract infection
D014946,9.09,NCT00557193-5,Arm C (Safety/ Dose Level 1),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,wound infection
D014946,9.09,NCT00557193-6,Arm C (Safety/ Dose Level 2),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,wound infection
10022117,3.57,NCT00557193-7,Arm C (Efficacy/ Dose Level 2),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,injury poisoning and procedural complications - other specify
10062169,1.79,NCT00557193-7,Arm C (Efficacy/ Dose Level 2),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,vascular access complication
10000636,1.85,NCT00557193-4,Arm B (IR/HR MLL-R Chemotherapy),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,activated partial thromboplastin time prolonged
10001551,0.48,NCT00557193-1,Induction (All Patients),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,alanine aminotransferase increased
10001551,1.85,NCT00557193-4,Arm B (IR/HR MLL-R Chemotherapy),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,alanine aminotransferase increased
10001551,27.27,NCT00557193-5,Arm C (Safety/ Dose Level 1),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,alanine aminotransferase increased
10001551,9.09,NCT00557193-6,Arm C (Safety/ Dose Level 2),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,alanine aminotransferase increased
10001551,17.86,NCT00557193-7,Arm C (Efficacy/ Dose Level 2),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,alanine aminotransferase increased
10003481,1.85,NCT00557193-4,Arm B (IR/HR MLL-R Chemotherapy),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,aspartate aminotransferase increased
10003481,9.09,NCT00557193-5,Arm C (Safety/ Dose Level 1),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,aspartate aminotransferase increased
10003481,9.09,NCT00557193-6,Arm C (Safety/ Dose Level 2),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,aspartate aminotransferase increased
10003481,14.29,NCT00557193-7,Arm C (Efficacy/ Dose Level 2),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,aspartate aminotransferase increased
10005364,0.48,NCT00557193-1,Induction (All Patients),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,blood bilirubin increased
10005364,1.85,NCT00557193-4,Arm B (IR/HR MLL-R Chemotherapy),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,blood bilirubin increased
10005364,9.09,NCT00557193-6,Arm C (Safety/ Dose Level 2),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,blood bilirubin increased
10005364,3.57,NCT00557193-7,Arm C (Efficacy/ Dose Level 2),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,blood bilirubin increased
10011368,1.85,NCT00557193-4,Arm B (IR/HR MLL-R Chemotherapy),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,creatinine increased
10011368,1.79,NCT00557193-7,Arm C (Efficacy/ Dose Level 2),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,creatinine increased
10016596,1.79,NCT00557193-7,Arm C (Efficacy/ Dose Level 2),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,fibrinogen decreased
10056910,9.09,NCT00557193-5,Arm C (Safety/ Dose Level 1),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,ggt increased
10056910,1.79,NCT00557193-7,Arm C (Efficacy/ Dose Level 2),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,ggt increased
10022891,1.79,NCT00557193-7,Arm C (Efficacy/ Dose Level 2),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,investigations - other specify
10024574,9.09,NCT00557193-6,Arm C (Safety/ Dose Level 2),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,lipase increased
10025256,9.09,NCT00557193-5,Arm C (Safety/ Dose Level 1),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,lymphocyte count decreased
10025256,9.09,NCT00557193-6,Arm C (Safety/ Dose Level 2),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,lymphocyte count decreased
10025256,1.79,NCT00557193-7,Arm C (Efficacy/ Dose Level 2),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,lymphocyte count decreased
10029366,1.85,NCT00557193-4,Arm B (IR/HR MLL-R Chemotherapy),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,neutrophil count decreased
10029366,9.09,NCT00557193-5,Arm C (Safety/ Dose Level 1),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,neutrophil count decreased
10029366,18.18,NCT00557193-6,Arm C (Safety/ Dose Level 2),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,neutrophil count decreased
10029366,12.5,NCT00557193-7,Arm C (Efficacy/ Dose Level 2),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,neutrophil count decreased
10035528,18.18,NCT00557193-6,Arm C (Safety/ Dose Level 2),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,platelet count decreased
10035528,5.36,NCT00557193-7,Arm C (Efficacy/ Dose Level 2),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,platelet count decreased
D015431,18.18,NCT00557193-5,Arm C (Safety/ Dose Level 1),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,weight loss
10049182,1.85,NCT00557193-4,Arm B (IR/HR MLL-R Chemotherapy),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,white blood cell decreased
10049182,9.09,NCT00557193-5,Arm C (Safety/ Dose Level 1),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,white blood cell decreased
10049182,18.18,NCT00557193-6,Arm C (Safety/ Dose Level 2),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,white blood cell decreased
10049182,3.57,NCT00557193-7,Arm C (Efficacy/ Dose Level 2),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,white blood cell decreased
D000138,1.79,NCT00557193-7,Arm C (Efficacy/ Dose Level 2),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,acidosis
D000855,18.18,NCT00557193-5,Arm C (Safety/ Dose Level 1),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,anorexia
D000855,9.09,NCT00557193-6,Arm C (Safety/ Dose Level 2),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,anorexia
D000855,1.79,NCT00557193-7,Arm C (Efficacy/ Dose Level 2),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,anorexia
D003681,18.18,NCT00557193-5,Arm C (Safety/ Dose Level 1),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,dehydration
D003681,18.18,NCT00557193-6,Arm C (Safety/ Dose Level 2),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,dehydration
D003681,10.71,NCT00557193-7,Arm C (Efficacy/ Dose Level 2),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,dehydration
D006943,9.09,NCT00557193-5,Arm C (Safety/ Dose Level 1),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,hyperglycemia
D006955,9.09,NCT00557193-5,Arm C (Safety/ Dose Level 1),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,hypernatremia
D006955,18.18,NCT00557193-6,Arm C (Safety/ Dose Level 2),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,hypernatremia
D006955,1.79,NCT00557193-7,Arm C (Efficacy/ Dose Level 2),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,hypernatremia
D015228,0.48,NCT00557193-1,Induction (All Patients),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,hypertriglyceridemia
D015228,1.79,NCT00557193-7,Arm C (Efficacy/ Dose Level 2),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,hypertriglyceridemia
D034141,8.93,NCT00557193-7,Arm C (Efficacy/ Dose Level 2),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,hypoalbuminemia
D006996,1.85,NCT00557193-4,Arm B (IR/HR MLL-R Chemotherapy),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,hypocalcemia
D006996,1.79,NCT00557193-7,Arm C (Efficacy/ Dose Level 2),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,hypocalcemia
D007003,9.09,NCT00557193-6,Arm C (Safety/ Dose Level 2),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,hypoglycemia
D007003,5.36,NCT00557193-7,Arm C (Efficacy/ Dose Level 2),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,hypoglycemia
D007008,1.85,NCT00557193-4,Arm B (IR/HR MLL-R Chemotherapy),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,hypokalemia
D007008,18.18,NCT00557193-5,Arm C (Safety/ Dose Level 1),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,hypokalemia
D007008,9.09,NCT00557193-6,Arm C (Safety/ Dose Level 2),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,hypokalemia
D007008,10.71,NCT00557193-7,Arm C (Efficacy/ Dose Level 2),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,hypokalemia
D007010,1.79,NCT00557193-7,Arm C (Efficacy/ Dose Level 2),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,hyponatremia
D017674,9.09,NCT00557193-5,Arm C (Safety/ Dose Level 1),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,hypophosphatemia
D017674,1.79,NCT00557193-7,Arm C (Efficacy/ Dose Level 2),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,hypophosphatemia
10049737,1.85,NCT00557193-4,Arm B (IR/HR MLL-R Chemotherapy),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,treatment related secondary malignancy
10053662,9.09,NCT00557193-5,Arm C (Safety/ Dose Level 1),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,abducens nerve disorder
10009845,3.57,NCT00557193-7,Arm C (Efficacy/ Dose Level 2),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,cognitive disturbance
D003244,9.09,NCT00557193-5,Arm C (Safety/ Dose Level 1),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,depressed level of consciousness
D001927,1.85,NCT00557193-4,Arm B (IR/HR MLL-R Chemotherapy),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,encephalopathy
D001927,9.09,NCT00557193-6,Arm C (Safety/ Dose Level 2),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,encephalopathy
D001927,1.79,NCT00557193-7,Arm C (Efficacy/ Dose Level 2),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,encephalopathy
D015840,1.79,NCT00557193-7,Arm C (Efficacy/ Dose Level 2),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,oculomotor nerve disorder
D012640,18.18,NCT00557193-5,Arm C (Safety/ Dose Level 1),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,seizure
D012640,9.09,NCT00557193-6,Arm C (Safety/ Dose Level 2),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,seizure
D012640,3.57,NCT00557193-7,Arm C (Efficacy/ Dose Level 2),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,seizure
D020521,1.79,NCT00557193-7,Arm C (Efficacy/ Dose Level 2),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,stroke
10037175,1.79,NCT00557193-7,Arm C (Efficacy/ Dose Level 2),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,psychiatric disorders - other specify
D058186,1.67,NCT00557193-3,Arm A (Standard Risk MLL-G),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,acute kidney injury
D058186,3.57,NCT00557193-7,Arm C (Efficacy/ Dose Level 2),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,acute kidney injury
D012128,1.85,NCT00557193-4,Arm B (IR/HR MLL-R Chemotherapy),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,adult respiratory distress syndrome
D001049,9.09,NCT00557193-5,Arm C (Safety/ Dose Level 1),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,apnea
10003504,1.79,NCT00557193-7,Arm C (Efficacy/ Dose Level 2),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,aspiration
D001261,1.85,NCT00557193-4,Arm B (IR/HR MLL-R Chemotherapy),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,atelectasis
D001261,1.79,NCT00557193-7,Arm C (Efficacy/ Dose Level 2),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,atelectasis
D004417,1.79,NCT00557193-7,Arm C (Efficacy/ Dose Level 2),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,dyspnea
D000860,0.95,NCT00557193-1,Induction (All Patients),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,hypoxia
D000860,1.85,NCT00557193-4,Arm B (IR/HR MLL-R Chemotherapy),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,hypoxia
D000860,9.09,NCT00557193-5,Arm C (Safety/ Dose Level 1),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,hypoxia
D000860,18.18,NCT00557193-6,Arm C (Safety/ Dose Level 2),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,hypoxia
D000860,7.14,NCT00557193-7,Arm C (Efficacy/ Dose Level 2),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,hypoxia
D011014,0.48,NCT00557193-1,Induction (All Patients),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,pneumonitis
D011014,9.09,NCT00557193-6,Arm C (Safety/ Dose Level 2),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,pneumonitis
D012131,1.85,NCT00557193-4,Arm B (IR/HR MLL-R Chemotherapy),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,respiratory failure
D012131,9.09,NCT00557193-5,Arm C (Safety/ Dose Level 1),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,respiratory failure
D012131,7.14,NCT00557193-7,Arm C (Efficacy/ Dose Level 2),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,respiratory failure
10037868,18.18,NCT00557193-5,Arm C (Safety/ Dose Level 1),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,rash maculo-papular
10040785,0.48,NCT00557193-1,Induction (All Patients),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,skin and subcutaneous tissue disorders - other specify
10040785,3.57,NCT00557193-7,Arm C (Efficacy/ Dose Level 2),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,skin and subcutaneous tissue disorders - other specify
10040947,9.09,NCT00557193-5,Arm C (Safety/ Dose Level 1),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,skin ulceration
10040947,5.36,NCT00557193-7,Arm C (Efficacy/ Dose Level 2),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,skin ulceration
10042613,9.09,NCT00557193-6,Arm C (Safety/ Dose Level 2),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,surgical and medical procedures - other specify
D006973,9.09,NCT00557193-5,Arm C (Safety/ Dose Level 1),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,hypertension
D006973,1.79,NCT00557193-7,Arm C (Efficacy/ Dose Level 2),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,hypertension
D007022,1.85,NCT00557193-4,Arm B (IR/HR MLL-R Chemotherapy),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,hypotension
D007022,18.18,NCT00557193-5,Arm C (Safety/ Dose Level 1),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,hypotension
D007022,9.09,NCT00557193-6,Arm C (Safety/ Dose Level 2),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,hypotension
D007022,8.93,NCT00557193-7,Arm C (Efficacy/ Dose Level 2),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,hypotension
10043565,1.79,NCT00557193-7,Arm C (Efficacy/ Dose Level 2),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,thromboembolic event
10054692,1.79,NCT00557193-7,Arm C (Efficacy/ Dose Level 2),NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,visceral arterial ischemia
D064420,20.0,NCT00565058-1,Pilot,NCT00565058,Combination of GTI-2040 and Cytarabine in the Treatment of Refractory and Relapsed Acute Myeloid Leukemia (AML),adverse drug events
D064420,13.33,NCT00565058-2,Phase II Arm,NCT00565058,Combination of GTI-2040 and Cytarabine in the Treatment of Refractory and Relapsed Acute Myeloid Leukemia (AML),adverse drug events
D064147,10.0,NCT00565058-1,Pilot,NCT00565058,Combination of GTI-2040 and Cytarabine in the Treatment of Refractory and Relapsed Acute Myeloid Leukemia (AML),febrile neutropenia
D064147,6.67,NCT00565058-2,Phase II Arm,NCT00565058,Combination of GTI-2040 and Cytarabine in the Treatment of Refractory and Relapsed Acute Myeloid Leukemia (AML),febrile neutropenia
D018450,20.0,NCT00565058-1,Pilot,NCT00565058,Combination of GTI-2040 and Cytarabine in the Treatment of Refractory and Relapsed Acute Myeloid Leukemia (AML),disease progression
D011014,20.0,NCT00565058-1,Pilot,NCT00565058,Combination of GTI-2040 and Cytarabine in the Treatment of Refractory and Relapsed Acute Myeloid Leukemia (AML),pneumonia
D018805,6.67,NCT00565058-2,Phase II Arm,NCT00565058,Combination of GTI-2040 and Cytarabine in the Treatment of Refractory and Relapsed Acute Myeloid Leukemia (AML),sepsis
D012131,10.0,NCT00565058-1,Pilot,NCT00565058,Combination of GTI-2040 and Cytarabine in the Treatment of Refractory and Relapsed Acute Myeloid Leukemia (AML),respiratory failure
D000860,10.0,NCT00565058-1,Pilot,NCT00565058,Combination of GTI-2040 and Cytarabine in the Treatment of Refractory and Relapsed Acute Myeloid Leukemia (AML),hypoxia
D000799,10.0,NCT00565058-1,Pilot,NCT00565058,Combination of GTI-2040 and Cytarabine in the Treatment of Refractory and Relapsed Acute Myeloid Leukemia (AML),angioedema
D009026,25.0,NCT00594815-1,Immunocompetent Pts With Newly Diagnosed Primary CNS Lymphoma,NCT00594815,Combined Immunochemotherapy Followed By Reduced Dose Radiation Therapy (RT) for Patients With Newly Diagnosed Primary Central Nervous System Lymphoma,mortality
D064420,42.31,NCT00594815-1,Immunocompetent Pts With Newly Diagnosed Primary CNS Lymphoma,NCT00594815,Combined Immunochemotherapy Followed By Reduced Dose Radiation Therapy (RT) for Patients With Newly Diagnosed Primary Central Nervous System Lymphoma,adverse drug events
D007962,7.69,NCT00594815-1,Immunocompetent Pts With Newly Diagnosed Primary CNS Lymphoma,NCT00594815,Combined Immunochemotherapy Followed By Reduced Dose Radiation Therapy (RT) for Patients With Newly Diagnosed Primary Central Nervous System Lymphoma,leukocytes
D007022,3.85,NCT00594815-1,Immunocompetent Pts With Newly Diagnosed Primary CNS Lymphoma,NCT00594815,Combined Immunochemotherapy Followed By Reduced Dose Radiation Therapy (RT) for Patients With Newly Diagnosed Primary Central Nervous System Lymphoma,hypotension
D004172,1.92,NCT00594815-1,Immunocompetent Pts With Newly Diagnosed Primary CNS Lymphoma,NCT00594815,Combined Immunochemotherapy Followed By Reduced Dose Radiation Therapy (RT) for Patients With Newly Diagnosed Primary Central Nervous System Lymphoma,double vision
D003681,1.92,NCT00594815-1,Immunocompetent Pts With Newly Diagnosed Primary CNS Lymphoma,NCT00594815,Combined Immunochemotherapy Followed By Reduced Dose Radiation Therapy (RT) for Patients With Newly Diagnosed Primary Central Nervous System Lymphoma,dehydration
D004381,1.92,NCT00594815-1,Immunocompetent Pts With Newly Diagnosed Primary CNS Lymphoma,NCT00594815,Combined Immunochemotherapy Followed By Reduced Dose Radiation Therapy (RT) for Patients With Newly Diagnosed Primary Central Nervous System Lymphoma,duodenal ulcer
D000069475,1.92,NCT00594815-1,Immunocompetent Pts With Newly Diagnosed Primary CNS Lymphoma,NCT00594815,Combined Immunochemotherapy Followed By Reduced Dose Radiation Therapy (RT) for Patients With Newly Diagnosed Primary Central Nervous System Lymphoma,reirradiation
D009325,1.92,NCT00594815-1,Immunocompetent Pts With Newly Diagnosed Primary CNS Lymphoma,NCT00594815,Combined Immunochemotherapy Followed By Reduced Dose Radiation Therapy (RT) for Patients With Newly Diagnosed Primary Central Nervous System Lymphoma,nausea
D014839,1.92,NCT00594815-1,Immunocompetent Pts With Newly Diagnosed Primary CNS Lymphoma,NCT00594815,Combined Immunochemotherapy Followed By Reduced Dose Radiation Therapy (RT) for Patients With Newly Diagnosed Primary Central Nervous System Lymphoma,vomiting
D005334,3.85,NCT00594815-1,Immunocompetent Pts With Newly Diagnosed Primary CNS Lymphoma,NCT00594815,Combined Immunochemotherapy Followed By Reduced Dose Radiation Therapy (RT) for Patients With Newly Diagnosed Primary Central Nervous System Lymphoma,fever
D000080867,1.92,NCT00594815-1,Immunocompetent Pts With Newly Diagnosed Primary CNS Lymphoma,NCT00594815,Combined Immunochemotherapy Followed By Reduced Dose Radiation Therapy (RT) for Patients With Newly Diagnosed Primary Central Nervous System Lymphoma,gingipains
D064147,5.77,NCT00594815-1,Immunocompetent Pts With Newly Diagnosed Primary CNS Lymphoma,NCT00594815,Combined Immunochemotherapy Followed By Reduced Dose Radiation Therapy (RT) for Patients With Newly Diagnosed Primary Central Nervous System Lymphoma,febrile neutropenia
D000069544,7.69,NCT00594815-1,Immunocompetent Pts With Newly Diagnosed Primary CNS Lymphoma,NCT00594815,Combined Immunochemotherapy Followed By Reduced Dose Radiation Therapy (RT) for Patients With Newly Diagnosed Primary Central Nervous System Lymphoma,encephalitis infection
D007239,1.92,NCT00594815-1,Immunocompetent Pts With Newly Diagnosed Primary CNS Lymphoma,NCT00594815,Combined Immunochemotherapy Followed By Reduced Dose Radiation Therapy (RT) for Patients With Newly Diagnosed Primary Central Nervous System Lymphoma,infection
D014947,5.77,NCT00594815-1,Immunocompetent Pts With Newly Diagnosed Primary CNS Lymphoma,NCT00594815,Combined Immunochemotherapy Followed By Reduced Dose Radiation Therapy (RT) for Patients With Newly Diagnosed Primary Central Nervous System Lymphoma,wounds
D006098,7.69,NCT00594815-1,Immunocompetent Pts With Newly Diagnosed Primary CNS Lymphoma,NCT00594815,Combined Immunochemotherapy Followed By Reduced Dose Radiation Therapy (RT) for Patients With Newly Diagnosed Primary Central Nervous System Lymphoma,granulocytes
D001792,7.69,NCT00594815-1,Immunocompetent Pts With Newly Diagnosed Primary CNS Lymphoma,NCT00594815,Combined Immunochemotherapy Followed By Reduced Dose Radiation Therapy (RT) for Patients With Newly Diagnosed Primary Central Nervous System Lymphoma,platelets
D018771,1.92,NCT00594815-1,Immunocompetent Pts With Newly Diagnosed Primary CNS Lymphoma,NCT00594815,Combined Immunochemotherapy Followed By Reduced Dose Radiation Therapy (RT) for Patients With Newly Diagnosed Primary Central Nervous System Lymphoma,arthralgia
D001259,1.92,NCT00594815-1,Immunocompetent Pts With Newly Diagnosed Primary CNS Lymphoma,NCT00594815,Combined Immunochemotherapy Followed By Reduced Dose Radiation Therapy (RT) for Patients With Newly Diagnosed Primary Central Nervous System Lymphoma,ataxia
D009462,3.85,NCT00594815-1,Immunocompetent Pts With Newly Diagnosed Primary CNS Lymphoma,NCT00594815,Combined Immunochemotherapy Followed By Reduced Dose Radiation Therapy (RT) for Patients With Newly Diagnosed Primary Central Nervous System Lymphoma,neurology
D006212,1.92,NCT00594815-1,Immunocompetent Pts With Newly Diagnosed Primary CNS Lymphoma,NCT00594815,Combined Immunochemotherapy Followed By Reduced Dose Radiation Therapy (RT) for Patients With Newly Diagnosed Primary Central Nervous System Lymphoma,hallucinations
D000339,1.92,NCT00594815-1,Immunocompetent Pts With Newly Diagnosed Primary CNS Lymphoma,NCT00594815,Combined Immunochemotherapy Followed By Reduced Dose Radiation Therapy (RT) for Patients With Newly Diagnosed Primary Central Nervous System Lymphoma,mood
D000339,1.92,NCT00594815-1,Immunocompetent Pts With Newly Diagnosed Primary CNS Lymphoma,NCT00594815,Combined Immunochemotherapy Followed By Reduced Dose Radiation Therapy (RT) for Patients With Newly Diagnosed Primary Central Nervous System Lymphoma,mood
D001519,1.92,NCT00594815-1,Immunocompetent Pts With Newly Diagnosed Primary CNS Lymphoma,NCT00594815,Combined Immunochemotherapy Followed By Reduced Dose Radiation Therapy (RT) for Patients With Newly Diagnosed Primary Central Nervous System Lymphoma,behavior
D003404,1.92,NCT00594815-1,Immunocompetent Pts With Newly Diagnosed Primary CNS Lymphoma,NCT00594815,Combined Immunochemotherapy Followed By Reduced Dose Radiation Therapy (RT) for Patients With Newly Diagnosed Primary Central Nervous System Lymphoma,creatinine
D051437,1.92,NCT00594815-1,Immunocompetent Pts With Newly Diagnosed Primary CNS Lymphoma,NCT00594815,Combined Immunochemotherapy Followed By Reduced Dose Radiation Therapy (RT) for Patients With Newly Diagnosed Primary Central Nervous System Lymphoma,renal failure
D000071477,1.92,NCT00594815-1,Immunocompetent Pts With Newly Diagnosed Primary CNS Lymphoma,NCT00594815,Combined Immunochemotherapy Followed By Reduced Dose Radiation Therapy (RT) for Patients With Newly Diagnosed Primary Central Nervous System Lymphoma,gubernaculum
D003371,1.92,NCT00594815-1,Immunocompetent Pts With Newly Diagnosed Primary CNS Lymphoma,NCT00594815,Combined Immunochemotherapy Followed By Reduced Dose Radiation Therapy (RT) for Patients With Newly Diagnosed Primary Central Nervous System Lymphoma,cough
D010547,1.92,NCT00594815-1,Immunocompetent Pts With Newly Diagnosed Primary CNS Lymphoma,NCT00594815,Combined Immunochemotherapy Followed By Reduced Dose Radiation Therapy (RT) for Patients With Newly Diagnosed Primary Central Nervous System Lymphoma,alveolar capillary dysplasia with misalignment of pulmonary veins and other congenital anomalies
D013927,1.92,NCT00594815-1,Immunocompetent Pts With Newly Diagnosed Primary CNS Lymphoma,NCT00594815,Combined Immunochemotherapy Followed By Reduced Dose Radiation Therapy (RT) for Patients With Newly Diagnosed Primary Central Nervous System Lymphoma,thrombosis
D064420,100.0,NCT00609739-1,Cytarabine + Mitoxantrone,NCT00609739,Cytosine Arabinoside and Mitoxantrone for Patients With Juvenile Myelomonocytic Leukemia Receiving Repeat Stem Cell Transplantation,adverse drug events
D003643,100.0,NCT00609739-1,Cytarabine + Mitoxantrone,NCT00609739,Cytosine Arabinoside and Mitoxantrone for Patients With Juvenile Myelomonocytic Leukemia Receiving Repeat Stem Cell Transplantation,death
D064420,75.0,NCT00620321-1,LY2181308,NCT00620321,A Study of LY2181308 Sodium in Patients With Relapsed or Refractory Acute Myeloid Leukemia,adverse drug events
D064420,81.25,NCT00620321-2,LY2181308 + Idarubicin + Cytarabine,NCT00620321,A Study of LY2181308 Sodium in Patients With Relapsed or Refractory Acute Myeloid Leukemia,adverse drug events
D064147,12.5,NCT00620321-1,LY2181308,NCT00620321,A Study of LY2181308 Sodium in Patients With Relapsed or Refractory Acute Myeloid Leukemia,febrile neutropenia
D064147,43.75,NCT00620321-2,LY2181308 + Idarubicin + Cytarabine,NCT00620321,A Study of LY2181308 Sodium in Patients With Relapsed or Refractory Acute Myeloid Leukemia,febrile neutropenia
D009503,12.5,NCT00620321-1,LY2181308,NCT00620321,A Study of LY2181308 Sodium in Patients With Relapsed or Refractory Acute Myeloid Leukemia,neutropenia
D013921,6.25,NCT00620321-2,LY2181308 + Idarubicin + Cytarabine,NCT00620321,A Study of LY2181308 Sodium in Patients With Relapsed or Refractory Acute Myeloid Leukemia,thrombocytopenia
10040741,6.25,NCT00620321-2,LY2181308 + Idarubicin + Cytarabine,NCT00620321,A Study of LY2181308 Sodium in Patients With Relapsed or Refractory Acute Myeloid Leukemia,sinus bradycardia
D013616,12.5,NCT00620321-1,LY2181308,NCT00620321,A Study of LY2181308 Sodium in Patients With Relapsed or Refractory Acute Myeloid Leukemia,sinus tachycardia
D000309,6.25,NCT00620321-2,LY2181308 + Idarubicin + Cytarabine,NCT00620321,A Study of LY2181308 Sodium in Patients With Relapsed or Refractory Acute Myeloid Leukemia,adrenal insufficiency
D015746,12.5,NCT00620321-1,LY2181308,NCT00620321,A Study of LY2181308 Sodium in Patients With Relapsed or Refractory Acute Myeloid Leukemia,abdominal pain
UNKNOWN-check-for-typo,6.25,NCT00620321-2,LY2181308 + Idarubicin + Cytarabine,NCT00620321,A Study of LY2181308 Sodium in Patients With Relapsed or Refractory Acute Myeloid Leukemia,D00
D044504,6.25,NCT00620321-2,LY2181308 + Idarubicin + Cytarabine,NCT00620321,A Study of LY2181308 Sodium in Patients With Relapsed or Refractory Acute Myeloid Leukemia,enterocolitis neutropenic
10015461,6.25,NCT00620321-2,LY2181308 + Idarubicin + Cytarabine,NCT00620321,A Study of LY2181308 Sodium in Patients With Relapsed or Refractory Acute Myeloid Leukemia,esophagitis
D005334,12.5,NCT00620321-1,LY2181308,NCT00620321,A Study of LY2181308 Sodium in Patients With Relapsed or Refractory Acute Myeloid Leukemia,pyrexia
UNKNOWN-check-for-typo,6.25,NCT00620321-2,LY2181308 + Idarubicin + Cytarabine,NCT00620321,A Study of LY2181308 Sodium in Patients With Relapsed or Refractory Acute Myeloid Leukemia,D00
D006086,6.25,NCT00620321-2,LY2181308 + Idarubicin + Cytarabine,NCT00620321,A Study of LY2181308 Sodium in Patients With Relapsed or Refractory Acute Myeloid Leukemia,graft versus host disease
D000069544,12.5,NCT00620321-1,LY2181308,NCT00620321,A Study of LY2181308 Sodium in Patients With Relapsed or Refractory Acute Myeloid Leukemia,encephalitis infection
D000069544,6.25,NCT00620321-2,LY2181308 + Idarubicin + Cytarabine,NCT00620321,A Study of LY2181308 Sodium in Patients With Relapsed or Refractory Acute Myeloid Leukemia,encephalitis infection
D011014,12.5,NCT00620321-1,LY2181308,NCT00620321,A Study of LY2181308 Sodium in Patients With Relapsed or Refractory Acute Myeloid Leukemia,pneumonia
D011014,6.25,NCT00620321-2,LY2181308 + Idarubicin + Cytarabine,NCT00620321,A Study of LY2181308 Sodium in Patients With Relapsed or Refractory Acute Myeloid Leukemia,pneumonia
D018805,50.0,NCT00620321-1,LY2181308,NCT00620321,A Study of LY2181308 Sodium in Patients With Relapsed or Refractory Acute Myeloid Leukemia,sepsis
D018805,6.25,NCT00620321-2,LY2181308 + Idarubicin + Cytarabine,NCT00620321,A Study of LY2181308 Sodium in Patients With Relapsed or Refractory Acute Myeloid Leukemia,sepsis
D012772,6.25,NCT00620321-2,LY2181308 + Idarubicin + Cytarabine,NCT00620321,A Study of LY2181308 Sodium in Patients With Relapsed or Refractory Acute Myeloid Leukemia,septic shock
UNKNOWN-check-for-typo,6.25,NCT00620321-2,LY2181308 + Idarubicin + Cytarabine,NCT00620321,A Study of LY2181308 Sodium in Patients With Relapsed or Refractory Acute Myeloid Leukemia,D00
UNKNOWN-check-for-typo,6.25,NCT00620321-2,LY2181308 + Idarubicin + Cytarabine,NCT00620321,A Study of LY2181308 Sodium in Patients With Relapsed or Refractory Acute Myeloid Leukemia,D00
UNKNOWN-check-for-typo,6.25,NCT00620321-2,LY2181308 + Idarubicin + Cytarabine,NCT00620321,A Study of LY2181308 Sodium in Patients With Relapsed or Refractory Acute Myeloid Leukemia,D00
D001711,6.25,NCT00620321-2,LY2181308 + Idarubicin + Cytarabine,NCT00620321,A Study of LY2181308 Sodium in Patients With Relapsed or Refractory Acute Myeloid Leukemia,biotransformation
D006261,6.25,NCT00620321-2,LY2181308 + Idarubicin + Cytarabine,NCT00620321,A Study of LY2181308 Sodium in Patients With Relapsed or Refractory Acute Myeloid Leukemia,headache
D001928,6.25,NCT00620321-2,LY2181308 + Idarubicin + Cytarabine,NCT00620321,A Study of LY2181308 Sodium in Patients With Relapsed or Refractory Acute Myeloid Leukemia,metabolic encephalopathy
D000073216,12.5,NCT00620321-1,LY2181308,NCT00620321,A Study of LY2181308 Sodium in Patients With Relapsed or Refractory Acute Myeloid Leukemia,mental status tests
D058186,6.25,NCT00620321-2,LY2181308 + Idarubicin + Cytarabine,NCT00620321,A Study of LY2181308 Sodium in Patients With Relapsed or Refractory Acute Myeloid Leukemia,acute renal failure
UNKNOWN-check-for-typo,12.5,NCT00620321-1,LY2181308,NCT00620321,A Study of LY2181308 Sodium in Patients With Relapsed or Refractory Acute Myeloid Leukemia,D00
D000860,12.5,NCT00620321-1,LY2181308,NCT00620321,A Study of LY2181308 Sodium in Patients With Relapsed or Refractory Acute Myeloid Leukemia,hypoxia
D012131,12.5,NCT00620321-2,LY2181308 + Idarubicin + Cytarabine,NCT00620321,A Study of LY2181308 Sodium in Patients With Relapsed or Refractory Acute Myeloid Leukemia,respiratory failure
D007022,12.5,NCT00620321-1,LY2181308,NCT00620321,A Study of LY2181308 Sodium in Patients With Relapsed or Refractory Acute Myeloid Leukemia,hypotension
D007022,12.5,NCT00620321-2,LY2181308 + Idarubicin + Cytarabine,NCT00620321,A Study of LY2181308 Sodium in Patients With Relapsed or Refractory Acute Myeloid Leukemia,hypotension
D064420,75.0,NCT00632749-1,5 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A,NCT00632749,BI 811283 in Combination With Cytarabine in Previously Untreated AML Ineligible for Intensive Treatment,adverse drug events
D064420,66.67,NCT00632749-2,15 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A,NCT00632749,BI 811283 in Combination With Cytarabine in Previously Untreated AML Ineligible for Intensive Treatment,adverse drug events
D064420,100.0,NCT00632749-3,30 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A,NCT00632749,BI 811283 in Combination With Cytarabine in Previously Untreated AML Ineligible for Intensive Treatment,adverse drug events
D064420,100.0,NCT00632749-4,60 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A,NCT00632749,BI 811283 in Combination With Cytarabine in Previously Untreated AML Ineligible for Intensive Treatment,adverse drug events
D064420,85.71,NCT00632749-5,100 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A,NCT00632749,BI 811283 in Combination With Cytarabine in Previously Untreated AML Ineligible for Intensive Treatment,adverse drug events
D064420,85.71,NCT00632749-6,120 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A,NCT00632749,BI 811283 in Combination With Cytarabine in Previously Untreated AML Ineligible for Intensive Treatment,adverse drug events
D064420,100.0,NCT00632749-7,5 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B,NCT00632749,BI 811283 in Combination With Cytarabine in Previously Untreated AML Ineligible for Intensive Treatment,adverse drug events
D064420,75.0,NCT00632749-8,40 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B,NCT00632749,BI 811283 in Combination With Cytarabine in Previously Untreated AML Ineligible for Intensive Treatment,adverse drug events
D064420,100.0,NCT00632749-9,80 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B,NCT00632749,BI 811283 in Combination With Cytarabine in Previously Untreated AML Ineligible for Intensive Treatment,adverse drug events
D064420,100.0,NCT00632749-10,160 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B,NCT00632749,BI 811283 in Combination With Cytarabine in Previously Untreated AML Ineligible for Intensive Treatment,adverse drug events
D064420,100.0,NCT00632749-11,240 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B,NCT00632749,BI 811283 in Combination With Cytarabine in Previously Untreated AML Ineligible for Intensive Treatment,adverse drug events
D064420,75.0,NCT00632749-12,300 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B,NCT00632749,BI 811283 in Combination With Cytarabine in Previously Untreated AML Ineligible for Intensive Treatment,adverse drug events
D064420,100.0,NCT00632749-13,360 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B,NCT00632749,BI 811283 in Combination With Cytarabine in Previously Untreated AML Ineligible for Intensive Treatment,adverse drug events
D064420,83.33,NCT00632749-14,420 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B,NCT00632749,BI 811283 in Combination With Cytarabine in Previously Untreated AML Ineligible for Intensive Treatment,adverse drug events
D004211,20.0,NCT00632749-9,80 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B,NCT00632749,BI 811283 in Combination With Cytarabine in Previously Untreated AML Ineligible for Intensive Treatment,disseminated intravascular coagulation
D064147,33.33,NCT00632749-3,30 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A,NCT00632749,BI 811283 in Combination With Cytarabine in Previously Untreated AML Ineligible for Intensive Treatment,febrile neutropenia
D064147,50.0,NCT00632749-4,60 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A,NCT00632749,BI 811283 in Combination With Cytarabine in Previously Untreated AML Ineligible for Intensive Treatment,febrile neutropenia
D064147,28.57,NCT00632749-5,100 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A,NCT00632749,BI 811283 in Combination With Cytarabine in Previously Untreated AML Ineligible for Intensive Treatment,febrile neutropenia
D064147,75.0,NCT00632749-7,5 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B,NCT00632749,BI 811283 in Combination With Cytarabine in Previously Untreated AML Ineligible for Intensive Treatment,febrile neutropenia
D064147,25.0,NCT00632749-8,40 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B,NCT00632749,BI 811283 in Combination With Cytarabine in Previously Untreated AML Ineligible for Intensive Treatment,febrile neutropenia
D064147,20.0,NCT00632749-9,80 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B,NCT00632749,BI 811283 in Combination With Cytarabine in Previously Untreated AML Ineligible for Intensive Treatment,febrile neutropenia
D064147,33.33,NCT00632749-10,160 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B,NCT00632749,BI 811283 in Combination With Cytarabine in Previously Untreated AML Ineligible for Intensive Treatment,febrile neutropenia
D064147,28.57,NCT00632749-11,240 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B,NCT00632749,BI 811283 in Combination With Cytarabine in Previously Untreated AML Ineligible for Intensive Treatment,febrile neutropenia
D064147,50.0,NCT00632749-12,300 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B,NCT00632749,BI 811283 in Combination With Cytarabine in Previously Untreated AML Ineligible for Intensive Treatment,febrile neutropenia
D064147,66.67,NCT00632749-13,360 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B,NCT00632749,BI 811283 in Combination With Cytarabine in Previously Untreated AML Ineligible for Intensive Treatment,febrile neutropenia
D064147,33.33,NCT00632749-14,420 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B,NCT00632749,BI 811283 in Combination With Cytarabine in Previously Untreated AML Ineligible for Intensive Treatment,febrile neutropenia
D007964,14.29,NCT00632749-5,100 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A,NCT00632749,BI 811283 in Combination With Cytarabine in Previously Untreated AML Ineligible for Intensive Treatment,leukocytosis
D007964,33.33,NCT00632749-10,160 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B,NCT00632749,BI 811283 in Combination With Cytarabine in Previously Untreated AML Ineligible for Intensive Treatment,leukocytosis
D056988,33.33,NCT00632749-10,160 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B,NCT00632749,BI 811283 in Combination With Cytarabine in Previously Untreated AML Ineligible for Intensive Treatment,acute anterior wall myocardial infarction
D056988,14.29,NCT00632749-11,240 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B,NCT00632749,BI 811283 in Combination With Cytarabine in Previously Untreated AML Ineligible for Intensive Treatment,acute anterior wall myocardial infarction
D001281,33.33,NCT00632749-10,160 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B,NCT00632749,BI 811283 in Combination With Cytarabine in Previously Untreated AML Ineligible for Intensive Treatment,atrial fibrillation
D006333,25.0,NCT00632749-4,60 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A,NCT00632749,BI 811283 in Combination With Cytarabine in Previously Untreated AML Ineligible for Intensive Treatment,cardiac failure
D006333,14.29,NCT00632749-5,100 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A,NCT00632749,BI 811283 in Combination With Cytarabine in Previously Untreated AML Ineligible for Intensive Treatment,cardiac failure
D009618,25.0,NCT00632749-4,60 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A,NCT00632749,BI 811283 in Combination With Cytarabine in Previously Untreated AML Ineligible for Intensive Treatment,nocardiaceae
D013610,25.0,NCT00632749-4,60 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A,NCT00632749,BI 811283 in Combination With Cytarabine in Previously Untreated AML Ineligible for Intensive Treatment,tachycardia
D000708,25.0,NCT00632749-1,5 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A,NCT00632749,BI 811283 in Combination With Cytarabine in Previously Untreated AML Ineligible for Intensive Treatment,anaplasia
D001766,20.0,NCT00632749-9,80 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B,NCT00632749,BI 811283 in Combination With Cytarabine in Previously Untreated AML Ineligible for Intensive Treatment,blindness
D001248,20.0,NCT00632749-9,80 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B,NCT00632749,BI 811283 in Combination With Cytarabine in Previously Untreated AML Ineligible for Intensive Treatment,eyestrain
UNKNOWN-check-for-typo,25.0,NCT00632749-4,60 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A,NCT00632749,BI 811283 in Combination With Cytarabine in Previously Untreated AML Ineligible for Intensive Treatment,D00
UNKNOWN-check-for-typo,14.29,NCT00632749-11,240 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B,NCT00632749,BI 811283 in Combination With Cytarabine in Previously Untreated AML Ineligible for Intensive Treatment,D00
D000069196,33.33,NCT00632749-10,160 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B,NCT00632749,BI 811283 in Combination With Cytarabine in Previously Untreated AML Ineligible for Intensive Treatment,gastrointestinal microbiome
D009325,25.0,NCT00632749-4,60 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A,NCT00632749,BI 811283 in Combination With Cytarabine in Previously Untreated AML Ineligible for Intensive Treatment,nausea
D009325,14.29,NCT00632749-11,240 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B,NCT00632749,BI 811283 in Combination With Cytarabine in Previously Untreated AML Ineligible for Intensive Treatment,nausea
D000071056,33.33,NCT00632749-10,160 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B,NCT00632749,BI 811283 in Combination With Cytarabine in Previously Untreated AML Ineligible for Intensive Treatment,anorectal malformations
D041742,33.33,NCT00632749-10,160 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B,NCT00632749,BI 811283 in Combination With Cytarabine in Previously Untreated AML Ineligible for Intensive Treatment,upper gastrointestinal tract
D001247,25.0,NCT00632749-4,60 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A,NCT00632749,BI 811283 in Combination With Cytarabine in Previously Untreated AML Ineligible for Intensive Treatment,asthenia
D003643,25.0,NCT00632749-1,5 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A,NCT00632749,BI 811283 in Combination With Cytarabine in Previously Untreated AML Ineligible for Intensive Treatment,death
D003695,25.0,NCT00632749-4,60 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A,NCT00632749,BI 811283 in Combination With Cytarabine in Previously Untreated AML Ineligible for Intensive Treatment,healthcare
D003695,28.57,NCT00632749-6,120 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A,NCT00632749,BI 811283 in Combination With Cytarabine in Previously Untreated AML Ineligible for Intensive Treatment,healthcare
D003695,20.0,NCT00632749-9,80 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B,NCT00632749,BI 811283 in Combination With Cytarabine in Previously Untreated AML Ineligible for Intensive Treatment,healthcare
D003695,66.67,NCT00632749-10,160 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B,NCT00632749,BI 811283 in Combination With Cytarabine in Previously Untreated AML Ineligible for Intensive Treatment,healthcare
D003695,42.86,NCT00632749-11,240 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B,NCT00632749,BI 811283 in Combination With Cytarabine in Previously Untreated AML Ineligible for Intensive Treatment,healthcare
D003695,25.0,NCT00632749-12,300 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B,NCT00632749,BI 811283 in Combination With Cytarabine in Previously Untreated AML Ineligible for Intensive Treatment,healthcare
D009102,14.29,NCT00632749-6,120 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A,NCT00632749,BI 811283 in Combination With Cytarabine in Previously Untreated AML Ineligible for Intensive Treatment,multiple organ failure
D009102,50.0,NCT00632749-8,40 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B,NCT00632749,BI 811283 in Combination With Cytarabine in Previously Untreated AML Ineligible for Intensive Treatment,multiple organ failure
D005334,25.0,NCT00632749-1,5 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A,NCT00632749,BI 811283 in Combination With Cytarabine in Previously Untreated AML Ineligible for Intensive Treatment,pyrexia
D005334,66.67,NCT00632749-2,15 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A,NCT00632749,BI 811283 in Combination With Cytarabine in Previously Untreated AML Ineligible for Intensive Treatment,pyrexia
D005334,25.0,NCT00632749-4,60 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A,NCT00632749,BI 811283 in Combination With Cytarabine in Previously Untreated AML Ineligible for Intensive Treatment,pyrexia
D005334,50.0,NCT00632749-7,5 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B,NCT00632749,BI 811283 in Combination With Cytarabine in Previously Untreated AML Ineligible for Intensive Treatment,pyrexia
D005334,25.0,NCT00632749-8,40 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B,NCT00632749,BI 811283 in Combination With Cytarabine in Previously Untreated AML Ineligible for Intensive Treatment,pyrexia
D005334,33.33,NCT00632749-10,160 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B,NCT00632749,BI 811283 in Combination With Cytarabine in Previously Untreated AML Ineligible for Intensive Treatment,pyrexia
D002764,14.29,NCT00632749-11,240 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B,NCT00632749,BI 811283 in Combination With Cytarabine in Previously Untreated AML Ineligible for Intensive Treatment,cholecystitis
D000038,25.0,NCT00632749-7,5 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B,NCT00632749,BI 811283 in Combination With Cytarabine in Previously Untreated AML Ineligible for Intensive Treatment,abscess
D001168,33.33,NCT00632749-10,160 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B,NCT00632749,BI 811283 in Combination With Cytarabine in Previously Untreated AML Ineligible for Intensive Treatment,arthritis
D000985,16.67,NCT00632749-14,420 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B,NCT00632749,BI 811283 in Combination With Cytarabine in Previously Untreated AML Ineligible for Intensive Treatment,antisepsis
D002481,20.0,NCT00632749-9,80 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B,NCT00632749,BI 811283 in Combination With Cytarabine in Previously Untreated AML Ineligible for Intensive Treatment,cellulitis
D003015,25.0,NCT00632749-8,40 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B,NCT00632749,BI 811283 in Combination With Cytarabine in Previously Untreated AML Ineligible for Intensive Treatment,clostridium difficile infection
10064687,14.29,NCT00632749-5,100 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A,NCT00632749,BI 811283 in Combination With Cytarabine in Previously Untreated AML Ineligible for Intensive Treatment,device related infection
10064687,25.0,NCT00632749-8,40 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B,NCT00632749,BI 811283 in Combination With Cytarabine in Previously Untreated AML Ineligible for Intensive Treatment,device related infection
D004238,14.29,NCT00632749-5,100 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A,NCT00632749,BI 811283 in Combination With Cytarabine in Previously Untreated AML Ineligible for Intensive Treatment,diverticulitis
D004696,25.0,NCT00632749-8,40 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B,NCT00632749,BI 811283 in Combination With Cytarabine in Previously Untreated AML Ineligible for Intensive Treatment,endocarditis
D000985,14.29,NCT00632749-5,100 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A,NCT00632749,BI 811283 in Combination With Cytarabine in Previously Untreated AML Ineligible for Intensive Treatment,antisepsis
D005499,25.0,NCT00632749-7,5 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B,NCT00632749,BI 811283 in Combination With Cytarabine in Previously Untreated AML Ineligible for Intensive Treatment,folliculitis
D005891,25.0,NCT00632749-12,300 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B,NCT00632749,BI 811283 in Combination With Cytarabine in Previously Untreated AML Ineligible for Intensive Treatment,gingivitis
D000038,33.33,NCT00632749-3,30 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A,NCT00632749,BI 811283 in Combination With Cytarabine in Previously Untreated AML Ineligible for Intensive Treatment,abscess
D000069544,14.29,NCT00632749-6,120 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A,NCT00632749,BI 811283 in Combination With Cytarabine in Previously Untreated AML Ineligible for Intensive Treatment,encephalitis infection
D007239,33.33,NCT00632749-2,15 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A,NCT00632749,BI 811283 in Combination With Cytarabine in Previously Untreated AML Ineligible for Intensive Treatment,infection
D007239,14.29,NCT00632749-11,240 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B,NCT00632749,BI 811283 in Combination With Cytarabine in Previously Untreated AML Ineligible for Intensive Treatment,infection
D000985,14.29,NCT00632749-6,120 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A,NCT00632749,BI 811283 in Combination With Cytarabine in Previously Untreated AML Ineligible for Intensive Treatment,antisepsis
D010019,20.0,NCT00632749-9,80 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B,NCT00632749,BI 811283 in Combination With Cytarabine in Previously Untreated AML Ineligible for Intensive Treatment,osteomyelitis
D011014,50.0,NCT00632749-1,5 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A,NCT00632749,BI 811283 in Combination With Cytarabine in Previously Untreated AML Ineligible for Intensive Treatment,pneumonia
D011014,50.0,NCT00632749-4,60 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A,NCT00632749,BI 811283 in Combination With Cytarabine in Previously Untreated AML Ineligible for Intensive Treatment,pneumonia
D011014,28.57,NCT00632749-5,100 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A,NCT00632749,BI 811283 in Combination With Cytarabine in Previously Untreated AML Ineligible for Intensive Treatment,pneumonia
D011014,14.29,NCT00632749-6,120 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A,NCT00632749,BI 811283 in Combination With Cytarabine in Previously Untreated AML Ineligible for Intensive Treatment,pneumonia
D011014,25.0,NCT00632749-7,5 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B,NCT00632749,BI 811283 in Combination With Cytarabine in Previously Untreated AML Ineligible for Intensive Treatment,pneumonia
D011014,50.0,NCT00632749-8,40 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B,NCT00632749,BI 811283 in Combination With Cytarabine in Previously Untreated AML Ineligible for Intensive Treatment,pneumonia
D011014,40.0,NCT00632749-9,80 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B,NCT00632749,BI 811283 in Combination With Cytarabine in Previously Untreated AML Ineligible for Intensive Treatment,pneumonia
D011014,28.57,NCT00632749-11,240 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B,NCT00632749,BI 811283 in Combination With Cytarabine in Previously Untreated AML Ineligible for Intensive Treatment,pneumonia
D011014,33.33,NCT00632749-13,360 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B,NCT00632749,BI 811283 in Combination With Cytarabine in Previously Untreated AML Ineligible for Intensive Treatment,pneumonia
D011014,16.67,NCT00632749-14,420 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B,NCT00632749,BI 811283 in Combination With Cytarabine in Previously Untreated AML Ineligible for Intensive Treatment,pneumonia
D001996,33.33,NCT00632749-2,15 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A,NCT00632749,BI 811283 in Combination With Cytarabine in Previously Untreated AML Ineligible for Intensive Treatment,bronchopneumonia
D001996,14.29,NCT00632749-6,120 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A,NCT00632749,BI 811283 in Combination With Cytarabine in Previously Untreated AML Ineligible for Intensive Treatment,bronchopneumonia
D018805,25.0,NCT00632749-1,5 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A,NCT00632749,BI 811283 in Combination With Cytarabine in Previously Untreated AML Ineligible for Intensive Treatment,sepsis
D018805,14.29,NCT00632749-6,120 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A,NCT00632749,BI 811283 in Combination With Cytarabine in Previously Untreated AML Ineligible for Intensive Treatment,sepsis
D018805,33.33,NCT00632749-10,160 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B,NCT00632749,BI 811283 in Combination With Cytarabine in Previously Untreated AML Ineligible for Intensive Treatment,sepsis
D018805,14.29,NCT00632749-11,240 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B,NCT00632749,BI 811283 in Combination With Cytarabine in Previously Untreated AML Ineligible for Intensive Treatment,sepsis
D018805,50.0,NCT00632749-12,300 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B,NCT00632749,BI 811283 in Combination With Cytarabine in Previously Untreated AML Ineligible for Intensive Treatment,sepsis
10040872,25.0,NCT00632749-8,40 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B,NCT00632749,BI 811283 in Combination With Cytarabine in Previously Untreated AML Ineligible for Intensive Treatment,skin infection
D013203,33.33,NCT00632749-3,30 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A,NCT00632749,BI 811283 in Combination With Cytarabine in Previously Untreated AML Ineligible for Intensive Treatment,staphylococcal infection
D013203,14.29,NCT00632749-5,100 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A,NCT00632749,BI 811283 in Combination With Cytarabine in Previously Untreated AML Ineligible for Intensive Treatment,staphylococcal infection
10048762,25.0,NCT00632749-12,300 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B,NCT00632749,BI 811283 in Combination With Cytarabine in Previously Untreated AML Ineligible for Intensive Treatment,tooth infection
10016173,25.0,NCT00632749-7,5 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B,NCT00632749,BI 811283 in Combination With Cytarabine in Previously Untreated AML Ineligible for Intensive Treatment,fall
D006408,25.0,NCT00632749-1,5 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A,NCT00632749,BI 811283 in Combination With Cytarabine in Previously Untreated AML Ineligible for Intensive Treatment,hematoma subdural
D007431,14.29,NCT00632749-5,100 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A,NCT00632749,BI 811283 in Combination With Cytarabine in Previously Untreated AML Ineligible for Intensive Treatment,intraoperative complications
D000111,20.0,NCT00632749-9,80 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B,NCT00632749,BI 811283 in Combination With Cytarabine in Previously Untreated AML Ineligible for Intensive Treatment,mercapturic acid
D002097,25.0,NCT00632749-4,60 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A,NCT00632749,BI 811283 in Combination With Cytarabine in Previously Untreated AML Ineligible for Intensive Treatment,c-reactive protein
D002097,14.29,NCT00632749-5,100 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A,NCT00632749,BI 811283 in Combination With Cytarabine in Previously Untreated AML Ineligible for Intensive Treatment,c-reactive protein
D002097,14.29,NCT00632749-6,120 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A,NCT00632749,BI 811283 in Combination With Cytarabine in Previously Untreated AML Ineligible for Intensive Treatment,c-reactive protein
D002097,20.0,NCT00632749-9,80 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B,NCT00632749,BI 811283 in Combination With Cytarabine in Previously Untreated AML Ineligible for Intensive Treatment,c-reactive protein
D002097,66.67,NCT00632749-10,160 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B,NCT00632749,BI 811283 in Combination With Cytarabine in Previously Untreated AML Ineligible for Intensive Treatment,c-reactive protein
D002097,14.29,NCT00632749-11,240 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B,NCT00632749,BI 811283 in Combination With Cytarabine in Previously Untreated AML Ineligible for Intensive Treatment,c-reactive protein
D000637,14.29,NCT00632749-11,240 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B,NCT00632749,BI 811283 in Combination With Cytarabine in Previously Untreated AML Ineligible for Intensive Treatment,transaminases
UNKNOWN-check-for-typo,33.33,NCT00632749-13,360 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B,NCT00632749,BI 811283 in Combination With Cytarabine in Previously Untreated AML Ineligible for Intensive Treatment,D00
D015275,14.29,NCT00632749-6,120 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A,NCT00632749,BI 811283 in Combination With Cytarabine in Previously Untreated AML Ineligible for Intensive Treatment,tumour lysis syndrome
D015275,16.67,NCT00632749-14,420 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B,NCT00632749,BI 811283 in Combination With Cytarabine in Previously Untreated AML Ineligible for Intensive Treatment,tumour lysis syndrome
D005208,25.0,NCT00632749-1,5 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A,NCT00632749,BI 811283 in Combination With Cytarabine in Previously Untreated AML Ineligible for Intensive Treatment,fasciitis
D009369,14.29,NCT00632749-6,120 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A,NCT00632749,BI 811283 in Combination With Cytarabine in Previously Untreated AML Ineligible for Intensive Treatment,malignant neoplasms
D009369,25.0,NCT00632749-7,5 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B,NCT00632749,BI 811283 in Combination With Cytarabine in Previously Untreated AML Ineligible for Intensive Treatment,malignant neoplasms
D009369,20.0,NCT00632749-9,80 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B,NCT00632749,BI 811283 in Combination With Cytarabine in Previously Untreated AML Ineligible for Intensive Treatment,malignant neoplasms
D009369,14.29,NCT00632749-11,240 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B,NCT00632749,BI 811283 in Combination With Cytarabine in Previously Untreated AML Ineligible for Intensive Treatment,malignant neoplasms
D009369,33.33,NCT00632749-14,420 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B,NCT00632749,BI 811283 in Combination With Cytarabine in Previously Untreated AML Ineligible for Intensive Treatment,malignant neoplasms
D000074042,14.29,NCT00632749-5,100 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A,NCT00632749,BI 811283 in Combination With Cytarabine in Previously Untreated AML Ineligible for Intensive Treatment,cerebral intraventricular haemorrhage
D000070624,33.33,NCT00632749-3,30 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A,NCT00632749,BI 811283 in Combination With Cytarabine in Previously Untreated AML Ineligible for Intensive Treatment,cerebral contusion
D012640,33.33,NCT00632749-13,360 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B,NCT00632749,BI 811283 in Combination With Cytarabine in Previously Untreated AML Ineligible for Intensive Treatment,convulsion
D004244,14.29,NCT00632749-6,120 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A,NCT00632749,BI 811283 in Combination With Cytarabine in Previously Untreated AML Ineligible for Intensive Treatment,dizziness
D003221,25.0,NCT00632749-4,60 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A,NCT00632749,BI 811283 in Combination With Cytarabine in Previously Untreated AML Ineligible for Intensive Treatment,confusional state
D051437,25.0,NCT00632749-1,5 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A,NCT00632749,BI 811283 in Combination With Cytarabine in Previously Untreated AML Ineligible for Intensive Treatment,renal failure
D058186,14.29,NCT00632749-6,120 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A,NCT00632749,BI 811283 in Combination With Cytarabine in Previously Untreated AML Ineligible for Intensive Treatment,acute renal failure
UNKNOWN-check-for-typo,25.0,NCT00632749-4,60 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A,NCT00632749,BI 811283 in Combination With Cytarabine in Previously Untreated AML Ineligible for Intensive Treatment,D00
D004844,14.29,NCT00632749-11,240 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B,NCT00632749,BI 811283 in Combination With Cytarabine in Previously Untreated AML Ineligible for Intensive Treatment,epistaxis
D008168,14.29,NCT00632749-6,120 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A,NCT00632749,BI 811283 in Combination With Cytarabine in Previously Untreated AML Ineligible for Intensive Treatment,lung
D010996,25.0,NCT00632749-4,60 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A,NCT00632749,BI 811283 in Combination With Cytarabine in Previously Untreated AML Ineligible for Intensive Treatment,pleural effusion
D011655,33.33,NCT00632749-13,360 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B,NCT00632749,BI 811283 in Combination With Cytarabine in Previously Untreated AML Ineligible for Intensive Treatment,pulmonary embolism
D012131,25.0,NCT00632749-8,40 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B,NCT00632749,BI 811283 in Combination With Cytarabine in Previously Untreated AML Ineligible for Intensive Treatment,respiratory failure
D012131,33.33,NCT00632749-13,360 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B,NCT00632749,BI 811283 in Combination With Cytarabine in Previously Untreated AML Ineligible for Intensive Treatment,respiratory failure
D007022,14.29,NCT00632749-11,240 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B,NCT00632749,BI 811283 in Combination With Cytarabine in Previously Untreated AML Ineligible for Intensive Treatment,hypotension
D064420,93.62,NCT00691015-1,Conditioning Regimen,NCT00691015,Sirolimus  Tacrolimus  and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant,adverse drug events
D001853,2.13,NCT00691015-1,Conditioning Regimen,NCT00691015,Sirolimus  Tacrolimus  and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant,bone marrow
D004211,2.13,NCT00691015-1,Conditioning Regimen,NCT00691015,Sirolimus  Tacrolimus  and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant,disseminated intravascular coagulation
D064147,2.13,NCT00691015-1,Conditioning Regimen,NCT00691015,Sirolimus  Tacrolimus  and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant,febrile neutropenia
D007962,25.53,NCT00691015-1,Conditioning Regimen,NCT00691015,Sirolimus  Tacrolimus  and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant,leukocytes
D008231,23.4,NCT00691015-1,Conditioning Regimen,NCT00691015,Sirolimus  Tacrolimus  and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant,lymphopenia
D006342,6.38,NCT00691015-1,Conditioning Regimen,NCT00691015,Sirolimus  Tacrolimus  and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant,cardiac rupture post-infarction
D006323,4.26,NCT00691015-1,Conditioning Regimen,NCT00691015,Sirolimus  Tacrolimus  and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant,cardiopulmonary arrest
D018487,2.13,NCT00691015-1,Conditioning Regimen,NCT00691015,Sirolimus  Tacrolimus  and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant,ventricular dysfunction left
10069501,2.13,NCT00691015-1,Conditioning Regimen,NCT00691015,Sirolimus  Tacrolimus  and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant,left ventricular systolic dysfunction
10008481,2.13,NCT00691015-1,Conditioning Regimen,NCT00691015,Sirolimus  Tacrolimus  and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant,chest pain - cardiac
D010490,2.13,NCT00691015-1,Conditioning Regimen,NCT00691015,Sirolimus  Tacrolimus  and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant,pericardial effusion
D001145,4.26,NCT00691015-1,Conditioning Regimen,NCT00691015,Sirolimus  Tacrolimus  and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant,arrhythmia
D013610,2.13,NCT00691015-1,Conditioning Regimen,NCT00691015,Sirolimus  Tacrolimus  and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant,tachycardia
D013617,2.13,NCT00691015-1,Conditioning Regimen,NCT00691015,Sirolimus  Tacrolimus  and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant,tachycardia supraventricular
D001201,8.51,NCT00691015-1,Conditioning Regimen,NCT00691015,Sirolimus  Tacrolimus  and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant,ascites
D003092,14.89,NCT00691015-1,Conditioning Regimen,NCT00691015,Sirolimus  Tacrolimus  and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant,colitis
D003967,12.77,NCT00691015-1,Conditioning Regimen,NCT00691015,Sirolimus  Tacrolimus  and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant,diarrhea
D005756,4.26,NCT00691015-1,Conditioning Regimen,NCT00691015,Sirolimus  Tacrolimus  and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant,gastritis
D006471,2.13,NCT00691015-1,Conditioning Regimen,NCT00691015,Sirolimus  Tacrolimus  and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant,gastrointestinal hemorrhage
D045823,2.13,NCT00691015-1,Conditioning Regimen,NCT00691015,Sirolimus  Tacrolimus  and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant,ileus
D003082,4.26,NCT00691015-1,Conditioning Regimen,NCT00691015,Sirolimus  Tacrolimus  and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant,large bowel resection
10065710,2.13,NCT00691015-1,Conditioning Regimen,NCT00691015,Sirolimus  Tacrolimus  and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant,small intestinal mucositis
D009325,14.89,NCT00691015-1,Conditioning Regimen,NCT00691015,Sirolimus  Tacrolimus  and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant,nausea
D015746,2.13,NCT00691015-1,Conditioning Regimen,NCT00691015,Sirolimus  Tacrolimus  and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant,abdominal pain
D009055,8.51,NCT00691015-1,Conditioning Regimen,NCT00691015,Sirolimus  Tacrolimus  and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant,oral cavity
10017999,2.13,NCT00691015-1,Conditioning Regimen,NCT00691015,Sirolimus  Tacrolimus  and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant,gastrointestinal pain
D014839,6.38,NCT00691015-1,Conditioning Regimen,NCT00691015,Sirolimus  Tacrolimus  and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant,vomiting
D005221,2.13,NCT00691015-1,Conditioning Regimen,NCT00691015,Sirolimus  Tacrolimus  and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant,fatigue
D005334,2.13,NCT00691015-1,Conditioning Regimen,NCT00691015,Sirolimus  Tacrolimus  and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant,fever
D005884,8.51,NCT00691015-1,Conditioning Regimen,NCT00691015,Sirolimus  Tacrolimus  and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant,gingival hemorrhage
D023341,4.26,NCT00691015-1,Conditioning Regimen,NCT00691015,Sirolimus  Tacrolimus  and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant,chills
D018450,4.26,NCT00691015-1,Conditioning Regimen,NCT00691015,Sirolimus  Tacrolimus  and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant,disease progression
D018450,2.13,NCT00691015-1,Conditioning Regimen,NCT00691015,Sirolimus  Tacrolimus  and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant,disease progression
D003643,2.13,NCT00691015-1,Conditioning Regimen,NCT00691015,Sirolimus  Tacrolimus  and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant,death
D000857,2.13,NCT00691015-1,Conditioning Regimen,NCT00691015,Sirolimus  Tacrolimus  and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant,dysosmia
D003643,6.38,NCT00691015-1,Conditioning Regimen,NCT00691015,Sirolimus  Tacrolimus  and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant,death
D000069544,2.13,NCT00691015-1,Conditioning Regimen,NCT00691015,Sirolimus  Tacrolimus  and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant,encephalitis infection
D009102,4.26,NCT00691015-1,Conditioning Regimen,NCT00691015,Sirolimus  Tacrolimus  and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant,multiple organ failure
D009102,2.13,NCT00691015-1,Conditioning Regimen,NCT00691015,Sirolimus  Tacrolimus  and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant,multiple organ failure
D003643,2.13,NCT00691015-1,Conditioning Regimen,NCT00691015,Sirolimus  Tacrolimus  and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant,death
D018450,2.13,NCT00691015-1,Conditioning Regimen,NCT00691015,Sirolimus  Tacrolimus  and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant,disease progression
D003643,2.13,NCT00691015-1,Conditioning Regimen,NCT00691015,Sirolimus  Tacrolimus  and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant,death
D000068538,6.38,NCT00691015-1,Conditioning Regimen,NCT00691015,Sirolimus  Tacrolimus  and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant,avodart
D008107,2.13,NCT00691015-1,Conditioning Regimen,NCT00691015,Sirolimus  Tacrolimus  and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant,liver dysfunction
D000080424,2.13,NCT00691015-1,Conditioning Regimen,NCT00691015,Sirolimus  Tacrolimus  and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant,cytokine release syndrome
D007239,51.06,NCT00691015-1,Conditioning Regimen,NCT00691015,Sirolimus  Tacrolimus  and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant,infection
D000069544,12.77,NCT00691015-1,Conditioning Regimen,NCT00691015,Sirolimus  Tacrolimus  and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant,encephalitis infection
D000069544,12.77,NCT00691015-1,Conditioning Regimen,NCT00691015,Sirolimus  Tacrolimus  and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant,encephalitis infection
D020031,8.51,NCT00691015-1,Conditioning Regimen,NCT00691015,Sirolimus  Tacrolimus  and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant,ebv infection
D000069544,4.26,NCT00691015-1,Conditioning Regimen,NCT00691015,Sirolimus  Tacrolimus  and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant,encephalitis infection
D000069544,2.13,NCT00691015-1,Conditioning Regimen,NCT00691015,Sirolimus  Tacrolimus  and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant,encephalitis infection
D001228,4.26,NCT00691015-1,Conditioning Regimen,NCT00691015,Sirolimus  Tacrolimus  and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant,aspergillus infections
D008172,2.13,NCT00691015-1,Conditioning Regimen,NCT00691015,Sirolimus  Tacrolimus  and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant,pulmonary fungal infections
D000069544,23.4,NCT00691015-1,Conditioning Regimen,NCT00691015,Sirolimus  Tacrolimus  and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant,encephalitis infection
D012141,4.26,NCT00691015-1,Conditioning Regimen,NCT00691015,Sirolimus  Tacrolimus  and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant,infections upper respiratory
D009102,4.26,NCT00691015-1,Conditioning Regimen,NCT00691015,Sirolimus  Tacrolimus  and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant,multiple organ failure
10017076,2.13,NCT00691015-1,Conditioning Regimen,NCT00691015,Sirolimus  Tacrolimus  and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant,fracture
D019106,2.13,NCT00691015-1,Conditioning Regimen,NCT00691015,Sirolimus  Tacrolimus  and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant,postoperative hemorrhage
10001551,12.77,NCT00691015-1,Conditioning Regimen,NCT00691015,Sirolimus  Tacrolimus  and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant,alanine aminotransferase increased
D000410,4.26,NCT00691015-1,Conditioning Regimen,NCT00691015,Sirolimus  Tacrolimus  and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant,alanine aminotransferase
10003481,14.89,NCT00691015-1,Conditioning Regimen,NCT00691015,Sirolimus  Tacrolimus  and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant,aspartate aminotransferase increased
10003481,4.26,NCT00691015-1,Conditioning Regimen,NCT00691015,Sirolimus  Tacrolimus  and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant,aspartate aminotransferase increased
10001675,4.26,NCT00691015-1,Conditioning Regimen,NCT00691015,Sirolimus  Tacrolimus  and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant,alkaline phosphatase increased
10005364,19.15,NCT00691015-1,Conditioning Regimen,NCT00691015,Sirolimus  Tacrolimus  and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant,blood bilirubin increased
10007612,6.38,NCT00691015-1,Conditioning Regimen,NCT00691015,Sirolimus  Tacrolimus  and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant,cardiac troponin i increased
10011368,14.89,NCT00691015-1,Conditioning Regimen,NCT00691015,Sirolimus  Tacrolimus  and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant,creatinine increased
D006454,23.4,NCT00691015-1,Conditioning Regimen,NCT00691015,Sirolimus  Tacrolimus  and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant,hemoglobin
D008049,4.26,NCT00691015-1,Conditioning Regimen,NCT00691015,Sirolimus  Tacrolimus  and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant,lipase
D008214,6.38,NCT00691015-1,Conditioning Regimen,NCT00691015,Sirolimus  Tacrolimus  and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant,lymphocytes
D009504,23.4,NCT00691015-1,Conditioning Regimen,NCT00691015,Sirolimus  Tacrolimus  and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant,neutrophils
D001792,25.53,NCT00691015-1,Conditioning Regimen,NCT00691015,Sirolimus  Tacrolimus  and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant,platelets
D007440,6.38,NCT00691015-1,Conditioning Regimen,NCT00691015,Sirolimus  Tacrolimus  and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant,intubation
D000138,8.51,NCT00691015-1,Conditioning Regimen,NCT00691015,Sirolimus  Tacrolimus  and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant,acidosis
D000855,12.77,NCT00691015-1,Conditioning Regimen,NCT00691015,Sirolimus  Tacrolimus  and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant,anorexia
D016895,12.77,NCT00691015-1,Conditioning Regimen,NCT00691015,Sirolimus  Tacrolimus  and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant,low-serum media
D005947,2.13,NCT00691015-1,Conditioning Regimen,NCT00691015,Sirolimus  Tacrolimus  and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant,glucose
D006943,25.53,NCT00691015-1,Conditioning Regimen,NCT00691015,Sirolimus  Tacrolimus  and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant,hyperglycemia
D019190,12.77,NCT00691015-1,Conditioning Regimen,NCT00691015,Sirolimus  Tacrolimus  and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant,iron overload
D008274,4.26,NCT00691015-1,Conditioning Regimen,NCT00691015,Sirolimus  Tacrolimus  and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant,magnesium
D016895,2.13,NCT00691015-1,Conditioning Regimen,NCT00691015,Sirolimus  Tacrolimus  and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant,low-serum media
D011188,14.89,NCT00691015-1,Conditioning Regimen,NCT00691015,Sirolimus  Tacrolimus  and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant,potassium
D016895,8.51,NCT00691015-1,Conditioning Regimen,NCT00691015,Sirolimus  Tacrolimus  and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant,low-serum media
D004039,8.51,NCT00691015-1,Conditioning Regimen,NCT00691015,Sirolimus  Tacrolimus  and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant,diet low-sodium
D001168,2.13,NCT00691015-1,Conditioning Regimen,NCT00691015,Sirolimus  Tacrolimus  and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant,arthritis
D001416,2.13,NCT00691015-1,Conditioning Regimen,NCT00691015,Sirolimus  Tacrolimus  and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant,back pain
D001416,2.13,NCT00691015-1,Conditioning Regimen,NCT00691015,Sirolimus  Tacrolimus  and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant,back pain
D059352,2.13,NCT00691015-1,Conditioning Regimen,NCT00691015,Sirolimus  Tacrolimus  and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant,musculoskeletal pain
10008496,2.13,NCT00691015-1,Conditioning Regimen,NCT00691015,Sirolimus  Tacrolimus  and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant,chest wall pain
10023030,2.13,NCT00691015-1,Conditioning Regimen,NCT00691015,Sirolimus  Tacrolimus  and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant,ischemia cerebrovascular
D001927,2.13,NCT00691015-1,Conditioning Regimen,NCT00691015,Sirolimus  Tacrolimus  and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant,encephalopathy
D000069584,2.13,NCT00691015-1,Conditioning Regimen,NCT00691015,Sirolimus  Tacrolimus  and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant,right-sided breast neoplasms
D006261,4.26,NCT00691015-1,Conditioning Regimen,NCT00691015,Sirolimus  Tacrolimus  and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant,headache
D000080867,2.13,NCT00691015-1,Conditioning Regimen,NCT00691015,Sirolimus  Tacrolimus  and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant,gingipains
D003244,8.51,NCT00691015-1,Conditioning Regimen,NCT00691015,Sirolimus  Tacrolimus  and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant,consciousness level depressed
D003221,10.64,NCT00691015-1,Conditioning Regimen,NCT00691015,Sirolimus  Tacrolimus  and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant,confusion
D000339,2.13,NCT00691015-1,Conditioning Regimen,NCT00691015,Sirolimus  Tacrolimus  and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant,mood
D000080867,2.13,NCT00691015-1,Conditioning Regimen,NCT00691015,Sirolimus  Tacrolimus  and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant,gingipains
D058186,10.64,NCT00691015-1,Conditioning Regimen,NCT00691015,Sirolimus  Tacrolimus  and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant,acute renal failure
D012128,4.26,NCT00691015-1,Conditioning Regimen,NCT00691015,Sirolimus  Tacrolimus  and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant,respiratory distress syndrome acute
D004417,8.51,NCT00691015-1,Conditioning Regimen,NCT00691015,Sirolimus  Tacrolimus  and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant,dyspnea
10065746,4.26,NCT00691015-1,Conditioning Regimen,NCT00691015,Sirolimus  Tacrolimus  and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant,bronchopulmonary hemorrhage
10065746,6.38,NCT00691015-1,Conditioning Regimen,NCT00691015,Sirolimus  Tacrolimus  and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant,bronchopulmonary hemorrhage
D000860,23.4,NCT00691015-1,Conditioning Regimen,NCT00691015,Sirolimus  Tacrolimus  and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant,hypoxia
D000080867,2.13,NCT00691015-1,Conditioning Regimen,NCT00691015,Sirolimus  Tacrolimus  and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant,gingipains
D010996,4.26,NCT00691015-1,Conditioning Regimen,NCT00691015,Sirolimus  Tacrolimus  and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant,pleural effusion
D011014,17.02,NCT00691015-1,Conditioning Regimen,NCT00691015,Sirolimus  Tacrolimus  and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant,pneumonitis
D011654,4.26,NCT00691015-1,Conditioning Regimen,NCT00691015,Sirolimus  Tacrolimus  and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant,pulmonary edema
D006976,4.26,NCT00691015-1,Conditioning Regimen,NCT00691015,Sirolimus  Tacrolimus  and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant,pulmonary hypertension
D001996,2.13,NCT00691015-1,Conditioning Regimen,NCT00691015,Sirolimus  Tacrolimus  and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant,bronchopneumonia
D003880,2.13,NCT00691015-1,Conditioning Regimen,NCT00691015,Sirolimus  Tacrolimus  and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant,dermatology
D005076,2.13,NCT00691015-1,Conditioning Regimen,NCT00691015,Sirolimus  Tacrolimus  and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant,rash
D005076,21.28,NCT00691015-1,Conditioning Regimen,NCT00691015,Sirolimus  Tacrolimus  and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant,rash
D006973,8.51,NCT00691015-1,Conditioning Regimen,NCT00691015,Sirolimus  Tacrolimus  and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant,hypertension
D007022,6.38,NCT00691015-1,Conditioning Regimen,NCT00691015,Sirolimus  Tacrolimus  and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant,hypotension
D016769,4.26,NCT00691015-1,Conditioning Regimen,NCT00691015,Sirolimus  Tacrolimus  and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant,embolism and thrombosis
D016769,2.13,NCT00691015-1,Conditioning Regimen,NCT00691015,Sirolimus  Tacrolimus  and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant,embolism and thrombosis
D035002,2.13,NCT00691015-1,Conditioning Regimen,NCT00691015,Sirolimus  Tacrolimus  and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant,lower extremity
D011655,2.13,NCT00691015-1,Conditioning Regimen,NCT00691015,Sirolimus  Tacrolimus  and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant,pulmonary embolism
D057049,8.51,NCT00691015-1,Conditioning Regimen,NCT00691015,Sirolimus  Tacrolimus  and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant,thrombotic microangiopathy
D009026,20.49,NCT00695409-1,Treatment (RIT ZBEAM ASCT),NCT00695409,Yttrium-90 Ibritumomab Tiuxetan Plus High-Dose BEAM Followed By ASCT For Relapsed B-Cell Non-Hodgkin Lymphoma,mortality
D064420,1.64,NCT00695409-1,Treatment (RIT ZBEAM ASCT),NCT00695409,Yttrium-90 Ibritumomab Tiuxetan Plus High-Dose BEAM Followed By ASCT For Relapsed B-Cell Non-Hodgkin Lymphoma,adverse drug events
10049737,0.82,NCT00695409-1,Treatment (RIT ZBEAM ASCT),NCT00695409,Yttrium-90 Ibritumomab Tiuxetan Plus High-Dose BEAM Followed By ASCT For Relapsed B-Cell Non-Hodgkin Lymphoma,treatment related secondary malignancy
D011014,0.82,NCT00695409-1,Treatment (RIT ZBEAM ASCT),NCT00695409,Yttrium-90 Ibritumomab Tiuxetan Plus High-Dose BEAM Followed By ASCT For Relapsed B-Cell Non-Hodgkin Lymphoma,pneumonitis
D064420,60.0,NCT00720109-1,Treatment Induction (Enzyme Inhibitor Therapy & Chemotherapy),NCT00720109,Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,adverse drug events
D064420,58.33,NCT00720109-2,Standard-risk,NCT00720109,Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,adverse drug events
D064420,77.78,NCT00720109-3,High-risk,NCT00720109,Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,adverse drug events
D000740,5.0,NCT00720109-1,Treatment Induction (Enzyme Inhibitor Therapy & Chemotherapy),NCT00720109,Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,anemia
D000740,4.17,NCT00720109-2,Standard-risk,NCT00720109,Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,anemia
D000740,11.11,NCT00720109-3,High-risk,NCT00720109,Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,anemia
D064147,6.67,NCT00720109-1,Treatment Induction (Enzyme Inhibitor Therapy & Chemotherapy),NCT00720109,Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,febrile neutropenia
D064147,6.25,NCT00720109-2,Standard-risk,NCT00720109,Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,febrile neutropenia
D064147,11.11,NCT00720109-3,High-risk,NCT00720109,Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,febrile neutropenia
D013616,1.67,NCT00720109-1,Treatment Induction (Enzyme Inhibitor Therapy & Chemotherapy),NCT00720109,Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,sinus tachycardia
D013616,2.08,NCT00720109-2,Standard-risk,NCT00720109,Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,sinus tachycardia
10005886,1.67,NCT00720109-1,Treatment Induction (Enzyme Inhibitor Therapy & Chemotherapy),NCT00720109,Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,blurred vision
10005886,2.08,NCT00720109-2,Standard-risk,NCT00720109,Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,blurred vision
10000060,1.67,NCT00720109-1,Treatment Induction (Enzyme Inhibitor Therapy & Chemotherapy),NCT00720109,Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,abdominal distension
D003092,3.33,NCT00720109-1,Treatment Induction (Enzyme Inhibitor Therapy & Chemotherapy),NCT00720109,Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,colitis
D003092,4.17,NCT00720109-2,Standard-risk,NCT00720109,Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,colitis
D003967,1.67,NCT00720109-1,Treatment Induction (Enzyme Inhibitor Therapy & Chemotherapy),NCT00720109,Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,diarrhea
D003967,2.08,NCT00720109-2,Standard-risk,NCT00720109,Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,diarrhea
D045823,1.67,NCT00720109-1,Treatment Induction (Enzyme Inhibitor Therapy & Chemotherapy),NCT00720109,Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,ileus
D045823,2.08,NCT00720109-2,Standard-risk,NCT00720109,Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,ileus
10055291,1.67,NCT00720109-1,Treatment Induction (Enzyme Inhibitor Therapy & Chemotherapy),NCT00720109,Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,intra-abdominal hemorrhage
10055291,2.08,NCT00720109-2,Standard-risk,NCT00720109,Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,intra-abdominal hemorrhage
10028130,3.33,NCT00720109-1,Treatment Induction (Enzyme Inhibitor Therapy & Chemotherapy),NCT00720109,Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,mucositis oral
10028130,4.17,NCT00720109-2,Standard-risk,NCT00720109,Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,mucositis oral
D009325,1.67,NCT00720109-1,Treatment Induction (Enzyme Inhibitor Therapy & Chemotherapy),NCT00720109,Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,nausea
D009325,2.08,NCT00720109-2,Standard-risk,NCT00720109,Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,nausea
10031009,1.67,NCT00720109-1,Treatment Induction (Enzyme Inhibitor Therapy & Chemotherapy),NCT00720109,Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,oral pain
10031009,2.08,NCT00720109-2,Standard-risk,NCT00720109,Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,oral pain
D053706,3.33,NCT00720109-1,Treatment Induction (Enzyme Inhibitor Therapy & Chemotherapy),NCT00720109,Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,typhlitis
D053706,4.17,NCT00720109-2,Standard-risk,NCT00720109,Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,typhlitis
10050068,1.67,NCT00720109-1,Treatment Induction (Enzyme Inhibitor Therapy & Chemotherapy),NCT00720109,Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,edema limbs
10050068,2.08,NCT00720109-2,Standard-risk,NCT00720109,Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,edema limbs
D005334,1.67,NCT00720109-1,Treatment Induction (Enzyme Inhibitor Therapy & Chemotherapy),NCT00720109,Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,fever
D005334,2.08,NCT00720109-2,Standard-risk,NCT00720109,Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,fever
10051792,1.67,NCT00720109-1,Treatment Induction (Enzyme Inhibitor Therapy & Chemotherapy),NCT00720109,Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,infusion related reaction
10051792,2.08,NCT00720109-2,Standard-risk,NCT00720109,Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,infusion related reaction
D010146,1.67,NCT00720109-1,Treatment Induction (Enzyme Inhibitor Therapy & Chemotherapy),NCT00720109,Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,pain
D010146,2.08,NCT00720109-2,Standard-risk,NCT00720109,Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,pain
D002764,1.67,NCT00720109-1,Treatment Induction (Enzyme Inhibitor Therapy & Chemotherapy),NCT00720109,Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,cholecystitis
D002764,2.08,NCT00720109-2,Standard-risk,NCT00720109,Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,cholecystitis
D006967,1.67,NCT00720109-1,Treatment Induction (Enzyme Inhibitor Therapy & Chemotherapy),NCT00720109,Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,allergic reaction
D006967,11.11,NCT00720109-3,High-risk,NCT00720109,Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,allergic reaction
D000707,1.67,NCT00720109-1,Treatment Induction (Enzyme Inhibitor Therapy & Chemotherapy),NCT00720109,Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,anaphylaxis
D000707,2.08,NCT00720109-2,Standard-risk,NCT00720109,Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,anaphylaxis
10007810,1.67,NCT00720109-1,Treatment Induction (Enzyme Inhibitor Therapy & Chemotherapy),NCT00720109,Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,catheter related infection
10007810,2.08,NCT00720109-2,Standard-risk,NCT00720109,Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,catheter related infection
10058838,3.33,NCT00720109-1,Treatment Induction (Enzyme Inhibitor Therapy & Chemotherapy),NCT00720109,Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,enterocolitis infectious
10058838,4.17,NCT00720109-2,Standard-risk,NCT00720109,Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,enterocolitis infectious
10021881,11.67,NCT00720109-1,Treatment Induction (Enzyme Inhibitor Therapy & Chemotherapy),NCT00720109,Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,infections and infestations - other specify
10021881,8.33,NCT00720109-2,Standard-risk,NCT00720109,Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,infections and infestations - other specify
10021881,22.22,NCT00720109-3,High-risk,NCT00720109,Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,infections and infestations - other specify
10051472,1.67,NCT00720109-1,Treatment Induction (Enzyme Inhibitor Therapy & Chemotherapy),NCT00720109,Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,periorbital infection
10051472,2.08,NCT00720109-2,Standard-risk,NCT00720109,Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,periorbital infection
D018805,3.33,NCT00720109-1,Treatment Induction (Enzyme Inhibitor Therapy & Chemotherapy),NCT00720109,Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,sepsis
D018805,2.08,NCT00720109-2,Standard-risk,NCT00720109,Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,sepsis
D018805,11.11,NCT00720109-3,High-risk,NCT00720109,Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,sepsis
10046300,1.67,NCT00720109-1,Treatment Induction (Enzyme Inhibitor Therapy & Chemotherapy),NCT00720109,Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,upper respiratory infection
10046300,11.11,NCT00720109-3,High-risk,NCT00720109,Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,upper respiratory infection
10062169,1.67,NCT00720109-1,Treatment Induction (Enzyme Inhibitor Therapy & Chemotherapy),NCT00720109,Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,vascular access complication
10062169,2.08,NCT00720109-2,Standard-risk,NCT00720109,Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,vascular access complication
10000636,1.67,NCT00720109-1,Treatment Induction (Enzyme Inhibitor Therapy & Chemotherapy),NCT00720109,Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,activated partial thromboplastin time prolonged
10000636,2.08,NCT00720109-2,Standard-risk,NCT00720109,Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,activated partial thromboplastin time prolonged
10001551,26.67,NCT00720109-1,Treatment Induction (Enzyme Inhibitor Therapy & Chemotherapy),NCT00720109,Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,alanine aminotransferase increased
10001551,22.92,NCT00720109-2,Standard-risk,NCT00720109,Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,alanine aminotransferase increased
10001551,55.56,NCT00720109-3,High-risk,NCT00720109,Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,alanine aminotransferase increased
10001675,1.67,NCT00720109-1,Treatment Induction (Enzyme Inhibitor Therapy & Chemotherapy),NCT00720109,Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,alkaline phosphatase increased
10001675,2.08,NCT00720109-2,Standard-risk,NCT00720109,Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,alkaline phosphatase increased
10003481,15.0,NCT00720109-1,Treatment Induction (Enzyme Inhibitor Therapy & Chemotherapy),NCT00720109,Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,aspartate aminotransferase increased
10003481,12.5,NCT00720109-2,Standard-risk,NCT00720109,Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,aspartate aminotransferase increased
10003481,33.33,NCT00720109-3,High-risk,NCT00720109,Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,aspartate aminotransferase increased
10005364,3.33,NCT00720109-1,Treatment Induction (Enzyme Inhibitor Therapy & Chemotherapy),NCT00720109,Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,blood bilirubin increased
10005364,4.17,NCT00720109-2,Standard-risk,NCT00720109,Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,blood bilirubin increased
10011368,3.33,NCT00720109-1,Treatment Induction (Enzyme Inhibitor Therapy & Chemotherapy),NCT00720109,Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,creatinine increased
10011368,2.08,NCT00720109-2,Standard-risk,NCT00720109,Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,creatinine increased
10011368,11.11,NCT00720109-3,High-risk,NCT00720109,Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,creatinine increased
10014383,3.33,NCT00720109-1,Treatment Induction (Enzyme Inhibitor Therapy & Chemotherapy),NCT00720109,Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,electrocardiogram qt corrected interval prolonged
10014383,4.17,NCT00720109-2,Standard-risk,NCT00720109,Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,electrocardiogram qt corrected interval prolonged
10056910,3.33,NCT00720109-1,Treatment Induction (Enzyme Inhibitor Therapy & Chemotherapy),NCT00720109,Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,ggt increased
10056910,4.17,NCT00720109-2,Standard-risk,NCT00720109,Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,ggt increased
10022402,1.67,NCT00720109-1,Treatment Induction (Enzyme Inhibitor Therapy & Chemotherapy),NCT00720109,Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,inr increased
10022402,2.08,NCT00720109-2,Standard-risk,NCT00720109,Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,inr increased
10025256,3.33,NCT00720109-1,Treatment Induction (Enzyme Inhibitor Therapy & Chemotherapy),NCT00720109,Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,lymphocyte count decreased
10025256,2.08,NCT00720109-2,Standard-risk,NCT00720109,Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,lymphocyte count decreased
10025256,11.11,NCT00720109-3,High-risk,NCT00720109,Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,lymphocyte count decreased
10029366,5.0,NCT00720109-1,Treatment Induction (Enzyme Inhibitor Therapy & Chemotherapy),NCT00720109,Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,neutrophil count decreased
10029366,4.17,NCT00720109-2,Standard-risk,NCT00720109,Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,neutrophil count decreased
10029366,11.11,NCT00720109-3,High-risk,NCT00720109,Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,neutrophil count decreased
10035528,5.0,NCT00720109-1,Treatment Induction (Enzyme Inhibitor Therapy & Chemotherapy),NCT00720109,Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,platelet count decreased
10035528,4.17,NCT00720109-2,Standard-risk,NCT00720109,Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,platelet count decreased
10035528,11.11,NCT00720109-3,High-risk,NCT00720109,Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,platelet count decreased
10049182,5.0,NCT00720109-1,Treatment Induction (Enzyme Inhibitor Therapy & Chemotherapy),NCT00720109,Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,white blood cell decreased
10049182,4.17,NCT00720109-2,Standard-risk,NCT00720109,Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,white blood cell decreased
10049182,11.11,NCT00720109-3,High-risk,NCT00720109,Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,white blood cell decreased
D000855,5.0,NCT00720109-1,Treatment Induction (Enzyme Inhibitor Therapy & Chemotherapy),NCT00720109,Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,anorexia
D000855,4.17,NCT00720109-2,Standard-risk,NCT00720109,Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,anorexia
D003681,6.67,NCT00720109-1,Treatment Induction (Enzyme Inhibitor Therapy & Chemotherapy),NCT00720109,Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,dehydration
D003681,8.33,NCT00720109-2,Standard-risk,NCT00720109,Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,dehydration
D006943,1.67,NCT00720109-1,Treatment Induction (Enzyme Inhibitor Therapy & Chemotherapy),NCT00720109,Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,hyperglycemia
D006943,11.11,NCT00720109-3,High-risk,NCT00720109,Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,hyperglycemia
D034141,8.33,NCT00720109-1,Treatment Induction (Enzyme Inhibitor Therapy & Chemotherapy),NCT00720109,Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,hypoalbuminemia
D034141,6.25,NCT00720109-2,Standard-risk,NCT00720109,Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,hypoalbuminemia
D034141,22.22,NCT00720109-3,High-risk,NCT00720109,Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,hypoalbuminemia
D006996,5.0,NCT00720109-1,Treatment Induction (Enzyme Inhibitor Therapy & Chemotherapy),NCT00720109,Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,hypocalcemia
D006996,4.17,NCT00720109-2,Standard-risk,NCT00720109,Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,hypocalcemia
D006996,11.11,NCT00720109-3,High-risk,NCT00720109,Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,hypocalcemia
D007008,15.0,NCT00720109-1,Treatment Induction (Enzyme Inhibitor Therapy & Chemotherapy),NCT00720109,Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,hypokalemia
D007008,12.5,NCT00720109-2,Standard-risk,NCT00720109,Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,hypokalemia
D007008,33.33,NCT00720109-3,High-risk,NCT00720109,Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,hypokalemia
D007010,8.33,NCT00720109-1,Treatment Induction (Enzyme Inhibitor Therapy & Chemotherapy),NCT00720109,Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,hyponatremia
D007010,8.33,NCT00720109-2,Standard-risk,NCT00720109,Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,hyponatremia
D007010,11.11,NCT00720109-3,High-risk,NCT00720109,Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,hyponatremia
D017674,3.33,NCT00720109-1,Treatment Induction (Enzyme Inhibitor Therapy & Chemotherapy),NCT00720109,Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,hypophosphatemia
D017674,4.17,NCT00720109-2,Standard-risk,NCT00720109,Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,hypophosphatemia
D001416,1.67,NCT00720109-1,Treatment Induction (Enzyme Inhibitor Therapy & Chemotherapy),NCT00720109,Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,back pain
D001416,2.08,NCT00720109-2,Standard-risk,NCT00720109,Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,back pain
10033425,1.67,NCT00720109-1,Treatment Induction (Enzyme Inhibitor Therapy & Chemotherapy),NCT00720109,Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,pain in extremity
10033425,2.08,NCT00720109-2,Standard-risk,NCT00720109,Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,pain in extremity
10049737,1.67,NCT00720109-1,Treatment Induction (Enzyme Inhibitor Therapy & Chemotherapy),NCT00720109,Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,treatment related secondary malignancy
10049737,2.08,NCT00720109-2,Standard-risk,NCT00720109,Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,treatment related secondary malignancy
D004244,1.67,NCT00720109-1,Treatment Induction (Enzyme Inhibitor Therapy & Chemotherapy),NCT00720109,Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,dizziness
D004244,2.08,NCT00720109-2,Standard-risk,NCT00720109,Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,dizziness
D001037,1.67,NCT00720109-1,Treatment Induction (Enzyme Inhibitor Therapy & Chemotherapy),NCT00720109,Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,dysphasia
D001037,2.08,NCT00720109-2,Standard-risk,NCT00720109,Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,dysphasia
D001927,1.67,NCT00720109-1,Treatment Induction (Enzyme Inhibitor Therapy & Chemotherapy),NCT00720109,Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,encephalopathy
D001927,2.08,NCT00720109-2,Standard-risk,NCT00720109,Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,encephalopathy
D006261,5.0,NCT00720109-1,Treatment Induction (Enzyme Inhibitor Therapy & Chemotherapy),NCT00720109,Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,headache
D006261,6.25,NCT00720109-2,Standard-risk,NCT00720109,Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,headache
10029205,1.67,NCT00720109-1,Treatment Induction (Enzyme Inhibitor Therapy & Chemotherapy),NCT00720109,Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,nervous system disorders - other specify
10029205,2.08,NCT00720109-2,Standard-risk,NCT00720109,Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,nervous system disorders - other specify
10034580,3.33,NCT00720109-1,Treatment Induction (Enzyme Inhibitor Therapy & Chemotherapy),NCT00720109,Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,peripheral motor neuropathy
10034580,2.08,NCT00720109-2,Standard-risk,NCT00720109,Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,peripheral motor neuropathy
10034580,11.11,NCT00720109-3,High-risk,NCT00720109,Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,peripheral motor neuropathy
10034620,3.33,NCT00720109-1,Treatment Induction (Enzyme Inhibitor Therapy & Chemotherapy),NCT00720109,Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,peripheral sensory neuropathy
10034620,2.08,NCT00720109-2,Standard-risk,NCT00720109,Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,peripheral sensory neuropathy
10034620,11.11,NCT00720109-3,High-risk,NCT00720109,Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,peripheral sensory neuropathy
D012640,3.33,NCT00720109-1,Treatment Induction (Enzyme Inhibitor Therapy & Chemotherapy),NCT00720109,Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,seizure
D012640,4.17,NCT00720109-2,Standard-risk,NCT00720109,Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,seizure
10001497,3.33,NCT00720109-1,Treatment Induction (Enzyme Inhibitor Therapy & Chemotherapy),NCT00720109,Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,agitation
10001497,2.08,NCT00720109-2,Standard-risk,NCT00720109,Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,agitation
10001497,11.11,NCT00720109-3,High-risk,NCT00720109,Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,agitation
D001007,1.67,NCT00720109-1,Treatment Induction (Enzyme Inhibitor Therapy & Chemotherapy),NCT00720109,Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,anxiety
D001007,2.08,NCT00720109-2,Standard-risk,NCT00720109,Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,anxiety
D003221,3.33,NCT00720109-1,Treatment Induction (Enzyme Inhibitor Therapy & Chemotherapy),NCT00720109,Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,confusion
D003221,2.08,NCT00720109-2,Standard-risk,NCT00720109,Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,confusion
D003221,11.11,NCT00720109-3,High-risk,NCT00720109,Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,confusion
10034719,1.67,NCT00720109-1,Treatment Induction (Enzyme Inhibitor Therapy & Chemotherapy),NCT00720109,Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,personality change
10034719,2.08,NCT00720109-2,Standard-risk,NCT00720109,Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,personality change
D051436,1.67,NCT00720109-1,Treatment Induction (Enzyme Inhibitor Therapy & Chemotherapy),NCT00720109,Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,chronic kidney disease
D051436,2.08,NCT00720109-2,Standard-risk,NCT00720109,Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,chronic kidney disease
10038359,1.67,NCT00720109-1,Treatment Induction (Enzyme Inhibitor Therapy & Chemotherapy),NCT00720109,Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,renal and urinary disorders - other specify
10038359,2.08,NCT00720109-2,Standard-risk,NCT00720109,Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,renal and urinary disorders - other specify
D004417,1.67,NCT00720109-1,Treatment Induction (Enzyme Inhibitor Therapy & Chemotherapy),NCT00720109,Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,dyspnea
D004417,11.11,NCT00720109-3,High-risk,NCT00720109,Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,dyspnea
D000860,3.33,NCT00720109-1,Treatment Induction (Enzyme Inhibitor Therapy & Chemotherapy),NCT00720109,Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,hypoxia
D000860,2.08,NCT00720109-2,Standard-risk,NCT00720109,Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,hypoxia
D000860,11.11,NCT00720109-3,High-risk,NCT00720109,Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,hypoxia
D011014,1.67,NCT00720109-1,Treatment Induction (Enzyme Inhibitor Therapy & Chemotherapy),NCT00720109,Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,pneumonitis
D011014,2.08,NCT00720109-2,Standard-risk,NCT00720109,Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,pneumonitis
D004892,1.67,NCT00720109-1,Treatment Induction (Enzyme Inhibitor Therapy & Chemotherapy),NCT00720109,Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,erythema multiforme
10054524,1.67,NCT00720109-1,Treatment Induction (Enzyme Inhibitor Therapy & Chemotherapy),NCT00720109,Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,palmar-plantar erythrodysesthesia syndrome
10054524,2.08,NCT00720109-2,Standard-risk,NCT00720109,Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,palmar-plantar erythrodysesthesia syndrome
D011537,1.67,NCT00720109-1,Treatment Induction (Enzyme Inhibitor Therapy & Chemotherapy),NCT00720109,Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,pruritus
D011537,2.08,NCT00720109-2,Standard-risk,NCT00720109,Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,pruritus
10037847,1.67,NCT00720109-1,Treatment Induction (Enzyme Inhibitor Therapy & Chemotherapy),NCT00720109,Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,rash acneiform
10037847,2.08,NCT00720109-2,Standard-risk,NCT00720109,Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,rash acneiform
10040785,1.67,NCT00720109-1,Treatment Induction (Enzyme Inhibitor Therapy & Chemotherapy),NCT00720109,Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,skin and subcutaneous tissue disorders - other specify
10040785,2.08,NCT00720109-2,Standard-risk,NCT00720109,Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,skin and subcutaneous tissue disorders - other specify
D006973,3.33,NCT00720109-1,Treatment Induction (Enzyme Inhibitor Therapy & Chemotherapy),NCT00720109,Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,hypertension
D006973,4.17,NCT00720109-2,Standard-risk,NCT00720109,Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,hypertension
D007022,6.67,NCT00720109-1,Treatment Induction (Enzyme Inhibitor Therapy & Chemotherapy),NCT00720109,Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,hypotension
D007022,8.33,NCT00720109-2,Standard-risk,NCT00720109,Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,hypotension
D013479,1.67,NCT00720109-1,Treatment Induction (Enzyme Inhibitor Therapy & Chemotherapy),NCT00720109,Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,superior vena cava syndrome
D013479,2.08,NCT00720109-2,Standard-risk,NCT00720109,Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,superior vena cava syndrome
10043565,5.0,NCT00720109-1,Treatment Induction (Enzyme Inhibitor Therapy & Chemotherapy),NCT00720109,Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,thromboembolic event
10043565,6.25,NCT00720109-2,Standard-risk,NCT00720109,Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,thromboembolic event
D064420,21.43,NCT00732498-1,ESHAP Followed by Zevalin and Rituximab,NCT00732498,Rituximab  Yttrium Y 90 Ibritumomab Tiuxetan in Patients W/Relapsed Stage II  III  or IV Follicular NHL,adverse drug events
D009190,7.14,NCT00732498-1,ESHAP Followed by Zevalin and Rituximab,NCT00732498,Rituximab  Yttrium Y 90 Ibritumomab Tiuxetan in Patients W/Relapsed Stage II  III  or IV Follicular NHL,myelodysplastic syndrome
D013921,3.57,NCT00732498-1,ESHAP Followed by Zevalin and Rituximab,NCT00732498,Rituximab  Yttrium Y 90 Ibritumomab Tiuxetan in Patients W/Relapsed Stage II  III  or IV Follicular NHL,thrombocytopenia
D004381,3.57,NCT00732498-1,ESHAP Followed by Zevalin and Rituximab,NCT00732498,Rituximab  Yttrium Y 90 Ibritumomab Tiuxetan in Patients W/Relapsed Stage II  III  or IV Follicular NHL,duodenal ulcer
D020250,3.57,NCT00732498-1,ESHAP Followed by Zevalin and Rituximab,NCT00732498,Rituximab  Yttrium Y 90 Ibritumomab Tiuxetan in Patients W/Relapsed Stage II  III  or IV Follicular NHL,postoperative nausea and vomiting
D000230,3.57,NCT00732498-1,ESHAP Followed by Zevalin and Rituximab,NCT00732498,Rituximab  Yttrium Y 90 Ibritumomab Tiuxetan in Patients W/Relapsed Stage II  III  or IV Follicular NHL,adenocarcinoma
D064420,45.26,NCT00742625-1,Bortezomib + Daunorubicin + Cytarabine,NCT00742625,Bortezomib  Daunorubicin  and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia,adverse drug events
D004211,1.05,NCT00742625-1,Bortezomib + Daunorubicin + Cytarabine,NCT00742625,Bortezomib  Daunorubicin  and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia,disseminated intravascular coagulation
D005335,25.26,NCT00742625-1,Bortezomib + Daunorubicin + Cytarabine,NCT00742625,Bortezomib  Daunorubicin  and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia,unknown origin fever
D006454,45.26,NCT00742625-1,Bortezomib + Daunorubicin + Cytarabine,NCT00742625,Bortezomib  Daunorubicin  and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia,hemoglobin
D006461,1.05,NCT00742625-1,Bortezomib + Daunorubicin + Cytarabine,NCT00742625,Bortezomib  Daunorubicin  and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia,hemolysis
10022891,1.05,NCT00742625-1,Bortezomib + Daunorubicin + Cytarabine,NCT00742625,Bortezomib  Daunorubicin  and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia,investigations - other specify
D001145,13.68,NCT00742625-1,Bortezomib + Daunorubicin + Cytarabine,NCT00742625,Bortezomib  Daunorubicin  and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia,arrhythmias cardiac
D006342,6.32,NCT00742625-1,Bortezomib + Daunorubicin + Cytarabine,NCT00742625,Bortezomib  Daunorubicin  and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia,cardiac rupture post-infarction
D006323,1.05,NCT00742625-1,Bortezomib + Daunorubicin + Cytarabine,NCT00742625,Bortezomib  Daunorubicin  and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia,cardiopulmonary arrest
D018487,1.05,NCT00742625-1,Bortezomib + Daunorubicin + Cytarabine,NCT00742625,Bortezomib  Daunorubicin  and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia,ventricular dysfunction left
10069501,16.84,NCT00742625-1,Bortezomib + Daunorubicin + Cytarabine,NCT00742625,Bortezomib  Daunorubicin  and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia,left ventricular systolic dysfunction
10033557,2.11,NCT00742625-1,Bortezomib + Daunorubicin + Cytarabine,NCT00742625,Bortezomib  Daunorubicin  and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia,palpitations
D001145,8.42,NCT00742625-1,Bortezomib + Daunorubicin + Cytarabine,NCT00742625,Bortezomib  Daunorubicin  and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia,arrhythmia
10014698,1.05,NCT00742625-1,Bortezomib + Daunorubicin + Cytarabine,NCT00742625,Bortezomib  Daunorubicin  and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia,endocrine disorders - other specify
D006980,1.05,NCT00742625-1,Bortezomib + Daunorubicin + Cytarabine,NCT00742625,Bortezomib  Daunorubicin  and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia,hyperthyroidism
D019252,1.05,NCT00742625-1,Bortezomib + Daunorubicin + Cytarabine,NCT00742625,Bortezomib  Daunorubicin  and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia,visualix
D003092,1.05,NCT00742625-1,Bortezomib + Daunorubicin + Cytarabine,NCT00742625,Bortezomib  Daunorubicin  and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia,colitis
D003248,9.47,NCT00742625-1,Bortezomib + Daunorubicin + Cytarabine,NCT00742625,Bortezomib  Daunorubicin  and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia,constipation
D003967,37.89,NCT00742625-1,Bortezomib + Daunorubicin + Cytarabine,NCT00742625,Bortezomib  Daunorubicin  and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia,diarrhea
10000060,4.21,NCT00742625-1,Bortezomib + Daunorubicin + Cytarabine,NCT00742625,Bortezomib  Daunorubicin  and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia,abdominal distension
D012469,2.11,NCT00742625-1,Bortezomib + Daunorubicin + Cytarabine,NCT00742625,Bortezomib  Daunorubicin  and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia,salivary glands
D003679,5.26,NCT00742625-1,Bortezomib + Daunorubicin + Cytarabine,NCT00742625,Bortezomib  Daunorubicin  and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia,swallowing
D004751,2.11,NCT00742625-1,Bortezomib + Daunorubicin + Cytarabine,NCT00742625,Bortezomib  Daunorubicin  and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia,enteritis
D004941,1.05,NCT00742625-1,Bortezomib + Daunorubicin + Cytarabine,NCT00742625,Bortezomib  Daunorubicin  and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia,esophagitis
D004415,1.05,NCT00742625-1,Bortezomib + Daunorubicin + Cytarabine,NCT00742625,Bortezomib  Daunorubicin  and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia,dyspepsia
D005884,6.32,NCT00742625-1,Bortezomib + Daunorubicin + Cytarabine,NCT00742625,Bortezomib  Daunorubicin  and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia,gingival hemorrhage
D005767,1.05,NCT00742625-1,Bortezomib + Daunorubicin + Cytarabine,NCT00742625,Bortezomib  Daunorubicin  and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia,functional gastrointestinal disorders
D000069478,4.21,NCT00742625-1,Bortezomib + Daunorubicin + Cytarabine,NCT00742625,Bortezomib  Daunorubicin  and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia,lisdexamfetamine
D013280,1.05,NCT00742625-1,Bortezomib + Daunorubicin + Cytarabine,NCT00742625,Bortezomib  Daunorubicin  and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia,stomatitis
D009325,31.58,NCT00742625-1,Bortezomib + Daunorubicin + Cytarabine,NCT00742625,Bortezomib  Daunorubicin  and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia,nausea
D007249,2.11,NCT00742625-1,Bortezomib + Daunorubicin + Cytarabine,NCT00742625,Bortezomib  Daunorubicin  and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia,inflammation
D005892,1.05,NCT00742625-1,Bortezomib + Daunorubicin + Cytarabine,NCT00742625,Bortezomib  Daunorubicin  and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia,gingivitis necrotizing ulcerative
D014839,17.89,NCT00742625-1,Bortezomib + Daunorubicin + Cytarabine,NCT00742625,Bortezomib  Daunorubicin  and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia,vomiting
D000071896,1.05,NCT00742625-1,Bortezomib + Daunorubicin + Cytarabine,NCT00742625,Bortezomib  Daunorubicin  and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia,somatic symptoms
D003643,2.11,NCT00742625-1,Bortezomib + Daunorubicin + Cytarabine,NCT00742625,Bortezomib  Daunorubicin  and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia,determination of death
10050068,8.42,NCT00742625-1,Bortezomib + Daunorubicin + Cytarabine,NCT00742625,Bortezomib  Daunorubicin  and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia,edema limbs
D003409,3.16,NCT00742625-1,Bortezomib + Daunorubicin + Cytarabine,NCT00742625,Bortezomib  Daunorubicin  and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia,myxedema congenital
10054482,1.05,NCT00742625-1,Bortezomib + Daunorubicin + Cytarabine,NCT00742625,Bortezomib  Daunorubicin  and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia,neck edema
D001037,16.84,NCT00742625-1,Bortezomib + Daunorubicin + Cytarabine,NCT00742625,Bortezomib  Daunorubicin  and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia,logasthenia
D005334,1.05,NCT00742625-1,Bortezomib + Daunorubicin + Cytarabine,NCT00742625,Bortezomib  Daunorubicin  and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia,fever
D023341,5.26,NCT00742625-1,Bortezomib + Daunorubicin + Cytarabine,NCT00742625,Bortezomib  Daunorubicin  and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia,chills
D008107,1.05,NCT00742625-1,Bortezomib + Daunorubicin + Cytarabine,NCT00742625,Bortezomib  Daunorubicin  and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia,liver dysfunction
D004342,2.11,NCT00742625-1,Bortezomib + Daunorubicin + Cytarabine,NCT00742625,Bortezomib  Daunorubicin  and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia,drug hypersensitivity
D004761,2.11,NCT00742625-1,Bortezomib + Daunorubicin + Cytarabine,NCT00742625,Bortezomib  Daunorubicin  and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia,clostridium enterocolitis
D007239,30.53,NCT00742625-1,Bortezomib + Daunorubicin + Cytarabine,NCT00742625,Bortezomib  Daunorubicin  and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia,infection
D000069544,8.42,NCT00742625-1,Bortezomib + Daunorubicin + Cytarabine,NCT00742625,Bortezomib  Daunorubicin  and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia,encephalitis infection
D000069544,10.53,NCT00742625-1,Bortezomib + Daunorubicin + Cytarabine,NCT00742625,Bortezomib  Daunorubicin  and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia,encephalitis infection
D000069544,5.26,NCT00742625-1,Bortezomib + Daunorubicin + Cytarabine,NCT00742625,Bortezomib  Daunorubicin  and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia,encephalitis infection
D009894,2.11,NCT00742625-1,Bortezomib + Daunorubicin + Cytarabine,NCT00742625,Bortezomib  Daunorubicin  and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia,opportunistic infections
D013921,1.05,NCT00742625-1,Bortezomib + Daunorubicin + Cytarabine,NCT00742625,Bortezomib  Daunorubicin  and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia,thrombocytopenia
10017076,1.05,NCT00742625-1,Bortezomib + Daunorubicin + Cytarabine,NCT00742625,Bortezomib  Daunorubicin  and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia,fracture
D000410,27.37,NCT00742625-1,Bortezomib + Daunorubicin + Cytarabine,NCT00742625,Bortezomib  Daunorubicin  and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia,glutamic-pyruvic transaminase
D001219,30.53,NCT00742625-1,Bortezomib + Daunorubicin + Cytarabine,NCT00742625,Bortezomib  Daunorubicin  and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia,serum glutamic-oxaloacetic transaminase
D000469,10.53,NCT00742625-1,Bortezomib + Daunorubicin + Cytarabine,NCT00742625,Bortezomib  Daunorubicin  and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia,alkaline phosphatase
D003414,26.32,NCT00742625-1,Bortezomib + Daunorubicin + Cytarabine,NCT00742625,Bortezomib  Daunorubicin  and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia,familial nonhemolytic unconjugated hyperbilirubinemia
D003997,5.26,NCT00742625-1,Bortezomib + Daunorubicin + Cytarabine,NCT00742625,Bortezomib  Daunorubicin  and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia,diethoxycarbonyldihydrocollidine
D009618,1.05,NCT00742625-1,Bortezomib + Daunorubicin + Cytarabine,NCT00742625,Bortezomib  Daunorubicin  and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia,nocardiaceae
D003404,8.42,NCT00742625-1,Bortezomib + Daunorubicin + Cytarabine,NCT00742625,Bortezomib  Daunorubicin  and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia,creatinine
D005723,2.11,NCT00742625-1,Bortezomib + Daunorubicin + Cytarabine,NCT00742625,Bortezomib  Daunorubicin  and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia,gammaglutamyltransferase
D000547,3.16,NCT00742625-1,Bortezomib + Daunorubicin + Cytarabine,NCT00742625,Bortezomib  Daunorubicin  and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia,amantadinratiopharm
D007962,21.05,NCT00742625-1,Bortezomib + Daunorubicin + Cytarabine,NCT00742625,Bortezomib  Daunorubicin  and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia,leukocytes
D008231,16.84,NCT00742625-1,Bortezomib + Daunorubicin + Cytarabine,NCT00742625,Bortezomib  Daunorubicin  and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia,lymphopenia
D007753,2.11,NCT00742625-1,Bortezomib + Daunorubicin + Cytarabine,NCT00742625,Bortezomib  Daunorubicin  and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia,laboratory
D006098,45.26,NCT00742625-1,Bortezomib + Daunorubicin + Cytarabine,NCT00742625,Bortezomib  Daunorubicin  and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia,granulocytes
D010314,4.21,NCT00742625-1,Bortezomib + Daunorubicin + Cytarabine,NCT00742625,Bortezomib  Daunorubicin  and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia,partial thromboplastin time
D001792,45.26,NCT00742625-1,Bortezomib + Daunorubicin + Cytarabine,NCT00742625,Bortezomib  Daunorubicin  and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia,platelets
10014383,6.32,NCT00742625-1,Bortezomib + Daunorubicin + Cytarabine,NCT00742625,Bortezomib  Daunorubicin  and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia,electrocardiogram qt corrected interval prolonged
D015430,1.05,NCT00742625-1,Bortezomib + Daunorubicin + Cytarabine,NCT00742625,Bortezomib  Daunorubicin  and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia,weight gain
D015431,3.16,NCT00742625-1,Bortezomib + Daunorubicin + Cytarabine,NCT00742625,Bortezomib  Daunorubicin  and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia,weight loss
D000138,3.16,NCT00742625-1,Bortezomib + Daunorubicin + Cytarabine,NCT00742625,Bortezomib  Daunorubicin  and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia,metabolic acidosis
D034141,20.0,NCT00742625-1,Bortezomib + Daunorubicin + Cytarabine,NCT00742625,Bortezomib  Daunorubicin  and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia,hypoalbuminemia
D000472,4.21,NCT00742625-1,Bortezomib + Daunorubicin + Cytarabine,NCT00742625,Bortezomib  Daunorubicin  and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia,alkalosis respiratory
D000855,10.53,NCT00742625-1,Bortezomib + Daunorubicin + Cytarabine,NCT00742625,Bortezomib  Daunorubicin  and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia,anorexia
D016895,12.63,NCT00742625-1,Bortezomib + Daunorubicin + Cytarabine,NCT00742625,Bortezomib  Daunorubicin  and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia,low-serum media
D003681,4.21,NCT00742625-1,Bortezomib + Daunorubicin + Cytarabine,NCT00742625,Bortezomib  Daunorubicin  and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia,dehydration
D003847,13.68,NCT00742625-1,Bortezomib + Daunorubicin + Cytarabine,NCT00742625,Bortezomib  Daunorubicin  and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia,deoxyglucose
D016895,1.05,NCT00742625-1,Bortezomib + Daunorubicin + Cytarabine,NCT00742625,Bortezomib  Daunorubicin  and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia,low-serum media
D008274,4.21,NCT00742625-1,Bortezomib + Daunorubicin + Cytarabine,NCT00742625,Bortezomib  Daunorubicin  and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia,magnesium
D016895,4.21,NCT00742625-1,Bortezomib + Daunorubicin + Cytarabine,NCT00742625,Bortezomib  Daunorubicin  and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia,low-serum media
D017674,14.74,NCT00742625-1,Bortezomib + Daunorubicin + Cytarabine,NCT00742625,Bortezomib  Daunorubicin  and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia,hypophosphatemia
D006947,5.26,NCT00742625-1,Bortezomib + Daunorubicin + Cytarabine,NCT00742625,Bortezomib  Daunorubicin  and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia,hyperkalemia
D016895,20.0,NCT00742625-1,Bortezomib + Daunorubicin + Cytarabine,NCT00742625,Bortezomib  Daunorubicin  and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia,low-serum media
D006955,2.11,NCT00742625-1,Bortezomib + Daunorubicin + Cytarabine,NCT00742625,Bortezomib  Daunorubicin  and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia,hypernatremia
D004039,6.32,NCT00742625-1,Bortezomib + Daunorubicin + Cytarabine,NCT00742625,Bortezomib  Daunorubicin  and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia,diet low-sodium
D033461,5.26,NCT00742625-1,Bortezomib + Daunorubicin + Cytarabine,NCT00742625,Bortezomib  Daunorubicin  and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia,hyperuricemia
10062572,8.42,NCT00742625-1,Bortezomib + Daunorubicin + Cytarabine,NCT00742625,Bortezomib  Daunorubicin  and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia,generalized muscle weakness
10023030,2.11,NCT00742625-1,Bortezomib + Daunorubicin + Cytarabine,NCT00742625,Bortezomib  Daunorubicin  and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia,ischemia cerebrovascular
D004244,6.32,NCT00742625-1,Bortezomib + Daunorubicin + Cytarabine,NCT00742625,Bortezomib  Daunorubicin  and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia,dizziness
D006470,1.05,NCT00742625-1,Bortezomib + Daunorubicin + Cytarabine,NCT00742625,Bortezomib  Daunorubicin  and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia,hemorrhage
D003389,1.05,NCT00742625-1,Bortezomib + Daunorubicin + Cytarabine,NCT00742625,Bortezomib  Daunorubicin  and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia,cranial neuropathy
D002607,3.16,NCT00742625-1,Bortezomib + Daunorubicin + Cytarabine,NCT00742625,Bortezomib  Daunorubicin  and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia,hereditary type i motor and sensory neuropathy
D002607,16.84,NCT00742625-1,Bortezomib + Daunorubicin + Cytarabine,NCT00742625,Bortezomib  Daunorubicin  and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia,hereditary type i motor and sensory neuropathy
D010146,12.63,NCT00742625-1,Bortezomib + Daunorubicin + Cytarabine,NCT00742625,Bortezomib  Daunorubicin  and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia,pain
D003244,7.37,NCT00742625-1,Bortezomib + Daunorubicin + Cytarabine,NCT00742625,Bortezomib  Daunorubicin  and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia,consciousness level depressed
D001037,1.05,NCT00742625-1,Bortezomib + Daunorubicin + Cytarabine,NCT00742625,Bortezomib  Daunorubicin  and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia,aphasia
D013575,3.16,NCT00742625-1,Bortezomib + Daunorubicin + Cytarabine,NCT00742625,Bortezomib  Daunorubicin  and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia,syncope
D000068538,1.05,NCT00742625-1,Bortezomib + Daunorubicin + Cytarabine,NCT00742625,Bortezomib  Daunorubicin  and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia,dutasteride
D013575,1.05,NCT00742625-1,Bortezomib + Daunorubicin + Cytarabine,NCT00742625,Bortezomib  Daunorubicin  and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia,syncopal episode
D003221,5.26,NCT00742625-1,Bortezomib + Daunorubicin + Cytarabine,NCT00742625,Bortezomib  Daunorubicin  and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia,confusion
D007319,5.26,NCT00742625-1,Bortezomib + Daunorubicin + Cytarabine,NCT00742625,Bortezomib  Daunorubicin  and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia,insomnia
D000339,6.32,NCT00742625-1,Bortezomib + Daunorubicin + Cytarabine,NCT00742625,Bortezomib  Daunorubicin  and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia,mood
D010551,1.05,NCT00742625-1,Bortezomib + Daunorubicin + Cytarabine,NCT00742625,Bortezomib  Daunorubicin  and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia,personality
D003702,2.11,NCT00742625-1,Bortezomib + Daunorubicin + Cytarabine,NCT00742625,Bortezomib  Daunorubicin  and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia,delusions
D005919,1.05,NCT00742625-1,Bortezomib + Daunorubicin + Cytarabine,NCT00742625,Bortezomib  Daunorubicin  and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia,glomerular filtration rate
D058734,1.05,NCT00742625-1,Bortezomib + Daunorubicin + Cytarabine,NCT00742625,Bortezomib  Daunorubicin  and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia,exsanguinating hemorrhage
D051437,5.26,NCT00742625-1,Bortezomib + Daunorubicin + Cytarabine,NCT00742625,Bortezomib  Daunorubicin  and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia,renal failure
D000308,3.16,NCT00742625-1,Bortezomib + Daunorubicin + Cytarabine,NCT00742625,Bortezomib  Daunorubicin  and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia,hyperadrenalism
D001750,1.05,NCT00742625-1,Bortezomib + Daunorubicin + Cytarabine,NCT00742625,Bortezomib  Daunorubicin  and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia,urinary bladder neurogenic
D012128,7.37,NCT00742625-1,Bortezomib + Daunorubicin + Cytarabine,NCT00742625,Bortezomib  Daunorubicin  and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia,respiratory distress syndrome adult
10036402,1.05,NCT00742625-1,Bortezomib + Daunorubicin + Cytarabine,NCT00742625,Bortezomib  Daunorubicin  and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia,postnasal drip
10003504,1.05,NCT00742625-1,Bortezomib + Daunorubicin + Cytarabine,NCT00742625,Bortezomib  Daunorubicin  and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia,aspiration
D003371,4.21,NCT00742625-1,Bortezomib + Daunorubicin + Cytarabine,NCT00742625,Bortezomib  Daunorubicin  and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia,cough
D004417,20.0,NCT00742625-1,Bortezomib + Daunorubicin + Cytarabine,NCT00742625,Bortezomib  Daunorubicin  and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia,breath shortness
D000799,2.11,NCT00742625-1,Bortezomib + Daunorubicin + Cytarabine,NCT00742625,Bortezomib  Daunorubicin  and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia,angioedema
10065746,4.21,NCT00742625-1,Bortezomib + Daunorubicin + Cytarabine,NCT00742625,Bortezomib  Daunorubicin  and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia,bronchopulmonary hemorrhage
D000860,16.84,NCT00742625-1,Bortezomib + Daunorubicin + Cytarabine,NCT00742625,Bortezomib  Daunorubicin  and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia,hypoxia
D016066,5.26,NCT00742625-1,Bortezomib + Daunorubicin + Cytarabine,NCT00742625,Bortezomib  Daunorubicin  and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia,pleural effusion malignant
D011014,1.05,NCT00742625-1,Bortezomib + Daunorubicin + Cytarabine,NCT00742625,Bortezomib  Daunorubicin  and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia,pneumonitis
D012141,4.21,NCT00742625-1,Bortezomib + Daunorubicin + Cytarabine,NCT00742625,Bortezomib  Daunorubicin  and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia,infections upper respiratory
D003880,2.11,NCT00742625-1,Bortezomib + Daunorubicin + Cytarabine,NCT00742625,Bortezomib  Daunorubicin  and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia,dermatology
D000505,1.05,NCT00742625-1,Bortezomib + Daunorubicin + Cytarabine,NCT00742625,Bortezomib  Daunorubicin  and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia,hair loss
D006470,2.11,NCT00742625-1,Bortezomib + Daunorubicin + Cytarabine,NCT00742625,Bortezomib  Daunorubicin  and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia,hemorrhage
D005076,23.16,NCT00742625-1,Bortezomib + Daunorubicin + Cytarabine,NCT00742625,Bortezomib  Daunorubicin  and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia,rash
D013262,1.05,NCT00742625-1,Bortezomib + Daunorubicin + Cytarabine,NCT00742625,Bortezomib  Daunorubicin  and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia,toxic epidermal necrolysis stevens johnson syndrome
D013546,2.11,NCT00742625-1,Bortezomib + Daunorubicin + Cytarabine,NCT00742625,Bortezomib  Daunorubicin  and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia,sweating
D000071072,1.05,NCT00742625-1,Bortezomib + Daunorubicin + Cytarabine,NCT00742625,Bortezomib  Daunorubicin  and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia,acute encephalitis syndrome
D005483,1.05,NCT00742625-1,Bortezomib + Daunorubicin + Cytarabine,NCT00742625,Bortezomib  Daunorubicin  and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia,flushing
D006406,2.11,NCT00742625-1,Bortezomib + Daunorubicin + Cytarabine,NCT00742625,Bortezomib  Daunorubicin  and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia,hematoma
D006470,1.05,NCT00742625-1,Bortezomib + Daunorubicin + Cytarabine,NCT00742625,Bortezomib  Daunorubicin  and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia,hemorrhage
D006973,6.32,NCT00742625-1,Bortezomib + Daunorubicin + Cytarabine,NCT00742625,Bortezomib  Daunorubicin  and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia,hypertension
D007022,27.37,NCT00742625-1,Bortezomib + Daunorubicin + Cytarabine,NCT00742625,Bortezomib  Daunorubicin  and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia,hypotension
10042554,1.05,NCT00742625-1,Bortezomib + Daunorubicin + Cytarabine,NCT00742625,Bortezomib  Daunorubicin  and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia,superficial thrombophlebitis
D016769,1.05,NCT00742625-1,Bortezomib + Daunorubicin + Cytarabine,NCT00742625,Bortezomib  Daunorubicin  and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia,embolism and thrombosis
10054692,1.05,NCT00742625-1,Bortezomib + Daunorubicin + Cytarabine,NCT00742625,Bortezomib  Daunorubicin  and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia,visceral arterial ischemia
D064420,65.38,NCT00823719-1,Ofatumumab + DHAP,NCT00823719,Phase II Study of Ofatumumab Plus Ifosfamide  Carboplatin  Etoposide (ICE) or Dexamethasone  Cytarabine  Cisplatin (DHAP) Chemotherapy Regimen in Relapsed/ Refractory Diffuse Large B Cell Lymphoma (DLBCL),adverse drug events
D064420,20.0,NCT00823719-2,Ofatumumab + ICE,NCT00823719,Phase II Study of Ofatumumab Plus Ifosfamide  Carboplatin  Etoposide (ICE) or Dexamethasone  Cytarabine  Cisplatin (DHAP) Chemotherapy Regimen in Relapsed/ Refractory Diffuse Large B Cell Lymphoma (DLBCL),adverse drug events
D064420,39.34,NCT00823719-3,Total Ofatumumab + Chemotherapy,NCT00823719,Phase II Study of Ofatumumab Plus Ifosfamide  Carboplatin  Etoposide (ICE) or Dexamethasone  Cytarabine  Cisplatin (DHAP) Chemotherapy Regimen in Relapsed/ Refractory Diffuse Large B Cell Lymphoma (DLBCL),adverse drug events
D064147,30.77,NCT00823719-1,Ofatumumab + DHAP,NCT00823719,Phase II Study of Ofatumumab Plus Ifosfamide  Carboplatin  Etoposide (ICE) or Dexamethasone  Cytarabine  Cisplatin (DHAP) Chemotherapy Regimen in Relapsed/ Refractory Diffuse Large B Cell Lymphoma (DLBCL),febrile neutropenia
D064147,2.86,NCT00823719-2,Ofatumumab + ICE,NCT00823719,Phase II Study of Ofatumumab Plus Ifosfamide  Carboplatin  Etoposide (ICE) or Dexamethasone  Cytarabine  Cisplatin (DHAP) Chemotherapy Regimen in Relapsed/ Refractory Diffuse Large B Cell Lymphoma (DLBCL),febrile neutropenia
D064147,14.75,NCT00823719-3,Total Ofatumumab + Chemotherapy,NCT00823719,Phase II Study of Ofatumumab Plus Ifosfamide  Carboplatin  Etoposide (ICE) or Dexamethasone  Cytarabine  Cisplatin (DHAP) Chemotherapy Regimen in Relapsed/ Refractory Diffuse Large B Cell Lymphoma (DLBCL),febrile neutropenia
D013921,26.92,NCT00823719-1,Ofatumumab + DHAP,NCT00823719,Phase II Study of Ofatumumab Plus Ifosfamide  Carboplatin  Etoposide (ICE) or Dexamethasone  Cytarabine  Cisplatin (DHAP) Chemotherapy Regimen in Relapsed/ Refractory Diffuse Large B Cell Lymphoma (DLBCL),thrombocytopenia
D013921,5.71,NCT00823719-2,Ofatumumab + ICE,NCT00823719,Phase II Study of Ofatumumab Plus Ifosfamide  Carboplatin  Etoposide (ICE) or Dexamethasone  Cytarabine  Cisplatin (DHAP) Chemotherapy Regimen in Relapsed/ Refractory Diffuse Large B Cell Lymphoma (DLBCL),thrombocytopenia
D013921,14.75,NCT00823719-3,Total Ofatumumab + Chemotherapy,NCT00823719,Phase II Study of Ofatumumab Plus Ifosfamide  Carboplatin  Etoposide (ICE) or Dexamethasone  Cytarabine  Cisplatin (DHAP) Chemotherapy Regimen in Relapsed/ Refractory Diffuse Large B Cell Lymphoma (DLBCL),thrombocytopenia
D000741,7.69,NCT00823719-1,Ofatumumab + DHAP,NCT00823719,Phase II Study of Ofatumumab Plus Ifosfamide  Carboplatin  Etoposide (ICE) or Dexamethasone  Cytarabine  Cisplatin (DHAP) Chemotherapy Regimen in Relapsed/ Refractory Diffuse Large B Cell Lymphoma (DLBCL),aplastic anaemia
D000741,2.86,NCT00823719-2,Ofatumumab + ICE,NCT00823719,Phase II Study of Ofatumumab Plus Ifosfamide  Carboplatin  Etoposide (ICE) or Dexamethasone  Cytarabine  Cisplatin (DHAP) Chemotherapy Regimen in Relapsed/ Refractory Diffuse Large B Cell Lymphoma (DLBCL),aplastic anaemia
D000741,4.92,NCT00823719-3,Total Ofatumumab + Chemotherapy,NCT00823719,Phase II Study of Ofatumumab Plus Ifosfamide  Carboplatin  Etoposide (ICE) or Dexamethasone  Cytarabine  Cisplatin (DHAP) Chemotherapy Regimen in Relapsed/ Refractory Diffuse Large B Cell Lymphoma (DLBCL),aplastic anaemia
D001145,3.85,NCT00823719-1,Ofatumumab + DHAP,NCT00823719,Phase II Study of Ofatumumab Plus Ifosfamide  Carboplatin  Etoposide (ICE) or Dexamethasone  Cytarabine  Cisplatin (DHAP) Chemotherapy Regimen in Relapsed/ Refractory Diffuse Large B Cell Lymphoma (DLBCL),arrhythmia
D001145,1.64,NCT00823719-3,Total Ofatumumab + Chemotherapy,NCT00823719,Phase II Study of Ofatumumab Plus Ifosfamide  Carboplatin  Etoposide (ICE) or Dexamethasone  Cytarabine  Cisplatin (DHAP) Chemotherapy Regimen in Relapsed/ Refractory Diffuse Large B Cell Lymphoma (DLBCL),arrhythmia
D014012,3.85,NCT00823719-1,Ofatumumab + DHAP,NCT00823719,Phase II Study of Ofatumumab Plus Ifosfamide  Carboplatin  Etoposide (ICE) or Dexamethasone  Cytarabine  Cisplatin (DHAP) Chemotherapy Regimen in Relapsed/ Refractory Diffuse Large B Cell Lymphoma (DLBCL),tinnitus
D014012,1.64,NCT00823719-3,Total Ofatumumab + Chemotherapy,NCT00823719,Phase II Study of Ofatumumab Plus Ifosfamide  Carboplatin  Etoposide (ICE) or Dexamethasone  Cytarabine  Cisplatin (DHAP) Chemotherapy Regimen in Relapsed/ Refractory Diffuse Large B Cell Lymphoma (DLBCL),tinnitus
10005886,3.85,NCT00823719-1,Ofatumumab + DHAP,NCT00823719,Phase II Study of Ofatumumab Plus Ifosfamide  Carboplatin  Etoposide (ICE) or Dexamethasone  Cytarabine  Cisplatin (DHAP) Chemotherapy Regimen in Relapsed/ Refractory Diffuse Large B Cell Lymphoma (DLBCL),blurred vision
10005886,1.64,NCT00823719-3,Total Ofatumumab + Chemotherapy,NCT00823719,Phase II Study of Ofatumumab Plus Ifosfamide  Carboplatin  Etoposide (ICE) or Dexamethasone  Cytarabine  Cisplatin (DHAP) Chemotherapy Regimen in Relapsed/ Refractory Diffuse Large B Cell Lymphoma (DLBCL),blurred vision
D009325,7.69,NCT00823719-1,Ofatumumab + DHAP,NCT00823719,Phase II Study of Ofatumumab Plus Ifosfamide  Carboplatin  Etoposide (ICE) or Dexamethasone  Cytarabine  Cisplatin (DHAP) Chemotherapy Regimen in Relapsed/ Refractory Diffuse Large B Cell Lymphoma (DLBCL),nausea
D009325,3.28,NCT00823719-3,Total Ofatumumab + Chemotherapy,NCT00823719,Phase II Study of Ofatumumab Plus Ifosfamide  Carboplatin  Etoposide (ICE) or Dexamethasone  Cytarabine  Cisplatin (DHAP) Chemotherapy Regimen in Relapsed/ Refractory Diffuse Large B Cell Lymphoma (DLBCL),nausea
D014839,3.85,NCT00823719-1,Ofatumumab + DHAP,NCT00823719,Phase II Study of Ofatumumab Plus Ifosfamide  Carboplatin  Etoposide (ICE) or Dexamethasone  Cytarabine  Cisplatin (DHAP) Chemotherapy Regimen in Relapsed/ Refractory Diffuse Large B Cell Lymphoma (DLBCL),vomiting
D014839,2.86,NCT00823719-2,Ofatumumab + ICE,NCT00823719,Phase II Study of Ofatumumab Plus Ifosfamide  Carboplatin  Etoposide (ICE) or Dexamethasone  Cytarabine  Cisplatin (DHAP) Chemotherapy Regimen in Relapsed/ Refractory Diffuse Large B Cell Lymphoma (DLBCL),vomiting
D014839,3.28,NCT00823719-3,Total Ofatumumab + Chemotherapy,NCT00823719,Phase II Study of Ofatumumab Plus Ifosfamide  Carboplatin  Etoposide (ICE) or Dexamethasone  Cytarabine  Cisplatin (DHAP) Chemotherapy Regimen in Relapsed/ Refractory Diffuse Large B Cell Lymphoma (DLBCL),vomiting
UNKNOWN-check-for-typo,3.85,NCT00823719-1,Ofatumumab + DHAP,NCT00823719,Phase II Study of Ofatumumab Plus Ifosfamide  Carboplatin  Etoposide (ICE) or Dexamethasone  Cytarabine  Cisplatin (DHAP) Chemotherapy Regimen in Relapsed/ Refractory Diffuse Large B Cell Lymphoma (DLBCL),D00
UNKNOWN-check-for-typo,1.64,NCT00823719-3,Total Ofatumumab + Chemotherapy,NCT00823719,Phase II Study of Ofatumumab Plus Ifosfamide  Carboplatin  Etoposide (ICE) or Dexamethasone  Cytarabine  Cisplatin (DHAP) Chemotherapy Regimen in Relapsed/ Refractory Diffuse Large B Cell Lymphoma (DLBCL),D00
D005221,3.85,NCT00823719-1,Ofatumumab + DHAP,NCT00823719,Phase II Study of Ofatumumab Plus Ifosfamide  Carboplatin  Etoposide (ICE) or Dexamethasone  Cytarabine  Cisplatin (DHAP) Chemotherapy Regimen in Relapsed/ Refractory Diffuse Large B Cell Lymphoma (DLBCL),fatigue
D005221,1.64,NCT00823719-3,Total Ofatumumab + Chemotherapy,NCT00823719,Phase II Study of Ofatumumab Plus Ifosfamide  Carboplatin  Etoposide (ICE) or Dexamethasone  Cytarabine  Cisplatin (DHAP) Chemotherapy Regimen in Relapsed/ Refractory Diffuse Large B Cell Lymphoma (DLBCL),fatigue
D005334,2.86,NCT00823719-2,Ofatumumab + ICE,NCT00823719,Phase II Study of Ofatumumab Plus Ifosfamide  Carboplatin  Etoposide (ICE) or Dexamethasone  Cytarabine  Cisplatin (DHAP) Chemotherapy Regimen in Relapsed/ Refractory Diffuse Large B Cell Lymphoma (DLBCL),pyrexia
D005334,1.64,NCT00823719-3,Total Ofatumumab + Chemotherapy,NCT00823719,Phase II Study of Ofatumumab Plus Ifosfamide  Carboplatin  Etoposide (ICE) or Dexamethasone  Cytarabine  Cisplatin (DHAP) Chemotherapy Regimen in Relapsed/ Refractory Diffuse Large B Cell Lymphoma (DLBCL),pyrexia
D006967,7.69,NCT00823719-1,Ofatumumab + DHAP,NCT00823719,Phase II Study of Ofatumumab Plus Ifosfamide  Carboplatin  Etoposide (ICE) or Dexamethasone  Cytarabine  Cisplatin (DHAP) Chemotherapy Regimen in Relapsed/ Refractory Diffuse Large B Cell Lymphoma (DLBCL),hypersensitivity
D006967,3.28,NCT00823719-3,Total Ofatumumab + Chemotherapy,NCT00823719,Phase II Study of Ofatumumab Plus Ifosfamide  Carboplatin  Etoposide (ICE) or Dexamethasone  Cytarabine  Cisplatin (DHAP) Chemotherapy Regimen in Relapsed/ Refractory Diffuse Large B Cell Lymphoma (DLBCL),hypersensitivity
D002481,7.69,NCT00823719-1,Ofatumumab + DHAP,NCT00823719,Phase II Study of Ofatumumab Plus Ifosfamide  Carboplatin  Etoposide (ICE) or Dexamethasone  Cytarabine  Cisplatin (DHAP) Chemotherapy Regimen in Relapsed/ Refractory Diffuse Large B Cell Lymphoma (DLBCL),cellulitis
D002481,3.28,NCT00823719-3,Total Ofatumumab + Chemotherapy,NCT00823719,Phase II Study of Ofatumumab Plus Ifosfamide  Carboplatin  Etoposide (ICE) or Dexamethasone  Cytarabine  Cisplatin (DHAP) Chemotherapy Regimen in Relapsed/ Refractory Diffuse Large B Cell Lymphoma (DLBCL),cellulitis
D004761,3.85,NCT00823719-1,Ofatumumab + DHAP,NCT00823719,Phase II Study of Ofatumumab Plus Ifosfamide  Carboplatin  Etoposide (ICE) or Dexamethasone  Cytarabine  Cisplatin (DHAP) Chemotherapy Regimen in Relapsed/ Refractory Diffuse Large B Cell Lymphoma (DLBCL),clostridium enterocolitis
D004761,1.64,NCT00823719-3,Total Ofatumumab + Chemotherapy,NCT00823719,Phase II Study of Ofatumumab Plus Ifosfamide  Carboplatin  Etoposide (ICE) or Dexamethasone  Cytarabine  Cisplatin (DHAP) Chemotherapy Regimen in Relapsed/ Refractory Diffuse Large B Cell Lymphoma (DLBCL),clostridium enterocolitis
10064687,3.85,NCT00823719-1,Ofatumumab + DHAP,NCT00823719,Phase II Study of Ofatumumab Plus Ifosfamide  Carboplatin  Etoposide (ICE) or Dexamethasone  Cytarabine  Cisplatin (DHAP) Chemotherapy Regimen in Relapsed/ Refractory Diffuse Large B Cell Lymphoma (DLBCL),device related infection
10064687,1.64,NCT00823719-3,Total Ofatumumab + Chemotherapy,NCT00823719,Phase II Study of Ofatumumab Plus Ifosfamide  Carboplatin  Etoposide (ICE) or Dexamethasone  Cytarabine  Cisplatin (DHAP) Chemotherapy Regimen in Relapsed/ Refractory Diffuse Large B Cell Lymphoma (DLBCL),device related infection
D000257,3.85,NCT00823719-1,Ofatumumab + DHAP,NCT00823719,Phase II Study of Ofatumumab Plus Ifosfamide  Carboplatin  Etoposide (ICE) or Dexamethasone  Cytarabine  Cisplatin (DHAP) Chemotherapy Regimen in Relapsed/ Refractory Diffuse Large B Cell Lymphoma (DLBCL),adenovirus infections
D000257,1.64,NCT00823719-3,Total Ofatumumab + Chemotherapy,NCT00823719,Phase II Study of Ofatumumab Plus Ifosfamide  Carboplatin  Etoposide (ICE) or Dexamethasone  Cytarabine  Cisplatin (DHAP) Chemotherapy Regimen in Relapsed/ Refractory Diffuse Large B Cell Lymphoma (DLBCL),adenovirus infections
D011014,3.85,NCT00823719-1,Ofatumumab + DHAP,NCT00823719,Phase II Study of Ofatumumab Plus Ifosfamide  Carboplatin  Etoposide (ICE) or Dexamethasone  Cytarabine  Cisplatin (DHAP) Chemotherapy Regimen in Relapsed/ Refractory Diffuse Large B Cell Lymphoma (DLBCL),pneumonia
D011014,1.64,NCT00823719-3,Total Ofatumumab + Chemotherapy,NCT00823719,Phase II Study of Ofatumumab Plus Ifosfamide  Carboplatin  Etoposide (ICE) or Dexamethasone  Cytarabine  Cisplatin (DHAP) Chemotherapy Regimen in Relapsed/ Refractory Diffuse Large B Cell Lymphoma (DLBCL),pneumonia
D014552,2.86,NCT00823719-2,Ofatumumab + ICE,NCT00823719,Phase II Study of Ofatumumab Plus Ifosfamide  Carboplatin  Etoposide (ICE) or Dexamethasone  Cytarabine  Cisplatin (DHAP) Chemotherapy Regimen in Relapsed/ Refractory Diffuse Large B Cell Lymphoma (DLBCL),urinary tract infections
D014552,1.64,NCT00823719-3,Total Ofatumumab + Chemotherapy,NCT00823719,Phase II Study of Ofatumumab Plus Ifosfamide  Carboplatin  Etoposide (ICE) or Dexamethasone  Cytarabine  Cisplatin (DHAP) Chemotherapy Regimen in Relapsed/ Refractory Diffuse Large B Cell Lymphoma (DLBCL),urinary tract infections
D007989,11.54,NCT00823719-1,Ofatumumab + DHAP,NCT00823719,Phase II Study of Ofatumumab Plus Ifosfamide  Carboplatin  Etoposide (ICE) or Dexamethasone  Cytarabine  Cisplatin (DHAP) Chemotherapy Regimen in Relapsed/ Refractory Diffuse Large B Cell Lymphoma (DLBCL),decreased libido
D007989,4.92,NCT00823719-3,Total Ofatumumab + Chemotherapy,NCT00823719,Phase II Study of Ofatumumab Plus Ifosfamide  Carboplatin  Etoposide (ICE) or Dexamethasone  Cytarabine  Cisplatin (DHAP) Chemotherapy Regimen in Relapsed/ Refractory Diffuse Large B Cell Lymphoma (DLBCL),decreased libido
10011368,7.69,NCT00823719-1,Ofatumumab + DHAP,NCT00823719,Phase II Study of Ofatumumab Plus Ifosfamide  Carboplatin  Etoposide (ICE) or Dexamethasone  Cytarabine  Cisplatin (DHAP) Chemotherapy Regimen in Relapsed/ Refractory Diffuse Large B Cell Lymphoma (DLBCL),creatinine increased
10011368,3.28,NCT00823719-3,Total Ofatumumab + Chemotherapy,NCT00823719,Phase II Study of Ofatumumab Plus Ifosfamide  Carboplatin  Etoposide (ICE) or Dexamethasone  Cytarabine  Cisplatin (DHAP) Chemotherapy Regimen in Relapsed/ Refractory Diffuse Large B Cell Lymphoma (DLBCL),creatinine increased
D001769,3.85,NCT00823719-1,Ofatumumab + DHAP,NCT00823719,Phase II Study of Ofatumumab Plus Ifosfamide  Carboplatin  Etoposide (ICE) or Dexamethasone  Cytarabine  Cisplatin (DHAP) Chemotherapy Regimen in Relapsed/ Refractory Diffuse Large B Cell Lymphoma (DLBCL),blood
D001769,1.64,NCT00823719-3,Total Ofatumumab + Chemotherapy,NCT00823719,Phase II Study of Ofatumumab Plus Ifosfamide  Carboplatin  Etoposide (ICE) or Dexamethasone  Cytarabine  Cisplatin (DHAP) Chemotherapy Regimen in Relapsed/ Refractory Diffuse Large B Cell Lymphoma (DLBCL),blood
UNKNOWN-check-for-typo,7.69,NCT00823719-1,Ofatumumab + DHAP,NCT00823719,Phase II Study of Ofatumumab Plus Ifosfamide  Carboplatin  Etoposide (ICE) or Dexamethasone  Cytarabine  Cisplatin (DHAP) Chemotherapy Regimen in Relapsed/ Refractory Diffuse Large B Cell Lymphoma (DLBCL),D00
UNKNOWN-check-for-typo,3.28,NCT00823719-3,Total Ofatumumab + Chemotherapy,NCT00823719,Phase II Study of Ofatumumab Plus Ifosfamide  Carboplatin  Etoposide (ICE) or Dexamethasone  Cytarabine  Cisplatin (DHAP) Chemotherapy Regimen in Relapsed/ Refractory Diffuse Large B Cell Lymphoma (DLBCL),D00
D003681,3.85,NCT00823719-1,Ofatumumab + DHAP,NCT00823719,Phase II Study of Ofatumumab Plus Ifosfamide  Carboplatin  Etoposide (ICE) or Dexamethasone  Cytarabine  Cisplatin (DHAP) Chemotherapy Regimen in Relapsed/ Refractory Diffuse Large B Cell Lymphoma (DLBCL),dehydration
D003681,1.64,NCT00823719-3,Total Ofatumumab + Chemotherapy,NCT00823719,Phase II Study of Ofatumumab Plus Ifosfamide  Carboplatin  Etoposide (ICE) or Dexamethasone  Cytarabine  Cisplatin (DHAP) Chemotherapy Regimen in Relapsed/ Refractory Diffuse Large B Cell Lymphoma (DLBCL),dehydration
D005183,3.85,NCT00823719-1,Ofatumumab + DHAP,NCT00823719,Phase II Study of Ofatumumab Plus Ifosfamide  Carboplatin  Etoposide (ICE) or Dexamethasone  Cytarabine  Cisplatin (DHAP) Chemotherapy Regimen in Relapsed/ Refractory Diffuse Large B Cell Lymphoma (DLBCL),failure to thrive
D005183,1.64,NCT00823719-3,Total Ofatumumab + Chemotherapy,NCT00823719,Phase II Study of Ofatumumab Plus Ifosfamide  Carboplatin  Etoposide (ICE) or Dexamethasone  Cytarabine  Cisplatin (DHAP) Chemotherapy Regimen in Relapsed/ Refractory Diffuse Large B Cell Lymphoma (DLBCL),failure to thrive
D015275,3.85,NCT00823719-1,Ofatumumab + DHAP,NCT00823719,Phase II Study of Ofatumumab Plus Ifosfamide  Carboplatin  Etoposide (ICE) or Dexamethasone  Cytarabine  Cisplatin (DHAP) Chemotherapy Regimen in Relapsed/ Refractory Diffuse Large B Cell Lymphoma (DLBCL),tumour lysis syndrome
D015275,1.64,NCT00823719-3,Total Ofatumumab + Chemotherapy,NCT00823719,Phase II Study of Ofatumumab Plus Ifosfamide  Carboplatin  Etoposide (ICE) or Dexamethasone  Cytarabine  Cisplatin (DHAP) Chemotherapy Regimen in Relapsed/ Refractory Diffuse Large B Cell Lymphoma (DLBCL),tumour lysis syndrome
D018908,3.85,NCT00823719-1,Ofatumumab + DHAP,NCT00823719,Phase II Study of Ofatumumab Plus Ifosfamide  Carboplatin  Etoposide (ICE) or Dexamethasone  Cytarabine  Cisplatin (DHAP) Chemotherapy Regimen in Relapsed/ Refractory Diffuse Large B Cell Lymphoma (DLBCL),muscular weakness
D018908,1.64,NCT00823719-3,Total Ofatumumab + Chemotherapy,NCT00823719,Phase II Study of Ofatumumab Plus Ifosfamide  Carboplatin  Etoposide (ICE) or Dexamethasone  Cytarabine  Cisplatin (DHAP) Chemotherapy Regimen in Relapsed/ Refractory Diffuse Large B Cell Lymphoma (DLBCL),muscular weakness
D001259,3.85,NCT00823719-1,Ofatumumab + DHAP,NCT00823719,Phase II Study of Ofatumumab Plus Ifosfamide  Carboplatin  Etoposide (ICE) or Dexamethasone  Cytarabine  Cisplatin (DHAP) Chemotherapy Regimen in Relapsed/ Refractory Diffuse Large B Cell Lymphoma (DLBCL),ataxia
D001259,1.64,NCT00823719-3,Total Ofatumumab + Chemotherapy,NCT00823719,Phase II Study of Ofatumumab Plus Ifosfamide  Carboplatin  Etoposide (ICE) or Dexamethasone  Cytarabine  Cisplatin (DHAP) Chemotherapy Regimen in Relapsed/ Refractory Diffuse Large B Cell Lymphoma (DLBCL),ataxia
D020820,3.85,NCT00823719-1,Ofatumumab + DHAP,NCT00823719,Phase II Study of Ofatumumab Plus Ifosfamide  Carboplatin  Etoposide (ICE) or Dexamethasone  Cytarabine  Cisplatin (DHAP) Chemotherapy Regimen in Relapsed/ Refractory Diffuse Large B Cell Lymphoma (DLBCL),dyskinesia
D020820,1.64,NCT00823719-3,Total Ofatumumab + Chemotherapy,NCT00823719,Phase II Study of Ofatumumab Plus Ifosfamide  Carboplatin  Etoposide (ICE) or Dexamethasone  Cytarabine  Cisplatin (DHAP) Chemotherapy Regimen in Relapsed/ Refractory Diffuse Large B Cell Lymphoma (DLBCL),dyskinesia
D013575,3.85,NCT00823719-1,Ofatumumab + DHAP,NCT00823719,Phase II Study of Ofatumumab Plus Ifosfamide  Carboplatin  Etoposide (ICE) or Dexamethasone  Cytarabine  Cisplatin (DHAP) Chemotherapy Regimen in Relapsed/ Refractory Diffuse Large B Cell Lymphoma (DLBCL),syncope
D013575,1.64,NCT00823719-3,Total Ofatumumab + Chemotherapy,NCT00823719,Phase II Study of Ofatumumab Plus Ifosfamide  Carboplatin  Etoposide (ICE) or Dexamethasone  Cytarabine  Cisplatin (DHAP) Chemotherapy Regimen in Relapsed/ Refractory Diffuse Large B Cell Lymphoma (DLBCL),syncope
D020258,3.85,NCT00823719-1,Ofatumumab + DHAP,NCT00823719,Phase II Study of Ofatumumab Plus Ifosfamide  Carboplatin  Etoposide (ICE) or Dexamethasone  Cytarabine  Cisplatin (DHAP) Chemotherapy Regimen in Relapsed/ Refractory Diffuse Large B Cell Lymphoma (DLBCL),toxic encephalopathy
D020258,1.64,NCT00823719-3,Total Ofatumumab + Chemotherapy,NCT00823719,Phase II Study of Ofatumumab Plus Ifosfamide  Carboplatin  Etoposide (ICE) or Dexamethasone  Cytarabine  Cisplatin (DHAP) Chemotherapy Regimen in Relapsed/ Refractory Diffuse Large B Cell Lymphoma (DLBCL),toxic encephalopathy
D000073216,5.71,NCT00823719-2,Ofatumumab + ICE,NCT00823719,Phase II Study of Ofatumumab Plus Ifosfamide  Carboplatin  Etoposide (ICE) or Dexamethasone  Cytarabine  Cisplatin (DHAP) Chemotherapy Regimen in Relapsed/ Refractory Diffuse Large B Cell Lymphoma (DLBCL),mental status tests
D000073216,3.28,NCT00823719-3,Total Ofatumumab + Chemotherapy,NCT00823719,Phase II Study of Ofatumumab Plus Ifosfamide  Carboplatin  Etoposide (ICE) or Dexamethasone  Cytarabine  Cisplatin (DHAP) Chemotherapy Regimen in Relapsed/ Refractory Diffuse Large B Cell Lymphoma (DLBCL),mental status tests
D051437,7.69,NCT00823719-1,Ofatumumab + DHAP,NCT00823719,Phase II Study of Ofatumumab Plus Ifosfamide  Carboplatin  Etoposide (ICE) or Dexamethasone  Cytarabine  Cisplatin (DHAP) Chemotherapy Regimen in Relapsed/ Refractory Diffuse Large B Cell Lymphoma (DLBCL),renal failure
D051437,2.86,NCT00823719-2,Ofatumumab + ICE,NCT00823719,Phase II Study of Ofatumumab Plus Ifosfamide  Carboplatin  Etoposide (ICE) or Dexamethasone  Cytarabine  Cisplatin (DHAP) Chemotherapy Regimen in Relapsed/ Refractory Diffuse Large B Cell Lymphoma (DLBCL),renal failure
D051437,4.92,NCT00823719-3,Total Ofatumumab + Chemotherapy,NCT00823719,Phase II Study of Ofatumumab Plus Ifosfamide  Carboplatin  Etoposide (ICE) or Dexamethasone  Cytarabine  Cisplatin (DHAP) Chemotherapy Regimen in Relapsed/ Refractory Diffuse Large B Cell Lymphoma (DLBCL),renal failure
D058186,3.85,NCT00823719-1,Ofatumumab + DHAP,NCT00823719,Phase II Study of Ofatumumab Plus Ifosfamide  Carboplatin  Etoposide (ICE) or Dexamethasone  Cytarabine  Cisplatin (DHAP) Chemotherapy Regimen in Relapsed/ Refractory Diffuse Large B Cell Lymphoma (DLBCL),acute renal failure
D058186,1.64,NCT00823719-3,Total Ofatumumab + Chemotherapy,NCT00823719,Phase II Study of Ofatumumab Plus Ifosfamide  Carboplatin  Etoposide (ICE) or Dexamethasone  Cytarabine  Cisplatin (DHAP) Chemotherapy Regimen in Relapsed/ Refractory Diffuse Large B Cell Lymphoma (DLBCL),acute renal failure
UNKNOWN-check-for-typo,3.85,NCT00823719-1,Ofatumumab + DHAP,NCT00823719,Phase II Study of Ofatumumab Plus Ifosfamide  Carboplatin  Etoposide (ICE) or Dexamethasone  Cytarabine  Cisplatin (DHAP) Chemotherapy Regimen in Relapsed/ Refractory Diffuse Large B Cell Lymphoma (DLBCL),D00
UNKNOWN-check-for-typo,2.86,NCT00823719-2,Ofatumumab + ICE,NCT00823719,Phase II Study of Ofatumumab Plus Ifosfamide  Carboplatin  Etoposide (ICE) or Dexamethasone  Cytarabine  Cisplatin (DHAP) Chemotherapy Regimen in Relapsed/ Refractory Diffuse Large B Cell Lymphoma (DLBCL),D00
UNKNOWN-check-for-typo,3.28,NCT00823719-3,Total Ofatumumab + Chemotherapy,NCT00823719,Phase II Study of Ofatumumab Plus Ifosfamide  Carboplatin  Etoposide (ICE) or Dexamethasone  Cytarabine  Cisplatin (DHAP) Chemotherapy Regimen in Relapsed/ Refractory Diffuse Large B Cell Lymphoma (DLBCL),D00
D010996,2.86,NCT00823719-2,Ofatumumab + ICE,NCT00823719,Phase II Study of Ofatumumab Plus Ifosfamide  Carboplatin  Etoposide (ICE) or Dexamethasone  Cytarabine  Cisplatin (DHAP) Chemotherapy Regimen in Relapsed/ Refractory Diffuse Large B Cell Lymphoma (DLBCL),pleural effusion
D010996,1.64,NCT00823719-3,Total Ofatumumab + Chemotherapy,NCT00823719,Phase II Study of Ofatumumab Plus Ifosfamide  Carboplatin  Etoposide (ICE) or Dexamethasone  Cytarabine  Cisplatin (DHAP) Chemotherapy Regimen in Relapsed/ Refractory Diffuse Large B Cell Lymphoma (DLBCL),pleural effusion
D011655,3.85,NCT00823719-1,Ofatumumab + DHAP,NCT00823719,Phase II Study of Ofatumumab Plus Ifosfamide  Carboplatin  Etoposide (ICE) or Dexamethasone  Cytarabine  Cisplatin (DHAP) Chemotherapy Regimen in Relapsed/ Refractory Diffuse Large B Cell Lymphoma (DLBCL),pulmonary embolism
D011655,1.64,NCT00823719-3,Total Ofatumumab + Chemotherapy,NCT00823719,Phase II Study of Ofatumumab Plus Ifosfamide  Carboplatin  Etoposide (ICE) or Dexamethasone  Cytarabine  Cisplatin (DHAP) Chemotherapy Regimen in Relapsed/ Refractory Diffuse Large B Cell Lymphoma (DLBCL),pulmonary embolism
D012127,2.86,NCT00823719-2,Ofatumumab + ICE,NCT00823719,Phase II Study of Ofatumumab Plus Ifosfamide  Carboplatin  Etoposide (ICE) or Dexamethasone  Cytarabine  Cisplatin (DHAP) Chemotherapy Regimen in Relapsed/ Refractory Diffuse Large B Cell Lymphoma (DLBCL),respiratory distress syndrome newborn
D012127,1.64,NCT00823719-3,Total Ofatumumab + Chemotherapy,NCT00823719,Phase II Study of Ofatumumab Plus Ifosfamide  Carboplatin  Etoposide (ICE) or Dexamethasone  Cytarabine  Cisplatin (DHAP) Chemotherapy Regimen in Relapsed/ Refractory Diffuse Large B Cell Lymphoma (DLBCL),respiratory distress syndrome newborn
D012131,2.86,NCT00823719-2,Ofatumumab + ICE,NCT00823719,Phase II Study of Ofatumumab Plus Ifosfamide  Carboplatin  Etoposide (ICE) or Dexamethasone  Cytarabine  Cisplatin (DHAP) Chemotherapy Regimen in Relapsed/ Refractory Diffuse Large B Cell Lymphoma (DLBCL),respiratory failure
D012131,1.64,NCT00823719-3,Total Ofatumumab + Chemotherapy,NCT00823719,Phase II Study of Ofatumumab Plus Ifosfamide  Carboplatin  Etoposide (ICE) or Dexamethasone  Cytarabine  Cisplatin (DHAP) Chemotherapy Regimen in Relapsed/ Refractory Diffuse Large B Cell Lymphoma (DLBCL),respiratory failure
D006945,3.85,NCT00823719-1,Ofatumumab + DHAP,NCT00823719,Phase II Study of Ofatumumab Plus Ifosfamide  Carboplatin  Etoposide (ICE) or Dexamethasone  Cytarabine  Cisplatin (DHAP) Chemotherapy Regimen in Relapsed/ Refractory Diffuse Large B Cell Lymphoma (DLBCL),hyperhidrosis
D006945,1.64,NCT00823719-3,Total Ofatumumab + Chemotherapy,NCT00823719,Phase II Study of Ofatumumab Plus Ifosfamide  Carboplatin  Etoposide (ICE) or Dexamethasone  Cytarabine  Cisplatin (DHAP) Chemotherapy Regimen in Relapsed/ Refractory Diffuse Large B Cell Lymphoma (DLBCL),hyperhidrosis
D007022,3.85,NCT00823719-1,Ofatumumab + DHAP,NCT00823719,Phase II Study of Ofatumumab Plus Ifosfamide  Carboplatin  Etoposide (ICE) or Dexamethasone  Cytarabine  Cisplatin (DHAP) Chemotherapy Regimen in Relapsed/ Refractory Diffuse Large B Cell Lymphoma (DLBCL),hypotension
D007022,1.64,NCT00823719-3,Total Ofatumumab + Chemotherapy,NCT00823719,Phase II Study of Ofatumumab Plus Ifosfamide  Carboplatin  Etoposide (ICE) or Dexamethasone  Cytarabine  Cisplatin (DHAP) Chemotherapy Regimen in Relapsed/ Refractory Diffuse Large B Cell Lymphoma (DLBCL),hypotension
D064420,21.74,NCT00831766-1,Phase I: Dose Escalation,NCT00831766,Idarubicin + Cytarabine and Lenalidomide in Patients With Myelodysplastic Syndrome (MDS)  Acute Myeloid Leukemia (AML),adverse drug events
D064420,46.43,NCT00831766-2,Phase II: Treatment at MTD,NCT00831766,Idarubicin + Cytarabine and Lenalidomide in Patients With Myelodysplastic Syndrome (MDS)  Acute Myeloid Leukemia (AML),adverse drug events
D001937,3.57,NCT00831766-2,Phase II: Treatment at MTD,NCT00831766,Idarubicin + Cytarabine and Lenalidomide in Patients With Myelodysplastic Syndrome (MDS)  Acute Myeloid Leukemia (AML),cauliflower
D017359,7.14,NCT00831766-2,Phase II: Treatment at MTD,NCT00831766,Idarubicin + Cytarabine and Lenalidomide in Patients With Myelodysplastic Syndrome (MDS)  Acute Myeloid Leukemia (AML),hemolysis elevated liver enzymes lowered platelets
D001145,3.57,NCT00831766-2,Phase II: Treatment at MTD,NCT00831766,Idarubicin + Cytarabine and Lenalidomide in Patients With Myelodysplastic Syndrome (MDS)  Acute Myeloid Leukemia (AML),arrhythmias cardiac
D013615,3.57,NCT00831766-2,Phase II: Treatment at MTD,NCT00831766,Idarubicin + Cytarabine and Lenalidomide in Patients With Myelodysplastic Syndrome (MDS)  Acute Myeloid Leukemia (AML),tachycardia sinoatrial nodal reentry
D006342,4.35,NCT00831766-1,Phase I: Dose Escalation,NCT00831766,Idarubicin + Cytarabine and Lenalidomide in Patients With Myelodysplastic Syndrome (MDS)  Acute Myeloid Leukemia (AML),cardiac rupture post-infarction
10069501,4.35,NCT00831766-1,Phase I: Dose Escalation,NCT00831766,Idarubicin + Cytarabine and Lenalidomide in Patients With Myelodysplastic Syndrome (MDS)  Acute Myeloid Leukemia (AML),left ventricular systolic dysfunction
D000855,3.57,NCT00831766-2,Phase II: Treatment at MTD,NCT00831766,Idarubicin + Cytarabine and Lenalidomide in Patients With Myelodysplastic Syndrome (MDS)  Acute Myeloid Leukemia (AML),anorexia
D003681,3.57,NCT00831766-2,Phase II: Treatment at MTD,NCT00831766,Idarubicin + Cytarabine and Lenalidomide in Patients With Myelodysplastic Syndrome (MDS)  Acute Myeloid Leukemia (AML),dehydration
D003967,7.14,NCT00831766-2,Phase II: Treatment at MTD,NCT00831766,Idarubicin + Cytarabine and Lenalidomide in Patients With Myelodysplastic Syndrome (MDS)  Acute Myeloid Leukemia (AML),diarrhea
D009055,4.35,NCT00831766-1,Phase I: Dose Escalation,NCT00831766,Idarubicin + Cytarabine and Lenalidomide in Patients With Myelodysplastic Syndrome (MDS)  Acute Myeloid Leukemia (AML),oral cavity
D005334,4.35,NCT00831766-1,Phase I: Dose Escalation,NCT00831766,Idarubicin + Cytarabine and Lenalidomide in Patients With Myelodysplastic Syndrome (MDS)  Acute Myeloid Leukemia (AML),fever
D005334,3.57,NCT00831766-2,Phase II: Treatment at MTD,NCT00831766,Idarubicin + Cytarabine and Lenalidomide in Patients With Myelodysplastic Syndrome (MDS)  Acute Myeloid Leukemia (AML),fever
D018450,4.35,NCT00831766-1,Phase I: Dose Escalation,NCT00831766,Idarubicin + Cytarabine and Lenalidomide in Patients With Myelodysplastic Syndrome (MDS)  Acute Myeloid Leukemia (AML),disease progression
D009102,4.35,NCT00831766-1,Phase I: Dose Escalation,NCT00831766,Idarubicin + Cytarabine and Lenalidomide in Patients With Myelodysplastic Syndrome (MDS)  Acute Myeloid Leukemia (AML),multiple organ failure
D010591,4.35,NCT00831766-1,Phase I: Dose Escalation,NCT00831766,Idarubicin + Cytarabine and Lenalidomide in Patients With Myelodysplastic Syndrome (MDS)  Acute Myeloid Leukemia (AML),phantom limb pain
D064147,4.35,NCT00831766-1,Phase I: Dose Escalation,NCT00831766,Idarubicin + Cytarabine and Lenalidomide in Patients With Myelodysplastic Syndrome (MDS)  Acute Myeloid Leukemia (AML),febrile neutropenia
D064147,32.14,NCT00831766-2,Phase II: Treatment at MTD,NCT00831766,Idarubicin + Cytarabine and Lenalidomide in Patients With Myelodysplastic Syndrome (MDS)  Acute Myeloid Leukemia (AML),febrile neutropenia
D000069544,3.57,NCT00831766-2,Phase II: Treatment at MTD,NCT00831766,Idarubicin + Cytarabine and Lenalidomide in Patients With Myelodysplastic Syndrome (MDS)  Acute Myeloid Leukemia (AML),encephalitis infection
D000069544,17.86,NCT00831766-2,Phase II: Treatment at MTD,NCT00831766,Idarubicin + Cytarabine and Lenalidomide in Patients With Myelodysplastic Syndrome (MDS)  Acute Myeloid Leukemia (AML),encephalitis infection
10061229,3.57,NCT00831766-2,Phase II: Treatment at MTD,NCT00831766,Idarubicin + Cytarabine and Lenalidomide in Patients With Myelodysplastic Syndrome (MDS)  Acute Myeloid Leukemia (AML),lung infection
10062632,3.57,NCT00831766-2,Phase II: Treatment at MTD,NCT00831766,Idarubicin + Cytarabine and Lenalidomide in Patients With Myelodysplastic Syndrome (MDS)  Acute Myeloid Leukemia (AML),gallbladder infection
D014552,3.57,NCT00831766-2,Phase II: Treatment at MTD,NCT00831766,Idarubicin + Cytarabine and Lenalidomide in Patients With Myelodysplastic Syndrome (MDS)  Acute Myeloid Leukemia (AML),urinary tract infections
D000068258,4.35,NCT00831766-1,Phase I: Dose Escalation,NCT00831766,Idarubicin + Cytarabine and Lenalidomide in Patients With Myelodysplastic Syndrome (MDS)  Acute Myeloid Leukemia (AML),avastin
D003221,3.57,NCT00831766-2,Phase II: Treatment at MTD,NCT00831766,Idarubicin + Cytarabine and Lenalidomide in Patients With Myelodysplastic Syndrome (MDS)  Acute Myeloid Leukemia (AML),confusion
D058186,3.57,NCT00831766-2,Phase II: Treatment at MTD,NCT00831766,Idarubicin + Cytarabine and Lenalidomide in Patients With Myelodysplastic Syndrome (MDS)  Acute Myeloid Leukemia (AML),acute kidney injury
D000860,4.35,NCT00831766-1,Phase I: Dose Escalation,NCT00831766,Idarubicin + Cytarabine and Lenalidomide in Patients With Myelodysplastic Syndrome (MDS)  Acute Myeloid Leukemia (AML),hypoxia
D016769,3.57,NCT00831766-2,Phase II: Treatment at MTD,NCT00831766,Idarubicin + Cytarabine and Lenalidomide in Patients With Myelodysplastic Syndrome (MDS)  Acute Myeloid Leukemia (AML),embolism and thrombosis
D009026,75.0,NCT00840177-1,Initial Cohort: Relapsed AML With Previous Remission ≥ 3 Mnths,NCT00840177,S0919 Idarubicin  Cytarabine  and Pravastatin in Treating Patients With Relapsed Acute Myeloid Leukemia,mortality
D009026,68.97,NCT00840177-2,Poor-risk Cohort: MDS Transformed to AML,NCT00840177,S0919 Idarubicin  Cytarabine  and Pravastatin in Treating Patients With Relapsed Acute Myeloid Leukemia,mortality
D009026,89.13,NCT00840177-3,Poor-risk Cohort: Refractory/Relapsed AML < 6 Mths Remission,NCT00840177,S0919 Idarubicin  Cytarabine  and Pravastatin in Treating Patients With Relapsed Acute Myeloid Leukemia,mortality
D064420,14.29,NCT00840177-1,Initial Cohort: Relapsed AML With Previous Remission ≥ 3 Mnths,NCT00840177,S0919 Idarubicin  Cytarabine  and Pravastatin in Treating Patients With Relapsed Acute Myeloid Leukemia,adverse drug events
D064420,27.59,NCT00840177-2,Poor-risk Cohort: MDS Transformed to AML,NCT00840177,S0919 Idarubicin  Cytarabine  and Pravastatin in Treating Patients With Relapsed Acute Myeloid Leukemia,adverse drug events
D064420,21.74,NCT00840177-3,Poor-risk Cohort: Refractory/Relapsed AML < 6 Mths Remission,NCT00840177,S0919 Idarubicin  Cytarabine  and Pravastatin in Treating Patients With Relapsed Acute Myeloid Leukemia,adverse drug events
D064147,2.17,NCT00840177-3,Poor-risk Cohort: Refractory/Relapsed AML < 6 Mths Remission,NCT00840177,S0919 Idarubicin  Cytarabine  and Pravastatin in Treating Patients With Relapsed Acute Myeloid Leukemia,febrile neutropenia
D009618,2.86,NCT00840177-1,Initial Cohort: Relapsed AML With Previous Remission ≥ 3 Mnths,NCT00840177,S0919 Idarubicin  Cytarabine  and Pravastatin in Treating Patients With Relapsed Acute Myeloid Leukemia,nocardiaceae
D009618,3.45,NCT00840177-2,Poor-risk Cohort: MDS Transformed to AML,NCT00840177,S0919 Idarubicin  Cytarabine  and Pravastatin in Treating Patients With Relapsed Acute Myeloid Leukemia,nocardiaceae
D006342,3.45,NCT00840177-2,Poor-risk Cohort: MDS Transformed to AML,NCT00840177,S0919 Idarubicin  Cytarabine  and Pravastatin in Treating Patients With Relapsed Acute Myeloid Leukemia,cardiac rupture post-infarction
D001861,2.86,NCT00840177-1,Initial Cohort: Relapsed AML With Previous Remission ≥ 3 Mnths,NCT00840177,S0919 Idarubicin  Cytarabine  and Pravastatin in Treating Patients With Relapsed Acute Myeloid Leukemia,osteoconduction
D001146,2.86,NCT00840177-1,Initial Cohort: Relapsed AML With Previous Remission ≥ 3 Mnths,NCT00840177,S0919 Idarubicin  Cytarabine  and Pravastatin in Treating Patients With Relapsed Acute Myeloid Leukemia,sinoatrial arrhythmia
D001146,3.45,NCT00840177-2,Poor-risk Cohort: MDS Transformed to AML,NCT00840177,S0919 Idarubicin  Cytarabine  and Pravastatin in Treating Patients With Relapsed Acute Myeloid Leukemia,sinoatrial arrhythmia
D001146,2.17,NCT00840177-3,Poor-risk Cohort: Refractory/Relapsed AML < 6 Mths Remission,NCT00840177,S0919 Idarubicin  Cytarabine  and Pravastatin in Treating Patients With Relapsed Acute Myeloid Leukemia,arrhythmia sinus
D005767,3.45,NCT00840177-2,Poor-risk Cohort: MDS Transformed to AML,NCT00840177,S0919 Idarubicin  Cytarabine  and Pravastatin in Treating Patients With Relapsed Acute Myeloid Leukemia,functional gastrointestinal disorders
D001526,2.86,NCT00840177-1,Initial Cohort: Relapsed AML With Previous Remission ≥ 3 Mnths,NCT00840177,S0919 Idarubicin  Cytarabine  and Pravastatin in Treating Patients With Relapsed Acute Myeloid Leukemia,behavioral symptoms
D003643,2.86,NCT00840177-1,Initial Cohort: Relapsed AML With Previous Remission ≥ 3 Mnths,NCT00840177,S0919 Idarubicin  Cytarabine  and Pravastatin in Treating Patients With Relapsed Acute Myeloid Leukemia,death
D003643,6.52,NCT00840177-3,Poor-risk Cohort: Refractory/Relapsed AML < 6 Mths Remission,NCT00840177,S0919 Idarubicin  Cytarabine  and Pravastatin in Treating Patients With Relapsed Acute Myeloid Leukemia,death
D000080104,3.45,NCT00840177-2,Poor-risk Cohort: MDS Transformed to AML,NCT00840177,S0919 Idarubicin  Cytarabine  and Pravastatin in Treating Patients With Relapsed Acute Myeloid Leukemia,infertility clinics
D000080104,2.86,NCT00840177-1,Initial Cohort: Relapsed AML With Previous Remission ≥ 3 Mnths,NCT00840177,S0919 Idarubicin  Cytarabine  and Pravastatin in Treating Patients With Relapsed Acute Myeloid Leukemia,infertility clinics
D000069544,2.86,NCT00840177-1,Initial Cohort: Relapsed AML With Previous Remission ≥ 3 Mnths,NCT00840177,S0919 Idarubicin  Cytarabine  and Pravastatin in Treating Patients With Relapsed Acute Myeloid Leukemia,encephalitis infection
D000069544,6.9,NCT00840177-2,Poor-risk Cohort: MDS Transformed to AML,NCT00840177,S0919 Idarubicin  Cytarabine  and Pravastatin in Treating Patients With Relapsed Acute Myeloid Leukemia,encephalitis infection
D000069544,10.87,NCT00840177-3,Poor-risk Cohort: Refractory/Relapsed AML < 6 Mths Remission,NCT00840177,S0919 Idarubicin  Cytarabine  and Pravastatin in Treating Patients With Relapsed Acute Myeloid Leukemia,encephalitis infection
10061229,3.45,NCT00840177-2,Poor-risk Cohort: MDS Transformed to AML,NCT00840177,S0919 Idarubicin  Cytarabine  and Pravastatin in Treating Patients With Relapsed Acute Myeloid Leukemia,lung infection
10065771,3.45,NCT00840177-2,Poor-risk Cohort: MDS Transformed to AML,NCT00840177,S0919 Idarubicin  Cytarabine  and Pravastatin in Treating Patients With Relapsed Acute Myeloid Leukemia,small intestine infection
D003997,2.86,NCT00840177-1,Initial Cohort: Relapsed AML With Previous Remission ≥ 3 Mnths,NCT00840177,S0919 Idarubicin  Cytarabine  and Pravastatin in Treating Patients With Relapsed Acute Myeloid Leukemia,diethoxycarbonyldihydrocollidine
D003997,13.79,NCT00840177-2,Poor-risk Cohort: MDS Transformed to AML,NCT00840177,S0919 Idarubicin  Cytarabine  and Pravastatin in Treating Patients With Relapsed Acute Myeloid Leukemia,diethoxycarbonyldihydrocollidine
D003997,2.17,NCT00840177-3,Poor-risk Cohort: Refractory/Relapsed AML < 6 Mths Remission,NCT00840177,S0919 Idarubicin  Cytarabine  and Pravastatin in Treating Patients With Relapsed Acute Myeloid Leukemia,diethoxycarbonyldihydrocollidine
D008231,2.86,NCT00840177-1,Initial Cohort: Relapsed AML With Previous Remission ≥ 3 Mnths,NCT00840177,S0919 Idarubicin  Cytarabine  and Pravastatin in Treating Patients With Relapsed Acute Myeloid Leukemia,lymphopenia
D006098,2.86,NCT00840177-1,Initial Cohort: Relapsed AML With Previous Remission ≥ 3 Mnths,NCT00840177,S0919 Idarubicin  Cytarabine  and Pravastatin in Treating Patients With Relapsed Acute Myeloid Leukemia,granulocytes
D012509,3.45,NCT00840177-2,Poor-risk Cohort: MDS Transformed to AML,NCT00840177,S0919 Idarubicin  Cytarabine  and Pravastatin in Treating Patients With Relapsed Acute Myeloid Leukemia,sarcoma soft tissue
D006470,2.17,NCT00840177-3,Poor-risk Cohort: Refractory/Relapsed AML < 6 Mths Remission,NCT00840177,S0919 Idarubicin  Cytarabine  and Pravastatin in Treating Patients With Relapsed Acute Myeloid Leukemia,hemorrhage
D051437,2.17,NCT00840177-3,Poor-risk Cohort: Refractory/Relapsed AML < 6 Mths Remission,NCT00840177,S0919 Idarubicin  Cytarabine  and Pravastatin in Treating Patients With Relapsed Acute Myeloid Leukemia,renal failure
D003997,2.86,NCT00840177-1,Initial Cohort: Relapsed AML With Previous Remission ≥ 3 Mnths,NCT00840177,S0919 Idarubicin  Cytarabine  and Pravastatin in Treating Patients With Relapsed Acute Myeloid Leukemia,diethoxycarbonyldihydrocollidine
D003997,13.79,NCT00840177-2,Poor-risk Cohort: MDS Transformed to AML,NCT00840177,S0919 Idarubicin  Cytarabine  and Pravastatin in Treating Patients With Relapsed Acute Myeloid Leukemia,diethoxycarbonyldihydrocollidine
D003997,2.17,NCT00840177-3,Poor-risk Cohort: Refractory/Relapsed AML < 6 Mths Remission,NCT00840177,S0919 Idarubicin  Cytarabine  and Pravastatin in Treating Patients With Relapsed Acute Myeloid Leukemia,diethoxycarbonyldihydrocollidine
10065746,2.17,NCT00840177-3,Poor-risk Cohort: Refractory/Relapsed AML < 6 Mths Remission,NCT00840177,S0919 Idarubicin  Cytarabine  and Pravastatin in Treating Patients With Relapsed Acute Myeloid Leukemia,bronchopulmonary hemorrhage
D000860,2.86,NCT00840177-1,Initial Cohort: Relapsed AML With Previous Remission ≥ 3 Mnths,NCT00840177,S0919 Idarubicin  Cytarabine  and Pravastatin in Treating Patients With Relapsed Acute Myeloid Leukemia,hypoxia
D007022,6.9,NCT00840177-2,Poor-risk Cohort: MDS Transformed to AML,NCT00840177,S0919 Idarubicin  Cytarabine  and Pravastatin in Treating Patients With Relapsed Acute Myeloid Leukemia,hypotension
D007022,2.17,NCT00840177-3,Poor-risk Cohort: Refractory/Relapsed AML < 6 Mths Remission,NCT00840177,S0919 Idarubicin  Cytarabine  and Pravastatin in Treating Patients With Relapsed Acute Myeloid Leukemia,hypotension
D009026,71.26,NCT00875667-1,Lenalidomide,NCT00875667,A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL),mortality
D009026,71.08,NCT00875667-2,Investigator's Choice,NCT00875667,A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL),mortality
D064420,44.91,NCT00875667-1,Lenalidomide,NCT00875667,A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL),adverse drug events
D064420,26.51,NCT00875667-2,Investigator's Choice,NCT00875667,A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL),adverse drug events
D000741,3.59,NCT00875667-1,Lenalidomide,NCT00875667,A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL),aplastic anaemia
D000741,2.41,NCT00875667-2,Investigator's Choice,NCT00875667,A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL),aplastic anaemia
D000744,1.2,NCT00875667-2,Investigator's Choice,NCT00875667,A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL),autoimmune haemolytic anaemia
D064147,3.59,NCT00875667-1,Lenalidomide,NCT00875667,A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL),febrile neutropenia
D064147,2.41,NCT00875667-2,Investigator's Choice,NCT00875667,A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL),febrile neutropenia
10025182,0.6,NCT00875667-1,Lenalidomide,NCT00875667,A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL),lymph node pain
10025182,1.2,NCT00875667-2,Investigator's Choice,NCT00875667,A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL),lymph node pain
D009503,3.59,NCT00875667-1,Lenalidomide,NCT00875667,A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL),neutropenia
D013921,1.8,NCT00875667-1,Lenalidomide,NCT00875667,A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL),thrombocytopenia
D013921,2.41,NCT00875667-2,Investigator's Choice,NCT00875667,A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL),thrombocytopenia
D054058,0.6,NCT00875667-1,Lenalidomide,NCT00875667,A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL),acute coronary syndrome
D056988,0.6,NCT00875667-1,Lenalidomide,NCT00875667,A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL),acute anterior wall myocardial infarction
D001281,0.6,NCT00875667-1,Lenalidomide,NCT00875667,A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL),atrial fibrillation
D001281,1.2,NCT00875667-2,Investigator's Choice,NCT00875667,A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL),atrial fibrillation
10003673,0.6,NCT00875667-1,Lenalidomide,NCT00875667,A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL),atrioventricular block complete
10003674,0.6,NCT00875667-1,Lenalidomide,NCT00875667,A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL),atrioventricular block first degree
D006323,1.2,NCT00875667-1,Lenalidomide,NCT00875667,A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL),cardiac arrest
D006333,1.2,NCT00875667-1,Lenalidomide,NCT00875667,A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL),cardiac failure
D006333,1.2,NCT00875667-2,Investigator's Choice,NCT00875667,A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL),cardiac failure
D006333,1.2,NCT00875667-2,Investigator's Choice,NCT00875667,A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL),cardiac failure
D006333,0.6,NCT00875667-1,Lenalidomide,NCT00875667,A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL),cardiac failure
D003324,0.6,NCT00875667-1,Lenalidomide,NCT00875667,A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL),coronary artery disease
D016277,0.6,NCT00875667-1,Lenalidomide,NCT00875667,A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL),ventricular function left
D009203,0.6,NCT00875667-1,Lenalidomide,NCT00875667,A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL),myocardial infarction
D013617,0.6,NCT00875667-1,Lenalidomide,NCT00875667,A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL),supraventricular tachycardia
D013610,0.6,NCT00875667-1,Lenalidomide,NCT00875667,A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL),tachycardia
D006312,0.6,NCT00875667-1,Lenalidomide,NCT00875667,A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL),deafness bilateral
D014717,0.6,NCT00875667-1,Lenalidomide,NCT00875667,A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL),vertigo
D015356,0.6,NCT00875667-1,Lenalidomide,NCT00875667,A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL),retinal artery occlusion
D015746,0.6,NCT00875667-1,Lenalidomide,NCT00875667,A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL),abdominal pain
D034861,1.2,NCT00875667-2,Investigator's Choice,NCT00875667,A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL),abdominal wall
UNKNOWN-check-for-typo,3.59,NCT00875667-1,Lenalidomide,NCT00875667,A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL),D00
D000069196,0.6,NCT00875667-1,Lenalidomide,NCT00875667,A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL),gastrointestinal microbiome
D007420,0.6,NCT00875667-1,Lenalidomide,NCT00875667,A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL),intestine large
D009325,0.6,NCT00875667-1,Lenalidomide,NCT00875667,A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL),nausea
D013392,0.6,NCT00875667-1,Lenalidomide,NCT00875667,A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL),ulcerban
D000071056,0.6,NCT00875667-1,Lenalidomide,NCT00875667,A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL),anorectal malformations
D000071056,1.2,NCT00875667-2,Investigator's Choice,NCT00875667,A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL),anorectal malformations
10041101,1.2,NCT00875667-2,Investigator's Choice,NCT00875667,A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL),small intestinal obstruction
D014839,1.2,NCT00875667-1,Lenalidomide,NCT00875667,A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL),vomiting
D003643,0.6,NCT00875667-1,Lenalidomide,NCT00875667,A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL),death
D005221,0.6,NCT00875667-1,Lenalidomide,NCT00875667,A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL),fatigue
D003695,1.8,NCT00875667-1,Lenalidomide,NCT00875667,A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL),healthcare
D003695,1.2,NCT00875667-2,Investigator's Choice,NCT00875667,A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL),healthcare
D009102,1.2,NCT00875667-1,Lenalidomide,NCT00875667,A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL),multiple organ dysfunction syndrome
D000799,0.6,NCT00875667-1,Lenalidomide,NCT00875667,A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL),angioedema
D005334,2.99,NCT00875667-1,Lenalidomide,NCT00875667,A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL),pyrexia
D005334,2.41,NCT00875667-2,Investigator's Choice,NCT00875667,A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL),pyrexia
D003645,0.6,NCT00875667-1,Lenalidomide,NCT00875667,A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL),sudden death
D002764,0.6,NCT00875667-1,Lenalidomide,NCT00875667,A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL),cholecystitis
D041881,0.6,NCT00875667-1,Lenalidomide,NCT00875667,A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL),acute cholecystitis
UNKNOWN-check-for-typo,0.6,NCT00875667-1,Lenalidomide,NCT00875667,A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL),D00
D004342,1.2,NCT00875667-2,Investigator's Choice,NCT00875667,A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL),drug hypersensitivity
D001168,0.6,NCT00875667-1,Lenalidomide,NCT00875667,A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL),arthritis
D001228,0.6,NCT00875667-1,Lenalidomide,NCT00875667,A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL),aspergillus infection
D001991,1.2,NCT00875667-1,Lenalidomide,NCT00875667,A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL),bronchitis
D001991,1.2,NCT00875667-2,Investigator's Choice,NCT00875667,A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL),bronchitis
D055732,1.2,NCT00875667-2,Investigator's Choice,NCT00875667,A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL),bronchopulmonary aspergillosis
D002481,0.6,NCT00875667-1,Lenalidomide,NCT00875667,A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL),cellulitis
D002481,1.2,NCT00875667-2,Investigator's Choice,NCT00875667,A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL),cellulitis
D012141,1.8,NCT00875667-1,Lenalidomide,NCT00875667,A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL),respiratory tract infections
D012141,1.2,NCT00875667-2,Investigator's Choice,NCT00875667,A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL),respiratory tract infections
10061229,1.2,NCT00875667-1,Lenalidomide,NCT00875667,A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL),lung infection
D008587,0.6,NCT00875667-1,Lenalidomide,NCT00875667,A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL),viral meningitis
D000985,0.6,NCT00875667-1,Lenalidomide,NCT00875667,A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL),antisepsis
D011014,3.59,NCT00875667-1,Lenalidomide,NCT00875667,A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL),pneumonia
D011014,3.61,NCT00875667-2,Investigator's Choice,NCT00875667,A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL),pneumonia
D001996,1.2,NCT00875667-2,Investigator's Choice,NCT00875667,A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL),bronchopneumonia
D001996,0.6,NCT00875667-1,Lenalidomide,NCT00875667,A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL),bronchopneumonia
D004761,0.6,NCT00875667-1,Lenalidomide,NCT00875667,A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL),pseudomembranous colitis
D012772,0.6,NCT00875667-1,Lenalidomide,NCT00875667,A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL),septic shock
D012852,0.6,NCT00875667-1,Lenalidomide,NCT00875667,A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL),sinusitis
10040872,0.6,NCT00875667-1,Lenalidomide,NCT00875667,A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL),skin infection
D004768,0.6,NCT00875667-1,Lenalidomide,NCT00875667,A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL),staphylococcal enterotoxins
D000985,0.6,NCT00875667-1,Lenalidomide,NCT00875667,A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL),antisepsis
D012141,0.6,NCT00875667-1,Lenalidomide,NCT00875667,A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL),upper respiratory tract infections
D014552,1.2,NCT00875667-1,Lenalidomide,NCT00875667,A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL),urinary tract infection
10040047,0.6,NCT00875667-1,Lenalidomide,NCT00875667,A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL),sepsis
D005147,0.6,NCT00875667-1,Lenalidomide,NCT00875667,A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL),facial bones
D000081015,1.2,NCT00875667-2,Investigator's Choice,NCT00875667,A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL),ototoxicity
D013851,0.6,NCT00875667-1,Lenalidomide,NCT00875667,A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL),underweight
D002100,0.6,NCT00875667-1,Lenalidomide,NCT00875667,A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL),cachexia
D003681,0.6,NCT00875667-1,Lenalidomide,NCT00875667,A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL),dehydration
D003920,1.2,NCT00875667-2,Investigator's Choice,NCT00875667,A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL),diabetes mellitus
UNKNOWN-check-for-typo,0.6,NCT00875667-1,Lenalidomide,NCT00875667,A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL),D00
UNKNOWN-check-for-typo,0.6,NCT00875667-1,Lenalidomide,NCT00875667,A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL),D00
UNKNOWN-check-for-typo,0.6,NCT00875667-1,Lenalidomide,NCT00875667,A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL),D00
D001168,0.6,NCT00875667-1,Lenalidomide,NCT00875667,A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL),arthritis
D010020,0.6,NCT00875667-1,Lenalidomide,NCT00875667,A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL),osteonecrosis
D010020,1.2,NCT00875667-2,Investigator's Choice,NCT00875667,A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL),osteonecrosis
10033425,0.6,NCT00875667-1,Lenalidomide,NCT00875667,A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL),pain in extremity
D015470,1.8,NCT00875667-1,Lenalidomide,NCT00875667,A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL),leukemia nonlymphocytic acute
D002280,1.2,NCT00875667-1,Lenalidomide,NCT00875667,A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL),basal cell carcinoma
D000072716,0.6,NCT00875667-1,Lenalidomide,NCT00875667,A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL),cancer pain
D000069293,1.2,NCT00875667-2,Investigator's Choice,NCT00875667,A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL),plasmablasts diffuse large b-cell lymphoma
D008080,0.6,NCT00875667-1,Lenalidomide,NCT00875667,A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL),liposarcoma
D020522,0.6,NCT00875667-1,Lenalidomide,NCT00875667,A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL),mantle cell lymphoma
D020522,3.61,NCT00875667-2,Investigator's Choice,NCT00875667,A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL),mantle cell lymphoma
D008579,1.2,NCT00875667-2,Investigator's Choice,NCT00875667,A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL),benign meningioma
D008168,0.6,NCT00875667-1,Lenalidomide,NCT00875667,A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL),lung
D002294,0.6,NCT00875667-1,Lenalidomide,NCT00875667,A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL),carcinoma squamous cell
D002294,1.2,NCT00875667-1,Lenalidomide,NCT00875667,A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL),carcinoma squamous cell
D000067251,0.6,NCT00875667-1,Lenalidomide,NCT00875667,A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL),symptom flareup
D000074042,0.6,NCT00875667-1,Lenalidomide,NCT00875667,A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL),cerebral intraventricular haemorrhage
D020521,0.6,NCT00875667-1,Lenalidomide,NCT00875667,A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL),cerebrovascular accident
D006423,0.6,NCT00875667-1,Lenalidomide,NCT00875667,A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL),hemianopia
D013474,0.6,NCT00875667-1,Lenalidomide,NCT00875667,A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL),sunstroke
D012640,0.6,NCT00875667-1,Lenalidomide,NCT00875667,A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL),seizure
D002546,0.6,NCT00875667-1,Lenalidomide,NCT00875667,A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL),ischemic attack transient
D001002,1.2,NCT00875667-2,Investigator's Choice,NCT00875667,A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL),anuria
D051436,0.6,NCT00875667-1,Lenalidomide,NCT00875667,A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL),chronic kidney disease
D002764,0.6,NCT00875667-1,Lenalidomide,NCT00875667,A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL),cholecystitis
D009846,1.2,NCT00875667-2,Investigator's Choice,NCT00875667,A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL),oliguria
D051437,0.6,NCT00875667-1,Lenalidomide,NCT00875667,A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL),renal failure
D000799,0.6,NCT00875667-1,Lenalidomide,NCT00875667,A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL),angioedema
D000081026,0.6,NCT00875667-1,Lenalidomide,NCT00875667,A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL),polyprenols
10003504,0.6,NCT00875667-1,Lenalidomide,NCT00875667,A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL),aspiration
D029481,0.6,NCT00875667-1,Lenalidomide,NCT00875667,A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL),chronic bronchitis
D003371,1.2,NCT00875667-2,Investigator's Choice,NCT00875667,A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL),cough
UNKNOWN-check-for-typo,1.8,NCT00875667-1,Lenalidomide,NCT00875667,A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL),D00
UNKNOWN-check-for-typo,1.2,NCT00875667-2,Investigator's Choice,NCT00875667,A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL),D00
D017563,0.6,NCT00875667-1,Lenalidomide,NCT00875667,A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL),interstitial lung disease
D007249,0.6,NCT00875667-1,Lenalidomide,NCT00875667,A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL),inflammation
D010996,1.2,NCT00875667-1,Lenalidomide,NCT00875667,A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL),pleural effusion
D010998,0.6,NCT00875667-1,Lenalidomide,NCT00875667,A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL),pleurisy
D011655,3.59,NCT00875667-1,Lenalidomide,NCT00875667,A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL),pulmonary embolism
D012127,0.6,NCT00875667-1,Lenalidomide,NCT00875667,A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL),respiratory distress syndrome newborn
D012131,0.6,NCT00875667-1,Lenalidomide,NCT00875667,A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL),respiratory failure
D014827,0.6,NCT00875667-1,Lenalidomide,NCT00875667,A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL),vocal cords
D063926,0.6,NCT00875667-1,Lenalidomide,NCT00875667,A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL),drug reaction with eosinophilia and systemic symptoms
D000074042,0.6,NCT00875667-1,Lenalidomide,NCT00875667,A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL),cerebral intraventricular haemorrhage
D006973,0.6,NCT00875667-1,Lenalidomide,NCT00875667,A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL),hypertension
D007022,1.2,NCT00875667-1,Lenalidomide,NCT00875667,A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL),hypotension
D020246,0.6,NCT00875667-1,Lenalidomide,NCT00875667,A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL),venous thrombosis
D064420,66.67,NCT00906945-2,Dose Level 2,NCT00906945,Chemosensitization With Plerixafor Plus G-CSF in Acute Myeloid Leukemia,adverse drug events
D064420,33.33,NCT00906945-4,Dose Level 4,NCT00906945,Chemosensitization With Plerixafor Plus G-CSF in Acute Myeloid Leukemia,adverse drug events
D064420,33.33,NCT00906945-5,Dose Level 5,NCT00906945,Chemosensitization With Plerixafor Plus G-CSF in Acute Myeloid Leukemia,adverse drug events
D064420,14.29,NCT00906945-6,MTD - Phase II,NCT00906945,Chemosensitization With Plerixafor Plus G-CSF in Acute Myeloid Leukemia,adverse drug events
D064147,33.33,NCT00906945-2,Dose Level 2,NCT00906945,Chemosensitization With Plerixafor Plus G-CSF in Acute Myeloid Leukemia,febrile neutropenia
10007612,33.33,NCT00906945-2,Dose Level 2,NCT00906945,Chemosensitization With Plerixafor Plus G-CSF in Acute Myeloid Leukemia,cardiac troponin i increased
10061229,33.33,NCT00906945-2,Dose Level 2,NCT00906945,Chemosensitization With Plerixafor Plus G-CSF in Acute Myeloid Leukemia,lung infection
10061229,16.67,NCT00906945-4,Dose Level 4,NCT00906945,Chemosensitization With Plerixafor Plus G-CSF in Acute Myeloid Leukemia,lung infection
D018805,33.33,NCT00906945-4,Dose Level 4,NCT00906945,Chemosensitization With Plerixafor Plus G-CSF in Acute Myeloid Leukemia,sepsis
D018805,16.67,NCT00906945-5,Dose Level 5,NCT00906945,Chemosensitization With Plerixafor Plus G-CSF in Acute Myeloid Leukemia,sepsis
D018805,7.14,NCT00906945-6,MTD - Phase II,NCT00906945,Chemosensitization With Plerixafor Plus G-CSF in Acute Myeloid Leukemia,sepsis
D000080867,16.67,NCT00906945-5,Dose Level 5,NCT00906945,Chemosensitization With Plerixafor Plus G-CSF in Acute Myeloid Leukemia,gingipains
10006002,16.67,NCT00906945-5,Dose Level 5,NCT00906945,Chemosensitization With Plerixafor Plus G-CSF in Acute Myeloid Leukemia,bone pain
D000860,16.67,NCT00906945-4,Dose Level 4,NCT00906945,Chemosensitization With Plerixafor Plus G-CSF in Acute Myeloid Leukemia,hypoxia
D007022,16.67,NCT00906945-5,Dose Level 5,NCT00906945,Chemosensitization With Plerixafor Plus G-CSF in Acute Myeloid Leukemia,hypotension
D006408,7.14,NCT00906945-6,MTD - Phase II,NCT00906945,Chemosensitization With Plerixafor Plus G-CSF in Acute Myeloid Leukemia,subdural hematoma
D064420,16.67,NCT00907517-3,MK-8776 40 mg/m^2 + Cytarabine 2 g/m^2,NCT00907517,Study of SCH 900776 (MK-8776) With and Without Cytarabine in Participants With Acute Leukemias (P05247),adverse drug events
D064420,33.33,NCT00907517-4,MK-8776 56 mg/m^2 + Cytarabine 2 g/m^2,NCT00907517,Study of SCH 900776 (MK-8776) With and Without Cytarabine in Participants With Acute Leukemias (P05247),adverse drug events
D064420,16.67,NCT00907517-5,MK-8776 140 mg + Cytarabine 2 g/m^2,NCT00907517,Study of SCH 900776 (MK-8776) With and Without Cytarabine in Participants With Acute Leukemias (P05247),adverse drug events
D064147,16.67,NCT00907517-5,MK-8776 140 mg + Cytarabine 2 g/m^2,NCT00907517,Study of SCH 900776 (MK-8776) With and Without Cytarabine in Participants With Acute Leukemias (P05247),febrile neutropenia
D005756,16.67,NCT00907517-5,MK-8776 140 mg + Cytarabine 2 g/m^2,NCT00907517,Study of SCH 900776 (MK-8776) With and Without Cytarabine in Participants With Acute Leukemias (P05247),gastritis
D009325,16.67,NCT00907517-4,MK-8776 56 mg/m^2 + Cytarabine 2 g/m^2,NCT00907517,Study of SCH 900776 (MK-8776) With and Without Cytarabine in Participants With Acute Leukemias (P05247),nausea
D014839,16.67,NCT00907517-4,MK-8776 56 mg/m^2 + Cytarabine 2 g/m^2,NCT00907517,Study of SCH 900776 (MK-8776) With and Without Cytarabine in Participants With Acute Leukemias (P05247),vomiting
D009181,16.67,NCT00907517-3,MK-8776 40 mg/m^2 + Cytarabine 2 g/m^2,NCT00907517,Study of SCH 900776 (MK-8776) With and Without Cytarabine in Participants With Acute Leukemias (P05247),fungal infection
D011014,16.67,NCT00907517-4,MK-8776 56 mg/m^2 + Cytarabine 2 g/m^2,NCT00907517,Study of SCH 900776 (MK-8776) With and Without Cytarabine in Participants With Acute Leukemias (P05247),pneumonia
D001996,16.67,NCT00907517-3,MK-8776 40 mg/m^2 + Cytarabine 2 g/m^2,NCT00907517,Study of SCH 900776 (MK-8776) With and Without Cytarabine in Participants With Acute Leukemias (P05247),bronchopneumonia
D006408,16.67,NCT00907517-4,MK-8776 56 mg/m^2 + Cytarabine 2 g/m^2,NCT00907517,Study of SCH 900776 (MK-8776) With and Without Cytarabine in Participants With Acute Leukemias (P05247),hematoma subdural
D006261,16.67,NCT00907517-4,MK-8776 56 mg/m^2 + Cytarabine 2 g/m^2,NCT00907517,Study of SCH 900776 (MK-8776) With and Without Cytarabine in Participants With Acute Leukemias (P05247),headache
D058186,16.67,NCT00907517-4,MK-8776 56 mg/m^2 + Cytarabine 2 g/m^2,NCT00907517,Study of SCH 900776 (MK-8776) With and Without Cytarabine in Participants With Acute Leukemias (P05247),acute renal failure
D000799,16.67,NCT00907517-4,MK-8776 56 mg/m^2 + Cytarabine 2 g/m^2,NCT00907517,Study of SCH 900776 (MK-8776) With and Without Cytarabine in Participants With Acute Leukemias (P05247),angioedema
D006973,16.67,NCT00907517-4,MK-8776 56 mg/m^2 + Cytarabine 2 g/m^2,NCT00907517,Study of SCH 900776 (MK-8776) With and Without Cytarabine in Participants With Acute Leukemias (P05247),hypertension
D064420,48.39,NCT00945815-1,Ara-C + Clofarabine + Epratuzumab,NCT00945815,S0910 Epratuzumab  Cytarabine  and Clofarabine in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia,adverse drug events
D000740,3.23,NCT00945815-1,Ara-C + Clofarabine + Epratuzumab,NCT00945815,S0910 Epratuzumab  Cytarabine  and Clofarabine in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia,anemia
D064147,19.35,NCT00945815-1,Ara-C + Clofarabine + Epratuzumab,NCT00945815,S0910 Epratuzumab  Cytarabine  and Clofarabine in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia,febrile neutropenia
D006323,6.45,NCT00945815-1,Ara-C + Clofarabine + Epratuzumab,NCT00945815,S0910 Epratuzumab  Cytarabine  and Clofarabine in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia,cardiac arrest
D015746,3.23,NCT00945815-1,Ara-C + Clofarabine + Epratuzumab,NCT00945815,S0910 Epratuzumab  Cytarabine  and Clofarabine in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia,abdominal pain
D003967,6.45,NCT00945815-1,Ara-C + Clofarabine + Epratuzumab,NCT00945815,S0910 Epratuzumab  Cytarabine  and Clofarabine in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia,diarrhea
10031009,3.23,NCT00945815-1,Ara-C + Clofarabine + Epratuzumab,NCT00945815,S0910 Epratuzumab  Cytarabine  and Clofarabine in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia,oral pain
D053706,3.23,NCT00945815-1,Ara-C + Clofarabine + Epratuzumab,NCT00945815,S0910 Epratuzumab  Cytarabine  and Clofarabine in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia,typhlitis
10011914,3.23,NCT00945815-1,Ara-C + Clofarabine + Epratuzumab,NCT00945815,S0910 Epratuzumab  Cytarabine  and Clofarabine in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia,death nos
D017093,3.23,NCT00945815-1,Ara-C + Clofarabine + Epratuzumab,NCT00945815,S0910 Epratuzumab  Cytarabine  and Clofarabine in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia,hepatic failure
10007810,9.68,NCT00945815-1,Ara-C + Clofarabine + Epratuzumab,NCT00945815,S0910 Epratuzumab  Cytarabine  and Clofarabine in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia,catheter related infection
10058838,3.23,NCT00945815-1,Ara-C + Clofarabine + Epratuzumab,NCT00945815,S0910 Epratuzumab  Cytarabine  and Clofarabine in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia,enterocolitis infectious
10061229,9.68,NCT00945815-1,Ara-C + Clofarabine + Epratuzumab,NCT00945815,S0910 Epratuzumab  Cytarabine  and Clofarabine in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia,lung infection
D018805,12.9,NCT00945815-1,Ara-C + Clofarabine + Epratuzumab,NCT00945815,S0910 Epratuzumab  Cytarabine  and Clofarabine in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia,sepsis
10048762,3.23,NCT00945815-1,Ara-C + Clofarabine + Epratuzumab,NCT00945815,S0910 Epratuzumab  Cytarabine  and Clofarabine in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia,tooth infection
10001551,6.45,NCT00945815-1,Ara-C + Clofarabine + Epratuzumab,NCT00945815,S0910 Epratuzumab  Cytarabine  and Clofarabine in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia,alanine aminotransferase increased
10003481,6.45,NCT00945815-1,Ara-C + Clofarabine + Epratuzumab,NCT00945815,S0910 Epratuzumab  Cytarabine  and Clofarabine in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia,aspartate aminotransferase increased
10022891,3.23,NCT00945815-1,Ara-C + Clofarabine + Epratuzumab,NCT00945815,S0910 Epratuzumab  Cytarabine  and Clofarabine in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia,investigations - other specify
10029366,3.23,NCT00945815-1,Ara-C + Clofarabine + Epratuzumab,NCT00945815,S0910 Epratuzumab  Cytarabine  and Clofarabine in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia,neutrophil count decreased
10035528,6.45,NCT00945815-1,Ara-C + Clofarabine + Epratuzumab,NCT00945815,S0910 Epratuzumab  Cytarabine  and Clofarabine in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia,platelet count decreased
D006996,3.23,NCT00945815-1,Ara-C + Clofarabine + Epratuzumab,NCT00945815,S0910 Epratuzumab  Cytarabine  and Clofarabine in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia,hypocalcemia
D007008,3.23,NCT00945815-1,Ara-C + Clofarabine + Epratuzumab,NCT00945815,S0910 Epratuzumab  Cytarabine  and Clofarabine in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia,hypokalemia
D007010,3.23,NCT00945815-1,Ara-C + Clofarabine + Epratuzumab,NCT00945815,S0910 Epratuzumab  Cytarabine  and Clofarabine in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia,hyponatremia
D017674,3.23,NCT00945815-1,Ara-C + Clofarabine + Epratuzumab,NCT00945815,S0910 Epratuzumab  Cytarabine  and Clofarabine in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia,hypophosphatemia
D001927,6.45,NCT00945815-1,Ara-C + Clofarabine + Epratuzumab,NCT00945815,S0910 Epratuzumab  Cytarabine  and Clofarabine in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia,encephalopathy
10029205,3.23,NCT00945815-1,Ara-C + Clofarabine + Epratuzumab,NCT00945815,S0910 Epratuzumab  Cytarabine  and Clofarabine in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia,nervous system disorders - other specify
D002546,3.23,NCT00945815-1,Ara-C + Clofarabine + Epratuzumab,NCT00945815,S0910 Epratuzumab  Cytarabine  and Clofarabine in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia,transient ischemic attacks
D058186,3.23,NCT00945815-1,Ara-C + Clofarabine + Epratuzumab,NCT00945815,S0910 Epratuzumab  Cytarabine  and Clofarabine in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia,acute kidney injury
D000860,3.23,NCT00945815-1,Ara-C + Clofarabine + Epratuzumab,NCT00945815,S0910 Epratuzumab  Cytarabine  and Clofarabine in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia,hypoxia
D012131,6.45,NCT00945815-1,Ara-C + Clofarabine + Epratuzumab,NCT00945815,S0910 Epratuzumab  Cytarabine  and Clofarabine in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia,respiratory failure
D007022,3.23,NCT00945815-1,Ara-C + Clofarabine + Epratuzumab,NCT00945815,S0910 Epratuzumab  Cytarabine  and Clofarabine in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia,hypotension
D064420,6.52,NCT00954941-1,Group 1: Ondansetron,NCT00954941,Ondansetron Versus Aprepitant Plus Ondansetron for Emesis,adverse drug events
D064420,6.82,NCT00954941-2,Group 2: Ondansetron + Aprepitant,NCT00954941,Ondansetron Versus Aprepitant Plus Ondansetron for Emesis,adverse drug events
D009325,2.27,NCT00954941-2,Group 2: Ondansetron + Aprepitant,NCT00954941,Ondansetron Versus Aprepitant Plus Ondansetron for Emesis,nausea
D020250,2.17,NCT00954941-1,Group 1: Ondansetron,NCT00954941,Ondansetron Versus Aprepitant Plus Ondansetron for Emesis,postoperative nausea and vomiting
D003643,2.17,NCT00954941-1,Group 1: Ondansetron,NCT00954941,Ondansetron Versus Aprepitant Plus Ondansetron for Emesis,death
D006261,4.55,NCT00954941-2,Group 2: Ondansetron + Aprepitant,NCT00954941,Ondansetron Versus Aprepitant Plus Ondansetron for Emesis,headache
D013575,2.17,NCT00954941-1,Group 1: Ondansetron,NCT00954941,Ondansetron Versus Aprepitant Plus Ondansetron for Emesis,syncope
D009026,25.93,NCT00992446-1,Treatment (Chemotherapy ASCT Bortezomib Vorinostat)),NCT00992446,Bortezomib and Vorinostat as Maintenance Therapy After Autologous Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma,mortality
D064420,33.33,NCT00992446-1,Treatment (Chemotherapy ASCT Bortezomib Vorinostat)),NCT00992446,Bortezomib and Vorinostat as Maintenance Therapy After Autologous Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma,adverse drug events
D064147,7.41,NCT00992446-1,Treatment (Chemotherapy ASCT Bortezomib Vorinostat)),NCT00992446,Bortezomib and Vorinostat as Maintenance Therapy After Autologous Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma,febrile neutropenia
D001281,7.41,NCT00992446-1,Treatment (Chemotherapy ASCT Bortezomib Vorinostat)),NCT00992446,Bortezomib and Vorinostat as Maintenance Therapy After Autologous Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma,atrial fibrillation
D015746,3.7,NCT00992446-1,Treatment (Chemotherapy ASCT Bortezomib Vorinostat)),NCT00992446,Bortezomib and Vorinostat as Maintenance Therapy After Autologous Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma,abdominal pain
D000930,7.41,NCT00992446-1,Treatment (Chemotherapy ASCT Bortezomib Vorinostat)),NCT00992446,Bortezomib and Vorinostat as Maintenance Therapy After Autologous Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma,antidiarrheals
D003092,3.7,NCT00992446-1,Treatment (Chemotherapy ASCT Bortezomib Vorinostat)),NCT00992446,Bortezomib and Vorinostat as Maintenance Therapy After Autologous Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma,colitis
D011014,7.41,NCT00992446-1,Treatment (Chemotherapy ASCT Bortezomib Vorinostat)),NCT00992446,Bortezomib and Vorinostat as Maintenance Therapy After Autologous Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma,pneumonia
D009026,21.05,NCT01035463-1,All Phase I Participants,NCT01035463,Lenalidomide as Maintenance Therapy After Combination Chemotherapy With or Without Rituximab and Stem Cell Transplant in Treating Patients With Persistent or Recurrent Non-Hodgkin Lymphoma That Is Resistant to Chemotherapy,mortality
D009026,17.5,NCT01035463-2,All Phase II Participants,NCT01035463,Lenalidomide as Maintenance Therapy After Combination Chemotherapy With or Without Rituximab and Stem Cell Transplant in Treating Patients With Persistent or Recurrent Non-Hodgkin Lymphoma That Is Resistant to Chemotherapy,mortality
D064420,47.37,NCT01035463-1,All Phase I Participants,NCT01035463,Lenalidomide as Maintenance Therapy After Combination Chemotherapy With or Without Rituximab and Stem Cell Transplant in Treating Patients With Persistent or Recurrent Non-Hodgkin Lymphoma That Is Resistant to Chemotherapy,adverse drug events
D064420,15.0,NCT01035463-2,All Phase II Participants,NCT01035463,Lenalidomide as Maintenance Therapy After Combination Chemotherapy With or Without Rituximab and Stem Cell Transplant in Treating Patients With Persistent or Recurrent Non-Hodgkin Lymphoma That Is Resistant to Chemotherapy,adverse drug events
D064147,5.26,NCT01035463-1,All Phase I Participants,NCT01035463,Lenalidomide as Maintenance Therapy After Combination Chemotherapy With or Without Rituximab and Stem Cell Transplant in Treating Patients With Persistent or Recurrent Non-Hodgkin Lymphoma That Is Resistant to Chemotherapy,febrile neutropenia
D015746,5.26,NCT01035463-1,All Phase I Participants,NCT01035463,Lenalidomide as Maintenance Therapy After Combination Chemotherapy With or Without Rituximab and Stem Cell Transplant in Treating Patients With Persistent or Recurrent Non-Hodgkin Lymphoma That Is Resistant to Chemotherapy,abdominal pain
10038064,5.26,NCT01035463-1,All Phase I Participants,NCT01035463,Lenalidomide as Maintenance Therapy After Combination Chemotherapy With or Without Rituximab and Stem Cell Transplant in Treating Patients With Persistent or Recurrent Non-Hodgkin Lymphoma That Is Resistant to Chemotherapy,rectal hemorrhage
10019805,5.26,NCT01035463-1,All Phase I Participants,NCT01035463,Lenalidomide as Maintenance Therapy After Combination Chemotherapy With or Without Rituximab and Stem Cell Transplant in Treating Patients With Persistent or Recurrent Non-Hodgkin Lymphoma That Is Resistant to Chemotherapy,hepatobiliary disorders - other specify
D005234,5.26,NCT01035463-1,All Phase I Participants,NCT01035463,Lenalidomide as Maintenance Therapy After Combination Chemotherapy With or Without Rituximab and Stem Cell Transplant in Treating Patients With Persistent or Recurrent Non-Hodgkin Lymphoma That Is Resistant to Chemotherapy,steatohepatitis
10055078,5.26,NCT01035463-1,All Phase I Participants,NCT01035463,Lenalidomide as Maintenance Therapy After Combination Chemotherapy With or Without Rituximab and Stem Cell Transplant in Treating Patients With Persistent or Recurrent Non-Hodgkin Lymphoma That Is Resistant to Chemotherapy,bronchial infection
10058838,2.5,NCT01035463-2,All Phase II Participants,NCT01035463,Lenalidomide as Maintenance Therapy After Combination Chemotherapy With or Without Rituximab and Stem Cell Transplant in Treating Patients With Persistent or Recurrent Non-Hodgkin Lymphoma That Is Resistant to Chemotherapy,enterocolitis infectious
10021881,2.5,NCT01035463-2,All Phase II Participants,NCT01035463,Lenalidomide as Maintenance Therapy After Combination Chemotherapy With or Without Rituximab and Stem Cell Transplant in Treating Patients With Persistent or Recurrent Non-Hodgkin Lymphoma That Is Resistant to Chemotherapy,infections and infestations - other specify
10029366,2.5,NCT01035463-2,All Phase II Participants,NCT01035463,Lenalidomide as Maintenance Therapy After Combination Chemotherapy With or Without Rituximab and Stem Cell Transplant in Treating Patients With Persistent or Recurrent Non-Hodgkin Lymphoma That Is Resistant to Chemotherapy,neutrophil count decreased
D003681,5.26,NCT01035463-1,All Phase I Participants,NCT01035463,Lenalidomide as Maintenance Therapy After Combination Chemotherapy With or Without Rituximab and Stem Cell Transplant in Treating Patients With Persistent or Recurrent Non-Hodgkin Lymphoma That Is Resistant to Chemotherapy,dehydration
D002546,2.5,NCT01035463-2,All Phase II Participants,NCT01035463,Lenalidomide as Maintenance Therapy After Combination Chemotherapy With or Without Rituximab and Stem Cell Transplant in Treating Patients With Persistent or Recurrent Non-Hodgkin Lymphoma That Is Resistant to Chemotherapy,transient ischemic attack
10038738,2.5,NCT01035463-2,All Phase II Participants,NCT01035463,Lenalidomide as Maintenance Therapy After Combination Chemotherapy With or Without Rituximab and Stem Cell Transplant in Treating Patients With Persistent or Recurrent Non-Hodgkin Lymphoma That Is Resistant to Chemotherapy,respiratory thoracic and mediastinal disorders - other specify
10040785,5.26,NCT01035463-1,All Phase I Participants,NCT01035463,Lenalidomide as Maintenance Therapy After Combination Chemotherapy With or Without Rituximab and Stem Cell Transplant in Treating Patients With Persistent or Recurrent Non-Hodgkin Lymphoma That Is Resistant to Chemotherapy,skin and subcutaneous tissue disorders - other specify
10040785,2.5,NCT01035463-2,All Phase II Participants,NCT01035463,Lenalidomide as Maintenance Therapy After Combination Chemotherapy With or Without Rituximab and Stem Cell Transplant in Treating Patients With Persistent or Recurrent Non-Hodgkin Lymphoma That Is Resistant to Chemotherapy,skin and subcutaneous tissue disorders - other specify
10042613,5.26,NCT01035463-1,All Phase I Participants,NCT01035463,Lenalidomide as Maintenance Therapy After Combination Chemotherapy With or Without Rituximab and Stem Cell Transplant in Treating Patients With Persistent or Recurrent Non-Hodgkin Lymphoma That Is Resistant to Chemotherapy,surgical and medical procedures - other specify
D009026,100.0,NCT01044966-1,ITV DepoCyt + Temozolomide,NCT01044966,A Study of Intraventricular Liposomal Encapsulated Ara-C (DepoCyt) in Patients With Recurrent Glioblastoma,mortality
D064420,8.33,NCT01044966-1,ITV DepoCyt + Temozolomide,NCT01044966,A Study of Intraventricular Liposomal Encapsulated Ara-C (DepoCyt) in Patients With Recurrent Glioblastoma,adverse drug events
D057867,8.33,NCT01044966-1,ITV DepoCyt + Temozolomide,NCT01044966,A Study of Intraventricular Liposomal Encapsulated Ara-C (DepoCyt) in Patients With Recurrent Glioblastoma,endoleak
D064420,79.66,NCT01074047-1,Azacitidine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),adverse drug events
D064420,75.0,NCT01074047-2,BSC Only,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),adverse drug events
D064420,77.12,NCT01074047-3,Low-dose Cytarabine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),adverse drug events
D064420,64.29,NCT01074047-4,Intensive Chemotherapy,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),adverse drug events
D064420,45.45,NCT01074047-5,Azacitidine-extension,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),adverse drug events
D000380,0.65,NCT01074047-3,Low-dose Cytarabine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),agranulocytosis
D000741,4.24,NCT01074047-1,Azacitidine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),aplastic anaemia
D000741,2.5,NCT01074047-2,BSC Only,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),aplastic anaemia
D000741,7.19,NCT01074047-3,Low-dose Cytarabine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),aplastic anaemia
D000741,4.55,NCT01074047-5,Azacitidine-extension,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),aplastic anaemia
D004211,0.42,NCT01074047-1,Azacitidine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),disseminated intravascular coagulation
D001853,0.85,NCT01074047-1,Azacitidine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),bone marrow
D001853,1.96,NCT01074047-3,Low-dose Cytarabine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),bone marrow
D064147,25.0,NCT01074047-1,Azacitidine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),febrile neutropenia
D064147,30.0,NCT01074047-2,BSC Only,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),febrile neutropenia
D064147,24.84,NCT01074047-3,Low-dose Cytarabine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),febrile neutropenia
D064147,16.67,NCT01074047-4,Intensive Chemotherapy,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),febrile neutropenia
D064147,18.18,NCT01074047-5,Azacitidine-extension,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),febrile neutropenia
D007964,1.69,NCT01074047-1,Azacitidine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),leukocytosis
D007964,0.65,NCT01074047-3,Low-dose Cytarabine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),leukocytosis
D007970,0.42,NCT01074047-1,Azacitidine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),leukopenia
D007970,1.31,NCT01074047-3,Low-dose Cytarabine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),leukopenia
D000072281,0.42,NCT01074047-1,Azacitidine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),lymphadenopathy
D009503,2.12,NCT01074047-1,Azacitidine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),neutropenia
D009503,2.5,NCT01074047-2,BSC Only,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),neutropenia
D009503,1.96,NCT01074047-3,Low-dose Cytarabine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),neutropenia
D009503,2.38,NCT01074047-4,Intensive Chemotherapy,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),neutropenia
D010198,0.65,NCT01074047-3,Low-dose Cytarabine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),pancytopenia
D013921,2.54,NCT01074047-1,Azacitidine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),thrombocytopenia
D013921,9.15,NCT01074047-3,Low-dose Cytarabine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),thrombocytopenia
D011697,0.42,NCT01074047-1,Azacitidine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),thrombotic thrombocytopenic purpura
D054058,0.85,NCT01074047-1,Azacitidine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),acute coronary syndrome
D054058,0.65,NCT01074047-3,Low-dose Cytarabine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),acute coronary syndrome
D016277,0.42,NCT01074047-1,Azacitidine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),ventricular function left
D056988,1.27,NCT01074047-1,Azacitidine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),acute anterior wall myocardial infarction
D056988,2.38,NCT01074047-4,Intensive Chemotherapy,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),acute anterior wall myocardial infarction
D000787,0.65,NCT01074047-3,Low-dose Cytarabine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),angina pectoris
D000787,4.55,NCT01074047-5,Azacitidine-extension,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),angina pectoris
D001281,2.97,NCT01074047-1,Azacitidine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),atrial fibrillation
D001281,2.5,NCT01074047-2,BSC Only,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),atrial fibrillation
D001281,1.96,NCT01074047-3,Low-dose Cytarabine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),atrial fibrillation
D001281,4.76,NCT01074047-4,Intensive Chemotherapy,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),atrial fibrillation
D006323,0.65,NCT01074047-3,Low-dose Cytarabine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),cardiac arrest
D006333,0.85,NCT01074047-1,Azacitidine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),cardiac failure
D006333,0.65,NCT01074047-3,Low-dose Cytarabine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),cardiac failure
D006333,2.38,NCT01074047-4,Intensive Chemotherapy,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),cardiac failure
D006333,2.38,NCT01074047-4,Intensive Chemotherapy,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),cardiac failure
D006333,2.5,NCT01074047-2,BSC Only,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),cardiac failure
D000072599,0.42,NCT01074047-1,Azacitidine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),cardiorespiratory fitness
D057895,0.42,NCT01074047-1,Azacitidine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),haploinsufficiency
D057895,1.31,NCT01074047-3,Low-dose Cytarabine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),haploinsufficiency
D057895,2.38,NCT01074047-4,Intensive Chemotherapy,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),haploinsufficiency
D009202,0.42,NCT01074047-1,Azacitidine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),cardiomyopathy
D016277,0.42,NCT01074047-1,Azacitidine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),ventricular function left
D009203,0.65,NCT01074047-3,Low-dose Cytarabine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),myocardial infarction
D009203,4.55,NCT01074047-5,Azacitidine-extension,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),myocardial infarction
D010490,0.42,NCT01074047-1,Azacitidine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),pericardial effusion
D010490,2.38,NCT01074047-4,Intensive Chemotherapy,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),pericardial effusion
D010493,0.42,NCT01074047-1,Azacitidine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),pericarditis
D010493,0.65,NCT01074047-3,Low-dose Cytarabine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),pericarditis
D013617,0.65,NCT01074047-3,Low-dose Cytarabine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),supraventricular tachycardia
D017180,0.42,NCT01074047-1,Azacitidine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),ventricular tachycardia
D002386,0.42,NCT01074047-1,Azacitidine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),cataract
D003229,0.42,NCT01074047-1,Azacitidine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),conjunctival diseases
D015746,0.42,NCT01074047-1,Azacitidine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),abdominal pain
D015746,0.65,NCT01074047-3,Low-dose Cytarabine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),abdominal pain
D015746,4.55,NCT01074047-5,Azacitidine-extension,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),abdominal pain
D015746,1.31,NCT01074047-3,Low-dose Cytarabine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),abdominal pain
D000069282,2.5,NCT01074047-2,BSC Only,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),canaliculitis
D000069282,0.65,NCT01074047-3,Low-dose Cytarabine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),canaliculitis
D001201,2.38,NCT01074047-4,Intensive Chemotherapy,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),ascites
D003092,0.42,NCT01074047-1,Azacitidine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),colitis
D003248,4.55,NCT01074047-5,Azacitidine-extension,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),constipation
UNKNOWN-check-for-typo,1.69,NCT01074047-1,Azacitidine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),D00
UNKNOWN-check-for-typo,2.61,NCT01074047-3,Low-dose Cytarabine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),D00
D004240,0.42,NCT01074047-1,Azacitidine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),diverticulum
D004381,4.55,NCT01074047-5,Azacitidine-extension,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),duodenal ulcer
D003680,0.65,NCT01074047-3,Low-dose Cytarabine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),dysphagia
D004751,2.5,NCT01074047-2,BSC Only,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),enteritis
D004760,0.42,NCT01074047-1,Azacitidine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),enterocolitis
D005756,0.42,NCT01074047-1,Azacitidine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),gastritis
D000069196,0.42,NCT01074047-1,Azacitidine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),gastrointestinal microbiome
D000069196,2.5,NCT01074047-2,BSC Only,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),gastrointestinal microbiome
D000069196,2.61,NCT01074047-3,Low-dose Cytarabine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),gastrointestinal microbiome
UNKNOWN-check-for-typo,0.42,NCT01074047-1,Azacitidine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),D00
D045823,0.42,NCT01074047-1,Azacitidine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),ileus
D000069196,4.55,NCT01074047-5,Azacitidine-extension,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),gastrointestinal microbiome
D007415,0.42,NCT01074047-1,Azacitidine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),intestinal obstruction
D050686,0.42,NCT01074047-1,Azacitidine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),globicephala melaena
D050686,0.65,NCT01074047-3,Low-dose Cytarabine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),globicephala melaena
D009055,0.42,NCT01074047-1,Azacitidine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),mouth
D009055,2.5,NCT01074047-2,BSC Only,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),mouth
D009325,0.85,NCT01074047-1,Azacitidine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),nausea
D000071056,0.42,NCT01074047-1,Azacitidine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),anorectal malformations
D000071056,0.65,NCT01074047-3,Low-dose Cytarabine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),anorectal malformations
10038080,0.42,NCT01074047-1,Azacitidine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),rectal ulcer
D013280,0.42,NCT01074047-1,Azacitidine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),stomatitis
D013280,4.55,NCT01074047-5,Azacitidine-extension,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),stomatitis
D041742,0.42,NCT01074047-1,Azacitidine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),upper gastrointestinal tract
D014839,0.85,NCT01074047-1,Azacitidine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),vomiting
D001247,1.69,NCT01074047-1,Azacitidine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),asthenia
D001247,2.5,NCT01074047-2,BSC Only,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),asthenia
D001247,1.96,NCT01074047-3,Low-dose Cytarabine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),asthenia
D002637,1.31,NCT01074047-3,Low-dose Cytarabine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),chest pain
D002637,2.38,NCT01074047-4,Intensive Chemotherapy,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),chest pain
D023341,0.42,NCT01074047-1,Azacitidine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),chills
D023341,0.65,NCT01074047-3,Low-dose Cytarabine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),chills
D003643,1.27,NCT01074047-1,Azacitidine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),death
D003643,1.31,NCT01074047-3,Low-dose Cytarabine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),death
D005221,1.27,NCT01074047-1,Azacitidine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),fatigue
D005221,0.65,NCT01074047-3,Low-dose Cytarabine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),fatigue
D005221,2.38,NCT01074047-4,Intensive Chemotherapy,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),fatigue
D003695,0.42,NCT01074047-1,Azacitidine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),healthcare
D003695,0.65,NCT01074047-3,Low-dose Cytarabine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),healthcare
D005334,0.42,NCT01074047-1,Azacitidine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),hyperthermia
D000075662,0.42,NCT01074047-1,Azacitidine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),injection site reaction
D000075662,0.85,NCT01074047-1,Azacitidine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),injection site reaction
10025482,0.42,NCT01074047-1,Azacitidine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),malaise
D009102,0.42,NCT01074047-1,Azacitidine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),multiple organ failure
D009102,1.31,NCT01074047-3,Low-dose Cytarabine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),multiple organ failure
D000799,2.5,NCT01074047-2,BSC Only,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),angioedema
D010146,0.42,NCT01074047-1,Azacitidine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),pain
D010146,0.65,NCT01074047-3,Low-dose Cytarabine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),pain
D005334,10.59,NCT01074047-1,Azacitidine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),pyrexia
D005334,7.5,NCT01074047-2,BSC Only,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),pyrexia
D005334,10.46,NCT01074047-3,Low-dose Cytarabine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),pyrexia
D005334,4.76,NCT01074047-4,Intensive Chemotherapy,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),pyrexia
D016757,0.42,NCT01074047-1,Azacitidine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),sudden cardiac death
D016757,0.65,NCT01074047-3,Low-dose Cytarabine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),sudden cardiac death
D003645,0.85,NCT01074047-1,Azacitidine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),sudden death
D002761,0.42,NCT01074047-1,Azacitidine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),cholangitis
D002764,0.42,NCT01074047-1,Azacitidine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),cholecystitis
D041881,0.42,NCT01074047-1,Azacitidine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),acute cholecystitis
D041881,0.65,NCT01074047-3,Low-dose Cytarabine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),acute cholecystitis
D041881,2.38,NCT01074047-4,Intensive Chemotherapy,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),acute cholecystitis
D002769,0.42,NCT01074047-1,Azacitidine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),cholelithiasis
D017093,1.31,NCT01074047-3,Low-dose Cytarabine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),hepatic failure
UNKNOWN-check-for-typo,4.55,NCT01074047-5,Azacitidine-extension,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),D00
D000707,0.42,NCT01074047-1,Azacitidine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),anaphylactic shock
D000038,0.42,NCT01074047-1,Azacitidine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),abscess
D012509,0.42,NCT01074047-1,Azacitidine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),sarcoma soft tissue
D012852,0.42,NCT01074047-1,Azacitidine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),sinusitis
D000069544,0.65,NCT01074047-3,Low-dose Cytarabine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),encephalitis infection
D000038,0.42,NCT01074047-1,Azacitidine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),abscess
D001064,0.42,NCT01074047-1,Azacitidine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),appendicitis
D001168,0.42,NCT01074047-1,Azacitidine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),arthritis
D001228,2.5,NCT01074047-2,BSC Only,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),aspergillus infection
UNKNOWN-check-for-typo,0.85,NCT01074047-1,Azacitidine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),D00
UNKNOWN-check-for-typo,0.65,NCT01074047-3,Low-dose Cytarabine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),D00
UNKNOWN-check-for-typo,4.55,NCT01074047-5,Azacitidine-extension,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),D00
D001991,1.27,NCT01074047-1,Azacitidine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),bronchitis
D001991,0.65,NCT01074047-3,Low-dose Cytarabine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),bronchitis
D001996,1.69,NCT01074047-1,Azacitidine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),bronchopneumonia
D001996,2.5,NCT01074047-2,BSC Only,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),bronchopneumonia
D001996,0.65,NCT01074047-3,Low-dose Cytarabine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),bronchopneumonia
D055732,1.27,NCT01074047-1,Azacitidine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),bronchopulmonary aspergillosis
D055732,2.5,NCT01074047-2,BSC Only,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),bronchopulmonary aspergillosis
D055732,4.55,NCT01074047-5,Azacitidine-extension,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),bronchopulmonary aspergillosis
D000069544,0.65,NCT01074047-3,Low-dose Cytarabine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),encephalitis infection
D002481,2.12,NCT01074047-1,Azacitidine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),cellulitis
D002481,10.0,NCT01074047-2,BSC Only,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),cellulitis
D002481,1.96,NCT01074047-3,Low-dose Cytarabine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),cellulitis
D002481,2.38,NCT01074047-4,Intensive Chemotherapy,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),cellulitis
D054517,0.42,NCT01074047-1,Azacitidine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),orbital cellulitis
D004761,0.85,NCT01074047-1,Azacitidine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),clostridium enterocolitis
D004761,0.65,NCT01074047-3,Low-dose Cytarabine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),clostridium enterocolitis
D003015,0.42,NCT01074047-1,Azacitidine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),clostridium difficile infection
D003015,0.65,NCT01074047-3,Low-dose Cytarabine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),clostridium difficile infection
D000985,0.42,NCT01074047-1,Azacitidine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),antisepsis
D003556,0.65,NCT01074047-3,Low-dose Cytarabine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),cystitis
10064687,0.65,NCT01074047-3,Low-dose Cytarabine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),device related infection
10064687,0.85,NCT01074047-1,Azacitidine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),device related infection
D004238,1.69,NCT01074047-1,Azacitidine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),diverticulitis
D001996,0.42,NCT01074047-1,Azacitidine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),bronchopneumonia
UNKNOWN-check-for-typo,2.5,NCT01074047-2,BSC Only,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),D00
UNKNOWN-check-for-typo,0.65,NCT01074047-3,Low-dose Cytarabine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),D00
D000985,0.42,NCT01074047-1,Azacitidine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),antisepsis
D004826,0.42,NCT01074047-1,Azacitidine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),epiglottitis
D004886,0.42,NCT01074047-1,Azacitidine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),erysipelas
D004925,1.27,NCT01074047-1,Azacitidine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),escherichia
D004925,0.65,NCT01074047-3,Low-dose Cytarabine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),escherichia
D004927,0.42,NCT01074047-1,Azacitidine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),escherichia coli infections
D000985,1.69,NCT01074047-1,Azacitidine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),antisepsis
D005667,0.42,NCT01074047-1,Azacitidine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),furuncles
D005759,0.42,NCT01074047-1,Azacitidine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),gastroenteritis
D005759,0.65,NCT01074047-3,Low-dose Cytarabine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),gastroenteritis
D000068016,0.42,NCT01074047-1,Azacitidine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),clostridiales
D009181,0.65,NCT01074047-3,Low-dose Cytarabine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),fungal infections
D000038,0.42,NCT01074047-1,Azacitidine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),abscess
D006562,0.42,NCT01074047-1,Azacitidine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),herpes zoster
D000070621,0.42,NCT01074047-1,Azacitidine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),cystography
D007239,0.65,NCT01074047-3,Low-dose Cytarabine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),infection
D007239,4.55,NCT01074047-5,Azacitidine-extension,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),infection
D029424,0.65,NCT01074047-3,Low-dose Cytarabine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),pulmonary disease chronic obstructive
D007709,0.65,NCT01074047-3,Low-dose Cytarabine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),klebsiella
D000985,0.42,NCT01074047-1,Azacitidine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),antisepsis
D008100,4.55,NCT01074047-5,Azacitidine-extension,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),liver abscess
D011014,0.85,NCT01074047-1,Azacitidine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),lobar pneumonia
D011014,1.31,NCT01074047-3,Low-dose Cytarabine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),lobar pneumonia
D012141,0.42,NCT01074047-1,Azacitidine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),respiratory tract infections
D012141,2.5,NCT01074047-2,BSC Only,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),respiratory tract infections
D012141,0.65,NCT01074047-3,Low-dose Cytarabine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),respiratory tract infections
D008169,0.42,NCT01074047-1,Azacitidine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),lung abscess
10061229,0.85,NCT01074047-1,Azacitidine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),lung infection
10061229,0.65,NCT01074047-3,Low-dose Cytarabine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),lung infection
D009107,0.42,NCT01074047-1,Azacitidine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),mumps
D009304,0.42,NCT01074047-1,Azacitidine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),nasopharyngitis
D000985,2.97,NCT01074047-1,Azacitidine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),antisepsis
D000985,5.0,NCT01074047-2,BSC Only,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),antisepsis
D000985,2.61,NCT01074047-3,Low-dose Cytarabine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),antisepsis
D000985,2.38,NCT01074047-4,Intensive Chemotherapy,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),antisepsis
D002180,0.42,NCT01074047-1,Azacitidine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),oral candidiasis
D000067148,2.38,NCT01074047-4,Intensive Chemotherapy,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),fungal viruses
D000257,0.42,NCT01074047-1,Azacitidine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),adenovirus infections
D002481,2.5,NCT01074047-2,BSC Only,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),cellulitis
D000038,0.42,NCT01074047-1,Azacitidine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),abscess
D010538,0.65,NCT01074047-3,Low-dose Cytarabine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),peritonitis
D010612,0.85,NCT01074047-1,Azacitidine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),pharyngitis
D010612,1.31,NCT01074047-3,Low-dose Cytarabine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),pharyngitis
UNKNOWN-check-for-typo,0.42,NCT01074047-1,Azacitidine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),D00
D011014,20.34,NCT01074047-1,Azacitidine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),pneumonia
D011014,7.5,NCT01074047-2,BSC Only,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),pneumonia
D011014,18.95,NCT01074047-3,Low-dose Cytarabine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),pneumonia
D011014,7.14,NCT01074047-4,Intensive Chemotherapy,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),pneumonia
D011014,9.09,NCT01074047-5,Azacitidine-extension,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),pneumonia
D001996,1.27,NCT01074047-1,Azacitidine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),bronchopneumonia
D001996,0.65,NCT01074047-3,Low-dose Cytarabine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),bronchopneumonia
D007711,0.65,NCT01074047-3,Low-dose Cytarabine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),klebsiella pneumoniae
D045729,0.42,NCT01074047-1,Azacitidine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),pneumonia of swine mycoplasmal
D011024,0.42,NCT01074047-1,Azacitidine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),pneumonia viral
D011550,0.42,NCT01074047-1,Azacitidine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),pseudomonas aeruginosa
D011023,0.65,NCT01074047-3,Low-dose Cytarabine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),staphylococcal pneumonia
D001996,2.38,NCT01074047-4,Intensive Chemotherapy,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),bronchopneumonia
D004761,1.27,NCT01074047-1,Azacitidine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),pseudomembranous colitis
D004761,0.65,NCT01074047-3,Low-dose Cytarabine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),pseudomembranous colitis
UNKNOWN-check-for-typo,0.65,NCT01074047-3,Low-dose Cytarabine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),D00
UNKNOWN-check-for-typo,4.55,NCT01074047-5,Azacitidine-extension,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),D00
D000985,1.27,NCT01074047-1,Azacitidine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),antisepsis
D000985,1.31,NCT01074047-3,Low-dose Cytarabine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),antisepsis
D012141,5.0,NCT01074047-2,BSC Only,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),respiratory tract infection
D012141,1.31,NCT01074047-3,Low-dose Cytarabine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),respiratory tract infection
D018805,5.08,NCT01074047-1,Azacitidine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),sepsis
D018805,2.5,NCT01074047-2,BSC Only,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),sepsis
D018805,5.88,NCT01074047-3,Low-dose Cytarabine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),sepsis
D018805,4.76,NCT01074047-4,Intensive Chemotherapy,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),sepsis
D012772,1.69,NCT01074047-1,Azacitidine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),septic shock
D012772,2.5,NCT01074047-2,BSC Only,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),septic shock
D012772,2.61,NCT01074047-3,Low-dose Cytarabine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),septic shock
D012772,9.52,NCT01074047-4,Intensive Chemotherapy,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),septic shock
D012852,1.27,NCT01074047-1,Azacitidine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),sinusitis
D012852,4.55,NCT01074047-5,Azacitidine-extension,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),sinusitis
D012852,2.38,NCT01074047-4,Intensive Chemotherapy,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),sinusitis
D018461,0.42,NCT01074047-1,Azacitidine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),soft tissue infection
D004768,0.42,NCT01074047-1,Azacitidine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),staphylococcal enterotoxins
D004768,2.38,NCT01074047-4,Intensive Chemotherapy,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),staphylococcal enterotoxins
D000985,2.38,NCT01074047-4,Intensive Chemotherapy,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),antisepsis
D002175,4.55,NCT01074047-5,Azacitidine-extension,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),candida
D014069,1.31,NCT01074047-3,Low-dose Cytarabine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),tonsillitis
10048762,0.85,NCT01074047-1,Azacitidine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),tooth infection
D012141,0.85,NCT01074047-1,Azacitidine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),upper respiratory tract infections
D014552,2.97,NCT01074047-1,Azacitidine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),urinary tract infection
D014552,2.5,NCT01074047-2,BSC Only,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),urinary tract infection
D014552,1.96,NCT01074047-3,Low-dose Cytarabine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),urinary tract infection
10040047,0.85,NCT01074047-1,Azacitidine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),sepsis
D014627,0.65,NCT01074047-3,Low-dose Cytarabine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),vaginitis
D000038,0.42,NCT01074047-1,Azacitidine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),abscess
D020096,2.38,NCT01074047-4,Intensive Chemotherapy,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),zygomycosis
D065227,0.65,NCT01074047-3,Low-dose Cytarabine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),transfusion-associated allergic reaction
D064386,0.42,NCT01074047-1,Azacitidine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),ankle fracture
D001924,0.42,NCT01074047-1,Azacitidine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),brain concussion
D006259,0.42,NCT01074047-1,Azacitidine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),craniocerebral injury
10016173,0.85,NCT01074047-1,Azacitidine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),fall
D005265,0.42,NCT01074047-1,Azacitidine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),femur neck fractures
D005265,0.65,NCT01074047-3,Low-dose Cytarabine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),femur neck fractures
10020100,0.65,NCT01074047-3,Low-dose Cytarabine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),hip fracture
D008022,0.42,NCT01074047-1,Azacitidine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),ligaments
D012253,0.42,NCT01074047-1,Azacitidine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),rib fracture
D000063,0.42,NCT01074047-1,Azacitidine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),accidents traffic
D006408,0.42,NCT01074047-1,Azacitidine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),hematoma subdural
D012421,0.42,NCT01074047-1,Azacitidine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),rupture
D065227,0.42,NCT01074047-1,Azacitidine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),transfusion reaction
10007612,2.38,NCT01074047-4,Intensive Chemotherapy,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),cardiac troponin i increased
10059895,2.5,NCT01074047-2,BSC Only,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),urine output decreased
D013851,0.65,NCT01074047-3,Low-dose Cytarabine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),underweight
D002100,0.42,NCT01074047-1,Azacitidine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),cachexia
D002100,1.31,NCT01074047-3,Low-dose Cytarabine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),cachexia
D001066,4.55,NCT01074047-5,Azacitidine-extension,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),appetite
D003681,1.27,NCT01074047-1,Azacitidine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),dehydration
D005183,0.65,NCT01074047-3,Low-dose Cytarabine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),failure to thrive
D011205,0.42,NCT01074047-1,Azacitidine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),unifluid
UNKNOWN-check-for-typo,2.5,NCT01074047-2,BSC Only,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),D00
UNKNOWN-check-for-typo,0.85,NCT01074047-1,Azacitidine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),D00
UNKNOWN-check-for-typo,0.85,NCT01074047-1,Azacitidine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),D00
D015275,0.65,NCT01074047-3,Low-dose Cytarabine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),tumour lysis syndrome
D018771,0.85,NCT01074047-1,Azacitidine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),arthralgia
D001168,0.42,NCT01074047-1,Azacitidine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),arthritis
D001416,1.27,NCT01074047-1,Azacitidine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),back pain
D001416,0.65,NCT01074047-3,Low-dose Cytarabine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),back pain
10006002,0.42,NCT01074047-1,Azacitidine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),bone pain
UNKNOWN-check-for-typo,0.65,NCT01074047-3,Low-dose Cytarabine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),D00
D018908,0.85,NCT01074047-1,Azacitidine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),muscular weakness
D063806,0.42,NCT01074047-1,Azacitidine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),myalgia
D010003,4.55,NCT01074047-5,Azacitidine-extension,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),osteoarthritis
10033425,2.5,NCT01074047-2,BSC Only,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),pain in extremity
D055013,0.65,NCT01074047-3,Low-dose Cytarabine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),spinal osteoarthritis
D015470,11.02,NCT01074047-1,Azacitidine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),leukemia myeloid acute
D015470,30.0,NCT01074047-2,BSC Only,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),leukemia myeloid acute
D015470,11.11,NCT01074047-3,Low-dose Cytarabine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),leukemia myeloid acute
D015470,4.55,NCT01074047-5,Azacitidine-extension,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),leukemia myeloid acute
D023981,0.85,NCT01074047-1,Azacitidine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),chloroma
D001621,0.65,NCT01074047-3,Low-dose Cytarabine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),ribrain
D010051,0.42,NCT01074047-1,Azacitidine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),ovarian cancer
D000067251,0.42,NCT01074047-1,Azacitidine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),symptom flareup
D000074042,0.42,NCT01074047-1,Azacitidine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),cerebral intraventricular haemorrhage
D000074042,5.0,NCT01074047-2,BSC Only,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),cerebral intraventricular haemorrhage
D000074042,2.38,NCT01074047-4,Intensive Chemotherapy,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),cerebral intraventricular haemorrhage
D002544,0.85,NCT01074047-1,Azacitidine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),cerebral infarction
D002544,4.55,NCT01074047-5,Azacitidine-extension,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),cerebral infarction
D020521,0.42,NCT01074047-1,Azacitidine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),cerebrovascular accident
D020521,1.31,NCT01074047-3,Low-dose Cytarabine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),cerebrovascular accident
D008569,0.42,NCT01074047-1,Azacitidine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),retention disorders cognitive
D012640,0.42,NCT01074047-1,Azacitidine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),convulsion
D004244,2.12,NCT01074047-1,Azacitidine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),dizziness
D004244,4.55,NCT01074047-5,Azacitidine-extension,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),dizziness
D003294,2.5,NCT01074047-2,BSC Only,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),febrile convulsion
D000069280,0.85,NCT01074047-1,Azacitidine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),intracranial electroencephalography
D000069280,2.38,NCT01074047-4,Intensive Chemotherapy,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),intracranial electroencephalography
D006261,0.42,NCT01074047-1,Azacitidine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),headache
D014474,0.42,NCT01074047-1,Azacitidine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),loss of consciousness
D054971,0.42,NCT01074047-1,Azacitidine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),orthostatic intolerance
D013575,0.85,NCT01074047-1,Azacitidine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),presyncope
D013575,2.5,NCT01074047-2,BSC Only,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),presyncope
D007427,0.85,NCT01074047-1,Azacitidine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),subarachnoid pressure
D013575,1.69,NCT01074047-1,Azacitidine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),syncope
D013575,1.31,NCT01074047-3,Low-dose Cytarabine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),syncope
D013575,2.38,NCT01074047-4,Intensive Chemotherapy,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),syncope
D013575,4.55,NCT01074047-5,Azacitidine-extension,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),syncope
D002546,0.65,NCT01074047-3,Low-dose Cytarabine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),ischemic attack transient
D003221,0.42,NCT01074047-1,Azacitidine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),confusional state
D000400,0.42,NCT01074047-1,Azacitidine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),swimbladder
UNKNOWN-check-for-typo,2.5,NCT01074047-2,BSC Only,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),D00
UNKNOWN-check-for-typo,4.55,NCT01074047-5,Azacitidine-extension,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),D00
D056844,0.65,NCT01074047-3,Low-dose Cytarabine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),renal colic
D051437,1.27,NCT01074047-1,Azacitidine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),renal failure
D051437,1.31,NCT01074047-3,Low-dose Cytarabine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),renal failure
D058186,1.27,NCT01074047-1,Azacitidine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),acute renal failure
D058186,1.31,NCT01074047-3,Low-dose Cytarabine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),acute renal failure
D058186,2.38,NCT01074047-4,Intensive Chemotherapy,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),acute renal failure
D007676,2.5,NCT01074047-2,BSC Only,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),renal failure chronic
D000308,2.5,NCT01074047-2,BSC Only,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),hyperadrenalism
D000141,0.42,NCT01074047-1,Azacitidine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),acidosis renal tubular
D016055,0.65,NCT01074047-3,Low-dose Cytarabine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),urinary retention
D000799,0.42,NCT01074047-1,Azacitidine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),angioedema
D000799,0.65,NCT01074047-3,Low-dose Cytarabine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),angioedema
D012128,0.42,NCT01074047-1,Azacitidine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),acute respiratory distress syndrome
D012128,2.38,NCT01074047-4,Intensive Chemotherapy,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),acute respiratory distress syndrome
D012131,0.85,NCT01074047-1,Azacitidine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),respiratory failure
D012131,2.38,NCT01074047-4,Intensive Chemotherapy,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),respiratory failure
D001249,2.5,NCT01074047-2,BSC Only,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),asthma
D029424,0.65,NCT01074047-3,Low-dose Cytarabine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),chronic obstructive pulmonary disease
UNKNOWN-check-for-typo,2.12,NCT01074047-1,Azacitidine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),D00
UNKNOWN-check-for-typo,2.5,NCT01074047-2,BSC Only,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),D00
UNKNOWN-check-for-typo,1.96,NCT01074047-3,Low-dose Cytarabine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),D00
UNKNOWN-check-for-typo,2.38,NCT01074047-4,Intensive Chemotherapy,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),D00
D004844,0.85,NCT01074047-1,Azacitidine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),epistaxis
D004844,0.65,NCT01074047-3,Low-dose Cytarabine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),epistaxis
D008168,0.42,NCT01074047-1,Azacitidine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),lung
D008168,1.31,NCT01074047-3,Low-dose Cytarabine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),lung
D001996,0.42,NCT01074047-1,Azacitidine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),bronchopneumonia
10068319,0.42,NCT01074047-1,Azacitidine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),oropharyngeal pain
D010996,0.85,NCT01074047-1,Azacitidine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),pleural effusion
D010996,1.31,NCT01074047-3,Low-dose Cytarabine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),pleural effusion
D010996,2.38,NCT01074047-4,Intensive Chemotherapy,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),pleural effusion
D011015,2.5,NCT01074047-2,BSC Only,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),aspiration pneumonia
D011014,0.42,NCT01074047-1,Azacitidine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),pneumonitis
D011014,0.65,NCT01074047-3,Low-dose Cytarabine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),pneumonitis
10036790,0.42,NCT01074047-1,Azacitidine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),productive cough
D011649,0.42,NCT01074047-1,Azacitidine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),pulmonary alveolar proteinosis
D011655,0.42,NCT01074047-1,Azacitidine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),pulmonary embolism
D011655,0.65,NCT01074047-3,Low-dose Cytarabine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),pulmonary embolism
D001261,2.5,NCT01074047-2,BSC Only,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),pulmonary atelectasis
D001261,0.65,NCT01074047-3,Low-dose Cytarabine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),pulmonary atelectasis
D000799,0.85,NCT01074047-1,Azacitidine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),angioedema
D000799,1.31,NCT01074047-3,Low-dose Cytarabine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),angioedema
D012131,1.27,NCT01074047-1,Azacitidine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),respiratory failure
D012131,2.5,NCT01074047-2,BSC Only,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),respiratory failure
D012131,3.92,NCT01074047-3,Low-dose Cytarabine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),respiratory failure
D012131,4.76,NCT01074047-4,Intensive Chemotherapy,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),respiratory failure
D012883,0.42,NCT01074047-1,Azacitidine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),skin ulcer
D020246,0.85,NCT01074047-1,Azacitidine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),deep vein thrombosis
D020246,2.5,NCT01074047-2,BSC Only,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),deep vein thrombosis
UNKNOWN-check-for-typo,0.85,NCT01074047-1,Azacitidine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),D00
D006973,0.42,NCT01074047-1,Azacitidine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),hypertension
D007022,1.69,NCT01074047-1,Azacitidine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),hypotension
D007022,2.5,NCT01074047-2,BSC Only,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),hypotension
D002406,0.42,NCT01074047-1,Azacitidine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),catheterization peripheral
D010689,0.42,NCT01074047-1,Azacitidine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),phlebitis
10042554,0.42,NCT01074047-1,Azacitidine,NCT01074047,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),superficial thrombophlebitis
D064420,15.0,NCT01141712-1,Autologous Transplant,NCT01141712,Autologous Transplant in HIV Patients (BMT CTN 0803),adverse drug events
D064147,2.5,NCT01141712-1,Autologous Transplant,NCT01141712,Autologous Transplant in HIV Patients (BMT CTN 0803),febrile neutropenia
D000787,2.5,NCT01141712-1,Autologous Transplant,NCT01141712,Autologous Transplant in HIV Patients (BMT CTN 0803),angina pectoris
UNKNOWN-check-for-typo,2.5,NCT01141712-1,Autologous Transplant,NCT01141712,Autologous Transplant in HIV Patients (BMT CTN 0803),D00
D012772,2.5,NCT01141712-1,Autologous Transplant,NCT01141712,Autologous Transplant in HIV Patients (BMT CTN 0803),septic shock
D020246,5.0,NCT01141712-1,Autologous Transplant,NCT01141712,Autologous Transplant in HIV Patients (BMT CTN 0803),deep vein thrombosis
D064420,50.0,NCT01158885-1,Single Arm,NCT01158885,Clofarabine With Cytarabine for Patients With Minimal Residual Disease Positive Leukemia,adverse drug events
D064147,50.0,NCT01158885-1,Single Arm,NCT01158885,Clofarabine With Cytarabine for Patients With Minimal Residual Disease Positive Leukemia,febrile neutropenia
10035528,50.0,NCT01158885-1,Single Arm,NCT01158885,Clofarabine With Cytarabine for Patients With Minimal Residual Disease Positive Leukemia,platelet count decreased
D000069544,50.0,NCT01158885-1,Single Arm,NCT01158885,Clofarabine With Cytarabine for Patients With Minimal Residual Disease Positive Leukemia,encephalitis infection
D064420,46.49,NCT01349972-1,Arm I (Alvocidib Cytarabine Mitoxantrone Hydrochloride),NCT01349972,Alvocidib  Cytarabine  and Mitoxantrone Hydrochloride or Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,adverse drug events
D064420,36.21,NCT01349972-2,Arm II (Cytarabine Daunorubicin Hydrochloride),NCT01349972,Alvocidib  Cytarabine  and Mitoxantrone Hydrochloride or Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,adverse drug events
10048580,0.88,NCT01349972-1,Arm I (Alvocidib Cytarabine Mitoxantrone Hydrochloride),NCT01349972,Alvocidib  Cytarabine  and Mitoxantrone Hydrochloride or Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,bone marrow hypocellular
D004211,1.75,NCT01349972-1,Arm I (Alvocidib Cytarabine Mitoxantrone Hydrochloride),NCT01349972,Alvocidib  Cytarabine  and Mitoxantrone Hydrochloride or Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,disseminated intravascular coagulation
D004211,1.72,NCT01349972-2,Arm II (Cytarabine Daunorubicin Hydrochloride),NCT01349972,Alvocidib  Cytarabine  and Mitoxantrone Hydrochloride or Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,disseminated intravascular coagulation
D064147,0.88,NCT01349972-1,Arm I (Alvocidib Cytarabine Mitoxantrone Hydrochloride),NCT01349972,Alvocidib  Cytarabine  and Mitoxantrone Hydrochloride or Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,febrile neutropenia
D001281,0.88,NCT01349972-1,Arm I (Alvocidib Cytarabine Mitoxantrone Hydrochloride),NCT01349972,Alvocidib  Cytarabine  and Mitoxantrone Hydrochloride or Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,atrial fibrillation
D001281,3.45,NCT01349972-2,Arm II (Cytarabine Daunorubicin Hydrochloride),NCT01349972,Alvocidib  Cytarabine  and Mitoxantrone Hydrochloride or Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,atrial fibrillation
10008481,0.88,NCT01349972-1,Arm I (Alvocidib Cytarabine Mitoxantrone Hydrochloride),NCT01349972,Alvocidib  Cytarabine  and Mitoxantrone Hydrochloride or Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,chest pain - cardiac
D006333,1.75,NCT01349972-1,Arm I (Alvocidib Cytarabine Mitoxantrone Hydrochloride),NCT01349972,Alvocidib  Cytarabine  and Mitoxantrone Hydrochloride or Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,heart failure
10069501,4.39,NCT01349972-1,Arm I (Alvocidib Cytarabine Mitoxantrone Hydrochloride),NCT01349972,Alvocidib  Cytarabine  and Mitoxantrone Hydrochloride or Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,left ventricular systolic dysfunction
D009203,1.75,NCT01349972-1,Arm I (Alvocidib Cytarabine Mitoxantrone Hydrochloride),NCT01349972,Alvocidib  Cytarabine  and Mitoxantrone Hydrochloride or Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,myocardial infarction
D010490,0.88,NCT01349972-1,Arm I (Alvocidib Cytarabine Mitoxantrone Hydrochloride),NCT01349972,Alvocidib  Cytarabine  and Mitoxantrone Hydrochloride or Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,pericardial effusion
D010493,0.88,NCT01349972-1,Arm I (Alvocidib Cytarabine Mitoxantrone Hydrochloride),NCT01349972,Alvocidib  Cytarabine  and Mitoxantrone Hydrochloride or Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,pericarditis
D010493,1.72,NCT01349972-2,Arm II (Cytarabine Daunorubicin Hydrochloride),NCT01349972,Alvocidib  Cytarabine  and Mitoxantrone Hydrochloride or Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,pericarditis
D013971,0.88,NCT01349972-1,Arm I (Alvocidib Cytarabine Mitoxantrone Hydrochloride),NCT01349972,Alvocidib  Cytarabine  and Mitoxantrone Hydrochloride or Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,thyrotoxicosis
10021305,0.88,NCT01349972-1,Arm I (Alvocidib Cytarabine Mitoxantrone Hydrochloride),NCT01349972,Alvocidib  Cytarabine  and Mitoxantrone Hydrochloride or Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,ileal perforation
10065704,0.88,NCT01349972-1,Arm I (Alvocidib Cytarabine Mitoxantrone Hydrochloride),NCT01349972,Alvocidib  Cytarabine  and Mitoxantrone Hydrochloride or Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,peritoneal necrosis
10041101,0.88,NCT01349972-1,Arm I (Alvocidib Cytarabine Mitoxantrone Hydrochloride),NCT01349972,Alvocidib  Cytarabine  and Mitoxantrone Hydrochloride or Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,small intestinal obstruction
D000069196,0.88,NCT01349972-1,Arm I (Alvocidib Cytarabine Mitoxantrone Hydrochloride),NCT01349972,Alvocidib  Cytarabine  and Mitoxantrone Hydrochloride or Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,gastrointestinal microbiome
D000069196,1.72,NCT01349972-2,Arm II (Cytarabine Daunorubicin Hydrochloride),NCT01349972,Alvocidib  Cytarabine  and Mitoxantrone Hydrochloride or Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,gastrointestinal microbiome
D003643,0.88,NCT01349972-1,Arm I (Alvocidib Cytarabine Mitoxantrone Hydrochloride),NCT01349972,Alvocidib  Cytarabine  and Mitoxantrone Hydrochloride or Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,death
D005334,1.75,NCT01349972-1,Arm I (Alvocidib Cytarabine Mitoxantrone Hydrochloride),NCT01349972,Alvocidib  Cytarabine  and Mitoxantrone Hydrochloride or Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,fever
D000080424,2.63,NCT01349972-1,Arm I (Alvocidib Cytarabine Mitoxantrone Hydrochloride),NCT01349972,Alvocidib  Cytarabine  and Mitoxantrone Hydrochloride or Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,cytokine release syndrome
D000080424,3.45,NCT01349972-2,Arm II (Cytarabine Daunorubicin Hydrochloride),NCT01349972,Alvocidib  Cytarabine  and Mitoxantrone Hydrochloride or Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,cytokine release syndrome
D018461,0.88,NCT01349972-1,Arm I (Alvocidib Cytarabine Mitoxantrone Hydrochloride),NCT01349972,Alvocidib  Cytarabine  and Mitoxantrone Hydrochloride or Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,soft tissue infections
D001064,0.88,NCT01349972-1,Arm I (Alvocidib Cytarabine Mitoxantrone Hydrochloride),NCT01349972,Alvocidib  Cytarabine  and Mitoxantrone Hydrochloride or Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,appendicitis
10061229,1.75,NCT01349972-1,Arm I (Alvocidib Cytarabine Mitoxantrone Hydrochloride),NCT01349972,Alvocidib  Cytarabine  and Mitoxantrone Hydrochloride or Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,lung infection
D018805,0.88,NCT01349972-1,Arm I (Alvocidib Cytarabine Mitoxantrone Hydrochloride),NCT01349972,Alvocidib  Cytarabine  and Mitoxantrone Hydrochloride or Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,sepsis
10005364,1.75,NCT01349972-1,Arm I (Alvocidib Cytarabine Mitoxantrone Hydrochloride),NCT01349972,Alvocidib  Cytarabine  and Mitoxantrone Hydrochloride or Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,blood bilirubin increased
10011368,0.88,NCT01349972-1,Arm I (Alvocidib Cytarabine Mitoxantrone Hydrochloride),NCT01349972,Alvocidib  Cytarabine  and Mitoxantrone Hydrochloride or Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,creatinine increased
D007774,0.88,NCT01349972-1,Arm I (Alvocidib Cytarabine Mitoxantrone Hydrochloride),NCT01349972,Alvocidib  Cytarabine  and Mitoxantrone Hydrochloride or Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,lactation prolonged
10001675,1.72,NCT01349972-2,Arm II (Cytarabine Daunorubicin Hydrochloride),NCT01349972,Alvocidib  Cytarabine  and Mitoxantrone Hydrochloride or Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,alkaline phosphatase increased
D003681,0.88,NCT01349972-1,Arm I (Alvocidib Cytarabine Mitoxantrone Hydrochloride),NCT01349972,Alvocidib  Cytarabine  and Mitoxantrone Hydrochloride or Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,dehydration
D006943,0.88,NCT01349972-1,Arm I (Alvocidib Cytarabine Mitoxantrone Hydrochloride),NCT01349972,Alvocidib  Cytarabine  and Mitoxantrone Hydrochloride or Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,hyperglycemia
D006943,1.72,NCT01349972-2,Arm II (Cytarabine Daunorubicin Hydrochloride),NCT01349972,Alvocidib  Cytarabine  and Mitoxantrone Hydrochloride or Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,hyperglycemia
D007008,1.72,NCT01349972-2,Arm II (Cytarabine Daunorubicin Hydrochloride),NCT01349972,Alvocidib  Cytarabine  and Mitoxantrone Hydrochloride or Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,hypokalemia
D007010,0.88,NCT01349972-1,Arm I (Alvocidib Cytarabine Mitoxantrone Hydrochloride),NCT01349972,Alvocidib  Cytarabine  and Mitoxantrone Hydrochloride or Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,hyponatremia
D007010,1.72,NCT01349972-2,Arm II (Cytarabine Daunorubicin Hydrochloride),NCT01349972,Alvocidib  Cytarabine  and Mitoxantrone Hydrochloride or Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,hyponatremia
D006996,0.88,NCT01349972-1,Arm I (Alvocidib Cytarabine Mitoxantrone Hydrochloride),NCT01349972,Alvocidib  Cytarabine  and Mitoxantrone Hydrochloride or Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,hypocalcemia
D017674,1.75,NCT01349972-1,Arm I (Alvocidib Cytarabine Mitoxantrone Hydrochloride),NCT01349972,Alvocidib  Cytarabine  and Mitoxantrone Hydrochloride or Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,hypophosphatemia
D017674,3.45,NCT01349972-2,Arm II (Cytarabine Daunorubicin Hydrochloride),NCT01349972,Alvocidib  Cytarabine  and Mitoxantrone Hydrochloride or Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,hypophosphatemia
D015275,3.51,NCT01349972-1,Arm I (Alvocidib Cytarabine Mitoxantrone Hydrochloride),NCT01349972,Alvocidib  Cytarabine  and Mitoxantrone Hydrochloride or Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,tumor lysis syndrome
D015275,1.72,NCT01349972-2,Arm II (Cytarabine Daunorubicin Hydrochloride),NCT01349972,Alvocidib  Cytarabine  and Mitoxantrone Hydrochloride or Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,tumor lysis syndrome
D012640,0.88,NCT01349972-1,Arm I (Alvocidib Cytarabine Mitoxantrone Hydrochloride),NCT01349972,Alvocidib  Cytarabine  and Mitoxantrone Hydrochloride or Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,seizure
D058186,1.75,NCT01349972-1,Arm I (Alvocidib Cytarabine Mitoxantrone Hydrochloride),NCT01349972,Alvocidib  Cytarabine  and Mitoxantrone Hydrochloride or Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,acute kidney injury
D058186,3.45,NCT01349972-2,Arm II (Cytarabine Daunorubicin Hydrochloride),NCT01349972,Alvocidib  Cytarabine  and Mitoxantrone Hydrochloride or Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,acute kidney injury
D051436,1.72,NCT01349972-2,Arm II (Cytarabine Daunorubicin Hydrochloride),NCT01349972,Alvocidib  Cytarabine  and Mitoxantrone Hydrochloride or Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,chronic kidney disease
D051437,0.88,NCT01349972-1,Arm I (Alvocidib Cytarabine Mitoxantrone Hydrochloride),NCT01349972,Alvocidib  Cytarabine  and Mitoxantrone Hydrochloride or Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,renal insufficiency
D000400,0.88,NCT01349972-1,Arm I (Alvocidib Cytarabine Mitoxantrone Hydrochloride),NCT01349972,Alvocidib  Cytarabine  and Mitoxantrone Hydrochloride or Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,swimbladder
D012128,1.72,NCT01349972-2,Arm II (Cytarabine Daunorubicin Hydrochloride),NCT01349972,Alvocidib  Cytarabine  and Mitoxantrone Hydrochloride or Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,adult respiratory distress syndrome
D000860,1.72,NCT01349972-2,Arm II (Cytarabine Daunorubicin Hydrochloride),NCT01349972,Alvocidib  Cytarabine  and Mitoxantrone Hydrochloride or Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,hypoxia
D000068299,0.88,NCT01349972-1,Arm I (Alvocidib Cytarabine Mitoxantrone Hydrochloride),NCT01349972,Alvocidib  Cytarabine  and Mitoxantrone Hydrochloride or Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,serevent
D019559,1.72,NCT01349972-2,Arm II (Cytarabine Daunorubicin Hydrochloride),NCT01349972,Alvocidib  Cytarabine  and Mitoxantrone Hydrochloride or Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,capillary leak syndrome
D006973,1.72,NCT01349972-2,Arm II (Cytarabine Daunorubicin Hydrochloride),NCT01349972,Alvocidib  Cytarabine  and Mitoxantrone Hydrochloride or Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,hypertension
D064420,100.0,NCT01451437-1,Pt 1 Arm A: MK-8242 30 mg QD,NCT01451437,Study of MK-8242 Alone and in Combination With Cytarabine in Participants With Acute Myelogenous Leukemia (P07649),adverse drug events
D064420,66.67,NCT01451437-3,Pt 1 Arm A: MK-8242 120 mg QD,NCT01451437,Study of MK-8242 Alone and in Combination With Cytarabine in Participants With Acute Myelogenous Leukemia (P07649),adverse drug events
D064420,100.0,NCT01451437-4,Pt 1 Arm A: MK-8242 250 mg QD,NCT01451437,Study of MK-8242 Alone and in Combination With Cytarabine in Participants With Acute Myelogenous Leukemia (P07649),adverse drug events
D064420,25.0,NCT01451437-5,Pt 1 Arm A: MK-8242 120 mg BID,NCT01451437,Study of MK-8242 Alone and in Combination With Cytarabine in Participants With Acute Myelogenous Leukemia (P07649),adverse drug events
D064420,33.33,NCT01451437-6,Pt 1 Arm A: MK-8242 170 mg BID,NCT01451437,Study of MK-8242 Alone and in Combination With Cytarabine in Participants With Acute Myelogenous Leukemia (P07649),adverse drug events
D064420,83.33,NCT01451437-7,Pt 1 Arm A: MK-8242 210 mg BID,NCT01451437,Study of MK-8242 Alone and in Combination With Cytarabine in Participants With Acute Myelogenous Leukemia (P07649),adverse drug events
D064420,100.0,NCT01451437-8,Pt 1 Arm A: MK-8242 250 mg BID,NCT01451437,Study of MK-8242 Alone and in Combination With Cytarabine in Participants With Acute Myelogenous Leukemia (P07649),adverse drug events
D064420,50.0,NCT01451437-9,Pt 1 Arm A: MK-8242 300 mg BID,NCT01451437,Study of MK-8242 Alone and in Combination With Cytarabine in Participants With Acute Myelogenous Leukemia (P07649),adverse drug events
D064147,25.0,NCT01451437-5,Pt 1 Arm A: MK-8242 120 mg BID,NCT01451437,Study of MK-8242 Alone and in Combination With Cytarabine in Participants With Acute Myelogenous Leukemia (P07649),febrile neutropenia
D064147,33.33,NCT01451437-6,Pt 1 Arm A: MK-8242 170 mg BID,NCT01451437,Study of MK-8242 Alone and in Combination With Cytarabine in Participants With Acute Myelogenous Leukemia (P07649),febrile neutropenia
D064147,33.33,NCT01451437-7,Pt 1 Arm A: MK-8242 210 mg BID,NCT01451437,Study of MK-8242 Alone and in Combination With Cytarabine in Participants With Acute Myelogenous Leukemia (P07649),febrile neutropenia
D064147,100.0,NCT01451437-8,Pt 1 Arm A: MK-8242 250 mg BID,NCT01451437,Study of MK-8242 Alone and in Combination With Cytarabine in Participants With Acute Myelogenous Leukemia (P07649),febrile neutropenia
D054058,16.67,NCT01451437-7,Pt 1 Arm A: MK-8242 210 mg BID,NCT01451437,Study of MK-8242 Alone and in Combination With Cytarabine in Participants With Acute Myelogenous Leukemia (P07649),acute coronary syndrome
D001281,16.67,NCT01451437-7,Pt 1 Arm A: MK-8242 210 mg BID,NCT01451437,Study of MK-8242 Alone and in Combination With Cytarabine in Participants With Acute Myelogenous Leukemia (P07649),atrial fibrillation
D005117,100.0,NCT01451437-1,Pt 1 Arm A: MK-8242 30 mg QD,NCT01451437,Study of MK-8242 Alone and in Combination With Cytarabine in Participants With Acute Myelogenous Leukemia (P07649),extrasystoles
D009055,16.67,NCT01451437-7,Pt 1 Arm A: MK-8242 210 mg BID,NCT01451437,Study of MK-8242 Alone and in Combination With Cytarabine in Participants With Acute Myelogenous Leukemia (P07649),mouth
D041742,33.33,NCT01451437-6,Pt 1 Arm A: MK-8242 170 mg BID,NCT01451437,Study of MK-8242 Alone and in Combination With Cytarabine in Participants With Acute Myelogenous Leukemia (P07649),upper gastrointestinal tract
D005334,25.0,NCT01451437-9,Pt 1 Arm A: MK-8242 300 mg BID,NCT01451437,Study of MK-8242 Alone and in Combination With Cytarabine in Participants With Acute Myelogenous Leukemia (P07649),pyrexia
D002481,16.67,NCT01451437-7,Pt 1 Arm A: MK-8242 210 mg BID,NCT01451437,Study of MK-8242 Alone and in Combination With Cytarabine in Participants With Acute Myelogenous Leukemia (P07649),cellulitis
D002481,33.33,NCT01451437-8,Pt 1 Arm A: MK-8242 250 mg BID,NCT01451437,Study of MK-8242 Alone and in Combination With Cytarabine in Participants With Acute Myelogenous Leukemia (P07649),cellulitis
D004927,33.33,NCT01451437-8,Pt 1 Arm A: MK-8242 250 mg BID,NCT01451437,Study of MK-8242 Alone and in Combination With Cytarabine in Participants With Acute Myelogenous Leukemia (P07649),escherichia coli infections
10061229,16.67,NCT01451437-7,Pt 1 Arm A: MK-8242 210 mg BID,NCT01451437,Study of MK-8242 Alone and in Combination With Cytarabine in Participants With Acute Myelogenous Leukemia (P07649),lung infection
D011014,100.0,NCT01451437-1,Pt 1 Arm A: MK-8242 30 mg QD,NCT01451437,Study of MK-8242 Alone and in Combination With Cytarabine in Participants With Acute Myelogenous Leukemia (P07649),pneumonia
D011014,33.33,NCT01451437-3,Pt 1 Arm A: MK-8242 120 mg QD,NCT01451437,Study of MK-8242 Alone and in Combination With Cytarabine in Participants With Acute Myelogenous Leukemia (P07649),pneumonia
D011014,25.0,NCT01451437-5,Pt 1 Arm A: MK-8242 120 mg BID,NCT01451437,Study of MK-8242 Alone and in Combination With Cytarabine in Participants With Acute Myelogenous Leukemia (P07649),pneumonia
D001996,66.67,NCT01451437-8,Pt 1 Arm A: MK-8242 250 mg BID,NCT01451437,Study of MK-8242 Alone and in Combination With Cytarabine in Participants With Acute Myelogenous Leukemia (P07649),bronchopneumonia
D018805,16.67,NCT01451437-7,Pt 1 Arm A: MK-8242 210 mg BID,NCT01451437,Study of MK-8242 Alone and in Combination With Cytarabine in Participants With Acute Myelogenous Leukemia (P07649),sepsis
D012852,25.0,NCT01451437-9,Pt 1 Arm A: MK-8242 300 mg BID,NCT01451437,Study of MK-8242 Alone and in Combination With Cytarabine in Participants With Acute Myelogenous Leukemia (P07649),sinusitis
10016173,25.0,NCT01451437-5,Pt 1 Arm A: MK-8242 120 mg BID,NCT01451437,Study of MK-8242 Alone and in Combination With Cytarabine in Participants With Acute Myelogenous Leukemia (P07649),fall
D003681,16.67,NCT01451437-7,Pt 1 Arm A: MK-8242 210 mg BID,NCT01451437,Study of MK-8242 Alone and in Combination With Cytarabine in Participants With Acute Myelogenous Leukemia (P07649),dehydration
D009369,100.0,NCT01451437-4,Pt 1 Arm A: MK-8242 250 mg QD,NCT01451437,Study of MK-8242 Alone and in Combination With Cytarabine in Participants With Acute Myelogenous Leukemia (P07649),neoplasms
D009369,25.0,NCT01451437-5,Pt 1 Arm A: MK-8242 120 mg BID,NCT01451437,Study of MK-8242 Alone and in Combination With Cytarabine in Participants With Acute Myelogenous Leukemia (P07649),neoplasms
D002292,33.33,NCT01451437-3,Pt 1 Arm A: MK-8242 120 mg QD,NCT01451437,Study of MK-8242 Alone and in Combination With Cytarabine in Participants With Acute Myelogenous Leukemia (P07649),renal cell carcinoma
D009437,25.0,NCT01451437-9,Pt 1 Arm A: MK-8242 300 mg BID,NCT01451437,Study of MK-8242 Alone and in Combination With Cytarabine in Participants With Acute Myelogenous Leukemia (P07649),neuralgia
D003221,33.33,NCT01451437-8,Pt 1 Arm A: MK-8242 250 mg BID,NCT01451437,Study of MK-8242 Alone and in Combination With Cytarabine in Participants With Acute Myelogenous Leukemia (P07649),confusional state
D003863,16.67,NCT01451437-7,Pt 1 Arm A: MK-8242 210 mg BID,NCT01451437,Study of MK-8242 Alone and in Combination With Cytarabine in Participants With Acute Myelogenous Leukemia (P07649),depression
10042464,16.67,NCT01451437-7,Pt 1 Arm A: MK-8242 210 mg BID,NCT01451437,Study of MK-8242 Alone and in Combination With Cytarabine in Participants With Acute Myelogenous Leukemia (P07649),suicide attempt
D058186,100.0,NCT01451437-4,Pt 1 Arm A: MK-8242 250 mg QD,NCT01451437,Study of MK-8242 Alone and in Combination With Cytarabine in Participants With Acute Myelogenous Leukemia (P07649),acute renal failure
D058186,16.67,NCT01451437-7,Pt 1 Arm A: MK-8242 210 mg BID,NCT01451437,Study of MK-8242 Alone and in Combination With Cytarabine in Participants With Acute Myelogenous Leukemia (P07649),acute renal failure
D011470,100.0,NCT01451437-4,Pt 1 Arm A: MK-8242 250 mg QD,NCT01451437,Study of MK-8242 Alone and in Combination With Cytarabine in Participants With Acute Myelogenous Leukemia (P07649),benign prostatic hyperplasia
UNKNOWN-check-for-typo,33.33,NCT01451437-3,Pt 1 Arm A: MK-8242 120 mg QD,NCT01451437,Study of MK-8242 Alone and in Combination With Cytarabine in Participants With Acute Myelogenous Leukemia (P07649),D00
UNKNOWN-check-for-typo,33.33,NCT01451437-8,Pt 1 Arm A: MK-8242 250 mg BID,NCT01451437,Study of MK-8242 Alone and in Combination With Cytarabine in Participants With Acute Myelogenous Leukemia (P07649),D00
D012131,16.67,NCT01451437-7,Pt 1 Arm A: MK-8242 210 mg BID,NCT01451437,Study of MK-8242 Alone and in Combination With Cytarabine in Participants With Acute Myelogenous Leukemia (P07649),respiratory failure
D012131,25.0,NCT01451437-9,Pt 1 Arm A: MK-8242 300 mg BID,NCT01451437,Study of MK-8242 Alone and in Combination With Cytarabine in Participants With Acute Myelogenous Leukemia (P07649),respiratory failure
D006973,100.0,NCT01451437-4,Pt 1 Arm A: MK-8242 250 mg QD,NCT01451437,Study of MK-8242 Alone and in Combination With Cytarabine in Participants With Acute Myelogenous Leukemia (P07649),hypertension
D064420,41.77,NCT01453205-1,Rituximab+ ICE/DHAP,NCT01453205,A Phase 2  Multicenter  Randomized  Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL),adverse drug events
D064420,48.08,NCT01453205-2,MEDI-551 2 mg/kg + ICE/DHAP,NCT01453205,A Phase 2  Multicenter  Randomized  Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL),adverse drug events
D064420,50.0,NCT01453205-3,MEDI-551 4 mg/kg + ICE/DHAP,NCT01453205,A Phase 2  Multicenter  Randomized  Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL),adverse drug events
D000741,1.92,NCT01453205-2,MEDI-551 2 mg/kg + ICE/DHAP,NCT01453205,A Phase 2  Multicenter  Randomized  Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL),aplastic anaemia
D004211,1.27,NCT01453205-1,Rituximab+ ICE/DHAP,NCT01453205,A Phase 2  Multicenter  Randomized  Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL),disseminated intravascular coagulation
D001853,1.92,NCT01453205-2,MEDI-551 2 mg/kg + ICE/DHAP,NCT01453205,A Phase 2  Multicenter  Randomized  Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL),bone marrow
D064147,13.92,NCT01453205-1,Rituximab+ ICE/DHAP,NCT01453205,A Phase 2  Multicenter  Randomized  Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL),febrile neutropenia
D064147,15.38,NCT01453205-2,MEDI-551 2 mg/kg + ICE/DHAP,NCT01453205,A Phase 2  Multicenter  Randomized  Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL),febrile neutropenia
D064147,16.67,NCT01453205-3,MEDI-551 4 mg/kg + ICE/DHAP,NCT01453205,A Phase 2  Multicenter  Randomized  Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL),febrile neutropenia
D007970,1.27,NCT01453205-1,Rituximab+ ICE/DHAP,NCT01453205,A Phase 2  Multicenter  Randomized  Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL),leukopenia
D000072281,1.92,NCT01453205-2,MEDI-551 2 mg/kg + ICE/DHAP,NCT01453205,A Phase 2  Multicenter  Randomized  Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL),lymphadenopathy
D009503,5.06,NCT01453205-1,Rituximab+ ICE/DHAP,NCT01453205,A Phase 2  Multicenter  Randomized  Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL),neutropenia
D009503,1.92,NCT01453205-2,MEDI-551 2 mg/kg + ICE/DHAP,NCT01453205,A Phase 2  Multicenter  Randomized  Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL),neutropenia
D009503,5.56,NCT01453205-3,MEDI-551 4 mg/kg + ICE/DHAP,NCT01453205,A Phase 2  Multicenter  Randomized  Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL),neutropenia
D010198,1.27,NCT01453205-1,Rituximab+ ICE/DHAP,NCT01453205,A Phase 2  Multicenter  Randomized  Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL),pancytopenia
D010198,1.85,NCT01453205-3,MEDI-551 4 mg/kg + ICE/DHAP,NCT01453205,A Phase 2  Multicenter  Randomized  Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL),pancytopenia
D013921,6.33,NCT01453205-1,Rituximab+ ICE/DHAP,NCT01453205,A Phase 2  Multicenter  Randomized  Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL),thrombocytopenia
D013921,1.85,NCT01453205-3,MEDI-551 4 mg/kg + ICE/DHAP,NCT01453205,A Phase 2  Multicenter  Randomized  Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL),thrombocytopenia
D057049,1.85,NCT01453205-3,MEDI-551 4 mg/kg + ICE/DHAP,NCT01453205,A Phase 2  Multicenter  Randomized  Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL),thrombotic microangiopathy
D056988,1.85,NCT01453205-3,MEDI-551 4 mg/kg + ICE/DHAP,NCT01453205,A Phase 2  Multicenter  Randomized  Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL),acute anterior wall myocardial infarction
D000787,1.85,NCT01453205-3,MEDI-551 4 mg/kg + ICE/DHAP,NCT01453205,A Phase 2  Multicenter  Randomized  Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL),angina pectoris
D001281,1.92,NCT01453205-2,MEDI-551 2 mg/kg + ICE/DHAP,NCT01453205,A Phase 2  Multicenter  Randomized  Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL),atrial fibrillation
D006333,1.27,NCT01453205-1,Rituximab+ ICE/DHAP,NCT01453205,A Phase 2  Multicenter  Randomized  Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL),cardiac failure
D006333,1.85,NCT01453205-3,MEDI-551 4 mg/kg + ICE/DHAP,NCT01453205,A Phase 2  Multicenter  Randomized  Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL),cardiac failure
D014717,1.27,NCT01453205-1,Rituximab+ ICE/DHAP,NCT01453205,A Phase 2  Multicenter  Randomized  Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL),vertigo
D005756,1.27,NCT01453205-1,Rituximab+ ICE/DHAP,NCT01453205,A Phase 2  Multicenter  Randomized  Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL),gastritis
D009325,1.27,NCT01453205-1,Rituximab+ ICE/DHAP,NCT01453205,A Phase 2  Multicenter  Randomized  Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL),nausea
D009325,1.92,NCT01453205-2,MEDI-551 2 mg/kg + ICE/DHAP,NCT01453205,A Phase 2  Multicenter  Randomized  Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL),nausea
D009325,1.85,NCT01453205-3,MEDI-551 4 mg/kg + ICE/DHAP,NCT01453205,A Phase 2  Multicenter  Randomized  Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL),nausea
D044504,1.27,NCT01453205-1,Rituximab+ ICE/DHAP,NCT01453205,A Phase 2  Multicenter  Randomized  Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL),enterocolitis neutropenic
10029957,1.27,NCT01453205-1,Rituximab+ ICE/DHAP,NCT01453205,A Phase 2  Multicenter  Randomized  Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL),obstruction gastric
D014839,2.53,NCT01453205-1,Rituximab+ ICE/DHAP,NCT01453205,A Phase 2  Multicenter  Randomized  Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL),vomiting
D014839,1.92,NCT01453205-2,MEDI-551 2 mg/kg + ICE/DHAP,NCT01453205,A Phase 2  Multicenter  Randomized  Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL),vomiting
D003643,1.92,NCT01453205-2,MEDI-551 2 mg/kg + ICE/DHAP,NCT01453205,A Phase 2  Multicenter  Randomized  Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL),death
D005221,1.92,NCT01453205-2,MEDI-551 2 mg/kg + ICE/DHAP,NCT01453205,A Phase 2  Multicenter  Randomized  Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL),fatigue
D003695,1.27,NCT01453205-1,Rituximab+ ICE/DHAP,NCT01453205,A Phase 2  Multicenter  Randomized  Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL),healthcare
D003695,1.92,NCT01453205-2,MEDI-551 2 mg/kg + ICE/DHAP,NCT01453205,A Phase 2  Multicenter  Randomized  Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL),healthcare
D009102,1.27,NCT01453205-1,Rituximab+ ICE/DHAP,NCT01453205,A Phase 2  Multicenter  Randomized  Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL),multiple organ dysfunction syndrome
D005334,1.27,NCT01453205-1,Rituximab+ ICE/DHAP,NCT01453205,A Phase 2  Multicenter  Randomized  Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL),pyrexia
D005334,3.85,NCT01453205-2,MEDI-551 2 mg/kg + ICE/DHAP,NCT01453205,A Phase 2  Multicenter  Randomized  Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL),pyrexia
D005334,3.7,NCT01453205-3,MEDI-551 4 mg/kg + ICE/DHAP,NCT01453205,A Phase 2  Multicenter  Randomized  Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL),pyrexia
UNKNOWN-check-for-typo,1.85,NCT01453205-3,MEDI-551 4 mg/kg + ICE/DHAP,NCT01453205,A Phase 2  Multicenter  Randomized  Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL),D00
D000985,1.92,NCT01453205-2,MEDI-551 2 mg/kg + ICE/DHAP,NCT01453205,A Phase 2  Multicenter  Randomized  Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL),antisepsis
D002481,1.92,NCT01453205-2,MEDI-551 2 mg/kg + ICE/DHAP,NCT01453205,A Phase 2  Multicenter  Randomized  Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL),cellulitis
D004761,1.85,NCT01453205-3,MEDI-551 4 mg/kg + ICE/DHAP,NCT01453205,A Phase 2  Multicenter  Randomized  Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL),clostridium enterocolitis
D000072139,1.27,NCT01453205-1,Rituximab+ ICE/DHAP,NCT01453205,A Phase 2  Multicenter  Randomized  Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL),megavirales
10064687,1.27,NCT01453205-1,Rituximab+ ICE/DHAP,NCT01453205,A Phase 2  Multicenter  Randomized  Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL),device related infection
10064687,1.92,NCT01453205-2,MEDI-551 2 mg/kg + ICE/DHAP,NCT01453205,A Phase 2  Multicenter  Randomized  Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL),device related infection
10064687,1.85,NCT01453205-3,MEDI-551 4 mg/kg + ICE/DHAP,NCT01453205,A Phase 2  Multicenter  Randomized  Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL),device related infection
D000985,1.27,NCT01453205-1,Rituximab+ ICE/DHAP,NCT01453205,A Phase 2  Multicenter  Randomized  Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL),antisepsis
D000985,1.27,NCT01453205-1,Rituximab+ ICE/DHAP,NCT01453205,A Phase 2  Multicenter  Randomized  Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL),antisepsis
D006562,1.92,NCT01453205-2,MEDI-551 2 mg/kg + ICE/DHAP,NCT01453205,A Phase 2  Multicenter  Randomized  Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL),herpes zoster
D011014,3.8,NCT01453205-1,Rituximab+ ICE/DHAP,NCT01453205,A Phase 2  Multicenter  Randomized  Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL),pneumonia
D011014,1.85,NCT01453205-3,MEDI-551 4 mg/kg + ICE/DHAP,NCT01453205,A Phase 2  Multicenter  Randomized  Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL),pneumonia
D012141,1.92,NCT01453205-2,MEDI-551 2 mg/kg + ICE/DHAP,NCT01453205,A Phase 2  Multicenter  Randomized  Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL),respiratory tract infection
D018805,3.8,NCT01453205-1,Rituximab+ ICE/DHAP,NCT01453205,A Phase 2  Multicenter  Randomized  Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL),sepsis
D018805,1.92,NCT01453205-2,MEDI-551 2 mg/kg + ICE/DHAP,NCT01453205,A Phase 2  Multicenter  Randomized  Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL),sepsis
D018805,7.41,NCT01453205-3,MEDI-551 4 mg/kg + ICE/DHAP,NCT01453205,A Phase 2  Multicenter  Randomized  Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL),sepsis
D012772,1.27,NCT01453205-1,Rituximab+ ICE/DHAP,NCT01453205,A Phase 2  Multicenter  Randomized  Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL),septic shock
D012772,1.92,NCT01453205-2,MEDI-551 2 mg/kg + ICE/DHAP,NCT01453205,A Phase 2  Multicenter  Randomized  Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL),septic shock
D000985,1.92,NCT01453205-2,MEDI-551 2 mg/kg + ICE/DHAP,NCT01453205,A Phase 2  Multicenter  Randomized  Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL),antisepsis
D014552,1.92,NCT01453205-2,MEDI-551 2 mg/kg + ICE/DHAP,NCT01453205,A Phase 2  Multicenter  Randomized  Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL),urinary tract infection
D062787,1.92,NCT01453205-2,MEDI-551 2 mg/kg + ICE/DHAP,NCT01453205,A Phase 2  Multicenter  Randomized  Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL),drug overdose
D016103,1.92,NCT01453205-2,MEDI-551 2 mg/kg + ICE/DHAP,NCT01453205,A Phase 2  Multicenter  Randomized  Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL),spinal fracture
D000081015,1.27,NCT01453205-1,Rituximab+ ICE/DHAP,NCT01453205,A Phase 2  Multicenter  Randomized  Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL),ototoxicity
D000081015,1.85,NCT01453205-3,MEDI-551 4 mg/kg + ICE/DHAP,NCT01453205,A Phase 2  Multicenter  Randomized  Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL),ototoxicity
10011368,1.92,NCT01453205-2,MEDI-551 2 mg/kg + ICE/DHAP,NCT01453205,A Phase 2  Multicenter  Randomized  Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL),creatinine increased
10029366,1.92,NCT01453205-2,MEDI-551 2 mg/kg + ICE/DHAP,NCT01453205,A Phase 2  Multicenter  Randomized  Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL),neutrophil count decreased
D007958,1.92,NCT01453205-2,MEDI-551 2 mg/kg + ICE/DHAP,NCT01453205,A Phase 2  Multicenter  Randomized  Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL),blood cell count white
D001066,1.92,NCT01453205-2,MEDI-551 2 mg/kg + ICE/DHAP,NCT01453205,A Phase 2  Multicenter  Randomized  Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL),appetite
D003681,1.92,NCT01453205-2,MEDI-551 2 mg/kg + ICE/DHAP,NCT01453205,A Phase 2  Multicenter  Randomized  Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL),dehydration
D003681,1.85,NCT01453205-3,MEDI-551 4 mg/kg + ICE/DHAP,NCT01453205,A Phase 2  Multicenter  Randomized  Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL),dehydration
UNKNOWN-check-for-typo,1.92,NCT01453205-2,MEDI-551 2 mg/kg + ICE/DHAP,NCT01453205,A Phase 2  Multicenter  Randomized  Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL),D00
UNKNOWN-check-for-typo,1.92,NCT01453205-2,MEDI-551 2 mg/kg + ICE/DHAP,NCT01453205,A Phase 2  Multicenter  Randomized  Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL),D00
UNKNOWN-check-for-typo,1.27,NCT01453205-1,Rituximab+ ICE/DHAP,NCT01453205,A Phase 2  Multicenter  Randomized  Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL),D00
UNKNOWN-check-for-typo,1.85,NCT01453205-3,MEDI-551 4 mg/kg + ICE/DHAP,NCT01453205,A Phase 2  Multicenter  Randomized  Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL),D00
D015275,3.85,NCT01453205-2,MEDI-551 2 mg/kg + ICE/DHAP,NCT01453205,A Phase 2  Multicenter  Randomized  Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL),tumour lysis syndrome
D015275,1.85,NCT01453205-3,MEDI-551 4 mg/kg + ICE/DHAP,NCT01453205,A Phase 2  Multicenter  Randomized  Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL),tumour lysis syndrome
D001416,1.92,NCT01453205-2,MEDI-551 2 mg/kg + ICE/DHAP,NCT01453205,A Phase 2  Multicenter  Randomized  Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL),back pain
10006002,1.27,NCT01453205-1,Rituximab+ ICE/DHAP,NCT01453205,A Phase 2  Multicenter  Randomized  Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL),bone pain
D002637,1.85,NCT01453205-3,MEDI-551 4 mg/kg + ICE/DHAP,NCT01453205,A Phase 2  Multicenter  Randomized  Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL),chest pain
D002490,1.27,NCT01453205-1,Rituximab+ ICE/DHAP,NCT01453205,A Phase 2  Multicenter  Randomized  Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL),central nervous system
D002490,1.92,NCT01453205-2,MEDI-551 2 mg/kg + ICE/DHAP,NCT01453205,A Phase 2  Multicenter  Randomized  Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL),central nervous system
D018365,1.27,NCT01453205-1,Rituximab+ ICE/DHAP,NCT01453205,A Phase 2  Multicenter  Randomized  Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL),residual tumour
D006501,1.92,NCT01453205-2,MEDI-551 2 mg/kg + ICE/DHAP,NCT01453205,A Phase 2  Multicenter  Randomized  Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL),hepatic coma
D004244,1.27,NCT01453205-1,Rituximab+ ICE/DHAP,NCT01453205,A Phase 2  Multicenter  Randomized  Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL),dizziness
D001927,1.85,NCT01453205-3,MEDI-551 4 mg/kg + ICE/DHAP,NCT01453205,A Phase 2  Multicenter  Randomized  Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL),encephalopathy
D006261,1.27,NCT01453205-1,Rituximab+ ICE/DHAP,NCT01453205,A Phase 2  Multicenter  Randomized  Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL),headache
D006261,1.85,NCT01453205-3,MEDI-551 4 mg/kg + ICE/DHAP,NCT01453205,A Phase 2  Multicenter  Randomized  Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL),headache
10027175,1.92,NCT01453205-2,MEDI-551 2 mg/kg + ICE/DHAP,NCT01453205,A Phase 2  Multicenter  Randomized  Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL),memory impairment
D012640,1.85,NCT01453205-3,MEDI-551 4 mg/kg + ICE/DHAP,NCT01453205,A Phase 2  Multicenter  Randomized  Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL),seizure
D000077260,1.92,NCT01453205-2,MEDI-551 2 mg/kg + ICE/DHAP,NCT01453205,A Phase 2  Multicenter  Randomized  Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL),somnolence
D013575,3.85,NCT01453205-2,MEDI-551 2 mg/kg + ICE/DHAP,NCT01453205,A Phase 2  Multicenter  Randomized  Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL),syncope
D003221,1.85,NCT01453205-3,MEDI-551 4 mg/kg + ICE/DHAP,NCT01453205,A Phase 2  Multicenter  Randomized  Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL),confusional state
D003863,1.92,NCT01453205-2,MEDI-551 2 mg/kg + ICE/DHAP,NCT01453205,A Phase 2  Multicenter  Randomized  Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL),depression
D000073216,1.27,NCT01453205-1,Rituximab+ ICE/DHAP,NCT01453205,A Phase 2  Multicenter  Randomized  Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL),mental status tests
D059020,1.27,NCT01453205-1,Rituximab+ ICE/DHAP,NCT01453205,A Phase 2  Multicenter  Randomized  Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL),suicidal ideation
D058186,3.8,NCT01453205-1,Rituximab+ ICE/DHAP,NCT01453205,A Phase 2  Multicenter  Randomized  Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL),acute kidney injury
D058186,5.77,NCT01453205-2,MEDI-551 2 mg/kg + ICE/DHAP,NCT01453205,A Phase 2  Multicenter  Randomized  Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL),acute kidney injury
D058186,3.7,NCT01453205-3,MEDI-551 4 mg/kg + ICE/DHAP,NCT01453205,A Phase 2  Multicenter  Randomized  Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL),acute kidney injury
D000081015,1.27,NCT01453205-1,Rituximab+ ICE/DHAP,NCT01453205,A Phase 2  Multicenter  Randomized  Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL),ototoxicity
D051437,1.27,NCT01453205-1,Rituximab+ ICE/DHAP,NCT01453205,A Phase 2  Multicenter  Randomized  Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL),renal failure
D051437,1.92,NCT01453205-2,MEDI-551 2 mg/kg + ICE/DHAP,NCT01453205,A Phase 2  Multicenter  Randomized  Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL),renal failure
D051437,3.7,NCT01453205-3,MEDI-551 4 mg/kg + ICE/DHAP,NCT01453205,A Phase 2  Multicenter  Randomized  Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL),renal failure
D000799,1.27,NCT01453205-1,Rituximab+ ICE/DHAP,NCT01453205,A Phase 2  Multicenter  Randomized  Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL),angioedema
D012131,1.85,NCT01453205-3,MEDI-551 4 mg/kg + ICE/DHAP,NCT01453205,A Phase 2  Multicenter  Randomized  Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL),respiratory failure
UNKNOWN-check-for-typo,1.85,NCT01453205-3,MEDI-551 4 mg/kg + ICE/DHAP,NCT01453205,A Phase 2  Multicenter  Randomized  Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL),D00
10065735,1.27,NCT01453205-1,Rituximab+ ICE/DHAP,NCT01453205,A Phase 2  Multicenter  Randomized  Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL),laryngeal inflammation
D010996,3.85,NCT01453205-2,MEDI-551 2 mg/kg + ICE/DHAP,NCT01453205,A Phase 2  Multicenter  Randomized  Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL),pleural effusion
D010996,3.7,NCT01453205-3,MEDI-551 4 mg/kg + ICE/DHAP,NCT01453205,A Phase 2  Multicenter  Randomized  Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL),pleural effusion
D010998,1.27,NCT01453205-1,Rituximab+ ICE/DHAP,NCT01453205,A Phase 2  Multicenter  Randomized  Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL),pleurisy
D011014,1.85,NCT01453205-3,MEDI-551 4 mg/kg + ICE/DHAP,NCT01453205,A Phase 2  Multicenter  Randomized  Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL),pneumonitis
D011030,1.27,NCT01453205-1,Rituximab+ ICE/DHAP,NCT01453205,A Phase 2  Multicenter  Randomized  Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL),pneumothorax
D011655,1.85,NCT01453205-3,MEDI-551 4 mg/kg + ICE/DHAP,NCT01453205,A Phase 2  Multicenter  Randomized  Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL),pulmonary embolism
D000799,1.92,NCT01453205-2,MEDI-551 2 mg/kg + ICE/DHAP,NCT01453205,A Phase 2  Multicenter  Randomized  Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL),angioedema
D012131,1.27,NCT01453205-1,Rituximab+ ICE/DHAP,NCT01453205,A Phase 2  Multicenter  Randomized  Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL),respiratory failure
D012131,1.85,NCT01453205-3,MEDI-551 4 mg/kg + ICE/DHAP,NCT01453205,A Phase 2  Multicenter  Randomized  Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL),respiratory failure
D007022,1.92,NCT01453205-2,MEDI-551 2 mg/kg + ICE/DHAP,NCT01453205,A Phase 2  Multicenter  Randomized  Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL),hypotension
D013924,1.92,NCT01453205-2,MEDI-551 2 mg/kg + ICE/DHAP,NCT01453205,A Phase 2  Multicenter  Randomized  Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL),thrombophlebitis
D064420,16.67,NCT01468311-1,Yttrium-90-labeled Daclizumab + Chemotherapy,NCT01468311,Yttrium-90-labeled Daclizumab With Chemotherapy and Stem Cell Transplant for Hodgkin's Lymphoma,adverse drug events
D008593,16.67,NCT01468311-1,Yttrium-90-labeled Daclizumab + Chemotherapy,NCT01468311,Yttrium-90-labeled Daclizumab With Chemotherapy and Stem Cell Transplant for Hodgkin's Lymphoma,menopause
D009026,35.29,NCT01546038-1,Phase 1B: Glasdegib 100 mg + LDAC,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,mortality
D009026,16.67,NCT01546038-2,Phase 1B: Glasdegib 200 mg + LDAC,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,mortality
D009026,25.0,NCT01546038-3,Phase 1B: Glasdegib 100 mg + Decitabine,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,mortality
D009026,16.67,NCT01546038-6,Phase 1B: Glasdegib 200 mg + Cytarabine/Daunorubicin,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,mortality
D009026,7.25,NCT01546038-7,Phase 2 Fit: Glasdegib 100 mg + Cytarabine/Daunorubicin,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,mortality
D009026,30.95,NCT01546038-8,Phase 2 Unfit: Glasdegib 100 mg + LDAC,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,mortality
D009026,41.46,NCT01546038-9,Phase 2 Unfit: LDAC Alone,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,mortality
D064420,76.47,NCT01546038-1,Phase 1B: Glasdegib 100 mg + LDAC,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,adverse drug events
D064420,83.33,NCT01546038-2,Phase 1B: Glasdegib 200 mg + LDAC,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,adverse drug events
D064420,100.0,NCT01546038-3,Phase 1B: Glasdegib 100 mg + Decitabine,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,adverse drug events
D064420,66.67,NCT01546038-4,Phase 1B: Glasdegib 200 mg + Decitabine,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,adverse drug events
D064420,62.5,NCT01546038-5,Phase 1B: Glasdegib 100 mg + Cytarabine/Daunorubicin,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,adverse drug events
D064420,50.0,NCT01546038-6,Phase 1B: Glasdegib 200 mg + Cytarabine/Daunorubicin,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,adverse drug events
D064420,50.72,NCT01546038-7,Phase 2 Fit: Glasdegib 100 mg + Cytarabine/Daunorubicin,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,adverse drug events
D064420,80.95,NCT01546038-8,Phase 2 Unfit: Glasdegib 100 mg + LDAC,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,adverse drug events
D064420,78.05,NCT01546038-9,Phase 2 Unfit: LDAC Alone,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,adverse drug events
D064147,17.65,NCT01546038-1,Phase 1B: Glasdegib 100 mg + LDAC,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,febrile neutropenia
D064147,50.0,NCT01546038-2,Phase 1B: Glasdegib 200 mg + LDAC,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,febrile neutropenia
D064147,33.33,NCT01546038-4,Phase 1B: Glasdegib 200 mg + Decitabine,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,febrile neutropenia
D064147,6.25,NCT01546038-5,Phase 1B: Glasdegib 100 mg + Cytarabine/Daunorubicin,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,febrile neutropenia
D064147,16.67,NCT01546038-6,Phase 1B: Glasdegib 200 mg + Cytarabine/Daunorubicin,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,febrile neutropenia
D064147,20.29,NCT01546038-7,Phase 2 Fit: Glasdegib 100 mg + Cytarabine/Daunorubicin,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,febrile neutropenia
D064147,28.57,NCT01546038-8,Phase 2 Unfit: Glasdegib 100 mg + LDAC,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,febrile neutropenia
D064147,17.07,NCT01546038-9,Phase 2 Unfit: LDAC Alone,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,febrile neutropenia
D009503,2.9,NCT01546038-7,Phase 2 Fit: Glasdegib 100 mg + Cytarabine/Daunorubicin,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,neutropenia
D010198,1.45,NCT01546038-7,Phase 2 Fit: Glasdegib 100 mg + Cytarabine/Daunorubicin,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,pancytopenia
D010198,4.88,NCT01546038-9,Phase 2 Unfit: LDAC Alone,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,pancytopenia
D000741,7.14,NCT01546038-8,Phase 2 Unfit: Glasdegib 100 mg + LDAC,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,aplastic anaemia
D004211,2.44,NCT01546038-9,Phase 2 Unfit: LDAC Alone,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,disseminated intravascular coagulation
D000380,2.44,NCT01546038-9,Phase 2 Unfit: LDAC Alone,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,granulocytopenia
D007964,1.19,NCT01546038-8,Phase 2 Unfit: Glasdegib 100 mg + LDAC,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,leukocytosis
D007964,2.44,NCT01546038-9,Phase 2 Unfit: LDAC Alone,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,leukocytosis
D008199,1.19,NCT01546038-8,Phase 2 Unfit: Glasdegib 100 mg + LDAC,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,lymphadenitis
D013922,1.19,NCT01546038-8,Phase 2 Unfit: Glasdegib 100 mg + LDAC,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,thrombocytosis
D056988,5.88,NCT01546038-1,Phase 1B: Glasdegib 100 mg + LDAC,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,acute anterior wall myocardial infarction
D056988,1.45,NCT01546038-7,Phase 2 Fit: Glasdegib 100 mg + Cytarabine/Daunorubicin,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,acute anterior wall myocardial infarction
D056988,2.44,NCT01546038-9,Phase 2 Unfit: LDAC Alone,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,acute anterior wall myocardial infarction
D006333,5.88,NCT01546038-1,Phase 1B: Glasdegib 100 mg + LDAC,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,cardiac failure
D000787,1.19,NCT01546038-8,Phase 2 Unfit: Glasdegib 100 mg + LDAC,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,angina pectoris
D001281,1.19,NCT01546038-8,Phase 2 Unfit: Glasdegib 100 mg + LDAC,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,atrial fibrillation
D001281,2.44,NCT01546038-9,Phase 2 Unfit: LDAC Alone,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,atrial fibrillation
D006323,2.38,NCT01546038-8,Phase 2 Unfit: Glasdegib 100 mg + LDAC,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,cardiac arrest
D006333,2.38,NCT01546038-8,Phase 2 Unfit: Glasdegib 100 mg + LDAC,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,cardiac failure
D012770,2.44,NCT01546038-9,Phase 2 Unfit: LDAC Alone,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,cardiogenic shock
D009203,2.38,NCT01546038-8,Phase 2 Unfit: Glasdegib 100 mg + LDAC,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,myocardial infarction
D009203,2.44,NCT01546038-9,Phase 2 Unfit: LDAC Alone,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,myocardial infarction
D013610,1.19,NCT01546038-8,Phase 2 Unfit: Glasdegib 100 mg + LDAC,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,tachyarrhythmia
D014693,1.19,NCT01546038-8,Phase 2 Unfit: Glasdegib 100 mg + LDAC,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,ventricular fibrillation
D009205,1.45,NCT01546038-7,Phase 2 Fit: Glasdegib 100 mg + Cytarabine/Daunorubicin,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,myocarditis
D013610,1.45,NCT01546038-7,Phase 2 Fit: Glasdegib 100 mg + Cytarabine/Daunorubicin,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,tachycardia
D015878,1.19,NCT01546038-8,Phase 2 Unfit: Glasdegib 100 mg + LDAC,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,mydriasis
D000069196,25.0,NCT01546038-3,Phase 1B: Glasdegib 100 mg + Decitabine,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,gastrointestinal microbiome
D000069196,2.38,NCT01546038-8,Phase 2 Unfit: Glasdegib 100 mg + LDAC,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,gastrointestinal microbiome
D005746,5.88,NCT01546038-1,Phase 1B: Glasdegib 100 mg + LDAC,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,gastric emptying
D009325,16.67,NCT01546038-2,Phase 1B: Glasdegib 200 mg + LDAC,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,nausea
D009325,1.19,NCT01546038-8,Phase 2 Unfit: Glasdegib 100 mg + LDAC,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,nausea
D009325,2.44,NCT01546038-9,Phase 2 Unfit: LDAC Alone,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,nausea
D044504,5.88,NCT01546038-1,Phase 1B: Glasdegib 100 mg + LDAC,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,enterocolitis neutropenic
D014839,16.67,NCT01546038-2,Phase 1B: Glasdegib 200 mg + LDAC,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,vomiting
D014839,1.19,NCT01546038-8,Phase 2 Unfit: Glasdegib 100 mg + LDAC,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,vomiting
D014839,2.44,NCT01546038-9,Phase 2 Unfit: LDAC Alone,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,vomiting
D015746,2.9,NCT01546038-7,Phase 2 Fit: Glasdegib 100 mg + Cytarabine/Daunorubicin,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,abdominal pain
D041742,1.45,NCT01546038-7,Phase 2 Fit: Glasdegib 100 mg + Cytarabine/Daunorubicin,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,upper gastrointestinal tract
UNKNOWN-check-for-typo,1.45,NCT01546038-7,Phase 2 Fit: Glasdegib 100 mg + Cytarabine/Daunorubicin,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,D00
UNKNOWN-check-for-typo,2.44,NCT01546038-9,Phase 2 Unfit: LDAC Alone,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,D00
D003092,1.19,NCT01546038-8,Phase 2 Unfit: Glasdegib 100 mg + LDAC,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,colitis
D003248,1.19,NCT01546038-8,Phase 2 Unfit: Glasdegib 100 mg + LDAC,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,constipation
D005764,1.19,NCT01546038-8,Phase 2 Unfit: Glasdegib 100 mg + LDAC,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,gastroesophageal reflux disease
UNKNOWN-check-for-typo,1.19,NCT01546038-8,Phase 2 Unfit: Glasdegib 100 mg + LDAC,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,D00
D041741,2.44,NCT01546038-9,Phase 2 Unfit: LDAC Alone,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,lower gastrointestinal tract
D010195,1.19,NCT01546038-8,Phase 2 Unfit: Glasdegib 100 mg + LDAC,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,acute pancreatitis
D012185,1.19,NCT01546038-8,Phase 2 Unfit: Glasdegib 100 mg + LDAC,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,retroperitoneal fibrosis
D018450,17.65,NCT01546038-1,Phase 1B: Glasdegib 100 mg + LDAC,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,disease progression
D018450,16.67,NCT01546038-2,Phase 1B: Glasdegib 200 mg + LDAC,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,disease progression
D018450,25.0,NCT01546038-3,Phase 1B: Glasdegib 100 mg + Decitabine,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,disease progression
D018450,16.67,NCT01546038-6,Phase 1B: Glasdegib 200 mg + Cytarabine/Daunorubicin,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,disease progression
D018450,2.9,NCT01546038-7,Phase 2 Fit: Glasdegib 100 mg + Cytarabine/Daunorubicin,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,disease progression
D018450,11.9,NCT01546038-8,Phase 2 Unfit: Glasdegib 100 mg + LDAC,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,disease progression
D018450,12.2,NCT01546038-9,Phase 2 Unfit: LDAC Alone,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,disease progression
D005221,5.88,NCT01546038-1,Phase 1B: Glasdegib 100 mg + LDAC,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,fatigue
D005221,3.57,NCT01546038-8,Phase 2 Unfit: Glasdegib 100 mg + LDAC,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,fatigue
D009102,5.88,NCT01546038-1,Phase 1B: Glasdegib 100 mg + LDAC,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,multiple organ dysfunction syndrome
D009102,25.0,NCT01546038-3,Phase 1B: Glasdegib 100 mg + Decitabine,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,multiple organ dysfunction syndrome
D003074,5.88,NCT01546038-1,Phase 1B: Glasdegib 100 mg + LDAC,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,solitary pulmonary nodule
D005334,16.67,NCT01546038-2,Phase 1B: Glasdegib 200 mg + LDAC,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,pyrexia
D005334,3.57,NCT01546038-8,Phase 2 Unfit: Glasdegib 100 mg + LDAC,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,pyrexia
D005334,2.44,NCT01546038-9,Phase 2 Unfit: LDAC Alone,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,pyrexia
D001247,2.44,NCT01546038-9,Phase 2 Unfit: LDAC Alone,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,asthenia
D003643,1.19,NCT01546038-8,Phase 2 Unfit: Glasdegib 100 mg + LDAC,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,death
D003695,2.44,NCT01546038-9,Phase 2 Unfit: LDAC Alone,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,healthcare
D007249,1.19,NCT01546038-8,Phase 2 Unfit: Glasdegib 100 mg + LDAC,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,inflammation
D000799,1.19,NCT01546038-8,Phase 2 Unfit: Glasdegib 100 mg + LDAC,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,angioedema
D003645,2.38,NCT01546038-8,Phase 2 Unfit: Glasdegib 100 mg + LDAC,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,sudden death
D002764,2.9,NCT01546038-7,Phase 2 Fit: Glasdegib 100 mg + Cytarabine/Daunorubicin,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,cholecystitis
D001064,6.25,NCT01546038-5,Phase 1B: Glasdegib 100 mg + Cytarabine/Daunorubicin,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,appendicitis
UNKNOWN-check-for-typo,6.25,NCT01546038-5,Phase 1B: Glasdegib 100 mg + Cytarabine/Daunorubicin,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,D00
UNKNOWN-check-for-typo,2.9,NCT01546038-7,Phase 2 Fit: Glasdegib 100 mg + Cytarabine/Daunorubicin,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,D00
UNKNOWN-check-for-typo,1.19,NCT01546038-8,Phase 2 Unfit: Glasdegib 100 mg + LDAC,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,D00
D002481,25.0,NCT01546038-3,Phase 1B: Glasdegib 100 mg + Decitabine,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,cellulitis
D002481,16.67,NCT01546038-6,Phase 1B: Glasdegib 200 mg + Cytarabine/Daunorubicin,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,cellulitis
D002481,1.19,NCT01546038-8,Phase 2 Unfit: Glasdegib 100 mg + LDAC,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,cellulitis
D003015,6.25,NCT01546038-5,Phase 1B: Glasdegib 100 mg + Cytarabine/Daunorubicin,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,clostridium difficile infection
D000985,5.88,NCT01546038-1,Phase 1B: Glasdegib 100 mg + LDAC,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,antisepsis
10058838,12.5,NCT01546038-5,Phase 1B: Glasdegib 100 mg + Cytarabine/Daunorubicin,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,enterocolitis infectious
D012141,5.88,NCT01546038-1,Phase 1B: Glasdegib 100 mg + LDAC,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,respiratory tract infections
D000985,6.25,NCT01546038-5,Phase 1B: Glasdegib 100 mg + Cytarabine/Daunorubicin,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,antisepsis
D011014,11.76,NCT01546038-1,Phase 1B: Glasdegib 100 mg + LDAC,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,pneumonia
D011014,50.0,NCT01546038-3,Phase 1B: Glasdegib 100 mg + Decitabine,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,pneumonia
D011014,5.8,NCT01546038-7,Phase 2 Fit: Glasdegib 100 mg + Cytarabine/Daunorubicin,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,pneumonia
D011014,22.62,NCT01546038-8,Phase 2 Unfit: Glasdegib 100 mg + LDAC,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,pneumonia
D011014,17.07,NCT01546038-9,Phase 2 Unfit: LDAC Alone,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,pneumonia
D018805,5.88,NCT01546038-1,Phase 1B: Glasdegib 100 mg + LDAC,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,sepsis
D018805,8.7,NCT01546038-7,Phase 2 Fit: Glasdegib 100 mg + Cytarabine/Daunorubicin,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,sepsis
D018805,3.57,NCT01546038-8,Phase 2 Unfit: Glasdegib 100 mg + LDAC,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,sepsis
D018805,12.2,NCT01546038-9,Phase 2 Unfit: LDAC Alone,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,sepsis
10040872,16.67,NCT01546038-2,Phase 1B: Glasdegib 200 mg + LDAC,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,skin infection
10040872,1.19,NCT01546038-8,Phase 2 Unfit: Glasdegib 100 mg + LDAC,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,skin infection
D004768,16.67,NCT01546038-6,Phase 1B: Glasdegib 200 mg + Cytarabine/Daunorubicin,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,staphylococcal enterotoxins
D004768,1.45,NCT01546038-7,Phase 2 Fit: Glasdegib 100 mg + Cytarabine/Daunorubicin,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,staphylococcal enterotoxins
D012772,1.45,NCT01546038-7,Phase 2 Fit: Glasdegib 100 mg + Cytarabine/Daunorubicin,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,septic shock
D012772,2.38,NCT01546038-8,Phase 2 Unfit: Glasdegib 100 mg + LDAC,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,septic shock
D012772,2.44,NCT01546038-9,Phase 2 Unfit: LDAC Alone,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,septic shock
D000038,1.19,NCT01546038-8,Phase 2 Unfit: Glasdegib 100 mg + LDAC,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,abscess
D001228,1.19,NCT01546038-8,Phase 2 Unfit: Glasdegib 100 mg + LDAC,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,aspergillus infection
D004761,1.45,NCT01546038-7,Phase 2 Fit: Glasdegib 100 mg + Cytarabine/Daunorubicin,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,clostridium enterocolitis
D004761,1.19,NCT01546038-8,Phase 2 Unfit: Glasdegib 100 mg + LDAC,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,clostridium enterocolitis
D003556,2.44,NCT01546038-9,Phase 2 Unfit: LDAC Alone,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,cystitis
10064687,1.19,NCT01546038-8,Phase 2 Unfit: Glasdegib 100 mg + LDAC,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,device related infection
D014552,1.19,NCT01546038-8,Phase 2 Unfit: Glasdegib 100 mg + LDAC,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,urinary tract infections
D006562,1.19,NCT01546038-8,Phase 2 Unfit: Glasdegib 100 mg + LDAC,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,herpes zoster
D004814,1.19,NCT01546038-8,Phase 2 Unfit: Glasdegib 100 mg + LDAC,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,epidermal cyst
D007251,1.19,NCT01546038-8,Phase 2 Unfit: Glasdegib 100 mg + LDAC,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,influenza
D007251,2.44,NCT01546038-9,Phase 2 Unfit: LDAC Alone,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,influenza
10061229,1.19,NCT01546038-8,Phase 2 Unfit: Glasdegib 100 mg + LDAC,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,lung infection
10061229,2.44,NCT01546038-9,Phase 2 Unfit: LDAC Alone,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,lung infection
D010033,1.19,NCT01546038-8,Phase 2 Unfit: Glasdegib 100 mg + LDAC,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,otitis media
D001996,1.19,NCT01546038-8,Phase 2 Unfit: Glasdegib 100 mg + LDAC,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,bronchopneumonia
D004761,2.44,NCT01546038-9,Phase 2 Unfit: LDAC Alone,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,pseudomembranous colitis
D012141,1.19,NCT01546038-8,Phase 2 Unfit: Glasdegib 100 mg + LDAC,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,respiratory tract infection
D000891,1.19,NCT01546038-8,Phase 2 Unfit: Glasdegib 100 mg + LDAC,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,antiseptics
D001424,2.44,NCT01546038-9,Phase 2 Unfit: LDAC Alone,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,bacterial infections
D000257,1.45,NCT01546038-7,Phase 2 Fit: Glasdegib 100 mg + Cytarabine/Daunorubicin,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,adenovirus infection
D001170,1.45,NCT01546038-7,Phase 2 Fit: Glasdegib 100 mg + Cytarabine/Daunorubicin,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,bacterial arthritis
D009164,1.45,NCT01546038-7,Phase 2 Fit: Glasdegib 100 mg + Cytarabine/Daunorubicin,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,mycobacterium infections
D010612,1.45,NCT01546038-7,Phase 2 Fit: Glasdegib 100 mg + Cytarabine/Daunorubicin,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,pharyngitis
D011020,1.45,NCT01546038-7,Phase 2 Fit: Glasdegib 100 mg + Cytarabine/Daunorubicin,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,pneumocystis jirovecii pneumonia
D000985,1.45,NCT01546038-7,Phase 2 Fit: Glasdegib 100 mg + Cytarabine/Daunorubicin,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,antisepsis
D000038,1.45,NCT01546038-7,Phase 2 Fit: Glasdegib 100 mg + Cytarabine/Daunorubicin,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,abscess
10056519,1.19,NCT01546038-8,Phase 2 Unfit: Glasdegib 100 mg + LDAC,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,abdominal infection
D000068016,5.88,NCT01546038-1,Phase 1B: Glasdegib 100 mg + LDAC,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,clostridiales
10016173,33.33,NCT01546038-2,Phase 1B: Glasdegib 200 mg + LDAC,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,fall
10016173,2.38,NCT01546038-8,Phase 2 Unfit: Glasdegib 100 mg + LDAC,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,fall
D003869,6.25,NCT01546038-5,Phase 1B: Glasdegib 100 mg + Cytarabine/Daunorubicin,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,dermabrasion
10051792,1.45,NCT01546038-7,Phase 2 Fit: Glasdegib 100 mg + Cytarabine/Daunorubicin,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,infusion related reaction
10051792,1.19,NCT01546038-8,Phase 2 Unfit: Glasdegib 100 mg + LDAC,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,infusion related reaction
D006408,2.9,NCT01546038-7,Phase 2 Fit: Glasdegib 100 mg + Cytarabine/Daunorubicin,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,hematoma subdural
D005265,1.19,NCT01546038-8,Phase 2 Unfit: Glasdegib 100 mg + LDAC,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,femur neck fractures
D013161,2.44,NCT01546038-9,Phase 2 Unfit: LDAC Alone,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,splenic rupture
D001468,1.19,NCT01546038-8,Phase 2 Unfit: Glasdegib 100 mg + LDAC,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,thoracica
D013129,16.67,NCT01546038-2,Phase 1B: Glasdegib 200 mg + LDAC,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,lumbar puncture
10001551,1.45,NCT01546038-7,Phase 2 Fit: Glasdegib 100 mg + Cytarabine/Daunorubicin,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,alanine aminotransferase increased
10003481,1.45,NCT01546038-7,Phase 2 Fit: Glasdegib 100 mg + Cytarabine/Daunorubicin,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,aspartate aminotransferase increased
D019411,2.44,NCT01546038-9,Phase 2 Unfit: LDAC Alone,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,clinical laboratory tests
D003681,16.67,NCT01546038-2,Phase 1B: Glasdegib 200 mg + LDAC,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,dehydration
D006073,5.88,NCT01546038-1,Phase 1B: Glasdegib 100 mg + LDAC,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,gout
D006073,1.19,NCT01546038-8,Phase 2 Unfit: Glasdegib 100 mg + LDAC,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,gout
UNKNOWN-check-for-typo,5.88,NCT01546038-1,Phase 1B: Glasdegib 100 mg + LDAC,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,D00
UNKNOWN-check-for-typo,25.0,NCT01546038-3,Phase 1B: Glasdegib 100 mg + Decitabine,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,D00
UNKNOWN-check-for-typo,1.45,NCT01546038-7,Phase 2 Fit: Glasdegib 100 mg + Cytarabine/Daunorubicin,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,D00
UNKNOWN-check-for-typo,2.38,NCT01546038-8,Phase 2 Unfit: Glasdegib 100 mg + LDAC,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,D00
D015275,5.88,NCT01546038-1,Phase 1B: Glasdegib 100 mg + LDAC,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,tumour lysis syndrome
D001066,1.19,NCT01546038-8,Phase 2 Unfit: Glasdegib 100 mg + LDAC,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,appetite
D018771,16.67,NCT01546038-2,Phase 1B: Glasdegib 200 mg + LDAC,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,arthralgia
D063806,6.25,NCT01546038-5,Phase 1B: Glasdegib 100 mg + Cytarabine/Daunorubicin,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,myalgia
D063806,1.19,NCT01546038-8,Phase 2 Unfit: Glasdegib 100 mg + LDAC,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,myalgia
D001416,1.45,NCT01546038-7,Phase 2 Fit: Glasdegib 100 mg + Cytarabine/Daunorubicin,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,back pain
D001416,1.19,NCT01546038-8,Phase 2 Unfit: Glasdegib 100 mg + LDAC,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,back pain
D013035,1.19,NCT01546038-8,Phase 2 Unfit: Glasdegib 100 mg + LDAC,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,muscle spasms
D018908,2.38,NCT01546038-8,Phase 2 Unfit: Glasdegib 100 mg + LDAC,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,muscular weakness
D002294,2.44,NCT01546038-9,Phase 2 Unfit: LDAC Alone,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,carcinoma squamous cell
D001341,16.67,NCT01546038-2,Phase 1B: Glasdegib 200 mg + LDAC,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,autonomic nervous system
D004244,33.33,NCT01546038-4,Phase 1B: Glasdegib 200 mg + Decitabine,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,dizziness
D013474,25.0,NCT01546038-3,Phase 1B: Glasdegib 100 mg + Decitabine,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,sunstroke
D020149,6.25,NCT01546038-5,Phase 1B: Glasdegib 100 mg + Cytarabine/Daunorubicin,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,neurotoxicity syndrome manganese
D011115,6.25,NCT01546038-5,Phase 1B: Glasdegib 100 mg + Cytarabine/Daunorubicin,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,polyneuropathy
D007427,6.25,NCT01546038-5,Phase 1B: Glasdegib 100 mg + Cytarabine/Daunorubicin,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,subarachnoid pressure
D007427,1.19,NCT01546038-8,Phase 2 Unfit: Glasdegib 100 mg + LDAC,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,subarachnoid pressure
D020820,1.45,NCT01546038-7,Phase 2 Fit: Glasdegib 100 mg + Cytarabine/Daunorubicin,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,dyskinesia
D013575,1.45,NCT01546038-7,Phase 2 Fit: Glasdegib 100 mg + Cytarabine/Daunorubicin,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,presyncope
D013575,1.19,NCT01546038-8,Phase 2 Unfit: Glasdegib 100 mg + LDAC,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,presyncope
D013575,1.45,NCT01546038-7,Phase 2 Fit: Glasdegib 100 mg + Cytarabine/Daunorubicin,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,syncope
D013575,4.76,NCT01546038-8,Phase 2 Unfit: Glasdegib 100 mg + LDAC,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,syncope
D000074042,1.19,NCT01546038-8,Phase 2 Unfit: Glasdegib 100 mg + LDAC,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,cerebral intraventricular haemorrhage
D000069280,3.57,NCT01546038-8,Phase 2 Unfit: Glasdegib 100 mg + LDAC,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,intracranial electroencephalography
D000069280,2.44,NCT01546038-9,Phase 2 Unfit: LDAC Alone,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,intracranial electroencephalography
D010523,1.19,NCT01546038-8,Phase 2 Unfit: Glasdegib 100 mg + LDAC,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,neuropathy peripheral
D002546,1.19,NCT01546038-8,Phase 2 Unfit: Glasdegib 100 mg + LDAC,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,ischemic attack transient
D020521,1.19,NCT01546038-8,Phase 2 Unfit: Glasdegib 100 mg + LDAC,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,cerebrovascular accident
D001714,6.25,NCT01546038-5,Phase 1B: Glasdegib 100 mg + Cytarabine/Daunorubicin,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,bipolar disorder
D000073216,16.67,NCT01546038-2,Phase 1B: Glasdegib 200 mg + LDAC,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,mental status tests
D003221,1.45,NCT01546038-7,Phase 2 Fit: Glasdegib 100 mg + Cytarabine/Daunorubicin,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,confusional state
D058186,1.45,NCT01546038-7,Phase 2 Fit: Glasdegib 100 mg + Cytarabine/Daunorubicin,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,acute kidney injury
D058186,3.57,NCT01546038-8,Phase 2 Unfit: Glasdegib 100 mg + LDAC,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,acute kidney injury
D012128,5.88,NCT01546038-1,Phase 1B: Glasdegib 100 mg + LDAC,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,acute respiratory distress syndrome
D012128,1.19,NCT01546038-8,Phase 2 Unfit: Glasdegib 100 mg + LDAC,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,acute respiratory distress syndrome
D012131,25.0,NCT01546038-3,Phase 1B: Glasdegib 100 mg + Decitabine,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,respiratory failure
10035623,1.45,NCT01546038-7,Phase 2 Fit: Glasdegib 100 mg + Cytarabine/Daunorubicin,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,pleuritic pain
D011014,1.45,NCT01546038-7,Phase 2 Fit: Glasdegib 100 mg + Cytarabine/Daunorubicin,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,pneumonitis
D003371,2.44,NCT01546038-9,Phase 2 Unfit: LDAC Alone,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,cough
UNKNOWN-check-for-typo,1.19,NCT01546038-8,Phase 2 Unfit: Glasdegib 100 mg + LDAC,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,D00
D010996,1.19,NCT01546038-8,Phase 2 Unfit: Glasdegib 100 mg + LDAC,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,pleural effusion
D010996,2.44,NCT01546038-9,Phase 2 Unfit: LDAC Alone,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,pleural effusion
D011655,1.19,NCT01546038-8,Phase 2 Unfit: Glasdegib 100 mg + LDAC,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,pulmonary embolism
D019390,2.44,NCT01546038-9,Phase 2 Unfit: LDAC Alone,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,arrestins
D012127,1.19,NCT01546038-8,Phase 2 Unfit: Glasdegib 100 mg + LDAC,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,respiratory distress syndrome newborn
D005076,6.25,NCT01546038-5,Phase 1B: Glasdegib 100 mg + Cytarabine/Daunorubicin,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,rash
10037868,6.25,NCT01546038-5,Phase 1B: Glasdegib 100 mg + Cytarabine/Daunorubicin,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,rash maculo-papular
D005076,1.19,NCT01546038-8,Phase 2 Unfit: Glasdegib 100 mg + LDAC,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,rash
D000081015,1.19,NCT01546038-8,Phase 2 Unfit: Glasdegib 100 mg + LDAC,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,ototoxicity
D007022,16.67,NCT01546038-2,Phase 1B: Glasdegib 200 mg + LDAC,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,hypotension
D007022,1.45,NCT01546038-7,Phase 2 Fit: Glasdegib 100 mg + Cytarabine/Daunorubicin,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,hypotension
D000074042,1.19,NCT01546038-8,Phase 2 Unfit: Glasdegib 100 mg + LDAC,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,cerebral intraventricular haemorrhage
D006973,1.19,NCT01546038-8,Phase 2 Unfit: Glasdegib 100 mg + LDAC,NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,hypertension
D009026,5.26,NCT01555541-1,Treatment,NCT01555541,Study of Intensive Consolidation and Stem Cell Mobilization Therapy Followed by Autologous Stem Cell Transplantation in High-risk Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma,mortality
D064420,26.32,NCT01555541-1,Treatment,NCT01555541,Study of Intensive Consolidation and Stem Cell Mobilization Therapy Followed by Autologous Stem Cell Transplantation in High-risk Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma,adverse drug events
10002167,5.26,NCT01555541-1,Treatment,NCT01555541,Study of Intensive Consolidation and Stem Cell Mobilization Therapy Followed by Autologous Stem Cell Transplantation in High-risk Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma,anal pain
10038981,5.26,NCT01555541-1,Treatment,NCT01555541,Study of Intensive Consolidation and Stem Cell Mobilization Therapy Followed by Autologous Stem Cell Transplantation in High-risk Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma,retroperitoneal hemorrhage
D006967,5.26,NCT01555541-1,Treatment,NCT01555541,Study of Intensive Consolidation and Stem Cell Mobilization Therapy Followed by Autologous Stem Cell Transplantation in High-risk Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma,allergic reaction
D018805,5.26,NCT01555541-1,Treatment,NCT01555541,Study of Intensive Consolidation and Stem Cell Mobilization Therapy Followed by Autologous Stem Cell Transplantation in High-risk Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma,sepsis
D014202,5.26,NCT01555541-1,Treatment,NCT01555541,Study of Intensive Consolidation and Stem Cell Mobilization Therapy Followed by Autologous Stem Cell Transplantation in High-risk Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma,tremor
D011014,5.26,NCT01555541-1,Treatment,NCT01555541,Study of Intensive Consolidation and Stem Cell Mobilization Therapy Followed by Autologous Stem Cell Transplantation in High-risk Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma,pneumonitis
D064420,33.33,NCT01607645-2,Arm II (Decitabine (Day -9 to Day -5) Idarubicin Cytarabine),NCT01607645,Decitabine Followed by Idarubicin and Cytarabine in Treating Patients With Relapsed or Refractory AML and MDS,adverse drug events
D000069544,33.33,NCT01607645-2,Arm II (Decitabine (Day -9 to Day -5) Idarubicin Cytarabine),NCT01607645,Decitabine Followed by Idarubicin and Cytarabine in Treating Patients With Relapsed or Refractory AML and MDS,encephalitis infection
D064420,40.0,NCT01653418-1,V-BEAM + Stem Cell Infusion,NCT01653418,Phase II Study of V-BEAM Conditioning Regimen Prior to Second Autologous Stem Cell Transplantation,adverse drug events
D003967,10.0,NCT01653418-1,V-BEAM + Stem Cell Infusion,NCT01653418,Phase II Study of V-BEAM Conditioning Regimen Prior to Second Autologous Stem Cell Transplantation,diarrhea
D009102,10.0,NCT01653418-1,V-BEAM + Stem Cell Infusion,NCT01653418,Phase II Study of V-BEAM Conditioning Regimen Prior to Second Autologous Stem Cell Transplantation,multiple organ failure
D064147,10.0,NCT01653418-1,V-BEAM + Stem Cell Infusion,NCT01653418,Phase II Study of V-BEAM Conditioning Regimen Prior to Second Autologous Stem Cell Transplantation,febrile neutropenia
D000985,20.0,NCT01653418-1,V-BEAM + Stem Cell Infusion,NCT01653418,Phase II Study of V-BEAM Conditioning Regimen Prior to Second Autologous Stem Cell Transplantation,antisepsis
D064420,50.0,NCT01701375-1,Arm 1,NCT01701375,A Phase 1 Trial of TST of PD 0332991 Followed by Cytarabine and Mitoxantrone for Adults With Relapsed and Refractory Acute Leukemias and High-Risk Myelodysplasia,adverse drug events
D001853,50.0,NCT01701375-1,Arm 1,NCT01701375,A Phase 1 Trial of TST of PD 0332991 Followed by Cytarabine and Mitoxantrone for Adults With Relapsed and Refractory Acute Leukemias and High-Risk Myelodysplasia,bone marrow
D006932,50.0,NCT01701375-1,Arm 1,NCT01701375,A Phase 1 Trial of TST of PD 0332991 Followed by Cytarabine and Mitoxantrone for Adults With Relapsed and Refractory Acute Leukemias and High-Risk Myelodysplasia,hyperbilirubinemia
D009026,33.33,NCT01729845-1,Dose Level 1: 5-Days of Decitabine-MEC,NCT01729845,Decitabine Followed by Mitoxantrone Hydrochloride  Etoposide  and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes,mortality
D009026,2.94,NCT01729845-2,Dose Level 2: 7-Days of Decitabine-MEC,NCT01729845,Decitabine Followed by Mitoxantrone Hydrochloride  Etoposide  and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes,mortality
D009026,48.28,NCT01802333-1,Arm I (Standard Dose Cytarabine Daunorubicin Hydrochloride),NCT01802333,Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia,mortality
D009026,44.02,NCT01802333-2,Arm II (High-dose Cytarabine Idarubicin),NCT01802333,Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia,mortality
D009026,48.82,NCT01802333-3,Arm III (Vorinostat High-dose Cytarabine Idarubicin),NCT01802333,Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia,mortality
D064420,4.21,NCT01802333-1,Arm I (Standard Dose Cytarabine Daunorubicin Hydrochloride),NCT01802333,Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia,adverse drug events
D064420,10.42,NCT01802333-2,Arm II (High-dose Cytarabine Idarubicin),NCT01802333,Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia,adverse drug events
D064420,35.55,NCT01802333-3,Arm III (Vorinostat High-dose Cytarabine Idarubicin),NCT01802333,Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia,adverse drug events
D064147,0.38,NCT01802333-1,Arm I (Standard Dose Cytarabine Daunorubicin Hydrochloride),NCT01802333,Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia,febrile neutropenia
D064147,1.54,NCT01802333-2,Arm II (High-dose Cytarabine Idarubicin),NCT01802333,Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia,febrile neutropenia
D064147,6.16,NCT01802333-3,Arm III (Vorinostat High-dose Cytarabine Idarubicin),NCT01802333,Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia,febrile neutropenia
D007964,0.47,NCT01802333-3,Arm III (Vorinostat High-dose Cytarabine Idarubicin),NCT01802333,Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia,leukocytosis
D001281,0.77,NCT01802333-2,Arm II (High-dose Cytarabine Idarubicin),NCT01802333,Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia,atrial fibrillation
D001281,0.47,NCT01802333-3,Arm III (Vorinostat High-dose Cytarabine Idarubicin),NCT01802333,Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia,atrial fibrillation
D001282,0.47,NCT01802333-3,Arm III (Vorinostat High-dose Cytarabine Idarubicin),NCT01802333,Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia,atrial flutter
D006323,0.38,NCT01802333-1,Arm I (Standard Dose Cytarabine Daunorubicin Hydrochloride),NCT01802333,Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia,cardiac arrest
D006323,1.54,NCT01802333-2,Arm II (High-dose Cytarabine Idarubicin),NCT01802333,Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia,cardiac arrest
D006323,0.95,NCT01802333-3,Arm III (Vorinostat High-dose Cytarabine Idarubicin),NCT01802333,Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia,cardiac arrest
D006333,0.47,NCT01802333-3,Arm III (Vorinostat High-dose Cytarabine Idarubicin),NCT01802333,Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia,heart failure
D010490,1.42,NCT01802333-3,Arm III (Vorinostat High-dose Cytarabine Idarubicin),NCT01802333,Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia,pericardial effusion
D002305,0.47,NCT01802333-3,Arm III (Vorinostat High-dose Cytarabine Idarubicin),NCT01802333,Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia,pericardial tamponade
D013616,0.39,NCT01802333-2,Arm II (High-dose Cytarabine Idarubicin),NCT01802333,Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia,sinus tachycardia
D013616,1.42,NCT01802333-3,Arm III (Vorinostat High-dose Cytarabine Idarubicin),NCT01802333,Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia,sinus tachycardia
D013617,0.47,NCT01802333-3,Arm III (Vorinostat High-dose Cytarabine Idarubicin),NCT01802333,Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia,supraventricular tachycardia
10000060,0.47,NCT01802333-3,Arm III (Vorinostat High-dose Cytarabine Idarubicin),NCT01802333,Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia,abdominal distension
D015746,2.37,NCT01802333-3,Arm III (Vorinostat High-dose Cytarabine Idarubicin),NCT01802333,Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia,abdominal pain
D003092,2.84,NCT01802333-3,Arm III (Vorinostat High-dose Cytarabine Idarubicin),NCT01802333,Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia,colitis
10009998,0.47,NCT01802333-3,Arm III (Vorinostat High-dose Cytarabine Idarubicin),NCT01802333,Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia,colonic hemorrhage
10010001,0.47,NCT01802333-3,Arm III (Vorinostat High-dose Cytarabine Idarubicin),NCT01802333,Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia,colonic perforation
D003967,2.84,NCT01802333-3,Arm III (Vorinostat High-dose Cytarabine Idarubicin),NCT01802333,Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia,diarrhea
D004760,0.77,NCT01802333-2,Arm II (High-dose Cytarabine Idarubicin),NCT01802333,Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia,enterocolitis
D004760,0.95,NCT01802333-3,Arm III (Vorinostat High-dose Cytarabine Idarubicin),NCT01802333,Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia,enterocolitis
10015384,0.47,NCT01802333-3,Arm III (Vorinostat High-dose Cytarabine Idarubicin),NCT01802333,Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia,esophageal hemorrhage
D004941,0.47,NCT01802333-3,Arm III (Vorinostat High-dose Cytarabine Idarubicin),NCT01802333,Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia,esophagitis
D005242,0.47,NCT01802333-3,Arm III (Vorinostat High-dose Cytarabine Idarubicin),NCT01802333,Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia,fecal incontinence
10017789,0.39,NCT01802333-2,Arm II (High-dose Cytarabine Idarubicin),NCT01802333,Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia,gastric hemorrhage
10017789,0.47,NCT01802333-3,Arm III (Vorinostat High-dose Cytarabine Idarubicin),NCT01802333,Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia,gastric hemorrhage
D005756,0.47,NCT01802333-3,Arm III (Vorinostat High-dose Cytarabine Idarubicin),NCT01802333,Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia,gastritis
10017947,0.39,NCT01802333-2,Arm II (High-dose Cytarabine Idarubicin),NCT01802333,Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia,gastrointestinal disorders - other specify
10017947,0.47,NCT01802333-3,Arm III (Vorinostat High-dose Cytarabine Idarubicin),NCT01802333,Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia,gastrointestinal disorders - other specify
D045823,0.95,NCT01802333-3,Arm III (Vorinostat High-dose Cytarabine Idarubicin),NCT01802333,Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia,ileus
10065732,0.47,NCT01802333-3,Arm III (Vorinostat High-dose Cytarabine Idarubicin),NCT01802333,Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia,jejunal obstruction
10051746,0.47,NCT01802333-3,Arm III (Vorinostat High-dose Cytarabine Idarubicin),NCT01802333,Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia,lower gastrointestinal hemorrhage
10028130,1.42,NCT01802333-3,Arm III (Vorinostat High-dose Cytarabine Idarubicin),NCT01802333,Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia,mucositis oral
D009325,0.47,NCT01802333-3,Arm III (Vorinostat High-dose Cytarabine Idarubicin),NCT01802333,Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia,nausea
D053706,0.38,NCT01802333-1,Arm I (Standard Dose Cytarabine Daunorubicin Hydrochloride),NCT01802333,Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia,typhlitis
D053706,3.32,NCT01802333-3,Arm III (Vorinostat High-dose Cytarabine Idarubicin),NCT01802333,Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia,typhlitis
D014839,0.38,NCT01802333-1,Arm I (Standard Dose Cytarabine Daunorubicin Hydrochloride),NCT01802333,Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia,vomiting
D014839,0.47,NCT01802333-3,Arm III (Vorinostat High-dose Cytarabine Idarubicin),NCT01802333,Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia,vomiting
10011914,0.77,NCT01802333-1,Arm I (Standard Dose Cytarabine Daunorubicin Hydrochloride),NCT01802333,Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia,death nos
10011914,0.39,NCT01802333-2,Arm II (High-dose Cytarabine Idarubicin),NCT01802333,Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia,death nos
10011914,0.47,NCT01802333-3,Arm III (Vorinostat High-dose Cytarabine Idarubicin),NCT01802333,Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia,death nos
10050068,0.95,NCT01802333-3,Arm III (Vorinostat High-dose Cytarabine Idarubicin),NCT01802333,Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia,edema limbs
10058720,0.47,NCT01802333-3,Arm III (Vorinostat High-dose Cytarabine Idarubicin),NCT01802333,Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia,edema trunk
10017577,0.47,NCT01802333-3,Arm III (Vorinostat High-dose Cytarabine Idarubicin),NCT01802333,Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia,gait disturbance
10018065,0.39,NCT01802333-2,Arm II (High-dose Cytarabine Idarubicin),NCT01802333,Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia,general disorders and administration site conditions - other specify
D009102,0.38,NCT01802333-1,Arm I (Standard Dose Cytarabine Daunorubicin Hydrochloride),NCT01802333,Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia,multiple organ failure
D009102,0.77,NCT01802333-2,Arm II (High-dose Cytarabine Idarubicin),NCT01802333,Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia,multiple organ failure
D009102,1.9,NCT01802333-3,Arm III (Vorinostat High-dose Cytarabine Idarubicin),NCT01802333,Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia,multiple organ failure
10054482,0.47,NCT01802333-3,Arm III (Vorinostat High-dose Cytarabine Idarubicin),NCT01802333,Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia,neck edema
D002764,0.47,NCT01802333-3,Arm III (Vorinostat High-dose Cytarabine Idarubicin),NCT01802333,Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia,cholecystitis
D017093,0.38,NCT01802333-1,Arm I (Standard Dose Cytarabine Daunorubicin Hydrochloride),NCT01802333,Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia,hepatic failure
10019805,0.38,NCT01802333-1,Arm I (Standard Dose Cytarabine Daunorubicin Hydrochloride),NCT01802333,Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia,hepatobiliary disorders - other specify
10019805,0.47,NCT01802333-3,Arm III (Vorinostat High-dose Cytarabine Idarubicin),NCT01802333,Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia,hepatobiliary disorders - other specify
D006967,0.47,NCT01802333-3,Arm III (Vorinostat High-dose Cytarabine Idarubicin),NCT01802333,Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia,allergic reaction
10058838,0.47,NCT01802333-3,Arm III (Vorinostat High-dose Cytarabine Idarubicin),NCT01802333,Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia,enterocolitis infectious
10021881,2.37,NCT01802333-3,Arm III (Vorinostat High-dose Cytarabine Idarubicin),NCT01802333,Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia,infections and infestations - other specify
10065755,0.47,NCT01802333-3,Arm III (Vorinostat High-dose Cytarabine Idarubicin),NCT01802333,Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia,lip infection
10061229,0.39,NCT01802333-2,Arm II (High-dose Cytarabine Idarubicin),NCT01802333,Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia,lung infection
10061229,1.9,NCT01802333-3,Arm III (Vorinostat High-dose Cytarabine Idarubicin),NCT01802333,Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia,lung infection
D018805,0.38,NCT01802333-1,Arm I (Standard Dose Cytarabine Daunorubicin Hydrochloride),NCT01802333,Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia,sepsis
D018805,4.25,NCT01802333-2,Arm II (High-dose Cytarabine Idarubicin),NCT01802333,Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia,sepsis
D018805,8.06,NCT01802333-3,Arm III (Vorinostat High-dose Cytarabine Idarubicin),NCT01802333,Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia,sepsis
10046300,0.47,NCT01802333-3,Arm III (Vorinostat High-dose Cytarabine Idarubicin),NCT01802333,Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia,upper respiratory infection
D014552,0.47,NCT01802333-3,Arm III (Vorinostat High-dose Cytarabine Idarubicin),NCT01802333,Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia,urinary tract infection
10000636,0.47,NCT01802333-3,Arm III (Vorinostat High-dose Cytarabine Idarubicin),NCT01802333,Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia,activated partial thromboplastin time prolonged
10001551,2.84,NCT01802333-3,Arm III (Vorinostat High-dose Cytarabine Idarubicin),NCT01802333,Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia,alanine aminotransferase increased
10001675,0.95,NCT01802333-3,Arm III (Vorinostat High-dose Cytarabine Idarubicin),NCT01802333,Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia,alkaline phosphatase increased
10003481,2.37,NCT01802333-3,Arm III (Vorinostat High-dose Cytarabine Idarubicin),NCT01802333,Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia,aspartate aminotransferase increased
10005364,0.39,NCT01802333-2,Arm II (High-dose Cytarabine Idarubicin),NCT01802333,Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia,blood bilirubin increased
10005364,3.32,NCT01802333-3,Arm III (Vorinostat High-dose Cytarabine Idarubicin),NCT01802333,Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia,blood bilirubin increased
10007612,0.39,NCT01802333-2,Arm II (High-dose Cytarabine Idarubicin),NCT01802333,Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia,cardiac troponin i increased
10011368,0.47,NCT01802333-3,Arm III (Vorinostat High-dose Cytarabine Idarubicin),NCT01802333,Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia,creatinine increased
10050528,1.42,NCT01802333-3,Arm III (Vorinostat High-dose Cytarabine Idarubicin),NCT01802333,Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia,ejection fraction decreased
10014383,0.47,NCT01802333-3,Arm III (Vorinostat High-dose Cytarabine Idarubicin),NCT01802333,Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia,electrocardiogram qt corrected interval prolonged
10016596,0.47,NCT01802333-3,Arm III (Vorinostat High-dose Cytarabine Idarubicin),NCT01802333,Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia,fibrinogen decreased
10056910,0.95,NCT01802333-3,Arm III (Vorinostat High-dose Cytarabine Idarubicin),NCT01802333,Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia,ggt increased
10022402,0.47,NCT01802333-3,Arm III (Vorinostat High-dose Cytarabine Idarubicin),NCT01802333,Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia,inr increased
10035528,0.95,NCT01802333-3,Arm III (Vorinostat High-dose Cytarabine Idarubicin),NCT01802333,Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia,platelet count decreased
D015430,0.47,NCT01802333-3,Arm III (Vorinostat High-dose Cytarabine Idarubicin),NCT01802333,Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia,weight gain
D015431,0.47,NCT01802333-3,Arm III (Vorinostat High-dose Cytarabine Idarubicin),NCT01802333,Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia,weight loss
D000138,0.95,NCT01802333-3,Arm III (Vorinostat High-dose Cytarabine Idarubicin),NCT01802333,Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia,acidosis
D000471,0.47,NCT01802333-3,Arm III (Vorinostat High-dose Cytarabine Idarubicin),NCT01802333,Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia,alkalosis
D000855,2.37,NCT01802333-3,Arm III (Vorinostat High-dose Cytarabine Idarubicin),NCT01802333,Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia,anorexia
D003681,0.47,NCT01802333-3,Arm III (Vorinostat High-dose Cytarabine Idarubicin),NCT01802333,Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia,dehydration
D006943,1.42,NCT01802333-3,Arm III (Vorinostat High-dose Cytarabine Idarubicin),NCT01802333,Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia,hyperglycemia
D006955,0.95,NCT01802333-3,Arm III (Vorinostat High-dose Cytarabine Idarubicin),NCT01802333,Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia,hypernatremia
D034141,0.38,NCT01802333-1,Arm I (Standard Dose Cytarabine Daunorubicin Hydrochloride),NCT01802333,Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia,hypoalbuminemia
D034141,1.42,NCT01802333-3,Arm III (Vorinostat High-dose Cytarabine Idarubicin),NCT01802333,Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia,hypoalbuminemia
D006996,0.38,NCT01802333-1,Arm I (Standard Dose Cytarabine Daunorubicin Hydrochloride),NCT01802333,Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia,hypocalcemia
D006996,1.9,NCT01802333-3,Arm III (Vorinostat High-dose Cytarabine Idarubicin),NCT01802333,Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia,hypocalcemia
D007008,0.38,NCT01802333-1,Arm I (Standard Dose Cytarabine Daunorubicin Hydrochloride),NCT01802333,Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia,hypokalemia
D007008,2.84,NCT01802333-3,Arm III (Vorinostat High-dose Cytarabine Idarubicin),NCT01802333,Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia,hypokalemia
D007010,0.38,NCT01802333-1,Arm I (Standard Dose Cytarabine Daunorubicin Hydrochloride),NCT01802333,Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia,hyponatremia
D007010,0.95,NCT01802333-3,Arm III (Vorinostat High-dose Cytarabine Idarubicin),NCT01802333,Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia,hyponatremia
D017674,0.39,NCT01802333-2,Arm II (High-dose Cytarabine Idarubicin),NCT01802333,Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia,hypophosphatemia
D017674,0.95,NCT01802333-3,Arm III (Vorinostat High-dose Cytarabine Idarubicin),NCT01802333,Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia,hypophosphatemia
D015275,0.39,NCT01802333-2,Arm II (High-dose Cytarabine Idarubicin),NCT01802333,Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia,tumor lysis syndrome
D015275,1.9,NCT01802333-3,Arm III (Vorinostat High-dose Cytarabine Idarubicin),NCT01802333,Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia,tumor lysis syndrome
D001416,0.47,NCT01802333-3,Arm III (Vorinostat High-dose Cytarabine Idarubicin),NCT01802333,Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia,back pain
10062572,1.42,NCT01802333-3,Arm III (Vorinostat High-dose Cytarabine Idarubicin),NCT01802333,Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia,generalized muscle weakness
10028395,0.47,NCT01802333-3,Arm III (Vorinostat High-dose Cytarabine Idarubicin),NCT01802333,Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia,musculoskeletal and connective tissue disorder - other specify
D063806,0.47,NCT01802333-3,Arm III (Vorinostat High-dose Cytarabine Idarubicin),NCT01802333,Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia,myalgia
10033425,0.47,NCT01802333-3,Arm III (Vorinostat High-dose Cytarabine Idarubicin),NCT01802333,Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia,pain in extremity
D001259,0.47,NCT01802333-3,Arm III (Vorinostat High-dose Cytarabine Idarubicin),NCT01802333,Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia,ataxia
10014217,0.47,NCT01802333-3,Arm III (Vorinostat High-dose Cytarabine Idarubicin),NCT01802333,Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia,edema cerebral
D001927,0.47,NCT01802333-3,Arm III (Vorinostat High-dose Cytarabine Idarubicin),NCT01802333,Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia,encephalopathy
D006261,0.38,NCT01802333-1,Arm I (Standard Dose Cytarabine Daunorubicin Hydrochloride),NCT01802333,Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia,headache
D020300,0.95,NCT01802333-3,Arm III (Vorinostat High-dose Cytarabine Idarubicin),NCT01802333,Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia,intracranial hemorrhage
10023030,0.47,NCT01802333-3,Arm III (Vorinostat High-dose Cytarabine Idarubicin),NCT01802333,Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia,ischemia cerebrovascular
10029205,0.38,NCT01802333-1,Arm I (Standard Dose Cytarabine Daunorubicin Hydrochloride),NCT01802333,Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia,nervous system disorders - other specify
10029205,0.39,NCT01802333-2,Arm II (High-dose Cytarabine Idarubicin),NCT01802333,Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia,nervous system disorders - other specify
D010292,0.47,NCT01802333-3,Arm III (Vorinostat High-dose Cytarabine Idarubicin),NCT01802333,Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia,paresthesia
10034620,0.47,NCT01802333-3,Arm III (Vorinostat High-dose Cytarabine Idarubicin),NCT01802333,Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia,peripheral sensory neuropathy
D054038,0.47,NCT01802333-3,Arm III (Vorinostat High-dose Cytarabine Idarubicin),NCT01802333,Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia,reversible posterior leukoencephalopathy syndrome
D012640,0.38,NCT01802333-1,Arm I (Standard Dose Cytarabine Daunorubicin Hydrochloride),NCT01802333,Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia,seizure
D012640,0.95,NCT01802333-3,Arm III (Vorinostat High-dose Cytarabine Idarubicin),NCT01802333,Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia,seizure
D000077260,0.47,NCT01802333-3,Arm III (Vorinostat High-dose Cytarabine Idarubicin),NCT01802333,Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia,somnolence
D020521,1.42,NCT01802333-3,Arm III (Vorinostat High-dose Cytarabine Idarubicin),NCT01802333,Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia,stroke
10047166,0.47,NCT01802333-3,Arm III (Vorinostat High-dose Cytarabine Idarubicin),NCT01802333,Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia,vasovagal reaction
D058186,0.77,NCT01802333-1,Arm I (Standard Dose Cytarabine Daunorubicin Hydrochloride),NCT01802333,Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia,acute kidney injury
D058186,1.54,NCT01802333-2,Arm II (High-dose Cytarabine Idarubicin),NCT01802333,Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia,acute kidney injury
D058186,4.27,NCT01802333-3,Arm III (Vorinostat High-dose Cytarabine Idarubicin),NCT01802333,Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia,acute kidney injury
D014549,0.47,NCT01802333-3,Arm III (Vorinostat High-dose Cytarabine Idarubicin),NCT01802333,Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia,urinary incontinence
10018146,0.47,NCT01802333-3,Arm III (Vorinostat High-dose Cytarabine Idarubicin),NCT01802333,Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia,genital edema
D012128,0.38,NCT01802333-1,Arm I (Standard Dose Cytarabine Daunorubicin Hydrochloride),NCT01802333,Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia,adult respiratory distress syndrome
D012128,1.16,NCT01802333-2,Arm II (High-dose Cytarabine Idarubicin),NCT01802333,Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia,adult respiratory distress syndrome
D012128,1.9,NCT01802333-3,Arm III (Vorinostat High-dose Cytarabine Idarubicin),NCT01802333,Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia,adult respiratory distress syndrome
10065746,0.95,NCT01802333-3,Arm III (Vorinostat High-dose Cytarabine Idarubicin),NCT01802333,Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia,bronchopulmonary hemorrhage
D004417,0.39,NCT01802333-2,Arm II (High-dose Cytarabine Idarubicin),NCT01802333,Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia,dyspnea
D004417,0.95,NCT01802333-3,Arm III (Vorinostat High-dose Cytarabine Idarubicin),NCT01802333,Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia,dyspnea
D000860,0.77,NCT01802333-2,Arm II (High-dose Cytarabine Idarubicin),NCT01802333,Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia,hypoxia
D000860,2.37,NCT01802333-3,Arm III (Vorinostat High-dose Cytarabine Idarubicin),NCT01802333,Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia,hypoxia
D010996,0.95,NCT01802333-3,Arm III (Vorinostat High-dose Cytarabine Idarubicin),NCT01802333,Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia,pleural effusion
D011654,0.39,NCT01802333-2,Arm II (High-dose Cytarabine Idarubicin),NCT01802333,Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia,pulmonary edema
D011654,2.37,NCT01802333-3,Arm III (Vorinostat High-dose Cytarabine Idarubicin),NCT01802333,Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia,pulmonary edema
10038738,0.39,NCT01802333-2,Arm II (High-dose Cytarabine Idarubicin),NCT01802333,Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia,respiratory thoracic and mediastinal disorders - other specify
10038738,0.47,NCT01802333-3,Arm III (Vorinostat High-dose Cytarabine Idarubicin),NCT01802333,Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia,respiratory thoracic and mediastinal disorders - other specify
D012131,1.15,NCT01802333-1,Arm I (Standard Dose Cytarabine Daunorubicin Hydrochloride),NCT01802333,Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia,respiratory failure
D012131,2.32,NCT01802333-2,Arm II (High-dose Cytarabine Idarubicin),NCT01802333,Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia,respiratory failure
D012131,7.11,NCT01802333-3,Arm III (Vorinostat High-dose Cytarabine Idarubicin),NCT01802333,Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia,respiratory failure
D003873,0.47,NCT01802333-3,Arm III (Vorinostat High-dose Cytarabine Idarubicin),NCT01802333,Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia,erythroderma
10037868,0.95,NCT01802333-3,Arm III (Vorinostat High-dose Cytarabine Idarubicin),NCT01802333,Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia,rash maculo-papular
D006406,0.39,NCT01802333-2,Arm II (High-dose Cytarabine Idarubicin),NCT01802333,Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia,hematoma
D006973,1.42,NCT01802333-3,Arm III (Vorinostat High-dose Cytarabine Idarubicin),NCT01802333,Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia,hypertension
D007022,0.77,NCT01802333-2,Arm II (High-dose Cytarabine Idarubicin),NCT01802333,Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia,hypotension
D007022,3.79,NCT01802333-3,Arm III (Vorinostat High-dose Cytarabine Idarubicin),NCT01802333,Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia,hypotension
10043565,1.42,NCT01802333-3,Arm III (Vorinostat High-dose Cytarabine Idarubicin),NCT01802333,Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia,thromboembolic event
D009026,2.94,NCT01806571-1,Treatment (Nilotinib Daunorubicin Hydrochloride Cytarabine),NCT01806571,Daunorubicin Hydrochloride  Cytarabine  and Nilotinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,mortality
D064420,91.18,NCT01806571-1,Treatment (Nilotinib Daunorubicin Hydrochloride Cytarabine),NCT01806571,Daunorubicin Hydrochloride  Cytarabine  and Nilotinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,adverse drug events
D064147,52.94,NCT01806571-1,Treatment (Nilotinib Daunorubicin Hydrochloride Cytarabine),NCT01806571,Daunorubicin Hydrochloride  Cytarabine  and Nilotinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,febrile neutropenia
D001281,2.94,NCT01806571-1,Treatment (Nilotinib Daunorubicin Hydrochloride Cytarabine),NCT01806571,Daunorubicin Hydrochloride  Cytarabine  and Nilotinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,atrial fibrillation
D001282,2.94,NCT01806571-1,Treatment (Nilotinib Daunorubicin Hydrochloride Cytarabine),NCT01806571,Daunorubicin Hydrochloride  Cytarabine  and Nilotinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,atrial flutter
D006333,2.94,NCT01806571-1,Treatment (Nilotinib Daunorubicin Hydrochloride Cytarabine),NCT01806571,Daunorubicin Hydrochloride  Cytarabine  and Nilotinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,heart failure
D013616,2.94,NCT01806571-1,Treatment (Nilotinib Daunorubicin Hydrochloride Cytarabine),NCT01806571,Daunorubicin Hydrochloride  Cytarabine  and Nilotinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,sinus tachycardia
D014717,2.94,NCT01806571-1,Treatment (Nilotinib Daunorubicin Hydrochloride Cytarabine),NCT01806571,Daunorubicin Hydrochloride  Cytarabine  and Nilotinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,vertigo
10017947,2.94,NCT01806571-1,Treatment (Nilotinib Daunorubicin Hydrochloride Cytarabine),NCT01806571,Daunorubicin Hydrochloride  Cytarabine  and Nilotinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,gastrointestinal disorders - other specify
10055300,2.94,NCT01806571-1,Treatment (Nilotinib Daunorubicin Hydrochloride Cytarabine),NCT01806571,Daunorubicin Hydrochloride  Cytarabine  and Nilotinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,jejunal hemorrhage
D009325,2.94,NCT01806571-1,Treatment (Nilotinib Daunorubicin Hydrochloride Cytarabine),NCT01806571,Daunorubicin Hydrochloride  Cytarabine  and Nilotinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,nausea
D010195,2.94,NCT01806571-1,Treatment (Nilotinib Daunorubicin Hydrochloride Cytarabine),NCT01806571,Daunorubicin Hydrochloride  Cytarabine  and Nilotinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,pancreatitis
D012003,2.94,NCT01806571-1,Treatment (Nilotinib Daunorubicin Hydrochloride Cytarabine),NCT01806571,Daunorubicin Hydrochloride  Cytarabine  and Nilotinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,rectal fistula
D014839,2.94,NCT01806571-1,Treatment (Nilotinib Daunorubicin Hydrochloride Cytarabine),NCT01806571,Daunorubicin Hydrochloride  Cytarabine  and Nilotinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,vomiting
D017093,2.94,NCT01806571-1,Treatment (Nilotinib Daunorubicin Hydrochloride Cytarabine),NCT01806571,Daunorubicin Hydrochloride  Cytarabine  and Nilotinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,hepatic failure
10019805,2.94,NCT01806571-1,Treatment (Nilotinib Daunorubicin Hydrochloride Cytarabine),NCT01806571,Daunorubicin Hydrochloride  Cytarabine  and Nilotinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,hepatobiliary disorders - other specify
10061640,5.88,NCT01806571-1,Treatment (Nilotinib Daunorubicin Hydrochloride Cytarabine),NCT01806571,Daunorubicin Hydrochloride  Cytarabine  and Nilotinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,anorectal infection
D001064,2.94,NCT01806571-1,Treatment (Nilotinib Daunorubicin Hydrochloride Cytarabine),NCT01806571,Daunorubicin Hydrochloride  Cytarabine  and Nilotinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,appendicitis
10007810,5.88,NCT01806571-1,Treatment (Nilotinib Daunorubicin Hydrochloride Cytarabine),NCT01806571,Daunorubicin Hydrochloride  Cytarabine  and Nilotinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,catheter related infection
10058838,2.94,NCT01806571-1,Treatment (Nilotinib Daunorubicin Hydrochloride Cytarabine),NCT01806571,Daunorubicin Hydrochloride  Cytarabine  and Nilotinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,enterocolitis infectious
10021881,8.82,NCT01806571-1,Treatment (Nilotinib Daunorubicin Hydrochloride Cytarabine),NCT01806571,Daunorubicin Hydrochloride  Cytarabine  and Nilotinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,infections and infestations - other specify
10061229,11.76,NCT01806571-1,Treatment (Nilotinib Daunorubicin Hydrochloride Cytarabine),NCT01806571,Daunorubicin Hydrochloride  Cytarabine  and Nilotinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,lung infection
D018805,14.71,NCT01806571-1,Treatment (Nilotinib Daunorubicin Hydrochloride Cytarabine),NCT01806571,Daunorubicin Hydrochloride  Cytarabine  and Nilotinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,sepsis
10001551,20.59,NCT01806571-1,Treatment (Nilotinib Daunorubicin Hydrochloride Cytarabine),NCT01806571,Daunorubicin Hydrochloride  Cytarabine  and Nilotinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,alanine aminotransferase increased
10001675,2.94,NCT01806571-1,Treatment (Nilotinib Daunorubicin Hydrochloride Cytarabine),NCT01806571,Daunorubicin Hydrochloride  Cytarabine  and Nilotinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,alkaline phosphatase increased
10003481,14.71,NCT01806571-1,Treatment (Nilotinib Daunorubicin Hydrochloride Cytarabine),NCT01806571,Daunorubicin Hydrochloride  Cytarabine  and Nilotinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,aspartate aminotransferase increased
10005364,14.71,NCT01806571-1,Treatment (Nilotinib Daunorubicin Hydrochloride Cytarabine),NCT01806571,Daunorubicin Hydrochloride  Cytarabine  and Nilotinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,blood bilirubin increased
10050528,2.94,NCT01806571-1,Treatment (Nilotinib Daunorubicin Hydrochloride Cytarabine),NCT01806571,Daunorubicin Hydrochloride  Cytarabine  and Nilotinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,ejection fraction decreased
10014383,2.94,NCT01806571-1,Treatment (Nilotinib Daunorubicin Hydrochloride Cytarabine),NCT01806571,Daunorubicin Hydrochloride  Cytarabine  and Nilotinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,electrocardiogram qt corrected interval prolonged
10024574,2.94,NCT01806571-1,Treatment (Nilotinib Daunorubicin Hydrochloride Cytarabine),NCT01806571,Daunorubicin Hydrochloride  Cytarabine  and Nilotinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,lipase increased
10040139,5.88,NCT01806571-1,Treatment (Nilotinib Daunorubicin Hydrochloride Cytarabine),NCT01806571,Daunorubicin Hydrochloride  Cytarabine  and Nilotinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,serum amylase increased
D006943,8.82,NCT01806571-1,Treatment (Nilotinib Daunorubicin Hydrochloride Cytarabine),NCT01806571,Daunorubicin Hydrochloride  Cytarabine  and Nilotinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,hyperglycemia
D006947,2.94,NCT01806571-1,Treatment (Nilotinib Daunorubicin Hydrochloride Cytarabine),NCT01806571,Daunorubicin Hydrochloride  Cytarabine  and Nilotinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,hyperkalemia
D033461,2.94,NCT01806571-1,Treatment (Nilotinib Daunorubicin Hydrochloride Cytarabine),NCT01806571,Daunorubicin Hydrochloride  Cytarabine  and Nilotinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,hyperuricemia
D006996,5.88,NCT01806571-1,Treatment (Nilotinib Daunorubicin Hydrochloride Cytarabine),NCT01806571,Daunorubicin Hydrochloride  Cytarabine  and Nilotinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,hypocalcemia
D007008,5.88,NCT01806571-1,Treatment (Nilotinib Daunorubicin Hydrochloride Cytarabine),NCT01806571,Daunorubicin Hydrochloride  Cytarabine  and Nilotinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,hypokalemia
D017674,11.76,NCT01806571-1,Treatment (Nilotinib Daunorubicin Hydrochloride Cytarabine),NCT01806571,Daunorubicin Hydrochloride  Cytarabine  and Nilotinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,hypophosphatemia
10027433,2.94,NCT01806571-1,Treatment (Nilotinib Daunorubicin Hydrochloride Cytarabine),NCT01806571,Daunorubicin Hydrochloride  Cytarabine  and Nilotinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,metabolism and nutrition disorders - other specify
10034580,2.94,NCT01806571-1,Treatment (Nilotinib Daunorubicin Hydrochloride Cytarabine),NCT01806571,Daunorubicin Hydrochloride  Cytarabine  and Nilotinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,peripheral motor neuropathy
D013575,2.94,NCT01806571-1,Treatment (Nilotinib Daunorubicin Hydrochloride Cytarabine),NCT01806571,Daunorubicin Hydrochloride  Cytarabine  and Nilotinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,syncope
D003221,2.94,NCT01806571-1,Treatment (Nilotinib Daunorubicin Hydrochloride Cytarabine),NCT01806571,Daunorubicin Hydrochloride  Cytarabine  and Nilotinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,confusion
D011507,2.94,NCT01806571-1,Treatment (Nilotinib Daunorubicin Hydrochloride Cytarabine),NCT01806571,Daunorubicin Hydrochloride  Cytarabine  and Nilotinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,proteinuria
D008595,2.94,NCT01806571-1,Treatment (Nilotinib Daunorubicin Hydrochloride Cytarabine),NCT01806571,Daunorubicin Hydrochloride  Cytarabine  and Nilotinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,menorrhagia
10003504,2.94,NCT01806571-1,Treatment (Nilotinib Daunorubicin Hydrochloride Cytarabine),NCT01806571,Daunorubicin Hydrochloride  Cytarabine  and Nilotinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,aspiration
D000860,2.94,NCT01806571-1,Treatment (Nilotinib Daunorubicin Hydrochloride Cytarabine),NCT01806571,Daunorubicin Hydrochloride  Cytarabine  and Nilotinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,hypoxia
D011014,2.94,NCT01806571-1,Treatment (Nilotinib Daunorubicin Hydrochloride Cytarabine),NCT01806571,Daunorubicin Hydrochloride  Cytarabine  and Nilotinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,pneumonitis
D011654,2.94,NCT01806571-1,Treatment (Nilotinib Daunorubicin Hydrochloride Cytarabine),NCT01806571,Daunorubicin Hydrochloride  Cytarabine  and Nilotinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,pulmonary edema
D012131,8.82,NCT01806571-1,Treatment (Nilotinib Daunorubicin Hydrochloride Cytarabine),NCT01806571,Daunorubicin Hydrochloride  Cytarabine  and Nilotinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,respiratory failure
D010612,2.94,NCT01806571-1,Treatment (Nilotinib Daunorubicin Hydrochloride Cytarabine),NCT01806571,Daunorubicin Hydrochloride  Cytarabine  and Nilotinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,sore throat
10037868,5.88,NCT01806571-1,Treatment (Nilotinib Daunorubicin Hydrochloride Cytarabine),NCT01806571,Daunorubicin Hydrochloride  Cytarabine  and Nilotinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,rash maculo-papular
D006973,14.71,NCT01806571-1,Treatment (Nilotinib Daunorubicin Hydrochloride Cytarabine),NCT01806571,Daunorubicin Hydrochloride  Cytarabine  and Nilotinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,hypertension
D007022,5.88,NCT01806571-1,Treatment (Nilotinib Daunorubicin Hydrochloride Cytarabine),NCT01806571,Daunorubicin Hydrochloride  Cytarabine  and Nilotinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,hypotension
D064420,68.18,NCT01829503-1,Decitabine + Cytarabine,NCT01829503,Phase II Study of Decitabine and Cytarabine for Older Patients With Newly Diagnosed Acute Myeloid Leukemia (AML),adverse drug events
D000740,6.82,NCT01829503-1,Decitabine + Cytarabine,NCT01829503,Phase II Study of Decitabine and Cytarabine for Older Patients With Newly Diagnosed Acute Myeloid Leukemia (AML),anemia
D006425,2.27,NCT01829503-1,Decitabine + Cytarabine,NCT01829503,Phase II Study of Decitabine and Cytarabine for Older Patients With Newly Diagnosed Acute Myeloid Leukemia (AML),blood and lymphatic system disorders
D064147,11.36,NCT01829503-1,Decitabine + Cytarabine,NCT01829503,Phase II Study of Decitabine and Cytarabine for Older Patients With Newly Diagnosed Acute Myeloid Leukemia (AML),febrile neutropenia
10008481,2.27,NCT01829503-1,Decitabine + Cytarabine,NCT01829503,Phase II Study of Decitabine and Cytarabine for Older Patients With Newly Diagnosed Acute Myeloid Leukemia (AML),chest pain - cardiac
D013616,2.27,NCT01829503-1,Decitabine + Cytarabine,NCT01829503,Phase II Study of Decitabine and Cytarabine for Older Patients With Newly Diagnosed Acute Myeloid Leukemia (AML),sinus tachycardia
D015746,2.27,NCT01829503-1,Decitabine + Cytarabine,NCT01829503,Phase II Study of Decitabine and Cytarabine for Older Patients With Newly Diagnosed Acute Myeloid Leukemia (AML),abdominal pain
D003248,2.27,NCT01829503-1,Decitabine + Cytarabine,NCT01829503,Phase II Study of Decitabine and Cytarabine for Older Patients With Newly Diagnosed Acute Myeloid Leukemia (AML),constipation
D003967,2.27,NCT01829503-1,Decitabine + Cytarabine,NCT01829503,Phase II Study of Decitabine and Cytarabine for Older Patients With Newly Diagnosed Acute Myeloid Leukemia (AML),diarrhea
10041101,2.27,NCT01829503-1,Decitabine + Cytarabine,NCT01829503,Phase II Study of Decitabine and Cytarabine for Older Patients With Newly Diagnosed Acute Myeloid Leukemia (AML),small intestinal obstruction
10011914,4.55,NCT01829503-1,Decitabine + Cytarabine,NCT01829503,Phase II Study of Decitabine and Cytarabine for Older Patients With Newly Diagnosed Acute Myeloid Leukemia (AML),death nos
D005334,4.55,NCT01829503-1,Decitabine + Cytarabine,NCT01829503,Phase II Study of Decitabine and Cytarabine for Older Patients With Newly Diagnosed Acute Myeloid Leukemia (AML),fever
10018065,2.27,NCT01829503-1,Decitabine + Cytarabine,NCT01829503,Phase II Study of Decitabine and Cytarabine for Older Patients With Newly Diagnosed Acute Myeloid Leukemia (AML),general disorders and administration site conditions - other specify
10025482,2.27,NCT01829503-1,Decitabine + Cytarabine,NCT01829503,Phase II Study of Decitabine and Cytarabine for Older Patients With Newly Diagnosed Acute Myeloid Leukemia (AML),malaise
D009102,2.27,NCT01829503-1,Decitabine + Cytarabine,NCT01829503,Phase II Study of Decitabine and Cytarabine for Older Patients With Newly Diagnosed Acute Myeloid Leukemia (AML),multiple organ failure
D010146,2.27,NCT01829503-1,Decitabine + Cytarabine,NCT01829503,Phase II Study of Decitabine and Cytarabine for Older Patients With Newly Diagnosed Acute Myeloid Leukemia (AML),pain
D007239,2.27,NCT01829503-1,Decitabine + Cytarabine,NCT01829503,Phase II Study of Decitabine and Cytarabine for Older Patients With Newly Diagnosed Acute Myeloid Leukemia (AML),infections and infestations
10061229,2.27,NCT01829503-1,Decitabine + Cytarabine,NCT01829503,Phase II Study of Decitabine and Cytarabine for Older Patients With Newly Diagnosed Acute Myeloid Leukemia (AML),lung infection
D018805,2.27,NCT01829503-1,Decitabine + Cytarabine,NCT01829503,Phase II Study of Decitabine and Cytarabine for Older Patients With Newly Diagnosed Acute Myeloid Leukemia (AML),sepsis
10040872,2.27,NCT01829503-1,Decitabine + Cytarabine,NCT01829503,Phase II Study of Decitabine and Cytarabine for Older Patients With Newly Diagnosed Acute Myeloid Leukemia (AML),skin infection
10016173,2.27,NCT01829503-1,Decitabine + Cytarabine,NCT01829503,Phase II Study of Decitabine and Cytarabine for Older Patients With Newly Diagnosed Acute Myeloid Leukemia (AML),fall
10017076,2.27,NCT01829503-1,Decitabine + Cytarabine,NCT01829503,Phase II Study of Decitabine and Cytarabine for Older Patients With Newly Diagnosed Acute Myeloid Leukemia (AML),fracture
10020100,2.27,NCT01829503-1,Decitabine + Cytarabine,NCT01829503,Phase II Study of Decitabine and Cytarabine for Older Patients With Newly Diagnosed Acute Myeloid Leukemia (AML),hip fracture
10065848,2.27,NCT01829503-1,Decitabine + Cytarabine,NCT01829503,Phase II Study of Decitabine and Cytarabine for Older Patients With Newly Diagnosed Acute Myeloid Leukemia (AML),intraoperative venous injury
10011368,4.55,NCT01829503-1,Decitabine + Cytarabine,NCT01829503,Phase II Study of Decitabine and Cytarabine for Older Patients With Newly Diagnosed Acute Myeloid Leukemia (AML),creatinine increased
10022402,2.27,NCT01829503-1,Decitabine + Cytarabine,NCT01829503,Phase II Study of Decitabine and Cytarabine for Older Patients With Newly Diagnosed Acute Myeloid Leukemia (AML),inr increased
10025256,2.27,NCT01829503-1,Decitabine + Cytarabine,NCT01829503,Phase II Study of Decitabine and Cytarabine for Older Patients With Newly Diagnosed Acute Myeloid Leukemia (AML),lymphocyte count decreased
10029366,2.27,NCT01829503-1,Decitabine + Cytarabine,NCT01829503,Phase II Study of Decitabine and Cytarabine for Older Patients With Newly Diagnosed Acute Myeloid Leukemia (AML),neutrophil count decreased
10035528,2.27,NCT01829503-1,Decitabine + Cytarabine,NCT01829503,Phase II Study of Decitabine and Cytarabine for Older Patients With Newly Diagnosed Acute Myeloid Leukemia (AML),platelet count decreased
10049182,6.82,NCT01829503-1,Decitabine + Cytarabine,NCT01829503,Phase II Study of Decitabine and Cytarabine for Older Patients With Newly Diagnosed Acute Myeloid Leukemia (AML),white blood cell decreased
D003681,2.27,NCT01829503-1,Decitabine + Cytarabine,NCT01829503,Phase II Study of Decitabine and Cytarabine for Older Patients With Newly Diagnosed Acute Myeloid Leukemia (AML),dehydration
D006943,2.27,NCT01829503-1,Decitabine + Cytarabine,NCT01829503,Phase II Study of Decitabine and Cytarabine for Older Patients With Newly Diagnosed Acute Myeloid Leukemia (AML),hyperglycemia
D034141,4.55,NCT01829503-1,Decitabine + Cytarabine,NCT01829503,Phase II Study of Decitabine and Cytarabine for Older Patients With Newly Diagnosed Acute Myeloid Leukemia (AML),hypoalbuminemia
D007008,2.27,NCT01829503-1,Decitabine + Cytarabine,NCT01829503,Phase II Study of Decitabine and Cytarabine for Older Patients With Newly Diagnosed Acute Myeloid Leukemia (AML),hypokalemia
D004244,2.27,NCT01829503-1,Decitabine + Cytarabine,NCT01829503,Phase II Study of Decitabine and Cytarabine for Older Patients With Newly Diagnosed Acute Myeloid Leukemia (AML),dizziness
D001927,2.27,NCT01829503-1,Decitabine + Cytarabine,NCT01829503,Phase II Study of Decitabine and Cytarabine for Older Patients With Newly Diagnosed Acute Myeloid Leukemia (AML),encephalopathy
D020300,2.27,NCT01829503-1,Decitabine + Cytarabine,NCT01829503,Phase II Study of Decitabine and Cytarabine for Older Patients With Newly Diagnosed Acute Myeloid Leukemia (AML),intracranial hemorrhage
D020521,2.27,NCT01829503-1,Decitabine + Cytarabine,NCT01829503,Phase II Study of Decitabine and Cytarabine for Older Patients With Newly Diagnosed Acute Myeloid Leukemia (AML),stroke
D013575,2.27,NCT01829503-1,Decitabine + Cytarabine,NCT01829503,Phase II Study of Decitabine and Cytarabine for Older Patients With Newly Diagnosed Acute Myeloid Leukemia (AML),syncope
D058186,2.27,NCT01829503-1,Decitabine + Cytarabine,NCT01829503,Phase II Study of Decitabine and Cytarabine for Older Patients With Newly Diagnosed Acute Myeloid Leukemia (AML),acute kidney injury
10038359,2.27,NCT01829503-1,Decitabine + Cytarabine,NCT01829503,Phase II Study of Decitabine and Cytarabine for Older Patients With Newly Diagnosed Acute Myeloid Leukemia (AML),renal and urinary disorders - other specify
D000860,4.55,NCT01829503-1,Decitabine + Cytarabine,NCT01829503,Phase II Study of Decitabine and Cytarabine for Older Patients With Newly Diagnosed Acute Myeloid Leukemia (AML),hypoxia
D012131,4.55,NCT01829503-1,Decitabine + Cytarabine,NCT01829503,Phase II Study of Decitabine and Cytarabine for Older Patients With Newly Diagnosed Acute Myeloid Leukemia (AML),respiratory failure
D006973,4.55,NCT01829503-1,Decitabine + Cytarabine,NCT01829503,Phase II Study of Decitabine and Cytarabine for Older Patients With Newly Diagnosed Acute Myeloid Leukemia (AML),hypertension
D007022,2.27,NCT01829503-1,Decitabine + Cytarabine,NCT01829503,Phase II Study of Decitabine and Cytarabine for Older Patients With Newly Diagnosed Acute Myeloid Leukemia (AML),hypotension
10047065,2.27,NCT01829503-1,Decitabine + Cytarabine,NCT01829503,Phase II Study of Decitabine and Cytarabine for Older Patients With Newly Diagnosed Acute Myeloid Leukemia (AML),vascular disorders - other specify
D009026,100.0,NCT01849276-1,Treatment (Enzyme Inhibitor and Chemotherapy),NCT01849276,Metformin+Cytarabine for the Treatment of Relapsed/Refractory AML,mortality
D064420,100.0,NCT01849276-1,Treatment (Enzyme Inhibitor and Chemotherapy),NCT01849276,Metformin+Cytarabine for the Treatment of Relapsed/Refractory AML,adverse drug events
10017815,50.0,NCT01849276-1,Treatment (Enzyme Inhibitor and Chemotherapy),NCT01849276,Metformin+Cytarabine for the Treatment of Relapsed/Refractory AML,gastric perforation
UNKNOWN-check-for-typo,50.0,NCT01849276-1,Treatment (Enzyme Inhibitor and Chemotherapy),NCT01849276,Metformin+Cytarabine for the Treatment of Relapsed/Refractory AML,D00
D018805,50.0,NCT01849276-1,Treatment (Enzyme Inhibitor and Chemotherapy),NCT01849276,Metformin+Cytarabine for the Treatment of Relapsed/Refractory AML,sepsis
D009026,88.89,NCT01853228-1,Phase 1 (Cohort 1): Dacogen + Cytarabine,NCT01853228,A Study of Decitabine (DACOGEN) in Sequential Administration With Cytarabine in Children With Relapsed or Refractory Acute Myeloid Leukemia,mortality
D009026,75.0,NCT01853228-2,Phase 1 (Cohort 2) and Phase 2: Dacogen + Cytarabine,NCT01853228,A Study of Decitabine (DACOGEN) in Sequential Administration With Cytarabine in Children With Relapsed or Refractory Acute Myeloid Leukemia,mortality
D064420,44.44,NCT01853228-1,Phase 1 (Cohort 1): Dacogen + Cytarabine,NCT01853228,A Study of Decitabine (DACOGEN) in Sequential Administration With Cytarabine in Children With Relapsed or Refractory Acute Myeloid Leukemia,adverse drug events
D064420,50.0,NCT01853228-2,Phase 1 (Cohort 2) and Phase 2: Dacogen + Cytarabine,NCT01853228,A Study of Decitabine (DACOGEN) in Sequential Administration With Cytarabine in Children With Relapsed or Refractory Acute Myeloid Leukemia,adverse drug events
D000741,12.5,NCT01853228-2,Phase 1 (Cohort 2) and Phase 2: Dacogen + Cytarabine,NCT01853228,A Study of Decitabine (DACOGEN) in Sequential Administration With Cytarabine in Children With Relapsed or Refractory Acute Myeloid Leukemia,aplastic anaemia
D064147,33.33,NCT01853228-1,Phase 1 (Cohort 1): Dacogen + Cytarabine,NCT01853228,A Study of Decitabine (DACOGEN) in Sequential Administration With Cytarabine in Children With Relapsed or Refractory Acute Myeloid Leukemia,febrile neutropenia
D064147,25.0,NCT01853228-2,Phase 1 (Cohort 2) and Phase 2: Dacogen + Cytarabine,NCT01853228,A Study of Decitabine (DACOGEN) in Sequential Administration With Cytarabine in Children With Relapsed or Refractory Acute Myeloid Leukemia,febrile neutropenia
D009503,12.5,NCT01853228-2,Phase 1 (Cohort 2) and Phase 2: Dacogen + Cytarabine,NCT01853228,A Study of Decitabine (DACOGEN) in Sequential Administration With Cytarabine in Children With Relapsed or Refractory Acute Myeloid Leukemia,neutropenia
D013921,12.5,NCT01853228-2,Phase 1 (Cohort 2) and Phase 2: Dacogen + Cytarabine,NCT01853228,A Study of Decitabine (DACOGEN) in Sequential Administration With Cytarabine in Children With Relapsed or Refractory Acute Myeloid Leukemia,thrombocytopenia
D007634,12.5,NCT01853228-2,Phase 1 (Cohort 2) and Phase 2: Dacogen + Cytarabine,NCT01853228,A Study of Decitabine (DACOGEN) in Sequential Administration With Cytarabine in Children With Relapsed or Refractory Acute Myeloid Leukemia,keratitis
D004864,11.11,NCT01853228-1,Phase 1 (Cohort 1): Dacogen + Cytarabine,NCT01853228,A Study of Decitabine (DACOGEN) in Sequential Administration With Cytarabine in Children With Relapsed or Refractory Acute Myeloid Leukemia,devices
D005334,11.11,NCT01853228-1,Phase 1 (Cohort 1): Dacogen + Cytarabine,NCT01853228,A Study of Decitabine (DACOGEN) in Sequential Administration With Cytarabine in Children With Relapsed or Refractory Acute Myeloid Leukemia,pyrexia
D005334,12.5,NCT01853228-2,Phase 1 (Cohort 2) and Phase 2: Dacogen + Cytarabine,NCT01853228,A Study of Decitabine (DACOGEN) in Sequential Administration With Cytarabine in Children With Relapsed or Refractory Acute Myeloid Leukemia,pyrexia
10061229,12.5,NCT01853228-2,Phase 1 (Cohort 2) and Phase 2: Dacogen + Cytarabine,NCT01853228,A Study of Decitabine (DACOGEN) in Sequential Administration With Cytarabine in Children With Relapsed or Refractory Acute Myeloid Leukemia,lung infection
D018805,25.0,NCT01853228-2,Phase 1 (Cohort 2) and Phase 2: Dacogen + Cytarabine,NCT01853228,A Study of Decitabine (DACOGEN) in Sequential Administration With Cytarabine in Children With Relapsed or Refractory Acute Myeloid Leukemia,sepsis
D002615,11.11,NCT01853228-1,Phase 1 (Cohort 1): Dacogen + Cytarabine,NCT01853228,A Study of Decitabine (DACOGEN) in Sequential Administration With Cytarabine in Children With Relapsed or Refractory Acute Myeloid Leukemia,chemexfoliation
10040865,11.11,NCT01853228-1,Phase 1 (Cohort 1): Dacogen + Cytarabine,NCT01853228,A Study of Decitabine (DACOGEN) in Sequential Administration With Cytarabine in Children With Relapsed or Refractory Acute Myeloid Leukemia,skin hyperpigmentation
D009026,14.86,NCT01890746-1,Eltrombopag (ELQ) QD,NCT01890746,A Safety and Efficacy Study of Eltrombopag in Subjects With AML,mortality
D009026,5.63,NCT01890746-2,Placebo QD,NCT01890746,A Safety and Efficacy Study of Eltrombopag in Subjects With AML,mortality
D064420,32.43,NCT01890746-1,Eltrombopag (ELQ) QD,NCT01890746,A Safety and Efficacy Study of Eltrombopag in Subjects With AML,adverse drug events
D064420,19.72,NCT01890746-2,Placebo QD,NCT01890746,A Safety and Efficacy Study of Eltrombopag in Subjects With AML,adverse drug events
D064147,1.35,NCT01890746-1,Eltrombopag (ELQ) QD,NCT01890746,A Safety and Efficacy Study of Eltrombopag in Subjects With AML,febrile neutropenia
D001281,2.7,NCT01890746-1,Eltrombopag (ELQ) QD,NCT01890746,A Safety and Efficacy Study of Eltrombopag in Subjects With AML,atrial fibrillation
D006333,1.35,NCT01890746-1,Eltrombopag (ELQ) QD,NCT01890746,A Safety and Efficacy Study of Eltrombopag in Subjects With AML,cardiac failure
D006333,1.41,NCT01890746-2,Placebo QD,NCT01890746,A Safety and Efficacy Study of Eltrombopag in Subjects With AML,cardiac failure
D006333,1.41,NCT01890746-2,Placebo QD,NCT01890746,A Safety and Efficacy Study of Eltrombopag in Subjects With AML,cardiac failure
D009202,1.41,NCT01890746-2,Placebo QD,NCT01890746,A Safety and Efficacy Study of Eltrombopag in Subjects With AML,cardiomyopathy
D018487,1.35,NCT01890746-1,Eltrombopag (ELQ) QD,NCT01890746,A Safety and Efficacy Study of Eltrombopag in Subjects With AML,left ventricular dysfunction
D009203,1.35,NCT01890746-1,Eltrombopag (ELQ) QD,NCT01890746,A Safety and Efficacy Study of Eltrombopag in Subjects With AML,myocardial infarction
D006848,1.35,NCT01890746-1,Eltrombopag (ELQ) QD,NCT01890746,A Safety and Efficacy Study of Eltrombopag in Subjects With AML,testicular hydrocele
D015746,1.35,NCT01890746-1,Eltrombopag (ELQ) QD,NCT01890746,A Safety and Efficacy Study of Eltrombopag in Subjects With AML,abdominal pain
D003248,1.41,NCT01890746-2,Placebo QD,NCT01890746,A Safety and Efficacy Study of Eltrombopag in Subjects With AML,constipation
D044504,1.41,NCT01890746-2,Placebo QD,NCT01890746,A Safety and Efficacy Study of Eltrombopag in Subjects With AML,enterocolitis neutropenic
D000799,1.41,NCT01890746-2,Placebo QD,NCT01890746,A Safety and Efficacy Study of Eltrombopag in Subjects With AML,angioedema
D005334,1.35,NCT01890746-1,Eltrombopag (ELQ) QD,NCT01890746,A Safety and Efficacy Study of Eltrombopag in Subjects With AML,pyrexia
D005334,1.41,NCT01890746-2,Placebo QD,NCT01890746,A Safety and Efficacy Study of Eltrombopag in Subjects With AML,pyrexia
D003645,1.41,NCT01890746-2,Placebo QD,NCT01890746,A Safety and Efficacy Study of Eltrombopag in Subjects With AML,sudden death
D000150,1.41,NCT01890746-2,Placebo QD,NCT01890746,A Safety and Efficacy Study of Eltrombopag in Subjects With AML,acinetobacter
D001064,1.35,NCT01890746-1,Eltrombopag (ELQ) QD,NCT01890746,A Safety and Efficacy Study of Eltrombopag in Subjects With AML,appendicitis
D001991,1.35,NCT01890746-1,Eltrombopag (ELQ) QD,NCT01890746,A Safety and Efficacy Study of Eltrombopag in Subjects With AML,bronchitis
D010272,1.41,NCT01890746-2,Placebo QD,NCT01890746,A Safety and Efficacy Study of Eltrombopag in Subjects With AML,parasite infections
D000985,1.35,NCT01890746-1,Eltrombopag (ELQ) QD,NCT01890746,A Safety and Efficacy Study of Eltrombopag in Subjects With AML,antisepsis
D000985,1.41,NCT01890746-2,Placebo QD,NCT01890746,A Safety and Efficacy Study of Eltrombopag in Subjects With AML,antisepsis
D000038,1.41,NCT01890746-2,Placebo QD,NCT01890746,A Safety and Efficacy Study of Eltrombopag in Subjects With AML,abscess
D011014,1.41,NCT01890746-2,Placebo QD,NCT01890746,A Safety and Efficacy Study of Eltrombopag in Subjects With AML,pneumonia
D018805,1.35,NCT01890746-1,Eltrombopag (ELQ) QD,NCT01890746,A Safety and Efficacy Study of Eltrombopag in Subjects With AML,sepsis
D018805,2.82,NCT01890746-2,Placebo QD,NCT01890746,A Safety and Efficacy Study of Eltrombopag in Subjects With AML,sepsis
D012772,2.7,NCT01890746-1,Eltrombopag (ELQ) QD,NCT01890746,A Safety and Efficacy Study of Eltrombopag in Subjects With AML,septic shock
D012772,2.82,NCT01890746-2,Placebo QD,NCT01890746,A Safety and Efficacy Study of Eltrombopag in Subjects With AML,septic shock
D002175,1.35,NCT01890746-1,Eltrombopag (ELQ) QD,NCT01890746,A Safety and Efficacy Study of Eltrombopag in Subjects With AML,candida
10001551,1.41,NCT01890746-2,Placebo QD,NCT01890746,A Safety and Efficacy Study of Eltrombopag in Subjects With AML,alanine aminotransferase increased
10005364,1.35,NCT01890746-1,Eltrombopag (ELQ) QD,NCT01890746,A Safety and Efficacy Study of Eltrombopag in Subjects With AML,blood bilirubin increased
10050528,2.82,NCT01890746-2,Placebo QD,NCT01890746,A Safety and Efficacy Study of Eltrombopag in Subjects With AML,ejection fraction decreased
UNKNOWN-check-for-typo,1.41,NCT01890746-2,Placebo QD,NCT01890746,A Safety and Efficacy Study of Eltrombopag in Subjects With AML,D00
UNKNOWN-check-for-typo,1.35,NCT01890746-1,Eltrombopag (ELQ) QD,NCT01890746,A Safety and Efficacy Study of Eltrombopag in Subjects With AML,D00
D000074042,1.35,NCT01890746-1,Eltrombopag (ELQ) QD,NCT01890746,A Safety and Efficacy Study of Eltrombopag in Subjects With AML,cerebral intraventricular haemorrhage
D020521,1.35,NCT01890746-1,Eltrombopag (ELQ) QD,NCT01890746,A Safety and Efficacy Study of Eltrombopag in Subjects With AML,cerebrovascular accident
D008569,1.35,NCT01890746-1,Eltrombopag (ELQ) QD,NCT01890746,A Safety and Efficacy Study of Eltrombopag in Subjects With AML,retention disorders cognitive
D000069280,2.7,NCT01890746-1,Eltrombopag (ELQ) QD,NCT01890746,A Safety and Efficacy Study of Eltrombopag in Subjects With AML,intracranial electroencephalography
D058186,4.05,NCT01890746-1,Eltrombopag (ELQ) QD,NCT01890746,A Safety and Efficacy Study of Eltrombopag in Subjects With AML,acute kidney injury
D058186,1.41,NCT01890746-2,Placebo QD,NCT01890746,A Safety and Efficacy Study of Eltrombopag in Subjects With AML,acute kidney injury
D051437,1.35,NCT01890746-1,Eltrombopag (ELQ) QD,NCT01890746,A Safety and Efficacy Study of Eltrombopag in Subjects With AML,renal failure
D011649,1.35,NCT01890746-1,Eltrombopag (ELQ) QD,NCT01890746,A Safety and Efficacy Study of Eltrombopag in Subjects With AML,pulmonary alveolar proteinosis
D011655,1.35,NCT01890746-1,Eltrombopag (ELQ) QD,NCT01890746,A Safety and Efficacy Study of Eltrombopag in Subjects With AML,pulmonary embolism
D001261,1.35,NCT01890746-1,Eltrombopag (ELQ) QD,NCT01890746,A Safety and Efficacy Study of Eltrombopag in Subjects With AML,pulmonary atelectasis
D012131,1.35,NCT01890746-1,Eltrombopag (ELQ) QD,NCT01890746,A Safety and Efficacy Study of Eltrombopag in Subjects With AML,respiratory failure
D064420,2.0,NCT01969435-1,Melphalan Carmustine Etoposide Cytarabine (BEAM),NCT01969435,Study of Melphalan HCl for Injection (Propylene Glycol-free)  Carmustine  Etoposide  Cytarabine (BEAM Regimen) and Autologous Stem Cell Transplantation for Lymphoma,adverse drug events
D009102,2.0,NCT01969435-1,Melphalan Carmustine Etoposide Cytarabine (BEAM),NCT01969435,Study of Melphalan HCl for Injection (Propylene Glycol-free)  Carmustine  Etoposide  Cytarabine (BEAM Regimen) and Autologous Stem Cell Transplantation for Lymphoma,multiple organ failure
D064420,44.95,NCT02013167-1,Standard of Care Chemotherapy,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),adverse drug events
D064420,61.8,NCT02013167-2,Blinatumomab,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),adverse drug events
D000380,0.92,NCT02013167-1,Standard of Care Chemotherapy,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),agranulocytosis
D000741,0.37,NCT02013167-2,Blinatumomab,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),aplastic anaemia
D001853,0.37,NCT02013167-2,Blinatumomab,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),bone marrow
D064147,11.01,NCT02013167-1,Standard of Care Chemotherapy,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),febrile neutropenia
D064147,8.61,NCT02013167-2,Blinatumomab,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),febrile neutropenia
D015614,1.12,NCT02013167-2,Blinatumomab,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),histiocytosis
D007964,1.12,NCT02013167-2,Blinatumomab,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),leukocytosis
D007970,0.92,NCT02013167-1,Standard of Care Chemotherapy,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),leukopenia
D000072281,0.37,NCT02013167-2,Blinatumomab,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),lymphadenopathy
D009503,1.83,NCT02013167-1,Standard of Care Chemotherapy,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),neutropenia
D009503,0.75,NCT02013167-2,Blinatumomab,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),neutropenia
D010198,0.92,NCT02013167-1,Standard of Care Chemotherapy,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),pancytopenia
D010198,1.12,NCT02013167-2,Blinatumomab,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),pancytopenia
D013921,0.92,NCT02013167-1,Standard of Care Chemotherapy,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),thrombocytopenia
D056988,0.37,NCT02013167-2,Blinatumomab,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),acute anterior wall myocardial infarction
D001281,0.37,NCT02013167-2,Blinatumomab,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),atrial fibrillation
D001282,0.37,NCT02013167-2,Blinatumomab,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),atrial flutter
D006323,0.92,NCT02013167-1,Standard of Care Chemotherapy,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),cardiac arrest
D006323,0.37,NCT02013167-2,Blinatumomab,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),cardiac arrest
D006333,0.37,NCT02013167-2,Blinatumomab,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),cardiac failure
D002305,0.92,NCT02013167-1,Standard of Care Chemotherapy,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),cardiac tamponade
D000028,0.37,NCT02013167-2,Blinatumomab,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),abortion failure
D010490,0.37,NCT02013167-2,Blinatumomab,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),pericardial effusion
D013617,0.92,NCT02013167-1,Standard of Care Chemotherapy,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),supraventricular tachycardia
D000708,0.37,NCT02013167-2,Blinatumomab,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),anaplasia
D015746,0.75,NCT02013167-2,Blinatumomab,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),abdominal pain
D020115,0.37,NCT02013167-2,Blinatumomab,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),progastricsin
D007249,0.92,NCT02013167-1,Standard of Care Chemotherapy,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),inflammation
10065712,0.37,NCT02013167-2,Blinatumomab,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),gastrointestinal stoma necrosis
UNKNOWN-check-for-typo,0.37,NCT02013167-2,Blinatumomab,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),D00
D009055,0.92,NCT02013167-1,Standard of Care Chemotherapy,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),mouth
D009325,0.37,NCT02013167-2,Blinatumomab,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),nausea
D010195,0.92,NCT02013167-1,Standard of Care Chemotherapy,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),pancreatitis
D013280,0.37,NCT02013167-2,Blinatumomab,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),stomatitis
D014839,0.75,NCT02013167-2,Blinatumomab,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),vomiting
D001247,0.75,NCT02013167-2,Blinatumomab,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),asthenia
D002637,0.37,NCT02013167-2,Blinatumomab,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),chest pain
D003643,0.37,NCT02013167-2,Blinatumomab,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),death
UNKNOWN-check-for-typo,0.37,NCT02013167-2,Blinatumomab,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),D00
D003695,0.75,NCT02013167-2,Blinatumomab,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),healthcare
D005334,0.37,NCT02013167-2,Blinatumomab,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),hyperthermia
D004864,0.37,NCT02013167-2,Blinatumomab,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),medical devices
D009102,0.92,NCT02013167-1,Standard of Care Chemotherapy,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),multiple organ failure
D009102,1.5,NCT02013167-2,Blinatumomab,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),multiple organ failure
D000799,0.37,NCT02013167-2,Blinatumomab,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),angioedema
D005334,0.92,NCT02013167-1,Standard of Care Chemotherapy,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),pyrexia
D005334,5.99,NCT02013167-2,Blinatumomab,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),pyrexia
D018746,0.37,NCT02013167-2,Blinatumomab,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),systemic inflammatory response syndrome
D017114,0.92,NCT02013167-1,Standard of Care Chemotherapy,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),acute hepatic failure
D002769,0.37,NCT02013167-2,Blinatumomab,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),cholelithiasis
D002779,0.92,NCT02013167-1,Standard of Care Chemotherapy,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),cholestasis
D006505,0.37,NCT02013167-2,Blinatumomab,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),hepatitis
D006086,0.37,NCT02013167-2,Blinatumomab,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),graft-versus-host disease
D000707,0.37,NCT02013167-2,Blinatumomab,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),anaphylactic shock
D000080424,2.62,NCT02013167-2,Blinatumomab,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),cytokine release syndrome
D006086,0.37,NCT02013167-2,Blinatumomab,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),graft versus host disease
D006086,0.37,NCT02013167-2,Blinatumomab,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),graft-versus-host disease
D000038,0.92,NCT02013167-1,Standard of Care Chemotherapy,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),abscess
UNKNOWN-check-for-typo,2.75,NCT02013167-1,Standard of Care Chemotherapy,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),D00
UNKNOWN-check-for-typo,0.75,NCT02013167-2,Blinatumomab,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),D00
D001424,0.75,NCT02013167-2,Blinatumomab,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),bacterial infection
D000985,1.83,NCT02013167-1,Standard of Care Chemotherapy,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),antisepsis
D000985,2.25,NCT02013167-2,Blinatumomab,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),antisepsis
D001922,0.92,NCT02013167-1,Standard of Care Chemotherapy,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),brain abscess
D001991,0.37,NCT02013167-2,Blinatumomab,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),bronchitis
D055732,0.92,NCT02013167-1,Standard of Care Chemotherapy,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),bronchopulmonary aspergillosis
D055732,1.5,NCT02013167-2,Blinatumomab,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),bronchopulmonary aspergillosis
D010272,0.75,NCT02013167-2,Blinatumomab,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),parasite infections
D002481,0.37,NCT02013167-2,Blinatumomab,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),cellulitis
D002490,0.92,NCT02013167-1,Standard of Care Chemotherapy,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),central nervous system
D000069544,0.37,NCT02013167-2,Blinatumomab,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),encephalitis infection
D000985,0.92,NCT02013167-1,Standard of Care Chemotherapy,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),antisepsis
10064687,0.92,NCT02013167-1,Standard of Care Chemotherapy,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),device related infection
10064687,2.25,NCT02013167-2,Blinatumomab,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),device related infection
10064687,1.83,NCT02013167-1,Standard of Care Chemotherapy,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),device related infection
10064687,0.37,NCT02013167-2,Blinatumomab,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),device related infection
D004660,0.37,NCT02013167-2,Blinatumomab,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),encephalitis
UNKNOWN-check-for-typo,0.92,NCT02013167-1,Standard of Care Chemotherapy,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),D00
D000069544,0.92,NCT02013167-1,Standard of Care Chemotherapy,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),encephalitis infection
D004927,0.75,NCT02013167-2,Blinatumomab,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),escherichia coli infections
UNKNOWN-check-for-typo,0.37,NCT02013167-2,Blinatumomab,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),D00
D009181,0.92,NCT02013167-1,Standard of Care Chemotherapy,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),fungal infection
D000985,0.75,NCT02013167-2,Blinatumomab,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),antisepsis
D060585,0.92,NCT02013167-1,Standard of Care Chemotherapy,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),fusarium infection
D005759,0.75,NCT02013167-2,Blinatumomab,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),gastroenteritis
D002177,0.92,NCT02013167-1,Standard of Care Chemotherapy,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),candidiasis
D007239,0.37,NCT02013167-2,Blinatumomab,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),infection
D058429,0.37,NCT02013167-2,Blinatumomab,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),gnathostoma infection
D007251,0.37,NCT02013167-2,Blinatumomab,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),influenza
D012141,0.37,NCT02013167-2,Blinatumomab,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),respiratory tract infections
D012141,0.37,NCT02013167-2,Blinatumomab,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),respiratory tract infections
10061229,0.92,NCT02013167-1,Standard of Care Chemotherapy,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),lung infection
10061229,0.37,NCT02013167-2,Blinatumomab,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),lung infection
D008417,0.37,NCT02013167-2,Blinatumomab,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),mastoiditis
D016920,0.37,NCT02013167-2,Blinatumomab,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),bacterial meningitis
D009091,0.37,NCT02013167-2,Blinatumomab,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),mucormycosis
D000038,0.37,NCT02013167-2,Blinatumomab,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),abscess
D000985,0.92,NCT02013167-1,Standard of Care Chemotherapy,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),antisepsis
D000985,1.12,NCT02013167-2,Blinatumomab,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),antisepsis
D010019,0.37,NCT02013167-2,Blinatumomab,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),osteomyelitis
D010033,0.37,NCT02013167-2,Blinatumomab,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),otitis media
D011014,1.83,NCT02013167-1,Standard of Care Chemotherapy,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),pneumonia
D011014,3.75,NCT02013167-2,Blinatumomab,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),pneumonia
D018410,0.37,NCT02013167-2,Blinatumomab,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),bacterial pneumonia
D001996,1.83,NCT02013167-1,Standard of Care Chemotherapy,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),bronchopneumonia
D001996,0.37,NCT02013167-2,Blinatumomab,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),bronchopneumonia
D001996,0.37,NCT02013167-2,Blinatumomab,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),bronchopneumonia
D011024,0.37,NCT02013167-2,Blinatumomab,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),pneumonia viral
D007968,0.37,NCT02013167-2,Blinatumomab,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),progressive multifocal leukoencephalopathy
D000985,0.92,NCT02013167-1,Standard of Care Chemotherapy,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),antisepsis
D000985,1.12,NCT02013167-2,Blinatumomab,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),antisepsis
D011552,0.92,NCT02013167-1,Standard of Care Chemotherapy,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),pseudomonas infection
D011552,1.12,NCT02013167-2,Blinatumomab,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),pseudomonas infection
D055744,0.37,NCT02013167-2,Blinatumomab,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),allergic bronchopulmonary mycosis
D012136,0.37,NCT02013167-2,Blinatumomab,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),respiratory syncytial viruses
D000069544,0.92,NCT02013167-1,Standard of Care Chemotherapy,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),encephalitis infection
D018805,6.42,NCT02013167-1,Standard of Care Chemotherapy,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),sepsis
D018805,4.87,NCT02013167-2,Blinatumomab,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),sepsis
D018746,0.37,NCT02013167-2,Blinatumomab,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),sepsis syndrome
D012772,2.75,NCT02013167-1,Standard of Care Chemotherapy,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),septic shock
D012772,3.0,NCT02013167-2,Blinatumomab,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),septic shock
D012852,0.37,NCT02013167-2,Blinatumomab,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),sinusitis
10040872,0.37,NCT02013167-2,Blinatumomab,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),skin infection
D018461,0.92,NCT02013167-1,Standard of Care Chemotherapy,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),soft tissue infection
D013203,0.92,NCT02013167-1,Standard of Care Chemotherapy,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),staphylococcal infection
D013203,0.75,NCT02013167-2,Blinatumomab,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),staphylococcal infection
D000985,0.37,NCT02013167-2,Blinatumomab,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),antisepsis
D000985,0.92,NCT02013167-1,Standard of Care Chemotherapy,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),antisepsis
D002175,0.92,NCT02013167-1,Standard of Care Chemotherapy,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),candida
10048762,0.37,NCT02013167-2,Blinatumomab,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),tooth infection
D000058,1.12,NCT02013167-2,Blinatumomab,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),accidental falls
D064386,0.92,NCT02013167-1,Standard of Care Chemotherapy,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),ankle fracture
10016173,0.37,NCT02013167-2,Blinatumomab,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),fall
D008508,0.37,NCT02013167-2,Blinatumomab,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),medication error
D062787,3.0,NCT02013167-2,Blinatumomab,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),drug overdose
D006408,0.37,NCT02013167-2,Blinatumomab,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),hematoma subdural
D006408,0.37,NCT02013167-2,Blinatumomab,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),hematoma subdural
10005364,0.75,NCT02013167-2,Blinatumomab,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),blood bilirubin increased
10005630,0.37,NCT02013167-2,Blinatumomab,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),blood lactate dehydrogenase increased
D002452,0.37,NCT02013167-2,Blinatumomab,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),cell count
10035528,0.37,NCT02013167-2,Blinatumomab,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),platelet count decreased
D000637,0.37,NCT02013167-2,Blinatumomab,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),transaminases
D013851,0.37,NCT02013167-2,Blinatumomab,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),underweight
D007958,0.37,NCT02013167-2,Blinatumomab,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),blood cell count white
D007958,0.37,NCT02013167-2,Blinatumomab,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),blood cell count white
UNKNOWN-check-for-typo,0.37,NCT02013167-2,Blinatumomab,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),D00
UNKNOWN-check-for-typo,0.92,NCT02013167-1,Standard of Care Chemotherapy,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),D00
UNKNOWN-check-for-typo,0.75,NCT02013167-2,Blinatumomab,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),D00
UNKNOWN-check-for-typo,0.92,NCT02013167-1,Standard of Care Chemotherapy,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),D00
UNKNOWN-check-for-typo,0.37,NCT02013167-2,Blinatumomab,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),D00
UNKNOWN-check-for-typo,0.37,NCT02013167-2,Blinatumomab,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),D00
UNKNOWN-check-for-typo,0.75,NCT02013167-2,Blinatumomab,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),D00
D000140,0.92,NCT02013167-1,Standard of Care Chemotherapy,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),lactic acidosis
D000140,0.37,NCT02013167-2,Blinatumomab,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),lactic acidosis
D000138,0.92,NCT02013167-1,Standard of Care Chemotherapy,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),metabolic acidosis
D015275,1.12,NCT02013167-2,Blinatumomab,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),tumour lysis syndrome
D001416,0.75,NCT02013167-2,Blinatumomab,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),back pain
10006002,1.12,NCT02013167-2,Blinatumomab,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),bone pain
D010000,0.92,NCT02013167-1,Standard of Care Chemotherapy,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),osteitis
D015470,0.37,NCT02013167-2,Blinatumomab,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),leukemia nonlymphocytic acute
D000772,0.37,NCT02013167-2,Blinatumomab,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),anesthesia infiltration
D000772,0.37,NCT02013167-2,Blinatumomab,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),anesthesia infiltration
D005334,0.37,NCT02013167-2,Blinatumomab,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),fever
D001037,1.12,NCT02013167-2,Blinatumomab,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),aphasia
D000074042,0.37,NCT02013167-2,Blinatumomab,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),cerebral intraventricular haemorrhage
D008569,0.37,NCT02013167-2,Blinatumomab,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),retention disorders cognitive
D003244,0.37,NCT02013167-2,Blinatumomab,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),depressed level of consciousness
D001927,1.5,NCT02013167-2,Blinatumomab,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),encephalopathy
D012640,0.92,NCT02013167-1,Standard of Care Chemotherapy,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),generalised tonic-clonic seizures
D000069280,1.83,NCT02013167-1,Standard of Care Chemotherapy,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),intracranial electroencephalography
D000069280,0.37,NCT02013167-2,Blinatumomab,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),intracranial electroencephalography
D013474,0.37,NCT02013167-2,Blinatumomab,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),sunstroke
D006423,0.37,NCT02013167-2,Blinatumomab,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),hemianopia
D010291,0.37,NCT02013167-2,Blinatumomab,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),hemiparesis
D006429,0.92,NCT02013167-1,Standard of Care Chemotherapy,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),hemiplegia
UNKNOWN-check-for-typo,0.37,NCT02013167-2,Blinatumomab,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),D00
D014202,0.37,NCT02013167-2,Blinatumomab,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),intention tremor
D056784,0.37,NCT02013167-2,Blinatumomab,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),leukoencephalopathy
D000066530,0.37,NCT02013167-2,Blinatumomab,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),neurological rehabilitation
UNKNOWN-check-for-typo,0.37,NCT02013167-2,Blinatumomab,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),D00
D012640,0.92,NCT02013167-1,Standard of Care Chemotherapy,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),seizure
D012640,0.37,NCT02013167-2,Blinatumomab,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),seizure
D000077260,0.37,NCT02013167-2,Blinatumomab,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),somnolence
D013226,0.37,NCT02013167-2,Blinatumomab,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),status epilepticus
D014202,0.37,NCT02013167-2,Blinatumomab,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),tremor
D000081013,0.37,NCT02013167-2,Blinatumomab,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),completed suicide
D000073216,0.37,NCT02013167-2,Blinatumomab,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),mental status tests
D058186,1.83,NCT02013167-1,Standard of Care Chemotherapy,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),acute kidney injury
D058186,1.12,NCT02013167-2,Blinatumomab,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),acute kidney injury
D002137,0.37,NCT02013167-2,Blinatumomab,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),calculus
D001743,0.92,NCT02013167-1,Standard of Care Chemotherapy,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),urinary bladder
D012131,0.75,NCT02013167-2,Blinatumomab,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),respiratory failure
UNKNOWN-check-for-typo,0.75,NCT02013167-2,Blinatumomab,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),D00
D004844,0.75,NCT02013167-2,Blinatumomab,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),epistaxis
UNKNOWN-check-for-typo,0.75,NCT02013167-2,Blinatumomab,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),D00
D000860,0.37,NCT02013167-2,Blinatumomab,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),hypoxia
D008168,0.92,NCT02013167-1,Standard of Care Chemotherapy,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),lung
D008168,0.37,NCT02013167-2,Blinatumomab,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),lung
D010996,0.92,NCT02013167-1,Standard of Care Chemotherapy,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),pleural effusion
D010996,0.37,NCT02013167-2,Blinatumomab,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),pleural effusion
D011014,0.37,NCT02013167-2,Blinatumomab,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),pneumonitis
D011030,0.92,NCT02013167-1,Standard of Care Chemotherapy,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),pneumothorax
D000799,0.37,NCT02013167-2,Blinatumomab,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),angioedema
D019390,0.37,NCT02013167-2,Blinatumomab,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),arrestins
D012131,1.83,NCT02013167-1,Standard of Care Chemotherapy,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),respiratory failure
D012131,0.37,NCT02013167-2,Blinatumomab,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),respiratory failure
D012135,0.37,NCT02013167-2,Blinatumomab,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),stridor
D000505,0.37,NCT02013167-2,Blinatumomab,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),alopecia
D012883,0.37,NCT02013167-2,Blinatumomab,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),skin ulcer
D065467,0.37,NCT02013167-2,Blinatumomab,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),transcatheter aortic valve replacement
D008310,0.37,NCT02013167-2,Blinatumomab,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),malocclusion
D007022,1.83,NCT02013167-1,Standard of Care Chemotherapy,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),hypotension
D002341,0.92,NCT02013167-1,Standard of Care Chemotherapy,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),carotid artery thrombosis
D012769,0.92,NCT02013167-1,Standard of Care Chemotherapy,NCT02013167,Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),shock
D009026,90.91,NCT02019069-1,Liposomal Cytarabine-daunorubicin CPX-351,NCT02019069,CPX-351 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome,mortality
D064420,45.45,NCT02019069-1,Liposomal Cytarabine-daunorubicin CPX-351,NCT02019069,CPX-351 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome,adverse drug events
D064147,36.36,NCT02019069-1,Liposomal Cytarabine-daunorubicin CPX-351,NCT02019069,CPX-351 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome,febrile neutropenia
D000740,9.09,NCT02019069-1,Liposomal Cytarabine-daunorubicin CPX-351,NCT02019069,CPX-351 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome,anemia
D006323,9.09,NCT02019069-1,Liposomal Cytarabine-daunorubicin CPX-351,NCT02019069,CPX-351 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome,cardiopulmonary arrest
D023341,9.09,NCT02019069-1,Liposomal Cytarabine-daunorubicin CPX-351,NCT02019069,CPX-351 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome,chills
D015470,9.09,NCT02019069-1,Liposomal Cytarabine-daunorubicin CPX-351,NCT02019069,CPX-351 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome,leukemia acute myelogenous
D011014,18.18,NCT02019069-1,Liposomal Cytarabine-daunorubicin CPX-351,NCT02019069,CPX-351 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome,pneumonia
D012128,9.09,NCT02019069-1,Liposomal Cytarabine-daunorubicin CPX-351,NCT02019069,CPX-351 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome,respiratory distress syndrome adult
D012131,9.09,NCT02019069-1,Liposomal Cytarabine-daunorubicin CPX-351,NCT02019069,CPX-351 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome,respiratory failure
D064420,100.0,NCT02029417-1,Treatment (Cytarabine Omacetaxine Mepesuccinate Decitabine),NCT02029417,Omacetaxine Mepesuccinate  Cytarabine  and Decitabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia,adverse drug events
D018805,100.0,NCT02029417-1,Treatment (Cytarabine Omacetaxine Mepesuccinate Decitabine),NCT02029417,Omacetaxine Mepesuccinate  Cytarabine  and Decitabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia,sepsis
D009026,22.22,NCT02044796-2,Newly Diagnosed Group Mitoxantrone Hydrochloride 14 mg/m^2,NCT02044796,Filgrastim  Cladribine  Cytarabine  and Mitoxantrone Hydrochloride in Treating Patients With Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes,mortality
D009026,22.22,NCT02044796-3,Newly Diagnosed Group Mitoxantrone Hydrochloride 16 mg/m^2,NCT02044796,Filgrastim  Cladribine  Cytarabine  and Mitoxantrone Hydrochloride in Treating Patients With Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes,mortality
D009026,16.67,NCT02044796-4,Newly Diagnosed Group Mitoxantrone Hydrochloride 18 mg/m^2,NCT02044796,Filgrastim  Cladribine  Cytarabine  and Mitoxantrone Hydrochloride in Treating Patients With Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes,mortality
D009026,60.0,NCT02044796-5,Relapsed/Refractory Group Mitoxantrone Hydrochloride 12 mg/m^2,NCT02044796,Filgrastim  Cladribine  Cytarabine  and Mitoxantrone Hydrochloride in Treating Patients With Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes,mortality
D009026,66.67,NCT02044796-6,Relapsed/Refractory Group Mitoxantrone Hydrochloride 14 mg/m^2,NCT02044796,Filgrastim  Cladribine  Cytarabine  and Mitoxantrone Hydrochloride in Treating Patients With Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes,mortality
D009026,66.67,NCT02044796-7,Relapsed/Refractory Group Mitoxantrone Hydrochloride 16 mg/m^2,NCT02044796,Filgrastim  Cladribine  Cytarabine  and Mitoxantrone Hydrochloride in Treating Patients With Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes,mortality
D009026,50.0,NCT02044796-8,Relapsed/Refractory Group Mitoxantrone Hydrochloride 18 mg/m^2,NCT02044796,Filgrastim  Cladribine  Cytarabine  and Mitoxantrone Hydrochloride in Treating Patients With Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes,mortality
D009026,37.74,NCT02044796-9,Phase 2 Newly Diagnosed Group 18 mg/m^2,NCT02044796,Filgrastim  Cladribine  Cytarabine  and Mitoxantrone Hydrochloride in Treating Patients With Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes,mortality
D009026,61.76,NCT02044796-10,Phase 2 Relapsed/Refractory Group 16 mg/m^2,NCT02044796,Filgrastim  Cladribine  Cytarabine  and Mitoxantrone Hydrochloride in Treating Patients With Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes,mortality
D009026,70.59,NCT02046122-1,Idarubicin + Cytarabine + DLI,NCT02046122,Adoptive Transfer of Haplo-identical DLI for AML and MDS,mortality
D064420,47.06,NCT02046122-1,Idarubicin + Cytarabine + DLI,NCT02046122,Adoptive Transfer of Haplo-identical DLI for AML and MDS,adverse drug events
D064147,5.88,NCT02046122-1,Idarubicin + Cytarabine + DLI,NCT02046122,Adoptive Transfer of Haplo-identical DLI for AML and MDS,febrile neutropenia
D001281,5.88,NCT02046122-1,Idarubicin + Cytarabine + DLI,NCT02046122,Adoptive Transfer of Haplo-identical DLI for AML and MDS,atrial fibrillation
D045823,5.88,NCT02046122-1,Idarubicin + Cytarabine + DLI,NCT02046122,Adoptive Transfer of Haplo-identical DLI for AML and MDS,ileus
10028130,5.88,NCT02046122-1,Idarubicin + Cytarabine + DLI,NCT02046122,Adoptive Transfer of Haplo-identical DLI for AML and MDS,mucositis oral
D009102,5.88,NCT02046122-1,Idarubicin + Cytarabine + DLI,NCT02046122,Adoptive Transfer of Haplo-identical DLI for AML and MDS,multiple organ failure
D017093,5.88,NCT02046122-1,Idarubicin + Cytarabine + DLI,NCT02046122,Adoptive Transfer of Haplo-identical DLI for AML and MDS,hepatic failure
D014552,5.88,NCT02046122-1,Idarubicin + Cytarabine + DLI,NCT02046122,Adoptive Transfer of Haplo-identical DLI for AML and MDS,urinary tract infection
10049737,5.88,NCT02046122-1,Idarubicin + Cytarabine + DLI,NCT02046122,Adoptive Transfer of Haplo-identical DLI for AML and MDS,treatment related secondary malignancy
D003693,5.88,NCT02046122-1,Idarubicin + Cytarabine + DLI,NCT02046122,Adoptive Transfer of Haplo-identical DLI for AML and MDS,delirium
D000860,5.88,NCT02046122-1,Idarubicin + Cytarabine + DLI,NCT02046122,Adoptive Transfer of Haplo-identical DLI for AML and MDS,hypoxia
D009026,16.67,NCT02105116-1,Treatment (Combination Chemotherapy DLI),NCT02105116,AML Therapy With Irradiated Allogeneic Cells,mortality
D009026,66.67,NCT02343939-1,Group A Phase 1b ENTO 200 mg + Cytarabine + Daunorubicin,NCT02343939,Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML),mortality
D009026,42.0,NCT02343939-2,Group A Phase 1b/2 ENTO 400 mg + Cytarabine + Daunorubicin,NCT02343939,Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML),mortality
D009026,100.0,NCT02343939-3,Group B Phase 1b ENTO 200 mg + Decitabine,NCT02343939,Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML),mortality
D009026,66.67,NCT02343939-4,Group B Phase 1b ENTO 400 mg + Decitabine,NCT02343939,Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML),mortality
D009026,62.5,NCT02343939-5,Group B Phase 2 ENTO 400 mg + Azacitidine (Safety Run-In),NCT02343939,Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML),mortality
D009026,70.59,NCT02343939-6,Group B Phase 2 ENTO 400 mg + Decitabine (Randomized),NCT02343939,Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML),mortality
D009026,78.57,NCT02343939-7,Group B Phase 2 ENTO 400 mg + Azacitidine (Randomized),NCT02343939,Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML),mortality
D009026,85.71,NCT02343939-8,Group C Phase 1b/2 ENTO 400 mg,NCT02343939,Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML),mortality
D009026,85.71,NCT02343939-9,Group C Phase 1b ENTO 800 mg,NCT02343939,Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML),mortality
D064420,46.0,NCT02343939-2,Group A Phase 1b/2 ENTO 400 mg + Cytarabine + Daunorubicin,NCT02343939,Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML),adverse drug events
D064420,100.0,NCT02343939-3,Group B Phase 1b ENTO 200 mg + Decitabine,NCT02343939,Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML),adverse drug events
D064420,83.33,NCT02343939-4,Group B Phase 1b ENTO 400 mg + Decitabine,NCT02343939,Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML),adverse drug events
D064420,87.5,NCT02343939-5,Group B Phase 2 ENTO 400 mg + Azacitidine (Safety Run-In),NCT02343939,Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML),adverse drug events
D064420,64.71,NCT02343939-6,Group B Phase 2 ENTO 400 mg + Decitabine (Randomized),NCT02343939,Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML),adverse drug events
D064420,50.0,NCT02343939-7,Group B Phase 2 ENTO 400 mg + Azacitidine (Randomized),NCT02343939,Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML),adverse drug events
D064420,54.29,NCT02343939-8,Group C Phase 1b/2 ENTO 400 mg,NCT02343939,Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML),adverse drug events
D064420,57.14,NCT02343939-9,Group C Phase 1b ENTO 800 mg,NCT02343939,Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML),adverse drug events
D064147,26.0,NCT02343939-2,Group A Phase 1b/2 ENTO 400 mg + Cytarabine + Daunorubicin,NCT02343939,Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML),febrile neutropenia
D064147,80.0,NCT02343939-3,Group B Phase 1b ENTO 200 mg + Decitabine,NCT02343939,Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML),febrile neutropenia
D064147,66.67,NCT02343939-4,Group B Phase 1b ENTO 400 mg + Decitabine,NCT02343939,Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML),febrile neutropenia
D064147,37.5,NCT02343939-5,Group B Phase 2 ENTO 400 mg + Azacitidine (Safety Run-In),NCT02343939,Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML),febrile neutropenia
D064147,47.06,NCT02343939-6,Group B Phase 2 ENTO 400 mg + Decitabine (Randomized),NCT02343939,Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML),febrile neutropenia
D064147,14.29,NCT02343939-8,Group C Phase 1b/2 ENTO 400 mg,NCT02343939,Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML),febrile neutropenia
D000787,5.88,NCT02343939-6,Group B Phase 2 ENTO 400 mg + Decitabine (Randomized),NCT02343939,Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML),angina pectoris
D001281,20.0,NCT02343939-3,Group B Phase 1b ENTO 200 mg + Decitabine,NCT02343939,Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML),atrial fibrillation
D006323,5.88,NCT02343939-6,Group B Phase 2 ENTO 400 mg + Decitabine (Randomized),NCT02343939,Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML),cardiac arrest
D006333,7.14,NCT02343939-7,Group B Phase 2 ENTO 400 mg + Azacitidine (Randomized),NCT02343939,Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML),cardiac failure
D006333,5.71,NCT02343939-8,Group C Phase 1b/2 ENTO 400 mg,NCT02343939,Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML),cardiac failure
10040741,2.86,NCT02343939-8,Group C Phase 1b/2 ENTO 400 mg,NCT02343939,Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML),sinus bradycardia
D003092,16.67,NCT02343939-4,Group B Phase 1b ENTO 400 mg + Decitabine,NCT02343939,Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML),colitis
D003248,7.14,NCT02343939-7,Group B Phase 2 ENTO 400 mg + Azacitidine (Randomized),NCT02343939,Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML),constipation
D003248,14.29,NCT02343939-9,Group C Phase 1b ENTO 800 mg,NCT02343939,Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML),constipation
D020115,2.0,NCT02343939-2,Group A Phase 1b/2 ENTO 400 mg + Cytarabine + Daunorubicin,NCT02343939,Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML),progastricsin
D020115,7.14,NCT02343939-7,Group B Phase 2 ENTO 400 mg + Azacitidine (Randomized),NCT02343939,Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML),progastricsin
D000069196,5.88,NCT02343939-6,Group B Phase 2 ENTO 400 mg + Decitabine (Randomized),NCT02343939,Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML),gastrointestinal microbiome
D000069196,2.86,NCT02343939-8,Group C Phase 1b/2 ENTO 400 mg,NCT02343939,Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML),gastrointestinal microbiome
UNKNOWN-check-for-typo,4.0,NCT02343939-2,Group A Phase 1b/2 ENTO 400 mg + Cytarabine + Daunorubicin,NCT02343939,Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML),D00
UNKNOWN-check-for-typo,7.14,NCT02343939-7,Group B Phase 2 ENTO 400 mg + Azacitidine (Randomized),NCT02343939,Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML),D00
UNKNOWN-check-for-typo,2.86,NCT02343939-8,Group C Phase 1b/2 ENTO 400 mg,NCT02343939,Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML),D00
D000069196,5.88,NCT02343939-6,Group B Phase 2 ENTO 400 mg + Decitabine (Randomized),NCT02343939,Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML),gastrointestinal microbiome
D007420,2.0,NCT02343939-2,Group A Phase 1b/2 ENTO 400 mg + Cytarabine + Daunorubicin,NCT02343939,Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML),intestine large
10015461,2.86,NCT02343939-8,Group C Phase 1b/2 ENTO 400 mg,NCT02343939,Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML),esophagitis
UNKNOWN-check-for-typo,2.86,NCT02343939-8,Group C Phase 1b/2 ENTO 400 mg,NCT02343939,Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML),D00
D013280,5.88,NCT02343939-6,Group B Phase 2 ENTO 400 mg + Decitabine (Randomized),NCT02343939,Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML),stomatitis
D014839,2.86,NCT02343939-8,Group C Phase 1b/2 ENTO 400 mg,NCT02343939,Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML),vomiting
D001247,12.5,NCT02343939-5,Group B Phase 2 ENTO 400 mg + Azacitidine (Safety Run-In),NCT02343939,Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML),asthenia
D000077215,2.0,NCT02343939-2,Group A Phase 1b/2 ENTO 400 mg + Cytarabine + Daunorubicin,NCT02343939,Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML),halloysite
10062501,2.0,NCT02343939-2,Group A Phase 1b/2 ENTO 400 mg + Cytarabine + Daunorubicin,NCT02343939,Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML),non-cardiac chest pain
10062501,16.67,NCT02343939-4,Group B Phase 1b ENTO 400 mg + Decitabine,NCT02343939,Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML),non-cardiac chest pain
D005334,2.0,NCT02343939-2,Group A Phase 1b/2 ENTO 400 mg + Cytarabine + Daunorubicin,NCT02343939,Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML),pyrexia
D005334,20.0,NCT02343939-3,Group B Phase 1b ENTO 200 mg + Decitabine,NCT02343939,Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML),pyrexia
D005334,16.67,NCT02343939-4,Group B Phase 1b ENTO 400 mg + Decitabine,NCT02343939,Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML),pyrexia
D005334,12.5,NCT02343939-5,Group B Phase 2 ENTO 400 mg + Azacitidine (Safety Run-In),NCT02343939,Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML),pyrexia
D005334,5.71,NCT02343939-8,Group C Phase 1b/2 ENTO 400 mg,NCT02343939,Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML),pyrexia
D000038,2.86,NCT02343939-8,Group C Phase 1b/2 ENTO 400 mg,NCT02343939,Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML),abscess
UNKNOWN-check-for-typo,2.0,NCT02343939-2,Group A Phase 1b/2 ENTO 400 mg + Cytarabine + Daunorubicin,NCT02343939,Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML),D00
UNKNOWN-check-for-typo,5.88,NCT02343939-6,Group B Phase 2 ENTO 400 mg + Decitabine (Randomized),NCT02343939,Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML),D00
D001424,7.14,NCT02343939-7,Group B Phase 2 ENTO 400 mg + Azacitidine (Randomized),NCT02343939,Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML),bacterial infection
D002481,2.86,NCT02343939-8,Group C Phase 1b/2 ENTO 400 mg,NCT02343939,Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML),cellulitis
D002481,12.5,NCT02343939-5,Group B Phase 2 ENTO 400 mg + Azacitidine (Safety Run-In),NCT02343939,Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML),cellulitis
D004761,2.86,NCT02343939-8,Group C Phase 1b/2 ENTO 400 mg,NCT02343939,Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML),clostridium enterocolitis
10064687,2.0,NCT02343939-2,Group A Phase 1b/2 ENTO 400 mg + Cytarabine + Daunorubicin,NCT02343939,Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML),device related infection
10064687,33.33,NCT02343939-4,Group B Phase 1b ENTO 400 mg + Decitabine,NCT02343939,Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML),device related infection
10064687,2.86,NCT02343939-8,Group C Phase 1b/2 ENTO 400 mg,NCT02343939,Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML),device related infection
D005254,12.5,NCT02343939-5,Group B Phase 2 ENTO 400 mg + Azacitidine (Safety Run-In),NCT02343939,Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML),feline infectious enteritis
D000985,12.5,NCT02343939-5,Group B Phase 2 ENTO 400 mg + Azacitidine (Safety Run-In),NCT02343939,Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML),antisepsis
D009181,5.88,NCT02343939-6,Group B Phase 2 ENTO 400 mg + Decitabine (Randomized),NCT02343939,Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML),fungal infection
D009181,2.86,NCT02343939-8,Group C Phase 1b/2 ENTO 400 mg,NCT02343939,Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML),fungal infection
D007251,2.86,NCT02343939-8,Group C Phase 1b/2 ENTO 400 mg,NCT02343939,Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML),influenza
10061229,40.0,NCT02343939-3,Group B Phase 1b ENTO 200 mg + Decitabine,NCT02343939,Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML),lung infection
10061229,16.67,NCT02343939-4,Group B Phase 1b ENTO 400 mg + Decitabine,NCT02343939,Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML),lung infection
10061229,28.57,NCT02343939-9,Group C Phase 1b ENTO 800 mg,NCT02343939,Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML),lung infection
10065764,2.86,NCT02343939-8,Group C Phase 1b/2 ENTO 400 mg,NCT02343939,Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML),mucosal infection
D010033,2.86,NCT02343939-8,Group C Phase 1b/2 ENTO 400 mg,NCT02343939,Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML),otitis media
D011014,4.0,NCT02343939-2,Group A Phase 1b/2 ENTO 400 mg + Cytarabine + Daunorubicin,NCT02343939,Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML),pneumonia
D011014,11.76,NCT02343939-6,Group B Phase 2 ENTO 400 mg + Decitabine (Randomized),NCT02343939,Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML),pneumonia
D011014,14.29,NCT02343939-7,Group B Phase 2 ENTO 400 mg + Azacitidine (Randomized),NCT02343939,Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML),pneumonia
D011014,5.71,NCT02343939-8,Group C Phase 1b/2 ENTO 400 mg,NCT02343939,Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML),pneumonia
D018805,4.0,NCT02343939-2,Group A Phase 1b/2 ENTO 400 mg + Cytarabine + Daunorubicin,NCT02343939,Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML),sepsis
D018805,20.0,NCT02343939-3,Group B Phase 1b ENTO 200 mg + Decitabine,NCT02343939,Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML),sepsis
D018805,25.0,NCT02343939-5,Group B Phase 2 ENTO 400 mg + Azacitidine (Safety Run-In),NCT02343939,Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML),sepsis
D018805,5.88,NCT02343939-6,Group B Phase 2 ENTO 400 mg + Decitabine (Randomized),NCT02343939,Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML),sepsis
D013203,7.14,NCT02343939-7,Group B Phase 2 ENTO 400 mg + Azacitidine (Randomized),NCT02343939,Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML),staphylococcal infection
D000985,2.0,NCT02343939-2,Group A Phase 1b/2 ENTO 400 mg + Cytarabine + Daunorubicin,NCT02343939,Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML),antisepsis
D014552,2.0,NCT02343939-2,Group A Phase 1b/2 ENTO 400 mg + Cytarabine + Daunorubicin,NCT02343939,Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML),urinary tract infection
D053821,7.14,NCT02343939-7,Group B Phase 2 ENTO 400 mg + Azacitidine (Randomized),NCT02343939,Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML),cardiovascular infections
10016173,5.88,NCT02343939-6,Group B Phase 2 ENTO 400 mg + Decitabine (Randomized),NCT02343939,Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML),fall
10016173,14.29,NCT02343939-9,Group C Phase 1b ENTO 800 mg,NCT02343939,Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML),fall
10001675,2.86,NCT02343939-8,Group C Phase 1b/2 ENTO 400 mg,NCT02343939,Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML),alkaline phosphatase increased
D000637,12.5,NCT02343939-5,Group B Phase 2 ENTO 400 mg + Azacitidine (Safety Run-In),NCT02343939,Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML),transaminases
10007612,20.0,NCT02343939-3,Group B Phase 1b ENTO 200 mg + Decitabine,NCT02343939,Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML),cardiac troponin i increased
D003681,2.86,NCT02343939-8,Group C Phase 1b/2 ENTO 400 mg,NCT02343939,Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML),dehydration
D003681,14.29,NCT02343939-9,Group C Phase 1b ENTO 800 mg,NCT02343939,Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML),dehydration
D006073,2.0,NCT02343939-2,Group A Phase 1b/2 ENTO 400 mg + Cytarabine + Daunorubicin,NCT02343939,Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML),gout
UNKNOWN-check-for-typo,12.5,NCT02343939-5,Group B Phase 2 ENTO 400 mg + Azacitidine (Safety Run-In),NCT02343939,Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML),D00
D015275,12.5,NCT02343939-5,Group B Phase 2 ENTO 400 mg + Azacitidine (Safety Run-In),NCT02343939,Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML),tumour lysis syndrome
D015275,2.86,NCT02343939-8,Group C Phase 1b/2 ENTO 400 mg,NCT02343939,Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML),tumour lysis syndrome
D018908,14.29,NCT02343939-9,Group C Phase 1b ENTO 800 mg,NCT02343939,Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML),muscular weakness
D015470,2.86,NCT02343939-8,Group C Phase 1b/2 ENTO 400 mg,NCT02343939,Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML),leukemia nonlymphocytic acute
D013964,2.0,NCT02343939-2,Group A Phase 1b/2 ENTO 400 mg + Cytarabine + Daunorubicin,NCT02343939,Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML),thyroid cancer
D020521,2.0,NCT02343939-2,Group A Phase 1b/2 ENTO 400 mg + Cytarabine + Daunorubicin,NCT02343939,Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML),cerebrovascular accident
D008569,2.0,NCT02343939-2,Group A Phase 1b/2 ENTO 400 mg + Cytarabine + Daunorubicin,NCT02343939,Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML),retention disorders cognitive
D000069280,20.0,NCT02343939-3,Group B Phase 1b ENTO 200 mg + Decitabine,NCT02343939,Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML),intracranial electroencephalography
D000069280,5.88,NCT02343939-6,Group B Phase 2 ENTO 400 mg + Decitabine (Randomized),NCT02343939,Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML),intracranial electroencephalography
UNKNOWN-check-for-typo,20.0,NCT02343939-3,Group B Phase 1b ENTO 200 mg + Decitabine,NCT02343939,Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML),D00
D002546,2.0,NCT02343939-2,Group A Phase 1b/2 ENTO 400 mg + Cytarabine + Daunorubicin,NCT02343939,Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML),ischemic attack transient
D058186,2.86,NCT02343939-8,Group C Phase 1b/2 ENTO 400 mg,NCT02343939,Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML),acute kidney injury
UNKNOWN-check-for-typo,2.0,NCT02343939-2,Group A Phase 1b/2 ENTO 400 mg + Cytarabine + Daunorubicin,NCT02343939,Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML),D00
UNKNOWN-check-for-typo,20.0,NCT02343939-3,Group B Phase 1b ENTO 200 mg + Decitabine,NCT02343939,Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML),D00
UNKNOWN-check-for-typo,5.88,NCT02343939-6,Group B Phase 2 ENTO 400 mg + Decitabine (Randomized),NCT02343939,Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML),D00
UNKNOWN-check-for-typo,2.86,NCT02343939-8,Group C Phase 1b/2 ENTO 400 mg,NCT02343939,Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML),D00
D000860,16.67,NCT02343939-4,Group B Phase 1b ENTO 400 mg + Decitabine,NCT02343939,Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML),hypoxia
D008168,7.14,NCT02343939-7,Group B Phase 2 ENTO 400 mg + Azacitidine (Randomized),NCT02343939,Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML),lung
D010996,5.88,NCT02343939-6,Group B Phase 2 ENTO 400 mg + Decitabine (Randomized),NCT02343939,Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML),pleural effusion
D011014,2.0,NCT02343939-2,Group A Phase 1b/2 ENTO 400 mg + Cytarabine + Daunorubicin,NCT02343939,Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML),pneumonitis
D011030,2.0,NCT02343939-2,Group A Phase 1b/2 ENTO 400 mg + Cytarabine + Daunorubicin,NCT02343939,Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML),pneumothorax
D012131,2.0,NCT02343939-2,Group A Phase 1b/2 ENTO 400 mg + Cytarabine + Daunorubicin,NCT02343939,Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML),respiratory failure
D012131,16.67,NCT02343939-4,Group B Phase 1b ENTO 400 mg + Decitabine,NCT02343939,Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML),respiratory failure
D012131,12.5,NCT02343939-5,Group B Phase 2 ENTO 400 mg + Azacitidine (Safety Run-In),NCT02343939,Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML),respiratory failure
D000035,5.88,NCT02343939-6,Group B Phase 2 ENTO 400 mg + Decitabine (Randomized),NCT02343939,Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML),abreaction
10037868,2.0,NCT02343939-2,Group A Phase 1b/2 ENTO 400 mg + Cytarabine + Daunorubicin,NCT02343939,Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML),rash maculo-papular
10037868,16.67,NCT02343939-4,Group B Phase 1b ENTO 400 mg + Decitabine,NCT02343939,Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML),rash maculo-papular
D012867,7.14,NCT02343939-7,Group B Phase 2 ENTO 400 mg + Azacitidine (Randomized),NCT02343939,Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML),skin
D020246,7.14,NCT02343939-7,Group B Phase 2 ENTO 400 mg + Azacitidine (Randomized),NCT02343939,Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML),deep vein thrombosis
D007022,12.5,NCT02343939-5,Group B Phase 2 ENTO 400 mg + Azacitidine (Safety Run-In),NCT02343939,Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML),hypotension
D013927,16.67,NCT02343939-4,Group B Phase 1b ENTO 400 mg + Decitabine,NCT02343939,Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML),thrombosis
D009026,100.0,NCT02351037-1,Ibrutinib Monotherapy Cohort,NCT02351037,Study of Ibrutinib in Subjects With Acute Myeloid Leukemia,mortality
D009026,100.0,NCT02351037-2,Ibrutinib + LD-AraC Combination Cohort,NCT02351037,Study of Ibrutinib in Subjects With Acute Myeloid Leukemia,mortality
D009026,100.0,NCT02351037-3,Ibrutinib+Azacitidine Combination Cohort,NCT02351037,Study of Ibrutinib in Subjects With Acute Myeloid Leukemia,mortality
D064420,57.14,NCT02351037-1,Ibrutinib Monotherapy Cohort,NCT02351037,Study of Ibrutinib in Subjects With Acute Myeloid Leukemia,adverse drug events
D064420,100.0,NCT02351037-2,Ibrutinib + LD-AraC Combination Cohort,NCT02351037,Study of Ibrutinib in Subjects With Acute Myeloid Leukemia,adverse drug events
D064420,100.0,NCT02351037-3,Ibrutinib+Azacitidine Combination Cohort,NCT02351037,Study of Ibrutinib in Subjects With Acute Myeloid Leukemia,adverse drug events
D064147,14.29,NCT02351037-1,Ibrutinib Monotherapy Cohort,NCT02351037,Study of Ibrutinib in Subjects With Acute Myeloid Leukemia,febrile neutropenia
D064147,28.57,NCT02351037-2,Ibrutinib + LD-AraC Combination Cohort,NCT02351037,Study of Ibrutinib in Subjects With Acute Myeloid Leukemia,febrile neutropenia
D064147,50.0,NCT02351037-3,Ibrutinib+Azacitidine Combination Cohort,NCT02351037,Study of Ibrutinib in Subjects With Acute Myeloid Leukemia,febrile neutropenia
D000741,4.76,NCT02351037-2,Ibrutinib + LD-AraC Combination Cohort,NCT02351037,Study of Ibrutinib in Subjects With Acute Myeloid Leukemia,aplastic anaemia
D013921,4.76,NCT02351037-2,Ibrutinib + LD-AraC Combination Cohort,NCT02351037,Study of Ibrutinib in Subjects With Acute Myeloid Leukemia,thrombocytopenia
D007964,9.52,NCT02351037-2,Ibrutinib + LD-AraC Combination Cohort,NCT02351037,Study of Ibrutinib in Subjects With Acute Myeloid Leukemia,leukocytosis
D001282,4.76,NCT02351037-2,Ibrutinib + LD-AraC Combination Cohort,NCT02351037,Study of Ibrutinib in Subjects With Acute Myeloid Leukemia,atrial flutter
D006323,4.76,NCT02351037-2,Ibrutinib + LD-AraC Combination Cohort,NCT02351037,Study of Ibrutinib in Subjects With Acute Myeloid Leukemia,cardiac arrest
D001281,4.76,NCT02351037-2,Ibrutinib + LD-AraC Combination Cohort,NCT02351037,Study of Ibrutinib in Subjects With Acute Myeloid Leukemia,atrial fibrillation
D001281,12.5,NCT02351037-3,Ibrutinib+Azacitidine Combination Cohort,NCT02351037,Study of Ibrutinib in Subjects With Acute Myeloid Leukemia,atrial fibrillation
UNKNOWN-check-for-typo,4.76,NCT02351037-2,Ibrutinib + LD-AraC Combination Cohort,NCT02351037,Study of Ibrutinib in Subjects With Acute Myeloid Leukemia,D00
D015746,4.76,NCT02351037-2,Ibrutinib + LD-AraC Combination Cohort,NCT02351037,Study of Ibrutinib in Subjects With Acute Myeloid Leukemia,abdominal pain
D013280,12.5,NCT02351037-3,Ibrutinib+Azacitidine Combination Cohort,NCT02351037,Study of Ibrutinib in Subjects With Acute Myeloid Leukemia,stomatitis
D007421,12.5,NCT02351037-3,Ibrutinib+Azacitidine Combination Cohort,NCT02351037,Study of Ibrutinib in Subjects With Acute Myeloid Leukemia,intestine small
UNKNOWN-check-for-typo,4.76,NCT02351037-2,Ibrutinib + LD-AraC Combination Cohort,NCT02351037,Study of Ibrutinib in Subjects With Acute Myeloid Leukemia,D00
D005221,4.76,NCT02351037-2,Ibrutinib + LD-AraC Combination Cohort,NCT02351037,Study of Ibrutinib in Subjects With Acute Myeloid Leukemia,fatigue
D001247,9.52,NCT02351037-2,Ibrutinib + LD-AraC Combination Cohort,NCT02351037,Study of Ibrutinib in Subjects With Acute Myeloid Leukemia,asthenia
D001247,12.5,NCT02351037-3,Ibrutinib+Azacitidine Combination Cohort,NCT02351037,Study of Ibrutinib in Subjects With Acute Myeloid Leukemia,asthenia
D009102,4.76,NCT02351037-2,Ibrutinib + LD-AraC Combination Cohort,NCT02351037,Study of Ibrutinib in Subjects With Acute Myeloid Leukemia,multiple organ dysfunction syndrome
D005334,4.76,NCT02351037-2,Ibrutinib + LD-AraC Combination Cohort,NCT02351037,Study of Ibrutinib in Subjects With Acute Myeloid Leukemia,pyrexia
D011014,38.1,NCT02351037-2,Ibrutinib + LD-AraC Combination Cohort,NCT02351037,Study of Ibrutinib in Subjects With Acute Myeloid Leukemia,pneumonia
D011014,12.5,NCT02351037-3,Ibrutinib+Azacitidine Combination Cohort,NCT02351037,Study of Ibrutinib in Subjects With Acute Myeloid Leukemia,pneumonia
UNKNOWN-check-for-typo,14.29,NCT02351037-1,Ibrutinib Monotherapy Cohort,NCT02351037,Study of Ibrutinib in Subjects With Acute Myeloid Leukemia,D00
UNKNOWN-check-for-typo,4.76,NCT02351037-2,Ibrutinib + LD-AraC Combination Cohort,NCT02351037,Study of Ibrutinib in Subjects With Acute Myeloid Leukemia,D00
D001996,14.29,NCT02351037-2,Ibrutinib + LD-AraC Combination Cohort,NCT02351037,Study of Ibrutinib in Subjects With Acute Myeloid Leukemia,bronchopneumonia
D002481,9.52,NCT02351037-2,Ibrutinib + LD-AraC Combination Cohort,NCT02351037,Study of Ibrutinib in Subjects With Acute Myeloid Leukemia,cellulitis
D018805,4.76,NCT02351037-2,Ibrutinib + LD-AraC Combination Cohort,NCT02351037,Study of Ibrutinib in Subjects With Acute Myeloid Leukemia,sepsis
D054517,4.76,NCT02351037-2,Ibrutinib + LD-AraC Combination Cohort,NCT02351037,Study of Ibrutinib in Subjects With Acute Myeloid Leukemia,orbital cellulitis
D000985,12.5,NCT02351037-3,Ibrutinib+Azacitidine Combination Cohort,NCT02351037,Study of Ibrutinib in Subjects With Acute Myeloid Leukemia,antisepsis
D007251,12.5,NCT02351037-3,Ibrutinib+Azacitidine Combination Cohort,NCT02351037,Study of Ibrutinib in Subjects With Acute Myeloid Leukemia,influenza
D000891,12.5,NCT02351037-3,Ibrutinib+Azacitidine Combination Cohort,NCT02351037,Study of Ibrutinib in Subjects With Acute Myeloid Leukemia,antiseptics
D000985,4.76,NCT02351037-2,Ibrutinib + LD-AraC Combination Cohort,NCT02351037,Study of Ibrutinib in Subjects With Acute Myeloid Leukemia,antisepsis
D012772,4.76,NCT02351037-2,Ibrutinib + LD-AraC Combination Cohort,NCT02351037,Study of Ibrutinib in Subjects With Acute Myeloid Leukemia,septic shock
D014847,14.29,NCT02351037-1,Ibrutinib Monotherapy Cohort,NCT02351037,Study of Ibrutinib in Subjects With Acute Myeloid Leukemia,vulvitis
D004925,12.5,NCT02351037-3,Ibrutinib+Azacitidine Combination Cohort,NCT02351037,Study of Ibrutinib in Subjects With Acute Myeloid Leukemia,escherichia
10061229,14.29,NCT02351037-1,Ibrutinib Monotherapy Cohort,NCT02351037,Study of Ibrutinib in Subjects With Acute Myeloid Leukemia,lung infection
10016173,4.76,NCT02351037-2,Ibrutinib + LD-AraC Combination Cohort,NCT02351037,Study of Ibrutinib in Subjects With Acute Myeloid Leukemia,fall
D065227,4.76,NCT02351037-2,Ibrutinib + LD-AraC Combination Cohort,NCT02351037,Study of Ibrutinib in Subjects With Acute Myeloid Leukemia,transfusion reaction
UNKNOWN-check-for-typo,4.76,NCT02351037-2,Ibrutinib + LD-AraC Combination Cohort,NCT02351037,Study of Ibrutinib in Subjects With Acute Myeloid Leukemia,D00
D003681,9.52,NCT02351037-2,Ibrutinib + LD-AraC Combination Cohort,NCT02351037,Study of Ibrutinib in Subjects With Acute Myeloid Leukemia,dehydration
D003681,12.5,NCT02351037-3,Ibrutinib+Azacitidine Combination Cohort,NCT02351037,Study of Ibrutinib in Subjects With Acute Myeloid Leukemia,dehydration
D005183,14.29,NCT02351037-1,Ibrutinib Monotherapy Cohort,NCT02351037,Study of Ibrutinib in Subjects With Acute Myeloid Leukemia,failure to thrive
D015470,42.86,NCT02351037-1,Ibrutinib Monotherapy Cohort,NCT02351037,Study of Ibrutinib in Subjects With Acute Myeloid Leukemia,leukemia myeloid acute
D015470,42.86,NCT02351037-2,Ibrutinib + LD-AraC Combination Cohort,NCT02351037,Study of Ibrutinib in Subjects With Acute Myeloid Leukemia,leukemia myeloid acute
D020521,12.5,NCT02351037-3,Ibrutinib+Azacitidine Combination Cohort,NCT02351037,Study of Ibrutinib in Subjects With Acute Myeloid Leukemia,cerebrovascular accident
D012640,4.76,NCT02351037-2,Ibrutinib + LD-AraC Combination Cohort,NCT02351037,Study of Ibrutinib in Subjects With Acute Myeloid Leukemia,seizure
D013575,4.76,NCT02351037-2,Ibrutinib + LD-AraC Combination Cohort,NCT02351037,Study of Ibrutinib in Subjects With Acute Myeloid Leukemia,syncope
D000069280,4.76,NCT02351037-2,Ibrutinib + LD-AraC Combination Cohort,NCT02351037,Study of Ibrutinib in Subjects With Acute Myeloid Leukemia,intracranial electroencephalography
D003221,9.52,NCT02351037-2,Ibrutinib + LD-AraC Combination Cohort,NCT02351037,Study of Ibrutinib in Subjects With Acute Myeloid Leukemia,confusional state
D058186,9.52,NCT02351037-2,Ibrutinib + LD-AraC Combination Cohort,NCT02351037,Study of Ibrutinib in Subjects With Acute Myeloid Leukemia,acute kidney injury
D010996,4.76,NCT02351037-2,Ibrutinib + LD-AraC Combination Cohort,NCT02351037,Study of Ibrutinib in Subjects With Acute Myeloid Leukemia,pleural effusion
D012131,14.29,NCT02351037-2,Ibrutinib + LD-AraC Combination Cohort,NCT02351037,Study of Ibrutinib in Subjects With Acute Myeloid Leukemia,respiratory failure
D012131,12.5,NCT02351037-3,Ibrutinib+Azacitidine Combination Cohort,NCT02351037,Study of Ibrutinib in Subjects With Acute Myeloid Leukemia,respiratory failure
D011649,4.76,NCT02351037-2,Ibrutinib + LD-AraC Combination Cohort,NCT02351037,Study of Ibrutinib in Subjects With Acute Myeloid Leukemia,pulmonary alveolar proteinosis
D019390,4.76,NCT02351037-2,Ibrutinib + LD-AraC Combination Cohort,NCT02351037,Study of Ibrutinib in Subjects With Acute Myeloid Leukemia,arrestins
D009026,83.33,NCT02416908-1,Phase I Schedule A (Selinexor),NCT02416908,Study of CLAG + Selinexor in Relapsed or Refractory Acute Myeloid Leukemia,mortality
D009026,73.53,NCT02416908-3,Phase II (Selinexor),NCT02416908,Study of CLAG + Selinexor in Relapsed or Refractory Acute Myeloid Leukemia,mortality
D009026,100.0,NCT02416908-4,Selinexor Maintenance Phase (Optional),NCT02416908,Study of CLAG + Selinexor in Relapsed or Refractory Acute Myeloid Leukemia,mortality
D064420,66.67,NCT02416908-1,Phase I Schedule A (Selinexor),NCT02416908,Study of CLAG + Selinexor in Relapsed or Refractory Acute Myeloid Leukemia,adverse drug events
D064420,41.18,NCT02416908-3,Phase II (Selinexor),NCT02416908,Study of CLAG + Selinexor in Relapsed or Refractory Acute Myeloid Leukemia,adverse drug events
D064420,50.0,NCT02416908-4,Selinexor Maintenance Phase (Optional),NCT02416908,Study of CLAG + Selinexor in Relapsed or Refractory Acute Myeloid Leukemia,adverse drug events
D064147,16.67,NCT02416908-1,Phase I Schedule A (Selinexor),NCT02416908,Study of CLAG + Selinexor in Relapsed or Refractory Acute Myeloid Leukemia,febrile neutropenia
D010494,2.94,NCT02416908-2,Phase I Schedule B (Selinexor),NCT02416908,Study of CLAG + Selinexor in Relapsed or Refractory Acute Myeloid Leukemia,constrictive pericarditis
D003092,2.94,NCT02416908-2,Phase I Schedule B (Selinexor),NCT02416908,Study of CLAG + Selinexor in Relapsed or Refractory Acute Myeloid Leukemia,colitis
D010195,2.94,NCT02416908-2,Phase I Schedule B (Selinexor),NCT02416908,Study of CLAG + Selinexor in Relapsed or Refractory Acute Myeloid Leukemia,pancreatitis
D005334,2.94,NCT02416908-2,Phase I Schedule B (Selinexor),NCT02416908,Study of CLAG + Selinexor in Relapsed or Refractory Acute Myeloid Leukemia,fever
10003012,2.94,NCT02416908-2,Phase I Schedule B (Selinexor),NCT02416908,Study of CLAG + Selinexor in Relapsed or Refractory Acute Myeloid Leukemia,appendicitis perforated
10061017,16.67,NCT02416908-1,Phase I Schedule A (Selinexor),NCT02416908,Study of CLAG + Selinexor in Relapsed or Refractory Acute Myeloid Leukemia,bone infection
10061017,50.0,NCT02416908-3,Phase II (Selinexor),NCT02416908,Study of CLAG + Selinexor in Relapsed or Refractory Acute Myeloid Leukemia,bone infection
10061229,16.67,NCT02416908-1,Phase I Schedule A (Selinexor),NCT02416908,Study of CLAG + Selinexor in Relapsed or Refractory Acute Myeloid Leukemia,lung infection
10061229,2.94,NCT02416908-2,Phase I Schedule B (Selinexor),NCT02416908,Study of CLAG + Selinexor in Relapsed or Refractory Acute Myeloid Leukemia,lung infection
D018805,16.67,NCT02416908-1,Phase I Schedule A (Selinexor),NCT02416908,Study of CLAG + Selinexor in Relapsed or Refractory Acute Myeloid Leukemia,sepsis
D018805,20.59,NCT02416908-2,Phase I Schedule B (Selinexor),NCT02416908,Study of CLAG + Selinexor in Relapsed or Refractory Acute Myeloid Leukemia,sepsis
D012852,2.94,NCT02416908-2,Phase I Schedule B (Selinexor),NCT02416908,Study of CLAG + Selinexor in Relapsed or Refractory Acute Myeloid Leukemia,sinusitis
D018461,50.0,NCT02416908-3,Phase II (Selinexor),NCT02416908,Study of CLAG + Selinexor in Relapsed or Refractory Acute Myeloid Leukemia,soft tissue infection
D000138,2.94,NCT02416908-2,Phase I Schedule B (Selinexor),NCT02416908,Study of CLAG + Selinexor in Relapsed or Refractory Acute Myeloid Leukemia,acidosis
D012640,2.94,NCT02416908-2,Phase I Schedule B (Selinexor),NCT02416908,Study of CLAG + Selinexor in Relapsed or Refractory Acute Myeloid Leukemia,seizure
D011654,16.67,NCT02416908-1,Phase I Schedule A (Selinexor),NCT02416908,Study of CLAG + Selinexor in Relapsed or Refractory Acute Myeloid Leukemia,pulmonary edema
D012131,2.94,NCT02416908-2,Phase I Schedule B (Selinexor),NCT02416908,Study of CLAG + Selinexor in Relapsed or Refractory Acute Myeloid Leukemia,respiratory failure
D007022,2.94,NCT02416908-2,Phase I Schedule B (Selinexor),NCT02416908,Study of CLAG + Selinexor in Relapsed or Refractory Acute Myeloid Leukemia,hypotension
D009026,69.11,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,mortality
D009026,74.31,NCT02421939-2,Salvage Chemotherapy,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,mortality
D064420,83.33,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,adverse drug events
D064420,31.19,NCT02421939-2,Salvage Chemotherapy,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,adverse drug events
D000741,3.25,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,aplastic anaemia
D012010,0.41,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,aplasia pure red cell
D000744,0.41,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,autoimmune haemolytic anaemia
D000080983,0.41,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,bone marrow failure
D004211,0.81,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,disseminated intravascular coagulation
D064147,30.89,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,febrile neutropenia
D064147,8.26,NCT02421939-2,Salvage Chemotherapy,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,febrile neutropenia
D000743,0.81,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,haemolytic anaemia
D007964,0.81,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,leukocytosis
D007964,0.92,NCT02421939-2,Salvage Chemotherapy,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,leukocytosis
D009503,1.22,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,neutropenia
D009503,0.92,NCT02421939-2,Salvage Chemotherapy,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,neutropenia
D010198,1.63,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,pancytopenia
D013921,1.63,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,thrombocytopenia
D013921,0.92,NCT02421939-2,Salvage Chemotherapy,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,thrombocytopenia
D054058,0.41,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,acute coronary syndrome
D000787,0.41,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,angina pectoris
D001281,0.41,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,atrial fibrillation
D006323,1.63,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,cardiac arrest
D006333,1.22,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,cardiac failure
D006333,0.81,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,cardiac failure
D000072599,0.41,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,cardiorespiratory fitness
D009203,0.41,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,myocardial infarction
D009205,0.81,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,myocarditis
D010490,1.22,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,pericardial effusion
D000069236,0.41,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,pericardial fluid
D010493,1.22,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,pericarditis
D013616,0.41,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,sinus tachycardia
D013616,0.92,NCT02421939-2,Salvage Chemotherapy,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,sinus tachycardia
D013617,0.81,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,supraventricular tachycardia
D006222,0.41,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,hamartoma
D061351,0.41,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,binoculars
10005886,0.41,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,blurred vision
D015746,0.81,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,abdominal pain
D005401,0.41,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,anal fissure
D003092,0.81,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,colitis
UNKNOWN-check-for-typo,4.07,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,D00
D000081032,0.41,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,haemorrhagic pancreatitis
D003680,0.41,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,dysphagia
D004760,0.41,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,enterocolitis
D005756,0.41,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,gastritis
D000069196,0.41,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,gastrointestinal microbiome
D000069196,0.92,NCT02421939-2,Salvage Chemotherapy,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,gastrointestinal microbiome
D005764,0.41,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,gastroesophageal reflux disease
UNKNOWN-check-for-typo,0.41,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,D00
UNKNOWN-check-for-typo,0.41,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,D00
UNKNOWN-check-for-typo,0.81,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,D00
D045823,0.41,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,ileus
D000069196,0.41,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,gastrointestinal microbiome
D007420,0.81,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,intestine large
D041741,0.41,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,lower gastrointestinal tract
D050686,0.41,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,globicephala melaena
D050686,0.92,NCT02421939-2,Salvage Chemotherapy,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,globicephala melaena
D009055,0.81,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,mouth
D009325,0.81,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,nausea
D010195,1.22,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,pancreatitis
UNKNOWN-check-for-typo,0.41,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,D00
D013280,0.41,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,stomatitis
D013280,0.92,NCT02421939-2,Salvage Chemotherapy,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,stomatitis
D013280,0.41,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,stomatitis
D001819,0.41,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,bluetongue
D014839,0.41,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,vomiting
D001247,1.22,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,asthenia
D023341,0.41,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,chills
D003643,0.41,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,death
D000077944,0.81,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,alefacept
D005221,1.63,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,fatigue
D005221,0.92,NCT02421939-2,Salvage Chemotherapy,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,fatigue
D000799,0.41,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,angioedema
D007251,0.41,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,influenza
D009092,0.41,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,mucosal tissue
D007249,0.41,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,inflammation
D009102,0.41,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,multiple organ dysfunction syndrome
D009102,0.92,NCT02421939-2,Salvage Chemotherapy,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,multiple organ dysfunction syndrome
D000799,0.41,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,angioedema
D005334,13.01,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,pyrexia
D005334,0.92,NCT02421939-2,Salvage Chemotherapy,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,pyrexia
D002764,0.81,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,cholecystitis
D056486,0.41,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,drug induced liver injury
D011681,0.41,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,pupillary functions abnormal
UNKNOWN-check-for-typo,0.41,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,D00
D006086,0.41,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,graft-versus-host disease
D000707,1.22,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,anaphylactic reaction
D004342,0.41,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,drug hypersensitivity
D006086,0.41,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,graft versus host disease
D006086,0.41,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,graft-versus-host disease
D000038,0.41,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,abscess
D012141,0.41,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,infections upper respiratory
D000038,0.92,NCT02421939-2,Salvage Chemotherapy,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,abscess
UNKNOWN-check-for-typo,4.07,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,D00
UNKNOWN-check-for-typo,0.92,NCT02421939-2,Salvage Chemotherapy,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,D00
D003092,0.41,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,colitis
D001424,0.41,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,bacterial infection
D000985,0.41,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,antisepsis
D001991,1.63,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,bronchitis
D055732,0.81,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,bronchopulmonary aspergillosis
D010272,0.41,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,parasite infections
D002481,2.44,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,cellulitis
D004761,0.81,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,clostridium enterocolitis
D003015,1.63,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,clostridium difficile infection
D003586,0.41,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,cytomegalovirus infection
10064687,1.63,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,device related infection
10064687,0.92,NCT02421939-2,Salvage Chemotherapy,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,device related infection
D000069544,0.41,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,infectious encephalitis
D004696,0.41,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,endocarditis
UNKNOWN-check-for-typo,0.41,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,D00
D000985,0.41,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,antisepsis
10058838,1.63,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,enterocolitis infectious
D004854,0.41,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,epstein-barr virus
D004925,0.81,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,escherichia
D000985,0.41,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,antisepsis
D014552,1.22,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,urinary tract infections
D014552,0.92,NCT02421939-2,Salvage Chemotherapy,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,urinary tract infections
D015817,0.41,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,eye infection
D015818,0.41,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,eye infections bacterial
D006192,0.92,NCT02421939-2,Salvage Chemotherapy,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,haemophilus infection
10056522,0.41,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,hepatic infection
D007239,0.41,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,infection
D007239,0.92,NCT02421939-2,Salvage Chemotherapy,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,infection
10058838,0.41,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,enterocolitis infectious
D007251,1.22,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,influenza
D007251,0.92,NCT02421939-2,Salvage Chemotherapy,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,influenza
D007709,0.92,NCT02421939-2,Salvage Chemotherapy,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,klebsiella
D000069544,0.41,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,encephalitis infection
D012141,0.81,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,respiratory tract infections
D012141,0.41,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,respiratory tract infections
D012141,0.81,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,respiratory tract infections
10061229,5.69,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,lung infection
10061229,4.59,NCT02421939-2,Salvage Chemotherapy,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,lung infection
D000069544,0.41,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,encephalitis infection
D010032,0.41,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,otitis externa
D010309,0.41,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,parotitis
10051472,0.41,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,periorbital infection
D011014,10.57,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,pneumonia
D011014,3.67,NCT02421939-2,Salvage Chemotherapy,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,pneumonia
D001996,0.81,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,bronchopneumonia
D011024,0.41,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,pneumonia viral
D011024,0.41,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,viral pneumonia
UNKNOWN-check-for-typo,0.81,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,D00
D000985,0.41,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,antisepsis
D055744,0.41,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,allergic bronchopulmonary mycosis
D018357,0.41,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,respiratory syncytial virus infection
D012141,1.63,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,respiratory tract infection
10062156,0.41,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,scrotal infection
D018805,7.32,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,sepsis
D018805,6.42,NCT02421939-2,Salvage Chemotherapy,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,sepsis
D012772,3.66,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,septic shock
D012772,0.92,NCT02421939-2,Salvage Chemotherapy,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,septic shock
D012852,1.22,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,sinusitis
D012852,0.41,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,sinusitis
10040872,1.63,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,skin infection
D018461,0.41,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,soft tissue infection
D004768,2.44,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,staphylococcal enterotoxins
D013203,0.81,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,staphylococcal infection
D010844,1.22,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,streptococcal ok432
D001424,0.41,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,bacterial infections
D000196,0.41,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,actinomycosis
D000038,0.92,NCT02421939-2,Salvage Chemotherapy,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,abscess
10048762,0.81,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,tooth infection
D012141,1.22,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,upper respiratory tract infections
D014552,0.81,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,urinary tract infection
D014552,0.81,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,urinary tract infections
D014552,0.92,NCT02421939-2,Salvage Chemotherapy,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,urinary tract infections
D014552,0.41,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,urinary tract infections
D012141,0.81,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,upper respiratory tract infections
D002481,0.41,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,cellulitis
D014946,0.41,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,wound infection
D000058,0.41,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,accidental falls
D000707,0.41,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,anaphylactic reaction
D064386,0.41,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,ankle fracture
10016173,3.25,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,fall
10016173,0.92,NCT02421939-2,Salvage Chemotherapy,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,fall
10020100,0.41,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,hip fracture
10051792,0.81,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,infusion related reaction
D004204,0.41,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,joint dislocation
D010329,0.41,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,patella
D007427,0.41,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,subarachnoid pressure
D006408,0.81,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,hematoma subdural
D006408,0.92,NCT02421939-2,Salvage Chemotherapy,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,hematoma subdural
D000081015,0.41,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,ototoxicity
10001551,5.28,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,alanine aminotransferase increased
10003481,4.07,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,aspartate aminotransferase increased
10001675,0.41,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,alkaline phosphatase increased
10005364,0.81,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,blood bilirubin increased
D003402,0.81,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,creatine phosphokinase
10011368,0.41,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,creatinine increased
10016596,0.41,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,fibrinogen decreased
D001794,0.92,NCT02421939-2,Salvage Chemotherapy,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,blood pressure
10050528,0.92,NCT02421939-2,Salvage Chemotherapy,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,ejection fraction decreased
D008133,0.81,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,electrocardiogram qt prolonged
D005723,0.41,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,gammaglutamyltransferase
D010805,0.41,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,physical conditioning animal
D008111,0.41,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,liver function tests
D006262,0.41,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,normality
10029366,1.63,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,neutrophil count decreased
D004845,0.41,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,epitestosterone
10035528,2.03,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,platelet count decreased
D000637,0.41,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,transaminases
D007958,0.41,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,blood cell count white
D007958,0.41,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,blood cell count white
D001066,0.81,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,appetite
D003681,0.81,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,dehydration
D005183,0.41,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,failure to thrive
UNKNOWN-check-for-typo,0.92,NCT02421939-2,Salvage Chemotherapy,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,D00
UNKNOWN-check-for-typo,0.41,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,D00
UNKNOWN-check-for-typo,0.41,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,D00
UNKNOWN-check-for-typo,0.92,NCT02421939-2,Salvage Chemotherapy,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,D00
UNKNOWN-check-for-typo,0.81,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,D00
D013577,0.41,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,syndrome
UNKNOWN-check-for-typo,0.41,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,D00
D000138,0.41,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,metabolic acidosis
D015275,0.41,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,tumour lysis syndrome
D015275,1.83,NCT02421939-2,Salvage Chemotherapy,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,tumour lysis syndrome
D018771,1.22,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,arthralgia
D001168,0.81,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,arthritis
D001416,0.41,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,back pain
10006002,0.41,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,bone pain
10023215,0.41,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,joint effusion
D007596,0.41,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,joints
D018908,0.41,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,muscular weakness
D009220,1.22,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,myositis
D010003,0.41,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,osteoarthritis
10033425,0.92,NCT02421939-2,Salvage Chemotherapy,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,pain in extremity
D000080867,0.41,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,gingipains
10065775,0.41,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,abdominal soft tissue necrosis
D015470,13.41,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,leukemia myeloid acute
D015470,3.67,NCT02421939-2,Salvage Chemotherapy,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,leukemia myeloid acute
D015470,2.85,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,leukemia myeloid acute
D000072716,0.41,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,cancer pain
D002490,0.81,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,central nervous system
D013274,0.41,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,gastric cancer
D003483,0.81,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,cutis laxa
D000026,0.41,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,miscarriage recurrent
D000026,0.92,NCT02421939-2,Salvage Chemotherapy,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,miscarriage recurrent
D009369,0.92,NCT02421939-2,Salvage Chemotherapy,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,malignant neoplasms
D009369,0.41,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,malignant neoplasm
D000230,0.41,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,adenocarcinoma
D012509,0.41,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,soft tissue sarcoma
D002294,0.92,NCT02421939-2,Salvage Chemotherapy,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,squamous cell carcinoma
D000647,0.92,NCT02421939-2,Salvage Chemotherapy,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,amnesia
D000799,0.81,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,angioedema
D000070624,0.41,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,cerebellar contusion
D000074042,1.22,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,cerebral intraventricular haemorrhage
D002544,0.92,NCT02421939-2,Salvage Chemotherapy,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,cerebral infarction
D020521,0.41,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,cerebrovascular accident
D008569,0.41,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,retention disorders cognitive
D003244,0.81,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,depressed level of consciousness
D004244,0.41,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,dizziness
D000069280,0.41,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,intracranial electroencephalography
D013474,0.92,NCT02421939-2,Salvage Chemotherapy,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,sunstroke
D006261,2.03,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,headache
D006429,0.41,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,hemiplegia
D006849,0.41,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,hydrocephalus
D054038,0.41,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,posterior reversible encephalopathy syndrome
D013575,0.41,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,presyncope
D012640,0.81,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,seizure
D000077260,0.41,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,somnolence
D013575,2.85,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,syncope
D014202,0.41,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,tremor
D003221,0.41,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,confusional state
D003863,0.92,NCT02421939-2,Salvage Chemotherapy,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,depression
D006212,0.41,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,hallucination
D001714,0.41,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,mania
D000073216,0.41,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,mental status tests
D058186,6.5,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,acute kidney injury
D058186,3.67,NCT02421939-2,Salvage Chemotherapy,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,acute kidney injury
UNKNOWN-check-for-typo,0.41,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,D00
D000308,0.41,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,hyperadrenalism
D017699,0.41,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,pelvic pain
D000069339,0.41,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,vaginal cervicectomy
D012128,1.63,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,acute respiratory distress syndrome
D012131,0.81,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,respiratory failure
D012131,0.92,NCT02421939-2,Salvage Chemotherapy,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,respiratory failure
10003504,0.41,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,aspiration
D003371,0.81,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,cough
UNKNOWN-check-for-typo,4.07,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,D00
UNKNOWN-check-for-typo,1.83,NCT02421939-2,Salvage Chemotherapy,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,D00
D000860,1.63,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,hypoxia
D000860,1.83,NCT02421939-2,Salvage Chemotherapy,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,hypoxia
D017563,0.41,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,interstitial lung disease
D008168,0.41,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,lung
D001996,0.81,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,bronchopneumonia
10068319,0.41,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,oropharyngeal pain
D010996,0.81,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,pleural effusion
D008478,0.41,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,pneumomediastinum
D011015,0.81,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,aspiration pneumonia
D011030,0.41,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,pneumothorax
10036790,0.41,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,productive cough
D011649,0.92,NCT02421939-2,Salvage Chemotherapy,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,pulmonary alveolar proteinosis
D011655,0.81,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,pulmonary embolism
D001261,0.92,NCT02421939-2,Salvage Chemotherapy,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,pulmonary atelectasis
D006976,0.81,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,pulmonary hypertension
D012131,2.85,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,respiratory failure
D012131,2.75,NCT02421939-2,Salvage Chemotherapy,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,respiratory failure
D016463,0.41,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,acute febrile neutrophilic dermatosis
10006556,0.41,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,bullous dermatitis
D003875,0.41,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,drug eruption
D011693,0.41,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,petechiae
D011565,0.41,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,psoriasis
D005218,0.41,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,steatonecrosis
D000077944,0.41,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,alefacept
D000081015,0.41,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,ototoxicity
D020246,0.92,NCT02421939-2,Salvage Chemotherapy,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,deep vein thrombosis
D004617,1.22,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,embolism
D004617,0.92,NCT02421939-2,Salvage Chemotherapy,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,embolism
UNKNOWN-check-for-typo,1.22,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,D00
D000074042,0.41,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,cerebral intraventricular haemorrhage
D006973,0.41,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,hypertension
D006973,0.92,NCT02421939-2,Salvage Chemotherapy,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,hypertension
D007022,2.44,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,hypotension
D007022,0.92,NCT02421939-2,Salvage Chemotherapy,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,hypotension
D007024,0.41,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,orthostatic hypotension
D020246,0.41,NCT02421939-1,Gilteritinib,NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,venous thrombosis
D064420,100.0,NCT02485353-1,Vosaroxin and Cytarabine,NCT02485353,Study of Vosaroxin and Cytarabine for the Treatment of Adults 60 Years of Age or Older With Previously Untreated AML,adverse drug events
10021881,50.0,NCT02485353-1,Vosaroxin and Cytarabine,NCT02485353,Study of Vosaroxin and Cytarabine for the Treatment of Adults 60 Years of Age or Older With Previously Untreated AML,infections and infestations - other specify
D018805,50.0,NCT02485353-1,Vosaroxin and Cytarabine,NCT02485353,Study of Vosaroxin and Cytarabine for the Treatment of Adults 60 Years of Age or Older With Previously Untreated AML,sepsis
D064420,50.0,NCT02535806-1,Treatment Arm,NCT02535806,Four Drug Reinduction With Bortezomib for Relapsed or Refractory ALL or LL in Children and Young Adults,adverse drug events
D012131,50.0,NCT02535806-1,Treatment Arm,NCT02535806,Four Drug Reinduction With Bortezomib for Relapsed or Refractory ALL or LL in Children and Young Adults,respiratory failure
D009026,51.28,NCT02560025-1,Alisertib / MLN8237,NCT02560025,Phase II Trial of Alisertib With Induction Chemotherapy in High-risk AML,mortality
D064420,69.23,NCT02560025-1,Alisertib / MLN8237,NCT02560025,Phase II Trial of Alisertib With Induction Chemotherapy in High-risk AML,adverse drug events
D000740,28.21,NCT02560025-1,Alisertib / MLN8237,NCT02560025,Phase II Trial of Alisertib With Induction Chemotherapy in High-risk AML,anemia
D064147,41.03,NCT02560025-1,Alisertib / MLN8237,NCT02560025,Phase II Trial of Alisertib With Induction Chemotherapy in High-risk AML,febrile neutropenia
D003092,2.56,NCT02560025-1,Alisertib / MLN8237,NCT02560025,Phase II Trial of Alisertib With Induction Chemotherapy in High-risk AML,colitis
D003967,5.13,NCT02560025-1,Alisertib / MLN8237,NCT02560025,Phase II Trial of Alisertib With Induction Chemotherapy in High-risk AML,diarrhea
D003680,2.56,NCT02560025-1,Alisertib / MLN8237,NCT02560025,Phase II Trial of Alisertib With Induction Chemotherapy in High-risk AML,dysphagia
D004941,5.13,NCT02560025-1,Alisertib / MLN8237,NCT02560025,Phase II Trial of Alisertib With Induction Chemotherapy in High-risk AML,esophagitis
10028130,10.26,NCT02560025-1,Alisertib / MLN8237,NCT02560025,Phase II Trial of Alisertib With Induction Chemotherapy in High-risk AML,mucositis oral
D009325,7.69,NCT02560025-1,Alisertib / MLN8237,NCT02560025,Phase II Trial of Alisertib With Induction Chemotherapy in High-risk AML,nausea
10001551,7.69,NCT02560025-1,Alisertib / MLN8237,NCT02560025,Phase II Trial of Alisertib With Induction Chemotherapy in High-risk AML,alanine aminotransferase increased
10003481,5.13,NCT02560025-1,Alisertib / MLN8237,NCT02560025,Phase II Trial of Alisertib With Induction Chemotherapy in High-risk AML,aspartate aminotransferase increased
10005364,7.69,NCT02560025-1,Alisertib / MLN8237,NCT02560025,Phase II Trial of Alisertib With Induction Chemotherapy in High-risk AML,blood bilirubin increased
10029366,30.77,NCT02560025-1,Alisertib / MLN8237,NCT02560025,Phase II Trial of Alisertib With Induction Chemotherapy in High-risk AML,neutrophil count decreased
10035528,30.77,NCT02560025-1,Alisertib / MLN8237,NCT02560025,Phase II Trial of Alisertib With Induction Chemotherapy in High-risk AML,platelet count decreased
D000855,23.08,NCT02560025-1,Alisertib / MLN8237,NCT02560025,Phase II Trial of Alisertib With Induction Chemotherapy in High-risk AML,anorexia
D017674,2.56,NCT02560025-1,Alisertib / MLN8237,NCT02560025,Phase II Trial of Alisertib With Induction Chemotherapy in High-risk AML,hypophosphatemia
10065880,2.56,NCT02560025-1,Alisertib / MLN8237,NCT02560025,Phase II Trial of Alisertib With Induction Chemotherapy in High-risk AML,laryngeal mucositis
D009026,36.84,NCT02642965-1,Treatment (CPX-351 and FLAG),NCT02642965,Liposome-encapsulated Daunorubicin-Cytarabine  Fludarabine Phosphate  Cytarabine  and Filgrastim in Treating Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia,mortality
D064420,55.26,NCT02642965-1,Treatment (CPX-351 and FLAG),NCT02642965,Liposome-encapsulated Daunorubicin-Cytarabine  Fludarabine Phosphate  Cytarabine  and Filgrastim in Treating Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia,adverse drug events
D064147,28.95,NCT02642965-1,Treatment (CPX-351 and FLAG),NCT02642965,Liposome-encapsulated Daunorubicin-Cytarabine  Fludarabine Phosphate  Cytarabine  and Filgrastim in Treating Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia,febrile neutropenia
D003680,2.63,NCT02642965-1,Treatment (CPX-351 and FLAG),NCT02642965,Liposome-encapsulated Daunorubicin-Cytarabine  Fludarabine Phosphate  Cytarabine  and Filgrastim in Treating Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia,dysphagia
10017947,2.63,NCT02642965-1,Treatment (CPX-351 and FLAG),NCT02642965,Liposome-encapsulated Daunorubicin-Cytarabine  Fludarabine Phosphate  Cytarabine  and Filgrastim in Treating Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia,gastrointestinal disorders - other specify
10028130,2.63,NCT02642965-1,Treatment (CPX-351 and FLAG),NCT02642965,Liposome-encapsulated Daunorubicin-Cytarabine  Fludarabine Phosphate  Cytarabine  and Filgrastim in Treating Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia,mucositis oral
D053706,5.26,NCT02642965-1,Treatment (CPX-351 and FLAG),NCT02642965,Liposome-encapsulated Daunorubicin-Cytarabine  Fludarabine Phosphate  Cytarabine  and Filgrastim in Treating Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia,typhlitis
10011914,13.16,NCT02642965-1,Treatment (CPX-351 and FLAG),NCT02642965,Liposome-encapsulated Daunorubicin-Cytarabine  Fludarabine Phosphate  Cytarabine  and Filgrastim in Treating Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia,death nos
D005334,5.26,NCT02642965-1,Treatment (CPX-351 and FLAG),NCT02642965,Liposome-encapsulated Daunorubicin-Cytarabine  Fludarabine Phosphate  Cytarabine  and Filgrastim in Treating Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia,fever
10061640,2.63,NCT02642965-1,Treatment (CPX-351 and FLAG),NCT02642965,Liposome-encapsulated Daunorubicin-Cytarabine  Fludarabine Phosphate  Cytarabine  and Filgrastim in Treating Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia,anorectal infection
10007810,2.63,NCT02642965-1,Treatment (CPX-351 and FLAG),NCT02642965,Liposome-encapsulated Daunorubicin-Cytarabine  Fludarabine Phosphate  Cytarabine  and Filgrastim in Treating Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia,catheter related infection
10021881,15.79,NCT02642965-1,Treatment (CPX-351 and FLAG),NCT02642965,Liposome-encapsulated Daunorubicin-Cytarabine  Fludarabine Phosphate  Cytarabine  and Filgrastim in Treating Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia,infections and infestations - other specify
10023424,2.63,NCT02642965-1,Treatment (CPX-351 and FLAG),NCT02642965,Liposome-encapsulated Daunorubicin-Cytarabine  Fludarabine Phosphate  Cytarabine  and Filgrastim in Treating Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia,kidney infection
10061229,5.26,NCT02642965-1,Treatment (CPX-351 and FLAG),NCT02642965,Liposome-encapsulated Daunorubicin-Cytarabine  Fludarabine Phosphate  Cytarabine  and Filgrastim in Treating Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia,lung infection
10040872,2.63,NCT02642965-1,Treatment (CPX-351 and FLAG),NCT02642965,Liposome-encapsulated Daunorubicin-Cytarabine  Fludarabine Phosphate  Cytarabine  and Filgrastim in Treating Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia,skin infection
10065771,2.63,NCT02642965-1,Treatment (CPX-351 and FLAG),NCT02642965,Liposome-encapsulated Daunorubicin-Cytarabine  Fludarabine Phosphate  Cytarabine  and Filgrastim in Treating Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia,small intestine infection
D018461,2.63,NCT02642965-1,Treatment (CPX-351 and FLAG),NCT02642965,Liposome-encapsulated Daunorubicin-Cytarabine  Fludarabine Phosphate  Cytarabine  and Filgrastim in Treating Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia,soft tissue infection
10005364,2.63,NCT02642965-1,Treatment (CPX-351 and FLAG),NCT02642965,Liposome-encapsulated Daunorubicin-Cytarabine  Fludarabine Phosphate  Cytarabine  and Filgrastim in Treating Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia,blood bilirubin increased
10050528,2.63,NCT02642965-1,Treatment (CPX-351 and FLAG),NCT02642965,Liposome-encapsulated Daunorubicin-Cytarabine  Fludarabine Phosphate  Cytarabine  and Filgrastim in Treating Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia,ejection fraction decreased
10025256,2.63,NCT02642965-1,Treatment (CPX-351 and FLAG),NCT02642965,Liposome-encapsulated Daunorubicin-Cytarabine  Fludarabine Phosphate  Cytarabine  and Filgrastim in Treating Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia,lymphocyte count decreased
10049182,2.63,NCT02642965-1,Treatment (CPX-351 and FLAG),NCT02642965,Liposome-encapsulated Daunorubicin-Cytarabine  Fludarabine Phosphate  Cytarabine  and Filgrastim in Treating Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia,white blood cell decreased
D000855,2.63,NCT02642965-1,Treatment (CPX-351 and FLAG),NCT02642965,Liposome-encapsulated Daunorubicin-Cytarabine  Fludarabine Phosphate  Cytarabine  and Filgrastim in Treating Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia,anorexia
D006943,5.26,NCT02642965-1,Treatment (CPX-351 and FLAG),NCT02642965,Liposome-encapsulated Daunorubicin-Cytarabine  Fludarabine Phosphate  Cytarabine  and Filgrastim in Treating Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia,hyperglycemia
D006261,2.63,NCT02642965-1,Treatment (CPX-351 and FLAG),NCT02642965,Liposome-encapsulated Daunorubicin-Cytarabine  Fludarabine Phosphate  Cytarabine  and Filgrastim in Treating Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia,headache
10029205,2.63,NCT02642965-1,Treatment (CPX-351 and FLAG),NCT02642965,Liposome-encapsulated Daunorubicin-Cytarabine  Fludarabine Phosphate  Cytarabine  and Filgrastim in Treating Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia,nervous system disorders - other specify
D013575,2.63,NCT02642965-1,Treatment (CPX-351 and FLAG),NCT02642965,Liposome-encapsulated Daunorubicin-Cytarabine  Fludarabine Phosphate  Cytarabine  and Filgrastim in Treating Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia,syncope
10046539,2.63,NCT02642965-1,Treatment (CPX-351 and FLAG),NCT02642965,Liposome-encapsulated Daunorubicin-Cytarabine  Fludarabine Phosphate  Cytarabine  and Filgrastim in Treating Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia,urinary frequency
10038604,2.63,NCT02642965-1,Treatment (CPX-351 and FLAG),NCT02642965,Liposome-encapsulated Daunorubicin-Cytarabine  Fludarabine Phosphate  Cytarabine  and Filgrastim in Treating Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia,reproductive system and breast disorders - other specify
D000860,2.63,NCT02642965-1,Treatment (CPX-351 and FLAG),NCT02642965,Liposome-encapsulated Daunorubicin-Cytarabine  Fludarabine Phosphate  Cytarabine  and Filgrastim in Treating Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia,hypoxia
D012135,2.63,NCT02642965-1,Treatment (CPX-351 and FLAG),NCT02642965,Liposome-encapsulated Daunorubicin-Cytarabine  Fludarabine Phosphate  Cytarabine  and Filgrastim in Treating Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia,stridor
10037868,15.79,NCT02642965-1,Treatment (CPX-351 and FLAG),NCT02642965,Liposome-encapsulated Daunorubicin-Cytarabine  Fludarabine Phosphate  Cytarabine  and Filgrastim in Treating Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia,rash maculo-papular
D009026,54.55,NCT02658487-1,Treatment (Vosaroxin Cytarabine) Induction 1,NCT02658487,Vosaroxin and Infusional Cytarabine in Treating Patients With Untreated Acute Myeloid Leukemia,mortality
D009026,44.44,NCT02658487-2,Induction 2,NCT02658487,Vosaroxin and Infusional Cytarabine in Treating Patients With Untreated Acute Myeloid Leukemia,mortality
D064420,30.3,NCT02658487-1,Treatment (Vosaroxin Cytarabine) Induction 1,NCT02658487,Vosaroxin and Infusional Cytarabine in Treating Patients With Untreated Acute Myeloid Leukemia,adverse drug events
D064420,55.56,NCT02658487-2,Induction 2,NCT02658487,Vosaroxin and Infusional Cytarabine in Treating Patients With Untreated Acute Myeloid Leukemia,adverse drug events
D064147,3.03,NCT02658487-1,Treatment (Vosaroxin Cytarabine) Induction 1,NCT02658487,Vosaroxin and Infusional Cytarabine in Treating Patients With Untreated Acute Myeloid Leukemia,febrile neutropenia
D064147,11.11,NCT02658487-2,Induction 2,NCT02658487,Vosaroxin and Infusional Cytarabine in Treating Patients With Untreated Acute Myeloid Leukemia,febrile neutropenia
D006333,11.11,NCT02658487-2,Induction 2,NCT02658487,Vosaroxin and Infusional Cytarabine in Treating Patients With Untreated Acute Myeloid Leukemia,heart failure
D014693,3.03,NCT02658487-1,Treatment (Vosaroxin Cytarabine) Induction 1,NCT02658487,Vosaroxin and Infusional Cytarabine in Treating Patients With Untreated Acute Myeloid Leukemia,ventricular fibrillation
D004238,3.03,NCT02658487-1,Treatment (Vosaroxin Cytarabine) Induction 1,NCT02658487,Vosaroxin and Infusional Cytarabine in Treating Patients With Untreated Acute Myeloid Leukemia,diverticulitis
D003092,18.18,NCT02658487-1,Treatment (Vosaroxin Cytarabine) Induction 1,NCT02658487,Vosaroxin and Infusional Cytarabine in Treating Patients With Untreated Acute Myeloid Leukemia,colitis
D003092,11.11,NCT02658487-2,Induction 2,NCT02658487,Vosaroxin and Infusional Cytarabine in Treating Patients With Untreated Acute Myeloid Leukemia,colitis
D053706,3.03,NCT02658487-1,Treatment (Vosaroxin Cytarabine) Induction 1,NCT02658487,Vosaroxin and Infusional Cytarabine in Treating Patients With Untreated Acute Myeloid Leukemia,typhlitis
D053706,11.11,NCT02658487-2,Induction 2,NCT02658487,Vosaroxin and Infusional Cytarabine in Treating Patients With Untreated Acute Myeloid Leukemia,typhlitis
D002764,3.03,NCT02658487-1,Treatment (Vosaroxin Cytarabine) Induction 1,NCT02658487,Vosaroxin and Infusional Cytarabine in Treating Patients With Untreated Acute Myeloid Leukemia,cholecystitis
D002764,11.11,NCT02658487-2,Induction 2,NCT02658487,Vosaroxin and Infusional Cytarabine in Treating Patients With Untreated Acute Myeloid Leukemia,cholecystitis
D018805,6.06,NCT02658487-1,Treatment (Vosaroxin Cytarabine) Induction 1,NCT02658487,Vosaroxin and Infusional Cytarabine in Treating Patients With Untreated Acute Myeloid Leukemia,sepsis
D016469,3.03,NCT02658487-1,Treatment (Vosaroxin Cytarabine) Induction 1,NCT02658487,Vosaroxin and Infusional Cytarabine in Treating Patients With Untreated Acute Myeloid Leukemia,fungemia
10014383,9.09,NCT02658487-1,Treatment (Vosaroxin Cytarabine) Induction 1,NCT02658487,Vosaroxin and Infusional Cytarabine in Treating Patients With Untreated Acute Myeloid Leukemia,electrocardiogram qt corrected interval prolonged
D000073216,11.11,NCT02658487-2,Induction 2,NCT02658487,Vosaroxin and Infusional Cytarabine in Treating Patients With Untreated Acute Myeloid Leukemia,mini mental state examination
D006417,3.03,NCT02658487-1,Treatment (Vosaroxin Cytarabine) Induction 1,NCT02658487,Vosaroxin and Infusional Cytarabine in Treating Patients With Untreated Acute Myeloid Leukemia,hematuria
D058186,3.03,NCT02658487-1,Treatment (Vosaroxin Cytarabine) Induction 1,NCT02658487,Vosaroxin and Infusional Cytarabine in Treating Patients With Untreated Acute Myeloid Leukemia,acute kidney injury
D012128,3.03,NCT02658487-1,Treatment (Vosaroxin Cytarabine) Induction 1,NCT02658487,Vosaroxin and Infusional Cytarabine in Treating Patients With Untreated Acute Myeloid Leukemia,adult respiratory distress syndrome
D012131,6.06,NCT02658487-1,Treatment (Vosaroxin Cytarabine) Induction 1,NCT02658487,Vosaroxin and Infusional Cytarabine in Treating Patients With Untreated Acute Myeloid Leukemia,respiratory failure
D004417,11.11,NCT02658487-2,Induction 2,NCT02658487,Vosaroxin and Infusional Cytarabine in Treating Patients With Untreated Acute Myeloid Leukemia,dyspnea
D010996,11.11,NCT02658487-2,Induction 2,NCT02658487,Vosaroxin and Infusional Cytarabine in Treating Patients With Untreated Acute Myeloid Leukemia,pleural effusion
10043565,11.11,NCT02658487-2,Induction 2,NCT02658487,Vosaroxin and Infusional Cytarabine in Treating Patients With Untreated Acute Myeloid Leukemia,thromboembolic event
D009026,100.0,NCT02666950-1,Arm A + Arm C (AZD1775 Combined With AraC OR AZD1775 Only),NCT02666950,WEE1 Inhibitor AZD1775 With or Without Cytarabine in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome,mortality
D064420,100.0,NCT02666950-1,Arm A + Arm C (AZD1775 Combined With AraC OR AZD1775 Only),NCT02666950,WEE1 Inhibitor AZD1775 With or Without Cytarabine in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome,adverse drug events
D064147,100.0,NCT02666950-1,Arm A + Arm C (AZD1775 Combined With AraC OR AZD1775 Only),NCT02666950,WEE1 Inhibitor AZD1775 With or Without Cytarabine in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome,febrile neutropenia
D015746,33.33,NCT02666950-1,Arm A + Arm C (AZD1775 Combined With AraC OR AZD1775 Only),NCT02666950,WEE1 Inhibitor AZD1775 With or Without Cytarabine in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome,abdominal pain
10017947,33.33,NCT02666950-1,Arm A + Arm C (AZD1775 Combined With AraC OR AZD1775 Only),NCT02666950,WEE1 Inhibitor AZD1775 With or Without Cytarabine in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome,gastrointestinal disorders - other specify
D005221,33.33,NCT02666950-1,Arm A + Arm C (AZD1775 Combined With AraC OR AZD1775 Only),NCT02666950,WEE1 Inhibitor AZD1775 With or Without Cytarabine in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome,fatigue
10061229,66.67,NCT02666950-1,Arm A + Arm C (AZD1775 Combined With AraC OR AZD1775 Only),NCT02666950,WEE1 Inhibitor AZD1775 With or Without Cytarabine in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome,lung infection
D018805,33.33,NCT02666950-1,Arm A + Arm C (AZD1775 Combined With AraC OR AZD1775 Only),NCT02666950,WEE1 Inhibitor AZD1775 With or Without Cytarabine in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome,sepsis
D009026,67.86,NCT02921061-1,Treatment (Decitabine 20 mg/m2 and G-CLAM),NCT02921061,Decitabine With GCLAM for Adults With Newly Diagnosed  Relapsed  or Refractory AML or High-Risk MDS,mortality
D064420,7.14,NCT02921061-1,Treatment (Decitabine 20 mg/m2 and G-CLAM),NCT02921061,Decitabine With GCLAM for Adults With Newly Diagnosed  Relapsed  or Refractory AML or High-Risk MDS,adverse drug events
D006333,3.57,NCT02921061-1,Treatment (Decitabine 20 mg/m2 and G-CLAM),NCT02921061,Decitabine With GCLAM for Adults With Newly Diagnosed  Relapsed  or Refractory AML or High-Risk MDS,heart failure
D018805,3.57,NCT02921061-1,Treatment (Decitabine 20 mg/m2 and G-CLAM),NCT02921061,Decitabine With GCLAM for Adults With Newly Diagnosed  Relapsed  or Refractory AML or High-Risk MDS,sepsis
D009026,100.0,NCT02954653-1,Part 1: PF-06747143 0.3 mg/kg,NCT02954653,A Study Of PF-06747143  As Single Agent Or In Combination With Standard Chemotherapy In Adult Patients With Acute Myeloid Leukemia,mortality
D009026,25.0,NCT02954653-2,Part 1: PF-06747143 1 mg/kg,NCT02954653,A Study Of PF-06747143  As Single Agent Or In Combination With Standard Chemotherapy In Adult Patients With Acute Myeloid Leukemia,mortality
D064420,33.33,NCT02954653-1,Part 1: PF-06747143 0.3 mg/kg,NCT02954653,A Study Of PF-06747143  As Single Agent Or In Combination With Standard Chemotherapy In Adult Patients With Acute Myeloid Leukemia,adverse drug events
D064420,75.0,NCT02954653-2,Part 1: PF-06747143 1 mg/kg,NCT02954653,A Study Of PF-06747143  As Single Agent Or In Combination With Standard Chemotherapy In Adult Patients With Acute Myeloid Leukemia,adverse drug events
D005334,25.0,NCT02954653-2,Part 1: PF-06747143 1 mg/kg,NCT02954653,A Study Of PF-06747143  As Single Agent Or In Combination With Standard Chemotherapy In Adult Patients With Acute Myeloid Leukemia,pyrexia
D002481,25.0,NCT02954653-2,Part 1: PF-06747143 1 mg/kg,NCT02954653,A Study Of PF-06747143  As Single Agent Or In Combination With Standard Chemotherapy In Adult Patients With Acute Myeloid Leukemia,cellulitis
D011014,25.0,NCT02954653-2,Part 1: PF-06747143 1 mg/kg,NCT02954653,A Study Of PF-06747143  As Single Agent Or In Combination With Standard Chemotherapy In Adult Patients With Acute Myeloid Leukemia,pneumonia
D018805,33.33,NCT02954653-1,Part 1: PF-06747143 0.3 mg/kg,NCT02954653,A Study Of PF-06747143  As Single Agent Or In Combination With Standard Chemotherapy In Adult Patients With Acute Myeloid Leukemia,sepsis
D009369,25.0,NCT02954653-2,Part 1: PF-06747143 1 mg/kg,NCT02954653,A Study Of PF-06747143  As Single Agent Or In Combination With Standard Chemotherapy In Adult Patients With Acute Myeloid Leukemia,neoplasms
D000860,33.33,NCT02954653-1,Part 1: PF-06747143 0.3 mg/kg,NCT02954653,A Study Of PF-06747143  As Single Agent Or In Combination With Standard Chemotherapy In Adult Patients With Acute Myeloid Leukemia,hypoxia
D009026,66.67,NCT03135028-1,ENTO 400 mg,NCT03135028,Entospletinib (ENTO) as Monotherapy and in Combination With Chemotherapy in Japanese Adults,mortality
D064420,44.44,NCT03135028-1,ENTO 400 mg,NCT03135028,Entospletinib (ENTO) as Monotherapy and in Combination With Chemotherapy in Japanese Adults,adverse drug events
D000741,11.11,NCT03135028-1,ENTO 400 mg,NCT03135028,Entospletinib (ENTO) as Monotherapy and in Combination With Chemotherapy in Japanese Adults,aplastic anaemia
D002386,11.11,NCT03135028-1,ENTO 400 mg,NCT03135028,Entospletinib (ENTO) as Monotherapy and in Combination With Chemotherapy in Japanese Adults,cataract
D000080324,11.11,NCT03135028-1,ENTO 400 mg,NCT03135028,Entospletinib (ENTO) as Monotherapy and in Combination With Chemotherapy in Japanese Adults,choroidal effusions
D005334,11.11,NCT03135028-1,ENTO 400 mg,NCT03135028,Entospletinib (ENTO) as Monotherapy and in Combination With Chemotherapy in Japanese Adults,pyrexia
D011681,11.11,NCT03135028-1,ENTO 400 mg,NCT03135028,Entospletinib (ENTO) as Monotherapy and in Combination With Chemotherapy in Japanese Adults,pupillary functions abnormal
D004761,11.11,NCT03135028-1,ENTO 400 mg,NCT03135028,Entospletinib (ENTO) as Monotherapy and in Combination With Chemotherapy in Japanese Adults,clostridium enterocolitis
D000069544,11.11,NCT03135028-1,ENTO 400 mg,NCT03135028,Entospletinib (ENTO) as Monotherapy and in Combination With Chemotherapy in Japanese Adults,encephalitis infection
D011014,11.11,NCT03135028-1,ENTO 400 mg,NCT03135028,Entospletinib (ENTO) as Monotherapy and in Combination With Chemotherapy in Japanese Adults,pneumonia
UNKNOWN-check-for-typo,11.11,NCT03135028-1,ENTO 400 mg,NCT03135028,Entospletinib (ENTO) as Monotherapy and in Combination With Chemotherapy in Japanese Adults,D00
D003920,11.11,NCT03135028-1,ENTO 400 mg,NCT03135028,Entospletinib (ENTO) as Monotherapy and in Combination With Chemotherapy in Japanese Adults,diabetes mellitus
